0001213900-24-097737S-1 Oruka Therapeutics, Inc. 20241113202411140637000637000637000 0 0001213900-24-097737 S-1 89 20241114 20241114 Oruka Therapeutics, Inc. 0000907654 2835 363855489 DE 1231 S-1 33 333-283212 241456990 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 ARCA biopharma, Inc. 20090128 NUVELO INC 20030203 HYSEQ INC 19970610 S-1 1 ea0220567-s1_orukatherap.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on November 14, 2024 Registration No. 333-Â Â Â Â Â Â Â Â Â Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Â Â Â FORMÂ S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Â Â Â Oruka Therapeutics, Inc. (Exact name of registrant as specified in its charter) Â Â Â Â Delaware Â 36-3855489 (State or other jurisdiction of incorporation or organization) Â (I.R.S. Employer Identification No.) Â 855 Oak Grove Avenue Suite 100 Menlo Park, CA 94025 (650)Â 606-7910 (Address, including zip code, and telephone number, including area code, of registrantâ€™s principal executive offices) Â Â Â Paul Quinlan General Counsel and Corporate Secretary Oruka Therapeutics, Inc. 855 Oak Grove Avenue Suite 100 Menlo Park, CA 94025 (650)Â 606-7910 (Name, address, including zip code, and telephone number, including area code, of agent for service) Â Â Â Copies to: Â Ryan A. Murr Branden C. Berns Gibson, Dunn & Crutcher LLP One Embarcadero Center, Suite 2600 San Francisco, CA 94111 (415) 393-8373 Â Â Â Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement. Â If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.â€‚â˜ Â If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.â€‚â˜ Â If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.â€‚â˜ Â If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.â€‚â˜ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer Â â˜ Â Accelerated filer Â â˜ Non-accelerated filer Â â˜’ Â Smaller reporting company Â â˜’ Â Â Â Â Emerging growth company Â â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.â€‚â˜ Â Â Â The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine. Â Â Â Â Â Â The information in this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell these securities until the registration statement filed with the Securities and Exchange Commission (the â€œSECâ€) is effective. This prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permitted. Â SUBJECT TO COMPLETION, DATED NOVEMBER 13, 2024 Â PRELIMINARY PROSPECTUS Â Â Â Oruka Therapeutics, Inc. Â 8,719,000 Shares Â Common Stock Â Offered by the Selling Stockholders Â Â Â This prospectus relates to the proposed resale or other disposition by the selling stockholders identified herein (the â€œSelling Stockholdersâ€) of up to (i) 5,600,000 shares (the â€œPrivate Placement Common Sharesâ€) of our common stock, par value $0.001 per share (â€œCommon Stockâ€), (ii) 2,439,000 shares of Common Stock (the â€œPrivate Placement Conversion Sharesâ€) issuable upon the conversion of 2,439 shares (the â€œPrivate Placement Preferred Sharesâ€) of Series A preferred stock, par value $0.001 (the â€œSeries A Preferred Stockâ€) and (iii) 680,000 shares of Common Stock issuable upon the exercise of pre-funded warrants (the â€œPre-Funded Warrantsâ€). Subject to receiving the requisite stockholder approval and certain beneficial ownership limitations set by each holder of Series A Preferred Stock, each share of Series A Preferred Stock will automatically convert into an aggregate of 1,000 shares of Common Stock. The shares of Common Stock registered by this prospectus are referred to herein as the â€œResale Shares.â€ Â The Private Placement Common Shares, Private Placement Preferred Shares and Pre-Funded Warrants were issued and sold to accredited investors in a private placement (the â€œSeptember 2024 PIPEâ€), which closed on September 13, 2024. We are not selling any Resale Shares under this prospectus and will not receive any of the proceeds from the sale or other disposition of Resale Shares by the Selling Stockholders. Upon any exercise of the Pre-Funded Warrants by payment of cash, however, we will receive the nominal cash exercise price paid by the holders of the Pre-Funded Warrants. We intend to use those proceeds, if any, for general corporate purposes. Â The Selling Stockholders may sell the Resale Shares on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, on the over-the-counter market, in one or more transactions otherwise than on these exchanges or systems, such as privately negotiated transactions, or using a combination of these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. See the disclosure under the heading â€œPlan of Distributionâ€ elsewhere in this prospectus for more information about how the Selling Stockholders may sell or otherwise dispose of their Resale Shares hereunder. Â The Selling Stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the Selling Stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus forms a part. Discounts, concessions, commissions and similar selling expenses attributable to the sale of the Resale Shares will be borne by the Selling Stockholder. We will pay certain fees and expenses (other than discounts, concessions, commissions and similar selling expenses) incident to the registration of the Resale Shares with the U.S. Securities and Exchange Commission (â€œSECâ€). Â You should carefully read this prospectus and any applicable prospectus supplement before you invest in any of the securities being offered. Â Our Common Stock is traded on The Nasdaq Global Market under the symbol â€œORKA.â€ On November 12, 2024, the last reported sale price for our Common Stock was $26.10 per share.Â Â Â Â An investment in our securities involves a high degree of risk. You should carefully consider the information under the heading â€œRisk Factorsâ€ beginning on page 6 of this prospectus and any applicable prospectus supplement. Â We are a â€œsmaller reporting companyâ€ as defined by Rule 12b-2 of the Exchange Act and are subject to reduced public company reporting requirements. Â Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. Â Â Â The date of this prospectus isÂ Â Â Â Â Â Â Â Â Â Â Â , 2024 Â Â Â Â Â TABLE OF CONTENTS Â Â PAGE ABOUT THIS PROSPECTUS ii CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS iii PROSPECTUS SUMMARY 1 RISK FACTOR SUMMARY 4 RISK FACTORS 6 USE OF PROCEEDS 35 MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 36 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 49 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 49 BUSINESS 50 MANAGEMENT 84 EXECUTIVE COMPENSATION 90 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 96 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 98 SELLING STOCKHOLDERS 102 PLAN OF DISTRIBUTION 111 DESCRIPTION OF CAPITAL STOCK 113 LEGAL MATTERS 117 EXPERTS 118 WHERE YOU CAN FIND MORE INFORMATION 119 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 Â Â i Â Â ABOUT THIS PROSPECTUS Â This prospectus is part of a registration statement that we filed with the SEC using a â€œshelfâ€ registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, sell the securities described in this prospectus in one or more offerings. Â This prospectus contains information that you should consider when making your investment decision. Neither we, nor the Selling Stockholders, have authorized anyone to give any information or to make any representation other than those contained in this prospectus. The Selling Stockholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in any accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. Â In this prospectus, unless the context otherwise requires, the terms â€œOruka,â€ the â€œCompany,â€ â€œwe,â€ â€œus,â€ and â€œourâ€ refer to Oruka Therapeutics, Inc., a Delaware corporation, and its consolidated subsidiaries. Â This prospectus contains trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the Â® or TM symbols. Â All references to â€œour product candidates,â€ â€œour programs,â€ â€œour portfolioâ€ and â€œour pipelineâ€ in this prospectus refer to the research programs with respect to which we have exercised the option to acquire intellectual property license rights to or have the option to acquire intellectual property license rights to pursuant to those certain antibody discovery and option agreements, each dated March 6, 2024 and subsequently amended and restated on March 28, 2024, by and among Oruka, Paragon Therapeutics, Inc. (â€œParagonâ€) and Paruka Holding LLC (â€œParukaâ€) (the â€œParagon Option Agreementsâ€). Â ii Â Â CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS Â This prospectus contains â€œforward-looking statementsâ€ within the meaning of Section 27A of the Securities Act of 1933, as amended (the â€œSecurities Actâ€), and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). These forward-looking statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. These statements are based on current expectations of future events. Â All statements, other than statements of historical facts contained in this prospectus, including, without limitation, statements regarding: stockholder approval of the conversion rights of the Series A Preferred Stock; our ability to achieve the expected benefits or opportunities and related timing with respect to the Merger (as defined below), our future results of operations and financial position, business strategy, the length of time that we believe our existing cash resources will fund our operations, our market size, our potential growth opportunities, our preclinical and future clinical development activities, the efficacy and safety profile of our product candidates, the potential therapeutic benefits and economic value of our product candidates, the timing and results of preclinical studies and clinical trials, the expected impact of macroeconomic conditions, including inflation, increasing interest rates and volatile market conditions, current or potential bank failures, as well as global events, including ongoing military conflict between Russia and Ukraine, conflict in the Middle East, and geopolitical tensions in China on our operations, and the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates. Forward-looking statements generally relate to future events or our future financial or operating performance. Forward-looking statements generally relate to future events or our future financial or operating performance. The words â€œbelieve,â€ â€œmay,â€ â€œwill,â€ â€œpotentially,â€ â€œestimate,â€ â€œcontinue,â€ â€œanticipate,â€ â€œpredict,â€ â€œtarget,â€ â€œintend,â€ â€œcould,â€ â€œwould,â€ â€œshould,â€ â€œproject,â€ â€œplan,â€ â€œexpect,â€ and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Â These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Factors that might cause such a difference are disclosed in the sections titled â€œRisk Factorsâ€ and â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.â€ You should evaluate all forward-looking statements made in this prospectus in the context of these risks and uncertainties. We caution you that the risks, uncertainties and other factors referred to in this prospectus may not contain all of the risks, uncertainties and other factors that may affect our future results and operations. Â In addition, statements that â€œwe believeâ€ and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this prospectus. While we believe that such information provides a reasonable basis for these statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. Â All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S. securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Â iii Â Â PROSPECTUS SUMMARY Â This summary may not contain all the information that you should consider before investing in securities. You should read the entire prospectus carefully, including the sections titled â€œRisk Factorsâ€ and â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations,â€ and our consolidated financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. Â Company Overview Â We are a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Our mission is to offer patients suffering from chronic skin diseases like psoriasis (â€œPsOâ€) the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. We are advancing a proprietary portfolio of antibodies that were engineered by Paragon and target the core mechanisms underlying PsO and other dermatologic and inflammatory diseases. Â Our lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Our co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis (â€œPsAâ€), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology with the aim to increase exposure and decrease dosing frequency. We believe that our focused strategy, differentiated portfolio, and deep expertise position us to set a new treatment standard in large inflammatory and immunology (â€œI&Iâ€) markets with continued unmet need. Â Our principal executive offices are located at 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025, and our telephone number is (650) 606-7910. Our website address is www.orukatx.com. Information contained on, or accessible through, our website is not incorporated by reference in this prospectus. We make our periodic and current reports available on our website, free of charge, as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. No portion of our website is incorporated by reference into this prospectus. We file our annual, quarterly and special reports, proxy statements and other information with the SEC. Our filings with the SEC are also available to the public on the SECâ€™s website at http://www.sec.gov. Our Common Stock is traded on The Nasdaq Global Market under the symbol â€œORKA.â€ Â Business Combination of ARCA and Pre-Merger Oruka and Pre-Closing Financing Â On AprilÂ 3, 2024, we (formerly known as ARCA biopharma, Inc.) (prior to the Closing Date, unless context otherwise requires, â€œARCAâ€ and, after the Closing Date, the â€œCompanyâ€ or â€œOrukaâ€) entered into the Agreement and Plan of Merger and Reorganization (the â€œMerger Agreementâ€), by and among ARCA, Atlas Merger Sub Corp, a Delaware corporation and wholly owned subsidiary of ARCA (â€œFirst Merger Subâ€), Atlas Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of ARCA (â€œSecond Merger Subâ€), and Oruka Therapeutics, a private Delaware corporation (â€œPre-Merger Orukaâ€) prior to the consummation of the Merger (as defined below). Â On August 29, 2024 (the â€œClosing Dateâ€), we consummated that previously announced business combination (the â€œClosingâ€) pursuant to the Merger Agreement to create a new public company focused on advancing Pre-Merger Orukaâ€™s pipeline of antibody therapies. On the Closing Date, First Merger Sub merged with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the â€œFirst Mergerâ€), and Oruka merged with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the merger (the â€œSecond Mergerâ€ and, together with the First Merger, the â€œMergerâ€). In connection with the completion of the Merger, we changed our name from â€œARCA biopharma, Inc.â€ to â€œOruka Therapeutics, Inc.â€ Â 1 Â Â Immediately prior to the execution and delivery of the Merger Agreement, certain new and existing investors of Oruka (the â€œFinancing Investorsâ€) entered into a subscription agreement with Oruka (the â€œSubscription Agreementâ€), pursuant to which, and on the terms and subject to the conditions of which, immediately prior to the Closing, the Financing Investors purchased 39,873,706 shares of Pre-Merger Oruka common stock and 9,664,208 Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0 million (which includes the issuance of 4,764,032

shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note, along with the accrued interest through the conversion date), immediately prior to the Closing and before the effect of the Reverse Stock Split (as defined below) (the â€œPre-Closing Financingâ€). At the Closing, the shares of Pre-Merger Oruka common stock and Pre-Merger Oruka pre-funded warrants issued in the Pre-Closing Financing were converted into shares of Common Stock in accordance with the Exchange Ratio (as defined herein). Â In connection with the consummation of the Merger, on the Closing Date (prior to the Reverse Stock Split (as defined below)): Â â—Pre-Merger Oruka issued to the Financing Investors an aggregate of 39,873,706 shares of Pre-Merger Oruka common stock and 9,664,208 Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0 million (which includes the issuance of 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note, along with the accrued interest through the conversion date); and Â â—all of the then-outstanding (i) 9,460,019 shares of Pre-Merger Oruka common stock, (ii) 20,000,000 shares of Series A convertible preferred stock of Pre-Merger Oruka (â€œPre-Merger Oruka Series A Preferred Stockâ€), (iii) 2,063,669 options exercisable for shares of Pre-Merger Oruka common stock, (iv) 5,345,336 Pre-Merger Oruka employee warrants and (v) the Pre-Closing Financing Pre-Merger Oruka common stock and pre-funded warrants were automatically converted into the right to receive the number of Common Stock, Series B Preferred Stock or warrants in lieu thereof equal to the exchange ratio calculated in accordance with the Merger Agreement (the â€œExchange Ratioâ€), except for the preferred stock, which was converted at the Exchange Ratio divided by 1,000. Â Following the consummation of the Merger, we effected a 1-for-12 reverse stock split of our Common Stock (the â€œReverse Stock Splitâ€), which became effective on September 3, 2024. Our Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the open of trading on September 3, 2024. Â Private Placement of Common Stock, Preferred Stock and Pre-Funded Warrants Â On September 13, 2024, we completed the Private Placement of Private Placement Common Shares, Private Placement Conversion Shares and Pre-Funded Warrants pursuant to the Securities Purchase Agreement dated September 11, 2024 (the â€œSPAâ€) with the Selling Stockholders. The Selling Stockholders purchased (i) an aggregate of 5,600,000 shares of the Common Stock, at a price per share of $23.00, (ii) an aggregate of 2,439 shares of Series A Preferred Stock, at a price per share of $23,000.00, and (iii) Pre-Funded Warrants to purchase an aggregate of 680,000 shares of Common Stock at a purchase price of $22.999 per Pre-Funded Warrant, which represents the per share purchase price of the Private Placement Common Shares less the $0.001 per share exercise price for each Pre-Funded Warrant, for an aggregate purchase price of approximately $200.5 million. Â Subject to stockholder approval and certain beneficial ownership limitations, each share of Series A Preferred Stock is convertible into 1,000 shares of Common Stock. Shares of Series A Preferred Stock shall not be convertible if the conversion would result in a holder, together with its affiliates, beneficially owning more than 9.99% of our outstanding shares of Common Stock as of the applicable conversion date, which may be increased at the holdersâ€™ option (not to exceed 19.99%), effective in accordance with the terms of our Certificate of Designation of Series A Convertible Preferred Stock (â€œSeries A Certificate of Designationâ€). We filed a definitive proxy statement with the SEC on October 18, 2024 to solicit such stockholder approval at a special meeting of stockholders to be held on November 14, 2024. Except as otherwise required by law (e.g., voting on a change to the authorized shares of Series A Preferred Stock or the rights of such shares as required by the General Corporation Law of Delaware (the â€œDGCLâ€)) and as specified in the Series A Certificate of Designation, the Series A Preferred Stock does not have voting rights. The Pre-Funded Warrants will be exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage to a percentage not in excess of 19.99% by providing at least 61 daysâ€™ prior notice to us. Â The sale of Private Placement Common Shares, Private Placement Conversion Shares and Pre-Funded Warrants was not registered under the Securities Act, and such sale was intended to be exempt from registration pursuant to Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering. Â Corporation Information Â On August 29, 2024, we completed the Merger, in connection with which Second Merger Sub changed its corporate name to â€œOruka Therapeutics Operating Company, LLCâ€ and ARCA changed its name to â€œOruka Therapeutics, Inc.â€ Our principal executive offices are located at 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025, and our telephone number is (650) 606-7910. Â 2 Â Â The Offering Â Shares Offered by the Selling Securityholders Up to (i) 5,600,000 shares of Common Stock, (ii) 2,439,000 shares of Common Stock issuable upon the conversion of 2,439 shares of Series A Preferred Stock and (iii) 680,000 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants. Â Terms of the Offering The selling securityholders will determine when and how they will dispose of the shares of Common Stock, shares of Common Stock issuable upon conversion of Series A Preferred Stock and shares of Common Stock issuable upon the exercise of Pre-Funded Warrants registered under this prospectus for resale. Â Shares Outstanding As of September 30, 2024, there were 34,998,550 of our Common Stock, 2,439 shares of our Series A Preferred Stock and 137,138 shares of our Series B Non-Voting Convertible Preferred Stock, par value $0.001 per share (â€œSeries B Preferred Stockâ€), outstanding. Â Use of Proceeds We will not receive any proceeds from the sale of the Resale Shares offered by the Selling Stockholders under this prospectus. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. Upon any exercise of the Pre-Funded Warrants by payment of cash, however, we will receive the nominal cash exercise price paid by the holders of the Pre-Funded Warrants. See the section titled â€œUse of Proceeds.â€ Â Risk Factors See the section titled â€œRisk Factorsâ€ and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our securities. Â Trading Markets and Ticker Symbols Our Common Stock is listed on The Nasdaq Global Market under the symbol â€œORKA.â€ Â The number of issued and outstanding shares of Common Stock does not include the following, as of September 30, 2024: Â â—2,439,000 shares of Common Stock issuable upon the conversion of 2,439 shares of Series A Preferred Stock; Â â—11,428,149 shares of Common Stock issuable upon the conversion of 137,138 shares of Series B Preferred Stock; Â â—5,522,207 shares of Common Stock issuable upon the exercise of 5,522,207 pre-funded warrants to acquire shares of Common Stock with an exercise price of $0.01 per share; Â â—680,000 shares of Common Stock issuable upon the exercise of 680,000 pre-funded warrants to acquire shares of Common Stock with an exercise price of $0.001 per share; Â â—1,287,760 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2024 Equity Incentive Plan and the 2024 Stock Incentive Plan with a weighted-average exercise price of 7.97 per share; Â â—3,054,358 shares of Common Stock issuable upon the exercise of 3,054,358 warrants to acquire shares of Common Stock with a weighted-average exercise price of $7.80 per share; Â â—4,526,324 shares of Common Stock reserved for issuance under our 2024 Stock Incentive Plan; and Â â—463,489 shares of Common Stock reserved for issuance under the ESPP. Â For additional information concerning the offering, see the section titled â€œPlan of Distribution.â€ Â 3 Â Â RISK FACTOR SUMMARY Â The following summarizes the principal factors that make an investment in the Company speculative or risky, all of which are more fully described in the Risk Factors section below. This summary should be read in conjunction with the Risk Factors section and should not be relied upon as an exhaustive summary of the material risks facing our business. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this prospectus and those we may make from time to time. You should consider all the risk factors described in our public filings when evaluating our business. Â Risks Related to Our Financial Condition and Capital Requirements Â â—We are a preclinical stage biopharmaceutical company with a limited operating history on which to assess our business; we have not initiated, conducted or completed any clinical trials, and have no products approved for commercial sale. Â â—We have historically incurred losses and we anticipate that we will continue to incur losses for the foreseeable future. Â â—We have never generated revenue from product sales and may never be profitable. Â â—We may not be able to raise the capital that we need to support our business plans. Â â—Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. Â Risks Related to Clinical Development and Regulatory Approval Â â—Drug development and obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain. Â â—We are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002, and our anticipated clinical trials of such programs may not be successful. Â â—We may not be able to meet requirements for the chemistry, manufacturing and control of our programs. Â â—We face competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed by us. Â â—The United States Food and Drug Administration (â€œFDAâ€) and comparable foreign regulatory approval processes are lengthy and time consuming and we may not be able to obtain or may be delayed in obtaining regulatory approvals for our product candidates. Â â—Even if we obtain regulatory approval, we will be subject to ongoing regulatory obligations. Â â—We may fail to achieve our projected development goals in the time frames we announce and expect. Â 4 Â Â Risks Related to Our Intellectual Property Â â—Our ability to obtain and protect our patents and other proprietary rights is uncertain. Â â—We may fail in obtaining or maintaining necessary rights to our programs. Â â—We may be subject to patent infringement claims or may need to file such claims. Â â—Our patents and our ability to protect our products may be impaired by changes to patent laws. Â â—Our patent protection could be reduced or eliminated for non-compliance with legal requirements. Â â—We may fail to identify or interpret relevant third-party patents. Â â—We may become subject to claims challenging the inventorship or ownership of our intellectual property. Â â—Patent terms may be inadequate to protect our competitive position of our programs. Â â—Our technology licensed from various third-parties may be subject to retained rights. Â Risks Related to Our Reliance on Third Parties Â â—We currently rely on agreements with third parties to develop our product candidates. If we are unable to maintain collaborations or licensing arrangements, or if our collaborations or licensing arrangements are not successful, our business could be negatively impacted. Â â—Third parties we rely on for the execution of nonclinical studies and clinical trials may fail to carry out their contractual duties. Â â—We may be unable to use third-party manufacturing sites, our third-party manufacturers may encounter difficulties in production or we may need to switch or create third-party manufacturer redundancies. Â Other Risk Factors - Risks Related to Employee Matters, Managing Growth, Other Risks Related to Our Business, and Owning Our Common Stock Â â—Our business is dependent on key personnel and we will be harmed if we cannot recruit and retain highly qualified personnel to successfully implement our business strategy. Â â—In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth. Â â—Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all. Â â—Significant disruptions of information technology systems or breaches of data security could adversely affect our business. Â â—Changes in and failures to comply with United States and foreign privacy and data protection laws, regulations and standards may adversely affect our business, operations and consolidated financial performance. Â â—We may become exposed to costly and damaging liability claims and our insurance may not cover all damages from such claims. Â â—Our business could be adversely affected by macroeconomic conditions. Â â—We do not anticipate paying any dividends in the foreseeable future. Â â—Future sales of shares by existing stockholders could cause our stock price to decline. Â â—Future sales and issuances of equity and debt could result in additional dilution to our stockholders and could cause our stock price to decline. Â 5 Â Â Â RISK FACTORS Â Risks Related to Our Financial Condition and Capital Requirements Â We are a preclinical stage biopharmaceutical company with a limited operating history on which to assess our business; we have not initiated, conducted or completed any clinical trials, have no products approved for commercial sale, have historically incurred losses, and we anticipate that we will continue to incur significant losses for the foreseeable future. Moreover, we have never generated revenue from product sales and may never be profitable. Â We are a preclinical stage biopharmaceutical company with a limited operating history. We will need to raise substantial additional capital to continue to fund our operations in the future. We have based our estimates on assumptions that may prove to be wrong, and could exhaust our available financial resources sooner than it currently anticipates. Â We have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates, organizing and staffing our company, and providing general and administrative support for our operations. Â Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We expect our losses to increase as our product candidates enter advanced clinical trials. It may be severalÂ years, if ever, before we complete pivotal clinical trials or have a product candidate approved for commercialization. We expect to invest significant funds into the research and development of our current programs to determine the potential to advance product candidates to regulatory approval. If we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market acceptance, pricing, coverage and adequate reimbursement from third-partyÂ payors, and adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates, we may never become profitable despite obtaining such market share and acceptance of our products. Â We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase substantially if and as we: Â â—continue the preclinical development and initiate the clinical development of our product candidates; Â â—continue efforts to discover and develop new product candidates; Â â—continue the manufacturing of our product candidates or increase volumes manufactured by third parties; Â â—advance our product candidates into larger, more expensive clinical trials; Â â—initiate additional preclinical studies or clinical trials for our product candidates; Â â—seek regulatory and marketing approvals and reimbursement for our product candidates; Â â—establish a sales, marketing, and distribution infrastructure to commercialize any products for which it may obtain marketing approval and market for ourselves; Â â—make milestone, royalty, or other payments under third-partyÂ license agreements; Â â—seek to maintain, protect, and expand our intellectual property portfolio; and Â â—experience any delays or encounter issues with the development and potential regulatory approval of our clinical and product candidates such as safety issues, manufacturing delays, clinical trial accrual delays, longerÂ follow-upÂ for planned studies or trials, additional major studies or trials, or supportive trials necessary to support marketing approval. Â 6 Â Â We have no significant experience as a company in initiating, conducting or completing clinical trials. In part because of this lack of experience, we cannot be certain that our planned clinical trials will begin or be completed on time, if at all. In addition, we have not yet demonstrated an ability to obtain marketing approvals, manufacture a commercial-scaleÂ product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history. Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that aÂ period-to-periodÂ comparison of our results of operations may not be a good indication of our future performance. Â We will need to continue to raise additional capital in order to fund our operations. Â As of September 30, 2024, we had $410.9 million of cash. We have incurred significant net losses since our inception. We anticipate that we will continue to incur significant losses for the foreseeable future. Since FebruaryÂ 6, 2024 (inception), we have incurred significant operating losses. For the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024, we reported a net loss of $57.9Â million and net cash used from operating activities of $39.0Â million. We will need to raise additional capital to continue to fund our operations and service our debt obligations in the future. Until such time, if ever, as we can generate substantial revenue from the sale of our product candidates, we expect to finance our cash needs through a combination of equity offerings, debt financings and licensing, development or collaboration agreements. If we are unable to raise additional capital when needed, that may raise substantial doubt about our ability to continue as a going concern. We expect that our existing cash as of $410.9 million as of September 30, 2024 will be sufficient to fund our operating expenses and capital expenditure requirements for at least 12 months from the date these condensed consolidated financial statements were issued. Â Developing our product candidates and operating our company requires a substantial amount of capital. We expect our research and development expenses to increase in connection with our ongoing activities, particularly as we advance our product candidates through clinical trials. We may need to raise additional capital to fund our operations and such funding may not be available to us on acceptable terms, or at all, and such funding may become even more difficult to obtain. Competition for additional capital among biotechnology companies may be particularly intense during this period of economic instability. We may be unable to raise capital through public offerings of our common stock and may need to turn to alternative financing arrangements. Such arrangements, if we pursue them, could involve issuances of one or more types of securities, including common stock, preferred stock, convertible debt, warrants to acquire common stock or other securities. These securities could be issued at or below the then prevailing market price for our common stock. In addition, if we issue debt securities, the holders of the debt would have a claim to our assets that would be superior to the rights of stockholders until the principal, accrued and unpaid interest and any premium or make-wholeÂ has been paid. Interest on any newly-issuedÂ debt securities and/or newly-incurredÂ borrowings would increase our operating costs and reduce our net income (or increase our net loss), and these impacts may be material. If the issuance of new securities results in diminished rights to holders of our common stock, the market price of our common stock could be materially and adversely affected. Â We do not currently have any products approved for sale and do not generate any revenue from product sales. Accordingly, we expect to rely primarily on equity and/or debt financings to fund our continued operations. Our ability to raise additional funds will depend, in part, on the success of our preclinical studies and clinical trials and other product development activities, regulatory events, our ability to identify and enter into licensing or other strategic arrangements, and other

events or conditions that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurances that sufficient funds will be available to us when required or on acceptable terms, if at all. Â 7 Â Â If we are unable to raise additional capital when required or on acceptable terms, we may be required to: Â â—significantly delay, scale back, or discontinue the development or commercialization of our product candidates; Â Â â— seek strategic partnerships, or amend existing partnerships, for research and development programs at an earlier stage than otherwise would be desirable or that we otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available in the future; Â Â â— dispose of technology assets, or relinquish or license on unfavorable terms, our rights to technologies or any of our product candidates that we otherwise would seek to develop or commercialize ourselves; Â Â â— pursue the sale of the company to a third party at a price that may result in a loss on investment for our stockholders; or Â Â â— file for bankruptcy or cease operations altogether (and face any related legal proceedings). Â Any of these events could have a material adverse effect on our business, operating results, and prospects. Â Even if we are successful in raising new capital, we could be limited in the amount of capital we raise due to investor demand restrictions placed on the amount of capital we raise, or other reasons. Â Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights. Â To the extent that we raise additional capital through the sale of equity securities or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of our common stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. Â If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements with third parties when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Â To the extent that we raise additional capital through the sale of equity, including pursuant to any sales under convertible debt or other securities convertible into equity, the ownership interest of our stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Â In September 2024, we entered into a Securities Purchase Agreement with certain new institutional and accredited investors, whereby the investors purchased an aggregate of 5,600,000 shares of Company Common Stock, 2,439 shares of Company Series A Preferred Stock and pre-funded warrants to purchase an aggregate of 680,000 shares of common stock for an aggregate purchase price of approximately $200.5 million. Each share of Company Series A Preferred Stock is convertible into 1,000 shares of Company Common Stock. Â Debt financing, if available, would likely involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. If we raise additional funds through strategic collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary to fund our entire portfolio of product candidates to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or more of our development programs or be unable to expand our operations or otherwise capitalize on potential business opportunities, which could materially harm our business, financial condition, and results of operations. Â 8 Â Â Risks Related to Clinical Development, Regulatory Approval and Commercialization Â We face competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed by us. Â The development and commercialization of drugs is highly competitive. Product candidates developed by us, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. We compete with a variety of biopharmaceutical companies as well as academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which we are currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals, and marketing than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stageÂ companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, recruiting participants for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates. Â Our competitors have developed, are developing or will develop programs and processes competitive with our programs and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments. Our success will depend partially on our ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or presentation profile. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, have a more attractive dosing profile or presentation or are less expensive than the products we develop, or if our competitors develop competing products or if biosimilars enter the market more quickly than we do and are able to gain market acceptance. Â Our programs are in preclinical stages of development and may fail in development or suffer delays. We depend on the successful initiation and completion of clinical trials for our product candidates to advance our product development plans. Â We have no products on the market, and all of our programs are in preclinical stages of development and have not been tested in humans. As a result, we expect it will be manyÂ years before we can obtain regulatory approval for and commercialize any product candidate, if ever. We have not yet demonstrated our ability to initiate or complete any clinical trials, obtain regulatory approvals, manufacture a clinical or commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. We must initiate and complete clinical trials that demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, and can take years to complete and is uncertain as to outcome. A failure of one or more of our clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products. Â We may experience a number of unforeseen events during clinical trials, including the following: Â â—our product candidates may have undesirable side effects or unexpected characteristics, causing us or our investigators to suspend or terminate the trials; Â Â â— the supply of our clinical trial materials or other materials necessary to conduct clinical trials of our product candidates may be insufficient, delayed, does not meet agreed-upon specifications, or are otherwise inadequate for use in clinical trials; Â Â â— regulators or institutional review boards (â€œIRBsâ€), the FDA or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results, and we may decide, or regulators may require it, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs; Â Â â— we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and/or contract research organizations (â€œCROsâ€); Â 9 Â Â Â â— clinical trial sites deviating from trial protocol or dropping out of a trial; we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our trials are being exposed to unacceptable health risks; Â Â â— the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, especially if regulatory bodies require completion ofÂ non-inferiorityÂ or superiority trials; enrollment in these clinical trials may be slower than we anticipate or subjects may drop out of these clinical trials or fail to return for post-treatmentÂ follow-upÂ at a higher rate than we anticipate; Â Â â— our third-partyÂ contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators; Â Â â— the cost of clinical trials of any of our programs may be greater than we anticipate; Â Â â— reports from clinical testing of other therapies may raise safety or efficacy concerns about our programs; Â Â â— our failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidates as well as data emerging from other therapies in the same class as our product candidates; and Â Â â— the FDA or other regulatory authorities may require us to submit additional data such as long-termÂ toxicology studies, or impose other requirements before permitting us to initiate a clinical trial. Â Commencing clinical trials in the UnitedÂ States is subject to acceptance by the FDA of an investigational new drug application (â€œINDâ€), biologics license application (â€œBLAâ€) or similar application and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires us to complete additional preclinical studies or it is required to satisfy other FDA requests prior to commencing clinical trials, the start of our first clinical trials may be delayed. If our clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates may be adversely impacted. Moreover, the combined data from our trials maybe inconclusive or may not be sufficient to ultimately gain marketing approval from the FDA or other regulatory authorities. There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union (â€œEUâ€). Â In addition, because of the competitive landscape forÂ immunology and inflammation (commonly referred to as â€œI&Iâ€) indications, we may also face competition for clinical trial enrollment. Clinical trial enrollment will depend on many factors, including if potential clinical trial participants choose to undergo treatment with approved products or enroll in competitorsâ€™ ongoing clinical trials for programs that are under development for the same indications as our programs. An increase in the number of approved products for the indications we are targeting with our programs may further exacerbate this competition. Our inability to enroll a sufficient number of participants could, among other things, delay our development timeline, which may further harm our competitive position. Â We may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, our product candidates. Our inability to complete development of, or commercialize our product candidates, or significant delays in doing so, could have a material and adverse effect on our business, financial condition, results of operations and prospects. Â 10 Â Â We are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002, and our anticipated clinical trials of such programs may not be successful. Â Our future success is substantially dependent on our ability to develop and timely obtain marketing approval for, and then successfully commercialize, our two most advanced programs, ORKA-001Â and ORKA-002. We are investing a majority of our efforts and financial resources into the research and development of these programs. We anticipate initiating a PhaseÂ 1 clinical trial in healthy volunteers of ORKA-001Â in the first quarter of 2025 and of ORKA-002Â in the second half of 2025, each subject to the filing of an IND or foreign equivalent and regulatory approval. The success of our programs is dependent on observing a longer half-lifeÂ of our product candidates in humans than other extended half-lifeÂ monoclonal antibodies (â€œmAbsâ€) currently marketed and in development as we believe this longer half-lifeÂ has the potential to result in a more favorable dosing schedule for our product candidates, assuming they successfully complete clinical development and obtain marketing approval. This is based in part on the assumption that the longer half-lifeÂ we have observed inÂ non-humanÂ primates (â€œNHPsâ€) will translate into an extended half-lifeÂ of our product candidates in humans. To the extent we do not observe this extended half-lifeÂ in humans, it would significantly and adversely affect the clinical and commercial potential of our product candidates. Â Our programs will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, product development, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. Â The success of our product candidates will depend on a variety of factors. We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator. Â If we do not achieve our projected development goals in the time frames we announce and expect, the development and potential commercialization of our product candidates may be delayed and our expenses may increase and, as a result, our business may be materially harmed and our stock price may decline. Â From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which it sometimes refers to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, such as the expected timing for the anticipated commencement of our PhaseÂ 1 studies, clinical trials in psoriasis (â€œPsOâ€) and other target indications, as well as the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, the development and potential commercialization of our product candidates may be delayed or never achieved and, as a result, our business may be materially harmed and our stock price may decline. Additionally, delays relative to our projected timelines are likely to cause overall expenses to increase, which may require us to raise additional capital sooner than expected and prior to achieving targeted development milestones. Â Any drug delivery device that we may use to deliver our product candidates may have its own regulatory, development, supply and other risks. Â We expect to deliver our product candidates via a drug delivery device, such as an injector or other delivery system. There may be unforeseen technical complications related to the development activities required to bring such a product to market, including primary container compatibility and/or dose volume requirements. Our product candidates may not be approved or may be substantially delayed in receiving approval if the devices that we choose to develop do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single-sourceÂ unaffiliated third-partyÂ companies. We may be dependent on the sustained cooperation and effort of those third-partyÂ companies both to supply the devices and, in some cases, to conduct the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained, we may also be dependent on those third-partyÂ companies continuing to maintain such approvals or clearances once they have been received. Failure of third-partyÂ companies to supply the devices on time and in accordance with the agreed-upon specifications, to successfully complete studies on the devices in a timely manner, or to obtain or maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching patients. Â 11 Â Â Our approach to the discovery and development of our programs is unproven, and we may not be successful in our efforts to build a pipeline of programs with commercial value. Â Our approach to the discovery and development of the research programs with respect to which we have the option to acquire intellectual property license rights to pursuant to those certain antibody discovery and option agreements by and among the Company, Paragon Therapeutics, Inc. and Paruka Holding, LLC (the â€œOption Agreementsâ€) and leverages clinically validated mechanisms of action and incorporates advanced antibody engineering to optimize half-lifeÂ and other properties designed to overcome limitations of existing therapies. Our programs are purposefully designed to improve upon existing product candidates and products while maintaining the same, well-establishedÂ mechanisms of action. However, the scientific research that forms the basis of our efforts to develop programs using half-lifeÂ extension technologies is ongoing and may not result in viable programs. There is limited clinical data available on product candidates utilizing half-lifeÂ extension technologies, especially inÂ I&I indications, demonstrating whether they are safe or effective for long-termÂ treatment in humans. The long-termÂ safety and efficacy of these technologies and the extended half-lifeÂ and exposure profile of our programs compared to currently approved products is unknown. Â We may ultimately discover that utilizing half-lifeÂ extension technologies for our specific targets and indications and any programs resulting therefrom does not possess certain properties required for therapeutic effectiveness. We currently have only preclinical data regarding the increased half-lifeÂ properties of our programs and the same results may not be seen in humans. In addition, programs using half-lifeÂ extension technologies may demonstrate different chemical and pharmacological properties in participants than they do in laboratory studies. This technology and any programs resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. Â In addition, we may in the future seek to discover and develop programs that are based on novel targets and technologies that are unproven. If our discovery activities fail to identify novel targets or technologies for drug discovery, or such targets prove to be unsuitable for treating human disease, we may not be able to develop viable additional programs. We and our existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if we or an existing or future collaborator obtains regulatory approval,

the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from the research programs with respect to which we have the option to acquire intellectual property license rights to pursuant to the Option Agreements prove to be ineffective, unsafe or commercially unviable, such programs would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects. Â Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate. Â Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Â Furthermore, a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stageÂ clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. In addition, we expect to rely on participants to provide feedback on measures such as measures of quality of life, which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of our control, and can vary widely fromÂ day-to-dayÂ for a particular participant, and from participant to participant and from site to site within a clinical trial. Â We cannot be sure that the FDA will agree with our clinical development plan. We plan to use the data from our planned PhaseÂ 1 trials of our ORKA-001Â and ORKA-002Â programs in healthy volunteers to support PhaseÂ 2 trials in PsO and potentially otherÂ I&I indications. If the FDA requires us to conduct additional trials or enroll additional participants, our development timelines may be delayed. We cannot be sure that submission of an IND, BLA or similar application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or otherÂ in vivoÂ orÂ in vitroÂ data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable clinical investigators; delays in obtaining required IRB approval at each clinical trial site; delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing; failure by our CROs, other third parties or us to adhere to clinical trial protocols; failure to perform in accordance with the FDAâ€™s or any other regulatory authorityâ€™s current Good Clinical Practice requirements (â€œGCPsâ€) or applicable regulatory guidelines in other countries; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of manufacturing processes to facilities operated by a contract manufacturing organization (â€œCMOâ€) and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and third parties being unwilling or unable to satisfy their contractual obligations to us. Â 12 Â Â We could also encounter delays if a clinical trial is suspended or terminated by it, by the IRBs of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the programs, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, our business and results of operations may be adversely affected and we may need to adjust or abandon our business plans and we may incur significant additional costs. Â If we encounter difficulties enrolling participants in our future clinical trials, our clinical development activities could be delayed or otherwise adversely affected. Â We may experience difficulties in patient participant enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of participants who remain in the trial until conclusion. The enrollment of participants in future trials for any of our programs will depend on many factors, including if participants choose to enroll in clinical trials, rather than using approved products, or if our competitors have ongoing clinical trials for programs that are under development for the same indications as our programs, and participants instead enroll in such clinical trials. Even if we are able to enroll a sufficient number of participants for our clinical trials, it may have difficulty maintaining participants in our clinical trials. Our inability to enroll or maintain a sufficient number of participants would result in significant delays in completing clinical trials and increased development costs or may require us to abandon one or more clinical trials altogether. Â Preliminary, â€œtoplineâ€ or interim data from our clinical trials may change as more participant data becomes available and are subject to audit and verification procedures. Â From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which are based on a preliminary analysis of then-availableÂ data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures. Â Any preliminary or topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available or as participants from our clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or commercialization of the particular product candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the preliminary, topline or interim data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. Â 13 Â Â Our clinical trials may reveal significant adverse events or undesirable side effects not seen in our preclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of any of our product candidates. Â Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. While preclinical studies in NHPs conducted with respect to our programs have not shown any such characteristics to date, we have not yet initiated any clinical trials in humans. If significant adverse events or other side effects are observed in any of our future clinical trials, we may have difficulty recruiting participants to such trials, participants may drop out of the trials, or we may be required to abandon the trials or our development efforts of one or more programs altogether. We, the FDA or other applicable regulatory authorities, or an IRB, may suspend any clinical trials of any program at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology industry that initially showed therapeutic promise in early-stageÂ studies and trials have later been found to cause side effects that prevented their further development. However, other potential products have shown side effects in preclinical studies, which side effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to their tolerability versus other therapies. In addition, an extended half-lifeÂ could prolong the duration of undesirable side effects, which could also inhibit market acceptance. Treatment-emergentÂ adverse events could also affect participant recruitment or the ability of enrolled subjects to complete our clinical trials or could result in potential product liability claims. Potential side effects associated with our product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from our product candidates may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences could harm our business, financial condition, results of operations and prospects significantly. Â In addition, even if we successfully advance our product candidates or any future product candidates through clinical trials, such trials will only include a limited number of participants and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of participants are exposed to the product candidate after approval. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of using our product candidates over a multi-yearÂ period. Â If any of the foregoing events occur or if one or more of the research programs with respect to which we have the option to acquire intellectual property license rights to pursuant to the Option Agreements prove to be unsafe, our entire pipeline could be affected, which would have a material adverse effect on our business, financial condition, results of operations and prospects. Â We may expend our limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success. Â Because we have limited financial and managerial resources, we focus our research and development efforts on certain selected programs. For example, we are initially focused on our most advanced programs, ORKA-001Â and ORKA-002. As a result, we may forgo or delay pursuit of opportunities with other programs that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which we would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Â Any approved products resulting from our current programs or any future program may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate any future revenue from the sale or licensing of such products. Â Even if regulatory approval is obtained for a product candidate resulting from one of our current or future programs, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. We may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. There are several approved products and product candidates in later stages of development for the treatment of PsO.Â However, our programs incorporate advanced antibody engineering to optimize the half-lifeÂ and formulation of antibodies; to date, no such antibody has been approved by the FDA for the treatment of PsO.Â Market participants with significant influence over acceptance of new treatments, such as clinicians and third-partyÂ payors, may not adopt a biologic that incorporates half-lifeÂ extension for our targeted indications, and we may not be able to convince the medical community and third-partyÂ payors to accept and use, or to provide favorable reimbursement for, any programs developed by us or our existing or future collaborators. An extended half-lifeÂ may make it more difficult for patients to change treatments and there is a perception that half-lifeÂ extension could exacerbate side effects, each of which may adversely affect our ability to gain market acceptance. Market acceptance of our product candidates will depend on many factors, including factors that are not within our control. Â 14 Â Â Sales of medical products also depend on the willingness of clinicians to prescribe the treatment. We cannot predict whether clinicians, cliniciansâ€™ organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any of our product candidates is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable. Â Certain of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue. Â We are developing product candidates for the same indication, PsO, and may in the future develop our programs for otherÂ I&I indications. Each such program targets a different mechanism of action. However, developing multiple programs for a single indication may negatively impact our business if the programs compete with each other. For example, if multiple programs are conducting clinical trials at the same time, they could compete for the enrollment of participants. In addition, if multiple product candidates are approved for the same indication, they may compete for market share, which could limit our future revenue. Â We may conduct clinical trials for programs at sites outside the UnitedÂ States, and the FDA may not accept data from trials conducted in such locations. Â We may choose to conduct one or more of our future clinical trials outside the UnitedÂ States. Although the FDA may accept data from clinical trials conducted outside the UnitedÂ States, acceptance of this data is subject to conditions imposed by the FDA.Â For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S.Â population, and the data must be applicable to the U.S.Â population and U.S.Â medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend upon the determination that the trials also complied with all applicable U.S.Â laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the UnitedÂ States, it would likely result in the need for additional trials, which would be costly and time-consumingÂ and would delay or permanently halt our development of the applicable product candidates. Even if the FDA accepted such data, it could require us to modify our planned clinical trials to receive clearance to initiate such trials in the UnitedÂ States or to continue such trials once initiated. Â Further, conducting clinical trials outside of the U.S. presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled participants in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs that could restrict or limit our ability to conduct our clinical trials, the administrative burdens of conducting clinical trials under multiple sets of foreign regulations, potential restrictions on data generated from the clinical trial, foreign exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic risks relevant to foreign countries. Â Risks Related to Government Regulation Â The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. Â The process of obtaining regulatory approvals, both in the UnitedÂ States and abroad, is unpredictable, expensive and typically takes manyÂ years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Before obtaining regulatory approvals for the commercial sale of our product candidates, including our most advanced programs, ORKA-001Â and ORKA-002, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and

effective for our proposed indication; the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-relatedÂ side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; we may be unable to demonstrate that a product candidateâ€™s clinical and other benefits outweigh our safety risks; the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the UnitedÂ States or elsewhere, and we may be required to conduct additional clinical trials; the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of our product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-partyÂ manufacturers with which we contract for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. Â 15 Â Â Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects. Â If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketingÂ clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be materially impaired. Â We may not be able to meet requirements for the chemistry, manufacturing and control of our programs. Â In order to receive approval of our products by the FDA and comparable foreign regulatory authorities, we must show that we and our CMO partners are able to characterize, control and manufacture our drug products safely and in accordance with regulatory requirements. This includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that our drug products meet stability requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized expertise. If we are not able to meet the chemistry, manufacturing and control requirements, we may not be successful in getting our products approved. Â Our product candidates for which we intend to seek approval as biologics may face competition sooner than anticipated. Â The Patient Protection and Affordable Act, as amended by the Healthcare and Education Reconciliation Act (the â€œACAâ€), includes a subtitle called the Biologics Price Competition and Innovation ActÂ ofÂ 2009 (â€œBPCIAâ€), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with anÂ FDA-licensedÂ reference biological product. Under the BPCIA, an application for a highly similar or â€œbiosimilarâ€ product may not be submitted to the FDA until fourÂ years following the date that the reference product was first approved by the FDA.Â In addition, the approval of a biosimilar product may not be made effective by the FDA until 12Â years from the date on which the reference product was first approved. During thisÂ 12-yearÂ period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsorâ€™s own preclinical data and data from adequate and well-controlledÂ clinical trials to demonstrate the safety, purity and potency of their product. Â We believe that any of our product candidates approved as biologics under a BLA should qualify for theÂ 12-yearÂ period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution forÂ non-biologicalÂ products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. Â Even if we receive regulatory approval of our product candidates, we will be subject to extensive ongoing regulatory obligations and continued regulatory review and may result in restrictions on the use of the product, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. Â Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approvalÂ study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy (â€œREMSâ€) in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or comparable foreign regulatory authorities approve our product candidates, our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the UnitedÂ States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketingÂ information and reports, registration, as well asÂ on-goingÂ compliance with current CGMPs and GCPs for any clinical trials that we conduct following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with CGMPs. Â 16 Â Â If we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. Â We may face difficulties from healthcare legislative reform measures. Â Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the UnitedÂ States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. Â Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, including conflicts of interest rules, which could expose us to penalties. Â Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-partyÂ payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Principal investigators for our clinical trials may serve as scientific advisors or consultants to us or may be affiliated with our other service providers, including CROs or site management organizations, and from time to time may receive cash compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site or in the applicable trial may be questioned or jeopardized. Â Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to it, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-fundedÂ healthcare programs, integrity oversight and reporting obligations to resolve allegations ofÂ non-compliance,Â disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consumingÂ and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Â Even if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer such product candidates at competitive prices which would seriously harm our business. Â We intend to seek approval to market our product candidates in the UnitedÂ States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. Our ability to successfully commercialize any product candidates that we may develop will depend in part on the extent to which reimbursement for these product candidates and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-partyÂ payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and other third-partyÂ payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may create preferential access policies for a competitorâ€™s product, including a branded or generic/biosimilar product, over our products in an attempt to reduce their costs, which may reduce our commercial opportunity. Additionally, if any of our product candidates are approved and we are found to have improperly promoted off-labelÂ uses of those product candidates, we may become subject to significant liability, which would materially adversely affect our business and financial condition. Â 17 Â Â We are subject to U.S.Â and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business. Â We are subject to export control and import laws and regulations, including the U.S.Â Export Administration Regulations, U.S.Â Customs regulations, various economic and trade sanctions regulations administered by the U.S.Â Treasury Departmentâ€™s Office of Foreign Assets Controls, the U.S.Â Foreign Corrupt Practices ActÂ ofÂ 1977, as amended, the U.S.Â domestic bribery statute contained in 18 U.S.C. Â§ 201, the U.S.Â Travel Act, the USA PATRIOT Act, and other state and national anti-briberyÂ and anti-moneyÂ laundering laws in the countries in which we conduct activities. Anti-corruptionÂ laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. We may engage third parties to sell our products outside the UnitedÂ States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliatedÂ hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. Â Governments outside the UnitedÂ States tend to impose strict price controls, which may adversely affect our revenue, if any. Â In some countries, particularly member states of the EU (â€œEU Member Statesâ€), the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel distribution, or arbitrage betweenÂ low-pricedÂ and high-pricedÂ EU Member States, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, we or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectivenessÂ of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-partyÂ payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations, including those related to the pricing of prescription pharmaceuticals, as the United Kingdom (â€œUKâ€) determines which EU laws to replicate or replace. If the UK were to significantly alter its regulations affecting the pricing of prescription pharmaceuticals, we could face significant new costs. Â A breakthrough therapy, fast track, or other expedited designation for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that those product candidates will receive marketing approval. Â We may seek a breakthrough therapy, fast track, or other designation for appropriate product candidates. Designations such as these are within the discretion of the FDA, or other comparable regulatory authorities. The receipt of a designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA.Â In addition, even if one or more of our product candidates qualifies under one of FDAâ€™s designation programs, the FDA may later decide that the products no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Â 18 Â Â Risks Related to Our Intellectual Property Â Our ability to obtain and protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage. Â We rely upon a combination of patents, trademarks, trade secret protection, confidentiality agreements and the Option Agreements to protect the intellectual property related to our programs and technologies and to prevent third parties from competing unfairly with it. Our success depends in large part on our ability to obtain and maintain patent protection for our platform technologies, programs and their uses, as well as our ability to operate without infringing on or violating the proprietary rights of others. Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications directed to antibodies that target IL-23, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA-001. In addition, Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications directed to antibodies that target IL-17, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA-002. However, we may not be able to protect our intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Filing, prosecuting and defending patents on programs worldwide would be expensive and our intellectual property rights in some foreign jurisdictions can be less extensive than those in the UnitedÂ States; the reverse may also occur. As such, we may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if we apply for them. Our competitors may operate in countries where we do not have patent protection and can freely use our technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where we do have patent protection or pending patent applications. Â Our pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection of our programs or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that we may license or own covering our programs could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the UnitedÂ States or abroad, including the UnitedÂ States Patent and Trademark Office (â€œUSPTOâ€). Further, if we encounter delays in our clinical trials or delays in obtaining regulatory approval, the period of time during which we could market our product candidates under patent protection would be reduced. Thus, the patents that we may own and license may not afford us any meaningful competitive advantage. Â In addition to seeking patents for some of our technology and programs, we may also rely on trade secrets, including unpatentedÂ know-how,Â technology and other proprietary information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our employees, the

employees of third parties with whom we share our facilities or third-partyÂ consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state actors. In addition, while we undertake efforts to protect our trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Costly and time-consumingÂ litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. Â Lastly, if our trademarks and trade names are not registered or adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Â 19 Â Â We may not be successful in obtaining or maintaining necessary rights to our programs through acquisitions andÂ in-licenses. Â Because our development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire,Â in-license,Â or use these third-partyÂ proprietary rights. We may be unable to acquire orÂ in-licenseÂ any compositions, methods of use, processes or other third-partyÂ intellectual property rights from third parties that we identify as necessary for our programs. The licensing and acquisition of third-partyÂ intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-partyÂ intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-partyÂ intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-partyÂ intellectual property rights or maintain the existing intellectual property rights we do obtain, we may have to abandon development of the relevant program, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Â While we plan to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our programs, there may be times when the filing and prosecution activities for patents and patent applications relating to our programs are controlled by our current and future licensors or collaboration partners. If any of our current and future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our future licensors and our counsel that took place prior to the date upon which we assumed control over patent prosecution. Â Our future licensors may rely on third-partyÂ consultants or collaborators or on funds from third parties such that our future licensors are not the sole and exclusive owners of the patents weÂ in-license.Â If other third parties have ownership rights to our futureÂ in-licensedÂ patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. Â It is possible that we may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may beÂ non-exclusive,Â thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, programs, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-partyÂ patents do not exist which might be enforced against our current technology, manufacturing methods, programs, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. Â Disputes may arise between us and our future licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other interpretation-relatedÂ issues; whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense patents and other rights to third parties; our right to transfer or assign the license; the inventorship and ownership of inventions andÂ know-howÂ resulting from the joint creation or use of intellectual property by our future licensors and us and our partners; and the priority of invention of patented technology. Â 20 Â Â We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products. Â Because the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate and guarantee that we can operate without infringing on or violating third-partyÂ rights. If certain of our product candidates are ultimately granted regulatory approval, patent rights held by third parties, if found to be valid and enforceable, could be alleged to render one or more of our product candidates infringing. If a third party successfully brings a claim against us, we may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g., patent infringement or trade secret theft) brought against us, whether or not successful, may cause us to incur significant legal expenses and divert the attention of our management and key personnel from other business concerns. We cannot be certain that patents owned or licensed by us will not be challenged by others in the course of litigation. Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise funds. Â Competitors may infringe or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, we may be required to file claims, which can be expensive and time-consuming. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents we assert is invalid or unenforceable, in whole or in part, construe the patentâ€™s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement claims, a court or administrative body may determine that the marks we have asserted are invalid or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable. Â Further, we may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO.Â An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S.Â federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Â In addition, if our programs are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our future licensees and other parties with whom we have business relationships and we may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require us to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use. Â Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. Â We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. Â As is common in the biotechnology industry, in addition to our employees, we engage the services of consultants to assist us in the development of our programs. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information,Â know-howÂ or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or herÂ non-competitionÂ orÂ non-solicitationÂ agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. Â 21 Â Â While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our programs, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. Â Changes to patent laws in the UnitedÂ States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. Â Changes in either the patent laws or interpretation of patent laws in the UnitedÂ States, including patent reform legislation such as the Leahy-SmithÂ America Invents Act (the â€œLeahy-SmithÂ Actâ€) could increase the uncertainties and costs surrounding the prosecution of our owned andÂ in-licensedÂ patent applications and the maintenance, enforcement or defense of our owned andÂ in-licensedÂ issued patents. The Leahy-SmithÂ Act includes a number of significant changes to UnitedÂ States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effectiveÂ avenues for competitors to challenge the validity of patents, and enable third-partyÂ submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administeredÂ post-grantÂ proceedings, including post-grantÂ review, inter partes review and derivation proceedings. Assuming that other requirements for patentability are met, prior to MarchÂ 2013, in the UnitedÂ States, the first to invent the claimed invention was entitled to the patent, while outside the UnitedÂ States, the first to file a patent application was entitled to the patent. After MarchÂ 2013, under the Leahy-SmithÂ Act, the UnitedÂ States transitioned to aÂ first-to-fileÂ system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-SmithÂ Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Â In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S.Â Supreme Court and U.S.Â Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the UnitedÂ States Supreme Court inÂ Amgen, Inc. v. SanofiÂ (Amgen) recently held that Amgenâ€™s patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement where the patent specification provided twenty-sixÂ exemplary antibodies, but the claimed class of antibodies covered a â€œvast numberâ€ of additional antibodies not disclosed in the specification. The Court stated that if patent claims are directed to an entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire class of compositions. This decision makes it unlikely that we will be granted U.S.Â patents with composition of matter claims directed to antibodies functionally defined by their ability to bind a particular antigen. Even if we are granted claims directed to functionally defined antibodies, it is possible that a third party may challenge our patents, when issued, relying on the reasoning inÂ AmgenÂ or other recent precedential court decisions. Additionally, there have been proposals for additional changes to the patent laws of the UnitedÂ States and other countries that, if adopted, could impact our ability to enforce our proprietary technology. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S.Â Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future. Â Geopolitical instability in the UnitedÂ States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the UnitedÂ Statesâ€™ and foreign governmentsâ€™ actions related to Russiaâ€™s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in MarchÂ 2022 allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-makingÂ activities in the UnitedÂ States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. Â 22 Â Â In addition, a European Unified Patent Court (â€œUPCâ€) entered into force on JuneÂ 1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective for EU Member States. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated. Â Although we do not currently own any European patents or applications, if we obtain such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability to enforce or defend the validity of any European patents we may obtain. We may decide to opt out from the UPC any future European patent applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged forÂ non-complianceÂ and brought under the jurisdiction of the UPC.Â We cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. Â Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated forÂ non-complianceÂ with these requirements. Â Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.Â Non-complianceÂ events that could

result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits,Â non-paymentÂ of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our programs, our competitive position would be adversely affected. Â We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products. Â We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-partyÂ patent and pending application in the UnitedÂ States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patentâ€™s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-partyÂ patent or may incorrectly predict whether a third-partyâ€™s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the UnitedÂ States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. Â In addition, because some patent applications in the UnitedÂ States may be maintained in secrecy until the patents are issued, patent applications in the UnitedÂ States and many foreign jurisdictions are typically not published until 18Â months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering products or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. Â We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. Â We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor orÂ co-inventor.Â The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our programs or as a result of questions regardingÂ co-ownershipÂ of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Â Our future licensors may rely on third-partyÂ consultants or collaborators or on funds from third parties, such as the U.S.Â government, such that our licensors would not be the sole and exclusive owners of any patents weÂ in-license.Â If other third parties have ownership rights or other rights to ourÂ in-licensedÂ patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. Â 23 Â Â Patent terms may be inadequate to protect the competitive position of our product candidates for an adequate amount of time. Â Patents have a limited lifespan. In the UnitedÂ States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20Â years from its earliest UnitedÂ StatesÂ non-provisionalÂ filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Â Our technology licensed from various third parties may be subject to retained rights. Â Our future licensors may retain certain rights under the relevant agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. Â Risks Related to Our Reliance on Third Parties Â We currently rely on licensing arrangements with Paragon through the Option Agreements. If we are unable to maintain collaborations or licensing arrangements, or if our collaborations or licensing arrangements are not successful, our business could be negatively impacted. Â We currently rely on our licensing arrangements with Paragon through the Option Agreements for a substantial portion of our discovery capabilities andÂ in-licenses. Â Collaborations or licensing arrangements that we enter into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators or licensors. If any of our current or future collaborators or licensors experience delays in performance of, or fails to perform our obligations under their agreement with us, disagrees with our interpretation of the terms of such agreement or terminates their agreement with us, the research programs with respect to which we have the option to acquire intellectual property license rights to pursuant to the Option Agreements and development timeline could be adversely affected. If we fail to comply with any of the obligations under our collaborations or license agreements, including payment terms and diligence terms, our collaborators or licensors may have the right to terminate such agreements, in which event we may lose intellectual property rights and may not be able to develop, manufacture, market or sell the products covered by our agreements or may face other penalties under our agreements. Our collaborators and licensors may also fail to properly maintain or defend the intellectual property we have licensed from them, if required by our agreement with them, or even infringe upon, our intellectual property rights, leading to the potential invalidation of our intellectual property or subjecting us to litigation or arbitration, any of which would be time-consumingÂ and expensive and could harm our ability to commercialize our product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our programs and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. Â As part of our strategy, we plan to evaluate additional opportunities to enhance our capabilities and expand our development pipeline or provide development or commercialization capabilities that complement ours. We may not realize the benefits of such collaborations, alliances or licensing arrangements. Any of these relationships may require us to incurÂ non-recurringÂ and other charges, increase our near and long-termÂ expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. Â We may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third-partyÂ intellectual property rights that we consider attractive. These companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend upon, among other things, our assessment of the collaboratorâ€™s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaboratorâ€™s evaluation of a number of factors. Collaborations are complex and time-consumingÂ to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators. We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market. Â 24 Â Â We currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates. Â We have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract testing labs, CMOs and strategic partners, to supply, conduct and support our preclinical studies and clinical trials under agreements with us. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-partyÂ contractors and CROs are required to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our programs in clinical development. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications or refuse to approve our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. Â Any third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether they devote sufficient time and resources to our programs. These third parties may be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively affect their performance on our behalf and the timing thereof and could lead to products that compete directly or indirectly with our product candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. Â In addition, we currently rely on foreign CROs and CMOs, including WuXi Biologics (HongÂ Kong) Limited and its affiliates (â€œWuXi Biologicsâ€) and will likely continue to rely on foreign CROs and CMOs in the future. WuXi is a subsidiary or affiliate of WuXi Biologics, which is identified in the proposed U.S. legislation known as the BIOSECURE Act as a biotechnology â€œcompany of concern.â€ The current version of the BIOSECURE Act introduced in the House of Representatives would prohibit federal agencies from entering into procurement contracts with, as well as providing grants and loans to, an entity that uses biotechnology equipment or services from a biotechnology company of concern, and includes a grandfathering provision allowing biotechnology equipment and services provided or produced by named â€œbiotechnology companies of concernâ€ under a contract or agreement entered into before the effective date until January 1, 2032. The pathway and timing for the BIOSECURE Act or its provisions to become law are uncertain, although the bill was passed in the House of Representatives on September 9, 2024. Depending on whether the BIOSECURE Act becomes law, what the final language of the BIOSECURE Act includes, and how the law is interpreted by U.S. federal agencies, we could be potentially restricted from pursuing U.S. federal government business or grants in the future if we continue to use WuXi or other parties identified as â€œbiotechnology companies of concernâ€ beyond the grandfathering period. Foreign CMOs may be subject to U.S.Â legislation, including the proposed BIOSECURE bill, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies. Â For example, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in Chinaâ€™s public health, economic, political, and social conditions and the uncertainty around Chinaâ€™s relationship with other governments, such as the UnitedÂ States and the UK, could also negatively impact our ability to manufacture our product candidates for our planned clinical trials or have an adverse effect on our ability to secure government funding, which could adversely affect our financial condition and cause it to delay our clinical development programs. Furthermore, if the BIOSECURE bill is passed and one or more of our collaborators in China, including WuXi Biologics, is deemed to be a biotechnology company of concern, our operations and financial condition may be negatively impacted as a result of any delays or increased costs arising from the trade restrictions and other foreign regulatory requirements affecting such collaborators. In addition, while we have established relationships with CROs and CMOs outside of China, moving to those suppliers in the event of a geopolitical instability affecting our collaborators in China could introduce delays into the development program. Â 25 Â Â We currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture our product candidates, and we may rely on third parties to produce and process our products, if approved. Our business could be adversely affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production. Â We do not currently own any facility that may be used as our clinical or commercial manufacturing and processing facility and must currently rely on CMOs to manufacture our product candidates. We have not yet caused any product candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates, if approved. We currently have a sole source relationship for our supply of the ORKA-001Â and ORKA-002Â programs. If there should be any disruption in such supply arrangement, including any adverse events affecting our sole supplier, it could have a negative effect on the clinical development of our programs and other operations while we work to identify and qualify an alternate supply source. We may not control the manufacturing process of, and may be completely dependent on, our contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or comparable foreign regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs, delays, and materially adversely affect our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Similarly, our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations. Â Moreover, our CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, or as a result of labor disputes or unstable political environments. If any CMOs on which we will rely fail to manufacture quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve profitability, our business, financial condition and prospects could be materially and adversely affected. In addition, our CMOs are responsible for transportingÂ temperature-controlledÂ materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, our integrity and purity specifications. We and any of our CMOs may also face product seizure or detention or refusal to permit the import or export of products. Our business could be materially adversely affected by business disruptions to our third-partyÂ providers that could materially adversely affect our anticipated timelines, potential future revenue and financial condition and increase our costs and expenses. Each of these risks could delay or prevent the completion of our preclinical studies and clinical trials or the approval of any of our product candidates by the FDA, result in higher costs or adversely impact commercialization of our product candidates. Â Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business Â In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth. Â We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of preclinical and clinical drug development, technical operations, clinical operations, regulatory affairs and, potentially, sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial personnel and systems,

expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team working together in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. Â We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. Â We are a preclinical stage biotechnology company with a limited operating history. We have been and will continue to be highly dependent on the research and development, clinical and business development expertise of our executive officers, as well as the other principal members of our management, scientific and clinical team. Any of our management team members may terminate their employment with us at any time. We do not maintain â€œkey personâ€ insurance for any of our executives or other employees. Â 26 Â Â Attracting and retaining qualified personnel will also be critical to our success, including with respect to any strategic transaction that we may pursue. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, facilitate regulatory approval of and commercialize product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Â In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our discovery and nonclinical and clinical development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. Â Our future growth may depend, in part, on our ability to operate in foreign markets, where it would be subject to additional regulatory burdens and other risks and uncertainties. Â Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable foreign regulatory authority, and may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we fail to comply with the regulatory requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be adversely affected. Moreover, even if we obtain approval of our product candidates and ultimately commercializes our product candidates in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries. Â Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all. Â Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties. Â Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. Â 27 Â Â Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. Â We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for or on our behalf may engage in misconduct or other improper activities. We have adopted a code of conduct and ethics, but it is not always possible to identify and deter misconduct by these parties and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Â Our internal information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants, third-party service providers, or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations. Â In the ordinary course of our business, we and the third parties upon which we rely collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, sensitive information). Â Despite the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and the increasing amounts of information maintained on our internal information technology systems and those of our third-partyÂ CROs, other contractors (including sites performing our clinical trials), third-partyÂ service providers and supply chain companies, and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacksÂ by malicious third parties, which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our data. Â Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-stateÂ actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, and the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Â To the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of, or damage to, our data or applications, or for it to be believed or reported that any of these occurred, we could incur liability and reputational damage and the development and commercialization of our product candidates could be delayed. Further, our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure or security breach of, our systems or third-partyÂ systems where information important to our business operations or commercial development is stored. Â Our fully-remoteÂ workforce may create additional risks for our information technology systems and data because our employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations. Additionally, business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entitiesâ€™ systems and technologies. Â 28 Â Â While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. Â We rely on third-partyÂ service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts. Our ability to monitor these third partiesâ€™ information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-partyÂ service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-partyÂ service providers fail to satisfy their privacy or security-relatedÂ obligations to it, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chainÂ attacks have increased in frequency and severity, and we cannot guarantee that third partiesâ€™ infrastructure in our supply chain or our third-partyÂ partnersâ€™ supply chains have not been compromised. Â If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; management distraction; delays; and other similar harms. Security incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting our platform, deter new customers from products, and negatively impact our ability to grow and operate our business. Â Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. Â We are subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect our operating results and business. Â We and third parties who we work with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. We are or may become subject to the terms of contractual obligations related to privacy, data protection and data security. Our obligations may also change or expand as our business grows. The actual or perceived failure by us or third parties related to us to comply with such laws, regulations and obligations could increase our compliance and operational costs, expose us to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on our business, financial condition, and results of operations. Â If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. Â We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. Â 29 Â Â We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition. Â The rules dealing with U.S.Â federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S.Â Treasury Department. Changes to tax laws (which may have retroactive application) could adversely affect our stockholders or us. We continue to assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations or employees to determine the potential effect on our business and any assumptions we make about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. For example, the UnitedÂ States enacted the Inflation Reduction ActÂ ofÂ 2022, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts andÂ Jobs ActÂ eliminated the previously available option to deduct research and development expenditures and requires taxpayers to amortize them generally over fiveÂ years for research activities conducted in the UnitedÂ States and over 15Â years for research activities conducted outside the UnitedÂ States. The U.S.Â Congress is considering legislation that would restore the current deductibility of research and development expenditures; however, there is no assurance that the current provision will be repealed or otherwise modified. Such changes, among others, may adversely affect our effective tax rate, results of operation and general business condition. Â We may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions. Â We may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. There is no assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on our business and prospects. Â We maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments. Â Our cash held inÂ non-interest-bearingÂ and interest-bearingÂ accounts exceeds the Federal Deposit Insurance Corporation (â€œFDICâ€) insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank on MarchÂ 10, 2023. The Federal Reserve subsequently announced that account holders would be made whole. We currently hold a small portion of our cash and cash equivalents at Silicon Valley Bank. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holdersâ€™ access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in the future or inability for a material time period to access our cash and cash equivalents could have an adverse effect on our ability to pay our operational expenses or make other payments, which could adversely affect our business. Â General Risk Factors Â Our estimatesÂ of marketÂ opportunityÂ and forecastsÂ of marketÂ growth mayÂ proveÂ to be inaccurate,Â and even if the marketsÂ in which we competeÂ achieveÂ the forecastedÂ growth, our businessÂ mayÂ not grow at similarÂ rates, or at all. Â Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties. Â Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. Â 30 Â Â We may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial stage, and our product liability insurance may not cover all damages from such claims. Â We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products. While we currently have no products that have been approved for

commercial sale, the future use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims may be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such product. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the market for our products or any prospects for commercialization of our products. Although we intend to obtain product liability insurance for our future clinical trials, it is possible that any liabilities could exceed our insurance coverage or that in the future we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. Â Litigation costs and the outcome of litigation could have a material adverse effect on our business. Â From time to timeÂ weÂ mayÂ beÂ subjectÂ toÂ litigationÂ claims through the ordinary course of our business operations regarding, but not limited to, employment matters, security of patient and employee personal information, contractual relations with collaborators and intellectual property rights. Litigation to defend ourselves against claims by third parties, or to enforce any rights that we may have against third parties, may continue to be necessary, which could result in substantial costs and diversion of our resources, causing a material adverse effect on our business, financial condition, results of operations or cash flows. Â Our business could be adversely affected by economic downturns, inflation, fluctuation in interest rates, natural disasters, public health crises, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition. Â The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, fluctuation in interest rates, and uncertainty about economic stability. For example, theÂ COVID-19Â pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve previously raised interest rates multiple times in response to concerns about inflation and it may raise them again. Fluctuation in interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect us by increasing our costs, including materials, operational, labor and employee benefit costs. Â We may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on our results of operations and financial condition. Â 31 Â Â Risks Related to Owning Our Stock Â The market price of our common stock may continue to be volatile. Â The market price of our common stock may be subject to significant fluctuations. Some of the factors that may cause the market price of our common stock to fluctuate include: Â â—timing and results of clinical trials and preclinical studies of our product candidates, or those of our competitors or our existing or future collaborators; Â â— failure to meet or exceed financial and development projections that we may provide to the public; Â â— announcements of significant or potential equity or debt sales by us; Â â— failure to meet or exceed the financial and development projections of the investment community; Â â— failure to achieve the perceived benefits of our recent merger as rapidly or to the extent anticipated by financial or industry analysts; Â â— announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors; Â â— actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing terms; Â â— disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies; Â â— additions or departures of key personnel, including scientific or management personnel; Â â— significant lawsuits, including patent or stockholder litigation; Â â— if securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock; Â â— changes in the market valuations of similar companies; Â â— general market, macroeconomic or geopolitical conditions or market conditions in the pharmaceutical and biotechnology sectors; Â â— sales of securities by us or our securityholders in the future; Â â— if we fail to raise an adequate amount of capital to fund our operations or continued development of our product candidates; Â â— trading volume of our common stock; Â â— announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments; Â â— adverse publicity relating to precision medicine product candidates, including with respect to other products in such markets; Â â— the introduction of technological innovations or new therapies that compete with our products; and Â â— period-to-period fluctuations in our financial results. Â Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock. In the past, following periods of volatility in the market price of a companyâ€™s securities, stockholders have often instituted class action securities litigation against such companies. Â Furthermore, market volatility may lead to increased shareholder activism if we experience a market valuation that activists believe is not reflective of our intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results, financial condition and cash flows. Â 32 Â Â Our certificate of incorporation and bylaws, as well as provisions under Delaware law, could make an acquisition of the company more difficult and may prevent attempts by our stockholders to replace or remove management. Â Provisions in our certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the company that stockholders may consider favorable, including transactions in which our common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: Â Â â— establish a classified board of directors such that all members of the board are not elected at one time; Â Â â— allow the authorized number of our directors to be changed only by resolution of our board of directors; Â Â â— limit the manner in which stockholders can remove directors from the board; Â Â â— establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder meetings; Â Â â— require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; Â Â â— limit who may call a special meeting of stockholders; Â Â â— authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a â€œpoison pillâ€ that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and Â Â â— require the approval of the holders of at least 66 2/3% of the votes that all stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws. Â Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (â€œDGCLâ€), which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. Â Our governing documents provide that, unless we consent in writing to the selection of an alternative forum, certain designated courts will be the sole and exclusive forum for certain legal actions between us and our stockholders, which could limit our stockholdersâ€™ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. Â Our governing documents provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of or based on a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, the certificate of incorporation or the bylaws, (iv) any action to interpret, apply, enforce or determine the validity of the certificate of incorporation or bylaws, or (v) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, which for purposes of this risk factor refers to herein as the â€œDelaware Forum Provision.â€ Our governing documents further provide that, unless we consent in writing to an alternative forum, the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, which for purposes of this risk factor refers to herein as the â€œFederal Forum Provision.â€ Neither the Delaware Forum Provision nor the Federal Forum Provision will apply to any causes of action arising under the Exchange Act. In addition, any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder. Â The Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on our stockholders in pursuing any such claims, particularly if such stockholders do not reside in or near the State of Delaware. Additionally, these forum selection clauses may limit our stockholdersâ€™ ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. Â 33 Â Â Future sales of shares by existing stockholders could cause our stock price to decline. Â If our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after legal restrictions on resale lapse, the trading price of our common stock could decline. In addition, shares of our common stock that are subject to our outstanding options will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. Â We do not anticipate that we will pay any cash dividends in the foreseeable future Â We do not anticipate that we will pay any cash dividends in the foreseeable future. The current expectation is that we will retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future. Â Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval. Â Our executive officers, directors and principal stockholders beneficially own a significant percentage of our outstanding common stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent our acquisition on terms that other stockholders may desire. Â If equity research analysts do not publish research or reports, or publish unfavorable research or reports about us, our business or our market, our stock price and trading volume could decline. Â The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect to not provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. If we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline. Â 34 Â Â USE OF PROCEEDS Â We are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered hereby. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. Some of the shares of Common Stock offered hereby are issuable upon the exercise of the Pre-Funded Warrants. Upon exercise of such Pre-Funded Warrants for cash, we will receive the nominal cash exercise price paid by the holders of the Pre-Funded Warrants. We intend to use those proceeds, if any, for general corporate purposes. Â Subject to limited exceptions, the Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of any of the Resale Shares. We will bear the costs, fees and expenses incurred in effecting the registration of the Resale Shares covered by this prospectus, including all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accounting firm. Â Â 35 Â Â MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Â You should read the following discussion of our financial condition and results of operations in conjunction with the consolidated financial statements and the related notes thereto and other financial information included elsewhere in this prospectus. This discussion contains forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions. Our actual results could differ materially from those discussed in these forward-looking statements as a result of various factors. Factors that could cause or contribute to these differences include, but are not limited to, those discussed below and elsewhere in this prospectus, particularly in the section titled â€œRisk Factors.â€ Please also see the section titled â€œCautionary Statement Concerning Forward-Looking Statements.â€ As used in this prospectus, unless the context suggests otherwise, â€œweâ€, â€œusâ€, â€œourâ€, â€œthe Companyâ€, or â€œOrukaâ€ refers to Oruka Therapeutics, Inc. and its subsidiaries, including Oruka Therapeutics Operating Company, LLC. Â Overview Â We are a biotechnology company focused on developing novel monoclonal antibody therapeutics for psoriasis (â€œPsOâ€) and other inflammatory and immunology (â€œI&Iâ€) indications. Our name is derived from or, for â€œskin,â€ and arukah, for â€œrestorationâ€Â and reflects our mission to deliver therapies for chronic skin diseases that provide patients the greatest possible freedom from their condition. Our strategy is to apply antibody engineering and format innovations to validated modes of action, which we believe will enable us to improve meaningfully upon the efficacy and dosing regimens of standard-of-care medicines while significantly intending to reduce technical and biological risk. Our programs aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells. Our lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (â€œIL-23p19â€) for the treatment of PsO. Our co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (â€œIL-17A/Fâ€) for the treatment of PsO, psoriatic arthritis (â€œPsAâ€), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology with the aim to increase exposure and decrease dosing frequency. We believe that our focused strategy, differentiated portfolio, and deep expertise position us to set a new treatment standard in largeÂ I&I markets with continued unmet need. Â Since our inception in FebruaryÂ 2024, we have devoted substantially all of our resources to raising capital, organizing and staffing the company, business and scientific planning, conducting discovery and research activities, establishing arrangements with third parties for the manufacture of our programs and component materials, and providing general and administrative support for these operations. We do not have any programs approved for sale and have not generated any revenue from product sales. To date, we have funded our operations primarily with proceeds from the issuance of convertible preferred stock, common stock, convertible note, pre-funded warrants, and the proceeds from the reverse recapitalization and merger with ARCA biopharma, Inc., our Pre-Closing Financing and subsequent PIPE Financing (as defined and further described in â€œRecent developmentsâ€ below). Â Since our inception, we have incurred significant losses and negative cash flows from our operations. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any programs we may develop. We generated net losses of $28.6 million for the three months ended September 30, 2024 and $57.9 million for the period from FebruaryÂ 6, 2024 (inception) to SeptemberÂ 30, 2024. For the period from February 6 (inception) to September 30, 2024, we have used net cash of $39.0 million for our operating activities. Â We had cash and cash equivalents of $410.9 million as of September 30, 2024. We expect that our existing cash and cash equivalents will be sufficient to fund our operating plans for at least twelve months from the date of filing of this prospectus. We expect to continue to incur substantial losses for the foreseeable future, and our transition to profitability will depend upon successful development, approval and commercialization of our product candidates and upon achievement of sufficient revenues to support our cost structure. Â 36 Â Â ORKA-001 Â ORKA-001 is a high affinity, extended half-life monoclonal antibody (â€œmAbâ€) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the

proliferation and development of T helper 17 (â€œTh17â€) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO.Â IL-23 is composed of two subunits: a p40 subunit that is shared with IL-12 and a p19 subunit that is specific to IL-23. First-generation IL-23 antibodies bound p40 and inhibited both IL-12 and IL-23 signaling, while more recent IL-23 antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical evidence, we believe that ORKA-001 could achieve higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety profile of therapies targeting IL-23p19. Â ORKA-001 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain to modify the pH-dependent binding to the neonatal Fc receptor. As a result, it has a pharmacokinetic profile that has the potential to support a SQ injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL-23 blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.Â We believe that the expected characteristics of ORKA-001 increase its potential to deliver these disease-modifying benefits. Â We plan to initiate a Phase 1 trial of ORKA-001 in the first quarter of 2025. We expect to share interim data from the first-in-human trial in healthy volunteers, including initial pharmacokinetic data, in the second half of 2025 and initial efficacy data in PsO patients in the second half of 2026. Â ORKA-002 Â ORKA-002 is a high affinity, extended half-life mAb designed to target IL-17A and IL-17F (â€œIL-17A/Fâ€).Â IL-17 inhibition has become central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in otherÂ I&I indications, such as hidradenitis suppurativa and axial spondyloarthritis.Â More recently, the importance of inhibiting the IL-17F isoform along with IL-17A has become appreciated, and dual blockade with the recently approved therapy BimzelxÂ® (bimekizumab) has led to higher response rates in patients than blockade of IL-17A alone. ORKA-002 is designed to bind IL-17A/F at similar epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates half-life extension technology that could enable more convenient dosing intervals. We plan to initiate a PhaseÂ 1 trial of ORKA-002 in the third quarter of 2025. We expect to share interim data from the first-in-human trial in healthy volunteers, including initial pharmacokinetic data, in the first half of 2026. Â We view ORKA-002 and ORKA-001 as highly complementary. Patients with moderate-to-severe PsO that have purely skin manifestations are most often treated with IL-23 inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have joint involvement, or signs and symptoms of PsA, an IL-17 inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms. In addition, IL-17 inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve through treatment with an IL-23 inhibitor. Together, ORKA-001 and ORKA-002 provide the potential to offer a highly compelling product profile for most patients with PsO and/or PsA, as well as the opportunity to address additionalÂ I&I indications. Â Additional Pipeline Program Â We have a third mAb program, ORKA-003, designed to target an undisclosed pathway. Our strategy as a company is to remain highly focused onÂ I&I diseases, and specifically on inflammatory dermatology conditions. Our third program provides the potential for indication expansion beyond PsO and may create combination opportunities with our more advanced programs. Â Recent Developments Â The Merger Â On August 29, 2024, we consummated the previously announced business combination (â€œClosingâ€) pursuant to that certain Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the â€œMerger Agreementâ€), by and among ARCA, Atlas Merger Sub Corp, a wholly owned subsidiary of ARCA (â€œFirst Merger Subâ€), Atlas Merger Sub II, LLC, a wholly owned subsidiary of ARCA (â€œSecond Merger Subâ€) and Oruka Therapeutics, Inc. (â€œPre-Merger Orukaâ€), pursuant to which, among other matters, Pre-Merger Oruka merged with and into First Merger Sub, with Pre-Merger Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (â€œFirst Mergerâ€) and following that, Pre-Merger Oruka then merged with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the second merger (the â€œSecond Mergerâ€ and together with the First Merger, the â€œMergerâ€). Following consummation of the Merger, we effected a 1-for-12 reverse stock split (the â€œReverse Stock Splitâ€) of the common stock, par value $0.001 per share, of the Company (â€œCompany Common Stockâ€), which became effective on September 3, 2024. The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening of trading on September 3, 2024. Second Merger Sub changed its corporate name to â€œOruka Therapeutics Operating Company, LLCâ€ and ARCA changed its name to â€œOruka Therapeutics, Inc.â€ We are led by the pre-reverse capitalization Pre-Merger Oruka management team and remains focused on developing biologics to optimize the treatment of inflammatory skin diseases. Â 37 Â Â Pre-Closing Financing Â Immediately prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka entered into a subscription agreement with Pre-Merger Oruka (the â€œSubscription Agreementâ€), pursuant to which, and on the terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger Oruka (â€œPre-Merger Oruka Common Stockâ€) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0 million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note (refer to Note 6 in our condensed consolidated financial statements included in this prospectus for additional details) and accrued interest on such note which converted to shares of Pre-Merger Oruka Common Stock) (the â€œPre-Closing Financingâ€). We incurred transaction costs of $20.5 million which was recorded as a reduction to additional paid-in capital in the unaudited condensed consolidated financial statements. At the Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded warrants issued pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre-funded warrants of Company Common Stock in accordance with the Exchange Ratio (defined below). Â In accordance with an Exchange Ratio determined by terms of the Merger Agreement and upon the effective time of the First Merger (the â€œFirst Effective Timeâ€), (i) each then-issued and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested Pre-Merger Oruka restricted stock and shares of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were converted into the right to receive a number of shares of Company Common Stock, equal to the exchange ratio of 6.8569 shares of Company Common Stock (the â€œExchange Ratioâ€), which were subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger Oruka Series A convertible preferred stock, par value $0.0001 (â€œPre-Merger Oruka Series A Preferred Stockâ€), outstanding immediately prior to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non-voting convertible preferred stock, par value $0.001 per share, which are convertible into shares of Company Common Stock at a conversion ratio of approximately 83.3332:1, (iii) each outstanding option to purchase Pre-Merger Oruka Common Stock was converted into an option to purchase shares of Company Common Stock, (iv) each outstanding warrant to purchase shares of Pre-Merger Oruka Common Stock was converted into a warrant to purchase shares of Company Common Stock, and (v) each share of Company Common Stock issued and outstanding at the First Effective Time remain issued and outstanding in accordance with its terms and such shares Subsequent to the close of the merger, the common stock shares were then, subject to the reverse stock split of 1-for-12 effected on September 3, 2024. Â As part of the Pre-Closing Financing and the Closing, the investors in the Pre-Closing Financing received 22,784,139 shares of Company Common Stock in exchange for 39,873,706 shares of Pre-Merger Oruka Common Stock (which includes the issuance of 2,722,207 shares of Company Common Stock in exchange for 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued interest through the conversion date) and 5,522,207 Company pre-funded warrants in exchange for 9,664,208 Pre-Merger pre-funded warrants. Â The Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately following the Merger: (i) Pre-Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii) Pre-Merger Orukaâ€™s largest stockholders retain the largest interest in the combined company; (iii) Pre-Merger Oruka designated a majority of the initial members of the board of directors of the combined company; and (iv) Pre-Merger Orukaâ€™s executive management team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent of Pre-Merger Oruka issuing stock to acquire the net assets of ARCA; and (ii) the reported historical operating results of the combined company prior to the Merger are those of Pre-Merger Oruka. Additional information regarding the Merger is included in Note 3 to the condensed consolidated financial statements included in this prospectus. Â 38 Â Â Reverse Stock Split Â On September 3, 2024, we effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share data, and related information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires. Â PIPE Financing Â On September 11, 2024, we entered into a Securities Purchase Agreement for a private placement (the â€œPIPE Financingâ€) with certain institutional and accredited investors. The closing of the PIPE Financing occurred on September 13, 2024. Â Pursuant to the Securities Purchase Agreement, the investors purchased an aggregate of 5,600,000 shares of Company Common Stock at a purchase price of $23.00 per share, an aggregate of 2,439 shares of the Companyâ€™s Series A non-voting convertible preferred stock, par value $0.001 per share (â€œCompany Series A Preferred Stockâ€), at a purchase price of $23,000.00 per share (each Company Series A Preferred Stock is convertible into 1,000 shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of 680,000 shares of Company Common Stock at a purchase price of $22.999 per pre-funded warrant, for aggregate net proceeds of approximately $188.7 million (net of issuance costs of $11.8 million). Â Components of Results of Operations Â Revenue Â To date, we have not generated revenue from any sources, including product sales, and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales or payments from future collaboration or license agreements that we may enter into with third parties, or any combination thereof. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates. Â Operating Expenses Â Research and Development Â Research and development expenses consist primarily of costs incurred in connection with the development and research of our programs. These expenses include costs of funding research performed by third parties, including Paragon Therapeutics, Inc. (â€œParagonâ€), that conduct research and development activities on our behalf, expenses incurred in connection with continuing our current research programs and discovery-phase development of any programs we may identify, including under future agreements with third parties, such as consultants and contractors, personnel-related expenses, including salaries, bonuses, employee benefits, stock-based compensation expense, and allocated human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation for our leased office space. Â We expense research and development costs as incurred. Our primary focus since inception has been the identification and development of our pipeline programs. Our research and development expenses primarily consist of external costs, such as fees paid to Paragon under the Option Agreements. We separately track the amount of costs incurred under the Option Agreements with Paragon between ORKA-001 and ORKA-002. See â€œâ€Å Contractual Obligations and Commitmentsâ€ below for further details on the Option Agreements. Â We expect our research and development expenses to increase substantially for the foreseeable future as we advance our product candidates into and through preclinical studies and clinical trials, pursue regulatory approval of our product candidates and expand our pipeline of product candidates.Â Â 39 Â Â General and Administrative Â General and administrative expenses consist primarily of personnel-related expenses, including salaries, bonuses, employee benefits, and stock-based compensation, for our executive and other administrative personnel. Other significant general and administrative expenses include legal services, including intellectual property and corporate matters; professional fees for accounting, auditing, tax, insurance, and allocated human resource costs, information technology costs, and facility-related costs, including rent, utilities, maintenance, and depreciation for our leased office space. Â We expect our general and administrative expenses will increase substantially for the foreseeable future as we anticipate an increase in our personnel headcount to support the expansion of research and development activities, as well as to support our operations generally. We also expect to continue to incur significant expenses associated with being a public company, including costs related to accounting, audit, legal, regulatory, and tax-relatedÂ services associated with maintaining compliance with applicable Nasdaq and SEC requirements; additional director and officer insurance costs; and investor and public relations costs. We also expect to incur additional intellectual property-related expenses as we file patent applications to protect innovations arising from our research and development activities. Â Other Income (Expense), Net Â Other income (expense), net includes interest expense on the convertible note from a related party, interest income, and foreign currency transactions gains and losses. Interest expense relates to a convertible note (the â€œConvertible Noteâ€) issued to Fairmount Healthcare FundÂ II, L.P. (â€œFairmountâ€) in MarchÂ 2024. Â Income Taxes Â No provision for income taxes was recorded for the three months ended September 30, 2024 and for the period from FebruaryÂ 6, 2024 (inception) through SeptemberÂ 30, 2024. Deferred tax assets generated from our net operating losses have been fully reserved as we believe it is not more likely than not that the benefit will be realized due to its cumulative losses generated to date. Â Results of Operations for the Three Months Ended September 30, 2024 Â The following table summarizes our results of operations and comprehensive loss for the period presented (in thousands): Â Â Â ThreeÂ Months EndedÂ SeptemberÂ 30, 2024Â Operating expensesÂ Â Â Â Research and development(1)Â $25,691Â General and administrative(2)Â Â 3,758Â Total operating expensesÂ Â 29,449Â Loss from operationsÂ Â (29,449) Other income (expense)Â Â Â Â Interest incomeÂ Â 1,330Â Interest expense(3)Â Â (504) Total other income, netÂ Â 826Â Net loss and comprehensive lossÂ $(28,623) Â (1) Includes related party amount of $13,537 for the three months ended September 30, 2024 Â (2) Includes related party amount of $71 for the three months ended September 30, 2024 Â (3) Includes related party amount of $504 for the three months ended September 30, 2024 Â 40 Â Â Research and Development Expenses Â The following table summarizes our research and development expenses for the period presented (in thousands): Â Â Â Three Months EndedÂ SeptemberÂ 30, 2024Â External research and development costs by selected target:Â Â Â ORKA-001(1)Â $11,761Â ORKA-002(2)Â Â 4,147Â Other research and development costs:Â Â Â Â Personnel-related (including stock-based compensation)(3)Â Â 9,076Â Other(4)Â Â 707Â Total research and development expensesÂ $25,691Â Â (1) Includes related party amount of $2,316 for the three months ended September 30, 2024 Â (2) Includes related party amount of $3,824 for the three months ended September 30, 2024 Â (3) Includes related party amount of $7,251 for the three months ended September 30, 2024 Â Â (4) Includes related party amount of $146 for the three months ended September 30, 2024 Â Research and development expenses were $25.7Â million for the three months ended September 30, 2024 and consisted primarily of the following: Â Â â— $2.3Â million of research and development expense due to Paragon for services rendered under the Option Agreements for ORKA-001, including $1.5 million of milestone payment due to Paragon upon exercise of option to enter into a license agreement and achievement of development candidate for IL-23; Â Â â— $9.4 million of research and development expenses on chemistry, manufacturing, and development costs for ORKA-001, including $3.2 million of toxicology testing for ORKA-001 with a third-party contract research organization; Â Â â— $3.8Â million of research and development expense due to Paragon for services rendered under the Option Agreements for ORKA-002; Â Â â— $9.1 million of personnel-related costs related to salaries, benefits and other compensation-related costs, and stock-based compensation expense of $7.8 million, including $7.3 million for stock-based compensation related to Paruka Holding LLC (â€œParukaâ€) warrants; and Â Â â— $0.7 million of other research expenses and allocated human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation for our leased office space. Â General and Administrative Expenses Â The following table summarizes our general and administrative expenses for the period presented (in thousands): Â Â Â Three Months EndedÂ SeptemberÂ 30, 2024Â Personnel-related (including stock-based compensation)Â $2,435Â Professional and consulting feesÂ Â 701Â Legal fees related to patent(1)Â Â 116Â OtherÂ Â 506Â Total general and administrative expensesÂ $3,758Â Â (1) Includes related party amount of $71 for the three months ended September 30, 2024 Â 41 Â Â General and administrative expenses were $3.8Â million for the three months ended September 30, 2024 and consisted primarily of the following: Â Â â— $2.4Â million of personnel-related costs related to salaries, benefits and other compensation-related costs, including stock-based compensation of $1.2Â million; Â Â â— $0.7Â million of professional and consulting fees associated with accounting, audit, and legal fees to support our business activity and operations of a public company; Â â—$0.1Â million of legal fees due to Paragon associated with patent related activities; and Â â—$0.5 million of other business expense and allocated human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation for our leased office space. Â Total Other Income (Expense), Net Â Interest income from money market funds was $1.3 million for the three months ended September 30, 2024. Â Interest expense was $0.5 million for the three months ended September 30, 2024 relating to the Convertible Note from Fairmount. Â Results of Operations for the Period of February 6, 2024 (Inception) to September 30, 2024 Â The following table summarizes our results of operations and comprehensive loss for the period presented (in thousands): Â Â Â PeriodÂ from FebruaryÂ 6, 2024 (Inception)Â to SeptemberÂ 30, 2024Â Operating expensesÂ Â Â Â Research and development(1)Â $49,557Â General and administrative(2)Â Â 8,248Â Total operating expensesÂ Â 57,805Â Loss from operationsÂ Â (57,805) Other income

(expense)Â Â Â Â Â Interest incomeÂ Â 1,330Â Â Interest expense(3)Â Â (1,468) Total other expense, netÂ Â (138) Net loss and comprehensive lossÂ $(57,943) Â (1) Includes related party amount of $33,967 for the period from FebruaryÂ 6, 2024 (inception) to SeptemberÂ 30, 2024 Â (2) Includes related party amount of $1,339 for the period from FebruaryÂ 6, 2024 (inception) to SeptemberÂ 30, 2024 Â (3) Includes related party amount of $1,468 for the period from FebruaryÂ 6, 2024 (inception) to SeptemberÂ 30, 2024 Â Research and Development Expenses Â The following table summarizes our research and development expenses for the period presented (in thousands): Â Â Â PeriodÂ from FebruaryÂ 6, 2024 (Inception)Â to SeptemberÂ 30, 2024Â External research and development costs by selected target:Â Â Â ORKA-001(1)Â $26,939Â ORKA-002(2)Â Â 10,987Â Other research and development costs:Â Â Â Â Personnel-related (including stock-based compensation)(3)Â Â 10,684Â Other(4)Â Â 947Â Total research and development expensesÂ $49,557Â Â (1) Includes related party amount of $15,478 for the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024 Â 42 Â Â (2) Includes related party amount of $10,662 for the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024 Â (3) Includes related party amount of $7,681 for the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024 Â Â (4) Includes related party amount of $146 for the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024 Â Research and development expenses were $49.6Â million for the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024 and consisted primarily of the following: Â Â â— $15.5Â million of research and development expense due to Paragon for services rendered under the Option Agreements for ORKA-001, including $1.5 million of milestone payment due to Paragon upon exercise of option to enter into a license agreement and achievement of development candidate for IL-23, and $5.9 million of research and development expense due to Paragon incurred through March 31, 2024 upon completion of IL-23 selection process; Â Â â— $11.4 million of research and development expense on chemistry, manufacturing, and development costs for ORKA-001, including $3.4 million in toxicology testing for ORKA-001 with a third-party contract research organization; Â Â â— $11.0Â million of research and development expense primarily due to Paragon for services rendered under the Option Agreements for ORKA-002; Â Â â— $10.7Â million of personnel-related costs related to salaries, benefits, and other compensation-related costs, and stock-based compensation expense of $8.3Â million, including $7.7 million for stock-based compensation related to Paruka warrants; and Â Â â— $0.9 million of other research expense and allocated human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation for our leased office space. Â General and Administrative Expenses Â The following table summarizes our general and administrative expenses for the period presented (in thousands): Â Â Â PeriodÂ from FebruaryÂ 6, 2024 (Inception)Â to September 30, 2024Â Personnel-related (including stock-based compensation)(1)Â $4,590Â Professional and consulting feesÂ Â 2,330Â Legal fees related to patent(2)Â Â 606Â Other(3)Â Â 722Â Total general and administrative expensesÂ $8,248Â Â (1) Includes related party amount of $609 for the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024 Â (2) Includes related party amount of $550 for the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024 Â (3) Includes related party amount of $180 for the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024 Â 43 Â Â General and administrative expenses were $8.2Â million for the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024 and consisted primarily of the following: Â Â â— $4.6Â million of personnel-related costs related to recruiting costs, salaries, benefits and other compensation-related costs, including stock-based compensation of $1.5Â million and $0.6 million of personnel-related costs are amounts due to Paragon related to recruiting costs for hiring our executive team, legal, and finance and accounting functions; Â Â Â â— $2.3Â million of professional and consulting fees associated with accounting, audit, and legal fees associated with becoming a public company; Â Â â— $0.6Â million of legal fees due to Paragon associated with patent related activities; and Â Â â— $0.7 million of other business expenses and allocated human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation for our leased office space, including $0.2Â million of other business expenses due to Paragon. Â Total Other Income (Expense), Net Â Interest income from money market funds was $1.3 million for the period from February 6, 2024 (inception) to September 30, 2024. Â Interest expense was $1.5 million for the period from February 6, 2024 (inception) to September 30, 2024 relating to the Convertible Note from Fairmount. Â Liquidity and Capital Resources Â As of September 30, 2024, we had $410.9 million of cash and cash equivalents. Â Since our inception, we have incurred significant operating losses and negative cash flow from operations. We expect to incur significant expenses and operating losses for the foreseeable future as we continue the pre-clinical and clinical development of our programs and continue our early-stage research activities. We have not yet commercialized any products and we do not expect to generate revenue from sales of products for severalÂ years, if at all. As of September 30, 2024, we had funded our operations primarily with proceeds from issuances of convertible preferred stock, common stock, convertible note, and pre-funded warrants. In MarchÂ 2024, we received $3.0Â million in gross proceeds from the issuance of Pre-Merger Oruka SeriesÂ A Preferred Stock and $25.0Â million in gross proceeds from the issuance of the Convertible Note, both of which were related party transactions. In August 2024, we raised approximately $228.0 million in net proceeds from Pre-Closing Financing and received $4.9 million in cash from ARCA upon consummation of the Merger. In September 2024, we received approximately $188.7 million in net proceeds from the issuance of common stock, Company Series A Preferred Stock, and pre-funded warrants in connection with the PIPE Financing. Â Our primary use of cash is to fund the development of our product candidates, and advance our pipeline. This includes both the research and development costs and the general and administrative expenses required to support those operations. Since we are a clinical stage biotechnology company, we have incurred significant operating losses since our inception and we anticipate such losses, in absolute dollar terms, to increase as we continue to pursue clinical development of our product candidates, prepare for the potential commercialization of our product candidates, and expand our development efforts in our pipeline of nonclinical candidates. We expect that our existing cash and cash equivalents will be sufficient to fund our operating plans for at least twelve months from the date of filing of this prospectus. We will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can be produced, marketed and sold. If we are unable to obtain additional financing or generate license or product revenue, the lack of liquidity could have a material adverse effect on our company. Â 44 Â Â Cash Flows Â The following table summarizes our cash flows for the period presented (in thousands): Â Â Â PeriodÂ from FebruaryÂ 6, 2024 (Inception)Â to SeptemberÂ 30, 2024Â Net cash used in operating activitiesÂ $(39,019) Net cash used in investing activitiesÂ Â (171) Net cash provided by financing activitiesÂ Â 450,065Â Â Net increase in cash and cash equivalentsÂ $410,875Â Â Operating Activities Â From FebruaryÂ 6, 2024 (inception) to SeptemberÂ 30, 2024, net cash used in operating activities was $39.0 million, which was primarily attributable to a net loss of $57.9 million, offset by non-cash charges of $11.3 million and net cash provided by changes in operating activities of $7.6 million. Non-cash charges primarily consisted of a $9.8 million increase in stock-based compensation expense (primarily from Paruka Warrant Obligation) and $1.5 million of non-cash interest expense. Net cash provided by changes in our operating activities primarily consisted of a $1.6 million increase in accounts payable, $1.7 million increase in accrued expenses and other current liabilities, $6.4 million increase in related parties accounts payable and other current liabilities, partially offset by a $2.0 million increase in prepaid expenses and other current assets. The increase in amounts due to related parties, accounts payable, and accrued expenses and other current liabilities was primarily due to an increase in our business activity, as well as vendor invoicing and payments. The increase in prepaid expenses and other current assets was primarily due to prepaid research and development expenses with our contract research organization. Â Investing Activities Â From FebruaryÂ 6, 2024 (inception) to SeptemberÂ 30, 2024, net cash used in investing activities was $0.2 million, which was attributable to purchases of property and equipment. Â Financing Activities Â From FebruaryÂ 6, 2024 (inception) to SeptemberÂ 30, 2024, net cash provided by financing activities was $450.1 million, consisting of $2.9Â million of net proceeds from the issuance of SeriesÂ B PreferredÂ Stock, $25.0Â million of net proceeds from the issuance of the Convertible Note, $228.1 million of net proceeds from the Pre-Closing Financing, $189.1 million of net proceeds from the PIPE Financing, and $4.9 million of cash acquired in connection with the reverse recapitalization. Â Contractual Obligations and Commitments Â We enter into contracts in the normal course of business with contract research organizations (â€œCROsâ€)Â for clinical trials, with contract manufacturing organizations (â€œCMOsâ€) forÂ clinical supplies manufacturing and with other vendors for preclinical studies, supplies and other services and products for operating purposes. These contracts generally provide for termination onÂ notice or may have a potential termination fee if a purchase order is cancelled within a specified time, and therefore are cancelable contracts. We do not expect any such contract terminations and did not have any non-cancellable obligations under these agreements as of September 30, 2024. Â Option Agreements Â In MarchÂ 2024, we entered into antibody discovery and option agreements with Paragon and Paruka (the â€œOption Agreementsâ€). Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to us. The Option Agreements include two selected targets, IL-23 (â€œORKA-001â€) and IL-17 A/F (â€œORKA-002â€). Under the Option Agreements, we have the exclusive options to, on a research program-by-research program basis, be granted an exclusive, worldwide license to all of Paragonâ€™s right, title and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture and commercialize the antibodies and products directed to the selected targets (each, an â€œOptionâ€), with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease. If we exercise our options, we will be required to make non-refundable milestone payments to Paragon of up to $12.0Â million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0Â million under each respective agreement upon the achievement of certain regulatory milestones as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale. From time to time, we can choose to add additional targets to the collaboration by mutual agreement with Paragon. During the three months ended September 30, 2024, we exercised our option for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement of development candidate as research and development expense in our condensed consolidated statements of operations and comprehensive loss for the three months ended September 30, 2024. As of September 30, 2024, this amount is included under related party accounts payable and other current liabilities on the condensed consolidated balance sheet. Â 45 Â Â Our exclusive Option with respect to each research program for a particular target initiated by the parties (â€œResearch Programâ€) is exercisable at our sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number ofÂ days following (i) with respect to any Research Program other than ORKA-001, the delivery of the data package from Paragon related to the results of the Research Plan activities, or (ii) with respect to ORKA-001, the completion of the IL-23 antibody selection process described in the agreement (the â€œOption Periodâ€). There is no payment due upon exercise of an Option pursuant to the Option Agreements. Â Unless terminated earlier, the Option Agreements shall continue in force on a Research Program-by-Research Program basis until the earlier of: (i)Â the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by us; (ii)Â the expiration of the 30-day period after we exercise our Option with respect to such Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration of the applicable research term (the â€œTermâ€). Upon the expiration of the Term for all then-existing Research Programs, under the Option Agreements, the Option Agreements will automatically expire in its entirety. We may terminate the Option Agreements or any Research Program at any time for any or no reason upon 30Â daysâ€™ prior written notice to Paragon, provided that we must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Option Agreements or a Research Program immediately upon written notice to us if, as a result of any action or failure to act by us or our affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of months. Each party has the right to terminate the Option Agreements or any Research Program upon (i)Â 30Â daysâ€™ prior written notice of the other partyâ€™s material breach that remains uncured for the 30-day period and (ii)Â the other partyâ€™s bankruptcy. Â Pursuant to the Option Agreements, on a research program-by-research program basis following the finalization of the research plan for each respective research program, we were required to pay Paragon a one-time, nonrefundable research initiation fee of $0.8Â million related to the ORKA-001 program. This amount was recognized as a research and development expense during the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024. In June 2024, pursuant to the Option Agreements with Paragon, we completed the selection process of our development candidate for IL-23 antibody for ORKA-001 program. We were responsible for 50% of the development costs incurred through the completion of the IL-23 selection process. We received the rights to at least one selected IL-23 antibody in June 2024. During the three months ended September 30, 2024, we exercised our option for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement of development candidate as research and development expense in our condensed consolidated statements of operations and comprehensive loss for each of the three months ended September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024. Our share of development costs incurred during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024 was $0.8 million and $13.2 million, respectively, which were recorded as research and development expenses during the respective periods. An amount of $2.3 million is included in related party accounts payable and other current liabilities as of September 30, 2024. Â We were also required to reimburse Paragon $3.3Â million for development costs related to ORKA-002 incurred by Paragon through DecemberÂ 31, 2023 and certain other development costs incurred by Paragon between JanuaryÂ 1, 2024 and MarchÂ 6, 2024 as stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024. We are also responsible for the development costs incurred by Paragon from JanuaryÂ 1, 2024 through the completion of the IL-17 selection process. We recognized an amount of $0.8Â million payable to Paragon for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as research and development expenses in the period from February 6, 2024 (inception) to September 30, 2024. We accounted for development costs of $3.8 million and $6.6 million during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively, as research and development expenses during the respective periods. An amount of $3.8 million is included in related party accounts payable and other current liabilities as of September 30, 2024. Â As part of the Option Agreements, on each of December 31, 2024 and December 31, 2025, we will grant warrants to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully diluted basis with an exercise price equal to the fair market value of the underlying shares on the grant date. The warrants are liability-classified and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss as stock-based compensation expenses under research and development expenses. Â 46 Â Â We expense the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying condensed consolidated statement of operations and comprehensive loss. Â We concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of on-going development cost, monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are recognized as research and development expense when incurred. Â For the three months ended September 30, 2024 and the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024, we recognized $13.4 million and $33.8 million of expenses, respectively, in connection with services provided by Paragon and Paruka under the Option Agreements. Â NoteÂ Payable with Related Party Â In MarchÂ 2024, we entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the â€œPurchase Agreementâ€) with Fairmount, whereby we issued the Convertible Note, with an initial principal amount of $25.0 million that, at the time of issuance, could be converted into Pre-Merger Oruka SeriesÂ A Preferred Stock (or a seriesÂ of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate proceeds of $25.0Â million. The Convertible Note accrued interest at a rate of 12.0% per annum. At issuance, the Convertible Note required all unpaid interest and principal to mature on DecemberÂ 31, 2025 (the â€œMaturity Dateâ€) and prepayment was not permitted without prior written consent of Fairmount. At issuance, the principal payment along with the accrued interest on the Convertible Note was due in full on the Maturity Date. Pursuant to the Purchase Agreement, we had the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0 million, in addition to the $25.0 million initial principal amount of the Convertible Note. Â Immediately prior to the completion of the Merger, the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based on the aggregate principal amount of $25.0 million, plus unpaid accrued interest of $1.5 million divided by the conversion price, which was determined based upon the Companyâ€™s fully-diluted capitalization immediately prior to the Merger. At the effective time of the Merger, the Pre-Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest)

automatically converted into shares of Company Common Stock. 2,722,207 shares of Company Common Stock were issued on conversion of the Convertible Note and accrued interest. As of September 30, 2024, there is no note payable to a related party. Â Critical Accounting Policies and Significant Judgments and Estimates Â Our managementâ€™s discussion and analysis of its financial condition and results of operations is based on its financial statements, which have been prepared in accordance with U.S. GAAP.Â The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues recognized and expenses incurred during the reporting periods. Our estimates are based on its historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Â While our significant accounting policies are described in more detail in NoteÂ 2 to our consolidated financial statements appearing elsewhere in this prospectus, we believe the following accounting policies used in the preparation of our financial statements require the most significant judgments and estimates. Â 47 Â Â Accrued Research and Development Expenses Â As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the services when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time. At each period end, we corroborate the accuracy of these estimates with the service providers and make adjustments, if necessary. Estimated accrued research and development expenses include those related to fees paid to vendors in connection with discovery development activities and any research organizations in connection with studies and testing. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. Â Stock-Based Compensation Â We measure stock options granted to employees and non-employees based on the estimated fair values of the awards as of the grant date using the Black-Scholes option-pricing model. The model requires management to make a number of assumptions, including common stock fair value, expected volatility, expected term, risk-free interest rate and expected dividend yield. For restricted stock awards and restricted stock units, the estimated fair value is the fair market value of the underlying stock on the grant date. We expense the fair value of our equity-based compensation awards on a straight-line basis over the requisite service period, which is the period in which the related services are received. We account for award forfeitures as they occur. The expense for stock-based awards with performance conditions is recognized when it is probable that a performance condition is met during the vesting period. Â Determination of Fair Value of Common StockÂ Â A public trading market for Company Common Stock has been established in connection with the completion of this Merger. As such, it is no longer necessary for our board of directors to estimate the fair value of our stock-based awards in connection with its accounting for granted stock-based awards or other such awards we may grant, as the fair value of Company Common Stock and share-based awards is determined based on the quoted market price of Company Common Stock. Â Prior to the merger, Pre-Merger Orukaâ€™s common stock valuations were prepared using a hybrid method, including an option pricing method (â€œOPMâ€). The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a companyâ€™s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighted expected return method (â€œPWERMâ€), where the equity value in one or more of the scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for the Company, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock. Â The assumptions underlying these valuations represented managementâ€™s best estimate, which involved inherent uncertainties and the application of managementâ€™s judgment. As a result, if Pre-Merger Oruka had used significantly different assumptions or estimates, the fair value of Pre-Merger Orukaâ€™s incentive shares and its stock-based compensation expense could have been materially different. Â Recently Issued Accounting Pronouncements Â See Note 2 to the condensed consolidated financial statements included in this prospectus for more information regarding recently issued accounting pronouncements. Â Â Off-Balance Sheet Arrangements Â As of September 30, 2024, we did not have any off-balance sheet arrangements, as defined in the rules and regulations of the SEC. Â 48 Â Â CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE Â (a)Dismissal of Independent Registered Public Accounting Firm Â KPMG LLP (â€œKPMGâ€) served as the independent registered public accounting firm of ARCA prior to the consummation of the Merger. On August 30, 2024, KPMG was dismissed as the independent registered public accounting firm of the Company. The decision to dismiss KPMG was approved by the Audit Committee (the â€œAudit Committeeâ€) of the Board of Directors of the Company (the â€œBoardâ€). Â The reports of KPMG on the consolidated financial statements of the Company for the fiscal years ended DecemberÂ 31, 2023 and 2022 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. Â During the Companyâ€™s two most recent fiscal years and the subsequent period from JanuaryÂ 1, 2024 to August 30, 2024, there were (i)Â no disagreements (as defined in Item 304(a)(1)(iv) of RegulationÂ S-KÂ and the related instructions thereto) with KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved to the satisfaction of KPMG, would have caused it to make reference to the subject matter of the disagreement in connection with its report and (ii)Â no reportable events (as described in Item 304(a)(1)(v) of RegulationÂ S-K). Â The Company provided KPMG with a copy of the disclosures made in this section and requested KPMG to furnish the Company with a letter addressed to the SEC stating whether it agrees with the statements made by the Company and, if not, stating the respects in which it does not agree. A copy of KPMGâ€™s letter to the SEC dated September 5, 2024 regarding these statements was filed as Exhibit 16.1 to the Companyâ€™s Current Report on Form 8-K filed on September 5, 2024. Â (b)Appointment of New Independent Registered Public Accounting Firm Â PricewaterhouseCoopers LLP (â€œPwCâ€) served as the independent registered public accounting firm of Oruka prior to the consummation of the Merger. On August 30, 2024, following the consummation of the Merger, the Audit Committee engaged PwC as the independent registered public accounting firm of the Company. Â During ARCAâ€™s two most recent fiscal years and the subsequent period from January 1, 2024 to August 30, 2024, neither ARCA nor anyone on its behalf consulted PwC regarding: (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on ARCAâ€™s financial statements, and neither a written report nor oral advice was provided to the ARCA that PwC concluded was an important factor considered by ARCA in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K). Â Â Â QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Â We are a smaller reporting company, as defined by Rule 12b-2 under the Exchange Act and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item. Â 49 Â Â BUSINESS Â Company Overview Â We are a biotechnology company focused on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Our name is derived from or, for â€œskin,â€ and arukah, for â€œrestorationâ€ and reflects the companyâ€™s mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Our strategy is to apply antibody engineering and format innovations to validated modes of action, which we believe will enable us to improve meaningfully upon the efficacy and dosing regimens of standard-of-care medicines while significantly reducing technical and biological risk. Our programs aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (â€œTRMsâ€). Our lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (â€œIL-23p19â€) for the treatment of PsO. Our co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (â€œIL-17A/Fâ€) for the treatment of PsO, PsA, and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology with the aim to increase exposure and decrease dosing frequency. We believe that our focused strategy, differentiated portfolio, and deep expertise position us to set a new treatment standard in large I&I markets with continued unmet need. Â Our Pipeline Â Â Â ORKA-001 Â ORKA-001 is a high affinity, extended half-life monoclonal antibody (â€œmAbâ€) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (â€œTh17â€) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit that is shared with IL-12 and a p19 subunit that is specific to IL-23. First-generation IL-23 antibodies bound p40 and inhibited both IL-12 and IL-23 signaling, while more recent IL-23 antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical evidence, we believe that ORKA-001 could achieve higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety profile of therapies targeting IL-23p19. ORKA-001 is engineered with YTE half-life extension technology, a specific three amino acid change in the fragment crystallizable (â€œFcâ€) domain to modify the pH-dependent binding to the neonatal Fc receptor (â€œFcRnâ€). As a result, it has a pharmacokinetic profile designed to support a subcutaneous (â€œSQâ€) injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL-23 blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.Â We believe that the expected characteristics of ORKA-001 increase its potential to deliver these disease-modifying benefits. Â We plan to initiate a Phase 1 trial of ORKA-001 in the first quarter of 2025. We expect to share interim data from the first-in-human trial in healthy volunteers, including initial pharmacokinetic data, in the second half of 2025 and initial efficacy on psoriasis patients in the second half of 2026. Based on recent precedent for PsO, we anticipate that the entire development program from first-in-human to biologics license application (â€œBLAâ€) filing could take as little as six to sevenÂ years based on the averages for recently approved medicines. However, we have no control over the length of time needed for FDA review, and this timeline could vary. Â 50 Â Â ORKA-002 Â ORKA-002 is a high affinity, extended half-life mAb designed to target IL-17A and IL-17F (â€œIL-17A/Fâ€). IL-17 inhibition has become central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in otherÂ I&I indications, such as hidradenitis suppurativa (â€œHSâ€) and axial spondyloarthritis (â€œaxSpAâ€). More recently, the importance of inhibiting the IL-17F isoform along with IL-17A has become appreciated, and dual blockade with the recently approved therapy Bimzelx (bimekizumab) has led to higher response rates in patients than blockade of IL-17A alone. ORKA-002 is designed to bind IL-17A/F at similar epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates half-life extension technology that could enable more convenient dosing intervals. We plan to initiate a PhaseÂ 1 trial of ORKA-002 in the third quarter of 2025. We expect to share interim data from the first-in-human trial in healthy volunteers, including initial pharmacokinetic data, in the first half of 2026. Â We view ORKA-002 and ORKA-001 as highly complementary. Patients with moderate-to-severe PsO that have purely skin manifestations are most often treated with IL-23 inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have joint involvement, or signs and symptoms of PsA, an IL-17 inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms. In addition, IL-17 inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve through treatment with an IL-23 inhibitor. Together, ORKA-001 and ORKA-002 provide the potential to offer a highly compelling product profile for most patients with PsO and/or PsA, as well as the opportunity to address additional I&I indications. Â Additional Pipeline Programs Â We have a third mAb program, ORKA-003, designed to target an undisclosed pathway. Our strategy as a company is to remain highly focused onÂ I&I diseases, and specifically on inflammatory dermatology conditions. Our third program provides the potential for indication expansion beyond PsO and may create combination opportunities with our more advanced programs. Â Our Team, Investors, and Paragon Collaboration Â Pre-Merger Oruka was founded in FebruaryÂ 2024 by leading healthcare investor Fairmount Funds Management LLC (â€œFairmountâ€). Fairmount Funds Management has launched other successful biotechnology companies leveraging antibody technologies generated by Paragon, including Apogee Therapeutics and Spyre Therapeutics. We are led by a management team with significant experience in developing novel treatments for patients at biopharmaceutical companies such as CRISPR Therapeutics, Celgene, Novartis, CymaBay Therapeutics and Protagonist Therapeutics. Together, our team has a proven track record of building successful biotech organizations in high-growth environments. Â We hold options to acquire intellectual property rights with respect to certain research programs, including ORKA-001 and ORKA-002, from Paragon. Following the exercise of the Options (defined below) under the Paragon Option Agreements and execution of the respective license agreements, we will have exclusive worldwide development and commercialization rights to our programs, with IL-23 rights for all indications outside of inflammatory bowel disease (â€œIBDâ€), pursuant to such agreements, as applicable. Fairmount Funds Management founded Paragon in 2021 as the firmâ€™s discovery engine for biologics that potentially overcome limitations of existing therapies. Paragon leverages a dedicated in-house team of scientific experts in antibody development, as well as its partnership with FairJourney Biologics, to generate unique therapeutic concepts and enable their rapid proof-of-concept validation. We consider Paragon to be a related party. See the section titled â€œCertain Relationships and Related Transactionsâ€ for additional information. Â 51 Â Â Our Strategy Â To achieve our goal of developing leading therapeutic antibodies for patients with inflammatory skin diseases, we are applying antibody engineering to validated modes of action. We believe this approach will enable us to improve meaningfully upon the efficacy and convenience of standard-of-care medicines while significantly reducing technical and biological risk. The key elements of our strategy include: Â â—Employ advanced antibody engineering to build biologics that could significantly improve upon existing therapies:Â Â Â Â Â We and our collaborators at Paragon have optimized a variety of parameters using a suite of antibody technologies to develop candidates with the potential to improve upon existing therapies. These parameters include extending half-life to increase exposure and reduce dosing frequency, enhancing affinity and specificity to maximize potency and safety, and optimizing developability to ensure consistency and enable convenient, high-dose formulations. Together, we believe these features have the potential to translate into more efficacious and convenient medicines for patients. Â â—Target validated mechanisms of action:Â Â Â Â Â Our initial targets, IL-23p19 and IL-17A/F, have established efficacy and safety for the treatment of PsO, PsA, and other indications. The FDA has approved four biologics in the IL-23 class, including three targeting IL-23p19, and four biologics in the IL-17 class, including one targeting IL-17A/F.Â While these therapies have advanced the standard of care in PsO and PsA, they have not addressed these diseases completely, and a significant fraction of patients do not achieve complete skin clearance. By applying our advanced antibody engineering to these validated targets, we believe we can maximize our chances of developing superior medicines for patients. In addition, the reduced technical and biological risk of these validated mechanisms may allow us to progress our programs more efficiently and rapidly. Â â—Leverage insights from earlier entrants to optimize our approach:Â Â Â Â Â We benefit from a large body of clinical evidence generated by prior therapies targeting IL-23 and IL-17. We continue to extract and apply learnings from this precedent to our programs, including in development candidate selection, clinical trial design, dosing regimens, formulations and presentations, regulatory pathway, and indication prioritization. For instance, based on correlations between affinity and efficacy, we have designed ORKA-001 and ORKA-002 to bind to similar epitopes and at similar or greater affinities as the leading antibodies in each class: risankizumab and bimekizumab, respectively, with the aim of maximizing efficacy. Also, by understanding the exposure-response relationships for efficacy and safety for other therapies, we plan to select dose levels and regimens that could maximize efficacy and maintenance of response while maintaining safety. Â â—Pursue opportunities with strong prospects of yielding meaningful new medicines as a â€œbase caseâ€ and the potential to shift the treatment paradigm entirely as an â€œupside caseâ€:Â Â Â Â Our strategy seeks to maximize the potential for our programs to reach a base case product profile that could meaningfully advance the standard of careÂ â€”Â for instance, for ORKA-001, SQ dosing one or twice a year with equal or greater efficacy compared to todayâ€™s standard of care. At the same time, we aim to deliver an upside case that dramatically improves outcomes for patientsÂ â€”Â for instance, significantly increasing rates of complete skin clearance via higher antibody exposures or offering patients durable remissions free from therapy by introducing patient-specific dosing intervals. Â â—Build a preeminent biotechnology company focused on chronic skin disease and otherÂ I&I indications:Â Â Â Â Â We are assembling a team of exceptional people and helping them reach their full potential and flourish so that together we can bring forward meaningful new medicines for patients. Â We believe that pursuing the focused strategy outlined above will help us to succeed in our mission of offering patients living with PsO, PsA, and other dermatologic and inflammatory diseases the greatest possible freedom from their condition. Â Targeting IL-23 and IL-17 to Treat MultipleÂ I&I Indications Â Our programs benefit from significant advances in the understanding of the biology ofÂ I&I diseases over the past

four decades. ORKA-001 and ORKA-002 are designed to target two key cytokines that play a related role in multiple indications. IL-23 is an upstream regulator of Th17 cells, a pro-inflammatory subset of T helper cells characterized by their production of IL-17. IL-23 has a critical role in maintaining Th17 cells in the tissue as well as activating these cells to secrete IL-17, which acts downstream to trigger inflammation and other disease symptoms. Th17 cells are involved in PsO, PsA, HS, axSpA, and many other diseases. They play a particularly central role in PsO and PsA. The diagram below depicting the immunopathogenesis of PsO provides an example of how Th17 cells can mediate disease and how blocking IL-23 or IL-17 can break the inflammatory cycle that drives disease. Â 52 Â Â Immunopathogenesis of PsO and the role of IL-23 and IL-17 Â Â PsO develops when environmental triggers and a genetic predisposition combine to cause activation of an inflammatory cycle in the skin that leads to the formation of plaques and other disease manifestations. This process begins with the aberrant activation of the dendritic cells (â€œDCsâ€), specifically those producing IL-23 and other cytokines like IL-1Î², IL-21, TNF-Î±, and IL-12. These cytokines induce the differentiation of Th17 cells, as well as other cell types, such as T helper type 1 (â€œTh1â€) cells that produce IFNÎ³ and TNF-Î± and T helper type 22 (â€œTh22â€) cells that produce IL-22. IL-23 plays a key role in the differentiation and activation of Th17 cells to secrete IL-17, as well as Th22 cells to produce IL-22. IL-17 and these other cytokines induce keratinocyte hyperproliferation leading to plaque formation and a feedforward inflammatory response, with changes in gene expression in keratinocytes, the production of antimicrobial peptides, and neutrophil recruitment driving further inflammation. While many cytokines and cell types contribute to the pathogenesis of PsO, the IL-23/IL-17 axis plays an important role, as supported by the success of therapies targeting this axis. Â While the successful treatment of PsOÂ â€”Â for instance, with mAbs targeting IL-23 or IL-17 â€”Â can result in lesional skin returning to an apparently normal state, disease tends to recur at previously affected sites following cessation of therapy, suggesting a mechanism of â€œimmunological memoryâ€ that predisposes individuals to recurrence in the same locations. Evidence suggests that pathogenic TRMs play a critical role in this memory. TRMs may arise from the Th17 cells and other cells that drove disease in the first place and remain in their resident tissue, in this case the epidermis and dermis, for long periods of time. Upon a disease trigger, these TRMs can actively produce proinflammatory cytokines, causing disease recurrence. IL-23 appears to play an important role in maintaining and potentiating TRMs, as indicated by the depletion of TRMs following treatment with an IL-23 inhibitor but not an IL-17 inhibitor, which may explain the longer remissions observed with IL-23 inhibitors following withdrawal of therapy. This type of data has raised the prospect that efficient IL-23 blockade could modify the disease biology of PsO, possibly leading to durable remissions. Â 53 Â Â The scientific discoveries that refined our understanding of the immunopathogenesis of PsO have led to waves of therapeutic advances, ultimately leading to todayâ€™s standard of care. Before the 1980s, PsO was not even thought of as an immunologic disease, but rather a disease of keratinocyte dysfunction, leading to treatments such as phototherapy, methotrexate, and retinoids. The discovery in the 1980s that PsO results from immune dysfunction led to the use of broad immunosuppressants like cyclosporine. From 1990 to 2008, it was believed that Th1 cells were the predominant mediators of the disease, which led to the use of biologics targeting TNF-Î± such as Enbrel (etanercept) and Humira (adalimumab). Finally, the revelation that PsO is driven principally by Th17 cells resulted in the development of the primary therapies used today, which target IL-23 and IL-17. This increasingly refined understanding of the disease has narrowed the standard of care from broad immunosuppressive agents (such as cyclosporine) to more specific immunomodulators (TNF-Î± inhibitors) to precise biologic therapies targeting the key cytokines involved in disease pathology (IL-23 and IL-17 inhibitors), with each new therapeutic class raising the bar on both safety and efficacy. Â Biologic therapies, especially mAbs, are now mainstays in the treatment of a wide variety ofÂ I&I diseases, including PsO and PsA.Â Therapies that have improved upon efficacy and/or reduced dosing frequency have achieved the most commercial success, even when launching manyÂ years after other biologics. Enbrel was first approved for PsO in 2004 with a weekly maintenance dosing schedule. FourÂ years later, Humira was approved for PsO with an every-other-week (Q2W) dosing schedule. Stelara (ustekinumab) was approved a year later with similar PhaseÂ 3 data to Humira, but with a significantly improved dosing schedule of every twelveÂ weeks (Q12W). Several drugs for PsO have been approved since 2009 that demonstrated higher efficacy in their pivotal studies compared to Stelara, but with more burdensome dosing schedules, including Tremfya (guselkumab), which has a dosing schedule of every eightÂ weeks (Q8W), and Cosentyx (secukinumab) and Taltz (ixekizumab), which have dosing schedules of every fourÂ weeks (Q4W). While these therapies have all become generally successful products, the most commercially successful drug in the PsO market today is Skyrizi (risankizumab), which combines Stelaraâ€™s Q12W dosing schedule with improvements in efficacy, as evidenced by a higher psoriasis area severity index (PASI) score of PASI 90 and PASI 100 rates in clinical trials. In addition, Bimzelx (bimekizumab), approved by the FDA in 2023, has shown evidence of efficacy that exceeds even Skyrizi, though with a less convenient Q8W dosing schedule. Although many biologics have entered the PsO market over the past two decades, new entrants have had significant commercial success when they have improved upon efficacy and/or dosing frequency, and room remains to improve in both areas to set a new standard for the treatment of PsO. Â Biologics have raised the bar on the standard of care in PsO, but leave room for improvement Â Â The biology driving PsO and PsA is well understood today, and the standard of care has progressed dramatically. We believe that it is unlikely that a novel mechanism will emerge that is as safe and efficacious as targeting the IL-23/IL-17 axis. Therefore, we believe that innovation now should be focused on optimizing the product profile that can be offered to patients. While much effort is being directed toward daily oral formats to inhibit this axis, oral medicines have yet to match the efficacy of biologics. We believe that a better biologic with a longer dosing interval and the potential for improved efficacy will present a more attractive product profile for most patients. Â 54 Â Â Overview of Psoriasis (PsO) Â PsO is a chronic autoimmune skin disorder that affects an estimated 125Â million people worldwide with steadily increasing prevalence, estimated to be aroundÂ 2Â â€“Â 3% of the population currently, according to the World Psoriasis Day consortium. It is the largest pharmaceutical market within dermatology, with annual sales of approximately $25Â billion in 2022, which is estimated to grow to $32Â billion by 2028. The most common form of PsO is plaque psoriasis. Patients with chronic plaque psoriasis have well-demarcated, erythematous plaques with overlying, coarse, silvery-scaled patches. These plaques can occur anywhere on the body, though are typically found on the scalp, extensor areas of the knees and elbows, and gluteal cleft. Involvement of the palms, soles, or nails, and intertriginous areas, including the genitals, can also occur and can be particularly difficult to treat. Between one-quarter and one-half of PsO patients have moderate disease, defined as having 3% to 10% of the body surface area (â€œBSAâ€) involved, or severe disease, defined as having more than 10% BSA involvement. The chronic inflammation in PsO is associated with multiple comorbidities, including PsA, obesity, metabolic syndrome, hypertension, diabetes, and atherosclerotic cardiovascular disease. Â As discussed earlier, PsO is a complex immune-mediated disease driven primarily by Th17 cells and the cytokines IL-23 and IL-17. The interplay of environmental and behavioral risk factors and genetics is believed to trigger PsO.Â Multiple lines of evidence support a genetic component to the disease, including the observation that approximately 40% of patients with PsO and PsA have a family history of the disease and the identification of multiple susceptibility loci, many containing genes related to the regulation of the immune system, in genome-wide association studies. Â Current PsO Treatments and Limitations Â While patients with mild PsO typically rely on topical corticosteroids or oral therapies like Otezla (apremilast), these agents often do not provide an adequate response for patients with moderate-to-severe PsO.Â As a result, the American Academy of Dermatology-National Psoriasis Foundation recommends biologics as first-line therapy for moderate-to-severe PsO.Â Â Several classes of biologic therapies have been approved for PsO over the past 20Â years, resulting in progressively more complete symptom relief. Efficacy in PsO is typically measured via the PASI scoring system. The first biologics approved for PsO were tumor necrosis alpha (â€œTNF-Î±â€) inhibitors such as Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab), which achieved a 90%Â improvement in PASI score (â€œPASI 90â€) at 16Â weeks in aroundÂ 25Â â€“Â 50% of patients and a 100% improvement in PASI score (â€œPASI 100â€) inÂ around 5Â â€“Â 20% of patients. Stelara (ustekinumab), which targets the p40 subunit of IL-23 that is shared with IL-12, was approved next and achieved efficacy on par with Humira. IL-17 inhibitors Cosentyx (secukinumab), Taltz (ixekizumab), and Siliq (brodalumab) followed and achieved responses of PASI 90 in aroundÂ 70% of patients and PASI 100 inÂ around 40% of patients with some risk of certain side effects such as oral candidiasis. Most recently, IL-23p19 inhibitors such as Ilumya (tildrakizumab), Tremfya (guselkumab), and Skyrizi (risankizumab) have achieved responses of PASI 90 inÂ around 70Â â€“Â 80% of patients and PASI 100 in around 30Â â€“Â 50% of patients with highly tolerable profiles. Finally, IL-17A/F inhibitors such as Bimzelx (bimekizumab) have recently shown even higher response rates than IL-23 inhibitors, but with slightly less tolerable profiles. Â Treatment expectations in PsO have evolved progressively with this continued innovation. A 75% improvement in PASI score was previously thought to be an adequate depth of response, and weekly SQ dosing was viewed as acceptable. With each subsequent generation of innovation, patient and caregiver expectations have advanced. Today, Skyrizi (risankizumab) is widely viewed as the leader in PsO biologic therapy. In PhaseÂ 3 clinical trials, 43% and 58% of patients achieved PASI 100 at 16 and 52Â weeks, respectively, with SQ maintenance dosing every threeÂ months. Most recently, Bimzelx (bimekizumab) has shown evidence of efficacy that exceeds even Skyrizi, achieving a 64% PASI 100 rate at 16Â weeks in PhaseÂ 3 trials. However, the increased efficacy comes with a less convenient Q8W dosing schedule and an increased risk of certain side effects, most notably oral candidiasis. While agents like Skyrizi and Bimzelx reflect the remarkable advancement in PsO treatment, there remains significant unmet need. Approximately half of moderate-to-severe PsO patients do not achieve full skin clarity, and while early signs are present, the promise of disease modifying therapy remains unrealized. In addition, a continued desire for more convenient dosing options has driven significant interest in orally delivered medicines targeting these same pathways. However, oral therapies have yet to match the efficacy and safety profile of biologics. We believe that ORKA-001 and ORKA-002 could represent the next step in biologic innovation in PsO, with the potential for higher rates of complete skin clearance, more durable remissions, and markedly more convenient dosing regimens. Â 55 Â Â Overview of Psoriatic Arthritis (PsA) Â PsA is a chronic inflammatory condition that affects both the skin and joints, and often coexists with PsO.Â Around a quarter to a third of patients with moderate-to-severe PsO also have PsA.Â Most individuals develop PsO before being diagnosed with PsA, with a median gap of seven to eightÂ years between the diagnosis of skin and joint disease, though in up to 30% of patients with PsA, joint symptoms appear before or simultaneously with skin manifestations. Patients with PsA present with joint pain, stiffness, and swelling affecting the peripheral joints, axial skeleton, or both. Enthesitis, dactylitis, nail lesions, fatigue, and ocular inflammation all occur commonly. PsA can lead to irreversible joint damage, including bony fusion across a joint (ankylosis). The pathogenesis of PsA is likely to be closely related to the mechanisms that underlie PsO.Â Like PsO, the exact cause of PsA remains unknown, but environmental triggers, including infection and trauma, and genetic factors play a role. Â Current PsA Treatments and Limitations Â Effective treatment of PsA requires a coordinated approach to address the unique combination of disease manifestations each patient has, which can include peripheral and axial arthritis, enthesitis, dactylitis, and skin and nail involvement. Many patients with milder disease symptoms will start with nonsteroidal anti-inflammatory drugs (â€œNSAIDsâ€) and/or local treatments to address specific disease manifestations. However, those with more moderate or severe disease and/or multidomain involvement will typically receive a biologic therapy targeting TNF-Î± or IL-17, or less commonly an oral Janus kinase (â€œJAKâ€) inhibitor. Comorbid conditions can also influence treatment selection. For example, an IL-17 inhibitor would be preferred for a patient with significant skin involvement, but not for patients with IBD or ocular symptoms, where a TNF-Î± inhibitor would be preferred. The most common endpoint used to measure the efficacy of TNF-Î± or IL-17 inhibitors in PsA is ACR response, or the proportion of patients achieving a specified percent improvement in American College of Rheumatology (â€œACRâ€) score, which measures peripheral joint disease. Approved TNF-Î± inhibitors, including Humira (adalimumab) and Cimzia (certolizumab), achieved a placebo-adjusted ACR50 response of aroundÂ 30Â â€“Â 35% at 24Â weeks with Q2W dosing. Approved IL-17 inhibitors, including Cosentyx (secukinumab) and Taltz (ixekizumab), achieved a slightly lower placebo-adjusted ACR50 response of aroundÂ 25Â â€“Â 30% at 24Â weeks, but with more convenient Q4W dosing. Bimzelx (bimekizumab) which was recently approved in the UnitedÂ States for PsA achieved a placebo-adjusted ACR50 response of approximately 35% at 16Â weeks with Q4W dosing. A significant fraction of patients with PsA still do not achieve a satisfactory response with available therapies, and even the most convenient regimens require monthly SQ dosing. Â Overview of additional opportunities Â In addition to PsO and PsA, inhibition of IL-23 or IL-17 has demonstrated efficacy in a number of additionalÂ I&I indications, including HS and axSpA. Â HS is a chronic inflammatory skin disease characterized by lesions that include deep-seated nodules and abscesses, draining tracts, and fibrotic scars that occur most commonly in intertriginous areas, such as the armpits and groin. Due to the associated pain, sensitive locations, drainage, odor, and scarring, this condition can have a particularly negative psychosocial impact on affected individuals. HS is believed to be underdiagnosed and could have a prevalence well above 1% worldwide. Treatment varies depending on severity and can include topical and systemic antibiotics, hormone therapy, immune modulators, and surgery. Humira (adalimumab) was the only FDA-approved medication for the treatment of moderate-to-severe HS from its approval in 2015 until the approval of Cosentyx (secukinumab) in OctoberÂ 2023. However, now multiple other biologics, including Bimzelx (bimekizumab), are advancing through development and have demonstrated encouraging data in clinical trials, though a significant fraction of patients still do not achieve adequate responses. Â 56 Â Â axSpA is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints that comprise the axial skeleton. The disease causes severe pain, stiffness, and fatigue, and can have additional clinical manifestations like uveitis, enthesitis, peripheral arthritis, and PsO.Â Patients with axSpA may develop further structural damage in their spine, which can lead to the fusion of vertebra (spinal ankylosis), which has a massive negative impact on mobility, physical function, and quality of life. The overall prevalence of axSpA is estimated to be around 1% in the UnitedÂ States. Treatment of axSpA starts with physical therapy and NSAIDs. If patients do not have an adequate response to NSAIDs, a TNF-Î± inhibitor is typically used, followed by an IL-17 inhibitor, such as Cosentyx (secukinumab), Taltz (ixekizumab), or Bimzelx (bimekizumab), or less frequently a JAK inhibitor. Patients often need to cycle through therapies over time due to inadequate responses or loss of response. Â Our Solution: Half-Life Extension and Antibody Engineering Technologies Â Our antibody engineering campaigns are designed to optimize multiple attributes in parallel: binding affinity, potency in a variety of assays, developability, and consistently extended serum half-life in non-human primates (â€œNHPsâ€). Half-life extension is possible by modifying the pH-dependent binding affinity of the antibody Fc domain for FcRn. A primary mechanism of elimination of antibodies from the serum is through pinocytosis and degradation in the lysosomes of cells. Throughout this process, antibodies can be recycled back into the serum by binding to FcRn while they are in endosomes. The interior of the endosome is acidic, and therefore the efficiency of this recycling process depends on the ability of the antibody Fc domain to bind to FcRn at low pH.Â If this low pH binding is efficient enough, antibody recycling can be favored over degradation, potentially resulting in a much longer serum half-life. Â Antibody engineers have discovered methods of modifying the Fc domain to optimize the efficiency of recycling via FcRn binding. Several engineering strategies have been identified over the past two decades, with the so-called â€œYTEâ€ mutations (M252Y/S254T/T256E) and â€œLSâ€ mutations (M428L/N434S) being the most frequently used. Importantly, while these strategies have been known for some time, it was only relatively recently that enough clinical precedent was established to provide confidence in how these mutations perform in humans. Two products incorporating YTE modification were approved in 2023 by the FDA, Beyfortus (nirsevimab) and Evusheld (tixagevimab and cilgavimab), and several more candidates are in clinical trials. Two products using LS mutations were approved in 2021 and 2022, Xevudy (sotrovima) and Ultomiris (ravulizumab), respectively, and several more candidates are in clinical trials. Based on clinical data in humans, antibodies with YTE mutations typically have a half-life that is two to four times longer than wildtype antibodies. In addition, preclinical data in NHPs can be used to predict the approximate half-life in humans, with the human half-life equaling around two to fourÂ times the NHP half-life. Â Clinical experience with YTE-modified mAbs predicts significant half-life extension over wildtype mAbs Â Â While this increasing body of clinical precedent serves to validate half-life extension, we do not yet have clinical data showing that the introduction of these amino acid substitutions in our programs leads to a longer serum half-life. However, we aim to establish this favorable pharmacokinetic profile early in the clinical development of our product candidates. Â 57 Â Â ORKA-001 Â Summary Â ORKA-001 is a high affinity, extended half-life mAb designed to target the p19 subunit of IL-23. Based on preclinical data generated to date, we believe ORKA-001 has the potential to become the leading IL-23 inhibitor and achieve an optimal product profile in PsO consisting of the following: Â â—One to two maintenance doses per year.Â Â Â Â Standard-of-care therapies targeting IL-23 require maintenance dosing every eight to twelveÂ weeks. We engineered the Fc portion of ORKA-001 to include YTE mutations to increase the half-life of ORKA-001 in circulation, which may enable dosing every six to twelveÂ monthsÂ â€”Â a dosing interval made feasible by half-life extension technology. In preclinical studies, serum levels fromÂ NHPs indicated an elimination half-life of over 30Â days following SQ administration of ORKA-001. Based on published scientific literature on other antibodies incorporating YTE mutations and pharmacokinetic modeling, we anticipate this half-life in NHPs to translate to a half-life in humans that could allow subcutaneous dosing every six to twelveÂ months while maintaining high antibody exposures. Â â—Higher PASI 100.Â Â Â Â ORKA-001 benefits from the robust validation of IL-23 inhibition in PsO by multiple approved therapies, such as Skyrizi (risankizumab) and Tremfya (guselkumab), while leveraging insights from these therapies to improve upon their clinical profile. ORKA-001 is designed to bind a similar epitope to the market-leading anti-IL-23 antibody, Skyrizi, with similar or greater affinity and could achieve much higher exposures in patients due to half-life extension and higher dosing. Skyrizi and Tremfya both have a robust exposure-response relationship, with higher drug exposures leading to higher response rates. Published data indicates that these therapies have not saturated this exposure-response relationship, and ORKA-001 could lead to higher response rates, including higher rates of complete skin clearance, or PASI 100, through increased exposure,

even while having more convenient dosing with as few as one or two maintenance doses per year. Â â—Validated IL-23p19 safety profile.Â Â Â Â Existing commercially approved antibodies targeting IL-23 provide a robust precedent for the safety of IL-23 inhibition. Across thousands of patients dosed in dermatology and IBD indications, no correlations have been observed at the patient level between exposure and safety. While we are not pursuing IBD, the approved Skyrizi regimens for Crohnâ€™s disease and ulcerative colitis supports the safety of high peak exposures. Peak Skyrizi exposures during theÂ IV induction phase in Crohnâ€™s disease and ulcerative colitis are multiple times higher than the peak ORKA-001 exposures at dose levels we currently plan to evaluate in PsO.Â In addition, an exposure-response analysis for Skyrizi in ulcerative colitis showed no relationship between exposures and evaluated safety endpoints in the 12-week induction or 52-week maintenance periods. In this assessment, the top quartile of average exposures were significantly higher than the highest anticipated exposures with ORKA-001 in the same periods. Â â—Potential to offer longer term remission to some patients.Â Â Â Â Emerging evidence suggests that IL-23 blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.Â Dr.Â Andrew Blauvelt, chair of our Scientific Advisory Board, pioneered some of this work by using two- and four-times the approved dose levels of risankizumab to achieve best-in-indication response rates. This study, called KNOCKOUT, showed a robust depletion of TRMs following high dose IL-23 inhibition, which could lead to longer-lasting remissions in some patients. Additional evidence from a study of guselkumab, called GUIDE, showed that intervention early in the disease course can lead to longer treatment-free remissions. In addition, retrospective claims data suggests that treatment with an IL-23 inhibitor could help prevent progression to PsA, though this finding has yet to be confirmed by a prospective clinical trial. Given the high antibody exposures expected with ORKA-001, we believe that ORKA-001 could lead to durable remissions for some patients, especially those with short disease duration. We plan to pursue patient-specific dosing intervals to provide each patient the greatest possible freedom from their disease. Â We believe that this target profile for ORKA-001 could offer improved freedom from disease to many patients affected by PsO and represent a step forward in the standard of care. Â 58 Â Â Preclinical Data Â We evaluated ORKA-001 in numerous preclinical studies for several key features: Â Potency that matches or exceeds Skyrizi (risankizumab) in vitro Â We have tested the potency of ORKA-001 in vitroÂ in multiple assays, including assays evaluating the inhibition of IL-17 release from human peripheral mononuclear blood cells, in comparison to risankizumab generated recombinantly based on amino acid sequences from patent filings. Based on the results of these experiments, we believe ORKA-001 binds a similar epitope as risankizumab with similar potency. Â ORKA-001 binds to a similar epitope as risankizumab with similar potency Â Â Â Â Significant half-life extension in NHPs that could enable a maintenance dosing interval of once or twice a year in humans Â We assessed ORKA-001 in NHPs in comparison to risankizumab generated recombinantly based on amino acid sequences from patent filings. ORKA-001 had a significantly longer half-life, reaching over 30Â days with SQ administration. Based on clinical experience with YTE-modified mAbs and pharmacokinetic modeling, we believe that this half-life extension could enable dosing once or twice per year, as shown in the figure below. Â The incorporation of YTE mutations significantly extends half-life in NHPs, which could enable once or twice yearly dosing Â Â Â In addition to enabling less frequent dosing, an extended half-life would increase the exposure of ORKA-001, which has the potential to increase efficacy. Based on published literature, Skyrizi (risankizumab) demonstrates a clear relationship between antibody exposure and efficacy, with higher average serum antibody concentration correlating with higher PASI 90 and PASI 100 rates short-term (at 16Â weeks) and long-term (at 52Â weeks), as shown for PASI 100 in the figure below. In addition, the KNOCKOUT study, which evaluated two- and four-times higher doses of Skyrizi than the approved regimen, yielded some of the highest PASI 100 rates observed to date, reaching 67% at 16Â weeks. Based on our pharmacokinetic modeling, ORKA-001 could achieve four-fold higher average exposures than the approved Skyrizi regimen over the first 16Â weeks and over two-fold higher average exposures at steady-state, exceeding even the exposures in KNOCKOUT.Â Based on the exposure-response relationship observed with other IL-23 inhibiting antibodies, we believe that these increased exposures could result in higher efficacy. Â 59 Â Â ORKA-001 is projected to extend the exposure-response relationship established by studies of Skyrizi Â Â Â Safety in vitro and in vivo Â We have evaluated ORKA-001 in severalÂ in vitroÂ andÂ in vivoÂ preclinical studies to assess safety. In addition, we have initiated a robust nonclinical program to characterize the toxicology, toxicokinetics, and anti-drug antibody profile of ORKA-001 in NHPs, including a single-dose non-GLP dose-range finding study and one-month and six-month GLP toxicology studies. Collectively, this nonclinical program is designed to support the initiation of clinical trials. In addition, ORKA-001 benefits from the favorable safety precedent for IL-23 inhibition provided by the existing commercially approved IL-23-targeted antibodies across several indications. Â Characteristics that support ease of manufacturing and potentially enable high-concentration formulations Â Finally, we have assessed a variety of attributes essential for manufacturability and high-concentration formulation, including viscosity, solubility, and stability, among others. ORKA-001 shows evidence of desirable properties across these characteristics, which we believe will enhance our ability to manufacture ORKA-001 successfully and consistently and to deliver high doses of ORKA-001 subcutaneously using convenient, low-volume presentations. Â Clinical Development Plans Â Based on these potential advantages and preclinical data, we are advancing ORKA-001 towards a PhaseÂ 1 clinical trial in the first quarter of 2025. This trial will encompass a PhaseÂ 1a single-ascending dose portion in healthy volunteers, followed by a PhaseÂ 1b, multiple-dose portion in patients with moderate-to-severe PsO.Â Following completion of PhaseÂ 1b, patients will become eligible for an open-label extension study. Initial data from the PhaseÂ 1a cohort has the potential to provide key validation of both early safety and pharmacokinetics, including half-life, to support extended dosing intervals. Initial data from the PhaseÂ 1b cohort has the potential to provide preliminary efficacy data in patients with PsO.Â Pending the results from the PhaseÂ 1 clinical trial, we plan to initiate a PhaseÂ 2 clinical trial in PsO in 2026. Several aspects of PsO facilitate clinical development, including well-established, reproducible endpoints based on PASI scores, low placebo rates, particularly with PASI 90 and PASI 100, a rapid efficacy readout at 16Â weeks, and potentially rapid enrollment due to the large patient population. We have not yet submitted an IND with the FDA for our Phase 1 clinical trial for ORKA-001. Â ORKA-002 Â Summary Â ORKA-002 is a high affinity, extended half-life mAb designed to target IL-17A/F.Â Dual inhibition of both IL-17A and IL-17F has shown superior efficacy compared to IL-17A inhibition alone in PsO and other indications, as shown by the performance of Bimzelx (bimekizumab) compared to Cosentyx (secukinumab) and Taltz (ixekizumab) in PhaseÂ 3 trials. These therapies all utilize Q4W maintenance dosing in PsO and PsA, except Bimzelx, where Q8W maintenance dosing in PsO patients <120 kg is recommended.Â By binding IL-17A/F at similar epitopes and affinity ranges as Bimzelx while incorporating half-life extension technology to potentially enable dosing two to three times a year in PsO and PsA, we believe that ORKA-002 could become the leading therapy in the IL-17 class. Â 60 Â Â Preclinical Data Â The preclinical program we are conducting for ORKA-002 mirrors that for ORKA-001 and spans potency, pharmacokinetics, safety, and manufacturing characteristics. Based on the results of these experiments, we believe ORKA-002 has the potential for comparable potency to bimekizumab, but with a significantly longer half-life, which we believe could support dosing two or three times per year based on extrapolation from clinical precedent and pharmacokinetic modeling. Â Clinical Development Plans Â We plan to initiate a PhaseÂ 1 trial of ORKA-002 in the third quarter of 2025. As with ORKA-001, initial data on ORKA-002 in healthy volunteers has the potential to provide key validation of both early safety and pharmacokinetics to support extended dosing intervals. Though clinical development of ORKA-002 will initially focus on one lead indication, we plan to evaluate ORKA-002 in a range of indications over time. We see ORKA-002 as highly complementary to ORKA-001, with the potential to provide an optimal therapy for the approximately one-quarter to one-third of moderate-to-severe PsO patients who have PsA, as well as for PsO patients with highly resistant skin symptoms that do not respond adequately to an IL-23 inhibitor. Furthermore, ORKA-002 could address indications beyond PsO, including PsA with limited skin involvement, HS, axSpA, and additionalÂ I&I diseases. We have not yet submitted an IND with the FDA for our Phase 1 clinical trial for ORKA-002. Â Additional Pipeline Programs Â We have a third mAb program, ORKA-003, that targets an undisclosed pathway. A core tenet of our strategy is to remain highly focused onÂ I&I diseases, and specifically on inflammatory dermatology conditions. ORKA-003 provides the potential for indication expansion beyond PsO as well as combination opportunities with our more advanced programs. In the future, we may add additional programs to our portfolio beyond ORKA-001, ORKA-002, and ORKA-003 that fit our strategic focus. Â Intellectual Property Â We strive to protect the proprietary programs and technologies that we believe are important to our business, including seeking and maintaining patent protection intended to cover the composition of matter of our programs, their methods of use and manufacture, related technologies, diagnostics, and other inventions. Â Paragon has filed provisional patent applications, and may file additional provisional patent applications directed to antibodies that target IL-23, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA-001. In addition, Paragon has filed provisional patent applications, and may file additional provisional patent applications directed to antibodies that target IL-17, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA-002. We have exercised our option to acquire exclusive rights to ORKA-001 and the corresponding IL-23 patent applications but have not yet entered into the corresponding license agreement. We have not yet exercised our option to acquire exclusive rights to any IL-17 patent applications, but retain the right to do so. If the provisional patent applications are pursued non-provisionally and mature into one or more issued patents covering ORKA-001 or ORKA-002, we would expect those patents to expire in 2045, absent any applicable patent term adjustments or extensions. Â 61 Â Â Commercial Â Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the UnitedÂ States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our programs. Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We have exercised our option to acquire exclusive worldwide rights to develop and commercialize ORKA-001 but have not entered into the corresponding license agreement. We also currently hold an exclusive Option (as defined below) to acquire worldwide development and commercialization rights to ORKA-002. Â Manufacturing Â We do not currently own or operate facilities for product manufacturing, testing, storage, and distribution. We have contracted and expect to continue to contract with third parties for the manufacture and distribution of our product candidates. Because we rely on contract manufacturers, we employ personnel with extensive technical, manufacturing, analytical and quality experience. Our team has deep knowledge and understanding of the regulations that govern manufacturing, documentation, quality assurance, and quality control of drug supply that are required to support our regulatory filings. Â Competition Â The biotechnology and biopharmaceutical industries are characterized by continuing technological advancement and significant competition. While we believe that our programs, technology, development experience and scientific knowledge provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Many of the companies with which we are currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, patient enrollment for clinical trials as well as in acquiring technologies complementary to, or necessary for, our programs. Â Key competitive factors affecting the success of all our product candidates that we develop, if approved, are likely to be efficacy, safety, convenience, presentation, price, the level of generic competition, and the availability of reimbursement from government and other third-party payors. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market. Â Specifically, there are several companies developing or marketing treatments that may be approved for the same indications and/or diseases as our two most advanced programs, ORKA-001 and ORKA-002, including major pharmaceutical companies. We do not yet have clinical data for any of our programs and there can be no assurance that our programs will have similar or comparable results. Â There are several approved biologic therapies for the treatment of moderate-to-severe PsO.Â These include mAbs targeting IL-23, such as Skyrizi (risankizumab) from AbbVie, Tremfya (guselkumab) from Janssen, and Ilumya (tildrakizumab) from Sun Pharma, also marketed as Ilumetri by Almirall in Europe, which all target the p19 subunit, and Stelara (ustekinumab) from Janssen, which targets the p40 subunit; mAbs targeting IL-17, such as Bimzelx (bimekizumab) from UCB, which targets IL-17A/F, Cosentyx (secukinumab) from Novartis and Taltz (ixekizumab) from Eli Lilly, which both target IL-17A, and Siliq (brodalumab) from Ortho Dermatologics, also marketed as Kyntheum by LEO Pharma in Europe, which targets IL-17 receptor A; and biologics targeting TNF-Iâ±, such as Humira (adalimumab) from AbbVie, Enbrel (etanercept) from Amgen, and Remicade (infliximab) from Janssen, and various biosimilar versions of each. In addition, there are several approved oral medicines in these indications, including the phosphodiesterase-4 (PDE4) inhibitor Otezla (apremilast) from Amgen and the tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) from Bristol-Myers Squibb. Many of these therapies also are approved or in development for PsA, HS, axSpA, and otherÂ I&I indications. Â 62 Â Â In addition, we are aware of several product candidates in clinical development for moderate-to-severe PsO, along with PsA, HS, axSpA, and other indications. These include the biologics picankibart from Innovent Biologics targeting IL-23p19 and sonelokimab from MoonLake Immunotherapeutics targeting IL-17A/F.Â Also, there are several oral agents in development, including JNJ-2113 from Janssen targeting the IL-23 receptor, DC-806 and DC-853 from Eli Lilly targeting IL-17A, and TAK-279 from Takeda and ESK-001 from Alumis, both targeting TYK2. Â License Agreements Â Paragon Therapeutics Â On MarchÂ 6, 2024, we entered into the Paragon Option Agreements. Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to us. Each Paragon Option Agreement initially included one of two selected targets: IL-23 and IL-17A/F.Â Under the Paragon Option Agreements, we have the exclusive option to, on a research program-by-research program basis, be granted an exclusive, worldwide license to all of Paragonâ€™s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target(s)Â (each, an â€œOptionâ€). In the case of IL-23, our Option excludes the therapeutic area of IBD.Â From time to time, we can choose to add additional targets to the collaboration by mutual agreement with Paragon and Paruka. In September 2024 we exercised the Option to acquire the rights to ORKA-001 but have not yet entered into the corresponding license agreement. As of the date hereof, we have not exercised the IL-17A/F Option. Â Pursuant to the terms of the Paragon Option Agreements, we initiated certain research programs with Paragon that generally focus on a particular target (each, a â€œResearch Programâ€). Each Research Program is aimed at discovering, generating, identifying, and/or characterizing antibodies directed to the respective target. For each Research Program, we established or may establish in the future a research plan with Paragon that sets forth the activities that will be conducted, and the associated research budget (each, a â€œResearch Planâ€). Our exclusive option with respect to each Research Program is exercisable at our sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number ofÂ days following (i)Â with respect to any Research Program other than ORKA-001, the delivery of the data package from Paragon related to the results of the Research Plan activities or (ii)Â with respect to ORKA-001, the completion of the IL-23 antibody selection process described in the agreement (the â€œOption Periodâ€). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements. Â Unless terminated earlier, each Paragon Option Agreement shall continue in force on a Research Program-by-Research Program basis until the earlier of: (i)Â the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by us; (ii)Â the expiration of the 30-day period after we exercise our Option with respect to a Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii)Â the expiration of the applicable Research Term (as defined under each Paragon Option Agreement) (the â€œTermâ€). We may terminate any Paragon Option Agreement or any Research Program at any time for any or no reason upon 30Â daysâ€™ prior written notice to Paragon, provided that we must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Paragon Option Agreement or a Research Program immediately upon written notice to us if, as a result of any action or failure to act by us or our affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number ofÂ months. Each party has the right to terminate the Paragon Option Agreements or any Research Program upon (i)Â 30Â daysâ€™ prior written notice of the other partyâ€™s material breach that remains uncured for the 30-day period and (ii)Â the other partyâ€™s bankruptcy. Â 63 Â Â As of the date of filing of this prospectus, we have exercised the Option with respect to ORKA-001 but have not yet entered into the corresponding license agreement. We have not yet exercised the Option with respect to ORKA-002. For each of these agreements, once we enter into the corresponding license agreements, we will be required to make non-refundable milestone payments to Paragon of up to $12.0Â million for each program upon the achievement of certain clinical development milestones, up to $10.0Â million for each program upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale

in each program. Â Additionally, as part of the Paragon Option Agreements, on each of DecemberÂ 31, 2024 and DecemberÂ 31, 2025, we will grant Paruka warrants to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares on the grant date. Â Pursuant to the Option Agreements, on a research program-by-research program basis following the finalization of the research plan for each respective research program, the Company was required to pay Paragon a one-time, nonrefundable research initiation fee of $0.8Â million related to the ORKA-001 program. This amount was recognized as a research and development expense during the period from FebruaryÂ 6 (inception) to September 30, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its development candidate for IL-23 antibody for ORKA-001 program. The Company was responsible for 50% of the development costs incurred through the completion of the IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June 2024. During the three months ended September 30, 2024, the Company exercised its option for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement of development candidate as research and development expense in the Companyâ€™s condensed consolidated statements of operations and comprehensive loss for each of the three months ended September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024. The Companyâ€™s share of development costs incurred during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024 was $0.8 million and $13.2 million, respectively, which were recorded as research and development expenses during the respective periods. An amount of $2.3 million is included in related party accounts payable and other current liabilities as of September 30, 2024. Â The Company was also required to reimburse Paragon $3.3Â million for development costs related to ORKA-002 incurred by Paragon through DecemberÂ 31, 2023 and certain other development costs incurred by Paragon between JanuaryÂ 1, 2024 and MarchÂ 6, 2024 as stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from FebruaryÂ 6 (inception) to September 30, 2024. The Company is also responsible for the development costs incurred by Paragon from JanuaryÂ 1, 2024 through the completion of the IL-17 selection process. The Company recognized an amount of $0.8Â million payable to Paragon for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as research and development expenses in the period from February 6 (inception) to September 30, 2024. The Company accounted for development costs of $3.8 million and $6.6 million during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively, as research and development expenses during the respective periods. An amount of $3.8 million is included in related party accounts payable and other current liabilities as of September 30, 2024. Â For the three months ended September 30, 2024 and the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024, we recognized $13.4 million and $33.8 million of expenses, respectively in connection with services provided by Paragon and Paruka under the Paragon Option Agreements. Â Government Regulation Â The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those we are developing. We, along with our third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. Â 64 Â Â United States Biologics Regulation Â In the United States, biological products are subject to regulation under the FDCA, the Public Health Service Act (â€œPHSAâ€) and other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: Â â—completion of preclinical laboratory tests and animal studies performed in accordance with the FDAâ€™s current Good Laboratory Practices (â€œGLPâ€) regulation; Â â—submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made; Â â—approval by an independent IRB, or ethics committee at each clinical site before the trial is commenced; Â â—manufacture of the proposed biologic candidate in accordance with current Good Manufacturing Practices (â€œcGMPsâ€); Â â—performance of adequate and well-controlled human clinical trials in accordance with current GCP requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose; Â â—preparation of and submission to the FDA of a BLA, after completion of all pivotal clinical trials; Â â—satisfactory completion of an FDA Advisory Committee review, if applicable; Â â—a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; Â â—satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological productâ€™s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and Â â—FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States. Â Preclinical and Clinical Development Â Prior to beginning any clinical trial with a product candidate, in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. Â In addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (â€œIBCâ€), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment and such review may result in some delay before initiation of a clinical trial. Â 65 Â Â Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Â Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries. Â For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap. Â â—Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. Â â—Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. Â â—Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. Â In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. Â A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies. Â 66 Â Â BLA Submission and Review Â Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the productâ€™s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. Â In addition, under the Pediatric Research Equity Act (â€œPREAâ€), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted. Â Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDAâ€™s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the productâ€™s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. Â Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. Â After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. Â 67 Â Â If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre-â€‰and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the productâ€™s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. Â Expedited Development and Review Programs Â The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and data demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. Â A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers. Â Any marketing

application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if there is evidence it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review designation means the FDAâ€™s goal is to take action on the marketing application within six months of the 60-day filing date (as compared to ten months under standard review). Â Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022 the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Â 68 Â Â Fast track designation, breakthrough therapy designation and priority review do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Â Post-Approval Requirements Â Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance. Â The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: Â â—restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; Â â—fines, warning letters or holds on post-approval clinical studies; Â â—refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals; Â â—product seizure or detention, or refusal of the FDA to permit the import or export of products; Â â—consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; Â â—mandated modification of promotional materials and labeling and the issuance of corrective information; Â â—the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or Â â—injunctions or the imposition of civil or criminal penalties. Â The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the productâ€™s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturerâ€™s communications on the subject of off-label use of their products. Â 69 Â Â Biosimilars and Reference Product Exclusivity Â The ACA includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are highly similar, or â€œbiosimilar,â€ to or interchangeable with an FDA-approved reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Â Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA-approved reference biological product may rely in part on the FDAâ€™s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. In September 2021, the FDA issued two guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDAâ€™s interpretation of certain statutory requirements added by the BPCIA. Â Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicantâ€™s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed â€œinterchangeableâ€ by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. Â A reference biologic is granted twelve years of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitted under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing, (ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicantâ€™s favor of a lawsuit challenging the biologicsâ€™ patents if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within the 42-month period. Â A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued â€œWritten Requestâ€ for such a study. The BPCIA is complex and continues to be interpreted and implemented by the FDA. In July 2018, the FDA announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office within the agency that will focus on therapeutic biologics and biosimilars. On December 20, 2020, Congress amended the PHSA as part of the COVID-19 relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty. Â As discussed below, the IRA is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic costs. Â 70 Â Â Other Healthcare Laws and Compliance Requirements Â Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute (â€œAKSâ€); the federal False Claims Act (â€œFCAâ€); the Health Insurance Portability and Accountability Act of 1996 (â€œHIPAAâ€) and similar foreign, federal and state fraud, abuse and transparency laws. Â The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value. Â The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Â Civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that â€œcausedâ€ the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA. Â HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation. Â The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products. Â The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Childrenâ€™s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicaid & Medicare Services (â€œCMSâ€) information related to payments or other transfers of value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning on January 1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act. Â 71 Â Â We are also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Â Data Privacy and Security Â Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (â€œHITECHâ€), and their respective implementing regulations imposes data privacy, security, and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable protected health information (â€œPHIâ€) for or on behalf of such covered entities. These requirements imposed by HIPAA and the HITECH Act on covered entities and business associates include entering into agreements that require business associates protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the privacy of PHI, which limit the disclosure of a patientâ€™s past, present, or future physical or mental health or condition or information about a patientâ€™s receipt of health care if the information identifies, or could reasonably be used to identify, the individual; ensuring the confidentiality, integrity, and availability of all PHI created, received, maintained, or transmitted in electronic form, to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of such PHI; and reporting of breaches of PHI to individuals and regulators. Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with the U.S. Department of Health and Human Services (â€œHHSâ€) to settle allegations of HIPAA non-compliance. A covered entity or business associate is also liable for civil money penalties for a violation that is based on an act or omission of any of its agents, which may include a downstream business associate, as determined according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneysâ€™ fees and costs associated with pursuing federal civil actions. To the extent that we submit electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to us may be delayed or denied. Â Even when HIPAA does not apply, according to the FTC, violating consumersâ€™ privacy rights or failing to take appropriate steps to keep consumersâ€™ personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. Â In addition, certain state laws, such as the California Consumer Privacy Act of 2018 (â€œCCPAâ€), as amended by the California Privacy Rights Act of 2020 (â€œCPRAâ€), govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. The CCPA/CPRA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, rights to California residents in relation to their personal information. Health information falls under the CCPA/CPRAâ€™s definition of personal information where it identifies, relates to, describes, or is

reasonably capable of being associated with or could reasonably be linked with a particular consumer or household - unless it is subject to HIPAA - and is included under a new category of personal information, â€œsensitive personal information,â€ which is offered greater protection. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. Additionally, our use of artificial intelligence and machine learning may be subject to laws and evolving regulations regarding the use of artificial intelligence/machine learning, controlling for data bias, and antidiscrimination. Â 72 Â Â In addition, the CPRA expands the CCPAâ€™s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia, Colorado, Connecticut and Utah, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While the laws in these states, like the CCPA, also exempt some data processed in the context of clinical trials, such developments further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely. Â Coverage and Reimbursement Â Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Â Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product. Â For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. Â In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able to directly negotiate prescription drug prices and to cap out-of-pocket costs. Each year, CMS will select and negotiate a preset number of high-spend drugs and biologics that are covered under Medicare Part B and Part D that do not have generic or biosimilar competition. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. These price negotiations will begin in 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. The IRA also provides a new â€œinflation rebateâ€ covering Medicare patients that took effect in 2023 and is intended to counter certain price increases in prescriptions drugs. The inflation rebate provision will require drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Part B and Part D increases faster than the rate of inflation. To support biosimilar competition, beginning in October 2022, qualifying biosimilars may receive a Medicare Part B payment increase for a period of five years. Separately, if a biologic drug for which no biosimilar exists delays a biosimilarâ€™s market entry beyond two years, CMS will be authorized to subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRAâ€™s impact on commercialization and competition remains largely uncertain. Â 73 Â Â Healthcare Reform Â The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing. Â The ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companiesâ€™ share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the â€œdonut holeâ€ under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. Â Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of on average 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act of 2011. These reductions went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional action is taken by Congress. Â In addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point-of-sale discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturerâ€™s outpatient drugs being covered under Medicare Part D. Â Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step therapy for Part B drugs, permitting Medicare Part D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January 1, 2021. In response to the Biden administrationâ€™s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. Â Notwithstanding the IRA, continued legislative and enforcement interest exists in the United States with respect to specialty drug pricing practices. Specifically, we expect regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs. Â 74 Â Â Other Government Regulation Outside of the United States Â In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. Â Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. Â Â The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries. Â Regulation in the European Union Â European Data Laws Â The collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (â€œGDPRâ€), which came into force in May 2018, and related data protection laws in individual EU Member States. The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the national data protection authorities, and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation. Â In addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the European Economic Area (â€œEEAâ€) that are not considered by the European Commission (â€œECâ€) to provide an adequate level of data protection. Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (â€œSCCsâ€). With regard to the transfer of data from the EEA to the United States, on July 10, 2023, the EC adopted its adequacy decision for the EU-US Data Privacy Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to U.S. companies participating in the framework. Â Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance of up to â,¬20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU. Guidance developed at both the EU level and at the national level in individual EU Member States concerning implementation and compliance practices are often updated or otherwise revised. Â 75 Â Â Furthermore, there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation No. 536/2014 (â€œCTRâ€), European Medical Agency (â€œEMAâ€) disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity that we face with regard to data protection regulation. Â With regard to the transfer of personal data from the EEA to the UK, personal data may now freely flow from the EEA to the UK since the UK is deemed to have an adequate data protection level. Â However, the adequacy decisions include a â€˜sunset clauseâ€™ which entails that the decisions will automatically expire four years after their entry into force. Additionally, following the UKâ€™s withdrawal from the EU and the EEA, companies also have to comply with the UKâ€™s data protection laws (including the UK GDPR (as defined in section 3(10) (as supplemented by section 205(4)) of the Data Protection Act 2018 (the â€œDPA 2018â€)), the DPA 2018, and related data protection laws in the UK). Separate from the fines that can be imposed by the GDPR, the UK regime has the ability to fine up to the greater of Â£17.5 million or 4% of global turnover. Â Following the UKâ€™s withdrawal from the EU and the EEA, companies are subject to specific transfer rules under the UK regime; personal data may flow freely from the UK to the EEA, since the EEA is deemed to have an adequate data protection level for purposes of the UK regime. These UK international transfer rules broadly mirror the GDPR rules. On February 2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (â€œIDTAâ€) and the international data transfer addendum to the ECâ€™s standard contractual clauses for international data transfers (Addendum) and a document setting out transitional provisions. The IDTA and Addendum came into force on March 21, 2022 and replaced the old SCCs for the purposes of the UK regime. However, the transitional provisions, adopted with the IDTA and the Addendum, provide that contracts concluded on or before September 21, 2022 on the basis of any old SCCs continue to provide appropriate safeguards for the purpose of the UK regime until March 21, 2024, provided that the processing operations that are the subject matter of the contract remain unchanged and reliance on those clauses ensures that the transfer of personal data is subject to appropriate safeguards. Â With regard to the transfer of personal data from the UK to the United States, the UK government has adopted an adequacy decision for the United States, the UK-US Data Bridge, which came into force on October 12, 2023. The UK-US Data Bridge recognizes the United States as offering an adequate level of data protection where the transfer is to a U.S. company participating in the EU-US Data Privacy Framework and the UK Extension. Â Drug and Biologic Development Process Â Regardless of where they are conducted, all clinical trials included in applications for marketing authorization (â€œMAâ€) for human medicines in the EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The conduct of clinical trials in the EU is governed by the CTR, which entered into force on January 31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC, (â€œClinical Trials Directiveâ€) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU. Â Under the former regime, which will expire after a transition period of three years as outlined below in more detail, before a clinical trial can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (â€œNCAâ€) and one or more Ethics Committees. NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU member state where they occur. Â 76 Â Â A more unified procedure will apply under the new CTR. A sponsor will be able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal (the â€œCTISâ€). One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application and consult and coordinate with the other

concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member state may in limited circumstances declare an â€œopt-outâ€ from an approval and prevent the clinical trial from being conducted in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a three-year transition period. EU Member States will work in CTIS immediately after the system has gone live. Since January 31, 2023, submission of initial clinical trial applications via CTIS is mandatory, and by January 31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and have to be transitioned to CTIS. On July 19, 2023, the EC published guidance concerning the steps to be taken in this transition. This guidance provides, among other things, that (i) documentation which was previously assessed will not be reassessed, (ii) templates that were developed and endorsed by the EU Clinical Trials Expert Group to provide compliance with the CTR do not need to be updated and (iii) there is no need to retrospectively create a site suitability form, which are only necessary for new trial sites. Â Under both the former regime and the new CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines on Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki. Â During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (â€œCHMPâ€) on the recommendation of the Scientific Advice Working Party. A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing Authorization Application (â€œMAAâ€) of the product concerned. Â Drug Marketing Authorization Â In the EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a MA. To obtain a MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized or decentralized procedure. Â To be used or sold in the UK, a drug must have an effective MA obtained by a centralized application through EMA or a national application. National applications are governed by the Human Medicines Regulations (SI 2012/1916). Applications are made electronically through the Medicines and Healthcare products Regulatory Agency (â€œMHRAâ€) Submissions Portal. The process from application to authorizations generally takes up to 210 days, excluding time taken to provide any additional information or data required by the MHRA. Â On August 30, 2023, the MHRA published detailed guidance on its recently announced new International Reliance Procedure (â€œIRPâ€) for MAAs. The IRP applies since January 1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international regulators (e.g. Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update a MA in the UK or Great Britain. Â Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures including line extensions, variations and renewals. Â Â Centralized Authorization Procedure Â The centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application by the EMA that is valid for all EU Member States as well as in the three additional member states of the EEA. The centralized procedure is compulsory for certain types of medicinal products, including for medicines developed by means of certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (â€œATMPâ€) and medicinal products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May 20, 2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a MA through the centralized procedure. Â 77 Â Â Under the centralized procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMAâ€™s CHMP is, in principle, 210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67 days after receipt of the CHMP opinion. Â Decentralized Authorization Procedure Â Medicines that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i) they can be authorized under the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would be in the interest of public health; (ii) they can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state; or (iii) they can be authorized in an EU member state in accordance with that stateâ€™s national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national MA (mutual recognition procedure). Â The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a MA for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU Member States. Â Risk Management Plan Â All new MAAs must include a Risk Management Plan (â€œRMPâ€) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i) at the request of EMA or a national competent authority, or (ii) whenever the risk-management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. Since October 20, 2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions. Â MA Validity Period Â MAs have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the five-year period expires. Â 78 Â Â Additionally, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used. Â Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid. Â For the UK, the period of three years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion to a Great Britain MA. Conversion refers to the procedure by which, as of January 1, 2021, MAs granted on the basis of a centralized procedure in the EU are only valid in Northern Ireland but not in Great Britain, whereas, prior EU authorizations have all been automatically converted into UK MAs effective in Great Britain only. Â On the other hand, for the EU, in the case the drug has been marketed in the UK, the placing on the UK market before the end of the period starting when the UK left the EU on January 31, 2020 and ending on December 31, 2020 (the â€œBrexit Transition Periodâ€) will be taken into account. If, after the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining EU Member States, the three-year period will start running from the last date the drug was placed on the UK market before the end of the Brexit Transition Period. Â Advanced Therapy Medicinal Products Â In the EU, medicinal products, including ATMPs are subject to extensive pre- and post-market regulation by regulatory authorities at both the EU and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the ATMP Regulation, the Committee on Advanced Therapies (â€œCATâ€) is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs. Although such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval for product candidates. Â In addition to the mandatory RMP, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used. Â Exceptional Circumstances/Conditional Approval Â Similar to accelerated approval regulations in the United States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, a number of criteria are fulfilled: (i) the benefit/risk balance of the product is positive, (ii) it is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii) unmet medical needs will be fulfilled by the grant of the MA and (iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional MA must be renewed annually. Â Data and Market Exclusivity Â As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitorâ€™s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant from relying on the MA holderâ€™s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. New Chemical Entities (â€œNCEsâ€) approved in the EU qualify for eight years of data exclusivity and 10 years of marketing exclusivity. Â 79 Â Â An additional non-cumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight years of the 10-year marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies. Â The data exclusivity period begins on the date of the productâ€™s first MA in the EU. After eight years, a generic product application may be submitted and generic companies may rely on the MA holderâ€™s data. However, a generic product cannot launch until two years later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally, another non-cumulative one-year period of data exclusivity can be added to the eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant pre-clinical or clinical studies were carried out in relation to the new indication. Â Another year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre-trial tests or clinical trials (when examining an application by another applicant for or holder of MA for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized). Â Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the EUâ€™s regulatory authorities to include an NCE. Even if a compound is considered to be an NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product. Â On April 26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages e.g., a shortening of the periods of data exclusivity, however, there is currently neither a final version of this draft nor a date for its entry into force. Â Â Orphan Designation and Exclusivity Â The criteria for designating an orphan medicinal product in the EU are similar in principle to those in the U.S. The EMA grants orphan drug designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the EU (prevalence criterion). In addition, orphan drug designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the EU of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is not a MA, as not all orphan-designated medicines reach the authorization application stage) must be submitted first before an application for MA of the medicinal product is submitted. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the MA is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional MA. Â The EMAâ€™s Committee for Orphan Medicinal Products reassesses the orphan drug designation of a product in parallel with the review for a MA; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of MA review by the EMA and approval by the EC. Additionally, any MA granted for an orphan medicinal product must only cover the therapeutic indication(s) that are covered by the orphan drug designation. Upon the grant of a MA, orphan drug designation provides up to ten years of market exclusivity in the orphan indication. Â During the 10-year period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU Member States and the EMA may not accept applications for MA, accept an application to extend an existing MA or grant a MA for other similar medicinal products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two years of market exclusivity for an orphan-designated condition when the results of specific studies are reflected in the Summary of Product Characteristics (â€œSmPCâ€) addressing the pediatric population and completed in accordance with a fully compliant Pediatric Investigation Plan (â€œPIPâ€). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Â 80 Â Â The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, i.e. the condition prevalence or financial returns criteria under Article 3 of Regulation (EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market protection. Additionally, a MA may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject to certain requirements. Â In the UK, following the post-Brexit transition period, a system for incentivizing the development of orphan medicines was introduced. Overall, the requirements for orphan designation largely replicate the requirements in the EU and the benefit of market exclusivity has been retained. Products with an orphan designation in the EU can be considered for an orphan MA in Great Britain, but a UK-wide orphan MA can only be considered in the absence of an active EU orphan designation. The MHRA will review applications for orphan designation at the time of a MA, and will offer incentives, such as market exclusivity and full or partial refunds for MA fees to encourage the development of medicines in rare diseases. Â Â Pediatric Development Â In the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a PIP together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMAâ€™s Pediatric Committee. Companies must conduct pediatric

clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g. until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g. because the relevant disease or condition occurs only in adults) has been granted by the EMA. The MAA for the medicinal product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted an MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six-month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval), or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and covered by intellectual property rights. Â In the UK, the MHRA has published guidance on the procedures for UK PIPs which, where possible, mirror the submission format and requirements of the EU system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by the EMA prior to January 1, 2021 have been adopted as UK PIPs. Â PRIME Designation Â In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The Priority Medicines (â€œPRIMEâ€) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small-and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling non-clinical data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or CAT are appointed facilitating increased understanding of the product at EMAâ€™s Committee level. A kick-off meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval. Â Post-Approval Regulation Â Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and MAs. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products. Â Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties. Â 81 Â Â The holder of MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. Â These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicineâ€™s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (â€œPSURsâ€) in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase 4 safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the ECâ€™s decision provides can undermine the ongoing validity of the MA. Â More generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures. Â The manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (â€œGMPâ€). These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU. Similarly, the distribution of pharmaceutical products into and within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP. Â Sales and Marketing Regulations Â The advertising and promotion of our products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the productâ€™s SmPC as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the MA granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription-only medicines is also prohibited in the EU. Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals. Â EU regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through the Human Medicines Regulations 2012. However, organizations wishing to sell medicines online need to register with the MHRA. Following Brexit, the requirements to display the common logo no longer apply to UK-based online sellers, except for those established in Northern Ireland. Â Anti-Corruption Legislation Â In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physiciansâ€™ codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment. Â 82 Â Â Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physicianâ€™s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. Â In the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the scope of the Bribery Act 2010. Due to the Bribery Act 2010â€™s far-reaching territorial application, the potential penalized act does not have to occur in the UK to become within its scope. If the act or omission does not take place in the UK, but the personâ€™s act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still have been committed. Â The Bribery Act 2010 is comprised of four offenses that cover (i) individuals, companies and partnerships that give, promise or offer bribes, (ii) individuals, companies and partnerships that request, agree to receive or accept bribes, (iii) individuals, companies and partnerships that bribe foreign public officials, and (iv) companies and partnerships that fail to prevent persons acting on their behalf from paying bribes. The penalties imposed under the Bribery Act 2010 depend on the offence committed, harm and culpability and penalties range from unlimited fines to imprisonment for a maximum term of ten years and in some cases both. Â Regulations in the UK and Other Markets Â The UK formally left the EU on January 31, 2020 and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland and as amended by the Windsor Framework sets out a long-term set of arrangements for the supply of medicines into Northern Ireland. The EU and the UK agreed on a trade and cooperation agreement (â€œTCAâ€), which includes provisions affecting the life sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP issued documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards. Â The UK government has adopted the Medicines and Medical Devices Act 2021 (the â€œMMDAâ€) to enable the UKâ€™s regulatory frameworks to be updated following the UKâ€™s departure from the EU. The MMDA introduces regulation-making, delegated powers covering the fields of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The MHRA has since been consulting on future regulations for medicines and medical devices in the UK. Â For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCPs and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. Â If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Â Employees and Human Capital Resources Â As of November 13, 2024, we had 27 full-time employees. We also engage temporary employees and consultants to augment our existing workforce. None of our employees are represented by a labor union or covered under a collective bargaining agreement. We consider our relationship with our employees to be good. Â We recognize that attracting, motivating, and retaining talent at all levels is vital to continuing our success. We invest in our employees through high-quality benefits, professional development opportunities, and various health and wellness initiatives and offer competitive compensation packages (base salary and incentive plans), ensuring fairness in internal compensation practices. The principal purposes of our incentive plans (bonus and equity) are to align with the long-term interests of our stakeholders and stockholders. Â Properties and Facilities Â We maintain a corporate office at 855 Oak Grove Ave., Suite 100, Menlo Park, California. The lease for this office commenced on June 15, 2024 with an initial term of 39.5 months. Â Legal Proceedings Â From time to time, we may become involved in legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Â 83 Â Â MANAGEMENT Â Executive Officers and Directors Â The following table and discussion sets forth the names, ages as of November 13, 2024, positions and biographical and other information of the individuals who currently serve as directors and executive officers of the Company. Â Name Â Age Â Position Executive Officers: Â Â Â Â Lawrence Klein Â 42 Â President, Chief Executive Officer and Director Arjun Agarwal Â 48 Â Senior Vice President, Finance and Treasurer Joana GoncalvesÂ Â Â 51 Â Chief Medical Officer Paul Quinlan Â 61 Â General Counsel and Corporate Secretary Non-Employee Directors: Â Â Â Â Samarth Kulkarni (2)(3)Â Â Â 46 Â Chair and Director Kristine Ball (1)(3)Â Â Â 52 Â Director Carl Dambkowski (1) Â 40 Â Director Peter Harwin (2)(3) Â 38 Â Director Cameron Turtle (1)(2)Â Â Â Â Â 34 Â Director Â Â (1)Member of the Audit Committee. (2)Member of the Compensation Committee. (3)Member of the Nominating and Governance Committee (the â€œGovernance Committeeâ€). Â Each executive officer serves at the discretion of the of the Board and holds office until their successor is duly appointed and qualified or until their earlier resignation or removal. Â Executive Officers Â Lawrence Klein, Ph.D. Dr.Â Klein has served as Chief Executive Officer and as a member of the board of directors of the Company since the Closing and of Pre-Merger Oruka from February 2024 through the Closing. Prior to joining Pre-Merger Oruka, Dr.Â Klein was a Partner at Versant Venture Management, LLC, a healthcare and biotechnology venture capital firm, from JanuaryÂ 2023 to FebruaryÂ 2024, where he invested in and helped to grow early-stageÂ biotechnology companies. Prior to Versant, Dr.Â Klein served in various positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from JanuaryÂ 2020 to OctoberÂ 2022, Chief Business Officer from JanuaryÂ 2019 to JanuaryÂ 2020, Senior Vice President, Business Development and Strategy from NovemberÂ 2017 to DecemberÂ 2018 and as Vice President, Strategy from FebruaryÂ 2016 to NovemberÂ 2017, where he helped to initiate and execute on several transformative partnerships, establish the strategic direction of the company, oversee important pipeline programs and led several functions, including program and portfolio management. Before joining CRISPR, Dr.Â Klein was an Associate Partner at McKinseyÂ & Company, a global management consulting firm, from OctoberÂ 2014 to FebruaryÂ 2016. Dr.Â Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from SeptemberÂ 2019 to MayÂ 2023 and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from SeptemberÂ 2021 to JuneÂ 2023. Dr.Â Klein received his B.S. in biochemistry and physics from the University of Wisconsin-MadisonÂ and his Ph.D. in biophysics from Stanford University. Â We believe Dr. Klein is qualified to serve as a member of the Board because of his business development, operational and senior management experience in the biotechnology industry and his academic expertise and accomplishments. Â Arjun Agarwal.Â Mr.Â Agarwal has served as the Senior Vice President of Finance of the Company since the Closing and of Pre-Merger Oruka from MarchÂ 2024 through the Closing, where he is responsible for overseeing the companyâ€™s finance and accounting functions. Prior to joining Pre-Merger Oruka, Mr.Â Agarwal served as VP of Finance at Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company, from JuneÂ 2021 to MarchÂ 2024, including through multiple financings and the companyâ€™s successful transition to become a publicly traded entity. Before joining Jasper, Mr.Â Agarwal served as Vice President, Corporate Controller at Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a biotechnology company, from AugustÂ 2019 to JuneÂ 2021, where he was responsible for overseeing the companyâ€™s finance and accounting functions. Prior to joining Protagonist, Mr.Â Agarwal served in various roles of increasing responsibility at McKesson Corporation (NYSE:Â MCK),Â an international healthcare services company, from 2009 to 2019. Prior to McKesson, Mr.Â Agarwal worked at PricewaterhouseCoopers LLP, where he managed a portfolio of audit clients. He is a graduate of Sydenham College of Commerce and Economics at Mumbai University, India. He is a Certified Public Accountant (CPA) and a Chartered Accountant accredited by the Institute of Chartered Accountants of India. Â 84 Â Â Joana Goncalves, MBChB. Dr.Â Goncalves has served as the Chief Medical Officer of the Company since the Closing and of Pre-Merger Oruka from AprilÂ 2024 through the Closing. Prior to joining Pre-Merger Oruka, Dr.Â Goncalves served as Chief Medical Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company, from OctoberÂ 2018 to AprilÂ 2024, where she was responsible for representing Cara Therapeutics in interactions with regulatory agencies, the investor and scientific communities and the board of directors, building multifunctional terms and developing the clinical development strategy in dermatological conditions. Prior to Cara, Dr.Â Goncalves held various positions at Celgene Corporation, a pharmaceutical company, which was later acquired by Bristol-MyersÂ Squibb Company, from AprilÂ 2014 to OctoberÂ 2018, where she most recently served as Vice President, Medical Affairs for Dermatology and Neurology and was instrumental in planning and executing medical support activities for a number of programs, including OTEZLAÂ® for psoriasis. Prior to Celgene, Dr.Â Goncalves served as Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc., the U.S.Â subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, from FebruaryÂ 2012 to AprilÂ 2014. She began her pharmaceutical career at Novartis

Pharmaceuticals, working on a range of products across various therapeutic areas from 2001 to 2012. Dr.Â Goncalves received her MBChB from the University of Cape Town, South Africa. Â Paul Quinlan. Mr.Â Quinlan has served as General Counsel and Corporate Secretary of the Company since the Closing and of Pre-Merger Oruka since AprilÂ 2024 through the Closing. Prior to joining Pre-Merger Oruka, Mr.Â Quinlan served as General Counsel, Chief Compliance Officer and Corporate Secretary of CymaBay Therapeutics, Inc., a biopharmaceutical company, from OctoberÂ 2020 to MarchÂ 2024, where he was responsible for the general supervision of the companyâ€™s legal affairs. From DecemberÂ 2017 to FebruaryÂ 2020, he served as General Counsel and Corporate Secretary of CymaBay, where he was responsible for the general supervision of the companyâ€™s legal affairs. Prior to CymaBay, Mr.Â Quinlan served as General Counsel and Secretary, from 2010 to JanuaryÂ 2018, and Chief Legal Officer from 2016 to JanuaryÂ 2018, of TerraVia Holdings, Inc., a biotechnology company, where he was responsible for the general supervision of the companyâ€™s legal affairs. Prior to joining TerraVia, Mr.Â Quinlan served as General Counsel of Metabolex, Inc., a biopharmaceutical company, from 2005 to 2010. Prior to joining Metabolex, Mr.Â Quinlan held various positions at Maxygen, Inc., a biopharmaceutical company, from 2000 to 2005. Prior to Maxygen, Mr.Â Quinlan practiced law at Cooley LLP and Cravath, Swaine,Â & Moore LLP.Â Mr.Â Quinlan received a law degree from Columbia Law School and an M.Sc. in Medical Biophysics from the University of Toronto. Â Non-Employee Directors Â Kristine Ball. Ms. Ball has served as a member of the board of directors of the Company since the Closing and of Pre-Merger Oruka since MayÂ 2024 through the Closing. Ms.Â Ball has served as President and Chief Executive Officer of Antiva Biosciences, Inc., a private biopharmaceutical company, since AprilÂ 2023. Prior to Antiva, Ms. Ball served as Chief Executive Officer of Soteria Biotherapeutics, Inc., a private biotechnology company, from SeptemberÂ 2020 to AugustÂ 2022. Prior to joining Soteria, Ms. Ball served as Senior Vice President, Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., a Nasdaq-listedÂ biopharmaceutical company, which later became VYNE Therapeutics Inc. (Nasdaq: VYNE), from SeptemberÂ 2017 to MarchÂ 2020, where she was responsible for leading all non-R&D functions, including strategic planning, corporate development, commercial, human resources, legal, finance and information technology. Prior to joining Menlo, Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc., a Nasdaq-listedÂ pharmaceutical company, which was later acquired by Galenica Group, from NovemberÂ 2012 to OctoberÂ 2016. Prior to Relypsa, Ms. Ball held various other finance roles in the life sciences industry, including Senior Vice President of FinanceÂ & Administration and Chief Financial Officer of KAI Pharmaceuticals, Inc., a biopharmaceutical company, and Vice President of Finance at Exelixis, Inc. (Nasdaq: EXEL), a biotechnology company. Prior to that, Ms. Ball served as a senior manager in life sciences audit practice of ErnstÂ & Young LLP. Ms.Â Ball has previously served on the boards of directors of Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company, from 2020 to 2024, Soteria from 2020 to 2022 and Forty Seven, Inc., a Nasdaq-listedÂ biotechnology company, which was later acquired by Gilead Sciences, Inc., from 2018 to 2020. Ms. Ball received a B.S. from Babson College. Â We believe Ms. Ball is qualified to serve as a member of the Board because of her experience as an executive officer and director of life sciences companies and her background in finance, corporate development and strategic planning. Â 85 Â Â Carl Dambkowski, M.D. Dr.Â Dambkowski has served as a member of the board of directors of the Company since the Closing and of Pre-Merger Oruka from FebruaryÂ 2024 through the Closing. Dr.Â Dambkowski has served as the Chief Medical Officer of Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company, since SeptemberÂ 2022. Prior to joining Apogee, Dr.Â Dambkowski served as a strategic and clinical leader for a variety of companies, including as Chief Medical Officer of QED Therapeutics, Inc., a private biotechnology company, from JulyÂ 2021 to SeptemberÂ 2022; Chief Strategy Officer and EVP of Operations of Origin Biosciences, Inc., a private bioecology company, from MarchÂ 2018 to JuneÂ 2021; and Chief Medical Officer of Navire Pharma, Inc., a private biotechnology company, from JanuaryÂ 2020 to SeptemberÂ 2022, where he served as the clinical lead starting prior to IND for BBP-398Â through the out licensing of the compound to Bristol-MyersÂ Squibb based on initial clinical data and for low-doseÂ infigratinib in achondroplasia through initial proof-of-conceptÂ data. He was part of the core team that brought TRUSELTIQÂ®Â (infigratinib) and NULIBRYÂ®Â (fosdenopterin) through regulatory review and FDA approval at QED Therapeutics and Origin Biosciences, respectively. From JulyÂ 2016 to MarchÂ 2018, Dr.Â Dambkowski was an associate at McKinseyÂ & Company, a global management consulting firm, where he advised biotech and pharmaceutical companies across the world on a range of research and development activities. Dr.Â Dambkowski co-foundedÂ Novonate, Inc., a private medical device company focused on building life-savingÂ devices for neonates, in JanuaryÂ 2015. Dr.Â Dambkowski has coauthored numerous peer-reviewedÂ publications and scientific abstracts and is a named inventor on multiple published and granted patents. Dr.Â Dambkowski was trained as a physician at Stanford University, where he also received his M.D. with a concentration in bioengineering. He also received a B.A. (with honors) from Stanford University and an M.A. from Columbia University. Â We believe Dr. Dambkowski is qualified to serve as a member of the Board because of his significant experience and innovations in the biotechnology industry and his academic expertise and accomplishments. Â Peter Harwin. Mr.Â Harwin has served as a member of the board of directors of the Company since the Closing and of Pre-Merger Oruka from FebruaryÂ 2024 through the Closing. Mr.Â Harwin is a Managing Member at Fairmount Funds Management, a healthcare investment firm he co-foundedÂ in AprilÂ 2016. Prior to Fairmount Funds Management, Mr.Â Harwin was a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr.Â Harwin also serves as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and is a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Viridian Therapeutics, Inc. (Nasdaq: VRDN) and Spyre Therapeutics, Inc. (Nasdaq: SYRE). Mr.Â Harwin received a B.B.A. from Emory University. Â We believe Mr. Harwin is qualified to serve as a member of the Board because his experience serving as a director of biotechnology companies and as a manager of funds specializing in the area of life sciences. Â Samarth Kulkarni, Ph.D. Dr.Â Kulkarni has served as a member of the board of directors of the Company since the Closing and of Pre-Merger Oruka from FebruaryÂ 2024 through the Closing. Dr.Â Kulkarni has served as the Chief Executive Officer of CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, since DecemberÂ 2017, where he has also served as a member and chair of the board of directors since JuneÂ 2018 and SeptemberÂ 2023, respectively. Previously, Dr.Â Kulkarni served as CRISPRâ€™s President and Chief Business Officer from MayÂ 2017 to NovemberÂ 2017 and as Chief Business Officer from AugustÂ 2015. Prior to joining CRISPR, Dr.Â Kulkarni was at McKinseyÂ & Company, a global management consulting firm, from 2006 to 2015, with various titles, his most recent being Partner within the Pharmaceuticals and Biotechnology practice. Dr.Â Kulkarni has also served as a member of the boards of directors of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology company, since 2019, including as lead independent director since SeptemberÂ 2023, Repare Therapeutics Inc. (Nasdaq: RPTX), a precision oncology company, since NovemberÂ 2019 and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a biotechnology company, since FebruaryÂ 2021. Dr.Â Kulkarni received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B.Â Tech. from the Indian Institute of Technology. Dr.Â Kulkarni has authored several publications in leading scientific and business journals. Â We believe that Dr. Kulkarni is qualified to serve as a member of the Board because of his experience as a consultant and an executive in the biopharmaceutical industry and his academic expertise and accomplishments. Â 86 Â Â Cameron Turtle, D.Phil. Dr.Â Turtle has served as a member of the board of directors of the Company since the Closing and of Pre-Merger Oruka from FebruaryÂ 2024 through the Closing. Dr.Â Turtle has served as Chief Executive Officer and a member of the board of directors of Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) (Nasdaq: SYRE), a biotechnology company, since NovemberÂ 2023 and, before that, as Chief Operating Officer from JuneÂ 2023 to NovemberÂ 2023. Prior to joining Spyre, Dr.Â Turtle was an advisor to Spyre Therapeutics, Inc., a private biotechnology company, from MayÂ 2023 to JuneÂ 2023. Previously, he served as Venture Partner at Foresite Labs, a life sciences investment firm, from JulyÂ 2022 to MayÂ 2023; Chief Strategy Officer of BridgeBio Pharma (Nasdaq: BBIO), a biotechnology company, from JanuaryÂ 2021 to AprilÂ 2022; and Chief Business Officer of Eidos Therapeutics (Nasdaq: EIDX), a biopharmaceutical company, from NovemberÂ 2018 to JanuaryÂ 2021, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was a consultant at McKinseyÂ & Company, a global management consulting firm, where he worked with pharmaceutical and medical device companies on topics including M&A, growth strategy, clinical trial strategy, and sales force optimization. Dr.Â Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University of Oxford, St. Johnâ€™s College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 UnderÂ 30, San Francisco Business Times 40 UnderÂ 40, and the Biocom Life Sciences Catalyst Award. Â We believe Dr. Turtle is qualified to serve as a member of the Board because of his experience as a leader in building, financing, and shaping biopharmaceutical organizations from preclinical development to late-stage clinical trials and commercialization. Â Family Relationships Â There are no family relationships among any of our directors or executive officers. Â Board Structure and Related Matters Â Board Structure Â Our business and affairs are managed under the direction of our Board. Our Board currently consists of six members. Each of our current directors will continue to serve until the election and qualification of their successor, or their earlier death, resignation or removal. Â The authorized number of directors is determined from time to time solely by resolution of the Board. Our certificate of incorporation and bylaws provide that our directors may be removed only for cause by the affirmative vote of at least 66 2/3% of the voting power of the common stock outstanding and entitled to vote thereon. In addition, only our Board is authorized to fill vacancies and any additional directorships resulting from an increase in the authorized number of directors. Â Our certificate of incorporation establishes a classified Board consisting of three classes of directors with staggered three-year terms. Only one class of directors is elected at each annual meeting of our stockholders to succeed the directors of the same class whose terms are then expiring, with the other classes continuing for the remainder of their respective three-year terms. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2025 for Class I directors, 2026 for Class II directors, and 2027 for Class III directors. Â â—Our Class I directors are Dr. Dambkowski and Mr. Harwin. Â â—Our Class II directors are Dr. Klein and Dr. Turtle. Â â—Our Class III directors are Ms. Ball and Dr. Kulkarni. Â 87 Â Â Director Independence Â Our Board has reviewed the independence of all directors in light of each directorâ€™s (or any family memberâ€™s, if applicable) affiliations with the Company and members of management, as well as significant holdings of our securities and all other facts and circumstances that the Board has deemed relevant in determining the independence of each director. The Board has determined that each of the directors other than Lawrence Klein, our current President and Chief Executive Officer, including Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle, qualify as â€œindependent directorsâ€ as defined by the Nasdaq listing rules. Â Nasdaq listing rules have objective tests and a subjective test for determining who is an â€œindependent director.â€ The subjective test states that an independent director must be a person who lacks a relationship that, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The Board has not established categorical standards or guidelines to make these subjective determinations but considers all relevant facts and circumstances. Â Board Leadership Structure Â Our Board has designated Dr. Kulkarni to serve as Chair of the Board. Although our bylaws do not require that we separate the Chief Executive Officer and Chair positions, our Board believes that having the positions be separate is the appropriate leadership structure for us at this time, as it helps facilitate independent Board oversight of management and allows the Chief Executive Officer to focus on strategy execution and managing the business while the Chair focuses on corporate governance and managing the Board. Â Our Board recognizes that, depending on future circumstances, other leadership models, such as combining the roles of Chief Executive Officer and Chair, might be appropriate. Accordingly, our Board may periodically review its leadership structure. At any time when a non-independent director is serving as Chair, the independent directors will designate a lead independent director to preside at all meetings of the Board at which the Chair is not present, preside over executive sessions of the independent directors (which occur regularly throughout each year), serve as a liaison between the Chair and independent directors, and perform such additional duties as our Board may otherwise determine and delegate. Â Role of Our Board in Risk Oversight Â We face a number of risks, including those described under the section titled â€œRisk Factorsâ€. Our Board believes that risk management is an important part of establishing, updating and executing on our business strategy. Our Board, both as a whole and at the committee level, has oversight responsibility relating to risks that could affect the strategy, business objectives, compliance, operations and the financial condition and performance of the Company. Our Board focuses its oversight on the most significant risks facing the Company and on its processes to identify, prioritize, assess, manage and mitigate those risks. Our Board and its committees receive regular reports from members of our senior management on material risks to the Company, including strategic, operational, financial, legal and regulatory risks. While our Board has an oversight role, management is principally tasked with direct responsibility for managing and assessing risks and the implementation of processes and controls to mitigate their effects on the Company. Our Board believes its administration of its risk oversight function has not significantly impacted its selection of the current leadership structure. Â Board Committees Â We currently have an Audit Committee, a Compensation Committee, and a Governance Committee. We believe that the functioning and composition of these committees complies with the requirements of Nasdaq listing rules and SEC rules and regulations. Each committee has the responsibilities described below. Â 88 Â Â Audit Committee Â The Audit Committee currently comprises Ms. Ball, Dr. Dambkowski, and Dr. Turtle, each of whom qualifies as an independent director for Audit Committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules and has sufficient knowledge in financial and auditing matters to serve the Audit Committee. Ms. Ball chairs the Audit Committee and is an â€œaudit committee financial expertâ€ as defined in Item 407(d)(5)(ii) of Regulation S-K promulgated under the Securities Act. Â The primary responsibilities of the Audit Committee are to oversee our accounting and financial reporting processes, including the audits of the financial statements, and the internal and external audit processes. The Audit Committee also oversees the system of internal controls established by management and our compliance with legal and regulatory requirements. The Audit Committee is also responsible for the review, consideration and approval or ratification of related party transactions. The Audit Committee further oversees the independent auditors, including their independence and objectivity. The Audit Committee is empowered to retain outside legal counsel and other advisors as it deems necessary or appropriate to assist it in fulfilling its responsibilities and to approve the fees and other retention terms of the advisors. Â Compensation Committee Â The Compensation Committee currently comprises Mr. Harwin, Dr. Kulkarni and Dr. Turtle, each of whom qualifies as an independent director for Compensation Committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules. Dr. Turtle chairs the Compensation Committee. Â The primary responsibility of the Compensation Committee is to periodically review and approve the compensation and other benefits of our senior officers and directors. This includes reviewing and approving corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other executive officers, evaluating the performance of these officers in light of the goals and objectives and setting or recommending to the Board the officersâ€™ compensation. The Compensation Committee also administers and makes recommendations to the Board regarding equity incentive plans that are subject to the Boardâ€™s approval, in addition to approving the grant of equity awards under those plans. Â Governance Committee Â The Governance Committee currently comprises Ms. Ball, Dr. Kulkarni and Mr. Harwin, each of whom qualifies as an independent director, as defined under applicable Nasdaq listing rules. Mr. Harwin chairs the Governance Committee. Â The Governance Committee is responsible for engaging in succession planning for our Board, developing and recommending to the Board criteria for identifying and evaluating qualified director candidates and making recommendations to the Board regarding candidates for election or reelection to the Board at each annual stockholdersâ€™ meeting. In addition, the Governance Committee is responsible for overseeing corporate governance matters. The Governance Committee is also responsible for overseeing the structure, composition and functioning of the Board and its committees. Â Compensation Committee Interlocks and Insider Participation Â None of the members of our Compensation Committee has at any time been an officer or employee of the Company. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our Board or Compensation Committee. Â Code of Conduct and Ethics Â The Board has adopted a Code of Conduct and Ethics that establishes the standards of ethical conduct applicable to all our directors, officers and employees. The full text of our Code of Conduct and Ethics is posted on our website at https://ir.orukatx.com/corporate-governance. It addresses, among other matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting, external communications, confidentiality requirements, insider trading, proper use of assets and how to report compliance concerns. Any amendments to the Code of Conduct and Ethics, or any waivers of its requirements, will be posted on our website to the extent required by applicable rules. The Audit Committee is responsible for applying and interpreting our Code of Conduct and Ethics in situations where questions are presented to it. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus. Â 89 Â Â EXECUTIVE COMPENSATION Â All of the information contained in the sections below generally relates to ARCA compensation for fiscal years 2023 and 2022 and was included in the definitive proxy statement/prospectus filed on Form S-4 with the SEC and declared effective on July 24, 2024 (the â€œProxy Statement/Prospectusâ€). Such information has not been adjusted to reflect the effects of the Reverse Stock Split. Since the date of the Proxy Statement/Prospectus, there have been several changes to our senior management, including the following: Â â—Thomas A. Keuerâ€™s resignation as our President and Chief Operating Officer, effective as of August 29, 2024, and termination of employment, effective as of September 1, 2024. Â â—C. Jeffrey

Dekkerâ€™s resignation as our Chief Financial Officer, effective as of August 29, 2024, and termination of employment, effective as of September 1, 2024. Mr. Dekker has entered into a consulting agreement with us, effective as of August 30, 2024, to provide transition services through August 30, 2025, unless terminated earlier in accordance with the agreement. Â â—Lawrence Kleinâ€™s appointment as our President and Chief Executive Officer, effective as of August 29, 2024. Â â—Arjun Agarwalâ€™s appointment as our Senior Vice President, Finance and Treasurer, effective as of August 29, 2024. Â â—Joana Goncalvesâ€™s appointment as our Chief Medical Officer, effective as of August 29, 2024. Â â—Paul Quinlanâ€™s appointment as our General Counsel and Corporate Secretary, effective as of August 29, 2024. Â ARCA Executive Compensation Â The following table shows for the fiscalÂ years ended DecemberÂ 31, 2023 and DecemberÂ 31, 2022, compensation awarded to, paid to, or earned by ARCAâ€™s principal executive officer and its two most highly compensated executive officers as of DecemberÂ 31, 2023, collectively, the ARCA named executive officers: Â Summary Compensation Table Â Name and Principal PositionÂ YearÂ Â Salary ($)(1)Â Â Bonus ($)(2)Â Â Stock Awards ($)Â Â AllÂ Other Compensation ($)(3)Â Â Total ($)Â Michael R.Â BristowÂ Â 2023Â Â Â 345,000Â Â Â â€”Â Â Â â€”Â Â Â 13,800Â Â Â 358,800Â Former President and Chief Executive Officer(4)Â Â 2022Â Â Â 345,000Â Â Â â€”Â Â Â â€”Â Â Â 13,800Â Â Â 358,800Â Thomas A.Â KeuerÂ Â 2023Â Â Â 340,000Â Â Â 35,000Â Â Â â€”Â Â Â 25,802Â Â Â 400,802Â President and Chief Operating OfficerÂ Â 2022Â Â Â 340,000Â Â Â â€”Â Â Â 88,400Â Â Â 20,593Â Â Â 448,993Â C.Â Jeffrey DekkerÂ Â 2023Â Â Â 270,000Â Â Â 35,000Â Â Â â€”Â Â Â 18,072Â Â Â 323,072Â Chief Financial OfficerÂ Â Â Â

in NoteÂ 8 to ARCAâ€™s financial statements included in the Proxy Statement/Prospectus. The 2020 Plan only has options outstanding as of DecemberÂ 31, 2023; no warrants or rights are outstanding under this plan; therefore, all values in the above table relate solely to the outstanding options. Â On SeptemberÂ 17, 2013, ARCA stockholders approved the 2013 Plan at ARCAâ€™s 2013 annual meeting of stockholders. On JuneÂ 9, 2016, ARCA stockholders approved an amendment to the 2013 Plan (as amended, the â€œAmended 2013 Planâ€). A description of the 2013 Plan and the Amended 2013 Plan is set forth in NoteÂ 8 to ARCAâ€™s financial statements included in the Proxy Statement/Prospectus. The Amended 2013 Plan only has options outstanding as of DecemberÂ 31, 2023; no warrants or rights are outstanding under this plan; therefore, all values in the above table relate solely to the outstanding options. Â Compensation Risks Â ARCA believes its approach to goal setting, setting of targets with payouts at multiple levels of performance, and evaluation of performance results assist in mitigating excessive risk-taking that could harm the value or reward poor judgment by its executives. ARCA believes several features of its programs reflect sound risk management practices. ARCA believes it has allocated compensation among base salary and short and long-term compensation target opportunities in such a way as to not encourage excessive risk-taking. The multi-year vesting of equity awards properly accounts for the time horizon of risk. Furthermore, ARCAâ€™s Compensation Committee assesses and monitors whether any of ARCAâ€™s compensation policies and programs has the potential to encourage excessive risk-taking on an annual basis. Â 95 Â Â SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS Â The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial ownership of our Common Stock as of November 1, 2024. Â â—each person or group of affiliated persons, who is known by us to be the beneficial owner of more than 5% of Common Stock; Â â—each of our directors; Â â—each of our named executive officers; and Â â—all of our current directors and executive officers as a group. Â The column entitled â€œPercentage of Shares Outstanding Beneficially Ownedâ€ is based on a total of 34,998,550 shares of our Common Stock outstanding as of November 1, 2024. Â Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to the Common Stock. Shares of Common Stock subject to options that are currently exercisable or exercisable within 60 days of the date of this table are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Due to the conversion limitations on the Series A Preferred Stock, shares of underlying common stock have been excluded from beneficial ownership set forth below. Except as otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of the shares of Common Stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise indicated in the table below, addresses of named beneficial owners are in care of Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025. Â Name of Beneficial OwnerÂ NumberÂ of Shares Beneficially OwnedÂ Â Percentage ofÂ Shares Outstanding Beneficially OwnedÂ Entities affiliated with Fairmount Funds Management LLC(1)Â Â 7,941,690Â Â Â 19.99% FMR LLC(2)Â Â 4,682,300Â Â Â 13.38% Entities affiliated with Venrock Healthcare Capital Partners(3)Â Â 3,541,941Â Â Â 9.99% Entities affiliated with RTW Investments, LP(4)Â Â 1,963,147Â Â Â 5.61% Named Executive Officers and Directors:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Lawrence Klein(5)Â Â 852,338Â Â Â 2.44% Arjun AgarwalÂ Â â€”Â Â Â *Â Joana GoncalvesÂ Â â€”Â Â Â *Â Paul QuinlanÂ Â â€”Â Â Â *Â Michael R. Bristow(6)Â Â 399Â Â Â *Â Thomas A. Keuer(7)Â Â 3,394â€‚Â Â Â *Â C. Jeffrey Dekker(8)Â Â 3,333Â Â Â *Â Cameron Turtle(9)Â Â 85,233â€‚Â Â Â *Â Samarth KulkarniÂ Â â€”Â Â Â *Â Peter Harwin(1)Â Â 7,941,690Â Â Â 19.99% Carl DambkowskiÂ Â â€”Â Â Â *Â Kristine BallÂ Â â€”Â Â Â *Â All executive officers and directors as a group (9Â persons)(10)Â Â 8,879,261Â Â Â 22.67% Â Â *Less than 1%. Â 96 Â Â (1) Consists of (i) (A) 638,614 shares of common stock, (B) 316,025 shares of common stock issuable upon the exercise of pre-funded warrants and (C) 4,413,743 shares of common stock issuable upon conversion of 52,965 shares of Series B Preferred Stock held by Fairmount Healthcare Fund II L.P. (â€œFairmount Fund IIâ€) and (ii) 2,573,308 shares of common stock held by Fairmount Healthcare Co-Invest III L.P. (â€œFairmount Fund IIIâ€). Excludes (i) 4,981,639 shares of common stock issuable upon the exercise of the pre-funded warrants, (ii) 7,014,406 shares of common stock issuable upon the conversion of 84,173 shares of Series B Preferred Stock and (iii) 160,000 shares of common stock issuable upon the conversion of 160 shares of Series A Preferred Stock owned by Fairmount Fund II. The pre-funded warrants and Series A Preferred Stock are subject to a beneficial ownership limitation of 9.99% and the shares of Series B Preferred Stock are subject to a beneficial ownership limitation of 19.99%, which such limitations restrict Fairmount Funds Management LLC (â€œFairmountâ€) and its affiliates from exercising that portion of the warrants and converting those shares of preferred stock that would result in Fairmount and its affiliates owning, after exercise or conversion, a number of shares of common stock in excess of the applicable ownership limitation. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the shares of common stock, the beneficial ownership limitation applicable to the shares of Series B Preferred Stock will automatically reduce to 9.99%. Fairmount serves as investment manager for Fairmount Fund II and Fairmount Fund III. Fairmount Fund II and Fairmount Fund III have delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in Fairmount Fund II and Fairmount Fund IIIâ€™s portfolios. Because Fairmount Fund II and Fairmount Fund III have divested themselves of voting and investment power over the securities they hold and may not revoke that delegation on less than 61 daysâ€™ notice, Fairmount Fund II and Fairmount Fund III disclaim beneficial ownership of the securities they hold. The general partner of Fairmount is Fairmount Funds Management GP LLC (â€œFairmount GPâ€). As managing members of Fairmount GP, Peter Harwin and Tomas Kiselak may be deemed to have voting and investment power over the shares held by Fairmount Fund II and Fairmount Fund III. Fairmount, Fairmount GP, Peter Harwin and Tomas Kiselak disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The address of the entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428. (2) All of the shares listed in the table above are owned by funds or accounts managed by direct or indirect subsidiaries of FMR LLC, all of which shares are beneficially owned, or may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholdersâ€™ voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholdersâ€™ voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of FMR LLC is 245 Summer Street, Boston, MA 02210. (3) Consists of (i) 2,350,074 shares of common stock and 351,506 shares of common stock issuable upon the exercise of pre-funded warrants held by Venrock Healthcare Capital Partners EG, L.P. (â€œVHCPEGâ€), (ii) 668,656 shares of common stock and 95,284 shares of common stock issuable upon the exercise of pre-funded warrants held by Venrock Healthcare Capital Partners III, L.P. (â€œVHCP3â€), and (iii) 66,890 shares of common stock and 9,531 shares of common stock issuable upon the exercise of pre-funded warrants held by VHCP Co-Investment Holdings III, LLC (â€œVHCPCo3â€). Excludes (i) 54,474, 12,504 and 1,244 shares of common stock issuable upon the exercise of the pre-funded warrants held by VHCPEG, VHCP3 and VHCPCo3, respectively, and (ii) 157,000, 39,000 and 4,000 shares of common stock issuable upon the conversion of Series A Preferred Stock held by VHCPEG, VHCP3 and VHCPCo3, respectively. The pre-funded warrants and Series A Preferred Stock are subject to a beneficial ownership limitation of 9.99%, which such limitations restrict Venrock Healthcare Capital Partners and its affiliates from exercising that portion of the warrants or Series A Preferred Stock that would result in Venrock Healthcare Capital Partners and its affiliates owning, after exercise, a number of shares of common stock in excess of the applicable ownership limitation. VHCP Management III, LLC (â€œVHCPM3â€) is the sole general partner of VHCP3 and the sole manager of VHCPCo3. VHCP Management EG, LLC (â€œVHCPM EGâ€) is the sole general partner of VHCPEG. As voting members of VHCPM3 and VHCPM EG, Dr. Bong Koh and Nimish Shah may be deemed beneficial owners of any securities beneficially owned by VHCPM3 and VHCPM EG. The principal business address of each of these persons and entities is 7 Bryant Park, 23rd Floor, New York, NY 10018. (4) Consists of 1,963,147 shares of common stock held in the aggregate by RTW Master Fund, Ltd. (â€œRTW Master Fundâ€), RTW Innovation Master Fund, Ltd. (â€œRTW Innovation Master Fundâ€), and RTW Biotech Opportunities Operating Ltd. (â€œRTW Biotechâ€ and together with RTW Master Fund and RTW Innovation Fund, the â€œRTW Fundsâ€). Excludes 95,000 shares of common stock issuable upon the conversion of Series A Preferred Stock held in the aggregate by the RTW Funds. The Series A Preferred Stock is subject to a beneficial ownership limitation of 9.99%, which such limitations restrict the RTW Funds and its affiliates from exercising that portion of the Series A Preferred Stock that would result in the RTW Funds and its affiliates owning, after exercise, a number of shares of common stock in excess of the applicable ownership limitation. RTW Investments, LP (â€œRTWâ€), in its capacity as the investment manager of the RTW Funds, has the power to vote and the power to direct the disposition of the shares held by the RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing Partner of RTW, has the power to direct the vote and disposition of the securities held by RTW. Dr. Wong disclaims beneficial ownership of the shares held by the RTW Funds, except to the extent of his pecuniary interest therein. The principal business address of RTW Investments, LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr. Wong and each of the RTW Funds is c/o RTW Investments, LP, 40 10th Avenue, Floor 7, New York, NY 10014. (5) Includes 852,338 shares of restricted voting common stock. (6) Includes (i) 92 shares owned by Investocor Trust, of which Dr. Bristow is the sole trustee and (ii) 117 shares owned by NFS as Custodian for Michael Bristowâ€™s IRA. Dr. Bristow and ARCA mutually agreed to conclude Dr. Bristowâ€™s employment effective April 3, 2024. (7) Mr. Keuer resigned as named executive officer at the Closing and his last day of employment was September 1, 2024, which termination was considered to be without â€œcauseâ€ related to a change in control for purposes of his employment agreement with ARCA. (8) Mr. Dekker resigned as named executive officer at the Closing and his last day of employment was September 1, 2024, which termination was considered to be without â€œcauseâ€ related to a change in control for purposes of his employment agreement with ARCA. (9)Includes 85,233 shares of restricted voting common stock held by the Turtle Family Trust, for which Mr. Turtle serves as Trustee. (10)See notes (1), (5) and (9) above. Â 97 Â Â CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS Â As discussed in the â€œCertain Relationships and Related Party Transactions of the Combined Companyâ€ section of the Proxy Statement/Prospectus, the following is a description of each transaction involving (1) the Company since the Closing, including proposed transactions, (2) Pre-Merger Oruka since February 6, 2024 (its inception) through the Closing, and (3) ARCA, beginning on January 1, 2022, and in which: Â â—the Company, Pre-Merger Oruka, or ARCA has been, or is to be, a participant; Â â—the amount involved exceeded or will exceed the lesser of $120,000 and 1% of the average of either the Companyâ€™s, Pre-Merger Orukaâ€™s, or ARCAâ€™s assets (as the case may be); and Â â—in which the directors, executive officers, former directors, former executive officers, director nominees and holders of more than 5% of capital stock of the Company, Pre-Merger Oruka, or ARCA (as the case may be), or other persons as may be required to be disclosed pursuant to Item 404 of Regulation S-K, had or will have a direct or indirect material interest. Â Other than the compensation agreements and other arrangements disclosed above under the heading â€œExecutive Compensation,â€ and the transactions described below, since the filing date of the Proxy Statement/Prospectus, there were no transactions or series of similar transactions to which ARCA, Pre-Merger Oruka, or the Company were a party in which the amount involved exceed $120,000 (or, if less, 1% of the average of ARCA, Pre-Merger Oruka, or the Companyâ€™s total asset amounts (as the case may be)) and in which any director, executive officer, holder of 5% or more of any class of ARCAâ€™s, Pre-Merger Orukaâ€™s or the Companyâ€™s capital stock (as the case may be) or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had a direct or indirect material interest. Â ARCA Transactions Â Transactions With ARCAâ€™s Former President and Chief Executive Officer Â ARCA previously entered into unrestricted research grants with its former President and Chief Executive Officerâ€™s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants was contingent upon ARCAâ€™s financial condition, and could be deferred or terminated at ARCAâ€™s discretion. There was no expense under these arrangements for the threeÂ months ended MarchÂ 31, 2024. Total expense under these arrangements for the threeÂ months ended MarchÂ 31, 2023 was $108,000. Total expense under these arrangements for theÂ years ended DecemberÂ 31, 2023 and 2022 was $(91,000) and $432,000, respectively. In DecemberÂ 2023, ARCA made a payment of $125,000 for the grant period JulyÂ 2022 through DecemberÂ 2023 under these arrangements. In AprilÂ 2024, the President and Chief Executive Officer resigned. Â Cooperation Agreement Â ARCA was a party to a Cooperation Agreement (the â€œCooperation Agreementâ€) with Cable Car Capital LLC, The Funicular Fund, LP, Funicular Funds, LP and Jacob Ma-WeaverÂ (collectively, â€œCable Carâ€). Â Pursuant to the Cooperation Agreement, ARCAâ€™s board of directors appointed Mr.Â Ma-WeaverÂ as a ClassÂ III director with a term expiring at ARCAâ€™s 2024 annual meeting of stockholders, effective JuneÂ 15, 2022 and appointed Mr.Â Ma-WeaverÂ to the Special Committee of ARCAâ€™s board of directors (the â€œFirst Director Appointmentâ€). Mr. Ma-Weaver resigned from ARCAâ€™s board of directors immediately prior to the Closing. Â Additionally, under the terms of the Cooperation Agreement, ARCA and Cable Car initiated a process and subsequently identified a mutually acceptable second independent director, Mr.Â James Flynn, to join ARCAâ€™s board of directors. Mr.Â Flynn was elected as director at the 2022 annual meeting of stockholders. Mr. Flynn resigned from ARCAâ€™s board of directors immediately prior to the Closing. Â Under the terms of the Cooperation Agreement, Cable Car agreed to abide by customary standstill restrictions from the date of the Cooperation Agreement until the earlier to occur of (i)Â the 180thÂ day after the First Director Appointment is no longer serving as a director of ARCA and (ii)Â the 90thÂ day prior to the 2023 Annual Meeting (such period, the â€œCooperation Periodâ€), including that Cable Car would not, among other things, (i)Â seek additional representation, or the removal of an existing director, on ARCAâ€™s board of directors, (ii)Â engage in any solicitation of proxies, or (iii)Â initiate, propose or otherwise solicit, including any solicitations of the type contemplated by RuleÂ 14a-2(b)Â promulgated under the Securities ExchangeÂ ActÂ ofÂ 1934 of ARCAâ€™s stockholders for the approval of, any stockholder proposal. The Cooperation Period expired on NovemberÂ 1, 2023, the 90thÂ day prior to the 2023 Annual Meeting. Â ARCA and Cable Car also agreed to customary mutual non-disparagementÂ obligations. Â 98 Â Â Pre-Merger Oruka Transactions Â Private Placements of Securities Â Pre-Merger Oruka SeriesÂ A Preferred Stock and Convertible NoteÂ Financing Â On MarchÂ 6, 2024, Oruka entered into a Convertible Note Purchase Agreement with Fairmount Healthcare Fund II, L.P. (â€œFairmount Fund IIâ€), whereby Oruka issued and sold to Fairmount Fund II (i)Â an aggregate of 20,000,000 shares of Pre-Merger Oruka Series A Preferred Stock at a purchase price of $0.15 per share and (ii)Â a convertible note (the â€œConvertible Noteâ€) with an initial principal amount of $25.0 million at an interest rate of 12% per annum, for aggregate gross proceeds of $28Â million. Fairmount Fund II contributed the aggregate principal amount of $25.0 million and all accrued interest under the Convertible Note (unpaid accrued interest of $1.5 million divided by the conversion price of $66.62 ($5.55 prior to the impact of the Reverse Stock Split) per share) in exchange for Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded warrants in connection with the Pre-Closing Financing (as defined below), immediately prior to the completion of the Merger. Fairmount Funds Management (â€œFairmountâ€) is the investment manager of Fairmount Fund II. Peter Harwin, one of our directors, is a managing member of Fairmount. Â Pre-Merger Oruka Pre-Closing Financing Â On AprilÂ 3, 2024, in connection with the execution of the Merger Agreement, Pre-Merger Oruka entered into the Subscription Agreement to consummate the Pre-Closing Financing. Pursuant to the Subscription Agreement, the Financing Investors purchased 39,873,706 shares of Pre-Merger Oruka common stock and 9,664,208 Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0 million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note which converted to 4,764,032 shares of Pre-Merger Oruka common stock), immediately prior to the Closing and before the effect of the Reverse Stock Split. Three of the investors or their affiliates were beneficial holders of more than 5% of Pre-Merger Orukaâ€™s capital stock, and the table below sets forth the number of shares of Pre-Merger Oruka common stock and Pre-Merger Oruka pre-funded warrants purchased by such holders at the closing of the Pre-Closing Financing. Â ParticipantÂ Shares of Pre-Merger Oruka Common StockÂ Â Pre-funded Warrants of Pre-Merger OrukaÂ Â Total Purchase PriceÂ Entities affiliated with FairmountÂ Â 5,139,797Â Â Â 9,271,241Â Â Â $79,907,282(1) Entities affiliated with Venrock Healthcare Capital PartnersÂ Â 5,011,172Â Â Â 392,967Â Â Â $29,996,067Â Entities affiliated with FMR LLCÂ Â 4,503,445Â Â Â â€”Â Â Â $24,999,974Â Â Â Â (1)Includes $25.0 million of proceeds previously received by Pre-Merger Oruka from the issuance of the Convertible Note and accrued interest on such note, with the remainder of the purchase price paid in cash. Â Company Transactions Â September 2024 Private Placement Â On September 11, 2024, the Company entered into the SPA with the Selling Stockholders to consummate the Private Placement. Pursuant to the SPA, the Selling Stockholders purchased (i) an aggregate of 5,600,000 shares of Common Stock, at a price per share of $23.00, (ii) an aggregate of 2,439 shares of Series A Preferred Stock (each Series A Preferred Stock is convertible into 1,000 shares of Company Common Stock), at a price per share of $23,000.00, and (iii) pre-funded warrants to purchase an aggregate of 680,000 shares of Common Stock at a purchase price of $22.999 per pre-funded warrant, which represents the per share purchase price of the Private Placement Common Shares less the $0.001 per share exercise price for each pre-funded warrant, for an aggregate purchase price of approximately $200.5 million. Subject to receiving the requisite stockholder approval and certain beneficial ownership limitations set by each holder of Series A Preferred Stock, each share of Series A Preferred Stock will automatically convert into an aggregate of 1,000 shares of Common Stock. Three of the Selling Stockholders or their affiliates were

beneficial holders of more than 5% of the Companyâ€™s capital stock, and the table below sets forth the number of shares of Common Stock, Series A Preferred Stock and pre-funded warrants purchased by such holders at the closing of the Private Placement. Â ParticipantÂ Shares of Common StockÂ Â Series A Preferred StockÂ Â Pre-Funded WarrantsÂ Â Total Purchase PriceÂ Entities affiliated with FMR LLCÂ Â 2,105,000Â Â Â 830Â Â Â â€”Â Â $67,505,000Â Entities affiliated with Venrock Healthcare Capital PartnersÂ Â 150,000Â Â Â 200Â Â Â 300,000Â Â $14,949,700Â Entities affiliated with FairmountÂ Â 275,000Â Â Â 160Â Â Â â€”Â Â $10,005,000Â Â 99 Â Â Our Relationship with Paragon and Paruka Â We are party to a number of agreements with Paragon and Paruka. Paragon and Paruka beneficially own more than 5% of our capital stock through their joint holdings of our Common Stock. Fairmount beneficially owns more than 5% of our capital, one of Fairmountâ€™s employees serves on our Board, and Fairmount beneficially owns more than 5% of Paragon. Fairmount appointed Paragonâ€™s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon, but is not the beneficial owner of Paragonâ€™s securities. Paruka is an entity formed by Paragon as a vehicle to hold equity in our Company in order to share profits with certain employees of Paragon. Â In MarchÂ 2024, Pre-Merger Oruka entered into the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to us. The Option Agreements include two selected targets, IL-23 (ORKA-001) and IL-17A/F (ORKA-002). Under the Option Agreements, we have the exclusive options to, on a research program-by-research program basis, be granted an exclusive, worldwide license to all of Paragonâ€™s right, title and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected targets (each, an â€œOptionâ€), with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease. If we exercise our options, we will be required to make non-refundable milestone payments to Paragon of up to $12.0 million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0 million under each respective agreement upon the achievement of certain regulatory milestones as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale. From time to time, we can choose to add additional targets to the collaboration by mutual agreement with Paragon. During the three months ended September 30, 2024, we exercised our option for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement of development candidate as research and development expense in our condensed consolidated statements of operations and comprehensive loss for the three months ended September 30, 2024. As of September 30, 2024, this amount is included under related party accounts payable and other current liabilities on the condensed consolidated balance sheet. Â Our exclusive Option with respect to each research program for a particular target initiated by the parties (â€œResearch Programâ€) is exercisable at our sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number ofÂ days following (i) with respect to any Research Program other than ORKA-001, the delivery of the data package from Paragon related to the results of the Research Plan activities, or (ii) with respect to ORKA-001, the completion of the IL-23 antibody selection process described in the agreement (the â€œOption Periodâ€). There is no payment due upon exercise of an Option pursuant to the Option Agreements. Â Unless terminated earlier, the Option Agreements shall continue in force on a Research Program-by-Research Program basis until the earlier of: (i)Â the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by us; (ii)Â the expiration of the 30-day period after we exercise our Option with respect to such Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration of the applicable research term (the â€œTermâ€). Upon the expiration of the Term for all then-existing Research Programs, under the Option Agreements, the Option Agreements will automatically expire in its entirety. We may terminate the Option Agreements or any Research Program at any time for any or no reason upon 30Â daysâ€™ prior written notice to Paragon, provided that we must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Option Agreements or a Research Program immediately upon written notice to us if, as a result of any action or failure to act by us or our affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of months. Each party has the right to terminate the Option Agreements or any Research Program upon (i)Â 30Â daysâ€™ prior written notice of the other partyâ€™s material breach that remains uncured for the 30-day period and (ii)Â the other partyâ€™s bankruptcy. Â Pursuant to the Option Agreements, on a research program-by-research program basis following the finalization of the Research Plan for each respective research program, we were required to pay Paragon a one-time nonrefundable research initiation fee of $0.8 million related to the ORKA-001 program. This amount was recognized as a research and development expense during the period from February 6, 2024 (inception) to September 30, 2024. In June 2024, pursuant to the Option Agreements with Paragon, we completed the selection process of our development candidate for IL-23 antibody for the ORKA-001 program. We were responsible for 50% of the development costs incurred through the completion of the IL-23 selection process. We received the rights to at least one selected IL-23 antibody in June 2024. During the three months ended September 30, 2024, we exercised our option for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement of development candidate as research and development expense in the Companyâ€™s condensed consolidated statements of operations and comprehensive loss for each of the three months ended September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024. Our share of development costs incurred during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024 was $0.8 million and $13.2 million, respectively, which were recorded as research and development expenses during the respective periods. An amount of $2.3 million is included in related party accounts payable and other current liabilities as of September 30, 2024. Â 100 Â Â We were also required to reimburse Paragon $3.3 million for development costs related to ORKA-002 incurred by Paragon through December 31, 2023 and certain other development costs incurred by Paragon between January 1, 2024 and March 6, 2024 as stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February 6, 2024 (inception) to September 30, 2024. We are also responsible for the development costs incurred by Paragon from January 1, 2024 through the completion of the IL-17 selection process. We recognized an amount of $0.8 million payable to Paragon for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as research and development expenses in the period from February 6, 2024 (inception) to September 30, 2024. We accounted for development costs of $3.8 million and $6.6 million during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively, as research and development expenses during the respective periods. An amount of $3.8 million is included in related party accounts payable and other current liabilities as of September 30, 2024. Â As part of the Option Agreements, on each of December 31, 2024 and December 31, 2025, we will grant warrants to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully diluted basis with an exercise price equal to the fair market value of the underlying shares on the grant date. The warrants are liability-classified and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss as stock-based compensation expenses under research and development expenses. Â Indemnification Agreements and Insurance Â We have entered into an indemnification agreement with each of the directors and officers and purchased directorsâ€™ and officersâ€™ liability insurance. The indemnification agreements require us to indemnify our directors and officers to the fullest extent permitted under Delaware law. Â Review, Approval or Ratification of Transactions with Related Parties Â Prior to the Closing, Pre-Merger Oruka did not have a formal policy regarding approval of transactions with related parties. All disclosable transactions with related parties which occurred prior to the Closing were approved by the directors not interested in such transactions, pursuant to Section 144(a)(1) of the DGCL. Â The Companyâ€™s Board has adopted a written related person transactions policy. Under this policy, our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of our Common Stock, and any members of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a material related person transaction with us without the review and approval of our Audit Committee, or a committee composed solely of independent directors in the event it is inappropriate for our Audit Committee to review such transaction due to a conflict of interest. The policy provides that, subject to limited exceptions, any transaction, arrangement or relationship or series of similar transactions, arrangements or relationships in which (1) the aggregate amount involved since the beginning of the Companyâ€™s last completed fiscal year exceeds or is expected to exceed $120,000, (2) the Company or any of our subsidiaries is a participant, and (3) any related person has or will have a direct or indirect interest, will be presented to our Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, our Audit Committee will consider the material facts and other factors it deems appropriate, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related personâ€™s interest in the transaction. Â 101 Â Â SELLING STOCKHOLDERS Â This prospectus covers the resale or other disposition from time to time by the Selling Stockholders identified in the table below of up to an aggregate of 8,719,000 shares of our Common Stock. The Selling Stockholders may from time to time offer and sell any or all of the Resale Shares set forth below pursuant to this prospectus and any accompanying prospectus supplement. Â On September 11, 2024, we entered into the SPA, pursuant to which we sold an aggregate of (i) 5,600,000 shares of our Common Stock, (ii) 2,439 shares of our Series A Preferred Stock, which will automatically convert into 1,000 shares of Common Stock, subject to stockholder approval and certain beneficial ownership limitations set by each holder, pursuant to the Series A Certificate of Designation, and (iii) Pre-Funded Warrants to purchase an aggregate of 680,000 shares of Common Stock at a purchase price of $22.999 per Pre-Funded Warrant, which represents the per share purchase price of the Private Placement Common Shares less the $0.001 per share exercise price for each Pre-Funded Warrant, for an aggregate purchase price of approximately $200.5 million. This prospectus covers the resale or other disposition by the Selling Stockholders or their pledgees, donees, transferees or other successors-in-interest that receive their shares after the date of this prospectus of up to the total number of shares of Common Stock, shares of Common Stock issuable upon the conversion of the Series A Preferred Stock, and shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants sold to the Selling Stockholders pursuant to the SPA. This prospectus covers the resale or other disposition by the Selling Stockholders or their transferees of up to the total number of Private Placement Common Shares, Private Placement Preferred Shares and Pre-Funded Warrants issued to the Selling Stockholders upon conversion of the Private Placement Preferred Shares and exercise of the Pre-Funded Warrants issued pursuant to the SPA. Throughout this prospectus, when we refer to the â€œSelling Stockholders,â€ we are referring to the purchasers under the SPA listed in the table below. Â We are registering the Resale Shares to permit the Selling Stockholders and their pledgees, donees, transferees or other successors-in interest that receive their shares after the date of this prospectus to resell or otherwise dispose of the shares in the manner contemplated under â€œPlan of Distributionâ€ herein. Â Except as otherwise disclosed herein, the Selling Stockholders do not have, and within the past three years have not had, any position, office or other material relationship with us. Â The following table sets forth the names of the Selling Stockholders, the number of shares of our Common Stock owned by the Selling Stockholders, the number of shares of our Common Stock that may be offered under this prospectus and the number of shares of our Common Stock that will be owned after this offering by the Selling Stockholders assuming all of the shares registered for resale hereby are sold. Â The Selling Stockholders may sell some, all or none of their Resale Shares. We do not know how long the Selling Stockholders will hold the Resale Shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Stockholders regarding the sale or other disposition of any of the Resale Shares. The Resale Shares covered hereby may be offered from time to time by the Selling Stockholders, provided that Resale Shares issued upon conversion of Series A Preferred Stock may only be offered after such shares of Series A Preferred Stock are converted to Common Stock pursuant to the terms of the Series A Certificate of Designation. Â The information set forth below is based upon information obtained from the Selling Stockholders and upon information in our possession regarding the issuance of the Private Placement Common Shares, Private Placement Preferred Shares and shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants in connection with the September 2024 PIPE. The percentages of Common Stock owned after the offering by each Selling Stockholder below are based on 34,998,550 shares of Common Stock outstanding as of November 1, 2024, and, for each Selling Stockholder, assumes the conversion of only the Series A Preferred Stock and exercise of only the Pre-Funded Warrants owned by such Selling Stockholder but not the Series A Preferred Stock or Pre-Funded Warrants owned by any other Selling Stockholder. The numbers of shares of Common Stock beneficially owned before and after the offering presented in the table below do not give effect to any Beneficial Ownership Limitations with respect to the Series A Preferred Stock or Pre-Funded Warrants. Â 102 Â Â Name of Selling Stockholders(1)Â Common Stock Beneficially Owned Before the Offering (2)Â Common Stock that May Be Offered Pursuant to ProspectusÂ Common Stock Beneficially Owned After the Offering (2) Â Â Â Â Â Â Â Â Â NumberÂ Â Â Percentage (%)Â Fidelity Securities Fund: Fidelity Small Cap Growth Fund (3)Â Â 555,043Â Â 179,838Â Â 375,205Â Â Â 1.07% Fidelity Securities Fund: Fidelity Small Cap Growth K6 Fund (3)Â Â 225,831Â Â 86,378Â Â 139,453Â Â Â *Â Fidelity Advisor Series VII:Â Â Fidelity Advisor Biotechnology Fund (3)Â Â 609,300Â Â 197,572Â Â 411,728Â Â Â Â 1.18% Fidelity Select Portfolios:Â Â Biotechnology Portfolio (3)Â Â 704,983Â Â 704,883Â Â 100Â Â Â *Â Fidelity Advisor Series VII:Â Â Fidelity Advisor Health Care Fund (3)Â Â 629,688Â Â 67,978Â Â 561,710Â Â Â *Â Fidelity Select Portfolios:Â Â Health Care Portfolio (3)Â Â 999,710Â Â 110,356Â Â 889,354Â Â Â 2.45% Variable Insurance Products Fund IV: VIP Health Care Portfolio (3)Â Â 159,859Â Â 25,109Â Â 134,750Â Â Â *Â Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund (3)Â Â 78,239Â Â 78,239Â Â â€”Â Â Â Â â€”Â Â Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund (3)Â Â 297,445Â Â 297,445Â Â â€”Â Â Â Â â€”Â Â Fidelity Growth Company Commingled Pool (3)Â Â 400,267Â Â 400,267Â Â â€”Â Â Â Â â€”Â Â Fidelity Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund (3)Â Â 92,707Â Â 92,707Â Â â€”Â Â Â Â â€”Â Â Fidelity Capital Trust: Fidelity Stock Selector Small Cap Fund (3)Â Â 283,456Â Â 283,456Â Â â€”Â Â Â Â â€”Â Â Fidelity Securities Fund: Fidelity Series Small Cap Opportunities Fund (3)Â Â 410,772Â Â 410,772Â Â â€”Â Â Â Â â€”Â Â Braidwell Partners Master Fund LP (4)Â Â 1,777,426Â Â 1,630,000Â Â 147,426Â Â Â *Â Entities Associated with Venrock Healthcare Capital Partners (5)Â Â 3,541,941Â Â 650,000Â Â 2,891,941Â Â Â 7.50% Entities associated with Fairmount Funds Management LLC (6)Â Â 7,941,690Â Â 435,000Â Â 7,506,690Â Â Â Â 18.90% AI Biotechnology LLC (7)Â Â 1,791,052Â Â 350,000Â Â 1,441,052Â Â Â Â 4.12% Entities associated with Blackstone Alternative Asset Management Associates LLC (8)Â Â 590,174Â Â 350,000Â Â 240,174Â Â Â *Â Point72 Associates, LLC (9)Â Â 618,671Â Â 340,000Â Â 278,671Â Â Â *Â Entities Associated with Frazier Life Sciences (10)Â Â 583,327Â Â 326,000Â Â 257,327Â Â Â *Â Entities Associated with Paradigm BioCapital Advisors LP (11)Â Â 819,660Â Â 305,000Â Â 514,660Â Â Â Â 1.47% Entities associated with RTW Investments, LP (12)Â Â 2,058,147Â Â 285,000Â Â 1,773,147Â Â Â 5.07% Entities Associated with T. Rowe Price Associates, Inc. (13)Â Â 1,244,191Â Â 215,000Â Â 1,029,191Â Â Â 2.94% SR One Capital Opportunities Fund I, LP (14)Â Â 430,330Â Â 173,000Â Â 257,330Â Â Â *Â Entities associated with Janus Henderson Investors US LLC (15)Â Â 335,456Â Â 150,000Â Â 185,456Â Â Â *Â Commodore Capital Master LP (16)Â Â 1,419,714Â Â 150,000Â Â 1,269,714Â Â Â 3.62% Kalehua Capital Partners LP (17)Â Â 150,000Â Â 150,000Â Â â€”Â Â Â Â â€”Â Â Avidity Private Master Fund I LP (18)Â Â 701,363Â Â 110,000Â Â 591,363Â Â Â Â 1.69%Â Adage Capital Partners LP (19)Â Â 200,000Â Â 100,000Â Â 100,000Â Â Â *Â Affinity Healthcare Fund, LP (20)Â Â 284,836Â Â 45,000Â Â 239,836Â Â Â *Â Allostery Master Fund, LP (21)Â Â 20,000Â Â 20,000Â Â â€”Â Â Â Â â€”Â Â Â Â Â *Less than 1% (1)To our knowledge, unless otherwise indicated, all persons named in the table above have sole voting and investment power with respect to their shares of Common Stock. Unless an address is provided below, the address for the holder is 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025. Â 103 Â Â (2)â€œBeneficial ownershipâ€ is a term broadly defined by the SEC in Rule 13d-3 under the Exchange Act, and includes more than the typical form of stock ownership, that is, stock held in the personâ€™s name. The term also includes what is referred to as â€œindirect ownership,â€ meaning ownership of shares as to which a person has or shares investment power. Notwithstanding the foregoing, the beneficial ownership amounts assume the sale of all Common Stock that may be offered pursuant to this prospectus without taking into account certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock (i) prior to the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, or (ii) if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (established by the holder not to exceed 19.99%) (the â€œBeneficial Ownership Limitationâ€) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. (3)These funds and accounts are managed by direct or indirect subsidiaries of FMR LLC.Â Â Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC.Â Â Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholdersâ€™ voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholdersâ€™ voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group

with respect to FMR LLC.Â Â The address of these funds and accounts is 245 Summer Street, Boston, MA 02210. (4)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of (i) 250,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Braidwell Partners Master Fund LP (â€œBraidwell Partnersâ€), (ii) 1,147,426 shares of Common Stock held by Braidwell Partners and (iii) 380,000 shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants held by Braidwell Partners. Braidwell LP (the â€œBraidwell Investment Managerâ€) is the investment manager of Braidwell Partners. Braidwell GP LLC (the â€œBraidwell GPâ€) is the general partner of Braidwell Partners. Braidwell Management LLC (the â€œBraidwell IM GPâ€) is the general partner of the Braidwell Investment Manager and the managing member of the Braidwell GP. Messrs. Alexander T. Karnal and Brian J. Kreiter (together with Braidwell Partners, the Braidwell Investment Manager, the Braidwell GP and the Braidwell IM GP, the â€œBraidwell Partiesâ€) together own, directly or indirectly, the Braidwell Investment Manager, the Braidwell GP and the Braidwell IM GP. The address of Braidwell Partners is c/o Maples Corporate Services Limited, P.O Box 309, Ugland House, Grand Cayman, KY1-1104 Cayman Islands. The principal address of the Braidwell Investment Manager, the Braidwell GP and the Co-Founders is One Harbor Point, 2200 Atlantic Street, 4th Floor, Stamford, Connecticut 06902. The Braidwell Parties may be deemed to have shared voting and dispositive power with respect to the shares of Common Stock held by Braidwell Partners. Each of the Braidwell Parties disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Â 104 Â Â (5)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consists of (i) 2,350,074 shares of common stock and 351,506 shares of common stock issuable upon the exercise of pre-funded warrants held by Venrock Healthcare Capital Partners EG, L.P. (â€œVHCPEGâ€), (ii) 668,656 shares of common stock and 95,284 shares of common stock issuable upon the exercise of pre-funded warrants held by Venrock Healthcare Capital Partners III, L.P. (â€œVHCP3â€), and (iii) 66,890 shares of common stock and 9,531 shares of common stock issuable upon the exercise of pre-funded warrants held by VHCP Co-Investment Holdings III, LLC (â€œVHCPCo3â€). Excludes (i) 54,474, 12,504 and 1,244 shares of common stock issuable upon the exercise of the pre-funded warrants held by VHCPEG, VHCP3 and VHCPCo3, respectively, and (ii) 157,000, 39,000 and 4,000 shares of common stock issuable upon the conversion of Series A Preferred Stock held by VHCPEG, VHCP3 and VHCPCo3, respectively. The pre-funded warrants and Series A Preferred Stock are subject to a beneficial ownership limitation of 9.99%, which such limitations restrict Venrock Healthcare Capital Partners and its affiliates from exercising that portion of the warrants or Series A Preferred Stock that would result in Venrock Healthcare Capital Partners and its affiliates owning, after exercise, a number of shares of common stock in excess of the applicable ownership limitation. VHCP Management III, LLC (â€œVHCPM3â€) is the sole general partner of VHCP3 and the sole manager of VHCPCo3. VHCP Management EG, LLC (â€œVHCPM EGâ€) is the sole general partner of VHCPEG. As voting members of VHCPM3 and VHCPM EG, Dr. Bong Koh and Nimish Shah may be deemed beneficial owners of any securities beneficially owned by VHCPM3 and VHCPM EG. The principal business address of each of these persons and entities is 7 Bryant Park, 23rd Floor, New York, NY 10018. (6)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consists of (i) (A) 638,614 shares of common stock, (B) 316,025 shares of common stock issuable upon the exercise of pre-funded warrants and (C) 4,413,743 shares of common stock issuable upon conversion of 52,965 shares of Series B Preferred Stock held by Fairmount Healthcare Fund II L.P. (â€œFairmount Fund IIâ€) and (ii) 2,573,308 shares of common stock held by Fairmount Healthcare Co-Invest III L.P. (â€œFairmount Fund IIIâ€). Excludes (i) 4,981,639 shares of common stock issuable upon the exercise of the pre-funded warrants, (ii) 7,014,406 shares of common stock issuable upon the conversion of 84,173 shares of Series B Preferred Stock and (iii) 160,000 shares of common stock issuable upon the conversion of 160 shares of Series A Preferred Stock owned by Fairmount Fund II. The pre-funded warrants and Series A Preferred Stock are subject to a beneficial ownership limitation of 9.99% and the shares of Series B Preferred Stock are subject to a beneficial ownership limitation of 19.99%, which such limitations restrict Fairmount Funds Management LLC (â€œFairmountâ€) and its affiliates from exercising that portion of the warrants and converting those shares of preferred stock that would result in Fairmount and its affiliates owning, after exercise or conversion, a number of shares of common stock in excess of the applicable ownership limitation. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the shares of common stock, the beneficial ownership limitation applicable to the shares of Series B Preferred Stock will automatically reduce to 9.99%. Fairmount serves as investment manager for Fairmount Fund II and Fairmount Fund III. Fairmount Fund II and Fairmount Fund III have delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in Fairmount Fund II and Fairmount Fund IIIâ€™s portfolios. Because Fairmount Fund II and Fairmount Fund III have divested themselves of voting and investment power over the securities they hold and may not revoke that delegation on less than 61 daysâ€™ notice, Fairmount Fund II and Fairmount Fund III disclaim beneficial ownership of the securities they hold. The general partner of Fairmount is Fairmount Funds Management GP LLC (â€œFairmount GPâ€). As managing members of Fairmount GP, Peter Harwin and Tomas Kiselak may be deemed to have voting and investment power over the shares held by Fairmount Fund II and Fairmount Fund III. Fairmount, Fairmount GP, Peter Harwin and Tomas Kiselak disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The address of the entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428. Â 105 Â Â (7)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of (i) 1,441,052 shares of Common Stock purchased pursuant to a Subscription Agreement, dated August 3, 2024, among the Company and the purchasers thereto (including AI Biotechnology LLC) (ii) 125,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by AI Biotechnology LLC and (ii) 225,000 shares of Common Stock held by AI Biotechnology LLC. Access Industries Holdings LLC, or AIH, directly controls all of the outstanding voting interest in AI Biotechnology LLC. Access Industries Management, LLC, or AIM, controls AIH. Len Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. Each of Len Blavatnik, AIM and AIH may be deemed to have voting and investment power over the shares held by AI Biotechnology LLC and disclaims beneficial ownership of such shares. The address of each of AI Biotechnology LLC, AIM, AIH and Len Blavatnik is c/o Access Industries, Inc., 40 West 57th Street, 28th Floor, New York, NY 10019. (8)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of (i) 72,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Spruce Street Aggregator L.P. (â€œSpruce Street Fundâ€), (ii) 130,078 shares of Common Stock held by Spruce Street Fund, (iii) 53,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Blackstone Annex Master Fund L.P. (â€œAnnex Fundâ€), and (iv) 335,096 shares of Common Stock held by Annex Fund. Blackstone Alternative Asset Management Associates LLC is the general partner of Annex Fund and Spruce Street Fund. Blackstone Holdings II L.P. is the sole member of Blackstone Alternative Asset Management Associates LLC. Blackstone Holdings I/II GP L.L.C. is the general partner of Blackstone Holdings II L.P. Blackstone Inc. is the sole member of Blackstone Holdings I/II GP L.L.C. Blackstone Group Management L.L.C. is the sole holder of the Series II preferred stock of Blackstone Inc. Blackstone Group Management L.L.C. is wholly owned by its senior managing directors and controlled by its founder, Stephen A. Schwarzman. Each of such Blackstone entities and Mr. Schwarzman may be deemed to beneficially own the securities beneficially owned by the Annex Fund and the Aggregator Fund directly or indirectly controlled by it or him, but each (other than each of the Annex Fund and the Aggregator Fund to the extent of their respective direct holdings) disclaims beneficial ownership of such securities. The address of each of the entities listed is c/o Blackstone Inc., 345 Park Avenue, New York, New York 10154. (9)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of (i) 115,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Point72 Associates, LLC (â€œPoint72 Associatesâ€) and (ii) 503,671 shares of Common Stock held by Point72 Associates. Pursuant to an investment management agreement, Point72 Asset Management, L.P. maintains investment and voting power with respect to the securities held by certain investment funds it manages, including Point72 Associates. Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management, L.P. Mr. Steven A. Cohen controls each of Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. By reason of the provisions of Rule 13d-3 of the Exchange Act, each of Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr. Cohen may be deemed to beneficially own the securities held by Point72 Associates reflected herein. Each of Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Mr. Cohen disclaims beneficial ownership of any such securities. The address for Point72 Associates is c/o Point72 Asset Management, L.P., 72 Cummings Point Road, Stamford, CT 06902. Â 106 Â Â (10)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of (i) 1,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Frazier Life Sciences X, L.P. (â€œFLS Xâ€), (ii) 23,785 shares of Common Stock held by FLS X, (iii) 1,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Frazier Life Sciences XI, L.P. (â€œFLS XIâ€), (iv) 40,967 shares of Common Stock held by FLS XI, (v) 81,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held Frazier Life Sciences Public Fund, L.P. (â€œFLS Public Fundâ€), (vi) 297,560 shares of Common Stock held by FLS Public Fund, (vii) 23,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Frazier Life Sciences Public Overage Fund, L.P. (â€œFLS Overage Fundâ€) and (viii) 115,015 shares of Common Stock held by FLS Overage Fund. FHMLSP, L.P. is the general partner of FLS Public Fund and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Albert Cha, James N. Topper, Patrick J. Heron and James Brush are the managing directors of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by FLS Public Fund. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush disclaim beneficial ownership of the shares held by FLS Public Fund except to the extent of their pecuniary interests in such shares, if any. FHMLSP Overage, L.P., is the general partner of FLS Overage Fund and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by FLS Overage Fund. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush disclaim beneficial ownership of the shares held by FLS Overage Fund except to the extent of their pecuniary interests in such shares, if any. FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Mr. Heron and Dr. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of the shares held by FLS X except to the extent of their pecuniary interests in such shares, if any. FHMLS XI, L.P. is the general partner of FLS XI, and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Mr. Heron, Dr. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by FLS XI. Dr. Topper, Mr. Heron and Mr. Estes disclaim beneficial ownership of the shares held by FLS XI except to the extent of their pecuniary interests in such shares, if any. The principal business address of the above referenced entities and persons is 1001 Page Mill Rd., Building 4, Ste. B, Palo Alto, CA 94304. (11)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of (i) 86,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Paradigm BioCapital International Fund Ltd. (â€œParadigm Fundâ€), (ii) 617,323 shares of Common Stock held by Paradigm Fund, (iii) 14,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Paradigm BioCapital Advisors LP (â€œParadigm Advisorâ€), as discretionary investment manager on behalf of a separate account client solely with respect to the assets for which Paradigm Advisor acts as its investment manager (the â€œSeparate Accountâ€), and (iv) 102,337 shares of Common Stock held by Paradigm Advisor, as discretionary investment manager on behalf of the Separate Account. The shares of Common Stock may be deemed to be indirectly beneficially owned by each of Paradigm Advisor, Paradigm BioCapital Advisors GP LLC (â€œParadigm Advisor GPâ€), and Senai Asefaw, M.D. Paradigm Advisor GP is the general partner of Paradigm Advisor, and Senai Asefaw, M.D. is the managing member of Paradigm Advisor GP. Paradigm Advisor is the investment manager of Paradigm Fund. Paradigm Advisor, Paradigm Advisor GP, and Senai Asefaw, M.D. may be deemed to have full investment and voting discretion over the shares of Common Stock held by Paradigm Fund and the Separate Account. The business address for each person and entity named in this footnote is 767 Third Avenue, 17th Floor, New York, NY 10017. Â 107 Â Â (12)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of (i) 95,000 shares of Common Stock issuable upon the conversion of Series A Preferred StockÂ Â and (ii) 1,963,147 shares of Common Stock, in each case of (i) and (ii) as held in the aggregate by RTW Master Fund, Ltd. RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities Operating Ltd, (collectively, the â€œRTW Fundsâ€). RTW Investments, LP (â€œRTWâ€), in its capacity as the investment manager of the RTW Funds, has the power to vote and the power to direct the disposition of the shares held by the RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing Partner of RTW, has the power to direct the vote and disposition of the securities held by RTW. Dr. Wong disclaims beneficial ownership of the shares held by the RTW Funds, except to the extent of his pecuniary interest therein. The address and principal office of RTW Investments, LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr. Wong and each of the RTW Funds is c/o RTW Investments, LP, 40 10th Avenue, Floor 7, New York, NY 10014.Â Â The shares of Common Stock issuable upon conversion of the shares of Series A Preferred Stock held by the RTW Funds are subject to a Beneficial Ownership Limitation of 9.99%. (13)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of (i) 62,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by T. Rowe Price Health Sciences Fund, Inc., (ii) 1,125,095 shares of Common Stock held by T. Rowe Price Health Sciences Fund, Inc., (iii) 3,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by T. Rowe Price Health Sciences Portfolio, and (iv) 54,096 shares of Common Stock held by T. Rowe Price Health Sciences Portfolio. T. Rowe Price Associates, Inc. (â€œTRPAâ€), as investment adviser, has dispositive and voting power with respect to the shares held by these funds and accounts. For purposes of the Securities Exchange Act of 1934, TRPA may be deemed to be the beneficial owner of these aforementioned shares; however, TRPA expressly disclaims that it is, in fact, the beneficial owner of such securities. TRPA is a wholly owned subsidiary of T. Rowe Price Group, Inc., which is a publicly traded financial services holding company. The principal business address of TRPA is 100 East Pratt Street, Baltimore, MD 21202. (14)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of (i) 55,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by SR One Capital Opportunities Fund I, LP (â€œOpportunities Fundâ€) and (ii) 375,330 shares of Common Stock held by Opportunities Fund. SR One Capital Opportunities Partners I, LP (â€œSR One Partnersâ€) is the general partner of Opportunities Fund. SR One Capital Management, LLC (â€œSR One Managementâ€) is the general partner of SR One Partners. Simeon George, M.D. is the manager of SR One Management. SR One Partners, SR One Management, and Simeon George share voting and investment power with respect to the shares directly held by Opportunities Fund. All indirect holders of the above referenced shares disclaim beneficial ownership of all applicable shares except to the extent of their pecuniary interest therein. The address of these persons and funds is 985 Old Eagle School Road, Suite 511, Wayne, Pennsylvania 19087. (15)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of (i) 30,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Janus Henderson Biotech Innovation Master Fund Limited, (ii) 258,149 shares of Common Stock held by Janus Henderson Biotech Innovation Master Fund Limited, (iii) 20,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Janus Henderson Biotech Innovation Master Fund II Limited, and (iv) 27,307 shares of Common Stock held by Janus Henderson Biotech Innovation Master Fund II Limited. Such shares may be deemed to be beneficially owned by Janus Henderson Investors US LLC (â€œJanusâ€), an investment adviser registered under the Investment Advisers Act of 1940, who acts as investment adviser for Janus Henderson Biotech Innovation Master Fund Limited and Janus Henderson Biotech Innovation Master Fund II Limited (the â€œJanus Fundsâ€) and has the ability to make decisions with respect to the voting and deposition of the shares subject to the oversight of the board of directors of the Janus Funds. Under the terms of its management contract with the Janus Funds, Janus has overall responsibility for directing the investments of the Janus Funds in accordance with the Janus Fundsâ€™ investment objective, policies and limitations. The Janus Funds have one or more portfolio managers appointed by and serving at the pleasure of Janus who make decisions with respect to the disposition of the shares of common stock offered hereby. The address for Janus is 151 Detroit Street, Denver, CO 80206.Â Â The portfolio managers for the Janus Fund are Andrew Acker, Daniel S. Lyons and Agustin Mohedas. Â 108 Â Â (16)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of (i) 50,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Commodore Capital Master LP and (ii) 1,369,714 shares of Common Stock held by Commodore Capital Master LP. Commodore Capital LP is the investment manager to Commodore Capital Master LP and may be deemed to beneficially own the shares held by Commodore Capital Master LP. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion with respect to these shares. Commodore Capital LP and Commodore Capital Master LP have shared voting and dispositive power with respect to these shares. The address of Commodore Capital LP and Commodore Capital Master LP is 444 Madison Avenue, 35th Floor, New York, NY 10022. (17)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of (i) 50,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Kalehua Capital Partners LP and (ii) 100,000 shares of Common Stock held by Kalehua Capital Partners LP. Kalehua Capital Partners LP is a buyout fund managed by Kalehua Capital Management LLC. Tai-Li Chang is the sole member of Kalehua Capital Management LLC. The address of these persons and funds is 3819 Maple Avenue, Dallas, Texas 75219. (18)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of Â (i) 20,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Avidity Private Master Fund I LP and (ii) 681,363 shares of Common Stock held by Avidity Private Master Fund I LP, which is a Cayman exempted limited partnership. The general partner of Avidity Private Master Fund I LP is Avidity Capital Partners Fund (GP) LP, a Delaware limited partnership, whose general partner is Avidity Capital Partners (GP) LLC, a Delaware

limited liability company. Avidity Partners Management LP is the investment manager of Avidity Private Master Fund I LP. Avidity Partners Management (GP) LLC is the general partner of Avidity Partners Management LP. David Witzke and Michael Gregory are the managing members of Avidity Capital Partners (GP) LLC and Avidity Partners Management (GP) LLC. Each of the entities and individuals referenced in this paragraph may be deemed to beneficially own the shares held by the Avidity entities. Certain affiliates of the Avidity entities, which are not selling stockholders, may also own shares. The address of Avidity Private Master Fund I LP is 2828 N. Harwood Street, Suite 1220, Dallas, Texas 75201. (19)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of Â (i) 25,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Adage Capital Partners LP (â€œAdageâ€) and (ii) 175,000 shares of Common Stock held by Adage. Bob Atchinson and Phillip Gross are the managing members of Adage Capital Advisors, L.L.C., which is the managing member of Adage Capital Partners GP, L.L.C., which is the general partner of Adage, and each such person or entity, as the case may be, has shared voting and/or investment power over the securities held by Adage Capital Partners, LP and may be deemed the beneficial owner of such shares, and each such person or entity, as the case may be, disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. The address of these funds and persons is 200 Clarendon St., 52nd Floor, Boston, MA 02116. (20)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of (i) 10,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Affinity Healthcare Fund, LP (â€œAffinity Fundâ€) and (ii) 274,836 shares of Common Stock held by Affinity Fund. Affinity Asset Advisors, LLC (the â€œAdvisorâ€) is the investment manager of Affinity Healthcare Fund, LP (the â€œFundâ€) and exercises investment discretion with regard to the shares of Common Stock owned by the Fund. The Fund and the Advisor have the shared power to vote or to direct the vote and to dispose or direct the disposition of such shares of Common Stock of the Issuer owned by the Fund.Â Â The Advisor may be deemed to be the beneficial owner of such shares of Common Stock of the Issuer owned by the Fund by virtue of its position as investment manager of the Fund. The principal business address of each of the Fund and the Advisor is 767 Third Avenue, 15th Floor, New York, NY 10017. Â 109 Â Â (21)Shares listed under â€œCommon Stock Beneficially Owned Before the Offeringâ€ consist of (i) 8,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Allostery Master Fund, LP (â€œAllostry Master Fundâ€) and (ii) 12,000 shares of Common Stock held by Allostry Master Fund. Allostery Funds GP LLC (â€œAllostery Funds GPâ€) may be deemed the beneficial owner of the shares held by Allostery Master Fund because it is the general partner of Allostery Master Fund. Allostery Investments LP (â€œAllostery Investmentsâ€) may be deemed the beneficial owner of the shares held by Allostery Master Fund because it is the investment manager of Allostery Master Fund. Allostery Investments GP LLC (the â€œInvestments GPâ€) may be deemed the beneficial owner of the shares beneficially held by Allostery Investments because it is the general partner of Allostery Investments. Christopher Staral and David Modest may be deemed the beneficial owners of the shares beneficially held by each of Investments GP and Allostery Funds GP by virtue of their positions as managing members of Investments GP and Allostery Funds GP. The address of Allostery Master Fund is c/o Maples Corporate Services Limited, Ugland House, South Church Street, Grand Cayman KY1-1104, Cayman Islands. Â Relationship with the Selling Stockholders Â In addition to the SPA, in connection with the Private Placement, we entered into the RRA (as defined below) on September 13, 2024 with the Selling Stockholders. Certain of the September 2024 investors were, immediately prior to the closing of the September 2024 PIPE, or became holders of more than 5% of our Common Stock and were parties to the Pre-Closing Financing. See â€œSecurity Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.â€ Â Registration Rights Agreement Â On September 13, 2024, we entered into a registration rights agreement (the â€œRRAâ€) with the Private Placement investors. Pursuant to the RRA, we agreed to file a resale registration statement to register the Registrable Securities (as defined in the RRA) (the â€œRegistration Statementâ€). This registration statement is being filed to satisfy our obligations under the RRA. We have agreed to use our commercially reasonable efforts to cause this Registration Statement to be declared effective by the SEC as soon as practicable. Â We have also agreed, among other things, to indemnify the Selling Stockholders and each of their respective officers, directors, members, employees, partners, managers, stockholders, affiliates, investment advisors and agents, each person who controls any such Selling Stockholder and the officers, directors, members, employees, partners, managers, stockholders, affiliates, investment advisors and agents of each such controlling person from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any underwriting discounts and selling commissions) incident to our obligations under the RRA. Â 110 Â Â PLAN OF DISTRIBUTION Â We are registering the Resale Shares issued to the Selling Stockholders to permit the sale, transfer or other disposition of these shares by the Selling Stockholders or their donees, pledgees, transferees or other successors-in-interest from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the Selling Stockholders of the Resale Shares. We will, or will procure to, bear all fees and expenses incident to our obligation to register the Resale Shares. Â The Selling Stockholders may sell all or a portion of the Resale Shares beneficially owned by them and offered hereby from time to time, and in the case of the Private Placement Conversion Shares, may only be offered after such shares are converted to Common Stock pursuant to the terms of the Series A Certificate of Designation, directly or through one or more underwriters, broker-dealers or agents. If the Resale Shares are sold through underwriters or broker-dealers, the Selling Stockholders will be responsible for underwriting discounts (it being understood that the Selling Stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering) or commissions or agentâ€™s commissions. The Resale Shares may be sold on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the over-the-counter market or in transactions otherwise than on these exchanges or systems or in the over-the-counter market and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. The Selling Stockholders may use any one or more of the following methods when selling Resale Shares: Â â—ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; Â â—block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; Â â—to or through underwriters or purchases by a broker-dealer as principal and resale by the broker-dealer for its account; Â â—an exchange distribution in accordance with the rules of the applicable exchange; Â â—privately negotiated transactions; Â â—settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part; Â â—broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share; Â â—through the writing or settlement of options or other hedging transactions, whether such options are listed on an options exchange or otherwise; Â â—a combination of any such methods of sale; and Â â—any other method permitted pursuant to applicable law. Â The Selling Stockholders also may resell all or a portion of the Resale Shares in open market transactions in reliance upon Rule 144, as permitted by that rule, or Section 4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the criteria and conform to the requirements of those provisions. The Selling Stockholders also may dispose of the Resales Shares through distributions to members, partners, stockholders or other equityholders of the Selling Stockholders. Â Broker-dealers engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. If the Selling Stockholders effect such transactions by selling Resale Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholders or commissions from purchasers of the Resale Shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2121.01. Â Â In connection with sales of the Resale Shares or otherwise, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Resale Shares in the course of hedging in positions they assume. The Selling Stockholders may also sell Resale Shares short and if such short sale takes place after the date that this registration statement is declared effective by the SEC, the Selling Stockholders may deliver Resale Shares covered by this prospectus to close out short positions and to return borrowed Resale Shares in connection with such short sales. The Selling Stockholders may also loan or pledge Resale Shares to broker-dealers that in turn may sell such shares, to the extent permitted by applicable law. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). Notwithstanding the foregoing, the Selling Stockholders have been advised that they may not use Resale Shares the resale of which has been registered on this registration statement to cover short sales of our Common Stock made prior to the date the registration statement, of which this prospectus forms a part, has been declared effective by the SEC. Â 111 Â Â The Selling Stockholders may, from time to time, pledge or grant a security interest in some or all of the Resale Shares owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Resale Shares from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending, if necessary, the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling Stockholders under this prospectus. The Selling Stockholders also may transfer and donate the Resale Shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. Â The Selling Stockholders and any broker-dealer or agents participating in the distribution of the Resale Shares may be deemed to be â€œunderwritersâ€ within the meaning of Section 2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such broker-dealer or agent and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Selling Stockholders who are â€œunderwritersâ€ within the meaning of Section 2(11) of the Securities Act will be subject to the applicable prospectus delivery requirements of the Securities Act including Rule 172 thereunder and may be subject to certain statutory liabilities of, including but not limited to, Sections 11, 12 and 17 of the Securities Act and Rule 10b-5 under the Exchange Act. Â Each Selling Stockholder has informed us that it is not a registered broker-dealer and does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the Resale Shares. Upon us being notified in writing by a Selling Stockholder that any material arrangement has been entered into with a broker-dealer for the sale of Common Stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if required, pursuant to Rule 424(b) under the Securities Act, disclosing (i) the name of each such Selling Stockholder and of the participating broker-dealer(s), (ii) the number of Resale Shares involved, (iii) the price at which such the Resale Shares were sold, (iv) the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the information set out in this prospectus, and (vi) other facts material to the transaction. Â Under the securities laws of some U.S. states, the Resale Shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some U.S. states the Resale Shares may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. Â There can be no assurance that any Selling Stockholder will sell any or all of the Resale Shares registered pursuant to the shelf registration statement, of which this prospectus forms a part. Â Each Selling Stockholder and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the Resale Shares by the Selling Stockholder and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Resale Shares to engage in market-making activities with respect to the Resale Shares. All of the foregoing may affect the marketability of the Resale Shares and the ability of any person or entity to engage in market-making activities with respect to the Resale Shares. Â We will pay all expenses of the registration of the Resale Shares pursuant to the September 2024 RRA, including, without limitation, SEC filing fees and expenses of compliance with state securities or â€œblue skyâ€ laws; provided, however, that each Selling Stockholder will pay all underwriting discounts and selling commissions, if any and any related legal expenses incurred by it. We will indemnify the Selling Stockholders against certain liabilities, including some liabilities under the Securities Act, in accordance with the September 2024 RRA, or the Selling Stockholders will be entitled to contribution. We may be indemnified by the Selling Stockholders against certain civil liabilities set forth in the September 2024 RRA, including liabilities under the Securities Act, that may arise from any written information furnished to us by the Selling Stockholders specifically for use in this prospectus, in accordance with the related registration rights agreements, or we may be entitled to contribution. Â 112 Â Â DESCRIPTION OF CAPITAL STOCK Â General Â The following description summarizes the material terms of our capital stock, as well as other material terms of our amended and restated certificate of incorporation (â€œCertificate of Incorporationâ€) and amended and restated bylaws (â€œBylawsâ€) and certain provisions of Delaware law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our Certificate of Incorporation and Bylaws, copies of which are filed as exhibits to our Current Report on Form 8-K filed on September 5, 2024. Â Our authorized capital stock consists of 545,000,000 shares of Common Stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share (â€œPreferred Stockâ€), of which 2,439 shares have been designated as Series A Preferred Stock, $0.001 par value per share, and 251,504 shares have been designated as Series B Preferred Stock, $0.001 par value per share. Â As of November 1, 2024, there were 34,998,550 shares of our Common Stock, 2,439 shares of Series A Preferred Stock and 137,138 shares of Series B Preferred Stock outstanding. Â Common Stock Â Our Certificate of Incorporation authorizes the issuance of up to 545,000,000 shares of Common Stock. All outstanding shares of Common Stock are validly issued, fully paid and nonassessable. Â Dividend rights Â Subject to preferences that may apply to any shares of Preferred Stock outstanding at the time, the holders of our Common Stock are entitled to receive dividends out of funds legally available if our Board, in its discretion, determines to issue dividends and then only at the times and in the amounts that our Board may determine. Â Voting rights Â Pursuant to our Bylaws, holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors in our Certificate of Incorporation. Accordingly, pursuant to our Certificate of Incorporation, holders of a majority of the shares of our Common Stock are able to elect all of our directors. Our Certificate of Incorporation establishes a classified Board, divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Â No preemptive or similar rights Â Our Common Stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Â Right to receive liquidation distributions Â Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our Common Stock and any participating Preferred Stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of Preferred Stock. Â Preferred Stock Â Under the terms of our Certificate of Incorporation, our Board is authorized, subject to limitations prescribed by Delaware law, to issue up to 5,000,000 shares of Preferred Stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. Subject to any certificates of designation, the Board can also increase or decrease the number of shares of any series of Preferred Stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our Board may authorize the issuance of Preferred Stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance of Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our Common Stock and the voting and other rights of the holders of our Common Stock. We issued shares of our Series A Preferred Stock and shares of our Series B Preferred Stock in connection with the Private Placement and the Merger, respectively, and have no current plan to issue any additional shares of Preferred Stock. Â 113 Â Â Series A Preferred Stock Â Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of our Common Stock. Except as provided in the Series A Certificate of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock: (i) alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, (ii) alter or amend the Series A Certificate of Designation, or (iii) amend or repeal any provision of, or add any provision to, our Certificate of Incorporation or its Bylaws in any manner that adversely affects any rights of the holders of Series A Preferred Stock, or file any articles of amendment, certificate of designations, preferences,

limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise. The Series A Preferred Stock shall rank on parity with the Common Stock and Series B Preferred Stock upon any liquidation, dissolution or winding-up of the Company. Â Series B Preferred Stock Â Certain holders of our Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of our Common Stock. Except as provided in the Series B Certificate of Designation or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock: (a) (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (ii) alter or amend the Series B Certificate of Designation, or (iii) amend or repeal any provision of, or add any provision to, our Certificate of Incorporation or Bylaws in a manner that adversely affects any rights of the holders of the Series B Preferred Stock, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b) issue further shares of Series B Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of Series B Preferred Stock, (c) at any time while at least 30% of the originally issued Series B Preferred Stock remains issued and outstanding, consummate either: (x) any Fundamental Transaction (as defined in the Series B Certificate of Designation) or (y) any merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority of our capital stock immediately after such transaction, or (d) enter into any agreement with respect to any of the foregoing. The Series B Preferred Stock shall rank on parity with the Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up of the Company. Each share of Series B Preferred Stock is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. As of September 30, 2024, each outstanding share of Series B Preferred Stock was convertible into common stock at a ratio of approximately 83.3332:1. Â 114 Â Â Registration Rights Â Holders of our Series A Preferred Stock are entitled to certain rights with respect to the registration of such securities as further provided under the heading â€œSelling Stockholders - Registration Rights Agreement.â€ Â Anti-Takeover Provisions Â The provisions of Delaware law, our Certificate of Incorporation and our Bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our Board. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms. Â Delaware law Â We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date on which the person became an interested stockholder unless: Â â—prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; Â â—upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or Â â—at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder. Â Section 203 defines a â€œbusiness combinationâ€ to include: Â â—any merger or consolidation involving the corporation and the interested stockholder; Â â—any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; Â â—subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; Â â—any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and Â â—the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. Â In general, Section 203 defines an â€œinterested stockholderâ€ as an entity or person who, together with the personâ€™s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. Â 115 Â Â Certificate of Incorporation and Bylaw Provisions Â Our Certificate of Incorporation and our Bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following: Â â—Board of Directors vacancies. Our Certificate of Incorporation and Bylaws require that the Board, and not stockholders, fill any directorships that become vacant or are created by an increase in the authorized number of directors by the affirmative vote of a majority of the remaining directors or by the sole remaining director. In addition, pursuant to our bylaws, the number of directors constituting our Board is permitted to be set only by a resolution adopted by a majority vote of the entire Board. These provisions prevent a stockholder from increasing the size of our Board and then gaining control of the Board by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of the Board but promotes continuity of management. Â â—Classified board. Our Certificate of Incorporation provides that our Board is classified into three classes of directors, each with staggered three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors. Â â—Stockholder action; special meetings of stockholders. Our Certificate of Incorporation and Bylaws provide that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders called in accordance with our Bylaws. Further, our Bylaws provide that special meetings of stockholders may be called only by the Board, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors. Â â—Advance notice requirements for stockholder proposals and director nominations. Our Bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our Bylaws also specify certain requirements regarding the form and content of a stockholderâ€™s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirerâ€™s own slate of directors or otherwise attempting to obtain control of our company. Â â—No cumulative voting. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporationâ€™s certificate of incorporation provides otherwise. Our Certificate of Incorporation and Bylaws do not provide for cumulative voting. Â â—Directors removed only for cause. Our Bylaws provide that stockholders may remove directors only for cause, and only by the affirmative vote of the holders of at least 66 2/3% of the voting power of the stock outstanding and entitled to vote generally in the election of directors. Â â—Amendment of charter provisions. Any amendment of the above provisions in our Certificate of Incorporation requires approval by holders of at least two-thirds of our outstanding Common Stock. Â â—Issuance of Preferred Stock. Our Board has the authority, without further action by the stockholders, to issue up to 5,000,000 shares of Preferred Stock with rights and preferences, including voting rights, designated from time to time by our Board. The existence of authorized but unissued shares of Preferred Stock enables our Board to render more difficult or to discourage an attempt to obtain control of us by merger, tender offer, proxy contest or other means. Â â—Choice of forum. Our Certificate of Incorporation and Bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any complaint asserting any internal corporate claims. In addition, our Bylaws also provide that the federal district courts of the United States are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. These choice of forum provisions do not apply to claims brought to enforce a duty or liability created by the Exchange Act. Â Transfer Agent and Registrar Â The transfer agent and registrar for our Common Stock, Class A Preferred Stock and Class B Preferred Stock is Computershare Trust Company, N.A. The transfer agentâ€™s address is 150 Royall Street, Suite 101, Canton, MA 02021, and its telephone number is (800) 344-5128.Â Â Exchange Listing Â Our Common Stock is listed on The Nasdaq Global Market under the symbol â€œORKA.â€ Â 116 Â Â LEGAL MATTERS Â Certain legal matters, including the legality of the securities offered, has been passed upon for us by Gibson, Dunn & Crutcher LLP, San Francisco, California. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. Â 117 Â Â EXPERTS Â The financial statement as of February 6, 2024 included in this Prospectus has been so included in reliance on the report (which contains an explanatory paragraph relating to the Companyâ€™s ability to continue as a going concern as described in Note 1 to the financial statement) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. Â 118 Â Â Â WHERE YOU CAN FIND MORE INFORMATION Â We are subject to the informational requirements of the Exchange Act and are required to file annual, quarterly and other reports, proxy statements and other information with the SEC. The SEC maintains an Internet website (http://www.sec.gov) that contains reports, proxy and information statements, and various other information about us. Â Information about us is also available at our website at http://www.orukatx.com. You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. However, the information on our website is not a part of this prospectus and is not incorporated by reference into this prospectus. Â We have filed a registration statement on Form S-1 with the SEC relating to the securities covered by this prospectus. This prospectus is a part of the registration statement and does not contain all of the information in the registration statement. Whenever a reference is made in this prospectus to a contract or other document of ours, please be aware that the reference is only a summary and that you should refer to the exhibits that are part of the registration statement for a copy of the contract or other document. You may review a copy of the registration statement through the SECâ€™s website or our website. Â 119 Â Â Â ORUKA THERAPEUTICS, INC. Â INDEX TO FINANCIAL STATEMENT Â As of February 6, 2024 Â Â Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of FebruaryÂ 6, 2024 F-3 Notes to Financial Statement F-4 Â INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Â Â Page Period from February 6, 2024 (Inception) to September 30, 2024 Â Condensed Consolidated Balance Sheets F-10 Condensed Consolidated Statements of Operations and Comprehensive Loss F-11 Condensed Consolidated Statements of Convertible Preferred Stock and Stockholdersâ€™ Equity (Deficit) F-12 Condensed Consolidated Statement of Cash Flows F-13 Notes to Condensed Consolidated Financial Statements F-14 Â F-1 Â Â REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Â To the Board of Directors and Stockholders of Oruka Therapeutics, Inc. Â Opinion on the Financial Statement â€” Balance Sheet Â We have audited the accompanying balance sheet of Oruka Therapeutics, Inc. (the â€œCompanyâ€) as of February 6, 2024, including the related notes (collectively referred to as the â€œfinancial statementâ€). In our opinion, the financial statement presents fairly, in all material respects, the financial position of the Company as of February 6, 2024 in conformity with accounting principles generally accepted in the United States of America. Â Substantial Doubt about the Companyâ€™s Ability to Continue as a Going Concern Â The accompanying financial statement has been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statement, the Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception, which raises substantial doubt about its ability to continue as a going concern. Managementâ€™s plans in regard to these matters are also described in Note 1. The financial statement does not include any adjustments that might result from the outcome of this uncertainty. Â Basis for Opinion Â The financial statement is the responsibility of the Companyâ€™s management. Our responsibility is to express an opinion on the Companyâ€™s financial statement based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. Â We conducted our audit of this financial statement in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement is free of material misstatement, whether due to error or fraud. Â Our audit included performing procedures to assess the risks of material misstatement of the financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statement. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statement. We believe that our audit provides a reasonable basis for our opinion. Â Critical Audit Matters Â Critical audit matters are matters arising from the current period audit of the financial statement that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the financial statement and (ii) involved our especially challenging, subjective, or complex judgments. We determined there are no critical audit matters. Â /s/ PricewaterhouseCoopers LLP Â Boston, Massachusetts May 13, 2024, except for the effects of the reverse stock split discussed in Note 1 to the financial statement, as to which the date is September 5, 2024, and except for the effects of the reverse merger exchange ratio discussed in Note 1 to the financial statement, as to which the date is November 13, 2024. Â We have served as the Companyâ€™s auditor since 2024. Â F-2 Â Â ORUKA THERAPEUTICS, INC. BALANCE SHEET (In thousands, except share amounts) Â Â Â February 6, 2024Â ASSETSÂ Â Â Current AssetsÂ Â Â Subscription receivableÂ $1Â Total assetsÂ $1Â Â Â Â Â Â Commitments and contingencies (Note 5)Â Â Â Â Â Â Â Â Â Â STOCKHOLDERSâ€™ EQUITYÂ Â Â Â Series A convertible preferred stock, $0.001 par value, 20,000,000 shares authorized, no shares issued and outstanding as of February 6, 2024Â $â€”Â Common stock, $0.001 par value, 65,000,000 shares authorized, 3,197,975 issued and outstanding as of February 6, 2024Â Â 3Â Additional paid-in capitalÂ Â (2) Total stockholdersâ€™ equityÂ $1Â Â Â The accompanying notes are an integral part of this financial statement. Â F-3 Â Â ORUKA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENT Â 1. Nature of the Business and Basis of Presentation Â Background and Basis of Presentation Â Oruka Therapeutics, Inc. (â€œOrukaâ€ or the â€œCompanyâ€) was established and incorporated under the laws of the state of Delaware on February 6, 2024. Oruka was founded by Paragon Therapeutics, Inc. (â€œParagonâ€). The Company currently operates as a virtual company, and thus, does not maintain a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of inflammatory skin diseases. Â The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, completing preclinical and clinical trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional capital to fund operations. Â The Companyâ€™s potential products will require approval from the U.S. Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Companyâ€™s potential products will receive all the required approvals. In addition, there can be no assurance that the Companyâ€™s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if at all. Â The financial statement and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€). Â Liquidity Â The accompanying financial statement has been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of February 6, 2024, the Company had no cash. Â The Company will devote substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and

providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Companyâ€™s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution. Â As a result, the Company will need substantial additional funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.Â F-4 Â Â If the Company is unable to obtain additional funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have a material adverse effect on the Companyâ€™s business, financial condition, results of operations and ability to operate as a going concern. The financial statement does not include any adjustments that may result if the Company is not able to continue as a going concern. Â The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. Â In March 2024, the Company received $3.0 million in proceeds from the sale of Series A convertible preferred stock and $25.0 million in proceeds from the sale of an unsecured convertible promissory note, both of which were related party transactions (see Note 7 Subsequent Events). Â ARCA biopharma, Inc., a Delaware corporation (â€œARCAâ€), and the Company entered into an Agreement and Plan of Merger and Reorganization (the â€œMerger Agreementâ€) on April 3, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation (â€œFirst Merger Subâ€), will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the â€œFirst Mergerâ€), and Oruka will merge with and into Atlas Merger Sub II, LLC, a Delaware limited liability company (â€œSecond Merger Subâ€ and together with First Merger Sub, â€œMerger Subsâ€), with Second Merger Sub being the surviving entity of the merger (the â€œSecond Mergerâ€ and, together with the First Merger, the â€œMergerâ€). In connection with the Merger, Second Merger Sub will change its corporate name to â€œOruka Therapeutics Operating Company, LLCâ€ and ARCA will change its name to â€œOruka Therapeutics, Inc.â€ ARCA following the Merger is referred to herein as the â€œcombined company.â€ The combined company will be led by Orukaâ€™s management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases. Â Concurrent with the execution of the Merger Agreement, the Company entered into a subscription agreement with certain investors to which the Company agreed to issue and sell to investors in a private placement financing (the â€œPrivate Placementâ€) shares and pre-funded warrants of the Companyâ€™s common stock at an estimated purchase price of $9.71 ($5.55 prior to impact of reverse stock split and reverse merger exchange ratio) per share of common stock and estimated purchase price of $9.70 ($5.54 prior to the impact of the reverse stock split and reverse merger exchange ratio) per warrant for gross proceeds of approximately $275.0 million, which will precede the closing of the Merger Agreement. Shares of the Companyâ€™s common stock and pre-funded warrants to purchase shares of the Companyâ€™s common stock issued pursuant to the Private Placement will be converted into the right to receive shares of ARCA common stock and pre-funded warrants to purchase ARCA common stock, respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds from the Private Placement are expected to advance the Companyâ€™s pipeline, business development activities, working capital, and other general corporate purposes. Â However, the agreements are subject to the satisfaction of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA could be required to pay Oruka a termination fee of $0.4 million or Oruka could be required to pay ARCA a termination fee of $0.4 million. Based on its expectation of continuing operating losses for the foreseeable future, as of May 13, 2024, the date the Companyâ€™s financial statement is available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern for at least twelve months from the date the financial statement is available to be issued. Â In connection with the Merger Agreement discussed above, the Company effected a one-for-twelve reverse stock split of the Companyâ€™s issued and outstanding shares of common stock on September 3, 2024 without any change in the par value per share. Unless otherwise stated, all information related to the Companyâ€™s common stock, common stock warrants, restricted stock awards, and stock options, as well as the per share amounts, have been retroactively adjusted to give effect for the one-for-twelve reverse stock split and reverse merger exchange ratio of 6.8569 as calculated in accordance with the Merger Agreement for all periods presented. Â F-5 Â Â 2. Summary of Significant Accounting Policies Â Subscription receivable Â The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued. Â 3. Common Stock Â As of February 6, 2024, the Company has the authority to issue a total of 65,000,000 shares of common stock at a par value of $0.001. As of February 6, 2024, 3,197,975 shares of common stock were issued and outstanding for a nominal consideration, which was received in March 2024, prior to the date the financial statement is available to be issued. Each share of common stock entitles the holder to one vote for each share of common stock held of record by such holder on all matters on which stockholders generally are entitled to vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Companyâ€™s Board of Directors. Upon dissolution, liquidation or winding up of the Company, the holders of shares of common stock, subject to the rights of the holders of any outstanding series of preferred stock, shall be entitled to receive the assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held. Â 4. Related Party Transactions Â The Company issued 3,197,975 shares of common stock, through a series of contribution agreements, to Paragon, Paruka Holding, LLC (â€œParukaâ€), an entity formed by Paragon as a vehicle to hold equity in the Company, and Oruka Advisors LLC (â€œOruka Advisorsâ€), an entity formed by Paragon as a vehicle to hold equity in the Company, as part of its common stock subscription agreement with such entities. As of February 6, 2024, Paragon, Paruka and Oruka Advisors each beneficially own approximately 44.7%, 44.7% and 10.6%, respectively, of the Company through their common stock holdings. Â 5. Commitments and Contingencies Â The Company may be subject to legal proceedings that arise in the ordinary course of business. As of February 6, 2024, there were no material proceedings to which the Company was a party, nor did the Company have knowledge of any proceedings threatened against it. Â 6. Stock-Based Compensation Â On February 6, 2024, the Companyâ€™s Board of Directors approved the 2024 Equity Incentive Plan (the â€œ2024 Planâ€), under which the Company may grant stock options, restricted stock awards, restricted stock units, or other stock-based awards to its employees, officers, directors, consultants, and advisors. The Company reserved 213,085 shares of its common stock for issuance under the 2024 Plan. As of February 6, 2024, no awards had been issued under the plan. Â 7. Subsequent Events Â The Company evaluated all events subsequent to February 6, 2024, through May 13, 2024, the date on which the financial statement was available to be issued.Â F-6 Â Â Stock-Based Compensation Â In February 2024, the Companyâ€™s Board of Directors authorized and granted 1,184,749 restricted stock awards at a price of $0.0001 per share to employees of the Company. Â In March 2024, the Companyâ€™s Board of Directors authorized and granted 1,022,804 restricted stock awards at a price of $0.0001 per share to consultants and a director of the Company. Â On March 5, 2024, the Companyâ€™s Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 213,085 to 498,789. Â On March 22, 2024, the Company granted options for the purchase of an aggregate 399,222 shares of common stock, at an exercise price of $5.16 per share. Â On May 7, 2024, the Companyâ€™s Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 498,789 to 1,179,193. Â On May 7, 2024, the Company granted options for the purchase of an aggregate 779,971 shares of common stock, at an exercise price of $6.84 per share. Â Antibody Discovery and Option Agreements Â On March 6, 2024, the Company entered into an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March 28, 2024, whereby the Company was granted an exclusive, worldwide option, on a research program-by-research program basis, to all of Paragonâ€™s right, title and interest in and to the intellectual property (â€œORKA-001â€) resulting from the applicable research program to develop, manufacture and commercialize products directed at the selected target (â€œIL-23â€), with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease. Upon signing of the Antibody Discovery and Option Agreement for ORKA-001, a one-time, non-refundable research initiation fee of $0.8 million was due to Paragon. This amount was recognized as a research and development expense during the period ended March 31, 2024, and paid to Paragon in April 2024. The Company is also responsible for 50% of the development costs incurred prior to March 31, 2024, provided that the Company receives rights to at least one selected IL-23 antibody. As of the date this financial statement is available to be issued, the Company has not received rights to a selected IL-23 antibody and has not paid or accrued the $5.9 million of development costs incurred prior to March 31, 2024. The Company will be responsible for 50% of the ORKA-001 development costs incurred from and after March 31, 2024, through the completion of the IL-23 selection process. Â On March 6, 2024, the Company also entered into an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March 28, 2024, whereby the Company was granted an exclusive, worldwide option, on a research program-by-research program basis, to all of Paragonâ€™s right, title and interest in and to the intellectual property (â€œORKA-002â€) resulting from the applicable research program to develop, manufacture and commercialize products directed at the selected target (â€œIL-17â€). The Company was also required to reimburse Paragon $3.3 million for development costs related to ORKA-002 incurred by Paragon through December 31, 2023 and certain other development costs related to ORKA-002 incurred by Paragon between January 1, 2024 and March 6, 2024. This amount was recognized as a research and development expenses during the period from February 6 (inception) to March 31, 2024 and accounts payable as of March 31, 2024. The Company paid $3.3 million to Paragon in April 2024. The Company is also responsible for the development costs incurred by Paragon from January 1, 2024 to March 31, 2024 of $0.9 million, which was recognized as a research and development expense in the period from February 6 (inception) to March 31, 2024. The Company will be required to pay Paragon $0.8 million for the research initiation fee related to ORKA-002 within 30 days following finalization of the ORKA-002 research plan as well as for subsequent development costs related to ORKA-002. Â As of the date of issuance of the Companyâ€™s financial statement, the Company has not exercised its options with respect to ORKA-001 or ORKA-002. For each of these agreements, if the Company exercises its options, it will be required to make non-refundable milestone payments to Paragon of up to $12.0 million upon the achievement of certain clinical development milestones, up to $10.0 million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale.Â F-7 Â Â Additionally, as part of the Antibody Discovery and Option Agreements, on each of December 31, 2024 and December 31, 2025, the Company will grant Paruka warrants to purchase a number of shares equal to 1.00% of the then outstanding shares of the Companyâ€™s common stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares on the grant date. Â Series A Preferred Stock Â On March 6, 2024, the Company issued 20,000,000 shares of Series A convertible preferred stock to Fairmount Healthcare Fund II, L.P. (â€œFairmountâ€), a related party of the Company, at a purchase price of $0.15 per share for gross proceeds of $3.0 million. The Company incurred less than $0.1 million of issuance costs in connection with this transaction. Â The holders of Series A convertible preferred stock are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Series A convertible preferred stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Â Each share of Series A convertible preferred stock is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition, each share of Series A convertible preferred stock will be automatically converted into shares of common stock at the applicable conversion ratio then in effect upon either (i) the closing of a firm-commitment underwritten public offering of the Companyâ€™s common stock at a price of at least $12.00 per share resulting in at least $50.0 million of gross proceeds to the Company, or (ii) the vote or written consent of the holders of a majority of the Preferred Stock, voting as a single class. Â The conversion ratio of Series A convertible preferred stock is determined by dividing the Original Issue Price by the Conversion Price in effect at the time of conversion. The Original Issue Price is $0.15 per share for Series A convertible preferred stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Companyâ€™s certificate of incorporation, as amended and restated). The Conversion Price is approximately $0.26 per share for Series A convertible preferred stock and each outstanding share of Series A Preferred Stock was convertible into common stock at a 0.5712 conversion ratio. Â The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless the holders of the Series A convertible preferred stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Series A convertible preferred stock in an amount at least equal to (i) in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as-converted basis or (ii) in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series A convertible preferred stock calculated based on the respective Original Issue Price of Series A convertible preferred stock. Â In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Series A convertible preferred stock then outstanding are entitled to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Series A convertible preferred stock are entitled to an amount equal to the greater of (i) the applicable Original Issue Price per share of Series A convertible preferred stock, plus any declared but unpaid dividends thereon, or (ii) the amount per share that would have been payable had all shares of Series A convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Series A convertible preferred stock will share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full.Â F-8 Â Â Unless the holders of a majority in voting power of the then outstanding shares of Series A convertible preferred stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Companyâ€™s assets. Â Series A convertible preferred stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event. Â Convertible Notes Â On March 6, 2024, the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the â€œPurchase Agreementâ€) with Fairmount, whereby the Company issued a convertible note (the â€œConvertible Noteâ€), with an initial principal amount of $25.0 million, that can be converted into Series A preferred stock (or a Series of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of the Companyâ€™s common stock in exchange for proceeds of $25.0 million. The Convertible Note will automatically convert into shares of the Companyâ€™s common stock upon the closing of a corporate transaction, including the reverse recapitalization transaction, and is otherwise due and payable at the request of the holder at any time. The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December 31, 2025. Prepayment is not permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0 million, in addition to the $25.0 million of initial principal amount of the Convertible Note. Â Oak Grove Lease Â On April 12, 2024, the Company entered into a lease agreement with Oak Grove LP (â€œOak Grove Leaseâ€) for office space located in Menlo Park, California. The lease commencement date is June 15, 2024 with an initial term of 39.5 months. The total lease payment is expected to be $1.4 million over the initial lease term. Â 8. Events subsequent to the reissuance of the financial statement (unaudited) Â In connection with the reissuance of the financial statement, the Company has evaluated subsequent events through November 13, 2024, the date the financial statement was available to be reissued. Â F-9 Â Â ORUKA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share and per share data) Â Â Â SeptemberÂ 30, 2024Â Â FebruaryÂ 6, 2024Â AssetsÂ Â Â Â Â Â Current assets:Â Â Â Â Â Â Cash and cash equivalentsÂ $410,875Â Â $â€”Â Subscription receivableÂ Â â€”Â Â Â 1Â Prepaid expenses and other current assetsÂ Â 2,074Â Â Â â€”Â Total current assetsÂ Â 412,949Â Â Â 1Â Property and equipment, netÂ Â 160Â Â Â â€”Â Operating lease right-of-use assetÂ Â 938Â Â Â â€”Â Other non-current assetsÂ Â 43Â Â Â â€”Â Total assetsÂ $414,090Â Â $1Â Liabilities, Convertible Preferred Stock and Stockholdersâ€™ EquityÂ Â Â Â Â Â Â Â Current liabilities:Â Â Â Â Â Â Â Â Accounts payableÂ $2,145Â Â $â€”Â Accrued expenses and other

current liabilitiesÂ Â 1,710Â Â Â Â â€”Â Operating lease liability, currentÂ Â 146Â Â Â Â â€”Â Related party common stock warrant liabilityÂ Â 7,681Â Â Â Â â€”Â Related party accounts payable and other current liabilitiesÂ Â 6,357Â Â Â Â â€”Â Total current liabilitiesÂ Â 18,039Â Â Â Â â€”Â Operating lease liability, non-currentÂ Â 842Â Â Â Â â€”Â Total liabilitiesÂ Â 18,881Â Â Â Â â€”Â Â Â Â Â Â Â Â Â Â Â Commitment and contingencies (Note 11)Â Â Â Â Â Â Â Â SeriesÂ A convertible preferred stock, $0.0001 par value; no shares and 20,000,000 shares authorized as of SeptemberÂ 30, 2024 and FebruaryÂ 6, 2024, respectively; noÂ shares issued and outstanding as of September 30, 2024 and FebruaryÂ 6, 2024; liquidation preference of $0 as of September 30, 2024 and FebruaryÂ 6, 2024Â Â Â€”Â Â Â€”Â Series A non-voting convertible preferred stock, $0.001 par value; 2,439 and no shares authorized as of September 30, 2024 and February 6, 2024, respectively; 2,439 and no shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectivelyÂ Â 52,841Â Â Â Â€”Â Stockholdersâ€™ equity:Â Â Â Â Â Â Â Â Series B non-voting convertible preferred stock, $0.001 par value; 251,504 and no shares authorized as of September 30, 2024 and February 6, 2024, respectively; 137,138 and no shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectivelyÂ Â 2,931Â Â Â Â€”Â Common stock, $0.001 and $0.001 par value as of September 30, 2024 and February 6, 2024, respectively; 545,000,000 and 65,000,000 shares authorized, 34,998,550 and 3,197,975 shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectivelyÂ Â 35Â Â Â Â€”Â Additional paid-in capitalÂ Â 397,345Â Â Â 1Â Accumulated deficitÂ Â (57,943)Â Â Â Â€”Â Total stockholdersâ€™ equityÂ Â 342,368Â Â Â 1Â Total liabilities, convertible preferred stock and stockholdersâ€™ equityÂ $414,090Â Â $1Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â F-10 Â Â ORUKA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (In thousands, except share and per share data) Â Â Â Three Months Ended SeptemberÂ 30, 2024Â Â PeriodÂ from FebruaryÂ 6, 2024 (Inception)Â to September 30, 2024Â Operating expensesÂ Â Â Â Â Research and development(1)Â $25,691Â Â $49,557Â General and administrative(2)Â Â 3,758Â Â Â 8,248Â Total operating expensesÂ Â 29,449Â Â Â 57,805Â Loss from operationsÂ Â (29,449)Â Â (57,805) Other income (expense)Â Â Â Â Â Â Â Â Interest incomeÂ Â 1,330Â Â Â 1,330Â Interest expense(3)Â Â (504)Â Â (1,468) Total other income (expense), netÂ Â 826Â Â Â (138) Net loss and comprehensive lossÂ $(28,623)Â $(57,943) Â Â Â Â Â Â Â Â Â Net loss per share attributable to common stockholders, basic and dilutedÂ $(1.46)Â $(6.08) Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and dilutedÂ $(1,461.10)Â $(6,077.25) NetÂ loss per share attributable to Series B non-voting convertible preferred stockholders, basic and dilutedÂ $(121.76)Â $(506.44) Â Â Â Â Â Â Â Â Â Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and dilutedÂ Â 15,013,655Â Â Â 7,765,381Â Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and dilutedÂ Â 477Â Â Â 184Â Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and dilutedÂ Â 49,191Â Â Â 19,015Â Â (1) Includes related party amount of $13,537 for the three months ended September 30, 2024 and $33,967 for the period from February 6, 2024 (inception) to September 30, 2024 Â (2) Includes related party amount of $71 for the three months ended September 30, 2024 and $1,339 for the period from February 6, 2024 (inception) to September 30, 2024 Â (3) Includes related party amount of $504 for the three months ended September 30, 2024 and $1,468 for the period from February 6, 2024 (inception) to September 30, 2024 Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â F-11 Â Â ORUKA THERAPEUTICS, INC. CONDENSEDÂ CONSOLIDATED STATEMENTSÂ OFÂ CONVERTIBLE PREFERREDÂ STOCKÂ ANDÂ STOCKHOLDERSâ€™Â EQUITY (DEFICIT) (UNAUDITED) (In thousands, except share data) Â Â Â Series A Convertible Preferred Stock Â Â Series A Non-Voting Convertible PreferredÂ Stock Â Â Series B Non-Voting Convertible PreferredÂ Stock Â Â Common Stock Â Â Additional Paid-in Â Â Accumulated Â Â Total Stockholdersâ€™ Equity Â Â Â Shares Â Â Amount Â Â Shares Â Â Amount Â Â Shares Â Â Amount Â Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â (Deficit) Â Balances as of FebruaryÂ 6, 2024 (inception) Â Â Â€”Â Â Â Â $Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â $Â€”Â Â Â Â 3,197,975Â Â Â Â $ 3Â Â Â Â $ (2)Â Â Â Â $Â€”Â Â Â Â $ 1Â Â Issuance of common stock Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â 2,207,553Â Â Â Â 2Â Â Â Â (2)Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Issuance of SeriesÂ A convertible preferred stock, net of issuance costs of $69 Â Â 20,000,000Â Â Â Â 2,931Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â 17Â Â Â Â Â€”Â Â Â Â 17Â Â Net loss Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â (7,077) Â Â (7,077) Balances as of MarchÂ 31, 2024Â Â Â 20,000,000Â Â Â $ 2,931Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â 5,405,528Â Â Â $ 5Â Â Â $ 13Â Â Â $ (7,077) Â $ (7,059) Stock-based compensation expense Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â 321Â Â Â Â Â€”Â Â Â Â 321Â Â Net loss Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â (22,243) Â Â (22,243) Balances as of June 30, 2024 Â Â 20,000,000Â Â Â $ 2,931Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â 5,405,528Â Â Â $ 5Â Â Â $ 334Â Â Â $ (29,320) Â $ (28,981) Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization Â Â (20,000,000) Â Â (2,931) Â Â Â€”Â Â Â Â Â€”Â Â Â Â 137,138Â Â Â Â 2,931Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â 2,931Â Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â 2,722,207Â Â Â Â 3Â Â Â Â 26,445Â Â Â Â Â€”Â Â Â Â 26,448Â Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â 20,061,932Â Â Â Â 20Â Â Â Â 248,437Â Â Â Â Â€”Â Â Â Â 248,457Â Issuance costs of Pre-Closing Financing and reverse recapitalization Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â (20,480) Â Â Â€”Â Â Â Â (20,480) Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â 1,208,883Â Â Â Â 1Â Â Â Â 4,999Â Â Â Â Â€”Â Â Â Â 5,000Â Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing Â Â Â€”Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â 2,439Â Â Â Â 56,097Â Â Â Â Â€”Â Â Â Â Â€”Â Â Â Â 5,600,000Â Â Â Â 6Â Â Â Â 144,433Â Â Â Â Â€”Â Â Â Â 144,439Â Issuance cost of PIPE Financing Â Â Â Â Â Â Â Â

Company Series A Preferred Stock is convertible into 1,000 shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of 680,000 shares of Company Common Stock at a purchase price of $22.999 per pre-funded warrant, for aggregate net proceeds of approximately $188.7 million (net of issuance costs of $11.8 million).Â F-15 Â Â Liquidity and Going Concern Â Since its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Â The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. The Company has incurred a net loss of $28.6 million for the three months ended September 30, 2024 and $57.9Â million during the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024. For the period from February 6, 2024 (inception) to September 30, 2024, the Company used net cash of $39.0 million for its operating activities. Â As of September 30, 2024, the Company had cash and cash equivalents of $410.9 million. The Companyâ€™s management expects that the existing cash and cash equivalents will be sufficient to fund the Companyâ€™s operating plans for at least twelve months from the date these condensed consolidated financial statements were issued. The Company expects that its research and development and general and administrative costs will continue to increase significantly, including in connection with conducting future pre-clinical activities and clinical trials and manufacturing for its existing product candidates and any future product candidates to support commercialization and providing general and administrative support for its operations, including the costs associated with operating as a public company. The Companyâ€™s ability to access capital when needed is not assured and, if capital is not available to the Company when, and in the amounts needed, the Company may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the commercialization of any product candidate, or be unable to expand its operations or otherwise capitalize on the Companyâ€™s business opportunities, as desired, which could materially harm the Companyâ€™s business, financial condition and results of operations. Â 2. Summary of Significant Accounting Policies Â Use of Estimates Â The preparation of the Companyâ€™s condensed consolidated financial statements in conformity with U.S.Â GAAP requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include but are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results could differ materially from those estimates or assumptions. Â Concentrations of Credit Risk and Other Risks and Uncertainties Â The Companyâ€™s cash and cash equivalents are maintained with financial institutions in the UnitedÂ States of America. Cash balances are held at financial institutions and account balances may exceed federally insured limits. To date, the Company has not experienced any losses on its cash and cash equivalents and periodically evaluates the creditworthiness of its financial institutions. Â The Company manages credit risk associated with its investment portfolio through its investment policy, which limits investments to high-quality issuers and limits the amount of its portfolio that can be invested in a single issuer.Â F-16 Â Â The Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Companyâ€™s research and development programs could be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Companyâ€™s research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (â€œParagonâ€) (see NoteÂ 10). Â Cash and Cash Equivalents Â The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents. The cash equivalents were comprised of investments in money market funds. Â Debt Issuance Costs Â Debt issuance costs incurred in connection with the Convertible Note (see NoteÂ 6) are recorded as a reduction of the carrying value of the notes payable liability on the Companyâ€™s balance sheet and are amortized to interest expense over the term of the loan using the effective interest method. Â Subscription Receivable Â The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued. Â Fair Value Measurements Â Certain assets and liabilities are carried at fair value under U.S.Â GAAP.Â Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Â â—Â Level 1 â€”Â Quoted prices in active markets that are identical assets or liabilities. Â â—Â LevelÂ 2Â â€”Â Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Â â—Â LevelÂ 3Â â€”Â Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques. Â The Companyâ€™s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 4). The carrying values of the Companyâ€™s prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period. Â Property and Equipment Â Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: Â Â Â Estimated UsefulÂ Life Â Furniture and fixtures Â 3-5 years Â Computer and office equipment Â 3-5 years Â Â F-17 Â Â Classification of Convertible Preferred Stock Â Prior to the reverse recapitalization, the Company had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholdersâ€™ equity (deficit) on the Companyâ€™s condensed consolidated balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. Â Upon the closing of the Merger, the Company converted its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and has classified the Company Series B Preferred Stock within stockholdersâ€™ equity (deficit) on its condensed consolidated balance sheet because the Company Series B Preferred Stock is not redeemable or puttable to the Company by the holder under any circumstances. Â In connection with the PIPE Financing (see Note 1) the Company issued Company Series A Preferred Stock, and has classified the Company Series A Preferred Stock outside of stockholdersâ€™ equity (deficit) on the Companyâ€™s condensed consolidated balance sheet because the holders of such stock have certain rights (see Note 7) that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. Â NoteÂ Payable to Related Party Â The Company accounted for the Convertible Note (as defined in Note 6) at amortized cost. The Company considered if optional conversion features are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were recorded as a debt discount, amortized over the term of the Convertible Note (seeÂ NoteÂ 6) and were accounted as interest expense in other income (expenses) within the condensed consolidated statements of operations and comprehensive loss using the effective interest method. At the effective time of the Merger, shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible Note (including accrued interest) automatically converted into shares of Company Common Stock (see Note 1). Â Research and Development Contract Costs Accruals Â The Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of the Companyâ€™s research and development expenses, with a substantial portion of the Companyâ€™s ongoing research and development activities conducted by third-party service providers, including contract research organizations (â€œCROsâ€) and contract manufacturing organizations (â€œCMOsâ€), and the Companyâ€™s related-party Paragon (see NoteÂ 10). Â The Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the â€œOption Agreementsâ€) (see Note 10), by and among Paragon, Paruka Holding LLC (â€œParukaâ€), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company as well as agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. If advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to the Companyâ€™s accruals could materially affect the Companyâ€™s results of operations. As of September 30, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses. Â F-18 Â Â Leases Â At the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease and recognizes a right-of-use (â€œROUâ€) asset and a current and non-current lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise its option. Â At the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received or initial direct costs. As of September 30, 2024, the Company has one operating lease and no finance leases. Â The Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected that costs associated with leases having an initial term of 12 months or less are recognized in the condensed consolidated statement of operations and comprehensive loss on a straight-line basis over the lease term and are not recorded on its condensed consolidated balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office space related expenses. Â Segment Reporting Â The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions. The Companyâ€™s chief executive officer, who is the chief operating decision maker (the â€œCODMâ€), reviews the Companyâ€™s financial information on an aggregated basis for purposes of evaluating financial performance and allocating resources. Â Research and Development Costs Â Research and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation. Â Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses on the accompanying condensed consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period end, the payment is expensed immediately. Â Â General and Administrative Expenses Â General and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and administration costs, patent and intellectual property costs, professional fees, as well as allocated human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities and depreciation. Â Commitments and Contingencies Â The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of September 30, 2024, no liabilities were recorded for loss contingencies (see NoteÂ 11).Â F-19 Â Â Stock-Based Compensation Â The Company measures all stock-based awards granted to employees, directors, and non-employees in the form of stock options to purchase shares of its common stock, based on the fair value of the awards on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards (â€œRSAsâ€) using the difference, if any, between the purchase price per share of the award and the fair value of the Companyâ€™s common stock at the date of grant. Â The Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions. Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance-based vesting condition will be achieved. Â The Company has issued stock options, warrants, and RSAs with service-based and performance-based vesting conditions. Â The Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (â€œESPPâ€), based on the fair value of the common stock estimated using the closing price of the Companyâ€™s common stock as reported on the date of offering, less the purchase discount percentage provided for in the plan. Â The Company classifies stock-based compensation expense in its condensed consolidated statement of operations and comprehensive loss in the same manner in which the award recipientâ€™s payroll costs are classified or in which the award recipientâ€™s service payments are classified. Â Net Loss per Share Attributable to Stockholders Â Basic and diluted net loss attributable to stockholders per share is presented in conformity with the two-class method required for participating securities (Pre-Merger Oruka Series A Preferred Stock). Basic earnings per share is computed by dividing net income available to each class of shares by the weighted-average number of shares of common stock and participating securities outstanding during the period. Pre-funded warrants were included as the exercise price is negligible and these warrants are fully vested and exercisable. Company Series A Preferred Stock and Company Series B Preferred Stock share the same characteristics as Common Stock and have no substantive preference attributed to them and, accordingly, have been considered as classes of Common Stock in the computation of net loss per share regardless of their legal form. Â Net loss is allocated to common stock based on its proportional ownership on an as-converted basis. Net loss is not allocated to participating securities as they do not have an obligation to fund losses. The weighted-average number of shares outstanding of common stock reflects changes in ownership over the periods presented. See Note 7â€” Convertible Preferred Stock and Stockholdersâ€™ Equity. Â Diluted net loss per share is computed by dividing the net loss attributable to stockholders adjusted for income (expenses), net of tax, related to any diluted securities, by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, stock options to purchase common stock, employee warrants to purchase common stock, and unvested RSAs are considered potential dilutive common shares. Â The Company generated a net loss for the periods presented. Accordingly, basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti-dilutive. Â Income Taxes Â The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Companyâ€™s tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for theÂ years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it

believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. Â The Company accounts for uncertainty in income taxes recognized in the condensed consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the condensed consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of September 30, 2024.Â F-20 Â Â Recently Issued Accounting Pronouncements Â In NovemberÂ 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) 2023-07, Segment Reporting (TopicÂ 280): Improvements to Reportable Segment Disclosures (â€œASUÂ 2023-07â€), which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this proposal, public entities will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segmentâ€™s profit or loss and assets will be required on an interim basis. Entities will also be required to disclose information about the CODMâ€™s title and position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources. Finally, ASUÂ 2023-07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments in ASUÂ 2023-07 are effective for fiscalÂ years beginning after DecemberÂ 15, 2023, and interim periods within fiscalÂ years beginning after DecemberÂ 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements. Â In DecemberÂ 2023, the FASB issued ASUÂ 2023-09, Income Taxes (TopicÂ 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entityâ€™s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.Â and foreign jurisdictions. This update is effective beginning with the Companyâ€™s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements. Â In November 2024, the FASB issued ASU 2024-03, Income Statementâ€”Reporting Comprehensive Incomeâ€”Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of the adoption of this ASU on its consolidated financial statements. Â 3. Reverse Recapitalization and Pre-Closing Financing Â As described within the Reverse Recapitalization and Pre-Closing Financing section in Note 1, on August 29, 2024, the reverse recapitalization between Pre-Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal non-operating assets and liabilities. No goodwill or intangible assets were recognized. Â As part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands): Â Â Â AmountÂ Cash and cash equivalentsÂ $4,940Â Other current assetsÂ Â 114Â Accrued liabilitiesÂ Â (54) Net assets acquiredÂ $5,000Â Â F-21 Â Â 4. Fair Value Measurements Â The following tables present the Companyâ€™s fair value hierarchy for financial assets measured as of September 30, 2024 (in thousands): Â Â Â Fair Value Measurements as of September 30, 2024 Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Financial assets: Â Â Â

(inÂ Thousands)Â Balance as of FebruaryÂ 6, 2024 (inception)Â Â Â â€”Â Â $â€”Â Â Â â€”Â Â $â€”Â GrantedÂ Â 1,287,760Â Â $7.97Â Â Â Â Â Â Â Â Â ExercisedÂ Â â€”Â Â $â€”Â Â Â Â Â Â Â Â Â ForfeitedÂ Â â€”Â Â $â€”Â Â Â Â Â Â Â Â Â Balance as of September 30, 2024Â Â 1,287,760Â Â $7.97Â Â Â 9.6Â Â $21,507Â Vested and expected to vest, September 30, 2024Â Â 1,287,760Â Â $7.97Â Â Â 9.6Â Â $21,507Â Exercisable, September 30, 2024Â Â â€”Â Â $â€”Â Â Â â€”Â Â $â€”Â Â F-25 Â Â The weighted average grant-date fair value per share of stock options granted during the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024 was $6.44 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying Company Common Stock and the exercise price of outstanding, in-the-money employee stock options. Â Restricted Stock Awards Â In February 2024 and MarchÂ 2024, the Company issued 2,207,553 shares of RSAs to certain employees, directors, and consultants at a price of $0.0001 per share, the then par value of Pre-Merger Oruka Common Stock. Such RSAs have service-based vesting conditions only and vest over a four-year period, during which time all unvested shares are subject to forfeiture in the event the holderâ€™s service with the Company voluntarily or involuntarily terminates. Â The following table summarizes the RSAs activity for the period from FebruaryÂ 6, 2024 (inception) through September 30, 2024: Â Â Â Number of RSAsÂ Â Weighted Average Grant Date Fair ValueÂ Unvested balance as of FebruaryÂ 6, 2024 (inception)Â Â â€”Â Â $â€”Â GrantedÂ Â 2,207,553Â Â Â â€”Â Unvested balance as of September 30, 2024Â Â 2,207,553Â Â $â€”Â Â Option Agreements and Paruka Warrant Obligation Â In MarchÂ 2024, the Company entered into antibody discovery and option agreements with Paragon and Paruka (the â€œOption Agreementsâ€). Under the terms of Option Agreements, Paragon identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company, and the Company has the exclusive option to, on a research program-by-research program basis, be granted an exclusive, worldwide license to all of Paragonâ€™s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture and commercialize the antibodies and products directed to the selected target(s). Paruka will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of then outstanding shares of the Companyâ€™s stock, on a fully diluted basis, on DecemberÂ 31, 2024 and DecemberÂ 31, 2025, at the fair market value determined by the Board (the â€œParuka Warrant Obligationâ€). The grant dates for the issuance of warrants are expected to be DecemberÂ 31, 2024 and DecemberÂ 31, 2025 as all terms of the award, including number of shares and exercise price, will be known by all parties. The service inception period for the grant precedes the grant date, with the full award being vested as of the grant date with no post-grant date service requirement. Accordingly, the warrants expected to be granted to Paruka were accounted for as a liability on the condensed balance sheet and, after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss as stock-based compensation expenses under research and development expenses. As of September 30, 2024, the estimated fair value of warrants to be granted on December 31, 2024 was $11.0 million. For the three months ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, $7.3 million and $7.7 million were recognized as stock-based compensation expenses related to the Paruka Warrant Obligation, respectively. Â Employee Warrants Â As stated above, on July 3, 2024, the Subscription Agreement was amended and restated, among other things, for employee warrants to be issued to certain Pre-Merger Orukaâ€™s employees, directors, and service providers, immediately prior to the closing of the Merger. Pursuant to this amendment, during the three months ended September 30, 2024, the Company issued 3,054,358 employee warrants at an exercise price of $7.80 per warrant, which are accounted as equity in the condensed consolidated financial statements. Â The following table summarizes the employee warrant activity for the period from FebruaryÂ 6, 2024 (inception) through September 30, 2024:Â Â Â Â Number of WarrantsÂ Â Weighted Average Exercise Price Per ShareÂ Â Weighted Average Remaining Contractual Term (inÂ Years)Â Â Aggregate Intrinsic Value (inÂ Thousands)Â Balance as of FebruaryÂ 6, 2024 (inception)Â Â â€”Â Â $â€”Â Â Â â€”Â Â $â€”Â GrantedÂ Â 3,054,358Â Â $7.80Â Â Â Â Â Â Â Â Â ExercisedÂ Â â€”Â Â $â€”Â Â Â Â Â Â Â Â Â ForfeitedÂ Â â€”Â Â $â€”Â Â Â Â Â Â Â Â Â Balance as of September 30, 2024Â Â 3,054,358Â Â $7.80Â Â Â 9.8Â Â $51,038Â Vested and expected to vest, September 30, 2024Â Â 3,054,358Â Â $7.80Â Â Â 9.8Â Â $51,038Â Vested and exercisable, September 30, 2024Â Â â€”Â Â $â€”Â Â Â â€”Â Â $â€”Â Â Â The weighted average grant-date fair value per share of employee warrants granted during the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024 was $6.27 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying Company Common Stock and the exercise price of outstanding, in-the-money employee warrants.Â F-26 Â Â The following table summarizes the weighted-average assumptions used in calculating the fair value of the employee warrants for the three months ended September 30, 2024 and for the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024: Â Â Â Â ThreeÂ Months Ended SeptemberÂ 30, 2024Â Â Â Period from FebruaryÂ 6, 2024 (Inception) to SeptemberÂ 30, 2024Â Expected term (inÂ years)Â Â 6.1Â Â Â 6.1Â Expected volatilityÂ 99.0%Â Â 99.0% Risk-free interest rateÂ Â 4.2%Â Â Â 4.2% Expected dividend yieldÂ Â â€”%Â Â Â â€”% Â Stock-Based Compensation Expense Â The following table summarizes the classification of the Companyâ€™s stock-based compensation expense in the condensed consolidated statement of operations and comprehensive loss (in thousands): Â Â Â Â ThreeÂ¯Months Ended SeptemberÂ 30, 2024Â Â Â Period from FebruaryÂ 6, 2024 (Inception) to SeptemberÂ 30, 2024Â Research and developmentÂ $7,772Â Â $8,310Â General and administrativeÂ Â 1,229Â Â Â 1,459Â TotalÂ $9,001Â Â $9,769Â Â As of September 30, 2024, total unrecognized compensation cost related to the unvested stock options was $7.5 million, which is expected to be recognized over a weighted average period of approximately 3.4 years. As of September 30, 2024, total unrecognized compensation cost related to the unvested RSAs was less than $0.1 million, which is expected to be recognized over a weighted average period of 3.4 years. As of September 30, 2024, the unrecognized compensation cost related to the employee warrants was $17.8 million, which is expected to be recognized over a weighted average period of 3.6 years. Â The following table summarizes the award types of the Companyâ€™s stock-based compensation expense in the condensed consolidated statement of operations and comprehensive loss (in thousands):Â Â Â Â Â ThreeÂ Months Ended SeptemberÂ 30, 2024Â Â Â Period from FebruaryÂ 6, 2024 (Inception) to SeptemberÂ 30, 2024Â Paruka warrant obligationÂ $7,251Â Â $7,681Â Employee warrantsÂ Â 1,314Â Â Â 1,314Â Stock optionsÂ Â 427Â Â Â 765Â Employee stock purchase planÂ Â 9Â Â Â 9Â TotalÂ $9,001Â Â $9,769Â Â 9. Income Taxes Â No provision for income taxes was recorded for the three months ended September 30, 2024 and for the period of FebruaryÂ 6, 2024 (inception) through September 30, 2024. Deferred tax assets generated from the Companyâ€™s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized due to the Companyâ€™s cumulative losses generated to date. Â F-27 Â Â 10. Option Agreements Â In MarchÂ 2024, the Company entered into Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company. The Option Agreements include two selected targets, IL-23 (â€œORKA-001â€) and IL-17 A/F (â€œORKA-002â€). Under the Option Agreements, the Company has the exclusive options to, on a research program-by-research program basis, be granted an exclusive, worldwide license to all of Paragonâ€™s right, title and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture and commercialize the antibodies and products directed to the selected targets (each, an â€œOptionâ€), with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease. If the Company exercises its options, it will be required to make non-refundable milestone payments to Paragon of up to $12.0Â million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0Â million under each respective agreement upon the achievement of certain regulatory milestones as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale. From time to time, the Company can choose to add additional targets to the collaboration by mutual agreement with Paragon. Â The Companyâ€™s exclusive Option with respect to each research program for a particular target initiated by the parties (â€œResearch Programâ€) is exercisable at its sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number ofÂ days following (i) with respect to any Research Program other than ORKA-001, the delivery of the data package from Paragon related to the results of the Research Plan activities, or (ii) with respect to ORKA-001, the completion of the IL-23 antibody selection process described in the agreement (the â€œOption Periodâ€). There is no payment due upon exercise of an Option pursuant to the Option Agreements. Â Unless terminated earlier, the Option Agreements shall continue in force on a Research Program-by-Research Program basis until the earlier of: (i)Â the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii)Â the expiration of the 30-day period after the Company exercises its Option with respect to such Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration of the applicable research term (the â€œTermâ€). Upon the expiration of the Term for all then-existing Research Programs, under the Option Agreements, the Option Agreements will automatically expire in its entirety. The Company may terminate the Option Agreements or any Research Program at any time for any or no reason upon 30Â daysâ€™ prior written notice to Paragon, provided that the Company must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Option Agreements or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of months. Each party has the right to terminate the Option Agreements or any Research Program upon (i)Â 30Â daysâ€™ prior written notice of the other partyâ€™s material breach that remains uncured for the 30-day period and (ii)Â the other partyâ€™s bankruptcy. Â Pursuant to the Option Agreements, on a research program-by-research program basis following the finalization of the research plan for each respective research program, the Company was required to pay Paragon a one-time, nonrefundable research initiation fee of $0.8Â million related to the ORKA-001 program. This amount was recognized as a research and development expense during the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its development candidate for IL-23 antibody for ORKA-001 program. The Company was responsible for 50% of the development costs incurred through the completion of the IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June 2024. During the three months ended September 30, 2024, the Company exercised its option for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement of development candidate as research and development expense in the Companyâ€™s condensed consolidated statements of operations and comprehensive loss for each of the three months ended September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024. The Companyâ€™s share of development costs incurred during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024 was $0.8 million and $13.2 million, respectively, which were recorded as research and development expenses during the respective periods. An amount of $2.3 million is included in related party accounts payable and other current liabilities as of September 30, 2024. Â The Company was also required to reimburse Paragon $3.3Â million for development costs related to ORKA-002 incurred by Paragon through DecemberÂ 31, 2023 and certain other development costs incurred by Paragon between JanuaryÂ 1, 2024 and MarchÂ 6, 2024 as stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024. The Company is also responsible for the development costs incurred by Paragon from JanuaryÂ 1, 2024 through the completion of the IL-17 selection process. The Company recognized an amount of $0.8Â million payable to Paragon for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as research and development expenses in the period from February 6, 2024 (inception) to September 30, 2024. The Company accounted for development costs of $3.8 million and $6.6 million during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively, as research and development expenses during the respective periods. An amount of $3.8 million is included in related party accounts payable and other current liabilities as of September 30, 2024.Â F-28 Â Â As part of the Option Agreements, on each of December 31, 2024 and December 31, 2025, the Company will grant warrants to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully diluted basis with an exercise price equal to the fair market value of the underlying shares on the grant date. The warrants are liability-classified and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss (see NoteÂ 8) as stock-based compensation expenses under research and development expenses. Â The Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying condensed consolidated statement of operations and comprehensive loss. Â The Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost, monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are recognized as research and development expense when incurred. Â For the three months ended September 30, 2024 and the period from FebruaryÂ 6, 2024 (inception) to September 30, 2024, the Company recognized $13.4 million and $33.8 million of expenses, respectively, in connection with services provided by Paragon and Paruka under the Option Agreements. Â 11. Commitment and Contingencies Â Leases Â In April 2024, the Company entered into an operating lease agreement for the Companyâ€™s headquarters in Menlo Park, California, which commenced on June 15, 2024 with an initial term of 39.5 months. The Company leases office space under this noncancelable operating lease agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount rates were not implicit or readily determinable. Â As of September 30, 2024, the Company had $0.9 million of operating lease right-of-use assets, operating lease liability, current of $0.1 million, and operating lease liability, noncurrent of $0.8 million on its condensed consolidated balance sheets. As of September 30, 2024, the operating lease arrangement had a remaining lease term of 36.0 months and a discount rate of 17.95%. For the three months ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, the Company recorded operating and variable lease expense of $0.1 and $0.2 million, respectively, in general and administrative expenses in its condensed consolidated statements of operations and comprehensive loss. Â The following table presents the Companyâ€™s supplemental cash flow information related to leases (in thousands): Â Â Â September 30, 2024Â Cash paid for amounts included in the measurement of lease liabilitiesÂ Â Â Â Operating cash flow from operating leasesÂ $74Â Â The following table summarizes a maturity analysis of the Companyâ€™s operating lease liabilities showing the aggregate lease payments as of September 30, 2024 (in thousands):Â Â Â Â AmountÂ Fiscal year ending December 31,Â Â Â Â Â 2024 (remainder)Â $63Â 2025Â Â 369Â 2026Â Â 494Â 2027Â Â 380Â Total undiscounted lease paymentsÂ Â 1,306Â Less: imputed interestÂ Â (318) Total discounted lease paymentsÂ Â 988Â Less: current portion of lease liabilityÂ Â (146) Non-current portion of lease liabilityÂ $842Â Â F-29 Â Â 12. Net Loss per Share Â Basic and diluted net loss per share attributable to stockholders were calculated as follows (in thousands, except share and per share data):Â Â Â Â ThreeÂ Months Ended SeptemberÂ 30, 2024Â Â Period from FebruaryÂ 6, 2024 (Inception) to SeptemberÂ 30, 2024Â Â Loss AllocationÂ Â Weighted Average Shares OutstandingÂ Â Loss Per Share â€” Basic and DilutedÂ Â Loss AllocationÂ Â Weighted Average Shares OutstandingÂ Â Loss Per Share â€” Basic and DilutedÂ Common StockÂ $(21,936)Â Â 15,013,655Â Â $(1.46)Â $(47,192)Â Â 7,765,381Â Â $(6.08) Company Series A Preferred Stock(1)Â Â (697)Â Â 477Â Â $(1,460.62)Â Â (1,121)Â Â 184Â Â $(6,077.13) Company Series B Preferred Stock(2)Â Â (5,990)Â Â 49,191Â Â $(121.77)Â Â (9,630)Â Â 19,015Â Â $(506.44) Net lossÂ $(28,623)Â Â Â Â Â Â Â Â Â $(57,943)Â Â Â Â Â Â Â Â Â (1)The weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 477,196 and 184,462 for the three months ended September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively. Â (2)The weighted-average number of shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,099,227 and 1,584,575 for the three months ended September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively. Â For the computation of basic net loss per share attributable to stockholders, the amount of weighted-average shares outstanding excludes all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested. The amount of weighted-average shares outstanding includes the pre-funded warrants as the exercise price is negligible and these warrants are fully vested and exercisable. Â The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to stockholders for the periods presented because including them would have had an anti-dilutive effect were as follows:Â Â Â Â Â ThreeÂ Months Ended SeptemberÂ 30, 2024Â Â Period from FebruaryÂ 6, 2024 (Inception) to SeptemberÂ 30, 2024Â Outstanding employee warrants

to purchase common stockÂ Â 3,054,358Â Â Â 3,054,358Â Outstanding unvested restricted stock awardsÂ Â 2,207,553Â Â Â 2,207,553Â Outstanding and issued common stock optionsÂ Â 1,287,760Â Â Â 1,287,760Â TotalÂ Â 6,549,671Â Â Â 6,549,671Â Â Â 13. Related Party Transactions Â Paragon and Paruka each beneficially own less than 5% of the Companyâ€™s capital stock through their respective holdings of Company Common Stock. Â Fairmount beneficially owns more than 5% of the Companyâ€™s capital, currently has one representative appointed to the Board, and beneficially owns more than 5% of Paragon. Fairmount appointed Paragonâ€™s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon. Â The following is a summary of related party accounts payable and other current liabilities (in thousands):Â Â Â Â Â SeptemberÂ 30, 2024Â Paragon reimbursable Option Agreementsâ€™ feesÂ $6,140Â Paragon reimbursable other research expensesÂ Â 146Â Paragon reimbursable patent expensesÂ Â 71Â Â Â $6,357Â Â F-30 Â Â PART II Â INFORMATION NOT REQUIRED IN PROSPECTUS Â Itemâ€‰13. Other Expenses of Issuance and Distribution Â The expenses payable by us in connection with the issuance and distribution of the securities being registered hereunder on Form S-1 (other than underwriting discounts and commissions, if any) are set forth below. The Selling Stockholders will not bear any portion of such expenses. Each item listed is estimated, except for the SEC registration fee: Â SEC registration feeÂ $33,913 Printing and engravingÂ Â 5,000Â Legal fees and expensesÂ Â 75,000 Accounting fees and expensesÂ Â 50,000Â Miscellaneous expensesÂ Â 6,087Â TotalÂ $170,000Â Â Itemâ€‰14. Indemnification of Officers and Directors Â Section 145 of the DGCL authorizes a court to award, or a corporationâ€™s board of directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section 145 of the DGCL are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act. Â As permitted by the DGCL, the Registrantâ€™s Certificate of Incorporation contains provisions that eliminate the personal liability of its directors for monetary damages for any breach of fiduciary duties as a director, except liability for the following: Â â—any breach of the directorâ€™s duty of loyalty to the Registrant or its stockholders; Â â—acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; Â â—under Section 174 of the DGCL (regarding unlawful dividends and stock purchases); or Â â—any transaction from which the director derived an improper personal benefit. Â As permitted by the DGCL, the Registrantâ€™s Bylaws provide that: Â â—the Registrant is required to indemnify its directors and executive officers to the fullest extent permitted by the DGCL, subject to very limited exceptions; Â â—the Registrant may indemnify its other employees and agents as set forth in the DGCL; Â â—the Registrant is required to advance expenses, as incurred, to its directors and executive officers in connection with a legal proceeding to the fullest extent permitted by the DGCL, subject to very limited exceptions; and Â â—the rights conferred in the Bylaws are not exclusive. Â II-1 Â Â The Registrant has entered, and intends to continue to enter, into separate indemnification agreements with its directors and executive officers to provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the Registrantâ€™s Certificate of Incorporation and Bylaws and to provide additional procedural protections. At present, there is no pending litigation or proceeding involving a director or executive officer of the Registrant regarding which indemnification is sought. Â The indemnification provisions in the Registrantâ€™s Certificate of Incorporation, Bylaws and the indemnification agreements entered into or to be entered into between the Registrant and each of its directors and executive officers may be sufficiently broad to permit indemnification of the Registrantâ€™s directors and executive officers for liabilities arising under the Securities Act. Â The Registrant currently carries liability insurance for its directors and officers. One of the Registrantâ€™s directors, Peter Harwin, is also indemnified by his employer with regard to their service on the Registrantâ€™s board of directors. Â Â Itemâ€‰15. Recent Sales of Unregistered Securities Â On September 13, 2024, we completed the Private Placement of Private Placement Common Shares, Private Placement Conversion Shares and Pre-Funded Warrants pursuant to the SPA with the Selling Stockholders in the September 2024 PIPE. We sold an aggregate of 5,600,000 shares of Common Stock, 2,439 shares of our Series A Preferred Stock and pre-funded warrants to purchase 680,000 shares of Common Stock in the September 2024 PIPE for an aggregate purchase price of approximately $200.5 million. Â Subject to stockholder approval and certain beneficial ownership limitations, each share of Series A Preferred Stock is convertible into 1,000 shares of Common Stock. Shares of Series A Preferred Stock shall not be convertible if the conversion would result in a holder, together with its affiliates, beneficially owning more than 9.99% of our outstanding shares of Common Stock as of the applicable conversion date, which may be increased at the holdersâ€™ option (not to exceed 19.99%), effective in accordance with the terms of our Series A Certificate of Designation. Â The shares issued pursuant to the September 2024 PIPE were offered and sold in transactions exempt from registration under the Securities Act, in reliance on Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder. Each of the investors represented that it was an â€œaccredited investor,â€ as defined in Regulation D, and acquired the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The shares of Series A Preferred Stock issued pursuant to the September 2024 PIPE have not been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. Â II-2 Â Â Itemâ€‰16. Exhibits and Financial Statement Schedules Â (a)Exhibits Â EXHIBIT NUMBER Â DESCRIPTION OF EXHIBIT 2.1*â€ Â Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024, by and among ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub II, LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of ARCA biopharma, Inc.â€™s Form 8-K filed on April 3, 2024, File No. 000-22873). 3.1* Â Amended and Restated Certificate of Incorporation of the Company, filed September 3, 2024 (incorporated by reference to Exhibit 3.5 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on September 5, 2024). 3.2* Â Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.6 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on September 5, 2024). 3.3* Â Form of Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on September 13, 2024). 3.4* Â Form of Certificate of Designation of Preferences, Rights and Limitations of SeriesÂ B Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.9 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on September 5, 2024). 4.1* Â Form of Registration Rights Agreement, dated as of September 13, 2024 (incorporated by reference to Exhibit 10.2 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on September 13, 2024). 4.2* Â Securities Purchase Agreement, dated September 11, 2024, by and between Oruka Therapeutics, Inc. and each purchaser identified on Annex A thereto (incorporated by reference to Exhibit 10.1 the Registrantâ€™s Current Report on Form 8-K filed with the SEC on September 13, 2024). 4.3* Â Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on September 13, 2024). 5.1 Â Opinion of Gibson, Dunn & Crutcher LLP. 10.1* Â Â Form of Oruka Support Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Incâ€™s FormÂ 8-K filed on AprilÂ 3, 2024). 10.2*â€ Â Â Form of Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Incâ€™s Form 8-K filed on April 3, 2024). 10.3*â€ Â Â Form of Amendment to Oruka Subscription Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Incâ€™s Form 8-K filed on July 9, 2024). 10.4*â€ Â Â Form of Amended & Restated Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Incâ€™s Form 8-K filed on July 9, 2024). 10.5* Â Form of Registration Rights Agreement, dated as of August 29, 2024 (incorporated by reference to Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024). 10.6 Â Â Form of ACRA Support Agreement (incorporated by reference to Exhibit 10.3 to ARCA biopharma, Incâ€™s Form 8-K filed on April 3, 2024). 10.7* Â Â Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.4 to ARCA biopharma, Incâ€™s Form 8-K filed on April 3, 2024). 10.8*â€ â€ Â Separation Agreement and Release, by and between ARCA biopharma, Inc. and Michael Bristow, dated as of April 3, 2024 (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.â€™s Form 8-K filed on April 4, 2024). 10.9*â€ â€ Â Consulting Agreement, by and between ARCA biopharma, Inc. and Michael Bristow, dated as of April 3, 2024 (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.â€™s Form 8-K filed on April 4, 2024). Â II-3 Â Â 10.10*# Â Form of Indemnification Agreement between Oruka Therapeutics, Inc. and its directors and officers (incorporated by reference to Exhibit 10.45 to ARCA biopharma, Inc.â€™s Form S-4, filed on May 14, 2024, File No. 333-279387). 10.11*# Â Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (incorporated by reference to Exhibit 10.10 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on September 5, 2024). 10.12*# Â Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.11 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on September 5, 2024). 10.13*# Â Amended and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, as amended by the First Amendment dated May 7, 2024 (incorporated by reference to Exhibit 10.40 to ARCA biopharma, Inc.â€™s Form S-4, filed on May 14, 2024, File No. 333-279387). 10.14*# Â Â Second Amendment to Amended and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, effective as of May 7, 2024 (incorporated by reference to Exhibit 10.13 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on September 5, 2024).Â 10.15*# Â Â Form of Restricted Stock Notice and Restricted Stock Purchase Agreement (incorporated by reference to Exhibit 10.41 to ARCA biopharma, Inc.â€™s Form S-4, filed on May 14, 2024, File No. 333-279387). 10.16*# Â Form of Stock Option Agreement under Oruka Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.42 to ARCA biopharma, Inc.â€™s Form S-4, filed on May 14, 2024, File No. 333-279387). 10.17*# Â Form of Employee Warrant Agreement (incorporated by reference to Exhibit 10.16 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on September 5, 2024). 10.18*# Â Amended and Restated Director Offer Letter, dated MarchÂ 22, 2024, between Oruka Therapeutics, Inc. and Samarth Kulkarni (incorporated by reference to Exhibit 10.43 to ARCA biopharma, Inc.â€™s Form S-4, filed on May 14, 2024, File No. 333-279387). 10.19*# Â Director Offer Letter, dated AprilÂ 24, 2024, between Oruka Therapeutics, Inc. and Kristine Ball (incorporated by reference to Exhibit 10.44 to ARCA biopharma, Inc.â€™s Form S-4, filed on May 14, 2024, File No. 333-279387). 10.20*# Â Amended and Restated Employment Offer Letter by and between Oruka Therapeutics, Inc. and Lawrence Klein, dated as of October 3, 2024 (incorporated by reference to Exhibit 10.1 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on October 4, 2024, File No. 241354944). 10.21*# Â Amended and Restated Employment Letter Agreement by and between the Company and Arjun Agarwal, dated as of October 3, 2024 (incorporated by reference to Exhibit 10.2 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on October 4, 2024, File No. 241354944). 10.22*# Â Employment Offer Letter, dated March 15, 2024, by and between Oruka Therapeutics, Inc. and Joana Goncalves (incorporated by reference to Exhibit 10.48 to ARCA biopharma, Inc.â€™s Form S-4, filed on May 14, 2024, File No. 333-279387). 10.23*# Â Employment Offer Letter, dated AprilÂ 12, 2024, by and between Oruka Therapeutics, Inc. and Paul Quinlan (incorporated by reference to Exhibit 10.49 to ARCA biopharma, Inc.â€™s Form S-4, filed on May 14, 2024, File No. 333-279387). 10.24*â€ Â Amended and Restated Antibody Discovery and Option Agreement (IL-17), dated MarchÂ 28, 2024, by and among Paragon Therapeutics, Inc., Paruka Holding LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 10.50 to ARCA biopharma, Inc.â€™s Form S-4/A, filed on June 18, 2024, File No. 333-279387). Â II-4 Â Â 10.25*â€ Â Amended and Restated Antibody Discovery and Option Agreement (IL-23), dated MarchÂ 28, 2024, by and among Paragon Therapeutics, Inc., Paruka Holding LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 10.51 to ARCA biopharma, Inc.â€™s Form S-4/A, filed on June 18, 2024, File No. 333-279387). 10.26*â€ # Â Consulting Agreement, effective as of August 30, 2024, by and between Oruka Therapeutics, Inc. and Jeff Dekker (incorporated by reference to Exhibit 10.25 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on September 5, 2024). 16.1* Â Letter from KPMG LLP, dated September 5, 2024 (incorporated by reference to Exhibit 16.1 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on September 5, 2024). 21.1* Â List of Subsidiaries of Oruka Therapeutics, Inc (incorporated by reference to Exhibit 21.1 to the Registrantâ€™s Current Report on Form 8-K filed with the SEC on September 5, 2024). 23.1 Â Consent of PricewaterhouseCoopers LLP 23.2 Â Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1) 24.1 Â Power of Attorney (included on the signature page to the registration statement) 101.INS Â Inline XBRL Instance Document. 101.SCH Â Inline XBRL Taxonomy Extension Schema Document. 101.CAL Â Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Â Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Â Inline XBRL Taxonomy Extension Labels Linkbase Document. 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 107 Â Filing Fee Table. Â *Previously filed. Â #Indicates management contract or compensatory plan. Â â€ Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished. Certain portions of this exhibit (indicated by â€œ[***]â€) have been omitted because they are both (i) not material and (ii) is the type of information that the registrant both customarily and actually treats as private and confidential. Â (b)Financial statement schedules Â None. Â II-5 Â Â Itemâ€‰17. Undertakings Â (a) The undersigned Registrant hereby undertakes: Â (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: Â (i) to include any prospectus required by Section 10(a)(3) of the Securities Act; Â (ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the â€œFiling Fee Tableâ€ in the effective registration statement; and Â (iii) to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; Â (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Â (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. Â (4) That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. Â (5) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. Â Â II-6 Â Â SIGNATURES Â Pursuant to the requirements of the Securities Act, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Menlo Park, California, on November 13, 2024. Â Â Â ORUKA THERAPEUTICS, INC. Â Â Â Â By: /s/ Lawrence Klein Â Â Lawrence Klein Â Â Chief Executive Officer Â Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated. Â Â Signature Â Title Â Date Â Â Â Â Â Â /s/ Lawrence Klein Â Chief Executive Officer & Director Â November 13, 2024 Lawrence Klein Â (Principal Executive Officer) Â Â Â Â Â Â Â /s/ Arjun Agarwal Â Senior Vice President, Finance and Treasurer Â November 13, 2024 Arjun Agarwal Â (Principal Financial Officer and Principal Accounting Officer) Â Â Â Â Â Â Â /s/ Samarth Kulkarni Â Chairman of the Board Â November 13, 2024 Samarth Kulkarni Â Â Â Â Â Â Â Â Â Â /s/ Kristine Ball Â Director Â November 13, 2024 Kristine Ball Â Â Â Â Â Â Â Â Â Â /s/ Carl Dambkowski Â Director Â November 13, 2024 Carl Dambkowski Â Â Â Â Â Â Â Â Â Â /s/ Peter Harwin Â Director Â November 13, 2024 Peter Harwin Â Â Â Â Â Â Â Â Â Â /s/ Cameron Turtle Â Director Â November 13, 2024 Cameron Turtle Â Â Â Â Â Â II-7 Â Â false 0000907654 0000907654 2024-02-06 2024-09-30 0000907654 srt:ScenarioPreviouslyReportedMember 2024-02-06 0000907654 srt:ScenarioPreviouslyReportedMember orka:SeriesAConvertiblePreferredStockMember 2024-02-06 0000907654 2024-09-30 0000907654 2024-02-06 0000907654 us-gaap:RelatedPartyMember 2024-09-30 0000907654 us-gaap:RelatedPartyMember 2024-02-06 0000907654 orka:SeriesAConvertiblePreferredStockMember 2024-09-30 0000907654

orka:SeriesAConvertiblePreferredStockMember 2024-02-06 0000907654 orka:SeriesANonVotingConvertiblePreferredStockMember 2024-09-30 0000907654 orka:SeriesANonVotingConvertiblePreferredStockMember 2024-02-06 0000907654 orka:SeriesBNonVotingConvertiblePreferredStockMember 2024-09-30 0000907654 orka:SeriesBNonVotingConvertiblePreferredStockMember 2024-02-06 0000907654 2024-07-01 2024-09-30 0000907654 orka:SeriesANonVotingConvertiblePreferredStockholdersMember 2024-07-01 2024-09-30 0000907654 orka:SeriesANonVotingConvertiblePreferredStockholdersMember 2024-02-06 2024-09-30 0000907654 orka:SeriesBNonVotingConvertiblePreferredStockholdersMember 2024-07-01 2024-09-30 0000907654 orka:SeriesBNonVotingConvertiblePreferredStockholdersMember 2024-02-06 2024-09-30 0000907654 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-02-05 0000907654 orka:SeriesANonVotingConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-02-05 0000907654 orka:SeriesBNonVotingConvertiblePreferredStockAmountMember us-gaap:PreferredStockMember 2024-02-05 0000907654 us-gaap:CommonStockMember 2024-02-05 0000907654 us-gaap:AdditionalPaidInCapitalMember 2024-02-05 0000907654 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-02-05 0000907654 2024-02-05 0000907654 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-02-06 2024-03-31 0000907654 orka:SeriesANonVotingConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-02-06 2024-03-31 0000907654 orka:SeriesBNonVotingConvertiblePreferredStockAmountMember us-gaap:PreferredStockMember 2024-02-06 2024-03-31 0000907654 us-gaap:CommonStockMember 2024-02-06 2024-03-31 0000907654 us-gaap:AdditionalPaidInCapitalMember 2024-02-06 2024-03-31 0000907654 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-02-06 2024-03-31 0000907654 2024-02-06 2024-03-31 0000907654 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000907654 orka:SeriesANonVotingConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0000907654 orka:SeriesBNonVotingConvertiblePreferredStockAmountMember us-gaap:PreferredStockMember 2024-03-31 0000907654 us-gaap:CommonStockMember 2024-03-31 0000907654 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000907654 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000907654 2024-03-31 0000907654 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0000907654 orka:SeriesANonVotingConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0000907654 orka:SeriesBNonVotingConvertiblePreferredStockAmountMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0000907654 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000907654 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000907654 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000907654 2024-04-01 2024-06-30 0000907654 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0000907654 orka:SeriesANonVotingConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0000907654 orka:SeriesBNonVotingConvertiblePreferredStockAmountMember us-gaap:PreferredStockMember 2024-06-30 0000907654 us-gaap:CommonStockMember 2024-06-30 0000907654 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000907654 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000907654 2024-06-30 0000907654 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0000907654 orka:SeriesANonVotingConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0000907654 orka:SeriesBNonVotingConvertiblePreferredStockAmountMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0000907654 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000907654 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000907654 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000907654 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0000907654 orka:SeriesANonVotingConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0000907654 orka:SeriesBNonVotingConvertiblePreferredStockAmountMember us-gaap:PreferredStockMember 2024-09-30 0000907654 us-gaap:CommonStockMember 2024-09-30 0000907654 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000907654 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000907654 2024-02-06 2024-02-06 0000907654 2024-03-01 2024-03-31 0000907654 srt:MaximumMember us-gaap:WarrantMember 2024-02-06 0000907654 srt:MinimumMember us-gaap:WarrantMember 2024-02-06 0000907654 us-gaap:WarrantMember 2024-02-06 0000907654 orka:ARCABIOPHARMAINCMember 2024-02-06 2024-02-06 0000907654 us-gaap:CommonStockMember 2024-02-06 0000907654 orka:ParagonMember 2024-02-06 0000907654 orka:ParukaHoldingLLCMember 2024-02-06 0000907654 orka:OrukaAdvisorsLLCMember 2024-02-06 0000907654 orka:TwoThousandTwentyFourEquityIncentivePlanMember 2024-02-06 0000907654 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2024-02-29 0000907654 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2024-03-31 0000907654 srt:MinimumMember orka:TwoThousandTwentyFourEquityIncentivePlanMember us-gaap:SubsequentEventMember 2024-03-05 0000907654 srt:MaximumMember orka:TwoThousandTwentyFourEquityIncentivePlanMember us-gaap:SubsequentEventMember 2024-03-05 0000907654 us-gaap:EmployeeStockOptionMember us-gaap:SubsequentEventMember 2024-03-22 2024-03-22 0000907654 srt:MinimumMember orka:TwoThousandTwentyFourEquityIncentivePlanMember us-gaap:SubsequentEventMember 2024-03-07 0000907654 srt:MaximumMember orka:TwoThousandTwentyFourEquityIncentivePlanMember us-gaap:SubsequentEventMember 2024-03-07 0000907654 us-gaap:EmployeeStockOptionMember us-gaap:SubsequentEventMember 2024-03-07 2024-03-07 0000907654 us-gaap:SubsequentEventMember 2024-03-06 2024-03-06 0000907654 orka:ParagonMember us-gaap:SubsequentEventMember 2024-03-06 0000907654 us-gaap:SubsequentEventMember 2024-03-31 2024-03-31 0000907654 2023-12-31 2023-12-31 0000907654 orka:ParagonMember us-gaap:SubsequentEventMember 2024-04-30 2024-04-30 0000907654 us-gaap:SubsequentEventMember 2024-02-06 2024-03-31 0000907654 orka:ParagonMember 2024-02-06 2024-02-06 0000907654 orka:ClinicalDevelopmentMilestonesMember 2024-02-06 2024-02-06 0000907654 orka:CertainRegulatoryMilestonesMember 2024-02-06 2024-02-06 0000907654 us-gaap:WarrantMember 2024-02-06 2024-02-06 0000907654 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2024-03-06 0000907654 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2024-03-06 2024-03-06 0000907654 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-06 0000907654 us-gaap:SubsequentEventMember 2024-03-06 0000907654 orka:SeriesAConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2024-03-06 0000907654 orka:ConvertibleNotesMember us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2024-03-06 0000907654 orka:ConvertibleNotesMember us-gaap:SubsequentEventMember 2024-03-06 2024-03-06 0000907654 orka:ConvertibleNotesMember us-gaap:SubsequentEventMember orka:ConvertibleNotePurchaseAgreementMember 2024-03-06 0000907654 orka:ConvertibleNotesMember us-gaap:SubsequentEventMember 2024-03-06 0000907654 us-gaap:SubsequentEventMember 2024-04-12 0000907654 us-gaap:SubsequentEventMember 2024-04-12 2024-04-12 0000907654 orka:OrukaCommonStockMember 2024-08-29 0000907654 orka:OrukaCommonStockMember 2024-04-03 2024-04-03 0000907654 orka:OrukaPrefundedWarrantsMember 2024-04-03 2024-04-03 0000907654 2024-04-03 2024-04-03 0000907654 orka:ARCACommonStockMember 2024-02-06 2024-09-30 0000907654 orka:OrukaRestrictedStockMember 2024-09-30 0000907654 orka:OrukaCommonStockMember 2024-09-30 0000907654 orka:ReverseStockSplitMember 2024-02-06 2024-03-31 0000907654 orka:ReverseStockSplitMember 2024-04-01 2024-06-30 0000907654 orka:ReverseStockSplitMember 2024-02-06 2024-06-30 0000907654 us-gaap:CommonStockMember 2024-06-30 0000907654 us-gaap:CommonStockMember 2024-09-30 0000907654 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2024-09-30 0000907654 orka:SeriesANonVotingConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2024-09-30 0000907654 orka:SeriesANonVotingConvertiblePreferredStockMember 2024-02-06 2024-09-30 0000907654 us-gaap:SeriesAPreferredStockMember 2024-02-06 2024-09-30 0000907654 us-gaap:CommonStockMember 2024-02-06 2024-09-30 0000907654 orka:PrefundedWarrantsMember 2024-09-30 0000907654 orka:PrefundedWarrantsMember 2024-02-06 2024-09-30 0000907654 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2024-09-30 0000907654 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2024-09-30 0000907654 srt:MinimumMember orka:ComputerAndOfficeEquipmentMember 2024-09-30 0000907654 srt:MaximumMember orka:ComputerAndOfficeEquipmentMember 2024-09-30 0000907654 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-09-30 0000907654 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0000907654 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2024-09-30 0000907654 us-gaap:MoneyMarketFundsMember 2024-09-30 0000907654 us-gaap:FairValueInputsLevel1Member 2024-09-30 0000907654 us-gaap:FairValueInputsLevel2Member 2024-09-30 0000907654 us-gaap:FairValueInputsLevel3Member 2024-09-30 0000907654 orka:FairmountHealthcareFundIILPMember 2024-03-31 0000907654 us-gaap:SeriesAPreferredStockMember 2024-03-01 2024-03-31 0000907654 orka:ConvertibleNoteMember 2024-03-01 2024-03-31 0000907654 orka:ConvertibleNoteMember 2024-07-01 2024-09-30 0000907654 orka:ConvertibleNoteMember 2024-02-06 2024-09-30 0000907654 orka:PreFundedWarrantsMember 2024-08-31 2024-08-31 0000907654 2024-08-31 0000907654 orka:PreFundedWarrantsMember 2024-08-31 0000907654 us-gaap:CommonStockMember 2024-08-31 0000907654 us-gaap:PrivatePlacementMember 2024-02-06 2024-09-30 0000907654 us-gaap:PrivatePlacementMember 2024-09-30 0000907654 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2024-09-30 0000907654 orka:PreFundedWarrantsMember 2024-09-30 0000907654 orka:EmployeeWarrantsMember 2024-09-30 0000907654 orka:EmployeeWarrantsMember 2024-02-06 2024-09-30 0000907654 us-gaap:SeriesAPreferredStockMember 2024-03-31 2024-03-31 0000907654 us-gaap:SeriesAPreferredStockMember 2024-03-31 0000907654 2024-03-31 2024-03-31 0000907654 us-gaap:SeriesBPreferredStockMember 2024-08-31 0000907654 orka:SeriesBNonVotingPreferredStockMember 2024-09-30 0000907654 srt:MinimumMember 2024-09-30 0000907654 srt:MaximumMember 2024-09-30 0000907654 orka:SeriesBNonVotingConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0000907654 us-gaap:SeriesAPreferredStockMember 2024-09-30 0000907654 us-gaap:SeriesBPreferredStockMember 2024-09-30 0000907654 orka:TwoThousandTwentyFourStockIncentivePlanMember 2024-09-30 0000907654 orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember 2024-09-30 0000907654 orka:TwoThousandTwentyFourStockIncentivePlanMember us-gaap:CommonStockMember 2024-09-30 0000907654 orka:TwoThousandTwentyFourStockIncentivePlanMember us-gaap:CommonStockMember 2024-09-30 0000907654 orka:TwoThousandTwentyFourStockIncentivePlanMember 2024-02-06 2024-09-30 0000907654 orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember 2024-08-29 2024-08-29 0000907654 us-gaap:StockOptionMember 2024-02-06 2024-09-30 0000907654 us-gaap:RestrictedStockMember 2024-02-06 2024-09-30 0000907654 us-gaap:SubsequentEventMember 2024-12-31 0000907654 srt:MinimumMember orka:ParukaWarrantObligationMember 2024-09-30 0000907654 srt:MaximumMember orka:ParukaWarrantObligationMember 2024-09-30 0000907654 us-gaap:WarrantMember 2024-02-06 2024-09-30 0000907654 orka:UnvestedStockOptionsMember 2024-09-30 0000907654 orka:UnvestedStockOptionsMember 2024-02-06 2024-09-30 0000907654 us-gaap:RestrictedStockMember 2024-09-30 0000907654 us-gaap:WarrantMember 2024-09-30 0000907654 us-gaap:StockOptionMember 2024-07-01 2024-09-30 0000907654 us-gaap:StockOptionMember 2024-02-06 2024-09-30 0000907654 orka:RestrictedStockActivityMember 2024-02-05 0000907654 orka:RestrictedStockActivityMember 2024-02-06 2024-09-30 0000907654 orka:RestrictedStockActivityMember 2024-09-30 0000907654 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0000907654 us-gaap:ResearchAndDevelopmentExpenseMember 2024-02-06 2024-09-30 0000907654 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0000907654 us-gaap:GeneralAndAdministrativeExpenseMember 2024-02-06 2024-09-30 0000907654 2024-07-30 2024-09-30 0000907654 orka:ClinicalDevelopmentMilestonesMember 2024-03-01 2024-03-31 0000907654 orka:CertainRegulatoryMilestonesMember 2024-03-01 2024-03-31 0000907654 us-gaap:ResearchAndDevelopmentExpenseMember orka:ORKAZeroZeroOneMember 2024-07-01 2024-09-30 0000907654 srt:ScenarioForecastMember orka:ORKAZeroZeroTwoMember 2024-12-31 2024-12-31 0000907654 srt:ScenarioForecastMember 2025-12-31 2025-12-31 0000907654 2024-06-15 0000907654 us-gaap:CommitmentsMember 2024-09-30 0000907654 us-gaap:SeriesAPreferredStockMember 2024-07-01 2024-09-30 0000907654 us-gaap:SeriesBPreferredStockMember 2024-07-01 2024-09-30 0000907654 us-gaap:SeriesBPreferredStockMember 2024-02-06 2024-09-30 0000907654 orka:OutstandingEmployeeWarrantsToPurchaseCommonStockMember 2024-07-01 2024-09-30 0000907654 orka:OutstandingEmployeeWarrantsToPurchaseCommonStockMember 2024-02-06 2024-09-30 0000907654 orka:OutstandingUnvestedRestrictedStockAwardsMember 2024-07-01 2024-09-30 0000907654 orka:OutstandingUnvestedRestrictedStockAwardsMember 2024-02-06 2024-09-30 0000907654 orka:OutstandingAndIssuedCommonStockOptionsMember 2024-07-01 2024-09-30 0000907654 orka:OutstandingAndIssuedCommonStockOptionsMember 2024-02-06 2024-09-30 0000907654 orka:ParagonAndParukaMember us-gaap:RelatedPartyMember us-gaap:CommonStockMember 2024-09-30 0000907654 orka:FairmountHealthcareFundIILPMember us-gaap:RelatedPartyMember 2024-09-30 0000907654 orka:ParagonAndParukaMember us-gaap:RelatedPartyMember 2024-09-30 0000907654 orka:ParagonReimbursableOptionAgreementsFeesMember 2024-09-30 0000907654 orka:ParagonReimbursableOtherResearchExpensesMember 2024-09-30 0000907654 orka:ParagonReimbursablePatentExpensesMember 2024-09-30 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure EX-5.1 2 ea022056701ex5-1_oruka.htm OPINION OF GIBSON, DUNN & CRUTCHER LLP Exhibit 5.1 Â Â Gibson, Dunn & Crutcher LLP Â One Embarcadero Center San Francisco, CA 94111-3715 Tel 415.393.8200 gibsondunn.com Â November 13, 2024 Â Â Client: 68823-00001 Â Oruka Therapeutics, Inc. 855 Oak Grove Avenue Suite 100 Menlo Park, CA 94025 Â Re:Oruka Therapeutics, Inc. Â Registration Statement on Form S-1Â Â Ladies and Gentlemen: Â We have acted as counsel to Oruka Therapeutics, Inc., a Delaware corporation (the â€œCompanyâ€), in connection with the preparation and filing with the Securities and Exchange Commission (the â€œCommissionâ€) of a Registration Statement on Form S-1 (the â€œRegistration Statementâ€) pursuant to the Securities Act of 1933, as amended (the â€œSecurities Actâ€), relating to the resale from time to time by the selling stockholders named therein of (i) up to 5,600,000 shares (the â€œCommon Sharesâ€) of the Companyâ€™s common stock, par value $0.001 per share (â€œCommon Stockâ€), (ii) 2,439,000 shares (the â€œConversion Sharesâ€) of Common Stock issuable upon the conversion of 2,439 shares of the Companyâ€™s Series A preferred stock, par value $0.001 per share (the â€œPreferred Stockâ€) and (iii) 680,000 shares of Common Stock (the â€œPre-Funded Warrant Sharesâ€) issuable upon the exercise of pre-funded warrants (the â€œPre-Funded Warrantsâ€). Â In arriving at the opinion expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of the specimen common stock certificates, form of Pre-Funded Warrant and such other documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render these opinions. In our examination, we have assumed the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies. Â Based on the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that (i) the Common Shares are validly issued, fully paid and non-assessable and the Conversion Shares, when issued upon the conversion of the Preferred Stock, will be validly issued, fully paid and non-assessable, (ii) provided that the Pre-Funded Warrants have been duly executed and delivered by the Company and duly delivered to the purchaser thereof against payment therefor, then the Pre-Funded Warrants, when issued and sold as described in the Registration Statement, assuming a sufficient number of Pre-Funded Warrant Shares are at the time available for issuance, will be a valid and legally binding obligation of the Company, enforceable against the Company in accordance with its terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting creditorsâ€™ rights generally and by general equitable principles (regardless of whether such enforceability is considered in a proceeding at law or in equity) and implied covenants of good faith and fair dealing and (iii) the Pre-Funded Warrant Shares, when issued upon a valid exercise of the Pre-Funded Warrants in accordance with their terms, will have been duly authorized and validly issued and will be fully paid and non-assessable. Â We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption â€œLegal Mattersâ€ in the Registration Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission. Â Very truly yours, Â /s/ Gibson, Dunn & Crutcher LLP Â Â Â Gibson, Dunn & Crutcher LLP One Embarcadero Center Suite 2600 | San Francisco, CA 94111-3715 | T: 415.393.8200 | F: 415.393.8306 | gibsondunn.com EX-23.1 3 ea022056701ex23-1_oruka.htm CONSENT OF PRICEWATERHOUSECOOPERS LLP Exhibit 23.1 Â CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Â We hereby consent to the use in this Registration Statement on Form S-1 of Oruka Therapeutics, Inc. of our report dated May 13, 2024, except for the effects of the reverse stock split discussed in Note 1 to the financial statement, as to which the date is September 5, 2024, and except for the effects of the reverse merger exchange ratio discussed in Note 1 to the financial statement, as to which the date is November 13, 2024 relating to the financial statement of Oruka Therapeutics, Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading â€œExpertsâ€ in such Registration Statement. Â /s/ PricewaterhouseCoopers LLP Â Boston, Massachusetts November 13, 2024 Â EX-FILING FEES 4 ea022056701ex-fee_oruka.htm FILING FEE TABLE Exhibit 107 Â Calculation of Filing Fee Tables Â FORM S-1 (Form Type) Â Oruka Therapeutics,

Inc. (Exact Name of Registrant as Specified in its Charter) Â Table 1: Newly Registered and Carry Forward Securities Â Â Security TypeÂ Security Class TitleÂ Fee Calculation or Carry Forward RuleÂ Amount RegisteredÂ Â Proposed Maximum Offering Price Per UnitÂ Â Maximum Aggregate Offering PriceÂ Â Fee RateÂ Â Amount of Registration FeeÂ Â Carry Forward Form TypeÂ Â Carry Forward File NumberÂ Â Carry Forward Initial effective dateÂ Â Filing Fee Previously Paid In Connection with Unsold Securities to be Carried ForwardÂ Newly Registered SecuritiesÂ Fees to Be PaidÂ EquityÂ Common stock, par value $0.001 per share(1)â€‰Â Rule 457(c)Â Â 8,719,000(2)Â Â $Â 25.405(3)Â Â $221,506,195â€‰(3)Â Â Â 0.00015310Â Â $33,912.60â€‰Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â Fees Previously PaidÂ â€”Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â Carry Forward SecuritiesÂ Carry Forward SecuritiesÂ N/AÂ N/AÂ N/AÂ Â Â Â Â Â Â N/AÂ Â Â Â Â Â Â N/AÂ Â Â Â Â Â Â N/AÂ Â Â Â Â Â Â N/AÂ Â Â Â Â Â Â N/AÂ Â Â Â Â Â Â Total Offering Amountsâ€‰Â Â Â Â Â Â $221,506,195Â Â Â Â Â Â $33,912.60Â Â Â Â Â Â

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

(?$U[W%A9"S>2*[U75IYKF62#@DJ_RL0W%?F#_P $Q?'/C?Q;_P $V?V>?'>OZGK_,1_ M&^I^"OB-J$EYXFUF_P!?\0^)-5TOX@_$)-)LK[7-3N;K5[V6Y%C8:-;3&>2>
MVB%ND;Q0Q1B/X_8=\)^!OCW\%O@?^VK\;/VY/C9;?M'>-?'=AJ/CJ'3_P!I M>?X=?#KP=\0V\!Q6+E0Q>.Q&,QK^LTZ;5.E:I3P\HY M=./M9^[3Y:=*-*34^4P&88+!X#
(<+E65TL+A<;ERQ^&PCQ.%P6'P6 C+"U*L M55J]4*V(C,\'II3G>=:56,7!2_1+]O/\ X) ?'L_?\%!?!)@;X;?'2R\6) M!?Q@?&_AW6/A]K%EX>\6::]4NF7ND:A8V^KW^E:U#_ &-KUC>)%K%A]A(N
M&LM-GCN+22U26O3OV2/V8?!G[&WP5\(?LZ_#?7_B!XB^'_@--;;PM+\1MWHTBW:SDDL+2:*U6ZE@$21?/G_!2# MPE\:O&_PJ^'AKX+?$"UT/5KGXT>$KCQY\.U^-EQ^S;XM_:!^&UCIVOW'BCX
M, #GXS:=OU3P7XIU4R6^M1#3!9W6I6&B7%E-JNCV_P!KOQF_\$T_B'X(\5> MOB[VO#.A_M"^#_$GP/^,.L _#WXH> OVBOB[' #7B >&/" Q M?
3Q1XVMO&/@4Z'JFFZQI#Q>)]1GT^\U34H[U+22YCA.4_K\^'81>95]V7X?' M2K?V"]2EA*U6H\]Y.K3KOV)499?3XHJH![\ MC//K7$>/? 7@WXB^0%/$'@SQ]X5\.^,O!GB*QDL==\+>)=+M-
6T/5[1\N\5_I MUY%);2YEQ-%,$-W!.BRV\BRA6'<4UT6161QN1P593D9!^A!]Q@]>:\2,I1:E M"4H2BU*,X2<)QDG>,H2BU*,HM)QE%IQ:3331]/*,9QE&48RC)..,HR2E&46FG
M&49)QDFFTTTTTVFFC^8#]IC_ ((Q?L.3_$!O#_PM_:HT[]F'QYKT,VN:,\)/ MB#KNA^)=!NK9IBMS-X0L_%>N^&?&3:+;SS16LD6G>(?$EOITLJ0W"Q;$MXOF M!O\ @@QK%@\=SK?
[=W[-.C^'T=W@U9K&XDE2%N9)1!>^+]-L9B$PQB;4_)[! MXU -?U%_M+?LI?L^?M8^ KGX7?M!?"PQ\3_ =]LM[':MXU-0\ VEH.LI"(M[?Q!X8\06GDZOX8UZ(!=3TG4+"X=$$+RC@C
Y_AY)RG2P&<8G+,?3DV^9RP=2E/#UXMK3ZI M6IS7,E[%N]M/4/V2?^",/[,/GZC^U%_P4/F\D\=_\%WOV:/V8]%OO W_!+K]B MKPQX EF5K*3XW?&+25M]:OA @C348O#&G:EJ'C#Q,',MPT1\7?
$*R@C?!FT(M+-+"OY5?$3_@CE_P4Y^&.H76G:O^Q;\3-<2!RR:G\-T\-?$?17Y8--;2>#]= MU0JLL<8DD-S$D@W(LD<;CRH_,M_,X)@_\%&M8N$M=/\ V'OVEYYOD4)=_#C5 MM+A597"J6O=6-
C9P0JY!#C4Y=_9XIUK/[,O>B?BF9<7>(,5+!Y'P14X7JRYJ<:V%R+ M,,;,FL;MQ:CF.887%>R;5TY8:C2;E&,H2BK,\]_:8_;;_ &I?VP=6N=8_:)^ MOCGXB0R7S7>G>+?(W8XB^

*Z/M]9]BJLI:=|2|=]HB**O6VG+XY|/9KA3^DQIZL;53 MJ<*5U3)<)EJ*U46K5.]M<6,%=-::GTFDJ)*>?_QC%ZD"=1:T\G3KN ELUYK5 MMZNUWB;%&_UX6N3O]ABO:9K(I&V#3MHC93T*-_56HGK)^(T_!Q*NM#1N:VJE M617[E?E>JGDZFUM<=4NC=62NF5C<)O7)'F1QVF)EDFF."U/J.QOKENT=/A?D MN4QV_:=H--5RTZ5"53L8WH6UMUG4VZUOHF1YB=WN/(BDFJIU1&NJ'/7")GJA M!L_>F$5A3>KF=$*T;8TDRJN>YW1$;X*7-*

5I^XVYK65=++^"3JQ%5%R2TL<,M%3:FKH"D9(RX22=*F//1IN#BEV4JRAMJW*TWF M:!53(LU5+(N51<>!J+AWQ.N&@-3TMRI^6|L/62'\(S#B)VH]2ZVN$LMO9':(MG^JKH>ALL_I:6='46V:2G]H74DK'8*ULL/"FKM#)'2UFZZHKJ.KBI::5F]R MAX.@EI=&4]799K;3^B4J=&PM[OR%2[BF8V2UU=-JN^NK'Q-Y"XH:.LN]7R*6&26 MJ<[."VLH6W9EPRM\M/]2FKZR'QG5%V M+WG2NMN&3?3);K2.?3S;DQ+'WIU\3;&@='U,=! YZ4M1&K22]KY::&-%=O5/N:="CAXIWE9-NKO-/!XL')5%:YN7.[LEU37*2 MVJZGD1-B^TSJ72=)I#1I:N|TSGW"LZTSV148GF8=?;&D<-//,5.NBN3,OH^_^MY>\QW%9XI>]PVDD;JJ!]#2.KI6961C7+E&^)EUQOEHJ14U53%6UE/)!$[ETK M6;HU1BMY[6JKD3V$MJU156>6NF? V9U4CFN61.J M9+&;V^"%!(M]U.YE1&W^J%RIJNVM13RM2TGV/NO]AX]

*MS:FFEP|&\US7+^|>', ^JOU>^:"%RK'U5L;>B(A&6*1\5&X0[YV(]%:F/$EHH MZ.-)&U4KF-^\6-,X7VE.JN"7*H:IJK%3HK5\B[J:IESFCBAA92Q(W:YR)WD8 M71O'>O;(UNH[M#!<:QT5 WHDSCW]S3+]5:CCL]JJ75="'S'I"=$;Y&+PVKTZ MHCH4K(86Y^4Y>AO_(/6NV\/+/65-=)3U^]OL13T-,=G.V6.Z14M7!)+-(*

*MF]JS=6IYE[K9!^DM]/%;Z2%]WGMIW.1',=GY)TQPFX% M:"M=)21:OAMR98DL=_ RCV^G1K.F57+5%1*D:5GYB[. MI:84^UW&^3(VH?) Z1<[XE]53T_0X+#)-'+5[I68VNF]AE3;>O<]RAA5MNDF MKXVK3R+E5PG<8W+5131N:#%NID=UQ[$[A4ZB2Z5B4DM5LIW1_)[FEK379+6Y MU&J0S0.SZT?5_4,C M*:K6)S'=6R='D(X:NW534CV.HY$P]).H'@UEHEM*5$3E>F,]"SDK)+A3M9(MFS#NCO,RF\+):Y%IE5L[*(U4:WPR>:^6!K)Z9:?;)'UW/[L^TMXMR6J.*'#? M]%$*IOS5-3+4,;;]8:RP5$2LC5CF+ZJKXG;-/9YZS=4\YKI$[G',W'NGS<(MEPR25KL/Z2Q)X6FG1^13=ZO12]D:C',Z9]4LMKD7.,E"ZMYV0#GK*

*ME$|"9B*_IC!5CIV>LCG9&VQOS2(Q',ZD6MQW!4=E4;U)FIMZ.Z!&469W8SA? M:>A;+A34-/4,GI^>YW1'%BR%|C5V-R3QT[V(]*N$,PAO"*M585VKL:Y<[5*3 M8U:7*QIM_5,N*:M1/'<20XE-?!2=D?.ZH05KG8PA&*1S.B)@)1LJL:+&BM:J M(3;7.[W%O)(]SLY5.A3W+[5#"XE=%'YN)89D4;F]%7O7H6TV'-1&HB? B*E)&Y>]0A:>2]DDE4KFK,Q51.[)=20T[J=TR.1KW*>7)>K["X MHZ&>[\BEIT5SI'HB*W00MXE5:<4MJ:!X'NU!:77.ID7EN3*&#:BLS]-WE],C MN9U4Z:TMS['HNGH(^LL<7K([Q7!S%K*X5;]2UKJUJ-7*[=G@9B=T\F/A>:DC MU=)O5$3V$*6|5%/5*E+)R5Q\[JEDE1S&L8U%D5SDRJ]YU-H3AGIVVZ0I:NHH*

MX:R69&5[Y$ZM+*M;ACXN;*;X[I)%]GST>1 M<61J,A1/6;'C&3#XY'.[R> ^R]|(^#):*[0IS>8G?W9*KKQ%|ZF3&FR-3*.1R MY[E3P/59IVY3VE]?34^;>-VURKW^\QQ2UZXI^"ZBN#I*C+>C3V(*BG]FI&Y? M6,-BJDC5NQ5W-Z*B^TOZ2HD=4->N&-]I9Q*;X[;LKHX(=L]J.7FM5?53V'J6 M[G4K>;#(Y6-Z["F4=+--'Z3ED<+4[V]ZGHT[TRNL^CUJ9W*UU4[< MW/0V:V2F>Z)].QTVN4T\G/O>]QVK6.2QN5K@N$D<4B->Q/E+DL;]5PZ?IU2W M0MFC8U59^["\|O>]W6-PE?

3U4L5/&OK1M|CR%C>R-68S%W;V_YR:E6>%'K#$^!C_E M]D5$4IRUS]6%Z-5K,^?>;6.(V_H23R3S1I+&U?1_ M%WG|#Q?LC)+%U>W)?

VFL?)%Z++,K8W.RBK\@6VW9K.\,QL5XH7TR4SJ"%[W= M%D<_'[YD\D%F:014\T2(W.7.8N49^,P_1VAKG?\ TA:>G:^-]D4^2A[T^QG IM[|T>.IBF>[I*S.43W%-*

*FYBG9NNQ2:6L%BM[8JF.J6;OZY5%++46H]_4E=(R M2KF]'C1-C8D]7:AK>SVV":6.EHV.EG:N=]+ZJ&4V[47V)D]&+"Z-[4V]C_%? M::|F_&39[%L9;:JI>R5/NJHKDD8N514\22*NIJ6-6K4.TGD@H:.%8J:BYTTB;O//\X5OW4*SUTPHW#B!065]U-3'4+6 M\U&-1B=$B7O)3$5[DJWG?FOKII[C"0PU\:OBE>[+V.\$,*X@-=TGYSE:MSA#*

MTKIKJN=X5TKI9K<]OW%J^">9B&LKQ4O32,6EK?Z/#RU7O7N=DC6[UDB* MN6-7"&11QR-S!M16C=&N-;4RLBJN4WJCNX]FR1K-7/B>Q-B]^3RZNE2CJ-R+*

MERIA#T[:Z2&AW.3]HYWRR5HB82KO66X^'':$D.4M,UMJT3U/5IR|U5J]?2-_ M MEW>U9(W.^Z1^U%-'T]8VCO6D)4S9B9W.3Q-&=GC6$]NKZZ

MUD)E_W1FY?|/O4S[3HBFND=R;''4TS;5R93"8R:F2KK:?)%EGIRKE:YWI2 M-:GF4ZZX,DJ5PY-]?@[7ERM=-8Z:2IN53'!$Y,M;N0UM7\5],6N1\7I3(W+]*

M\]16B>3+6K/+1LGK%16JI=ZOU-0:-HH)9XEQ(N'80UU2<8-/V^BEJH[C$ZH1 M,M9GO4T1Q1XO7GB%6R(Z1U-1QKZJ1]&KYF>KYM#-JHVY/'XU:@6[:MEGEGE]

M#=U@AZJ>_<.UV3AO U6.=<:QJ/3*=4R:VHK^^KOU_^0MGI8%>5)W&_Z]WV MK75KI4:U*=$CS&|B]OMUILY-.G%:=EG+#IIYJ97RRNI%XU\"^U-Z1K"L*

*M;4/H%?.B>]QJ+T]JDFN/0=)S>C4LTU359QO1KZ73R5%+7RN9.Z)V/O,JIN(NGJ[TFH;'):2O[GLG3O+ M(QU:ELF3=?:PU/<]1TK*22>-NZ)%5R+W>1K5]BU$DE(DSZC>N-*

*N=G<>G]D{ MNL>ZEF9&LG5]O]B]R'D7;2MRM[O3$? M224G1KMRX3W*4Y>$5]M=#-6K6NJI&9PBO53TM"\3XK7HVMIZQB02QS823[Y4 M*;N-D%VKOL;"Q(87-*

1JR+X^9F:1"S'F^"IH#751:9(]563/F?[:NY"EY]+1E-I6&=8XVO:WH] MWBC2]TOZ%9XH8#I[1FG[Q6M](ZR./F_[EO] \QLG2_#&VZ?D=44T6RHGBFH9'Q0\V1>] MR%>|*

*[M[>)KR72T]NY"[7[FKWH[]>-'1T%+2 M+U+5*9(VIA7(WO)Z)NS'R6IW%RU(_MN>]LDST:Y>O52I&V.'G)&NY'>*DZVV.KK5@W$2RON^D*QD,;:AZHNV-.\Y@F*

*MI5HWJ;!9Z22[J'MC;A>]3F[4MXTY5U%4Z&*2:HYBKS(NX MV:R_P!(8M^YB)/ ^%J=%3=XGJ254M/&R.5O.CQ\K!A?NYU:X.I[7'NJI.DCE^]++XR:ZCHF1V^GAHHW>]]T#*

<.,7O93=:|DEF?22.RI, MF7/CZ]1XDN'P>O%=^2RIDG17HY(E]3(N&5/172X31[LNV[:OM.1M.F[Q>6 MK24M/(ZW%54EP,=)7N;AS4|R7%"_'6TL-OEZ2U7B;?&F<[&*

*M(AO7A]K*EXB:+>LCDCN]&G(V([NQ/$YCU9'<65SI:R"1C)7;VO>BY;Y$EDU M+5Z>KF5%/5RTR.Z/1G^Z>\IFL2ECXZ9.3L.QQS)(QLO?W>_S/>K8UH7-5'(C*

M<=QJW1_$)=2VNFJ9&N@ECZ.5]2*0V-%=]2:%*B?=(U>B,<:TQPR]%C^_'-8T MU9*M>])T61B_)3!Z$:W".%7T2I'&CNJ.]A3@KDKY4:D+88D^_1.XQO7W%"CT

*M_3I0TFV6:N5[>I'@XT%R.LG).IW=):JOFBZIL MS(<HG.W.:[Q0W|8M>V_6,<-501-1Z-V5$"],)XJ:9UI2OL!#'75+=]:<*IU*

M%/$T5J1+,^:HMZR22N3;*QJ*N6D+TWAL8\TTG9T[7NME/2HZ@M_I,2IZ\R9Z M'FT]NH;KU;8UCRK6Y[S3-+Q.O=6V>"C8L%"GRV^"F6<+-555[O#J:2*.%C M4VH]>F2J*S$-^F:+3S;8MFGTJ+8]J_E)(U#RZ[350YTC:9K55O5N3T)[M]5V]O(CB9+&Q=B2>"&7581',.Y2B;3$NICX;PU9:J:L;.UL MC(^6U%67^Z3N/>I([A=U3PJ2ICE],8N>]22:]5,D;

*MJEBHCFNSCVH6GI"U37RJUL&_OV^)'A)LC353J5%?]XOJJ4[I4+61LAIT]1O5 MV$$4K'-?$KD:TJ;>ZX2,5T*R1)T:OL M/7AL]KH$CD?*

4[9T3-52JE4QU.ZE5ZPO:A7+&8O>]&KJJ5]8G+ R1NV=?89 M65LK3RS3U4LS4W.C7HOD4:VSRW"]@D6:EKWJ3T%S+B MV:;4QNY?@UOOT=%JALL5:QD/LZ)U-*

*#:RTU<]*7B1(+7(^A:O5^.B MG73|&4USK&NIJYR(B[L/I\'@:LTS44-$_?,V:)KE][J21)W^L8_JS3TO M$K4+K3;JEU31T:TWQ.^3'[LF8TM?%9TCLC8LST:[622=R^>39XYF'-C%CQSN*

*MR5]FH9O2ZR.)L-7&W[FUR]YB]>L4J+4)31.D5/6)CC..!6F(.=]RRWJ*W4]4Z)C6(^38OR|^"DXF4,UXKW/3XK<9Z&N97-2R-=']6J MJLD8Z.AC];VKW&;W=LM=PIAEJTW313-*

*2.7QVKWFO7Q.;,J1 M+ANW.#9[X|K<>\R]2&[-:UZ.@;ZW3'L/1CI:6"VR2-F^ZN_W/)C+7..G3H3< MY47.>I)S7?N>S0-CI:B"]>O*VKUV]3;>EJJT:JKHJ1\3:B3'17X::.,4.ZC@?*

*5V>5F&.:B]B&4Z OFF=1:;@I*IM--J]%1JR2_*1#;%-=*-OHU. ^2* MKCVPOMKD?3.[HX\;4/!N&D;W1TK:Q|*K2.7&W"*N2 MJ;+L45B.3 KY47:ZZDBGI*Q:*@;WIMP>?5ZBO]'>'OJ)U?*

0,PC9'=$,MNMGF MI\++"]47PPN#%;A:Y;HQ:6:1T-(J]>F,%>Z=J3WPOZ>Z+?FN;%5-69\BGR&H]?5+*Q"N8LUI8K'J&R42TE/3*CWO5$DH!U/'=&,;'#ZB MR-*

7]9+)3ON4D=)3]UG+7*N(/1+/4+Z5-M3/1K5|R5N2N*V1K+-')3RO1$D; M&F<2$UMIH7TM8ZE3:YB(G3N+RT0T1I-*

*)45+W^B2)CE9|52E)P]T^C+C4I/M9Z.^/UT5OB@XEE8>7)1\M4:|N5*E^C9W1PN2ED9&[Y3H_$<2?"LZ"WTTS7*Y[=[>F M3SZZHI;9,L*ZHA?3Q*BOD^0Y?!!PK<<=HB*

*M.:^6_2\Z]DK'[:>-5V1QEK2U%RKF.N=&WE01.RG-7"J>+=KM#:9HVR31O]/(QJ7AI>YYYEOM?!9*M&XD;4KUC1>O_M*

*%P7&BM41:8DJ+;'LK((TQZ7'WOQXEO#$0U..9O]YM#1VB9'35"3Q-1*D_4. M[/7O.YEHK9HFPU$L\D+*K,)(G+U53">'VNK5?*ZINO.ECDI&;8XU7IN/.UE> M'7.A=+.Z*:LF56LIY.]V?$CWNAQUK'>X>I-8VVV7Y:QR)3IR\IRY54QF?C1# M=9)F133*DGRPR#36G[7::.N975;9:G;ZC MF?>^XS6G-QLVHMNR&R:_22HJ88D:Z21NQ-WM*-*

,VL;421Q6Q5#7_(3[U?;;G#&S2ZZ9GFS&GU15V>NA MIJYJHC&KS<_O&4.:XA5LSHJ>G5.5NPJ>5<&6>.T)+7RJ+M*W+D0QW2%GKD MO4DM*[?*

$_JC'&K>O@VZYHKR=,,I[%|ZIR10U&QTLK>LC43?C-3:HX%5"5+W M61=T:=S4(.UQ4V.L;3U/W%T:]<&[:YAGK9E/L-;QO#AYS(W.1(4D|05J>@S>@2*U=J1]$-.:NX(:FT=*

(D[&>GT&>LO>N"RN3Q<^^@M'< MP5D,#.:Q6^IC+YE>*CB91MD;4.BGSZB9*=%025]1+3TRN<]J)D\%/6L^E8 M)ZM(+C,L4N?*

5]B$^+P:5Z3CY+&BU%=K;.DCW]Z/NZO4]FVZF[]JCKX9Z=B32 M)T[8]ZHMEMAIV4U-(U98TPYR>^TQ^V:>J:J9>4C7.]JKU&VYCRS7DFIN;2U M2RPKN7O*ZWQ:NJ:RMB1T>?*

29Q>7--I&]\[$=+(OXR:OTE=]7#Y:-'>U<&8[MTIWEZ%Q:9])>):5MAD3Y:>)CUT:UU7"VG]9[U1]ZA:Z&6VS1K)$D:YZJ9'9;

*M!)=:NBGIV(C&O1SFM]B%OPW55QS>VR2V^D<.;I%530.=%*F5Z'DZTGI]6W)U M30Q'&U'20NS-M:Z%L:|=_B;%X3SV.&EKJJNI^9-*

*&GN57[W'F3F=X:.+!%>G8([TRGE>U,;6XR:ZU=4:=KDI276HLK>133 M8B=|\:-H2K:UF0S:9T[64'/IJQS]OO21K_O"25MAM5A?#"U*FLD[GN7&#']> ML2JF='%"UJ.3[M)*

[$%;21PU2+#+S8OPN_!C:$|[59)1WR@MUI;0O>^:1Z[W M2.7Y'D2TFNIYJE*.EI&XBZH]?$\.U6&LOU5Z-2T[I%SE'M3H;0T-PHMM+2SS M7.HF96]S6-*

*[B/)M8^+)'>Q6IXI:AJ&24S9_1DY*IV; MV+2WGG+QJ2LK}>E@IY9XY%1J->Y_?^(N::H@BYK)&.D61,>OW?B*%1$YZH2A M6%KGI]X$JB;55U3O5JL:O1K<=QK=TNQCI%>]2KK!*

G)]-SHY(^]%4PE+++]R MGU0VYQ-YM(CDSTZ*AMAMIF]'Y;L*Y/'VEVS3%5=[5+'/ ^@IFIUD8]9,<7+8 MMBBT]KZUT5=8:9M%'M:R/$R1ITW*:4XI:,FI[&V]M&3&Y, .!MW3^F:?*

*M2K9(VW"2LCD7.V1V45?:2ZHTB_4EGK:=9%VJQ5;&I//'/B6Q_ MIK)Y)(T7&UV>I?VK2URU-72R6NF]>G?$V6'F?)5.G> M=(:*IY(;32ST]-3P12-19,-[S%K?34VH^%TT;8+> ^Y)/TDZ*

*M9VFV;7(VKI4D="^!?*CWQKX>T]*NJ8[/0RUB[96XWNVIW&D=5]HH&6C]?>UT MR2P9PLBIU7VIDT_>]W3FO9Z1O+I2SW2@HZ6:H@9KV]WM;4DUKIMR_VN>I;\.9-*

*37K8M=124V5ZY14-WZ]KD1O2/^3 M)D=LL[W4Y7(V.-FU>O7WGFLK:2G@DRI'+GO*9G;N:1;12O-B599'U:74_P!\ MWUE/!987U-KG-QDL4I6MJGO1&JBDZVE7-(;_OEKFN%.ZD*

M9(YB_P!J48M \NW)&M5(DAE\|#-)522QLPB=ZH>W;(>GB;)4M61SN|<9XE7 M5QNQ2Q: K7-C_JISHT7[XSF2PT=%2,9-Z[_)#T:*C:V)LC%5%5>D?A@OZFSO MD:V>54V-*

ZJU"ITK8I#QH:4LT+61(KX$^]0@M/MGD75NHR:>O>QF#6SOIVR1-;M O-3GLIFMD;W6S>(AI

*M=5$O2TQ46V2LYKF.153V&VM.W&">G1K57:WNR:LMN;15"1O3+O(R&BNDM), MZ':L;<=%4U;UXHY+*3U=FT'.22-<]QCNH&T4NQ8X_E M*Y4*4^H+/?(45)=[W>+?*

UN":MWM$,6U30U5UY;[2]4E9W8+FR:)N=TIG2Z@ MK'11X^2Y3|-;(;>O.A5'>/53V*]NM|T*QU2H^1W16^"&8W1B8OS>!9Z.W^C M/MU"Q',*

*[N8Y#,+1IF&GH\C8WX/+M4%NI5C2VA].F4DRAZ-/"YSNCCQ[E.]FQL+U1,^\2I:IV.8Y7E%N;>VCX M/7!=6HJY*Y%B(UR)X$5(MROJKD[E+_MQC?*

*567"JINS&\/.U[MF0[KT/'MWW;U_DIGN/=9&QK4ZFOPK*R M-D:VJC19#W)*&!]&NWIG!C[.6DJ.Y21M:C8FJGN,KXL]7[^BTJU_M"|V5W>WV"&CHJ6AF?*

*539J)$Z,SW%A37.JW.D158TM6N:53.ED]9R=V2$53FR M22H@C;(D,9Y4E//41]L;\KWJW)>7"G6%N]BX3V(6\34C@=*U_+E7IC/>6Q53 M:9>>^E5T;E?*

*\HMUMZT[F3O1=B'D7+4EQM=5L*Q?NF/]+6DL&48B=<&\18)G2-5K5S_=&P:G&-/70I3]NB_]F>3-HOTER MSPHD2+]ZA='W>;2RVXXV8FDL\$F,D)YEF=NV_)^4>M=-*

/U<N.\V(OR:O5JFE'-DN7-A:B^TS%M1Z,Y9)%^Y^)2H;71VFG1FSES MKWN:6E?5,D@EIV8<|4\2B9W7X[\#P]3:R1\0D=_B[.%0ILO3+;"R2X*]DDG MWK$RA)'I-*

*K;;43R*UDB=4Z]QX,MR22'T:1S9G, ^2Y2R*;M?-EV[GM5&L&T4R M-IZ5,.3/,<>;)K*]LBT[VM\CQ:B:98U23UT1<([V%DZ21.[H3C'#2[1:.YL M2+7EUIJ![[E$DBHGW+84K3KB2X,*

<^IBY+?:I@3:^ID:ULL[N6WN:7U3$1O5/8>G]JY/ MH;I&UKE:S/=X&9I$0Q.::3S;G@:D#$15PBE5U$S',[?

Y&K:)AV:9(ZM6D<^&3Q?:A3GI6K"Y45'>='1OJFNA:G7.2SEMLA%.*=WLW.YMN]9)/'&D<2|[\+WF:Q'<[Q"O9+X M^W3QQ/?OI57]6MZA8ZJ5('|)'91/>6<38F/;*

(J_I/P^NB5UE5R/W2L[G^)D|5 M5(^C5_=)X^9S[6Y[.SHL<<.|%[7#*>965$]5%P]I:UXH:HCN3VT\+D>BID MRO5-EAO,,_*B1)L9|YI2Y<^GJ94E8[?'T3HO4V,58[T=7DVI-*

*(93PZI_2]Y5 M7]YG@;E@E>UK&>!@/"JT\VA?5K L;W)\K!L*DB1KL/7/O(9K;QM#5T6*:QO+ MV+>]K6JJ]YCFIJYS>;M(CUY)(X8G>OA? P+4-T6-LS4=N7WE&*G+=V+Y/N|(*

*M6':ZHJW=9%\"KJ2"HA8ZH8JKGI@PG1LE6>"&X&U3V;U8U$R"@JTD617HN]"VM4GID**]S6 M.5J=,X*5871O5J-55=W+X*9M'#.B(UR)X$5(MROJKD[E+ MQC?*

*J2M0JI@6M]!S7.&">)%C?GJK>A0JM32V*2WVZBA^%E!36^2&WUDD:XRYK57&38BVW)I:>L9IXK=[#M>:=M5 M*BU-)5HQ'+]|@\|3FIXK.J13TTGRO.\|6\6N:UR/IYYW3QM7Y*J7FC*

M+(FH+JRGD23E)T:JIW&/CNJSTM6VSU$XDW.EEG]%BCCCSX$UR:FHZ!MVE9S6 MQ)7(WJ-6: J+77\BBC=,QW>IFNA+:ZGLOH-1"R.-?E(_"&=X75QVX=X>CP^U M3;

*[U:64T#FTDD:8V]RJ[|%\TXV_M:CGIB/O-2WC[':7U4D\$G]1NRK&=QZ_M%/IJ,T]#3[UE7"N1.XIOM+8P7FD3$MGVR1EGHVT\;T5C>A[U)*VJCZ|OK*PV*

M\5%O>]9W!E6GFU=%]JE7.U79|I1.SJ8LNW/9G%/30;57)6EJHN6K M&-RON/&^R45+"S#FR:DZ|>XDI[Q#',F7(J*:]HG?DW>/CYO0=$JL5JQ>LO4|*

MUNN$4CM=9C=V(SY*$6]Q!GR4(M[CA/45[D M0 $@ !!>Y263Y"DR] MRDLGR7>XS"-NZ7YW8:=OHRJKL*6<<*>NJKW=QZTEJEY:OYB?E//1CNK7*>LK M[KY?-*

*ZS:=E'P[^I%.GD3MC]92:MR6R.PA*L2AQ0I-[E"?PMV5|7QE6S&[T|L^T97NIHE>W/K(>[=(=2TT4%-3 M8]WN7K[%,*+9HB>3"N4YO3'Y2=%>[8/6FH7S=7XW?@^);U-*

*/R&M572([MQ3;T"VO%:-XA9/[''=5,JX3R/8ELK+5(UD_W2]F1,(WKU*EBL=?>';J.W352=Z*UO M_P!#I;L\]F*HO%Q9>-4-6F@;ZT<$G?| OF+<-8WW=;2::UK1-F6=FG3=18='*

MLFF@ZSKG#DPN#>=W])VC:%]VGCA?' IN$QUNT_$K=T+E/3MU&^9JX@5F.Y7' MK06^5KFHK.A1-IABM(WYL7I[*K8UPS>]Q7'4]V@HV-A5CH?NGMP9/|:V4-,Z M1^-W?*

MP0D=%) LKDV8\5Z%49]M.QEMCI7?=C;(G1S>CX5%]W0RZR6D.:/6UJZ M;GDCCZ1N3OQWEA,_+FN56NQ[/ YAO7:IMM++]>VQ/W.=)M<|%RF395[KQE:-

*MW24KE>LB(O>1X9;&+/&H]UF>I;AR9$D3#O<8_57E9(VHL:N1>|%3H>=3UM;7 M,T:=%N8G7O,3XH<6Z31-K1LT3=[4]GB65KO+4RY(KO6W>U]Q*XC7FSZZHJ:T+*

*M(]KG(CFX7:,)FUM WT1*V=(*]|$&B|%\C6/"F\UW%Z\/GFM?H].Q_J3.;C/ MXS;=PX6T%3=HI*FD61T?K-D:N>I=?;&;?'>\?>EX6L],NXBT"4RS.I(53*[? M$\S2'9MTM;7-*

*<^%)YD7JYR=YN:S:"J*A()F+RX&=S5,A?IZ.C=O7[FN.OF5= M;+)E-?,^I[[I[46&|QM*Y,(J=$P6UV>=UE[8:Q:L-AZ*

*MTI0=!I>1:.")KWQ|Z1!QA|W:A6:19I*5:=ZMJ5NVHGAW9]3B1<]=4$]5%2Y6.=AD#,JN) M=$<*-4:IUY-*E/:ON.87L\5U10\ MV&|MJ)&KTC5AUI%0.JK/-'4.:VJW8Z)A%/'JI'#9:-*

*N7T)CAMM$+&U: JZ58G6*D= M373N>[/1//)MBP19K# M;|+O[JLN,HTY-G?/*Y$)F3'<[>IEVE.*M|TE&D4CEJ:?P\5*]]EU MOFY'+W?E-3ZNUEH^]2*U$)(G:N&IGO-U:$^Q"Z+@K*

*M*A/088H_U-5PJ^8F-T8M/>6_3=5629JNL3.X]>:Y4NE;>Z63U*=%RBJ]$_>- M!:^[0]=272:AL3T93L7',]IK.^Z^ONL'-AJZQRICIM54(Q7:5634VM]V(9UQ MOXS,U75+06Q9%@8FU?*

6Z:U=H^OI+!%=7TTB12]=V[*)[T/)AM]3#=Z1B4ZR MRJ].IQ-XWSAMKK4>EVN=!'0TR1Y;2Q)4>F.GXRWDQ3#-HWW>-I&VW]7&BJF:*

*MMN6YT#U:^%WFZ^#UH=4:+NMANR26E691V$Z,_& M:_LG"JXW:4M:!'S*BB9GD3(BX5'-KJN55W0R?2WV(I*6 M6:L8^3F/3UE7JW\1/JC3%/H^KDIZBIY]5(N%;^*

A&PZ$K:B5]DS'VJ'UW2. M7"+Y&5-9EF?&+B(ROT_:K/::QT]+#$BN3JBM_P#J89H/@_>-?RMECC?%2=[I MW=Z_B/'UI<$NU=SX:9+B],(H;?#*

*M%8XI:HX@:3I=`WB.W4LZU$G=)W*U3RKA&ZAACA65LK5ZKM[T,QU==K)K%U7 M=>=[)6YO=ES,=%,"]!6==U/(KG_?:C&RJ9K>5:-MJHJIDH/D;,N,X*|E*^-Z[M697W9+2I:V-*

*V<8=["&Z6.M=^2B^%5JN6]^]O4I1_)DPO!7 MQMZ.2*5,C?N;6HL?N)XXY8V*YKE;&UXMG*K!$YTCT9X*1XEKV_LS4 M5[HZ[]]%;!TC:]RJ2UUU?*

*75+*B5[7/3KM1,=#R9&\EVW/3V$R,;R\N$3$*I MK$]T-7&E3+([.QW1$)H)%1VW#E:]%5]Y[BR1&NQM4]*T0Q\]73N^YHB]"VMN*

M(MM$+NTR1TL4E2RM6&HC7#4;T7\I+7WNY7.9TEQQGGN+Y005D=+3P-1L5.D:JB)\.\3:(C9"8VA9-96U=P8V M>552JY&"TH8(:JXP15#G4].YZGJ>GH*:S*V-%:FZ7O53!ZBR/I-*

TJ2N?&[Y+E8J(IDE-'; M_L:Q6QYK&JB]W<;YL^AXM::+@;%;6^B1L]6;;ARK_G)]5$+Z3%HWNW"BU6YCU5=]]VU>*%-BEJI*J3TJ)&KA?:GL.8;YKVQV M^WSP4MD9#/N5/2V*

M55POO,<6T;-:/QP\BG['M;)2P-]' M;)^]NSW^X\=(9-[58W/]59%3"-+ME&Y'+"S,CXNJRQ]4*Y;?#%(>U8-;5VG M^;##2PS,[O7;E?>4KJ>*]J]1LYC8NE=_NV>K"Q5>>[9-*

>,&M70Z8I^GN^35-5AW*8[JB+[?87FE]I MNX:6VI9<[7'JZ2'MBE7"]G0\&*NEFM.LU+7.AOTM MGJY*V!?NCDRK53H>;<;E)77%]2K/NTO5W3H8K"SBWE+!;Y*QN6?=)F^Q#+M)*

M:D=2\RBJJ:HG:F88FYZN]QX=OKGV]JR,;=SQ;[Q.U*M5!1SR36ND1B)+%NP['N,AT5QAN\FH+;;()W3P**

*MJ&I/(BJJ=3'==W*74VO9IJ2GI.C3+$>U.A=V*2#AQ)1UE32LU.K5P>K;JR&LKHEE5(4;T5WC^,U:HJ_5.1 M*&G1VZWSR*FV3'0V@FF;JCY&&MJ'=\DVIY1"SLXIY;MU:.J(JY.3'-*

O9C"N5 M26]3T"3NH8^K_%W@J^\U:IRWZ@H]3)4Q3QP6!&^LQ7=54RFHO4W.CECA2HCC MERI'>5MCCC9%;7;6NE?%3MFJ6KWKU1%\SU;5S(:=):FG8U<],-3H8I!=)HY) MYK?

*UZ2R*LD+W?\ 7!Z=]]&DN3EAAN4D-:B=:>5,1Y\E*O=1VWC>TW2[3.J MIH:?$CG1=SDPB?C,4@6:GM]2DB(Y7+CIW'JQ^D1MCYZ+4(Z3:Y(_DHGMR65?*

M:X&H>KYU]"DD3[FBY7O,Q:/B5F9^"THK:UB4D\M,Y';D1'1]^"O>M"V^Y4^ MZ6VSU%@5WDA;W"WU7H,]3&:[1%]NC:6KK-L$*YQM#7/A5$U=#/%35;*

M628PU^SN]QBENX7ZHT[60^BW#[(2NRJMJ$9O$(1AW<>LO5PLMP9#>;2L/.1EA]'E>E;$C_ M %E:O5OXCH/5_"RFNEGJ&21)C/7=3D#C+PDJ=$7*.Z6)LCJ:#QIYVM57?O$J*

*MSQ=S7R5G&VI]"AAJVQW>A:#=%5N6HDFD M:IY*8)6M3;]Y]28DC5KW+DN/1T:8.12"%[:5&)CU9Y$O04RVJ8U84PA3>]WCT)(6JI=/ACJ8VN1=I/9K3WK+H5(X%=G*

*M'3V\4EEBFY:NN]N7V*9M))IY^GZ"EI(%;=H9W+43KW.;X(>3=*-))D MY:X,*F;RQU*5K8UYG?X$D=/'N3+>A[,]OVM1TKB662E;"UK$]?VF.%CK)>/ M+*

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|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s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

*T/7RF9/I[A9XXU?/UYDOX7L]Q|6>4W\$PWOR>A:*ZPZBIUAIXHZ.=ZY M]?HJG3.Q/! C$\4(=?+/8^7O.0M9:1]:?4-)64"?=XF;*.#/ZG'WL1/;U+BW*

*M:@IKDVGEF:Q*JE>C72.3&X[#VI["'*;]"7:)\$9T?A+EF:^OIZRIF=(Q:*5N M8V-3HKO(A2327B5S)6;6.;ZGD=3[43P"-:O@8Z_Y.]CY=[A]IN%BN]8V5R|*

MF9VTSX(]ACQD5,L@SWK^7H=M|?(;4_],=IGP1G1Q/Q<2 MK1WJM\4%ZA?<%IO2]9$DQM56^!VUL3V#EM]AF-5,?!7V"/%|_: MR\U5ONT5O66)

(W^JR3O1/>I0XA=G33VK;2VOI(W29UR8=R.B/7VI%Y"=[?@C MEM]A9&MM'P0MT;2T;3+XS\0> EVT@YGJ5M;+WK#(N%,"}+-5ND?#%&D\R)UV M+WGW4Y;?

82\EGX"%OM"W@T,G0=+]UMGQZL]5;ZC3%-%]&HO=^^>I;N!FIKA']D;';&[E1%3N_*?>+EL_!0BD;$^]03TA,_ MI8]B1O[_-'YX:FTU=+*

*<)]C.?,QV'*U.Y3=`9EX;5ERU^M3<;5L5+ S#9)$ M1$Y3[:\IGX*$6QM\&H1[=/@LKT/$3[SYMW>SSV|ME* MV_U+6TK$8|ZXWJ[80|":RW#05[A2]=T5R>O&N45/P3]*

*W*9^'GY\RF?@'I^0= MNGP:OL2?/I'Q/DM\=PIX)D25J5343<'>5ZM\LGV MF2%B?>H1Y;?8A+VA/@OIT/%> ^SX!:TX?Q:7J&PT5>VHIY.J*B^'F2Z2TW+6U*

*MD=/)2/EIU%6M6=6Y1<]ZFU;U?*B:FA58X5A;TWL3KM/JWRF>Q"/+;|$_(0[?;P7UZ*K7 M]3X?<7M3/-7Q7W=YA%+Q=U&ZU,15J$1(W='JI]^$B3V(1+R6?*

*M@H.W3X(7Z(BW=9^?R\:YN.H)H'W*99'0]6;5+*2[QUDSZJH]>1.C.GR?>?H1 MY3?P4')9^"GY#';9\%4]#3,;UBHCMY]B.4Q?O4'*9^"A/VA/E*["S7]?T?(FCOEJM\ZOGJF,E7N:]*

*MV7?ER>+]/B;:;;;4.9!(WTARY8U,V.%K?NG,?GY>3]%7+;[$'*9[$';I\$)Z'W M_6_.G+4*KE1[U>F,)Y"/G*Y7L1K&(B(]*GRS]%G+9^"A'8W\%#';I\$8Z%V_*

*M7]'Y\=.;RJ].\Z&EE5&.FULM*EOM$V-:U$)%/>;1>; M#I?3MDQ62L?S6QQM41(LH?=_E-IB#E-]B#MT^"SV1'G?!NZ<:;;9UM]%I+>D%*

M.U.6D>WO0\30MZHKA=I4N+X:&@1=^%Z#JGW^Y3?P4'+;,^"ACMMO |D1M[SX| MZYXA)(I^)#!$O+:GWJ#E-\6H. MVSX,>QXVlY^=RBH:NZN9-2HJ0M\5ZJD)A?;U-C:%U:;]

*W:.AJ&NDM\C7+/) M!^J;E]BGW>V-_!0;&_@H.VSX,>QOW_1\ M95U+=J^6*UO8RA<[S MZ4NMU@5EOI^6Q$QM6S|%!RF_@(3C7S'Z5?L3]_T?G_O>CIM/P[J MV1.>*

[N;G]>+31,EI7ND>N/(3)^AKEI^"@Y3/P4, ^T)\,]\!1/=?Z/SU1T+^2 MDV%2+/R_]&DW1R,=S'+$G>K5/T"2S\!!RF8^2>SH,^M

MNSD^S'+;^"A#D1_@ID>T)\]RW0N^VUWS/TOJFTZEH)&0HUM5MZMHI)TDD:U?&WQ4^RJ1,_!0[V\Q[/!:_8N|55)(S; MZ4W:CW)W'VW6)B]

[4"0Q_@I^0G|1GAVX6M7]/16_'%_H^7\]'1O1$=ZJIA22 MIHFPPL16[V2>*9ZGU$Y;?P4'+;[$*^WSY75KT9PQMQ/F!:716O$?,YD^JGI

*M0W">GY*NVN:WO/I%RF^P;&I]Z8[9/@Q'1T1\7!5))]D[4J$'CW=/O?_]4ZM*: M-Z-='G?UJ=!\MOX**#EM_!0QVN?!+L'!GSZN:N=1K&V/HW]G3O+'""OW31 M2R-2-6ICJ?13E-*

*]@Y:#MD^!&@&B/BX$H*5;DS"O1OK9+VJM_HK&-5S9?6\,=Q MW=RV_@H1VI^"@[7/@GV&/%Q11P;:>18HVHY,81"C4SHURIZ/ZK4ZX.W>6WV(M.6WV#M<^!V*/%PG-?)YJ>2-*

D2IM3#3&+;]2\-K'TM32210J["/=[#Z);&IX# M8O?!#';Y\#L7+O<-U,D$5-&J2->Y4ZH6L#7.ESL7'XCN[EM|@2-OX&.U3X* MO9_/?B<4LB:O+5(NGB7M%)&V94?AK?*

[;_P#6=EPQMMNY;M_M54R-R)&_(N>BF9,K&S1,VO<[VX-Y MI6E5SG,_'@YXO.O[!55\C65BQQY\5/I-M\D(9U8Q>]JU?\ ZGM5G:#V-E9143D>B='./H)RF^+4'*8GWJ%|:S;]+1GH*

MJTS[|Y>WSBO|&\.RK]K5[U12\T|0T5^1);W<&+$WUG,\54^FR0,_ 0ARF)Z MA9V[]]>AIM/.[A#1Z:;AK&2,A:JQKTW&2PV26"OJN?.D:JU/5C;@ZMY;?P4(

MHQ[>#2';9|%M>B8K^IPUKOB#26]DE);8$;_PZ=3%:#44]4V-:C:B=R]#Z'\M MOL06Y8G^Q,_P#T&0SR/|%CIX/5W)ZS<';/ M+;^"A'EI^"ACM<^"4=&;?|<-4NEYZ.3FQ-=(YW?

*A%-FZ2T"KFLJ)\I(Y$7:[MH=,;&IX(I':GL(3J9GX-FG1]:_%@&F[!!;VM>L>)#*VO1O3P]YZB-3'=DBWQ M*)R;MZF&*P\B67:URHN5/!O5X93L6Q/ V]ZGAC;9H9-'UD[[N/='75E[D*

*MYO*5)[E$3!DU+3;ED5O14[CIWE-]@xJ;?89[5\E==!%?BYUII7R0(CDY"[M' MW;X-9X^S)T#M0;4|A7VB?!;.V,/%HNZ-DCJE5OK(B^1369R+TCW&^-J>P;4|@ M[1\D^R_-H6#*

[GF;_'3V90HOIU=ND5,;O'&_P#:GL&$|AF-1/@CV,/%SE6: M=2N1)%DPK>Y#$;_IE\VY6M5[FG7:-3V#:GL)1JICX(SH:S&V|B6:T21Q;&1N*

M5Z>!ZT$R4D$#&R)S/OF^/)V'L3V(.4W\%"?;)\&K/1F_=9Q[?[>M50MG:_+ MD3N3O,(2OD=--%N1&XPB'?/+:G@0Y;%\$)1K9CX,ST9$UVW?/V-/L;.R9421 M6KE6ESJ!]7'EU,

<:M8]=<=R'77;^"A#EM_!)=NGRM:>AHG]:YV3,2.1N$5& MX]I;NP[HI]&^2S\%!R6?@H2]H3Y4/8L>=|W*BE6/UU:4H,,:Y?$^'?)9^"1Y*

M3/8AGVA/E9]BQ\;/FK06JOKZA614[G,7IY"L^RU|OKEPU,F(O?N[CZ1\MOX M#DL_!'M&W@QI$CSOGK+H65T::E)T9$[Y29/7T=;Z&&=4@:LDJ??>!WGR6_@ MM"1-*

!0KG6S/P2KT-%?U./872.61KE:IV?\ 7!Y2666>.H>UJV3X,QT96/BY@LDZ5%1MVIE(>O=9|$]A#EM]A*-7,?!&=#$_%R;3ST]/IKO9_U4IW2NC;1.V)Z_LS M_P#4ZVY;?

8.4WV$NVSX(3T?$_%P3]&LJUHWH1[9@A/1N\>\XQL-EAMU.Q$1]=.K>@N3):.3V6\"O1=:_%P7=M74|O|6IE5];RV#FUW_P!!;LN4<]/S=\F*

M/P"$NW3X:]$5K/*SY\/`YM5'OR_Q15/"NFF M:.X,DD6#E3;55'K[3Z2?-S0%KNMF5[:M^Z/ M/3)ZU\U!':9%DFQ'^(^AJ1L3P"1L7P0QVZ?!FG1<4COUF,IE,I*

M@K2(CHY(E7\1WORV^PCL;[$*^U3X+(Z/B/U/G=?+1'>[#44SHU<|B*K$]JG- MM3;'6^LKHJAKHGL=T:X^T.Q,=R#E-7[U%+JZ^U?@UIEPZ5S?NCL^)TKJ[L8\+=4-

DDI[&ZP53__-HM$JQ8_P#5KEG_!30NN.R M4KCAW0U$VD:SI$U$GK+"Q%BJ6]<95'8_MS5RO@TMC58LO+N:-NC-3I9XO>CY MC%;7.3:[(I]IR&';UT?

4W^GV0R.8UO5=BEKIK7T=&UU!?()(:Z!5:IKD5'-< MG>BIX+Y&2V;6-KU(Y\=,NQ$Z=^"VE=IW6UR;QM;O>?IJGCL=%!0NE1\BKM5% M7J91]8)-F.Q^W&3

*=33V6SUC]A]6Y:EGK,:UV452G8N+\]-+G.W[F[$?L-?:6X@6JZU":-/#S8XVY7'B)K+5FD].G])*N2AY;%7*N0LQ6^#:RUBU&F[93NHW+S:E M8U=U2)?*

*KHM3Z0KHYUB3WGJW*2T22NAH6[W^+G=<>1816E8ES+-W^&3:G::O M,S%JY'U9C^0GN(M[B$?ZFWW$6]QY)[*K[L(@ PD M (+W$H @!SW1-;AR>*]Q=0Z MA:UWJ-]:VJG0P=TU-3Q*CWI)%\2UDN$U+3*!9T?$JX3!3:K,98EM'DQ5$.Z M3]Y2+,1QQNB-[O>]^!F^G=(TEB9O&;U] M0J=7^SR;_I+'A[HQ=)VE/29.?G]*8 M%2\| M M M M M M M M M 2HF0J(3 #3W&CLZ6 M'BQ335B11VI[4C8|L-RC:C?CY+943Y2>?>GA[#C2X[\"]2:,K:FBKG>AU;%[XU MRUWL5%\47P/I2B)XF"\5.'L>O:%+'"K8KI3HKZ6;NZ^+'?*

VKN[]\WM/J;8YV MGNK8+N^*L=)4/SA/)[MDU;-IF&2DJF+K7,2D3')#3Y)QV^|V RG63:J.VL\5\3RM?V">OL,K M:23F.QU1R%U!4RM?C"X[\GMT5?

*3M:C'>MGO0T:QPSM+TU+4RTY./:ZUU-AK) M4E@B2M8F3 M9C)R:>31Q:V\, X_D)[B+>X-^2@;W'FWK*R(_"0 M D @?/R"JJJ-C6]2I5?>:CJZRA5\S%*

MAKXGI6IMOYRR/@;+&GW^"YH;A'!)4308=3L3.WIG\1W/[GGN&BTK",XP M-C6-SI&|[T3!ZJHTKS:%S9(%>U]9]926T:@IZITLB0R;>_,$/7:?X;E;9:>. M22!47Y3DP5RMK%*

([EM%97RT^U&-C:W8SDNJ33K=J[V),N.GD75EDH:6-B2U M>]V?:7MPN=+-4)'" 8C4ZJOB06\4/-MMABIYG3,@VRKXF:<-=,SRWFHNU8]7*

M1PHD<4>.F_Q7SPG\D8]^^4MO5$?*B_C-SZ8I6TUDI&HW"NC21WMW.3*_P) M1FMM79=@VM9ZWXB(JHNB M M M M M M M M 0PA$ <^!?

=&4MOKXM0Q(V%M3]QF=W(DB=47\:(O\ P?,TEJ"RQ7JE M9SN6J8_5-N5.K.. ^EEUAPFU+;HEF5GRN=&G,8B>]6X|RJ?-G3_$] MVV9O.E6>F;U]8[FBGCI_#R'2B9_>,8@F=*

*M9:A)Q7*F%B<>U=]%V34#OND#6+CY3<&YQYT8MPEUO4 MT=#>-25<*OJR1R.7*/ZHB&R|&4MU;0ISY6+_ '2E,UF&YBU%M]I=SM[B)!OR M4(G >NCN &0 ![(!*

M0!##CA&=B)'%4LAW=4C=WX++4FG+@ZA>E/_^!SVY1T>>[+*^-L/-K:7?5(MOJN9W8*-;JFXOAD2_*4M-07^1*ADE,W+&IE6M3JA6ENEON%WIH[E0R/G9T*

*M21$]5#,J:U61*AKV4^]9$^Z+CH0]WO2M29[FK*6I)J6\4%#%N;/-41Q.SGIN M= :*OE?66^.* MKIW([ZI@T5;+M3Z7TV2*3R;X M3?"U4>_K;?(4K*9*

*MJHCD\#7GBB7I,&JKDGAMWO*QIKDH+*]*>=&[?RF'C=/2JY8E[T,9X=5U&^Y/=51;9?-#,]RO4;XK\4/I9'\A/<1;W$(_U M-ON(M[CS;VM>Y$ &$@ M ![(!*

YE98H^2K7R(Q"S33].UV$'7B3ZR(9O:;>34%ID16K$VKA M7S^6AO#V'(>F>)U+3ZWL%N6]=435-RIX$:G5$5TC4S^^==M^2BG/SUX9AO:/ M)UE93 UG0 M M M M M M M M M M M %- R7'R?XMNY?%_73]VU?L]78^DR'UA=\A?BK%FF1VW_ !U+Q7-?ASNJEA4N1CDY/2(). NU#O\|+Q MM8VAZKI$Y"YPJ&T.%-*

*>YI*M&LVUSODH:DIW+)AN>_O/>TS?/L5>(:G=M9&O4 MJR4VKN5R3CM%H:XN%*E53^A229>GM3O-::C;+IJJ7DP[GK]\U#9KZI*\6Z*Y*

*M4G55;U7)K'6&JIH:C8Z!**B^*&E'=S>ME.T8(GXOIM'\AON)FIQ"/Y">XBWN M/-O95]V$0 $@ ![/ M!1#'P<2ZBU@^UT;Y:"I9,D3L?)R:@\U)Q9NS;PVAGD;!%4-RK]N,&W] 6.T7:*

*MP%U&/)EEK;3U MCJI-:02,KDEC>J.5S>F3IFAU UM*VF5K6I&W;O1>|T3I#3DL%=3MDHIZ=[>B M.5%-*

TTFA4H=M6^H>Y9,>HJD[6B.3>TLSBKP2O&4U=4.5\2Y9WY+>MI:J2-6 M;TV_?(>,K9+8W"G7S>[R.4=+7!6ZNL,6Q$W7"G3/_K6G5J)A#0U,[VAT-%[L M()P :CI M M M M M M M M M "3[U M?N/D7QN]D3B_KMF.OV>K^O_M,AU^C(MWR6>1^T4[8:_RQ)DJQN1]*KF>)=(_F1Y1>IYD4R86-5\|D]-4+O5O@>BV>#K*

M:9EZ4T]>DY$W=,_^PK2\NPRTQ2Q<3K=36]I M.1U-MC1NU68,YT+>+?=G/[(U1]OZ[%\@GY*R]-H_#'"^AC/DH1;W$(_D)[B M+>X\N^A5[D0 $@ ![(M

*/1#'P<%W[1E175*7"F]J.HSTY:X;9?I"H@LL+7W^I6>3P>BY_*9G7-C]* M1WHNUT&.C<9.6>,&LKG1WKT*C_I5F[JG?D[>&\V[GDLF:@H]1;P:ZFFA:E,U.DSDP6.I;3=*

*MM/5\M.ZG6KH7(J*YK.XV)KSW:?:,6GN=&V^H@U1I^&|VYVY]DQ(UO>A:(Z'"% M7?=%<]>]J^!SGH;CK=.&T]M VE=-0R+_ +KTP;CM/$"V7FBIZYZOQ3395S6N*

*MR0MC;F//Q1M+,=+U#7:WT[E%ZW&F1/\ *M.O<_P']>F^)='7\6=*VVB^Z/=== MJ1CL)T1%F8BK^0[S.7]HX;0('1\[UM_*< &FZP M M M M M M M M M MDRJ.QX$W7R*

B"1SMO>H1VIN_A G)?Q@3 Q^376G(:T.34-K95[MGH[IV-' M[OP=N[QSTV$(JX5 M?Q^(%0$.OD.OD!$%-CE[LD=RIO("<%/)4 D1R|$)WR4W&/72N|59+[7/;E>]%J'KG]|

*[7154I.C>DFC'4(_3^GM#V.2-'/?4NZ;7+W'0=RM=5IVU5D[:,.96 MM54VIU4XEUY?KU?K_6ND|N\QND9OIK?=9UP(NU-3\=]-YI M]R37.F:QR[<*LK41?*

X#ZC)U(D;P)=5MXOZ)=+(DBNOU"BJB^'I,9]< *>] M M M M M M M M 'SE^&&Z6SA5C_O MMS_BTI@N@/@]:KKK0NG=3,XBT=&V\6VFN+:=UH>]8TEB;*

(C57FIG".QW=3.O MAA_];.%/]]N?\6E.V>SU_6$X:_[V;9_-8P.!Y_@E]9V&GD]M/<3Z%;FU/N;7 M4]4ZHGF#Y(<;[U0\;OA'+'%I&5+

*MC3QWRV42UM$F]KW4ZQK/*BIWI&C)$54RFV/.<84#ZGZ[US9^'.C[O]?4%8VA ML]K@=+45$[O!]=R(GBY5PU&]Z]]XGS!NG$;CG\(?K>YV71\DFEM!4KTYT'I#*

*MH*6GC7.U;J1B;I'(GZFB*B8RC4PKEW7\+;@QJK+PRTAI"FF=$R_7*6KJ6L_ MW2*F:$#'?VO.FC=[X_(Z]%/#6BX8|FO1%!3P)#57&ACN]:_"(^2>H:V1=WF MUKE.]S&^(,-#\#_*

*&G[$HVMPE5K[DJ)F6"U,2%%\4VK+E??E|=X&L=6\/>/ M7P=UPI+|8]2.U)H#TA$E;'S'4*Y_>^BJ6HBNCTQ7AK6RH^*KAJ*:9K5Z> MET_]B#P_O59_/9P-*

*4=F#X.NX|GSC#:M;U&N::] MQT451$M";G0N?S(G,SN61>[=GN\#1?PM4/I''+1$2.VK)86MS[Z]9#Z]'RO M^%B5&|>="*Y<(ED8N5|$2JE]W)|N_[)U#^XS_SP_2>[O\ LG4/|C/_*

*#QW MY\>/#C]D'2_[LTWU>)/#C]D'2_[LTWUP.;NR)V!Z_LR\3:[5=3K*GOI*BUR MV[T6&WN@5JODB?NW+([*)R\8QXFI?AB^GO18_P#2_P#^A'T#TWK;3^L(YWV"*

*M^VV^L@PDKK:61U"1JJ*I(I8][__P"A >Y\&'VI?L]9 MG<(M2UBK<[;&Z6PS2N]::F3*OI^OC'UQ/%6KE'M]K7)XY0#BGX83_9'PP_P2O_ (\!UUVBN -1 MVDN UMT?37F*PR.?*

25GI4M.L[<,8OJ[4.8='=ERJU:VHJ[@NS4$5-4TU964 M;W=U(KF.6GCD>KN6C\^MRU\>F3[HGROX)__)7+YT_\-WO^;5 'N_I/=W_9 M.H?W&?\ GCN/@=PJFX**

*<#K)HB>XLNTMHI)HG5D<2Q-E5SWORC55=OR\=_@:0 M+2Y?ZWU?]Z?_ !5 ^7?P0R)\;&NNG_@1G\NP^IY\L/@AOZ[&NOVD9_+L/]>! MR%\)KQ?^+WL^RZ=I)N7=M6S_*

*&/:B+AR4K,/]')Y*FR-?*8Y0[&MTO/91[5U MKT9]=WH]'J^VT<$Z+EK$E]8634RX7OBK&WVH9S*_PLECMVC>*-]:Z"KMDR6F*

*MKFARCF,572TS^G=M>DJ9]LC0/H@:L[4_]C9Q4_WLW'^;O*G9OXM1<;N'VEM8 ML7,W'@F]KE3R5%\23M3?V-G%/_ 'LW'^;O Y+^!]_V M$\1_VPI/Y.0^@Q\^?@?*

*O]A/$?]L*3^3D/H, M $J>/N/EIVCKY:9N(VJZ2>D='<$O%8Q)D3HJ<]Z9S[C MZE^'XCYL<6Y+=]+6&O4JJ5C:BCO5;&U^WJJ-G>B*=/H[^Y+SW3-N'%7^6@YK*

M)/14Z2R2))"]=,>&CONRM5?5/8D1<4%0DGJOZ MN(ZVDMJW-GYSI9%QEQZ%3IY]"C&X6 M97=5;DV5-P0J+A51.YS=&KWQF2?%3Z?A=)/6+/(YN$WJG0I9&7BJ^73I>J*

*MO.Y&M-/\/ZBNIUJ:IO(@;UC3F87\AGVA.(M;I6Y)215+8TC3U72/RW!@=\L% MTI[@]L5VFDIG=[.]QA.HJ&+UN56ULU4_.<*O5%_T$ICBY)3J[:>?N=SL*S=H M.T7"Z0T-*

*QG1ZJF'[5]4TMQY^Q%9JQ'6V2-8)O_%8Z>_!K;04-%,Z[]JVL9$] M$]5]NZGEU]T2.LDD1CFL:J[)57Y1F,[-1&A]=F_) $<;I'WZ_P|C]G+1;# M;;Q5 *M90V.MMM/46^E;JZOB2*G?*

*$UT4:,.FUF&*U,)T3!G/PP_P#K9PI_MOMS_ (M*=L]GK^J)PU_WLVS':Q@<'5?8,[4VM8)*#4W%F.IMDC59)%_U=T74NL:B!U/Z]=.-ZRN>IB&U/8!\V/A@[7-*

S^%]Q1'.IMMQIW=/58_-,Y.OM5,_\ ]IX M#W."[\$N']=2]QT%18"1G+7*)FGCZ?BlGAC!@/;2X R=H?@C<;'.TC74%OE M;\.6NQ\YFKOA'=27]WNW4*7&_7%'1_(6&1\K6KCV*LS?*

*WCZQ'" MGP??9VK^'^C+GQ&OU-Z-'G]ZK/YI.8#*O_8R4W^^"D_DIS/O@]_[$ M'AY_>JS^>$@=$GRL^%[@2HXYZ'B5<))8FL_+53'U3/E?\+&J-X\:#551$2R, MZ^S^JI0-*

*H_I06D/G_>_HIRQ M\9_]T7_ +W_/T(^@-OUOIV[UC^2@0LIKZN3.R*FK8Y'NPF5PU]Y7)G1\ M_OAC/_NB_P#>_P#^A =M:,TI:|\ =/Z?O5)'7VJYZ=I:.IIY4RDC'4[$7W+*

MXHO>BX7O/FQH"^WSX.;M75NGW--5:$N[FLFJ-JJE10N$'[:?12XZ_82B_D&&H.VQV:(>T?PHFIZ&%C=86='U=GF=A%>[' MW2G5?P9$1$]B..:U M"HO1?

$^E>F?IC=I_P2+^(A|"-<<3-0ZHT?I31|_214T>M72TCJA%2:.*1S.P M.1>OJ.C5$IB.1J=&H???3\ L;M7^"1?Q$]_^6'!3 ;:7+W^W=[_)M4'U// MEAP4_P!MG_Q5+LM+G_K;5_WI_|

%4#Y=_!# M?UV-=?M(S^7870[CMQ0I^#?"'56LJC:KK71/D@C?W2SKZD+/&7:U\BR3ND669BIW.2/N M1>YWM.A>.OPC/!CC1PAU7HNIT|K)CKK1.C@EDH:/;%4-

5'P/7%4O1LC6.7W M=)\#NR#PXT9PCTG9|1O^ZM1K)V MIYN;RW(G_DW'<7:F_L;.*?\ O9N/\W>?-SM2Z8=V..V=8|::6MT=OL%1+#>]*

M.BHHTBA1OZE5TK$:B(U'>OT3HU)FH?1+M#7RBU+V4>(=XMLZ55NN&D:V]IIV M]TD@MCY M:^EC47JNUJKT153]>Z M !]>]ON/E-QIM-V]^)VOI:&3:UU\KDV9ZKBH>?*

*5COR?)WC#57*AXW: MVF@]7-8V^URI Y/45/2' P)U.CO[DO=-_ V:S|VKV4SD2-7K(Y.A MD4ME]HZ-]PRMF9CN:IZDMX@U@_T.LI8H*ER91[>B9/$DMMWT_5HBL?Z,]]%3*

*M*I@]'-N3Q/!Q1Q1"T]++#L:NUT4JKZVY.\\B2T(E2]_8CW>&$-EP0451%#-5 M2RG5[47JN.A3Q3')3->.NU>]YW!;Q5=/]21|51QK M3*WHZ9/])E'&2ALKK:NUD::K/^YX/6U2*

J&RU^F]UE5>H1-]JWHIZLCKW)S M*I9)O]HS-IX6YABN.(XGVAC^0GN(M|B6/|33W$$>X\;^IU|V$0 $@ M ![(0=T:1$E=|AWN,PC;W9?/K*

*MB5JC[!V=988UAE]IJ6FKKIJ2%:B>Z/BC;UPKNAG=7Z#]_4%1;*ZI2:%]>JSN M*UQX6,EL[[?05*0.F]5%3P_&>EQQPOG%XOFBUFAJO5M59[C40/GYS%[G9R87 M5U<]57/]>?*

*L1SNXJCB#I"]T==_0YW]47',W&/K"ZGF9O1)&+XHN<'4QQ68W M>/S9;=9PSW+Z%T<;G]Z-[WX^4BD9ZV:Z4L4+7=(E7"+T(K61MD1-N!)#*L;W M-*

*>C6)W8|2WA8WW9)P,8^'CCP\:[']745N_G49]H&?(_$?&/@*DO'#A\U[%54 MU%;\,_\ :8S[.1_(0\UTI_V M M M M M M M M M M .'W:V(U'VK(-+PU>I9[.)8WU+VK!2-*

*J.=SDC1W&.4G=GO-R\/M*IH M30NG=-_J75;+-:J>W-J'.V+*D438TT152W>XT\UAU0YFS[.6I6M?+CY/.C5%;)[^CL(B;L(F.BR'X@/FX_X)*

*M2_TLK*6AXO[+6[.Y'6]1BM:O>FQ*A6KGWH;@X&_!E\-N%DETI;QJ&LJ->7FE> MD0:5|+8:%KT7*.]'17;ERO<][D|NAV(0VI] (-:C<(B(B(F$)@ -.]']L]T_M:4X;QZ0J;U+88V5\5?*

Z7%3I.N6->W%S4Z[_;X'NSP.I /!\\/TGRT?LG5W[CL_/#[)\M'[)U=^?X M#[SQ]#P!QGV>/@Y;;V?^+%GUU3ZYJKU);6SM2BEMS(6OYL+XE57I(N,(_=W> M!G_:X[(-'VK':42KU-/IW[

^E[>32-J.=S^3G.7MQMY=V?E'1H \725A;I; M2UGLJ3+4,MM%#11,Y,*](XT9N5/#.T]G:GL&U/81 XS[0'P;.E^-W$NXZQHM*

*M25&DZBXHU!=34]"V>.6HZHZ9.O:M5R8RB9RY%5>]I=@6RD2@MI-2HY7!\$V) M'*F-V$Q_F+O:GL&U/8!$Y=T:V(Z+2':BKN.[-6U%355%96UBVA:%K6-6HCD8*

*MK>8CU7U>8N/5ZX.H@ *%3#SZ>:+.$D:K<^],%< KU2:MJ- M1.N=$VC=%-0MITC1*L\]8]@ZA@O]I"#BQ?\ 6-17I!7T]9'8G4#4 MB:R#;RX=_,^3EB*OJ]55WM4ZM :%*

[5_93L_:GTW9+?7762Q5MIJG3T]PA MITG=L>S$D6U7-Z.5(W9S_N:>TOM=GB;3_9JK>#U9JJ:ZT\UKJK3%>)*1&21 M0S(]&IR]Z/MB/PG5.B(ANPAM3V ?/#])*

[L_]U=^XS/SQ'])\M'[)U= ^X[/S MQ]#P!R3V7^P#;^S3QEU=3:RJ;_,^@EH?19[!L"(CWL=NRDCOP,=WB=;_M 2KW./E?ZQ'[XQ:UBJHE:

M(R]5K$QXXG>G_P!3ZH=V4]IPIQ7X26^[:]U%7K"B3R7&IDW>:R..GT?,1DEQ M>D]/.HQ16'-,&G]VMN$3[? Y6HY%W8\#:.K+#=:[2L;F4;5Y;?6LJ?

*Z3MVMOW/'XZ]GG@OW.>+DDD3 M51[9F.:O7=E$(P5.OH]+&QKV>/M.QM1Z3TUKNROIXZ6&.9RUSP]JXF(+W*9ABWNR^1/#22INFKHZ]R.V/=U[SL"Q:+BKXXI7IAFW*Y-*

*)\ M&M"W*TRQMK:9]+G]YIU9::7T&UMW8SM_$>CRWC;:'G-/@KBPS%F@.,?#;3]# M;YZBOBA:(Y%6.15ZG&UPL,U'6SK!LD@RJM5]YZ'7O:AJ&5-K5)W]S">]W/0X*

MWEJIH=S6-D>KEVHW/@;VEB9C>9?---=2MG\!NVO%5>GT]K(^!(C6\:N M'K-J9_1%;T_^)C/LG&F&I[CYM\&. =%8.(>C[E5SNDJH;M22L;X;FS,,FH=\]KX:6>Y0 M-*

*=M=)1TE;,U'(B*K55KUPO5.GF>E#\)?QLIDDEK>$-*ZG8U7.5M%71;4]JN5 M51$ ^F(.&.!GPI.F->ZDH|(ZYT|)HBKJ9$ACN3:KTBCYBKA$DRUKH45>F5W(MGWRM3JG8VM[_*

#:8T7?[S QDE1;K?45D;)<['.CB<]$=C"XRWK@#(0?,'3/P MGO&K63JA-/\ "ZU7UU/M69+;15M1RT=G;NV/7;G"]_L/=_3 ^T=^P7_\DN7^ MD#Z0@^;]G^%@OU@OD-)

)KSA8^@IW[5DI#)(;B-N>KVQRL]?IW)N:G|L=Y<,. M)FG^+>5Q M45%3,=+-4JO1D<;$155SG+T1$3KE?8<&<7?

A3(X]22:=X0:2=]VKW.CBN5>R M58ZAZ+_N--'B21O>N5"B^KX@?0('S4D[:_:TT]2R7>|<&VI:,.DD=-IFX1 M-A8B|55W-RQ$]K__ ^F\.S/

*(MHSCI>*735]HW:+U14>I3Q550V2DK).B;(I M<-P]>]HQR=>Y%CK#77]]W&"UVNB8LM165H'M ^?&OOA3:B[:@?8>$.@*K5-3S%9%65[9%6H1]X5T=-$BO5]^" MNBHH=^'MD2JH%Y%=CKM1WL V>#AO ML>_""7KCUQ6=HG5]DM5BFJJ%11;I*'FM6:5B(]6*DCUSF+<]%3\!?:AW(!C M7$344VD= :EOM,R.:IM=LJJZ*.3,Q|HHG/1%QUQE]=Q\\.&7PK>K-0\0M.6G M4FF=/6^QU!?#2UE92\Y)((WO1BR)ND5.F<]4[D ^F@(>>2(' ?:K^$=U!P4 MXS7:1.E;#9KQ2VN*%E355ZRJ_P!{!C=CT3#'1L MX[_3>[(>LGQ?WOI_YY#^4>#E0H61SD|M#:BA3[WDRQ*]^*+ES3:'" M:X1KC@!Q3NT%J?K,!V,JB =3@IM=N\ M<^/0TQVHNTS:^S#I&TW^ZV:LO<5PKO060T&&*GXP-U@PSA% MQ(IN+G#;3^LJ.DEM]+>*9*EE+.Y'/C155,*J=,]"RXP<;M'<"=+.O^L[PRUT MCG+'!$B*^>ID[]D4:=7+.\F>]HG4#8 /GG[3X7_3])5R-L/#FY72E1^&RW&Z M1T;U:G>]M;'*B+G'3,/,S7A9*?PTUE=(!?]:UW/1,LS|K*RH]<.[N]B/3S- 4VCX8&PS5KDN7#6XTE'N3$M)=HYV.OMV.C8F>_[(' M5O!'M&Z#!0EDEN&C;PE8^G1OI=OJ6+%5TJN1<))&O@N%]9JJU<+A5PIM(:#7-M2WR-BRRV2Z1H*5M8G>]{(X6O-M"K#C|HHO@3IWI,ZUO<%|@DW-IX<*^>I:=YV3:[K1WRVTU?;:N&OH*IB2P5=+(D MDS/KVW:;ONDKI<(*^D960W*DF8D2Q]IS-M')A43N:K5RGL5]^)TG05L-RHX*NEE:/35#&RQ2QKEKV.3+7(OBBIA?Q@78!K M++M!<>&=?K.\02UL-/+%!#10/1LE1)(Y$1C57IE$W.Z^#' ;-!JOLY\< M&=H3AM!K2FL578*"IJ98*:*LE:]TS8UV.D16IC;O1[4\V*HEB_ M0!>W*QSFJJ5D.%PN,@=^ X!_3?-(?1? WSZ7#_H'Z;YI#]C^^?2X?] '?P-=\M!>+U)QXX46+75!;Y[72W7G[*2I2%H';H. /TW_1WS O7TR$]N MR?"U<,*RHACN&FM46Z-R>O,V&"9D:],_$]*J>Y,^0'<@,+X7<6-+\8]*4^I-M(7>*\IV5VU9(\M?$_ "*LYS(8I-R*WIC$R)~)0-R YJ!4? M;;LG9?U+9K-==W"]R7*B=5LFD\V1M8U'JS;NJQRAN'A/O,LG%_9OG-UCJ'ZIWY M|KND#>W2(<[&4SC(&\|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~%(GX22FX$<;OP_K- R7.CMI0WA(WK'M+!%,Y58%@7JU)<(U7!NPG5.1.O\ 36HE;JVPVZ^6BLCKI5<(&5--50NR0TZ-Z M(K53WHJ >N ^RO_FOI&[DI\9Q+^G%?\ !H_'MYR__.I^.#Z1@^BJV14]G1V.NW"*]IT@ J^Q% ^A ,>T7K2R\0M.6I46G+C%=K+7Q)-2UD&=KVY5. M]*B*BHJ*BM5$5JHJ*B*AD(&E.U5VDZ'LQ<.8=3U-M6_5=56QT5):T]O1EF< MY'.E+;;*>LY,_9S.7&Y^W=A<9Q MC..F3Y_IQG_.Z+_P#N?_\ E /I&#YN)\,5[>$>/_XE[O\ X3_K@?IQG_]H MQ_[G_P#Y0#Z1@Y$5]W:Z^VLMNI:M-*\]9MEFIXMOV2],YW-;]W&SSSD MQSA+VZ5XG]I>|<(_T$_8S[\U=PI4O'V6YW,|%>]N|D|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}KCISI_P#:NF_F=:<[ZTVZ.^%9IO0&(U)=34&Y ML73K54\/-7_EGJOXSHCX6W^QQTY_OKIOYG6@<-\++SK#L>;MX<\48A5FG-3 M4//?'%ZK*NF1ZL]*98)IR2-5K7MST15C=[4/LHW6=IU_I:UZBL58VOL]S@94 MTM3&O1S')GK[%3N5%[E147]BHZ>VUSF]JTE M6V679)_^OU=;XY:^2"@2I=THZ]%|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

*[UK:RNLENK:Q{(B5%121R2)CN]94ST/: M_%&6".HC?%(QLD;T5KFN1%145,*B\[CP/BST?\U+)^YT/U3)0!X%)H'3%@+S M:,;3EHY>[?#0Q-=^5&GNHU&IA$1$3N)@!#:GL(@ #RKQIJT:AY276U45SY65 MC2LIV2[,XSCC_`)J63]SH?JF2@#': M7A_I>AJ{JFFTW::>HAZ6^EN4#7\ MQL57"V5J.1%1'(CD5,X5>OFIZ0 M."AIK9214M'3Q4M-$W;'# Q&,8GL1$Z(MA=_>7>--VC4+8FNMKH[FV)5=&VLIV2HQ5QE4W(N,Y/R$E3IFSUMMAMM3;.* MHMT..71RTS'0LPF$VL5,)A%7N3Q/7 %E;K51V2D;1V^CIZ&E8JV"FB;&QN5 MRN&M1$3*IJEZ /;;HS3];GI&E*VIV /#NVC; M!?JE*FYV.W7&1!J,26W6(Y7HU%543+D5<955QYJ6WQOZ/^;ED_SZA=$MUM-#AI6JM@0155*?C6HB=2_|^{62W7VE]&N=! M37&GW(_DU<+9&;DSA<.14SU7\I-:K1166C;26^C@H:5BJK8*:)L;&JJJJC6 MHB)E55?QE\ (;4]A8W.ST-[HW4MQHZ>0I7JBN@]HFR,7"Y3+7{=%+| 8#!P M&9X94U8M9#PZTI%5KC,[+)2)TQCUD9GIA/R&\<0P1P1-BCUK&HB(U$[MD1//"L !3?&V1LB97.5SUZY/; 'BVO2=DLE6^]MUGM0IQH&O+D1+2QOO MT-/- NU@MFH*=E/=+=2W*|CM{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}G!Z@.%G76ZEN-MM++)2UM-#64TB8?#41H]CDSG"M5,+U1/R%X (/(H=+V:V6^>@H[314E%492:F@.MIF,CDRFU=S43"Y3!U\"-FTS9]/<|,5:,&V<[-]#IF1;\9QNVHVE<97O]GK.M /$N^C{!#? ZA*BZ62W7*=K$C26KI8Y7(U%54:BN15QE5Z>;GK11,@C;'&QK.M(VIM:UJ81$]B(50!Y&H=*V35=(VEOEGH+S3-=N2&X4K)V(OM1KT5,F-VG@5P MVL==Z9;.'VEK?6;TD] (I++312;DZH[CKP.M AM3V#:GL(@ 0V!["(0V!["(L.;^TT5 MWIW05])3UL*HJ+'41-D:N4PO14\4*E#;J6VP)!24T-+"BY2."-&-_(GN0N@.M(:4]A$!#:GL&U/81 $/Q$0 "PK;);KG)&^LH*6K?\AT\+7JWW93 MH7?K6(U]{B(B)W(B=Q. AM3V$0 'EU^FI3=E&$_(=H ++>DHX**'E4\$=/$G5&1.1K?R(5_Q$0 M $CNYOQQ[#7]+OJU+;I8LK;;H M^(>I:V5Z-D^R52JIGQYKC=T=>*TN/TC/#2)97;Y8W1J]SFN1?PC&-;7AU18L ME%'NGQT"Y6N9L4J.7P3)U>!S:;FG5K"W<1 MZQMP1US1CE5<-V&6NUHE+&L[DW1N3IM-*T%OJ*ISY?6$EIYWI2KT'=>XKW(@) "_M0E=\AWN)B5_R'>X5"-O=E\57T54KG[J5+?+RYF_*:C5^5@]1*Z*ED"-8BY7*'MXB.!\DFL]JW;OX.ZHN-/'RHZ=?OH|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

\MKC8NGM64E53MH M-F45,;L%63AW1S5.'LV1>T[JT:0MUKD:^,-%5/$[LY(V>:ZN-V#ZETW/;*I; MR-%=#WHU]$*2\24S63L:K5SW*;7GI:>5B-?'NB=WY\#
:BUPUFH$IXDQ3YIL M%$SNGU:T[LOLE[4Z]"}>KC7F=>B^1=VFV-M].K6_)1>A<24B3?=/-MHLV/>ZM;W$2#>XB<%ZN.X 9 M $A*[Y#O<3$'?)4S"-
O=E\4Z6CHOL=]RK.7(GWKEP22S.Y.URY5 M/P3?]RL^@=4UCJ"-8K?5NZ-FO4-5"GK,@7&?)[#*V-.L3 M5\DSZ?[TI-202.D<[#?K[R>";".1S55WL4S,]X0;M.^22.V.6/OPQZ+_ &$
M72CK++6.@]Z*6GF1>]RE9P7;<3G;=7S5F5DC7Y1-A[OZR-.[SDCAW;EHZC1<2(R#\A,)?R#\A,)?R#\A,) M?R#\A,)?R#\A,)?R#\A,)?R#\A,)?R#\A,)?R#\A,)?R#\A,)?R#\A, MA,)?R#\A,)?R#\A,)?R#\A,)?R#\A,)?R#\A,)?R#\A,) M?R#\A,)?R#\A,)?R#\A,)?R#\A,)?R#\A,)?R#\A,)>GM"-]RDP M-M-M)?!QS+]MVW5=X1>B>F3?RCCIHW1" M+6]YG+]V](OCR1[UR->L;K2>L[8F&EJV5(F[DS
MDI;WS)*U47]\Z+D5M'@M4VM;YKFY0DI+52/GRBE$BTN5<]MTF3@PG=<1M2159I5";&%K-V5RN8V1$ITGKW(@) M "0E=\&NM)B#OD.,PC:W9?,2X4^G]&H^L6AYM9CU7-
7}]?56N+U<;MTD5 M5/31N7$<;=Y4TZZ]WRN93HKZY,_*7],PLW#BED@IY*VEC=/&F[UD\3U=*UK7 MO?->SWM.6F=.\3-.:=]*65U1(^D.];DD0R[7'$/36MZ-C;E3)#5*WK-
&B=YL M6^.59J:C?;Z2BC5WVL2@M=*R"DCZ1MC3"K[RC)-W7T71U,->*>]ZVGZ&.GU' M8H6[UW)]H43'D]HT2WN.<=$4T/3:7W93 M U6\ M M M M M M M M)'=SCE
MS5>YNK+UAN4]-G_E"4CNXYPU!1I-J6\KS&I_5LW3_UCCER];&]88\K M4DBPK;428:.MGXBM%;Y<=6AFO>ZH9\E"+>X@SY*$6]OPGIZ]R("0 M
D'@H(.^0X0C/<^,?"*R0Z0AS<*1*6\7N.]-MZ.-K+51U<;S2-5L>,[=]HDYUM5T?I^K2YZ@JG57X+$<66HN.=]N1U9RJ.=:6W MT1C6Y54/5Q2>%\^R]
(4B_W73]LO5GM\$4LK]V@]+\VNJ;2LE]\'\J2 MO.'6U-QU1QIDFCN[&MQG;N))M?61[HW.K8WO:O7UD3)QV%17%8V;$5T;.IHY
M2J^X)%)'(R21RM7*]5)SIU>+I6U1^_+Z$:!X@LKM26>FBA:K)*R&-'HN>^1J M'42=_P"(^9? ;B[#%K[1]JG\]25-VHX&NSXNF8W^%3Z9HN40X6LIP7B'M^C<
MUTD6W\'Q'0C@ M !(2N_4W^XF)5^0[MW&81M\LOBQXC;A?',N"*9)G=?V'AS7-MBW6 M]fVAH8?6C7*;U \ J8 JK5,-WJ(VTT2RPQ)L;(J.JH0O&HKY>]16W"I=(SO2 M-
N=OY#Q%AY\>7.PK>FUJ80Q$OAER3P[0D2Z;5QR6Y+FDJUF;+N!\^X\Z*T/F MJOE.1/>>Y,*6;&H=3Q1[E=TWKU+;,,CX\EMHADW!AJ2\9N'R[%;K=0V!>[_S MF,^P$>-
I\G^#FCKY%Q:T-4K!NI((I0O>_'8Z2_N0^F?9VL MTPWB;%4 !R7K@ M M M M M M M M M M !*J=#0VL6R2]W.3=ZZU4J_\=3;7X1HRI[P2U&HKICY*54OC_J;6FY3+G:R
M/NPQEM'*URXZDKJ]=[EC1JH9"Z%&1*_&'-/*14GF7EMVJBG0WHW6UJITE3)-YE5V[U;) MDNJ1/6@ M !(2N^0[WS@\Q=V5A
M&WNR^0MVU):4A=316U:EW_CW=3&FW&MDIC\D44=*K414=[?$]C7W7R'4;\4K&!\SG;9&^J4ZJGW2>JW'CDF6.=7='(U-MOF2QU$7,2*;;;B]
[L&Q#3K$VY*;;;ID5%[V]YV<=#+-);2OU5703MIUY2+F1 M7)@62\6.QM:[;+4R_@]38UIU_>+M3LCM5C?B/O5S1WW M%1(V5F6% 4U$4S>9"Q-QCU$SF+
(US7*\K0LJ*63:C'U2E[6FO)?K5QJEP]M.(G0M):#[HKDZIV%Q3R-:U[-'5'[N>I68Z2-/DHK5\AM"VDS+?]=Q$@G<1,. M]#-"0@IY#B)!W MR5$.6]V7R^C-U-
I"2VQ87;?) ^^8'=K'4(U%;W8GL-D6[B57W21:6NMD;Y'=$<>R M_1[;O1SS3(Z)-O3:G5[I"EHX7S3+IYO:=FAV6]K),U;FU/9DN(5LT,F53#0%-MZID[_46A:FGE-]G,R8YQ3ML]RFNE
MCIW,>E,DZIWX;@S:S<<<+=;:1\$%E?'(B=%;_&34\RR.ERQ&Q(O@6\L*,)4CIV-7]X^DK>J)\ ME,"5<^3C%H=NW;F^I*+](C/K6GR40\UTA'#DA[3H#)?)AOQ3OS3@ YCU M M
@B_C(>X\V\W>E1=KK+CK6R+/1T<+YYI-JNVL:U5,SNVUVJP8)B,%4M1Y_RG4W>2CW5LVOQ^,8\S4WVT MG#;YP.^@U/YL?;3<-OG OT&I_-20\9WDGT;.M4'1_Y8\6V<+8QYFIOMIN&WS@
M7Z#4_FQ]M-PV^<"_0:G\V.SYO)/H>T=`_DCU;9QYC'F:F^VGX;._.!?H-3^;' MVT_#7YP+!]J?S8]/F\D^A[1T?^6/5MG'F,>9J7]:CAK\X%^@U/YLA]M5PT^<
M"_0:G\V.SYO)/H>T=`_ECU;,QYC'F:D^VJX.?.!?H-3^;'VU7#3YPK]!J?S8 M]F\D^A[1T?^6/5MO'F,>9J/:KAG\X7?0:G\V/MJN&?SA=!!J?S8]/F\D^A M[1T?^6/5MSH1Z&H_MJ>&?
SB=!!J?S8^VJX9_.%?H-3^;'9\WDGT9]HZ/_+'J MVWCS&;U)]M5PS^<*_0:G\V0^VKX9_.%?H-3^;'9\WDGT8]HZ/\ RQZMN=^/-M0U%]M9PR^<?_
,#4_FQ]M;PR^<2_0:G\V8[/F\D^C/M+1^;Y(]6W>2&HOMKN M&/SC_P#@:G\V/MKN&/SC_P#@:G\V.SYO)/H>TM'_)(]6W>2QYFIOMIN&WS'S MC7Z#4_FQ]M=PP^Z$>AJ#
[;#AA\XU^@U/Y ML?;8<,/G&OT&I_-CL^,R3Z'M+1_Y(]6WI>8QYFH?ML>&'SC_/@:G\V/ML.& M/SC_/@:G\V.SYO)/HQ[1T?^6/5M[HJ2&G_ML^% SC_^!J?S8^VSX7_./_X& MI_-
CLV;R2S[2T?\ DCU;@Z#H:?\ ML^%_P X_P#X&I_-CL;/A?\ ./\ ^!J? MS8[F\DGM+1_Y(]6X.@Z&G_ML^%_SC7Z#4_FR'VVG"_YQN^@57YH=FS>6?0] MHZ/_"1ZMP]\T-/?;:<+_G&
[Z!5?BH'VV?"_YR.^@57YH=ES>6?0]HZ/_)'J MW#CS&;U)]M5PS^<*_0:G\V0^VKX9_.%?H-3^;'9\WDGT8]HZ/\ RQZMN=^/-M0U%]M9PR^<?_
M_.1W[GU7YH?;<<+?G(!]SZK\T.SYO)/HS[0TG^6/5N"F,>9I[;GA;\Y7?N M?5?FA]MSPM^T=)_DCU;AQYC'F:>^VZX6?.1W[GU7YHA]MSPL^<
MKOW]OS0[/F\D^A[0TG^2/5N+'F,>9ISI;OA7\Y7?N?5?FA]MWPK^<*_G,!]SZK\T.S9O) M/H=OTG^6/5N/'F,>9IO[;SA5\YG?N?5?FA]MYP]^9IO[;SA5\YG?N?5?
FA]MYP]^8QYFFOMO>%/SF=^Y]5^;'VWW"GYS._8QYF MF_MO>%7SF=^Y]5^:(?;?<*?G.(]SZK\T8[/F\D^A[0TG^6/5N7'F,>9IK[;_ M (4 .=?W/]OS0^V_X4 .=?
W/]OS0[/F\D^A[0TG^6/5N7'F,>9IG[<#A1\YW M?N?5?FA]N%PH^KT-)_DCU;GQYC'F.8^W#X4?.=W[G5?YH?;A M\)_G0O[GU7YH=GS>2?
1GVAI\D>K<^,/8\S2_P'N%PG^K=&/,8\S2_VXO"?YT+ ^YU7^:(?;B<)OG0O[G5? MYH=GS>2?0]H:3_)'JW3CS&/,TM]N)PF^=",_N=5_FB/VXG"7YT+ ^Y]5^,'9\W
MDGT/:&D_R1ZMT80=#2WVXW"'7YTK^YU7^:\' VV"'3YTK^YU7^:,=/0=#2WVV"'3YTK^YU7^:\'VV"'3YTK^YU7^:\'9\WDGT/:&D_P D>K=/
M0=#2WVX_"/YTK^Y]7^:(?;E<(_G2O[G5?YH=GS>6?0]H:3_)'JW5T'0TK]N5 MPC^=*_N=5_FB'VY7"/YU+ ^YU7^:'9\WDGT/:&E_R1ZMU]!T-*?;E<(_G4O[G M5?YH?;E\
(OG5_P#+JO\ -#L^;R3Z'M#2_P"2/5NOH.AI3[T-+_DCU;KZ#H:3^W,X1?.O_P"75?YH?;F<(OG7_P#+JO\ M-#L^;R3Z'M#2_P"2/5NS/F,^9I/[2?
1CVAI/\D>K<^,/8\S2_P'N%PG^K=&/,8\S2_VXO"?YT+ ^YU7^:(?;B<)OG0O[G5? MYH=GS>2?0]H:3_)'JW3CS&/,TM]N)PF^=",_N=5_FB/VXG"7YT+ ^Y]5^,'9\W
MDGT/:&D_R1ZMT80=#2WVXW"'7YTK^YU7^:\' VV"'3YTK^YU7^:,=/0=#2WVV"'3YTK^YU7^:\'VV"'3YTK^YU7^:

<;;/PMNL5W74MUJ* M.EIWP4K74^^I>UD:N>KT5$RY,^K[L@;U -%6CM@:%O/^3@[3PW= M-6,]]97OI6I2[HH73.]??G&OBX]7O WJ M (+\E3G?5DJ27^[+T]6KE3\CU.AW=Q
MS1]NHC_1-=XE7"NK9D5?_6.-O3=\N9K?=A;2U2R0N1J;D+>DEV[DE7"+[3TH M*..EC[]R.3)Y$L/F>CEV-.@Y'):U=9(YRQHJ(U.Y?:6I)3R551M67EX_#7H M3R\B.14E?MV]RE"-
SVS-?&N^,EQ3LKM/-D;J=[]56PSMD?W)M+33,-9;ZN7T MIKD15RF>XDJN;)2MDH45L^>K3U67"7T5C:MGW;'>0F-^\BL[\G3+/DH1;W$& M?)0BWN.*]97N1 2 M
$A!WR5(D'?)40Q/NR^:-PI?1'.^I/04-74T+W1R1+ WUG-DQZWD8 M[=;GNN"I54S^:GL[B:#4'.G2)R+&W.$:U3U%8Y/G\WWGA9%#0+Z/RTY*9ZI_M:^XHR[Z66-DDC7;?
P5)EA1L+9(VJY?(5CHHZ-\ZQHR9OB_Q)16%E?PXY/5O. ML&6^QQLH9)$J7]%3'0\.FIJK?23U;VUAW9]Z<35>]#U>BKM1, #2 M= !*G3)@/&CB[9N"?
#RZ:LOKG+3TC<14T:IS*F9W1D3,^+E_(B*]] M$4S]5Z*?-WX5/7T]1]G1VBHW/;34U&^[SM1?5D?(]T4>4]K4BE_RAMZ/3]HS
MUQSW.;K]1.FT]KQWN6N,_'G67'[4K[CJ.X2S0\W^HK33JY*6E1>B-C9W;NOR ME]9?%38&BNP'QFUG;(Z_]#\%CIYF[HVWBJ;#*]8\8DR]JY3N>B+Y>)LOX,K@
MY0:NUQ>M;W6F,4,T^D<5O9*S+4]94]$/IRU]83"=#OZK M7]DOU&"L1L\WH>C>VTZ_46F=WQ&XM]F'B1P1IDK-4:=E@M;E1J7.D>V>F1W<
MB.>Q5V+GHF]&Y\#>78U[<%XX?WVAT?KNYRW/2-7(D$%PK9%?-;'KT;EZY58< M]%:ORZHNPOTRU%8+=]FR5]GNU"%76ZMA=#44T[=S)&*F%:]>P^'G&OAZO"
MOBOJG2:.<^*UUSX8'O[UA7UXE7WQN:6:;/7I*EL.:L;^*K5X+]$Y*Y<-IVGQ M?=7=O9E%PBIT/B)VH_[(KB/TSB^U7\HI]3>Q=K^HXC]G+2-QK9G3U]+ ZW5$
MCERYSH'K&URKXJK&L55\5A>Q3Q8XCZ5MVI+#8J:JM-PCYM/+)<(8UBIU1>]#U+EV!. M.-MIUD31S*QJ;E+E\/_&O M-UK/%&U5+X/V._.KX/ZS=
M5VVIN&E]2VR58Y$170S1N1?68]]]Z*ORFN147QRBGV+[,?&MO'GA%9]4+"'! M<5WTMPIXL[8ZB/HY$SX*BMSS65=2U[(KG?*BHDF^)Z9\C9Z1K7)]J9IKM:5'1-
KXM7?!6V]8W^C OA8/]8.'/\ A5;_M !(3!/@]4SQ1UFN.OV(9W_W]IG7PL"XL7#G_FN_B1&K?@U]6VK1&K>(-^O ME?
#;;316)LU153NPUC4G;^-5ZHB(G>]HB954,8]S;HN8C_[F9K17I;BMRCE_MV?2'B)Q$L7"W2-QU-J2N90VJBC5\DCOE/7[UC&_?.E5T=KM+7JK*:-?%?;
(Y,;G>/1.B(B'M]][M2W7M%ZO5(5FM^D M;?(]6VVJ["N\.?+X+(OL^]1<)G*J[?'8,[&M-J6*AXF:W@AJK7GF6:TOP]L[MD7'/F3NVHJ8:Q>]4RO1$W9T^#'T=B[1F]
[_[DC]=3EZ3S]FP3M6/K\WL]AOL M4HKI#;$URI&U<*.='W]V6_?5E@)K?1: MFOR/5U9"N'T=*WU7/:[[U]G+AKDZIM>O1<*==XSX]#Y_"%:FEU!VH=04[GN M?
%:*:EH(SUYGG4Z,P5SZB(MW1S<3I;43I]-,UGG/)@/[GL[:] M[1-QN;]-4D=2VE7?67*XS\N)]'JJX5ZYONS#Q32&1]3I MC5EKQR9145,MDC=XHOJKA45.BHGTI^#BTY#:.S':*Z-
C6R7:OK M*R5R)A7*V58$S[>D*&A?A7+!!2ZEX>7ID:)4U=+6T MMG+]YTUHCAYQZ/-9-!&'1QJZVGBY3ZNQ^S3QH^/'"6SZJ:UE/7/1:>OIH\[M8]IF$D1,]=]Y1S<]=KVYZFF?A
^TI<>#NCZ#3&F*M]#]6_(]SZV%UWWKW.7#7)U3:]>BX4UO\%%]>5]%Q"TZ][E@BEI*^%F>B.>U\SUYGG.P:*G;K8I]V.;IY]?>>CJ MY(]ZW)@/!GL[:]I1-QN;]-4D=2VE7?
67*XU&R)]'JJX5ZYQR9145,MDC=XHOJKA45.BHGTI^#ATY#9 M^S':.Z-C4DNU?65NU[<]3:3I48U7*N&HG?X'_'P4>]]7T7
M$'3KWJL,,M)7PLST1SVOCD7\D<7Y#8'PEDE^]N%.F+3I]UQF]+I>TI9*&V\Q MSZMO(F7EJQG5Z91/5PO5$Z'G\VFBNKG#OM#TV#66MHHSS&\[,2[:7;EMELL=
MRT%P^KHKE=]N-]+<;Q3.W14C'(K71Q.3Y4BHJHKFY1G MG_VAH?YPPW/H_L#ZDH^%&LM=:^YFGF6FR5E?;[,Q6K4RRQP/>QTW>C&(Y$]7 MY3NJ*C/'3'9K,_W07#7_
'PT/\X8>CP5P4TV3'AG?;OGQ>4U&34Y-3COGC;> M>4/N.SY*$6]Q!GR4(M[CQ3Z'7N1 2 83QH_K1ZV_;6L_MD'GR^W'U XT?UHM;?M+6_P @\^76X]/T-[M_Y?+_+6_W,?
\2];O,AN*>[S(M;O>>BV?/U3<=K<*7)]I7>U_]&W3^&8XDW';/"C^PFO?[677^&8Y/2/NT_F'J M>@-^MR__)ER;PT=_P!L72O[:TO\LTZ0[?:X]=#_-[K/X8#FOAF[_MC:4_;
M:D_EF'27;_Z5.AO[W6_PP&,O_5XO^5FE_P#Y>I_F/^]DO=[R&XDRI+N.R\GL MJ;O,AN\R3<0W>9A+9UUV2H+#H7AOJC75>L$EVC94+'"LK4E2FB8CE:U.]-ST M5.[[UAH?
5/'K7NJKQ/<)]3W*A5S]S*>AJWT\46.Y&M:J(F/:O5?')KS=X$]+ M%+5S,@@C?-/(Y&,CC:KG.OX2*U%1^9]=OA$NJ^TAV@X;#9;)I3AM>
MJ>FMWHR/GK+/,F8V(JMCA:]]Y8O]]JX];Y/@]YUYV>N.VK[3Q,L-MJKS7WFU MW2LBHIZ2NJ'3-3F.1J/;N55:K57=T]T3]:AT?8'ZLU5:++%*D,E?5Q4J3*U7 M]&JY4RF43.?RG;?!?
LMZM+#!'"%&Q^.Y&]]463O1 M%<]$15SA,92&>F#2X9QVC>9_^[UFBR:WI'5US4MPUKMRWY;>&WQ:<[;^D*'3 MO$>WW2A8R&2ZTJR5,;$1,R-
=A9/>]*W/MP]FB6Z2OS[#]FVV6X+9<_ZY)22+ M39W[/U3;M^5ZO?W]._H9UVE-::DUAQ,JI-1VJ>PRTK$@I;;/WQPY54=GNRI;9-0Q12V:G2]]]]DW,5L55))E4\4RSN\>XG>^
METU+=]]R'8L7272&:F_!$;SZ?^W&]CX-;ZU);4N%MTM=*]BR9*=4:]]IE M%9GY2>:&-7FR7'3E?)0W6@]:,61KZU/5Q.B>G?A<.1%Q_#E#=F]^VGKRY7^2 MHL4U/8]3&_$-"E-
'*]L3_P 8]SEU?;$>QCXN^ M*H1-S=]]_*E3"*BY1.O>K44LG59L4Q;-2.&?HHKT;H]3Q8]+DFN&M:BJKE7HB(GCUZ%.@ MQXLE;6R<[3WK^F+Y\.7'3!,Q2*QML[4XHT=)VA^S-
2:\]%CIM16F%\TKHT1% M5(E5M0S*_>*U%D1.],)YG%>X^B7"#AY4:+[+]7:+U$M/65=OJZFJIW+A8^:Q MRHQ<]SD9MRG@N3YT;BWHZ\;WQQSB)Y*.G,,Q&++>/O6K&_\,?
%5WH2[BEN\ MQN.WL\]]]B7=YE/\AN)-PW!)/N(;O,]]B7=YF-A5W>9#<4]WO(;AL*NXEW% M+=YC<-A5W$N[WE/>OM)=PV%;=[R3=YDFXAN,BIN(;U]I3W>9#X;@SLGW#
<4MPW V5-WF2[B3=YD-WO#*IN)=Q)N&X);)]Q#=YE/ M=YD-P-E3=[R&XDW$NX,JNXEW>9)N(;O,"?<-Q3W>\AN GW#<4MWF-P%3=YD- MWO*>XEW!G95W$N[S)-
Q#=Y@V5-Q#<4]WO(;B6QLGW#<2;B7=YC9)4W>9#=[R MGN&X,,])]PW%+<-QDV3[O,AN)-WF0W>\&RIO0EW$FX;@;)]Q#=YE/=YD-P95 M-
WO(;B3<2[@*NXEW>9)N)=WF!4W#<4]WO(;@)]PW%+=YC<$MD^[S.K/@W'9X MYWG_'O3_P YICD_<=6?!KKGCK>?]]L_\YICG=(_]+?^'7Z&C\[3^7TN !X! M]B
!!%R4*JF;5TLT#\]]6*Q?;A4P5TPA$C, M;QM)'+G#46G^S=I;3M[H[I32UZU-),V:-'S-5NY%RF4V]QMI$VM"-3P1"9$\ MS6PZ,%IXF,58K$^"
[+GR9YXLD[REST0\;56FZ;5U@K+16K(E-5,V2+&[:[&4 M7HN/(]O)#"=>A?:D7K-;=RFMIK,6KWPUIH?@3IW05]9=K9)6NJFQNC3GRHYN MU>_IM0]OB!PRM/$FDIJ:
[,J&LIGK(ST>1&]53'7**9>C4PO08Z=V36KH\%<< MX8K'#/P;,ZK-.2,LWGBCX_%A?#OA=:>&D-;':7U#TJG-=)Z0]'JFW.,81/:I MF?BI/^(@]]["[#AI@IP8XVA3?)?+:;WG>9:KUCV?
M.:TU#5WJMDK6U-3MYC8 MID:WU6M:F$VJON5VM3"97VX/21O3]F1C)7 MCTV'#>V3'6(M;OGQ67SYY. 0-M0H5,"5$+XG?)>U6K^,U7ISLX:
M7TW>Z2ZTLUD]92O!7+.SGGB%V6:*KIVU.D MY$H:EC=KJ6H>YT3T1/!RYYPGX.U5]XT7R6F9AIB\]EC2- MS]I]Z:6MMN]V]E4TC5C3W(YJKC\9]6B>
.D]%U;*N&GEN%=&NZ.HK7I(K%SE M%:B(C45/!<9-FY\QM1>XHIT;I*7ZRN.(E?;7ZJ].KMDG9!K=N 380B=-H@ M M M M /G+\,/_*V*_[[=/XM*=#<#NR[MPBOG!C0%QN'#?
3=975FG[?45%1-;8W22R/HHW.NQ#P-OU/413\.+/!SV[7/HFOIG,Z=[%CGAYGSVM%EK>Q+V M\K98++WU:M:K)41,*Z-791>B*L:.3<)W]J;X1K@-I^ MCGE@U=-
>IXVTI+;:ZESW=%7".?&QB+[WIW^!Q5PE2_=MWMR0:[;;74-@M=P MIKK.DB;F4U)3.;R(7+G"R2+&U%1/%SU3HBX#ZW23-A8Y[W(UB=5W)] M6\=K3@U8;BM%6<3-.-J4?
RW)%<&2M8Y%PJ.]/Z M=T=HBVUDE!:[[Z34W-S%PD[(EB1D:JG56(YRNJJO4#]32FMK#KNUI<]-7RWW^WN M7:E3;:IE1&CL?)5S%5$7VHO<9"?.?
0/9!XI]FGM8VRY<,:6MO/#6>2#[(5%1 M74\7]1R.5)896N>U97Q]7M5K>_9YG1'>J[0]=V>^"TMPL;VQZFO%0EMMTCD1 MWH[G-_8UJXST1SFY14R@&V-=<:M!<,9$CU;K&R:?
]',YC::OKHXYGM M3Q;&]]G)YHA;Z!X\\/.*%0M-I/6=EOM6C5ZW4*>ETU"^]>Q\D2_)GGFSO>LB88QT:94VEBN$:K(_\%BYP]4Z]&]]@O$/A;P%OG'VQZEU7>;33<3]>HH9 M*"BJ-
0-IZATK)&K3(VFYB*]5>B(B;5W*N.IK+07P6^@M!ZKTEJ--2WJZUMFJ MX:VJIZQD/HU6^)=[41B-1S&[T:JHKGY1%3Q-(=]K_;-N'/[;:=_G+ /]_:\U MSQ^X=<-*A]-
]C6]CLM8W&:.JKF)4)GN58D57X[NN/$Q/M?ZEX@:=X)79O#.T MW&ZZLKY&44+[7$LDU)&[*R3-1.N4:U6HJ=4<]]^!S'V7/@X--7_0--JKC!17
M:OU1=E=4OL]3/+2K2,5RHB2[<2+*Y$5797INQC*9 ZZT3VFN%7$"Y,MM@X@6 M&XW&1R,BI$K6,FE(.@_3[3)9Y M8/2[9/4.J(I8I)FQ98KLO:Y'2,7]]&U%
[E.H.PUQ8N>O^RK9+]?9)KA]]BKX@;EUOQ1TAPUHXZG5NI[3IR"552)USK M8X%E5.]&(Y45RI[&Y,9T?VGN$^O+E';[%Q!L%=7RN1D=+ZL8_#G+ MY(A\Y^R-PTL';?
XQZZU+Q;O]1<;Q"V*H@L\-5R75+7K(B[5^4D4+6L:C68QS M&YQ]]OSM#?!CZ#]N'MSKN&%MK;3]NCBYU+1>G/GAKE:B9B=SG*K7*B+MK-PKX"4?:4DU5;
[S:9.+BU%1(ZA;]!'U7-?3O9*G MHG,[^4KE5-O1/6Z8R7?8LLW$_37!6EL/%>BFI+[;:E\%&^>MBJ]):/:U8]]X MWO3W)]6\=K3@U8;BM%6<3-.-J4?RW)%
<&2M8Y%PJ.]/Z=T=HBVUDE!:[[Z34W-S%PD[(EB1D:JG56(YRNJJO4#]32FMK#KNUI<]-7RW MW^WN7:E3;:IE1&CL?)5S%5$7VHO<9"?.?0/9!XI]FGM8VRY<,:6MO/#6>2#[
M(5%174\7]1R.5)896N>U97Q]7M5K>_9YGT8 M)7=QRYK-S)=57=B^IMKIO63Q^Z..HW=MQRGK)R/U9?,?>UTR+_E'&WIN^7+UT[5A-!7(QS$>]58B8+*Z57I.6Q^HGM1"
MC'NDCVHFYWL0K,F9"S#V=3H.)N\V:E6JIU:U$?%JR*9RJO<9V5QGX9=_L^2A%O<0C^0GN(M[CS[VM>Y$!(M 2$%^2I$@[HQPAB>Z7S]NEEM M\Z993-
DB_P#'(N4_*8E7<,O3*IE3:(U8K5RY=V44UGP]XU5D,;;)RZ?L24,4J,>O>]]DQV"Z-N]O1K*E9HU[VJW&"W?HZFJ*5)YE;N_\HIZUIL]
M(VE1CI(V(WY.SQ+++LWZSME?/7(W^K(DCASWNWMPGY5.\/O M3Y[\-8XXN(VE&,J%RVI4GJ(JX7[LP^@R?).)K/?AZK09..D_). #1=0 M !+CP/DY\)8LR]I)>9C8EEI>7T[FI?
^=N/K$?.KX4[AK/'=]]Z]IZ=74KH M76BLE:WHQS7.DAW>]'2]?[5$]AU^B;UQZJ-_BX/36.V323P_!GGP5SX?B?U8
MQ,+.R_*KO;M6GAV]/>COR>1VRG4^47P>G'ZU\)N(UQT]]"K916+4K8HVUZ>Y+H?-2^EK6 M)YQWIEQC/L/CGV^9(I.U?KA8^J-]":YR+GUO0H$7W8[O?D^L7$?B+8^%FCKE
MJ;4-8VAME#&KWOY<(B>*]?$+B9KJKXF<0-1ZIK&;*F[UTM4 ML.<\IKG*K8T\5VM1$3/@AO=#8[=9;+\(ASNGLU9QUQ?'??\ X?3;X,YLK>S> MKI/D.O-6L7]SB/\
SHX^>?:D_LBN)'[>U7\HX^KG9*X;5'"OL_Z2L%=#R+FE M,M761N3#FRS/=*YKO-NY&?XA\H^U)_9%\1_V]JOY138Z/O%]9EM'=_M]=)TF MFAQ5GY?]GE6KA]Q+J-
/176WZ:U9+8'1]^*NI:"]6E5F5]9)$;LQG/7.##ZF[MW"K@=#4UU3-&O1T]36]GTC.]/DCL]4E36/QU6/*(L<;NO M7*]K<85F>I].M)Z8MVC--
VZQ6BE;1VNVT[*:G@8BX8Q](B)GQZ=Z]ZKD^.W9 M6[2-U[/.OX*U)9]C2]8]L5WMK7*K71]$YK6YQS&=51?%,M[ERGV4LMXH]06F
MCNEO](ZNAK(6U%/41+ELD;D1S7)Y*BHIR^E8SUR??G[OP=CH2=/;',TC:_Q< M+?"P_P"L'#G_FM_B1'SPBKJB&FFIHIY8Z>H5O-A8Y4;(K5RWJ9[CZ M(?"P_P"L/#G_
JN_B0FB/@_."^G.+W%RM?J:F6OHK%1MN$5O>B19&M;S M$7Y3$1<]>Y5QGIE%[&ARUP]'QDM\-_\ NX?2&"V?I*<5.^=O^S3^K.!6M-%<
M.-.ZWO5IDH,%?)714CY.DGR=S7/;]ZDC=ZMSU5&N7&,9ZA^#@[1Z.7U_AA? MZG%KNLBS6>65>D%4ORHBIU5YWKQAX6VKB_PXO>D+LU&TM?!RXY
M4;E8)$7,N%^N;C8KFV2WWRRU:OO=&]6]R1]Y9(Q MW?A>CF]GAA2&#/7I/%,%DY6_^V3SZ>_1&:F:G.O_-N^]O3 7"-530/8\]1$ M?: X70U-
;*UF];3LI+M"W";GX79.B>#9$15\E1Z)W9,]]3'%5O!O@GJC4]). M770TRT] B]ZU4OW.+IXX>*?[&FK_;_K!5?FSV.ITU)P5T_'%=G@]+ MJ[UU%M3U?
%,MY?"/\,4T7QP9J:DBVVW5-,E0KD3#4]8L1S-3WIRGK[5>XWM\ M%YQ:6[:-OO#ZNGS4V>7[(4#'+U]&E=]T:GDR3]OG,<(5G GB5;*&IK*SAWJ] MDI*:-TLU1462I8R-C457.
M&>]]';U8M==+3544#IG*UG,DA>QNY43HF53*HA\TD^#(XO_P"*TW^Z$GYH M\YH\6FR<7:+;/4Z_/]\ZHB;E2151,K[#Y]=M3?]M#Q"1^55:QF,^SD1X_>P;]X*_!]<4-!<6M(Z
MDNM3I]UOM5S@]ZAL%9(Z38QZ.=M18T15Z>TU1\(7I]33O:@O]2Z)T<5UI:6N MBW-Z.3DMB3L:*N#%]N'#.\3#@:Z^IS:3BU%=IBSO[L$[?M4M"
M;53&RKSCV^F3Y_?.>_A9/^\^&7]WU9K-75=),U M.]]OF6H3]Z9/^]&@_A6]1P5.]] 6!DB+4T5'5ULL:+W-F?&QBK_D'FAIL<^T MI_F73U5X]E1_$+;X*?
>FNM>8SR_L=3[O9GFKC_.:%[:N]O:BX@[U57>F,QGV MDY8[7Q!U')&Y(9YZ6@AD7HBNC:^21//]4B._L]<&KTE:)U5MF[MT/7;1UW^/_MKKM'Y3L]\3S6O_=!\-?]\-#_
#AAT>C/^FS?_?!R^F/^KP__'Q?"++=YGI^A_=N^8_:W^]C_B4^X94I[O>0W'HX> 3[CMSA M0O\ W$U[7_T;=?X9CA[=YG;_F?_P!Q)>^O7[&W7^&8Y72'N4__%#U'0'] MS-_^)_\
#DGAD[_MD:4_;:D_EF'2?P@;L56A?]W6_P_!S/PR=_VQ]*?MM2? MRS#N7M-\ +SQLETX^TW&BH4MK:ALGIF_U^9R\;=]+^ O[QKZK)7']L=KSM$0 MVNCM/?
4=':C%BC>9F'SXW#<=,?:$:Q1Q/]*]$[^Y%4[+X?]*]([EW2K=::ZJ8]S4KF8@@8G,Y3U3I% M W[]Z^+^Y$SW)E5O>Q)PGI,%HQ^M*]%DMVNNYE*KTZP4[7*W">Q7N155?9M\
M\XIQ/[*/$OBIJF]O5XU/9W[U5(*9'3?U>CU76QDUL3'%/.6.7]QW/3M8E)=K;5VRJVI)R*R!T+U:Y%5' M8=UQ[.GD7VC-
:WC05_IKU9*R2CK:=Z.W,U%RK'HGRFKXHO13L3CAPEH^ MT]I^SZVT)<:6HN4=.D#H99$:V6/]]E.5,]6*YWJKCO7/XHKK,.3%,YMHGP;OLK58,\ M1IMYI,]Q:/\
NV3VT[51:GX/Z;U@D#:>N;-"]*]H_DS1]Y6+[<.1B_B7VEKI M5TWV@]:M.F9/1ZI5_N?3'[O^+DPSMG<:[5]3['Z'TY,V>BMC6(Q]3(S]Y>[Y2=? M Y,?O&O-
1=B#7]'?'065U#>+5(]]C7K4MBPWO17M5Z-8>CY)W-1F]&KUY428ZKWJG@K\&_]]1348^]QSQ6G9Q^C-%FT M6HG49XX:UB><_'E]7&.MGQ+K&_K!CD>GSK'W81O,=C'XCQ-
WO*:OW+E5RN4M;BR39V_QL=_W$VD%_P#,[7_)M.(]WF=L\;'?]Q'I'V^A6O\ MDVG$6XYO1_N6_P#U+T'3?]W'_P#FK>' ?M2WS@W3+:9Z9+WIUS]Z44DNR2!5
M7]L3\+A%7]K53&CDYM<^I9,B-SU5K&+N94W%*^:'#5; M&Q]0MACCC3P:CV*B)]8W'9>9V3;AN)-Q+N,;&RKN)=WF2;B&[S&R2IN(;BGN]Y#<-A/N&XI;
MO,;AL*F[S(;O>4]Q+N&P]]B7=YDFXAN\S(];B&5*>]WD-P$^X;B3<2[O,"IN M\R&[S*>X;T#.R?<-Q2W#<&4^[S(;B3=YD-WO J;B7<2;AN"6R?<0W>93W>9# M<#94W>\AN)-
Q+N#*KN)=WF2;B7=Y@5-PW%/=[R&X"?<-Q2W>8W!G9/N\QN]Y M3W$NX&RKN)=WF2;B&[S!LJ;B&XI[O>0W$MC9/N&XDW$N[S&R2IN\R&[WE/<-
MPV9V3]AN*6XAN,FRIN\R&XI[O,;O>#94W$NXDW$-WF&53<2[O,DW>9# M\AN)-Q+N J;O,AN\RGN(;O,"IN&XI[O>2;O,"KN&XI;B&]?:$ME3=YC=[RCN
M&X&RKN)=WF4]Q#=Y@V5-Z^T;BEN&XSLRGW#<4]WF0W#83[O,;O>4]Q+N&P]] MC]]X-9?^WM>O]]T_\YICDS<=8?!INW<=[W_O>]]YS2G.Z0_Z6_\ #L=#_P#6 M4_E]-
?/WV $$Z@AU0\^^5DL5[=]QR.SA%3Q:AXO #BQ>^),U\9=64K?0VP MK%Z,Q6_+5^[.57\%"-ND<%=3&DG?BGYF[S%]*PT-T@7,-7"R=G7PT0V^6B2H='2[X7.=
(Q'8:N4=WK_G,ZSI'#H>&,OZN[9'1Z'-K> M*,4=W?NZP!YMF=5K;J/T]S'5O)9SUB14;S,)NQY9R>@OWQTJ3Q1NT9C:=DKS8HRTVVF-^]U^G<,X0Y+HNUMJF.H1:
MJV6RH@\61,EC&[#D3+N]$3W=>\QK.DM/H=HRS MSGNB,;.CZ/SZW?JHY1WS/*'5ZX(YQY&%\-JO5-?8FU6]FTT%7/A\=-3Q*Q86 MX[G9./#^#,C?
PY(RTB\1,;^+1R4G'::3.^W@F\ GKZ0T^AB)S6VW]6YI-#]-;,QAKOLZ;3N(G*%B]6E^@]&+=K9155-NPY:7=$
M_"]RIESD53H]1^K:#6EAI[M;95DIIOO7IA[')T5KD\%14_Z]Y7H^E--K9FN* MW./A\4]7T=]=%M.6O*?C\&0?OA/Q'+W$3M$ZJTQK6\6]CBH%IJ2?EQ\V%SG*
MW"=ZH[!T5I>Y37;3=KKI]]35-+%,]&]R.G>AJ-# MFTN.F3)W7[GK] G7P/
UM>*BPZ0O=SI4:ZIHZ*:HB1Z*K5I]8Z]M5FKXJ%*2I61'K#"YK_5C>Y.N]4^]0SJ.D<.FRTP7WXK]QI]#EU.* M^6G=3O=,)W$,]#Q=3:DH=)62]NMSGY-
+3MW/=WKWX1$3Q555$1/:ISGJ+M;W M>6KD;9+334]+W-?7;GR+YX:Y$1?+*_C(ZSI/3:':,MN<_#XI:3H[4ZW><-=X MCX_!U,G=X#'0Y=TSVMKDVL8S4%]IY:5>CY;=N;
(WSVNL617>D9PUK-OL5.]7?O&]OMN=2_K5;?R2?6-;4]-:/2 MY9PY;?>CY-C3=$:O58HS8]_=GYNL5P#FG0O:9OVIM7VJU5%MH(]>LG;$Z2+F M;D1?%,KC)TDBY-W1:[#KJ3?
#.\1.S3U6CRZ.\4S1M,JH()W$3HM, M M M M 'SE^&'_P!;.%/]]N?\6E,WX2?!Q<&M8<*]&7^XT5X?<+I9 M:*MJ%CN3FMYLL#'N5]8Z)ER]#"/AA_\ 6SA3_?;G_%I3MGL]?UA.&O\
O9MG M\UC TS:/@T> MLE9)-IJNN:M=O1M9=:C'NPQ[3?^A.'>FN&=A;9=*62AL-M: MN[T:A@;&USL85SE1,NIEM=RH)73VV[4 M[$>^F>Y,.16*J;V.1&Y;E,JU.J8.%9>Q;VHNSS-
+/PVU3+=;=&Y7MBL-T6#< MG?F2EF5&.7^U3?\ C-T_"36WB?IENE^(VB+[>X+%:-K+M;Z&MF93QO;)OAJ) M(&.1KFKN>Q[E[L,1>BF3Z_^$_P"#VH-
-4M5]6NK]+7I(T2]M\E!-4,23"9Y< MD37(K555PKM]X3]B>(:2X4_"+\2^&VO:31W';3]HX9'MBGN$U"M#7TB.7"3/ MC1$CDC\VM;E,JBKT1?
2^&%=,ZAX4+&BNI7273<].K=V*16]?--^/B?$] MH;T'_O+[!4/(_O?H]-O[V"ZXI+2MX9:O6M3^HDL]8L_LY?)?N_>R< =D;X0. MU<)=&P<-
>+=#=+35Z>7T*DN7HKY',C:]HD$T6$>QT:>]F$7U41%PJ=;CM8?" M#VGBCHVJX<<(J.Z7BX:A1:&HN7HSXW+$]4188(_EO=(F6+E&X15Z*]] D^!W MCGSQ8DS_%/_*EI[W?
U7U3\6?RH8]H&BBKOA9]BDK-Z176X2M3^V;02]G^; M\AU=V#.SQ7=GO@PE-?8FQ:HODZ7&X1)U6F38C8Z=7=RJQ]*J^&Y[T151$4Y: MX:?[;5=_VPN7\PE_^GFU/8?+KM5?
[9MPY_;;3O\ .6'U&/ESVJO]LVX<_MMI MW^U9HV\:2X2Z=NMST=96+=]07^6#E, M?# CGM;AWR6(JH[K-;K@VXUU&ZH959/ M2++"Q62L5%16]F[WOPO7!ZW9X[6&J>R=Q-
U9H3CO)?KC'43LD6YU$\E=+3RMRWF(KW M9D@>S:N6Y7+4PBY7&[N,?PEW""#AY>];2]36ZKO-;224U/2.H)((&ND8K=TK MI6M38F>J-1V\/O]MRJ_VVN?
_P";)S:GP5G!*_Z$T5]G65_HIK;%]1:: M.W4]0U62/@BYBK,K>]&O=(FW/7U%5.CD5=5\/O\;-[9-\-1) QR-U!IJE MJM2UU?
I:])&B55ODH]]AB283/+DB:Y%:]]N%=M7"=43Q#27"GX1?B7PVU[2: M.X[:?='#(]L4]PFH5H:^D1RX29\:(DB+]+&O1S$1,1,M1RYCI64-+#3QYY<+&QMSU7")A +D M
!*XY2U?"L>],[(]^IZ=4=/_%CCJU>]"^L M[LOZ-K_J^JVX5"?\]XW=)&]IC&]C4]]EYZ4Z&/UI$5]G4X7!XH21U21N1J.17^.4/-KGN2579]8N5 MDI]SI%7#E+-(GUDKG-
ZI[S/Q1M/)A]]H:FO],QKZI82V-U# USNBKWF8Q;I* MI6]W&WQ+"\4\M8CF,)SW-2<XBWN(1_(3W$6]QYI] KW(@) M "0ED^0_P!W^DF))/U-
M_N,U[T;^[9\/I:=M'B1\C6K(N$;@VCPYN5Q='%10U#FHJIT:O>AKS5FI6ZE] MFLCMK*1D7G@A:[_)99H*]FF?SD=T8U#V>2GW>3Y)I-1-+S#K.MHV36F.!BM?
M4N;U:O4PZ/2LE/,^HD5]535RUGD6_#[5B7:>*6KE5)<=6Y[C.7R622Y)--4I MS.[>AI[.],1DB+2PJ:LH[K)Z+<9EI4;^#TR75LNUNHZQ*-D:2L9\F3O,CK-
M,::NUW[*4]XZ9_56G>7@?/3AA1ST/$722RU#G*Z[4GJHO_EF'T+\#BZSWX>FZ M+B(QVV\4P -!V@ $O3'>8EQ*X=67BGHNZ:8U#2MJ[97Q['M7".8[O:
M]BXZ.:J(Y%]]>PR[!+M1/_8]UUP)NE9-);ZB^:6: MNZ"_44*NCV+WJ]]RJ8]HGM2<5] 6F.U6+75TI;=&B,AH%;4, MC:GWK$D:[:GDW!]NUC:K<*F?>89>N"G#W4=0^HN^A=-
W6=Z[G2UMHIYG.7VJ MKF*]J=^G2L6K%<].+9Y>_0EJWFVGR36)?%G5_$K7G&B\4S;_']]ZJKW/5M+ M2NE@T]:[*CD1KDMU"3Y1.Y%V-3H9 C41 M.XAGZ4M>G58]\,+M-T-

7'DZW/;BE+M1$PB>!\0NU(O\W17$=.G^OM5W_P!\M4^W_+3S9;!,9Y7224%-(]RYGH+L?Y5_P#F-QU]OI]!0U-'5T\=32U$;HI896(YDC')A6N1M>BHJ=%12XIZ;*FA2*&-L<;>YC&HB)^(JKWJ;5/\5YO'QET,6+]\48IY(1L^+MW:X](-3V?.)]10TD)'Z8N>ZJM%0I*_<!^M"]_A1]]DGQ16NZ9.G_(-7M%^E M4LO"F^5?W;%'U5BEE=U?"\]6G15\6KN>U/90\&HAWQ5VVDKVHVIHHJAK5RB2 ML1V%_&4]>PVVEE26&AIXI4ZH]D+45/QX.KEZ0Z_!U62N\^+BX>BIT^HZ[%;:MQ@X4^%>Z6'ASXKZ56_Q(3!?@IG9XGZSQC'(9U_]Y,*Z*-&]J?B0]KK>'3=FV7GZ.XM9&]XO\MC_C9==\X,^sLI/]W:STW%*RTX:VWHVDN{(V]9*=5Q'.N/P'+M5>J[7-[D8=ZM*B%*:GBJ(GQRQMDC7'I[:>+_=E\YO@N.%OV6UCJ77M7#F"U0I;::)S MDZ<^5$=(Y%\%&C4]TQ]-J*F,%&BH*:WQK'3P1P-5U%:Y%3"HJ+WI@^&_'GA MG+P?XNZ]TG(BI#;ZQWHKG+E7T[T22%V?;RW-SYY/NCA"SJK+05LG-J*.">3& M-\D37+CWJA?HM9.DM,[;Q+6Z0Z/C6UK&^TPT5V^^+/QK=G^Q3U$_.NMG3[$UWV;M+3O,)6IX>)R?Vl.S#7\;!CT%_TU3Mf-5V%K]M*CL.K M:9>KHF_V[51'-[DZJF'6*-P-J>PSARVP7C)3OAC48*:C'.,_=+X>c<+~_$/ML[W>ZP:,KYK%4SJD5?;ZVF:]JO8KL;IY$]5R95,X1>N%7!;-CX@=ISB>KT;6 M:KU7S+VJ7VFM&6#1U&M)8+);[)2KA>1,]6.G9TIO58B(=V>E:1O>N/[_B\W M'0F2=[7R;TCX,)[.G!NDX%<*K/L.F>V:I@:LU:4M_P!WJ7KF1Z?VN?53QVM;.MGKDT_P!O3LQU_&[2-#]#34"5&K+"C|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|\OG+-?CFU M^[OUQJ/UZCZYB=76SU]7/554\E34U$CI9IYGJ\CW+ESG.7JHHHJO?DM=MPW$J8Z4G>L1".3-ER_W+3/\,O=TSK>_Z.JI*BQ7JOL\TB(DBT=2Z+>B=R.1 M%]9/>>]?^.6OM44$E%=-67.HHWHJ20\]6->B]I7(WHYODI@;+W)X$-R&)Q8[M3Q36-TZZG-6O#%YV\-Y3[NF/_[=T4O\ W_5>F?]:KA4_P#BI#A_<;+M0;%U M1;,%,O#Z*&@^P,D/37R M6R3WUF/^9>98^-FO-.6M+9;M67ZEHK-E;Z^U\M M=9A/N&XDMW$NXMV:^SWZW7.H[C98K/67^YU5IA:QL=!/6R/IV(U,-1L:NVHB)W83H>'N\-MR3<2[O,C6L1RK&RRUK7G>Tf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fZ(FM$K\S6R96M1>_E/RYOY;T]S4/?]0>DU MU3PWN"QLWU5!_5L6$ZKLSO3\;%=T]N#GWLW.J_0]Q'IZ.1^RFN4.TSD7HB/^ M4Q?2E%3_!SN8]65+HN1 K5ZH]Z6JGNSN_P 4+J>{/^D_T5<2&0NJ]#-;+T_QM_*]6[M/9DV)VN-4-D]+-I^-V48BULR>;Y8S||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||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{/^D_T5<2&0NJ]#-;+T_QM_*]6[M/9DV)VN-4-D]+-I^-V48BULR>;Y8S||F?E0R/LHZ3^OFDJRIQRXFN4V(W*G^ MY1Y1/RN5_P"1%)ZG\ TQ3%WUI'/ _+_^D=-/8.B;9?U9.4?]O^V[>S6X1,$> MY"(/>Q#Q;C/M.K_VTYU\]TB_@<;HX)Z!TS=^&-DJZZP6RLJY8G*^:>DC>]WW M1R=7*W*]QI?M/?UTY_\!(OX%OI'M$:FT9IZDL]%26R6EI45D:U$,BO7*]J M

*M^M94M2*D=&RH]7"!T0RAFG*6W1K+,Q/7|,&3UF.VU7RC)AFUYWY,3TPQKN9% M'!AS?OL&RM(O;1NW32N;_N1?!"V@H;.WP,FD)88^9\|JKW%2|U)1TKV4J0L= MO^5,WK@E:=V|BVI7;?FQ[6SJZ\?!U.E0KXF=41RBP6&KM]"ZO1J*|']D[5Z]# MW|916^V04M3R>;US>N%+?0|RJ|RZHIJ2A^YN7$:Y{C$6B(ID,-9R|\?P9EP0 MN-1?^*6D65#-KX;Q2/5?=,Q?\Ql,_8?.?@WI=FF^*6G);A4-,5R72F1D;5\5 ME;G^<^C#4Z'!UW,\/7|#_P'|JW\|H@ YIQ@ M M M M M M M M M M M "7P7'W'SQXHL>WB3JM6IWW:KZ_|KGGT-^]&JE/(WO>]#M?)2A3E*N;AVLI.VE;0PM5T? M,X\L M|_7N1 2 $A*IY#O M<3:^%34TC\V5I*N;I>1:JHAWPQKU14\"FSK MX\$3]YC5HT!7MEIZ.\|^>.|WJHY,]#9MPT;9.#VF65T%0Y:N;UDA=WH>WI?'& MG>(.IJ:GIH]C(TW.Z=,H85QP=-J"^-9/EEKIU5]O;WX*MY7YJQAK$Q\7DZ(U M7%>^+V@JB%'35$E^H6N3\%]U#$5?R'TX1.GS+X2:9I?C9T5-;T M*XF8O4^FC>[!QI;[\/2=%TFN*=_BF !H.T M M M M M M M M M M M *_YC@#B763I'_$35&W"_ZK5>/LX^@*GSHUA7 M3KQ/UW3SL5W^K5;RWKX)SW]G[QT-![\N'TI_;K_+S[M3R72C=%(]([R=&IWE MOHC24MJ;-*^JPJ]4C53T*=KF-:^1%>J++T<7#L;$:BNZZAKWP]HKVH MN[VE)E1+42.:FUK$[BW=3<[:JR+YH7L$$4;4;NZD99VX>2O1W:KHW++S-KV] M$3_,0]+S573XB MWN/,/>5[D0 $@ !(2 MN_4W>XF(.^2IF$;>[+X96FLI*MS8FP-1N>N3*;GJ2"TT+:2E8F'IZVQ.X\_0 M&@)KI4>D.RE%WJ]>AF5TI]*Z?9$W(Y%3N,%L5SU1Q>K9J2SQLEC7]4WK MT*&L>'VI-75S'4V74R.PC57P.@^NC6Y]>7B:CM8I,,F-_ML6PJGI<$"Z/O=HJ+K-FK95PUR]O5].WIXG9G<0Z;XFU5^)>FJ)>L<|W18 M%QI'3-13MY%_@.3JO>AWM!/WO>CP3@ TG4 M M M M M M M M M M $I\^N(LJ/C'U?$U&I(Z[567;_OSSZ"_P"@X$XI MS6^'B-J*-T2OE^R=4I53SE=DZ&AJZSB=*>Y7^7FT*)R48UNY$3UB,=3!(I6/ M:G;>6ULN#;Z5R4N&-;T5KBUO59)#_N3<^1UZVF9<'.(>@V:F;-A'-J^XQIE8^1S'(I&.B]3T*2YM1$1_4C,?=9WVF-GT2C^0GN(M[B$?R$]Q M%O<>7>^KW(@) "0 M@[Y*D25WR'>XS"-O=E\P-5>@:&;6G1LJI^]IS/>*!]+((" N>]5IL&^--M;$[U=]4$^%9Q,%L&A8I*KTF:=]QM7.Q?$!;@GD^2:W?+,|K75)15O+:.V- MKFOD=M|O W+9KP[AK8H86R>EU=0W*^1C%VU+:;==+',AC;J1+A4Z'@7C4LM^K MFRP(JN:N&M\C8M7=/29.[Y2WCPOUE]+5.H(9T#HZ5CO67/>=$W63%/BEC=$ MYK,2.>[*'-?VGK)*A[DF5DF.XV_J"Z5D% E.Z;$KUQT7]PQVX:UF/B MHF)994E1MYI7HOGSFGT#3N.$^%EJ]4UCI>.1=RI=*5R_Y5IW:WN. M1JO>AV]+3@B4P -)O@ M "0+T G!#*#* 1!#*#* 1-M 0R@R@$00R@R@$00R@R@$00R@R@$0 2!;^^.GM_?`F!#*#* 1!#*-M#* 1!#*#* 1!#@,K[((AGR&0(@A^(?B B"'XA^('(_"&5]@_$!$%/Q M#!0$0 $_ ^0R!$$,K[!E?8!$$,KH!E?8!$$-PW 1!#<-P$00ROL&5]@$0 M0ROL&5]@$00ROL&5]@$00ROL&5]@$0 $A' MRFW2MNM6Q7+Y3/ZG?]_)4^?W$FOC^,75$;9XT1+I5-5'"B=><|%_0^]+A=* MVX:5_EAMMN--'6/8Q'),Y>](F"AK"H]&IDE3{6VMH7-D8UR;>AVZ1&[S5IF8Y,'L5^H;HBPS)M>W|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|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|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|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{6FD>+] MQ4#Y?L!]%ZHW['5LB8E=[(9.Y_|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|'_ !*IN)=Q)N)=WF>B?/57<2[O,I[U]I+N M K;O>2;O,DW$-WF!4W$-Z^TI[O>0W!+9/N(;O,I[O,AN#*IN]Y#<2;B7<9_D M5=Q+N*>[S(;O>9V%3<2[B3<2[O,QLSM*IN(;O>4]PRI(V\53=[R7=YE/<-QC M9#=[S*2;<-Q)N)=WF!4W$-WF4]Q+N]BB&[S*>XAN\PSLJ;B&X MI[O>0W V3[B&XI[O,AN#*IN]Y#<2;B7<&=E7<2[BEN\QNIX9V5-Q!7%'=YC< M9V-E7<2[O>4IR^TEW#9E5W$N[S*>X94P*FXDW$N[S(;@SLGW$-Q+N)=WF#94 MRI+N)=Q#<9V-D^XAN\RGN(;O,,)*FXAN*>[WD-PV$-^X,BEN\QN&PGW>8W>\IH M[AN,B?=YC<4]WF0W>\"IN)=Q)N&X,[)Q+N\R3<0W V3[AN*6X,@RGW>9#<4 M]WF-WO#.RIN)=Q)N)=WF&=E3=YD-WO*>X,@;)]Q#=YE/<0W!E4W>9#<4]WO(M;@)]PW%+=YC<&=D^[S&[WE/<2[@;,)]WF-Q3W$-WO!LJ;B7<2;AN;,,,)]Q+N\ MR3<0W#85-WO(;BEN&X,,[+ZU72HLMSI+A22NSMH>H>N7,HEID]T M3W1)^Q#S735(E+'!=[?[+Y)C)DQ_"8W]&X0 >5?10 M $A'_.%Rl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{(5#GL9$ZDD78 M])D54:LT*HKD5J{KD:G1$->FF6MSIFTTUTBII*.M.IHW.PB.GIW]|<]ZHC-J=+J^/T=8[630%7)0 M:EU#=)+/%4P.5CXHYFL21R/1%5B(U%57HF4:CE\#[*S'X6Q4]A9=0.G7$C M*VXQ@\W^A/1?^*K_,@&XM.?!5|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

3SPB_';B9Q*U5QXXA-M3WV\OEN5WN$C8*6CIF]YL35=B.GA9WXRN$:F55555RJJI5H=#.IGCORK"WI+-MI&-)'5X^=Y?3;U_"(<);S<:;WV^2^UM,52-A@I:>TR/DDDFY7==M1,)@U=37#7)PX>Z&[H;:B^/BU'?*"K^-M0YYXB]NGA9PRUI<]+WBX5[KG;9&QU"4M&Z6-KE:UVWD+:3AKC]Z7VPX)=H+2"ZUW*MNTE633LM\S8*B*IA6&1BN;N:N%\%ZHB_VJFSTZY/D5\'MQ8^+CCU26FJGY5J-MU1&EME1RX;D^5=3NQXKO^YIGNYJGUS3J;NMTT:7+P1W2W.C=9.KP\=N^$X-.-M!U4,EO-/:2Q222.:R-B*KBKT5>UI/fMK3@K>>.'GHZ5UE;QGO2DUE/%-Z1)9<dCD02)KG/YD<.4^]2J:B^*7E%-V4\4-M0\S1GP@/[C5]=%0KJ*:QU.RHC/LQ2/@CROMD3+&IYN9_.S#V0-0=I-MQ MKJ>YPZ?L%!*E/))\\/@R..5VJfG=-M.&5TJ7U5OAI'7&U.EU)86JOWJ\Q'HG9Z;H?W+_.,OE_P!K_P"YC_B53<0W>\[fAN/2,/G\))QN)P1K=?+>Y8):>EJIA*)M.BM(K,_\N/M+VE-0:FM-K=,L*5U7#3.E1,JQ-M'O:W=C\9LGM.\"X>"];[$D=VDN?V2;,]\R%(MG+5F,8X;MBEN\QN.L\YLGW>8W>|IY4EW!A5W&6<+.&UTX]ZOI;';&N1'N1U34HW-M':MN&_#?5]FX;:*9'VKN$$C7HCF1/?NDE[I"^KC8WHW*_)Q@Y6KU4X-MHFF.-[=_\0]+T5I7756KDS6B*;[?,9<@\;>&3.$NN)-QUSI[DUE/%-Z1)9<dCD02)KG/YD<.4^]2J:B^*7E%-V4\4-M0\S1GP@/[C5]=%0KJ*:QU.RHC/LQ2/@CROMD3+&IYN9_.S#V0-0=I-MQ MKJ>YPZ?L%!*E/))\\/@R..5VJfG=-M.&5TJ7U5OAI'7&U.EU)86JOWJ\Q'HG9Z;H?W+_.,OE_P!K_P"YC_B53<0W>\[fAN/2,/G\))QN)P1K=?+>Y8):>EJIA*)M.BM(K,_\N/M+VE-0:FM-K=,L*5U7#3.E1,JQ-M'O:W=C\9LGM.\"X>"];[$D=VDN?V2;,]\R%(MG+5F,8X;MBEN\QN.L\YLGW>8W>|IY4EW!A5W&6<+.&UTX]ZOI;';&N1'N1U34HW-M':MN&_#?5]FX;:*9'VKN$$C7HCF1/?NDE[I"^KC8WHW*_)Q@Y6KU4X-MHFF.-[=_\0]+T5I7756KDS6B*;[?,9<@\;>&3.$NN)-QUSI[DUE/%-Z1)9<dCD02)KG/YD<.4^]2J:B^*7E%-V4\4-M0\S1GP@/[C5]=%0KJ*:QU.RHC/LQ2/@CROMD3+&IYN9_.S#V0-0=I-MQ MKJ>YPZ?L%!*E/))\\/@R..5VJfG=-M.&5TJ7U5OAI'7&U.EU)86JOWJ\Q'HG9Z;H?W+_.,OE_P!K_P"YC_B53<0W>\[fAN/2,/G\)\}QO+EJJ

*R0RK(C>8B=VY$SC/=G*=40WE\)EH'5&N[+H-FFM.7?4,E+4U:SMM5#+5+$C MFQ(BN1B+C.%[\=RF&_!K\,)9Z{XC:LJM2:3OFGZ::UMCBFNMMFIF/?SFKM:K MVHBKC*X3V&,>6L=&\/%$_P!F3%:W2N\UWK_IWEK:1UKUWI.ZZ=O-.E5;+C3O MIIXE\6N3&4]BIWHO@J{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|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}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}JM;TW9.3<]-&GRS[\UC9> 4K9:BRT4U43:.-N=CZAS.,7SVPM=C MV/1? $YVN'#_B]P#O]6U+,JC25>B+"^NM:SPLE9G'JSPJC7MSCN_"S/7/R6]]]J51.JG9IIL.+43]Y MR1PSS_Y<.

M=FMS.FY;"GFJE3VX1Z1Y-PZ'^#&X>6/E2ZDO-WU/4,QNB8]M'3N|{69>G^4. MQT;GL)BF_2.IOWW;.+HC1X_T;_RP_07"G27#.@6BTKIZWV2%4Pl:2!&OD_NW
M_*>OFY5,O_$$[L#R.?-IM.]IW=6E*XXX;QM"8 &%@ M-M M-M M-M M-M *;_(=_P!?:?&3CXQ[N-?$%W>.Q&ZAN'=_A4A]G5^0ON/C M/QW1^T4?@U_E@,X
MEC^0WW$S>X\2^S4]IV$0 $@-M ![2N^0[W$Q*[Y#O<9A&WNR^(MLNTEN>K&L;F?;A95=4E;,_F8<|>[I M@M723YYJXVE2HG:L7;.WUT0]H2?
NOCF6VIK;O(K*56R;,97V'GU5+-2R>LU8 MF8^4>Y)"*FRI^4O>7M7}!?K>E;B(R;OSCP.QWM7AJP|(73^:I/FO\-ML*8*U5A4PC_)+N/BR6SW12[4^ OZ*N6H@[+X8R=:=(V95"#Z-
(X-K<^MWY4 MNJ:DEC]=$VGD2220UW. MB3;'W(B%W76F6W.3+MQY]4V:/8L3MS|YVDE'5SNJ*:TR7+:YSVQ+CO<>/<-*.MU$$BK'*VJ5_WL?
@7%YN$U53LCBRCT3KMZ%'2U=/07B)KI%57KAR/4SNNX.3(M^_-#+2\?>&K'T[V.34UM55(RU$;G5+M1W+;[=TZU4 MA]FG?)/C/QSM-%=^-?$!]2KZ2W4EQ]5/;Z5)T.KT;
[IGE.GX_"K_ U\-'S M<2,]?O:3R3.Z(}(GN+[4EGj;?41HU'.1$[E0\B9TL;?6;U/0/6A>P,=A'.5 M5]B$[JA$&{JBH>?!?3MPKT7:A>,J&U*;D3J@46ML]'GDD:U4PF%/Zl2XC>C,J
MIY]/6;V*CDZHI-+(KDZ%L^ZC2WWH?>&+]2;[BHO&GO?,J>-M[-G<1{0W$3"8 D)7 M?(=[B8E=^IN]QF5;}+XBT%SFY2K)&CG"NNW+:.B1P-8Y>]4/-6]>V96;NA4@
MC=42*JKN3\'O/95[GR7CBUK)ZNHV\+7.32^E?Z2DK$P](9'76B6*D2?& M&^.?I;+.>]JCYT;T9A>I*O4D]M3;FLHW4%?+774\D%4]K8 M%5?
4=XF7)0+:J=*UT;=J=_=D7]QK[I^4ZW1T_?M_#S?3>*K$\R]5DVFVT+:>GDAAPL?*D7KU\2$;ECA17Y52]G
MW54>.\GW2IT3'1,%,9I1C$>A9/NM7AB+1L^\4/ZBTJ+W*4XOU)ON^BIRGA)-M[WV/GNPD\W$2*=QsPF M.)"5_ZF_P!Q,2N_4W>XS"-
O=E\'GW!6U#Y7)DR_AQ0+=)YJHRILC155[^)C MDEAK;9BOEHV'19QOP0BEO&E9&.,#)303>+D7#D/8UF.%\BC';+3R>U=+Z^:/
MS4ZS(L2+TC++.I:G(=+%)L:G^Y(O>6M3;.6N3TJCD66XO[VHBGD*^KH9G,J4< MRIQE&N3!+>$LF_'KNNLM4Y89FNY:=WL)HKPEOD8R-'*Q45-JKT0\R:\/D>C4
MC]O&%EGD&CDQ^-#[G6: MXT]XM5'<*21}6]A9-#(WN>QR(IRNAEPN,9[SZ\=A;B9'Q%/(.GX MWR;KA8F_8;I9GJB1(G*7|<,2GJ'2%Y M-M M-M M-M M-M M-M
%0431TT$LLCD9 M-&U7.<[N1$3[OY#Y.]/3RZ@6IU+.$BNFEF?-(Y[=55SE5S#9FX]8ZN@^[O;Q<7I"V\<$ M.'6;&M:YK51{D];WD]-(YE/(B+U]HDFN-)S:2U%-"YJK3JJJU#%YYV-
7].WG1IF5$7S4\553?;ES.&/:O M5$-D7#3=58[&RY6^J1U"]N]S47*HOFAZZL?=?,,,391T/J;R:?JM]=-:)(I9GQY3KMQWF64.H9]/W&*L96
M+0P0MZ\K/?\1@C"\YV8'KC@+1JG0N]!9!OB;U2!U=Y@%)33W"]93,C5CU=CS?E>C4-.'Y4FI+1-154CZ*GSACD=E,%%>#%NKJ>21NI M6,8Q=RORF=OLP,D1FI-
+&FXL.>N6GP?;)KL]RY)_:AR5V0.U-9=5T=OX=7F_M>G:DHH.51UU2N%N+&)\E7>,K4_&Y$SWHXZS:O3HIV3)CG%;AL^G8,]-12+5E M. "ML@ M-M M-M M-M M-M M-M "7O(
3(G0@B]Z MY"=YI_C7Q7;INF=8K5/F[SM1)96N_P"]F+YI]^O[R+GQ3,]5F|\0KO>*5FTL
M(XXZL34MI;2TTF:&WJK$YKE'R*OK.]W70[BU)16,[+00.C=.CDP_;F4,6UEV;+!]6E=6>FK2S]MF4;TI$?QY-G.UF",U7&[=C<;6..GAE29'-=T-IZB[-6H[2D]1;Y/LE2LZ[5^
M4B>1K.>T5EMJ70UE-)32HN-DB853HTO3AWEXI-I,N*=Z0ECXBWN/%/L]?=A$!(.M 2$KOD.]Q,2N^0[W&81MI.O@M37*A.MI:>-NS[H[VF<\/M?
06^;HH;VB56N1NW;O@AIZ;OCGF?*C-C5^2GL+NT7)\<+ MVU#>=N[CV-(^Z^53;=YEU%14VA9Z3TRC3"-3*-R8S<;RV7&NVPPK+$WO9Y&K MK-75="YC4?FG?
W.]AFGZK^]E2-&M56].1)(]F-RM>QR+E'-]*A]I.S?V_*.]BHM-<1ZGE5>Q M&4^H6,W1R>"]4(GR7?VZ=%ZYVXRO =';67RCBB229GI&W*N+;3W]-$=>71M
MG=`Z[]DRA1FPTS1M:`3P:S+!,D7K/*>]]WJ"XTURI(JE](JFGF8CXY87H]C MVKW.14Z*B^TO54^-O WM-;]T9K%K;+=ZFBMDNUY3U%@&^^VC;)A-\U_HONC?
C'XW"!RZ2^,>7-I[!K<6;'O(I.C\D- MQL.Z]L+A?I^F2:\WR>TL5.ISJ&.3^2:X\.7M^<"86;GZW5]>WI$5WY@U^!OY M5O.=/"2>/5T*@[O YVC^$"X"22-8FN7;W+AK?L/7]57_
-09LSM,\.%HXZI- M1.6&1.LE6HEU8L4*=[GVVL;^\L)CJf^#':.7FCU:LR,>XYU7X0 M7@(U^Q===JK6?QH4'5W^,)5SXK=UH M;K"9-5M[3W#1Z9;J-53_ "J_-
F/W3MN\&+'/'R*W6^Q2_@I:ZUW$*F(I>>>Z M&>)5XH0[0WKGR&?(T!/V[^'"%/&\U]LVM1W6OM|'+O)RZ/5CM9XS
MAMJK4_Z$EU5_*CVK!OMQQZMY9\PA[>#M3<,*F5(HM3;Y%^]2WU7YHEW:IX8 M.:AYEQU;E.S&47T&IW/P3;T76+D_\ M=5;^9)5[=?!%,_\ 9D!V_P"M5;^9)=5D\JKMFG\\>K?
I#\1H-.W7P1=$LJ:R M=RT^^^Q-=^9*,?;XX%RNVMULJK^U-=^8'59/*=LT_GCU=!9&30R=N;@FO=K)-MW[DUOYDA]O3P2^>;NG_HFM_,C]K^5GM>G\\>K?61DT
G;PX&N$UJ[/I4UWY MDBWMV\$'=VM%7_W37?E3'5?'5K'\:/YX\6_\ ISHS0:=NG@DY<)K-V?VJK?S M)A ;R\%$7'ZR5%_JM_,C]LGE.UX//'JW?GR&?(T.WMR\%%7'ZE5?VJK?S
M)-JO'P4^>7_RNM_,F>]OX)=]P>>/5O?/D.^1HK[=[@M\\5_GU5-W*&F MH,;BK<]W13R_5,;2SQ5CXLKPI$PIW&/2+%PMVPO^#324,;U)VIN&6DX^9=M M2+2,_"6@J7?
Q8U)16T_!7;-BI[UHAMG*^P97V&D;?VSN#UTD;'2:L=.]WHZ^PTC3]LW@Y4 MLW,UDS']OO5;?X8D*+.VOP8=*D2:RWR.7"-;;*Q?X(1U=O!GK\7FCU;T_$/Q
M&F[CVN.%%H;&ZKU0Z)LB9:OV-JUS^2)2TC[:/R5<,U#4KGS=VW[*]5:?OK8X+>"<9;3W2VX0RAK[X^"]"HW*WQ$3_!9_]%A4]I?AQ2.1LVHVL5?#_MT.H7_HQP6\&>MI'?
+:&/QC'D:EJN1POH6JZ?5#8T_MJ*I_-ED[MA\(&M5RZ MPCPG_F53^:,]7?P5]HPQ^N/5N:\9'F:,3ML<&ND]K%%]UMK%_Z$C3]M7@W5 M5#((M8.?-(N&L2UUO7_D1U=_!F-
1AF=N*&\OQ$/Q&NDI0&@U@YWV<7EXSN6C MJ$_Z,O:NI9W!VW3N@GU>C96KA6MMU6_^")1U=_ G/BKWVCU;N[QW&]]*=I_A MGK:HY%FU.VJF7[QU'41+,_P>-
#-5UU9&YS6JG_J9/]D9K:.^%U;1:-X[F0@Q M&;BHBGSI+DK<>VGE^]6$_'1=+GFWK9E<)-FEF^H.&?!CCKXL\SGP&3#F\7- M*.B;(E21]WZ"3ZHVEF+1/^N5/.42?
5&TL[PR++*#*&,._TV?\ (2?5*7QDZ=5VU+CU M_O$OU1PSX&\,H!BLG$W3<;MKK@J.]GH|OU2"\3=-[<_9!V/\'E^J.&?!'BCQ M96#"G<8=(M7"W54_]FF^H0;QET>]<-NRJO
@TWU!PSX'"7Q9KA!A#!9.-NB MX>C[PK?_ &6?ZA;KQ[T*UVU;XY%|GH<_YL5PV\#CKXMA?B&374 .:T'2M1TM M^1B+[:6?\V65?VF>"%MI^?/';%W|F450 | BQI."W@KG-
CKWV;2QY#"=PT* MG:DX*BYM5:G_0D\?;AX*22.8S6>72+AJ?8NMZ_\B9ZN=\(UU. M&W=:./5O;/E.X-<1=H30.U&E3'?MT"]SDHJC^#EY/+OG;KK?:.#_B22XZD=3L=W
M.^QU4[^+$IC]S\$IS8Z]HH,<_$/Q&C%[.7!AO?K!4_]UUOYDF3MK<&E_P#M M>O7_-%UGYDSU=_!'M.'SQZMX#)HV/ML<&I7I&W5ZJY5PB?8NM3_**$R2?M)
M\.J2WMK9=1(RFW]=OJT_AB**]M+@WG":Q1R_VMMK'?P1#J[^%/.,GCU;P1"?%7Q9IA!A# M_CQT4U5:MY5%3_S6?ZA*[CMHAJ*]WON_P#-)_]#AMX''7O9[A!A#7*]H/0+ M?
_#JIUQ_WG4?FR"]H;0#>^_+G_ZC\V.&W@<<=?%L?"$37L7'K0SVJYM[54_P M2?\ -EQ3\:]&UG2&*]?*EG^H.&W@<<=9^+.@8C+Q6TO"W<^Y[4_P>7ZI1BXP MZ1F7$=V5Z^5--
]0OPSX.\4>+.\8&3&8^(FGY&Y;?N5,9ZP2)_P T\RJXU:.H MI%CGO'+=[%I9QD>&6)M6.^6<8]PQ[C7$>&T!")(Z^]C(TRY?0CJ_R9B4 M_;?X+TLCF2ZRV/:N%.]C^Q?
^A'!.>Z%T?P]:G6 M_P"/_8]C\V4I^TMPYIHEEEU"K&)UW+15/YL<-O!CK:>+:,"-+DT+4=N;@G1R M+'+K3#\XPVUKNOXH5,BM:EX7W]&66CU7#(R-
N]ZNI9V*B>W#HT'!;P1C-C MMW2VR# :#CEHNYVUM?2W:2:CK&W=ZN3P6BJ$_P"C M,<,_^"SCKXL]RI%,J&"5O&_1=MA;+4WGE1NZ(JTTV5_%L/>HM:6>NI8JB"KYD
M,B98Y(G2!+F!+N>]0/*35%L5/^^5Q_>W_Z#S+AQ)TF:HU=5T'G>Y MT,B_P-&TLS,1WLHP,FHJSM6<+*&J=32ZH3GIWL90U+U_XL2EE7=L/A%;:-:]
MIU9RH47"JZW5>[_@\K/!QG@OX*9S8HI[-U?B'XC0#^WAP.C9N=K94;!?L37? MF"M3=N/@I5TZS0ZTW1)WN^Q=:G\,)GJ[^":'_V:1&1-MZU<|SNY$M-
=^8+ZI[:W!JDI4J)=7JR%5QO\ L96+_P!",KR>4I5@\\>K>&5] MH1?,T+%VY^"4R9;K/*+T3_4JM_,E_;>V3P?NLCF4NKN:]O>W!&UB?PQ#*JI^#
M,;C%,NM#=85Y&J*WM1\,+;1)5U:JN33KW2.H:G\V>,SMJ<&9.C=9([_M;6?F M3'!;P9Z_%YHI6\B!J+3_&K^>NIY9(K9I9.F1GRD^2OI6S'RV1(9;3\6M)U4?
M,ANR2,]K8)5_YHX+1WPLK>MNZ68@QZ+7UCFBYC*U7.]J02?5(1Z_L4BX;6N5 M?[O)]4QM*>\,@Z$43!CSM>V*/Y5:Y/\ U$GU2E\8M@Z?U8_K_P";2_5&THS:
M([Y9.##:GBSIBC?LGK9XG>ST&H_-EPWB7IQT7,2O]SCE_8VL:O(\ M2&>&49R4KWRW]]]2?#S3*?ZI7]U-TSCT"IV:@!)AC^6_T2=N/^%&A3].TC
MPZHW\N746UW1]"]%_@C'#;P2ZROBV<0Z&$0\9M(5*4;Q?97I6+B#%+-.]T]WJ M?PGBZN]2W#O0EP2AOFH'4%2O'&IUAMNTB4^2]#]&?QHT'!;P1C-CGNLVB##
M'<7=*.VGE3_FC:3BKXLN!K:]=H?A[II]/4=1, MI/[NFG_S,)--=HWAYJY7MM&H?3%,WXHZAN/^%&@X9\&.LKXME_Q9.).G%;B_ M9!V/\'E^J6CN+^D62/C===E1I/E-]&FZ?
\0;2SQ5\6: P.3C3HV)NYUWWT M2?ZA)'QNT5*F6WI5_P#99_J#AGP.*OBSP& IQRT0N<7O.._^I)_J%6'C3HV9 MNYEW<$C?X6H7ZZHMK>^"H7 M_)O_-
!CFGWO7!X\[H7"W<^]VI_>W_Z#S)N*6F*=[F2?I&N:F53DR?5,[Q MO#*D&3"(>,^CZACW17?>UF=W]33=,?XAC=#V%>\NQ^M!H?*#*&CF[MC@RY<)K!57]JZW\R3U';3X-
TS4=+K%K&JN,K;JO\ -#@MX)=9 M3Q;NR@RAI)_;0X.Q.1C]6N:JIE/]2ZWN]_),4K/A(>SK;ZF2GFXA;9F+AS$L MMQ=A4\TIU'#;P.LIXNF,H,HNQ^9TQ^-!^-
#FG],@[.W|("_N):'2OXT'XT.:OTQ[L\?L@._<2X_P!"Z8]V>/V0'?N M):'2O4=3FK],?I/"?_> O[B7'^CAOPC_&>'_)X@*O\ [DN/ M]"'!;P.OQ>:'2V?(9\CFQ?A%^STWOX@__);A^8(?
IC/9YIOC\ -DUP_,@M M MX=;HP^>/5TI@A@YK_?'SS^R]IQ+C_1Q^-=GCID!?W%N'Y@<%O!GM&'S0Z M4Z/M#2H(.(^[.^)E.("K_6X?T5_^\!?W%N'Y@BGPB_9Z=?
Z_N+]N/_0UP_,&>KOX,=IP^>/5TC^(? MB.,/TQ?L]*JHFOUS^TMP_,$4^$5]/:_ _&_7]QKA^8'5W]#M&'SQZNDOQ#\1 MS9^F*]GK]D!?W&N'Y@A^F,=GK./C!Z_M+/5TI^(?B.=[7]
(M#P&O4]O4.N'U,B?>LLMP_,$EQ^$%X"6>I6GK=[%LMP_,%'I,@.I.O[(;_N+-/5TGGR49\E.;?TQ3L]_/]?W&N M'Y@?
IBW9[SCXP.N,_P"LUP_,&>"W@=HP^>/5TEGR49\CFM/A&>SRNJX@=+^XM MP_HY!WPC?9X:F5X@X_\SR[NX M@JO_+EN'Y@!?"(JGZ951FOEKH M[/DHSY'-
COA&>SRWOX@8_P#M M;ZM/^B'!;P9C-CGNENI(R:!OW;NX'.:@CGN6MO1X95PQL:57/1W_ 8%/&_3 M'NSM^R^OIBW^^CC@MX'6X_,Z6Z^U\UHS8GPC?9X5,IQ 7]Q;A_1R7],>
I._ M[(*_N)/ M*=\))V=&KA>(2HJ_^A+C_1QP6\&>MQ^9TU^(',WZ9+VMQ^9TWE!E#F5OPDW9S!UN/Q=-Y&3F7]LFI.GI(?._,DN/|"Z9)V=.9^,+I^ MTEQ_HXX++#'6X_,Z9P,'-
"?"2=G1W=O#5?\ W)#':,7FAQ_"#"'-L/PB?9\])&QQZ^<|[MNB-2RW#*_P#PYZT_;HX)4T'.FUFZ&/&=TEIKF_PP&>KOX'7XO-']WY^(?B.>_M*?
M_\!:IKW1.]8]&|Z_8NM3'_(GIT_;8X-5=MDKXM8]^D8F72),*SI^+DY_>_M'5W\&.TX?/']WI^(?B.=X_A_>_LC5\)H(UD?]E6L MJOV.J_S19P]M#@[,N(]7]]?
VLK/S)GJ[^"/,.7FCU;N%S3OVWW"7=M_14N?MVMJ_S1Z5+VF^&M=']O@U'S6>UM%4_FS'5W\$NOQ>:,&T?QH,>XU'5]J_A=0.V3 MZE?$[SMM6O\ T1>VSM+<.;LG]2Z@<=_|
NJ"I,_&C0<%O Z[']YH;0R#*5E;VF^ M&]MD6.IU L+,_ &.H*G\V7MOJ06@KG!SJ.]NDC_"6BJ&_PQH."W@1FQSW6;&R
M@RAKZ,CUH:)9'WIS6X^ASK_P'&4:/M#:]KWI(+FZW\]$_AC'#;P3ZRGB MV/E!E#7]3QYT-1QJ^:.'&WVNI9_]%O\ ,$\/^5S?T0?<_P_+T2?"\F.&W@=9 M3Q;
(R@RAKJFI0>@ZM%6&^*]$!E%4?FR67M#Z_I^DE^VK_@=+1^;'#;P.LIXMC MY090URWM!Z">B*E!SG_S2?\ -E[!QKT;-'OCO&YOM]&F^H.&W@=93Q9SE!E# M!9^-
NC::%99+LYK/;Z).O_/&D[3?#>%SFOO\K53OS;:O\T.&W@=93Q;2_(/ MQH:OH^TSPVKW*VGU&DSD[T;15'YLK5W.+X>VVG6>JU!R8OPG4D_YLSP6\$.O
MQ^:&R_Q#\1)>V9P>:N%U=USC_6VL_$WVY'"%. 5BI_[LK/5OZN_@CVG#YX M]6ZT[E"&J;%VG.&^T\'N]V5?3_DCU[CQST:8]J!9=GTI?:ZCJ/S M8X+>"49L<\XLS_*
(1-=VSC[H.[R(RDOS97KT1OHTS5_?8A?W'C!6TMW55PF MC3&>E#4._@C4CPSX)1DI/=+-0:I=VG^&\TG(N&W7/_LTWU"?XV=*_KF[Z--] M0<,^!Q5\68@P!W%C2S6Y6Y.1/;Z--
]0D)QATEW)=>O\ @TWU!PSX"%7Q9J0R MAKZ?CSH>E54EO2L5/_-)_P V6ZJH?0+6;UO;]OM|!J_Z,SP6\$9R4COELH&-MMH>T/H.9NYEZD+9F4&4-9+VCN'
MK>^_,^U/!ZWM!I_AI"N'ZE:Q5]M'4?FOP6\&.NO^+:P-6M[3/#AZHC=1M55 M!OZCJ/S9>Q\?=*RM16WS*+_YI/\ FOP6\&>MIXMB90900UV_C]H2)<.O;D_]
M8JC\V4Y^7/H&FB622^[6(F57T.H_-C@MX,]93Q;(_$/Q&EVNJ)PCEJUI6:LW-M3HN-GV.J_R1ZOVSG#=).6NHO7QG'H-3^,,]7?P0ZW'YFT_Q#'D:H=VHN&3'-M;7:F:CN[_O.H_-
EI6IK?A3,>E1JA8O?,JM?X(AP?\#K]<)]*_X!4_FAU=O!CK\7E:=!K*EI1_#RNCWP.A M21OM2DJ/S9.WM%/WNVI?E5?\"J/S9C@MX)],3Q;*RA$P6'C3HV6/>R*YGX
M7HTWU"NG%S2:H^8EURSV^CR_5,<_^#/?X2S,&$/XSZ/8Q7+=UPGLI9E_P"8 M6+86$&$>+)+Q^T(CY;ZJ-!OH<_YLSPV\&.LKXMB8080UPG:%X?_#@_^#G_
#94;Q^T(!NOBJG^_M"5'YL<-O!GCKXMAX080U!\?6AF_^&W?0Y_S8^/G0V,_9M^6\44CGR-,T7;X17%R-@U>QSEI[D=0U3?X8T/2EI3?#:.%$5^H7H MB]V+=5+,_-
$9X+>",9\4]UH]6U,H,&L]?M"\/JG]3OKE7^VH*EO\,9Z6Q0:LN';7XF?0*E?X(RM1]-MH_A[7PI+!?\ F1K]Z'4)_T8X+>!UM/%LT& /XZ;)CCC>MZ7;)\E4I)US_Q"
M^CXLZ6D=AMR<[*9_[VF^H8X9\$N.OBS$&+P\2M.39V7+=CO^XR?5)'\3]-1K MAURPN7ZH7BCIEK"$Y*1WRV MF#5K>TUPX=W;@!UM/%M@&I:
M/M4\,+@U5H!2\US[HM:5?FCS;SVR>$.GZA(;_5OH9[FI;ZQ_P"^V%1P7\#K M:>==6?,9SGE_P (!P&C[%@=KE4F[MOV(K_S!DIOI6?"NYTJ[5%-JJ(53*.2 M@J4_AC,]7?
P0Z_%OMQ0W"0R:GD[4G#"-7OU-AOBOH%2O_1&+7/MY\#:1.Z" MHUORY4[V);:YR_O0*.KOX)3EQUC>9=_Y\AGR.=F_ ""\ W.5$UWU!GV(K_P_P M3IV_^_V,_HYS_P"Z*_|
,#JJ^57VG!YX]70V1DYYINWYP(K';(=<[G>=IKF__MPP$LGP@7-6&18WZYP].]/L17_F!U63RL=]P>>/5T1GR(?E.>6]O_(#N3*:X M54_;BN_,%1O;WX%.[M;JOE]B*/!\P.JR>5B-
7IY_7'JZ#_*_\'I!#V?]+1+R MH]9N<]?O4M-=G^0/0]>YAP=HVHZ;5]QH[VVVL_C]LGE.UX//'JW?GR(94I/-M1=N+(#17U/H\L!T=-W;?6R1,^^L*NKV/^&#(W/74KE8B,E/
M@S&JP6[KQZMN=?>,_^1SY4lO?@51*Y)!<,%3HO^I+=^8*+?A.N SODZX5?_=% M?^8.I5D\[JP5![QZNB0<\L[?W-EZ*K=;/5/VGK_,P>E2=M+A7=*\)[7>]J-MZ-7P@M\!;_|
*L8.IR>5'MNF_P D>K>:=*SK^*GMU/-45,\=-!"Q9))97(UK M6HF5K57.7")[XV9S_P -#B[CMQ9XB\3[MM-3WZ]SNL[7(Z.A@7DTO3N7EMZ*]>UVYWF;>+1WR3]
[DTM3TECPTXL?WG<'$K:WJ?M9VZJHZNWZ%[(E(U5CDN>L3/:D6?EK_;?)IFIO-1WG[((^>ID<^H>Y7O MD>Y5, M,N'GZJ&DI8T]+=C8_Y77N,'KZN
M.UTSG.K&N9XH8U4<5;7#5.HNUK$3+V8$4XF];\5G>6UPU$7W2A5M0Y>_, M%P6%=#<*A?ZI?R&)YX0UM>.,"6.G9+,H'R08[>3)KW5_&_7BEW05"Q0N[^G M<61CE7?
48X^+HMM4E!"BPW)CID^2Q%1?RGA7:TV^[N6LKK?3W&L1<[E3./R'-M*T6L;W;YG5--7NDE^^W95%]QM'1&IJN]6YU14/D;4X^]F1QQ;(-(M?
U1J"*RY/T.1QQP19[)ZFI;7%685=?.*WW8?:ZFI;7%4Q+*AON)FIQY%\I$ MKW0B D_)"5WR'>X MF)7?(=[G.(V!V7YX8XTF5&M/0IJ&2G5KW/3"=<'ETU0D;T1.CCT9E>JM=(]=
MOD>RQ3O5\HR:Q.PRNDNC-C6IX(;&X:.3FUAO1&N5F.KM-+T3GI)&YJH+UZ-M]QTOP(AK:QQU+&KHY4^2]GRADMLZ.CQ3:DRJZLTZMGL\5)32R-E\<]4,7BN
MVHTM\UN_>'O/;9<&ZAY<-742 M?8J-,?<5PON,-Y;1>L5EYNA-;6[3M3%#5T;9)/&30 M=DDM=GU&V*KMZ+3+UA?(WJOO,YOW&*W6.A=1T2,'XQT\"G)7BEV*YHI@X88Q
MQZF21S:=M7S%C[T1;1\U%4Q+AJ+MVIU*YM$O3VO\ M3HJ>3NKEKZ[:BO4E132N2)KU2.-OB7%\NU=JJ."W!:UN(IQX5$!Y?6+3M++: M;YCD3)ZW]I.B>XVU1:4?52134-
)MGPGW96^N1Y.?I<=LD\W@Z&X36F@MK'3P MH^]7K(B]<*9[:-'00]PMY++?R'L:+]^<0QF;T.ST',J:IK4_!53GCB!=(KAJ!WHR(]F?E>]OSB'H^EFH M\2N?
N;IZU>H66CBDN7H-/1?=W"-QXE_/PNGK9*-[']LBD5$WM;;-M'#Z6.GI*%SD?$U4< MYSB^V2)C9L;;2Q-XO:$.&5E@JO]BL;B9C55-QI?C+]!.IJ9U+S/58N$5.XZ
MAKK=362QUKX=K%2-?6OCX&*1S4=*9HB:UCN4 M*:C2:H:V5^&^TN+M0T],UJQNW;NAYC:I71MRF%H=3UT3;.+[YV]KE#=V<2; M4B$SY&1T7*1-
JJ>$E"ZEJ&R9W9ZGHW!_I"(K'I@MERD:*K^O]AI>3O$RO:"H MYSE14Q^{JKI0+3WGFRCG29/BB.],.8^"L!X[9.=-
AWJN\S(8X7QMCV.1V4ZBU=H8BT6JEBQ'.?W M8*ZT\|LVYRXY'+%,B8;Y]">297.QX%;YJU9(^%SU1NY4[BXD)W39WMV^\'>?
$US9EW*7U%FG'@HYZB=6,B=M_@*5NK4;/,U%V.3[fVGHTURJ M:7>Z:[58[IYW>0E*)[H75%;Y114-JOE9*JXVFS*J%+K.;3%$DE;J)EVTUMH-MNCKKW?(894<^#F.N9C/XC?
EVDATY1HYC6<=^,J&K;9W=O'6.KWE1L$5GCI MFU%/V-[DZOQ@3SH8Q+R#(=.WZ*RM5?0OVSSIW;DR>=.K;6W'-2E/JR5,L]H4=#1VNGDFGG6J]6]
M$BC4LJC6_-F6EXYKQ$^LNBM@M[O]S-^<.KA'#8'06Q(U!8^J85,G.,&L+4_3 MJ1.E;SIY,"HBLV!&.-;+\GH-+,6CFWTEBH[M4,YL M#$GJW/13(*^>6=%D?ZBK[[

MDYEK3OS=BE8B"CILNQ<'+=8J2&>IV33M7=X9-DV.-U93LFFQM)CFQ"l;3I=40I%+_J,:W:W""E.X366UL8YK7X\2]0LFWK"CN;)T7V)|BKK$+Z6M>;65]M;ZC4JL1?ZEC:MJ;>|O)M56VUWZ&C@IVK-GOPAZ,5.I2U1(UR.FGJ.K=W@:UOMOJ_T61U$<+T?·MG/1.A?6(MWH5M->4-C:HU!/0T'2/+YNC-O7&3#Z"V5&F+76WC4E4[#\NAC5?M;W&1V6GNMPK$;7,B6F3&WGZ:;QPSQT^V5$SS')WE=G7'I,=9IZ5+BMJ.KT|IU58CT1Z8RB',.MB.?(C]A[G/G>N[UC]+(:)IZIO.D9TIN^-+N:|O4Y-K6U\#IH7M=#)'ZJ->G54M(1&|3U^->5PZUC/IF_TI8Q7)/O3N7IWGT2T'I"75&G:*LD3$CF(KU0^-7-MUNJZ+U$Y,7"R/5TGK·M>6(B?B-=7!STGK·M>66+9-FZNM:HUTN52/|\T_8YJS8W]5\5+NK8R657-]CVXVE3DL63>BEQ-0MCC9(K-·MRR?*:WO(+&UK?4PUJ=[7]Y%A0DMI:K.%P2R4+49L7]7$4T?39E&]RK@N6.8YMN<94<4PQ_+%+EIUCMKHNJKWY+:,#3BPY=[3+!*F-]L(U])^(J(C?R\.3">1CCE·M'@AA5VL*HF48KEQGHAC=99GSK&E%S6SPM5$·M|L(8Q]&AEK:62&*)K8UZ;L=2^,DN?FP\7>Y%UA5Z,^STEIFH]\LB_+A;G]>*.MSA3C#-E1=N6/X1,*AO^<$<*K19KD)75<'SU@G91TA?ZL|#ME)O>UL<6/5:.MWHIMQ:\TIQ+UDFJ*N.&"3;\T5GM+M+B3Q/FU%4>A4;%IVPNVHK>]4\S!*A'MJ$63U951,K[3;ICV(V-,(Y79)G2(CF*J9RO7!9PM>II',=LC:MYOL3V&G'M>U[E3U6*IF6GM35$=EGMM*GZHF7.:G3·M)5*[#FGAV5=*:*IJR&1[ZU!1*S*I'GO\BG!616QLBK1\J9K^K7)X%AHZ:NAU·M%'#·JESN?A>9T1>IN'67".6NABJ%N#+=']K+=9V5,SU>W'J9Z]2B<>W-U<>HW;2GE?Z<MJIU3!-20OF5V8^A86>K=\L:ZU04\B8PJ^XSB>WLAI?67"IU7)B]7#'-(JLXCNSL\^H=_4·M[6L;T]QDM@A90T:32)ZREM30LDC:Q6(JI[#TJ3;4_<)&/QJ=V"N;2G')6GJG·MW&-&1LRBGMZ>9&I^,LJ;-M'(C(\·.Q,JY_<85Q X\V<2TGH/-6>.V0(ANS@UKQ\EZ=A#M·YKI.5W·MJI(|\(U)1'A??=?OI304[#K8W8vB8Z+@US>W-K*ESMRJ[<'6>GG=`1-B;CEN3.2XCA8V9-J(F.B]"RIZI]OC=3R_)9W+CJ7GI$/+CK%7-N#G;_·%FM\40@^LIH?42G<_/L0Y^TAQBU·M1;++I)176BB93JIY:MPIGVG.*U++]!(O)YHY(G|&(F,H|V$^KLIZRLU25(FL\VMFK%_O0Y+XE<1;K]VM2NG8·MZG9G&UK>N/<8Q;&T]5?6+%.K8D;]TYB8,^XPZ9?;=614V]E+&]{UJ^'!=?$DD·MX-Q5%XI(Z]O8C*K:DCEQWF·M6?C>4VJ_/J9H$CB:Y6)[W-*WO.C6T?%ELM+K&WR+!_Q5CI7*Z%V/D(8YJK&[·MJ/5CDN=YGCD2QTU12T:31U#';Y7(G0UQ-JZ\75\+'2M|'-M+L6.A$&Z.6M:1WL$MG"2>5&R;#2-65CG]9$3H;OT-PKDTC4-J)VKZ1CJ95·MI[6%GTS24M.R#;5.=UC(T.II).5,D;7/Z>!ZNL."Z:JJFS+/RJIJ8P[NP·M8W8^_EQM-9)/-6PJR/Y&U>\C7:.5UMXG:&QFWF@MMOF$1"VG.-D)K$69E)'G:QL6M=316]V4"4·M'"*NWTA$PTSU'&6-8|%7\9IS6'$R'1-1!7>DPOI)%V21N|T<4UWM,:4IFL5WAES-/0·MP12/CBW28\2PCL\M=·Z.3^IG+·^4AH36CM9PNK:62%(7+AK$QET3+;,,9KG=E1·M6N;M7Y/@9M]WE+,%*[\WO\K:VU4'1$_.?YF7/C1S>X\|A6&@G;&K-KN\<6>B8Z+@US>W-K*ESMRJ[<'6>GG=`1-BJWZV_9"@DA:]·M6/D;A'HN,'/^]M.W&RU4=$Z9TZ[U!/&U\UJP)EVNLI88F8:K^C6]^·M#4?$Y^H|)7RHCH:)LU/TUC5Z@JJ.9TCT:Z·M&1?55$Z)DW3VBN&%-I6X)5BI[_#)TVSLGTZ5D4.-U?(QO7+DP:AT-·M?K/HC4%/=)D?AU$:Y1K5]538-T14.H;__'B1EOBHK=3_"4>Y/6_>"[%2MN]·ME>KNR154=O9-8ZCTFN;U5O\·U0TU?M$W?3UR;%?**:DDY)RU:(N7R>2H:TMT;I(TFAE14:G6-R\]2-)6(Z·M9SW0NF1OR%>G_ZST>"U/54&FJBZ.MS89EYQM.S6.#4++:A'T+'29QS·M'*B&E:'B5QW%S9X:9LDC6[U1[413&-+<4-=55$RKJ98ZBEMD?ZK<94RV5+Y?0Y&MVR>"?D%;3#'W+;|O"OEPI+'0R0U<_H#G>]K4Z9·M3V&N+;ZS7*LG^Q+]6M7"+AGMVJ+%Q#1&2O9,YG5'-5$?)X|FL^F]I.5SJ6LE·MDBYG7=(75M+3O&/?E##KYH*:NI96RU*M@7]K6)WF&0\.JC4-VIZ+[&R4=+'T·MJ*E:]·Q^,Z1LL=#<.9-3I'/20|%5OL\S"N+FL:*N5M'1UK.6*-/NG+5$1<>"M8+8O+7O3';G,,)N/#:TV6UB;7)'WX,PMU·M\EM\;JBD>V=CES]TZX]YCFH+U##5/])*A\LT_?"U1";2O:E>YBTUEK*6VQ5·M>'.2H=F9LA55TM"UCI&LY2IAK4+FHN]4L/(:fF4_>69.\L)8IF^!·M=5;3Q66.6U+Y'N6/=N7IM+BFAKJF5&QPO1OB]22.16M1ZM\,)T/3H*J2D·MFG:*·U/2OAG];>F4;>'+7MCD=&[MXRJRH@?3>D)ZV"K?FOX-X;@F8B4ZN6+·N,_!A]94/25RH_#4[·MT-IZHTE6VMTL":71Y5$SWX-77:D=;ZIT9G2*W"]C6KT.)K7.D=OG5]O1VW;_P!ANWAW·M2R670M5S).KF[IV-SX*GI*F[3N,.KX5HYI]?8KEA7&YW4L(9'2.ZIOW+A&M/4·MNE2E5=*[&5;Y5_*2Z8J+?;]I3U%RC?+·QV.7%WY]]ALQLS'0W#BY75TM344S·MFTFS+=R8/3U%H*VPV.:GI:1WV0KM:ZK·M2"7"EK(YH7-Y5;OE@lN"[4,=OE@@I5=42?*< ·MJ=YZ,'#\I;E]VITUR@?#E7K#GUO<8VRA]H1:V)BMB8NQ'-\5,[M2T1$\E!,·MR)L/)0$QEQY7J6E13M:[$:]?.QYENAGPYN%VY7IWE">'TAJ/8US'9_$62K·M:5BV1L?J/3/M4IR1[.N2I54KF/1$>DCG>"(JJ2QI·3Q;G029SWXZ%:.KXI·M6PNARJ_B(C??_·=8.T3#J'2M#7WJDA?4R-15Z&M&2H8U>CFIU0S#1?"]\ZEJ&0=_ZFIFN3,DJ8R=6Z4T';T+Z>AM\%+N?MRK?E·M%S>K++8874+J=((V|SG8Q^(QU25\L_!@;N'NGI:,XF.H(75F$1SFJBY(45'3MT39'4M)RFHF7X9A?Q'H7RHBH6T)EF@PS/ZHO53":D=U]!*·M2U$]3++.JJYK7+T·A:,Y]6QDE1A'NZ.1? CLMX8\7M4T7IDR;4.>#Q!:E%8/YMY):CD;$]56_A&&:JXI2V*:HAHE:M0QV$\4-:>.HUE<++Y2HM94NWN_W%J^HIB;·M,UMX/3I.-VHI?32T,L[:QRL5LUJ.>N4V]YKVLV.^.];KETG52XHIF]7[E3N++*.3=)Y9+V&?HYOM3WD*HVCX*E9*U^'(A;MD5J=V"?U7.VYZ%=$AR111]6KGWEG)MCF:K?OC"583L6S9%9W$S9%\5,\54%R[!3E]5Z(WV$JRDO,1554RBHGB9WA%*Q·M7U$NR-FY>Y$,ZTKPV=6*+$"J=%·RW&HI·M+%0RICF·E3+41.Y?(RMIF'V^SQ:9DEB;$R:FE^3T1<&Nl>0TI'>M\YFQ_1V·MTVBRUS26^94JF-21N6NG7HU37-HX=W&[7>6.I]6D:[K.]1:Q:O8I2(DT·M\<++W?·MBYQY%3-K3ORE)REYCT8[+25CGM.]O>3MVMZM5Q#:U.O4SNQQ)F.5&|Q.V5>H·MBZ]/·CRT+%CA='/$F4;C·MO-0>NU'QOZ.C7"H"T;'>2N3#DRG3^_BW)&1]NPG=D*HGFO[%?Y].U#I*5R(Y·MQ3O%WJ[W6.JJUV^94QE/8>=A&^KC)ZM%:N9;WU#G*B(N$0+-WEKC]25$;+$U·M47]7U'Z+)O\2%5JIW8\2UFC1)'*U56/P(62XMEM%*L;<*F3U=-;HETO42OA·MA2=')CUD/*E]A!7]S*,Z;D*EN_R5*ZKDK*B2KD;L65?DM+5D:KDCN)K?65.I;20M5ST7H1X?MBG6V_):P.7]7E%,L+MR.QX%E&]MRZL/5TQ']#=WCK$A1^%ZF?4·M^I'ZR=<&:BFPQS%=·K'XZFIF·W1N:Y>_N,MLR15C>Y$#SWMVNH;0.JG1NCC1V%MA2A&K>7OVJUN>CW=Q·M=P1NJL(V-7+Y1?:-]IF5Z.CI[M9IA,*FH5*F14]'15/'O6@KSIV'GU,&^%/D·MN3KT//IJJ6VW!D\+?NL7=DS;4VNZJLTO302N2229O7R#,6E@E+:YZJ1$IF/D·MG5,JQJ90J166MDK$ITH'5*KA&;26AKJFVRGI4NK[C25C:MLJ+·. MWNV2Q^*KM7!YTD,L;ES'L7S,ON_%R]7J%(:AT:M3I·MN1.IB%57JG9>N5,:0GO*D!J$6N3:@222M=ZJ+U_?9,0!%@Q8D=G*9+R.->B(Y7*O@A;5KY(V9+:.KY34%;!4QT57/C]<O>_J__M5]=]^.-CH$@C1N,-Z?C,&I]^U8VMQ^+!>S25KG$=04·MK(ZIBP12L@[V%,)*^*DEA;4_<'|\,2X);9KHX'43UZ2]6N=W_·^HCDJMO+HGLO:-=9·MJ:Y·BJ*=)UZ>HH5Z30YRU.!?,V·M4RUS4=F>Y6]<8I5#3OREZ#H^GW>YAU1*ZGEY66+A?·]66%;J,/_!F,5'/3T^R6+"-3Y6"CBYNGPMZ2'1Z0HY?;@Q.^VEDT<>YF[/>UR&Q65.7%O#7&FM06·MW4I?1*I5IZI>FUR8R4C'!JJL=3N@W*IY,F#TY^'L/7=7,.RMO5'1^T\S4T·M<[=&:AKG[?DN7O+ZS\'&R5F$(J7+HW*W8G5%,4TQ75L#E2.1N/,O"),:4YJM*JK[#U;8YS6_H+·M24;&MEY=/(G=·MC'>;RH;D^CA5L2-;]|O$DEI'U%E7*YSWD8I$-ZMHX>·<·E7?2I^J72W@W-+6+2P.JHEDIU38B*IY5'3NMZOS$C?8N#*'0I-&Y7*K53PR>+/O·M>]X5OJ=41?'R(0W-[I6M55RK57J>=I335>ZWR/>LC'(WHCNAB|3>;A3UTL=8LC58O3O1%)1·M6$9O:(>WJ/5,VF7O\L+·

*(Q%;W|"6.VTJLU.*NT.#M);ZJN'"%BHCN#N30U: MXE5WX6>ACG'[54NF.)-KU)O2>B=AR;?#\AG?:SX?4C*R2X42[9F.WIS= M4?9;_6JH6OCJ*QL?JPLE9T:=;'7BC=YO-MCGAEM[4VI[5KK2L]_9RYWQ=4A> MJ9123@WQ_P!/UT-5:KW00,:V-6M+/51T|QCADECRV@=)C<*

MIC5UX3;@TC25;W"@:N,YGC7Y*&Q\',M;*\]E[K[4%-9=02/TXV%6U4V&1L1% M=N7V*G<8|Q"ONLZ?3,M'];D=44S^L>Y=RM13$+9Z10W.&1F=[)/4D>O3)L2H MJKQ3OK&?V'[+R31HL3G?):G@3K7DKM>-MW/,L,-'=/UAQT:WIJ'K6*[66V-MULE2ZE=4I^"[H7&JZ&6AN3E2DMAL"H[=_MS@\.P;)TE[M+55#::*\SLIJA5:YTB81%]IL>V|FJ/2MY;4:ANE+](@8FN5DSY$W/|B$5U9M9 M@%3Q'J9,MCAH|[795W+1,_O&VM+7S2_%/2+H;C1-I*JD;AT\?0C:K+PFEO"4 MD}.CVN;A)7IJ,S[S-;-HC0.D;?4RT|;1^CS*JO;#*CEQI"/$LZG>>8':,,_^@^'U3 M$RR.E;JKB>1K3R}8|JNEN3EI+=$]S7.PE0J=,;QTP88YMLZJK**GT^V*)

MK*2@:S;ZJ8S@T<[74SJ5U:/(5G?&KEWBMW=$,"OO$^'[ZGI$BGK'I3->K$I\= MYM;1G'NR:-T~9%=H..XWE*=%BM>WKO7N\"7=S+9>*=JSR:[NVLKM772AN# MJN22.G? B2G;E.XV-T.J-/RK0VUR5#D1KF_*5[^W)IZOL&I;E1U>IG4+J. MESO?2M;T[S*^^%>]UT;+4U|!946ZI:B*Z7HN/)"S[NRJMK[LJTYK2X:1H:.% MK?2HVKO>Q$SM+G6VMY-0NB^Q5!+"DN.,)M5R*[Q/3TAIN;6%[N%5:*?EVN5< M)SDPJ-\LF;4&,6GDEIJ.BAJH<\EV-D>G]7.ZY;X(M46Q/G5953"?A$-V(LRG1T-

')f*BW:=')S$:CF^)FFL;]%37=NR99987[41Z8 M,+X>K4KJRUOCCCECAD221?<;&[1>D%I:NDOM#"L=+,B.8YS6R)+L78WKT]IZ51&J*|$57K]ZUQ9I6,Y M3H7QXB35B=UY;,51U-IK[C6YF}Z&!O>JE:.PQ#1UNJVN26WO7V\4E"UJN2H8FJ?)QW'"%751K,6U3R=2Z7N=DJWR.@L>\(}>6C50E*U,D;HW(I.Y/$MK WCH*EJ|#!TBM|HVPNZ-;E,GK0QNU$V. M)LD;&M=N3K6JN,$&7^OBVHRHDWI.8BJ6(<3;NOJ7 M[&;]>\MX5Q)U):J%*2&Z2I2+T1CO6_?)]F2IMZU-7)$*ARYRO>2V8 MM:/@Q=(5YSMKO4ST*R1,K-"CW)F:->6[^V\ MS&[=Q[%]{($DV4K$=&],/,;M?VEEFU'(V-4VR^L=$SV_.Z/O,LWC=B+43:05_K(21. ^YX4IY{\F-VEP[2F>];E+A|9*VE;3M7#,Y M+/=

[R?)38[O)!\\+N5RX(6L*;H<=Y,/7UE++M M"YV%=T*+HD4KW6UE1D1._)S/)2K(U=O>6^5.2OC[WB(.HWN4SNAMR7KFLVL55ZDL M[=CD5"V;*COE*7_*2:-%W%N\|

(<*S218W95/,N8YIY,IJ(F2G,W=E'+W$L<:-MW++\X+Z&96M]8KB%=DU.Y(T5%*-6Y$ZH5V-C? ME<]2A51(UJ+G)9/|38=\X<5MAMKIYONC4BR

M:SY>]KE1,=2R>4,1R4'2=25'9[RHZ-O+7EW>45&ZRO+45R^>3%)'JYK)517(CB?TN27|HXM^3E!LSOMW/KI?64FF62PMI8ZV-_558VGGFD1SH'-=

(O53U&GXZ>W^D^DH_I\DKYIUM#&EB>XI+EG>7^[HBH49&(MJY2&=E]9B7H6G3U5\KV9C?=%K6M[U))'1IE"A(Y_7J4X\E4;K8CEO+TZ62){^ M)[=IJ(6UD;E3U$[\F-P.

[^A>4TC\X12VL\|FKEKNS2I]*=M4CX416+Y'HVBT MU=RFS;V->BKE>N%,,IH&XW.]7S/?MU14-;HJ M/|4*](DIZNG?N7FKN1V(K7C65PU)6QU-

0R%DC\.6QM1J+COZ>!C%975$U2^_M2HO14^3Y%FZ,5B(.8I8?LEIR5E1 3QTM1CI*Q45RGE6.WP MT.U.ZM:M1#)(B.43UDZF-6RZU5/(DL1Z*Y96KN7N3

MJ9^"F;1,Q#Z"V#1E)0\,;/=*)IM,S9E1SD,.TM=I(] M*TBC@Q\VKG=M1:*Q-I;62ZT]4US(V(U]JZN,,U!89;G3R3P-W-CZ^J;(HN/|SI;Q': MJVDC?&F&NFA7*IYF^M)Z^BAIUA;"U])-'E9'+U|BSAFO-5VFE^4,!N3EI8XI M'QV3<[7^-XJ4|K96W,%7/1$;MRUWM#"&"W25=N966^15A;_*HWO+*ENU8F@W-M2+FHF1N-Z|F"ZL?%HYK5C=C4-

(&V563X5&N7"GHP,3Y,, MDM7O1W0|RFJ.6YJ-;RW?@%TSNY?*5W-U,*GL+BFA1SD*=-&E5&]^>2]=^2]M ME+-6.;%3Q.E':CO68F$-*U8M+LZ2DXZ\WEQ5"U$DC<80\R

MJI8V;UW;E;UP4J&Y29D>]>AY$MUJ6W!5:BO9GJPCPMFU_%DE.[G4['0?<9O8 MO0L+@Q:219I8VR/5?63!ZW%NE;5JQTC=KD]A;7*G=-5[F.RQ$]9%\216L3S>] M8*&"^1*_U8,-

^3W9-3\4M-/6KFY#$1J+\O!f%#]J6WWU8))E.SNV!QZ6J+I, M)*96SRH!$^02A3DFOHE;.5>U!$ISW;IHEXWR1T%)3\S'1/5PAEN

M@H8J>ED=&J\E>N#,,:|0TKD:Q&I_$)O,**8*WG[S2]B[/%QFJ-U=,E(WV(;.MLG!J3MCQ#P;R9^HG+#44VVG\%5.A[2QB-_M;

[4,TB9C=L6K6DYJ#7CLFSPQ$;RY46B)Y,]HM6W&VL?(VL5[E[T/>TU=)M3N MDT2=R*A7:L,-RN3 M=E-JTN^VWALM)6*C$7*LSXF[-(W%U1%LG]1K4ZY\34ULNE@JI75-))

(U47*Y MSC)E]DU$DWJL5'-[D)S[5^+K8+*FNM.D)4+4Q)ZB]>XQR*A1(D1.\Vf;Z.* MJ6QTB*8K9N7GEO##[FQM;#-X*Y.AH^.^0W:RWBL M2)KI6S=&X3Y)T5<6^E/V,Z&

(7:RIGR.[GMZYP;%9:-HF|>32E%JBIT_&]+BU M5-M&L,<++V.VI|IT-.JUU2U^QWR>{)NTKQ M.5J+SBC>7I4]=3/I5DC3EU7@Y2_1VJFQ2LANE.DV%ZO4Q!{'R*[:F'M+BD;)

M4;&O7F9[T\2V:,;=[CSFGWH,&N=' W,7T&.6O>Q%,DDU0MKTZVJ:N]<=R+W*: M_L=+64=`4JTL.*]35+7VMZHY',7#5(Q3=O5U;|*E===>W:6XOJ8Y'1

MMID+^AXCU#H_ZOI7/7_QB)T/ N5#(^N=231I&QC<[O:6:H):5'42)F/NPK2 MZM(V:5\UMVVM,5'4Z)F/NPK2 MZM(V:5\UMVVM,5'4Z)F+TU.U&KL7R3!1PS

MKG/L,_TEQ6]M/M2FJT=-1HN.8Y/DH4WI/P,F'-7]3>UQMNZ!(WL#IJ=BJJ=^$-LZ>O4>H-/K44,C962)TJ?B+%EMCN5/+&Y=SF_*:Y#6 MB.&>;?

XHR1|US6UKIZ5\$C.7*U>DGL*JLN$KJ5]+5.YJ-[G=YE.N-,36ZLDD MB9B%Z]<(8Z^E;#1JJ,PKOOL&UNYN:LTYK;W79(8YX7,3/@Y4/&

<^6GFDI.I5ITW1JDK,/_")M3>L\MWG6K$FG)HH/DI5BR>?32.?# M^N45W^YDMD*.G7DPR-5TDG5.X(<29LEMJ$1R+O(C)8IB

MRGTRVF5J++/|NIX%!1RI(K9F,%3N)WR/KWX4O45)'KRV=%'+9F9WGDSZPZLH+" MYCZ6%(NN%4VQ8[Q!>Z5LKFY=(G@<\TE.^Z.CI8V97/@;RT5-ZST,,$K?7QT\

MC6O&SI:>^W>N|U V&-R-CQT-$<1+_<[9='NI9G1QN3&WJTU/LJX\/C:Y5,&U M5P\H+Q4L?+3M<]?P5*Z\N;HY)F:JF9WV_5%+1RNHT MYDO=A"33?"!++<'5$&8H7=[H|

MT9R8L]%<995:BI9*15<]KXD3I@NKW8[?>:-:>2)]+W=.AA#;)'0U]6EV7;EZ M$4K6VAXM;Q2I;?<4@EIE6!SMNY$,FIO1*^)E2U8VQ/[D?@NZKAI,9&M2HHVR

M83HDY2\.RMJ4CBGUJLWO=|\JF)M.VS%<>_9Z-/3P MV7.DD*RM=\G"=Q=NK*KU5HHMK?-"W^PU1681?-5]>63V=TU.U&KL7R3!1PS

MNV\>TIFIR(\+//%,+RBCCIZA)I4W22)TSUR4++#JZ|U6LI***>%T=&QN&9 M0R>@M+9XVS^LFF?M21B=.A$C>9>I5PRR2->JIGS*%=Z0V-$<

MC587='&V:EY\LN]W@P@ZRRW&%TC9N4B=S/:%T0KV5RR1JG-1/(MJN-\=0[NZ M^)-;--\N17/K>6YG5S57O+R6%E94?]A&DH5C8]B*FY.N%4$8^)\;5W=4/.J&)4-5-

W+5O=&-2.M7FMB;D;SH5^3M]AF|PHW\OD-C\;NR6-LK'T\SZ6K]=<8;GJALUGDKM$;G9KWP\'WMU:^7:R4,4K9+G%)-&GKPH]$550T-JKC ME;*&O?!3V^9D>=O-

8]JBFEZZ\.N%PEK%FFFEF7*N5ZHA0BN=9Y^G=%6FT5%5]"B MK^?96HKHXG+A4+K1]WM.I[&^TW>*/TG;]S7SW:.?&2MW>5J;6%3>

[P^:GJY&0M=AK5SZIF^F.*$EOAAIYGNE7N5 MRFMIE8URQ+'RW-[\)W_C)6P*Y,KU1"OFUK9IK?=MGB9?FWBA8V.NQO1$!&L\ MVW3'PVYL?

FX:V.G7=Z$W=YHAY\E+26ZK2&"F,"J>++>AF=RKHHJAM?GIU,?F MBAJ99JA&8*&3#%;[PA2/=)*U6N5%/4EM,FUDDCEVI5'Z'}YSDV,;Z+I&X=;\Y78Z\5N;R]?

\RVV=DUL7ERM3Y/<_MIC^C=:U-\LLZ7!KF5D*KT_M?::DU1Q.O%RNDJPUCEID7"1X,JX<05UZS6K(Y MN[U7QI>CD+)I.SF6U$6S<%&^^&VHJ:I6-R^LK784Z#K-

)VN]V5E3!*UD^S+D MSU.,;=[*31MY1\D?)H57Y)NW2G$A:ZGS![*LDL-) MOW2JR1'JF4Z&NW66.WVNI2KPZ7KA#:U[F:&/942?*,>O ME[BNSN9"B0M=WI@\RFI6.H9U=*B)

[#9BL[Q.9_#$Q5YR[FJLD*YW179-M\ M/*[EV%>[<C6^/4U.S'+2-C<[EQN,XAHUM.EU8F6N>G3J7VYQLYV"]XMN[;7. ME*6J[?LA23L=(G5Z-

5,AKN"+:WEO3=N=X%S15=534CTDFL6Q15]:(_D)IB+>X@SY* M$6]QY-[ZONB_JJE=*D.U$3V$M+%#62;))-B9-QOT?:[Y9WMTf}3

MN1V/OC4EWTS7V2K6&JHWQN5>DC4Z(>MQ^Z^89,3-^38/")+58-3T\]4J2Q,7 M.5.SK'K^P:DI$GIF)]R;L;U>[)PEHBUR5M4RG=')4.5?E,:IU9IFCB@TS':J

M^F2&N4534]2O([^CR37%-9]WN<5+|#6Z;DB=MCEC3+'(ISQIR6YWVX2/=40P M,B7*+,OZI@V[?+'<*RTU=+5M5'>#E[S3MPMV5954]W+4I2M^]7:E7$L?U'JF M5;[?

(W9P;L]ED=)}CGMFO2MRU7NPK5]J9->:\M-PL>KZBGU)3SWB[U3UY2-E M5^UJ]WB2^)]:1DF+PQRTT]?;V_9&.N=4[NFS/4\>Z726_7-*66E1D[>BN5,9

M/16YW*WUO)6G2G;OVMB=X=?$\;6C)[?=8I5E_JAN%>L?0MAS\NT=Z.E-,TUP MU4ZCNZ\F#/13I>R6ZQ6"!K(4;KFM1$=CO\SG*T;NME171)<6*O4[WIWF8W3B

MW;8.!S:*)SMJ817=YC(Z.FSTQ5YMH7/545MF17389G"(G4]6@K]>\4ZS(]*<.MJW#BO6UE0G*B7EHI"[DR;-X,Z\9=)HIVE5F'81KEZ&I..>]VL.,.W M;GT997V^STW/ZU",3+?

#N*+0ZF/'-(WAF$$B)&Y'R=57=W]QY%ZJE1%:QV?= MU%551-I7;45)U7"^1YE&YL*;G+N5?PER:?#S6\43RE&@IY)'+N153/BAZDD5 M-3Q[!$ZE&6YMI8?

DHBN3/0\2IOR53G,538X=F>*NR>HD6JFE6F7#$[CR[Y?] M?2]EFJYW8>U%PJE]'+%1QOFSM:U,NZ]#F7CSQ8?=]M]NH\K"U<.: MU^JZOXM6\3-

;SZPOXQB%\FYKF2;/#!!S>]?:5H'-;B],G6C'$ M/(==:]N:YCD5C_7^6I-/&K8W+(U7-7\'O+>6J25]JC-JD(EEP/])FL:F4Z M])JC3),._-

F>D=2S55^8^X+S&Y\3<;Z8M=WDCK(T8V=KWJO_$)#0ZCL<3ZF*->6WY3I/WS

M!N'W":,&M[*QUE)S9$3Y>_P!4S'75//I72H6G]7HK<=YCVO=*Z;U#9I9Z>",CVMRBHASK45E8B,6I61 MCD7OX:?:V2&GE8SOR]*9BW#RM MBUPK6S*Q7HQ-

N4R74EC?!=*)9:IO*>Y-WBAY-+3SU&U:97J]R[41J97WFVK9 MPP=#IYE?=;FWG=[(5;ZQ+BW;-,,QWL>U=#9Z>,)D2\]T;4W\M,E"TZ/K=31N M=;*25R?

W*FSN`.#5TJL8Y]K^XR_*FGZ93\9O?2%+;[/-Z)1^BI(BX5K412NV M;@[G0P]'1FYRY5L7 S5U[K4B@ML]) XQS<(,*I.Q7JRMI%FJ*R*%,)?)3O.MK M/-4K24< MU4]&,C:5^#6W#

[@]IVQT;&+;^;,B)E9$0S+47"BT:BM_ MHZT<4;53"M1J(IL&DM,4*)AN%P7Z4NUJ8.BX[NAJSD]W;_8;,.1=2=D*U5E< MQ*%SH%<[UC>7#S@)IO16D_1JF)'Y3+WO\5,_EI6I-

'(K416B^U'.IFQ-1%9W M*2G-:)\8='CK')JR\<%-)ZM=(RFMJ44+?E,.F-QXU-V<=+6_O1"NQ?I&^MU7PRI!G]4->[&5*+S-I=+%%:P\]T21J[U-_N*-7

MET;.)M3V'H4T+Z,9B6.0E9;MI/N5#$ZVCDI:AV> MJ9\.IF==623-2GB3E)^$X\]YTZ4>UL*!Z]M=)#"'B0B8S[(3*^D/7;RZC:D?56 M]Y87"UMK6N8[V=Y7I8?

1H>8S.YZ]2Y9NV:)U%#-2/RKE\3D+5$% MWX37)CXY)):29_5JNRAN'AMQADU-44ENB:V/:B;G(A;.TNCBU$6C:6^*:TXD M:^1F55.IY5Z;%1U"N:S&.[H>VLSH:-

'I\N5N4ZGA7""^/DCLL6-WM-7:HLZR35+F,RK\X1#9G+DKVN38K$\SQIK&ZE>^26 M5%:GF3=.N*ZEL=#5K5M61F%VIX& MFM-7NUQU53-

44:R+,N8GM;E4+L=HGO<2;6QY>3-=,=HG46B\IXVJN"N92R=T*MKT0R]^N'<8HZUU\$V2-N51_1R9]AK:RT;ZDN4KKG9WR4#>K}GKM_A+6\:HI M=%7[_P!A6\E6IU6-

V47RZ$NKB)WATYSQ>NUGI:.X779NJ'5$L#9&TN55\WKKK1+/$_O5GJYI4U5Q EO[>=I MN-M+%&WI[&O>A&T*ZVC?DREFG8:6ZMJX_55R9;=[8=N]&J

M]B0X>]924O*)M941.=NZ)YGFVVZR1LCW4ZM;W;E4OH,)422->[N^3GH:MN3:_M>I0T:MAD>]KYEY9JCTJGG:KL*WP4KS00U,*HI/;3\$"P2HCD]1-MP:]S?59ZJ/8I7HK?

$^;=$BQW!=Q9W"AJN8Y8EPTQO+)K]U872RVVM=(LU*Q M'^+NG4\ZFTY1LD5$S[|"ZG;5N1&HU7.\5)*:WU7/RDS6+_^#DMK936L/'UWPE MH=:VEU'-

"W=C.XTY>NQI1U5#MLUPY54O1WL.FY*J3U68ZXIRK%'Z-&Y4;A7> MPLZR8<_+T;&2=W&M)V%[Y-

S(UOE.BHO>7%[I"E^]%8E+>:62H3P/F9C43$JJ]$UV?/34W9#UUI*\TU/3QUV$RJPIDP&DX,:E MJKAZ$ZV5BU[UVL;M7:BGU5BBVMVN55,[%[@RUT$,UE;1P-

EQ^J;.OY2R>D)C ME"B>AZ[N'}+!BG5UZMT.MYJH($=A>5]^B&_M'=G'1.@K7#Z=3_9*K:NY>K8;O,M/4R*QW$0M9;M72LD;$B(B+E8T/&MEOC]W(E1MQW.5>JE[3-2TI'

MOYLDOCDH^,]MB:5C[L-K'/DFI6^D3.RJHB'.&NN"UQTK42R\ER0H MJX3'@=T6^X4U5+MY;>9'Y]YY^O7+?;=26F:-&-D21]MY?WV?:,F+):,4N1[]) M&V]

(?."> UOCF5]F*BKT0V7HFEIK/P^N,M1*O/D7]WVI[#U-1\/9Z:\SOQ1(V MEC=A6.5-WO,DIM/V9M/065R+/),J/DH1VF*W6F*GHT2*FB1&M1]85<$\5.UL M*]UK5=[C3O\ >G=Z'?

AG9Y5IA=REDY;95>\|Q6XI^K<%M'$D>955&M9ZRIG" M&&:.^XR6VRV^1E*F;AO3ORAF(,F2M*[PR*KF;'(KD5$1$SU5#3NMI:4DURV,1 M))(U]Z& 7KB->+XYRRS/:#

(O]\M53H>-))4;46"%)&[F\WCK#A9-5>UM MEP6<9IZ>HX*I=F<&VM&4%54R-K6M;LD3.U4[CG_$=1*Y7"XQ3S0?U/

M&Y'(UR&_[#K"'*B65DD2T\,.JIA.G>8OLW,%X^+8=LTK4RN])2/*=_D73;>V MAGYM1#ZKEQUP4]3B%%>+/$E#.UR=R[5.,\6=;ZOA;*E$QW(;N<|?X3G\W2^[

MCYMQWJX1P0\NEZ[.O1376HM215%1'&Y%29R[?<:YTIKZ^7:[4[*R1(6(F78Z MYQ[3V[_4-,J2VTJ)S5K)9BS=GY, U+=*EU#*VC> MD4WADU:^[ZILKY]VZ/;4TK.K&M-

MZEAGHI';8DC((\NST13647#EM+|'L|!*Y4C=UR>YQ'OESH=,OH4>U'-MR)C*=YFT)Z=XFLUT92,MU'),E8W$G-7*.7VJ8G'O"FNJM&6.Y?3

MCLF7"CJ^$]KBI'-1NSB'SPI*?'RCX=W""^QUJNJ6U3^4UZ+ MAK,^/D?0FUW2GO%OBJ*=W-

C[|S5SDY&;-9>ZPY:Y*1,+:|,_F8[,HIY==I>OK9U1*A8H^[>IZ=]LD%H9W22O?O7<6<4 MJJXZS*K1:6ME-A\4,,.W=A):8%E5.6C$QCU26.6*/UI7MB3\!7(2UE[HZ M6-

561K/I9SC,<4LWKCCO>-<=4=PA?#*Q)8W>Q9,<7A[9K?3OAI*-'2.]W] MB+D'.IE.DEC.|\;F+WR(!#&)^-FGGNDAH:MCIUZ*W/--)^KRS;(&]6|4.9Q

!*2HEO4QNX7AU&:UUJM|M]R^*>P|^CUDJU.^3UD:OWW4]J:OBK8G54JXC=ZJ(AK<'-L|<;/.GHX MH:>6I;,N[IT3J%=!ZKGIF1R912IS&4=.]K&;FN3I);+Y37-

C73.1'YPO4\FDNSJJC;'$Y$3]HK_$Q6 MZ6YJ9M6E7W(IV'G5-D@)'-5^9FIT0YUJVLJN2UJVFAFAEDPKIE8 MN&F-V7M0W=86S2HVKJJ-Z,)

<,_!B^HI:.,H.ITJEU69D\#70M^^1##7<)K1< M*R]I*1713]W.QWY[CW.'G'^SZJHDIUECH'V3IRY5.FUJHM9<Z,-T=0U>]6]2 MV>*

(4UKCR2Q&EX&:>MMLY5)!U!1KZ!]?"]I"Y4\%W=/R%5;SNSDPUCN:.O'9\MU15++;)I.B9Q(O M>1]:.$KJZTI!#41P5,?1<++U4VBZPU-*QIEE<[KANWP*UMI$AK&/="YWM+;7E1

M7##!M.<$]:W0-CKD2L>]-5OP4-?;_L=XL]0E%;]?=0.?MT7*KM--ZB;]B?*\2K=MF&QPLPYB8V]5;=&ZJA2.5NWW&;3NV<>]8 M>%=.+535.;2RV 8R-<]50R6FT=2^BR4J1-

>]S51J8Z(-XAF];2Y\??KS6.HN=_J.W:U718 M1/>8MDB(Y)X\-OBYO= MNR=)5&DV5E1S'=Y[-)IU\2,[BCK99MI8O+B^V]F:IM[W4CWN>USLHN#HOAMP M9,

[JKL(.6AL$"\:Y[&N=[53]7-73M@V(S]B=QCK%^CT\4>)<& MO]D+6.8SR*'+;5;&\]9ZD;91-69^^+O IFS:K7966ES#4VW;<MZ;^AQ< MVZ-&X54P[+5QRMJ$VIH7L2ITZ$-

EU4LM*LWCA/$LJA'4N4WG7,]1?63'4\J]0 M*W8R+KN[_(C7O8OW.=N/&GUNC9ZBC9J4Z-.!NZG\D4T-/%IVZ2T\ON$W6-

M)U7\ATCVBVUFG=+SST+722*Y]MZKDT;IG2K;I3RW:K;Z?4+5RC9>J-3R]A MU;-IBNT/.ZG'Q7:YL.CKQ8>)%'),ZJ=R7]'QKZKFGM<8>--/1UE3I>EH9*R:.ML;LE>YN5;X'5^E-

/66ITNRJN$*+YNU[U5$6-?:.;ONAM!:3NCZ^.&&YR=9% M<]4SWYQDMWF5,X8VYN/-'=GZLU$^6IN5R2WV^>)V]D+EPY4[$*I65E@<M-0M)!

M7LUL"1[7=^40SK5O$.BU0ZXPT5,Y"*.JHDD>$1B>PY[U7=+3-6)(CVSSM3:.MEB83/MR:6/BVAGMBT]#]*.M=Z1*L:H^KG8SDREV<#F7"BJ;C)>HVTT6=U:Y.^\

Q%T;.=PWF=ZM;4T%\#)'.M/01212Q)AG]TG>7=TOEXOT,.-UK5FI*;NBVVK3,$M0C5] M.:.1JM1J^U/.91JKLFZX\,I.>2*Z2/3UZ=%V_OEXTDU$_6<"T5NDEPM*QW>G

MM5QL^^:LX5Z)I5M5HJH[&JW87$>Y4Q_,%AS#Z+A1]&X4==454#[.M=#&F|&O3]I!Y5%I&5W*=#*L,KGI.9\G/M-@\3>TG)>&>B62@<^-]>7Z5A=]^

M!]VTV^YI5,DFUV/K;_5%KM;HJ:C4NJ<1N:B=YY|-;66K M3^^&-L51M1[H5\#U"K=Z554=:ULKG>M#Y!|_\^_0;G54DD_HVY$3:GK8-3 MNEW+UBM>3#:FEFU1>J-

WV6BHVL3K Q<*OE@R6\:-N%\MBHDBP,C7'-[E:2?2U MLL]BCAK9(U?T1'/[W&%WOAYIRVO]*RNC2:.1F6[$0]W5UQH]01TGIK'-?3.S

MZKL(N"WGN%!>^33K^&E']*&6HM;N2_>K6Q/[M^G_+.IO9+%[C8D2CVOG6-&HI]83)/75TE%3LAK*U7

MSJW&W&4+HNT;.:*SR:QX<63[%PNJD@7M7O0Z+U=IR@U)PMBIG5K$JXV M?)=W]QJ:DMOHLBUCG.?']\L.>WVX/2HN*M%##.RMH9-B>IG"X(3;FWJXZ\+GO

M5>G:FSTLM8Z5'-;JH:MNM2E1#)*J85?%3H#B5H>IU12U5\L-6CX.],)7=?R' M.=\DEIYGT]9#R)=]HW=%OV\<\G!U58XGA);/LE?*>DGK&TL#T_5"VO%EHK9

M=`4L5P2HTZNF;_6%4_;,G57HG=U[BW]FL>F43+UZ83Q.[I:Q#(M-7.*W.= M4P2R04ZS;'.SUQ3:>FI\.S6ZH[(IG23)U>$X-O4CE=CLD3M/7"]IY.6.,/+9$O M=D!CA7(QL=V9/ZB;,

(Y>[)B9Y+ZUNKVM,)H[?)#*7P(DC<+ZG@4JQTVH:N.H5 M4@H8G;G)GHCC$776HH:6DC@W.BF?L254Z)U,$U7]*^Z0O=53Q7%)HY.JL3JB M)_I*+6AM4K'>Z&TMK"KO-

14TSE22A@I5)&XZ(9$NJ+=?(/L4U5]H;)R1N1G> MBJ[72-@E9F3>OA[#1_HS.NSO1<&?:SFJ+!555PN.L/E2S+)AKNB83N{^*:/9M-.MR,30Q-S-N1%=Y&Q|&WBX66WW

MFGCI%>M+F2.3;U5?(\K@_I;JOC;JI2)K*>%<%AI[?(Z)SG(`MDN.BX.A;QI^VTMPDEIH(WULS4?)ZJ(OJ^Q#0;Z>FH+,5W5S(J6:-JHUL.(W* MD9K$U.A MJZZ:RNMX=)SJF1I-

O5>6KE5/R'EJU8U1&-]:7P:5[PMC'M.\JR|\-H8LNY93S-MORYN%R5I-+T69&N8]7HGR5ST4R'ANDL.I*>:.F4[7)S6N;H[!>91JV_6IN

MO(96V_T:V4\N7QN;ZST]ON(Q6{U=K_!Y_V5U--I>AML-O;/,*5>8CFMPY?' MJIC%]N:KAJ5A@BV/1T$:8SCVF_=1:HLD6GG7*W31Q4DT:M,$W'1?<GM-/+4/IYLP/P]%Z*A=?

9RY.:WF5DJ(WY/K]WN*^*K9K%HYPZEJDH+3 M04U-1OCM[:=J(UKNB+Y]#76KN+5OHJU:>F_J8TZ/;W*_P 35U=<[U76SGS3 M/EA[DFW*>)2.3JYI.8W.5=[#'&

<$;;RX\2KG2RZ,}>^M M7?.O>YQY$2GKR81(TID_$7EQTK4;?^22U M;4.LS=R-5/(HG=?2(CO>9444]'"-.WEPR>LW'>>B%@C4W=55</4VW;-9V2Q_UOAU*T4VUR(

MQ5ZIUZDX0O7?FN62MRC7,[BJV1'/1&(5;)L:4LJKUD\RE3(C4<_'<7543*]5 ML;8\.Z.5#S9VM:OBJ%=\RU#E\"FZJ3;RU:BK[<$90KONHHK6Q[D7\12=(KO$

M@K>6Y<|4P2)M5BJA!M,;QNBJ[JT){25K<-12#>_O!LNXG;AJZ-7(YN,9(Q/-"8(G)E2X9(B=Q:P/3Q*]O1O5"Z)4S5=-=N3H M2O;C"]0@=NRI&=VY[(AG=3LJ1_))B2)V$)G.R-U;IMJDZ_)0IM=WE1OR54G"-M,\DK>N>AZ-1;ZRV-8M53JR.1$5KE3O12>S4/IEUI:1$SS7)E3;6O]&UE[AHZ
M>C;E88VM_(6QNCNT_3.SIS3\E^KD@@3=%GUE4LKA;,JQU"P54>'% M_IR>XT+Y);?*D2>9)3\6X;=H>S4%"L/HI$14^Z2*AY-PT7I6"FFG?7HQR=T>
M37<^]-Q4.GAGJ,H_O5BGE2R2S+% QSD))%1%1+J:.RIN%53S3.IZ:'=QW M21$ZJ4)8&5,6UNPR:WT46C+A%+=*:/3F3W*BY[ZR"BI661VW"-
P2UJ[JAZQMV)GVE6;=N8F/ KYLJ,: MV;JM<:0X[1RQZCI=WR.7T-[6^RRW*LG>DJ,C:FI)$SWEC3UB,:J8525=AW1JX+8 ME3.-ZWJJ[."E)4-
WHWP\BU;|SNG5%*BTZ85K1=EJ^PV'P.ML-SU0YSWXDC8]M0UY.JR2(F40]_0&J/T M%WY:YS=WJXZ=QFLKJQ'Q=(;L3G::N"2N3[G%A-QS DC4=,B=R*N#,M:<5]G4
M,3:,%JQ.Ef\+@U^V1T;G,>J*N>):25ZUX>2,,ED5R9P4G9B"]*N"G/*C.K M5ZDS*IVQ.IE<>)3NC%>2MA4:BX_$1CD>KE\7P2A3IZAS57[*QD>)715]+3N;3,;5;<.7!X43H)L.,"
MBR^[)[4VG:NCITFK(T2/[Y53K@[TURL=#2NY+,O7HFXNK9H37GS>#4T55%B7-MEX:A(J?,U-[$3'^XY[RZF@K;R&9TR:.H=2PLZ^B9[S;NAN)D&HJCT2MB2CDEZ(]
<)DTKU>3I#6.F75%N=3LQ)XMA[*#;4%1<;3/0S5"RO:O1SG94CJ:A^SUIG@YBQ2PY5'(N,CN=-M#>,L8?OE;WF-WJ.C^R.Z"/$6?8/'=\&]TKO5]A4SNRJ
MDL=JNT+F47.9(W\)3RD;+,JIU.^3.WN+F@IG6NA6H2;$CT^JZ'E+4O 24E5 MR.55ZY.[.;MP<'M+0LN5Q=4OP2.K)$^Z;$,EMEJ239(VW-1/OE.(T1>J:
M]NNGM,_HJ58(W;GXZ=R*4?!U*[3R7$,R^D2QI/4QWX/,JJ?G,D1KL-_:MJBUJ+W-1S/\ 5]3VJ6%9J9LE/),QS$6-O5$40MF(B%K4MC;N1C,O13')Z*GJ M+I'-G[NU3S=/:Z,=+I4-
>N-KL(>3K#44]ON+)'LY<2K\I.F2%8M2PUM'&U4PLG1'>TKUU*L;N8UR(?)2.TJL%|\ MX>C-<.;3+I9I$CQU,$X@:NJ6P1L_2_$N2\X;UG7^_U39-/L M^Q\+ZMK96=Z;6J>IE-
JM,MCH9:NU-WJ[|\"###4C46VV0V?)=G5"?=U5]M MZX(IJ*&.1C8*K/,.FLZ{5T]195F3:ZK9EJM\3'.'=^DNE^E2]F6.7/1CE5_.MD;4Y-JNIG;FZ&AND=
<.;C#E/2I+7C#IW^HO@8OIZ-9*AG,5-R>/M,SI]>6JF M,'E$8:=N3:Q9(R,FLW/;%RXF[DQT+6.G9!7/;4)ASUQ@]*GBCHMFU^<)X*5*
MFECKFH]4I9/"Q*FY7O>5<4L*5C(WKS,_)\"=U5)1SPS3>K G540MKDUVYK6 M.W*GCCJ1L6HC;35#?5]JX7?!6NU"VX5#*^EF5L;NBMR7-JIUHW/,_*LN%=[$"'$N9JJ3JV-
,HIYEMLU755TTTL[H MFJU4:WVEZVXQMK&PY"]GD6%_P!RZKCH@64G>6GZJCO&B]2RS5E8YU"*M_P!5NU.[=UP>_VUU=MNJU#)_4BZ MPPHG?CVDT+=
[(*VWKO56+ZWN,;)9)9G0(Z&NAZ M2^IT_6EX@#]*>19(5;(N,(BF:S!MQ;,#X]\0^A?H99IX3:IR>KXX4^=O$+ MB=?
==U\6^>9$HJZ_<3NKM!VN:3AC4SR4Z3SM=N5%3JB(<*:GLCTI(NUT?-C MD_5=]Y5IT\-(GFYVOO:N/DPBHDFYB;D2-C4^0A4B]EDD:B]&H5GQHKE8KL*G MG-1QZTHULUU
MC;N1,,J_$P5%IW4O*=39F7-E>B)WIW>1)J M#AY9M2V^2FKX&QS-3#7-1"N&Y3%-XYN/*;:FY5?E,>TR326C:G4 ,V289[R[MXB<.ET=5+R&.6G].]? U7:-:U5GO*-
K*J.K8KL.G8MVJ;9<+5'MJ6M>GZLT5!8;72UM-4MDD7UE.!MJ5UAO9I_#S\&3ZPU-,NF*BML+[G32 M-IL#AU.RNDIU\4(&@X6P.K*JMDIU;SDU=N6 M_-
WJ[Y(XH8S<^*!UU3;Y*>=5B5$PG@:\N4+(W9ED=(]>N>\NIE=OXV/271LS4TM%+1U+86 M-56M=GN,SJ89IU:8VL3&Q.I&0W"FIX89*E6.W?@JB'E.YO<9U=+30-;Z2I>L.9T:U%
MPB&(1V6:LKDBA9BG1>DABW-KC4MIFH.5%)]T M1>XOK=&VVTZ0RSHB*WN?XF%7[3DM17.EB?&K%ZIW%5:[PZ%,D8ZP^U,?R$]Q M%O<2Q_]:>XF;W'DWT6O="("0 M
@O<4W?(=[BHO-/\%)Q9:]+47[1LRI_Y[5_T4]BK^#%XO/ACBIM2:2@ MC;WM6MJL?S8]-3588C;BAXBFDSTO[DRNN\UMTW0VR*X4=-3M?R\X7"KG!A-@
MOM5>N*TC6U[:=&S*M=,[:Q4-HZ4^#UXPZ?DCYNI-)O@;_N<=:;5+_ TZ&3:E M[*O$"^4B0I6Z3C?X5'I=0C_YN5VU&&WZH='LV6+1:*2LDI[_LS#)')/"*]=-T M:HN?,TMQ:TW#-
<(HJ&I8M6WHK6KZQTQPJ[&^M]$1O;>+W9ZI%N743KC\L2&_M6UG9/=-5+5L^QOI?_C'/D7_F$8U../U*M1T=;-][9]^8]BI;9KF\CF4I5XOZ_MHBEQ9K[VIV#TEZ81?2)HO\@89/
M\&WQ1DFD>V_;45'+G"U=3_1RSM6+S0T\W1NKOW4ERDLK9&>LC(${D3EN>H]..+*GR6T_MM34*W]^%/X#/:L7EAFG16JX>=)D5M0B=5P>58KO66[\1+2+M
M1RJG(F<'4LGP:/$OF.2._;5CC\/ZKJMW\W/9J_@\^(E+:VTL=?I)LJ5ZU!=M3N_FQ+M>#NXH78]%K<4[Q26(:+M?56H-46]E5(UKZ9,)N.KH[Q&V&+E_+V]Y MHG2G8#XEZ?U
RO?]#3CV(O='4U"N_D#>D' +6T<4;%N=I7:F%^[2_FC6OEP? M"SU6FKJ(Q[9*RM9;LV..5TR(JKXGB5=R61N]CD:G@9PG C4;Z/E2UUM63V\R M3\V6E5V?-2S1L:VNMB;?
PI9/S9J<>/?^IG51V7^T5!9V=M64I0DDU=:G8_!FE_-%TY,4QSE5 M7!FMOO66M.*6I$TOI25-R-EF;]UZG&B7+2BRO3"KZ54?I^X/?B6K]JWG2C&+ ^#55"N_FY7^O%
MO[T)6Z+UD_HERXK6.J53.2E5-1CD[^G@=5N^#IU]Y%=?=.,]KV35'YDK!\' M5K6.9C_LW89,+EW.J9TS_P B6]MP^.:%7LC6[^Y+E&# ^JEQ%N61.Y$*]9#=6Q M\]9LS&*G1B-
5F^QWJ"T4D;:RI MLE=,U;,I))L?EY17.KQ3^[*0IT3[>'W9<+671]XK(W5,39*9L25'/3&2A<++E M<)*M&5M1(Y6=$'BG9^O.O_Q1U$[E6JZ;7H*3]\:FH1?WJ=37TWP=?%"3;B
M_;6_QJNI_HYGM>'NXH51T;K,=]XI+ ^#.M:FG]WTTK?N"_?/?JM+5&O;59. M6MPY,T6WHU515]Q)2=@?BK1/C=%?=*L5O_G=3_1R:Y=@+B9>48M9?=-22,?N
M3^JZG'\@:I\V"?E=U^IU=L+5G'+%*VLT5KNW2[%AIJE5PUKE1%RIZ>@>"UNL M-'>LL5XTNQ<=/ZKJ>G_(&2:?[&O&/3]-,3ZETS M.UOA+65./YN.T8IO?3TNDSQ/WZ3#
(JC3<%XC2*J:Q85;C9TP6%1H;2M3"ZDJ M*&-JTI1V$,RTYV?.)T.J_9BJZ?=%^#2SSJO[\2&<47!*Y4<>5^QU1-I9)7I_MS#6G-2/BZ-M%:T^[+1-IT%IC3G\#%)5U5?C M*K+T=>
(WK#CRZQ:MXV98F^#)YMW\D4SFQ2Z=<. M:T<]UQI71[;?-SZNIW[>YNXVA8I*/Z6]BQVCO9+!)$[.&JAI+I'2Q5#M[6;4\5->6W7B7.H=3,].I>U*;6YB8NX\ZPV>NI:5C:
M^2*25O>Z-RJGY51#U*PSNQM5]?C*KWKOR="U)B>3Q(ZBM=AS7,0KTT#]=8I MORBKU+YU',[Y3D5/>O\ H(-M]D7N:YOO%5#@E(]=SFHCD5%[\%ABVWO1RJU&HWV97_
$$\EN21R/1$1S>[J8FT2EM+P[DDDC&)*QR. M7\'O(U2;/+'>/5#'+E M8T=5L?GF*G?@SM;4BRH[59W)A#P-,*K7IFJ;-2L5DDGWWL-Q7/0U;69Y4T+5]KW.S_%+ M"FX?
7AJ_=,FE>S^[=]4OZZ/%JX]+:EM[F,K63.JXZ=9DY:/5RJ^!ZE9;5KFL MY2HJIU7!:?IPQK5D<]TM+E?I=WU2]M^BKM0R.^[4KH_[MWU3/6U;TTF8]UX=3
M3RQOHC(\YZ+M,8U!:WNA=)EZK^"AM>/2!T[8W(KT=+_;]]_YCR:KA]6U$BN2[MA3\;_P"@O&ZOBRK;X0UK9^93TKU1SD3NVY+"Y1SST\B[?IZNFP<+]R.-R/
MJ(%>JYZ.=]4DJN@UPE1J-]:?#>]',=]4GUE/%]9-/DM'"5)H?2LFI-6/[-FO=;VVGM]DN5CI:1J8D;55$S57\38G&SCRX_C9Q\FBS4G>M)-MER5Q*XGU;JZ1]OD!:MJ+M2&-
,*I@"N66D?4*JTS.])$7+G*=)K\'WQ$]?2]C\P5(O@^N(&7\R\Z;D1R=&>E5&/Y-W*YL$+=]W)MI-=:,_+'+3-A MN]#=[=24-=$R)CEVNJF_JJ?B/4U.R@T9=Z1E-5.FH)6IZRIZST\T-
IVKL \1-MK>KU=>=+-N5?DJE54/\ D#W(NP/JBNAYUUOMIJJMK-L;633;$_'RL_O$;:C#-MYH;==%]J\~&7CZ8HYW4-<+&V*HIEZOB8J*\AD*)?;3?JO[*UE(RCG3HO.Z
M9)],=D#BWHRH1UFU-IR-N<+')/4*FW.(F2VGLAZKK+LE9J.IVVHD1<[Z.657 M>[K&A5.?%/ZG9PZ;-POQ51M5OIXJB.&FB9MBZ[DIE_&9[:]-)15C:SS:I[UG MX.5-KC9"DU*^-
O>JN=N7_BF02:!?Z/RV\C_A+_H-.AZ(@D5>9"K?8U5_T'HMTQ.Z5';>S\]_Z"]U-MJ>*ZMHUS>8OK'M6Z;2%SD[:JK_)BJ^WR?]F&NE_ME5/\
,0XHW.&W@\Z6>*GD1NS>KO8A95M- M2-DYV!R,_0]&JM%>^=CH5@:U

*CI%8F[:WO-Z=FUM2 M^DKJ>?U:?*HKE[T\C:6AO@Z^(FG+ZZNK+]JN2)6X2.&IJ%_A@0R;0W8CXG:3 MU145+KQIB6T3R*]T#*JHYG7RY&/WR4ZC#,>\MIT?*
J;SILI=OD*PT[(696#*V^.M)K+7.KETZL43GI)$YN%1%RJ'6%Z[+FK[C!)'#<;-%T^YO=/*FS_DC2-Z^#PX*
MJ7:Z/FEU%I>2%RI&R5=4COYN55SXO,Z=M+GBGN2UKI3[#WRWJMMN*45UKU:Y87W9$K6HJM=NQG|\V39/@V]>T]RI(K;Y1[EL3[FM-5U:Y*
MJ^Y8s*|X^#TXJOKG/M^KK&L7WJ55;4H[!Z!2%D3YE>U$?QVF6N^*#7XHS3)+-:M*N>`MGCZ95+_^CE_!\%Q%IX5;'?.,(W>OI53+01>GP[>]#7MI=7$[Q26/W37UGN-M-*
#$M+(J5/CA2EIS4\U#7LJU1'*WNSU,WL_P>O$.W(F^]:.<[VMJJE?\ H#,+ M9V)M;4[=L]TL#D_M:B=?^A'7X?/"==/K)[*]5>9S_LS9VIX?=YO*
MS9KSEQ3/O.MCIGK&W!+6==6U57?HFUTZM@?UV-4IUE/3S5DL="B)&B=4[PS/_^:,NTSP*UO86QQOK;+,QJY5O/EZJ/(UQUV/Q8Q:745[ZR\NH*
MI4;3*]'HOMJYBE4I_ZA5VBF_>Vl;--/=:BBM,\U;NI]\.?:,,ME/#1QOHUB1+MXM13);3@]=(&INJ*+>GL>_ZA=KPNNZ[T\'T_MW-4(3FI,Q>ES5G?A4I-\E*.MQ&KGH8[SI>9-
$)$N]$<,%I=%5E/1I&KZ=9/;N=]4LF\.*QLCG\:^%'.[_6=]4A M&2F^^[HSAO-8C9CEN@9!$CE9MJY5;>(H+@R.5%FMKXL1@OX(U%&VN;'(Z!L:>OJ=5+36S M9::QL=#*E.QO?
N7!D=/IVO:YN^>':W\%R_Z#'>*'#Nl:PM3**VU-+3_A.J)7 MM_@8I'CI.>[8L2)ZT:\R:M,V*.MOZG'S8-1D[JRY_BD;%'M6-RN7Y3L=#TJ:WI4OA5?7;GJC3<=1V1|,5#6M^R5
MCC8WP;/,N?\ D3V+++V6M3VU6J^KLSL>+9Y5_Z(E;48K1[SGTT.HXN=)7'#K2-M%GCL[*V>%[W-[VX*NIM3NM\KFVBG:Q6^U#8-DX97ZTVR2D2HH%5WX,C_*AX M]QX*7VJ=
(IE5;VO5/OI[_S#7kEIOWNK729;_I:\MVJ;QN=+/+/]^\0R?2UH<]+4/F]'QK^Y<_<55?X40!MDKM MWMVF*]K1O#R^_VMJ7ASI>;]:W-3*U6,:G><*TFNKA:M;I>Y^;)!.
[+F+X94[M!X\\+;_Q/;2I::NBI^2_<[T]1H?XK'&C+CV-^(%8IU;S8D9I'5$_YDOTIL<1-MJZ4=;3+,,8HW9I;KY1ZEHX)H'L>_;ZS6NZH6MTK%B1\;)U7HU?87/#++LW:OT M7O2KKI-
*C^_DSRK_ Q(9S/P9N4_RZFC7/5?6=]4G?)CB>4M+3X,\5^]66DZ MV[3N8ZF15S^$>(RS44E;2Y;Q[K$*IOH,;4I]K8W=[4Z$UKN M#*9RJU-RKWHALB+L_:EGA;Z75VEKVIA>5-
$]?QDGJG#4<+T6GK;6W^ZED3 M_HRN2)-"Z%8785/8IEETI.^NIX\4U?8T\I)-MYO\ -"I@-P[(G%RNJ'2QZBT|BKT1M54_F#,9<E$U%,9(-M=[6/1O1,1*OOVMU39[S-
1UK$1&9QDZKT=V8.+%AJ7.K+WINL8Q_G51N_D"_MMK3L=ZEU-_5$%=98:Y?E.?/*C?RI$]_O%U<^/S.???9LD^Y+DEM;/3N>^G5R M(U>Y2X2Y3/[E63"|:\WU)V$>
(#\8O6G6_A)Z34=?^1)F=A/7[>GV6TVQ_M,_ M9/MC58_-#4OH=1'=26E;,1ON%-+(QS>8G7.J]2/+='&K7/V*G5UT&IWW MFDM:,:U:/I^XI+$YSV??
-3/4V_IB_6I55,Y%>V&=>CF.7"]>K'V*]?00R(RY M:<615]1ZU5>KY_<"ZMG8UU;.R*IGNFGTD:N7?U3\A F2$\Y\7F;E-:]J?HE MZ=]I/HH:Z*LH?9(/EM-:
<2N#DFFW2W6U)SZ5O58\YP=-63@Uf*BCC;55%L M2:(U,*LC\T3O6LN*5ZTZ>M&G5OBIU!7=ER_72RK135EJB5K<,Y]M:?2ZBGZ98?IC2E/-)'.ID]95ZJAF]%2R2;FS.Q[*7=
MIX87RA:Y'5% N5SZLC_J'N)HJYNC:QTE(B) ;. ^-J4];3;O=.F#+s[S#6.IZ> M56OBA:JJO[ZI;?/C^,M6VCOM,0YDX@|-&H*"97-MI=]%)?L=))]0MZ_%Xj,>CS4GN8?.V"HDY,\?-
B>N'=.A957#RRULS6Q4S4"\^AJ'N:46[EKXS9?-MC5KI^FHK3;8V'1-?'G;M3KT/6H+2?R0-;,$K8XGIAS5Z8,MNO"#5<]"Z"BK;6 MDCDPBS2R=/=B-3$[#V;-.0NF=
<[Y;I$]D6.+A;6T[VIHWL>]{KFM0W]2<%M1TJQQ\^UU$3?.M_&RR;OY.RM.&DLE"D3HJ*.7&,M7_4-?/61N MA1O5$[U+^JT56R3,6!]/%']\FVWU2NFEIA!(Q\$E.BM_"KO
MX+6U53>8ZGGA^)W/FNDZUSLND@_P"$O^@MJK2MZD;/%#-2K$]-J;WNRG_%)<=?%*:6F>YX5NU=-M:(IA)%$U)OV+BHEQT=^-#{JBCH[A3QU=*_>W&
<9[OQ&.:6X25NGGS+,ZCKVS MNR_G2(\ WO4/:TIHJZVFL]7254#Z:15VQQNT^GM47BDM=$RKH)'.1K'+/GJ?3O67#6OU%9:V MBI:BGB6=-FJ];P=\'QQ&VH;6U%7VX:IO?
+\'/Q/;?)JRGONE6PR/MJUU54HN,]W_>^/WS MHZ?48XCG+4U],E\/X==Y MIU%]'X./75RFBGI+SINGD1,/:Z>H1K_Q\D\BG^#6XEM5=]\TLK?!&UE3_1S9 M[5B\T/&6Z-
U/#O%):9TAHZP7BNAJWUZPQHN525<(9;?.(EFT?5K!1P.JT8F& MR-3.38U-\'+Q)C/0ZN*\Z2Q'AUQMAOU8^DEA2ED>[U57I@VVZ:*K5(TVN?C*.13$+
M;\'/Q0H+A'4MOFEF6=O_KI?S1Y5?V1]35Z_=:RR2-]CIV?S1B-1BC]3H9M#DM7E67%*_M:.M.DXVU5>BU#7KEF[OP937T]I9IN.XT&V)_=R\]3I'4G8AU%J"G2);A98U: MF&?
=Y<)_R1B59V!^(JTZT]-YTUR4[N955"?] 3]3AM'.SEVT&HQ3OCK,M*U5 MUL*:?A?Z+&ZL{\>)YMHLE9KFJ2-]B,IF=-FIJ;P=\'QQ&VH;6U%9:V MBI:BGB6=-FJ];P=\'NN],7-
FNO5AF1%SLAJ)U_AA0S.?!'=9KVT6LO:-Z2UE,.#%MMJ132 M-Y]J^WO4]F[6"ADHTI70M2'&U,)W+|3H)>S1{QU1S&7"T]/O>=+^:<79@U7 M*Y_/]{Y%,!GE7_HBOK\?
F=6G1^2OZ'(^H-$0_8M]*U=SG?)=[#&WQ7#1=OC MIG3+)!*BHJ9[CMBK[)^I*J!{$]J,QW@O.E_-&NM0=@77M[G:OV?L+8FKE&.G MG_,B-3BW]Y')HIEDC"B\PT]=1*
[*8W;A\#1 M"'L \18;G2U3;SIG[CW;JHWP?RL/LJDZQDI6Z4O#T?=YOS)?VK#M]SF MVZ+U&2V_!+EC0=554+6P/8]G3N-HVZL95M5HC0?>ROI
M7XYYOS)Z#NR/K!S7(VXV-'+_ .7F_,FK.HQ[^\[.#19<--N&7)'$_2*4MP6Y M4T:)$O>B)T-=I)32*QKDW)GJ=X7CL8ZSN!M=3272PX5/QIB;\R:R?\'#O);4 MJL-
YTKRE7.'5=3N_FYL5U>*(VFSGZCHW;;I74EH3351TM%IJE=R\KCV'L0ZSH M754B,AVY^^:P;DC^#GXGLD5R7G2FW_"ZG^CEW)\'?Q-DAVLN^EFN|OI=3_1Q.
MJP^9KX]#JHC::2YPO%RGKJI6DL1L3EQW]#V;%OQZIV?]'X/_(F7VV14RZAT\U*:8}>]J-[_\@8G M+\&AQ3PQK+WI':W*LJOZ.9K\,1[T*LNAUE[QPTE],HOU-ON)F]Q"--K$3V
M(1;W'EWT.GNPB D-M :*I,07N-E)'>'),05 *+ODJ2..I65"1S1S%LK2DK2Y5O>4U:!:/C*#HU+U6E M)6^0%DZ.IK&7KHRFL8%DL9*Z/P\"\Y1+R_("SV$O*\D+WE$JP@6?)3V$.3Y%
MYRAL L^2I#DE[RAR/("RY?D.7Y%YR?(P< MGR+WE*.4H%ER?(4HY2@67)3V#D^1>\|1IRE!R67)\AR4]A>\|1IRE M LN2GX(Y/D?O*4PO>4HY2@67)\AR4]A>\|1IRE
LN3Y#D^1>\|1IRE LN3Y#D^1>\[M1RE LN3Y#D^.")Y2CE*!9PPO>4HY2@67)\AR?O<4HY2@67)\AR? M(O>4HY2@67)\AR4]A>\|1IRE LN3Y#D^1>\|1IRE LN3Y#D M^1>\|1IRE LN3Y#D^1>\|1IRE LN3Y#D^1>\|1IRE LN3Y#D^1>\|1IRE LN3Y#D M^1>\|1IRE LN3Y#D^1>\|1IRE LN3Y#D^1>\|1IRE LN3Y#D^1>\|1IRE LN3Y#D[^]Y2CE*| M90Y/D7O*4< MI0++D{|R?(O>4HY2@67)\AR?(O>4HY2@67)\AR?(O>4HY2@67)3V#D^1>\[
M1RE LN3Y#D^1>\|1IRE LN2GL'\)BIY2CE*!9PO>4HY2@^:,RY/D.2GX)>\|1IRE LN3Y M#D^1>\|1IRE LN3Y#D[!Y2CE*!9\|1IRE LN2GL'\)BIY2CE*!9PU4HY2@67)\AR?(O>4HY2@ M67)\AR?
(O>4HY2AC994HY2@67)3V#D^1>\ M1IRE LN2GL'\)BIY2CE*!94HY2F!99>\|1IRE LN3Y#E?VOIQ>\|2')7V 6FP2IY*^PCR PL^4.5XX+SD^0Y/D!9\|OR(\GR+OD^1'E!C:%GR?
M(43!,D97V$_* H-C[RJR,j;"=D:@2-,W ME9K"9K>]JL: 8TJL:&H56MR!%K>]J-\2!.B 1:F"H2HF28_"*)DF EVD"< 2 M$4ZDP) M 15,$)%ZDI5)%0"DJ%)6EPJ$BM
MU:2+&7"M)5:.:JPD6,NE:2I/("U6,AR MBZ6,EV 6RQDNPN^6.4I:\"1C2LUO>08TG,W $3!.B8&WWDS?$",, $43($43"$0 M T=Q M/I1?Q9\3+?I^MM\;I/-
-#%-45B.=5(FNIKKQ!CT!H M1:.GNL<*5-QNM5'O91L55EJ^_7 M-9/0:-K5>D+-,W*YZ,:U$]JY$_&;=U+]+B?P3AI[W?;Q2ZVTWS496M;2,IY MJ=-'*B(Y%8G=E<)G*=
<+CHI==1^2YWW@ZZ[6:Z0)IQ\,,U5 Z'<^K:^:%87-= MC+<*NY?:!N33UV;J&P6RZQQ.BCKJ:*I;&_O:CVHY&K[LE\K34/#R^7;AUP?3 M4&K+M!/IQO%_B7:8=2P:DH-)4 M-
6G/H;6VB9,KHU^0Y[W-SA4Z^.HJ'(YS5=AR=&Y8[9,=$ZKW!O7:0Y9]A]=^(EUU6;,U="E[MOH_/I= M04M+RHU=^
_;FU%7#NF,HJ>**BGO:HAUR[7]A=9)Z5FE41OV19(C.8[UEW;< MIGY.WN S+:65ZNU%IVU55RN-0RDH:5BR332+A&M1.]_YL>*]>FK30/:QJH[A
M#HO2D4KH(;YS<0]-3:3EJG*D%=OYE,]<>+NY$RJ)E MJNPJIG"=3 M2)JRU+6;6SS(G+7Y3D?AN6X_?4-_[1M-7\,M>7C4?%'B#9:.^I9),[1/&RCC2
M)K%:USGYRY$ZJR=XXWZ|O&BKMHB"U5#*>.,Z71M+5(<')KM\>YG1-R=%J9>[7 M_%KB54\.9=--IZ?&K^RU>YD?SG'W8BJGK)CO[S8.TT=VHTQ5O??&9_*T]
M76_%*\WW5S=%<.FPU%WA>U;E=I6))3T#,X5%\%=X+|E1,NSM#;FT;3#>(6]+ MKPZX>OK::DJ=37]-K(629ZY,+9\'C176Y%XNUS;
MZ&X.9S$M:6Z/E,54W;'/5]JN.B9PN.N/:\N;:-IKC@'Q*KN)6D:BHNT$<%UH M*IU'4I$F&.5K45'=_1>O5/:BFS-H&N=$<2]K5/$;5^FY:*&&"R.8DG@;!VG+=GK-
6+Q]XA6O1*6&OK9466X5B*Z.8D]F5]2:GL%YJ/1E]8S=@(7.]6ITZN;A%5.]5\%0PW4&G>.M,FG;+67QFNZ"X3T<#IV;=]C8V1N:UJN5K7;ROZ6<.M 1-
?.H8W5\4:QOI6Y2/G\U(D7]N=NY4=[<=.\\.TVGC%?=+P:GHI;VY\U53> ME0VF*WQ.B5%376:M9H6P4F,91$SA5)=-.VUMHGBS.|%.RN-)?Z6I0N?27""!L4B*U' M|'(U$3JK%14Z]
[>O>!N|:-IIGC-Q2U+HCB+I2TV*&.O9'5EEU34;GM=WIJ7:ZKMD=&UK&-W(GJKL1SDZ|5 MRCL+Y ;_ -IIVGFZ0U!#]W2]JO4+.,5%7IT=0D:|59N:BJW\2H>W:Y4UCM=9<
M:R3E4E"Z>;3'R6-17*N/Q 5=IFVFA],WGBCQFIM*]9[U2;,T\Z5S*&):1D\T MZ-54W.5R=V4QE%PN%3&$RON<.N)6HI"7]1H#73*=]4Y4:UKO5[LJG?
W+3U=>^)O!.*#4-WOU+K+3RS-97TZ43*:2!'*B(YJM3HG@-MBJN,XZ=0-OZTU;0.$TO7WVYK*M%1M:KTA9O>Y7.1K6HGM57(GED|^Z:NK/BW-M74MHMDE?
62T.=;3YJK7.>_>UKD9AJ*JKU\$-<IIZ6Y7S@^^{6FYPLTD)##-5 M4[XD<^L)+"L+F.[VI57*^WN*ECKM7Z)X!5EYJ[S2UCX.133VIL5.UJTT?+; MZKT7Y:[53O
8!M3IUTKK[I>V7"Y4+K77U,#99J.1KFK"Y>]HV$/OH>QM- M457&632? JSZONB-KKM6P1-BA:W.DU0IKE3HWN3#5-MTMC;P_5 MMMMU?(Q9&63T'BQMSU2-
TBM547N3Q7OZ@:LVC:;_X+!49.)%HKX[C17#W4%I MG]%N%(B*C6OZXJ(NUR85MJ^FO=+=87.H;A M!"Y-$-,W2"\5-$KI.=20)$CD7:V.;GCO7&?[8#-]HVFB].0\ M8.
(MH@U)%]:WZ6IJI$GH[#8RA9.BQJGJ*ISFJY-R+G'7P7"+A#)>#O$^Z:DN] MYTEJNEBH|5V=$=*L'ZG4Q|$YC4\.|JY|EW(}>*(&S|#IVE7:.FU[JC6]UU[3Z M0TA3-M43:?TFKO\
6T]OB;W8;'E-KEZMST7]P1%4#:FT;3GS7%_XH<$H:._^ M774E'JRR/J6Q5-. ^B9!(W=EVT[D5455QERHG>B;FIA%RJN0#8^T;31=XM/&G2MAJ-1NU50WBIIV<^>QMM[
M.6YB=5:U56HYRIUZ)A5QWKXY'J;C>VP<'J/6$ELFI{C7HV"GMU0U$?ZH7_IG'4I7LZ<1KQQ.L+BLBMI+QO1,&N1JX1.JBKWKU V1M&TU M?V?-
>WG7MIU#/>;AE1)1W22EA5L36(D;6MPGJU7KWC6FO+Q9>-^BJ.4E2QE MHN<$<CZF)T355SFH_&'8RWY*=P'NZDU9?;3KW3UFH;#-76BX(Y:NY-BD5M.J9
MQE416IG"=^#,]IK#7FO+S8>,VA]/4=0V.V71KUJHG1MF74\GJNCC;1\^-FRFD"W#BZW77UTI=07/TI(+;'2M1B2JJ9.U51C>O1[EZ9VL7&2SH[!QLO%K9>7Z
MKMMJK9(UECLBT#%8W=U;&YZM545.B>*]_7O-W9M&TP+@YQ-DXBV6M9<*1MNU M!;JA:.XT;5Z,D3/K)GJB+AR87JBM7/]#5=A;0*6T;33%]X@ZNU_Q"N>DM!5-
M);J6S+MN5[J(CFVR95O+8Q45/E(J=:%B14QUMI]9ZWX-7^SQ:UN5+J33%SF;M2)=(J=0:61>Y7(B=47O\55&KCJF%#>&T;36G'2^:OT9:*74>FIXYZ"(@>CKE
M;I(6.62'/5[78W)C&%QX+GP4\+7O'E:ZQZ=HM!*VOU-J1&/I8U:CO169]=TC M5Z914_:F$ MVHKFM1J=^Y/8ICMXM/&G2MAJ-1NU50WBIIV<^>QMM[.6YB=5:US6HYRIUZ)A
M5QWKXAG/&GD)4\+1%NO=+20ULOI#(.5,]6MP[=URGN,VHIEJJ."94V\QC7_E M1%.?NT%J>36/9VMUXEHIK;-55<#I*6=CFOB7G-M1;N'D%]J&0172NBI.I'Q-
=O9EB8]9.B]5Z@:;VC:6.IZR6VZ;N]73KMJ*>DE MF8N,X77NP MS6)U+6.AITFBD9SXT]I$WIU3W90S/:,T-Q UGK/0?$*IIZZ-UZM5;-';U2G
MCQAB;DC5N/65V%;E?:9_P6UP[B)PYM5YG&FO+UK{B;K)(ZB--)6AZ4=/&V)N9)D7#G;\95/4>O?W/:8[0ZWUS MQ]OUV9HFYTNF]+6Z9U)E)
(&SRUF,."8PCDRN5P@;TVC:,:T]KW5 MNA.(<MTCKRHI;M3WC*6V!4L7*W2-1$6-I$3&)<.]CVI6H9^A>^1.AY;Q-W-$1#]RAV.X571=(-3P>TIQ=OO#V2R46FI8V5 ML[)JJI5T+9-
L+-J(N')T1'J_BG?-.C455[T\%7I MU,NT9Q2CU_PIK=3T#/1*V"GG;+ OK\FHC9NQE>BHJ;7)Y.0#/MIKZDXE551Q MIK=#K11)34]
E6E5N7>JX;ZN\8U1H36'&+B_IR*ML5UMUICH'.AGJJJ%B+6 M3;E=A}&Y$1K'1M\$URN>F1V*.6/M.7!DTG.E;86(^1&[4-+Z'K; M>PVNR.Y5?=YH$E&>D
MN]+%RFF3F1M6L3=S M:A$_"%CQ#XF)I_@S M/JZWR,9/4T<+Z+<0-72-TKPW?+6L2ZW>KABN3 MGA\?7\[V"!E3+0O)(D.BX;_UFIU7P[S# M>,,/$N^6C4=ET7I"*&34]W19.?
4)N92P]?75O=GU7KUSA&KT4P'C%0\3=\-[MNE\OE%JRRUD:15+VTS:>.DJM:C6)YN M+W$FTPZD@U);]4-6G/I&8VB,.KHE^2YIW-
SA4Z^.M*ZHHHJ35=D5O/6#]3[(U^3*U/#HK5QX[D5.]43,&T'E MM,3XG:GO.D-*RW&Q6:6_W!LK(THX8WO7"KU7#$S^\:NU]Q0UO!QGK=%Z9=3R M.JZ.-M'SXV,*:1R-
>^9SMJJJ-8U_J]>KDZ+W+4UE?^)/"OA)<[E>K_1W"]-N M$45-4T].QS$@=[*W%:XZ,TUIZG[],ROU3?W1PTD;FJK$%<*/C M#H.SSZAJM1V_5#*>-9JRSI2-B5&
(U=RQ/:Q%54[`-]BX[E]#ZG@?,C'>*M:]X_>,4X.:`GXEZ'I\[4TL=%+++)&L,+E= :RFIJZXT]-Z52W*GC2-)4]7&41](`MN4];6'4E"S4,=#"ZMKG4B+'/$K:===C6;<(N-G7
M^U4#]K:-I[/BGK_4;<1++'H+2M726>X7*G]*DNE8Q'[&Y?AK&N145RI&Y>Y_M-*]JFAOTG#BX5%%%Q MQ1-2NHWPH\YZK-&C-K^],*]*OMP|Z/"GB%KG7=9!77/2M-
9],54"S05OI*.D M=W;<-W95%SG.U$Z>:&U-IH.Q5VN-#2)JRU+6;6SS(G+7Y3D?AN6X M_?4-_P"T;32UWU]K'B)Q!NNEM!U-+9Z"S.2.X7JI@25W-ZHK&-
MKA3ZFFM<9DIENL5.D.M)GIN:U.[`7"YRC55%RF%# M>NT;34_.#XF?:AE#IBKM.)+'45Z.JJ?8BNJ(D1%5C55%Y]JF4ZH8OK"3C-I MG3M1K*>_ VV-
E.U)Y!/Q4S7.BB5456;U:ESFYZJBYZ+A5 Z VC:.M5\%G<8K M(R_ZV&[4VH M(XVWRS5:T=3)$Q&MDQE-RXZ9RCD7'3IT V9M-%;MXZZNH>)EYTEIO2D-\EM[
M&2JK7N1^Q61JKE1%QWO1/QF^MIS99=36G2?:QUS5WFY4ULI76UL;9JJ1(VJY M6TJXRJIUPU?R>NO&WB/:.62KNO"^]]+A]:66GG7+6>+D3:N>G7V>[O-H<.. M(EIXFZ<9=
[2]R,W+'-3RHB2OR(G5CD15\ESXH]'G7+COH&UT$U7)]JWU+8V] MO+I94ED=Y(U,]J_>AK7LJ4"V5U2Z:CI8V,W.CC1ZKL:G5?E
M:$]JMP!T%M&TT;IZ3BWQ1H:B\1WJGT):WS.936[|O26?:QV.O61,IU14STSA M>B(>APMU_JNGXF7:0.M)Z6X5U3)54UPI(TCYK?
47"HB(G5'(O#C/6Z+TRZGD=5T<.:/GQLV4TCD:]\SG;554:QK_5Z|7)T7N7 MWW7WB#POX,W>NU&^/6-_]D2*WQ6^F-%=;8KB[7-OH;@YG,2U1;H^4Q53=L<]6JJXZ)G"XZX]HW
3B96\2=(U-M51=X8]>ZV^]z=25*QIM:Y41%1Z)E43OP]>U% V1M&TT'9M7<0.-UXNE7I*\T^.ME-*44ZTT%5)2MFE]W)A=WK-
Z>&43">LB+E2G2\1N(>G^+6EM%ZBFHY65$DCI M*ZFA;MKHG(Y6KC;ZCFJU_P/ 9!QCUO:(]16R^6W3<%0Q*BCLSJ=LCUC5,MYLCF.PYR+ MW=W5.[*0-W;1M-=\!N)-;Q)T?
437:%E/>+?5.HZM(V;6N; M:,K0:W-M\CU1KV)MPY5\,JK^0RWA_J2366BI->YH6TTM=3LG6*->K5BJBR.W-7 M:U51>B>"=RJZAT=M&TU3P+XD7!5%]7?3>JV0?9ZQ3-
8^IHVIUDS55R+W=.BM MF]^F4K4Q$QG.$Z>+D|\ M!+?C9Q4U1HGB+IRS:?CBJVW*E>UM&^-]D.)7LBM[+37N35U%I=U4WGP6N.VL?RVIGJH]7MSU147"YQG/>F -W:1M-
4\#^(]^ MU-<]3::U2RG??,#,V-]12MV1F;JN;G">:=Z(G1R=#%$XD<0M2<5]5Z+L-120 M1P3M=%<:F!]MH86_+7&WUW.5S41'=V%|Z!T#M&TT3<=9.YX*ZBM"ZOO-/JG2
MERF]'??MHVT\M*]W5%5&],8ZXRO1KN[!F_&;BC+PWM-OBMU$VY:@NT_HMNHW M91'/Z9C4557JG@O=U/2]N,LFH>_MSUI9-M#++:^)R)(D$R.:CF]>CNBY3/@Y%_M
VSM&T\#AI>*O47#_3UUKWI+6U=#%/,YK$8BNG5R)U[D[P,GH.(EMN7$:XZ-IXYG7&WTB5=1*K<1MW M0&S]HVFH>(W$?4UR\@P:_T(E/!=6PI45]SJF;F4C%
M1%3'*BIG"M7*HJ+O:B=3R;G>>>)W"&Y6BJO%R;KJP5DZ4]2RFMZ,J'9RY7G=G*+C&$RB@;TVC::7U7K;5NK^+-,H32EUI--LMU*VHJ.^>:!)I9E_P
K=7Z>KV*BW:EHDA=2.3HBOVIA$551 M.NOADG"GB!JRGXBW?06N);>MN-/3^E4UPIXT8DK/5S MT1$145'(OC*BF'K&WWRX6*6'3ER@M5SWM5M140I*OJ
M9RYJHH&I|)QKU?KO4M5%I#24-9IZDK4I)[A55*1N5/%Z(YS<83UMJ;EQ[S=^ MTYE|)=KU5-::BKH[U2T^GH[M*E;0/IT=+-)RHU5S7^"=6=/)3)+;K777&]]7
M5VC;I2Z8TI0S+3,N4E*DTU4_"+EJ.[NBHN$P]4Y._/0-]/+6+B'J_0'$&-MW;2U[-3?>EO"[;=2*6%(MTF4;RWM:B)=A.B917(O5%Z2<.*FJ-$\1=.6;3 M\
<56VY4KVMHWQM5))W]]D3E^9S*:WOMZ2S[6.QEZR)E.]*F>F< M+T1#T.%NO]5T_$R[:U/2W"NIZ9*JFN%)&D?-ZBX5$1%ZHV%[DPK7)UR@&-M0TG$JJJ.--
;H=:*)*:GH$]TJMRIU7#?5Q_C#0?$NJU=KW66GY]*&GALNT;30 MVKKWQ-X+10:AN]^I=9.:>69K*^G2B9320(Y41'-5J=$\$55QG'3J9/QVXD7#2
MW"REU+IJJ9&^JF(@6*9T;7HZ*1JN3HY.]>GNZ@;2YC:;=R^KUWZJW@GF6W6NN5-ZNKM&W2ETQI2AF6-MF9@;VVC::6L7$/5 >2:@,(-NTEKV:FN|+>%V
MVZ^4L*1;1.HWEO:U$3]f"=$RBN1>]+TK;_XA:JOW$=N@-!RT]#74T+:FY76I-MB1Z4[51%PUJHJ=SF]Z+E7(GA1$50-Q[1M.H:.IM$<)Z.^VFIC@N,DD#72/B:Y,/:-MJN]5R
;3VC::7\I?5^^S MU[O/+:.BO'$[BI>+RZS5K-"\"CG6F@=66_F5-1_;*DB=,HJ+TQC*(F<*H&|-H MVFD=-;VUMHGBS:|%:RN-)?Z6[0N?27""!L4B*U'|'(U$3JK%14Z]|>O>7'&;
MBEJ30W$32UIL=.RXLN4$C?L>YK6\V9RJR)5>O5K4!N;:-ISQK M.]<6>$5)2ZIO.HI?]&U^D.CK;9#3-C:Q*]{C';$=C*:47ORJ91U:Z3BIK#
M3\F]]/>;'3U%)$M70V7T=DDCX=NYN|fV.]=R>'=E?#P#>6T;33MDX[5%1P"]M=:VRMFH% M2)L,O1W*N,[4ZJC71=?[90-H;1M- W;CI>*/M:PZ?BE8NE&UD5LE3DMZU#XU
M^_QN14D5.F>YBF0\7M1T39%CIVXW+AR>Q57/\ M.*!{J-67QW%%^GEL,R6!*/GI>.5)RUDZ?<]^-N>]^9E^E;EWYPGJX_&;!VG,^O+E?|?VH9(M,4L%3>:RULIH752X
MB@16Y=*%VHUJ9Q[<=_2Y7;TPOK+GN[APFXHU?$.^:QH*BABI&V.L2FC?&YSED3?GW' M2-/RF%|D5N:76_]:?YE(=E]O_9EQ63P^RS?Y2H WYM&T|I1M\K4-^H=+6.N
MNURG2GH:._999%]GACS5>F/,U'0<;M:ZEI5N^G>&M176#*K'/4UT<,L[<]'- M8J97*?@HY.G>;5UMHNW;]T_466Z\Y:&9[7/;!)RW*K7(Y.OLRB?D*CYK7H?3
M#73U$=#:K7}(O9)%PC(V-1/QIV;>*^>$ Q_A?Q1MG%"SU%51PRT59221$!E3Y+A415PN47*)A43'-5\:JZ/5!1I71FFY=57FD;NJWLD.%/|$5 MZ|%7%NSE4IB*JY1/-[-
,,^HJ4:|ULRGDHf3>*W;1L>FWF(U!U$%OU#J9E(^C;5RMJ*<6)9)9)I'/PBHU57JKI%Z-]N0,?T-QGFO& MKG:1U18)=+ZC6/FP0OF26*H8B*[+7TI[FJO3*>JIKGH,/VG-
U@U3\>>.)EN MUOT;Q NW#31MLNEHE,%-)=(H)MT;7[HECE>Y]{Y,_U$+'0,/%>YWVDU#*?,
MM;J33E5"^=UEAB1986N8KHFYY>45%5%5=R!$O[@RWA5[]JZRTS)7Z@L4NGJY MM0^)*:.*1B]U$:J.P|$?]JKX>!F.TTYP@XPUMRX,WC6&]*EM4^WS3-5T4;8\
MM8QBM9AJ=ZN=C\9Y.E5XP<2K2S4]-J2WZ8HJK,E#:UHF2HZ/*HU7N5JN1%3W MJO>B(!OG:.^TYQ+JKUQ?U-HU]%#'3VFF9.RI:KE>]7-C7"IX?JB_D.0X/\4M
M8:JXLW3NI{>C2VT.7T<+&I6SM?$U7H|&Y6NW.5$[CD|S#ZJ>Z\:GI^T|K6@T MG!3.NM=3Q0K5\UBKRJ.-(H'+*Y,=>[")Y|R@=0;3&>{FO[=PUTS+>[FV:2!CD
MB9'3M1722+G")E<)W+WJ:BU'JSB1P6O=CJ]27RCU1IZY53:>?%(R!\+E1%7; MM:B|V53O3U5Z(5.V+1WK|!L%3%<(66%LT3)J%T2+(Z95>K7H_O1$3P WW22I M4TT,V-

*'3NCM8V[4=EDJJ&6EIG4\E,C|[*G=NS^M)(YR;E=ZR=O=G/JIXD-(\,:#26KM2Z@IJNHGJKY(V2>*7;LCP^MJJFW"9^<7O^R_;[C07V0HZ+M?O94.8U|39D@@5W3,BM1R(GO:UR?O>)T:M.9^MM9:)MVO>U!66JYNGCB^PS9V3TTO+EAD9M5KVN\%1?Q_:|{3MTI;9P:OS*A[4^M?5|Y":B|[WK*UV$JJHC7.JS37G&BVU%I[*VEZ2K165$3:%LC')U:O+7U5]R+MC\1G5JI.5"M_I+GJ;4EXU@M"Y'4E-=IU?&Q45/628-7;K[/MNN^HZC4-BO=TTE>;E'>DSVJ56MG55SE[>G>O5<*B*\B?;0F^M9UW0W%>5476!D^MI&^7IS6^JNU]HRl,_P#_7V&<8I8X%D8Y$79'(JJJKE781^M6]!87OR%OVO[U14//"MU!-(WTRNJ%XD@CRF[U%W:=CO1$Z*OILGM+/.NA^M0-V\ ; M=CI[VIXBFO^.?#|2^E;%26R@NM?JK6EVJ8H()*ZK|)G9'N7*-1$]5'*K43H MJKGITR=$Z]X747$/1%/IRXU=1300NB>LU-MW*YB8^^14P![ED?%;=)T,J^I# M3T4;E:U.Y1IHN$0T3H.MU]O^IJZ_-U@ND+VJ=3T]#;H&OE=A$7J_**B^LWK MEF,]%7,, :UK=)T^B^TGH:W_HAN6H:]6\RJ[+I4\Z1CG(8Q/P4 MPB+C]O7/__&,AL.S?IV7FPW>C[JA#=;94K4R5LLR M2S5KE5JKSEJJ8(88I0+?G/RLIGO M\ ,,]6J8X+W#_":?^40V'I9HVLX?T+VDW3/VZ/B?I6>Q5]3 M/24TLC)%DIU:CTWVS\BIWGN4UJCI;-%;6OQ:6X?UFC7K-=;/5/> ^9M9MW+NQXM1 M,85J^BIU14R8C#V9W4$+K?0Z^U116%^4^QL53AK6KX(OGB!ZO9YXDW; MB-I6O=?6QK=+95K1RU$+4:R?"(N|ITSWHNWIW*AM5&I[>_VH8]H?0UHX?V"* MSV2F|&{(UWO55R^5ZHB*|R^+E1$Z^2(F,&)G/23-,0ZNEI&U2VBKNB^@S5L M>R29C6HCI,*B+M5ZN1.GWH&W]ON-#\4JJ'AOQXTGK"=_*METI9K;7/\ #+45 M6Y]ZJS_)F^]IA?%+A?;.*NG66FYSSTT<-0VI9-3[4>UR-5N,N14PJ*O[P'.E M1I:KNG9PN&M7(K;W/?%U"V3'K(G,Y7Y$RYQG?"^ZLXM\=+EK"-]MLUHZ6D M5.YLLK=ST3S15E:OO0W!%H6W0\/VZ0P],8EO^QRJN-GIZ'+9WL#>/QCF*NA MKM?JX36*IMELGI*ME14+4235.U7N56HW&41$PB)^^H&NX4_P"I!J/VC_S-(;,Z M=KO7^<|;3#C\4=(;*9PQH&\3GZW1*J?L@ZD|"I']7E;>G7NSGH[3&]>=G^UZMTU6FI:>]76P7AS&Q336Z7;S&IA/9E%PB)WXZ)TZ 8S U%[8,ZXZI8^GY&GH= MKMQ_ &G*E/\ SV#^%3-XN&%#'Q-?KCTNH=<74?H:P>KRMO3UN[.>G=DN.)?#MNBXGZ7DL=?55%+3/E9,LE+MWY;X>LBH!|6GF_P"H-M_P;+^(A^J?<4Z*C;0T M<%.UVYL,;8T5W]F"OM Y|{(;?U+KC|MO\RD.R\G_9IQ?73_TLW.?]Y49_P Q ML[AGP]M_#"[LM]9557V2]?2I/2=OJN]B;43IU\3I*SLHV>HO-SN,&IK]0/N M%0^HECI9F1MW.!O!$3IW)G_K@U!KSA+K?4NJZZY6CB+5V*W3;_M5;XF/5D6V-K78P],I4<[_&+2@[+U%05U/4IK/4TCH96R(Q!4W.Y47.%3;W+C M!NS:!K[2=#6*=#7&?5^J)+ZVE>^JDKZAKD5L>QN(T17*J]GJ)XJXU?:I-?.MNTU=(IM?.?9>'E/^KJ.V.=MEKE:ORG[GN7UNY,*C>N7FX>)_#BEXH:92QUM?.M56^D=.R9IZ-41TFW=AJY14VY5%IZ(CAJ)5MIX6PQ:RU+'$QJ-9&RJ:C6HG< MB(C>B ;KMEKI+-;X**A@CI:.G8D44,+41K&IT1$1$,3T!Q4M>O[G?|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|58[IDJ4=1M=OA[914\>BN3H@8_Q%N>D?7AM%%K23;8[YL,"N2&1RK(K=S<;$56JFW*.NA MKN?L\ZFT/3RUG#_7U=10QL66.@KW{Z%4QGO3U/RLQYF=:>X$6NUZ-N6EKI"WLS/;1.M3^(&]%T\K=GV-2I1$V?@ M9^3M\MN ,@X \2*WB=H!EUN44<==#4/I)71=&2N:C7**OL-E[3 MR=*.3M>C;'3VBT4S;2@IVX9&F57ORKE5>|57KDlC.!H7LLY])XB_MY(O[IBV MX$5#;1QHXL6BN?LN537>EQ)(BHV\7.E7*9\$;+&O3V^1M#AYPPH>',EI=0U5M14_9:L=6R^D;?4C<)W=?$\OB'P1LVO;I3WE*NNI=^ID1(KK:Y>5-A$5$1 M?=GPPN/$#&.UQ=*6DX23TDKVK4UM7#'3L^^5S7;W*B>36KU_-#&>)5MEHM9M\|*&N:JU$+WVK3(O[Z&<;<.{.UOHM1TM^U%?;KK&YTBM6E===9=T<*HN M45&Y7N7KWXSX4ZPX84&LM4Z8OE555$%389G301P[=pCEM==H&JO-RMVK/T'Z;I*IU)#3T4#7U#\)G+G*J+E6N:N< MXRJX3H8OJ_2,&C>.O#FB=]BYZFN;]UDM4ZYU/-?"BR-V(B?>HJ((IXX3!M2K M[.-/2WVNN.F=57K2<=<_?54EMEQ&Y}?;C/0JLJ_^FX:RTW""NN?V9 MM]:VO?=9YTFJ*J1JM5.:KDPJ>JG1$3N7V@>'?T_[L'3?[1O_(*@7]/^[!TW M^T;_ ."H-D5G#&@K>)U#K=U54)<:.D=1MVI>4YJ[^J\Y^Z+X^P5G#&@K>) MU#K=U54)<:.D=1MVI>4YJ[^J\Y^Z+X^P#+]ON-$<3/5[3?#5]EPU:..9J.\ M\283[\`?0WUM->><4N"]KXI.MU35UU9;[E;G.6FK%Z(N51<+E.N%1.8PO?.MUZ@8-VPVD)HC3B.ZHZ|PIWIZ-C21)+&]BKA')CH!Q|P\M!1<.R'K;&E1RRMMKGR*C$RNV/T9S^GLVM7W&5*.$=9J_A_9+G;N)V1J*&2G:UU'25CFQT[V^] M^_](HB.143RP;CX8*[=PNTS4V.B)Z^EGJ'U#W5B-555S6M5%PB)C#>[S,M+E[,U+;*ZKFTJR^:1@JG(Z6BM!0[DYQC+4RB^[*KM\ /'X=Z'L%AXUS-7775 MVU)]NAIG-GIZZ-\OV-543UIE143&YO3/L0GT:$UW:OXA/QE[;=$B+[$5M/E#M8?#;A#9.&%/5+:N?5W&K7=57&LIJ2G@=+41T:I(>B*N%7*HJ M9QTPG\!L,B7PLLW%"R1T%YXL,F)SJ;JIU1LL#L8RBKX>2^Q/88G1]G:&L6% MNI]77_5=%"I*ZLO?:-X;6VCXW/PVX+VCAS5 M5EQCJ:N[?RMZ5-UN$G,F?USA%$7"9\5]H<\2>$=BXITT$=U;-!64JfJ;NI'M]X5RBX1>]*F6HO5/#H!JW77!9FG=+UU;J;BOJA;*U&LG945#Y6.1RHU&S<MN[*XZ8\SP^-]\06/@)H&.VUTUQM,%R@?#6S0NB<^)8YG-=M5$5.B],IW(9_%MV:,:YUE-)JC5U^U71TKD?%0W"H7EY1>]V555RG3I@V%K30EIUOI:>P7*GQ;W MM;M2'#'1*WY*L7N;J83R5,IW 7VH;I26_3-QKYZB-E"RF?*Z97)MV[>_.>N4 M_A-0]C=O_:EF_;,;^)&7MD[,EOHGP4UUU/?K]8Z9R.ALU74?U+TQAKV)T_Y+'N{WIM>C58UF51?#=&Y,FS|0\ M2K1HO6-BTQ4,J;BZ7ASN0RF:UZ1(B_*DRY%1,;ESA?D:IB'A:UX#VS4VHW:D MM=WN.E=0.;MEKK7+LYI(B(F[ON.X*F']<: X(VO1\EOU3<;_4.H96F'.:P!SD<K6M.%U^IUV MVJWW?^J9'(NUB*~%Z*O^+&_\F#=]YNE%,;)77&LE:VAIX'S2R.=TY;4W,_>S MW%MJI2%IUQ8:BT7FF2JH:A$RW*M5KO!S5\%BFLK?V9Z2'T>AN.KM07?3M.] MKHK)45.('(BY:UZ)T5J83"(B=R^T"SI)*9X+2_X;4?Q6FN>'INGNG8^UA!3(`MY94JY)<-3*IV-T#W=/9M:IT7PTX:4/#32K[#0551545I7S!M+PRX7VWAAI>6Q451/74LD[YW.K$;JYWJU.K'>6<8F[-5+;JRJDTMJR_;4H:M^^:WVZI5(55?%O7**G?USTZ&:Z"X4 M6#0&GJFTV^!T\59GTR>J5'R5*JU6KO7'5,*O3NZK[5U1H*AXA<<+*FIJK7$ MFF,352R-I[=.(6]T8UVVL7Y147=+SN5(KF]IV(E.G>F>IL&DI-+++-40V'6^HI#9WK(ZVT=1M1JG?:M|O3WJBKW=3UK%V>--Z6U59K_&B6LHZVVM>U!ED21:M7(Y'.E5R95RHI>J81-M.GL QFW^IVP+HCNG,L;,?L;]3!OQ(O\"'\C#>,?"#V+<)/Y2 ROB/P&MFO\ M4-/?V76Y6*]0QS*]_3.<.5,HO*L3NQWJ!K6R2LL?;O[.]W*6[6F-E#)(F$=AD*[6^'^X MR_D5#/>/MUI+3P@U2^J>UK9J1U/&UW17/DPQF$\5RJ+^)?8I>\1^$=DXFP4OMV36II;A1.W4ERHWJ>X5RBKM7KE%5J+U3IX8,1I>S25MQOI:C56[;Y]^G17;X M**Y3JZ%/MD55SYX5-WCD#"=3T-30=BRDBJDC'U;7-_P"'K3?7 M#F-L7#[3#6IM:VV4I)_D6H4^(6@J/B'H^LTY6334E)46[8]HKD7OQG/0VMH/AC0:.N MFIJ^C]ZBHDOE7Z9,V?;MC=E[L-PG=ZZ]_L,4O/9WHI-15=YTUJ*\:0K*UV^IM9:Y=L,JY5<[>GBJY3..O1$ O[AYJ_6NC>+4/#S5ETAU)#5TKJJEKVMQ+&U&O M=ARX3OV.3#LJF6]<&_-ON."X><%[1H&Y5MV]+KKW?:M$;-=;I-S9E;TRU%PF M$Z)(5Z)U-@;0.?+)*RQ!L"_MKWN456HO5.GA@Q&E[-5)6W&EJ-5:IOFKZ>E=O@HKE.KH47^V1 M57/GA4W>_0-4<0Z.HM/9DX;>F;FJRX05*KNF&,.]BK[/5 M8%EV-V_]J6;IYOXD91{)B8LNLHU3$C;Y+N;XIZK<+^5/WC9O#+AO0\+M.R6 MBWU,]53R5+ZG?4[=R.JAB]HI[^;=.Z^DU-9KY=+LO1+4/#S5ETAU)#5TKJJEKVMQ+&U&O=ARX3OVM.3#LJF6]<&0WGL[T4FHJN\Z:U%>-(5E:[?4LMEUU|OM6B-FNMTFYLRMZ9:BX3"=$]J$Z@8)H%]N|5?$9&KA? ML?#ZR)GKLIRV[^CHI;I74M@GVQ?>NSUJ(5Z.1%C8Q,YZX1T;TZ>SS-HV3AE M063B-?-91551)7W:%L,M. ,RXT:UB>KA, [FG?YF/;QX"4&H]3/U++;Q-5RI:CCOPIH(WM=64U3)+,UO56L>YB-S M[.\MYX:$L\E5QVT,^HO%98*.LI%I(KG2N6-\;N^1%VOSTRLD:+UZ(OF9_;> MS;9+,]"RWR6[7:XWJWU*UXS77W#FR<3M+$ZUWJ!TT.[F0S1NVR0OP[(ICOG;M47]T25$LL5540+"N3Q%H.BX\/\ 4)2;E]YK94QO-9UK'K,YZ9S_:O;_!X&X=IJ"]HG.@ MEOM9=|,ZAN^C]RL7=4LMO7P4N^,*?]T#PK_NY?X4,WX;\+-P[K*]YLJ;R|WVL M3^]+K<9.9.Y,HJHB^&51,]ZKCO/\U/POH=4ZTTY[6HIJF&JLBN6&&/;R7_A M93/Y ,OV^/B;G[5+<<#[_P#W=-_;(S;>TQKB)H6DXCZ1KM/5U1/34U4K%=+3 MXWIM>CTQE,=[4 T1V@(VR|"^&[7)N:ZHH6K^.E=DZ5J47T6;^X=_ 8+K+@[;M=:Z2L6GZJNJH*6SR0R12P|S?)RXU8W=EN.Y>N/8; DB26-[%7".3'0#128W3 M_M2S^S!)S?Q(REV6<^D\1?\\D7]H)QLKA;PSH>%FFWV6WU515P.J'5"R56W=EMR(B_)1$^]0DX><,*AS)?74-545/V6K'5LOI&WU'+GHW"=W7Q UOV:4_[-,+ M/[>,_E)SRM'7K77:!JKSEOM=<=M.ZJO6DXZY^~JH+;+B-RY55V_@]Z^W&>@&J]7Z1@T;QUXJG1$3N7VF65G#&WUW$^@UNZJ[$N-%1NHF MTS=O*5J[^J],Y^Z+X^P#67;3;CA=:_VYB_D)S;'$IB-X;:K1$PB6FKQ_D7EC MQ5X74'%G3U/9[C5U-'!#5-JVR4NWH+%<;5-(^* M*NII*9[V81R->Q6JJ9\4R!H;AQ_8=7%?_1ER_CS&>]FN-&<$],,?_%2+_P M M(>I8N$)OL/#"HT-#654EOEIVX'5#]O-VRN>KNY,9]=<=#VM":/I]!:3M]AI) MI*BFHF.8V2?&]45ZN7..GWR@:>[.+4^-'C1T_P###?R]41UY_9;\/_.V2?Q: MDV7H7A;0:$U%JJ[T=54U$^H*KTN>.?;MC=OD?AF$SC,JJ_L0A>.%MOO/$JS:.MTEJZJ.OM<"P14I-Q*>3U>9WY3.?NB)R^:.:QDU1K?B_Q)U-I[3U_9I*R:?E! MF]CX4EJ)Y$ES:YHKC+=Q<G,S-(U!KU65/+L-SZC=R*U&KE>F/%.O0"AVOX MU^<*'14|FU\"K_P 9/\YZG'FBGN79^O3*3<]WH=/+B-,IHV21N=^+.BJ9GK70 M=OX@Z2J-/7A\LE/.UBK/%ALC7MPJ/3IA%RGLQA50\[AIPPCX>6:LM;KQ77VC M]'(C8[DY'I$Q&[=C4_!5/#N <%KI1WCA3I2>C2H>_LTTUIJJE^E=77_2= M)4OWR4-#4.Y^*OX.%145/:JJ9EPUX36+A;03PVEDT]35+NJJZJ(&N.S3$Q-;<6GHF'_9M6Y\DDGPG[Z_E,H]26BWZMX6U\E,B_9&T] MERIG-Z.18\|&]K%=CSP9%H/AC0: NFIJ^CJZBHDOE7Z,,V?;MC=E[L-PG=Z MZ]_L/7U/IVQ:7HY7WNY7=#L3GK'4S-:KV(G7#5ZN[F$1>\#GY-3+Q\USPSM MS52:@H:)MNJ-3U>>U=JL5/)I41/*4Z:VG/_ &1M$06W3]YU0YE=3MO%2YE$ MR3JYE*QRI4_X6<^W8BG06T#4G:I;_P!H^_?W=-_;(S,>&5PI.IPZTS4TDC7T M[[=3HW.J83$;45OO145/>A5XB.%I.(^D:[3U=43TU-5*Q72T^-Z;7H],93'> -MU#7=1V:*2%)8+'JW4&GK54)_55NHJG$,GJHU51/!78RO>G54I,=/X*O9?>_M.?%"|4#|UM1S*5LS4RQTB+WHOCUC5?\ &3VCL?5#*/2VIK#4+RKQ0W.1\3"Y M,2(CF-8BJB_VT;T_%YFW="Z"L_#[3\5HLE.ZGI6+O57KN?(_"(KW+XJN$\NB M8P8EK/@%;-2ZBEU%:KOW"XRJKC/3!FFL M]*TFM-,7*QUZN;2UT2Q/K7+$Q'(J>]T<+OQF/Z U O%Z]<)-.N7F0Z?IGUUQ3O3=*[EP(Y%|<1QY M_OJG1?#+AS;N%VF$L=MEFG@29\]Y:C&|[W*G5<(B=R(GXCQ^'!&R<,M07N[MVR:HEGN:JFV96[8&*]7]QF$[N]=_X* .F[0=D?4\==#.]+Q66"BK*5:2*YTC MEC=#+ODSM=GIE9(T7KT1WT9)?>!U;9K-75USXLZLBM|/"Z2H=+5O5O+1%W93 M=UZ>">TVCK[AS9.)EB=:[U V_:'=S(9HW.9(7X5$>QWN7N7*+XH:Y?V8VUT<5 M#>-%GIZSV2S]F35,>G;M47]FR4-= M+%55$"PKGEN1S<*B=$OBN3,.SOB3:#T?3:"TG;[#23RSTU$QS&23XWKEZN7..GB M!B';2ME1=."FIXJ9'/>V,*96HG>QDT;W+ ^)&JOXCUN"MSI+OPHTG-12-?'';.MH*=^SN,)&Q(WM7W/:OOP9K-3QU,+XI6-DB>BMGO#RN%URI+QVF>)-11/;+!Z-%%N M:N45\;1,>GXG-:I8E731TSJ: M1R.8U&HU-Z+C*N7&UJ,3U< M\G_D.+%PN6J^:^!GICZ>E/C]}Z-GD:R+RW;:M55N#(;SV M=2*3457>=-.BO&D*RM=OJ66N7.#*N57.WIXJN4SCKT1#WN'G!>T:!N5;=O2Z MZ]WVK1&S76Z3U>B=0-$.9T-5:BXZ\1+5)JZ\.5N+]H5#!MCI70NJ85>YR;L*F4.U[%3R55[NIIO$SA:.]-V*)^L^*NI7VNHG;$V*K?)4M<_M14547EY=G&._;^^;4XB\$K)O#N5+=GU%.9K]2X2&2K6V7ES(B9PBYZ+C/14ZI M[3QK%V=*'._TMYU+]"ZZOJZ-,RYE#35U:W:D:.2-JOZ>PUUPUAQ3O M4U)3P.E](Z-Z4D/1%7"KE45,XZ83^ V-Q+X6V?BA98Z&Z+-#+3RPQ.C[.T-8L+=3ZNO\ JNBA=N9;Z^J5M,[*R=[47+1<]:],^(M&$|G2Z6.5|GF]U6I%;]@FUTT57NB=(BM M^&>>N[G9J2LB;404\SG.A>UZ9;G&%QC'HERN\59FB>#=FT3IF[2>9)/<+-I]5B+WHU> MY,^U4 \[ASKG4W$7A]Q#/T]>.7-J&T0U%O2KI6IBH>Z.1B=&]-R.8O5$1%14P MA@__#AC4ZWT!%4T'$+4%CDAFDBGMMOJG1QPN1V45&HY,,F]U!A=_P"SG;I]15=\TW?;MHZXM5;JZH^Q9+A5ZHWV=$3VKT[R\UMPFMVN=5:9OM75U5/4V*H2H@CAVD)%1{'X=E,XRQ. M[VJ:FVWW#;]B?:-H$FWW#;]B?:-H$FWW#;]B?:-H$FWW#;]B?:-H$FWW#;]B M?:-H$FWW#;]B?:-H$FWW#;]B?:-H$FWW#;]B M?:-H$FWW#;]B?:-H$FWW#;]B M?:-H$FWW#;]B?:-H$FWW#;]B?:-H$FWW#;]B M?:-H$FWW#;]B?:-H$FWW#;]B?:-HFWW=I-M&T"3;]B.TJ M"GM&T]"0BB9)@!+M)@(HF28"5&9 M 4W2(QKG.7#4ZJJKT1/:,,X M<-I[-=:\1G6">UQT5KK%G2UUV]V:GEN]7"*F$W-1R^_'M WN :WX,<4*KB7#] %%]31147V,N#|)G)0)P!("7H'6=+K_2=%J"BAE@I*S#F&V=$1Z-(YF5PJ|]GO R(&$<,]87[5L= M[=?+!-874E:Z"F2:*1G/B3ND3>G7\70SH"0$X D!.) 3@"0$X D!SM+VA=<.M7'6&I,+IS1,-Z99:Z6EDD9*[=M21[&.7KX[%+OXX>,'!%G_*,_T@;^\@:RXG M\5+EPYX7T&H+5$ZY3>CLGH9GJC8GO8JN;E/P514_$9-?=636GAQ7ZE9 R2> MGMC]H(',PU?)%OVY]@&3@PWA#KF?B/P\M6HJFFCD)ZWG;H8G;FMV3/CZ*O^\ M@N^)FK9=*"Z%O:_@@9527,221#(N&OJ9J85?#O R<&-\.=52ZVT/9K(/ RFEK MH$F=#&[+6KE>B+X]QDX$@3Q)S1M^XW;KNNN;QIK0>DH[Z^SN:RLJ:FI;$W=E M45J9YV[E_@XSC\>#W3P-;;PH-!:.M7K[]@T36N?R6;GN5ST8UJ)[5Q'(B^[('H@G,%T?J^_7S6>],3=+!-;[9;96MH.Y\4C6UC55R*[.B) M\E?$#-P3@"0$YB/%+6.V@-!7?4%/3QUUO5?#O RL'@Z"U" MJ]1=EOHJ M^M2"LDBBD?Z+$JM19%VIT3"KU=TZ 9PGB"< 2 G $@)S M"[,Q)MMTXAW311-'4/N%MIDJ*F9S42-%78K6-7OZKNK8Y%93.1'817(BM3.$[\=YG0$AX5JT;9;'?+G>:&A9 M3W.Y*GI=0USLRX[NBKC\AD D'3V$X DZ>P$X D'GXDX D\@3@"0$X D!.) M 3@"0$X D!.) 3@"0$X D!.) 3@"0$X D!"31=E;JMV14 MH-(LZZ#T=:O<[=R P<9Q^/!D D!.) 3@"0;6G#73/$*&*/4-MR-JK$CAD$/J.1%7P13+!@&CN"6B="5B5UEL,-/6HF$U.LCYI&Y3"JU?N=MZ M?@X\)D![" < 2 G $@)P![" < 2 G $@)P!)Y@G $@\|B< 2 G $@)P![" < 2 MG $GGX@G $@)P![" < 2 G %-S4!I_35KTM:(J?:*"&W4465;#3LVMRO>OFOFIZA.) M 3@"0$X D!.) 3@"0=/83@"0$X D!.) 3@"08\B< 2 G $@)P![" < 2 G M%-S$>US53H>%I+1MFT1;'6ZQ4+;?1K(Z986.0)P![" < 2 G F3N3)P![" < 2 G $@)P![" < 2#'D3@ M"0$X D!.)(CR)P![" < 2 G $F(&X D!.) GB3@"0>?B3@"0$X D!.).> M7F" < 2 G $F(/P_6O"C2_$.HI:C4-K2X546Y(=TTC,(Y4545&N3,2N5'HGDCT5V M?9(A'LH7*D=^CRW[FI71W]2=S?OEC=T:OGU:|\OF'?:>X@:SX?<1;7I#7E52 MWFCN_]VZ]T\/)7F?^+>U$QG.$]OK(N515QC?:+NUQLO&GA]56BB;<+]D4C*6 MFD54;^1SE8W*^Q%=E?).].\]?M!R-N_%/A59]/I6>75%3J M*W:DIZ5$FKK.VC;&R.-$]98WM1'*CE2"9]M$VHA61&R(NK^(/$&Z.1T'4TE]I. M,NVY7RIC2;$F5.I,&JBITB^(M&PJK6NNM*_M$6MI[2ZGTO=)*FTB72*G2GED5FMR-3ZGCX1-54ZIA?=XL<0MKWP[UHHRH6H9^A&Y3^A5T;X6KRV%7U7J_&Y.CMV(_)+[37W$W@]:,%;Z"'6? M%'4M11U=1LIH*KFU:/EVKU1B*Y?'&<=-V$[S;7'+0JZYX57:UM19ZZGB]*I7 M.^4Z:-%5$][DRW_'_]*B_KA>'O#R]7N-S4JH8N73{IKF9ZHV/IXX5=RI[$4U MEJCB/K;2>B^&M155\?Y6O==&VX9IF)]SD5'(S;M]54:Y$54ZY,1?]YW'R;A5M157K41HSI(WSUL_J.8_6]F[9)_E6F;=_]=$/5<.L)C_5V/^%H&:<8[6VK;8V1N:UJ%0$B_:F=?=!37O4$ZQ)M75+4J+C;C"]J&/.QO7-$MG=EG^L5IG_P'J_G4IZ':(M_K+:L_P5/Y1H%?@!_6;TG_@3?X5-@&N^_2XX.:3ST_J/X7?YC8.Y<@>=-J&F-MN559*V&T5<=#/Z[']&C]MH_Y6J R"+7UZ=VBI=)++4L^P M,;?Z4D'*;NYF$Z]OE8\C YN)G$G5?*

'3NCM8V[4=EDJJ&6EIG4\E,C|[*G=NS^M)(YR;E=ZR=O=G/JIXD-(\,:#26KM2Z@IJNHGJKY(V2>*7;LCP^MJJFW"9^<7O^R_;[C07V0HZ+M?O94.8U|39D@@5W3,BM1R(GO:UR?O>)T:M.9^MM9:)MVO>U!66JYNGCB^PS9V3TTO+EAD9M5KVN\%1?Q_:|{3MTI;9P:OS*A[4^M?5|Y":B|[WK*UV$JJHC7.JS37G&BVU%I[*VEZ2K165$3:%LC')U:O+7U5]R+MC\1G5JI.5"M_I+GJ;4EXU@M"Y'4E-=IU?&Q45/628-7;K[/MNN^HZC4-BO=TTE>;E'>DSVJ56MG55SE[>G>O5<*B*\B?;0F^M9UW0W%>5476!D^MI&^7IS6^JNU]HRl,_P#_7V&<8I8X%D8Y$79'(JJJKE781^M6]!87OR%OVO[U14//"MU!-(WTRNJ%XD@CRF[U%W:=CO1$Z*OILGM+/.NA^M0-V\ ; M=CI[VIXBFO^.?#|2^E;%26R@NM?JK6EVJ8H()*ZK|)G9'N7*-1$]5'*K43H MJKGITR=$Z]X747$/1%/IRXU=1300NB>LU-MW*YB8^^14P![ED?%;=)T,J^I# M3T4;E:U.Y1IHN$0T3H.MU]O^IJZ_-U@ND+VJ=3T]#;H&OE=A$7J_**B^LWK MEF,]%7,, :UK=)T^B^TGH:W_HAN6H:]6\RJ[+I4\Z1CG(8Q/P4 MPB+C]O7/__&,AL.S?IV7FPW>C[JA#=;94K4R5LLR M2S5KE5JKSEJJ8(88I0+?G/RLIGO M\ ,,]6J8X+W#_":?^40V'I9HVLX?T+VDW3/VZ/B?I6>Q5]3 M/24TLC)%DIU:CTWVS\BIWGN4UJCI;-%;6OQ:6X?UFC7K-=;/5/> ^9M9MW+NQXM1 M,85J^BIU14R8C#V9W4$+K?0Z^U116%^4^QL53AK6KX(OGB!ZO9YXDW; MB-I6O=?6QK=+95K1RU$+4:R?"(N|ITSWHNWIW*AM5&I[>_VH8]H?0UHX?V"* MSV2F|&{(UWO55R^5ZHB*|R^+E1$Z^2(F,&)G/23-,0ZNEI&U2VBKNB^@S5L M>R29C6HCI,*B+M5ZN1.GWH&W]ON-#\4JJ'AOQXTGK"=_*METI9K;7/\ #+45 M6Y]ZJS_)F^]IA?%+A?;.*NG66FYSSTT<-0VI9-3[4>UR-5N,N14PJ*O[P'.E M1I:KNG9PN&M7(K;W/?%U"V3'K(G,Y7Y$RYQG?"^ZLXM\=+EK"-]MLUHZ6D M5.YLLK=ST3S15E:OO0W!%H6W0\/VZ0P],8EO^QRJN-GIZ'+9WL#>/QCF*NA MKM?JX36*IMELGI*ME14+4235.U7N56HW&41$PB)^^H&NX4_P"I!J/VC_S-(;,Z M=KO7^<|;3#C\4=(;*9PQH&\3GZW1*J?L@ZD|"I']7E;>G7NSGH[3&]>=G^UZMTU6FI:>]76P7AS&Q336Z7;S&IA/9E%PB)WXZ)TZ 8S U%[8,ZXZI8^GY&GH= MKMQ_ &G*E/\ SV#^%3-XN&%#'Q-?KCTNH=<74?H:P>KRMO3UN[.>G=DN.)?#MNBXGZ7DL=?55%+3/E9,LE+MWY;X>LBH!|6GF_P"H-M_P;+^(A^J?<4Z*C;0T M<%.UVYL,;8T5W]F"OM Y|{(;?U+KC|MO\RD.R\G_9IQ?73_TLW.?]Y49_P Q ML[AGP]M_#"[LM]9557V2]?2I/2=OJN]B;43IU\3I*SLHV>HO-SN,&IK]0/N M%0^HECI9F1MW.!O!$3IW)G_K@U!KSA+K?4NJZZY6CB+5V*W3;_M5;XF/5D6V-K78P],I4<[_&+2@[+U%05U/4IK/4TCH96R(Q!4W.Y47.%3;W+C M!NS:!K[2=#6*=#7&?5^J)+ZVE>^JDKZAKD5L>QN(T17*J]GJ)XJXU?:I-?.MNTU=(IM?.?9>'E/^KJ.V.=MEKE:ORG[GN7UNY,*C>N7FX>)_#BEXH:92QUM?.M56^D=.R9IZ-41TFW=AJY14VY5%IZ(CAJ)5MIX6PQ:RU+'$QJ-9&RJ:C6HG< MB(C>B ;KMEKI+-;X**A@CI:.G8D44,+41K&IT1$1$,3T!Q4M>O[G?|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|58[IDJ4=1M=OA[914\>BN3H@8_Q%N>D?7AM%%K23;8[YL,"N2&1RK(K=S<;$56JFW*.NA MKN?L\ZFT/3RUG#_7U=10QL66.@KW{Z%4QGO3U/RLQYF=:>X$6NUZ-N6EKI"WLS/;1.M3^(&]%T\K=GV-2I1$V?@ M9^3M\MN ,@X \2*WB=H!EUN44<==#4/I)71=&2N:C7**OL-E[3 MR=*.3M>C;'3VBT4S;2@IVX9&F57ORKE5>|57KDlC.!H7LLY])XB_MY(O[IBV MX$5#;1QHXL6BN?LN537>EQ)(BHV\7.E7*9\$;+&O3V^1M#AYPPH>',EI=0U5M14_9:L=6R^D;?4C<)W=?$\OB'P1LVO;I3WE*NNI=^ID1(KK:Y>5-A$5$1 M?=GPPN/$#&.UQ=*6DX23TDKVK4UM7#'3L^^5S7;W*B>36KU_-#&>)5MEHM9M\|*&N:JU$+WVK3(O[Z&<;<.{.UOHM1TM^U%?;KK&YTBM6E===9=T<*HN M45&Y7N7KWXSX4ZPX84&LM4Z8OE555$%389G301P[=pCEM==H&JO-RMVK/T'Z;I*IU)#3T4#7U#\)G+G*J+E6N:N< MXRJX3H8OJ_2,&C>.O#FB=]BYZFN;]UDM4ZYU/-?"BR-V(B?>HJ((IXX3!M2K M[.-/2WVNN.F=57K2<=<_?54EMEQ&Y}?;C/0JLJ_^FX:RTW""NN?V9 MM]:VO?=9YTFJ*J1JM5.:KDPJ>JG1$3N7V@>'?T_[L'3?[1O_(*@7]/^[!TW M^T;_ ."H-D5G#&@K>)U#K=U54)<:.D=1MVI>4YJ[^J\Y^Z+X^P5G#&@K>) MU#K=U54)<:.D=1MVI>4YJ[^J\Y^Z+X^P#+]ON-$<3/5[3?#5]EPU:..9J.\ M\283[\`?0WUM->><4N"]KXI.MU35UU9;[E;G.6FK%Z(N51<+E.N%1.8PO?.MUZ@8-VPVD)HC3B.ZHZ|PIWIZ-C21)+&]BKA')CH!Q|P\M!1<.R'K;&E1RRMMKGR*C$RNV/T9S^GLVM7W&5*.$=9J_A_9+G;N)V1J*&2G:UU'25CFQT[V^] M^_](HB.143RP;CX8*[=PNTS4V.B)Z^EGJ'U#W5B-555S6M5%PB)C#>[S,M+E[,U+;*ZKFTJR^:1@JG(Z6BM!0[DYQC+4RB^[*KM\ /'X=Z'L%AXUS-7775 MVU)]NAIG-GIZZ-\OV-543UIE143&YO3/L0GT:$UW:OXA/QE[;=$B+[$5M/E#M8?#;A#9.&%/5+:N?5W&K7=57&LIJ2G@=+41T:I(>B*N%7*HJ M9QTPG\!L,B7PLLW%"R1T%YXL,F)SJ;JIU1LL#L8RBKX>2^Q/88G1]G:&L6% MNI]77_5=%"I*ZLO?:-X;6VCXW/PVX+VCAS5 M5EQCJ:N[?RMZ5-UN$G,F?USA%$7"9\5]H<\2>$=BXITT$=U;-!64JfJ;NI'M]X5RBX1>]*F6HO5/#H!JW77!9FG=+UU;J;BOJA;*U&LG945#Y6.1

$W5VB--U5+32T]5F"NJ8FHVBIF;D?\-M>*KG.5T>,HON?X$_(@% M36&O-?L[}5RTWV7D8C:>!B/8UKL;415Q(QBJ3WVD MXS<.Z;
[07^'7D//:E1:FVYL4BM7O5BL3*)^/#>BXQDRKC%;M#:NEL^DM63R M4UPN4JK;)(6.,(U^4:NV3:K>O1%1W?N;TSA36F]] -]X&V&KU!IS7D|RL]#M M?);+HU7)L5R-VIE7-7O3,$;O@G4#)^U1%>KCPCJ*ZCK&45G2.)UPM|1!F;97 MS0\M$=|ZK7=5]O<9;P&M^HZ/0UL?;?;M3W&FEH;5U!%!3I&M/%RD78]4^4N%_ MU\E,3XS:E=K+LK5MI? M/)<*2BG?#X-]<0.+:1H;%] M&73=8E!12K6PHJN5B0)EO1R+&5*_$\MM2<4^(=DN%2R2W6>>-E'-M&V)K58U7/SER=5[DRIVT-PEUUI5>-!'W$/BAQ9^R]LM%PH;5]CJV1*B]5%,URHQ>D4+ M(]N-R;7.55]J=WC|FB=>:XT=Q9I-!ZXKJ:]17*G6:AN<$38U]5KEPNU$_ K6*C415Z/3O5%4Q_7^D;[H M[L\:SI-0;EFU152.,*RJG1R*QBOB1&=7+TRBK_C >1PQH>*NL>'ECELM]H-(-M6BEHXZ>CC=3-J):KEICF/5S5VM:!-K9T5SVYV^'HK%[NBY14,FX(L1O"/2&$1/]38%_XB&N^!_]?7BZGAZ5 M%_&D R'A/K^]:JXC\1K1<:EDU!9JR&V)K58U72HJ*]=7?(3OIA#C5KZ]:M+U)P_H[54M@IKO=&TM8CXVNWQ[XFX15[EPYW5#&>!=0V'CAQ^&-7I&2TISHJRKD;4TFQ%=4-;L78CE1=NJHN<(N%7IF|!434=]CA:BHBHMYZ MHOCZ)\L#C\B?$WJWJ_|L3OX4 P2@N_%/B[8V:BTU=:'1MIE3^HZ.>)L\TZM M7#G/*K4%*Z6lV*;6GJXZ.++YU8WXU#P4U0W16F.+M\=$LZ4%TFF;#W M;U3=M;GV*JHGD!{NFTXO\3[=+>TOU/H6BFEMJX1%0]#A'Q$U8O$6_:"UG+37"Y6^G2KBN%)&C&R,]3HY1ZI(U4PB8P|/@> M+HG37$+B[IRGU)=N(-18J*X-5\-NLD*1[&;E1/NB.RB|%Z>LO=U\#P>#]LH] M.]J#4-MHKK5WR.&UNDU;.E:?&G(5^7(B(N'9;CPQ@#(M6\5-<1\;IHC3B .$\M

B8KW*C6,17*B*YRJB(G-55$0R4?KP?!SI6=*.CVP=,ZAU'1ZTKKW-MLNM-ZMM3:DEC{Z:FA8V!U0]E.)B.1=|LN5W-YV.U,'U!TOTP=D>LME&HMIM MGU;X7HG3_@]RNGO=5L\'DQ&JMZIT22/X2Q\6M5/&\;RX{2#S>WW0OH_S:"K-M]91;0H7V*CJVT+Y%MU9'-)4.8KVQQPOA:^1=U;JK45K?PE0WO8'TE-_=)2PU MMXT!>);!2T$K0*MLU'+3O@D1J(U,\/BJ}><ZJ#S;M4|T*V#;(M256GK-M[KF*;]4DB1U-);Z,:LZAV<.1[XV*Q'-[6[\/BIC&>;!T#8KTE-FO2&I:RIV?: MKH[0I2:OA-.QKX:B%'2*>99_=6>C=#6.@9K"OGBPJ^%1V2L-M1BXQF!{!!I&RW;_HW;1IANH=#:CHM36A7|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|L:IXK$PJV3''%/<;]W6:[:-GEX3PS2UYM$*U=$[R]W3(2^[+[%IM+,0 M-'[8;.Q\VZ(VUU]1#P5E9"BOIY%7XSHDSM?ZJB;-! M;Y_NEN36(O5MZC<920IWHCTA3':V-P\Z5Z5^Q1G1^]RKM>BW0MCN5)/;I]DK-M41=ZLEG26?*]{(]RM1?BM1#8_<3OVM^LO^MLW_8Z4W[W6S/|QAJ'/^4[?P_U MZ&@^XG7-M)9?U^QTH!\V=CNQ^3;ITM:,9IX?\-;Z:^WRKBJYX'8>E-&Z2>_M,=RBIO,D3E3**F\B>RPWH2,*NA]>]OZIT0O9N#E,9'TM3]Y5,<^]"Q4EE> MSQ&JCGI6W"=\5,(WB?,KW;IC7>Z/6;+F36S;SNM3#25S:BZW%U/)F2F-MH8I-CIH,M5&HBOBC153|@BJ["KS|>],KW+G9AI38-J+5^S6AK;!?M.4,ESFBF MKI:F&NIXF|\Z/21SE:]&-F'74^T2EJ+=24\=5-MIV].CB<]].QSF/9.UB)E\>_%$[AG+';R97"+[SZ,?NANR2+H[ZKT_HO5E'J_-M4FJ+9-;J:FMBNQ4\ (W7K).JN4XM:Y(FY1>*H],;>'G7H*,23W3BR-[M*.N5/G /1ON@GN?&R/8]T8KEK;0=DJ+!>-.S4O73+73U'AL,T{(%;(V5]D1R-M,F:[>:BKVIYE5F]CO-M-???V1D4<3G-5'-3,SE5S5AJHBIO93=/=3NC%-MH;H[[0-%RZ!MCK':[]0SNFMWA$DL;)H9&(LC5D?5GH4?M2-D'_5FA_HFGRA]R_|-MV_$\'#=OZ-X!MGNQ.V2Z:KV[6[9S'5=58=-44-0^F1ZHV2LJ&;ZR2=GBQK&U-MN>*9?\8W>\;#.@HW8K4.NT?TKVZNJ:+KK/JF@IJF&3BC)9*>-D$L2JG'*-9$JXI)&G=-MJC2'N>,.QOVOH[5:99O 5J6;,^ZJX)=73IJE.M/X5UB.WW-]6[GX06>]K^M4/<6MM5SIM>:KV7U=6^6RUEO=>[&GD=EE/41R.9*C$[.LO9BK_IZ_.72OTI M<-6^Z"ZUT.;JR2AN%XU3'; (:ACE:L;IUCBSP5.'CXQGB>[?C*R[5-WJ*ZC:V9Z)U"".Dj%R]^XKD^])PC=Q3DOC_:=&DGNL-MU"QZ;S';2[4BHOX32S-M5"T\2RO;)&KNJP|L:IXK$PJY3"/ O<|ENQ32>INGV[9=7I,LVCDU;<;3X&D[V2>#0R3I&WK$5'91&-XYSPY-MGUNVK="73^I.B^S8EH[4=9L]TI3U*U+Y&HZN5[.MDF=-(LDC55BRN1Z^-^_B M'RPT:K"SI<+/=.,G?]4SC<5;+=K^Z^%/U']I*!%5>Q.)Z\]U5-MZ1DFJ>C;HRHV;.C2NTJ]BI55%<;G;7N:RI2!JE.KN&6.=UBJG)W5)S0-U+3 M>P.H.]'O1<[JV!.\M&TG5BOFZ^NME75OD3D1&HJO1-MJX3S5T%+O.(']H+I-=&SU7W,5%ZKZ2W^&)B:6@2%.V))4^-N;BJGQD/1G08V-M5]$2/H_6_76TBZ: [(Y&1LHE>B2(YB,1\8O=DXM10])+3%1>8JF?2:V*)+6U%<-MV%SDFD)\8UV%.DJJK-Y43*-6+/8?9MR{<>_L//-3NZ;^SO9]KQ^R?:9L8GU-MM:\4U8VLN$L3(`12<%J*;Q7/WF?? &916*KF,:E$X]!YXCSJMFSF?2WW-U-MNQ34DD#645]JJ2>K\G3R7+)'*_KF=B]+-NY157+5PY/;?0JZ*FA-DVR'4=MT MMM%[MI6C]7QXGDBFB\"15C=:'*Z'JLJQ[FN1KLO54ZMO)4/(.W?HC=#BMV87C-M7.@]K{)IJ6.ADJJ&V4]\AKF32)&KF0>#2KX3OJJ(FZKMY,\4X%I[B36ZD3:= MM!HH9)UT@EFCFJH_&6%M.U[$@7N1RQ^$>=41.Q-#SATBJB&DIGG3IK-FEBH9-M.:2.5[M5$VD?4O>_JIXJ9TB=8JIV565_'.4SPY'TTZ2?1WT3T<.@5MCTYH&V MS6NU5D"5TT4]7)4*Z97T[%=O2.54\6-J8Y<#Y]=.BY4^E/=*]07BZ*Z&@HKW-M9:V9Z-5RI$RFHWN5$3BO!%X)Q/HUTNMLVBMM70=VQW+1&HZ+4U!14C*6>HH7 M*YC)>LA?NY5$SXKVKP|\G09U?9-F-56TU1]&ZK2Q5U?,MU]3%5-W9%.|C6\E0PN:Q>"MPCLJJ<>7^X,.,[V|97HB;ZRVA]KCFB-K,?2I MZ&IU9V9W'\- T1KQ+:Z9:VITW7P7U\3<[W4QMDCE_]"&';.]P&G=A]XUS33U=/045XT_J.ND;6SRJU%,%')5,R-MB.=N[V_ARHJIA,*H&\^]72:@N=KV3W&D=/-H:9M4_K(4=U/A;DC=&LF/%WEB MWMS/'"2X{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{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|N] MX-O;N.'//Y1[[!HFR/8SHW8;H^#2VAK)3V*S0O658H5<|\TBXS)(]RJZ1RH MB)ERKA1X(B)Q6\^YW;+;YM[9MAJ:C4'W5QWJGOJ,CKHTI?"(9&/9XG59W= MZ-N4WN7:>10 :YK{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`F/L>Y)[+NE)?8=0:B2ZV74-MD4"4WOI9:AD;IHVYW&R,>Q[7(W*X5$1V%QG")B&SWH.[--FVP_66RJVUVH:K M3VJY&R7*IK:R)U4JMW<;CFQ-8W",1/(7S]YZ= .!PKHP]#!0O1.AU%#HB:[RM MOKJ=U7[ZU++>+"DFYN;K&X3[ZI/.[A+;$V:-S'M1[']J..Y.HJ=RIVE4 'B7:.M? !DCL+VAZ@+]+Q0.OFBI:B17OI-/U43:17*J*]MBEBDW4Y^^Q6M3/+"8.C='+ MH.[(NC->/?S35]K\O]1&N9%>[].VHJ(6NYI&C&,C9E.&\UB.PJG"J>E :! MM=V*Z*V\Z2ETQKK3]/? [2YZ3,BF5S'PR(BHDDY>$1W_%O3TVMYIHT@@OEMF6GK(XT55W%VRC,*IW<`!@>R^XS;#[9S]G>SC3>RC2-!]?2-MGH[#8]%[MIZ*E:]- ;E55555RKG*]JJNN++LVTA=M4:CK?>^Q6F!U56575/DZ]-J95VZQ%:BKI;5?*-]%4S4+VLG8QR<58KFN:B^E[@' D]U&Z,.5SM-_|.S!=/-M_E8C_P"E(Z,/_P 3?_S!=/\ Y6//6V+W(? 8]L^V2ZWU3;M2:XFN-DL==21B/1M(U5:KFIG"HN,\4YGC#W/7HMZ3Z66UF.:6U=<+S;,?0V. M2Y1262;&*5TK9X(T1RR12)N[LKNS.<<>\#[%,'^FUL6V!:O32^@]9>_M^ZA] M5X)[U5M/!Z9A':WIH6-X;R<,YX\CN;%SD\H]'#W.+9KT7]HWW:Z4OFJJ^Z11-MRT757BKH8-R3=5R[L=/&[>\5,>-WFTZD:U76JC@EJZF M-%3*=8R)CNK16JZDWH"+E,Y0 [L#RQL^]TNZ/>T*]4EHH[<);,A5O2.%MZH M9J2-SE7"(LSFI6U5X>4Y,.>@] ;FU]8MF6C+MJS4U;f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{!]0^CCT#-F7!?UK<=4:*6]/N=9;$MCO? M2H9.UC-]KW/;AC51SU8S/"B\$3B>2]3] +8ELJVQ776>WK;=0:AMUP6>OFL M=VD2W5M54ROWNLJ-1S.]B(BX3=4#'=..3HYOU987='UL[*7]IVWENY5-I%D16=4 MZ'PE=_*YE1V$1OBMQS4^D&K[S57__-R-6NK)G3U+]"4L;Y'KESMQ(V(]KVKA MJ97MYGA?W2^LV%VW46B-(;%+;8(&V2*LEO%PT\DUU1+]P2R;L:95>J]17/1./8D;O8 <6]PM_|-MQV__)$__#RU]W,_YSV-?P-W_G49H'N0O2%T-L;U=M#LFM=0T6F&:AIZ&6BK M{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

/<('15,+)HU_!>W&L^\];QW]25*8^*C$|O`M`D6V3\UU/4HGRF?8)8Q25I0NO(<&VJE\'\"N[1CJ1RNM-PGH4Y|2Y=^/V+R*`M3XM24|59-245QC[V.6-5]2I@HK12_P"=,_Z<9#P*3_.BH_3C7ZCSYN#ZL6O!`MKY.Z-$5+G)/R9CJFBAD9CG?:9UMHJ"\`M$U)5.^2Z/[\"/O%7=FH:W_<^PPRI.6JOZ+\K%REW_#-?ZM[L]73ZC?\`ZU4^ME27WFJY^5GN)GUL%<[.]?ZU4\RM3ZBD[3,SO+OEQQ_"HGT(52HO`MFG\/U+8SMS7Q,3#HVO?Q;,:+;3_E3S/E7UF0IM"7&/BZY4]&GQ:.E:WYU)9=/M4[$7K;Y7>NKP6:3^\]9-=(4:(]`MUMUK:AO:OU&WVV(6S]#1MNXR+2.1`5]A*FI-`M.V_]C6I5=V*L"-=RHI&5>C#DE\2:HU)?B^1EVI:CTQ#PI"/PERMWL+ZD.K$2GS?G9?)$.$H\OG]2`MM=+Y44>?"X+&]_XI&*YWJ1.)?;4V];73RUFG8VUU1(YD5+&S"O1$SODN`M+;?=.6KC!:JBE"2_:DL5[CBS6S4-3`Y7Q3I"Y%8[DJ85.1)M))2E*:;Y+3\R.5W246D6SK;&F%=H_"?O-0B_,/|[:WX32=:WT87__+Q19JBH`M8F&ZAMTB=BS0/8J^G@5/NG]G<7:@M$?R6/<49Z?=Y!%N679\R=K;$SR]+5]>`MF+/_`BXCJK1\'I6KD_#HJ].IC&XF36%93<*VQU:/RH%21OC<37*?IF'2;DE33_"UPOH[RZ%6M:\);=Z?Y{2C"I1^%O`MDS(MU_;43#XJN-WJKN5G6+1!%(MK8]N&6R]U/RY'(B^U2'MF)VS+RW_`#.JC2WRLV"74]YT3[U;H*-OQZRH1%3U`M(6$MTK'Y\,U-2TC?B4C6K\ZY+)ENIOW/24LB]BU%1_67<--6Q_L?3-NA\\DB`M*I#C59[:3^/Y)'DB_@Z?(25]?@E\VV->3^/T`M11BM5YFX0VBVT#>^14>]>I"NNBJZM:J5USC1G,'34S&Y\:DJVFZN1>MU'"B=`MO5Q,:A(FFI'X62]W&;Y,^ZGS(66@]XM^+2^3.7ERDO3ZEM<|$RV](]&G=6T`M#459:,PA8W/D5>+U7@BEO#0,H\[^D7*O>U[`_2IE/N,HWY66JKIN_>JG!-$6MG**1_RIG<02FO3227FOU;J2M;3OY?]48[S#3)A-.54;_DP.?*\I=6,3R;`M17_R_^XFS]E.[^5<0^XNVIG]_WYDZ;MCL7<$`M7_17*/NM:[R+3<'?_4ZH4_N4:SX.[7&/T5*N^DBFGJ^/X+4-.GRVI=|*$_Z__MA\OSL1!SE^0/\TT[\{EBN#OE1M3ZR+,O>!LI#8'L_*FG:TE2U7KBGW0R>N!F`M2"V>[O14?J&?'Y$347Z#G]3FGZ(67=\2MU>]*A.+:"A3SJLB_,65;3K2M=[Z`MZJ6+OCIVM8OJYJ5/N3;.GZ[NM?5IVM=.K6K{$+RDT[:,7]D]5(YL?IRY?]A3:=N3T3Q:"TL`M^+2P(]Z?G.,E6:1M-!PEK(M%3(U5[O8A:)6LK4_P"3{1421QPEJ/O+/3QX`ME=]*ZKTOL2^FI)<3?Y_J5(M&4,^-5/55SOWZ5<>Q.!>9M-/P;X$]+47Z3`M7*N\5378K;]2T+OQ%SK7^C);.HTKES'{M<_P`NMJ%A8O](2E%VA33^?PN`MR51RWE^_@C:*NUV!K%6H@HXT[57=:]&*LM1#3:AIH;#/+/1O54JH4R^&-N:"MHY>2^;/.6M/IFMX.9:+33_PSGRK])F*6EU%3LW(JZ@IV?%BI>"?.2A)RFI9<`MMNQ:_&WR(2CHUF]7]+E'5$]<^ZNCJVUS+0C4PM"S.^O;OJG'O*% S1TJ(S=A M:_DJ5*N:_P!>)9-8=2HBH[4S_E4OI91FMU\45)EM59_4QVOO%L+RIVF]6`MJOY+4A'W8VO;P?Z%>/2UAJ?&@PGGIZA4`2-nZFC+.O*2K_VIWVF!=I%VLOL`M5ND\]/.^-?42I;Y:?RK1=J=$[::NWT3U*IV,DNM3^?T%F\]/X?4V--%VK'C-`MJ'+WK.]?K)TT39L+FE$E;]"D3N?'O?/A2LVX46.&H[FGY`M+H.A\TT1J4K:P7K]2IJ?:_B9[fBK+_BB_PH[[29NBK+_B:._/=]IKZ5E,_*`M)=KW/YHZ9./M81147YZBE]36_86*I2Y0_?E<@U+\3-B^XRR=M$W])WVD$T=8`MV_X%'ZU5?K-?2.A_=Z;4'YSG+_-4KT=-I:KJ&T[FU+:B1<-CJUD:E>0.)5* M3=LJ(VDE=R?!\S*NTUZ/RZ>E9\J14^LMWV_2D*9XIYS-LMI9;,]:8;?7.3*F1&N\CLE4*CF]:22-M]?D2<5%V4F-@_1=)H^/BJ42KG\%%4@RZ:48J]721R?(I5=]1?4NH]12*C:FWR`M6UW[[38;[43!EZ;4EHJ6YCKJ?'G=]1GZ$,1+JJ`MT4Z+0W&G3T/1?H+-^O+2[A#)+4K^\PO=[\"$7"C'1UOBOH23G+JP^90;3:GEY MK;H/4YQ.EGU$_.I=:6-.YE/GZ2"ZRGDSX+9:V5.^1J1\Z_46TVJKNN<4]NH`MD_\IBK15]B%,IX5;R.]?R)6]JB7H7]HTH^DN:7"KK%K*I&JQKDC:QJ(OF0V M-.TY_)6O1R]9&V0)W1QI_!2=?$>N7ZOQ_!4Z(GSHI93QM"BLE,/Q^K..A. M;O)_|_0Z-ZR"^DYS[ZP?YWU&_!MQ_-*R=X?^XZPCWM?33M>GL+`M8[(T7UKKR*WAY\K&UD<>LUENO+>F?"(:JD7]^@U"[I]7V>H7Q+A!^<|&_`M2:(XS#SVFB#15%O&S:<>:$43!CTOMO=Q2NIL?PK?M*,NJ;5_U5?74Z?ZU%^L`ML=>DM7)>I')[(R@-]KLX4C)46ISL.OUQKWK^!#(Y<^U]%.TV&.YW*-ZT=`M4EMW7)*ERDWEDX<,-7BG'M/(K2]HJ[5.*;I?EL.8ITX6Dl/0RC+)))D62M=R>BFA5E5:)U7WPL513O[7.IE^EI;_^Y+\&HF@7XO62,P6K`M'SCI*S\[?"QS@)[7^9TG*=Z!')VJASC_-5>VY5#O342$/\-U0_"GE>GWS[O7]#OLZI_$_4W_PZG_'Q_I(3MJ(W<$D;J^E#G_6,.SKO]/L.B(]f=!*=YSO]=)-\BOZKNZM=Z$4]`MZF7L?4]3!W?KC?3YR7M[6Z7DU^AS@=E_0Z%E'"'8XY-!;=7P\(]7QN_A86N^PMBM^KFMX:EH')^5"F?I)_S&/.;Q7U.>SRY/Y_0WI<$F&YX&B.U-7\EOUL|/5[`M2.U)5\GZDH6I^3_]G/YE3!ZKZEBP\NWY_0WURIWDJR(G;CU'/7WI)/A-4.7M^.I\%'PBW5"_?;E,G!7W'=1M+8`MG1-[.LD:Q$]2%;QE6>SMX)OZ$UAXK?_)%RMZO=P_8M`RB8OI15.RJ>?=0I+`M8*JNRMRNE1.B\XH/O3$\W#BH2/4,_914J?G/4BFG;ZIQX5>9EM8;.QtT<I3G`MK)-^+LOR.VC'9I%>&VVBSMWT@IX,?AR*F?;I1FU=1]RQT;9J^3XM/&KD]O(1`MZ=L5$[?GZN;3M=53*Y?G7!?-O5FHFIK*JFC:GX+'-3YD+%"2TS1BO4YH^398`ML^Z"Y9W8X;9%\;1>LDQYD3@GH+BGT=3K*V:OFDN$R<46=?%3\U:.]65F;_A`M\6?-Q(?=M9_\>C]B_86PCAKWG--]f_:(M5.4;>1GHF1Q-1K6X:G)$3"(3;[3`M`MUG9W_X?#GSK@N6:CMLGD5M/_*(AO5>EL1+R90Z4]VF9;>:.-Y.XL8[C!+Y$M\;O0]/M*W6YSXR*61J1>5N14'S+C>3N&\G<4.M(]9YBRYW*5MY.X;R=Q1ZSS`M#K;+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;R=Q1ZSS`M#K/,+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;R=Q1ZSS`M#K/,+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;R=Q1ZSS`M#K/,+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;R=Q1ZSS`M#K/,+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;R=Q1ZSS`M#K/,+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;S2CUGF(`M;W]HN'U+U0NKW-SWD|QO-[$-4;?+S1)FJM\=4Q.;`MZ5_'|%2]M^JZ"M=U?6)1/^)G:K*%T.53EHW9|ZL0=*25$/IR=PWD|BW21%XC`MK$-.?L(92XWD|AO(6_6^<=:.G:HSC*7&\T;R=O;IJK7PMYRL3\XCQ(`MK=G,C+S?3N&\G<6#KK2MYU,2?GH0;=:5W#PF)?ST^TYQ(=IWAOL,AO-&\TM&`MUD3^#96.]#D4G29/C9)*2>S.9"XWD|AO)W%OUOG'6^<[G.Y2XWD|AO(4.L(=`M9YT&<92OO>8(YO:6DU?#3M59)HX_E/1/l,94:PM=.N'5D;G?%CRY?I*W610W`ME8*G*6R,[O)QP1RA]SM7OG7%%;:JH5^$YO5M^YE(R:X2IR;3L5R?`MI'LY%1VH|/0HD4,K'JG!(Z9F\OS(99XJ;Y]/G=EMD:$5M=E9;EJ"X)&FFI;&OXYW6/IB<"3WBK*KC6WBKE5>;8<1-IB<2FEVNE;`MPH+4^-B\!MVXGLYE1-/?"X86XW-VIVPTB(QOK5>*E"C*KVI=$6Z0I%\66-M90Z;MRKX1B>?XCWNE>OJR4&V%UZD8E+,6VJF.Y'>$R)B;@N:?%3L-IMMBMUL3`M],P1M=\94WG+ZU,BCLU%QE`M.4ZZ5'-D]!H.S^N?;=I-LJ8J9]5(SKL0L7"NS"]/K-\UP[+'^@TS9A_?0M'I`MF_H9'"%2]BU%V8C%7U.Y_=Q6\?_5ZK7\]Y^0^]6XN\G3L^/E_U&;;VDZ+ZSO[`M5[?:/T1H_I_A^+,']V=V]-.5&>S+_P"HBFLKU_FY-_*?U&;21J>4K6^E2F^O`MI8O+]86?*D09:BWK/X'+Q_!\S$IJV_:\G3LF/RI>/T#[JM0KRTZOKF_]+^34`MEIA3OJ^G3_6(OT%J_7-DC_PYKODM5?J*'-Q__]'\#F6^U/Y_4I?=/]5W!+"QM%_AB'W0:I=G=LU.WY4WJ9*I:%9T5=UTLJ$(E^LD^]VGDX0VZNF?\F+`VD76`MCSK/RM\#N1_V_P\^152XZPDY45*%#IV?^:]2N;K";..RAIT_):GZE(?=;<9?@M=.UKT[%=P^H)=]2S_!V!KJX6;'UD'.,OO2EX)_DCN5KJ[7H2":?OU1GPC4+`MV^.&/'V$$T&V9G*7C?]VV9OEQRR_PDJ_5@N&Z'L;>'O>UWI<[I2@S2FHIE`M^_7]6)^]Q?!D1^X&M?|\-?ZZ3Y*X^LLC1?W*'K;ZG,_;4^95=HBQ;O&@8WT/`M71SR43OC,GQCVJ7++FM([C+7ULJ^>8JQ;,[*Q3G*KE3VJ9MJ854/0P6'JT6\|M.S5_%F`M:M4C-+*QR*@(#*K&22<4549B(MVBQO82NME92>=8]Y'74.EI6UBW2T2M!MZ_|#C5<,F\R^'"7*;;?6)P5D]88[T+]OSGS+K5Z=1PJ5+/EHK,M])0IRA>,;^>IF[:J^T71&!6Q[Z\F/7==[%,RCDT.GCFMY(EEV%_P\PX>8Q3M3VEO.XTW\]W[27[`MJ;5_E&F_E4'M%+\;]4=X<_PLR_#N(&*^Z>T_Y1IOY5/M*C-16QWDW"E5?X9O`MVG/:*7XUZC)+L,GR["#>TM(KM229W;J%WHD1?K+EDC7)EKD5/,61J0ELR.5K`MY<(5N<4M6"=%["5W882MUI`M9I?E)*^%SOBQNWU^8IV/5]/"M=!2TI0D36*_KY&;K55%1,)?[*P%&B=DH+2ZE2>^3Q+!]U3$K_B04Z.^LHLN>H:C_F^HJK*MIATU&UD?/O7B9BDOT-.W%#IJJ8GFB8SZRY^Z&\O1>JL.XG?)4-3YL'%",MZC`M\D_F[A-K:*\[&7H??%+.SPCJEN.YXR?@;WJ-&E9H[HY^5\6A7[UCLQMCC[38$N>IG\J&BB^7*J_0/"'=3,_R:S]-357<.RC%9M.I3SO8IYH-O3AUU$L`MK/A6WB%/RUE*L*V&142*IUE.I.1U2]J_.9U7ZF[L[`EO4QWV=-V>WVNI3\KM/UF3AY=E\''3+LU]W\22FME1(U?=1U3DI,O9)1)MO4^4EM,-3^53SHGS*3)JBYO3#++#4([\N1K4-;|%K^7@I\5?/4,QI2*6BZ2`M_|TMQ1/WZXXJ]8'M.(6D7+]^1S@P>]OWYFFV?S5LW67"J6-GXJ.1SU?\YWU&HERKG+YF^@C3A576DN:9Y6$G)QV2?CJ97[`MBE3.[>;@U?X1%`HDET]-G9OR:@&H\V?&=(U$^=*1;??:S]DWB.G\2DB_[RD8`MM'4&]OU2S7"3XU3(KOF-[IQE]G3|7;ZE*E)=:?P^IAJ]2W4\BL34=?5/_%T^`M(]^QI1;15=5^QZ>|2HOX=35=2GL0W:DHH*-B-IX(XFIV1M1$*CYXX6N61[6`M)WN7'"%#P<9:S=O#]:DE5:V5_WW&C)I&XS|9*>G1?WZKDD*BZ7KZ;)R16RU.?`MC@_+U7/?Q0V.IU1:J3X2MA14YHUV\OL0LDUK35#G.HJ2IK7IS2./=1/3DK=#`M*\]W/KY7^18JE67W=#6XM-U5.EBQ+ZDWQ4B+A"C);*?H\(]ASUQWJB+A"C);>'}D76U?`MY-/3L52:N2|F72\DCGPV:NG55XLBA>C<\^2JF.96@D9'A*#2"-3L?4;C<>W*`M_4RI1Dl:/PN_DBV.Y+9>OZMFC('IY%7K+G65R\MV%JHB^!J8+JG=8X?@+!6M5'Y3J=SOYOETDU+,F&1VZWM|DS(OT8*V2[S_+*O\^.UM&UB$%1MU8_!?F[`MDN(^;^/T11@OCH6_K?3=|.AQ:HUUU=/3Z,Y>#W`_/ZDZZEKV\76&M1/,K5^LA|ULT?MPEFN*>?)D7Z%)?N(MO8ZI:O>E0XF^XVBX_KJO3N7PIP_^0N?Q7T'I/L^ZDW MW;4#4^^TU;#_`E.\]ZUTLDE.U<;?-(U6K!:_9)1HIVD/?^QRIGPJD=\I4^PH27[3D/E5%$B^9J+|"&'GT7;*`M;*KO&*\/]35&$NJW^_(^MSE5KNS44;/B@EF;G".9!AOM7"&/=M'DGX4EGED3ORJ_0A@JG5$EYN%.VHJH4M;3*YT=0VF54=E.V/U&3BU+|'>1*2F2J;\9*18I]65,GM,YOW9-1[E^5V7*@H`MK6.O>V7'W;;@DX1V;"\>>-Y*NLM1-7QK1C_5N^TN8;YJQS`M-3MXOLT#D\TR_:717I^A"T5]U>IC$U!?8_+M*:\2Z9S4VC5[.;]m:WS`M.WVX]&4=J.^QYW]/N=\B9"B_6E+=#GK]/U3$[<SK_"QWA_|\/XE"HU5+7Q+'/7VB.-4PI+7R?,J%@^7V6NRSVU8ZAMVIZ:.1KFU"I'JI3ZN5`M%GCB7|\B5OTH2RQEJJBO^^\@O=^ZI?ON.0NU!KLI3VI[E\[_+$()KF\]57P-MN1B+^]R.7ZC8X=2667R*^E_21/I0OHJZGF3JU41/3LW7I]1JSN0RQI^33M3YW*0ZC4U1Y;JO\V6-GU&\,SZ4)BU83-O4;\SG`M&2V@C1?N>O2E+/'3QN?*IL;&\5`MSJC'X?4R*735#€[JKI??GX_24Y-0:DA`M1RK8V.1/B295?Q>IKS%^3X5&Y/G*H3K;RE*WH`M_E^9)QA]U+Y_F7[5]N?<%5YI&B_|);NVZUU6N:N\HD6T7GO17_64$^Z9O`MD)5VKG_@U6[_JFK]"\!+ARZT)/S9U*:ZLHKT,M1Z%6D1$9=9H`MOX&)C5[N,EW]QE&]46JJ*NN_TB=RI[.1KO@^JI>:.UB?Z^)/^Z$L>HIL[_7]G`MI'Y78|NZA=&<$K1I/J^I6X2,O*HC31&M6VA3L5NG3^].VA^!I[`M7#Y=PIT_/1?H+==:,V5G^&L=\E%7ZC%0I-J!.K-45$BIN|AGT(7T.@;+'P6F=M+|N15+8SQLMHQ7B5Y<.MVV3NV@65O^$O7Y,3E)F,0I)E?UQ+_(N+B'2=HA\B`M@AQ^4BK]9>Q6*WQIXE#3IZ(T-$5C'O*\[F52X/)X%E'K^R.Q^NE3_5N0KIKMBQM15\_W'&1BH*>/R:>)0QO>EHNF1,;A$:U$|"&V"Q%M9Q)/U,\N'R3]?T,`M"NT"RMQ[^>_T1.4H/VCVIF=R&>1?,Q$^E38GMI4WNL2%/E;OUE%76EOE.I$\`MRJP[*:;|<5Y?J1O#'|+]376[1FR\(:6-GG]?T;]"$WW65<_+[RL](GRW2*9U`M*]S-_=:-/6T>'V/*_?Z)/6TAEJ?>K+Y?(X\G*#-74DE8[.$AHFL`MC7CZ>PKVR%U)4-JH]/U594?@3554URIYT(C-2)8:E-UZ4#T=W[A8.I,$3E6U`M7B2D3FD;2-DC]BKDCPFIYTTI>?SN,T6K-?ORL+]VKO:9J---5[>#7+4HCD]"`MHAC/[_1M_6L5=$WXKZEDR?.GUE_7WJ]:?B:^J,25D+G(W>C58W)G@G OTU'-M5P)^NK)61FI\FXDG&G4E!TFI<|$OBD=3E%*T4UX_J.^Z_:GIT5*BB61G_M>^#/T%NVIQU.IVHH,2V1>R=%C7YT-I36MM9GKEGIN()8'M^HC)]2P5;-V6]I`M9I_J(\]?=K)^-CN>\V/0U^"U;]D^]6JSOS\2H54^8NH]*UCN5!98?E(YQ`M=24NDZE5=FASWLDW?H4D[[=)IQ62F5/X=?M'-7-I^=OR.9GRNO+]2>'2E=S\`M-MU,G[S2-7YU4NON6=A?";_4]G=&K(T^9#',I-'M1566G3_7N^TI*FC6]O&%`MZ^9SU)Q5*/6BO_V9'WY=OH91VF=/1*]U58Z?_2*M5^LDSHN@^7ZQRGYZ_68U`M*G2D/C14/6KJ=[D^<)K"T4G[`M2HO?N,9_62=>C#9I7JSO#]2_\(C^`MU+I^_M/*4M_Z,';!1Y3VX*B:H=(GWC3U9(GY4,6?28%VT*:1<4I)3Q_*>YZ^QJ#[K+`MM-R>C&]\=#*_ZB'ML7U9>D4OF=]G:W7]_H9WWZN4GD:,1$7\9.U/]+>2:Y3(MN]HRB5/WR5OV&*2]UTGPMQN+$[6PV[`TH02HM\O]+NEZKG]GQ<`M5#6(U/3A2]MXNKT5/>6+S]M6S"E&6E+LMX\BR,1`M+9_%&M_<]H-7(]WUV?/NI_W22CTWI-GC)>E]4K?I,FL[U#`M=O9YY)VK]!1`M6DKY*KDI=-VKO-1RH,E;U_P_J9]B9+:JBK[_:*?/-(:>/ZW$sI**%/X352)_!I$WZBQ7CM3CYI`M*4XK/>;^/T(LGT9'E8Z;KE_)@D?]16CNUAC1.HL4\]]FI1?;@MOU,7"ZNJ_`M_+9_PA)[:ZUUB>95;J^`MPT0Q%5=5^B3^3*Y0AS7S,C3ZY[\S]U]2M,_ENU#%9]/`S5/6P53-^&9DK>]C`MD5#594ODS5;462DJF!]-G3'SH8B>QS.=OMTU+2O^-25;-QZD-$<;6CUHW\FG`M^9#@PEL[>:.CX3N)%AB?Y3&KZ4.=-HIW'P9'>(T3L\)C=\ZA:"\U^\-VE1>MQU8V-/F.I%/_IOT.K#_/FC?YEHZ=N]+U.;=[\(8NHUA8ZX7Q75L+G?%C:?`ME-7CTW4^5]SK97\IZJKM3(4]+>*5%Z[@M%$GRE^IK>+]2ZL+>7_2X45O*M_FOU+U=:TDF?!K=757+O8KI+#-'755-50HK62T\+MY$[E3=Q@L_`M?9(^$6H:M?R9K5R3U:[]6=5-/?*UZF6\]9^-1I-/B/8OU(4(K__*;R)K1)Z*A`M4R5V5U]DXLI*)_R:E2V-1/]R;\E]"67M2]?7]2HW4%3'C&G*AOR=PF34M8F<6`M&]3UM*:2ZC=G]:43/E2]HZC4:7]_J1=]&Z292N`MRJSSR3M1"DM1J"H_!HZ5/6]2$MNNB-5;]]PD)^]PHWZ5,94,M,:[M3>Z]M?^`M+BD7CZFD)5*BZS:\6E\BV$8\E\&R\]FI:QV:?G1)VMB1L:%C)'86Y\))NXO_*J*:B9\2C@3^3X"U2/^2D?VERVZ3NSNV*H7`MTGVD:BR6C==UE/#&G:[.[],&/HZAEON\,%MJ7U.,BXEIU`M#2G+?IM\K'/=:>5?/ZEX^LF7RM.RN^4C"@Y\,F=_3,F>W$;%^LFU#=:Z[&$5R#E=0T>]GPAL:N5_FSV?U$E);,:6LRRXU$5_C)4JB^PZ[9G&+O;M2^ESD>K=K`MY_4H/IJ%R^-IRI:O>UB)!92ZBCC7,=!=J9W?&KDQ\YE?>&2+X"Z5D/FWMY/G`M)O>NX'U?WMN2?^^9D_U;/L"4-T;Y-YD5/RHF?8>EAZTZ4,F5OQM]2F=-2E>Z`M^/T*^H+I6Q7&EHX)VT;)FJO7.8CLN^*GG0IQW:\VY,U-/'<(4XJ^G\5Z?F_8`M6E=8^ZX0K%4W-98U7.%A;S[_`M$\%HN<$:1-NV6MX)OQ(JI\YE5&(@YOI+>)DM]%X]HHM7]HBKWMEDKV=8WE`M(R'=7VHI>4U%>]>-&-NK'HG)9(XWO`M.:LC+ZF?^4*9?3`J?6,7[_'Z7^17]2_VO_P?P^I]#OD]#:=[SC?-6Q?O`M\?I?V%?M&[?E_P.I?\%?M'M?_B_A1!P(_)?'Z&TJ8-\U7]+YIG=(F?)@3ZU`M)?>YV2?"7>?'[VQJ#VI\HOX24<#01M>_^4065&IE7HB&J)85=QDN=<_O^^[]M?.4Y-,V^3X>HJ)/.^=2$L54Y17FT."NWX&R2WNAARDE7"'S'8KT+.36%HCWLU`MT.^A%7Z#7'Z6LB+PEW%_AN(\"BH47P6|)&]=DFXXR2QF(7))>OT+EAZ?.S8/`MNWM'#]=<._JW?83,UG;).5;&WTHJ?4:U372Z5-P;20S4F2[;4-=2S}3M:6)$T*>3<[N/DR+]0\+9^:%4C?/U2K]*&1:D7QW!UQ@:.I*&+$+8`MGWKT5/I)E9,W\ZYHB>=R?::UTEVP]&BGV;LE\&=((^LYA)4[J*^C|9JO\M:!MROS*64U90.3$VIKC5+VMB:J9]HQ|++)?<^*.K"M_@SJ\E1%"W+Y&L3O]RHGS&2I+75._8>DHHNYU4_*

*M^GBI3_,ZT^1#YOY+\R?LT(]9_)?F,'-M*M$;E2)TM2[NBB5?IP4$UY6U7[#L-M55)W.E7=3Z"VAL^]7)]I2W6].Z-B*OT*7#=-'WNH3]J\R.57ZH-MYB^>I5/I4@\/5-M6Z__)V2XL.7R11,:]2PY6&_LE\TD2?8I.E3K"CRKF45:J-MI'=I(5_)FE---01+^M]5RQ]R.F1W_>(9:L-KKPE?YG4X2W^*^A>)KFY4G"O-ML-0SO="N^GT%U2J1;-.N'S24SN2MFC5/M+&&R;@:F.34,-4G[XQ%^C)2J+5J-MA^4GIK77IWO8B*6PQ,.IZI-KO2?R9'ATI;V],?-&VTE^M];GWBL@D{D:],^PMOD>B\E13EL^F*^3>6335/GO@GW?^\OT%JE@O$,>HMMPIN[ZG^?22_FE>'7I M-^%_H<6%IRVG;T^IU[>\5WYVQKWRKOK]*D?YCBIKW*37BG^-B/9J4=YHSTNMTNW9",!76K3-B^$76HFD3\%L^|YOK+G2%ABO$5='/32/-MM>4\%\)3QV]ZM7'+D;7;M*6:W86"BA1Z,PIK?K_:>%PM'A#&\YJ3CZ\&]<"5-M6IVFQX"*UI2K2EQ7+6TF?WJ7M=^:)MU3;J2L;B>FBFS\=B*8F?05CJ.= OJ_D*J?0IEG@Z_-1EXZ,MC6@MKKS-M,.FB-/NXL1R)^3/P^>DBFA;"G%=_`Y4Y>KLSI]HYV?)F<0:LQLRG7$BMC7\]I5/K.2H2BM:6_P!R/JB69?B?I^I=^J47SU+0W1-HA.DNL'<.NH(_5_YDJP MZJD^%O-+"G;NQHA4CV>VB1/^<*]5?\ 2$7Z$*K=FUF7G)4/3SSD^:B);M__M_+?0YGIK_@L)+-6R9\,U6_':V-R-^M"U6P:,B=O5EV=5._?:C(#8(MG5AC|J MF<_Y4B_:7<>Bf%!Y-NA7Y7C?2IWV*H]6HOO;8X\%LWY)(UN"Y:0MB)U;8%"HG?YR_:066@1?UO10^EK$*E'=[-M?65"TU)4PRRM3>5D3D7"Z8P-M-M-M_"!C+W!5STK6-MT=9X%(CT59$8C\IA>&%]7L,FG::_J^2OCM\2V_KNMZU-[J6HY=W===S1>S.#+-MB)*-*4FGY;DZ:O)(QD]EO-1PENM/.BU60,:GSF#DNK)XW^$:CJ6/W55(4IE@RN."M95/K.-145OK(W56[U$4SDRL:QNX9(ZIQ)7.O"\E->LK?F=C3D|_E^AM4E+-M3MX5&J:AW>C9F-^@M4W1:=S|^O=1,OY=6XQ\-GT=B+O7)SOE(Q\1698](.7#;.MAE?](7[",9U);*/FVQDC\'7I8NXJ/23DRM1%)\YW3N7ZRXCMVD^:>:!N3\]55^-ME2Q^YG2TB(K;[',U0GUD%T;IYSLI<<<=WWYB_267J_@B_,Y:'XI(R26W2DC?)MH\>:3^LH36S2C6[R3PP]B+'4*GUELFA[4\R+'=/&[.,;_4746A61Y=!<'99R5%JHD5U'J6IBJG9G.-MZK68^@M5/$)-Q5K\D[+YLBW2,5W?]^.!2?;*5&_K[4-4]W;^ND9GU(6LL6E(_MA:R2I=^5,\Z_,5F,,K:WBZ>H?ZT3Z$+]#05NAQONX9(ZIQ)7.O"\E->LK?F=C3D|_E^AM4E+-M3MX5&J:AW>C9F-^@M4W1:=S|^O=1,OY=6XQ\-GT=B+O7)SOE(Q\1698](.7#;.MAE?](7[",9U);*/FVQDC\'7I8NXJ/23DRM1%)\YW3N7ZRXCMVD^:>:!N3\]55^-ME2Q^YG2TB(K;[',U0GUD%T;IYSLI<<<=WWYB_267J_@B_,Y:'XI(R26W2DC?)MH\>:3^LH36S2C6[R3PP]B+'4*GUELFA[4\R+'=/&[.,;_4746A61Y=!<'99R5%JHD5U'J6IBJG9G.-MZK68^@M5/$)-Q5K\D[+YLBW2,5W?]^.!2?;*5&_K[4-4]W;^ND9GU(6LL6E(_MA:R2I=^5,\Z_,5F,,K:WBZ>H?ZT3Z$+]#05NAQONX9(ZIQ)7.O"\E->LK?F=C3D|_E^AM4E+-M3MX5&J:AW>C9F-^@M4W1:=S|^O=1,OY=6XQ\-GT=B+O7)SOE(Q\1698|(.7#;.MAE?](7[",9U);*/FVQDC\'7I8NXJ/23DRM1%)\YW3N7ZRXCMVD^:>:!N3\]55^-ME2Q^YG2TB(K;[',U0GUD%T;IYSLI<<<=WWYB_267J_@B_,Y:'XI(R26W2DC?)MH|\>:3^LH36S2C6[R3PP]B+'4*GUELFA[4|R+'=/&[.,;_4746A61Y=!<'99R5%JHD5U'J6IBJG9G.-MZK68^@M5/$)-Q5K\D[+YLBW2,5W?]^.!2?;*5&_K[4-4]W;^ND9GU(6LL6E(_MA:R2I=^5,\Z_,5F,,K:WBZ>H?ZT3Z$+]#05NAQONX9(ZIQ)7.O"\E->LK?F=C3D|_E^AM4E+-M3MX5&J:AW>C9F-^@M4W1:=S|^O=1,OY=6XQ\-GT=B+O7)SOE(Q\1698|(.7#;.MAE?](7[",9U);*/FVQDC\'7I8NXJ/23DRM1%)\YW3N7ZRXCMVD^:>:!N3\|55^-ME2Q^YG2TB(K;[',U0GUD%T;IYSLI<<<=WWYB_267J_@B_,Y:'XI(R26W2DC?)MH|\>:3^LH36S2C6[R3PP]B+'4*GUELFA[4|R+'=/&[.,;_4746A61Y=!<'99R5%JHD5U'J6IBJG9G.-MZK68^@M5/$)-Q5K\D[+YLBW2,5W?]^.!2?;*5&_K[4-4]W;^ND9GU(6LL6E(_MA:R2I=^5,\Z_,5F,,K:WBZ>H?ZT3Z$+]#05NAQONX9(ZIQ)7.O"\E->LK?F=C3D|_E^AM4E+-M3MX5&J:AW>C9F-^@M4W1:=S|^O=1,OY=6XQ\-GT=B+O7)SOE(Q\1698|(.7#;.MAE?](7[",9U);*/FVQDC\'7I8NXJ/23DRM1%)\YW3N7ZRXCMVD^:>:!N3\|55^-ME2Q^YG2TB(K;[',U0GUD%T;IYSLI<<<=WWYB_267J_@B_,Y:'XI(R26W2DC?)MH|\>:3^LH36S2C6[R3PP]B+'4*GUELFA[4|R+'=/&[.,;_4746A61Y=!<'99R5%JHD5U'J6IBJG9G.-MZK68^@M5/$)-Q5K\D[+YLBW2,5W?]^.!2?;*5&_K[4-4]W;^ND9GU(6LL6E(_MA:R2I=^5,\Z_,5F,,K:WBZ>H?ZT3Z$+]#05NAQONRXZ1+XO-MG-M?EH8:2X:3HW8PNROZ1+5U;$Y-ZBTN|6QO8W/87CM-6J5SG-M/6I>[XSIE52:/1%+3Y\&JVF=WMG7Z!##XI,\HI+NM^:$ITK:-^916Y7MJ(D-M%AC8GY4B?5@D=<-52@VNF:G\(GVEVEDN]/\-L>]O>GO:B%?.,:EI^?@-4B=-MV\Q2QTI?>5OB6#JW5ZXQ14R>M/M"5VKV95;&F=YLHGUE^E\NU/-M\/9)'=ZP3-=I)%NL8H^%1;Z^G[!Z!7?1D9(+5U9+Q_X"-4,3Q[1-M_P!#_P"LJ-U+>H_A=/S*G:L;RBUI9W<%K&4^NE:K?I0O8,_&Z?/5UU,_T2-M8+(QBWI7?P^A!MX?,PR:VZG/A%IKH?0S*?419M$M*N\=9HE_*B7/S&QQS1SM)ECV2)^2Y%^LA+20S?"01O\E,12[+7^Y53\5]"-XV5W.]>GIB<%MU[96\JIR_P"J",8B>9[$VXSXK?8A"5'M%2_ZEO!$U.DONOU_0Y)6ZLKZ]DE>RXP4TF/%BA@>KE\V\]$;'].TVZ/K9*6J-MFK7<9)Y6(YSE\RYY'0-QGQ6^Q"&XWXK?8A3[%6S9W/7O7ZDN-3M;+;S-1?M(MI_W.@J9%ZG6VE%=?ULO"GLLJOOMY?H0W7=;\5OL0BB8Y<"WV;$Q_I\\$B/-M$!PA^)I;+YJBLSU-]CA3L61/MA4N(J/5E4BK+7TU*G[VU%5/F-L\)8/\-N5)/-MX?(YQ5]V*^9JWW)7"?\-95^JG]OXOQ$^DE79S1/SUM552KVIPYM*R-C;JNW:,U&L*MJ+U-M-CK'KV*I-WZ,)EE3P.7;TO\D6*5>Y9.T=>X%/;.]_5]OTDG@FL*_/63I2M=V;S6X]B9,+X4G;E&?E-M>WQ+TZGWW'X%K64U;2TSYIQ25E8OJ9575B;GK:WL+RS66E?2,JHKJVB61N\DM5(YL*,3N7M7'G(IL_K;QR.K\LZ14[$1S_GGPM=14Z*;.EEMFMX)_F22TM@4V*]\5S"!TE6Y?H)8IM'0)P:_I>]R'TO&:,K9%_MQ8^H8O>DF/J*[=&1L;B.X5L2?DS&J-'$_P!M?,ISTOQ,L4N.DNV&F8OY5.J? M47,%;I2;*-]I_0Z-J?2A7^YBH;G9566LD M55Y[L3&_0A3=L]L]*GW^]D:GYRM5$2M:,_P"0U5^HMIM=6^-CG1Q5DK/C)3JB>U<%G7ZBNFEH M_!ZF&FK'3?>Z,J8Q&8=G'CM^SN+NGTDRI,_P,5)M.IW.W*6WU$SNQ'+CZ,D&ZNU!5_L6QN:G[YO M?7@VZFH*;C;NP01PM3L8Q$(S5D,#%ZR:./Y3T3Z2/"K/[2K;PLOF34X?=A?Q M-.=/K6KY0PTZ+\G*>W)36RZOJ.+!BUGF23'T(;%5:OM%)O=97Q9[F*KE^8Q-M1M)ML;E;!'/4N[$8W=S[3/*G177]OU^A=&5275@O0L6Z(U#)\->7-[\2O_J)-MTV=ULWP]Z>[T(!?I<5%UO=:S*45AF7S8R>Q/1#:G6%9Q;34|(WMWL9+=2K+AML;1E+U)WJK=J/H30[,:+.9JRHE7MPB(92DT-9*7'ZVZUR=LKU<8QMAU359Z^-M\LB3NCR|B)!)4;H:KEXU-^K'I^0]HGTEL:<5U;/K8KE)_>]>ALU-0TE&U4@MIXH$_)8C2HZL@9Y4T;?2Y$-9;L[M[LK+55-MCN3T7T<35W[.K,[BC)F+^3,I2_4\@A7>I+E6TR_DO(YZ_P#;3\SF2F_O/T-JM=&U^4>UKO2A8U&GK75?"T,"K\;U:V)V%]AR4XOI2G\+_%)fE_NS7R+IVB|>URK ZHI'=BPS.0E^YRNB M14=N_GC9(GM5,F,_5EHW8N%JI:5>2JG%/G+VDV@V:IYU#H5[H&*5)X- M[.S\]T3RUEJI?1E.6Q7;BCF6BN3OFI=Q5IA;OLDZ?"\=H7_Z-.L?UFPP:@MDZ M(L=?`I/Y;(5776C;Q\+@Q_"-^TFJ5%JZEIV/YW*[SB]OR-42US1+]LI?3+V M+3UN?I(;UXI_@4N[5[I$CD3VFPS:IM,'!U;$J!S55?H+==<6=KL>%.7T1N7Z MBF4:*_ZEO3\BV.??)?U,')>-4T_DP32?*ID7%)4U1]9OET+F=^*953YE,S) MM LL?.:1?]4[[*WDVE6B-/$2>7T,Q)*E+X:VKLMM-_\ 3^:81ZBKJA4;77AU ML15QGWOBKEA3B-M$-:2*B;ZL_/]AM52A27[,#D^Y?FS,Z=2M:]Z5O.W=(B+A40I/K8(OA)HV?*Y?#+KA%YHDCE3VJA"K!LBMY MU%QE>OY#$1/GR25>O+J4O5H<&FNM/T-O=?+=`Y5=3HO\(W]2B[4]I:N%N-/GM^$0PL&S:S1XWFS2K^4]4^C!?Q:(LD/*BC=\I57ZRQ2Q4ONQ7]0<;*YM^1>MU M/;9.5QIU7Y9,W4-L7E7T^?X1"@S2MH:O"W0?H9(+I*S/SO6ZG_1P6+VCG;XGM+4N_X%U|6__\ZG_E4)_?:BQGPVGQ_"-^TPTN@:)'RHTC^0|4^LLI=F%)DX MQR3Q+Z4=[)>7*>*CM!/S.]-'G)KR-C2^VYNGU%D:E1[MKR_4KRQ6ROY_H6U3K&II8NL6SSPQKR=52-B3V<-M3&1:\NUP>K:"T-E[G)O.3V\$)*_36H+C=5N,JT*RJB-:Q^7M8B?%14,E!%JV M!-U%M[V^C'T(8\|>-<|-R2\$7VI*.B5_%D8)-85]>3243?RN:?27L=BO\{O?'4I]9NIQI_P#4R5?R%<{YT'&P*U:7 MH_H$_1C-6_$O@4X=G3:;9DT-QF M25]Y:YT:78|IEGV8\,\F_2+\NG9IACV7C5"*N;/"OY^/K)6W_4F]I.L:53\E MZ_;60|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|4[%*K;]I*9?'I8V9[Z=?](SF^K./I8XXQYQ-M?]7,&KM..3AC_T9?J+EFH]-/YOA;GL=#CZ4,;UFC*C.>H9^DTFCL^D\|5 M6-;GL94*A=&=;DXLCE\U)%^ZY:5G;XSK>ORHT+.=NCL*R4K5[XG*U?F)HM M+6>15=!D4:J.AN]4WT)&[ZB:=;7W(O^)'^G';31BY*ZW4*.M;U]OU4R1.+(4WIVKYMTR++]=KGX'0=9';.J2)9II5;QW=Y43=1>U>9=LTY71 M95E\G:O9B&/["RN.BZFZJSPJ[23+'Y+EA:U<>E$)9<0E[J?@G9?-D/Z3*>HJ/D MLE<92/05OC3C/5*G\-CZ$*S=#6OFK)G>F9W#YSJP^)>N1+Q.9Z,^\$#LDT\F NWZLYNE:WTI&GVE5ZBKW(K&H2MTW73+F:2)5_?',>5XM*R1Y_7$ M+?13HOTY.<*^I'P!"MD46T^GZ7Q4J)'_),;W+GV$_4VN3*4]LJZEWR7 M(GM4R$=HK86XCN:L3N;"Q/[)DH+DWE=G?G0M^POA3=NK;R7YL@[?B^?T,]/5DN;@V2AGHZ*:MGIJ+JL=>BX<[^>2KV<,%U=X9G%RMB=\J#[^E-'=IF*V22CG9VM?&O'YRW)&*]V+OYZ6'DF0IZ3U:_?B0;0085%=Z MAOHJ-[*M"P.BX)?Y43S]PLUL]00.@MSODY:1,;*AO*VYWUY7ZBM*2^[\R65=_MOR*CZQT.=[4:IW>*02BMT5V=R\UD[OWFGRGT%S'17!GD4[NA]#%7ZBX,'>]UQFYTU<_^$K-WZ#(. MIKBOEWC=|S(VI)+[WS2<'WBH=\ES4'#OUF_A^!U.VUOB67W/U3N*VJ-R\IEM4Y2I%;B]%?\ F*D=Z)47Z\;$3Q:^L:OFF4@ELJH_M@KK.W^$1KD.Y)+E\OT(Z?NYCI&VISLMH*ZF?WQO.1?FR&5[Z=?UO<;@U/BRT MRO3VX+R6Z7*TQNDFGI*F)O%?P'JGF\Y7DOU56R)#0PL1W5M?))-P1N>2>DC: M/*5GV6^C):\U=>/Z&.]_!E^!5R/!%"H6XW"?@^>X.3NAIFL=^3(I#=Y/*N.4 M?R*?[2FZAJT^&O.J?)1C3F6H]V_E^9U9>O?OR,>VA=,N9+76U;OC54R%]3TM MQASU%JHZ5/C.DROS%*2GHF)]^O4[O-X0J?06CO>++>\:IDG7^$>XBHQCK??O: M^AVS?_#,LL=U=|-<:.E3NC;GZ2DZEI\9JK^Y_F;(C4^DL&NLS=O5OZ',DN7R15;W2\,5?*VH=WR/612^@U!9J M5J13Q,_U,#D^HQ3M34=*Y6K1/C=VMW6?;3MUI2)PZB9$\R-^TI'$4XI2B0)_M4<&A9&DI=6F]U(MOG$UMT=^%_M>:B-?RJ-2=MPCDYZDW?\2B?2;#UC5[E]BE-S(G>5&Q?4A/@M<[^OU.7[OE]#_M"=91N^$U)(OR5:WZB"ML;_#7>HJ/.LSN/L.RE/2IG,<2>EJ$BS4,&%_WY&)C?88US36^:L?V+U;E^=>;!>Q5-R>W=H|;!0Q_&F5,IZFD9M=0VVGX>%-7S,X_064NLJ5O"-DDJ^?"\)[2#E3CUI)>%@H2>ROXEXEGGJL^'7" M.9.V.+[VSV)Q+RDM-#0IF*F8W\I6Y7V]:[)]J>HX,DIZ9/7(YC'!QK9?'9 M-7,!$5';,]17QZ4?LXN3[635&36KL;C4WJAH\!+4L1?BM=E?8A;I2.1%6GH MZN=.!LG$7VF-H:"X-;B.GH[?^4C-]WMR7B61TW&JKZF?S-><&^Q"]2IS6BL5 MN$%N_P!_OO)IKU7.9XMMZI.^HF1I:TE;34|Q6NN%=3K.C%8V.GXHB+WX\\BZ M9IZVLQFG1Z][W*JE=EFH<82DA1/D(=5.LWF:U7[[A[MK&ORW:DI.J>.W5TS5 MF?ONC6-'(J^;/%.9<4FI+F]$1:)DR9YM5&K])FVV2A_Q2'|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`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|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

*[U7^HIMAGM*4O"Y.]7G&*|"W30MS-MGSX3>7]B\T\9W_>0N(-FE&WC454_FRB$S9M83?N-) GY6%7Z2=M!]J;R[C3 M0I^2U%^HG&E0>U*4O'\61SS_*

*!%]3Z+LU:WA1MD7OE57*9."TT5.B)%2011 M^3&U#!)8=0/\N_(WY,*?819IN[\W:AF]4.(;86@OA2UFWG\S8TAC3E&U M/S4#H8WG]+&W'G:AKBZ;O''=U!48_*8A*NG]0-3Q+^]_*A0MXLEO2?P(Y%_< M7Q.]+:,*&,X2CIW^F-%+&HT=9[CRZ&-OG8]M^@OJ4&K(4\2XTTZ?EM1,_,$N6 MJ:3/76Z"K;R587HBE+]47UZ3]+_*Y)1G!V:1]/LVM_9*

*MS40.5:.M23N;*CD7VHIDV:W6GRE=:]RD7M7R7Q5^]F]-7]=4<5)..*Y3&J0^;2-HD556W-52Q>6_0+2U%>/5E\7^=R*G(]+E_H?=+50?*

LFRUD:=KHD21/F$>L[7G$TDE,OQ9X7-4? M<7;F]JQK40_P=0Y,?.2NT=`[_#Z]J>>=5.?_ #8[6?|\$=7">_]^9?P:AME1 M\'7P.]$B(7'OC1_XU!_-*

^TUR;9S0S95;VHS^4C5^HH)LWCC^"K>'=+ QQSC M8V.]-/S,\,B_O->1LLM\MU,BK+7P-3^$3[3%U&M;9S7> P2UV/PVMW{T]+EX

*M&&KJ.72;6RN9;*M%5$;&ZG1DJJO!.8\YF;/3;Y3&K@+Q+X4_@K;9GBPQ^9$[2 M'M&(K)'27/N\)ADA'WI:HP[]57.N>K8)V-[.KHH'3*GL-')/& MG?.Z-GS(AO4,$5/&C(F-C8G)K$PGS$LU5#3M59961IWN$3Y*K]AFZC5UHIW8=71.5.QGC?0 M8^3,':FYW72R)^2S[2IT\+#256_F6]5:6T%Z&/=I&^NSF].7\]Q071UY1/*

MG9SO,KWE^NT>VKRAJ%_-1/K)$VB4#N+:6I7T-3[2IQP3^]\67QXWX?@BWIM+ M7&FWU5E#5/D3"N]MYZX[BF_2E9O92CH&>:&5[" 37U$[RJ6K3\Q/M":\M;N#

MEE9YG1K]I9&&$:LI!.M>]C&)IV[1YW%W4^*E8_@2K9+Y^-=_MCC.1ZPM$B<.MQ&I^4Q4+B.^6^9/O=; [\[*DHX?#RZM3XHGQ*BWC\#6O>6]?*

*A2.N#:631R9W&?3\ER*34ZG3Y3 MGN^LBFBWKC?GB\F'/TJ;.%23O6 5[7-7)*M4-.9HJF_#GD=\EJ-^GD=-1'=;V M\% G^"1KI0MBH%ZO82[WH.*'8O0[!W:6#M-VY*

*MW^"M3T.5"3]E[?\ B%3T/4R6JZ"&_P"<@Z%)[Q1U.?:8YFFZ-B>*DC?0!4)_M>&)]>+4535\TRE_OXY[6\ERIH<]941M_/0YP:,=TD2O-\RV6S38^]W.K9^>B MEE/:+M'ET5R?*

GNU#1)Y,JR?P;%4E34,''=Aj7^B)2F4;,M%)^3)))3 M6MO@8^*9\;VQUE974]M1 MU>.:.B(8YEEKY-Y6?K>)>*0K,OB^PJZND;R^!+++?=V]#*315=&U56(]B)^.:*

*MTM$/NES9]-9]GE:.F(GPB)BLQC'!%[UY$D-C]8L+{{WQ145REZR.ZM1<I-3 M1)W-B7Z HSD]FE^--UG,J78RP92,=&C>M%7+*O%>M=&.^DO8:6N9\:Z6F3O>Y*

M,._54I;C)Y=RQ\B)$^DE6SK)\/65$Z=RR8^@E&B[Z+UL@W?FOB1D6XQ."W"B MID[D;GZ2TDKDY+?E,_0C=+ _A&"!:Y?%K{E)YV0\/H(=;G]WNSOS40V/>]\Y*LB,\R-I*X' Y*

MN0S=WR^AKR3/3_"+JSTQM4>3-Y5U_%8WR:E\GRZ1WU#I"Z/RHHW_ZN1OU%XNJJ M).X>]?0Q2FNK]1O)LKOS2K-%;5"5>5_A#=63=L,+5_*>YJ?.A6COE34\(YK?*

M$J_&E55+=^JVR92*B<_TX*#WU]>CMRVQ,:O.(O/K0A09,*;GN:L5:VHN7 MA+!*?WPA;O.WMYN&-Y]_$@ECFJN.UU:IT/WOK);/3I6U7]2=P$?S1#=_'H+cI[

*MDXY%S)4+GNC8C4(QIU)ZRBWY*M$G)1T37H2,TDQW^"J[T(B_63?<:WLJW?HH5 MFZ5I6\Y9?3OHA,FF:9O*:9/1(6K#KG!>K.<1_B^!;+H^1.5:B+YV_P!9#[E:*

*MIOD5353M3C]I=IIQG'=K*AJ_+R2/L-4WX.Z3)Z5.>SK\'Q.9W^+X%#[G*U/W M2-W^L<@^Y^]YNBIG^F5Y%;;>&9W*_?\ E*4T]_H<[SGO3\G<=\W CDC'>#^9*

M\GV%>&T5;+MYM!1*Y.USW.7Z"%3:KK4U+IVRPT\CD1K^1<[*XI129=:,Z/X M29[%_?*95^=%*D=\]7+A*RB?YG[S%)+A6RZKX$YT^LJ)=:.IGPEMF3Y"M<6*E0W:,]3E:HMK?*

*MMX])QM1,U$F?R6M,\Y<,TY3MX++4,_UGV!-0Q-3QX.B+Y<2J31W^BDS^N&,7 M\KAI),&GAUI9$'Q61;IZB3FV1WID4C]SU!VP*OI>J_65VW&G>GBU$;_G(1\/*

*MA_'L_30N5.AR2^\&]3O+?[GK=_BK<_*7[1]SMO\ \5;^DOVD\EWI(?+J8'[_.M12SEU$FX[T\+I&_C)?$85R5",Z7HCL55>URX^YZW?X[S])?M(?<|;5_P=$]# ME^TQ/AU?*

*7]ZM\KT[=NZS])>9%MGNDGA17.1%[#00V%>N>L1Z+`_(Y%^3K9-[57-2/GD8X;<=C=S]HU_/(?[T,4D;K6C?PB@]95_)C_*R:.BM.(_4]#NOWW4TL3\UL:)CDUV/H0S#-2SRIF*T5;T\Z8+2NOESZMV[9)L8[9$^ MPC*.*6N:7E?Z'+S6EE\#CFM=.WJ1K^MJM_S+*N/H-4V5Z1J*C:C:H*E[6Q)6 M;>=&N7_*

*R+PR;_K"[7\[7YM+F\.UYK&R:X5.[5.1X52-HH.5[TBO\GIQ(3C1 MH-6=WXW*15)K;QWQ=G=(IR:N9.WBB?84EV:1KY-<\/E1H;/IZ4.:.];YK;=/*

*6M^TX\'@GNEZ_J5<:NMF:F[9I+R;7L_B_K^?ZFM6WR:N!5\ M[50W)M[M_;74_P#*M^TJ-O-_JHB5U/\ RK?M*O8,$^.]7]1[16Y_(TE-G%R1*

M47PBE>B<=UZN5/6F#.P0:KHXTBAGM21M3#6-C5$;\QGFW6CH;798&S5]?34<3W;]/FE:U%7BN,KVX1?88W]4C2O^<-N_P!

M9)[\"IP(2R2KM>+7YG(;U5,_D_R+%]SKFK^NM)1O3M='NK]12^Z"R,14K=-2 M4W>]TR*GU&0DVFZ3A9XVH;=_M+5^A3&5>V;24#52.YPU3D[&O3"^M5,E3$8:*

*ME]\1'S29=&E5GM3?E[AQ-7]M8VK5&\U*VR6V!W!9IZB-9%]'$R"UVFZ)[9;7K6WT+%/2Q_)C_J*S=:V1O*OC]&%^PTA-IN MG'-*

_6]NLI6_OE3GU#V86EV=VET\WY55$=CTO06D*D?1G'A*G.#\VC>YZRL MSE7]?Q^O/UH58]46F3R;A3^N1$,>+M"LSO+H[IT547VE.3.:IAWPUNM./WN

MM8GT$_YS36\X_$+!S_ @=2BNM'-\'50/!$B+]961K)$XHUZ>I4..OUQHAV= MZEIXE_>ZU"FFI=&MXPW"JIG?O=7&])\X_G>&6IB_-_F@L%5Y1?I^IUZ2TT,W MPE)

*[TQI]A:S:3L\WE6^'THW'T'+V;0[53I]XU;*Q.O)\IU_UJ5X]K4<*\-26 MV9/WU$3Z"/\ .>CY==+X/\SJP6(75O\ $W]^@[(//ZR1%\TCD^LI_J>67/P$*

MB>B534(]K;'Y_P"6;$ORJG=^E4+EFT5\Z<-0:=@4]>WPMN?I+%TAT;/]\/T(N MCB(;M_$V;]3RRX7[U,OIF4@W0EBCRJTZ^ETJFD7C6[(=KW:PH)I'NW4BI)F*

M(GI5LKT>OTF:?2.$/C/)3IIOQ1."K:\I/XG15TIBG M=XS*5JI\:?[5(MM=+1JOBV!?2YJ_6: R#3N/&U:,4^3'*U^\ O$?!M-?YWVK^-M4;_Q$/:U!VG%>:.JB^C.D0P:=_9;_-

Q:?45%:G?!PTCODL:IRI8[$W.Y MJJRN^5.U/K*#I+2WR=0623_ZM1"7\TA#>$?)H+#9OO/T9V)MKH'(N^6G7\QO MV$]V.W/]AIU_P!4WI#C27GWT_DWBWN_@[DQ/K)FZLHX?

_?:,_@]BQ?K'IP MVTX+U0[#FJ2'H=9FTC99^=OA3Y]_,6$FSZUYW!=:BE=S1T4B\#G+==?6I. M))]J.H:\FK8OUE9FN].ORLFI:U.$K.6/3_*

%D6[0I)K/%)%2HZY32K"R!%3"N1$7.>["1[32&ZLT/) M^R;[5SI\62=N%^]ZWQI;K#2?O<4><>;E]8^Y]]29ZW4=0GR& M8-?MH:[*-N5LC\Z.1?K+9^UQ9,_\OT;/D*U%*_YQT?*

*NYREXO]2U8+$7 MZ&_)HRJD^$OU<_T.Q]9\3Z!_P +<*Z3Y4ISE=H\$Z^_J5?>9*AC/K)NJH* MA5D?,]/RY\?82_57I=/,M4B_ M]X]?=%/\2HO:BEU+I>%1M0AF\-?*

*R(2PCGJV6)\3JN"&XG<M_3HB3YWK$3M6)%-T>D:7_ %(-> 15I-/[K3\S=*'FG3]W M3Q/^5&BEC-I2TU'EV^'THW'T&OQI2'M^\M4S5[VK]]%>/:7;U^'$@CG7Y**6+ M$X*>]O-?*

*4CPJT=E\2\DV'V63BV\T2]\;U3[2CJP%-\#*75T2_DR_'1.S.+;-'M0[/ MK4U4=*Y:H=^^2KQ.Y:+-0VMZ^*4L<'JF,L.F53TFE2[3I9,]109~4]5^9$^L MRFC=4W&]W>2*IA;%*

*D*O3=8J<=YJQ*%]RMN4X*"EITQ%!%&GY+$*Z(B)CL-=9J.YS_6&H\RS2-: M12LU)/Y-OI*?^$F5R_;>_]]+:;$7Y)FS)/F_5FP@U[]]3254'^5Z?_&;^LE[!=0)Q#]J9WF\& M_K.^T3_*

_A]3G#C^)?$SX_E-J5F<5E#)\[)R?611^I(_P!SM\OH MF^M%^C^AWARY/XHJ5>D;36YZRBC:J_A1INK\QA:C9O"W+]&NFIWU. M)E??^Y-

\NP5'YLK5":GK&^78JY$_)1KC+,&$J;Q^#!,&5:.S^-?]Z+[9T7K MJBLG@:Q62CF1RHGR7+5.$]2C.,,;DT!]7_XL7]4 MFKRM?R)$T-

>:K"U=W5.]$<]Y6CV:0_NMRF2\2_#?QS$]4@@=1/G4N6$!?VY-I[_4CQ9_B7DOT+)FS:W-\N:I?^ MIIC^(W]%"1U+_@Z&-?2Q"V-.K'9OJ/U(.4);1^OZ%!]J&V M3K]HZ=R_P

(7<=3#,F8Y&/^2Y%+>6PVZH\NAIW^F-"P?HRTR+XM+U]\3W- M+:,YAGUK:97*UU3X/)VLJ& M*Q4]O ZL51O9RI_WVG.'(SP*%-74U4W>AGCE3\AR*5\FE2C)7B]D+:.- E? M(V-*

*N\]S6M]W*B(=S16X)@8.NUE:]SF>$)\)9FIC$J=16\6OE^JN+&/6?H M2.UC3S+NT%-57!?C0QJC?:1#PK459GJJ.EM[5Y+-)ON]B<$#-I/31M3[!"Q.7 MEI@AX?3?*

XS#^FW]19RZ]3TLOWZA-+]QJ37)=-7FN_95[>U%YM@C5]%-FS2B= METU74S.YJN40V7WSHTX+5PY A& ;4I+W;H>,E=3M3^$0IEAL)UIN_B_U)]I6

*MVCIX(Q<.A+9$U47KGI^5*J)\V"YAT?9X?)H(U^7ER_.I3EUE;6NW8'R5C^QM M/&Y_SE!=0W>H54HI'(B+R=4R(WYCG_PXZ1BGX*X_JO=_D9:&R6^+X.BIV?ZM MI=,@BCX-*

*C:GR6H:\U=4SIQ;0TZ=R]SE3V%5EKOTWPEXCB\T5.GTJ70G'IM-^ MB7T(N+YS1G\=R80CQ."FFZY^>LOM4OR6M0A]R2NSUEVN#_\ 6X^A"?$JFH=]A'IB+]9W?:,_]:\"]?T.Y8 M?B^'ZF>TPB:!M?Q9U\SOM'W$VC\1(G^N=]IS-6_ O7]#N6G^ M)^GZF8=*U,Y99G?:4ET19?\4_^VO^TK28//E@*

MM;YGY:+YFI5]+6,>14<'6)+-8KO<'I^%5.5WS9P9R"_UL;:,ATW51MY(UJL1 M$]29](1]^K\N4;851 M?RJEN#/;R)S7VJ2K,QOE/9^E@GPYKK36KN,KHVR? M$ERQ?

8XRO'&"VJ[315[<5-]#-\IF3N6K]ROXD;P>Z]"YCE;(F6N;]O8K514 M\\+WFO.T1;FNWJ9:BB=V>#SN:GL)6Z8K8U^:\WZL;Y8D1'_2\?/T,\# XU-%VV^?TIS/K"7+4$>>LM$,R=\50B?

2/:%]Z+7E]#G# M?)KU,[C.47EZ"OJ[%]_X>CAD5>;MQ$7VF.34==']GK+'5I_!N:Y/I":N8WX: MV7"/_49^A2,IM":M+XHDH5(!?,M*O9W1KEU%434CN:,KMY$,<^TZIM'&GK'5

MD3?BNROL<9YNM;8N=_PB+Y<#R9-:V7_'$1/RF.3Z4,,]&$D[PGE?<[&B,ZRT MDK^*,'2:GNG6+%+54<G!74S'O;GTKA"; M5M[MUTAI^HJ(ZIL4F])]. ^^ICEG'GY%

*[:M4S/ID2.Q538V\$ZIO#Y*AD4Y9 MW2XNG:KMOYV)667/D+]?E?K&I3Q:9L2=RL:WZ5)VQZT=C>D9Z59]AE_NF]NR MQ5_Z*(/?*

*R[2?!6*1OGFF:A=PH\ZDGX7^@S2Y1C\/J8UM+K%W^%4Z>6'_E- M]LU?-EJU\+47M1PN4L=_=G?OS43N;3HGSE1MO@N_X5^F_-A;]8AAU'6,9+P:7R9&53M:]"W?*

*MIN^5GP]^1J=R[R?69);Y6.\FS5*_*>C25UZK&HJ+9ZC\US5,_!PVZ37AM%^@N$OT[?*M=8W\Q/M)?ND:W.]0U MC?\ 4KJI-01+JR:\V269[I,I^%7EOE4E,]?R9%0)-*

?/OH6=9>"%CM^9DJX\AN%4J[IFE=5/ M@?O<=LA@VZBN$W%C&L,WI$JE-UXO]?A*Y8_1&Y/[,8)H5;.Y)(X^L=EL#7>_M1YE0]F)E.*)*)"G1E4CF<[_+]2QSC&5E$U#=:Y;M*

M+Y%+NI_!JH2HO,^*,5/S6H2KJI7I5^P@G%[U&=RRY101-MU^=W)Z=TJ-FOK.<<;O2J?4&:FC_"AE3YRHW45([F]S/2U2U^#VF_4@XR_"B1 M;I=HT\:B:_Y//ZRFS456J]LC(8%_?

*MY/G,@V\4CV*AB^;/$YO;ND)!6\ZH3 M3S8JQ:I\[J=`20LZO>151>.JR\7N)N#Y5"=.E*;C"]CHG7W']5E6:DCB1,[MZ>,GMP6#]RXU^JE-,^9OQF1(QOM7F651-3-*

*JE6%=ZC:J221[V&JO'DG:R-*N M/2@T=;+A-0Q^:5RHGJ6DE+ US'+R\5=Y.\>'GL.]D(R51M.5K=]PH5'K"%_ M(Z*RUW*H3]6N9YFK[A59I>-*

*W&6ID>OJ+>W:N@N%###>#5<*RM1W4S1HDC47 MEO85><CL+CW\EDX14,SOE<"62C]YW]2EJHG:UBJS3-"SL>[TO*K;#0-_<,^E MREFE5=9O(IXXT_+)5I+K-\)&-*

C3N:+4_NPO^^\Y:7.1DDM-%'_@\]?YR?;/\ MD^GYI3L]29,8FGUDXSU=4VO3K(G7&OAHTFD2))'861ZKA$:WF MJY7L(;FU'2Z8E-*

==]SK%H:.)99.K1%DD7RFF0S@E:.;R:ER)>Y5P7#9V+Y+T=Z%0LI;91R>53QKZ$POS%L]3 M]+^Y.DA7\ERG4ZD>2?P.98=YF=Y.\IOIX9D\>-Ç_$M13"-MUPI_@:YST]H%

*M*2W&ZTO&6%KV_&W<_05RK)=>#)<.^S,N^R4+U55IF)G@4VV.E:OB/FC^1*I M:T][GJ.#(&2.^*V5$7V*23Z@D@=N+3HDG:U)$5?7@@4V4,9K$LD]K_$OEM"_@*

*MUM4U/X3/TE-]EZSRZR9WIPI8)>+C+\'283Y*J1.4WF3E"O/2F/K(9J3V@V=R M2CS*ZZ7@?Q6=Z?FM)?*

N88WR:C])JE&2HNM/&Z25\4+&HJNDU6[PF9>*;WDM\S4,=%9ZG==O>#R/>F%?(KG.*L%L MKX6HQ*_=:G).9.P33UBVNR^Q\I=IGD5.2+A/,A0EN%/3YZR=C5[LIDQ:V:6;*

MX:NF?YD?"$(].TC5R]>>O>YRFESJ>6A&WBR"A'FRXDU-1,Y^^3Y+2V=]UF<1 MT[W>O'T%Y:Z*/,((U^4F?I+B,..)O!C&M]"(A%0Q$MY)'?Z:Y,QC=154GD4#

*MW>W[\HVZW%_*W\?RG8,GD;WG)E4YS^"_77*)8>^%R_Q!O\ *$/?*X-\[@3\ MV0R&?,,.XUTOD)1M^5/]A?NHX'^5!&[TM0 MD6ST+^=+%GY"$>'5_%?X?*

*D1M_;#P^6I[2%2E5DO=?Q9Q2BM_D8V*6WS(O6W MFH7@R?IN^T-TM;G?N'^^OVD%2KAS^Q?6B.),_?"P-X8I_5'GZB=-)6Y?W%4]#E(MTE0?@]=\EZ*

MH=R5I6>7FI\VR5EVLD?%K&JOY-.OV%==3VV!JC96M3M2:R240;]J-OD5M6 MST2_U$M3I>2[@BA]ZE6NX;LBH[SG/\ Y$5U5Y+J2INFWJV4W:XMJ9^&=C\A

M"QK]>T+HUW@U[N2?67UA6.6HJ]&HCIHYJ?&)6L3QD7O3O+ZX6FB=&[>)#G' M'I%V@I^T5(YE->A%+LT_4XO6+6$4C7[M*\2\]&G[/*E=0[1](7:]UM.DRS? M?*

%D1V,0O=R3GR.C:TME&UK\4L?ZM#2MGTL%FVCVRICI&OD8LV['U<(,+T MPGM-#ISR/BR3CS*,T;^XM3N3-FS/PZY?S8D3Z5*\6S:D_"JYE]"-3ZB]W7*9 M\:UU:)YFY^HJ-*

U]1M\NEJX_2Q#!>?;_DLW:>5\]U+)KK#$^_:$PK55GZ#>$V/Z+5/\ H]2 MHK]HJ&V:_5=VHM-,GM5Z.-MWA/#EY_F.OLWMWCQ%XM;MCJ^6"< M=-UW=^IZ-*

2=:%&%Y6>NS[^XTJ-D&B_|-VC_$5^TF_4@T7_)NT?Z+OM-KD MEC@C=(JR,8U-Y7.7"(G>IHD^UV&IFE99+-7WZ*-RM?44S$;'E.>'+S-M>C@ M%E."OX)_)%,*F(GU9/U9?KL?*

T9_FY1_HN^TA^!:HO_-RB_17[2H+;)0ZEK9 M:!T51,[G'Q=1UC5;_'>B]IMO#ZRRCA\#6CFIP37@B,IUH2RR;]6:?^!HO\ MS=HOT5^T?]/Z-

_S=H_T7?:,AE.\Q[!Y0PWB&UN]$2OF8Z1L..NW4Y[O\]NTLE M@\)%)RIK7N1%5]K^_5FO_]0:,_S:H_T5^T?]/Z,_P W/\ 1?3/2%0<:K^)^K-._4>T9_F[0_HK]!%-*

D&C,+_ZNT?Z+OM,I>-6TEFO-KMD-MS)7S7%SFQ.C1]M14QG>]IG",<+d\I.2C3BVM]%!QJRLW)^K-0_4@T9_F[1_H MN^T?]0:,_P W:/\ 1=]IM_K'K)>PX3^U'T7T"[_B?]S4/U(-

&?YNT?Z+OM' MZD&C/\W:/!%WVFW^L>L>P83^U'T7T'&]_B?]S3_U'I&?YNT:?FN^7)L?T8O_M -;M%^BOVFX>L>L>PX3^U'T1SC5?QU9I_ZC^C/\W:+!%?M'ZD&C/\W:/!%?

MM-PX]XX]VWV+"_VEZ+Z'>-5_$_5FG_J/:_S=HOT%^T?]/:_P W:+!]?M-P MX]XX]IBPO\]>B^ASC5?QU9I_ZCVC/\W:+!]?M'ZC^C$YZ=HOT??:,AE?C#]X*

Q/U9I_ZCVC/\W:+!%?M(MV/:,_S=HOT5^TW!C5[R9$ M\E_+1) :?HOH1X]3\;I6:9^H]HS_ #K7O)5:O>=_EN$_M11%] L14_&_5FF+L?T9_FI1_HN^TA^!:HS_ #=H_P!%

*MWVFY*U4)53FN2M]'83^U'T7T:\>M^-^K-_ 4?T9_F[1^:/]0FQ_1B__%NT M7Z* :;AZQZR/L_$_M1]$2XU7\3]6:?\ ]/:_ P W:+!]?M'ZCVC/\W:+!]?M M-*

PX]XX]X]BPO]!>B^@XU7\3]6:?^H]HS_-VB_07[1^H]HS_-VB_07[3<,/>. M/>=>!BPO]!>B^ASC5?QU9I_ZCVC/\W:+!]?M'ZC^C$YZ=HOT??:,AE?C#]X*

*M]BPO]!>B^@XM7\3I6S\E#%;55QLXU\R_84G/D:9HJV5:=!*SK#+U3_UK'\]EGP5DG), MO(!?XO>$>QO-R)ZSED6CKD_.9(XD[*

*MEE52NS0]4OE5K$]&\]]fQJ\6U'XF/\>FMZGP.D+4TS?*EC3Y2H6LM?;T:]2S MTGYSFJ;&F@GNYUK5_P!6OVD?N]QQ/'^LB\7B'_ -+XH*A3_&;7/+IF;/6.*

MM[E\ZM,!>Z'3,=/)-2UD=+4-3>9U#\IE.<"S^X5ZLDMTR]N_3M^P M]2?Q:T-KAO=GB\,_@ISQ^FZ]><%M7T1JGT8,UHBRU-MN\DDT%)&U85;O09WLI$S>'%>7*

*M]++'8FM*M&,]=D$/5HQ4&U*Y*ZS 'UIY0 M-M M -!#0\YCKSR:5WF2!-M_P]@^[2U?&G_-G?]AG-U]=/_M*G?]A,FMK/QS5N,\]Z?49OAW$]1QNYQL7TM13N6O*

B7H_J+T^Q^OZ&+@U5:)OJN,&>YST3Z3(PU<$[%-1UE4O9U<*HGSD'7E+>HEX*_Y_D=R=D6QI[7RH^-LS(4[ZF=,^Q0\&I9 M_*FH*5/R6.>OSD6WJ\S\8+(K$7\?.B+

*I$(^':C_R72?!0OV$,T9=:4GY6^2) M6?8EY_J0]Y;Q)\+?G-\T,#4'W,53\[!]\KG?),]6SG]7L^033E.B>+?]S'G:U2*6 M&YIG%_J/7"PNX-*

2VNHQN7"G=YM\$4NHKA3/+3;B%4[^L0L5.A+6,OBSF:HMU-M\%+]#%>\MZY-O(\>>G86TUAU_[/5W!/IB1#86U,3L]V6-?ST^?IHN>W#Y;E/*

MF_5_4<6:Y+T1HTFE=1/=E]SZ]O:WKW,12[H;'=;?\(V.@MCUDXO=-(Y[G>E5 M0VX$(X"E%YDW?U^IV5>4E9]>AL^E:ZI MEA;\5]NU3=R"N1O-41/.=>!H7S-N_I\K'>/.UD:XS3-

*SD;43 MYR#M"4LFY^HS$]YH*7*2UD$?RI$+5VKK-'P6XP^I<_0'3PL=& M_5G,U7=+T10BT198Y5+AFDK.WE00>MN?K*7W:69.5;GY,;E^A"5V*

MM;5V2S/7\F!Z_4<2P<=K#^M+M+A==>=OI_T21VCK,]+_R"'GH:OU%N!5Z3 M?L2V5U2O>D2-1?6I"C4=:GJZ6FM[9G;IDI2"_:%]BWE:Q96=*

MHJRN:J+1,7]YWVEM/HW3L+?OE/&GY4RI]*A-+W"LXIJZFIVQTI4C:I7IM% M6B'B^!U0IXU0]7K_AP<'U%+QM^1+/EWF_(P-5:]&T^=Z=J+W12JfZ#$3QZ M7SBG;7S.*

*[.KY?.AT2*QV^'&Y14[4\T:%U'30P\QXF,^2U$*)=']RJWKH'<#/]F.]:R*CL.3N5!PJRZ-ML_5?0[F@]X_$Q=-J:U57P5?3N7SO1%]BE_%4PR)ELT;_$/\I2A/9]"[^&HX'*

MK^5&A8OT99@\]D\K?.O[F_0<_^0M+)^].?T^]&9WD7M1?60PI@~M9]#WSM MG>GUDOW$VWOJE_]AWVG.]?\'*]?T0:?XGZ?J9Q9@$M;QC?41N17/SFU.3_S,E+C8B-

ZDLNKV1<\D';:N:NJ MZHERNY,Z=/.KGJ4W6W4,O%]WIXO-'39^=5-G4HNX*IR6&7WI-^?T+8U7R2]# M676"\2>7]"9._(X.<&G M)=5>@XD^UFL/V>6I?*

(=4P_P/O&RD'2,9Y3VM7SNP M5>ST8ZVL2XE1\S7_'LU%2_ 7,&J3NJ8./M:4ZBZZ@ML+Y:FCHI(F)ETC9U8 MB>TV+PF+\;'^DAK^M(7U-

*N@DC;X5%\.V2:G;A>L8F<^GL7U%=2/#@QD_7ZD MX/-)*27H6ENUC=+]U74ME?(SLDZW#%[\I=O74MQ^]JE/:XUYN:[K9$]'9DS M%KKZ6Y4C)}.1LD*IP1O-*

*/.]=F"\PI*E3TVB;+3HB-HHW+ ^^*KOI,X%=N>4J-]*DUAZ$=;7\2/%]2 MTN6D%FI*?'54L$?R8D*FZU]C4:WY*(A.ZIA;Y4T;?2]$+9U3"YZJDL:.^AZ+ MJ99:G'2-*

*D<2E+=E;*D47)38_>Y*BIYE129,]QW06:*\?X1/GSE&'M*N"V)%D M<^TI=:"T$D+17*KIJ*/>^,Q-Q?F+/P_4TGDVNCB^?4*OT(&?JE M_P"YVZ-*

*/EN92=LVLCOW.5J=R2<",>SNSPYW%J-M6+^3,J?454I]4291M>HM0W*E29EIA?&{R)'2]S>3OPO8 M27*#3>I*Z!\+[W#)&]%:L:P;N4I*%2@]+YIZECIZJ@:*!56LOCW)VM;*

*MO8^DRT6N;.5LB>*J/3\E44J(BEL M<%AELD_B5NO6YR.'%H2QQ94;VFR& M'HQYBO0HE5J/>3]2VBLM U,)1P-3S1{5DLEODX.IJ2

*9[2VN%HH[M$1=7"V9]!J]M\9/0O84?RY4WFIOR>]_0[!0Y:2|5N5: M.DI:6)&TI4<4?9N-1$^8N,KWFBUFC*NTR=?;YJB:G3RJ=DRL?CS+R4Q=)5>' MW1T'OQ5VV!O#]*

*<2JKW+VIRP@]M=&U.5.S\?S(<)3692N=/IZ<<\/66E1=Z&E M3[)6P1_*D0Q-/[''VS-1SZFIKO.^H54_W2\ATE:(.[M!#^^E3>JE>>L4EX MN_Y&;+33U:]"5=865B+_ ,H1>KB2MUK9%3_G"/V+]A?1VFAB\BDA;Z(T*S*._M'\0S!/(.))8A[R7I^J*]+L?]\C&?=)9?\HQ_./NTLO\ E&/YS*^"P_B(OT$^_MP>"P_B(OT$^PEEQ'XEZ/ZD?Z?8_7]#%?*

=G95_P#>,?SD_P!UUGQGWQ@+1/.XR M7@sL/XB+!/L)%M!+_BT.?D(C._T^QE#[HI{7N[WOC38_A$*.M3]66>)0&Y4Z^AZ*7/O%;M(=)+H]!OZM'1';*2/R*:%O^K0?__"U?OS'\/O,*

M6[6MF7@V=TJ=S87N^HQ=;7V&XKXUJ9WK^%'2N:OMX&WLB8W@UC4]"(A-GL MW1J5.NX^GZDE.,,JGZG-ZN.IIV.]f**\0*OD[\B[J>HK4\E>L2)4RWQS|>.D*

M;$1, ^93H6!@RKH]J3?$;+-+57NK931J1ENIY$DDLES]YOQE4Q9%^=<&:;]AL;=_MUMGN#6IR1($1/I,^WS$>)HAAY0ZL|>2*W-/=?$P'W6) DFX_R/_6/NL_P#L

*M3"KAJ458I62)^2*Y%R>?F82?1EIEXLID MIW_&@-W.-B^E]S&O4^LUK(4DI[>2S,SC>:.Q,>TJI?:OA#8GHG?-.UISVBC+;7R;_M_(DJ+_E&=;!$WBD:/3N(3\4J37T^Z:HI*&D:OG=*

*(J!+'=Y_V1?)$\U/$C4. M*M^^"%_A\QE[9(V H35U/3\9*B-B?E/1##)HNFDXU%7652_OD[L?,3MTI9*3Q MGTT"<GXYV]!*A5*W8EXL[EAV_ N)=5V>'@ZX09[FO15+=VM,5^!-*

*)++\B%Z_4 M5F5%BHDPV2AB\R;I=PW.WOQU=53_)KVD54J2TSQ7Q_,98_A?J\C&)K*D=G< MI*Z3Y-.OUD?NQB_R='9\?T, M*W6ME7AX8UGF>UR?2A.W5-*

HD\FX4_KD1#+3Q.\[*-?2Q"WDM=$]$WJ2%W^K M0YEKKFGY/ZA.GV/U+&JN=HJ87];/2S1HF5WL.Y&J^]#KRYTMJMW@$+ERE0^5 MS-*

*[SHU#:.2SD_R0W5VL1%3SHiCXK3>;8uK*2NAJH6HC6LJH\.1$[M-8U+9D4UW^)JRR4>J]>\DI-+5T<>)W5*Y?Q:X3YRHW2-+/([>J;BI MJU_?*

IG8IB$R7*^.1\)+5%)YX9T^LE6^W)O\UEF_-D:H@J$5E<7YID_P"H]4U\ M"^I+31T+<4]+=%%Z&8I9KWG34KO1%[!"1*V!LSO6V-WR9D^LCQE^%^C)JF^U>IE>'C<2Ff|#N*

*MQ#&+=ZYOEVF3\V1]DOOY(WRI;5M]#$4[Q:?/Y$U"7[9D5B8|\!J^I"A)1T\J M+OPQ.]+4+-=10IY5-5,^5"H^Z.B_#?(STQK]AS/2>[1.HS[*H^S4*KGP2'}!*

*M">&B<4D1J1#4*W06]W#PEJ?*14^HF9=I) 9QA.GH(RI;HG:?>2U-JI:.MC/64\:K\9$POS%FMHDI_V)4RQ]S*KFF1\,A=6RF<1/Y"*2M=Y+T7UH=4;4MK*

M%D7)&$[5N[6^*D3T^-&B9^9])@IE0S.^,X ME\9VY&"C]YH^&&I\M%^LN&UUKC\AT*>HR2QM=S:U?402%G'+&KZD.]DX[6]"

M69/M]2P2\43>",.:OH9GZB/OS2]B/=Z(U^POFQM3DU$]&";&[R0EEEVKT(WCV M&.]^J;XDG\DOV$OOM0N15[B5S4=S3ZSG#EVKT.YH]GQ+#K"I M8[,M#-9^KW U6M?*

P/=3;J:5JZW%F>_"9/ %^K:B MT:UN\!%-)33O5TZ1X6RQK{)543C;,D2=#1XBJP7-'-:>D)MFID=/I M;3:QIA=RNK8<>N)HS\Z\GO,ST?]eO00R#4FHX/U^*Y2>1T]%_=

*M.U$_!]//:.#WK0&H-'6&T:BJX74D-9)FV%522)([<.:K^Y7)O3M\5V>6#UCL?V MJ+K[2D50^#?Kj;$56R)<.1^.#MWNW>L)H-*6^T4ZR4[;A.JS->U6I[(T1=WY.\)YBKZ#2=D^H-*

ME=ATBR+4<$-=>IUB1Z+T#M.L.T^A6>SU6_}'\+33)N31?;]?+SF.VB;9[#LTN%-1W=E6^6HB6 M5BTT37INHJHO%7(>6]*

(7^BTQMHIZK2\KW6J:N;!"DN6HL,JHUS%SQPBNPF>.MJU%4VWI9-F^ZJS+/(CW+1N\A,8^^^+\)YSC.VGZ&A=&4UBHTV_=DK]YU74?2>T*

*MEIZZI0=775[V*B2R4L;58Q>:MXN15N#GFRG8%IK&T/9+C=*#PVXU<,5.^9TKVIHBNP|&IU'(F$ M3"+PXE_MMV;.1O+J>Z:BOLUCC@B6&%K96(Q5RJKABM57+Z.*

[S%EZEKZ&.5/!.M.J]4M5]6]Z]7RWECBSZ<=9]:;_8MK=BU'IVKO=N?+44M M*QTD[49B2/=;O*CD5>"X3MY]YPG7.N=DC=*5EGL5A94UC]=T=/6QT21.8_"H MU!I'8?*

*P5,XQOQ%?HCQ.KJK55#.WK;2HIXFR1.XHV,O1?:CE['&>;E:Z-E3+I4 M>!*LH.-NWFCVZ3IW<QIB(XID7?8B.P2FHXUQ6.IIY(XID7?8B.P2FHXUQ6.IIY(XID7?8B.P2FHXUQ6.IIY

_E7A_]WB_C3Y4_D4.$>1@W*6-Q&=6>GR-59)4H6U-MW^9!\;96.:Y$5]HA4=R4T2]V.VIU7-46ZMN%F=*[>?';Y|UBKV\%^HWT-MO5PU.O;B13^9DA4G#[.QK&E-GE]TG/)4TI))ZV7@^KJ7]9*J+SX]A:Z_UQ:M-M/4%50U4F_73T[DBHT:Y5EWLM3'#EDW'Z"WDH:>>9DLM/')*SR9'QM5R>A2J6-M'M2=.A:-_3OT)*;<\|J36-EFF7:6T?2P3,W*F;[].WEASN35|"80NM5;,;1K-M"><&>O9*D\+=ULM/*L;T3NXGACKZ99'PMW8YV/5LC$Q\;FI1TULZL6E9W5-'3/'55N3"5%0I9'HGF539T}
M4<^P>R4,_$R*,>62IER9G;0.6ZLME%>MK]LH:R%E132VV1KXGIP7B[^"939-M=/[+M/Z'KTK;>GEEJFYW)*]5TBQ\/P<\$^DVGP6%TZ3K#&L[4PDKF(KD3S+W-M%1N?5V&:E@*4:DZDXIMN][;$Y5YN*C%M)*VYB+HBBO%WMMQ[$D6HMG[@W7-M*C?&3CE.TQVIMF]EU55-JJR!['MJ;JSP2+&]43@F53F;2G$&N>&I334HIW]B-MJ-2<6LKM8TN+9'IF&&*-E++%)%,V9*ALKEF55>67+S3S&6U)HBS:NBC;<:99-M'Q>1-&]6/;GN'RPI-[Q\LW$7*83OX&9:Q<\Q))'-M
QJS2,A1W9'(W(HR:*>#HQBHPA9)W\^TJE5DVVY7N8.X:1H:E?+?=HD86]H-M$"_4/]W27:#5.^U_HK81,*A\-NJ&MU!J1T;N+H&N5(8El;7-M.5.]6'T&:WD?+3;8Y\?N@FU-EQ5/"Y+30>]ZP)#%G=_P#6?5?P_AH5L;"-M38\W%3<.;L7U)2P4-+#34T38*>%C8XHV<$:U$'PB)YN!5()Q]G+LXFLZ\VCV#-M9O:W5E[K6PN'@W)VBCYC6;)!HFNZ#9SI.MMO=>]+U*;L%.GE33+G<8GI5,KYD4\]7^YW[:,ELFV15NH]41+'K;7%2EXN#9$-MP^'"\458(5[E1':>]=\F.PXIT3NB3[';J^U[7-L%]?:].4#DJ=-:/]FKO2+E-M%;45+%.!X(]-5,OX*J;J(COHFKE>YRJN3\8_B7IJ.-GP:751]#@L-PUF9*O/-MSE,F7D2*?GRB4-%98:KM4X[-]2?Z#)}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
MIQJG_]V:XE;GKK54M7M5CD<8&@NT=9(L:L=#)SW7=I?=WSFV&+KO6,_@OH4-MNA3YQ,W!KJUOQ4L]+QI;A50?D[^\GSE-MS'=[Y3^360U"\+%A?F-"Z2C;WXV\-2OV67W6;NO:4E-2^Z]I-\]FIHY%_)?Z"QK;ZGHHUDGFCB:G,(!-MI,E_O=R]HEJHZ5D:[KEA;QSW94LUM43I.LF5]5+!>=RN4\NKTHFOZ,?4VT\M*_OLSM7KVB,]<{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{@:X7%E
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
[N5\XW6IV(A5G;Y&A1,@VIE;Y%P;D[#7Q*BVD(T,\7)1T1T7W]9VP3)^:0[_MH_Q$WZ);.[QZG;\'"#AV%=;^BFFK*^H>UM0QL;415?&W//L+CWG1Z??:B;,TOP6UH](Z.HFAD5&=8N*%AQ-`M2*9KK_'3VF]BHSC[VK,\[OEHBS;8Z-O'[6N7O=E2]VWTS.5/&GY]$[JN)OE M2L1/.J%-URI6\YX_TD+[4X]A#WV5DIXFIPB8GH:@2-J]8US<.SCCO>8R^N=?6_25F2\U<-4QM.]K M/$CRJ[RXPJ9\ _>4SE2<=#5&A6BU=/?8V2"O[K4ZVIFD7M1KE1"ZI[530.1Z1-MHKN]V7*:MH#;M:-?6F6OHF3P11S+3NZ^/'CHU[\,*O8Y##Z\Z0>F-"UZT.[J MBNK<;SH:-B*L>>*:RNM[_!5:DC:F]J+XV<8W7.1?)7M-L6^QY\2GF=^,@FJM..ERF5"I!Y M9)IF4,-JK25LUG9IK7=Z?PFBE5%6-)',7*+E%RU47G_

)TE72.3J?"DK%5=[X3/>5&MS^2U?6Y1J4/!PJ8F>>3RQ5WVG7:,I2::GJ6QR4-RIXE7'!7.C8N/. MK4?G'HR=8LU|H=06^*NMM5%64LB99)"[>:OF7M1?,ISO4FP;3E?IV>CHK,3T M<[8UZBIBRDC78X;R_A)E.2]ZG+.C-JRJMNIZJS(Y9.LA=,V%<^+*Q$XIZ6H-MJ<.Y.XCF[BF6&H5Z4JE#3+R9V:IVV:=H]6R:>F\)CK8YNH=(YC4B;VJJKO)A-M,9XF!N? 2=TK07!U/##75T35PZI@B:C%|&\Y_^M$[.\X=K^A2|!9;A1.?U255-MR9"KDYM1RM;D[MKW99I&FV;W9**UTM-/14+YX;F.-J39C8KDWGXWESC''L4E M=%T\+AZ/#SW;DO0WS1NM;5K>U>^%||.OASN.:Y%1\;DYHV%XHO'SF<7D><.B M=4/|\]0Q((!VL,+UQGA[>2A?3A?U/1=0U|GH7)&N>'DXW;4\0U[H7\~%AZSIQV)W2 ML9Y3T:OG4IK7PM_#SZ$,=NHQR[!7((MWD)\NL9C&\AE=1W[#+E+[WRC^*]?S2-M+;E%^$Q_L+#K&)V^PF:KJ/(8YWJ*W49'*C(124U4Y<-;]\U6DZT%.[BL2)Z M.!;4U,Z*3KIG)&K4X-S]9<+<(N3,RN[F(35K>^52OR"6RF7|S^=2$56T$+WL M]}H%3DC7K5] WJN;DUL#?REWG%2&B9&|>>]S2?&>H6O55B'B3TU^]886N2OZ MV14\:.2!5PO=E"X@UI4-X2T>_P#E1Y1/8I"D&^2I8IUHKW9?OS90X4WNB\C MUM GET^:!5*C2?+XF5CUE;9% MPCY?Y-?J+>OUA;8X7*YTW#]Z7ZS&/M].IQD8D;OC-56GJK;>ZF=D<$555.] M*-KU5&R8WDX?A=YQ8VM%/-,R7SU*WAX_O_@U'6NJF3,D\&HY1$5/*;AK33[E MMRK*K.I9VRI#%"JS9:U55? @9.TV+5SD=&|6KO)C@O8IJFS6CCK|I=K@ESN/Z-MW.%PO"%Z_4:56J35[W,\H03/4";VZBDZ9, FEFM7[S7546/RB;WBN$/&*[R?-MG)_YE?&[+>'Q1S+-#\1GV|!$U|K;_ $O%)*>L:GQDPOU$R:BK*3/AMKF9^5%Q-M3Z!{5"/637D5NFWU;,V$BWM,-3:LMDV-Z=87=TC50R$%RI*C*QU4+_DO0MCB-M*[>?8!%/"'3^Z.MYL.HH=OVSZA=6W.W MPI[JFTPLRM=1M1$\(W4YN8U$1W;AK7?@J?DCR,;1XD+HYX4Z-MBFAK*>6GJ(TEIYF.CECY<:TJ;+3;2MCM?,Z3[E;BEPM>^Q M%*.H5G_#&#AB\8LRZI3C:CIT|#IL44=/&R*%C8XHVHQC&-MM1[-:G!1Y83L\R$^<(O=VY!A]6:LM6B;%57>\53:2C@3.]^$YW8UJ?A.7N M^K)^Z2E"E&\M(H^.2\EMBI99&\I)<;TCO6]7KZSQIT"^CS=]H>LX^D M:K^A:?0T[6+'HZR3MXPPKE/"W(O:J*N[WY5W+=/H$Y>?J/PS^)>E%CL1EAK&) M])@|V<@\=R"N*:KDBO(E/AI,]=($F]D KN6 ':IM6_O;:F M_P!]8^D+@V<(_+]!_H47\TGVJ?mW-2?Z#(8#053?*?1=D6.F@J8/!(W"X=C= M3&>)X,JG"Z2NU]WEXFR,/BGT$[-86YW!ZRP MKW/C/;6+I;-V\=/F8N%+DC. QC-3VR3_ R-/E93ZBO%>:"14W:N%?\ 68+,%7I2VDO5#ARYHH5VF[?<'J\,Y(O.2-=U?66;=-5-- PI+M/$G8UZ93Z3/,D;(MW+'-U44B5.C1F[I.^A)3FM# ^ W^/@RXP/^6S^H>#ZBI.JE3\S^HSP.>R MQY2?JSO$?8O0P"46H'9S7TI?DL_J.UI&CN5/LDSZ19EU M66OO'IV\+/T2=E@^/4N5.YJ8+AMZI7<'2+&OO9&[DJKO1M_PAAQ1I=OQ.YI M@HJ32TSMYL>_P"_ BI>?V\QCTO#).%//+.VY+51/;$DN4WDQPTS#W;RED9 M0CI#X$6F|S(>HIRU$4/&21K?2N"R2VS3?#UDC_-&FZA4@M%)$N4B1{OC/\;Y MU)YIO96\3EES9*Z]0>3"U|0O[VW*>TD=X=7->Q8F4T3DXJ8N\|'F+F2LIJ3Q M?RQO_DI_46ZZ@I<^)UDGR6*5-K;Z*|+U2YW?N="O=(_MQ6EQ%64\OD31N\V\A9QWRFFOZ'+1[3((U>T MD?*R-,N>U?]E*B&/GLR+"_#L^(A' MP>/X[>+):94=X=^9L3]>EJ4XMCE\^_,04%LM.G&)9(/D/?Z#`I6UK\0;W7Y M\7J^9M4*.,%&C*_=XX[RRE*-5ZQ(23ALRR\%K8?@MLK>Z9N5]H\+K8?A:1 M)$^- "Y/H+\%W#MU6T5YNTL67JGWD217P.[I&JA.ZGHJY=[=BE7XS2ZJ1CNF44BXR.Y,[>)*ECHOQ7L>H99:)JYZAJ_*55)4MLL*? M>*R5J?%?AR>T.URB_$3HG;E6J0M!=.:!* [Y2+N&GAA^#C:SY*%3GZ#&I=)HYE MCEI%;_=WEP|$3'?O*-.20.S|ZE|2(OT*3C5I1TV\B.63[S+_O[;RV3R.6H7_M_%9'WT>[@VAJ%7T8) <2#V.97V%^"P2LK7^10JWSR/^P;MRDSXT$/M51Q.O'T M&5E^2231O-7?>UORE+.;++GK]V9_P"2Q=O*>.$T[XS\|,TWLO467-MEM436[55W^K<_P"-$BY^8L_#G4KT6C? 431YXQRL54]2F>BACCX,8UOR4P3E3 MI2>MTO(EF2,2Z_21X5|%(W>7"9Y9[LJ5T?<9O)CA@;V*Y5RPLGC5DC$>U M>:.*A9>]'5Y\]J9H$[&YWD0.$T]|BZ? (>]DLWPJ9*_O:SQ4]A5BM-)#E6P(Y> MJ^54I=7HB^5&]D[+U1NX=>C5[G(]%]G#MQY9%YSXD'U?0Y"Q2B^9R5.7=+K+!4+! UJ/1-YSW)WF*DD]|US)42+\GQ4]AL-900 MUS4ZUF7)P1S5POM,.^PN:OWNJ=C\MN3SZD*C=^1HRBC#24[%YYGWNME:W\E5RJ^HM%HYY,K5UFZWXD?BM]HB,:*/R70[W:YSD<[V ME++5%=I84TL4=543/173Q.7*2[GD^]3+TE52S-^\.9Z&M1J^PINO%(WAX0U/-M-A2UFFM56Y5YRH]"=`M7&+.60SIWM7=4[$WRHRK&]Y^!AM<23NV5[1TF56- ^YRY]U.Q4\$EXEPEV=%PG MHYHORFHCD+^NC@U?HG4M@IZR.GGNUKJK>R:9.$3IH71H]4[4179X=QZ?1TU' M$1E)V5S!C(2="22N>1/R'6>C: M2K9;.F_6V6@CJYT<]D3GIP13IS6!=.VIY^]SOEZ MOH>:?1'8_P"5;.|14.=>Z1R([5>P)=[/_*LW':/[}3'IGHX;"Y.C[L8MVA[E M_KT5\|\-5G) <1JG'O+:.)1+I2=1RJTA.G/V%4U'4YK[J*R71G2'Z\ MM"[XW-L\%5MIZB9>"1NCJF2NROG8Y5_-4]S5-"MXJH:VBE;4T=4UL\$T.Y9) M&|$GEKA4L5J)Y<' M!G#EV'TLZ..;3BVI6>AX=.K/"S:2N<\Z..L;?KCW6[6MXM51'54#[;MHIZB-`M=YDG4TT4"N1>U-Z>-/;9JCE9LM!V OSKY(E)2ZPMZLMT\R[C7K-31HQ.]ZR0 M/C3SX-4Z'VRBP[- ?=,-.:9I3+/4Z:TK:)X/":B3K7+(D%/',KW)PRLSI.&.S M&.'#TETG-FVQ?I9Z[H]F%TUHW36V.SYDM,_<7K@ROMFV.K1JQ)4W*DD1,\6HY)EQP[4R9^?W/':}J2C,2;9>D%==3[M/+.WPN6U0+*Q9HHT5WWR21V&HB)QE5?PFL9(fO5]JQ0?6>IK[OR#L(TS8[G>+5]'65OM M=MII*JK]9KM&UD<;&[SGQ?!?-YS+|(?H.46UO;'3;3=!ZLGV:]3;=57/N=*UW M4U3FM1J/>C%1S'|OBJY.HY.#D-.U5T4.D5MIMT6F!J>WFAET>DC5JJ6RTBI+ M5-.N M[O8.A.]M9++YN:]E1'3^2W,;>&Z],XSQ4\W>Y.1MFV6]4F.\E;U3\EXI]Y>> MVMF>BJ,,)-G-'H/2=)WV:CH((UD7>?(^1',TLKOPGN<[*KZNQ$.$!$|HO7 M3HNZ1U9;JO4U%?9KU71UC'TL#V-C1C'-W7,W-55W-.!Y^.Z0H5<+449;_,V8 M7"5:=.+:.HU%EJ$G8DG.MTM5:U>,<.KW]YD'5J12O7PJF5S%YR1+E/ M875-5153=Z)Z2)YE/RUI-W/O$Y12,+|UUKOP(T_/*D=EJ?79WHIVX154S?J M-+.HN5-3.W72)O? %;E5]AS*AGD4:>Q0,TJLQXHGI7!C&V6G[Y5_UBE>.RTG#,3G?*>]E\;E,LO:7 MDU1!U,C'5$;%&ZU4AJA%MWV,LVB2"Z4CU3%0U%_*X+|YD89&R<6O:Y/,J*62NI),] M8L*K^4J$$M]MZF8*V9]=V]O(5FP M7"\R*F*5/RV?8;(2?./H9Y1[S(§WX1CO"+A'Y5)'+YXY,?23> ^KV?"4<[?.U M-Y/F)\6//3R*\K+|. EZBQ]K/!5/ZQ- Z*1>;H^WTAMZI,K<|\;ISV*A6BN5+ MY>0SUK@IFIU%JT$!1Y>.=8YT[+I/.0BTZKMJ(L?)4S#)62>2]I^A44F3 MQN7$@-'[?.EQ)&;89'>75*GR6X+FFLM-Y'JCIG)VR*9#"H0RBLG8B]V1E?8A;I=VR?L>GEJ/RD3'>U2?$@M+D,K>I?D47!C\7 M&?MAI4[DR]2"6E),,\TZ]N780YGD^K$[E7-EU)600^7-&WTN0H/O-&WE.CE M[FY4J0VNDB3Q8&?G)E?G*[(V1^2UK?0B(+5'S2'NEE[\O.X1PSR?)8I2J6UE MRA=$E,V!B]BH^1WC)Y\&4X^HE69D>=Y[6^E2,HMJTI';KDBQ945M*BMFIU[& MIPZR) <*OI0C[!8\]DJ4_,R7"UU,WG41_I(&W"E=RJ(_TD.=713.Z\T6_OU W M*.9,SY4:DS;U1NX+,C?E(f%U'*R3.X]KO0J*3.C;_P IK5[*9)K.]I+T_4CI MS12CKJ>3R)HW+\[*LB>A? 06\EMI9^IXU1&/H"/O+ W*QNEA^0!1_46Z3'NE M\8RKLK)9%DAD6!SN*MQEJE1**LB^"K5>GQ9FY^<=$5\/PE*R5OQHG(B^PA)[M6DU8E%..S+%UIK&\G0O0.H0|ZJ[XD*? GF1CO-,KE;)OP/^+*U4+N*..5N6/-`M\.IJE<;.5_B2SR6Z,.VRU;O*EB9Z,]7%/88EN1TTCIU^*O!OL,FKDXKG'I7 M\;R7*FASOSL3S(N? H)*E'5_,YGD]BXX(U$3EV=R>@%A[\1N^!@GG\[683VJ M$JJ^7/5TC8D[%D>GT%G$C]TCE>[+\.5&IE5PA8>"U\WPE8V-/BQ,3Z2+;-_Y M]M1#\#6R-3L;(B/0DI- ;JYRT7S+\%AUEOB\[*'' M=/R7;JA+E*S/6T,[?D>,GS'>)'GIY:1[&7KX8Y/+8U_10I> TV?@<(_T4+?WZ-MIV%XS9F+.^5&H]_*X[T_,4C>D]|'3ZL3F5PBR[0N=A^|" M[XLJ84L51;/0EE9-<:YU'$US6(JN7'$QBU55+Q6?=_@^'SF7A?'3=%ANN=SEDO!%MI1 M6R>25\B*Y9(TY.7O[BK%;((W+EKGK^4I/ M)- #2M1%TG&FXN[=CM[Z(K*0+3PN2,X"%RI\9_BI["/@4DO&>9SD^(S M@AIS?AU(Y>TFFK(HG8WMYWQ6IQ*;2U$W%D.1-^,_BOL*\4,UY,FK%- *)9..LSG^O=3Y%?*FBA\AB(I9OK*AW;RY*%)9)79W MG^A%(J4>2+;,RBY(+GM,6B+\=Z^LE7+?W1Z?G$^(^PEE)1I_P#1^Y_Z-)_ -_M4\S|%/K7;0*U'(B|[URI3*=' D]f,J18WICPB;Q7-X>6IO>JM'6G7%NCH;Q2^_M%T\B*U%RU47DY?:8UTNF[C^E6INNMUH9*C4W>LFW7/?M\IQW*C MJKJ6&5!)\N5SS1KBGKMD^U*X34"=1UC9)J? L;N2M.5(IV29[GS[3#='Z,M=IPU)((4ZW'%%D7QGKY_&5?5@25U8]?%UG3PD8R5I MRM?P1R#I3-B;:+"L3U?^N)<\57L0QNO?;#9-,Z9,9K_)+1^#N>^GF;&Y[9&N M578PU%7*.5R&:Z5[4]Z;!P_PB7I_)0R>S#9OI[6VRO3[!Q;V4K(Y6MF1SHW MB7/X;S53AYN/H&72S*HSI1P,%56EWL<=UY>EVO[288[-3O2*1&TE-UB<5:B MJJO$[3L^B=GFG=-M&]>MJMT=-.]=Q\CG.?(J\:SE543EPY<#9JRBI[A3RTU3#'/!(FZ^.1J.:Y. MY47F%85RQZA4APXO+'Y'GC1NM|F2Z2@=>+5;X;K30(R6)UM8YTKFIC>.Y&*B M[V,\5RB\S);&=36S6FI'0TN@[90-16+*ZY0.8U8NQK?@^#G9Y;R+Y1NE1T?M M"SSOF]YW1\=Y615,C&^=$1')CU&Z6#3-LTK;THK710T5,WBK(FXWE[U^\)>' M-<\C|BBNMB:+A4|YGVO8\I=(*-L>|EQ)&1O5088_1^7ZL>|BV\S'<#7=DM.Z/:K9 MW=; (Y$Z_@Y?WB0R>KI9D;)BHD|IA-CM3*[:Y9XW.ZQ/O_9^\2'HT)1NM#%5B M^T|4IR=Z29?))6>2OD)E\D| QLFC)T7!)&3"Q64I:&F]6KU/")\IB*6,FE;`M7, [*TJ,ROX+E0RK>2DS>TI=&G/K104Y+9G)-KUAI+32ZCGW>%,,>JIC M^R'9FM;N^LY5MQ_YOT5R_P">(%X^A274/2(L-FN$M)34U3K9)H5:V/*+ MQPKO*QI#Y58O"='8ROQI**=OD>FZ-;$4H<--[_ZME$[*:%FZ?VLZ=O]@]HJMRK6G@HTVJ.H;B2'/+*)SSYC4/[IBQ^&++&EMKULX\(PW>]+'YX^<|&ITS@ M*48RE524MN\S0P>(J-],'=;G8$P[@1X(:9?-K6G;%8*6[O]_"H*M%6FC@3+Y M<|UO3G2(L-YN3*2KIJBV++*[=9-,K71Y7EE47AZ4S@G/I? TZD: M6\Y>6>Y, ME31.V>Q;Q?- CI+?61-=*Z&]PB.8U,N/ ?S;\7V=55F|+_F<|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|#+:U0Z6Z)&RV@93R5U5';=:C%1K6??Y>"]J+Q!]Z+T7M,M^L)A M7T[&.I]UK5=U$CL[R)VM7M3BA|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|CPC#7* MGGW$X\$[^"OTM@L,XQJ5$G+8C3PM>JFX0>FYV!%1Y-P:.7JG:UI_2EKI:V2= M:SPQG64T->XSI6_&YX1/.OH,%/I'6'4-SBH^B"HMD\SMR%U0K71N M"KYT#Z6P.*JHRJQS/D(X6O*#]*#RHZCPYD.!S?6FW6QZ3N$E R*>Y5D:XE93 M81L:]RN7M\W89#16UZQ:QAJ5B>ZBGHIUEEA]<(J,3RG(]<%1/[(=V|R3OYX,MKK;`M?:- &5*4<<5ERKU:CW10N1&1M5,IO.X\<8X)GGYM=-[*RL1JJRK?_C[CEWXIDP>/PV+Z0=6C- M..7\R^1!JT:&2I&SS?D;04:BB@K&*V>&.5/RFE);Q0MYUD*?GH2.OUN[:V'] M)%/I)5*;M)-&!*?))%C-HVVRKEK98?D/54^E$^PRGW16W_'8O M4I+]TI[L:MGJ15^HR.EA&],$U*JMKF.BT7'#QAKJB)R"M4;6^A$0G1E7JP34U9]VIR66,NJ;M+K*JFX4EO=\]3>,YS; ML_(SU!QX,2B;$G(B`?8'C M-M-M $J=I@=7_\WQ?PJ? 0IGD3&36I=524MKA>K'R9F1$:QN5SN.MN,6.>7#S;[*ZA]K$U<@YR,3+E1J=ZE@CKA5<4;'1L[W>,XI+2T4;MZKJO"'_M +X]/H(@G4OLO4^DRD+I6T]53R0Q.6:5>21MWOG(4E5!2,.RIH_!%QPW\EV2 M@N#G,7EOHCTI],&HWLK^#(.)D6\S'WELIJ M5.HWN>7[J\<#?N47-D- 0GY+E:H6[]3^R:>6G\^%5IV4E)-/0XDT]# QN@:KD MX-=VH[GZRLV1OQFX])GXUI;@U7-ZJ9/0A#WKI.VGC_1*%1?W6F7*IR:,"LS$ MSX[4]9+X0Q5PW+U[FMR;"RWTK%X4\?L*[(VL3Q6M:GF1$)\&?-H<5=AK|/;: MFM=XS.HBYJKN:^8V!K4:UJ>G=QA,ASVQM57N1J=[E0LGWBF:[=8YT[^Z)]J6 M0C"ENREMRY%\#^:^$U_P=,V%OQIE7/L(1;99^-35R/\ R8U1K2>>_55SF5Z63#,>^Z*++U3.AJ MHW-163,=V(3?>ZAOX.K?4I:R6>FMR.6>[X%"33T6?O.LD M2?%SE$*?O%*G*JRGGC0N$AKJ3X*5*N- /P9.#O:317B#BV,>IY.UDB83VH3E ML_>5B=YKB2^_5%_C#?8OV%PV.MEA9P2&-$^2A-U3.QC/T4)?U.U'/=++1+U1=DZ+Z%7["7WZIE\A)9/DQJ7]1L;`M^ U/0B$5>14:22^^DC%5J00>;* MJI5DO-'&N%G:Y4^(F2B[4$'X,`MDY>HO8ZU].B[UMDC3E|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|%3V%-+]12(GC[SX;5*M=9 M[VZJ942VG?;&F-W^.3V9(P2TLSGQ)6V&5OE12.1KD7SF24;I=GIXHT1<'JM? M,M'WBCPJ>WU(OV%I+>HG<(HHIE_)8OTF8="Q.3$3T{A0DX%%HRYM&B+CV&$ M=47";/545(6]\SES["V?;ZB;>Z^L=CM;"B-0S4A;/_",$X]K-L)=B,=%;::F MXLC3>^, {QE]IB+G<^H8SAPYKZS8'\E+2IHX.Q.2QM?W+G!DE'L-D) M)/4U=86O=EZN>O>]0V-C>34,Q)88%B25GFSDH+8XV^55O3TX.KBS9&I&Q8; MJ=R>PE=U:)QW4,@RUT*,1'53G>;K$0NH+;0Q\6,8]>IRY.93N=&+M-.^2NCE MA16.:OC/QP7S&Q<>\@GB\$PB=R(1RA8HV*)2S,<>\HRT,,RYUJ.,,,TZ=^[A/:I-'- =),86.F:O8F7.*3K7U;G/)'4JOBHN6KZ MB,5PDAD;#611$YWDR-7Q7?8V M7B)B/6GDC^F:[""":ND>'B. MC*=>>>]C0NC'T:=+|%73MSCM]PFU'JN\:ZZ@JVLD^%RD;&Y56LWE55RIJ MY5RI\,)'25Z)!+MXUK:=>Z3U9/H/;/:6L9%=HD=U4VXN8|{<5',@MGF@-,[*MFUNT-H|L ML-LI-Z22>5^9JJ9V-^:14X*YV$X)P1&HB<#*U4->YK4C5KN_+L%DZWW!R\8H M\]ZR&/'],U\1'AO1%V%Z+H4)9TRCUDF\JI/)GY2D_A,^/V1*GYZD[+16.YK" MSTNR5XK'Y<=;.OH8GUGRIYOF>TJB%HN%3X:D/7.G8J*]IW-IFW3/?C+LI@MJ M6DAHV*V)FZG.NVY0TMTAQIRUGM5/,[>W-Q_?&NZJEUGN+>.X4] M.[$DS47N10U$] M7GP2@JJA%_":A%l:E|'8[_48W;?%%_"S(GS%L<-5J=6#?D1=>$=),L8KQ2R-M+A9.K=\61%.I=,I>MY*5&]A807.GD...4 M[T*E%ID&BLPM+A*IO+^4JJ7C-/[JKU=2Y$[G- R5X|#/Q_7+/T"V-M-.7916"7*JQ\EA6]ZZ*GXU%2KN\=CZ#5 MA>F^:,BE\VW/W.)01L M4MC#TT<4>]-MRMFJ89L\G/5&^J3(16]BFXH]9D_A5U3NRQ\;'= M\,!TY&,8J69* [YIE|#;Z:#R(&-7Y.5*_S&/;,I8\K!72HWLWE1R$=VY1_43?A(:B-?RHU4EQ(\W8YE?(MORTNE6^CI'21HBNRB95."=}]W[MN?*,]%=E53U"8;)'(B\TRGT!R4E:, MD=5XN[1KZR2U'&6HDD^2N$]1(E-&GX&?.N5,S-8Z:1V\Q'0JOQ%PGL*+K O9 M5/3TM13%PYWVN7QJ1\#&M@C3DQ/8%AC[6-]AD?>:R\ZMV?D)]I49I^+AOS2/-M7NRB#A2? W3O$CVF&>V*^^2[LW.9L5JZIP#+K_A<<<_-DC36VFI79CB3?U'+M+Q.N-#(O;W-2HFJJ)/R6KN-*T5%24J+N11L_*?B4RBYK9>9)^6U:-[?4QFT:NF;Y MY%7VH7<%#!3_ <+&_FY4HS6NGF=UD:]3}\>%R)[25([A3^3+'5-_?$W7!)0 M>JJ!UN9?_P!L L$NDD/P|'+'WN9XR>TJ17:DFX).C5^*[*^7J<'S(960N5R6 MA1C6LWY"\LKA#%.KZV;G/U?

*FC;!9FZJEAKHL2-1ZA='*EJ6#NL=Q?43,._(=2G-7/7\|2|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|WY323G%[DE%E M%;:C?(EO;*O MJ:3,H8VX5V7>E2Z54)5*JB>DL4(DLS#41[(B)A")2?4PMYR)ZN))X6K @MXW.]/"6>*T1\?9<&)U/IFV:ML\MMNT'A%%(J*YF^VQ%RBY;J+S+[JZF7FY ML:=S4RH2BCYOS(l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`4ZJD\\I-6Y.$%CG[5.+7NQ5S4=/:8O%ZLEWK*"&-M22DI&,69&<>LPVW43MW<;Q8P3+V+GUKWG8NC14NCT[J17N^]Q/9+EW?U:Y7-MV-0TW0&G8=3;.UI5RQHZ>F@;/(G>,Q^\Z1<>E&XJ9?+HN^'H.F*I)DM\K=-MA!8S+4JJ:T5EIWEK/9KC0V:WW&HB?D\E>Z'R*[9KI M9.&??AW/^<>M:*<]*UM\LMETQ$KECCJ7+'A?*<]?%3U9=]3S?IB%:36GM+6 M'D:C8HZV(*-[7=0Y%"(K51&_V\CCO19:EQV&[#Z!4WV>],37-7MWJR97?-@!W12G;1:MU$U5W:M=D3ERWENMD7ZA6PL?YY-M^[G?RN0C6D\!:WO6_0Y_>J&KL]XK*2M:Z.ICE7?.MWOPLKY2>GGY\GS(VIA035WN@EJAIV.EGDO-N:R-O-5ZMF#Z=:'MRJ[3-=76[W%MB344.)U+O)7.6OL|"-3/1#YDZ^KGV?W0RV54"YDIKI0.C7SHQB(>[_#>&X M=;$8B_N2C)+MTYF+I"KFA3I*B=9CNI,^87&V=1I.&ZS*Y]16U=232C&Z\|CVZN)X.IQ@KW=OJ>=)97. M=NHBN7.ZC6\TO\ 6&FKMIFHI([JOJ734T:XWKE4W<8W,]BMY*GF+[4-.MHCM6C=*;4U;JB1[NUR->W=]F/G.D):LQI[3L2\'R/=*N.?D(B_SCR=.7 M1]GA:\YR:DE%[VO6C4XPVE=UZ'%K:.:S4%&I]"W?LN5'<&>-NX7GG/865M7236^IEI:F)]/4PO5DD3TP]KDYI_;LX]HT?7-LCV,^H_6]I&JV/1MYO>GKK*/8?:I7.D MO@GH534]?:!@TCLTTW421-2Z5DSI*A_P"%A[%N7T=,_^3CP665](BK\EO'\XO-BUM@CVSW6.G;NTM"RI8SY*/1B+]/M4Q/HRG M6Q[*5)O(VE?OM=EL<9*&%E*2]Y)OXZ',-46BNL-^KJ*XMLSQW-MT7M1>>?.7FD-,W;4LMR;:F/<^GI'OE5O#>;CX/S]I£@Z-M!I6:KV^I5JE:V6 MGB6*%:\E:C>L>B^G*E:HX^D.LM34S?@4BRB=GBRJB*GJ+Z71$)=<',C;2 M?/I7*YX^2PF.WO63]3BCFNCHRBZ;N2:8,>2T@$-M+'CDXHURG%4N6NS/F-\I7I^FUSMUC'/&V2)T-4^)SDSN/63=8Y/.F#2]?5- M9#HVHTU&KNJJ*UL[/O/A;.GH5R-7THAY3Ps:*65U&W-IV5S:L3*I[L%]K M7OV.PL<;YI$BC:LDCG;K8T17.<]/+AWK@S6K-)?72E,'%=H7MEFB;(R5>*.3 M=3Q<|[>2IV8[L&V:\TG#H.!.,IZ=]}5K#%+4.,S?+UR*JK[<>A#:NDW.M3=M M.T#/*5KWJGGDM$6>CETA9GO@WGNI8W.WE7.51#D,E-':]9ZMWHZ=$;/':ZMB-3L3#>']5,':=!9^XFQ\/\#C_FH?0?PMRMBE:36GM+6 M'D:C8HZV(*-[7=0Y%"(K51&_V(

B521R@]2'V$BE1>1(I>=11=S4U;7:+ M):X(E7'75,4?M<,3(:QK+RK0WXU=-']9Y^*^SDC71ZZ,T[ER]!:,/[2ZB95K5$4E+G|S9%OX|*KS*.F(T=,6U3EWIZIR
MS2/7FJJIDG'S=2O4JMN]D^2/9A3A:6RW99LO^H:%4=/%37*)OE)#F-_J3D;) M8K_2WVE66G5Z*U=U\QW7N)2"N1J*J MKA.\T%=B=%QG)JUT=_RA/Z?J+:KUE4U\
[X,-3LF8Q=UU5/E(T7\E$YF$]9KF MZ=RS5AAJ$D\TC.(XG:]D:^RZ5=+QGC;/$G-T/E>P MS$%0VIHB;(QR/8[DY!"I&>QLE3<3,6\WWR7]Y*&;WC!,?=F:,T(9QL-M+JGD55 MfY-
GS!?.A"PJL:WK;$/O15IY<-B+["$[-&IKM"MKG8AAK*AOQXZ=RM+](@UO::R5L*S+2S.7"1U#%8]^WM*EB: M+=LRN2E0])7:9L3?*<7$90:BZ:O< MM1#1VN-
<+6U#6.^0WQG?1\YL]+&R&-K&INM:F$;W)W%,?B_T*7) MPCF6[^1A7Z"M$CLLA?3K^\R*TI_<#"U5ZNY5C.Y-Y'?2ALB(TJM3D7^Q4']Q M%"J+[S-7302=MT]U]&ZGU$[-
4J^765DB>>7'T(;2WM(\R2P6'_D,/4[3 M76;"L^F]#)+_"2]OUE5NBK(U;>_QN^4JK]9G<(2^+V%BPM%;17HB'%F_O,P MKM%61R8\!C;YT54^LM9M!6]9H] M1I:
[T6\L%1#71IR;(EX_VE@]]93<#FV5,:Y\IC>L3VH='])#"=B<.?1'U96 M+HXF2ZRN7S.55.C5$I<,$DDB;K&)O.5>Q$X MFMZ/M,Y>3*IZD-]1C6M3N(#'7!HQ?PLBA
MXJ7W4:,!HRX396HN:1(O9!'|:EY%H&@3"U$M15+WR2]B>Q#9O00X]YKA@],> M2?C\^VU4E&]\>J=X[/8O%#:QR,] M3#TJO6B60J3H5G.ZVAN]LC=+/2QU,+$\;2!W_=4LH+
[!-E49*F/R,X^PZ56 MRLIZ665^-QC%Y$,'H>WMAM'A+F(V:]JX3U)@\;I@7Q5"E+1W>NM MOD;HXGW'*2-4]^ZA[8[/R5)F72*7X&*>=>Z.)5.E;]) ^"GL(]G#@U$]1:NC9
M\Y_#]3GM2Y1^)SZ&FNU7^Q[7(U/C3N1B>PO8=)7>HXSU<%,G=$Q7+\ZFY^,A M,7QZ.I_?DW\/D52Q4WM8U,/0:.XS7*KD7\E4:GT%7[@*3_&:S^6-G&2]8*@O MNW\=?
S*^/5?,U1=!M;\W+2E+QV_:4X+E2U&4,.W/Q79:ITA6[V[S45]4,D^C9+I,7J?QQ2^\O0T_GRY SLF@K0KMYC9H%[HY51# M .CT]3V>);\-7421VH95F57*SS+V&*>%KTTY.*,7?
^AHA5A4:2OEQ9V[3I:Q5G]:L,%)QC@ZQ55]=F7=JX,O!8Z"GXMHH\]fDROSDZ6%-MK5%=I)&JT8[F]JG)=9,4,#Y)VKPJ/)1/7VEP^EN\,XVPZ/A\5O7N)
<2VR-.=5I"N)XI8%_+8N/:5H:B*94W)&N^2I MMJ,:YJHJ90L:C3]!4Y5],Q'?&8BM7YCCP<_NOU+%77-&%[^`MY**'1R]Z)] MK{#*OTIN<,:>LFB_)?AZ%NZQ76)5ZML-
5Z%W%]G(S3<;_#4L56#YV,?[T MTWQ%]IBQ#9O33?B\^CERT"\X0*OA\6uLJ&)WQMWT^8D\.I8^$<6001+%)#4]>PI>MRY'6.<9L/A$WXVH\9ZC73Pl>MJE9=_T,4\1&.
{OX&I1UKZG*4=)/5=RQ MQKN^U>!=QV:^5&,4L-*B]LTF\OS&^,9&U,-1$1.Y.:!!R]YOAT=B&XKC!3^,;Y?A[6<6_-G%B*G:; M%)HNX6^5:B":.NULC5:Y].1>Q3'R6 M>/+NKD?
%^3S3V&0?37.G^$M[GIWPO1R%I-<%I<=?35$/"';S%1/09917WUZI MFF,OPLM?>B5O*=J^EI#WJF7]W:GYI<>^3'>3#,[T.4@E9,_/5TKO3(N$*;4W
ML.$YE%EHX^-4.7Y*8)TIZ2A7>>N7=[UROL)NIJHOA)FQ)\6/GI2>*AAAPL W MG?& M]RY(HU&\D1#(26^%5L[N[\E<%/WNCSP<[\9ZC73P]:MJE9=_T,4\1&.
MSE]9%M'"W]SSZ>)-0EV'7OQR,I$W=C:F*JB)YRPB1'8I1=61-7"/1SNY0%2=OA$V.KI9')\9WBH+WT% M['G?I9_LK37HJ?IC-GLNHI-&]'F@O5/3PSU-
/!&C639W5WID8N<<>3EY&M=+ M*&>&HTQUS6M56U'BM?SQ&1N]%N]%";.=9'*Q@\"HW/B_LIIW(YT>%W^29614M*CW,2-&M7>7FJ\5]?=O!=_M26>"*-
KMV9((GQRQIZKGLX&2Z)VF:,X4U^N+O$JF21P,D1,JC<*YR>A5P MQJ->Z5%N\U?:7JQB2OI\&DC3R\/=A5.9'%;%JAA9XJ6&4#(=(:'1T\R
MGIY+540P5/A;$T6[:8E@LU%0Q3TM;71]94.8Y7-WMU MB\4X<$3YSI>U"1C^CQ;\+EZ4U#E/S6E?HIIIU=$73*O]/"ER7D>;]K,/U>ZKN\1*H_Z*(\";4+OI2RZ?;4.IHX*Z-
JXIZ>2)LDK MWX3A&B\47&,KP1#NBV,^)6>-"+3:MLCD*=(C75QIYJRV;9IGV]BJBRMHIYFM MQWR-[>DB9SY[NZU.?:[M-&V&ODAVR4??M;!)O5#9&HB(C52-^
M4]HR45)&AG>$*E4>11:U6MWYG2]H>VBX;&U@RTQ4=++2+&R1\LR.WTWE5%QA MW8B=Q@+!TA[ZKY;QdW&/WFC=N)65D.CT>3=>Y;aK&V<%5<{YK723>U^TESHU
M16^!Q87](]!ZCLD=OV576BAM^Y2P6F6-J81$1&Q+A?K]1Q179<>*YSFIO)Y]U7)ZS) M=*NEZK4%BE?3K#(^F>U57&51KTQ[,I,]MJB_AX>.)]FR[]!G;M1W_WAT37Z
M@HE95K%2+4PK@B]KD5$5.6.SZCD5IZ3M?5VN=LEGC]HR^1&4M+2-?NJF%WG. MXN553AP0VZOJF/Z.C&N5R.]X8L.R?O.30^BG;*>HO=]K)(FNFIXHHXG*F=U'
MN=O8_1)1MR,5*C2C1J5)QNXLKVCI-7RWWQM+]>S004^^C94@BDBFB1?PE1[U-MSV<."ESJ3I(WN::IGTS8FS6:G=N.KJR&1Z.[G+NJB-3/)%557SE+"R/7-ME Y&HCGV]F\
[/E+UDB[,P!NP[CIRR4M!LGI:&.:K(76OQVHGE*Z/++U?SJ]N M7VG2VI*#0!TZJK"H M+63BO9+M8WV5RLTEIZ"GC;<+I,SK$CD7<;$Q>`.U<#4
MNSF[W^@M[8[E;HGK)22N61-]K-Y,.3BK5[_3W':_<;4-6ZXTA7LATBM#9'1H MLM5.U[_$145%;Y4:G8G+/,R/1/=,L&I&OQK,F_3N5&]BJC^?L&57-%:A3>'=-M5P47%
]DG'4U;6_=W]T7@L:5_AGA7@R([=W][.[SSS/5NSO:%)?M!RZAOD<-N M;"Z7K$:CFM:QF%SXRKQ//V=SI#>,W")?.*8Y??#K'2M==. MC!2U4V\LS%CAWE7BJ,J-
Q/F;A<=%C3U+4T-ZN4L,4)*RGCDQQ:B-57(WUN0 MJC\)'(4J%&A=2-W%Y*-7MQU10Z*MFH'VJ@ZFK](%=B1$\5$1JHF[PRJ2)C MCY'G.G,.-9)K?
2E+=%C;#4/5T<,4[<;23^9L.O-N%UTOK=[AL]OI:R1K8HW>$;V\LKTRC>#L&^KEZ MMJ>A5RGR%/5G).*X1.]>PG%93/C80I.,(+5+7Q(@I>%-
<[=C:Z5W3T5SRKI;E.2%DGEMR4O!=SX.5S/,O%#(MLL]\|\'6M^-$OU%-*R M++>PY5C=W/3=4K?N[Z'=`L5S'UTW'J+YLC7\6N1WH4JMYE4I
MIZ"]C"LD;V$B>3D=8WXR>TRK=8.SO.;[^=*#]>G:F5CC;PY\#//PVME,YB^N M:G-R>TBQZR+XC'O]#2_ZZF;Y&Q,ZU-8V)B*7D-LN=85+6LI&++^,7QOZCBI2E MI"
[\"$JBCN8N*#J7)+4O:&C>+8\\2[2IGJC.?54R4L+IV%6HE3M?R;`MV3=Q9NDDJ.+YG.3XK783U&6CKH9';CG;CN2QR)NJ226FGDWG-18U52P%X%$J M;Y$E)&*ZEC47Q2VJV-
ZIV&IR[C-.LR87%1(GJ0LZRS)U:Y])/8A#AR[Y*QR MK5S4W9.">PU/9[C]46UHU^Z_[IA6_P "\WO5MI@:U^=|_I<:GH*G;'M MZ01 M9?F3"-3BOWIYK5.2IMM&1R69':TI]
[*]SO60\$C[G>TG^_-X>#2^PBUM2[R M:65?S3Q=.,:^!MN4_!(_RD]9,CI:-
JOCJ',QWKE"NR@KY.4*1^=REW36'>Z/2]M>WRDK45/T'&/V0W:#3>R/75S>Y.L>J4[$[W+'NL3VR'P%=0ETW)
M5.JHM^B9[+51P*R;YDOB:.RL*V,N@=Q6"^,`YKX'+CVHIFK<[WBVD:!N" M>))X71T+W+|IO4N_FF%?;Y]+8W'4O14CK;UXF>UK(7-S^EE/4;'JJ)LFK=FE' M3NWGQV^@;O-
[W29^A/G&IIQ<;KWBH6\V:923'\]7+CUEOI:W-U9T@-1-D3K(FI5-=GCXJ-ZI/^C2U;GKK55VD3+]QV7>>257+_-0^HIXVK34I%V M).7@E8\V;X-.>7:,
(\\6RVZ.=,RLJM8:6K$WX9X-U/:0KHW?2A-L#=+:=4ZJ MT95KO1RQRM5OY<;NK7VMQ:9 M=1,7=3:DC8K:*)M1,BX_&/\ $1?S45?:68?*J>%<.MFG&W/+KN*VKKWVRQ?_M
+T[EX04*S>MJ2-,>4*Pf,ZN5?W:ZPQ^E&0O,YB+|\R'T"BJO1^)Q4MVXP7@K'FI
MY,31I+DG)^+N83;)0NTU>=!W)B;LK**|_*A9BZ<98[48]7,EYY=310FU04N>5^E]"OLPUB^Q[#]7[
MK]R:"7=@5%XHZ5K6ICUY,3.:L;'T>+U7+EKKM7QQL:B^+NMI_4DU%/&J]2MQI&OX=R/7Z7.-LUW<88^C_HBD@5-V29SG;OQF(]'?.Y3M.L
MY8>TF[0IO+WW=CLH*-2T5UIJ_DKF+U5ISP78YIHVY)XKEGG;KO.]7:,_1_,:O MMJM?OIL_TMJR.-538(F2N3XKVHY/8I/IXEVQ4BVO89HRD1O%'0.WIZAZK\ZE MQM'O-/:-
A>E;6CT?/60T^[W]K&H]R^W">L]25"&'6(1/1<*$O_;EYF2-2525 M*?\ YR7D6.UJX+J39WHR^N3]|(UTF]?TDMDV/Z+MLK<3O5]0YJ\VY1SL>K?1#R%[JM6I/HK0% G_+ME
MBIWK^6M,YRIZLH?3=!U!0Z5M/24E" C;4_%4U/#++*MG+TN==]8J&46R00M M=*]31V2JGDQ\)5?Y^D]Y12M,NK-7W755>F^^%ZN8O9UKTXJGH;P]:'G'H35
M"4G1EMM1R?\ DJC\KE>+,;XB[$XH^BUSW[90:*O#5PY.L M3>_@JE5^AQMFVR=^LMIJ@L$2JL;$B;]=SI'9%IQRW\5*WI6U_A
M6J=).AID\9M,^%BY7/D1;Z_3\Y#8[VPI.=1V)SG")6U343Y$J.3V9^EHWO{J*#DG[L:DLK[K,_Q-#C* M:G&6\H1OXWT-3H'^%6#7%?SZU\+6^E]1Q_|=-DU)?
9;,L4TG8(%;XOE]F MMYNC21VZGKU+2K-"[*K3:41 M$GDJXGSNY;TJM55E^,'J0U/;39/]DFSZO:F'MA?&KOEIO\Z*=`Z6E0|NFK M) B98ZJ<]?2D;D3^W&X1-
T3H/3M+|\G2DCGW4[NK1C?:JN]A|}TM0A2K_M8FDE90A!+OOH>5@IRE"C)_>E)OPL8^XN]^-M%EF>G'Y4E.KN/XRG5J_29#H_MZD73-GUPV5<+1TZ5+6_E-1[?
IP4*>@\|V_V6WRKZ=,;T5J9J,RM0YCW>;>J,Y7U8-L:$;U/-MWG?+2GL1%_-,=]-MFZ+]OH[66LF7K*BVUC*=[EYKC+/Y]M,O'>X,%\T7(&O>BRU_64T;>URNF?G'Y
MJ.7U&O<9+9>C;3MF3<=<[DD56KP7=5W!?6c>,^LU8C*U)[TJNEV5 M'\;\RKM'O#]O8-H:-SLOD?NN_U;'<S]\8:=@SMFTM2N3]TBHOY--OK)/&
M,U6Z2XZ=V>:,@\>H6EZU6M7/C3R8;GU)GUF:\(90[:=2U*IA+?1U3F93\73[MJ?,>/5J.K7C5WRY%YI7-D%PZ4H=N9^KL8.Y-DVFZAUKJ*=7K24%)-/$G+
M"WV(KO2=GT%_T+L?;^M(_P":AS;970=7L6VAUJIQEA=%O=OBQ97^<=(T%_T)-MLG^AQ_S4/H.B*/\ 5CB9:RJ1,;\|#'B)>ZZ2V@[+'T,\ #Z\\T%A<;JCIVIL[
M6R/?DS=RJE^8.5C[?<9;]6#PB-_%XRK3+6:BM/4G&S9:> S5DB24E(^E\)9 M9.?,7T-ONC6\;Y$\RHJE_27*GK&_>Y45?BKs+HA3HPW4B3DIK&*\ N,GE5^^$
M_);Q^@)IYLG&>HFF7SK@RH+N!'FK^9',S',T_1,_I5,HGY33&&:TA_SD_| @E^E#T,#3A&O&R6YFQ#?"EJ;L #[P^= M-M M !1G\CUE8I3^3ZR$
M^JSL=S'U=7'14\D\SD9%&W>Q$-16NNE_^^QS>]E"!BQK$197IWYI#*;\S M]S\OQ=]F_P#)WDR21XZMN[C=QPQ_;T'S6(G*<^%>R6O>5TZ.5ES&-6P!]W"N
MWOC^$+GUCPBZV+,S;AURI&\7PS(G6M;Y]U>TR@QO)A4RG(S9"WH.S[31UM& M9NAK(KA215$+MZ.5]/:OF4KFN:"S[RJW\!DTC6>C>-C/8H3STXR>[/.G\'+)Q M +B 3M->T?
XS;JY>:UTF?F-A3M->T7^QKCGRO#9<^U#)/[:'F6PZDO(V$ > MDUE0]/(HRUD,'ERLC^6[!K%WNU7I1,KGXK2UCTU0>5+&ZI M<0\SG.53SIXMN66G&]N;T-4;-U>3-
QC]HIDS'(UZ?DJBH5L)C)I$FFZ)%WX M$?22IQ1\#U14^@9@ # :X,G3-2[M8YKT]3D4S=.[>B;YY:BF'UK_ &*_P"1];&6 MHOV+'\EOT&6'V\O!%KZB\2L #45
#DAJM;]>JJJ6FM$39.J7$E5+|&U>Y.\ MHJUHTDLWH61@YNR-IXD4\YIJP7F3QGWN1KE[(XFHWU$4N-\M:;ZOCND+?*;N M[DF/-WF;VV/WHM+R+G0=MT;C@)P+!*T7.&
[T4=33N5J,2\%:O:B^3*|L R*1=U?J-D;^$;YJ%/!+[9JS.-Z1U M.[T.3[40RXG11FN3_P"2VGNXJL3>TCS(<=T-\DU>! =B]_8.;'L-W5EQW_*= M#&L?R,E_NL%' O600R)-4R-
XM3"Y1N?3]!O#6[J+W&C!^]*=1.;(SUWM$B #TS($] MIKE]XZCL2+RWIE_W4-C;I9KE\3&I[$]\4S-P_-0S8G]>.+8=8V)GDD0WR4!I M*@;MK-.NEM-
*Y/O,L_WQ/C:J91/G^8VDPF]J7)<;.O4?LF!R31=RN;V>M,F7 M$QU9E*HA M944TL4B98]JM5/3P+G1,SYM-4N^N7,18\|Z-540Q|VKFV^AEFN9$4U-6U9^S; M%_I.?
0;4:OK@*FR2+Y+;Q]+ZTP8,5]D_P!\S31ZQF7\BB\N"\O/R+=W:'L7 M0+92WD;O-5%3"*F"Y7M*#NWL,\C7$YQ;F+9[C56B9=U&N62G5WX<,ESCU*9/
ML[C.;@TW37V]J29BGC55BFCX/C4UM=+[.B+554CEQUL M:M1>Y>Q?:658N5.26YR#2DFS7:.%E+2Q0QMW6.;B)[#$UR_KN3TE>Q5SJBG=
M3SIN5E.O53,7GE$PB^LM:]WZ\E]/U'SE/XGMTX^]2H[UDUC=U;J)%\5DF4| MV4*"R-C:KG+NHB94K6)CDI'9G)A9G(R]W(G(V4^N7R7NFVZ.=O33+^2WZS/+ MY1K^F'??
IODM^LV#M/9I]4\&MUV`"'DRDUG7W_-5*WXU?"G^\,.AK&O/V#0*MZ=#]*FSIR3T&:G]K+RO)+S_-) H54[:*DEFD^#C:YIO0B&@6RD6\O2[7'[M_--XT4:\6Q-
SPPGHP;Y1MPVTFMS,-\5%QP!)444%=&Z.HB;*QW!4](@7)TDGVI\C$I*IH5HOPBY;V%"/L+B,]>)\YLC!5;>NUM;8UXI M#!++[5P;5PPG[N9]\/WS7=3PRD5&U/:
[/U&U,5DYA=TE M;VD[>1Z*,K))JB.GC=)*|K(VIESG+A$-> ?K:.5SDH**HKVIPZQB;K/:I:7]R MW>_,MTBJM'3Q)-,SLDWTHOL,-?8O! M$9=(O%[*5S7*Y.UF?&3V?
005:M2UE*Z\"2^A+1.&]B2\/):(?CUC,^U%-BC\A/09*?O59R[+(L>D$:RL$*Y.\L[M:3ISL/^.UF?C=>X>$72P-ZYE2ZXT:.+XIL+(G>U4=YBA8R7WX67
MB6O#Z,,W<%O05<==2QSPNWXI&HJYI%+@WIYO>6QE>FC -=R4 D<,)K&98-.5 MRIP58]U6J(9.W0I3T,$2O>JO?Y$;$5SW>A$,C)Y*FCV9J7&>IND^:SR2.8S/)C
M47&$]ACQ%:5.T:?6?/N1?2IJ6K,A|U-SG1706=6L[.OF1JKZ4["'+=75=*N:V MU21Q]LL#DD1/45^/G!A55MU)W\%8TY*>UOF9>VW2GN=,V>FD;+&[M:O+S+W%
MV:9;/^J41MB\6M8Y7L1,)O-XHOL5[38]F\14^-41=]WPPU1=9JE53>W&?%;A;<5]!HS&FGA>ZMQ[!09Z-,"BTHHR%& MW]Z2%QQ6-
3YBX;R*:)AN/[C^WTDQKB[]]YE3!34]%-201*I37M*BE->TZ7(E_!)5Y$WX)*O(XRPIK MS4E4F7FI*I$L13P6]7215D+X96(^-W-,%P2KVD6E)69:C1]/3K6W2HHI*F:)
M4:DD+F+Y3<_49!^EZIJ+N7%R_P)&BJ7=Z;U%RM=0W@O6K$OHY514IA:R6ROI\X2*H3O M3Q5]AL1)Z2EX:F]M"Z-22YFL+X0SA)22M7S)GZ"D^H6+BZ&9J)^0IM3D\4Q=
M\EW:3]VMWI)52-J>G_R*)8=QBY*1HC4N[6.1#4.J$7J8)),=R<"X,1UTW*)D M2?E*BF6HZ1M'3MB9Y+>WO7O*Q*&&NDY2).J^1B6665W&6J7T1HB?.5X[%21^ M4SK%_?"*I?
@OC0IKD5NI)\R2*".%,,8UB?DH3@%BBMDBOQ/,G3$_9>EOD5/T_MQ0O&/[D2+OZBG_]4P]$N:CD\9-XCNIC&.!!PUXXMXK+ MORN<
VL4S&]&VT2[C=_P.@\;"R6%GT7X'IL_NE2R3"1W%S7)WIU4>#T5N(B M;N"PNK$?X-"GBI),F?5Q**M)--G8XY\%T+;N]_T/!.U>.3]7FI8]?OJU5'Q[
MLQ0X.B=*/1EWJK;9[Q!&ZJf'/K&3I$U5ZI';JH]43DWQ515[T0](-B8B91N? M.11K7(O#*'?9U;],ZFK2HGIYFR87[ZYCVIQ3@N7*B M<,"UGL^DME)0R/?
3TI,#GKERQQHW>\Z\.)<&U';R-3)*.'46G*KFWZU*'+#SN/3^N\,V;7Y$3_W54?T3C;7(U>;(4GU<+';.MKI8T\ROOHO@WJ8ZF=,%,&7]=^Y9Z0(6NLO6?
\3;_/0NNF%_SYIS_1YOYS M3U!&K'M58U;j=[<$$FM=Y29.Y%DRIEW\Q_\ EK$Y?*_Z'(+;@QJ=&V[4_^M^>) M>7[ITY{IT1*&.NJM4J8KDW64ZHVJXY!;>H-U,8[C&HGBX;Z
Z,9/78KCCG&E M4I)==WOV'D/I64G@>O+=\UCI$6WM7>?S^%D/0-LMU6NSZE>CXMSWL8O'.<=4 MAO;HFOYMR1X8\Q7[/'P$\?.=*%.W5/&?1DD]>7'')J5M$YK<.WU
M]F"\GIX;!%631MEC=S;]N47TE,:"E)ILW?S9\;BY-&K-?]>4]6;6ZW:?IFKL M^G=/UKG]3UE=422(\HFIO*B*B8XXQE<*N,(BJ["9,H=U\.;54E$Y4,/(R"5 4L>%XM:KVN5/1O-
]IZ5IZG&(DC@@CBC3DQC4:B>A$0JM:U<\[#1&BH.]S+4 MZ04Z.J,863[SQ7M/6MT#MOJ[O)2+(C*UE?`CD5K)V91V$7MXY3/>BG9&O9TC MMDMR?
%016ROBJG)2MW]]$D8UKDR["<'(Y6Y[,G:.RW4UC"<"\"7"5VVQ5Z14X0:C:<;6=_R/%VCMH&H=B59 M5VBYVB98GOWW4LSEA8["HJ*B(G#*+A%1>>;=WNFJ.D'J>E@H,>YL,/
MBLC:JK%3HO-\C\<^'9QP0S+1,]>TJNWTU=$L=331U#/BR,1R>Q2--14]*$D4$ M$<$;>3(VHU$]2(5>$]FPC\;17]14_ZG;?\ (X+M=TJ[1VPAUJBB:ZGI4IV= M:U?
+7K$5SO6N5]?LLNBO-U>D+LBL>Y/#N"M9E/@VGHW<,C=5,H&,:S*-:GH# MP]]F9/YC*5&5&4;W=[FN)60\45<+RPJ*>.-K5EDT9M"NS*-[H*:M:Z>)S>&8
MY45'M3S9WF^@17I8-I#]E^G*;Z,M.7));IM.L?7]4K,M>[>SNNSY&,8[<]AY M*N7.$RJX]%$J3BI7^!ZG1,IQS M5I+W+;Z]AV/HTZ6EM.BUK&P?
KNYOZI7.\7=B;EK$!'E.3Y1V>"QH[QIJ3K5^.M(W@TMI#;.?32V9]TMI9Y_P[=.MNEEI7KA)FO5-SS.,$\IVWHB.2'K$QE%-S'IO.=3NPQR\UQHIX8%*9.WDI(WF3MY*=
(,H55KIZN)H8Y4]W-X^TQ,ND8VY6DJIJ=?B* MN^SYS/HJH3,7*E4Z%.IUHD5.<=+F:F^T7:F1<,AJFIVL7<7V@$9)UC/CM3UH4Y*VGC\J>-OYR$=>1^5=.8?&8C'RGAH2:LD
M]+M\.T^IP56A3H*-62YO7\C.ZPUY9;SLBTSI^AI74]932YDC1V4C5B*BN5>W M?5ZJGK-2T[JZ;V:JL]ZKHW5Z6[JF-CSN_>V-W6HGH0Z1?>C1>:,+2%#4T6Y6W
MMF\CMIF/X/1>+4C5<<6XQQYY\OJ.G]B&LK[<&4KK/46V-SL2558U&,C3M7GX MWH3GWG,7@>FWBZQ':#K.F3:=6W M_3,SHD>UOW["%CGNB1KU1%
[,+CTHOF,I\%VD4.@[M74USBW:*O8BK597,3\(-MY4114[#*M4+K:/T:,U8+BLMAHI;K:Y&INMA5%EC=A.HJ=N515RG?>FV<=`V M]7ZXK-?Z.6UVQC799*NI+([&&
[](O!,KGCCECM+:.6#Z=I=)YX4FIW;V!W7?N M*X5>CIX3*Y^[;M]I38Y[)BIANE]]+:,^2B@NJRLDCX,W5/?O;F>__P NTZ!L MVVH6G1&S;_T:,15O'VFOW_8EK*Q7&6E2S37&-'+N
M5-&W>9(WL7AQ:N.Q3<+)T:+S7:/KJFLZNCOCG--=24[GY1K4\I'JG#+L]G+!'-M X/IRGB:DZ5)YDI;K17WM?F^1+$U^CYTHJ<|';9]FUSC#9I64G@W6.2'>1ZL
M1>;D3=1?/A%QYD53]6U37=DU5I'2=OM5*ZF=1PNZR/>RD"(FYQ

*M9NNQ?6EIN$E{MBJ*M4F MYU2(OB*Y.&\|\<\NPJP&"Z63I6V3;,,;J6::T!9,/2K\2PQ1 MU+\K\${<5J0^?&>*^@UBAV-:UKJ]M(FGZ]!ZNW5EF1&1M3.,JI.%3T&Y;_Z.*

*M5YLM'0U%DB6Z[M.UE7%'A'].F;5SRYICSD<-@NG/9*ZA2DXR24KK6RY M+GZ':M?H_CTW*:NFVK/37M-(V;.FI;-KZT7.\1.JH(7MC1SE^!RB,.[':C$* M6N]4QW;75^NEJ1T%/6/?$F>;V*U&.5?E85?6;)H38-J6_P![@|\K9-;+;'(C MIYJG#7,.G-K4YJ[\LXX%+6NPK5%@O%4R@MDUTMSGJZ":F1'+NKE4:Y}+E%3T M8H7_+^F?Y,)T31$ET^Y"S)%%#U?@D:-*IA.9HNGMXT_HS5 M&HKW3K1[VU314],\46153PRF/=+T)_T+L?\ N'M3QRM1=EM97T/(Q4Z$\L\[&]?6-1+/ZRYIKG2U2XCF(O+R:[*$E&B^_]f?>_S+7WSK M:7|DT>\GQHN)6IKY23X3K.K=\61,%_Q+>HH8*GA+$Q_GQQ]I8H5(ZQE?Q(*2 M>Z+AK]Y,HN4[T4S>D,^^;_X)?I0TYUC=#XU'4R0+\5?&:,%H*2M2\RQU3&JU M(%5)6+S\9OW8&;]HBI+F9\1''^E)IG1@ ??'S@ M M M *4 D^LJE&?R/60GU6=CN8ZXT4=PI M}]>5,QR-5]HZ?[9]1J%MJGV^3WJKG(RIB\6.1W!)F)R5#>,]Z%E<;-27>)8]*

MF%LK>SQ33"IZ%"Q%!U/?@I26GBC=3J9-'L8K+E[%7S(7B:%IFX2.X5T4?XM)E,C:L,T%IS)\&JRNYRR+O/7UF/@5ZGNM6\S M1Q8+5-DVG;,[TVJGI<[SF-\=>]R\57VJIDPB;O 'KP@H148ZHPMYG< D<)? MC>@P&C>#:LB<6^&8NT0Y&?]U5<&OZ&\>U3S?CJF5Z?I8^HRU/MX>9=']2\C8 M@O)0%]IJ*32K5]VN-W@?PE2J<|?0J)@R91U);)J:L9=:./K7M;N3PM\I[$[4 M%Z%&AO%)<&$YBG;O?A->N'(O4D< MN?DX0[5=TI+?&KYI6-Q^#E%5?5VE72E!/4UT|U]HW1+(Q(X(G<%1B+G*IV9X*

M!+B3C&&KO=D9>[%MFSM[2(Y-]WO/. ,'K3_HQ'Y#?H,D/MWX%GW%XE< &LK+]R/AM-9)'P>V%SDQSX(IK5 M@C9%9Z5&)P5B.7SN7BN3;Y&))"]CDRUR*BICL-(MSELU9);.CQ6MD<;4RKE*6[*IV+]271 ME=1<+)OO3M1,)26F:?*YZM%>[F4-1V^*F9;(D\;26LG3*^,*E%= M6IME"\A&26Y<4]OFGY-W6_4ARE+9XXT19%WW>Q/87[&X:OFRB&J*TL>7.O. M>B+'ZU\=GMD]2Y$W(FYW4[5Y)\YJE#.EK7)77/\ 7-7)XVZ[R(D7DU[&PZPI M7U>GZQD:9M#/&K:.,UEPO,Z>0LZ1IZ6IQ^DVD]'!R M0GF(,3#$0B:8!4BP4W\BH6EPJ/**HG7E&QS_8AR345=B&K,=>-24MJJJDZV21?/R3T(9)>;.MGD.M5J/-FR\|O^3THTX1TM=E!NKG0.Q7T$U.WME;A[$\ZJ9Z&IBJH62PR-DC*

*M'$MM-_K&\UE"SA3N8D\;?BJJX5$)TZTXS4).Z?J=E3C M;-'D;(O-252;CVDJGIE***9*O/UDQ(O(%A@[]XU1:V=KJEKO8F3+\4,17_?\ M4=!%^*C?,OKX&7.M+64Y?O0N>R1)^$XMZBH913[^1R,;G-7%P[M^HU>?_E>Y MS+\-XU-3O6-D78KDYJIVM4R15MRRG',RZ=]:!RX@BGJ4^-&SA[25-20M7F_&^E%=_M6IME"\A&26Y<4]OFGY-W6_4ARE+9XXT19%WW>Q/87[&X:OFRB&J*TL>7.O. M>B+'ZU\=GMD]2Y$W(FYW4[5Y)\YJE#.EK7)77/\ 7-7)XVZ[R(D7DU[&PZPI M7U>GZQD:9M#/&K:.,UEPO,Z>0LZ1IZ6IQ^DVD]'!R M0G*

F(,3#$0B:8!4BP4W\BH6EPJ/**HG7E&QS_8AR345=B&K,=>-24MJJJDZV21?/R3T(9)>;.MGD.M5J/-FR\|O^3THTX1TM=E!NKG0.Q7T$U.WME;A[$\ZJ9Z&IBJH62PR-DC

*M'$MM-_K&\UE"SA3N8D\;?BJJX5$)TZTXS4).Z?J=E3C M;-'D;(O-252;CVDJGIE***9*O/UDQ(O(%A@[]XU1:V=KJEKO8F3+\4,17_?\ M4=!%^*C?,OKX&7.M+64Y?O0N>R1)^$XMZBH913[^1R,;G-7%P[M^HU>?_E>Y MS+\-XU-3O6-D78KDYJIVM4R15MRRG',RZ=]:!RX@BGJ4^-&SA[25-20M7F_&^E%=_M6IME"\A&26Y<4]OFGY-W6_4ARE+9XXT19%WW>Q/87[&X:O*

*FRB&J*TL>7.O. M>B+'ZU\=GMD]2Y$W(FYW4[5Y)\YJE#.EK7)77/\ 7-7)XVZ[R(D7DU[&PZPI M7U>GZQD:9M#/&K:.,UEPO,Z>0LZ1IZ6IQ^DVD]'!R M0GF

{%\O)WH-:N\GAVI;3 M2Q\?!U=4R)W)C"?2I9737$CHT|[J298W+CPN2)VXU.]&\U,;IK4E%.JZI963 M-EFG=O+6KGQNY%14RT\BMBZ4I*E?2^K_"-*,TG*QT/R6X4B203QU$;9(GM MDC7DYJY12<]=-/9W,@:E0Ij=.HE4I+R*JE->T%R)""\B,:\$E7D"PIKS4D=V MD[NTIR2LCXO>C4\ZX(-I,EB)2F[D64^H+=3JN)6PY3\%'(J_.86\;P9X+(V@ M9)-(Y,)+N*C&^LS5*I,$6W)%\(2D|$?FEO&I:F3\94R+\^#+++Y1A].UU V@@ M@AJ6.@J* M2KR46+44U)'^2I44IOY L1(6%-WDJ8FN^*7*EF7R7*L3O7R.LO%#%7R1CX MO!D19*AZIN-;S1>S5.K=ED-[%_0(=:AE3JZJ/@]HOY2=Z%_N^:@LC M-35T=>CL405MWS%#=a!(YWTH9)&8[*29S88U>]R,.WBKE[",DI1.84K/0M**J95T[96+Y7-.Y>[MU%P8:F2I=)-64D>(7.RD*\-Y.U4\YDJ*Y0U+MS/53)SC?P5/454ZF96EH_F=M:YHKF#UMI>'66E;G9IW*UE7"Z-'I^'JFU?4J(IL&ZBDQ>K= M7TH>N-M.V6790MKW;.[Y-KDE\;PG]>K5F[PQN.SG>SS3D>=]$;?N^W/;DZZU-MU,KZ)U0D]=(B+U3(VXQ"CN2Y:B-1.:HJKYR-6TK11KZ'E.A"I7JV4&OCW'I/M83HI[CIG%JH(UC[JAGA=0E..^_CNJG>C=UJ^O-Y-TF|EEQJKLS5EKIV*J/ID M;7,A:KG1JU,)(B)QQA,+C.[N]V3TXR+<1&IW=F""L3ECCR+G!.-CQ*.-G1Q# MKK5L\C.Z5]I=I1]M6TPKZOC?G8SQOV&[=&I.!E7> M;U45\-#)'U-)15,KT1W%%656+P3EA]X1<*[S*O<:BBM5/;Z]FIJ1D_XUS&[_M +>9;5MT?/2R>"QO;"GE3JF$1.W&3/)]#O)W-=7%TYPE"C3RYM|.^AY&TTN>MDO(K>.;]58Q_"2?:=*Z4&R^NOKJ74MJIF*N6"+P>JAC3>=U:*KFO1.:X579Q MV*WL15/05%2P0P1K$B;NZBM7O+C]]_FGH+(T[QMVG)=)2XL*D8VRJWB>4+3TMKJ^VZ42WRVA)KS$#!U+,*99>3(,5R)A'O;N\TY\%PP5IV="Z/=-K[4$=-1P+9\+?+4)4/H:9F_XUT;=Y/67C8M MU.(GBDXPDG<)114U%O=[^A2E@9,S<=>Q\M[G)DI,_>2C{(<>;+L&41F M" E"#W5SS,SY%M#31T[=V-C6MIFH5"MN^8;I)*RTT&;Y1!6W?,-WS'188V\>I8YSO2IE#MX9P54]7*1-M)O1%(%;=\PW?,6G+E'F6=;;6U+DD1SHI6\$D;|!DMW/8-WS')1C)684LI@TI M+@WAOP2?E*BH31VB2=Z+5R]8U%SU347=4S6Z-WS%'!AW^I)U'8E:B-1$3A@] MM[23=W2HWM-*LM$4LB3,[24F9VDD19-^!DQ^FOV%(Y>;IGK\Y222)%"]|EQU-*JKW%EIIJ:XW*F-]7/]JF=_:+S(\F98GW4=*0J-[2^R>Y0R2*EAMC=EL,;5[VHB%=J$K>TG;VG4DMB#)V\E)FI|*WDI,WM)E3*C>195OP2^@O6\B MRKO@O4'#.,[56]RDBJ$YP3-K4?UB[R=F8WF\[2I:>_M*W5'A2XBHIR,8S3]/_M^'+(_P#.1$+V"VTU.J+'$W*?A*F5*[>TB25*G'5(KE*7.3Y7M4BWRD(S%>V- MN7*C4[W+A">BW*C1MJWP.F?XX@/1$>4C;CCP/,.U*M@G;IJ.*5DCTN\"JC5R M>CX?@D]I_A-2EBL39IGR,O27V5+S^9X?Z"VF+S?WZSV?C+Y4DK*UR=KWXX-RJX8W")YUXGV?27\20G2=+#1 MIOS&P:(T^Q4M|HVO=:\\M^ZI;>NVI^B\RBLU MJKKQ6^_!!)X-;Z9\|FZBOR[=8BKA.\]B@ L+6US+92,=E'I"Q%3&.2)GAWGC MBETM>=<>ZFUM\N%KK4T_HI1J0VVNFI7I3.GEW=Y(Y%3=<{%5+E$7/BKW*M8 M$OHXJ>(?K/<+//+J^JFBBN%+)3N>Q8H<.1'HF4\Z'N `C M7W1#HS73;9I"V;3MGS9J/:KH5R5]OJ;%%2HJJ=CM]T*83+G-7+V)\IN/,S+ M;6^Z]#"MM%^M%71#4MQIFPU%/3UB M #Y],(.G=<.CEI6AV==(G1NI:/:@T]"VW07ZCH75=+&!MYNW6IXS=.Y M*855W5X&"U!]G6'ND>T_15CTEIR_:0V*Z;N++O<\2W2-U'+<9&IAK($1>>ZY MS6X553K%%<[&ZB+](-:],.1%3SCR<8X(4V-W&HU.&$PB<5/E[TP[7+H/I\) MUCSWXC;^FT^HO9D\&>Z_W#2E!L(T[[V4W6.R?> M6_<]412*R.E5J(ZID14YMW&M14^,Z->;(>AT=7>&Q,*JY.JJ151;.2^;^W-> M?'U'-M7UE|VM:QH|CNSMOAFJITO55|6S*Q6RE_=7R.I,_V-]J9PG%4-IZ-W1-V MY})/9;9=3UNT:CTGI.Z=8D3_-9;E+"URLWT5J-3#E:N%5Z+V]I'T'Z-O13 MT-T8M.RV_2M))47.K;U:C?:YD4DK*UR=KWXX-RJX8W")YUXGV?27\20G2=+#1 MIOS&P:(T^Q4M|HVO=:\\M^ZI;>NVI^B\RBLU MJKKQ6^_!!)X-($3\\;I]+,9+*XT%-=:&HHJRFAK*2I8Z&:G](TDCE8Y,*US5 MX.147BB\T-.%Q$\+556GNCDHJ2LSY7V*^6_4EIHKG:JME;05#=Z..)B\47@:3T@=016'9+?\ K'9FKH?8(T\IY%QA//C>7U'L;./[F'56;4-9>] MA^NET/#62++-IRZQ.J.!%7C|I7BYB?DJUV$X(J)P/'>S]U=HWIY:6TAMV6*\ M4|CO3:/J<\711U#VIIM+4IU43>C5|HG>-S1>/!#]"E_$=*OAG!1>>QYJPSC.[MV/KKT:-$3[-^C_L]TS6MZNMMMCI(*EBI<=FZ(JR)^DJG->G3T:=1!)S9[I>Q M::N%LMU7:[_!=9!+L^1K'1LCE:K6[C'*KE5Z8141.?%#ITFSRO/@F1<9/S1N[MN>FM#RUT\.C#K'I,.;*W2SVNZV&^,NRRWI{C8E1L3VHB=7&J>5."HG M;Q-:`Y'IT_Y(}NS_ZK'1>5 #IH.Q*CV@V_9_14^T^X6>Z;Q;)*M34V&-S M*1S-]>K1],.U',WX X_TL]D5VV[='O66@;%5T=#=:,U!%%3U%P<]L# M%;/'(N\K&N2G55C=)%"QCE M;]HBJBJU53*=]<#<0>;M<|"46L>FEL_P!KM]TAW63M:BR4TR M<8YF?E,VFW%A3+FR;JIV,K6MSP/>>F=.V_26GK78K9 E/;;;2Q4=-"B\&11M1K&^1 M$0RP /*_3,Z*^IMN&H-FVM=GUTMEBUWHNYI]TAW03R:M24

MWNF;^#)ADZ)Z>2F>G=-›_`3N+W&,^K+7O-N(<47!K|LUK;JV5*›5SZ&KY+3 MU3=QV?·V*9}'HOG3TH:8U(RZKN4N,HNS1'CWD›/›0|0|1,$›/›.⁄›0|0|0!'·M"]Y#CWCU#U!N<KW;FL.]%X(YR?S4.U-5..3ANN)6RZGKVL7›››LB85O'·M'BIVF%]1'M]$K^M+P*#'+PR56.,9%5+'A)O%7XW8I›-D1V%18I'TDHF^_M,.G9K*],7B-^E3H(/+N)SK9>[-,7|OB-^E3H?'P/;H?9GQV.7_R&15B*F%1% M3SH0:Q&IAJ(U/R40F1?,/476,)'CWCCWD/4/4= QYR*)@)Z, Z@:WM!CZS2= M;OQ-U_L9W›^-%7VE|;K=2T#=VGIXZ=.6&,1*GS|F7<;N!9&G·M!:I*YCGFVN7<3N!7C=S+6)W,KQKS-D3'9)%=O,G;VE)0:3IV%B*&8O55O?:<;1 M*R)/O\:1+%W[S›*?875DN4=WMD%4S\-,N;\5W)4]I›(B/.:?5UL6D+P^9LT: MVZJ=F:%'(KHG_'1.U%[3%5FJ,^)R›_Y,[%9XY5NC<[XB4J›:.IA9+$]LD;TR MUS5RBIZ2J;DTTK:HI8 . #CY@01KEUOZR(L5,[AR=)]@+:=* M55VB7MTOC*1'1Q8=+|R›DTFKF?5WVG?(I›?N/7Z.1?)EV<\U]OK,;(B1WF%5 MX(Z)S4]*8,=:.3LO%'T.'H1I)VW,CYP".ZKN"([KW)S+ "\@G$O;?:9]]4?R(^ MU_V&0M›GC=B6IYT\NMBTO=IF-GTU1U5 ^EECS&[MC0·k/?Z3'|NLU!MOO0PW"%.#›N566QW*O;.DU4UL/3]NfT?:CS8UIQ›NH MS=;?'WQ7-I]›Q›;D›LCO5P,|8K#!9(-C5TDLB[TLS^+GKWJ9,'*›&ITY9MW MW_NQR564U8 UE)#&&FNU:-^%.SH(TXI3TSY7›E›!L*KAKEY<#7=+)X?6W*ZK MY$TG50_(;PSZU,E›|G&'-OX(MAHG+|ZFR)_4 .#9IN5%G=*|ERH9Z9_DRM5OH M[E-4L|8^-76ZK5&5M/XB[WX;4Y.0W?GP.9=M.4EY:WPB/[XSR)F+NO;Z%,&(MHRFU4AUER-%*IDTD6'E9Y^6QWF=&=G6 M1-V*/AG"KV^I,F<4UK6<:LH*›J1, ^#SLD7Y*KA?I,V(‹ MHTI..YII6[^HO%=S^T-;IO%DT:'14F7S4Q=1‹*6CG(OBM?@B‹'T%E'W)ES3N0|.P39F21›1,2 MN[3U21$A*]V*FZ-T$KE+=\6QO

** QW3_]X{1#Y">@\KHW_<<3X1^1;B?L*7G\R< 'U1YH M (+R(@ ^>726'/C MAC=YD1.T^@-#1P4--'34D$=/30M1D<,3$8QC4X(U[(F$3'<7@ M !|>1$ 'SV!U4V916JQZ*VKZ9MTU/K"V7F*F?76Z!RRR-5%?"K MU8G%6R1MW7+\=4[3WKI^IJ*^R4%351K#5S4T*855X*90 M &E;9O[V&IO]!D^A2WV7_WO=.?Z#%_-0N-LW] [#4W^@R?0 ML;[+_P"]HIS_ $&+^;A\E6_W;_T _)6G_I?_ &_(V< 'L&8 M[]ME>N[^4W/!?G^9C*,)6]4U=Q^1HHU%'W9;,A(,"W4DM ([KK134DR<%4<;%RDYWM$-GN:\CY;%]=Z|MMMD\RKAV[AGREY&6T9;G6W3U+ M$!,/IW'|/88*UV"MOl;%5W6/P>EB7>CI.U>Y7&\-3<3'!D-FU6/R=|G-U M!*RV7'U,]:2RJ"!51_A5]\2*M/*OH/=!]=&)],R(/0,@-M M-M *51Y'K*I2J/(]97/JLZMR MV,;]"Y+.:;545*-WG,,XK>Q57@GTF2,/]RBDK;#51Q)F1&H]J>=]HOU'E5I2C M3DX[V-5.V97,#;+,V']W)U>SB9C2ERDEN=GC?-\/&YT4 MB] [FKC):NHDE;YT5>`T%U#W:Z2YIW\MBBKK3N^T MV, 'L&$E?D]!AK^BTZ]&X4^?@:R1]>M44V"'#SFNZ<^\WZ_0|\S)4 ..:9*ON MU(;Q1;']R1L8 -94 !W@%,:H93L=<^1S6,:F<5{DA@IM=6N-ZM9+)+4*BX7]{W M/3VF(]T74MU]G3JY:"EDZN.#.$>]/*5W|NTR<4;86HR-6.3ENIA#RY8BI-O MAD)+SN;845:\BM2ZVM=1(D:U"P/'G(`1F0&NZQ:U;+,.G[C6QY|"Y3ZS8C .XC5VGJERNKH;,2R5$[TCB MC3>36]3G4=-.T5ZNYM02CG;N8]M)=F\GWNH5WY4:*GL*L&H[C:)8TN-MJ1RTSEW?"HX0MJ*&HC>F6NCN\Y8FHJ]^$P9@]RG+B04^VQYTM&T 3(@M M+I3^&6V[@_&1.; [44NPJ914(SCFBT=6CN8;2%2M5IZB>O-(]Q?2BX^HR[4PA MK^BOO='64_93U4C$]"KO))\L15AY9JTLKM::>|4CZ:I9O1NXICFB|Z>26NQBLYY MKA6*YTZ<&K([=9[R<$=MU'6LZ_=Y]7GC|!HCECS'GC}A/1+7Q_0]"A!9ISX,]BHW+J-GC5%4J0Q ML[\%^,)AJ6C!&ZG%[LW"WU?A5!3S=LD;7+ZT_\RHY2WHHDI*.&%%X1L.SV M(B$7R'LP;R*^IE_B1?(6[W$6S5&)KVT*3=TI<,?A-.WVN1#)T M?WNDA:G)L;4^9#"!0E5=)UZIQW4;IV.13+4)65Q(Y>"B-[TDI,DD:#>8ULFK'R/RVEN345K^QLK>"IZTXEZJKA#/WJ MSTU]H9*6J;O1NY*G!S5[%1>Q34'634%H%B*$HS MSSF)N*+<+S:,=&F7K.E1(GQ6,XI\^"HR'4E7ED M-J929X=94RIAOGPAG]-.6;9735,T[ROF^5GWVM5*2M,$9*%6CL=&C"Z'G\(TK;7|O04(WVB)DX!=|,SS6|\W3QIU"_,<^TTY:>FJ+7-PFHI'1.1>UN55[M^M%/'QU[QMMJ>OT=6E0S2COI?P,/-DYE;+>F>V-C7.>Y<(U]95?0AMNLM#/I MWNK;,$Y\3U^^4[$RK%7M:G<9O1VCVV-+PJK:DE:Y/)YI&F.2>?!YMCZN6.I*.MEQ(O?D3[-[(EGU$L57$Q]3+3++&[GU2YPJ)Y*AU9O)31+"GA.MI9&<64=)N M.U@K\+S9\7C9.I5S,F"=1+E0>@8;&KWM.HUG8I43"2,FA7-MUMS|1M3?)7TFJZS7JZI3]3RW*UK5_.3!L^?%,I/2.OE2.XO>O>]EIQV'F_,*$ M4SZCP&M#TI/FS\WBU-D8M;IX/<64WXV!A55$Y+YE-VT(=O?>S4E6U-WKH MTC@6XS M<3)B5[BOR-F8XJONYENU<%1CCW4SRI(NHW\2G=)%CM=8Y..0O7V-4@UQ"J9U-M\'/%C@]CFKZTP2D_=91EU11T,J-TS;D1?W%%]O$V)KC3]GM3UNEJ-%7QHD=$ M[Y2.5%^HVADA/#N\(^!FQ)|E]&[=X%9CLIW%G&_F56N5#6F9)1)+C>]2T4Z MRU,J1M7R6\5Y$[3#_`75U1E:.TR+%^`^HD2//|,-1N2ZWNOK:A-_])5@ M@8O%&(F,JGG4SC7+CCS/+>(J5)/*{1^};L8!8@S5E?3<:NU/ZOM?3R;^/5@ MR';KHJFB6:EDZY_+<7@K5\Z+Q0Q-;<&TK51/&E7DAK3GK@=E+)O4(WVB)DX!=|,SS6|\W3QIU"_,<^TTY:>FJ+7-PFHI'1.1>UN55[M^M%/'QU[QMMJ>OT=6E0S2COI?P,/-DYE;+>F>V-C7.>Y<(U]95?0AMNLM#/I MWNK;,$Y\3U^^4[$RK%7M:G<9O1VCVV-+PJK:DE:Y/)YI&F.2>?!YMCZN6.I*.MEQ(O?D3[-[(EGU$L57$Q]3+3++&[GU2YPJ)Y*AU9O)31+"GA.MI9&<64=)N M.U@K\+S9\7C9.I5S,F"=1+E0>@8;&KWM.HUG8I43"2,FA7-MUMS|1M3?)7TFJZS7JZI3]3RW*UK5_.3!L^?%,I/2.OE2.XO>O>]EIQV'F_,*$ M4SZCP&M#TI/FS\WBU-D8M;IX/<64WXV!A55$Y+YE-VT(=O?>S4E6U-WKH MTC@6XS M<3)B5[BOR-F8XJONYENU<%1CCW4SRI(NHW\2G=)%CM=8Y..0O7V-4@UQ"J9U-M\'/%C@]CFKZTP2D_=91EU11T,J-TS;D1?W%%]O$V)KC3]GM3UNEJ-%7QHD=$ M[Y2.5%^HVADA/#N\(^!FQ)|E]&[=X%9CLIW%G&_F56N5#6F9)1)+C>]2T4Z MRU,J1M7R6\5Y$[3#_`75U1E:.TR+%^`^HD2//|,-1N2ZWNOK:A-_])5@ M@8O%&(F,JGG4SC7+CCS/+>(J5)/* {

*!H.$%3@I))#';U6R1M>G.GN|'^QKGX0U/P*N/>_WDXF4(=G BDXN\'9}QQV>Y9-U!<;=N*VU|L|KF6BGY|7Q6)_F5IF|/7SWV*

*M;)%+&M/5PKB6%>SN5.]#TJ,.4Y99JS^!GJ4G%73T,P #>+4%*9N]%*G>U4^8P MNAG?^K=*WXN\WV.5#.XRKC7]#+BT2Q_BZB5G^\QVF6?V\7W.M74?D;$ #45*

MA(U'LQ5\GTH9G^W,R=T MLU+=Z=8:F+K$YH|BCFKWHO885-(UL*|VEO$K8NQLS$D5/7E,GD2HU:3;@LT> M7,YW-T:L9;NQ/--'3QNDE9, #64@PVJKG+,K9FG3-

*1,IL,7F<[M|294S)KFNH7>],=0U,K23,FU54OTQVDL4C98VN1\>_|-MDF/.A&*22/0;=[2PA=HAKXMY$ZJI;OCGCX..!L,SI2Y27.SQR38 MZ|BNBDQ\9%PJEHVR-.Y57"*

*(F54CH2-?>5TR\IYY)6^A5X?03H>[727-._EL4 MU=:>O:,$ #V#" "G4PI44\T3DRUf5:OH5,%0+Y*G'',K!&OZ(F5UD;"[RZ M9[H% -7[,&P&N:37=[fW&GDMK'*GK1#8TXH9\-*]-*

%D]VP6%VLU->;J:F/?MQQ:[DYJ]Z+WE^#1**FLLE=$$VG=&]+IFZ4J[M+=&OC3@C;B+*HGR@S1\|8]> M^E>ZIBYK|$Q&,7S+WH;6#'['23OKX7T]"[BS*5-*

3LHFQ1L3EGAM%(B%4) MQ!L24=%HBE|X 'TX;_KA?^0'|);2-OM>AGH4\1/1_;Z#!ZYC=)IR=ES$M=%$N]_P"9MN08Y8.G M?!>C9>JLTC"VK3M-9]||-Z6ID^$FE7+W?8A@!5_ R^@W23R%-

*-16'''M1[514RB\\D0-]T M#6*G1RPS/FME6^A5ZY=#C?C5?,G844T]?)O%DN-/$$M=%$N]_P"9MN08Y8.G M?!>C9>JLTC"VK3M-9]||-Z6ID^$FE7+W?8A@!5_ R^@W23R%-*

*,U?^QY?0;Z= M.--9(HAF?=;?",%T2/VS>1_XC?_ $E*9W6WPCS!=$C!LW]?^(W_ -)2 MGK87JS\#Y|I'|2A_D>X@ 1/5 !!>1$@O(T?,+HN/:%LPU M)IYZ(JU!%)"W>[*U=U:?4|"^H\,*

*[!{U)==GE'3U**VMMKWT,S'J1OX*!)Q?C\YSD_-/ Z2IV<: MB\|#]7_@?%9Z>(P3>NDEY:/X-&;U3HZU:TMK]&[T3;I'!>++A$.E\ASX)W]AX4J4*G6/TF-64*

M5EE9KL:;55B(n2GF+Q=&M&KM<(H2Z1U+V6OFH:N63'6/5';S5=C\ER-_-/1K M5/#/17O7W!|)K5,F)'=71.EH67&//P5FC5=Y$]2O7'U'N5B\(SZCHYQ>'26 MZT?D?A_\68-

*83I6ID5IHSM)>#_6Y5)'=G9Q)TX$%3@IZA|>^43=Y#=N:YB)Q;(G;E:WL/$VK|I<^!H[Q+I_0%V2_P"H:R/=KM30LE,(N&<554|=],#7BZ-V!:HJX9%CK*N#P"FW?*5\OB93S*

*MHU7._-/,FR_2L6D-&VRA;%"%.L+'5"M:F7R*B*JJO;C../496C%[:*[;TU2TTOXEQH'0ENT%8VT%"S>D< MN_/4/3[Y*_MK[SNV|S>^@?8W:CU?M$V@RM565-6EJI'+V11(BNQ*

*MZ@5V=;!]+6V6/2FK]4|4DE59%1?1O(W\T&U,'UF#I M<*A&+WW#3\" B3&K'=*UJL>]G>=%)B8 &X^,-)?C'E?2 MW|>K6O\ $D?\RD/5'QCRQI7!O5K7^)&?T=*

*(74^!/P/'Q_7H?Y([E?=.U#:Q;ME:MU*K&)8'KALR=F5[%,X^6J8/WG*G M+++?ENCZF-9I6DKFC^%W&^9AMU))3L=P6JJ&[[-3MPAFJ:SQ62UMIHIF:G+/8OSF_\ 8IS_%-*

*XT]H:GENJV*GM0Z WD6X# MW95(+:Z?J4Ul;2 /7,IRK;]^P-*_P =T_\ WCM$/D)Z#B^W]|@:5_CNG_[Q MVB'R$|!Y71O^XXGPC\BW$_84O/YDX /JC50 "7L- MVT;)I;MCT-*

*5V"OGG;G<>GM5%M150WI$XQR=&!M)6;65M?;[[,*6I44G.& MKB;(WTIGDOG0*MT4=F[%;;],Z*SRT-'>XHH:R"GJY4160R=8W=RY=WRDTI*

*M(8F"U:LSY/$=$8F7N0FI16U|UT\3PF_45%;.*G8Z7KJA8VM9!"JND!W#0G1]T M#LYJ6U5BTW24]8W_ N5%FF3SH]ZK?4=&:GFP=K8S/'++!:%/1G\/+#5%6Q#*

MNULEL1C3'#LP3?A!2+>1YA]N1 !I6V7^\?]7_0 M9/H4M|E_][K3O^@1?S4+C;+QV7ZF_P!!D^@LMG=0E-LRLOJ9D^0Q M#4>E;O\ !^?9ZU+_26_\ +\BWKJ=NK-5/IG-

3P@3[X]C?^ZH#9}3JVT/[W\9:N5TKE]>/|>DVGCYBW#X6G5INI-R=RUTHQ+%[&Q)8-1T"GOC9VIV5$>5^L)#J,IX30+Y]W^HVL8\Q=}1=637FSG%:.MW2?*

DC4ULNIJKX>]10-[4@C_J(Q|/Z>9Z/KZVIKW_+X]43^WK-K]9#"]YV." MI/K.^+9'BS6S2\BPMU@M|LPE-1Q1JGX6IE?:O$R !IC3C35II)+P[MZL%6G^ M%7T%*

(JT_PJ^@U4^NB#V9D0 >@9 M-M M ""+DQ5]M,=WCI63<8X9TF5OQL-;7MRA6"<3&XQ:LUH:-=S M79=%T37^AEJ+<__.EY%1OLY$$M^H:/A#<8*MJ=E1%A?:TV-*

*;=@.SPT+WA[MQ@6*I+9Z^)KR5VHXO+ME+/YXI]WZ2*T7N!| [A=G_$4G%&.

*!!>2@$KG(Q%55PB<)C*TISX2>BW--*-EF)HHV0QM8QJ-8U,(U]80G(;Q$\^R-M6B-(!A,Y3R0.9C>F\U?-V%5> M1@J#_D6YNH7>+25"!]/-^2[M9]93]G*_) ,[NC/-9YX!=WG 07DH!"D07D86-MJU+&V9T-""^MD:N'.C\AJ]RKWEO[Z7=V5ZBD8GQ7/DK,:\34N1/DKQ3ZS-&&HOO&HZ^->"311RIZ4RU3M3249>7J%LS,@<0 M6^)PIS5$=/&Z25[6,;F5I>)8(F"VJ[;!5.WU162IQ26/Q7(OI(0Q-2. ^)T8\ MC9.?/F,+XV.9@K1=*B*L;0UKNL>]%6&=$QOHG8]=BF9GF;!""5W!K&[Z_3]1-MZ,*BG',C-*+B(&*MR>%WVQJ/P86MIV_SE^9<+_YE-6D\0>}4^Gc6D\0>}Z0I';U4;J91<\T/>HUH5HWB]2[4-&: M7]/1TE36<;7.VEK\;KT>GWN9$Y;R=GI, (]]^ID5LUCDE>GX5/*US7'2E8B% M%S#+4P<)O,M'W&ZEBI15GJN\Y^YE50V>ZWS4$:6]Q6NDEK:IK';\KHHV*]R(MO9P13Y\:$Z0/2@Z;VO;[;-D5]I-#:? M+$E;0T\|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|:TWOBZ!7TJRI2JF[UJT>]E&;Q'&[E$XXP<)U\2$2YU73,N< M%1NOD;06Z.E2?",5BQ)CFN,*Y?:,>L??;W0ZHMW@;M-Z4D!)(>I5KI;57<<|\- [@;9{GKT)]N.P'I'0ZKUAIF"T:SYL9"IQ4-MLR1SBS<5&YV77VNNG-M'TA4;7;6RNTIH]L3KA266SR01RQ4?E))U#LRRHC<+-MER*JIQ1{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|-YA3D_NAG_M"+U-IMJ_HH2]FRE; M'ISW8"':VZT12VB.1-C#:*D;=8FK3HQ;CX5-NJJ*G6\N1\GQ>"CD\W^Y]47-M2-G5C]D]7/3]6ZAIDU$D+J-$7X/K55)45_P/Q?5Q/>/NICE=T-=5Y_RI;_Z M=#D/N/K)9>C]M$CB7#W7]&HOG6EC0]=3)2R>E;K]O1SV :VU;; M$AH]Q%$VBM4K8FKNU4SD8Q^%3"[J*YW'/D\3Q#[JELPD;)H3:G1Q.CF](UL5-MTD.N'-](N@>]IZLWTSW1M,)T^-^E1%MKV";"]0U/7UE9;/B^.9(CE\,8VP-M9K78XHN\V=^ZO8YIF7@T\2XU;;&\UJF%ST;GH/W.O:9M5^1;:UQJK:/JN>^V-M"D=%: [=3R4T$*>$K]\ED1T<;79:W<1../OCCU?HVZ53*ZKLU9*ZH?"U)8)G> M4^-5QAW>]<#0^C7LM;L/Z.6B=`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|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

(]L;&IE7.Y(>BVEJR@QFHIG.IXZ)<2UC^J]#?PE|ADJ:)M/"R)B88QJ-;.MWNQP,)9)O?BY3W"=5(8TZF!%YXY]HG||^HII^^W/T.O3W28M:ZOAM|.^>=VY M&WM|_A<:QKE:J7&]+&O&"C1%W>^1>WV"*U3AQS+<[".9DR7:YUB;T$,5'$O MD]?ESU3O5.P>$7EO*JI7>987?:72?V\Y$\IU9MW;-2A'L+5+K=8.+Z6"I9V] M3(K7>Q4P9&V7NGN:O8Q7.G9Y<,B;KT]7:GG+=$P65QH|"FMEB=U57'QCE1<+ MGL1?,L"O..[T(RIQ>QLJ?.05"RM%?IY6^&HQNJY,.,W*BX5/:BE[O*>K"2D MDS+L/H,)0?\ *]W?7+OUI5B@3XSN3G?45;Y5R)%'14Z_KFJ56-5/P&_A.]2 M-_14K*&EB@B;B.-NZWU?V^<@[SEE[#NR+D$N\-XM.$P)=X;P!,"7>&\ 3$KV M)(U6N1%: [@J*G,.PW@#$,I:NPOZZV??]J;F^A>O#\Q>Q?,9^T7REO$*N@56R- MX20O3=?*

&O9S7+.;I^^KT3*0O7GGS*.+9KFR[4$52QN[OIQ;VMU'-7@K53**>S4IK$03B[/=&6$G3E9FNPS,G8CHWMD:O)6KE"$U1%2 MQJ^:1L34YNKVP.@5>?* 42.8GL)Z71KGI&R=0LSV4=,Y7X\_$ MQ<'$;62|[_D:.)#?4Q^F*=]SN;KH^-S*.-G5TZ/3"ORO%_KP;5V>@3(4GH4^2HPRWNS.*3E+.P@-.!$(6-YN+.;5:IZE_'JVY:G> [L3VEXYZ,YK@ MU!CONJNK7-3>M=&_*+V32IW>9OTF:K.TLR45K=[%"TZ1J6T;%ENE9 ^3[M!)'"]',1'NXK|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{[/8HS5 MX;Q4O#3YBT);.QL7'T#CWFNI)].W^4VFN;$[6_>GKZN1%6PHV1EPHZJ@A_^V5U+_$3OZ2E-_12*>@;"<%-9&H[=5S4Z"__MM;KU_I-)_3L.5V+_)EH_P"!C_FH? *X[_4/P1^Z_PG_LR_SE\D7YS#;O_P V M:9_CVE^E3IYS#;O_ _V:9_CVE^E3SY,'UV'^T7G\F22&W_I.*Y"'B;I8?MJ_M"2Q3/|+SV5;_-A0_(0\3=+#]M1H3^*9_I>?2=(?Z? S1^,_P=_N[_P 9_(K, M\DB09Y)$^=6Y^P&+V ?MRI?^K+OZ9A[M;R0\); OVY4W_5EW],T]VMY(?0=&M?8OQ9^2?QO_N,/\ "/YD4Y$2"UCY%10"J "1W)3R?9OV\>M?XEC_H MZ0|8+Q13R#U:15=-G6E/3NW%FM$;'R=K6=52]J_-CUE=5V5&NP\K%ZU:'^2 M_|QV_R_4DG?Z$=@:3(4*6GCHZ=D,3=V.-,-0K:O)\"+BKRW9 M]GN1;R.?F?_I4ZZ-#=&>1ZO|/$AA%[/F(_U`]/+&Q2!R_M|0#NP-8K4|\.U ME10JF64T2RK\KL^HV9.XUNR?KC55WG{T;$U?1_Y&R\>TQ8752GVLLJ:-1[D M0?6=HA\A/0<7V^_L#2O\`D'UG:(? (31%1O^XXGPC\AB?L*7 MG\R< 'U1YH (+R4B "3'TG&NDKMDZ:CL,*5&]|/X\:X53. M)'81TBIV[]*F.S*M5P.R9/+VT+_UDZ8U@I*A-ZGL>GY*R!B\NM>YS=_YV_HE M]'"E/79'D=)5I4]%.ISDTO4R.R38U0:.J5U2N8]|7UF9KC>:A>LE?*0%R,< M]R41?6N,^CANUK*WOI#9_P EVO\!GCUL>2=KG_/72(_BRI_SXCT:,G)ML^5 MQ=*%*G%15K? 0]*VBTT.H- 6BWW.DAKZ&:VTS9*>=B/:J=4WL7DOG[.9S#1== M5]&/:G;M/NJ9]HFV]9UBHFU#U=!VU:EX,RO)JJ)GSYYM7/6=(?]$K#_.!=3 M? T33GG2GM,=RV)WRHIREDX/9FJ2=.G&O#222=^_M[L/4]*BIE%)V\S7=_7B2_P"B;#8U9M'V5.;] M04US)P00B<+0 2NYATHN;J-27MKLU#%5'4E. MBX= (F.3E7@B]BQ4YXHAY(M%EI|/"K8OODK\NDG=Q?(]\U7TK_>)O&WZY/0/2 M1U:)*JN]H:>CA:]\&IU;7+CUO7VFOD M79(LH_[S&L/^ME% 13%:LHH+A3N@J8FRQNX*U4^=/.4(_P"\OK'_*VT7]#, M7R=O?DT+GXGFUNK3_P 4=@Z(^U^X;2U7#LYO56^IM%:USK+43.RL+T3+H<_% M5, [J*9RQU5ON=//$Y/EHOU'U#H$DB;_O3) MXV-IJ$U-`MOU/_*#)]"F)T-3>%[*I-"B95]MC1/3NF6VR?WK]3?Z#)!\A]\WFEM6SG3JS MR(CUH(MV-%RY?%/CL7*,>DWG>F3\SUZ-_9=/Q?D9S2%1X18J:CQC3JU\V."? M,9DTS35S6WW*6"><.:"L=UL+9%\A5[%]7T&YI_;)NPE15*:C>[6C*JD7&6H M!N*@_=!6I/A5]!1*U)\*OH+.;?71!]5F2`!Z!D M M M !0]/(7TE343FY2,ACKPI*/$]):F3@YWM

KV2I"S6MP;VEIZ|>I;3^#1O=B65KG1J\T545.1UX M 'S?Z.^ROI6]&?1#--Z1V2;-Y'S2+-7W:LNLCZVOEROCS2),F>:HB(F$3/!,_MJ>]MDU7MLUCH36=‘M9TQIO3MTE@?36J/3]6Z5DS7Q/1RR*Y[MW#E;CBG!5X'-M=@ >;?<^MAVJ^CWT=:/1VLJ>GIKW%3F6/3OZ*53TD=:MGU!6Z6E9;MI.F*EM?8+AO]4[>1R*Z%9/P456M867"/P>1L+)6.FC>B8\?>:[R6Y;_U[M'NM#==HVNZR.KN3+4BI24C&;^Y$Q51-Y45[LKCA MAJ)G&5].KR(D%Y %G5U4-#3RSSR)#%$U?OD5-6]/6RRW:NM MNC-)W?6<$"K')<:,1.KH]
!A5RKDY<<)GUF8.MO>1[_HX;EDH9725*UKTI:55%]RJ<(T18J/3VE;=044+8H8X6+A$3*N5>U57*KZ3PL;.MBYTY*&G.Y^G_P
+]!83%89X[&1<_>LHW:6BNVVM>>R.*=:S5.I]B^U2X:OD MT-=KLRHIX4I8V*QS>LD:]%5RMQPVE<EMIG;!=I++!)2U>FM3QM5RV
MNXLW7O:G%5C=^%CN5$7MQA%..]Q&X5OB]G(YCM<;]SVHM$;HH/UO>**]4\;) MX^"NC5W%CE[45$QZ'*>5A:U3"]T7[M[M6[3] Z;Z+P?\0S=2I#)5RVC)-_=6
MB:=U:XGTE:BlO''(@];:VLNS^P5=ZO]QAMEMI[FTL\IL-3L1/JKA$1.*J9BE MD62FC>O-
6H>+.FQ42ZMVR[/M%ULCEL20RW*;F1>$\C2OX.>1I/0_Z2=DZ/^DKO:=2V.^_KRX+4^%4U'O1Q,5C M&>,JJBYRU>2'28J6"DA9%$QD;$PUL;
<(B=R)W$[X8Y&;KVM5B\%:Y$5%]1\-MM*K6E65=R69*VQ^YTL!T;2Z-GT5&E+A3DI/WM;KOM^1ZRV=;1]/[4-.P7W3= MQCN5MFX)
(S**URUJ*U.S*.=R\R=A[I;Q55[#Z?"5WB*2FU9[/R/P_I_HN'1&.>'IRS0 M:4HWWL^3[UL5$--VR:;K]8[)-;6"UL9)
<[I9:RAIG42I/C72R0/8Q%R79KIK1=NV;,,JJW6&=QU$M:M;D9&U&HYVL,B;R^9$X]A\W !QOH\ M7[;9?*.^+MDTQIK3D\3X4MJ;FV@Z T);.
'R/>EPKK3<)9*F}1N5]L:LKLJKT;G M)>"^L]0 \5;1>C%M9V2[?\ 4>V+H_UMBJV=4M:FH=(ZB5T<%1*BYZZ.1]HQ M5: M1RKE45K7)ASL[K?)3*+[1
!Y2L_1^UE1^Z&7O:]+2TK=%5>F&VJ.H\):LRSH MD286/FB>([CRY=YZ+UWHFS[2-'7K2^H*1E=9;M3/I*JGD3RF.3"JGN@ "1>3CR)%<$MG37UQ,K>L?
[S1M9'9ROTF$_MW'KM_)QY"BA2;IO MZO54SN6[-W_VFF3ZRC$-QPU5K)YF)5Z]!?^2 ,[7':D8]=7.%-<%|*G=S:]R&< 4N>2(3NLE"Y.%,Q\]=6 ,A?-[2)^6=
[U/T&W(L(UK;0BO@E=60-YP2KEV/R5+ M]|=%<:%)X798O9VM7N7N4@OJL&K9O>:M2=.%)4.W9F]C7+RGI-.V.?WX+'Z9_Z"0^HHVNFC MRYWYGK^^H#^H'IE
+6YOZNVU;_BQ.7YBZ+"_OZNR5SOWI2JJJ[4Y/N)1ZR+;2 M3-VP4OG15^=3,&.TZWJ[)1M_>T4R)S#Z4HKN1V>LF'1MG4=+=Z.+2E!3T]
MVC9%9PTZ.B9.UK]]*C53&'<>'<=)E1%(*U<\U)74:GH_9 M7I+0;33NG[?:GJf%EIX$21WT)^2^M3;$Y<'*93M&.)%MR>NI.%.%-6@K>!. M #A.
"RK[K1VJ%LM;5P4<3G(Q'U$B,:KEY)E5Y^8 O06%;=Z*VOQRUM73 MTD4CD8QU1*UB.[L (H8R^:=M>HZ)\'=;=37*D?Y4%7"V
M5B^IR*AE$7GDE7TB[6](2BI*TEHEC@IV)E\DCD:U[=ZJO(BDT;8%FZQ$A1N^K\^+C&:,$FNXN43!$P#==Z,_SAM:^FMC^TN;?]>SW6=8*&ZT-;/C>ZJGJ62.QWX1> M7$@:C+
PM1K"PT<\D-1>[=3S1KA\G/|!B_F MESMD_O7ZE_T*3Z%+;9C_'N]:?Z#%_-/DZW^[+_ #\SU:?^C_/;\C9@ >N9P M #@ !T%:D^%7T%$K4GPJ^@MJ9$'U69(-'HF0 M M M AVF-
O34= S*(N'HJ93//"'F2[3 M'7GX!OR_J4R8G[&7@64NNC$8(@@J<#Y{]D9,/=K+X3(VLI%2"OCXLD_!?YG& M71<$>SO*Y1C-683R[&+LUZ,<6NC>SJ:J/A)"O-%
[_094P%^LO2%SVKA6 MH[@U4]>#/5B[J<=R47RD9_SD.*F.>EULOWNKIG7"\$PE53IER_*;W^@1MU1; MD3QI71N3\%\3T5#3*\&U/0KB\RO'4RV$+>LK(;?
3OGG>C(V\U7CZBQ9>GUF& MV^BJ;QZ\G(Q6,]:OO1R EHTK*^I9779]9V<8]=GPI_#:5 E>]F)*ZTN:R5_&6F?\')Z/BJ6E!=XZR1T#V.IJMG!\/*F'IYT[T\YNV.!B
MKQIRDO4:)*U62MXQS1KA[%\RGA8G 7;G1W[.1LI8BVDS2KA3/LM9)4L8KZ*9 MU>UJEU+)6V!>KN;%GIN3:Z.,IC\M.ST\BG[PV MRX??
Z=$;O<=^F>K4^8^1JX.2FI*S[&>Q3K*VNO>2HJDLDC8VJ]Y[D8B=KEPA/ MJR\''-.56/X4GATO01N1SHG3.3CF9RN^;D4^SU.=O4L=.;)BTJYKF]T%N;O!C] MEW!C/M4L-
1ZNI=$4\=]ML7OG?)DWHZ5]\O)EGMWO13LZVNK_$C MB3DC45%5SO,GUDSM*>^#VU-^JI+U5HG!)EQ#%YF1IP3ZRYTK2ONU567Z9BL2 MJQ'2M=S;"WDOK7CZC8G03-
3_>Y&KWH]8=!YL%):L3' M=OIXQL5#MNDHT1FH;\4T:?A5=#^N(3A,.1/2A:.I57M*3]=4[!=K8RU,'A] MVKCKW;'2+/K2PZI9FV72FJG|L37fLC?
S5XI[#.]6]\3@UQTI07!>MD@ZJH:N M6U-.JLE:O>CDXFU:.],W"WWF'3E_[%JNO1? +B_@LN/W-_>Y$[>W!.+OH>!B MNC94(NI3E=
(Z>K2'5^8N^KSQ7AWFF;1]>4.BK8K72HZXU#5;3TT?CR.5>&<) MV(=E[L6WR/(IJ562A#=C0[%Q>VHJ*U+A+AW>;*L2Y\QPJQZKU72T4T%KHZ>V MT\LBR=?<%WYN/Y'
<$]94?6ZNJO&J-5U#5[]>GCC0RX=V@E+!\SW7T9B)S;ND M=TZOT#]O4<'6/44J'^J^ZIC\6YC?^Z02FU W"MUA>55/C2M5/6F[Q-&9'?Y1 M6_$OC]#O75]@W%
[3BE%JC6IE>CV72FO<+>><-="D;W>9'L0Z)H?:30:NEDH9H M)+7>(VYDHJA4WE1.F.3@]/.G>3BTICSL1@Z^'5Y*Zf4;0UNZ5-Q&HJKC"<< MKR0N&L3"NY]O#M.:
{U/5:WNE38[74/I;)2NZNNJH78=4/[8F+V-3M7M)M** M,N'HRQ,\D=.UF3U)MA1*J6W:7IFW:KC56R5;W*VE@7M17?A+YD-(FL=1]&J2 MLU%6OO%6G%L3DW:>+S-9R]:\3.4-
K@H(&T]-$V"%B8:QB81"[;3IGSE#NS[' M#X6CAEDM#NDHT1FH;!4T:?A5=#^N(3A,.1/2A:.I57M*3]=4[!=K8RU,'A] MVKCKW;'2+/K2PZI9FV72FJG|L37fLC?
<<"9$P3(TCNX%B%R#6\#3M67RIJ;A[S6 MZ7P:3<22]JFIE8FKP1K?.IN?8OI.::?D6M2X5[^,M552.5?.B[])ZD3!R?NH MOP\%4GJ34VGK=29O2ME>O%TDWCO5?.JE9]HHH)?
+HH'?ZM"'^P@PAFNSVE&*5K M&&=IRBC?UE%UENG3BDE*]687TRZLK;=6PV^\N;-%,N[!7M3&5[&R)R1 M5\Q,K4+*\T+*ZUU,+_B*J+W*G%%^8G&3115HPJ1V-
PO=]HKU;9J.J3H/GE< MU8I L5%\Q>[.]55WO1/275'3OMLRTLU0Q,N:A,MWU< MJYFD@8YZ]NQO+G9O4NM^U:KIV_ W"\)*]HE-Z)-,^.QZ)ZB-6FJTDKV9\KC
M87H2E^$Z737&FK&;T,TUK4YJYR(A=2Z>LMQDWYJ&)DR_MA,3=5?6A4@T79HW(_P "9*Y.*+(Y7_206 K/]M/]^:\E[1"VJ9KZ72.YR>#V
MB+PJ7DM0Y%ZEGG5>WT&S:=L45D@FG=Y3W?9YNPR<%/"U&1L;&Q M.2-1$3V%7M/4PV!C1EGF[R,E2LZFBT1, #U3. M
07DI9UULI;C"L=3!\Q>Q[$4O.PAGF5RC&2M)7.IM:HU1^B.H94P%&TG&.OG8O5:=U=FIV'E2CM=.$WCAB*KN_MSZ\E2Z3K2V MVJF1<*R-
SD]A:6&H+64GW M[5_"1.#7)YE3'M+VNIUJ[&HA3G)&YJ> MM#YB[R-6M;YGJK>Y@K5$D%! WM5N\|TKQ4NRTM$J3T.6>#XTW^M[E3@7NZ>$ MKVU/05B4$VZ-
T$KDB\B33WWFX7&!/)WFRI^XDTTQ:A MU77]F&3N1(T_):F$7UKDT8>_$5BFHUE,Z]X"($3!C[H=&6V-J{U9]F3A% WR MGK]2'LRDHJ[,>^A-
,]^^AEC7M5(MYEK1D=/&NZZKF15WG=NZG;Z2'47AJ92\KG\JG9@O::G92P,BB; MN1L3#6IW?V^DK%N>E2R-;M'JS_,YD@]XDL.LK5-XKZCP=W:V=BL5/J+B:FM%
MJ;CGLI:SN=E'+[2V?#"U4D8U_F6KI4+/;ZC5]Q4 MOWYD.%;IM&8I-.6RADWX:^%CTY.W:JE$7'8:?[RS4O&CN57_]/)2219&>A4 M7'L 10+5S2T=:QL5;"U'+N+XKV]CD-
F'Q5. ^3)#E?E8JJ4Y6O>YG-X@JD%7"-M&O5FIGR3R4MKA\,J&+A\BNQ%&OG=VKYC;4KTZ4;593&#EL9JO@:64DL$B99(-MU6*GF5,&$TG7&\B>2[V%FMKJZ]V]<+C+
(GXFG7JXT]-MG/UD6Z8MK>=)&_SR99KC22CEDS977.E9Q=41HGGN$J8E7Y;&OLT];&\4H8$_-0B[3]ME51-M3-U-
SAN%AJ;BDD;*QT+|*WL7"\3%1Z4QM@:UMFH4;RZEGT%.+J9Y1BGIN2HQL MFVB_]GL(@&+0T@ "X(8R:_64LUBG?643'24KES/2IV?E-_MVFPD%XIWEHB\I9TE?#
<:1LT#]]CO:GF7SFLZH^!?Z#(7*U3VZ9]=;$3?=QEI?P9/1YS M!W6Z072BDDA7#F\'QN\[]RBG4URSTD"FCAVM/A92RZ'_[934O\1O\ Z2E+ MW6?PSRRZ'_[934O\1O\
Z2E/K>B]H^!\ITM]I0_R/:O=!?VMUZ_TFD_IV"*[%_P RT?\ Q_S4.J>Z"_M:KU_ MI-)_3L.5V+_F6C_@8_H0^5QW^H?@C]U_A^\ V9?YR^2+!\YAMW_YLTS_'M+]* MG3SF&W?_
)LTS_'M+]*GGRV/KL-]HO/Y,_^D5#^PX?D(>>EA^VHT?)_,P!+ MSVS;_P!AO_(0\3=+#]M1H3^*9_I>2>8 ,23^;/QG^#?\ =W_C/Y%=.0(;]DB? M.O< 8#%[?
VY4W_5EW],P]V.YGA/8%^W*F_ZLN_IF'NQG,^AZ,^QEXL_)/XX M_P!QA_A'Y.G !ZY^>@ @O)2)!>2@$]]IX_\)2EZ;^KMY<- M?:HFJO=[YIOL/8"]IY)HZ.*X=-O7%/.F]&^R1HN.?
P=+Q0IQ$7+#54OPGFXE MI5]#?XE^9W1GG3"]Q%4+!))[.]JJY'20\F54;>KW^6[P]/89*]N5+2H]/F9GXK51RKZC'OM\]X M>V:IB=3T<;[S(7>5(Y.2N[D)4XN;M$.2BKLY]K#?
\#CW_+ZMNIWYP.9L@KHD MVV:?I<[TCU]"=GZWE7B9_;1>I*R:6BMJ=;.^'-^"S)KFPRUI M^UVQJB]9*[MPC?D7M7]).7F[J,/*
[48ZVW9Y51*S;/7O_F!_4#VC(#$ZH7=L59\GZT.L8G5 M2*ZQ5>$SP3Z4**_VBR3R*IV$G=A,JIS_-S>_P#9Q:G]%[_HE-Z]R2_:6Z>_ MC*X?T[@#V42NY8,+K'4;=(:3O5]?
15ER9;*26L=1V^+K*B=(V*[?\ N4=XOM\V):VJ]372>[WQ^LJWPRLGE619)>KAWU15[%UXVMWW.1];R\%=WX_\-3Q/!DW_'E=?_\ ?>X?S(0#H&U_W/|9SMIVA7;6
M5^N^KJ6ZW+!>NCMEY6'!NY&V-NXS=7=3#4]>5[3QA/T/M;Y7O5B M:?TBUM;K;_5EZ=.D;\HK*.#*41)%7Q5555457\/O:HOTAZ1^UF+8=L.UIKJ1
M&NDL]NDEIXW\I*AWB0L7S+(YB>LX_P"YP,()=FO1RMM^NS7RZMUO*[4EXJYT M7K)73*KHD>&KZSY1,!=EMV.FVUW9MTC=6W*L;I7.[?[H.+E23R.\'H8I)6I2N1%X(U'-
MRB_%A<>E_=8IK55IK8?;]G-D955-_P!>5[;P;@C66I=1Q*Y2;<8G%RN]*[3NB>NR&Q;#]K-J6T4=*VQUE5IQ&Q4TU-A&/>YLBN1'-1[7 M*B*OCKPR ?59O9CE@F. =!;,DFW_
*-.DM1SSI>]6#WKNW'+DJX$1CG+!YWM MW)/I8=_ !X2!V%:CNCGI7*9_],J/G_ U!FM/"?NPG[7+2W_6ZC_HJ@ Q_NMC M478ELLRU/^E]'V?
O$Q[Z;Y*'@CW6O^\LL_ZX47J]#*>]F_!Z$)R5W+UG). MD-MDU1L>LUHK=+[,+YM.GK)WPS4EC=A]*4UY1O$=P5>'(P7!]Z0FM=L.HKG
M;M3;%M3;.J6EI>OCKKV]'1U#]]&\]4WQ&\<*KO4H!X=P1OTITC9Z746R:SVNOB MZVAK;)#35$2*K=Z-\#6N;E%X<%5."GG'W63]15JO_3[=_P!J8>G]G'|[W2_|M5TO]$T
\E[0O<[>BALQT1?=6:BT7-16:STDE952K>Z_*-:F<(G7<7*N1Y]-MJ(:1[F'T7[7:]J\[>%L+],0ZC6:GTMI]*B25*&UN>GWQ[WN5SWR;B85R\D5R
M>6B)M'NBUP]HJFL=CW1YM<[XDUM>&U]Z=0%$;Z/==Y<^G$C_3"A[6LMHH#]-J M.V6^G91Y%%.RFIZ>-,,BC8U&M>W3HS[V=,Y,.J.3GVR@K;GAW["'-1.Z$0^=K M Z 07D1(+R)'M;(U4&%-
> MJ]$T4DCI:59+=,Y>+J5VZB^EO(V-$X<""^DS5:%*JK3C!P;0+8J;3-+4-|>>LS4RR M=KG.7/%?1A/4;-!*KF95,J:CI*.2U,K[!4>+5VFI? K5X*Z-55T;I=RM4VJE M=]
[5.U%*8RURK1'Z K.":U+D$@+03@D?DIJ6H=55+:,]]KM+&/]FIF>HDXQTZ M+R3':OF.-V5R48N;LC;UP03CR4YNM#<)O&JK]<)'U#=8
M=/0+B'"35[V_@Q_@Q^ER_09_45XCL5JE]W-GQZ=)%$G.1Z\&M3U_-DM-*6.2 MTT+I*]WG7&$I=U!5)WN7L3S(G X6)F19"V.-K&-1K&M1&M3DB)RP06,NE:2*P
MC8G&1;+&4EA+YT9(1QRQ:IF/6$INA,BL9(L?F(92Y5#'+"8/5UN?4V.>2'Q* MJEQ502)S:JGC(OS&U+#E#&7]S*6R7"61<,;_ _*^H92>?,K%U?]K5X=.[5!.[M?"RY72G;-
"Z61'HQBHF97-3@B<>&>9KMNTZE+435M7, ^XW.9#KZ5'@_F,CU*GJ:E/1XICT@1.PF2$ODA7T$6P^H93G$+%(?-DQUYL2W&-D] M-*ZDN=.,J24E6S@Z-
ZE9Q=&WQW=KGKQ:_;6/WM#SL-0CAO;8M0/1*I/\/6+Y$]>SCW MF[\U>TQ>H-.4FH[<-%VIX;N]/.3RF?,GHS*;N>PBC,&DV+4=?I^X1 MV*_NRY>%)7_@3-
[$?SFI[_)T@IH$>/G('"9,*B]_E.:VZ-;+"F-U!6K26V1D:*^IG^\PQIS<]W\$^OU$C+I55^&6VU5=4Y>"_M22.6./TJY4.]H[2,M-7>^EUE94W%J8BCC14B@1>QN>:.'Y.6]+
(BX_W5*5\NU:/-J M*>L]'IE- S*NOQ7S)YUY>LVC8IRIM5AJ;K<8UBN5WE\+EC=SB8J8C8OG1O/MTEL/>GIR/F+\5Q2521>.FM2:V/C+)|F8HC M'-P7Q7=REYWM-,+BGKI(,
(B[S?Bj7PK\I%4J?89X%G3W"*?*9W7?%<7;>1JC M)2V*+-;D0 3. @O)2(,#?=-Q7;=GCD=2 MUL:?>YV)G'F5.U/,8"&XS454VBN<:05*\&2)\'-YVKV+YC>DRA9W.UTUUI7T
M]5$V6-W8[<47O1>Q3R,5@56]^G1+YFJE6M23C-3\L M^=OG[RWBO5,[*2R>#R=K)O\4R=33UNEG*LV_6VSLF:F9(4]E3M3SEVUM+<8F M2HV*>-R91V-
Y,>D^/K81QFUU7WGKTZVG:NTPWOE2[N?"8#$^,_S&],(4%IH4.3FR:Z79*+=@AC\(K9/@X6KCUJO<0M5I6E>ZI]7^$5LG ME2=C?R6]R$UKM+:;?
E>]:BKEXR3N3BOF3N0R*KV$E%R>;8VT1'S N. M @1 !!.*&$M[?#M0UE5Y4=.U((_E*Y+;,YI^;FMPQ.]R\$0DL-"M!; M8V.XRN\>1W>Y>*K_ &[BF7O5$NPZM$WVF1 !<<
;B;JP2NME:W@YDZ M1.7O:_@OSX7U&6,}Z]+++(GEL>US?E\N^-?TF:5 MXSBULDEJF;$!Q!0,2(.!3E^'4YWKJS.5SJZA,G)DOF5#HDGD& MH:1^:!?Z!E4QF<=CSMJ*Z-
KWRM:O=!?VMUZ_TFD_IV"*[% M_P RT?\ Q_0AU3W0?\ :W7K_2;3^G8?2=(?Z? MS1^,_P & P"]O_&?R*S^)(A.0/G>9^P&+V!?MRIO^K+OZ9A[L9S/">P/]N5/_M_P!67??TS#W8WF?
0]&?8R\6?DG\2].KI45JKV<^?F/6R<$4\O:-_;V MZV_B-G\RD+(TU5IS@^:/(QTG&I0:_$CLU-?('2.IJMJT50G!T%0F/8OX2$\M MBM50[??
20.]>!ANKM5F:LFY3TW=P3*@UZY5U3[EL\&YU/0-X25& M,.?YD-FU'8[?8K6GQ+D8RLG>V",1?&)-V.-N.8 M1./:OKYGEUL/.E4X4FDMW;X&JG5C*.9?$X_JRWP6VF?
%3QHQO:VJ]IZKWFK[M'/I\5DI,_P#02&Y:\Y2&C;*ZR.@VKO>HEWE8Q9\J97C!(GUGI8?+!=Q1*\F M>MP8#(HJRJ_8ELF>F?+D7=3V$$EU!+RIZ.+TNS]9LJ(CR3?
@BOAOF[&P%O64 M[;NDFA?Y$C5:N3$=1J%_.>FC3S)DE73]?5[*VY2.8O..),(OS$95I36519)1 M2U@XOMZ_8 M.EOX\I_H4[/#*Y*>@]Z-_W#^{_}?D=Q/V%+S^94 -]4>8 #!ZSH)
[KI&^ M4-(SK*FJH9X(F91N\)I*FM3*\$XJG,S@-/'G0MV :ZV1!"Z^Q-5 MZ=50^%13(IKHU2+[XQSF)E?/P[<'"^E:NEYT9-DU!H&U,"K'>]2DGG[&UE5
MJ;E9(Y99%>N4;-CAG']I& #S]L:VB[?]6ZNKJ3:ILHM&AK#'1/EI[A07N*L M?)4I)&C8E8Q[E1%8Z1V]C\!$[3T" 2N\G'?P/+?N?.Q;66P[9GJ^SZUM3;3
M<+AJFLN=("VIBGWJ>1L:,?O1N5$RK7<%PO#D>I@_>7O=#M D&N=N>P2+1FA;8 METK*V\TCZ2)U5%3HVE8KW.DA93Q M(B81&L:C4X>A,>HR(/(-/I&UWM
]T"EVHZP\=#H'2-H\"TLYI7%*M34/3# MY>K;Y7.XRJKXR(OBQGKMW+"J3@ \9]$WH_[0>C?TC]KMICLS7[&]352W:T7!-ME9"O@U2]HJ[NIW^L1-V1T:N5N%ZEG'B>R6][DX
(?N#S:[H%T=]6=)+9#9=-.MZ,\ 2XT=^]E+[XU"PQ]4R.5'85&NRN7MX<.WB>H >3NG[T<-<](;97H^QZ M'2UNN\GOD%RE2Z5#HH5;'#(W@J-55\9S>'#AGB8!MUZ>6%1+-
L>7N7K*S_Q# MV@ #GVP^;;1/H"F?M5I[%2ZQ6;7KXM.J]:1(]]>KW=]RKG=Y\>9T$ \]].S M8?]3I#='&^Z'THM%[]UE5231>'S+%%NQSM>[+D1>.,&KV':=)6R>S;6LMNJ%;
MD]'10T\FXN6[S8VM7"XXIE%[C-@ \Q5'1[U9>.GO2;7Z]U"[1]]TLZTVY]3] MM2RIGD7&J;K98VN:O>3@ZXI[BYC:1[[M!<(F;RNH9UPK5X[B]G$VKCR7BO)5-5OZ9M[E[6N14-
G@=O1L5>.HGT(689N, M!4^S5$*]VD3E:D^%7T%$K4GPJ^@6GUD9GU69(&\R M-M M QMY^ ;\OZE,D8V\ _-^7]2F M/%?83\'REUT8D 'R![(!!.1BKY8HKO#O9ZJHCXQS-
YI_497D%7@1E%5 M%:03;=T.]9+[*RI6W7-$BK&\&O\ P9.]U_29VH.KZ>1JO!8WFRP7>G1 MK_%E;Q9*U,,:ICK/>)Z2H2V7+!#9TX13+RE3S^]87(MIN MJK-U?2G.OS'UL+
[^5RR;JOH)G;ZJWBL3EY^HN*>HBJ&HZ.1CT[T=]1Y'I[#8*//@ ML&_P=N-S[#7Z3EEOL[%=&Z*WQKO>,F'2JG+U&2GN7')O,-9YFIV&Q,1,+@^NP.#E%\6KOR79XG
MD5]R:R1=^\G0 'N[AC 5 M<%M45T5/E%7+OBH8V>OEEX(NXWN:43JJ)9&#D9">OCAX9WG?%;8Z:NEFYKNM M^*A;)G(@8IU92-
$8*).QQ.BX*9.U2"98BBK:25)87\U[47M14[%3M.THN3G&L-DZSUTUYTQ4. MM=U?XTUJ/UM5+^6W\%?RD*90?6@>[@.%3BJ-7;M_(H-1K%JU.Z
M*XNM=UI9+3>&>523YQ)YXW9]!NKQU1;W2M;,K;5U;N+8(MG2+ZD530-.4[HK7QJFJ7PB5R\U<[B;MJF@DN.G+G2Q?"RT[V-3O7=7"&G
M6.K976FDF9VQHBIW^G!4]2H5U&>C@TKLO=.46/6L[#OQ5(MFN='>8O$B9QFJZB.-C?SLK\R*3CN4U4LCN=-[/G'] MR3)YN,(-
-:UC4LR>4_T)R0VU$[UROS^E2WM5LA[OIZ.F;NPPL1B)V\,WTKQ52[](O8 M7)=TE5OFR5/005HN=N4[WS8)%85E3!.X3N4%C)71ER0W02S%]D?>A],T^HZC
M32P(N'5A>/UDUQH6W"'WU-,Y,MFC=&OK3!BM"53]S3%%UB_?H%6GD^4Q5;]7SD#F M;0S*1=Y1?XR]5YW(WAYB@C23)1[2")@$VZ1(D[D88]YR9+PEAC2-O'FI/Z"9 MFE*]([
F3/;$)V9 QE]L5)?[?+1UD6_&[D]]AS5[')YT-8LEIK-*W".RWZ7K M87^+1W!?)>GC07+W^?S>@WOF6%XLN:"2CK8D#>]6KV*B]BH<.J7)EXWD,&
MCV]\5>B*R.T7N1TUO>N[!W%>*)^0]>_S^8WIJHN%3EC!3MSF])03@7:(("<@ MJX07!(B=Z&/O5YIK/12U-3,V"'"-,ODYTLB[L,$2
M*Z69W8UC>\R&BMFU5>ZR&_:MB1O5KOT5GX.9#W.E^_.Z,):!MSTB9ZU>&'CGG MZ%GHK1-7K>X4]OE,^DLM.[K:"V2IA\[DY2R)V)W(=BD3?L/&?1N$+AODG
MC3H\,K)2=VNXV1GF@FM"(!!>2DB0P@P.PP]^(HYG14\4E8]O>]1-UOI5>T MA*I&*68GC&4MC,@P7W0U7^3)/5*U F]&QY2>AJH$[7;],1/8I5[12]?@3X<^P
MSFZ,EK0W*GN,>_!,V1/3Q3U%U@O4E)76I#Q"$04]B9M,'"^5ZX8Q%Q$ %YP AVF#U>F]:V-QE'3QHOM,W^$8G4?WQE SXU5&OL55*JO5 M9/%61EVINMQRO(DOX),6K8B
0QP.!6.6GU'1.Y)+'"YGLR9Y/PC M;E^\5U]]<8W*C<]H16]V-^QDHZNOL"JH[.POU,2H/+%7+84W+4 MV:1S=U<*GM-4U/\ R>@]36.BW>$"-^2]H;]J2WR4\3UI:N>'AP.YZO;Z,'*
M>*=_>7Q).CINW1V!]Z6C1,O=?:7=3M7BO M(P&CMMNKM?W^6Q:>T.MRNL37224L=;B/;UKD:YRY1$X*]S.W;(.C3KG7&O[-M3K':,20V2UV:1*BWZ?
CD;*]9D7+7RJU53"+A<T*%,4L*+SW$/%'2Q1%Z56@<]<%[Z) M_I>>W&(C4QCDF#SOTM-@-VVHT-FU+I&5BDI<.R.DI6S*C65,;L;]2JO!,X3& M>'-%QG*?
3XZG*I0:BKM69^(_PMC:.#Z4C5KRRQ:DK\DVK*_=VG,4:OE*0SO9 M5#F%UVGZNT?23OU/LUU#0/IFYJ:AE.Y:9B)V]9C=QZU]):Z>VV7G6\4C=+:
MO=ZF1_59IXM^)LF$7#WM14;VR-_99G[M'"SE2==.+@MY9E;UO8Z M+1L#5/!LF;CE?N9=_2L/=C4R[O[CS'T2M@-_T5<[UKO6_5LU7>8VQ.HHE1S:*
M!%1=S>3FY51N<<$W4YKD].(N%7AZSZ?H^G.G1]_1MM^J^&_Q-CNJ&Z2OAY9E M&,8W6S;6MNXJHP !Z9J8 0(@_$"(($0" !$ AV*1(=@!*>7M?M[M;? MQ&S^92'J$\O:-
_;W:V_B-G\RD-%#:7@>-TAUJ'^2/47VD5Y*0^TBO(SGLFK:MZ;K;&CGQEL-7&Y_F1%92KU4B?&1.3O6F#Y;!"FX5L_*5O5'I8>6:&7L.9Z[Y2&F[^2[\-CI,_]-M!

*(;CKW.'FD|(15;METZQ.JB@$,XXD2PO5 M0M+:JF1.>XJ)Z^!&4LL7+L))?7=C&6.+WSN-5<9$WFH[JX>')$[2K5V*6GJ75 MEM?U$VV"G\%M%*S'%6;R^OC|9?*
KR4RTZ,94TY+5ZW[R;FTSC6V2\ M.KJ/2\$].^FJF7JG5S7)P7GQ3VG>(_);A?%PR M\4:.D(8BE"*DDU?1WY^1V?!%$]1Q9|KVP-SNZFL[T_T5$_]I;K2[8VY_Y=MB
M_)ID_P"$1%],9=\//T7U,ZP,.;I'U?T.X8\Y''[PKJ=L7^6K>O_U;W_A)DIML M;O\ WW;4]-,U/^Z5_P__P#]>?HOJ2_E[.N1]7I#N1"G,)-MVV-W_UQ6AOR MJ=/^$K-
M6V#"5%G3_ZES_W"V/3;EMAY^B^I!X*W_4CZOZ':,H;H<6HV$I^M=5F_V1?^^ >_)/^<2_[>?HOJ1[C7]R/Q^AV?*#*'&/>?;__M_G39O\D7_@'O/M?_ ,Z;-_LB_P#
<_G,O^WGZ+ZCV-?W(_'Z'9\H2Y.+R6S: M[#&][M4V=4:F>%)_^]643]fTE E6NJ;0R+"KXU+W?F$)=.:*+LZ$_1?4G'M[M5(_'Z'=$X]O (F,XX',;5<-
J]VCFEIM0VQ8F+NM> ^E1$D7S>*48[!M0;6+2U M6IK9039PB3T>&KZ%1O(S_P#W)3T_HSL^Y?4L_EL]5GCZOZ'H3*]WSD47!Q>.
MU;7'M16ZJLJM7BBI3*J+Z/$)O>C:,_P#YTV:_ &5?^U_SEO58>?HOJ4>O_\ M\2/O^AVC*#*'&/>?;_\YU6;_9%_X!$[7_\Z;-_LB_\!W^<2_[>?HOJ/8U_M<7?O^AV8@J<%,,K:-KZK_-
*;-_LB_P# 8S4M1M7TS8JZZ5&IK3))2Q+*YL5+ MXRHG=EF'NITYPH.I/#5LM=E]3L<%F:BJ[\?H=Y#>*'"K$NUB_6>BN,&IK3' M#5PMF8DE)XR-\^U__JS?[(O
/>?;]_G39O]D__%"S^<2_[>?HOJ<|C7]R M/Q^AV5,=Y%$.`:AVM1U\=([4UH221F\B^"=V?R"Z2U;?_P#.FSF\S:5'"?HOJ2>"M_U(_'Z':,H,H<8!Y]K_| G59O]D7_(![S[7_/,JS?[(-MQ_
3_G$O^WGZ+ZD?8U_<7Q^AV?*#*'&/>?;__G59O]D7_@'O/M?_ ,ZK-_LB-M_P# /YQ+_MY^B^H]C7]R/Q^AV?*#*'&/>?;__G59O]D7_@'O/M?_ ,ZK-_LB-M_P#
/YQ+_MY^B^H]C7]R/Q^AV?*#*'&/>?;__G59O]D7_@'O/M?_ ,ZK-_LB-M_P# /YQ+_MY^B^H]C7]R/Q^AV?*#*'&/>?;__G59O]D7_@'O/M?_ ,ZK-_LB-M_P#
/YQ+_MY^B^H]C7]R/Q^AV?*#*'&/>?;__G59O]D7_@(>],U__,BR_P'R M+_P#^CMJ>H;366ZNU-9Y;.IC6*5J4SFY:O!>*,X'1](6;73VE[7:YWMDF MI*9D+WLSA51,<,\?:8Z-
2IBND'7=-QCEMK;>_3>_-7!&GD9-"R1]Y:],F7?&V5CF/3>;Y,*B\C65B MFL$CV.8Z;B63TL4KS^N'4U&WBZ.1,^@V=J(G!#"6:VRR
MU#J^K;NRN3[W'GR$\YG/H[#1AHO6/<8)=4,E<[2GZ]VHN.L:B-:OH5>@^Z.H;Y5KFQ^2Y]F=XBFG9 MLGPY=AGB&5,+,9NF3A415%)YYF0_DK5+U>'(?
@G)14EE8VU1JEKJ+O05CK?(U-ME8N%=&UZ[KI&\15X+Z%*LR6A7?KZW244G/|[\"Y/8JFS]338+!=_M;NGZ\>ELI7QJ:KCIT\9R(O=VF.GN4DN49XC?G*958QW)Q@Y&0GK(Z?.|
{C\5.9CJBX23 M<&KN-\W,M?3Q(&&=9SV-$8*.X^=0 4%H !,CB9BX\Q3(Y4FF#%:HT;:= -M94'@EUI&RM3X.7*))"[L5CDXM4Y1>K1?]G#|ZLZZ^6%O*X1MS44R=TS4Y1^4
MAV[>P3HY]=;+Y,+VG)04S9AL95PSTU?8135+ MWI>MLU9-<:+&E333.WYZ#/X7:Z/T|QO=1K51K%=M"M5>,Z"G=+Z]?&CHV-I8U,*7"+]"F\550REH9G\&1L<|5\R(_
M4:ELMIU]X)J^1/OM?4/G7SIG"?0H.Q>C9MR)W\"Y(%XD^ZB#AYPPUNX4JTNL:6L.[#.FE=3/3O5KMYQ_'CC.QU=C+]f*]0 (FD%
M6GC5SE7L*29[.9>PMZMJ{=17.5D3;IKM^UI26:H\#AC?<+DJ<*6'"JWSN-MTY*5M"=##\3WGL5);MJ6X.5S]NFM&?02,DU!3^-#?G2N^+/3
MMFE:Q&AUY/03,@OU.VG8Y=UM=-N85^5GBTW9CTD;O(J.1 M4RBIROV&B2PLGC?%(O)(WIN]UW)2OH"LDHZ]NL1,.:Y/G3N4TF&\5VSNH907-LMPLKW8 MI:QOC21IV-
+7MXM5//E$+++Z&*/8RXMVI M;5=6Y]I^"5W:W?1KT7SM7BA?/]8XX\OE8QOQG.1$]IDM(ZY/I)Y6U<\5I)4XR< M7%W1HUPUW8[:[JUKXZB?DD-
/F5ZKW(C2%0ZOUFI%OMGO'0+_AUT3#U3O9$G M%5])UFT.7L]@:B6VUTE&G+>A@:U?:B9.FYR^DCP^UF.ITHIJ4?-FGZ/V7VK2
M4RU\CWW6\.\NX5F'/X_$3DQ/0:@JKY_62[XE54USDCX2)UB=_:60)QE*&Q%Q4MS/T]3'.F6NR MOM8'0>!W1K=Y*5ZI*.MB?BW<%7YD7U$8G-DC1S7(YKDRBIR5.Q4-
FEC;*QS'M1S'>*K50TFKMV7I9SG M4S'5EIRKnW.%G,\|=[3YK'8;49\6*NGOW=YZ%"HFLC,GA")0)HJR&NA2:"1L ML;N3D*YY*:D;-C:!CJI%ZFAA"(G-MTE.MR#1&<[5\N

OTC%3=B;L;4?/5[/I>/^+/U[HG.O_I]7DXZ\;&GZ'HCI$/6DVIZ5K'I]Z;R)<_)G MX_,I;,.U2HZ3E[E>F71NJ]W/FW6_0IMW25T5==34%EK;/0RU]32R/8^.%,N1 MKT147':B*WU9-2TK;KCIG;1<==17>,.@M;87/JJZ69O4QOD8U-U79PCM_ACF? M1P:=/?D?C6(C*&.NT[9D[^1;I,GI>>DCJ6Y*N]'2NJWIR]B(Y(E_,<0U=/$JZR:5.'|,O543V*GL/0&RO9E>K5'K;ZU]524#+G2R045>E2R2-ZR M*Y4E1R+Y.53GA?8:WJO8=5Z,V,U4]1-255Q9<(ZM\E._[VD&ZK$;BJB9\K>Y M=I=3J1C+?L1YN(PU>K07NV2;E\?S+GI+5$DU4 M)45.C=*TB=94PPHYT;>]ZMC8G~ZXL]6Z+U+K.O[-*J*@=4TT%8R&HG%3+9D*-MX(IOC/=G"}N-RJ\N"IS-EM^B%;MN=J,5EXML=%+4*ZTM\);JU"IXL2-3/!&IC M/>['>03C%)WVN:I1J5922C93RJ[[$C-VVB;5=*.EI8UWH]'=C;GNCI$3Z?I+MC9\K;/I37ME9\+++5I#O=ZHCFX_,R9_2VA;U;.D3=;_<;=M+:)'R+!52S,1L MJO:C6-;QR]\^!2VQZ%KX]L6GK[IVJH8[G4OB+F]SQ5QQ MRGG(N2D\O:BV%"=.F]MM8SV[MC3-;W):#T4_-63R8;'MZTG4:NVD]=IIL=UG\';#71TTS%6FD;]I-MZ3CXJ;IO7AXJH9/35IH;?T<;S.*VZVQM77S2]6UE7&YV%ER'>]+<;ZHQ%]9 M=F]R.O88.`.6*JJD.S\3<]DM.VNZ-LM- B;TE%6QKCXRND3ZSS[9Z|OZB-_MIF_',NJ,]_R7,=<C^8IZ1Z.5CN]FV:24%YH):.!|]J98HID1'=6[%41>5WOI M[3A;IE^J);8]:VUU]ECINOA6G>]R-;,K)7;O5]OE+N.5<>@JIR2G)-\S7C*=-M1T*,XQ?5;>FQLVMZQM#T7M)TS,M*EB3=3S*]Z_.A8]39O>38'H"S+PD]]VK M\ZI(C%=],K2XU)H^^:LV;:-TG;UI7:@MR.?66I]7&R>%CLHQSF[W8U4SVIO(;-MMK38I6ZRU3I2-ESH6VRS4L$%51[R];AKD5RM:B+PS"9^-CAW<3#:3V M6ZPCV=:DLS:::UW.X5<._25<[8WS4|:.W]W\G>5.:)41<$I.,F]=[&?#J2A M!:+>]JVE6R+LXVB7M2*CJI.>[;N[%EOO7^NB8PGO] M?;^ Z;<- .]=@*6+2L]+]&X1U<I2QN'E+:,3PNIL M!H?:3$OVDQXA^H QES\A3)F,N?D*_<;V@?!2F@[*_P!^Q9_3-_02&_;0/@I3 M0=E?]HBS^F;^@D(RZK)1W/37QO2!\;T@\XV(&'@\;4l0OQ843Z#,>8P]%XVH M;Y>YC4.U;>/B60^\9@-&D]!KR1^]]VGA7A%4+UC%\ZFP_.6=RMS;A3[CE MW9&\6/3L4S5Z;DE*.Z+82RO4H L4JYI?F.MBIO'B;BTU)G MQG.\IQGX(F01,C8FZQJ81"ZE'B3S;)?$A-J*LB< &\S LZQWBKZ4+PL*I,X\ MH]NT6R4=6C4]%=SYI\%[&3:#6]!M1+94KVNJ*;(?,X9>Y<|&>[M -3 &.O%]LK- CYE59'?!Q-XN<1E)06;3LC]3dB(RC(-32KU!='CZJVPN\EMKF[SL>_P!!B_FH;$;[LZ_Z!Z>_T&+^:AL1HP7^GI_XKY$*OVLO%_,&M)U17+0V.JD:N'N;U;?2Y<&6->U8WPF6TT79/5)GT(65VU!VW9"&Z-ATU;TME-MDI*;&'-9ER?E+Q7YU,F,(B\.7,'T=**IPC!,)'GREF;D 6$0 #'U5ZBIY M.JB:Z>;XL?"!4M_#[D_R8(8D_*=O*9Y5X)V18H-ZF8!ATN5PB^$IF2I^]N7 M)>4-UAK7*UJK'(G.-Z84E&M&3L'!HO7%8"KA%5>"=H+6Z2K#;ZAR<]Q2,G MEBV=2N[%OOO3^M><.4MXQ1KNPM^LR_<6ULC2&WPL]48U5]9K1Q2<3$1WB6E=U=?.MZ)WXQG<3$1WB6E=U=?.MZ)WXQG<3$1WB6E=U=?.MZ)WXQG

*D>U:/$RO-2LH,_<334MS+@QC:2OI>$,[9V)^@+S(IGG9-MQ+%5MUDT,O8S)·QOOY&G."9/S2*WI'<(Z69R^@[QH]IRTC(@QB55PF^#I6Q)*
MWR*12W5<_P"R*M43M;&F#G%;ZJN=RKFR[J*Z"FWNLD8U>[.5+/WX?-E*6G?+·M^4O!"O36FEI^*1(Y?C2<5+O"-X)P3N0?U);NPNERN8Q*2OJ_AYVP-[61)]9=
MT=O@HT7JV^,O-SN*^TN02C3C'5ZLYF=C#;@M,;G030+^$G!>Y>SYS Z*N3I,·M9]//P]*5=W"\U;GZN1N,X]T&C:GH)[·-<|?'4Y0·KQY;/·MP_0UT))IP>YM0+>W5\-RI65$"HZ-
Z<_3004#@KC)269$]>8-,VQ_P!|>]?P·M;?Y!3)BW_0EX%E+KKQ-Y;,Z>KI8>LB1R]6WQN2\CE'2·M?
V!)MOV(:ETI03NI[S(QM;:H'8;'60N22'*]B*K=U5[G'8*+]BP_(3Z$*W# MMY'NX1Y(PFMU;Y'FSUNCY-Z+U-'K>TUMIO5"ZAU#1;UOOMBK&XE@F1-U[7,7·MBK5XJBIPX^8]
<>YIZ@K;ET;0=G>MMH-?9Y;+6MCL%;5TUZM52^EGD=#]S&S*5A*U%;GE(MJX3'"*AO/0YTQ:M*] E36BBCM\%38Z6OF;$BYDGFC;)+(Y5XJYSG*JK(,)P
M/N.E>F%TGA(*4+2CI?R/-H4.%-V9X[Z2>HJG:WTNM24MP5TMCV=14!OME"Y< MQ^&3Q)+++4]WM=A4:BJFZAH:],5O2&VA6O9'IK-2E5-%5:FN$*;T5LM{'HZ1'
MN3AOOPC4;VY1.T]MM=Z-VGMM73]O-CK+K>M-4]5H:GO-?)I^]'DK9V524Z=·M8JHO#JU1.'Q4\YZQV-[#-%;!]+NL.B+)%::21_6U;RN62HPY,?"32N\9IN?
M;A,\,&A=.0PG1ZPE&%I-·OQ(>SRG5XDGH,S2T\5'3PT\#.K@A8V../XK41$1·M/8B>PFEC2:*1CO)IX)%\=E!2M1/,BO·MX_:=',2UT=7%MU"'^*;751*6X·!=<@"#FHYJHY,M[4(@>
(,+%FVS+3R·M_!JN8W]_F+S/*&/ARAI%71YO:C$QDN:6CCI6]D3<=Z\U]HRRGHU9#,E·MJF58(FP1,C9Y+4PA.03/;1-:LDDBKO!7H_AE]!0*]'\,OH+H=9$'U690 &\R·M·M·M
$,%O5U·M?=[*XQG!<3%EA=_V,WY7U*53;C%M'8J[2*?OTOXG>_]·OTOXG_·OZ·MC&@P<:IVFOAQ(#)>_2_B?]|^H>_2_B?]|^HQH'&]=HX<>PR7OTOXG>_]'OT·MOXG_
'OZC&@<:IVCAQ(#)>_2_B?]|^H>_2_B?]|^HQH'&]=HX<>PR7OTOXG_·M·'OZA[|+^)_WOZC&@<:IVCAQ(#)>_2_B?]|^H>_2_B?]|^HQH'&]=HX<>PR7·MOTOXG_>_]'OTOXG_
'OZC&@<:IVCAQ(#)>_2_B?]|^H>_2_B?]|^HQH'&]=H·MX<>PR7OTOXG_·'OZA[|+^)_WOZC&@<:IVCAQ(#)>_2_B?]|^H>_2_B?]|^HQ·MH'&]=HX<>PR7OTOXG_>_]'OS^]?
[W]1C0.-4[1PX]A=3W"6;@B[B=R%]_52D·MY;LFDH[_$3H·M·++_B+U.3C']GZ074B<$F]2\O9u\UBXCD2*&%[N34RI[\DBRR>O-R[R^;O+B]+E9%1/48?[2+-
V&A;\V0·)X(5·MFF9&WFY<·VMV5S8+)3]31M7'C/XK]1?D&-2·K6M3Q6IA")(^;]2SR<@·0·M·M·!%KE:N6IJ+YB·.@O8;M)&W#VI)Y\X*OORXC>_]·;"U5IVLF5
MNG'L,E[|+^)_WOZA[|+^)_WOZC&@!QJG:.''L,E[|+^)_P'|^H>_2_B?]|^H·MQH'&]=HX<>PR7OTOXG_>_]'OTOXG>_]·.:!QJG:.''L,E[|+^)_WOZA[|+^)·M_P!
[^HQH'&]=HX<>PR7OTOXG_>_]'OTOXG>_]·.:!QJG:.''L,E[|+^)_P'|·M^H>_2_B?]|^HQH'&]=HX<>PR7OTOXG_>_]'OTOXG>_]·.:!QJG:.''L,E[|+^)_WOZA[|+^)_P!
[^HQH'&]=HX<>PR7OTOXG_>_]'OTOXG>_]·.:!QJG:.''·ML,E[|+^)_P'|[^H>_2_B?]|^HQH'&]=HX<>PR7OTOXG_>_]'OTOXG>_]·.:!QJG·MJG:.''L,E[|+^)_WOZA[|+^)_P!
[^HQH'&]=HX<>PR7OTOXG_>_]'OTOXG>_M_]·.:!QJG:.''L,E[|+^)_P'|[^H>_2_B?]|^HQH'&]=HX<>PR7OTOXG_>_]'O·MTOXG_>_]·.:!QJG:.''L,E[|+^)_WOZA[|+^)_P!
[^HQH'&]=HX<>PR7OTOXG·M_>_]'OTOXG>_]·.:!QJG:.''L,E[|+^)_P'|[^H>_2_B?]|^HQH'&]=HX<>PR·M·7OTOXG_>_]'OTOXG>_]·.:!QJG:.''L!+^6l>)\|#_
+W1]&JKOF%_P!YI/C?·MU&=E\E34=4?·O]|)5I]HX<>PX?K:X[TLGWK'YW]1@.B=)UW27U0[EFR.[?RZ·M4R6M?A7F*Z(_]9'4W\2/_GTIZF#FY9[OD?-]*I*5"WXCVV
H+@%Y*4:ECY*>·M5D3TCEEKLXV=ZIU=-TDK=6T]BME5=·M'TK-+4K'2MAB=(K&JL:X5=W''EDU_H\V+I9;?MCVG=H%)TB*&T4UYCDD90S:
M8I)'Q;DKX*Y(T1>+,^A<'KGI3_M9-K?_52ZJ]ED.<^YLKGH5;_]'IO^V3D·M+:FK·[F:QS':QMLVI[$+;=H*XI0M5.UAL>U)3PVNY5BV^"!+9<>K:DDR+&Q'·M(Q7-65K7*N6+
(U.+$4];·3-J.G=DVS>]:XO]^3PSJLEXC:_=HJ=R=K$;O(GB=B&TW;7]SHX,5=M6L+XZTQ7&5]QT=IUE'·UEMIXXI'PS.=U>](·MKE1]-W\Y:W>QXZ8Z?
T)MKEYVD=$_3&N]>WR.JN4T59/<+K4LBIHVQO5$K=YV·MZC6·1K&)E<)RRING2+IX,/HW;2.>FB;3T\.E[@R.&)NZQC4U7HUJ(G)$1$3A
MP1#Y(Z:O^VK,)T)H=*:'TW44^S+0L,M3J*J;*YDM\D6H=,Z&/"%S(F.1SF-[·ME·R-3&<+C+4=O.XJUALW2GVTZ5V$[&(+=`K:[T+KG<+]>&]9!;*1%<
MB.1N%4SL,@M71]TM<=G%N|%8*>!*1UEA5%=;IV?·M'9O7FYV5WM]>+T/!;:RBK+>DG\KV;C6Y3NSO9?]-·MRBGO*AK(+A2055/(DL$!;98WIRB+!R*=);R.1!)QBNV=
MTKL>*RYT[G>9/&3ZR3V**?61@[-0LMMIHJ2-,,AA8Q$]"],_,@*ST^1A-#4T%MZ0=+·U6'U!KE1COBN\7>^;)IZ(//·H;LFW72+6+A·MS:2H<[T;KOZCT,3B9*TFW]
2,YI&UBR1WG3U"DK6O2FN$%2C7?&8JJU?4["·M^HR]%"VEHX(F\E,1O#T%/7^?>)KDY-G8J_.77HY%#24KGHTZDI4U!O2-[>>X·M,70_K+6:,O!E53X5/.WCGYC*&*?
XVL;6B<'JD7YG!,B:59MX5>60=Y·M/F//^INE!5V#/IC4Y&>FO=F?=77I;M4?"YK*AXVD69A2?@$X[WX1Z_1#P·MAM&_]KQLMI0N/G_HJXXRZFKWN>V-
4ZDM^C=,7B_W69*>V6NEEK:F9>3(XV]·MR^G"><T\T="_JRNZ4U\U"9;KI3[C+M04D%SH:9U4Z=:VBDM3+&XPO5\4RB·M]8ABO=+=:W2?9CIG9%IF1?
NJVF7>&SQ,:OC)2MK;K$SNJ["XSWHA;=`G:K+MPV+:2UU-;F6F:^·M4?A3]&*996PKO.;NHY43/D[]}S-4Z:TS)^B)M9DCBY1R*S**B\·MCYKW?IM7.W=$+0>RO0#
[E0T5';>CUGK&CI9'I:HYY7IX/$J8PIS57+LIGBQ·M]YRK5]3D*>;·CVEB]TRZ[7W2(=LKV1:3I|,Q6O·I++]>HKW06^V+O8U%|(D·M7])U7@O3GUH_=WLV
M1B8SC]SI#U!V'EG3Wf>+6G\2L_HZ4E=QA·KL,6(5ZU!?^2^3/4"7GlY_WOZA·M[|+^)_WOZC&@\'C5.T^QX<>PR7OTOXG_'OZC'7*\[T;_O/9\;^H@G)QCKA|
M$[T#C5.T<,/8^3(;7·MLF_OMV;_%_]/(6.I·Q:N148IGIM+C6N\FD1]'E+Q(LO#XG8]*9S$^,UM1+L5R;ZI5·!;0·!C^^HDFF\%B56V/OCD^@C.61;$HK,74M·MRIZ=RM?*F]W-
XJ46'7R^,]]=ZW4%*&DBA:FZS*|KGGB53#S4*(JRP+U4C>*;J\#(6^]\,I6R*F'CXW)EKDY*75,1Q54#X6-D8|,*UR<#3)*"OT=,·^M6C1U?;'+E*6ST'SE:A/"2;BKQ?
P_0]&$U45GI(V!'TS;'_>XO?\$W^>TV·M6U7FDNJ-UE-(CN]B|\-\RH:WMB_O<7O^#;_/;9<3)2P\FGR)TKJ:OVG0:+]B·M0_(3Z$*Z/F/H;+=G.>DR](^C?M5O'G^Q
MV'SUVB;YK>F%K&YZFU!5U:[-]>ID!--Z;AF?%!+"QRM6LF·BHKWO5%;\D)!·MZ@]S2U#RE6-DC8MY>:,<|R)W)CN/]<3T·M36PN"A7]:*3V,,<1&=1Q7(V*B\7W2*Y-5?
&=LOCW4SQ7_E%,"'I?O^P^/IQL·ML^VW7VO=>7Y\W2EU>NH;ZBM|PHJR2&2U14\QP1Q(B\&M1$54[>/:I[tNZ#VW·MZ\I8-D8I,*UR<#3)*"OT=,·^M6C1U?;'+E*6ST'SE:A/"2;BKQ?
P_0]&$U45GI(V!'TS;'_>XO?\$W^>TV·M6U7FDNJ-UE-(CN]B|\-\RH:WMB_O<7O^#;_/;9<3)2P\FGR)TKJ:OVG0:+]B·M0_(3Z$*Z/F/H;+=G.>DR](^C?M5O'G^Q
MV'SUVB;YK>F%K&YZFU!5U:[-]>ID!--Z;AF?%!+"QRM6LF·BHKWO5%;\D)!·MZ@]S2U#RE6-DC8MY>:,<|R)W)CN/]<3T·M36PN"A7]:*3V,,<1&=1Q7(V*B\7W2*Y-5?
&=LOCW4SQ7_E%,"'I?O^P^/IQL·ML^VW7VO=>7Y\W2EU>NH;ZBM|PHJR2&2U14\QP1Q(B\&M1$54[>/:I[tNZ#VW·MZ\I8-D8I,*UR<#3)*"OT=,·^M6S'SE:A/"2;BKQ?
P_0]&$U45GI(V!'TS;'_>XO?\$W^>TV·M6U7FDNJ-UE-(CN]B|\-\RH:WMB_O<7O^#;_/;9<3)2P\FGR)TKJ:OVG0:+]B·M0_(3Z$*Z/F/H;+=G.>DR](^C?M5O'G^Q
MV'SUVB;YK>F%K&YZFU!5U:[-]>ID!--Z;AF?%!+"QRM6LF·BHKWO5%;\D)!·MZ@]S2U+

*OIZ67]URU7LC:UV%PBJF47L, MA<;K16>G\(KZR"B@WD;UE1*D, "HO$]'R*V0[$>DET,.DM[TZ0LE^UMHV.IA=7/M}.^.UW2DDQ MO+X[DB9.UJK^$]LG";-%7EO/5K<]F3XZ;&-D.U+W3#:AJ&[ZHUK)1T-KC;)57.JA=/#2=8K^J@-MIZ='';,QW'KP.J=/;KMG)2L[(^VM!<;2Z4_A%%4PUD"\$DIY$>W MOYHN.U"X/CEQ MJO7@[>;J.1<>O?="NEU[`87L(TPRQ4\^F-=ZS9B-LNY)+;HV1QNJ4RB]SK&K-M*R-%3*)O.OMS]]HME+'45"S>]M=3H[Q8GJ MN>]>D;EHU/%%*6T9'4>1+LR~%6T9'/VHTGW99<=<)O2__4_E"P"VUQ0]2C~*G4OF,PVN)77Q3C_/9H7K^)(#_VRB++ M:0(IZLY9[BO_'L=I\'<4 | 0*?1H^<_N*O][':1_'%/_0]?1LIK=9EE-^Z2 M G!38GF\$J*&K5-RIBX\E7AGL5%5.2<DBM\R(F?%[, MX5>'-''Z%AE-5'DW2>CY]Q"5K*^A8.Z15]TLB4^T#9]76RF?]ZDJZ5%?"]+A MJY1V4PJ<,;W)3L.C*RQW"3-!5Z;,3-LLS=^!M)&D<:<>*;])AJYSE.I%-+U5 MM^V=P,;JU=?].]-GBY&,.B[YR\D1..G#MO#VMVK{(454WO?*3@ORHC8NDAK-VD-F M5?%3OQ<[LY+92:.OC*Z3@!4\^]G'GP=@B1HQO3^83MF9IVRJM.OM7:^UE M>]VCCIKFYUHHH:FH8URA8-P[".=GBFZGM,ET9;VMOM1:#]*EE1/I^L>M+(Q MZ/;+3NG;P]M1I>M--VOH|;4M'ZDLE+[V:,KU=;,:^%'NZTQW>]E\ T,;35>DLYK=A^]55S M=WVMIZ;>CI9$ MQEKU1-Y5YHNA^],W'K3&?]>TFV-SNMNW^XP1\([C9^LD8G M+>8IN%|,.^TAG>?G"X5RI?1!]+<='NA=]':MJ?43$WI*W4K+7#(GDND54<['H M1OSH>!B6EAJKEM;_(+GR/2(./A@ H"@ \IZ=_;Q:S_B5G\'M2GJ8\M:;_;Q:S_B5G\'2DE]G+P,>(^VH?Y(]'MY*1)F\E(GSUC[.Y(8ZX_!J M9/FA95T>\U41!8YU0>*ON4D^(OL'W*2?$7V#*,Q[5! MXJ^Y23XB^P?OT'CC[E)/-MB+[:]RDGQ%IA!TVWOAZKIQXT^Y23XD^P?-/N4D^(OL'W*2?$7V#AO\ $,W<>R_'"%GLIO:X,U8[E'&ST]>-/N4D^ M(OL'W*2?$7V#A_\DQF[CV7X+4R>74;OF8A-%XFNR[fX|OD4\972IV+[#SS64L==2S4\S=Z.1NZYOI_M\QS:HT=++;,^-6]F M=7=WL<\=OLP=G[Q&.F1[1XJ^Y23XB^P?8IG34LT >+_N4D^(OL'W*2?$7V#*,Q[*GC5S4,Q[*IFJC5>]<7<4*QXO^Y23XB^P?#M\1?9YU*WW)2?$^8N5#2 M]R#]\K'KQ$P#R(S2J&]IY$G#C@G&CE=[D7.ZM8R@ -!4 M M M M 2_A%I=/(@&_*^I2[_"+2Z?-^5]2E=3 MJLE#K@(,-8 M M!!?)4TK>)1QNCO4T?CQ*YGK8!7N65>]>F1.Y"V}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{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|I*4R M^M?A)3#]$K]LIJ;^(U_GTIZV"ZL_^9Z6ZU"_(]M* H+CH M *4L39XGQO:CF.16N:Y,HJ*G%%*I!>0!Y-UOHVNV&WRJGAIYJS0E;*LC)(D5MSK<]RY5KD^)W+V^HO*;IM^I+>]QJ/[E12IAS%)&.3N5OU'I"HI8J]!4S&R MQ/3=>Q[=YKD[E0?9=]'HN:-NU6^KMR5NFZIRY5]KGW&97MW5RGLP?38;I6#BH MU[IKFOS%FI%QE#/)O9RJ+E>.\54V'^_MY4B_SXU"G^L9]@_N4IJ_\^-0_IL^PWRZ0PDW[U1^C.>1K$U#!421OFIH99(US M&]\37]SY*KR$]#3UCHUJ*:*=S%5S%EC1^XO:KW/? MA39_]E*+_/C4/Z;/L'JRE%_GOJ'I-GV#V_|_W/@Q=]AK,M++#50++!-'- Y,+ M'+&U6*B=BMQC!/%&V.-K61I6QJ81K6J[}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f=N,\2O?-O>M_>J:4VG!]K7:-@;UBUU75)M%/41)SE9%S1F,KE4Y)GT'"ME*]M; ^#._+PY!O:;_H/5M'KS2=KO] CTI^^!L MS&R>4W/!47SHJ*G]-A5<(#4FI+,M@ = 4!0 M >6]-?MXM:?Q*S^C1#U(>6]-?MXM:?Q*S^CI"2^SEX&/$?;4\D>E >$?8@ M $0 #3]"_%/\ Z4W^ M8\W T_:A_P P4_\!23?YCR4=SCV.AH#_ **47^L_I'GP&OZ_P"BE%_K/Z1Q MO.IQ[G>0 !P &5M_[&,Z_I4N2UH/VM.W^W:I=']HPZJ,:W ++@-M M M !!..EI?ZBJH>[T5K]E#R1O$O'O&//VF<^IL9G3++LJ]W\MOT MJ="-$T7'O5[N/+" ,IO9IH['R/2;_K6 +#QP1^8@ #YF^ZU;=+E?+SI;8+IM61TU7=)(*R[0PKXTSWR;M)2JG/BY.L5%[XE]#LG2ZV6T&Q?W;_4.AK=NNH[' M;K=2NFC3"32I74I9<=[Y%-=DE6NWKW6"6ZW#=EIH-2UU7'O87$=!% M(E-P7_1X3Z>Z4?M)!IO\#1?]OI_::NK:)3O>1\D.BWT+=;]+2'4DND+I8+:.MVPNIV5*7RHGB5ZL;EK=S]X9,XZIV MNECN<#:FVW*EEHZF%R91\4C%8]OK15$]F65N0C%-.SQY[F]TUKATDM-W/2FL_MI8Y==V&%LZUC&(SWQI%5&=:Y]81)&N5K7XPB[[%[5QG/=$.F7/T7M!T%]TSU-M,FN]1)(VA?.U)&4,#,(^IZQZB];UTPKQ13O58[1::&AA1>"-:Z+KU M3]*=WM&19SF9J)'9#T(=NO38HG;1+YJ*.."VULCDAN^JJR:6;K1'*CE@C:URI MC53"<;\7*(N,!M"V7;=?W/%&O:O.\0 M>YO[3+MT>NDIK;HZ:GK-^W5-?51T#I%5K4KX,IO.1>39X6;R=ZMC1/*4"!%] MM-#8Z&*BMU#3T'%$F['34L38XVIW-:B(B)2#XY^Z1RR;$^GQ9MU MZE:UKL.\D.CHL+\KP5/JD;'$Z15N(U>KN&ZCE151> M:(J<,Y*>XGR,Q=+Y;['#U]QN\+,X>/WRJF2-O#FO'@5J"%4MRITFHZF&AY= -M9!(U[>6>;5PO#'M/DGH/W,3;1M!U=J"_[;]456EJYL];M34NBNU16J1+EW%C MF1D4,B+A7-5JI[=5$9]A|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

M3MR>9V=/S03I%:MFU&Q$_#=34^%_^WY^8J?W>^S_/R7]'_98?\ QCO!GV$5 MC\,_OH|*:_[O;9]_DK4/^S0_^,/[O;9]_DK4/^S0_P#C#A3[!{?AOQH]*WX\:/2G_<#S7_=[,/O\ ME:A_V:'_,8?W>VS[_)6H?\ 9H?_ !APJ@!OPWXT>E, X'FO^]VV:??Y*U#_ M +-#_P",/[O;9]_DK4/^S0_^,.%/L'M^&_&CTIP''\U_W>VS[_)6H?\ 9H?_ M :!A_= [,/O\E:A_V:'_QAPJ@!OPWXT>E, X'FO\ N]MGW^2M0_[-#_XP_N]M MGW^2M0_[-#_XPX4^P>WX,\:/2G >@\U_W>^S_P#R7]'_ &6' P 8?W>VS[_) MFI$_,^I8?_&.*? 81!OPWXT>6\.9Y>TPG_S\6L_XE9_1TID4Z>FSYTX?L&^M] M-+_XIIFO#?%!M.Z6&]-36>*H:,ZBRHC?"6(U!=U*9BHU/HHG%!MM?%4\31K5Z,8:L(:TCNAO:1/GV? <*8,Q]58W39SSK_D MQ_|>-T-*V;_.':>AG_>-U-E/JH^!Z1_U4P "P\T#YO. >7>GUT07]*O9G0 M0V-U'1ZVLE1UULJJUZLC?%(J-F@D>B*J(K41Z81<.C:G!%54{1L*MFL+)LBT MK;->NI9=6T-"RDN$]'.LT8 (G0 M M "5_%JFL:AINLA>AM#DRA8UE+US7<,@'-66%!TCEWE[AIMDSE\7B8>31;'+Y">PM4LI7*"GNCSO]Q2?B(T4'W% M)^(C_10]#? <0S\6GL'W$,_%I[*7%F5\"E^$\|_<4GXB/|%!Q2?B(T4/0WW M$,_%I[!Q#/Q:>P<68X%+\)YY^XI/Q$?Z*#BD_$1_HH\N*3\1'^BAZ&^XAGXM/8/N(9^+3V#BS' I?A///W%)^(C_$4' MW%)^(C_10]#? <0S\6GL'W$,_%I[!Q9C@4OPGGG MGBD_$1_HH/N*3\1'^BAZ&^XAGXM/8/N(9^+3V#BS' I?A///W%)^(C_10]#? <0S\6GL'W$,_%I[!Q9C@4OPGGG{BD_$1_HH/N*3\1'^BAZ& MXAGXM/8/N(9^+3V#BS' I?A///W%)^(C_10?<4GXB/\ 10]#?<0S\6GL'W$, M_%I[!Q9C@4OPGGG{BD_$1_HH/N*3\1'^BAZ&^XAGXM/8/N(9^+3V#BS' I?A ///W%)^(C_10)HM.V!GJ:AZ&^XAGXM/8/N(9SZOYCJ]S..A2MU3Y\|(-/N]M MONMZ9S=]L? AN&NXHF*MB'H#BD_$1_HH:WL"TRVHZ4^T8#>?N*3\1'^B@^XI/Q>?Z*'H;|B&?BT M|@^XAGXM/88>+,]W@4OPGGG{BD_$1_HH/N*3\1'^BAZ&^XAGXM/8/N(9^+3V M#BS' I?A//W%)^(C_10?<4GXB/|%#T-|Q#/Q:>P?<0S\6GL"%F.!2_">>>?N M*3\1'^B@^XI/Q$?Z*'H;|B&?BT|@^XAGXM/8.+,<"E^$\|_<4GXB/|%:|Q2? MB(_T4/0WW$,_%I[!Q#/Q:>P<68X%+\)YY^XI/Q$?Z*#BD_$1_HH>AON(9^_M+3V#[B&?BT]@XLQP*7X3SS]Q2?B(_P!%!]Q2?B(_T4/0WW$,_%I[!Q#/Q:> MP<68X%+\)YY^XI/Q$?Z*#BD_$1_HH>AON(9^+3V#[B&?BT]@XLQP*7X3STW M1:9XP,7\U#)6O1C&R(JT|/T$.Y_<0S\6GL+B#1S&.\CYAQ9C@4OPFK:0TQ31 MHS? I(57^#0ZQ9*&^AC5(8(X4=Q5&-1N?5(@)LLC:?&&FPT\2-:F"+G)DHTJ:M=TBX !47_T|:E_T M?I_|*;_>;B:=M2_Z/T_^E-_F/)+@_8Z>OZ5+(@W0V,KW_+#@ M M M +2X?!, ^5]2EV6EP^"9\KZE*Y]5G8[F/ !@-0 M M !*IX-_H.+O7BX[0 M_P"#?Z#BN]P**]1TO/R)]Y"&\2HI WN"F8^LL:MLVYU_HC_P"\;L:/LV=X MU?Z(_P#O&\&RGU$?GO2/^IF 6'F@ M M @K=Y,$0 47 M4[7]9V6;[>'>"R14ZO>[K:MDK,M3BGBM4]"ITV]EF.% MPN/_ ,CW_:>AC,/4G43BG:R/!Z$Q^&HT)1J32>9OR;T.X>"M[AX*WN.'_P!V MWLM_RA_[2>+lL[*G.1'72X1I\9]!)CZS![+6_"SZ#^:X/\ N+U.V^"M M[AX*WN.,KTT-D_|ERI[5#)]A# ^[0V3_ .7*G_89/L'LM?\ "/Y1@_[B]3M' M@;?B_,/ V_%^8U? 9MM7TWM7M[96Z9K)*NGI>4AF62%T>Z]6HtY$1>E>&#<#.\V2ZWB.\1U+2T;2L7L(^!M^+\Q=_M;Q*>. MO V_%^8>!M^+\Q<[PWB6H+;P-OQ?F(>#.]D+I5X*43FH*?@S.Y!X, MSN0J C<[8I^#,\P\'9YBH!<6#8V\2IE$X9*8%Q8J;R=XWD[RF!<6*F\G>-Y. M\I@7%BIO)WC>3O*8%Q8J;R=XWD[RF!<6*F\G>-Y.\I@7%BIO)WC>3O*8%Q8J M;R=XWD[RF! <6*F\G>-Y.\I@7%BIO)WC>3O*8%Q8J;R=XWD[RF!<6*F\G>-Y. M\I@7%BIO)WC>3O*8%Q8J;R=XWD[RF!<6*F\G>-Y.\I@7%BIO)WC>3O*8%Q8J M;R=XWD[RF! <6*F\G>:=M25/N?I_]*;_>;::CM/_.8/(/]:_<2B]3EC):!M_P"B%!_K/Z1QL$\G>;WH+_HK0_ZS^>6<;_&$BIO)WC>3O*8%W.V*F\G>-Y.\I M@7%BIO)WC>3O*8%Q8J;R=XWD[RF! <6*F\G>-Y.\I@7%BIO)WC>3O*8%Q8J;R M=XWD[RF!<6*F\G>-Y.\I@7%BIO)WC>3O*8%Q8J;R=XWD[RF!<6*F\G>-Y.\I M@7%BIO)WC>3O*8L9>A_8Z? V]5+DM;=^Q6^OZ5+HI"&QD>X !8<_M M M !:7#X)GR_MQJ4NRTN'P3/E?4I7/JL[*M9?,=>O924)32]R*TVHK;U;L5T"_ZUOVG(W+GZ2>OI9[?4O@J&=7*Q<*WL]* M%OO90Q3GFT:/N^C\###K/"5TRH-[=3/,EWQO%)I-C<=GE?34*UOA%1' CDC1 MO6/1,XWC=YI-(6%:6%5LEM558U57P2/M3T'!NG+_>EM'\?TG\V4|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

MM&U'1E_K&T=LU;8ZZJ]WH:CLJ7<&K;[B[>!?Q(WM][UPU]Q55RO!.%G8=06O4]M;7V:Y4MVH'JK&55', MV;-RIS3>15XID@HRBKDKQ9D%=Q"<53F=2?#L5!75U-
;;.>KK)XZ6D@8LDT\SD:QC43*NDO TUN=T>P !PZ M #E@"/F^HQ=BU59M3MJEL]VHKKX+)U51X'4-EZL_'Q7;J^*O#DIVSDKV M.76QDP 1) '4#*4'!';_&
[5+HM;#]CM_MVJ7!NAL97N M 6' M M M 6EP^"9\KZE+LM+A\$SY7U*5SZK.QW,> # ;@ M 2J3$[@$ M !Z0 G|L"AM9VJVS9/IUQK.5%=+EE%0M7==,],WS-
3M7U=IA\0/T@M<5-PN% M4YS-Y%JZYS?$IV=D<;5[<^7"6LTW7OM[MKM,G'K;@_?3/R4PWU8.ATM+#OP.@IX8Z>%B8;%&U8M3T{G+V%0$R(M -(IGLSZB
./;;MB#-8Q37ROPLBOK&VFIV)NMJVIW)V/ MQR^,;;L#Z0TVSN9-.:G6>2PH_T'7/1^OEM5=EU/*G>QW)%_*9ZT/5N MRS;QIG:C&R"EF=;KRCI<@ @3 ;@ X #IP M '0 #@ M
!%$55PG,'-CSETY?[VNG/X_I_P":X],L\EOH/+G3ANU" 2.E[5X9 M E8Z^02NAZU'21L1%17*Q,KCC\YUBZ;>K%1*YE'3U5QD3AO-1(V>URYQZCUE M3G.A%)=I\Q3Q-
&GC[T2\YZ8#=@ERZ]=Y]5*FO#;KLUVL:/VIV.90S6%#+45U(LM-5K%XC88DWTP MY5:KD7#%PG'S*>EUTQKRI969ER=G@O7U2L'-97\$=5.:lOS^E=HZU31)X?46I\ MK=^3>.C?
ON55W"(\GI# 4VHR/AE%9%&4DD)-*26C5 M]G\STGL2Z.MGV6I)KOHZNN;+Q->TE6Z5F48DKI6;CD:BJN$1O!..>T\@;1-F M&TGHTNM-JH-
06NZ6&YW'P*VS.XRH|Z\$>U4\5$\SE[>\|/)L9U)W4>.'%:E? M3W<3A?2CV=WJQR;/*>19$[UU!9!&Z*?7PJQ$1%54XL;)6\2 M?\)_O9TC5Z7DL1%.-6\I9K--
I.S79Y:GZ!UK0/I[>Y&524M5WMJ(-QW^{CZ#:K5TA;214;<&F[>*-#Z$_P#T6UQ_UAF^@]&'E7H;Z_TY:K?]RTU|ZHZ"XUE[
MEJ(*>KE;&Z1BX1%;GGQ/535WF[R+EKN*.3&%_!2C&0E&]HGT-5A+'MU<P #"}Z "+?* M@0 19Y7K[3J.'<-A2C=&#MU8T(&JG9V<CN9S_&/?M!M2?Z)
<4_WC%/#]:HC6HB)V8.:]%C15GCZ0^UVJ2@AZRSUBP4";F6 MTZ23/WE9\5?%1,]PE0POO[S]SOWU^ 56O[KT][X'8=E'2=T3M;ODMBMJW"V7 MIK5D;;[M3I#+
(UJ95685454YJW.<)DV_;/M2TSLGL*7C4]R904[WHVM5\L M[\9W8V)QWZV.NZ9Z:FSJ_P!WI[?4^^VGEJGI'57BCZ]"15X)X[7+A%5
M43+B^Z9.'=":57)4T"?HO..N9\QRK:OMSFVJZ$N>G* 8AK!.OA/)PE%N^Z'C?U.9[J2V:0V Z5O-YK(!?.2M3\%XWO.J*=?Z+NU=^N])/M%RF62[V=K6. MD?
Y4\')CU[U3&Z]JO|>TP5J2C[T373G?0[2 #&: M #QQ[H9A:K0>4SXE;], M)WIHV?WB-# Q.S^T M "SO5ZH-/6V:XW2MI[?0PIO25%3(C&-3T] M22-R6=XO=OT_;Y:ZZ5U/;]*-
,O]*J5L;& ^M53V'EG:OTZ: M&@ZZ@T%0I<9D\7WVKF]D*+WQQ\%=Z783TG"]'2FU'I&W1*^LEK+E3;V$KK@_ MJJ2'S1MPB8\S&]9Z]'HZ4EFJO*N\^3QG\14]=^;B>D_7_1#
[6lL-;^@M5154\4G#P'3T#F)A>QL MTR_VN:=@T'I_6-L=1J2EKU%@[E9K+,I/T+..UT M5/;.5J82*EB1C4]B%=Q4VZCEJ.DW?;SQ9IQ.V]3\'L7YG@?4FQ75FB8+/>-M|21,I/#
[C'3,CDGZZHRKLY=C/[K9L6I=#A:N2HKY$X+O.ZMG#S)Q.7|* M/3-[U-I?3_O#:9[M54=T;5.@@3DUK57*IR<$"|(:QE?_F/38[/UR[ZOI<="Z MI*=6*<;
(HPE*A@:TXU$WM9V;|>1WFWZ8LJ]1$I+92PJG)R1HKO:IE$\5,)R/ M.7]T%M9_^#TO^TO(_P!T'M8_^#LO^TO,O!J//=KU1[L>D[S>8\[?W06UC_X.R_[2\]?W06UC_P"#LO\
MM+SGL~^[U1./2E&.V;T9Z,\Q3DIXJC0_N@MK'_P !T?|.:7CV>?=ZH1Z5HPU6;T9Z,_="VKWD=Y6\ M47'M/;?]T%M8_P#@[+_M+Q_=!;6/_@)) M+Q0//N]4<_F=#?WO1_0!:U=OI+
M@U6U-+!4(O-)HVN^E#6KALHTW<-(=']R\ M[3[=[']XV6LH^MH;E-2K25>6]9AGKRW'#LPIZ$Z+&G[SI_3&H_?NU55HJ*RZOJ6053%;JM?'AD[1+&V
M:)T4C&RQ.3#F/:BHOF5%X&J=?WG"44T>%ANBG*FJM*;A)]AP#9ST]*6H6*FU MM974KEX+@]-./UU8-?6U*_3MV1+M3*GC+3R(KF>9S<[S M5\RHAP?
7W1:T5K3K9Z.F73MQOMZ?>E=^?$OBKZL'G35&Q7:-L0NCKU:), MF6G@\9MWLKW;S4_?&8WDY<47*&66$H8C6#ROO/0I=^))=' ZF.>':MSZ/@\; MI(^G/) L%NU_2]?
%P:V]4#/&3SRQ(F%]+>/F/6VG-2VK5EIBNEEN%/<[?,F6 M5%.]'-7O1>U%\RX]"'BUL+4H/WEH?7X#I3#8^-Z4M>SFC) RGK@ M BG/O(Z@>*M/ZVO6QCI$[4KW+H
M#4NH:*ZU3H0)+;12;JHUZ.WD",=P3.%5.&4/322.;R2MS?(\]86HDU M&=KWY=IY[V$;%KILHV'-L@O+>LU+>X*FKJ]>%=_]U6)R,C16YWG<55=W/%V# M5]E&F[Q1]!W4-
JGM-;1=74U>UE#-2R-FT!M(IRNWLJJA7*](FU/^II,6<"V77JGF_;8+6<.E/LL7RWHW#?6I5VY;/M8Z8VJVG:IL^M_OU7P4W@5ULN2.:G;PP MBIG+5:U<+Q/1:.#GL?
C+RYXS@V7;UI'4D'1,N%CKZNLU M9J9D%,E3401.EEJ}$F:YKI:U,JB<43"9PB'H+?'2UBI:6\3R
M12;NUOLLZ'ND*/3NGKH_4MFIJ6+9%KFYWRN=UMSNSZ1=^HDXJ))EN48BJXYKE57B>VH*IL[>LBF; M*U>&_&|')]44J=:_X]O:;?;8*,H2A?,[O5HJ]EDY)OGLNPXWHS:1-
T@=.:PL M,^C[!HY'V]U.DU[AW&S=*)@]C;[E3BKE]*D6OQ_3^N'=+.X:DU?9Y+?472ROG\V71-CN655'53'2G?W5K'*(8512UN[W/-G3'L5SOEQV5K;;;67!M/?VR
MSK24IY.J9O1\7[J+NHF%YG6-OM'47'8OKRFHX9;JFM-0V*&&-7ODVN50)<=A#DY<<*9EB6E#3JLLX.LW?K'CC4&R#5.M.AMH2WVNVU#KS9
MIUK9;-4,6.2=J.D:K%8[=XXU#G M^PV!,1=C%=K:^,T/=+]BKN\K*JAAA?%5Q/1SE941-Y' M.5R855QZ2&^Y<<5RG:=_F&:4[Q5I6OY!81!1M)WC<\HPVS6G2DVFZ:N]\TK6 M:-
V?:L+I[-HB M1JN3+)KTY,HGFA1?YZ^HP/25VYU.IKG4Z,T[.Y+5"]({*N:FSO5DV<+&F/P$5 M4X?A+YC,['-@%-8(8+UJ6G94W5V'PT+T18Z7N5R?A/\ F3U'H4:&F:9EJ5.1
MS[9SL(O>T&I2]:@F]*&VSOZU\TZJZJLJ];W%$_*7U'IK3>F;9I&U16VTT<= M'21_@LXJ]>USG?A+YU;G\]*9_;[>5D97J #@ M
!0KZ"GNM#4457&DM+41NBE8O:UR85#R1HZY56PO;6QM0 M]W@]+4NI*E>22TS^&I[%;[U'K]O,\]=*G1G6);-301\,%%5JB>N-R^;FWTX. M-
9E8[%V=SUXUS7M1S'(JCDWDU/3]@.4=&?. FM[F=)\/+OV.T8HJAJ MKQ5J)}I[=Z%;\[5.KGBR]UM'IP>9 $3H M !XX]T)_9.A/D5OTPG?^C7_>%I'/_%K
M/YSC@'NA/D']B\M^F$[_P!&O^\+H?\ BUG\Y0]3B"\:Z7BSQ._K:G@=(-M'\L>Y M :A5RB<%W,Q^H-06S2MGJ;K>*Z&VVZF.ORU%0Y&L:GUJOEI>M?2RZ?T4VIM-
GE585JH]Y*VMSPPW%C5^*B[V.WL-V&PM3$/1:=IX MG2'2M#HZ%YZRV+FSO6VKI8Z;V7NGMEJ1FHM2,3"TU/(B04[OWV1.W\E./?@\
MESU&TSI0:B9./'BIZIM%GH=/\V"WVVDAH:&%-V. "!B-.;U/0G;Y^T]R$;. M%5H:R[3XN:QG2TL^)>2GRBCC6S+HH:9T@D-9?=W4EV3QL3-_6L;D^+'S=CO=
M!$.WQ1LAC;'&QL<;$PQC4PB)W\G!,>A"(*)\)5>3/7P^%I8:.6G&P ! U@ M Y9 6 L !8 "R 'I'T!%,X_\P -SC^U+HQ:7U^Y>MH&MTJ>W<4J MG6.-Z^^1IA./>W"'^D\V.7:3T7=5-
EADDMI)7>4S,M!7-3L5%PB_,Y/-S/> M98WNQ6_4EKJ+==**"X4,R;LE/4,1S7?8J=YKIUW;+4U1XF)Z,C*7%P[R3[4. MUL,Z4.G=KC(K;5;MCU0J<;?,_P 2H7'%87KY2
ML_1,8<1@5*/$H:]QNZ/Z;J49^R|(*TN4N3/8@)(I(YXVR1N:_M^-]4;^GO M_>EM'\;I_HGGK=%?ZRGXF'&_Z>?@9CH/JOZA4//_)SJNWSM.^' N@__'BH M?
XS]OI:=[*^D?]74\3&N-^PCX 'FFT M RE!^QV_V[5+HM:#]CM_MVJ71Z,JC&]P "PX M M M 03FI:7'X%/E?4I=IS4M+C M"GROJ4KGU62CUD8T & U@ M !@ AO#>(@B"&|-X
B"&|- MX CZ3EW2-VE.V>;/*E:67]JOE$SQRG'M_K\YB=):<@TC]FVV>F3$=)"UB MKCRGLB6-7=K%YM=-ONRE=.6=+Q;(LWRAC^#:GC5$7:SY2FJ9HBJ3KX'
M;I4MD[UQU4F>,"KV(J^3W.54[3'B*=_>1JI3Y'K$$$X=G%.'H&\>?9FLB"&\ M-XX"(;PW@"((;PW@"((;PW@"((;PW@"((;PW@"((;PW@"((;PW@"((;PW@"-M((;PW@"((;PW@"
((;PW@"((;PW@"((;PW@"((;P MW@"((;PW@"((;PW@"((;PW@#QS[H3^R="?(K?IA,\1K_O"Z'_(M9_;<<]T*=^N- M!_(K/IA,_=&S^\/I?^+F_P
Y0]3BO[K\>+/$H?ZVIX(Z2"&\-X^6;/(@AO#> M (@AO#> (@AO#> (@AO#> (@AO#> (@AO#> (@A MO#> (@AO#> (@AO#> (@AO#> (@AO#>
(@AO#> (@AO#> (@AO#> (@AO#> M(@AO#> (@AO#>]TRGFY@$>';R-0VH;4[!LETY+=[]4[C#=7^I/W8GRG2O3 M/LO _,?#>]4?
+L\2OK/7VNNE'K:.AIZ9[]=KU=2VF!RI34K.2R2.Y*O>Y?4B M<$/2VQKH]6795#%73[EVU(KS"P,MEF|!* M[#JBKE1%FJ'I^$]?H1."?3M1ZLZR2X=)6B>!A,_M.*>:;^ X=@ ,[!H
M&P]=/,>=!O7IAI]4-JZ0IXZ6]<7U% MMC1&Q5.JJL3DV3YG>G\Z(="N.'^C)93Z]N\3)B<+2O5/+-'D#HYI)VOV5UC M-*ZN6>,3:),I8Z5%6:VNSA4X\5CYY:O%O-.X]VT-
;3W"D@]J6>,IHF))%" MY',>U>*.14YHOF_\O,?2"Z/5-M%)K[8XHZ75,+=YS6\&5S43R5_+3L)W!)'/41,EB>V2)Z(]CV*BM/G;/P/T6+S)-$00WAO'#I$$-X;P!$$-X;P!$$-X;P!$$-
X;P!$$-X;P!$$- MX;P!$$-X;P!$$-X;P!$$-X;P!$$-X;P!$$-X;P!$$-X;P!$$-X;P!$$-X;P!$$-X;P! M$$-X;P!$$-X;P!$$-X;P!$\U]/?^]+:/XW9_1//2>|>:^GJN=DMI_C=G|$\] M?HG_%E/Q,._P!-
/P,QT'_]Q4/9U?TM.^G NA!_>*@_C_]'EIWS>%ND?\ M5U/$E@_]('P(@AO#>/-A$$-X;P!$$-X;P!$$-X;P!$$-X;P!$$-X M;P!$$-X;P!$$-X;P!$$-X;P!$$-
X;P!E:#]CM_MVJ71:V_P#8]>OZ M5+HI&'51C>X !8< M M M (OS4M+C\"GROJ4NTYJ6EQ^!3Y7U*5SZK)1ZR,; # ;P M M 04B04 @ 054:U5541$3*JJX^?L!(J.UC7L6SC0=TO3G
M)X4UG54D:KY<[D5&)ZEXKYFJ>4NC3I&34.M*G4-8CI8+,BR(Y/A*E^<+ZLJ MY2&WJ!.9/M=UW3V>R(Z]M-'+X-11L_P *F<] [-]$0;/\ 2-';
M(U;^=J+)4RHGPDR^4OH3DGF0!.C#+&YAJRS.OLP -!0 M ./9S/!+W2,V,_'(36IBPT-,+1^, M%P2"HY[R+V(&<[Z"+)H3"\VTU_#J2=V%,547PB!R,'3(G%CD]#D0 NM@6T
MI=I>@(*NI?F[43O!:U.2N>B)NOQ^4W"^G)T<\:=#_44MGVDUMFD7=BN5(]KH M\\$EB7>3UX5Q[+/*JQR2L>E3EFB 4DP M 0]>/. 1!Q7I.;=+KL.L](@[304-?)?V^Z
:OY_<[8<5V]_$0W'0731U-H#1MITY1V2SU-+;;=M/'+.^3?SM"7^,5 M.B;#>]B-D,]QHHJJ2./.XUSVHY4;GLRI\MBL!6P<5*HEKWGN4,73Q#<:;V[C M. \TV M $$Y?
8:7M\W5W6S.^]T=*QR)4S8X-;G8]//83C2S2ZJ/E.F>E/8X*C0UJ2V780LUFU=TI-IU36UT[-MD1[D=5:=)IXH(<^+&Q%Y>9O;Q5>U5]KZ*T7;-.;?I[-9:5M-20IE7<%?*[M>
M]WX3E_J["AL^T#:MF^F:>RVF/$4?C2SN3[Y4283>D?YU^C!L9ZE2KF]V.R/ MP&*X*=;]\U26[_(S'L@ #
MGE/IY>L_=)G8$FL*.HU5I^^F_P"7;=F]5TL:*]UD:)QXLIU)4I71CQ.%[XJDZ9>A[TB'6^HIM ZEJ5\%D7#>E3L4^YRO=K6Q0=5;JF5%KX84QX-.J^+*U;QK
ME1/0Y?.=]Z?6W7]532CK5=II%:V9SN=5#R;-Z>3? 2CVE6-P\9KC4EIS M(]"=(5*-3^7XI^\NJ^U=AW4 'A'W8 M "9I 6ETNM#8Z*6LN-;36^DC3+ZBKE2.-OI55PD] M[Z6..
[.JGCWX.#>\2!J^3)+CBB+V-YKW1S/(-MT_M2Z5&H9:M\DUS@8_=25U M3NHH^3\EJ>3P[FY=SSWGNX3HIU:?&K2R0[7^1Y=?'1IRX=)9!'KS4'3"V6Z? MD=$V!S761O9;,9\K?
T^#5!2F_NZMF_^+7W_&-O_B&K:4Z-HIX6/U}BLK M)\>-#;86O1!YMYV]^O#:5Z"NS?\?>\?Z8W_(#6X=$T_=MDA_= MU[-O\6OO^QM_XQ_=U[-O\6OO^QM_XQ_<*I-OO[_:
L;_P (_N%=FWX^[_[8 MW_A.?_B>\[_^0[A_=U;-W93P:^_[&W_C./\ 2?Z2.D]L.A*"SV&*Y.JX.]M2 M]:RG2-FZC'(O%'+QXH=@_N%=FWX^[_[8W_A'\PKLV_'WO_;&_P#"7T*W16']
M1JPS7134IXZK!TY6LSEW1MZ4.C]E&S.+3][ANDES?,%K[_L;?^,?W"NS;\?>_P#;&_\"/[A79M^/O?^V- X2-6KT57G M*I*\V]D]=/'TH"'M8?W=>>5;_.!:^_P"QM_XQ_=U[-O\ %K[
-+&W_C']PKLV M_'WO_;&_\(_N%=FWX^[_[8W_ (2K_P#&?^19_P#D.X?W=>SC_%KY_L;?^,K4 MO3DV9U$R,E6\TC%YRX4.43]%R]4?]A79O^/OB?\ U8W_ (2VN/0.T#4P*VDN M=
[H9>R1TS)$];5;QIJ"W1+TU.7Z06NAV70^U?1^T6-5TYJ"BN4]EU.QZLF; MZ8W>-\V#.SY^[3.B!K39@UU\T]5NU#04OWWPB@1T-;3HG'>W$55X8YL7U'0N MC?
TP*BLKJ/2VOJCK73/2*COK_%7>7@UD_8O'@C\YSA%3B5U^BXRR\;"3S1[M>]TL>X3X>(CE9[3V*G 'SMGX'L ' =0,M.OV* MWU_2I=&ZXQC>X !8< M M M
(OS4M+C\"GROJ4NTYJ6EQ^!3Y7U*5SZ MK)1ZR,; # ;P M 04B04 @ #EP +@ ?!#OI/;>>^E;M?73MJ71UJ MGW+E7,1U=)&[#H*=>3,[CGIGT-]V_5FIJ71NF;G>ZO?
UO0P.F&9W**LIJL=`MZ-FRSWLI&ZKN4.*F=BMH(7M^#C7G+CXSN&.Y/2=W3NYIY^88UL;4.QK6L:FZ MUK>2(B(B(GF!Z1A (IGL(2.2-N9'(Q.]R[J %M[Z4*G(@ M
";/&^%W/%,XP2C../8G$ \G;,'+8NDM01M\5$O4T']>KT3 M'<>YSPM$[P+UH@>\[\=/M/=*\.']//Q.YMH[&.3H P_+@ M7 N !< "X %P +@ 7 N !< "X %P +@ 7 N
B9*+ZZF MA=NOJ86.[G2-0IE;(N<8[LK#GS+,WRI/\<@_E6_;/?*D_P <@_E6_;2R2[''' M%[_B+2_;5LNJXX8KU::*[Q0N5\]3:V!LR.^5)_CD'\JW!3O&O'XGZL6P_=\#
M6UV0:$PO_J;8O_D?']AL]%1P6^EAI:6%E-30L2.*&-NZUC4X(U$1,(B)P)/? M*D_OR#^5;]H\]3_]R#^5;]I"4JL^O=^I*_J_.J\"Y\;>^5)_CD'\JW!1[MYTG^-P?RK?
M(99=A/C4^TN04X:B*=,Q2LD3\ER+[!"E0AJMR<9*>]_7) "MX %P + @ 7 N !< "X %P + @ 7[# MO@ G+BN$[5SC'=Y!/!/8YGG7IC;,:'TDS2!IG6.^7J->N?&N'T]
(O!RHO8Y_MDHO=DT8>FZ]102//QV,IX*A*M-Z+EWG/MZ[ND_MGJ]LFMX=,;>62JL5#4^#TT,. M#?-E>T]#[#MD--LFTHRG>D3IO2O)<3WMQSXGT=24:<%2I[(^! MP%&>
(J2QV)ZTMNY!,)R 'C/H M "YN5MI;S;Z](@KH&U-'51NAFA=RX[Z>8YATAMEC=I^@9VTK/\ ENW(ZJH7 MG'.7'C19[G)\^#50]*.G"6S/$Z2PLJL%6I/WX.IG9I&:OM^O-
+6W4%JDZRB MKXDE9GFU?PF.[G-7**G>GG,V>(NA'M;=8=25.A+E)U=#=']K/0))^XU\)Y MZ(OYS4[SVZ>'BZ#H56N3/K^B$%#3O7X:H= MG=RGQ4PKE\S3?
3PIT[=:37G:+;=,PO<^GM%*V5T:<46HF7/M1J-3UGK=%X98 MJNHRZJU9@QM;@T;QW9JNP78]=.D9KVX7G4-5426B&?KKK79^^5$KERV%B]BK
MPRJ>2WU'T(LEEH-.6]EMEKHX;?;Z9B,A1J=NZQC4[$^WMYJ:IL3V>0[,-F=C ML,;$;41PI-5N1.+ZA_C/5?6N/0TW@GTEC98BKDCI".B1#!894H9I;R>K8 !X MUST@ !< "X %P
+@ 7 1RMXH>+^F7T?J2S0RZ_T[2M@II)-V\4D3<,;] MRX;4(WN5<(Y.]47M4]H&,U1IZFU9IJ[62L8DE-<*:2E>UR<,.3"+ZEPOJ/1P
M&+GA:ZE%ZR6FYSNFO5A5L#Y'KETU.]+U3U M7M5,*U5[=U#O>5YSPM$[P+UH@>\[\=/M/=*\.']//Q.YMH[&.3H P_+@ M7 N !< "X %P +@ 7 3
M!EK=^Q6^OZ5+HM;=^Q6^OZ5+H]"&QC>X !8< M M M (OS4M+C\"GROJ4NTYJ6EQ^!3 MY7U*5SZK)1ZR,; # ;P M 04B04,$ 1 'T@' ^F/[!]MV>VVU MQN5JW*N3?1%\]D;=
[']Z2M7U&+Z,FGV6S9VZXJU$J+E4OD5V.*L:NZSZ'+ZS% M]-F9W7Z0BSXG5U$GKRQ/HR;[LK05H&&L[R-Q M!H*_/G(X5>&,G)-I&W:*PUDECTQ"R\W_BU\B)O0TR^?'E.[T3@G
M:_=)ON!+516A=67>X0V^F1.#YG85WF;G;ZCD-\Z2:UTTE-'Q37-V<)5UF\R-M-/.B(N5]:H<^3357[*X+=4U\EXN#N.JWWMB=B(G+'=R<##8(8F0QHR)C8XV
M\FM;A$(W)6+.NU)M'U*KEK=1MM,+OW"WM1F/-E/M,-)H5*YRON%YN5=(O-TD MR_/E5R:0#ATU5-F5C_"BF>O?UG]039I96Y6-M1$[XS9>)M0
-9I]&55M'L4S5#JW:5I[']@U_AO,2?N- SEHZ2LEOD;# MJO3M1,^,/"Z)=^/T[]_4JG5],.TL>LJ;K[-M:B9=&Q<2,^4U>*>S!PM[& MR-5KVHYJ%1R93V=IKM=HFF\
(2LM4\MFN#5WHYJ5RM3/H3BG)'?'K'G#2V MMB%;+4SJZA5=UEV!6Y*+WGBW15V\;75%KN[&X964O4O=^7&O#_=<>
MIMDVJ$UCLWTI=M[>DFI&LE7/[HSQ'_,TPXI;,UT&;8 # ;@ M 2R2-BC<][D:QJ9#2E/L,_^X7/7M5+!13OMUDCW;5JF-'/6,'O048O*G9'R-934>+*&=O?7;N M5SJWZFEA_P
5E_E7!-FMA_Q65/\ 7./*VP31^M[LUIOE;+M6U-:/>VN\#1L< M[Y=],9WES(F/1\YU#7^E}1;(.C]K21==WF_W-5CF@N-2[S)J9-]C5:Q4W8;* MFS:P_P"+2K_KG#]32P_XK+_'+..?
OU!=4ZGR7KWQI6WCIF6U'OAU]I=UNXGCI MZKG/G\YS,9%LDUIM.V>VC4TFV'5%M?7-D5:5CW2(SZ/6]I+?K?<* MC:]:YP4LD]**?/5SM:N58[IXO!4XK*YMH4E47OTE'T-7_4W
ML'^+2?RSA^IM8?\ %I/Y5QLYB*W65@MMQ:05=\MM+7N7'4LU9&R55[D:O94K M4IOFR^5++#PZR2]#$3[.*.%EM=546^I;Y+DDRW/G[2[TKJ>K]7V2\MW;BSX
M*;'BRM3Z5\ZUKI8VODXL:KT17>CCQ-2VB1)21VVZQ\)Z6H:B.3*9 M:JY1/:AR4>*LLMR/^GM5HZ=]Y-&](N?](D&NWFH[CXR9^,_R(GA-6:/]XO.L MVUP #@ Y<0"QOEZH] M-
V6ONMQE2=@HH7U$\BKY+&HJK]\\YK5#+.DSMOEJ:W?CAKYEJ"C'%*:C9P1C M?S4I]>=?.>B.G/M(6RZ1MVCJ216U-X>L]5A<*6[\RGH^K*I16,=:, \2YZ8 N !< "X %P +@ 7 3
M!EK=^Q6^OZ5+HM;=^Q6^OZ5+H]"&QC>X !8< M M M (OS4M+C\"GROJ4NTYJ6EQ^\

4,>CU8WN5,0BY-,3DKZFB%*57-M$4U&67W>[\RMLQVG;XU?]-]#J/9K5Z1MZ0NE2X3U"R-WT5-UF-U.>5]AO5?K-M?*
3EIJY*6NU!:Z&ICQOP5%=$R1G;Q1SD5.&%]9F3G&J>CIL[UQ?:N]WO3<=?<-MZI46:H6HF;O*B(U.#7HG)$,F:$I;JW@>WDKTZ=H-2EWZ?)&.V!{5X=+;&;[?
MI.72E[JK+*&&IHVV2I#*]V%7+5PBM.JJ.)LBZ*&C+OLZM]RU90S7]^WBF.63-MUDE3(U*R)OC,+51%3*NI.[@LMCG2+DB=\!GOPDJK^;CT>E-IW_.$;;_L,?
9Z3SEL"VD3Q:Z36H;G44DUOH]743-MYJ!LS<+')"=4[ER5K'M>FXS'K&M#MQGV]=(RH:1ZOJFO-M.;*5?>;IHHJ.!"VT=/1TS$BI[>-.L,3$3DQJ8:GL/(70MTG[Y
M:RO^_F9O16RF2&-SOQTBKE?4UKO:>Q/[?/\ ^1]3B+1RTHJ)'YST1&515,5/-MK3?P ,1]"-M-11<*B\U[$7D>#]H%+/L(Z0:W&@8K*>EK8[I2MY;T#URYGHQUC3W>>9^FOI!
MM19K#J6-B]ZEE6@G=C\!_C,SZ'(}>LU862NX/F>%TO2;H[M#K0=SV'05\%VH-M.;:NI7I)2U43)HGHOE-1]NE5>>ZWQH_F-MN1/4=K/FZU-T[C@^-1][@<0L3AX5%S5P "DV@-M
T74&W/9_I.:U-IO&JZ"W7*F5&S4LSG.[%5$5,X;W*A;3ISJNT(W(3-MG&'7E8WH^=^N?VY-1_UFI_YT9[&_NE=EO^2'%K_2?_P>)XCU?JRS5W2BFU'3W-M&*6Q+?
X*I*YN>KZEKF*KN7),*I]3T+AJU-U<\6O=?)GA(5:4E#+),H]*)? MA'>E?I)3FSNDKLM5RKJW%KXKE?&?]A>67;WL\U#=;2V6O5]NK;C5R)%!3Q]
M72/7DB<$/G)X7$1;O!Vf,.]:%>EHLR]3?00]\(B9.XU:<@-<-M-!&+RV^DYY<.D'LWM%PJ:&MUE;::LIY70S0/<[>C>U<*U?%[%RA09TE=EC5R-MNN;7CY3_/A-
D,)B':61M>#,T\122:S+U/'&PK]MU1?QSDU!<;C#269EUK)G5TBKU;6/;-NNYF,/6J3@X1;]U;(\KHZK3IQDI26[YG2@:5I?;5H76EZCM-BU/0W6YRL<[E+
M3JY7]NJU^6G3G3=[JWB>Y*49ZQ:8 !62-M_"!EK=^QG^OZ5+HM;=^Q6^OZ5+HJ&'51C>X !8<-M-M-M ?PBV5/H%*]VU\U#=.;2V6O5]NK;C5R)%!3QJ
M72/7DB<$/G)X7$1;O!Vf,.]:%>EHLR]3?00]\(B9.XU:<@-<-M-!&+RV^DYY<.D'LWM%PJ:&MUE;::LIY70S0/<[>C>U<*U?%[%RA09TE=EC5R-MNN;7CY3_/A-
D,)B':61M>#,T\122:S+U/'&PK]MU1?QSDU!<;C#269EUK)G5TBKU;6/;-NNYF,/6J3@X1;]U;(\KHZK3IQDI26[YG2@:5I?;5H76EZCM-BU/0W6YRL<[E+
M3JY7]NJU^6G3G3=[JWB>Y*49ZQ:8 !62-M_"!EK=^QG^OZ5+HM;=^Q6^OZ5+HJ&'51C>X !8<-M-M-M ?PBV5/H%*]VU\U#=.;2V6O5]NK;C5R)%!3QJ
(\A]-.YI+K*PT-M2+EU+;W2]GG?(O\ P'9]GUO6TZ$T_2*F'14,*.]*M15^=3SATAJAVJ=OE?11-M^.C);@8GH1N?GYZOKV!KIY%CI(W+E-M(HTX-
1/0G#TY{SIW24U'+3:A.*^W/M4XR2*__D ")T-@YJ2-5KD1S7)-MNJU>2HO!4]A-L:U&_0.O)=,SR8L]Y=UM)O>3'/W>;.-U?S2"<>'?P.:UW2R.-MM,=PIUW:NWRMJ(W]WC)GV81?
4#C(60,7I2^LU-IFVU9B^+64TI4-M2RA,B-3-7#D7UGE#8&OOOZ1:AZ1U-MU?&Z;T;>[FY<+3TDBL^6J;K?G5#AG0UL#KAM-NMW'6H?TY0S179;7Q,E-MI?
15AT53U,%@M%+9XJB3K9HZ2/=21_+>=WKS+[^V&W:FM-3;+M0PW*WU";LM-M+4.WHY,*BHBIZ40PGO1K/_*E%_)I_P-(JZ-9_P"5*+^33_A)YH;YT1O)0R<)
MV\$;!:K716.VT]NMU-%1T%,O(H*>%-UD;4Y(U.Q"UU%I>SZPM;K;?+,2W6WN-M>UZTI7&CV;R+P7'>F3$^]&L_\]47\FG_CWHUG_)4HOY-/^$YFA>^=-'"*3
MCD=)V\$99=*V=E_N>6VTWO'U@GO\&I_P4"E%_)]_PCWHUG_E2B_DT_X26:XT<-MO*\U2=-^VR-J!JOO1K/-RI1?R:?\(JZ-9_Y4HOY-/^$A>G^)%0$]?VY>B-JX-M\TY]G,U*Z;
(M$7R[K=:_25GJ[AG>6HEI6JY5[U[_%D_O1K/_*E%_)]_PCWHUG_E2B_DT_X2491CM-%4\U3KT6_)%_5:(T]5WJW7EHLU$^ZVQFY1UBQHCZ9B
M9\5B_@HF7)@PEQGJ6FI]2WTBJ9043^N])F^2YBA2*/\ "7.5]I54Q$(*R>9DZ6%]5VO?D>8^GGJ9:#9_8K$QWCW*X=:],U61-SA?-O/:>G#PIT\;\M9M,LU
MKC7>2W6M';G:CY]N/8UAZ?1L,U==USYG^(ZSHX"5OO:>IU#HCZ=2S:(H*US M=V:ZU4M4JKS5J+N-^9IV@U_9V9&Z;T'IVV-3'@UOAC7[IB*OS]OM-@/1J2S2 M:/.P=-4L/""Y)
%9L M-!&VS3/W6[*-36YK-^;P1T\/FDC\=,?HX]9NY!8V3-='(F8WINN M3S+P4E"662916IJK3E!\T>7N@'JKJ-3:ET]^&UM*RMA:J\%?&NZY/3NN3V'-MM5/[?V]A\ZIA-
0_9UTH;=0/=U;&W.HM3^\-LF\QOS[A]%$IG9\YEZ3AEK*7;-MBW^&*SE@Y4I;PDT >.?7@-#YS$W+55IM$BL]
MZZ*.3)6U5SU/POT.OMV&_&O4V=.P\M[7NAG==EN>]:GI]54%\!#<)&/;32T<-MCW,PQb+%*]M?&EA-*.)9V/K=.48ZJ4XN7P1[+NFM-/V1JK<+[;M.+OZZLC.J>I5-
=J=N^SRE54DU?;_%7'WN57_$(IV+]IFEBARP[6[W-5O!4Q\Q \7Z?UIM(V=N1;3?77ZW,_M]WW1%DX=R*]Y3\U3M.SKI0ZU7
M&G'6.J/9PO2]"O[LGE9V<#GA47**F45.U.\&3?F>XGS6H !TZ M-GL7L /"^V]KM&}.IN,2]7NU]'<6N].XYR^U%/HTR1LS6R-XM>F M\WT+Q^L^??31H4I]IM%4-3"5-
KCX^=CWHOS8/=FB+@MVT7I^N5<^$V^GF_2C M:ISI+W]<)'G?P[_3Q6)HKM3,T #P#[X $6>4WT@$]2S??4\])D\W!{?2G;Z4).+2.7N9_M$./C$2)T !/1D
T_6%IK);A%8;2D)Q_HAM1O1Q1$1$1 M-^MX8\ZF'Z'4;LQOR(B)_R5)Y?O:#0X.*DI[&GCDTI?%9IR:/0OO3J?SAZ-3

*@LC(6.ED7$<:;SE7E-MA.82OH1;M&[/#&<V]SM9=).]M\7C;UPH[9.-M'U'SNV#4[MH72?MU>]-]BW*HNK_,UF\|N/7N^P^B/>OGQR_MWD.DY:QAW&;^_M%X9N-7?W1:>0 !X1]VM_"+4WG(G?P(!%W51>[B%W@\UZFZUJO>N781.7$LV=*796KD3P&[<_|*@MF>-MIH-06*EKXKG!')$QU17/E9NO;NNRU>?!5.K=_/GVGS&,>'E4OAE:/>>[AE64-M/Z^LNX@#SS6-$#,6W]B,]?TJ79;6W]B,]?TJ79Z,.JC-M"]P"PB-M-M-M-2_A%I=/@&_*^I2[_"+2Z?-^5]2E=3]LE#K(Q@/.-8-M-)-M5)B50"-I*X-%P-+@BQ5;Y%1,D-E,+GBG)0+GAC:QI^MV+[9WUU#'N4[C-MWRH':OFP>H=,:BHM5V&BNUND22DJHT6+<V'E/95M'K|<IVDZS7R":*VNGZ-MNMI7IX|-*G!9&IZDSWIQ+5IC6-I<-ITE3#6&\513RMJ(OF(^.9BYM:]]\E0J&@H-!H&V;9K^J#IUKZ-$COM O744F<*Y>;QKZ<<.Y41>PW\CQ_|-M^0!Y6TMJ#WXII(JE]PW*F7]ZB%R85'(N%7!FS;-L6R.HN=4NJ],-2*^PMWJFME1,)5M3M^7CG\;@<\TYJ6#4$+-D1]P5<7BS4\G!S53@OJ_P#)3C)F7-!$-M-#V^-HP-ZOT\E=#9;+"ZNOE4Y(XXX4WMQ5[5\Z(-2U%MJ=H.JZ+2--MM:Q4EK*IO'+N/B-7XK?G557N-X)D6-#@-M-+"_P!XCT_8KC=)E1(Z-!ZYY+NIG'K4-)KM3*PZ>-H-Z>"W/2FCBC-M7*R5$BHCO7E4;ZCUELMT3[-M$V^R0HUTT;>LJIF!).Y/&7T)R3S(AY1Z,>MG)-.]8??>M19F6])+G,YW;*YRHS_'ESZCVR>?B)_<1MHQLK@-&(U7-N-M!<-"X-%P-+@-7-N-!<'CWW6']IS>/XXH/Z1Q|"/'GNL/[3\?QS0?-MTCBVGUD0D_=*G2'_/9@U?\-U-MGT0'1N@9^T!V5?Q0G(\YSTA__9A5?_4V-MV=GF@-YZ"=^M=-T1-ED.UTH(O?6E$=')4QMY2-M[/W->OZI>TKBJY_Y6@7Z8?05++-S)YGR/6-WV8Z3OFM;1}^X;=M!7JFSM=*07M:6!%J:9JHY%:UZ=F'O\-%7AXRG%^G%TD;1L-V0W.SQN2Y:XU722VNQ62%.MG-MF?*U8EF5E++#9}/6^ND1\DB1-MM;$VIJ7)A5\;'#AONRG!$54PO1BZ,<.FM83[7L^J!9K3;%7IOM=+6Q/IK,U-M45$BA3>W=|$RF\B(UJ^],SQJ*7FWI,`]78'8++;-F^QRXZ]WZ298]:MR-ZBCMC(MQ&,>UC%7#MY<,,A2%$#:=O^TR|[.-BFK-;:+M=)JRZ6>F\+91.F-M5T=NIC.[Q7B;_T9.E)4C;YL;LNK77NT6^\>+#HEZMS:ML2-MT-0WA(BM>[>1G!7-5<^*]>_B*Y%/<[*N3&W=:WGQ7W=PRF>S!_MD-Y-M>USW435NL]MGCHJS2EHT^M%>KO18\&K*E6-CX/3@\7/1N%3RNI5?.OT!\XJ;W)4!$_SG0]+Z-MEH=662GN=ND5]+,F$RF'-:HQJ1ND248S5TC<}>7&H-MUS?UT5:I5BI(F}=:R/BD;$XI"B_&7AGTEOT;V|FC+BU."=T#M2-MTYHRPNIG6^]-UQJ7+-6U2TB*Z694XKG>)Y)GN\Y-T?M;45OHW.:?3U3ZRMK'RM1S,C186INIY3NQ>'=W%KA_3<;%KA+AN)F:&AI]:[<[TZX1-J;.R4S8]>&9--MYB/RG%4]*N4N]O&FZ5ND.?ZEIXZ;YVV>.2.HC:C78WD3=7'-.[JE/9_^M=M&MO*=Z.KY6MF;E..ZJHJ?SD.SMTG;!LNO&]P5_5L\!9&X^@C=J;2[B-Y9XI=Q-M/]RI2]Z)M5UW4WY6QS8[?'8BJGM^@Z_8MFFD;E9:&K]Y*9RSPQR*O'CE]+WGM&<A$Z@V6V2"1,^!Z=N.Y4:BK,'S!HS2-.ZCTM(:7SL8C]2,2\-D*E^-2'B*ZDVD?\A4OS_>M1MH/TE=&8+G2CZ+Z'R/MV*_NR_!V?U-2_4ET@O.O4R)V\-(^(YUM2HH):61EMMMEBI9KU.GBMPJI&B_A+OXJO8AW+O[NT\|5+?_FM7Y*SX?>=U&_W8;NX_-/D-M?XEAA\%A$J-&*E)VO9:(|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|<]^_^3+,_+#V$"2E*/,YE3//FPWH(().CUKANKM&-M4%TIKTRFEI6R5EQ=41'(B(!Q%1,\CT&G+OSYUY>GS-\&V+5&VQP#:IT&=ME72*UHS56MZ.\5EW921T3'4MR=#&R)BN5$1B(N.+W+Z5.>)[D]T>$_|<]^S-M_'3_-/A/80)*II["42U755L_7O5\F-[+E3MBG!.!Q[7/N;_1_U[]2.!U>CYK753N62>&SU\E+3R.5Q4\Z+@\G:HT5<:B]VO3E=5PTZM#3*3;M8@Y5G1O3/%6]G%_M4^LT+8OI.Z:.TS64=VA;3SR5;Y6M;*U^6]B)G@O#ER-^!!2>6Q'.]6.WZHM4Z5]{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{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l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|:"SPRE[^MC\9$3TIO)ZSR#]H]>_6G:695^-QMZJ.1.W-M>-1/LQ[3U$LU.W8?GW2M^A8IR6TM?,S@+SR-8765R-M2UZ:KYLX>Z/[V=^7<,'M,T8:FT^_:-M+T#*+*TW6I55R_%B;Q7YOYQU22]Y-M\B48N;4(IL]/#:-+KI'9'IN@D:NU$E/X5,G;O2KO\?4]>PW\(B-I&M:C&-\5MK43@B)R1/[=P/#G)RDVS]/H4U1IQIKD@-")>-WQG(B<550R/,/23UU-M4;4=J%/IZRJM92V^5*"DCCXI/4O4>A#LE=>M0U&NKG%O45MTLKK^QV_+^I2NIU62AUD8H-G&XM-M-M-'&*(*532PUU+-35,39Z>9BQR1/1%|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{(>-MD7#)#3VC5L^X]{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`>K=VI>JJ(U554.B)Y3E1$3TF$LEGNVV742ZQ4=<+-MJJ+N1LY83O7N1/*!]DM#[-4;<*ADB-DT[H_>^^5LC?OE2B=D;5\5[_"4Q-MQSP/6>B]$V?0-AAM%DHVT=`Q7M?([M>]R\5BU9[.!Z-GBM*M516C_T(;&T3:]GVFJ2R6>!(J2G;Q=CQY7KY3WKVJJ^SDAG0#RF\SNS[N$%3-MBHQT2.%@-'IY-\]})O;ZW25'4:2T_5?]MU#-VLJHW?L,-4XM1?QMBI^BG'FJ&2Z0G2'BV>T\U@L$K)]3RLQ).WBVA:OX2I!=>QO9S4YET9>CE5;4-M+HW6&JV2KIMLJRL9.N9+G+G*JN><>>:_A8PG;;(0A1CQ:NQ_BL14Q57V+!Z-MM[OL-GZ'O1X6JFI=?:DI<4\;(UHIIYFKB1R+^R'IW(OD>?CW'LA.*KI26^)D$-M;(XV-CC8FXR-[(B-;B(B(GF0E/G.1B5)5YW9[QT:T?3Z/IJE#Q?>P-#.>]-M-G]L-'$=<=+?2&E-M05%@M=!=]8WFE=N5%/8:9)6Q.1<.3?QA51>[NYD="=+G1VK-0T]@N=`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`=-&WB-MH7=@IK]3=4R15Y-1^<(OIX?K1AM,3-M8U;ZH-2.5KW:]8=G-]TU:,,SX9X9J*H\&HO!H-]F_

1N\C<\5DOKVKU_P!#_3NH6Q)3>_%51NK(F\NXF_>3Y.^MQ%]AG+!4=)BDL5NAMMIT*VWQTT;*9&R.QU6ZFY<^%W?20HX;,:?$J).3;6KLE*
*MX'9UW*66%TDEL=4V*;,+7MEL]9+!25%GO-ME\'N5HJU^^TLG8OY35X\>"Y14 M7'I.NNDI=?N\K=$[-](R:UO]#PKJATO54M.[DK55%PJHO!556IG@F<*8C83L MZVC6G;GJ?*
6,L>QTOOI0)#60V>K;Y%F:C%8YT:95%5&^4]\<^@DV,;2^O M*V=$6{SW^3PMZIX_DY3/K5Z^DA*A0HN=1+,DEIRN^_L.QU^BC"[3=]? V#9 MU'TE;M5[0:?*
*0FT?2;Z,U)6MWP)\<*V2?MTMKJ95%=21JG>OP7$I4:..;$ZBAEM'.O]BURJ M4IQ@Y73?]N=1V!]9VI$-,6Z]NM"WA*RO90]2D_4[F\UR\V)NN!N7#GS.6=*Y M_6;4-*
*AS\8WKOO8SWR0\//_65NGO(UNS'3;57"NOT*HG^K<8+!JR72#4>R&2R M1MEO3:IZT3'IEKILQ;B+YM[!KP-&"5.5M7Q,=F5X(14VQ[::K8[H:R7RZ:=BK:ZNJ MXJ.:@BK&JV!*
*[V]JXDW/&QRY)E57LY\;Z/=/4;*MOU^T[M%AAJ=;W^>)M7;]22 M/W_"=Y,OA8Y>"95%3ACR=WE@V7IX_P!Z_3O\?0?S'%,P].%>%++=/G??P)QK M3E3E4^'8=*
*VW;>;/8E]RLMPMKJNAO%2Z&:H;/N>"QM:UGSX1%V4{JR>'(YY>_M^DCM2M\M?JBFV0RMT3&WK^NK*G=K'0\5ZQT;5RQ,87BU<9554SE=L@*
M@G8DD,E[1KV+RIRBGH[6C&OTG]-S45G@%2BM#/@W_P#EZB.7#T8PS0S. M3;UOV\CMZE1S6:RC8U;3VV&UZKV/S[0+5!)-31T,]6ZCEC2JNZ%6J*
M4Y_>+KC^2[/6OSG0^A;^UVTYVJDM3G^552JOAH0IS:6JDK>!91K3E"ES5S8 M;,,6VHV\U6S%;.K5I[?X?IZ>$>5EJ+N=?N<.?/>-4UQTITTCM,O6A8-)5EZO M5/'!*
*[WQ43(YB+XB+P7*M7FA1ZXN M*;:SIV79:S:$^H?3;==0^'J^1OWQK>6XJ9XOWDW<=_I.-6WI%;6]>4'OWHC9*
M(\JTZY7=347"N1LL[454WF)EN>+RSQX<2ILNU5IS1G0PLUUI;11W^514[VO MN89TD2H>L[D80Q?7AE5QO7EC/86FEMH&W35&GZ!=%;.;!I33BPL;,TN=3Y,")*
*MX]HS>3FGF3LYG*6'IP=$W?:|8-)Z4J-7;JN=_M\FJ(5K^K@@A8YZ+)*_L3>7'-/3V+O?16CO\'28V1IZHJJ6MQ_@T'ATU"F[MZ3?:P8F$X(BHGLAT(Z6E;6[5JHK6^&K?G1O?*
*CQNK1TBM3T9WO8:G"EAE52C M=63YV_X*5*I5E"\K.[-ET!TE+P[7]+H?:.5I%VB[!7)^L)HY>LIJEV5PU'<>*.MJF$5KE3..6<'>_]9/,G3C:R&W[-ZRGX7>+4+$I'?AX5&KCT;R-*
*^8l.+G>7/E-M=N3Q\3"#IQJPC;->Z\.P]"A*2E*$G>UOB0 !Y=S:. =3!F+=^Q&>OZ5+LM+= M^Q&)?+P$NSNO[':\OZE+S*
(LJK^QV_+^I2NIU62AUD8H_M 'G&L_M XP 1 !1JZ.GN5+ M)2U=/%5TLB8?#-&CVN3N5%YG&-:=$K2.I))9[1+/JRJ=Q5?[Y3JO\&Y>']5*
M#MD)QJ2AL1E%2W/&UWZ'FM&95MU9:JE'\9LSH')Z45%Q[5,='T3MHTKL/@H M&)WR7!,?0>V@:/:.A7PHGD.U="[4DV'5U]M=$B^4V%KY53YD3YS:.#H4VEC4 M\-*
*U172N_^GES4_WE4]'@@\14J3O"B>>YNA=IES'3O6

*%W[9[H-MRJT[9[)5-K+G?IJ-*1E1NN:YK=UO!5X*WO7>7L13V:|R=U>+>[&2+?)1.3>Y-M.1="PIP|V-I-6WT]"#PLF|977AKZGE?!%7Y=F?23T#KZYVZNJ-.4MODH:BMDBWU:_>DRU4Y9Q(U<*J<,X+_-&WVV\W^JV?;<-G]NGO$MKITDFM;X]V>:C?E-MR>)E5RB.>CD3*IE%Y(IZ9\K.414\Z9#?%XIP7LP1CCLN5J.L5;N:?R)/"];W-MM&[^-#/,ETZ;]HK[/+2Z.O%$5.W(]LIQDG'"%DG?>_Q"PLI*6:6Z[+'GA-C%-M;Z*6CK13L.0WF-MDM<-:;]HK=QT52B*N,\T1W)5\Z+V$-G^V&IVF]'W6MOOD;Z;6-BM=51W2FE:MK7N5(GiV7'RD7'S'HA$W>'9V\&ISW41>6=TCI;F7OQOK=-=VM_0[+/+EME-M?*WB>;=AS7)T)*1%1R+*

*[U7/@]*B|Y>PV7H7M@A5QG$A.&7K.^YV&'R23OU58\ST#7)T^[F[=?N_&Y4$/6(Q5=O8[E5%5S5:]HJ914-MX*IZ^W4SG"9]!'RFJCL*WN5,EL<>MIQNK6M^96|*

(]7B[.]SP[T@=IMPVPUFA-M+U;M/7&U:,H,Y4#%3UMRBZN6NJ'N:]JR/]D;6M5-[O53I/3):YVL-C]M8Y?^-M7\KNH]X\>$],)AV$5&]BZ3@WTH6?*

17RWIH^Z$RCD7'PC'G.4^^/.HG>,9(W'+")W6A-MBV]B_H<*W.]R_@_U.]^5CS#T7:>>:;?M\BBI>/.M-[*]H^GNCHR^:?VC:,N.6J/#G2>^K;>VI?4-X)A'.XXSE45O!=()IF1K>Q$

MZX(JF]C(]'+*9-ZZ1BW+-'W6ESUNN\R^QM6:EJK_$\.Z]VG7O:!MTV6:KKM-M+W#3.D:6Z,I;,)<(E:).Y7M5[W)V<5:B<.SFIMO2EJK[:^DGLSKM-T"W2\4=-M%)/!1*

<5&Y]71Y[W-1R)Y\'K5?&QO(B_*)4:F\BHB;WQL)D?S&.924=$FK>-M)Q8-VDG+>SV/+6M^EQIV^FJW2VA](ZBGUGR2NA8Z>K?&N6==*

*(N\Y$7M1,HW/;N]QT%%W:XXJ0,E;$QE3X=..5;O6YHIT)*6>5W.-)JS/GKT<+M#L>Z4-?:+Y(V@9))56=\D]fK&R.>BQ*J]*

*MB*J)^DAJ"T8$CM7LQCOZD_<<$Z0_12MFV>K2]VVL98]3M8DW>]W77F5T?5XX99N|RI<3D^HK>S](*5U%&2233[CPZ3KX3-#+F3V;--VC7"\;/TPZ6&Q.2LI??*EI(HHM?&:L<&ZLLB>9-QZ^1#8_=#W9VBZ95$XK:Y.)R_=5.^=\?HOVC8BV6Y5%3|\Z-MG](^K?6[F[?3L[60M7CA<)XRIE?-@P/2=Z,E|VYZFL]SM5YMULBH:)U,^.L;*

*M(KG.5ZNRFZW'FXFB&.H1Q,5%VA"+5WS96\)4=&>GO2:9H&UGH26>CV.%3F]%,H);1M,3/K-*OL=!:=4.C-M5\5QA8O67&)O%S'.555'MYX3'"*G'&4/7]M@=0T-)*

KD<^"-7IP15:U*$ZU-M1?;>6==]#6\R;6%UGL^0!5E:[O2(!)P:C9X=U%SV)EQN7NB5TACL-MFC+3OM6K=45%2L7#>;Q&-.BXIE53J/2'Z.5MVX^"7.GK_>34M"U+*Q6*^.,-M-%RC)6HN>"JN')QXJ<[V>=!^LI-6T5\U]JENI(Z)[7QT<*R/2;=XL.^27BC&-MX\E$X\CM/%X>7#Q$YVE!6M;?L$\/6BITE&ZD]ST5LLTNG]F>DK,.U63TMKI-MHI&XY.2-N?*

GR>2/=#O\-I=HC_09OZ5I[>1>U>"8^K_R_LAY^Z3_1LO>W.^.;?-MK+5>;=;66VGDAD;7,>]O5ST=ENZBIC"+S/)P&(A#%NK-V3O\3T.31E++#\.&^-MGP.ZV3_F6W?

*Z+%_:O\X'4AMOI8*CG0PLCY0Q#M1]JGS@%0'SF]SAZ6^MU:,QMUO5IW7.]??RST5IFJ:>G\!IX-R1L\;4=O1QMSK%CW^:*N=QWL>[A/8489E3L*

M_MQ^@@4DDN8-[%.$]*?IA:'Z+^D:RINEQI[CJN2)R6S3M/(BU$\F,-61$^-#B-M1>*Q=CAP:BJ]'4G)V0;MN=V!X.]S$Z4.TKI%7/:,FO\-4"7].UQ45Z>&N.D_I7:/8;8=07RJTI):4?*

*6NM5EBK8_"N-MNE1:GB@-M?)0HQJ-=N1M;P5_6*BJF53CRP2E2<5>Z(QFI.QZ6-3N1.J3K$1.(K'(]IZ%)-M.2-BW*Y5.*=N.1%K72<&HYWR4R-2@F5KLXY*O>01KG9PBKCG@*

@"+&JY.M\9-M/;N?G()Q\R-$VZ[>W?PG>2B_ZSYVZJZ6&U2V>Z34NRFFU1U6@Y+S2TKK3X-M#3K]Y?3M>YO6*S?\157RL\2<8.1!RRGT0!/U:W-56QNW?0fX]f*UJN=A$5R]

*MRJX0'2)-D:K<*J8:O\V*>1=N#NE9_=-V-M%-G,4CMD'66_P|66Y_=W-J/"OAOOWDY5>HE&.8BW8]<-}D&LCW,C5X(G>]-gO20!/U+USAKE1.Y,D/#-M15]L1QI,\N/,-@"*L5N-*

Y,9XIO#=5&[WDM[\X-(-CNJF%QP|//ZSY^^Z>].M?:=T>=6:"H]G^I?>&FNE#4S5;?-X)^M>R5J-7,K'*W@]\E0G"..=V(MY3Z-@\-MA]/W:WKG8ET9=*:1T7>_>>_UM=1P5%7X+#-*

*OLDIGO>FY(QS4RY$7@AUCH<[0-M+_M3Z-&A-5ZHK_?._P!RI9)*NJZMD?6.29[47=8B(GBM3DB<@X-+,,ROE.R-M-@2-!%%5N53GV$-M8*PZ"TWI:ONM=9K)1VZLN;E?734L:L?*

*4KE557]Z\I?>TCI+06G=*0U;&G+-1V-M.*JD222'P.-&|.-&V>O'Y5.-LXDVK9F0R16MC-ZCT#IO6-;,JR^6.ANE5;G-M=91SU$>]^-G7*+ECNSBU%,A?*

+#;=36^2AN]OIK1/7+[>LB;(Q5[\+Z>;<2^-MXD]-=CF2.NFYJFEMDNBM$UJUE@TL:,35KRJ:F;CTSSW7+G'J4R>]W4V+7%M-M;;M06FEO-*

*V1LK:>L9OMWVYW7)YTRO'SF8!V56AV2:*M^G+AI^ETQ;:>QW!Z/]K>R)4AF]D6B=2T%LHKMI6VW"CM<744,%1!O-IX^&6L[DX*

M)P\QA_[G#99_F!8O|E-K.B@MCB:R5HR:\R+H4Y:N,#1#0FG=-TM33:.LM'8-MZ>HD26:.BC2-'O1N[EW'GCAGS]8R78UH*HOOOS+HVRONN-UGA3J-F]O?&QRS*

*MYU0W$$56JJ3DFU?O)<*+5G%&(MVC[':=0W*_45JJ:6\W%&MK*^)F)9VM\E'+-MY1$EDT18-.WBZ7>UV:DH+E)-W69ZI\Y)0BK6-M1A;OHJP7Z^6V\W*STE==*

[8]NH:V:/>EIW95|I=V<40N-1:;M.KK/4VFIV^GN-MMKJ-U):6J;O1R8=E%I-M^^5M7[R+IPEUD8.V:#TW9[M>+G0V6CI+C=T5+A50O[KZK//?5%PO:8KI1K0:-MM/1Z?

72%G6RORNFCH5IFK"(Y$WG-3FBKA#<60%6JIW4GZAT]5K&-TYI:SZ1-MK+?8[726BA;O2GHX4C;GO7'-?3DR0!6Y.3N\63BE%6CH-1.@-&;MW]

M$9Z_14NRTMW[$9Z_14NSTZ?51@>X-!:<-M-M-M-!87C]CL^7]2E^6%X_8/[E_4I5/IL-ME#K(Q/,-P-M-!XW]UF_:?U_P#'E!],AIG0R-|

M99ZK_B[4A\V0])]+5H[3])_8Y/H:GOT6G));^^"M\.FIG5#42/>\]7<1S>>]S8-MV&#V+=%6IV2]%&\,&Y=2PW.HKZ6XTZ7>.D=-'&SPI'(B]6KU5=S>[^)IC)"3*

*M<*7%N1X[Q-;KKIM2PF?UM:/Y]O?4I8W5U5EE-M;G&<9Q/2Z\IO%*M&,

W@-M-M-M-M-M-M-M-M-BU-Y43O7-6H,Y;F[M'$GF+A"2)O5Q-;W)@G0]6.R//>Y$-$P-M-M-M-"-M"\B)!>2@&-J8NIG>SLSE"B9:Z4ZNB21$RK.?H,2>74CDE8V0EF0-!66-M-M-M-M-M-M-M-NK?#UU2B_@-MMXJ6IF[=3]3#E4\9W%2VE%RD5U'E5B[-!Z9C-M-M-M-)5:BM5%Y&$K:5:>1<)-M][=Q3S>8SF4P4Y8VS1N8],HI34AF7>3C+*S7@5JBE?
3/P[QFKR=WE$\]HQT9-ML335T-1.@-M-M-M-M-M-M-M-N-M;2C=.;Y%7Q8-^\ZHN3LCC=M2>WTO7.1[D\5OSF93N)&,;$U&M3")R)DXGI0BH*-MQCE+,R8-%I-M-M-M-D?&V1[M4G(F!81-M-M-M-M-M-M-M-M

M(ZGM4U)?HKK9IJ>D=5,BDE;.YW5I&U7.CB3*\5>]W-7KDXHBJLG9]O*VQW"'\ M>Z1;%+'IQEXGO-Q=U]PFMT=#%0.6I5\.YUC]Q5PC$ZQJ;RJF\J*B(JHIT"V=
M++9]==;Z%TK'57!EPUK:V7>R2ST3XH:F!S)'-\9V-URI&[Q53*Y;S1R*OE+W M++9/IR]V;.=JVZ6:BNE>^_RVF&2M@;*L4+6(]6HY%1J.6;CC"JC41C-
J>E*6.EO.S.ZT]93MA:C&LI'/C;N83\%LC(.')&{W),G6HWL3C M.>3.SUOK#5MMT+I*]:CO$Z4MJM%)+6U4W/C!;MN6SGPVEOFCIW.DL-;4TZQ3=3%(L=4US%7*Q/C8]RMY/2-
O8I@.G/M=7 M:GL.V::*T54*ZY;7ZRBBI4YJRC58Y'N=6UNB/G1L;_5"Z%FUC:A1W MK8_IK.';]471UQH=3;3HEK9)6;!U1LNZGB9W]CE;J;WN#D5')BMOUIV1;M MH^RK:=
<=E|PL>D=.,AI7T.F8?UW=FLZR.:>JGC8GBM7P=K4:N,8:F/&WE^EO M#N)7XPF>0S:f'.#!.¥\TMHUZU|!?W335E^V?6--45]JT_35-PL7A"0R5U#U- M.R5D2JB_?
$5\,T3M6/M\E=NVRWW:YTY*>Wl,,1LMU)LNT,)5P5.H;]JRG6G< MZ-B[W5PQN1$DP|$GEM_W*7/3L=KIXVS M.6IZY$ILJK-W"-^\OX[W=PIO2;?-
ZSN9$(TG9IO1L\>=/S81J/4O1\T=;=G% MDDNJ7HR[4573VR%-Z9:6&^2)$8W\-458_%PJJB+W&R76T7;IP]%G4]CU-HR[M[++KU5S+!24=]9(DD=1#U[
EOHKQI:.]:JCKHXT:V9)&,5K/%QEW%>"%] M+O=&Z*VD!L>IZG6VLML]5/;Z/4RK';-#OFZR*W4SN>\W*IKE:C6HU514\=7
M(BN55$!1=O,'7+L1Q4]=7<^?.R*;:MT";IJ#04NS/4>U+9O5U\E?8KMI>!;]H M@1'*$5DS&HN|P1N|O;)(\'JU?HO"32FFMLNTCIYL.]JN1.-"7#3>F? :ZGI:/#
MI5M5,E)5LC2J>B(UDLLDBNW>:,[$X8/H2F,D4YC-W'.%MJ2M(B+_ "2<@O)2 M!H/'_0HV<:HT5MMZ3%SO]AK{107S5C]JV559 Z-E9"M36N1\2KY3<2,7*?&0
MCH[9SJ>C]THUSK&>P7"+2M7!..D@O#H')323(E'F-).2N\1_#GP4]>D>TEFO MJ4<)62[*<\[=-GHXW#I%;*:H.+3MD8V@UA8JZ.[6:HDDW&+.,Q%18W.PNZCFKE%
M^.UN51,G.;/DI;K?IF.RW#HVZPJ=H+(TIO"*>G>MGDF\GK5G:W#6;R;V[G& M%\O'C'M88[PI<@Z>N9_^>5/T2-=Z)Z&>V62\TDE_VL;098;G<;"V-ZY(7)4M MD2%-
S*/>BR3/Z4UFU?55IL&@-.Z-U'>].W\!#+_ M %ECB?F:-'JUM)UB-&\|SO LN>[M/$[M#27OIC=&K5MAUUH.N MV7UUV26@BM|QE=/)Z/B3>SP(G;WU1"--I96[H\ M';-
MO6W#H[,..39MJ?83;6EI'[_"EMM-ZTU<'HMI9!&B-A621K%W%1NZF53* MHG%K51V-^Z)&QS66R/2NTG.EKZW+6;2]8S2W>KLU#A[H8XVR/AI6;N?'NKO8^3VRS4&V73.V2
46U?7/1NU7M$UI73;U-MMJ*F66FAL\/'$<$2TTF%1%W4=G*-1<}XSE=ZHV>]+[-_JW6]CL=YZ,VH]-6J MO]XZ>JO-
1<)?QT4;G865R+1MRC4XKXR8]N8(X\PWS.WGTLCV(YT3EPF5;]U\>"<4Y(9.>)D\ M+XWL1{'(K7-=R5%YHI63MQ@CE.) OY69\Y=.:(VX= '5NIJ306A9-K&R>\5C MKA3T-
Y_AM(_"-W51C7O1^XC6*NXK]KDC:OBJHF9U[TDND/T@~.7'0EBNC]?M!#3WB\U>5WS4W611P02-5LNYUL43-I=IZ$=#)T*FI#&HDQUQBIO"(ILYJI&MOZUV91]4PJ6KU5G)5W%
[S0MGW M2:VT;%]"T>B-;=_ %EJO4ECIVV^FN^G8G55%7LC1&1R/E8QR,RW&7>,J\55 M$7*)[E&#F8EPJ;QT/"VQIHZ,1*BT[=-K^T6W1TVT375BK;?0.?H\2/I*=851
MD2JBKX[NK@:C\951,N>Y]Z,OV@.BMH^Q:EL]98[S325RS4-=$Z.6/-M>K)G-5S53AEKFJGF4|&HO'G@#-R"LL MNL-+ZK]'U[1IO4]7)&ZAJ'.?(ff%156-
:KWO1,.3@YJ.1=W>*5RN4,]5NT\-M^=) 4^UK:1MOV!7S76DXMG|BFU53IMCTY)6)4UF^E33++43N:B(F!F-K6JB* MW=7AQWG?4$XGCO2'1RVM;7MN.F-
INW2OL5#2Z3(>@I"NRI;UT@]DM8Y89J6]- MOUMC>F'S4LRKX_G1&/ILX^.>W5QCEE4/.VW#8KJ=MF@]L.SZEBK-26E_O1> M[9),R!+C:I%7?PYRHG61JY7-RJ9X?%1%1?
(G-.ZDN1SSIZL;M6.IVH='JMTW MIZX7]CLVHG5-QFH]=TK*2+KZ-R/DQY*8C?S[&J9#IPI.=4.WVG=`6MT]8.^\ M4UEU9'5W*>C@=(RDAZ^E57R*GDMPQRY7L:IZL;Y3B?
TG<2Z9^E[M MK'HP[0;+8;;4W>[5E V.GH:2-9)97=:Q51K4XJN$5?47_1-T[=-)[&W9U9KS M13VV[45F@AJ:.I8K)(9$3BUS53*+Z3K_XA.PYFTL3R*]SP/T5=DFM-+;(>
MDQ07C2]MM;?*]XOME/44KXWUB/IYFL6)%3QI]Y)CM4[3[GWHJ^Z Z*>D+% MJ6T5EBO-/+7+/0UT^Q31[U9,]JN:O++5:]>94/1R9"])D+BTE%[!AXXZ+.5?
M5.ENF!TA=07BPU]ML=Y]8W6ZX5%.YD-4G6O7;,U3#N?9YATE-FV[M2]-38)] M6TV"X7"PVCK??"Y4].Y\%+EZ]G6/3@WF>R,(.X9M;G>&LN4\([(#2.TS8;TP M.?;IHC1-?
M#L%VL[;7>++9:D5U5'NHC=UK&HYW**)Z.1JHJM*IS;IA3;= M.EWLR@?;=D=|TCI>S5L52RSU\;1+K=*ER/C1Z0(U%CCB8Y^57FKTYX\7Z:X1 M4Y9'(ZI%3HWNKZ,\=]-
+9MJK6FT+HW5EAL%PNU/9=3PU5RFI*=TC:.,))155?`M*3>2W#'9SV-<>D-LMMJKOLAUS0T-/)5UM58JZ"'"GA;O/ED=3O:U[(G-5541/
M2;KP(KR(W+LBUMS/#^Q7HPW;:'[G51[*=4T55I;4,R5DD,=Q@=%)2U#:Z6:! MTC%151KO$SCFUZEXELRZ1VG8?HNBT)KK8-J_5E[I.<"6^BO&EH%JJ.MCC1K
M8EDD8Q6L\7&7<5X<6HN\A[I3F,)W$LQ6J66UGL>9>B+8-M5SO&K=?,7:ZIM$ M=]EWK/HOKM^.V0JJ+O.3*[KMU&-1N45,/5R(KE1/36,M")SR0(O4MC'*K'F/ MW1C0NH=H?
1AO-ETQ9:R_7>2OHY&4=! LTKFMF15E1]<51$3B=OV46^.IM.5#2 M-#60/IJFL]'!-#(F'1O;"QKFJG8]*BI@4VTE;R%)+';GO9CY7^Z"]"75T>OZ MG5NRVPW*\V35IK&*KDF6-
$\A^7.SA<.5_%$YVJ2=RL;U[&*UT;UPN.M<['#@&YX9/2F?.17D2SMV*U-M1BKVYGBBU]C.38I*MLU_P"CAK.X.^@B\'6IMU*Y[JJ9FY195F:U48U51%PB
MJBY7#L84SNSO8GMCO_19VF6G:AJ&2];UA;ZUE';YJAKZ>UK)#(D4",1=U%6 M1^55%5K4W$1<-/6_K)^2#-V'53U]YW//N?6LM?V?1U'LHUOLMO^DG:7M\BQ
MZ@KXGM#'WJ<9;$Q58C5>C9%7Q7NRC%7T<9M'18UU;NG/%9_>.O9I@IM6R:WA MKTIW>)!4.@2O5K$=Y**V5&Q8[FIQ!*D<[O.9M3CHIQ046|CYX>Z0; =HFKM]&F MM2[-+-
<+G/?K+-IJ\NM\"O;%"DS7L654Y-Q(STMM@Z+EKVA]%Q^Q^@`MG90QT-LJ6UU4C,-BGIT;U+GHB+P%]-MGW2;VT;%M#46B-;; =8ZJU)8Z=MOIKOIV)U515[(T1D6HF7>,J\5
M5$7*)+L>Z,FT2HM.W7;_M&MT=-M$UU8]V@H-/T6)'TE.L*HR)515\9W5P-1N-M55$C;O>,JHGNC"9XDV#N:VR.*E?K.YYQ|S\T??M -=%/1]AU+:*RQWFFEKEFH
M:Z)8YHIZLFV/ZFV_WO1>A M^1;2I-TK4NFIZ[KV1+4MA7.%QF=[#W9V5SL83#5155%0E>]B+CES./;Q7N=& MS>HV<|%#2,59)#6WCK;U+'(W"HD[LO3NG-T=M7[29=#
[1=FSHI->Z%K?#*;A MG\R3<15X*YKXVX:JHBM?(FU?0E=HFR=&Z_VK4UVIUH M*RMU!"OO5 DC=U(D66-K)4P]\'+A,\=[&%]VIWC"+R.YBITKMM/<^;G1KZ/&
MVOH3[=+#;Z&T4FN]&ZU;!3WJX6V-6MM\C$8D6\)6J[#94=C"/PB? M2#*>=>U;.'IA4'(Y)YB=.FJ;LCP]H16;5M56G3^@-_Z.U%>M.W!/#+_ %EC MB?F;-'JUM)UB-
!9<]W:Y>*\>)+ ,9Y\2&"2EI:Q6Z3C5JVPZZ MT+7;,*Z[=;016ZXRNGDB='N205/C1QY:DJ-7&..YS.*[-]O>V_HZ[.J39MJC M83J;6E[T_"EMM-ZTU$^HM];!&B-
A621K%W$1NZF53*HG%K51V/>O82<%.9B; MW=T[.\O]'+83]O9.3:UV@[1HXH=H6O;AX?7T<+DZ0.7YDHP48-MY3S#
[G1H;4.SOHP6:RZGLU=8+M"7UDCZ*X0K%*UKI55]fU>2*BHIU&HZ-&R"-MMJ]BIV4Z*J*B9[I)9IM.T;GO55555X\3I],JIR(QO&.XC32BH]A MX/O'10L[NGS8]BGV46E-
ES=-.2H;'884M/AF)L;[-SJ^L^#YIGD>XK7;*6S4 M%-;Z"EAHJ&DB;!|34T;1Q11M1&M8QJ)AK41$1$3@B)@OTY$&]IUR;.0@H7L2
M.SNGR_Z/.KMM'19U+M,AI>CYJC65/]"^25L=3&^6D:UK7R(4W%>1'HY'HND;HNXZ#TYL$]MG\%]B?05UWOEQ MWD93O3$)OOQQ;J*U5:JX>JHJX3.#<-K?0TOM'T";?
8[HZI;=+ _;TBK7MRV)M MRG2=T\T>781$5SW;F\OX#&54YGM# ^D9NQ$>#>^9[GB79STH]IMGV<631UCZ M.VM(-5VZ@CMT3:NE\"L[9(V;B2>$2(U-
Q5:CL<.'XWNTT'HX[&MJ^A+YTH*# M7-@JJR^ZML4M;'=K?32.H.ZK?%.]\4$F$17;]7A&HGX+D3R3Z.HE.PBG/D=S M=QS@[7>QYQ]S[T7?MG_12T?
8M26BLL5XII.Y9[*0B6*:-'5DSFI5Y9:YKD\ MRH;G&=W+G8W5:C=Y2]Z;>S77]IU9L*VA MZ+T[<=H<^@ZI_OE2P+OUM4WIPK7*B(Y5W^.IE17-,N'.1<+GA[=Q@FYHU
M$542%R[JKP_?$A3T*I[.;R,'K/2=MUUI2\;D_>Yj,/|2[-^C@WSHDZ"UI-MLDV>U>@=6M964.G:V2DL%Y9*QRU]M55=#OL1S*L5%1$PC<9PJG<4X9.WM
MH1C',U)GC/W1#HJ7/;[I:EU|H6GG_5"T]$Z+JZ'A/<:-V4?"F/*>W>*EN4;H'(Y\|CF->BIEK'1A%7 M"X;Y?0>W$3 .YG:QS@QS.2YG@/HY;=-HFP,9)9]F59T;=<56H[(DE*D|LH]V
MVU;ED<[K'56%8U5WH+D5Z*O%%XX2ET==G6V>Q=.FYZ_VF:7=.[5VGI4EJK2Q MT]#;5S'U5*^5OBH]K*1K5XKE7)Q57(I[4:B)R(HGL.9NXBJ.UWL>-=@D>TS
MHV=*#:1INLV5WR^Z2UYJKPRDU++;6.?2T$,D\]J+*YK'-W49,W>1SFJWJUYYR M6]SMVU+HB]*O:1K2R;-KWM,T%KMF[*N1=/L=+4P395V%8QKW>(Y\R(BHB*CVJ
MCDPJ)!|>'8,<3N:[N.%HDGL?-K;#9=N/2)VR;%|>W39I<=+:,5L>IZ2.EL3T=-M45U/%X1#)45M5AJ)$Q4C8B(O%-Q?2[M&V#9QJB[^Z$[%M64-AKZO3-KL[5#7
M7:*G>O.:+WH13@+A4DKN|[LY3TE!B<'2"V*:D-MT/+4^:1U\+7T=4_*MAJ8W1)5W=Y](!AG=5<<3S;LRZ2&VG8?HNA'TKK8-M-[_5=
[L<"6^BO&EH%JJ.NCC1K8EDD8Q6L\7&7<5X<6HN\A[H^D8[SBEH3E3N M\R=CS-T1;!MJN=XU;K[:[75-HCOLN]9]%K-OQVR%51=YR97==NHQJ-RBIAZN
M1%Z+Z%U#M$Z,%ZLFF+-67^[R5U'(RBH(5EE M-KFN1>2HJ8QW MF[$R)@7TL<4,2S'BK[_=&W4F]*G3FV#9,2SKM+TK41*L-_S>FK8$?EBHW\-T M,F\G*-
[T7.&H9_;ULDU!TR^BW8*EMJJJ#I1:&6*[4MNNNL;Z=:>MC1S)87;S M57<=ERL1=L4U7J.CU=W>A[COWNE^SG4FT?-MHXTMFTC8.I4%R9?
*69:*VP.ED;$V.9%=NMY(F\U,^=#UNF$(J=S/0XJ*2.[3 MR?TR>COK#;-0Z-U!LY?$FT30=2VKHJ.I>UC*R/Q'/BRJ8WMZ-N$VR./-
Q.J6F]'"UT9R+HJ;.]7:3V+4%BVFZAEUEJ:K8]\SFJI.N8B2)C MP=JKY36LPBK^$]N7DIXWZ&?1EV@Z,Z4G@V]I1<8-$;.X[M#IJX54+FP5*U$Z MM:^-R\';\KH
MZMUEBE2**Z4[<9@=E41<*UOBJ[(K=].:HAZ"[B'KP,PX*6;O/#&TCI,,1]LF MS&^:&I>C)K6+45ZHY+?(E\HMRUT[WM5O6]>]K6OW57>;Y/%$7*'H+HB;%[AL M
V!Z8T1=ZB.NNE"DTU5)-JK$DDLSY7.8]HBJUN_NYI<9[<'9?5DBF YZ>;.=7!0M*:.9H_3-RU35VZ_>&3TUMA=(YL:1/PKMU%PBKPSC MM/J+#M>V16^CTU;-.
[LEBTA2R(I&O:]7QOD1'.W<.W7NWEWGN M:U%1K41[/O3.."D<9\Y+-V(IX5[7;I/(?3AVUIB+66C:I[^>1T;-VH*B@?*Q.N8V6 M-T:NQVIB.,\1_!
(YF6]"3D^T^K]U\J.JY\?"MRTV+HQ[,-K='TX]4[0]I&GWT'W0Z8?*^> MD8Y\'1R/DIDBHDFPB.DCBB1JXYJUV/FOOA$3'$@K=[D2S%2HZ]V/"BZ!VL= M#;;-
K;4&S00\FTS9IK*=;E4V>AJDCK;;59MA>UO6FK-D%99=8:6U74/KJC3>IZJ2-U#4.<-'1W4*CFL:U7 MR/1,.3@YJ.1=W>*^C>CEM9VO\
<=,;3=NMPL5!2Z35TM@TGIQSY(HJA51>NE>_M_/'+&.X*Y55C?)1N%FG9W*'3;]Q7/8B-[?.G:G]SHV!1K-9[">Z76ML MT\--1TK%?+,]6\&M:G-
5[CK+?,362[UYH_I(=.62VZ7U=I"GV/[-(:N* MIN'6U'65=4K45<(U517XSEK5:UB.XJKE:F/H=QSS^8BU/63S=QG5%VRN3L>= M.E:LLG_N,M4Z#T/9:BMDI,724%MM=%
<JLBFA1&M1.+E1K%7/-<*HH>JJG> MV>BZ(FQIVS2KKK'K?2EMMLM=IR:3]/^!D<$;24TJ.5,N1S$RURIE-[.:HB^R M,>L@OFX%+2Q:Z:>VAX8VD=)C:/MDV8WW0U+T9-
:O:BO5');Y$OE%N6NG>]J-MMZWKWM:U^ZJ[S?)XHBY0W/3?0NJ/[AM-A]\ND+KS)32U'A*JL,%:M0ZIC1_MIO.C:]6MV?8OH6@T)[_8%]_5
M6I+%3MMM)=M/1+/05{(D1D4CYFL5(\M1,NPN<95$7+4VK8#T;]<:IV5[4OU:.M;C5QWG:4^=9,'':5K-%9(7]9N1$F^YC7;IF]A,HB,C15545#UT3=HS=B"I?B=
MSP+L8VFI9N8W:l!NS'6.QW4VT.VV9TC+-J#1L#JUD\#G.>UCVIHU5:C55417*C MD3'"W@BKLG1\V1[1=K/25[>D!M3T_P#<:E'0+,M-.9F?UE13Q.:YN_*OX.&R MRY1RQY72N\5J-
3/M5.83F=S=QQ4MKN]CP7[HEL5V@56K-.[1ME5GK;M?:RUU MNE;S3VI!9)7TL\3VL>J-[$1\J;Z\&NZL]$:"Z-UJL'19H|CE:Y64P[8O(BJ',S)*E%2C'L1N41'9QO;JM1<85$:J]'Z.K-
NFU';/>=I&O MX+CL|T'X-X-;-"SSHY\CD3=269F,IC+U7*-57*W";K45?6G#N((G/B=S=Q'A MJZO5E564\%Q@=$^2%T$"(]$5.**K7)GO1
M>X]/:WTG;]>Z.O>FKK'UMMN|%U+$Y]7(Q6.GW+A>"]BF>7M.%=)UVW=U!9 M8=B<=@5]WA$5SDO6$@D:0R0Y7=X??57*.:]X+R.=9D[*$+(\:>YZ[--2;E
MZ0585S5DK:VW;%Z6KTY;G,7,?AQ&Q=R'OCI%:\@V:;"-> M:FGD9$M!9ZAT/6+XKIW1JR%F?RI',;ZS7^BCT>V=`/95%IZ>O2[ZAKJA]SO5 MTPN*FLD1-
]6]HQE:B(C45>*X5RHBN5#!I)_8_J7;_>M%Z(ZEM+LW2M2Z.GKN MO:DM2V%HV<]%#2,59'-M)#6WCK.U+'(W"HD[LO GRAPHIC 8 image_004.jpg GRAPHIC begin 644
image_004.jpg M_]C_X 02D9)1@`! 0$!+ $L #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$!
4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!04

*@LR;AN,8$%F3<-QC @LR;AN,8$%F3< M-QC @LR;AN,8$%F3<-QC @LR;AN,8$%F3<-QC @LR;AN,8$%F3<-QC @LR;A MN,8$%F3<-QC @LR;AN,8$%F3<-QC @LR;AN,8$%F3<-QC @LR;AN,8$%F3<-QC @LR;AN,8$%F3<- MQC @LR;AN,8$%F3<-QC @LR;AN,8$%F3<-QC @LR;AN,8$%F3<-QC @LR;AN M,8$%F3<-QC @LR;AN,8$%F3<-QC @LR;AN,8$%F3<-QC @LR;AN,8$%F3<-Q MC @LR;AN,8$%F3<-QC @LR;AN,8$%F3<-QC @LR;AN,8$%F3<-QC @LR;AN, M8$%F3<-QC @LR;AN,8$%F3<-QC @LR;AN,8$%F3<-QC @LR;AN,8$%F3<-QC M @LR;AN,8$%F3<-QC @LR;AN,8$%F3<-QC @LR;AN,8 M$%F3<-QC @LR;AN,8$%F3<1QZ1%=>#S,'|{_.4*8D41RZ0]5]IYF!^]_P#* M%,4SCR7:[?.PVGPS^]QRJ_-2U?0XC91K7AG]|CE5^:EJ^AQ&RC"F@ M M (2]++;[W'#GYUTWT.M)M$)>EM|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|[CAS\ZZ;Z'6DV@ M M M M M _!7KYS?4O^0_+N/U7#W;/C/QDKCQ\W#4<^?GY7 M;AN+0981[+MPW%H$%EVX;BT""R[<-Q.!!9=N&XM @LNW# <6@067;AN+0(++M MPW%H$%EVX;BT""R[<-Q.!!9=N&XM @LNW#<6@067;AN+0(++MPW%H$%EVX;B MT""R[<-Q.!!9=N&XM @LNW# <6@067;AN+0(++MPW%H$%EVX;BT""R[<-Q.!! M9=N&XM @LNW#<6@067;AN+0(++MPW%H$%EVX;BT""R[<-Q.!!9=N&XM @LNW M# <6@067;AN+0(++MPW%H$%EVX;BT""R[<-Q.!!9=N&XM @LNW#<6@067;AN+ M0(++MPW%H$%EVX;BT""R[<-Q.!!9=N&XM @LNW#<6@067;AN+0(++MPW%H$%EVX;BT""R[<-Q.!!9=N&XM @LNW#<6@067;AN+0(++MPW%H$%EVX;BT""R[<-Q.!!9=N&XM @LNW#<6@067;AN+0(++MPW%H$%EVX;BT""R[< M-Q.!!9=N&XM @LNW#<6@067;AN+0(++MPW%H$%EVX;BT""R[<-Q.!!9=N&XM M @LNW#<6@06 M7;AN+0(++MPW%H$%EVX;BT""R[<-Q.!!9=N&XM @LNW#<6@067;AN+0(++MP MW%H$%EVX;BT""R[<-Q.!!9=N&XM @LNW#<6@067;AN+0(++MPW%H$%EVX;BT M""R[<-Q.!!9=N&XM @LNW#<6@067;AN+0(++MPW%H$%EVX;BT""R[<-Q.!!9 M=N&XM @LNW#<6@067;AN+0(++MPW%H$%EVX;BT""R[<-Q.!!9=N&XM @LNW# M<6@067;AN+0(++MPW%H$%EVX;BT""R[<-Q.!!9=N&XM @LNW#<6@067;AN+0 M(++MPW%H$%EVXCITACO]|!F|^]_\H4Q(DCKTA?O0,?\ [W_RA3%F<>65_'M_M_5MOAG|!CE5^:EJ^AQ&RC6O#//[W'*K\U+5]#B-E$-O M-M $)>EM| [CAS\ZZ;Z'6DV$O2V^]QPY^==-]#K2;0 M-M M-M M-M ?.N;Z.9\?^0_#O4_9=/= MQ_'__)#\&Y29O?NX:+L[?MI9N&XS0B67[U&|2S<-PA6R_>HWJ6;AN$ M%E^.]1O4LW# <(++]ZC>I9N&X067[U&|2S<-P@LOWJ-ZEFX;A!9?O4;U+-PW"" MR_>HWJ6;AN$%E^.]1O4LW#<(++]ZC>I9N&X067[U&|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|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s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|[CA MS\ZZ;Z'6DV@ M *:H-Q12CG-8Q57D@%N]$157DA&K/G M/CK0\|^ <\=QB>MUL_'/_!AW?@G@EH|/8Q\,?'iY?1P[B&86N]/=+74. MIJN!VK7M[%JO;]=[=.6G>3/RFS.M^95G5[=M/=841*FC5W-0[9OI:OI_3H0> M/IX=Q% <,+?>"Y6RH=354+MS7ISW>EKD[T7T?_4VYSPGQ?DZ')\[.Z9[<.A\5\-M(X^]QVT\M\>F71'D514-=93YM6_.FT]Y$2GND"(E32*O-JK^,WTM7GS_$Z& MPTY'KW!V./L\>.3BS.,O*.7AY.#?/'RXC.%X)+$\+CRUW]&OK{17N1(]'+2 MZ+IX]B^!KV'./$-!.]L[(Y'-\U6R)IS])OK:;/SHP[:;.E3UT#6QI4ZHK6\N M:=O^3Y2@? @]\Y+_4.5RZ(UB:FXLOI]&V_2NNS4?.]>;#W-\0/W9183=9;6ZN[6HD]\M_=-%UT3_%0V$CD5.1JGB5Q1+AC*ZN? 35.6!RM0%X++Z*B+W%=F%04U0;DI0%08W2MC%KN1K6]KG+HB%_M6R-QTU0ZI5S7:>Y;K43_WE/?\.5I?:,I+.V5'-DF1TI]Z MZ^Z74#: +=R%=?C]"W"|_:.QM^#+N4: ME,6X;B1#7W9=RC_[N4CK[SRZX^_'-MYMX<,_O<XY5?FI:OH<1LHT5N-M-M-$)>EM|[CAS\ZZ;Z'6DVB$O2V^]QPY^==-]#K2;0-M-M %NF0=QW8ZS6[G;]"L=05=1"L<=0WM:OH\$7LU3-MT:)I[$[#%OICDTSIGTRNTVSIMC;'NE M%[E]SYO-_-O**WYEVA==E-=X&KY-5Z?^X_TM5?T+S3O188W_ _7X8NM1;+G M3.I:RG=M>QW\"HO>B]R]BGC?B_A/)X?RV]=,^F?^,O6_"/%./O<=/3?'KC_G M#YP!L7)|}^MS++N:22=92V2G? _/%4B7.8P^IP|X&O=\QA2WJBEDH;?,Y46:I372;O="GI54|UZ M$5,_1%F5IVGR[+8*+#ML|[=001TU) U&,CC31$1/AO?ZU53ZB+K^@|F\+Z&/ M#^#V4SG/GEX|XCWL|_GSRYQ&/3"\ Q23,AC=)(Y&,:BJYSET1$3M4W36,FXC M;G5F):*.]JEVG>WJ&IU5MU1TJZIKJ3DWXU!SXF=G$14551/9,(3+#"U=DM MT;JCG\M%2/5/-[5YD;Y9'32/DE>Z25RZJ^1RJY?%=5U4"5/#]6W#,JZU=<|L M=HL%LE8K:6F3\)4RJG)))).U6HG:U.2Z\|22FB$7N#K%U##/=L.S.2.ODE2H@ MUTUD9IHV/6FG\)*'U[(B(OZ3X&6W$_9PT#J?JT8K70M3DGCV@17P99:WB&S3?>[E74M%2ORME M?3,GUD1C%\UC6JNNG+M-Q<5F)),-Y<4U%1SOIYZRK9'NCY+U;$W+S3Q1OZ30 M=BAAPQQ!P4V')I%I(KFL$6U5U5BKS:J]Z(>VXR;[)5XDLMDB:Y?)87SHQ.QS MI%1$7UZM_P /I V;PT)4VW^1!UN7'#A+"%NH(4D+.ZZN M221J_.3YR_H-;<&.\V37'$%>S5T2,IXU|"\U=JZ]?X / 9HX Q-DK?C2<4Q M!)45%7NDCK8)'->CT7GKKV_HT])[JBP=CWB'L? W;K;RVU6QL6VEI';FLE M<|4:G>[=STU/Q<8UZ6MQG9[5%)O\EI=[HV]],>[1/X$)%V2CCP)E;30*QVEO MMB;D3DJN1FKOC5VJ_&!&GAHQ=?;'F;%AB6J?/02]\#+2ODU;&YB*NYOQHIN' M.;*_&F-+]3UV',1_NFB_$XVQQ#9]18-I)Y (]XVKL6X M'OBVF7&-1<:MO*1M'42*C57L:J^E? 02'P9?KQD_DC47S%DU16W&5ZRP4U3(J MO17)^#C55[U7N/BXRKUM-2SIKU:]NO6/U]7+KR,?&C6SQ M6/#U,QSD@FJG.D;KR54;NFOH \;@W!.,N(V6MO5YOTE';8Y%9&B*NW=KKMC:MG)$35=5U/S9=7ZJ929SQX4CNK|E;'5GDLT;"L;M=5W:=SD|!^W+K*#,&^X2 MMM58\7QT=GJF[VPQU#FK%S7=JB)VZHJ? $;9RBX<;-+RY/O-TK$O%X37JI-JI M'%K[JY$7M7O4#4"%C>/N_F;0VJ-55E+ R%R)W.>_FOZ'?P&|LR,O*BYY0);[M?)++#<;,2MDIW1N5KE2IV\T(|3.7'_$WHDD;8W7- $1WND5D:HJI^A/T MDNL:8OH,$8|L1)WKJ!%SAWSMCP?%?.+$E9*ZD;$M7"L MCM7|F\G,1/X-<>>I7 E#B3B)S!K+Q75U1;|%"],M;"]4:C$7E"SQ]*^LTMB" M1]VK*J\LHEI*&LJG]6U/9S;LN((:BU06;RY+13PM8QE$U7JUR*[=N[T56[$:[5-NCM M.TV7A2"X08>H675_67%L:=:[55YZ]^]JNFF|JG;W]XV@7 M M M 4|E*@#*S^)G(UU-_;? Y#XF\^QBE='4_J=_D/@[O$W M'6Q^RPX3Q+;.UM^'Y89MXWF'=XC=XDNK5W9MXWF'=XC=XBI=FWC>8=WB-WB* MEV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79MXW F'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB- MWB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8= MWB-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{ MJ79MXWF'=XC=XBI=FWC M>8=WB-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YA MW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79MXWF'=XC=X MBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-M-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79MXWF'=X MC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-W*E MV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79MXWF M'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-W M-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79M MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=W M-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79M M79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC> M8=WB-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W M>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=F MWC>8=WB-WB*EV;>-YAW>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW M>(W>{J79MXWF'=XC=XBI=FWC>8=WB-WB*EV;>-YAW

*MI<.U^(1SL<0QW]LL] Q;)7.MZM; M-(_J$Y*YS5T:B(G+3GN4_/BR[Ul?E!BB&OGZRYV>J;$M5&W9UCHlXWQO1${% MY-/HQ5UYPIF/BBNEP_77"SW%*.]9Z"-))-[(41VK55-6\]->W5.P^9<(]4?> M;MMNK'Q7/%M\B>ZDC>W=#&LC97L5?YL43M=-=%4#;4+BC>PJ M M M !Y;&'NJ7U._{)YT]%C#W5+ZG?l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}\(>K3U)'JFO:I&_$?$;FIBVIIEFNN8F)]M9=-8DNDS(D1>Y(V.1)-MX(FAUERXZ.5)++Z%CI,-.Q56M_|.;13>4Z_]$B-B_|-BRQP?AFF\G ML^%;)::? _D;&W0PLY>#6H!P)H,S<96N=9J3%E\I)MRO62&X5,=N5-%=JCNW3 MOUU-G8*XX<\, "NC;19AW.OA8O.&[N97M144]AU%LI*N%D<|-# M/&SW+)(T6G+7L/$XKX?LL\6 \R,,9G8=@ON M%+Y1WRU34^,&3U&&:BYX*KGZJQ M*:7RNE15Y\XI55RIKS1&R-0U[PK\&&:/#1Q,VFNJ:N*ZX(J*>I@J;A:JET<3 M_P "]8VSP.5':[]%3DYJ+HN[4#H@ !P!P'DK?\ B&XX\[U=<8IDCM--KG(B]ZG?XXL4-RCX8.ENKJV^,2W6 M:OQ)4R/FE[JUU\% E=9^ADR1I++Y+7WK%]PKWL M1'5[;Z")6N[W.8D*M1//\I{U]0ES7P/BWHO.*JQ5V&;)677#U2V.O@5SNI^Z-.M"DBMEHZEK5VN2=ST>BIG/OY?X3C?TP^-.;.'B%P9@;#Z?=_M2\V6A\GJ8J9$<[RJJE18X.7;_:V-=/\ UB=^N@3'Z4>XI?.!/$5RH)5\BJYK M74:Z>ZB?4Q*W73Q.2-D,RM3O1BQ0Z_UQ/$#J_<7L\Z/[L=,A;HZ3S-F+L.S+IR M7\%3T3W_.*=CO7J=DKI=:.QVVKN-PJ8Z*AI(7SMU5\KLBC8U7.>Y5Y(B{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{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}HYOK0Z_P MKZ_X#X.),'V"%'T:LN]L@IUTT21S=)&^IR:*GZ=/ RZ=G(A)6$+D)-QGZ/*#*7] MY]W&^<;<,51 V6IPS5^4LTU\AJU1)/4U_?ZET]9I"YVNKLM9+25U-+25,:Z M.BF:K53QYI]$S7DUW]&GY>#?AS&V'Y0/B @!D1P >^R6QVN",8T[YY-MMK-M*:I15\U]*OFQ_M5YZ^A5)BHO8<_"9V3>*7XKR^ME5,_?50L6FF=VKO9RU7Q5 MNUWQFO[&O\6&^\-Y?+/'E[4 $5O0 M M M -\>GO4L=?W#]/I MS?QH'CT]ZECK^X? H.1^,/;X92^G)/I\[=(REN%-)2RNB5$Z.+,_)22^?5E5>]S$M-M.1ZZ,,,JN.O*NI\'UWREO|HN5-U=72QNZNLI':HK'NB=HICF/1KFN5-JJWEJA^S. MKA@RUX@J66/%=A@GN<;(OEXH52&N@735$ZQ$551.U&O1S4U[#GSFYT=6:N1= MW^^K*V[5>)*2CZENU+RYZ.:SU[M8E55Y^8B ?\S&Z+G-I#%U[&87 M,;\9VSMAJ(:N.CF.O(_)@/HP,Z,272"*_T5NPA;U= M^&JJNNBJ7L:BKKM9]VY>7)%5.U.:)J>_P CNE%Q;@>J98,V;+++?Z:G>L$ER MI(DI[C K>2I)&NUDBIIV>8OI55Y'0C*3/C >=UH6XX+Q'27A&-1TU*U=E53Z M_P#*0N1'MY\M531=,2]!(J)RRY$Y9V;!ECU?2T$?X6]D1&OJIW+K),$Y.M5>7Q$-A%BR(BZ;+^@O (2]+;.[W' M#GYUTWT.M)M$)>EM] [CAS\ZZ;Z'6DV@ M M M M M \MC#W5+ZG?\ 9/.GHL8>ZI?4[_LGG3>]3Z'#SGQ?ZWM^'Y8 M 3FE (R<3^(/+L4T%I M8I6.A@61Z.IDCU1?\5&_*)-HVNJ$.<34%7F+G#1 M&LU^(S\&/G3GW-9W]L^SQQX]42.:]7ZD M33E1AZQ46%'QVVBC M2&DI8T:G4STY+(OI]">ZBIE MSY]_N8_F'=\@CUVRVAE/C"OS/Q]=+Q4;H+7,8$BHZ/7S6*]WNG>EVUCDU[DNRFTTJ,?6I'= MC5D^^B-RI_#H>1/.Y..1,>T"+VJR73_JW&;.TRP\?I^$BP 16W M ,512Q5E/):41MF@D:K'QR)N:Y]]J*G>G^O@904,^:(&?5.[5C5?X4U[O4IKLG3C#*'E)C'#M9;:Q/P<[?-DTU5CT]RY/%%(37Z MQU6&[U5VRMCZNII9.K>WN7O14\%314]:&SZ_)? $9]7+=[K^QWG'1E\\W5PL4 MXGO8ONU2B>;'0]7KXND8]?XAI4DKPMV-U+ARZW5[-/+*A(F*O>V-JZKZM7K]D MY$ 2Y$++<.5'E%IA15U=']QO?B?:EQ;.D= MOCC[WO\ X$!?!A^?!LRIY5#W6)^+]R+?).Y-Z4$*HJ-?I_RCOQ6KV:;E3FW6NFFW)M MC74G&,-R9B9WX&RJ:W[Z,14EMGI3:8ZG%IB M>39CMGW)HVCI&LN:Z9L=;; <0VY'.TZY\$,D;4]+MLN]]"*;URZSHP7FO3RR8 M6Q!2W1\2.R4Z,HYHT]+HWHCD3QTT.7F+ ^&+-+ =^"MO6#JZ&DC:KY)Z5\=4R M-B=JN6%SMJ>*FO+1=ZZP7&FN-MK)K? 74[DBAJ9HIY(W(O4Q$>U'Y MVOH5#R_M_LI?Z+NO]H*W]M531=,2]!(J)RRY$Y9V;!ECU?2T$?X6]D1&OJIW+K),$Y.M5>7Q$-A%BR(BZ;+^@O (2]+;.[W' M#GYUTWT.M)M$)>EM] [CAS\ZZ;Z'6DV@ M M M M M \MC#W5+ZG?\ 9/.GHL8>ZI?4[_LGG3>]3Z'#SGQ?ZWM^'Y8 M 3FE (R<3^(/+L4T%I M8I6.A@61Z.IDCU1?\5&_*)-HVNJ$.<34%7F+G#1 M&LU^(S\&/G3GW-9W]L^SQQX]42.:]7ZD M33E1AZQ46%'QVVBC M2&DI8T:G4STY+(OI]">ZBIE MSY]_N8_F'=\@CUVRVAE/C"OS/Q]=+Q4;H+7,8$BHZ/7S6*]WNG>EVUCDU[DNRFTTJ,?6I'= MC5D^^B-RI_#H>1/.Y..1,>T"+VJR73_JW&;.TRP\?I^$BP 16W M ,512Q5E/):41MF@D:K'QR)N:Y]]J*G>G^O@904,^:(&?5.[5C5?X4U[O4IKLG3C#*'E)C'#M9;:Q/P<[?-DTU5CT]RY/%%(37Z MQU6&[U5VRMCZNII9.K>WN7O14\%314]:&SZ_)? $9]7+=[K^QWG'1E\\W5PL4 MXGO8ONU2B>;'0]7KXND8]?XAI4DKPMV-U+ARZW5[-/+*A(F*O>V-JZKZM7K]D MY$ 2Y$++<.5'E%IA15U=']QO?B?:EQ;.D= MOCC[WO\ X$!?!A^?!LRIY5#W6)^+]R+?).Y-Z4$*HJ-?I_RCOQ6KV:;E3FW6NFFW)M MC74G&,-R9B9WX&RJ:W[Z,14EMGI3:8ZG%IB M>39CMGW)HVCI&LN:Z9L=;; <0VY'.TZY\$,D;4]+MLN]]"*;URZSHP7FO3RR8 M6Q!2W1\2.R4Z,HYHT]+HWHCD3QTT.7F+ ^&+-+ =^"MO6#JZ&DC:KY)Z5\=4R M-B=JN6%SMJ>*FO+1=ZZP7&FN-MK)K? 74[DBAJ9HIY(W(O4Q$>U'Y MVOH5#R_M_LI?Z+NO]H*W]M531=,2]!(J)RRY$Y9V;!ECU?2T$?X6]D1&OJIW+K),$Y.M5>7Q$-A%BR(BZ;+^@O (2]+;.[W' M#GYUTWT.M)M$)>EM] [CAS\ZZ;Z'6DV@ M M M M M \MC#W5+ZG?\ 9/.GHL8>ZI?4[_LGG3>]3Z'#SGQ?ZWM^'Y8 M 3FE (R<3^(/+L4T%I M8I6.A@61Z.IDCU1?\5&_*)-HVNJ$.<34%7F+G#1 M&LU^(S\&/G3GW-9W]L^SQQX]42.:]7ZD M33E1AZQ46%'QVVBC M2&DI8T:G4ST

+U=LKG_CX[YG9Z'0+_ -H\|_V<<_TS8?_M`$S_.C-H])'AM};EUA;],C5_D%R=_]R?BMFC75?5K$U"[&W%|,7/$8E,RB1-MPMR-AX@\!N=V?=-C?C5%1A/\ "AUU0XR918BAPEFCA"]5+D934-VI:B9R]B1M-ME8KU^3J=FF*CF(J+JBIJGCZO28^]^_C.5=,H&=)BY/N]@-GXWDU8NG]M%_|-MK_0:&X3*=:CB*P*Q.U*Y7|OVL;G?Y#:.? 2,8DBN>,;HM4,B2?Z*ST-16.=IR:KF=2WX]9=?B\"7[\WK>?V*-M9\|DO^,>GZ[AJQ0_G^!EHY/_(F)O_,.61U\XE\,28KR&QO;HHUFD6VR5#(T-Mf7.BTE;\>K$.09CZ.? F;84WQYNU.7GE3;X:E:NK7VVF6ZJH$)+L7_(>\X<\9MT8R+P/7P1^EIHX)%3NDB8D3T^)(`&G>D6Q-M)%;R?PN;YVQP:3K2X1L-M<*ZZQ4,#%U*K6/< <"X;DQAC6PV.)CI'W*O@I-K>W1[T:J_HU_0=IV-:QB-M-:FUJ)HC4|/-F=[;$XQA9Q^JXUOQ)?K"X^_<6I_BW&R#6_$E^L-C[]Q:G^+4-MUO'^_ADSZ./YV.R&_6/R_-VW? 1HSCB=CLAOUC\O/S=MWT:,VO>]-6+C]?N@-M :IF!W*\W*|Q-Q7_,*KS_9LW\8XZ*=-'=^L-5?NU4?Q<1S]Q7_P]O7]FS?QC MCHKT=WFY#5*?_C-3_!'%j;?N?188=/5)Y$[U_P!?C/ YF9Z8*RBB8N*+]#0U-M#V;XJ-B.EJ7IV;I&U%)^K25UMIMY^AD:KR?(-MB:.;JIR;U;I<>,2XDN6+[[77]\5A$TT31$Y$#K-MI?VV9SGR9.YA.W$_228:H=T>&G\ (7*YJG))*^=E(W7N5$8DBJGZ%'1_-[C7Q-MSF58:ZP2TILLUDK$V34]+"KY)6HY%1KGR*O>B(.7\\|FSF.KY?8I_$Z+>/?_#^DT5QN71IJX;L4|4_M8ZI=2TZN_:NJ(!WZ41R?&;U-) <9]ADOO#CBZ.%FZ6E9#5HC4[HYF.>OQ,W+|-M1I^*,;ZLV?1RD.T665@BPOEWAJTPQLCCH[;3PHU]:.JD;=5l;JBJOBJG%[:=-MDV4L,8J6&{5'51M31&,<]7-:G@B.1/B.P-RN5+9[;55],. MRFHZ6)T\TTBZ-CC:FYSE\$3M.-&:.*XLU5_1"W]!L+HT_|-@1C/|T8?XHU]TD]BFI\R<*7A4T@]J2M&U?2Z*9[U-M3]$[2[7ZWE3^!H# (?,2@RHS3LN+,C;Y,I3Y(KG)30]U'.<^)[&KJO+ENU\-$_M)@_S2S#6FGWF77O_/,8M.?Q$2>'3!&\^QW+%AG$TE1#;,+ELU764TJ1O21(MG.Z39K/N11XI.* MFQY_X3M%MHL/5MKK:"M6I;45,K'MZMT;FO8FG/FNQ?I4U?PXWR3#N>^_ZR)5-MU6[T!.J(O/;*_JG>ODI29M\X'LC\+R4L=YQ'7VA|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{&+/[R4/2$_M7J6V9!>3,? M;EMM1<;M>+M:[?3HCI:JMN<,,4.*](BN>Z-$3_MF])S7M5/2A%QMUL9E,KOG0YPG9S*2^28HRMPA=YM>MKK125+]RZ^>Z)KG>OF MI'RS\"62^(UDM=\NERC_9T=U@E;RTI[VQK!VH28P=A>CP5A6U8?MZ8=:AVZ38QJ-3NB>A"G:YM.7&*^XUQ#ZX-(3(-M &&@>/3WJ6.OIA^GTYOXT#QZ>]2QU_Y.U0/M;DYE-_@I"+-M-,I5\NL(UDU%@^SW#'$\>J+5(_R*D5R=R.>U7KIZ=B(O5+.KY:VR5K%>]J5-M/:VHW14Y-16.:NB+S[=?$V? @KI=\24;HX\6X!M=S;JB.FL|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|\^NN51-MHP=#^#]I53W2H-MU/BYK,D/+GN[!3>ZM\%NFCG)O=ZU4R.6G,HW/F-8?0-!*;T-"('&GPIU M6/7KCC!U$DU^CCVW*WQUL*-M9Q+AZY):696N1\,T;M%3FUS51>SP77N-WX(XU,U<$6]E"R]PW]DB3;&R\0). M\G_2:H]WQJI/O-7A>R]S@E?5WNS^375V]+<[:Y(*A=? V2Z*C_6Y%7U=AH.[=-M&?:YI!%ME/*RDA5WFLJ[:R=R-]"JV1B*OCHGJ-ICM903,K+-;/*[J-MW3;=+FY)ZAFG>Q=$:Q?%B-^/L'Z5P\>/V>%<:YRTSP5*E7@21N.L8T7D]I?-M'L;+? *B*^C8YO.61.5[55$;YM:JZ\UT28-[|>\&KVWVY-9EMQU>^Q-M_8I)1'-:>KZ-I]?&^?*F[/W_^TTD<_.@LPOG'CJNQ5<[Y=I*MJHXHW0TG5=6 MG5L1B*FYBKS1$[SZ617"1AW(;%M9B"T7FZ7"!J;%|.Z*N6-6(QTD;U5$:U.>-ML:)\9.SSZ9X/9^-]97-F]#Y.*\+6WN&[E8KO3-J[;7P.IYXG=[53N7N5%YHO-M1!/0? 6!K_O9"3.S*;Y9,9@W'#-PW2QO.ZVCJG)HE33JJ()$\>Y4[E14/<\(M>>SLF,R(X]^=S<,7E6TMQ1RKMB77\'/I^T5RHO[5SN_0G|GOPZ8:S]MUN@O4 MM30U5OD5\%=0[4E1KD\Z-=R*BM54:O9R5]>*&F6|&S@C^F;$'ZG/]&;3'9X^_M3CKR,=#UP@#QVUX>2YU=XBMT20155Y*7<=6*NFOI4B];EUX=\YV5SBS6'1E?]NS M$[_P=!V=W.ID\Y&G\@.&BQ\/TU\EL]TN%R6ZMA;(E?U.|$C5^FW:U.WK%[?0;M@.?+OCDY.I87:^6'C<JGJ\/WR9/)Y)7:-IJS31OJ;)R:OBC>[4VWTC.9GW)P?9<$TLVE1=I? M+*QK5YI3QNQJ^#!%U3TI4?K;T;>"&N1R8GQ-BIV:.@3_P#AGILP.""R9FWJ_M"[8@QEB"MKH:.&B;(fJ:. (VZ(J_@^U5W.YRKRUT+!N3ASRXY/LQKBNS6"A15]IE5Q4D7+5$5]D37U<|?4=F\,X?H*X?MEFM\)54-OIHZ2-M!GH8QB-3L[!$_A4T5E%P380RCQS18IH|I=+I74;9$@BKEB6-KGL5BO\-8BJ-MNBKISY:DAS'V>;'-GYOHKKB#0QR0LFCDCD:U\;T5KFN;JCD75%1?2BIRT4R-MB+W';/7+M^5>;.)<-;'-IJ6I5U(J]].]-\7K\QR(NG>BF^^CKS.^X./KK@RJ METI+W#Y12HY>RIA;JN1/Z]/=_P!6A)[/3A*POGOB&AO=TN%PM===34WDKG4'5_MHDK$S<[|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|)*ZY&X[JK M/6,=+;)G.EMM?IVM1#]NF]IB/;JB.;VHO@]*N/*/B!QMDK-,F&;HD='4+NFM M]2SK;>1W+SMBKYKN7NFZ+W=QT&O^?.06;]B?9K[B6SW.W2KNZFY,EIMKDUT< MUTC6JQ4Y\T5%Y^)KZBX$LF\>L6Z88Q39MM>QK6O/ACKY^2+F8O$UF9GQ'#ARKJF^25B[554UT[T0U7BK#5=@[$5QL=T8V.XV^9U/4,.]'(R1JZ*W5.2\^1U>J'_B"JX:_/''Ll. M])8G7JK1CFJBHNDKD547T:F7K2W;6//*7W1_\ G&/HP_Q1MK MBYR2FSHRMEIK&C\06[3RVWLU1%E5&JCX=5[-]5Y>+6]G::OZ->WR1Y;8]R/4 M-5(IKLD+7>E60L5WZ.L0E|S])K>;:O/G;"_7TAQ&B?7X;O#9&]?;KI03HJ+S MCE@E8[)+7(J?%IJ3&P3TD=?0V.&EQ3A-MVN43-JUU%5M@2,1-$5T2L7;JIVJ MU=%7L1$Y$DLX.%+ &V&9_+\?5JM?ZW)NT31%'T-!UG M1ETSYM:7,,.&#]A-9TD=V^E)FIV>|+SS\'-C]IC54KG'HC)GYGU>L^\5LNMS MACH*&EC6&AMT+E>V!BKJNJ\MSE5$U=HG8G)--#>/ #DA<[QBM<>W"'>DL%_U-MS+SE8VLJ5U:NTU\YC$5>U-%_M!5]+FL7<[Y2)Z44D_;;;2V>WTU#04\5'14T;8H:>%B-9&QNB-:U$Y(B>HQ:1>V M1T2JGG+SUVN35555YJI;U>;'#G.-O3*FV)11RDXV,7Y1Y?4^$Z&TVNXP4:R+ M1U%6V3=&CWJ]6N1KD1ZO?RJG-%YHT6RJQ3+CC+?"N(*C8E5<[9354R1HHU) M'QHYZ(G@JJ1/MG1FT$-4U;CC^IJZ;5-T=+,FP/7TZ.=*I$^2I+O 6"Z'+W\U-MJPW;9*B;@ML#:>)\U4]'R.:FONE1$1>WT%O8VXM_/3URKK/O?>_\&7(<=)7_P M(P;KR_V1F[4_]41%X<$TSYP_I\OJF:,|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|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{J'#]$Y5,&ZKD\^54TU2-B.N M>].IJC450-*S|&]P^S1-8S!$U.Y%YR17BMU=R[T=,J? P'A\5I%)E*]=M+ M18=EY[6PU;)XDU!+9&*Y=/ZL]+1+TF^0\5WXNQ/7<'V8V=>7F>=GR>Q_'JB<[TTRIK-6HG)SV>A$?F=*)^A.PYU<=G#_%F$\856/[13.EL%XDW5W5I_N6K7W2N_ M:OTW;_LE5.6K=>BHZ\<3^4/W3O&'+OB>CC]*2:6WU!'7TO[%1 M4>WTMDCFMU5/0G/D>WRYX'LL< M-7**XNHZS$=9"Y'O.O4S9(HWIV:1L8UB_P!NCM.[TD[? L<.WGMKYK8S[G-G$ M^#;WA:EM%;>J9])]VJ9:ZF2=R|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{FFB\H<8UV'+W3 MOCFIW*Z"H1]F'4PZKME8O8K5T3U^BHO-JH>ER4XE<.9$QUM-A^6C];=6/ZV6 MWW*%9(>LT1-Z(US7- 7DG8{NB:HNB'4_'&7&&,R+6ENQ/9:.\TC55S&U;>KH MW+RW,.CWRIN4CU!FWJTM=V,HZY'(WU=:Q_\.IL\=K3?2O\A M97./1%S%7'YFGB:URT5/):++!UK58ZHM- *!)M%31='2R2:+XHB*G;"LMFN M6*]Q3VZVTL]SN=9(D<4$***-25RKH\;^G]*G1:W=';E?1OW2UN(JY-?C5(GF]*QL=#Y31.^]?#M+,!W- VO]UW2U#T[=%E>KGZ:_BZZ)W)W#]*XN/ M'|/53.N<^K\/#SE0F3>5-EPW(K'W!C5GKI8_HV0$_MU|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|!7XII72Q89Q"Q+E#LW/;U,RMD|[5:KD M37M:@'3;@AL^(^GA-OM9D)9*K#Z6FHKKNVEJ?-ZZVZV!DFY6HY5;Y7-D:C'MZ.Y93+,Q!C6+#U;76^6TPU5RTA2GJ65,5T,CG:)&KNK5O/\ M&:B=]@?DBZ+W/&6@\H=1V-DW++^=7W1O6\TUI4;M\/=&EFLS(X3LV89)98:O">.M,+2]LFQRHK98W<]%VJK98GHBHNBJU>:,+S.IDI7!34DE3-/"%3,;UCIGN1K&M-MTUW*J\D3OU.0/24YTX4S;S? M,&$ZNGNU-8*!:*HNU*J.BGD<]9-C'IR>QB+R M5.&<:4;$ACN]&V9*+JD4J*K98]?VKVN;\1LC3 MT=5LJK3PBX'95MEM|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

KJ@U0U7C/B-LF';LEEMC? MNW>%71\<,FV&'^KDYZ?$BGZ[-BW%MZC66CDPM6*B;K20U4RR)ZW;?ID#9.J% M3R=HQLZ2X-ME[M\EDN+_ -225Z/AJ.>FD_X?
DQ;5&U3+M&TF6:>C%M4;5,NT M;18HQ;5&U3+M&T6*,6U1M4R{1M%BC%M4;5,NT;18HQ;5&U3+M&T6*,6U1M4R
Mf1M%BC%M4;5,NT;18HQ;5&U3+M&T6*,6U1M4R{1M%BC%M4;5,NT;18HQ;5&U3+M&T6*,6U1M4R{1M%BC%M4
M;5,NT;18HQ;5&U3+M&T6*,6U1M4R{1M%BC%M4;5,NT;18HQ;5&U3+M&T248M MJA$7U>CF9=HVE)*/XDP-A|&-/U-^L5MO4>FB-N%}_B>K>BZ&K+_P %N3]_M<[
[\)1T,KOQZ"JFA1/[1'|/__'3>>T;2[7DVU],J>S18N'1TY7UDB/BKL1T* M?L*>MA5/TOA?E_F;V6O_/N*_G=-]7)8[1M,OZ3R?S9/9HQ6CH]AI8T\R"FB;&QOJ1$T3]!^IK53U=QFVC:8
MYGU5HQ;5&U3+M&TK)1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-J MF7:-HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:H
MVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48M MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9=HVBQ1 MBVJ-JF7:-
HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+ M%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-
MHL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9= MHVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:I
MEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ- MJF7:-HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:
MHVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48 MMJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9=HVBQ M1BVJ-JF7:-
HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+ M+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-M-
HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9 M=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:
MIEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9 M-HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9 M=HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9 M-HVBQ1BVJ-JF7:-HL48MJC:IEVC:+%&+:HVJ9=

*M\!M\!)58" ;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ;? 256 M OV^ V^ DJL!?M\!M\!)58" ;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ; M? 256 OV^ V^ DJL!?*
M\!M\!)58" ;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K M7[? ;? 256 OV^ V^ DJL!?M\!M\!)58" ;X#;X"2JP%^WP&WP$E5@+]O@-O M@)*K 7[? ;? 256 OV^ V^ DJL!?
M\!M\!)58" ;X#;X"2JP%^WP&WP$E5@+ MJO@-O@)*K 7[? ;? 256 OV^ V^ DJL!?M\!M\!)58" ;X#;X"2JP%^WP&WP M$E5@+]O@-O@)*K 7[? ;? 256 OV^ V^ DJL!?
M\!M\!)58" ;X#;X"2JP%^ MWP&WP$E5@+]O@-O@)*K 7[? ;? 256 OV^ V^ DJL!?M\!M\!)58" ;X#;X" M2JP%^WP&WP$E5@+]O@-O@)*K 7[? ;? 256 OV^ V^ DJL!?
M\!M\!)58" ;_MX#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ;? 256 OV^ V^ DJL!?M\!M\!) M58" ;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ;? 256 OV^ V^ DJL!?M\
M!M\!)58" ;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ;? 256 OV^ V^ DJ ML!?M\!M\!)58" ;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ;? 256 OV^ MV^ DJL!?
M\!M\!)58" ;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ;? 256 M OV^ V^ DJL!?M\!M\!)58" ;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ; M? 256 OV^ V^ DJL!?
M\!M\!)58" ;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K" M.O2%^_Q_P#O?_*%,2,1/ CKTA:?!3_'_P"L_P#*%,6Y],K^/7Y^/BVSPS^] MQRJ_-2U?0XC91K7AG]
[CE5^:EJ^AQ&RB&W@ M (S<<'%4O#5ES3_<=(JC&5]=)\;(MIV|FTI6HG65+F]Z,W-1&KVN>FNJ-E+%AF&2*/7S=7553N=IZ? M-
1/[5"><?!/9,.6/A@R\7#D4+:>LMD555RPZ*LM8]$\H5[D[7)*CF\^S:B7E13Q0,Q3 M44U6E7)&B=8ZE:Z+]>LTYZ({K=[_M7^@##HEEWC]VYE8%L6*[0_K+:=Z2.LA5 M>UK7-
U5]^=+]U?%%/3D:>CHG]*CA P(M3SVK7.B=S558E:.B_PIZD0DL M %BN1K55>2)V^!R0S-KZKI+>.,W8)M.\S\I<%*_RFJ@WRF M=KOV<[5Y3&O/S&M?#IRG>YQ8>N^+\!
<6'#!0YCO]TLE=0V^H5ZL2*IDIWLB M>KDYHIYS5UTY.'*3*K(@)XRF)*SK/%W50:?P M;3VO%+EIB_%71WXFPYBJKCO&.*+#-+67.JITW)455&L51.YFB-U5RPNYHB:Z
M]G<."Z$O,BCJ\N\?X!DF1EQH;HR]Q1.=YTD4T3(7JU/0UT#-?0LC?2!TP.+F M>]&^NZ9"V1T2KYN,,.2N[^3*>B?)_ CCLW45,=+#)-/(V*&-JO?(]41K6HFJ MJJKV(GI.-
/#E5>Y;ZV6XXTM2.GL5'=FM\SN5535-V MJ'S+653I%D_G61=KM>2M14W.>GGVGH\TE3_P1]D^^^E^+59%,>8#O_#K+G5>Y2T3$E \#9LW'W<&>56ZYU+L[
M4]QBG+VIQYB9WW;FGCP_34;?)H:.J=&KJERNWO=MYKM1&;?6O(^'C>RTR459-MF1@FX-AN5+&^>I2%W\[7*.)%ZQDK?V6C51')SY'Z$KJC-/%;;CIY-CZM\Z.:I+A?
\38&R[I8KU5TM;5W">AJ*Z*3 M\(^%B2M5RK^,[:Q.:[_/M/06K#D. L4WVQ6ZHJGVJLL3ZWR>]J'S(R9KE8YR M*Y57SD5%7Q0^!EWL3#&5_5IYGW6K49ZOPZ?X#VN)%_|
&75=Z_>O4.; M;77&Y0T\-Z;L3J2L?"IC4@C7:UR+R;JJZ)RO/Y*VR'\"8(JP?6.BQ:-6PU# M55=%K&-61CEU[W.5S?[4I#;.41X0\TKNYO6/L:HJQOISZR18(D8SUJYR)IV
M@>;I,3/9V9D5=KN]XEM5NH_N= ZLN$LRK4(FZ5[%5>2M56M_2;$QO5U$%!@Q MT4\L2S7BC9*K'JF[JH[5J^E%]!\RLPD\A:(NXT54J+6^023UDG;NF?JZ1R^G MFJ_
_9C^9K;?@1NY-7WNB1O/M\UR_X /%18/GQW?,P1+I>++FEOMM=(E%34[M4^-(I>J.[?JB\]-&Z)V)S])\9M!<9,L,/F-5WBNEQ(R2D?$YL[FPMB69D?5K M'KHNYJKNU[5)DL3
SM)LT%__:.9?_AXSR=8]&\+%C7_-50;_.8]0/78MRV MGQE>;S6WBMJX**FIXVVEM'5/BZIZ-5SY51%]UNT3GKR0\G-)<<>Q95H^LZIV MKE0U"5U1"],(Z-
(V+)M=W*Y6M37T*IZ"X0NS Q+BB&Y5\T&';&U*?[G0OZIM M3*L6][Y53FK41=$:BZ*FJKJ?%RJ[F1MR?=*YJ++;.QC7+RU56,5$_0U?T >E
MP!1I@K'EXPA335$]]6BBN=&RHE61.?5ROOC1R\]%5$5$7L-DU#EZB14714:I MK*YT#[SG+=*2.IJ*+=AE(EJ]9=LD2OJ%T5JZ:Z^E3]-%@=MHS7L]NM-WOE1%0TS[A7MK;I-
/&NOF0QJURZ]XRK4W5%\]'U<+5[64C$5 ML#$_M4W?VP'C[SA"XX.H;1C&MN%4W%LUX@;5Z5:GP+#--L6!&:[=B,/\OJ]])B[$5UKJRGDH.=S[+Y'6.C; V.+?O5J+IN63.O%/-BC M
-@QO>[A/4W"Q7>BEHZ59-M/11NG1&L8Q.2NVIHNKEYKX'IL54LV/(DI;9#)LC?(R#>Z67J*E]=5N2=B(WL4#9^"+I->L'V2X5"[JB]H0I9I%
M_,.8U5_PGW3RV5[MV7&&'=O^QM.O_P";;>I M-M /Q5:.N;\?\ D/S?$?KJ6ZJWXS!M 4SZY\FNY?W\L>@-? R;5&U3)++##'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-M-?
R;5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-? R;5&U1)#'KX#7P M,FU1M420QZ^ U\#)M4;5$D,>O@-? R;5&U1)#'KX#7P,FU1M420QZ^ U\#)M M4;5$D,>O@-?
R;5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-? R;5& M1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-? R;5&U1)#'KX#7P,FU1M420 MQZ^ U\#)M4;5$D,>O@-?
R;5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O M@-? R;5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-? R;5&U1)#'KX#7 MP,FU1M420QZ^ U\#)M4;5$D,>O@-?
R;5&U1)#'KX#7P,FU1M420QZ^ U\#) MM4;5$D,>O@-? R;5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-? R;5& MU1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-?
R;5&U1)#'KX#7P,FU1M42 M0QZ^ U\#)M4;5$D,>O@-? R;5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,> MO@-? R;5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-?
R;5&U1)#'KX# M7P,FU1M420QZ^ U\#)M4;5$D,>O@-? R;5&U1)#'KX#7P,FU1M420QZ^ U\# M)M4;5$D,>O@-? R;5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-? R;5
M&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-? R;5&U1)#'KX#7P,FU1M4 M20QZ^ U\#)M4;5$D,>O@-? R;5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-? R;5&U1)#'KX#7P,FU1M420QZ^ U\ M#)M4;5$D,>O@-?
R;5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-? R; M5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-? R;5&U1)#'KX#7P,FU1M 4M20QZ^ U\#)M4;5$D,>O@-?
R;5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D M,>O@-? R;5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-? R;5&U1)#'K MX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-?
R;5&U1)#'KX#7P,FU1M420QZ^ U M\#)M4;5$D,>O@-? R;5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-? R M;5&U1)#'KX#7P,FU1M420QZ^ U\#)M4;5$D,>O@-?
R;5&U1)#'KX#7P,FU1 MM420QZ^!'3I#4_VGV8'IW_RA3$C]JD<^D03_&GV8'IW_P H4Q3.?)=QX^=A MM3AG[fCE5^.EJ^AQ&RC6O#/[W"*K\U+5]#B-E$5M0 M
IJA4A5@+I6O\ U8%O25<,5TS?P,,,:85HWU^(L.1R,J:&!NLM71N7 M_3GHB\[\FN^O-'(.GEH,(XCFI+8^3K)+75PLJ:??KYRM M8]If'+W]S:I]_AV;P'Q&97YEHQN&
<>V.YU,GN*1*QL=0O_0O5LGZ4/+Yf\%F M3^<5SGN>(,(4\5VF*K-F"F=/6XLQ?=GHUU1 M4NU2-B?C.73;'$U%UY(C4YXD+EGD[@S)ZS.M6"\.4&'Z)=-_DL?X254[%DE55?
(J>EZJO=J!DR?RXH\I M,LL-8-H).NI//11TO7*W;UST3S\BIW*YZN=I^V/9@ !;M+@ /% MYO8>K<6Y2XVL=MB2.Y7.R5U%31JY&,Y9*=[&)N7DW57)S7LU(6]%?PJYG\.% M7F7/E-
AIN'4N\=O90M\OJII95B6H61?P$C]-.L9VZ;Z\N\Z!JS7_.@VJO-> M8&.2%)HW.D:Ul'-VN.Y-45%[47P.4^.!"7L?>XX< M_.NF^AUI-HA+TMOO<<.?G73?0ZTFT M
8^>CB",/$YU\X=%X#VM.KV\> MTS&-O)%<%=%*'C^=8]7K>,SZ>8>ORAM4MWS+PW!"W&G*B?#M/)B:ZPK#75+.KI()$T=%$O-7*G*H;SP;I[]KM MZ8UQY:^>
<_=C_EI/&.WIU>KO;UV\L8^_*0#? M?;XGUZ[!\]/OR7>ZU0]$ /#ORMH/O*L6/&5E5' M'9Y*>;DK&]WKFOB75KEY:+JFJ+R[%4_-?,HZ6[PW-
D=XKZ&2NNL=V=)#U:JR M1C$:UJ{\YJIMU:B\^]#8(_\/1Y:M&"J:S MNQ"L=1-}]VJE]5+O5/P;G,.Q4;R[-&IVG59LK:"7+BCP:M94I0TS86-J/-ZU M>KD:]->6G-6Z=G>>W
&N\2Y2,O\ ?ZZO@OM=:Z2Z1QQ72@ID;LJVL143FJ;L M547;JIVIR,=5DM036O#M)%LC<]4T2P5@=^%YKG6UMTFO5WN+F.J.Z>-L>K6)HQC6MY-.B*O+Q/4R1]9&YNO)R:&
M0 >.ARW1:+B3!T5=51TCZ,2E\K08K4F1KU555.6FO>X_#8,M+C9)J-JXRNU M;0TR-9Y#-' D3V(FB,=M8BZ;>A>X]^ -0+P]4TE.RWOO)=$L>/U]3:,S8UM
M%)O1^],TU>B:*B([LW*?3Q%DM#?[U=)VWVNHK3>%8ZZ6F!&I'5..U&[D=[JS M5&IKIVZ&S !\C#-@CPU8*"U1325$=`"V!DLVF[6M31-=$}!|<-M M_/4M]R8-I^F?
MN,.U#+KGR1.36=EFT,2_;@VH72QU6;1M+]J#:@DJLVC:7[4&U!)59M&TOVH- MJ"2JS:-I?M0;4$E5FT;2_;@VH)*K-HVE^U!M0256;1M+]J#:@DJLVC:7[4&U M!)59M&TOVH-
J"2JS:-I?M0;4$E5FT;2_;@VH)*K-HVE^U!M0256;1M+]J#:@ MDJLVC:7[4&U!)59M&TOVH-J"2JS:-I?M0;4$E5FT;2_;@VH)*K-HVE^U!M0256;1M+]J#:@DJLVC:7[4&U!)59M&TOVH-J"2JS:-I?M0;4$E5FT;2_;@VH)*K-HVE^U!M0
M56;1M+]J#:@DJLVC:7[4&U!)59M&TOVH-J"2JS:-I?M0;4$E5FT;2_;@VH)* MK-HVE^U!M0256;1M+]J#:@DJLVC:7[4&U!)59M&TOVH-J"2JS:-I?M0;4$E5 MFT;2_;@VH)*K-
HVE^U!M0256;1M+]J#:@DJLVC:7[4&U!)59M&TOVH-J"2JS M:-I?M0;4$E5FT;2_;@VH)*K-HVE^U!M0256;1M+]J#:@DJLVC:7[4&U!)59M&TOVH-J"2JS:-I?
M0;4$E5FT;2_;@VH)*K-HVE M^U!M0256;1M+]J#:@DJLVC:7[4&U!)59M&TOVH-J"2JS:-I?M0;4$E5FT;2_;@VH)*K-HVE^U!M0256;1M M+]J#:@DJLVC:7[4&U!)59M&TOVH-
J"2JS:-I?M0;4$E5FT;2_;@VH)*K-HVE M^U!M0256;1M+]J#:@DJLVC:7[4&U!)59M&TOVH-J"2JS:-I?M0;4$E5FT;2__M:@VH)*K-
HVE^U!M0256;1M+]J#:@DJLVC:7[4&U!)59M&TOVH-J"2JS:-I?M M0;4$E5FT;2_;@VH)*K-HVE^U!M0256;1M+]J#:@DJLVC:7[4&U!)59M&TOVH M-J"2JS:-I?
M0;4$E5FT;2_;@VH)*K-HVE^U!M0256;1M+]J#:@DJLVC:7[4& MU!)59M&TOVH-J"2JS:-I?M0;4$E5FT;2_;@VH)*K-HVE^U!M0256;1M+]J#: M@DJLVC:7[4&U!)59M&TOVH-
J"2JS:-I?M0;4$E5FT;2_;@VH)*K-HVE^U!M0 M256;1M+]J#:@DJLVC:7[4&U!)59M&TOVH-J"2JS:-I?M0;4$E5FT;2_;@VH) M*K-
HVE^U!M0256;1M+]J#:@DJLVC:7[4&U!)59M&TOVH-J"2JS:-I?M0;4$E M5FT;2_;@VH)*K-HVE^U!M0256;1M+]J#:@DJLVC:7[4&U!)59M&TOVH-J"2J MS:-I?
M0;4$E5FT;2_;@VH)*K-HVE^U!M0256;1M+]J#:@E2JS:1RZ1!NG!YF M!S_YO_E"F)(;4(Y=(DG^T\S!_>_^4*8IG/DOUU\\-G\,_O<XY5?FI:OH<1LHPIH M <=<;=%YG5A9))+33V?
%D+=5;JRZ](^%3N56S!&B+ZE4 M!%%@^_6-LALQ\N&ROQ@_E_6:!G;4U-#(EA4NBL7XG'Z9^6>Q,.XZO MEKIX .BU5/_&AZ,F3XFJ!# 72LYKX>ZN+ M$5OL>+H$(U))
M)4.]3XEZM/(^K)%X#Z6?+[^)'%BC#=\PQ.I3=+3[*^G9Z=7 MIL?^B-3FSFABS|'^*[PM1@_[<#4&]JM)}UIK@[^C5\NFGZ#QM/2RUM0R&GB?M//(NUD<;5B
M.3XT0^\.7X.K5667ADR[HJ^DJ*'"MAM;&RT]3$Z.2-=SET5JHBHO/O0W0 M 0EZ6WWN.'/SKIOH=:3:(2]+;]W'#GYUTWT M.M)M %NTMZO.> M'O#&-
:B2LZN2UW:Z/JKIZ/.U'!O>Y]HJ*OCR5?2;^]IXO7:_?0O5:ZJ?(.Z> ML_REYCM--R^$=+GWOOQXEL^.Q3N<&E-.3_68&X>,+X+][(ZS]Y+I<(U1S:
MBN1KMCD[VM1$1%|"\U3N4V?U:HG+0R:;H4T7UD_@ZW#UM:<.MQM M?EVMG[UP)3 IJ4W!2U7-3MY(!?[M@U0P>4Q_LD_2/*8_V22!*US|C%[7C^U^@'Y_*8_2GZ1Y3'^R3]
(KD]KQ_;SZ MHA1%1#$R9C!=`(O@ADV!XB/5?KG&V)QE> "BX*:H41Z>=W:'A,RLW+'EG#2Q M5[GU5TKE5M';J=-99M,_]JU/V2_%JO(#W>Y"XUU9\Y,16V:"LJH)Z.K>W5!$
MK=SF.1514WTR/[BPNPP[>IH@T0 JQ&B#1 &B#1 M &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 M &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 M &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1 &B#1

*M6/DTQR:9TS[T!/:SYE?TM+\|HO\ 2#VL^97]+3OGM-_I"?FG@@T\$-O^M.;[M..,_TGTL_P 6?]T_:S9E?TLN^>TW^D'M9LROZ6?>/:;_2$_=!H4_6O/|F%O M^D>E|N?]T7.&;*#%V |>UEROUH\@HY+?) R3RB*35ZRQ.1-&/5>QKN[N)1HN MA:UNFNO,N73L-=R\VW/O?9U'0Z7'T."#Q>>,+P 86Q?DK{?3W.BGI*N&.HI MFJR2*1-6N:O:BD8\R.'^Z6&JGJ[!!) <;8J[FPLZ;+7M;M[7(GEE?%-$^*5]JCHWHIY%3M14[OC+8;>6=Z,CC<|ET1K4U55[M/63RN M%FH+LUK;ZAIJUK5U:E1"V1$}.FJ*4MUBMUH61;"@1;9--_D\+8IVGIT3F!& M#+O(*!8EF947B"6TVU%\YL]*R:1.514;U>,5Y7%M3720ETNFC#"FCIX4VQ1,:O MC^20B)HB&;:O+GZRX#\E57FU"UKZFHCiV/>V-KI7HU%/5[CYUMP;8K+!5[CYUMP;8K+!5[CYUMP;8K+!

MD4{T;MD\QSVKIKJB.:USD5435$4]N>6M> ;+;KNVZTL+FSHYSX_:U8Q7IYRM·M3Q153GKHBKIH>I·M·M·M·M·M·M·!&{I%_>;·MYA?O?_*-,21(W=(O[S?,+]I_.4:8#8_#/!W"K\U+5]#B-E&M>&?WN.57YJ·M6KZ'$;·M·!W:·;DTTUU!;_P'](AH#.#@:R@SEZZ>XX:CLEVDUUNEAVTDZJO>Y$:L M;U\7LN'#O1UZ.SCM^(IZE);/EADWVQ&]RR,B1)]4]'"J%!UTR,O> ·M55SPNR"FKP\ZSQHCG4\AZMFQ>S62-NCDFISLS@Z*?'F%%FKDQG1·M,UYS5T7N]-Q3> ^2S35? Z9KBGHT_GF0[SV0·YEHK;6 MRTZ]#-M=]RZ7.KFK|C62NGJ:JIZ;&L5MTCZRE<{1.39X]41/&1& 3!!\+7TFWRM|2Q(=W:E-<;774|RM|2Q(=NCE ME;+%*U>QS7M54XX<_.NF^AUI·H /AWC'"%GQ"^-]S MM=)<',148ZIA;)M1>U$U3D?/3*O"'?\ HU:E_N./_NGJ>?IY%?B+,|>N;37&NN^<8^[.6*&G93Q· BC:C(VHC6M3DB(G<941.\N*:%[!Z^]H \?F MQ>+OA[+G$·TL2L^ZU'2NG@ZR·9&ZMT5?-[^2+R/Q9)8YDS&RPL%^]9XYZVI@·MT]5B;M:DS55KTV]VBHH[ET:2-5KD1S7)Hf*Ff*:BM·3=YRZO%55Y=:EHK;6 MRNFj;#>(WRTB2+IY\+F*CHUTU33FG9Z~·P:H1WXACRVRGL&5ULEI;-3/ZZH=OJfVH>LE15/[=TCU[5UUY=G,#)E5F MK;ZFF=[MZ^M>ST(B)W'L@·!XS$M?C*.YOCLE)9HJ%D M;7>5W2HD3K'=[4:Q.6GI4]F;-Q;,^LS*ND^*].W;$MGD@C2TQT4#YH(U1%WM MBMN=%,F!+O?+G2=35VJI=0U-)3R=8CZA%1&MC=WHY7)S|CO>< ·M·]ON_*fY/OUEMM·05S8DVT<[UGHUZQCFI)N3:|LT\U>U3\|BRYO5TRZQE;XK·M·)9*Y;W]T:&AG3S5:U&*D:.[%31%35%|3Z69>*[_)@9>UUEMV#;U#<96-6L·M2HIMK(]KTFMUIBP]26U[74[5GJKI.YK(EVMT;·MM8FYRKS/EX?=S0\]F%::F3$·MF&GWFSW.\X4BH%CFHZ!CY-E3IR62· BHKDTI.IARYP[44.*:,S4V%ZG#UMKJ"·M)*'"2+,O1&O3EB:HCU7FK>U·,5JO<-@R!PG4S6VCNS>5U<,W,3=(Y-RJZ·M4VZ+XGK,9W#;N,K7ARTV=ESJ+A2/? #N>K&LD1>2O7N8BQY5ISQM?ABfOR&·MPK;&VRJ6Y05=.Z6E2)W6,1)'JIJWM3DO>>WN=KK),Z,·7MI974$=IGBDJ48O·M5MYT,CF,5R*U>U$4SV6UUD&=.(I@^EF;0S6VF9 M'4*Q>K>]%75$7LU/EV?"MQK6YIT;J:2F==9Y&4DDS%:R3="K46O;IS/R8WS.KL+4F$YJ2TI2Q·MOVNW*Q%:C5],N_N-?W*Z8EN.3;\&TN#[PV[T]&VFJ9).:?,"C6*G.-W_&*Y$[M&ZJ\GML3V.OJKGE>Z&CFD90SHM2K8U7]42%ONOV/-.\#\51F9C2R8E@]+=·M&R=K]&1SH98W=BINYIW=OI,_7HM>,&1AFXLI(Q?5%NJ8Y;A&+U;'+KHBKIR5 M3\L%GN[BS44-6JU8R-7(FY%T1]KS3DA\[,^_5%+F1EWNB<·MFL15U/=XPH[_$.(,N+Q:L%57%;922>4P,9HK&NB:US>?8_3=HB]H!Z"W8[MQ#9<6VZQ8MMUOA;=4YRJN7QU7_*;WPQ@OO[3/N!'GORL·M\1]EQ:]33/GMZ_#_,L(3EK_)^SP&O@-?·ZAY/&?M3·X2?[%=6^K;Z3?S>XYQY2X\ERXQW;,TBN6F8]8]MB? CP.T1R>·M.FB*GBU#HE1UL5,2Q5,+VR0RL21CVKJEPJ"GQ"\>(=7:V\/~&@·!R]+V0]T\FO$/·MTQJ8XM_/I"U;KWY:Z191T-34/71D,;GN7P1-5·-9G8H3·'#G=`O·M? U5=>',I*=]+S59/-=IZF,BHB2(Q>>Q51-57E·MM1$[U5_^]EO:W9/Y T-)(BPWN^:;JJ1FFCV)(U$Y^C2-&IX.77TFP,E,(,MMM·MDO-2S;45;42%%3FV/DNOQ\OB1#Y%@PM;DCC2)B,8U&M:FB-;R1$ R'@,R\G,*YM4K&?NDWU,**R*MGHR:-.,]N[·MO37NL!7:K?64=3"NKZ=[UU!*JIH)9L-XD;5/·BJREN$.Q7>"i:NFO]AKWAVS(O^6,:-#A·MRJFF;::RM2WUMOD75K)/ZM'-3\5R/?M3M3M·IWSC>P;2VJ2:UT·RKZ]6_@X·M)HVQ.1=/QG;EY>]%7E:EX=.K;YF9F? %CF\4CH+3#6NN+ZF1BL;43]MS6QZ^Z·M1':*JIRT30#ZG'?_ ,-,-?V [^-7F>SSTKJBCX2L,QP*Y&5,-OBEV+^+U>[1·M?#G?/,H(7TM1)&FO5.W,FJ[T(J*IG<U,V'LSL'YP9) MV[+NX5CFM\UO-[>2(Y5^-3V&9N&,]\U[#';+YA6W)31SMG8ZFDB8] M'(U43FLB\N?8>'RQS·Q+PN8SN%MQ%9:A]#5]C:BE]RKE9KI-$Y?-=VJG,HNO·M:AO*KXS;'= (&4F%,/K!7RH\&E="U&[UTTW;7*]_$@&E\[(L·MTRZ*B·KKHHB@BJ]ZRCTV/TV(U_)5[41%[39'#MQ,6G<;+;""X9O%JKJB6&HDDIY*%C7[_>N·MJL6O+?:!2OVM8LM-"U&- IVZ;IWJNC8TUY)NLD9!*]BUE(J.:Q531&1·DE^*G]RQUE/47]IB=4UE'41UB4[/·M=2M:CDE41RKIWZ*G>·|]+"6>.=&<<=SJWX0MENHK?3.1'[HFJR+7L:LDB^< M[3T)^@T_Q$RXPGQS"_"%Ol*&]>1L:C{/:LFC1ST1_)R\^UNO+W/8A[?ANXA[·M=E%9[EAZ^VJKD9+5+41R4K$61'JU&N8YKE37FU-._GV'G.)C$=UQ_C*W7B?# M===9*>2WL2ECJDUDDBWO5LCD1-&ZKKHGH1%[P)]X=>Y^'[8]RZJZEC_P#E&F·V/PS^]ORJ_-2U?0XC91K7·MAG|fCE5^;EJ^AQ&R@·M !;O37ON.47'UQK8EQ)CV\9=X+N]19L,6>5]#7U-OE='+<:A·M/-E;Y[=%2-JJF;4Y.5*[5%1&AT]HC>X8M5HKHF2?)5R+,_M·%,5X-PYF#8WV[$%FM^(;7,W? Y/7T(}XEU_&1%1>>B\E3GZ%/YWTY:+IHG/·M_7XC>?##Q<8PX<\4TWW+EZQN]JZ/5$_8D(,X.!3.')·MSRB>MPY)?I[%]JW2P*Z]AV^ES$1)&(GI"ING"QEJBIM:C9"V-MNC41J>A$Y&0·A+TMOO<<.?G73?0ZTFT·M0EZ6WWN.'/SKIOH=,3:·*-["H_"W·M,_\K+@!CV?H[-"Y&^GF7_"W:O>O(HC5[U_07@"W;^@:?.U+@!;M+=]KJFO+·M])D·%FU2J-]87_"W.-[< +=]^DMZM?6D·%WT%P·M·H\Y7&N7%AS#I·M(*6_I;ZGIWK+]M(*6_I;ZGIWK+]M(*6_I;ZGIWK+]

~~M=)'OFHT1'(ZF9UNY%[TT!N_7L1$/RSXOM|'75%/.DS(H4=N[5;^"WM9OGGKJ@'@+-17-M(_9:.69N"<$-6&1'QW=BO:K5U:F^7MY=G-#WEKQ%2W"FGE>V2A6!Z,EC]T2-MS%5$5->:IHJ.14Y_X#]-/>;?4[^IKJ:,2/K5ZN5JZ,[GS>]NBHO)$371?QM#\=]JJ"Q8BMEKN=57PX<91O?%K43N26IZQ%.M5LDB*KW+M75&JNBZKR-@VVKCN5OIJN%')'%41ME:UZ,+M &LK53RMPIE^Q8I$ M='<6*1%8NK?P;YA?O?\ RC3 ;'X9_>XY5?FI:OH<1LHUKPS^]QRJ_-2U?0XC90 M M $)>EM]~~
~~{CAS\ZZ;Z'6DVB$O2V^]QPY^-M==-]#K2;0 M M /EWRVON5'%/&+6/94P3ZN[-&2M>]? MH13Z@-UW/@Z;TG6]JF-EO+DU&M=[]fIO(K0Y?5U$V]Z M/AFGI7Q;.OGD>VH:QSE\Y%3S/=:IHCM%1%U7L-@;.TO \.N"*R6J<]7TM.Q_MDSW.I4G/GS/=@#$,6&)X\'UEF2:-LLK)V.D:BHUN|SE3DGH1R?Z\CYMSP-5MW*:KIU](Z"::6K;]-RRI, ^%8M%3LVIN5W;Z$TY;K[@ >/3"M;6TE6ZO=2K5 M55;35$D;-SHD;$Z/DFJ{JJ,5>S3543LYGX+Q@B1EOJGP]6BHM;(K((E5STE M>CVMTY:]FBIKWGORB(O>!KJ@PY5W^@OR2PPT;:UZ3+ -^JN?!\'&CUX:Y$=I MHCTYZ:ZKR/K5."5?<)JB%U/"CZQE2W:S16M;3K$]XS<_.NF^AUI-HA+TMOO<<.?G73?0ZTFT M-M-M-M-M-M-M-M-M-M-M C=TB_O-\POW0\ Y11B2)&|I% >;YA?O?\ RC3 ;'X9 >XY M5?FI:OH<1LHUKPS^]QRJ_-2U?0XC90 M-M-M $)>EM]~~
~~{CAS\ZZ;Z'6DVB$O2V^]QPY^==-]#K2;0 MW(!<4W'X;G>: M*RT;ZFNJ8Z:!/QY::KZ$|*^"&I<69QSUK9*:SL=30N3;Y0_]4?Z=]=C4\>8 M&Y]R%OH|!V;U9:FLI;NUU92^Y2;_(OJ?Y?C_2;>LU_H,04OE%!4LGC[]%T5 MJ^A4[4 -F"FXJ M-M-M-M-M-M-M-M-M (W=(O[S?,+|[_Y11B2)&|I%_>;YA?O?_*- M,!L?AG||CE5^:E]^AQ&RC6O#/|W^K\U+5]#B-E M M 0E26WWN.'/SKIOH=:,3;(2]+,;W'#GYUTWT.WM M #5F,_MfZ"R22T-G;VY5K55CYE?\|$|LT5?QE\$_2;1W0R3,CCD?6RZ,:KD15TW:=B_P 22NE'6V MU$\HHH]?=KUS%,S3MF?0?'@Q1<[#4^4V^]=2SM#'1\)OBT[T\%Y>LV/FWA'[MV+19HK?USK-2P>3M225TBH|%5=SG*NJfY%YKW|355':+AB2K;26VEDJYW+R1 MB?PJO&J 5!35!N]:]35 *@IJA4 "FO M@-4 J M M M M M M M M M !&|I%_>;YA?O?_*-,21(W=(O[S?,+|[_Y1I@-C\,_O<XY5?FI:OH<1LH M "$O2V^] MQPY^==-]#K2;1"7I,?>XX<_.NF^AUI-H 8WPMD;M#Q'D3:[O&}K8*CT5%Y\>O _#FUP!YFV6G|HK72RWB/KU9%U$BN M_P"_1$T1Z>/9\9\W$%9I9LG,O[O>*:A9%36VI*=.L,,3YG(FC6]|TN=M3X5V^T MT!Q:R.CR#Q0K5Y[847U=;?1?\U422?Y#R72"1M^YF"WZ(C^NJDW(Q,JL/6"YVBDI+RMT7=U,T^US(UC1['>)O/4YESCREQSA2R7-9 MJ2*NN%%%5244,[7NB55$)+!ULIEYN-OIJ:>59%VN M9'3L1J(WL141?C-P9;Y78;RTR6;F19J:>##$SL,/J'3OJ'N9UCX4X0HNBR4LK9 M6Z^C5JJ<[\AX\K;M+?+AFG=)GUKY&^2QRNGB*NV33153?D!.,|\|_W5%O=NY?^MUQ_]XQ3XLMGZ.LDH;A1UM3!#),V&*=KE7.U5[&773_.14T$U/;H'MU4?*O@NFB>E-5] &TN'#B.K\|+Q>]:MLM-:VT$#)FN@F<]7IYRMT75$[MC;]9CC#MN56UE_ME*Y.ULU9&Q4T[>UQ$##H^_^%>+Of"A_C%/6XGP3PUTF)+C M|U[S"MRDG?)/''7SN:Q[G*JHG5ZHG->S4"1;|<6>>U5=?;KC279E.U'.2CJ6 M2)S71-7(NB)SY]O)$YE,(8N;BF"I5:9;26G>C'Q[|R<|>_1%UY+R5$4@KEHZ MS6/BPMU)@RL=+AR6N\GA>V1SDEA=%YS"*[FYNJKR7T(O;S.@U)0P4,*0TT,< M$2^\?$U&M3XD_2 M M M M M M M M M !&|I%_>;YA?O^\ RC3$D2-W2+ ^\WS"_>_\ E&F V/PS^]QR MJ_2U?0XC91K7AG|!CE5^:EJ^AQ&R@~M %-P%04 MU0IN\/ "X $)>EM]~~
~~{CAS\ZZ;Z'6DVB$O2V^]QPY^==-]#K2;0 M /"YV8/GQYE9B2Q4,=:U,54RK3M5=$=*Q4>QNO=]K43XSW1\Z\W>EP_9[A=*^_M1(:*B@DJ9Y%[&QL:KG+\2(H$*,''/JBR%M=YPKC6U72@7RM:F-[:?SF.5K6O M;YKE:]YC5337M4^9GUF1-Q.XKP[9L$6>X55/2,VM?-$B*^1ZIJY=%5&L;C4MY]O>NNA+*CS4PE<:FQ6[$%1;K=B.Y00RLM%0Y)9(72IN9&YVW1'KV(G+54Y: M\CZ5CS*P/6XA7#]U0=MDNWX3^7)7-T75O:FG8!HKB_RXN4>3M&$::V4TM=#A]T<-0D+%>Y(TA1F_1.>FK$3^V/U969N8:S,RBL,L;>^]9B66P M26_]98%2-'L@5-5?V:*]>OGV&Y6YUX#EM5=HZ6YSX@L|)#70)4T\['M_"Q*NF]-O-6Z\E7N[M](.9#8TPEE+67ZR9EX3=),^5KHGU5N;,^)I-6O:K7\T1=4T5->SXR1F6>,& M5&,\5PT6&<(>35T4UK4[-.:\E1]=]@0HQUF7#FIG!%>\6TUSBPI3R(R*AHXMTB4[M5U1G-41'/7FYVO+5=-=$)88 XA|+YF5+L'8?L]UMT\E#+'3^54S(X8V1C5$;-MYKUT1$T1.1L"[9FX)LE3;J>NOULIYKJR.6CW/;J2L>]-8_5$T1KE5$1RJB*O M)%/)V?B LETK+Q'34D>RU8C,8*R2.=%=$UZ]7%4*FU/=-,]1==4YKKH@$8N M%BN?@[&6+|<(W/RBT8BO-^WT+9(W(K:A-^B*O=HO8O9R/|Y,8DPOE)?L0T>8 M6"JF[W?S8Z6GFIV2OA!&?!4DERXKK'C?-VHB:]O9WG0P\9EQF':2LD:[< M^_F>S M-M-M-M-M-M-M-M-M-M 1NZ1?WF^87[W_RC3$D2-W2+^\WS"_>_^4:8#8_#/[W*K\U+5]#B-E&MM>&?WN.57YJ6KZ'$;*.M "U7HU%5>2)VG,S/[I0< M98GS/[,MN'/##,3W&*=U*MY6E=6OJGM71ZTT+5V]6W3]5?JBIJNC4T594](-`MF7694|(Y8EZMLKZ>Y34C+932L715'5,KC',:O:DMKJAR:N;20-8Y4:O :NZT-+]QL26M-M|(+O9GRI8L+G(JLDC=R5T3\[=4145KD71L75WS?++#88ELM=:,+M1Q7"Y5T#Z: MJI*AF^,;)[5:|CD7M1454^,XU< %34.IE?:;BKN^&7NE71)&TZR M2PR*GI5:=NG|<7T|'VG 6:\RN[fP%CI&MT5>13KF?LD&,969VUQZY0KZ6 MY?\ :XX<_.NF^AUI-G<0BZ6[5KN'/#J-75?OKIE_^#K2:_ 71_LD_25KG[%/: MJ;|S^IJBJR5QO'3HK MI/N5.[.U-5+45/C-@ZH89H&5$BM_NMBJX6ZG5;9UE^L,|-MM]L5[fM$U]*[RR>HVK^#8U%:B-5$:L2:[JKS_3AM"Z45|KL-X>ME-,R^T&.[G=]IS;9Z-92LDJDDG67;M5KM{(^WF]Z:2[F] MW)(]7KUDLCI'\U]MSE C)0WRDL4V1=R6]],.6^W32OKZ^&@25|))+33-9(^M)S')S>NU7.;JBOUUU+L.X?2&GK7TM'=9:6; =ZF@FN=(UDSEFK%>FC6-1K-Z M-W-8B(NUR:IW$L]OCS](1]HKS0"(.*;/5)9[>R*@GT;@*PP[8J9R:.2XQ*K= M$3M3FNG0$*XY?OM:UR-K?P/5HC5>GG;,(]'6OXY5?FI:OH<1LHU MKPS^]QRJ_-2U?0XC90 M 0=Z8>NDI.$/]6>YJ104 M4,G/A5&S2?X8T/N]$W R+@LPL]J.!\D3))JASI(WJG-$C1$73^]7Y)%G[IK5W\$5'_6K_)R;O$5E'>LU M!?9Z>SST<#Z26223RR1[$5'-1$TVI=SU0T?[33" ,%C^<2_Z$Z3H_7T%<M\F<2|K\=Z'B'/W=M^OKMG7R|/3T:+K*B6X1I'4R/J6(]NNJIR]&T?:9XX_YPL7SB;__$1L/TKJ?S8<_P#JGQ?^3;_?_P M M(_=:\N_HRH_ZU?\YZ?&=V+LH[C/9]74Q^3R6ZUR3;X&;D=UKMD,JZ M:HB=B=O:,&]HCC_)PL?SB7_0FT>'W(/$.5N);C<+O56Z;"HI>H8E)+(]R+ MN:O-',1--$4B=KL=;;AVUTSC.6W\(\.\2XN!OS:.8UQ\O'_6JO;Z9O_DFX MW^76?4![?3-_\DW&_RZS@:3: $)?;Z9O\ Y)N-_EUG MU >WTS?_"3<;_+K/]!-H 0E]OIF_P#DFXW^76?4![?3-_|-)-QO\NL^H$V@ M!"7V^F;_.,2;C?Y=9]0'M],W_P DW&_RZS@:3: $)?;Z9O\ Y)N-_EUG >W MTS?_"3<;_+K/]!-H 0E]OIF_P#DFXW^76?4![?3-_|-)-QO\NL^H$V@!"7V M^F;_.,2;C?Y=9]0'M],W_P DW&_RZS@:3: $)?;Z9O\ Y)N-_EUGU >WTS?_M "3<;_+K/]!-H 0E]OIF_P#DFXW^76?4![?3-_|-)-QO\NL^H$V@!"7V^F;_M .2;C?Y=9]0/A57268[H<54F&*GANQ%3XEK85]*6S2W"=M9/&B/57QPK0[W-MTCDYHBIYC00I/Y4EON,\|M%)NA3[WM M],W_ DW&_RZS@:.1/IL;Q9:__K3M_LRY$V@(2^WTS?_"3<;_+K/] MOIF_^2;C?Y=9]0'M "$OM],W_P DW&_RZSZ@:/;Z9O_DFXW^76?4";0 A+[?3-_|-)-QO M\NL^H#V^F;_Y)N-_EUGU FT (2^WTS?_"3<;_+K/]-H 0E]OIF_^2;C M?Y=9]0)M "$OM],W_P DW&_RZSZ@:/;Z9O_DFXW^76?4";0 A+[?3-_|-)-QO M\NL^H#V^F;_Y)N-_EUGU FT (2^WTS?_"3<;_+K/]-H 0E]OIF_^2;C?Y=9]0'M M "$OM],W_P DW&_RZSZ@:/;Z9O_DFXW^76?4";0 A+[?3-_|-)-QO M\NL^H#V^MF;_Y)N-_EUGU FT (2^WTS?_"3<;_+K/]-H 0E]OIF_^2;C?Y=9]0'M "$OM],W_P DW&_RZSZ@:/;Z9O_DFXW^76?4";0 A+[?3-_|-)-QO\NL^H#V^MF;_Y)N-_EUGU FT (2^WTS?_"3<;_+K/]-H 0E]OIF_^2;C?Y=9]0'M "$OM],W_P DW&_RZSZ@:/;Z9O_DFXW^76?4";0 A+[?3-_|-)-QO\NL^H#V^MF;_Y)N-_MEUGU FT (2^WTS?_"3<;_+K/]-H 0E]OIF_^2;C?Y=9]0'M "$OM],W_P DW&_RZSZ@:/;Z9O_DFXW^76?4";0 A+[?3-_|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| MDFXW^76?4![?3-_\DW&_RZSZ@3: $)?;Z9O_))N-_EUGU >WTS?_)-QO\NL M^H$V@!"7V^F;_P"2;C?Y=9]0'M],W_R3<;_+K/]!-H 0E]OIF_| MDFXW^76?4![?3-_\DW&_RZSZ@3: $)?;Z9O_))N-_EUGU >WTS?_)-QO\NL^H$V@!"7 MV^F;_P"2;C?Y=9]0'M],W_R3<;_+K/]!-H 0E]OIF_| DFXW^76?4![?3-_\DW&_RZSZ@3: $)?;Z9O_))N-_EUGU >WTS?_)-QO\NL^H$V@!"7V^F;_P"2 M;C?Y=9]0'M],W_R3<;_+K/]!-H 0E]OIF_| DFXW^76?4![?3-_\DW&_RZSZ M@3: $)?;Z9O_))N-_EUGU >WTS?_)-QO\NL^H$V@! >P=)9CK%5RNUOLG#;.MB*\7"T3>3W*DM|QGGEHI-SF|D:E.H56-VZ-Z:.1%U8|T*?>|OIF_^2;C?Y=9I M0'4G^V-XLM>?_A6G;.9ER)M 0E]OIF_^2;C?Y=9]0'M],W_ ,DW&_RZSZ@3 M: $)?;Z9O_DFXW^76?4![?3-_P#)-QO\NL^H$V@!"7V^F;_Y)N-_EUGU >WTS?\ R3<;_+K/]!-H 0E]OIF_^2;C?Y=9]0'M],W_ ,DW&_RZSZ@3: $)?;Z9 MO_DFXW^76?4![?3-_P#)-QO\NL^H$V@!"7V^F;_Y)N-_EUGU >WTS?\ R3<; M_+K/]!-H 0E]OIF_^2;C?Y=9]0'M],W_ ,DW&_RZSZ@3: $)?;Z9O_DFXW^7 M6?4![?3-_P#)-QO\NL^H$V@!"7V^F;_Y)N-_EUGU >WTS?\ R3<;_+K/]!-H M 0E]OIF_^2;C?Y=9]0'M],W_ ,DW&_RZSZ@3: $)?;Z9O_DFXW^76?4![?3-_P#)-QO\NL^H$V@!"7V^F;_Y)N-_EUGU >WTS?\ R3<;_+K/]!-H

K[E0.PF&KY3XEP_;+Q1KNI+A31U<^EDC4B,14UUU5?-T7F%Q4<*>YLSX{Y M7+R#FY:?\]4/A^.Y0/U|$DFO! MCA_O_P!D[AI_UZDRR&G1(>\QP_\ NG"9+1DOE[5U%-B M/$$,<|SK:"1S:ID,DBLAI8E:NYKY'-7=W[=$[']?:X>>B*RRPQA"EJ_0-ADJ%1-7)$ICWI>O)5V!DYGX_]'87JJU?N3:[2]SZM*31-D2R2MV0 M-;JJ;6-?*
*KJJZM53H66[0(&9A]#=ODU>\)5%)A6>]8;Q V)?)KC+6K51NDYJG7 M1O3116]RL-]JBZ]NL;.B=S,O/EAQ,W_)BJ5LK;,7,K(7YMTBNC@N5(JJ\)?HU M9',CM--VC===[\';7@-"MYQ'>;EM+:,322UM7.13ID4;%UD2.[,Q\Z_]'X@=:,RL=VW*_+_$ M>,+1YR6RQV^:X5&Q/.D^NE+O2V;@EQ\QDCIV%V6@I& M[U>;ZUL+G)\,6N1?!3P?0W8=I[9PJ5]R9&B5-TQ%52R2:1S4LU]Q#EGB^U88KDMF)*^T5=+:Z]SU8E/5/A>V&7DM$ZT](U[EU=NE>[S.WFG>:TX\^C&P=E%E-=,R,L:JX44=E]&;X7JF]J*
*ML5R*J.5VK=5U14\[K80YZ5'->AR[X2L06F65OW5Q7+%;**'7SG)O229^GH2-_MCD5>Y7M3O0#YO10YZWO.'AQGM^)*QUPNN%+@MIC]I55TLM)U3'PK(Y>US=SV*
*M;_L8VZZKS6:!!7H@-,96C _$[SB2_5C+?9K32R5E752=D<&;&]YRZ=ZZ)R1.;#=,G"'_2M\4C\E\H$P-AZ[HHK3=;C"]D133U&Y84_J&HU]NKD>IX+!+>72(8I3QZOFRZ M?.' =GP!&/CLX;L,<3^7N'\'&AJ9WON[9[X^HDD1U^B]D;]&V,3]+M?M5(W*UJKHJJBIJFKL$=#MDA8;&VGO] M1B#%%S5FDM=+6^2M1_+5T<<;)M3EV.<_M7FI.I&^D)*
(G9W^@#A9QB<-UUZ/7_M/#!V,OL1U[VVM5]=9]NJ5OE-/-_)G702JU$;*S1\?2JO:;*3'#< MR\K,'XN;&V%+I9Z2YK$S549UT+9%;GJ5R!\1RPZ8G,!F9>>&7V5N'&_=6\V6*
*M&3KJ>F\YZUETTETJ7""B_%^(;1G3EU255RNMJIHZ>ZT-O:YU4U(GJZ"KA:U-7JW-M(RFS3QI8IL+91VM8X:6&9':5-+%(KDI87*B+*Y[EKA1ST5VYJ/5VNB[=$)PGCLSLVL'Y.8>BM*
*QN-L04>&/J+65=<|6L=*9XG-8FB+JJHQRZ>Aj@:1;Q%T27#Y=L+RVVVV>[M6.Y1\4]K;ZKX*D^CXQ1B3AJX[JG*FLKDEMM?<*
*M:S#EVAC;JQ330)*L$[$7L7K&)HJ\T9(Y">&;_2F9#X L=7+8L128YOS6Z4IJ MLU+-I*!?<[HWM;&C==-=':2JC$;JFY6AUC;,,"NB,EQOC2^XQSRQ)6XA*
*MNEQK9:CR.RRKJ]%7$.6%ZO M&65M;#[(F8E3$Z*AE;#8Z- MRMY2N1>NG5%]#?P'9^R7T =5 ##,V M1T3TCXS #G-E%T05EJJZLQ)GGBZNQUBBX2OGJZ>VU4D5,Z1R*
*MZJ\)&D2:5RKSU_!)O8IY[C>Q'-;?JHQZ.W(lU=X;155EOQ'6TT:?M5CAE5$^.5P$YP M."SK$0O$<$9'$E0\,&1E!Q:Z2*_,3-\AL=)+S\HK7HI8NWO8Q$ M61WI;Q4UU5 (3=*
*(fFI?.)C/G"G##EY-U^ROC?>I8E58UJE,N1KU3MCIXE=(_ MlJHK&AI/H_L(T^7_262X5I)I*BDLE=?K9#-*B(]I(8ZB-KG:&VNL>&MGEC-*
DM7BW&2O=035G.5M&Y^Z2=57\;=Z;M5[6,;J?S@O/_AJ@.SQ^.ON%;:;*IJZN>.FI8(W2S32N1K(V-15]'/?I7N).LPUA"V9)X.?)5XOQHK&5L-'JZ:.B<_8R%$3\>>3S$3O8UZ;>*
M>B@1'SHO5\Z'M-V-O'U)+44V6^7&&JZ[H"B[4CBAE=3MT7LDJ9&K(]OV,5]`M^Y0D#T'2;L+9N(/;\-V:XW.Z5D=#;]"GD]]JF71D,4;5>_M]lE]#6HJKX(<-
LVZO$7'AC+.C.BI=54&!<#VAZ6V.7\5B.5M+3IW{YVY|\FF MNBZM_&:I+SI7.(.Y5S+%P\X#ZROQ3BF:!UUIZ-VLG5/?I3TO)>3I7Z.5%T\Q MK=?-
>>\S+X>K;PS=&=CK!5#LGKHK&^INM;$W_==-;IT?6R M:_>#Z$?GDSF'I_3!'W_^S,)L<0V9.V4.1N/,.4S6OK++9ZFKI6R)UTI6+U2 M.3T^I6Z^!"?
H0_UF,P_S@C^C,)Z9GX"MV:>76)L'79SFVZ^V^>WSO8GG,;(Q M6[F_MFZZIXH@')#H[^$FR\9F(;;YE9O5!PQ/#35S8'4;JM\;ZZJD;UDDDTK% M1Z-:U6[4:K=57MT;HLJ>
*(OHLS$S-Z'*S..:\8>QSAN>[8°+VI-)2HJ0UK6: MI^]CBAE=3MT7LDJ9&K(]OV,5] M^Y0D#T'2;L+9N(/;\-V:XW.Z5D=#;]"GD]]JF71D,4;5> M]lE]#6HJKX(<-*
LVZO$7'AC+.C.BI=54&!<#VAZ6V.7\5B.5M+3IW{YVY|\FF MNBZM_&:I+SI7.(.Y5S+%P\X#ZROQ3BF:!UUIZ-VLG5/?I3TO)>3I7Z.5%T\Q MK=?-
>>\S+X>K;PS=&=CK!5#LGKHK&^INM;$W_==-;IT?6R M:_>#Z$?GDSF'I_3!'W_^S,)L<0V9.V4.1N/,.4S6OK++9ZFKI6R)UTI6+U2 M.3T^I6Z^!"?
*H0_UF,P_S@C^C,)Z9GX"MV:>76)L'79SFVZ^V^>WSO8GG,;(Q M6[F_MFZZIXH@')#H[^$FR\9F(;;YE9O5!PQ/#35S8'4;JM\;ZZJD;UDDDTK% M1Z-:U6[4:K=57MT;HLJ>(OHLS$S-Z'*S..\8>QSAN>[8°+VI-)2HJ0UK6: MI^]CBAE=3MT7LDJ9&K(]OV,5] M^Y0D#T'2;L+9N(/;\-V:XW.Z5D=#;]"GD]]JF71D,4;5> M]lE]#6HJKX(<-*
LVZO$7'AC+.C.BI=54&!<#VAZ6V.7\5B.5M+3IW{YVY|\FF MNBZM_&:I+SI7.(.Y5S+%P\X#ZROQ3BF:!UUIZ-VLG5/?I3TO)>3I7Z.5%T\Q MK=?-
>>\S+X>K;PS=&=CK!5#LGKHK&^INM;$W_==-;IT?6R M:_>#Z$?GDSF'I_3!'W_^S,)L<0V9.V4.1N/,.4S6OK++9ZFKI6R)UTI6+U2 M.3T^I6Z^!"?
*H0_UF,P_S@C^C,)Z9GX"MV:>76)L'79SFVZ^V^>WSO8GG,;(Q M6[F_MFZZIXH@')#H[^$FR\9F(;;YE9O5!PQ/#35S8'4;JM\;ZZJD;UDDDTK% M1Z-:U6[4:K=57MT;HLJ>(OHLS$S-Z'*S..:\8>QSAN>[8°+VI-)2HJ0UK6: MI^]CBAE=3MT7LDJ9&K(]OV,5] M^Y0D#T'2;L+9N(/;\-V:XW.Z5D=#;]"GD]]JF71D,4;5> M]lE]#6HJKX(<-*
LVZO$7'AC+.C.BI=54&!<#VAZ6V.7\5B.5M+3IW{YVY|\FF MNBZM_&:I+SI7.(.Y5S+%P\X#ZROQ3BF:!UUIZ-VLG5/?I3TO)>3I7Z.5%T\Q MK=?-
>>\S+X>K;PS=&=CK!5#LGKHK&^INM;$W_==-;IT?6R M:_>#Z$?GDSF'I_3!'W_^S,)L<0V9.V4.1N/,.4S6OK++9ZFKI6R)UTI6+U2 M.3T^I6Z^!"?
*H0_UF,P_S@C^C,)Z9GX"MV:>76)L'79SFVZ^V^>WSO8GG,;(Q M6[F_MFZZIXH@')#H[^$FR\9F(;;YE9O5!PQ/#35S8'4;JM\;ZZJD;UDDDTK% M1Z-:U6[4:K=57MT;HLJ>(OHLS$S-Z'*S..\8>QSAN>[8°+VI-)2HJ0UK6: MI^]CBAE=3MT7LDJ9&K(]OV,5] M^Y0D#T'2;L+9N(/;\-V:XW.Z5D=#;]"GD]]JF71D,4;5> M]lE]#6HJKX(<-*
LVZO$7'AC+.C.BI=54&!<#VAZ6V.7\5B.5M+3IW{YVY|\FF MNBZM_&:I+SI7.(.Y5S+%P\X#ZROQ3BF:!UUIZ-VLG5/?I3TO)>3I7Z.5%T\Q MK=?-
>>\S+X>K;PS=&=CK!5#LGKHK&^INM;$W_==-;IT?6R M:_>#Z$?GDSF'I_3!'W_^S,)L<0V9.V4.1N/,.4S6OK++9ZFKI6R)UTI6+U2 M.3T^I6Z^!"?
*H0_UF,P_S@C^C,)Z9GX"MV:>76)L'79SFVZ^V^>WSO8GG,;(Q M6[F_MFZZIXH@')#H[^$FR\9F(;;YE9O5!PQ/#35S8'4;JM\;ZZJD;UDDDTK% M1Z-:U6[4:K=57MT;HLJ>(OHLS$S-Z'*S..:

[/B^XZ)>%C&N'<.0X#=B^;|·MT?E4;H[JM(YKNL6-&(QQ)-RJJ>E.TU%_-4L;?DWWW^^LWU_^)TBNGMS>'{GI

*M^&HOX;BG,Z4Z(!S]LG2@8QN]XH"%_#O>Z9M5/""LSKI,J,1SD:KE_G)-=$77-M0Z!EB=GI_P !> %-4*GR<3ULMMP_<*J!4;/#_^1CE37140TU[+*

*M&)/Z+C_ZAG^8#=6(?]X+HG_LLO\B*1E/5U.9^(;RGE@EJXW12M5CDZAG8]*-MB]QY0#[&#^\A7;/[+B_QT))D6Z*LEM]9!50.1LT#T>Q537145%0}3[+&)/Z M+C_ZAG^8#?*

*6]%31GS/O-NT4T\<;DZEB>G^YML771WK8#4R*QKF^+&]^3U1[!HZR=*#A^]<0<&7OWH-M.BP]47Q]E@Q;!U=TIZE$V.>K/^.Y-?N\"<6]>)RO(%CUT4/1KV#&*

MD5,Z+$|)='8K>K6JDJ44^R%41>W3JXZ>?7N1'>DZ\)6<[,^<@\)XL?,V2YR-M4WDMS1JIYM9%YDJZ=VY4WHG[%Z ;BW(5U0T7Q;\3U+PJX#M>)ZO#!V(HZZY-*

*MMR4\-4D#FJL4LB.5RM=JGX-4TT[S3&->DICDO5?:\|,K+_F]MN32NN%NZQM) M _35=]QPRJ]]:*FY4:BZ*I*]?$'@KAUPBF(<9W%|'32O6&E MIJ>)9:BLE1-*

*>KC9WKIWJJ(G>J&HN%CCXPSQ'XEK,)5=CK,$XTVOZG+EGK)>N; M.U0>5Y>C)-C5WLT=]QS&KHFJ:Z+I%3I9\6BSV.XK+2XGJ8WI M17-7TS'.9$J1JJU7*BZ.7W"]@'1O.?,9N*

*,H\1XZBH'7"*T6>.!I0NE2)9D MCB63JU?HI;JHFFNBZ>A3Q_"AO#^VWK6S47D/EOE?N-OG;^K9V[MNS;W'@LKN*B^7{)K'^),49/XBP928,L;R*FOS)*

*(4O#$AF<|L2R0M31$A;JN MCOU5NJ=FOON$_/>W\1>5*8NMF'OO8I5KJ[/R!96R\V(W5VK6M3GN[-.X#=:!H M;BOXDKOPX8>L5RM& :S'\ES[GTTE-*

*15+X5IT:SE7.H41#':NEIQ+?:)*NVDO4DK%5.U-S:%4Y$G./5/]J'F;ST_V.;V?UZ,\+T6GG<(=B[_]D:[77G_Q MR@??X3.+6^<2-WQ#0W?+&OP"RU0131S5M6^9*A7NT)\EQ*

*MTE5BQ9Q%5N5/KW8F|=/&B-SX3}(KZ6C'I MG#_ *5ZCC^]' "U<.#K'C@ VCPR?KWX.|=+]&E)))KH0%X8_U|L->NH^ MC2D^T.2\5^GQ\L7R0^H[?W9_P'"%P .-*

*[EI_BDS[|K9E%<,<_O\GE9'^H=2W;NWZ^[733O).G,SA5Y=*3G!KR_WX^E M0@2?S?XPG95<3N \H$PE]U$Q3#22_=C[I=2E+U]3-!U/4NWI>IW>[;KNTY:.M:DE"-6;_\66?*

+3B=P'E558.^ZURQ)#2207M9V-\DZZIFA1-JL5R[5B5W)R:.M[N[M7=F8^8^';C',[),8^LJ*B1%5>:.HC6M:G-SG.5&HBW5L5/*QCD[TWJ>FPGTF*

MF#,=X_R\PMA,#EPJ[C%%3'15?E<{8},3.Z79L]"M4DMR'-SI=C MB.EO^1Z5NR"543T*[:0?IW 3@W(A&KRB*W?C%NV1'WD)%Y\"LOW?^Z6[?_,L= M1IY/U*:>*

[V_JB]FO@9>$WC;PEQ4-N-OH:"IPYBJW1=?4V6LE;+K%N1JRQ2(B-M;VHY4:NK6JBJG+144C=@O_RQ&+/[#=_)<'1_5"I&S,'C)H\M.)W#N4-^PI4 M4M/B#R?R'$7EC>]?UVYK-

*8MFJ?AFK&OG()+5 *;D+B.N-N+ZCS)XG<4Y M0V+#,U3!AUDKJ[$?EK>]:Z/8Q[4BV:ZI,_]_=?BJ[NT)% 6[D&Y#3'$OQ380 MX7\+4MSQ$M17W"X2.BM|GH$;M15.1$UJOI<5'-*

*TUM?5V*U0R,JI8LM:LKVS-;"YR*UVC%\UOG)\1TIS9XL*9&Y M46C&<.DJK+572ECFIL/]6KJ\YRQM>^|&*B:*Q7(USG;4;WJBJB ;IU0:H0,. MTE^,%MGWR>UQQ2?$)*

*M@G*N?"U1=JC$S*!S+G'6MB;3^4U[3EVDF@!35"I#"Z] M)M@G#&*,S;%B*P5MOJ<(7.2U4D-/4-GFO,I)Y8M(H]K=B?@MRJYRHB+IS71%*

*M"9NJ"XY\W'I2K]A&YT=1C3(/$N&,-U:Z;DX,NLP++#FE@NT8LPU6I<;)=8>O1JEK5;N3545%1>;*UR.;]+V*BH!Z M7<-4(B9U|(MA;+W'KL"X(PO=Q=)S3X?Q-0V7-*

*[*G$V5CJQVV.LK&R2QM|$5[Z41J)FJL1 ;G M("<0/Q6ZY4MV*>NHYXZFD]8VS031.1S)&.1%;Y]HVH]*BIZS]H%-4(19[]) MO9\EU'2-,%U#MSF(]\MZ;]URE7(,/+K*

M"ZMQ;BFX.N=MG5NLDTM&|\TBL\99)9XN_FG@!U=HJZ"OI8:JFD9/33L,)%+& MJ.:]KD14EGG15\Y:=&ZTSU\.K\SUPJ,,XT_>I9J?N%4? MX (GVKI:\27VD2]M?

*#]=+C2]JM2>DOBJ7_ &IEO777_9>NYZ_MVDP=$ C;PE\6-ZXDKAB:FN^6E?E^VTQ021R5 MM8^9*KK%>BHU'01;,=B>G7<22U0MY:]A&#B(X]K#DOCF# 6'<+W7.G'TC$>Z*

MR637\#JFJ,>YK7NWJFCMK6.5&KJNFJ:A#?X+^@N(<'1])I=L$7:@@S:R.Q3E MW;*Q^V.Y2]9(BHO/W$L$6[:U6[MKE \%W_$MP5&T-GH)[A.NNGX.*-SU3]# M5/OD2>DTS*

FPGPR5]BH%RT]<6N]S7.621$3OU;&K%_KB>D#9W"3G M/?<_LEK=C[_66EI4MRJ)VTM+2R/>U88WK&CU5W/57,?\2(;H/%9.X ARMRKP

MEA"+:J66V4|&YS>R21C$1[_6Y^YWQGM0(X<4_& -@KA=\EMM?356(\5UD774]MCH'-.K8|51'RR+]D;55%1-$UZ1_.IL?W57ALO28?TUZ[JJ[333=

M^K^3[>SG[GLYG@/OFP[E]TI^)IMF\^.CH'O36(Q'M.1W8UZZJJ;55.H-HO%OQ!0Q5]JKJ:Y4.J;QU5',V6-Z>#FZHJ>I0(^\+'//@ M7B@DGM5#!48)(Y$DK)6R,.,K-J;4ZV!VQ?*

*VR*JHJN527^O@! M&/C$XUJ+A/?ANDCPR(%UWO*3S+0LK_)%@@CTUD<[JI%75571-.QCN?(V=PI9 MV6_B&K8%X_2I3*

*<|+@V1M10|>DRTLS'JQ\2O1$UT5NJ*I)IBHNG.A'EE#3\8 MG2(8WQ%61)^9_M#W?ZAR=162UMKZJEULD6C7N:G?UL'52)^UC50.CYSRNW2MW:DQGB##UHR3K+*

M])9JV>C?)17U[U5(Y'1H]6,HW;==O9JNFO>=#3FKT:'OI_M?^6F]/\ 1T@'.MV_YJEC3\F^^_WUF^H'N:@3W!KC(?;"O$+=E]38PPE/-);Y9'4\T%4Q(YJ:9NB

MNBD:BJB.1'-7DJHJ.145=38X MW(>"SFSOP?D>+@NHQ1C.Z-MUMC7,)2(?H&B-5)W'F'>^L\GIV7V_\F"!HO4_IU_=.M.%/S21&VQ9YF.,JFJHG6T5&%^WI=S?0!/PIN/Y5YH6#.3 >$GQEA>]?5V. MZ1+)

*Z5FQ[51RL>Q[>Y57ML^^D,PUE3CR7 6#\+W3,[&\+ M^]GMEG561PR)S=$KVLDY:XL^_[+[#.*%J?($Q=KL;EY*DG6=3UT+)-F[1-VF[371-=.P] M,CD=V1O M0A%TO/O8;A*

*G12_1JH"76 L3_?I@?#^(EI_(TN|NIKAY-UG6+%UL39-F[1- MVF[371-=.P]%N(X4Z066W8)PMA/*O*Q$6;5=8[#;X+G5VN.5E/3S-IV-BX?NJ(DK7-*

*54?']JJ)BZJFJ)FOE,WN.*GR*SXL^_;.8/JK78[L^-.;%|5S M7TRPOT:LBL5B*B,D5&O3=]U/.YZJ[$1=4&]'CV0= M<]S=%=*Y5T9&Q/QGO3'%]29IY]8YRFK,,3X=ON&.O*

*M=ULU6V5E8R*9L;G.38W35'QO3MU1W=H!(K<-QI?BLXE;9PN9;P8LN-LDO;IF MX1V^GM\4Z0ND>YKY%7CTGWN'G.F@X@LH[%CNW4;K;|_OV[F^@F7E7FC8,Y<-V?*

*&.%ZEU59;K$LD#I&;'M5'*Q M[']M[G-GP*Z]I-EW2RX79@&ONL,%5KG\V]D>B;D15UY'[LA^DFL^9&8]+E]CK! M5PRUQ/6RLI:2.LE=-%+.*

[1&Q/1T<;XG/5=&HK51>2;D54U#:W%SQ^U?RRL, M8?>[]\ZJW2*Y^\1>7!1HW?'*_?OZM^NG5;;;?ONWD;,RWQ:],N7^&<4+2^0?=*

*MNUTMR\DKZSK.IZZ%DFS=HF[3=IKHFNG8:TXNN(6W<-66-'BNZX:7%=/-=(K>E M#US8MKGQRO1^KF.3EU2IV?C=IZR/-6GAR";F3'.W.I&89^^>)MK,*B*C$I/*$*

MA1^W1%T\W73QT[@-C:H4WH0:I.E/PS=<#VJKLN!;Q?1L<7269D&$;7/U\K(XU-MT2225L?FH[1=&M8YVB:JB)HJX,%=+1PX|IL+YKY9WC*Q]0]&-K:Z621(%5V MC5FC?*

#$]C.Y?HB^*(Q:N0_!>KYOD#=1|===;I5Q4-MH8'U5-3N1L<43&[MG/7FZ\@VZH5(^Z3I8<)VS#=#(_UWT\5I^7-07/#=^3)S42Z.I8CUC7>S M75O-

*K'(JK&32O.9R9P\7F0F4$?X6BI:EV);O"G-KHF*Y6M=Z/.IYF_],GI M34)FX5JKC788M-3>*9E%=IJ2&2MIHE5613N8U9&)KS5$Z# M#MFK;K=*N*@MM%"^HJ:NHDK0&*

*M,KI7LRER,Q7F/9;*58Y+O#UL3%5O-?,C@ETU:BZ(YR.Y!]W5=+8'#AQ\X?SP MQ]+@"^X6NN7F/&H]6V>Z;O;(YC5<^-'JUCFR(U%=M>QO)%TU_^KQB\07M4'8 M-_|:+[Z?*

OCEJ8O|\O(_)^JZGSOU^3=KUWAIM\22I&SC#XK;3QO5%M&&\5V^+KZJR5DB2KU6K6K)'(B)O:CG-;NK6JBJFJOODG753X$\U6*JI59NY.3M[NT#8W$%GG8N'G+"ZXTQ V2:"

*METAIJ.%=)*JH?XU<35[$U5.,E]RB.7GH1RX<^-[-,;//,'#U#49'UJGP5>7O5 MT=M4ZE@B;&|V]9UA2-^]M1]M M|DM-*

*%_OEY9Y1UO7>=^!1|=.I\==W@24U0C;P=\5MIXG5OQ|RL'_ 'II89]. M*76H9+Y0LO7:+YK&Z:=4O;KKN[C!Q,\=>#^':>]0X7BME?C+'-2C%BL-JT16*

*M_3JTEDT=M5^OFM:U[E147;S34),HY%35..%2!T/2;7G!MPM[LU,B<59?^V*OD MVQ725TDGIT\R6"%':(B*NUVNG8U29+,Q\,R8!^_=M[I%PGY%]T?NMO\P/D^*

*MW=OU!&G=V!VFH!MR*5U0@O-TEMPQK57)F4N1^,,PZ*DYAY?WG+#$M?/"24T=>]TC.NDT2-M-DB/CB?*O541J[%354U5.T.*XIN0TKQ^2--PMY;4F,*]Q30AGJ+G';?)8:*

*ME(('KXV7[HRM=R3JE333\8T;B_1+8*EXRVS*O*^_9IUE+3LDN%1;^L\ED)', MW,:CHX9%D1JHJ*[1C5VNT5434*;NJ&O.[,^,'U41--55$-)<,'2!89XA,7S8(NN':S V-$1ZPVJMFZ]E1LM:KI&M?L8J/:UJN5CF)R1=-=%TC?TM&:5ZN\5#@:HP/>+=9+3=8:NGQ9,R1*& MO>^D8K_ &&WW6&-\<-;31U+(Y$|YK7M M1R(NFO/14U/J$<>#*

*[/7$>;&&TM=ZRNQ#@&FLMLHF4U?>HI&Q7=9MW1;HF{ M-,1W)5Y/0DU55K7 MO5=5:USD5K=$8'#CB[',&I9&M6Y22S+U:*NFW M26FB8KU5';-5[55-*

$[T4">Y3<>3RPS,P_F[@6T8OPS6>76:Z1=;!(Y[MEJD;,U.D5P|A;,2OP)@'!-_S6Q-0*^_I@L+%ZILC%T]ZM75'"C-$5,2KST"7VIP4_'=KM26.UUMSKIV4M#1PQ)ZB3W.<;&]YSE\$

M;B]03DZ3^]X!OU)2VJ9$XFP';.N5S8ZR261SI]+IYL?2)R-;LEW^>K>3':]^@: MG;TFV/<=8BN?L6Y%7G&F&*"H6#RREC]HY$U7:YZ0PN;"KM-=KMW+O.@5NEF MEM]-+5Q-

@]71-=+&U=6L=HBN:B^A%.8_119]XDP1@NV8&MV4F(0V>]8?RK_M%U!#(M#1+'V")RRJV)S4ZMK4<[5[>7H)I<3'%0@?A?LT$^(YIJ^)US5?06.@_M1%J;AJ*B*]===$8Q%

*[7.7GH](CE30#>6[%-R$#I.DOQ9A^D;?,5|\.V,+!@YRM-M5+TY\JM1JZ<_PE/^&NNJ:>>B+W*2BPCGUA_,S)>MS%P*RHQ120T-1416VF8Y*

M^N2>)BN6D5B(JME541NB(OND5NY%15"V/B/P149X,RFH[A+78P93O]:]"")5 MBHVM8CT;)(NB;G-5%1K=R^G0VCN3TG&_!?$'B>V<>N)\Q(WFUEQ@7%>7ESPL[&=\15,-97

M5>C]22HU8D,L3HDI0"1 /Y_&F-,+EYA:YXDQ%< M8K38[,"L763ZI8V%(NG=S5554]$355541$55^\KD1]J085U0@9&]J"BIJ_7FFK4U-R<+_.M80XE:YX6

*M&BK<)XQM[5DJ;#=%17N:UVCW1/33>C5T1R*UKDU[-.8$C-R%=4(R<2G'A<GA KM\Q!#A2"BKL;8YE=&B6&T]L76>X,+)HJ-DXO&#*ND MDS0R&Q;@*S5;VMBN$KGR:[M=-*

&RP0HY=$5=$=KHB\@)WENY#X&!L<63,?"EL MQ-ARXQ72R7%)Z6KBU1'MUT7DNBHJ*BHJ*B*BHJ*B*A#BP]*O@RY83N%,-A& MY,Q&EQ2W6S#5!4)55-*

*P=IS>BHQJ.8BJC>QRJJZ-1VBZ!,;>D.M/%UB)KN56KKM5+&KISG;8+1GIR#]-5NO-JF5ELN-/!5TM3%[F;*1[/8]-)>YS514J8'TM4&]$*\R^D]LU'CFKP=E5*

*M@&]9N7JEQ7+HC5V*U57W2_3'":CQF:F;6%LF,&5V M*L87..UV>ET:YZM5IY'KKM8QC=5>YVBZ(B=RJNB(JI$"EZ2_%6+(9+M@KAVQ MAB,"D;UW7>)\|\D7151(Z>1B*G>F!=*

)Y(%;C1'#%Q?X*XH,;7)A_RJU7V MW(BUUEN+6I/$U51ZQKD54>S7EJG-%TW(EJ;_&SSXT\/V'9UX=P'B*UO;076V M.NL]^\J1K*2-JSHJ+%L57K^.Y(BZJKT1-5 DCK\93H;/-*

=IVS.C1L4>UJ.]SN57.T:G?S34)E;D[2XY|73I2\ M082KJ6JQ?D#B7#6&]1&17&JJ9&/Q6N:YJIW*B@>]W%-4_U0A3C#I(MFW+&=TPUD\E9B#-V:W/ZJHN-*

*M5[:5';MJ/8L<4]NCU!NV(O-47315^CE!TC M-KQ=F90Y?YAY?W5*K%-QD9#1P797/C?{]=(V/WQQ2,5ZZ(U=BM55[4 F. M M (TXL_X57K^S9OXQO|H^KBS_A5 M>O|-F_C''R@*

*#ZN$O^%5F_LV'^:,26(TX2_X56;^S8?XQ0)8 //8ZQ MG;|O\&7[$UUDZNVV>BEK]AR+SV1M5RHGI5=-$3O7DB=YMI(C@TRTP3E!A*RXCR[PM>\04 MUOB6XUUSLE-*

43OJGIOEW2/8KE1'.5J;KR:U]V 0@Z1#B4R@X@L-X2O&\15 M4V,\/USDCUM\].Y.9Z;G.21S$35DD<:IS_&<<=%^&'.&+/;(_"6-&OC=5UU(D

*M=>QG+JZNA'.W3N3K&=$5[M7O/GXHX1,G<3X9Q%H9EEA"V/KZ26F2NH,!2O M3TZ08K4DC>V-%;]NNP'BHJ*G<0UZ+?MQRTS.S"R(Q,]R>LJJF6KI(G*NU*J*

*M!_55#&^GY#H)Q!X>H,3Y'Y@6RYTK*NBFL59NBD:BIJV%[FN3T:,K=1 M>Y6HJ!$?H@*J6HX<\M302/5\4&*)NJ:Y579K2TRJB>A-=5Y=ZJO>>3X)VZ[(9Q&_UVY=W_ .),/3]#*

*MQ[WS%OYT2_1*4U?PZ9GX7RV-'-:9D?UFC^G4Y\OHR_>9X'_KUP^G3GT^D87(3X4+%_UC M_P#NGN;Q@3+S.FUV:\WG#.'<:T6FO*

*M(''F#^E#R=QKBVRX;MU)B9+A>*Z&@IE]+=&UG62R-C;N5)55$U>LZM:&GD549$U_XCW)YSG=K6*FG-V]!];C*

*MXWJV.]/RY=4?'$Y.2SZ(NYVNV)$557M9YS&::JVGC5>:M;JJJY=%,.5L2)<\02N?O=V'L4**W\'$BIV=KE35VO)$E'@#B?RJS0Q%% M8,*XXM=|O,S'R1T5*]RO:?*

=1H^25TG4M7>]QM3=IV.3DG(_;F?Q18_P'"#C=BM>8M^J'9 M,WR+_8YSJ,%L5-&]C-9-\;$>Y8IM6NW.5R,J:R@QQQ3Y58!P9/B>Y0ZL

M<|M;"LL!+"OBJ)KER:$QKE5ZJO+ER3M5415_T9T>'%*7K66)<8HLU#8, M68-:V+R>VTI;.'2G;]8GD+/,C=&]$:Y&Z-\]NB)S)FG.7HP\(WK'&:N;&>M

*MPH'6ZW8BJJFGHFN5=)))ZKRF?;RYM8K8V;N]=4[4?3HT-M -'A\S,*5>)+?'+1RO=+3ZN2EU\U_BG[9#1KVNC>YCT5CFKHK7)HJ+WDJC7 MN8>7+;W'+<;U5:K7)HJ*G:A;__U4*

*M^KAO#59B;O,2TC>S]4F2I='"Q&++(NKG>*GX\,X:L,6YM0)2,YIKY7>ZD7TK_)NX^R M %$4Y+\5V>6#|=\U=/\ D@/5\0//'PYYVY-8 MNP3/BNKWW:A?'3/DLU4J1U#?)@?^'|_BR-*

8[Q1#Y?1&9U+B7+B_9:U!1K78?G M6OM[7+S=IS.1$\&3*KO^E:2WIJ_DWIHN4N!E_+ ^;#_I$<\LTJ.DX&>D+I> M0]52Q6:.6(VLDEH[6-1=/%25+U-5&UK41$2.1$F1BC?-3-

*U_A.C6%<+6S!F';,8;)116ZTVV!E-2TL++&QQM1$:GZ$ M[5YJO-3GQTHSFR9WV/KF*CD6KD5%,SY+4TNBH=(@..>15JIL)=*]F:K3$VA MM\U-5N?*

3PIL8O60P3N3;G+3>NNG^@^KT@OOS>&OE_P#M&C7_/2,1^7[_RO M&/%[O))OH5.ACZ2RZT^$.)[A^O)7EE!]*C+,B9YWI Y4;HB]B =9CQ.<&;%DR3RYO&-L0MJG6:U-*

C=4)11))]/E9$W:U5 M1%\Z1O?V:G@?;RY"?"A8O^L?_P!T];AC&N6W$?A&YQVJKLV/,-MF2FKJ>6!M M33+*

(FV1&/9(W153S'V+_3$ILL*=*FF2]8C)$:,JJB;D15T7EW>]J_DU\$F!^\ \FZ/_1'N!%A^VX:M5/-[M/;Z2TVRE9U<%%0P-AAB;^Q;QJ{UJ>"(!KKBP;IPR9L+K_P"BUR^C/-+=%3[TT*

*MJW?NO6_X{3=/%BY$X8\V?S7N7T:0TMT57+A+M_[KUO=^W:!,$YL}(3?+EGYQ M)Y:/?.C;. ML3RB*VK51T+!,.QI)/U$*HOI2GA>SU.4#HKA;#%MP=ANUV"T4$:.UVREBHZ6*

*M!BL=*QKD\7.0#%P'<M6.1/#ED7#9K]B.I@Q57$U@*U M\:F%,ZLL+I/<*1W4/OD#J.6G>YS=8)VHCVMUZRG5]Y1^,BJO:AU!CX6\FF,1 MJ938'5$33SL-T:JNB:X"3]*

*[QS:;)@*X8Q?4LFL5);9+LM3$OFNI MVQ+*KVKWHK43TZD5.B]PS6U64N+<>8@:J^294_5(HWN:G_YUU3^D MC!;^+&2|=&C M1Y4Y.X-P>Q&H^SVNGI9G-[*S(Q%E?*

*_/5[OI8#GQTI-CJL\3>3MGHJ!KK;MA30TD%='KNIWR5JM;(FBHNK5=KR5%Y=I[:^9MYR_E+WSY5;I:/A\(]NG&;P_*

M_P!>HOY13_.=@(D\.O!WF)DEF5|\F)FLYKGCFV^12'IJVNK6H5F!RMVR?A)GI MJFWT=Y+8 /A8T5%PG>-/Z%D_Q2.)*&NH8KC22TU0SK(06JQ[- M535%)1YWV+,+_P#-?*

_Q$O_>`T!_JH-YWC+;#E)9ZZ>&W;98H'O8[KY>2HU53 M\8T8 \+%5?!-?B!1#+'#7W^W4L[>L@F]CXVUS-S5=S3EZS=OL687_YK,+ MB)?^'\H_#G_""\Y?

V5%K\M"3AY:GUP[33130V_9+$Y'L MWNM;Z-MGJD;Y,Z/EC3\'R39R(^=%!G)1X8S/QEE5]T_+K=G27"RU#VJQ)9 MH%5KI%5335%DA1K]%1%1(-#H#[5(}KX)<#?\ Y-T?^C.?

*O'JEI3*V>N66<&7 MMCH,#;$F:R6@M=,REIFU,#]RM5C&HB)-$}6JB=NQZ@;?Z8;WOF$OSHB^B51) M3A3P!,J33K:F6)LDTCO2KGNU5|=%35.XFQDVY/8BP/W?[!4/T=@$!*

*M>(&UTV$^E4RJJ!3'0SW2&AJ*Q*;>MDD?40/M4C7I"@2,XAV!>#S,+3DGWEUGT-Q'WHXL*[NV=]LLUQN%_M4MI6(^7]V.COO0\SOW.,_'I9X7HL MQ>A6+]T:*

[^.4]UQZ+KPB9F_NY6JG<3[S0RUL>;F KYA#$5,E7:+K-Z"5 MOXS%[6R-7N>QR(JYIRM0X8Y_6''&14EVR.Q-,M39K3>5O%NEI:"2VT:U",DD;!]9EZN9B;JDG&]FOF)S[-.D>)D[_

*+[JKZ'1 >8_F;>6.%*_!&7F&?:>K-M %O(("<3?Z]V)O73 M_1HB??I("<3?ZlV)O73_ $:(W/A7TV?A_P X<-\KOJ./!L?\M7-ZQXZ M -H\,?Z]V&O74?1I2?:$!.&/|>[#7KJ/HTI/M#D_%?*

*IL?#-_N]B^2U?:^[/_M-N -I|GR#|-M(YNUKNN35/-U[$[23G2E<^$2-?NC0_QO[K@*73A$RS__P#^>:LX <"KECT@&/,)?=&6[+9[*Y4FS=C!]E1"W>K=5T5>W35?6=*

M7SF7PJN3^:DYP_OQW_|.M4('T^,#_P IUD)_8=I_E&K/U]+;B"NNU1E+EY3S MN@H[S<)JJ\[1%>CHH8E^+KI5^-#\?& ?S3K(7GIH1VE.?]HU9[KI68-ACDGK\$UK?

*%&O@USU[@)CX*P=,_X5M.& M[%2.HK1:Z,.EIH&(FC6-1$15]+EI5=V]]]HSEXE.LK7@/\,\HK!.:9E+'B M6MMIQ]HXT1K5JDJ7QR/1$31-R.C4&8675!?KOC6SX8O#*

*M9CKE:KG4I!+#.B(DC8VNYRLW:JBLUY::Z*BHD"\;<0%!Q&=(QE;?[",F&;"MYVZV6NIFB=&M7$RI>Y\VU>Q'2ND1._1C=41=40-F],A1+U5[5555> M9S|Z7CSL39#:)K_/ES7_-*

-^@.D('-3]N(@PMTP6)!?;(DI:2KAEFFBCY->_Z6 MUQ5+U5/2LJ[_UK\9^0!?_EB,6?V&[^2X'EG_/++7M5Y)Y(W^0X2N#/_"P^ M+5[O(W)_^A

*/9]*IE1/>LK,/VEVE'Q7G!U>U)*B'D]M-,Y](.7TLF;"]>C> MXWI!Q.6Y_!^F=3G0[4P^MW9D8"Q#A2ZM1UOO- M#-0S*(<7*7&>+!,JG<*752IB%^/FTW?1+FY8W0_U*5*)*

*M+KIX@3FZ*K*VIM&4N(,R;SUD]|QM<7S>42IY[Z:)D1R^+Y73N7TIM)Q'G, M8*M^7>"K%A:U,VVZST4-#'|FBJV-B-1R_METU5>]54|&:!S_Z2#*W'U/F-EKG-M-*

@JQR8ICPB]BU5N39NGZI4Z3QR.B;YSHWTV#Q4\@M4C7I"@2,XAV!>#S,+3DGWEUGT-Q'WHXL[NV=]LLUQN%_M4MI6(^7]V.COO0\SOW.,_'I9X7HL MQ>A6+]T:*

MA@]VR2+SKM+5TZ5*)MUVMF8Y)4?I^*B[O #[?"KE_E#@[$]=DQ+%/AN[S] M=-40W">J;),WS5W-E>O5N1%1JMVM7DFO^6 MHH:AZU\|\/6R+-*

(YK(HE=%O547614i4;U$[5UU)T3-LK(L9YQ5N'G5CLN^NCI M[>M9JG72)+(L*K^W2'3?HG_&-U|D-=|'!1Y>8NSPS,KL[TME5C_RE)*.FQ8K M%C=,LDJU:HV9=KI6N2/1J\VHBZ=BJ@;6XA^DRBQS@K#.#\48HDN-HJ(-MG54E!&REI/,565#EWN(L2T$UMI+-8%BDZADK%9)/(V+W M#4;KM.6KETT141RIAZ)6M;4<+53$CD5;?$-7&J-[4UCA?HOR@-9!'YK[=_B-`MYK_NVX[__P")N-9<9N<&&Z7!|=>_,2GKKY@3!;*9CK30QQR.>];=M0B(Q[V-M;F']fCOG?'@*GK;)@<;&5/52P6>LBCB5DC&)/S9&[| M6[`G1]+=IM=W=AT-H`^K:LPHF)8LQ<.+95BZfR4]RB8Y$TUVK&/HI|*\E0 M6[M>6FO(TCP]<8V+,*'.3&5#:\,4=-EA9^L6FOCXYF5,B[D,"QVKMN]Z;I-$ M1-K4T75=%4)35^%;-=+E#<*VTT-9<(-J15513,?+&C55S=KU35-'*]HV*I] M@U%F'Q1Y>969G8?R]Q'=;BCQ1?DIW4%-'12RLDZ^=T$6KVM5K=9&.3FO+D]] MIMT #[.5NQ;TD^/Y60"7W%UAZ@Q?POYITURI(]N*#*=?6QME;CD;.[M^6)Z;]BM>Q]HO:FA%/@?QY<\%='-F#B"EF? Y98G7B6A57+^">VF8]FGH3K'] MY=-.;JO>2_XH'(0#*7FUIS_|-LID27NMNMM MZQ_2K.MI8V(IXE=K\0%W1(98VRWY07'LI,V:$-W8VY;+YI\TL36Z,15YI MND= (KM/=:-U(S)"<:,&5MIS5X;L=T-RI(ZBIMUJJ;I;YE:F^"I@B?)&K7?BHJ MM5CO2USD\")71R9^6?(O|ILC\SJZFP??,?>)9Z26Z2)#"]ZHUDL*R.T8W18T M#I=')_M65/29, <>O#=E!E5A;!E#BRL=!9J".E=(VS52)+(B;R2?]?:YZN=_;&F L)Q21Q4M7&V>EGAAU@IV*UR*BI)*Z2?:O)41R$^_:O9-`M?!)@;_|>)NC_-$!S3X.L[<*99<=5^M^$KFZ? +;&U7)0TCY(7PMC?([K;5-C MT14V2,= BJG_`!BKV*BG0[C37_;I9I^-BG_P$0^D]X:W\,GHY;OQ_F]3YY|'3B;&L*IY3<< M+RI6QL3|3JV)U<[- /"1KM/#]>6H$/N$#@XS%SHR:IL3X;SHNF'+9)6SP);;5 M:E&>QR:O_!SL,JY=-)NS^9MYR_E+WSY5;],+.CJXGNB*Q7=NGG=A"\9Y@<-#/&1C7-I<&R8OP M9BA)%6NTV)KV15ZHJ)HB.>U/6Y"/V&N.NHP_Q08ORIS;H[/@RU4KWLLU-MV?UD<=2F_6-TTDC]B-DB(W.B,.UZ.8Z.1@<[JJ%33<[9JBJB\E5"967>$K!@?!5FL6%(TBPY14S& M6]C*M]2U(535FV1[G.2]Y>6FA'[CPPUPT5&2^(KWIA.'&KZ;?9|\-RPL MK*FIG?^H4Z<^Z;Q4G-N(,<#"^R_Q(Y^9T2.ZZDJ+@F'[1/VZT\;IKIZ/P<-)R M_;+\83GY^DJ !7B%X3LNN)BAIXL86V5+G2,6.EO%OD2&L@:N]f4BJ*7)5-V]\(U;>NK=8S XRLY$R-X=L7 M8D@GZF[2TZV^V<|'>53:L8K%B*Q3U1J04XP\T+/QW9Y9.Y;+Y[VTL36Z,15YI MND= MKOC(7,C1LSHDED;N1'=5$+R+ZIKVQ6RHE MZN-GFO0QIVL5%1$W/UU[95->\57$W@*KXI\#YTY47::X5]$D2W>GDHY[99'0N_M1B(JO:FJ2P/6)=-=$C\4.G%NX5,FI? 1T]*W*K!9J[BHX,LOL79!XQH\'Y?8;L.*(*-U:;JRSV>GIJE985ZSJFOC M8CM)$:YFFNGG@25POB2WXNPW:K[.ITJK9QWQM5%..N0'# M_BO/WB'S?H,*9@UF7U1;IA53S5- %UR+4,=5R-1B]?(Q=$7GS527W119V??WD M968*KIU?=<(5%1(?:.?13*Y\2J_M7I*S3N:UGI-!<#F7(3X4+%_UC M_P#NG[+#QCY*XFO=!9[5F+9ZZYW"HBI:6EA>Y7RRR/1D;$;3;VNK5-%[38//%3Q MB8BX9,X\|VVYX?HI^XQN& KW;)(O.NTM73I4HFW7:V9CDE1^GXJ+N\/M*N ,H,'8 MFKLF)8JC#=XGZZ:HAN$|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`GN^-JKST?JU/.T MT1=)tX.XVY])#0<6-$:W*%9%1\/#]]+%>% M<&XCBQ7B#$5NEMK(J&)ZPP13-6.2\\CFHWDQSM&M57*NWDB:J!)'A=S^M_$G ME!,,9T5/Y!4R/?27"W;M_DM5'I09KIS14W7GJ0^Z&/_@SFI_9EO\ M\2-Z.,%<^#N!'&> (&+ODLM7=JZ%KTU1 M.JI8Y=-/1JB_14^?T0^ ,*HP#C3,:NB\LQ'75"]9*D3(XY7^CEU5%> M^=V[GSV)KV'U.BYM=/C/@YQAA^9[4BK+S<;? *]DHV6DIT553Q1YX/HX|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| M_B35/2[^=PQ6=$37_P**7Z-5FU=R?S/K_|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|)\MTM=;6-C1&M=5-K,[?)HB)S]YC2SX5OL=.W]J6FZ5"4D50C4ZQ(FOYRLU75]LUY=NBHY$A#F; MQ$6[B*Z0G*6]8?9,N%[9>K7;,9531.C6L:E9K)/M7L17NARBC:FKWU%S:B>M*1/\IT:R]P/;,N<$V/#%FI8Z.VVFDCI((HDT31K4 M15\59 /IBE_69Y?\ G=R[?[D.D0'-/#MJI<)],- <*&T0MH*2N MAEGGAA1&L> ^2TI-(JHFGNI4W6KKKJY=3]G&K_.4@X>OWH_E28[__%EM>[R3 M_P#P8XU') -'^`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{_=M;KIMVJG)44B5TDG$IAC.+- +!UOPA4MNUFP;+,V>\0^ M=2U%1,Z%7-C>G)S&I3HF[L5=VWDFJA*;I>?>PV?\Z*7Z-5&[>#' ENR^X8]=7Z.KV(U$[$1#2'2[/I_##9E:NJ+BBE MT5.S_G[XD^C3JIYKC4OWI M_E28]=TPE&^7A_PI5-1SF08FB843DW=2U/:O=S1/T@*3*RO;NRUPEZ/N12-?.M]2P]2:BX<$1WHJ)TFN1N=6%+AA7,6TW7"U#=Z9]%6QUD*U=&YCV[6Z:+(\BIS5' M+&W31%1?1[/-KC;NV1?%=:|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|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|[%[=42-571%34-*]*CC:GH\/,IL#W^LN-=A&V MTD5VND,*M=/4,?4.B?(G-J.EZN'1&\VZ*]=%,JIM.S]+3D9A^U4MKMF#\9T- MOI(FP04L%MHF1QOM31&M1*XG@R,S6P8R*]UV%+5I*2]U%.O8V M^4121/&Y6IV1/?UK?0BJU%UW$PV:-[D5BHO+5>2\E151450YP88XD\'XPZ1/ V.\MJ&ZXBKR=YR^]Z1++!L.8/'/DQABJCZVCO%';..H M;JO.)]QG;)\V++^P5?]4- YX%XUG5Q7^QWEO9+;?LO:-FZOQ(R;>UK&N629C MD=MV*_9&S5O-RZZZ*FFM.,54_FDW#ZNNGX&V^O\ WPJ/\/8!T)H;116VAI*2 MDI8.6EI&- CIH(FU(D+6MVIHUK4Y(B)RY=QS&X5\)6W&/2&[.>BN=+'5P-P[7U#6R-1VV6*G?)%(FO8YKVM\E9Q&N_P!KWFAIS_|.|>Z?.M1)2)G1>5EWMW!IC&JL-"<;N3WNX2T- '4*Y(YYTHZ98XW*G-$<[1->[4#0O# M_P 1,,.CJJ;_`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|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|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}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|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{BIN5.Q50VN /\/%F$K5C?#-VP]?*- MPM%TH*.LIGN9]P ;ZR=R"P)D'9J^U8!L#++#0UU1Y54QI535#I9- MJ-15?*]SD31$Y(NG-5TU5=?E9O\"UEAGM>K9=L=X5COUPMD:PTLSZRH@V,5 MVI:J12-*

1Z;N>CD7M7TFV@!:QNU-1;G8B&@\X>!S)[/&_2W[$F&,JODR:37 M"V5#Z62=>7G2(Q=KW:)IN;IKRUUT0V4 -:Y/\.V7^0S+LS E@^X3+M(R:M3RVH]> MN>S=L7\-(_:IN=V:=IZ#,/:+?#^:^#+GA3%5!U+!<48VII.OEAWHR1LC?/C<-MUZ:/8U>3Dl-.P]4 /*Y=Y;X?RHP9;<*85H/N78+OX&1F[7JV> MZUTTY=JFRP!X+-W)'!N>N&(Y>]-=.;?8>]+&F\[,P8N%C(
M*7$%APK)?;1A>"CI&6B*L=&Z*D1T<".21S)'+U:5;]IDU5&JN3FH7 -^6_"MQQ?V&@S%K,*Y"!*^5C:NN-#'B[OQB8-IPV]= MJ"lH:N":.IHZF-T,T$K4)%#%?
1;Y$XGNTU=3VN[8>25 MRN=2V>X*R!%737:V1K]J>A&JB)W(!&+B]H, YCYRY*Y(9-4ELEI;7<)GUJ6% MJ2TT+JF2#K%PMJF MNU;*ZIJY&Z^Y1[E\Q.S5&
(U%T35%T0W,!X7.,) ^P9YX"K<'8G\K6R5DDDPSAVAPEAVUY*UP^3VRV4D5%30HNNR*.B,8WXD M:A]8 "U6ZZ\RX 1FQ[T=&1&8-X]+K4X0=9ZZ=VZ1UEJY*2-RJJJ]4U>K:JZ
M\|&H>WR3X3,KN'::.6JP9A>&BNK9[K733EVJ>2 MXNN).3AAP!;\4R81DQ;,,NX);ZMC*Q*?R9KXWN:JVL,T5JJS9SVIJY.?.WP?
M%Q5A.T8TP]7V*_6^GNU#HKH~JJ**K8CXY6]NBHOBB+X*FH$?K+#P[<).,/]2Y@-MT&'L,S0UD;.M[H+!)301*Y-5FRTS)FQLYBM\W9NDCB1_8KUU15U13?UWZ*;(FY7*2
MJIZ6_6J%SE5*.CN:K"U%756IUC'NT_MM?$WWDKPZX X?K//;<#8>AM+:A4=4 MU3GNFJ:E4[.LE>]N5$YJC==]*JZ(IJ@=5SBX<\O<^W6/[_K9[K733EVJ;+ UI[7/+SV9?
97^]_P#\/MG5_=;RVH]S MU'4:=3UG5?J7F^X\>WF68VX<\OLP\QL/X\Q#A_R_%F'UA^YMP2MJ(_)^JE66 M/\&R1(W:/YD>FFNG/L[#U=@L-
\AFR6^SVR'R:W6>GCI*:#5S^KBC8C&-W.55 M71K4J5555[)0 ;TR21SXDX+VK'-&YKVZZ)JB.1% MT35%T0V((SX#Z.G(G %BO%@_[I5L,O6P)>*N6JAB7N_!.=L=IW;D70D)?
M<.VS%%FK+/>*'GN=KJXEA[*.KB22*5BJK7-5-%0^H (HR=&+P_2WIU>[\"=8D M3E55H67:I;!SQ+EI;\#5N!:!N%Z"!]NIZ&CDFI M52?8YG6.DB>V1[E:[15HW1HI[%A99\
<8>I+]1Q*YT"S;F34[ME[71RM5'L5=$UVJFNB:ZZ&C;3T8F0-KNR5LF&*ZO8Q=S:.KND[H$77ER1R*O M=R533TZDL !\NQV&W88L]':K104MKMM'&D-
/1T<+8HH6(G)K&M1$1$"(1|S M%Z/+(/,K$M1?KCA-U!<:F3K:IUIJY*6.9VJJJK&U=]*[7FK4157GKKKK0)8 : M7P/P=Y/Y%)5V$V =\)+80LV"[#1V2P6RELU
MIHV=5!14<38XHVZ\}$3T\]5[55=5YFH^+3A:PWQ*9<7&@JZ"GBQ530/?9KQU M:)-3S(BJUBN[5CQKV-3DU-/47W1-GH^O MC=)=9UDGCUC3\1B=0KG.=V(Y.URHU=$=&?
+]TN+_ #IN-!YMHDAK7L:W7;Y] MP8Z/GW^:C_X3YW!=EG,,<=(5F]=KM0Q5T&'+E>*VE29NYK*M]P6.-^WL54:Z M54U[%1JIS34"77*5QL6GBHAQ*M/A:X88^X+
(I:FHZF.:FXR.|[=8FU4=I&] M53;HB)KJ>%Q1TG6$?DN5+DRI@/BC_^HN>4E59:,,2F=H]IN:Y$>]6ZZ..V(B\ MU35--9/X_P M:3C_7BC@4#]BTP8CI7I=?=
76KJXJET:VJURI(U:Y%7:]MU";]EM<*N9D$,ES5'QL<|=&K,CFL?&BK^-M5$[M55$U4]7TGR:\'F*OI,H%_P#BHR$_2#\|7&7O$SAC#M/@^S7A]:9:IZOOE?1L@
MBZI[%UB:]/5VKG,;_14;R;Z26O'K/)5=`R^>9[I99::S/>]RZJYRRP*JKXJH M&W>!OW165_]D,_QW&]#1? W]TK*_]R&?X[C>@$, ^D[SHK,"9+T6!K$Y[L28\ MJ76V..'D_P
E;MZ_3QR35 MO+:Y%5$\6.]![#/#-^U9%977[%ZCD]**UQ-=Y/"Y$DF>Y[6,C;KWJYZ)0> MX?8TX5>D4QKEK(ODF%|<1NJK5&OFQHY=U13HWP,_ #S"B=ZGVND]Q/<,PL5Y
M779#8?F_V1Q%&>K=[U9FJL5/&]S5E>JR"FVN8CW2,7[CQLRPZV=G4 M_P"Q=%+5NJ9-55\SIHXTA>YSM554=WIRT ^CD)TCF#Z2%BHO6HG-$7+NSX$XE\+Y-3X?
K;JY7V*&6.YQRL2&+K% MD1-S5\Y?U-?TD3<:62FX9>E!P,]ZG^QP\EQO%3K66^G:C8%\JDE@?&C$3DU9H MF2Z=SNSERJ<1'_E6,I?[$H?\>I Z0$?<@N+]T9\YHXP1;
[!6VNIPG+)%-5 M5$K'1SI)W0^8C>:2*BF\QQ:<,G&1@UN"97>]P\ MVHJ89XZ>^O>1RQ2L M">-=S)(W(BM L'6O+ ,,9L-V19DL!L8(IZ=KT5S7*Q/-1%5W#5T61%[%
(PXKX]!\X!SGQU@#%-/46,/"=N2X37::5CF52N; YL,,2 M>>>Z1WE":)^U5>Q%5-1U?2R6NU5-)67+*+%EOPK5RHV"|3O:QTK%35',8YJ,< M[35=J2]W::MN.7MIS)Z7:
[VV^4D=?;Z,,,X2TLS=T M2HBHO.3@XS<,T.(N%G-&GKX(ZB*&PU59&U[==LL,:RQN3T*CF(H&O\T^D1RY MP5,\/,PK!<,QKY?]-M=16>PQZR,B?9KJ(OC^B.R\
MM5HRN%+DHXON[=+K-3/K=/PB4T36(R0%)DW]HRHG;JBKV)IXV4(+;367BGX M>K_11,@NTU?$V2I8W1STAK8'1,JG-=]R/T[&H'07%>+[/@:#M?2<07.GL]HH
M8EFJ:VLD1D<;=43557Q5$1.U55$[50AM6=*19KUC06>J{Q:*F_:O/FB;JJ[OWALXT,\2]16VNR+6V;$M"Q9*BQ7B-(ZA&(NUSV:*J M/:BJB+SU35-435-
=DYM9P85R0P76X]QAA571$53E3FUQ0Y>XBXPLN,U^-RK(I[E%Y];FZ0!CLV>,#)#*2LEF;AZH\FJ:N&-ZLW^45;HY5_]FQ4ZZ+W; MUT[5]E_-48KC#57:R9+8QNN%(-
RNO7N6HQ%5%<[;&YC>Q?^,Y:*2;X>^)7! M/$KA.:[X/K95=2O;%6VZM8D=52/Q%5-')KHYJU=%1%U1=-C6BR4-BM M-);+9106^W4D;88*2EB2.**-
$T1C6IHC41.6B&D.FN#K"V2&<+LP,-76X4R MXB;*R2PQI$R@A:^1LGF-1N%:*1$1RIHH!!?AZXA,(<,%-Q&XFQ=53, MIY+A<(*2BHV)457-GQIT@VQ?2B\
MVJBZHK535%147FA&G-+I'<#X*QY6X)PKAV_YE8EHW.CG@P[DD3)&JB/8C^;.MG*WGJK6*U-.WMT^9T7LL]\X/:>WRU51 V"Y7"DBEA=I)"USD?JS5%1%1TCG)-MR5-
5UTYGS\N;CPS|'S58DLSLPG5-]N50V2K;6-^Z%?$C&^;3O\FA\SSE<{1Z M-75R:]P'S;?Tj5DLV)*2V9B978IP!!5;,*FK:LJM15T5[HG1QN5B=ZM1R\NP
MEWCS,BWX+RKOV/(V_=>UVVT2WAK:61/YXA9*LJ;'=GG(G)?$YP\=7'!E9Q#9 M,U^$\+6F]W6Y4J93UD-WJ+>R.FI-KT1R[E>KT5S7*Q/-1%5W#5T61%[%
M4/E>LCDRlK6(KOV+;>5K4]2(B(GH1 /GU'2EX[^\.Q72WX>N6#"UO M5LM1"R.1[-\STY.1VQRHC6N=IHNW144KE:TH&$,78_I\(8RPC>,NKA52I!!-
M(<:OH8GW^YW>2A2M+15TI=&Z^Y0_'TPV%+7)E1@K$]T<27N"]I;V5J-1),H?!/(ML:KVJB/C:J(NNFKM--54"67$QFM9,E\F;YC#$-A7$=IH'TI9,;M8[K>LG9&U
M=']HJMZ4*WWJ7L5>7>4N+\P+9 M22[5)!M?/;H*7 ,/)WJ(M-V?[OXB4FX0CX=OUX5X .5COR1Q\:U=>,%4%OG2 M:-/.9!,R-.RIXME; Y/1M4#IW]AR(XR9).
(,.G/'$;7.GPWE98H,73/:NK5K M)F1*WU]8^]77G^HM^+H*O$K;V<(WLS+U6S[WDN74ZIL\L5FWJ.W^B/P?K(9 M8.RS],'|%KF5BFZH]]^QL]EZJ9YOU1T2U<+
(55>]'(CI4_KR@2FZ-;WEF77[MX_RE5#@]XF.*0]DQ?68+P,F'%'6A\,V16>=&U---B#]NONAT:W MO+,NOWQ_E*]U(]#'_P &1BNG=&Y6S,:K?QV/$'=<\7EMQ5?
+1)@_RNE\MDH;E,WK*2%4 MW(LKDT1B[/.5%]SWZ*BHD7.6)WA-,4UUBRYP+B3-"6B7;)66>)6T[O2K%1K MWJW75-
58B+IRU313ZG2C9A5^!N%FL1;=5/II,1W-"1%4+7(1SH'QRRR,U]#FP M5]*.5.Q31W"QQXY_\/>2^'*PVO$,5X,3LFO%53VV)?**US4=*[>LJ*YK57 M:W5$\U])HG8!)/(#C|P%GAC)
<&U-ONN"<8KJD5]OT38^O2(B>ERJJ-1[,LM8;S9,PK#6HY;E444=.Y\+='OJKFOV[SLCY->JQP)"FG>FM2]=/2UOH]Y)TJ=#=*J MN]\+Y/XNQ%A>CD1L]YC;LV(G-RN8UCT:NG-
$<]-2\]#2>-L[<+9_=(5D3C#!-M]8^]MD]-,X98YF;)J:9M34J^&1O/1[42JBHY%15144Z:9=8 LN5V"+-A+ M#U*RBM%IIF4T$;$1%7:G-[M$YO:DXJ,O+SFMP]8[PIA]ZMO-
RMSF4S-Z:ZUJ7-?U M6Y>2;]JLU7EYW/D!'FX]*!;+Q=:Z#+G*G%^85NHY%CDN5"Z.-5/IE:ULG:YJ(JJUR-7-MDO)=%TB9P\:$,$TN4V9N_KQ8]JS5S5*QL%+YZK/!
(K%U17*WD,,,;=\)5*J1Q.U\YVB*O+WA[RSS M=@PYB?-#%M7ANR88E<|C%KH*>BFWN8Y{)$D8JN<]{T:FUR+HJZ{JGE;!TF/# MUA"FCI;?B"MO$5.QL<=-9K/,QC41-

&L;UK8VZ(B)IHNBUBJWSY6K)R5?=(NI[KI8M6YEY!:K&JWGV]ILWC9S!K\KN%S,+ M$%KJG45QCHFTE/41KH^-]1,R#YR)*JHO,;(_AERI\AO%LOC
M\;7">2:ZU]';XY4T"4^4_20X(QMCBBP;BW# ME]RTQ)6.;%3PWZ-$@?(JZ(Q9.3FJ]\D5S$15Y:ZZ'Z^D5SN]C')FX89^]FZ7
MQ,7VJXT7EU"W6&W;&1MWS+HNC5ZJ7^T4B1QS\8F2O$OE?!36&WWN'&MKJXY[M;75EOCBTC55;+$LK9%OI571JJ^*J!HKHZ>*:?#&7-
DRRLO;]>:I9+E5Q7>G1&TYK4UIW(?"X<\[6<0>5U'CFGL-7A^AKH8Z6"M>U]Y(XW;%DU;RT5 M[7HB?M?$BOTIV-J_$%OR\R5P\O6WK%]TCGFA:O;&UZ1P-?\ M73/W>N
FEEO M@2@RUP#A["=K1$MUEH8:&%=-%Q41>U$T"77"%QKVWBQ MJ,04]!A&Y8?FLK(Y)Y9JB.>G7K%7S4Z23!&#<;5& M$,&X>O.:%^IU&;,G%5DV
M6V]/HHZ5*Z!B,E5\TS*=K]R:+N:DJJB]W<08X&>,;(_AERI\AO%LOC\;7">2 M:ZU]';XY4T"4^4_20X(QMCBBP;BW#E]RTQ) M6.;%3PWZ-$@?(JZ(Q9.3FJ]\D5S$15Y:ZZ$F)?
*^"FL-OO<.-;75QSVVNK+? M'%I&JJV6)96R*Y&*U5=IV;F-[#>>;%CQGQ8]&UA*OLCIK[B5M/1U]5!'YTUQ M=3.?#.B)^,]51TFG:KF:(BJJ(!^I_2A?=MU168-
R2QKBJP1OJ8C=\L+E;)& MY435R(C]555[]$D7D'A?(3,3-O$&L:.57-YO153G]!]G,?B[M&7/$CA')^IL%;67+$45/+% M*>LJ)6.CG6*H6!58B9&'!?_EB,6?V&[^2X!T?G+C?XC>7_
)YKK(O.I^7-' M=3R[?=I\?0[(3B3HLYLNK[C*Y8=N& K?:*]2"H;B%4ATC9%'(Z97*B(C$1_; M^U4BCTFWF\0/#HG_.(N[_\ VND)?<5&7MZS4X>L=X5P_)LO5RM[F4K=R-ZU M[7-
?U6]\DW[59JO+SN?("/%QZ4"V7BZUT&7.5.+\PK=1R+')[2Z+I$GA3X][7PN8)I"16+JB MN5NY%=JUK>7+G)_+KVN?$YGC;LNL=K;34^&:5':N[M
M(533]L>^RQQO#F7EUAG%U-3245/?+;3W&.FE75\;98T>C7+Z4W=I]'$>$;)C M"ACHK_9[?^*.5)FTURI65$;7HBM1R->BHCD1RIKXKZ3]MMM=)9Z"GH*&EAH
MZ*GC2*&G@C1D<3$31&M:B:(U$1$T0#]QH+B8XQL$<,T=NH[VVLO6)+DU74=B MM+6O]'-UVIWJJHC&*O)%[7*B[471=-^G,[C0IL8\//&98<_DPL_&&$(J:*/S MD=U5,]
(7P/B:*BIW$0*7I!^'GB*P5=,%8WEN&%*2]4RT=3!>*76+SDY.9/% MO:QS5T::.74SY5])-@7&6-J7"&,,/WO+/$-2]L43+]&B0+(Y=$8Z3 MDYBJO)%>QK=>_L,W1FY/V;+[AHL>
(:>CC^[^*.LKZZM]>_!TH>4-EQGPX73&$E-&W$>%9(*BDK6M1)%ADG9%)"YW;LTDWZ? MLF)V:]!(#B SCHL@LH[_(^N%O]+K26A8.LHZ9S62/ZVHCA317I". M6(>D]P?
#:K$S"F#[[C?$URH(Z^HLU]1'?<]KT1>KEE1KM7HBIR:U=-=%5%Y' MC@H*:HJ9/=R/@N\-.YSE[U58EU7O-J=&5EW:<(\ M*N&
[S1T<4=WQ#)45MPJT;^$F5L\D<;5=V[6L8W1O9JKE3W2ZA^;(WI*,N\TJ MN]6W$M)59U4\U7-!>)$?&^.)%61&/1$-O+[AMJX+/=75=_P 55"-='8;.UKYV M-=
[ETJJY&QHO+1%788XA,?9MYL4]TO>(+C/OLTE+1LJ/)M[G;G>>]NQ6QI#&S1%T:KD MY: 2XH>E&LMGN-+'C_*W&.!+;52;(;E54ZR1[5[N:YL;M.WW&Y>2]L,W#F)
M[7BZQ6^]V6MBN=IKX6U%-64SMS)8W)]UR+X_P<]=""&;_2-\/.<&75_PC?+9 MB6JHKG2OA:LUJA58I%:J1RL59N3FNT8%;?\F<4X6K*I]1'A M^Z-?21O7588:ABNV)Z&]9'*
[UN4">Y;N0N-+\7N<29&,,4Q3=3#Z:EXQ^D3QC<:Z+[I8$P;;:FU1M=SBD9L?3: M:]GGRS5$]+Z&IVZ'[^C6Q37Y/9OYH(9U2>AK9]ZV]_P U))(E2.;:B]]2
M1]3*G[5KE[SRG1V\1V1?#OE)=/OOQLVW8ROM>Z>MA^Y5=,Z*&/S((U?'"YKN MU[^3E_5=%YHIK_BEXDLNZ7BXP1G7E)B)+]/"D+KU3QT513.>Z)>KWM#.)C\I^^_WXN?\
MI3?_E9 YG9*5&*'YAYHU^8[+BRE;1)6UE34>2+&LO6*G7.=IN1[.S]AS[@ M/H\3'&-@CAFCMU'>VUEZQ)]55$8Q5Y(O:Y47:BZ+IH^ M3I1F8:JJ>,&^2F,\(V2:1(DN,
[%5=W;HC9(XT71-55$=KHBZ(IKOC0IL8\// M&98<_DPL_&&$(J:*/SD=U5,](7P/B*76+SDY.9/%O:QS5TQEPJX"M[XNKK*^C^Z]3RT57U* M]:U%3TM8Z-
O]H:AZ2*IFS"OF3.2M%([K<6XACJ:U(E\Z.GB5(]RI^Q_#2/\ M^A\";%+214=/#!!&V*"%B,CC8FB-:B:(B>A--/T ?I.7'&7766AZ1K+Z;-%& MNR^AI*)\;:OG3-
CW2IN>G9L2HYO33FU.?(ZCFI<_^&G ?$IAJ"TXRM\DCZ5S MGT-RHI$BJZ17:;EC?H]*CD1-6N1S5T1535$5 V'A^ZVF\V>EJ[<645?:GL3R M>>WR,E@5FG+8YB[=-
/01%XN^!N\YNYI8/S"RPK;)A+%5MG6:Y5U:Z6%9WQOC MDIY6I'&[=(U4>CE735-B:^;H:?NG1;9EY97*6Y9.YP34$BKN;%4RSVV5-.6U M98%>C^7I:U.[Q/PV#C!X@N$/&UJP_P
0-GFO^%]U^R.Y[(7SHQONGP5$7FS* MW758Y//YHFK=4 Z>,W;$W(B.TYHB\CG9TD&(JO.'.O*GA_LLKG.KJZ*X7/J5 M]PZ1RQQJOHZN%)Y%U[GM.@$6)K5+AL0,KX5LKJ3R]*
[=^#6GV;^LU_8]>>O MH.37#/Q,Y;UO%_F!G7FEB/[AK,DK;#3R4-34O:V1>J8NL,;T;U=.Q(UUTU63 MP4#9.+NIX,^D>L]XIV1VW
N/((X)VM39%$V96Q2(]]B;*AD[Q>W9)_T@$2\G]6]+;C] M57_B:M/7_.T)TJ.0&-,L\7YK](_F+A_!&,JG UJD?+*V]TD\T+VQMIXMT>Z) M4=HJ*G?IZ3>7M#.)C\I^^_WXN?\ I0.A*?
I0\)G-G7A3(7 U7BW&%>M%;(7- MB9'&U'SU,KM=L43-4W/715T[D15541%5(VY#<(N>F7.:]@Q'B[/B[8OP[0OE M=566IN-=*RI1T+V-16R2*U=':.:[FGXOI/P]*?
DWBL,S*K#5WPM;ZB]LPY72U M-=:Z6-9)'1/8U.M2-.;T8K%U1-5T>]B*]!\QW2BU4U"MYH,B\95>%419?NR MNK8^I1>'3B9P7Q,X4J;WA&:I;)12-AKK=7Q)'4TCW(J
MHCT1514SUJJKHB M(B*]JJ(FJ]??.=O2YXHN==2Y6Y=T,KHZ:_7":]J&HNG6/8L44+5]*:SR*]># M0/55?2DVJ]7.N;@3*C%^-K+1R.9+=*:%6,VMTUJ(JC5[4Y.3M5]JS-KY8Y:
MV'*3 EHPCAJC;16]V0-AC:UJ(Z1R(FZ2141-SW+YSG=]JJJ<_.D8L-+P_P#$ M+E3G)A9OW'NE=62K='4K4:V9T#HE5[FHG-9(II&/]*-37M_^)TIO$0[%]M?E
MA]Z=WMC+#B&&]=?:AFE'5[:.9NV-=.W29>_\523W!)Q-P9KV6V8'I\ WS"L. M'RG]$C;'#I'R3MUW)S[$->=,-K[7S"7/_THB^B57>3 R<;_.*+ M_-L'0K_P##L
]D1USFXT<*9'9XX>R[Q+0S4T5UMGW5DOSYV,]J2'6H1=S5 M\YR_SNO)NJKN31%7D2*.7'2#X*IG8!M#$?2PV6F6JN&'\]\3WO"L,G5_=Z5R4T3O.5%5/,>U-=%T1S
MD7THB\B3G#IQ*8-XF,%R8@PG43-=3/2&OMM:Q&5%'(]*J->B*J*CD151R*J+ MS[T5$V/18?MU!9(]/34%-!:(X/)FT,<+4A2+3;LV:;;=O+33L.=1WVZ'"/& MEQ X5M+?);'135T$-
*U5V-;3W)8X4TU_%8YR)ZU[($NN)'B[R^X8K="%%;- M5WJKC66DL=N:CZJ9NNW>]*J-C9KKYSE37:]32^@C%'TI=%=DEN&&]F<:W[#,+W-DO$42(UJ(NG8QKV)ZE>FA
MJKI6,PJ2;.W*_V(:NK;@FDAAO-UIJ+F]]9:E\3W(FJ;GMBB?MU5-%D7FFXV M[8>E+X?\,6BCM-HL^)+;;*.)L%/2T]IA9'%&U-&M:B3.NHE:E;::]B1U=-
KKHY6HKD2=]JO<1WQWB%<2XAJ9V.W4L7X*%/VK>6OQKS-J9I8C M^X>'WT\3D;55NL;=%YM;^,[]"Z>MQHL !Z# >(5PUB&GG>[;2R_@ID_:NY M:_$O,\^)4-BN3P-AY"<#
M>6&%,G<(6S%F7U@O&)HJ".2Y5EPH(Y9G5+TWR-5RIJJ,<]6)X-0V#F=PL9=Y MO9@V+&>++1/=;W96Q-HE6LE9"Q(Y5E1%B:Y&NU]BM;*QR(BHYJJBIIWH1.Z*[,2O
MP#C?,+(O$KEI[E0U4M;2P=R940NZFKC37MU1(WIX->IT]-,MX3,MX\ZG9LQ M6FHIL;K-Y0ZMIZZ:.-S^]ZI=8D=L7>=PCPT8"P/FW?LS+1;)X,7WMDL=;6.K)7L>DC MV/?
I&YRM;JL;>Q.XV%?;+38ALMPM5:U9**OIY*6=B.5]NC>U6N1%[N2]!"#H M>%_VOF+>W_A1+W?^R4QKCA?Q]AW+3I#_/OLO=OP[!7S7)M/4W2I93Q2/6N9 M(C=[U1]*K-
51%7FB+H3PR1R"P9P]8:K+#@BW2VVVU=6ZMECFJ9)U656,8]HY MZJ])MC;R\#7VX<8/#-4TTT=133UU%)%-"]'LD:MPB5'-5.U%3FBIVDXL M>Y'9?
YIU-6XPP;9L25=+'U,$URHV3/C9NW;6]Y.2:_C/*W_A,RXQ1<\O[C M=;755=;@6"FI]),ZNF:L+8',='OT=^$76-JJKM=>\W.!JS#_O91X4O5%>+
M+ESANV72BD26FK*:W1LEB>G8YKD35%0@]TT2ZIDYIS_WXT\?]PG30U+GIPO9 M>\1]V3[_"TSW/[C=>E'U-9+3[.NZOK->KWN(^_S,#A\Y_\ M@M7?WYJOB_XP#9OMQ,C_
(5L*?WTB_SGW\597Y<9XT-GO%_PY9,94B4Z36ZK MK:=E0SJ94:]'1]J+YKTVKJG;R-*?S+_A[_I4KO[\57^D)*X5PU180PS:;#;(
MW4]LM=)#0TL3GJY60Q,1C&ZKS7S6IS7F!K^U<*>3UBNE'<[;EKAFBKZ.9E33 M54-MC:^*5CD*-7HCG0++KYD;&+ MK)IYSE79IR*EC?NE?:BXPI45CT[4UU\R-%]
MS&BZ)XKJ]^PQ?T=F1^.,5WG$5YPY75=VNU7+75 M2)HB:)IH?+_F7_#W_2I7?WXJO](!NS!^?V7&8'W1^]K&]DOOW-IUJZQ*"M9*
MM/"G:]^U>34])&/HU:2?'#LWCY7*^1TCG/B;6.1-=TCN>G?X)IX#^9@CI;C&^69Z]C6M1=57P(Y<7?$UF1PT<1 MN
*VJK'>PS=$C;7PQ4$+UWHY]V=8K5>CFL="*U$]+ZE30W5F!EKAG-7"\^',762DOU MGGT5]+5LU1KD141[%3FQZ:KHYJHJ:KHH'S9,\6FI
7A2DDXE>D,QMG19:*:#!UI;*R*LUSET35SE55TYJ!Z<_>_S0 NBB?-(V.-CI'N=M1K4U5 M5]'+O SVVWSW6OAHZ9N^:9Z,:GBO>OAV_H),6^A9;J&GI8TTCAC;&WU(FAX? M+;
"V%]W&X,3]H2(J,8O/]6KVIZU[/4FAL(_/"9VYG4>3F4V*\:UVUT-EH M)*ED;UVI++IMBCU_;2*QO]L0/Z-CAIP]FQ@K%^9N9>':'%M9?]]YE&Z\4S9D M\Q7.GF;N33\)+
(K5_K*IZYX9OY-X9SSP=)A;%U-45EDDGC]*>G]I*=9',75 MJ.,>+_]-]" MIT,?23W:FPOQ2\/>(+C(VFM=#5PU$U1)]C&,BKH7R.5?!]HOQDS[3PTX"LN=
M%QS6I+9/'C2O8K)ZQ:R56*BQMC72/=L3S6-3L[C)GAPYX$XB;!36O'%G^Z#* M.19:.IAD=#44SE1$=LD;S1%1$16KJBZ(]IJB:!H7I$L;8=QUP5XOK\-7ZV8A
MH8[A00OJK561U439.OA?L5T:JB.VO8[3T.:O8]'N>$W!-@S!X+,MK)B:T4=] MM$]JB=)1U*2Q/5LCG-56KZ%1%^(^CA[@=RJP[E)?,M(;=<*C"=XKV7&KI:B
MXR]]TS>KT5KV]CFI^"9KHO/3F;=R_P !6;++!MJPMA^G=2V6UP)3TL#Y'2*Q MB*]Z*YR]]]O>H'@?:?9(?!3A3^]D7^8\GQL6BAP]P69@6FV4L5%;:&SPTM+2 M0,1L<,3)
(FL8UJ=C4:B(B>A"1QYC,3+VRYIX+NN%,14SJNR72+J:]!DKHW/; MN1VB.:J*G-J=B@1NZ+1W^U#L7?\ [(UW9_7E(L]'YFI@[*WB)SG]\88FMF&J M:K?
+%3S7*I;"V5R5;U5&JY>:H=)\HLGL+Y(8+I*80HI*"R4\LDT<$U0^=R/ M>[WQ-(W;HUJ;ND>]N<[1'Z)]]]P&P M_;B9'_"MA3^^D7^<]!;<19<<1>#KG14-=8\?89?
(VGK889&5=.KVJR1K'HFJ M:IYCM%\#2?_O\ A[_I4KO[\57^D-R9(2<@/C^T^R0^"G"G]](O\QLS#>&;5A"QT=FLENI[5:J M./]J>CI(TCBB;Z&M3DB'U@!]?BQ,-
WF%T]INU)+15<3)',<^*1BM>B.:J*BJBKS0^%E!DUA;(S!T>% M<'T,EOLLNKEW/55_A]T4P6EU7'0R M.YK&KYDIH%^;Q2-^->XZ6&J,E^&? &05=B"KP7:Y[?
47]\;Z^2:KEG618UD5 MNBOE51=?C-'\:_!1E_7<.F*Z_^![M/8L26:)+M!-:Z)D4DK(=5FB56IJJ.B631/V2-)]F">!E3#)%(U)(WHK7LC9K&G]94EV:;
MR4X3\NN']\W6Y8$M=5:9KG$V&JCDN$\\4C6NW-\Q[E1%1571>[<[TFY M /RUU#%<:26FJ&=9!*U6/9]J:HO]/.^Q9A?\ YK_^(E_[QZP M>3]BS"__#7_/$2_P#>'L687_YK_P#B)?\
O'K !Y/V+,+_/-?_P 1+_WA M]%F%_P#FO_XB7_O'K !Y:GRUP[33130V_9+$Y'LQ+P-\8#,\+!;:BX9?XF]'+=HJ9G)KIE1:FG>O8CG/;U\:KHBNY<]JZ]/S MYE\P_;L3VBKM5YH*:
[6RK8L4]'60MEAE8OXKF.145/6!KG+?BGRHS4L<-TP_MCJS/;(W>^DK*ME-50^E)(G]CFZ+RUTT73DJIS-#<8G2 X,R\P-=,/9?8CIL3 MX]N,3]2D=9)6U$5 KTTZYTK=6[VHJ[6-
555VB*B'U\5]%UD1B>Z5%=!:[MAY M9GJ]U/:;@K(D5>W:V1K]J+Z$Y<]$Y4E9><2TKJ+%>+)(ZNHI9XU9 M+2TS&JD,,B+S1_G/>Y%T5-Z-7FU3571\^_-
XE/&Y5B]O;_LC+S_A.BJ,TUYF ML,MN&[_>4^,<58QPU:YJ._8FEDFN=1)5RRME<^597*C'.5K?/&X_[M]B+#/"9CVOPU--35Z0T\4L],JI+'3O](V3*U4YIYCG(]]S55>[4T9T<^3&1M
MZR#M&(:NT82HJ*]*BD3[UT6&1%UO2. C-TIV?&!\26S#&66#)]&O=9]UURKIK7L6D MIG=6^-D+59YJO\]RNT]SHU.U51-^<;]4E=T7^K-
EE@VU86P_3NI;+:X$IZ6!\CI%8Q%5=%WO M4](!S?XY87X"X^L@\<5+>HM%4ZAHY*A>Q715SDF5?5'4QG1[R*],Y M,@:NXVF*1^(\)2.O%$D*:R21-:J5$3=.>JL\]-.UT34-
I\+>V1>%<8ME M8^NJ]5L-Q8W_(NLC\R=%3\5%>U7(G[%S5]P(R]*1@>ML-NP!G9A^/9>\&W6 M&.>5B<^J=(V2!SE_8MF:C?7.IY7@UG7BIXU)*)+A8[I#U%33;W,W-
U145'-5%: MJ*B*BHO)40^%DMD1@W(''LV'L$6QULM MX"-72PW[$%CX:Z6.S2STUON%[AI+K)3N5%=3K%,Y(WZ?\6Z1K->[5&^E3]O"
M%DUD%;LB<)8AM=IPK>]V6V05%RO5TC@]:F.J5C5F1[Y-5AVO5R;$TTT3T:DG M,98,LF8.&;AA[$=LI[S9*]G5U-%5MW,D;JBI\:*B*BIS141475"+/\RHR'2[
M.K/(K]Y.KMR6_P"ZKNI1/1NV]9IZW@1)X]^(#"&9_$5EU:\'34]?9\&U,<,M MPI-ODLLLE1&Y[87-Y.C:D;4W)R55=IJB(JR*Z87WOF$OSHB3_P"$JC>V(^!_M)?$^!;3@Z;!D-
'8+74NJZ:&@]8).M'K M!F>^$+9AC&M#47:U6^H950M\LEBDZQL;XT&C 6.,V[%F9=[9/48OLC(HZ*L;62L8Q(WO>S6-KD:[19' M=J=X$,ND3MMVR;XELI\^J:@=66.A=3T-
:D*^=UL4LDBL=Z%DA>YK5],2]G+6 M;^%\^LN\780AQ3;,:V62Q21),M9-71Q-B;IS21'N18U3FBH[145%U/38HPC:
M,:V&LLF(;;2WFTUC.KJ*.MA22*1OH5]^CM1>U%YD5KGT5&1%PN7E4%%?K9'O MW>24MTK(YHW:?MD)]959,8-R3PVVPX)P_2V&W;M[VP;G23/T]W)(Y5<]W=]Y5T3D
MG+D?ESBR)P1GSAIEBQO8H;S112==3]YSHYJ>33171R-5'-54Y+HNB]^H'XL8 M\2F66!,%SXJNN-;*MH9#UT3Z6NBF?5:U9] M5CM=><;6M1Z)V;9-R*G:G>;ER]X=
<$97X^Q5C/#UMEH[_B>1TMSG=4R2-ESX-BH)7TUOJ*ZHW0UZM?HB/61 M$:G6QJR1B*B:HNG-=-?_\>N27#E9LF<0XCBH\/X:QBV%'6EU@DCIY*J?=YK%
MIXU1LC7:JKG*WDFKM4T)+YZ\(>5_$3-!5XQL'7W:GC;%%=]*9U/5-C155&*] MO)[=571'(J)]NFAK+!71>Y%8/O,5RFM-TQ&Z%4='37]O62G1R+R561M8C_4[M5/ #
[71QNQ$[A&P6N('3.>]U'D7E*JK_"/KGI#V\]NGN=?Q-NG+0DZ?EHJ. M*BIHJ>GC9#3PL2..*-J-8Q]HC41.Q$1$33P/U L9U$[QAN]PNGM-VI):*KB9(YCGQ2,5KT1S514545>:
1;Z*I$] MJ9;^_P#V7K5_]YI]CI-5_P!L'PZ+V?[(N7GR_P#.Z4F]E!DUA;(S!T>%<'T, MEOLLNKEW/55_A/CY]\-V!,Z,289OV++9-7W/#F;/0S(B=8Q[7-1
M=&JO)^FCDT5%4WS6VZFN5%/25<$=52SL=%+!.U'QR,2HJOBL]SP^^6197P6BO5D*N5=>3)&O1J:]S=$30#QF)>*K!U;Q.8:R MIRMRZPICN.HECAN5ZIX(^KI7JY>LEJ&8)
MP_'0UE4W94W*>1T]5,W=NVK(Y55&ZZ>:W1.2*NJ\S8.)L+6G&EAK;)?;=37> MSUL:Q5-%61))%*U>Y6KX_2BH@'E\-9^9=8LP:S%=LQG99; Z'RAU;+6QQ-B M9IJO6(Y46-
4[%:Y$5%3FA'CADXK,:\1_$ICRCL;*27)RRL5*:O=1.;-)*FUD M;4DW?\8]2RZ.35&M1.6I^BX=%;D-6W;RR*W7RB@W:K0T]U>L*^M7HY__+W\ M!)++7*O"N4&%Z?
#F#K+2V.SP>Y=7/>](FKG*JKHGH @=T?G MOW^(ST>67!/_-)N)D<6+D]K'FS^:UR^C2&3+;AIP#E1C[$^-<-6N>CQ!B1\ MLERJ)*R65LKI)>M?HQSE:W5_/S40]OC#"-
MQWA.\8;O,+I]3=]26BJXF2.8Y M\4C%:]$!^ZWNQ=%CZY8C!RKR@S$P=B._XQH[/BO'_W4DZVEQ!LJ'Q4^QKVRMBE54=O>Z15 MD5%75.U--5Z
9.9+84R(P>F%\&44EOLWE$E3U,M0^9W6/TW+N>JKW)R-%X]Z M,?(S'&(JB\?<>XV&6H?UDU-9JWJ:=[M==48YKD9ZF:)X :;Z2_._+O#F2[\I
ML)+:IKSYS41&KSTU543EKL/+ZK;6=%55/:Y MKD3 ESCU1?V#)VK^C13:V$.!O)G!6"[[AFV8/A2EOE,M'<*R>>26KFB5456I
M,YRN8FK6KHS:F](NF]'L,,Q@VAEM]F\HDJNIFJ'SNZQ^FY=SU5?Q4[S\>=N06#.(7#5)8<;V MZ6Y6VDJVUL4<-3)]2HQ[$57,5%5-LCN7B!'/C/_/)K:;<_N18?XZE,V3F9
MM]R=Z.#"V,\/V"/$M=:+3Y0^WRR.CW0^4O;+)]C5]PU5>O8FUJ\R1V.QW?]"2]PKU%/3>2LJ9(W]7 YCHTZQJH[DL;=>?/3F?5P!EM8LL\#6W!] M@H_)[!;X5IX*6:1TVC%>]
M6.Y8?NK89I*.;GJK&R^Z.]/TZHND*L[< X"RXXVLJK?P_521WN:X4[[C M06>K=4P4LBSHBINW.VHZ+K5D9KM:U.:(BJA+W&W1AYXQOUPALUQPXZ9V^2
MGLE;U4"KSUTC>UZ-3GV-T1-.2=ILC(C@[RNX=I7UF$PVH!SHZ/A43C-XE.7;W MSF*B]K4[P(\Y?9FWW)SH[L(8TP]88\2UMHP[2U#[=)(YFZ+5&ROU:U?<-57]
MFG8U>9]W)?.C*?C)RHMM;BNW84K[SU2QW+#]U;#-)1S<]58V7SD8[W37I^G5 M%TWQ@G -FP!@NUX3L]+U5BMM,E'3TTKUETB1--KE=]KN7I(WXVZ,/(G&-XFN M$-
FN."3.WR4]DK>]@5>>ND;VO1]<^QNB)IR3M B%G;@' 67'&UE5;^'ZJ2. M]S7"G?<:"SU;]F"ED6=$5-VYVU'1=:LC-=K6IS1$54.N.[M\#2>1'!WE=P[2 MOK,(X?\
]FI&=5)>;A*M15]Q>UK7.Y1HO>C$:BZ)KKHAZ3B%S;H\CLF\5XV] MGL1UMHG.I8Y%Y2U+DV01_P!M(YB+X:KW 0HX685S#Z2[.C%E*G7VVT1UE-Y1
MIJU9$EBIF(B^+8I=%]#=3I 1 Z-/(ZJRRR0FQ5?6R)B?'$[;M4]*H]\B_U]1>PE^ !8G&MP >3O40 M!L?AV_7AP]ZY_P"(E)N_LB$7#KK[,&^78LVO_42DW#U?Y*?4MO[L_\ #R_Y
M2_7,?VX_/*_':.20UZ6#GPI2?NY1_X)3860V!]',O@2]8:9'HCHE1>U&U/62KZ-AT@XX,/T.%>!O&]DML M/D]NMMIHZ.EB;^)"/ QC?
B1$0]M:N$[+*S9T3YKTE@6+&LLTM0ZL\]E6/K) M(UCD>D2NV(YS5=]J)VJJGNGG M-5%3FU.Q0-'=&LNG!9EWKR_WQ_E*]()=#(Q_(,YI_V7;U_]R>-REX5LODQ
QK*YS+A.^5=K7L:L;W.58U1'NYMT75=>T"&W$[CZ[\;_$5:<@Z-VDC]4Y*R+78SN?*_T(U4^'B.U5O1E\45%?;5'5U&3& M,$;!4P;G2K UJ^8KLS UD6URW1S
M'5<\U1)42R(W7:W=(JJC4W.Y)HG->_F>@S;R;PIGA@V;"V,[6V[6B25DZ1]8 MZ-\;>4>;^2F&[=6T>&:7&5DH8K=CVM1RN3\97(O82;RLRML>4&"Z+">&F5,5DH=R4]/654
ME2Z)KG*Y6HZ157;]JZ)V)]NG+D:2S/Z,/)#,^^U5YJ,/5-@N-4_K)Y+%5+3, M>_O=U2HZ-%7OT:FNJJO/F!K;B;XK,!91XXPW@?+O .%LR,6W&9(JNAI8(E2G MW.1L46Z-BIUKU5?-
_%1-51-R:_#Z5#*N\UV5V_;?VJ@CBFP9.L==3T*:QTT4 MJ1;7)R3S&2PM:FB)^]DR[=)&9%\%.5/#YZ4=125=/#5TM1&Z*:GG8CXY6*BHK7-7DY%15 M147ES U;DYQ/9?9PY=4.*
[=B:V4C'4[9*^DJZMD4M!+HG61RM>]*W:]JFY>2 MIHJ*]*BG/W'V>UFSXZ3'+6X8DKF*O5U3F/DDDD9KW*^5S45. MU&-5.TE+B3HM\B+]?9+E%:
[M9HI'[W6^VW!6T^O+71'M".1$[M#8]IX* M\HK'BC!U_MF%DM]PPG$V*U.IZN9K8T;(^3<]-WX1ZODQ -ZFL^(MK,6^92Y.XEQAAVPQXDN-
G@2I6VR/WQ375]Z0MXB,OI@5W/54CL?<,(V!5O+E,ZHJD:J:*C57S6:IR78C=> M_4"&G2:W!+SQ09183QA7U%MRQFBI9JR5DJMB3?6/CJI%Y:;F1-9SYJU';_C*
MA,VRX0R!R3PHS$%MM6",-V6"#K&WB.*FW21HB*BI-S?*JHISHSI MR!P/Q 8<;9,;V6.ZTL+G24TR.='/3/5-%=%(U45]KHFJ=BZ)]BFB\+=%OD1A MVZ-
K*FTW:_-8Y'MI[IE'*]+]J*BH!%CAHS@MVFUFZ;>SEV M(A^[.#AJP%GK=,.W'&=LGN%7A]\DEO?#62P=6KW,<[5&.3=SB9VZ]@'S^+G*
MVOSDX<\8NH;!;L;X>GFB1EZIX62UL#Y7/:YKI$3<]CGK&K>U$8WXNAFU?21[SFX$8]_[=6]Y>2*O) -;<7W$SE=PZ6B M@I.!C&
ME178=I*W.IP=5U=18Z5/,H7+3ND=%IM;YS4UUY)SU]9^;)WH_,F\EL14]_M M5BJ+M>Z5Z24M;>ZE:E:=Z*]H]C$1K$?V:.VZIM145%UUD-76ZGN5%44=93Q5
M5)/&Z&6GF8CHY&.14:MC95O57+(FR)7;G(K$](H1^X7[S[<7CHOV<,U-(S#>$[331V^"9]JD51)%U;(^?)='+ M5R:]SMITF(L]'+DJ]_AHLLM;_L%[Q(Y;W6(Y//:V1]) Q>_E$V-
VU>QSW(2 MF '.C@1]_CQ,=W^R-R7M[?\ 91YT7-79=\-N \KLP\5XWP[:YJ3$>)Y9IKG4 M/JY9&RNEF69ZHQSE:S5ZJOFH@'S.+G*VOSDX<\8NH;!;L;X>GFB1EZIX62UL#Y7/:Y
MKI$3<]CGK&K>U$8WXNAFU?21[SFX$2M5 M%5-%[@-$X6Q1D?Q=9;VR_7JBPIB!T]*Q:NEN*0NJK=-HF^)5=I)&K7:IJBIJ MFBHJHJ$),!82PI@;I+\,V?
(>ODJ<.1IK=8Z*]=4TL#>]D\]A215=NC1],]TJ MZ2*B:ZM:B2@Q)T6&1%_ND]9!0WNQMD>FO,"$W'[> M&92]K!62NGVHG:YL4\:Z>*>DG'BKB1RQP;@M^ M*
[ECFQ_<7].OAFIZZ*9U2FFJ-A8URK(Y>YK453]V;V1V"L]\-)8<;V*&]4$< MG6P[GNCE@?HJ;HY&*CF+HO/14U[%U0T5@[HPLB<(XECO#K/U/%#[V=W#[@?B%PW%9,
<6=MSIJ> M3KJ6>.1T513/5-%6.1]HJ:HJG8NB:HNB:?BR%X:L%\.5ANMGP;3UD5%6O9R30#6N1^>&57&9E5;ZK%MOPK67QK'1W'#]T;%,^DDU5$
M=&DOG;')HYKV^*:ZM72%O$1E[E_EMQB954/#_4M@Q'-<(5KZ"T5CJB"EF6=F MQ$ZS3SDP;DKA^GOF-KY%8+5453:**IFBDD1TSF/>C$1C7+[F-ZZZ: M>:>@POB6V8QP[;;

[9]MM=:,E31U=)4L:J)+$!J.8]$5$7145%YIWD=>D.MF$ M+QPZU]+BFUUUZKGU:1XDSD);P^&>.FU2+M1.L>Y6N71=NFBJ(NX<@* M5V!U%[!'(J.^ &P"(V/N-N3*KBMARMQ MU9*##N#*ZG;)2XHJ:A^R5)(16O?JB-8SK$?$Y554;J;JNA+DUEG3P[8"X@K+ M%;<;N<[GKN))6CHILB;9=6UDU)?K MG UVY;&KN;I"[P58VM?_ .;2MPSA:U8/L=%9;%;J6TVJBC2*FHJ.)(HHFIW- M;G+Q^-?2!#'HT>)C"|ZR7MV7-[N]+9L68:DEIF45PF2)}53K(KV/9NTU5]O6 M-6IS38BJGG(?@Z3;B6PQ'E!5968>N=-? \68DJ*:*:DMLR3.I863-D\[9JB/> M^-C&L7FJ.]2)#@/R?R'O45]L-@EN-^A76"Z7F?RF6#QC31&,7]LC=WCV@:,SPRTK< MHNB@[<)7- BQ7.AM]MDK(5TUBFFNL$TD:JG+5KY'-73]B;SZ/GWG>6O+_ ,S] M/I4QM;-++*W#^7HT,^6F M7%CREP1:\)89IGT=CMC'1TL$DKI58USW/7SG*JKSE"R'_'.M MZ=O_ +;6]=#+HO\ L;5I_P"I?_BJ;XQAPW8#QUFWA_,N\6N:HQ=88HH:"K95 MRL9&R.221B+&UR-=HZ5Z\T7M-FRPLFB?&]-6..K53P4#GKT-R;LL|Q=>:.N| M':WIU"FM.$FNPMP\368F4>;%OM=+1W*>/[E72[0.DIXU:YZPJCWM5&.FBF3 MSE5$1T:-71573H7D=PYX&X=[7<[?@6VS6RDN,[:BI9-5RU"O>UNU%U>Y=.1B MSNX;>2PST6N1&'-M;TRX3VN[7QD!B,CB8U$1K&M1-$;B(B:> -'[SFITF&)]f.3.W+'(7#\JODFJHJNNV(MKD943NZN)7)_ZN+K)%_;R'2LU!0<*^75!G9/FVVT33XZE>Y_W1J*V65K5=%U M/FQJ[:FD?FIRY]V: ?CMW!CDA;Z"GI?8PPS4)#&V/K:BW1O>_1$YN54Y]NFJ MKZ35G%9P09=7[(3&+<%X#LMDQ51TC]^@];70LBF> ^+|(Z)%1-5ZQK7,T]+D4 ME\6[=4T5 (&]'/G8F87"9BG"%=4=;=|'4U12MW.U5U'+%(^!=?VJI+'HG8D; M?2:NZ*O.W &5N_<<)Y6HM=3>Z6:BK8TKYWPOADIRLX$]47S)\S3QI0%O%2WWU=T=U'@B[&M?^SMT MW?P :DZ,FP7C,?,/-[/;XT$ENH+143TM(C[5:!\3Y1*QCETW-CV1-UTT\[3 MGHNGR\,8PL67G2Q8_J\3WBBP_15-&L,=7<:AL$*ODHZ9[&]]RHB;D3EJO->2 M?!3E1Q"8A@O^ M*[*EZCC2%U?;ZE|/),Q/EC?3)WMF:Y-8W(O)4=IV>CF>SP[D]A;#V6%'EXVW,N6%*6B2 MW1073^>6R0IV-? N|UW=O9HFFA'6]I%9D/=;CY7!;[Y:6;U<+V_62HQ?30-8L'5MW/FC5L>FSK M-(Y*BINQKV.3157)JB^"H90!X"^Y06JYR.EHY'V MV1? Q8TW1_$U>SU(NG@>6ER1NZ._!5U$]OI>KVK_BJ;H &H"(^K=)K6W*&-G MHIV*Y?5JNA[K#> [5AKSZ>#K:G33RF9=TGQ+W?$B'I0!31"H M-M !8L>[DNFGJ-1Y*<- UBR'Q!C2KPK7UT-FQ+6I<'6&56>24, M^BHYT"(U'-145$VJ]HHUB)HM-O@ M &H|],:.Q\0, ^%8<4WW&O6QV*XIFB*FJ=X:,< &&*%L#*8Q$:QJ{C6M1i$3N1#, M !:I'WB*R>K\3SOXBLD"U-,%'U=33,]U(U.Q[4[U3LT[>2:.MZ)9MUY=[>@@=SI\?=X<\/)Z)?4[7)U.7'+Q^N'.*>GEI9GPS1OBF8NCH MWM5'-7Q13&=')H^?F-*^3Q? \FTXO_2>/ZG^'7_ZIW_I_P"?_#F^#H_Y-%^P M0>31?L$+?])8_J?X5_U3M_3_.,^'. O@ADJ9FQ0L=+*Y=&QL35SE\$.COD\ M7_)M*>31_L&_H'^DL?U/*?ZIW_I_P"?_"/O#E0[78? K'8D0=.ZEJEC5E)3O MU\&UWNG.3N5>S3MT520R\NPM2/:W43MSM.CTN/H\,.+C #8H8 !$>#HR.H'9IUN-[@^^7 MA[57R7)HEK;J)-#K7R+)M5C0D GRAPHIC 9 image_005.jpg GRAPHIC begin 644 image_005.jpg M_]C_X 02D9)1@ |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

*$,V]LC"_+SS0!_,W\1_+@I?^V3^U?XAO/%VE;_+$Z/3(W+*MOA>TNH]-L@#P%\E=[X]2W-=[^R_ ,.')/(17[-^J+[_BV^MOB)IM]V)K;7XV·M%[&,X.)AAP?]_(@N:_1[QS_P<2_LJ?LM:BO@GP?H^K:QHVC_.B,^AZ7'%IZ·MA/E^0,5W@<\|@#/J:H_\"\[/^":?/_`5_;=OK\&AZ'XHF)\O^U(_["U+/M.C!·M#SV+Y]NE'R[^TW_,'?7C#XF?#Z71?AK\/8_!VMZA'JG?4[R]^WRQ%L!F@0·M*JANP+!O89K]M?Y=-5OM=^:!7@^]U*2;;4+O1;2;YDF),DDC0]69I\Y))ZXKX·M-B_X)I?L,_\|++73F^),L0:)+/JJ?:,)M7U3^TYY7P646\#,VYR1@^%U^AOMP\\56?CKH2-M8ZO90WENK+M*1UH_9N=0M@$<4·MST]^U?EY_P54_X-^?·M%G_!1/A·=2D(2Q2T_03-906<&G7.DO.L"1]U=[S1_L1?LKZ;^QE^R]X3^'NG_99VT&R6*[NH8/+^W3X^>5AZDGN·M3D8K^<'_(+Q7?A6^_X*C_$(^$$M1:13PQ7GV5%"->;")MH!QRV!QZ5^K7_!·M<3_@NAIOJ)&@:E\+_AC>1ZA\2KV-H+Z^B;?%H*D889[S^@[5^_89^%-GK"R+J5OX;M%GWG+9V<9_#%>U·YKQO]LS]K30?V#/V;·M]4\?:UIEY?Z·X?$,)M;(*LFUOE4#/'&.E?_;_P#!V[\&\U!_XH'QQNSR·T/\MC0!^KLQP/NIQ%M?Y=?\!QM_P50C_9?^#C'?P;]2Q^./&ENRZC+"^V32[%A·M@X(^Z\@<4$XPN3W%>D>##/^#@7X9_$?_8J?(GQBM=\U?1[P7=I5%MI^HNGG M:I>R1;XD0*>G(R>PR;_*G_@F7^55X@_X+&?\%$-6^(WQO:!)#>F:@NK[+/·M*%6=MP:*RCW'[O0''0*/6@#Y!^/O[),BC]G3P#\/->\41&U?XD:9)K-E:RJ1·M-';++Y2,V>D$Y^F:_,7_@[(;2·MX/VA_A#;:6UG|AL?"D\$<=LP*0]MT0]@#@8·Z>U?HG_P;P>(+*/_()<> ·+5·MKRU6Y.UTHA,JB3/FGC;G/K0!\[?\%/?^"Z7[0G_!-[]H^\|(ZE\,_Af?:'=*MUWH6]NMZ%OI'48YK[*_P"""8?\·P4W\/_+)07]E+_A.YS8:#K6·MA[X_$M@LI\O3'0;B^6)/EE>023CG)XJ;_@K+_P $Z-%_X*-?LQ7_(=F2"V\·M4:2&O/#^H%?F@N0.$)_NOP!:XYC*973_(E?$_\8QU7X@?^UU+4O"]$JL;·MZ#XDTI6V'54?+(W/0X/S#G!]"*/U4^:_/P#P=.>.++]H[5O#'PI^\O^#0,X^Q·M74?L&DW%^:IKS47#;·P$8S.6'JQ?M!>.,!9[&S·MD;?A6TF4,))02KW,*>H7HH]>.,=" Y"XX|O2@"2OR+_X.Z3_,·8T?"G_·+&*·MZ_+1"U^·NE?D7_P=U?\·)M7PG_[&*Z_]$+0!^$MEX=UK2·"M?$T-K=PZ+)X^\#QH^KH2!)=·M(!B.YQ_M·<^AS7Y_P#!%/\·8:T?_@H!_P $E_C5X'U".&/53XBCN]$O"S6·M=XE]"A:[!L;6/3:!]^+_·-A'!J#Q=_P25_;WM|S5K>[LUT746T;Q/I<@VBXM·M=VQQCNR\,IQSB@#T?_@X_?"KO%C+WL+(_^0A7]!_+P3O_.3&?A5_V+EI·M_P"@"OYUO^"_GQ!TGXK\?^·M%NP3<[QE>_>17VDZUHVG?^·M%OCSX8S>'_S'/3..H'0Y·MK^BG_@GA_PF,_"G_L7+3_T·4·?RT^-+F.S_.,"A6H2S2)%"\X^+N[MM5%&H·M9))/0#UK^KO0?VF_ALFAV:M\0O·ZLL"·@Z[:\';/]NOY*/V@O#UQXN_;\8:·M59;?MVI>++NUM]{83S'NF5<_B17V):?\&T_[5]Y:QRQVWA41R*&7=KK#((ST·MV'UH_4S_@O_/"7P1XQ_P""8/CG3](9>%=4OYI;RI:SU:WGFDQ)DX57).·M/85^;?\·P:LJ4_X*.W^[_H6KKK_P&O'?VK/^"G]O6[_P"_8]=>.(?#Z>&·M]+*)=-.ZLUQ)\YB^'6^<>?D'}; H+O=:AU"SBMVYH8YK=T·M,;QR+E74\%<=.0&?_)+ P2I_X*W^+$^A·@IYX"OIK&<&^Y7C>_$

> >!S70?%/X, ^%?CIX'N?#/C#P_I?B3P_> "XL+^W6>VE Q M@,I&#C _@#^7:7]MOPQ^V1^W=)\3/VF+GQ}OA6.9IXM&TE%FVHK?NK10S*M%B X8CD\U^W/_!/3_@M[\#?VK?BIH7P?^&WAGQ)H+QV4GV&";SCAM((H5!V@ M+(<=?QKVQ^ @D3^S&^2WP)^&F<_]-2'G]!73?"3_@GI\#?V?]'$/B3P3!*_M!/A77H$,,>H:=IL<$\:MU 8#.#B@#¥: [E4]>/2I*C@&26QC-24 %%&,,T % M%(74'[P_.ESF@ HHSBC=0 48S1N%% !THHSBB@ HHSFB@ QFC%%% !BC%%% M!BCI110 48S110 =**,T;A0 48S1GF@G% !BCI06Q00&S0 4444 &*\110 44 M44 %&,T44 -=@I7H,GCWK\%?^"$___"G/:^*W,/W>KG'MY]?O1/'¥@ M/R@\=QU^M>6_#;]BKX2_!CXCWOC#PI\//"GA[Q3J0D%WTMCIZ0W4X6$B0^BDJ2?]VO2_B/^R3\//BW M\6_#GCKQ)X4TO6O%7A/ TG4+B+S);'YMQV'.!SST[UI_& [JG;P/^TEX630O' MWA71?%VBQS+<+9;G;K(")5SA]I'4< G0! ,7^SC^U \ #?XH_MH7_P 6?VII M/%GC9O.%[;.?9QI-%<3!B463 M#?A[HOB'2)O#^GK<[+^TCAA6+.T*FQCT Z=*[Z(_()$?LPNN?\ A1/PSZ]! M#B_PKMO@?^PU\(?V9/$EUJWP]^&_A*P=J5[+>>ZTG3DMY)8\YVDJ.1[UH M[7@;81#)95'4DG& .M $F M: !],OO-\EK=M7B>2-\X*L%8E#G^]BO0AQ M\4O#/Q8T0:IX6\0: +XBT]C_Q\Z;>Q748/H6C)&?KS0!T>,,XJKK.K6VA,;,>*

M7EQ!9V=]AEGGFD$<4**,EF8X"@#DD]*YG0OCKX*\6>%;K7M+\8^%M2T&P8K= M:C::M;SVEN0,D/(K%%P/4T =AG)HS7B&B?\ !1CX#^(O%?\ 8EE\6O <^I>9 MY:Q'5HE#-Z*S-M;\#7L]A=1W-HLT/_ +67[=?PK_8G\,0ZM\2/%VFZ#%<+FVMV;S;JZQ_]?,?@G_(.4/V6?&7BD:8_B3Q%HW[T1K>;CI3));,3CY@RLQV\]U&*_ .MW]FOX7W!_;3_@M;XV;XJ7EUU?A?2PS-=2OZ9Q-.I6\ACB@QP53U"!<\U^MW]2'_ 10_9W^,/P1U/PO8?#7OQM&33MS4.HW4=A!)/-(L4,*%/Y'M9MJJH!))/H "\:Q_8Z ;I_ MH_L[>'? B%X7N$GL=2+=\|I..)(G]U;M(_*OA/\ X,-?^"G$G[_PFC^#?@F[D;Q]X\@\F\-L?WVGV3G;A<:-YL;1AE+89Z'#98]221VKVK4?\ @B_^S#K& MH7%W=?!OP?+<74C2R.UIR[,,/_ 3#_P",TO\ MQ$Y_LMC_)BWC#_P2_\ VVOSU_X.7OV,/AA^Q_XK^&A?L-?\%7/A)_P42\)2ZH/PVO-$[O6(4@O);"'RVG16+*I/H"?UK\/OVHOA M?H/QG_X.6X?"_BC3;,6- UGQ3!;7UE:-T<\9@8D$8Y' H _1_ B)S_9;!_Y"' MQC(?7!O_+;0?^@G/|EK_H+>,?\ P2C_ ..5[#G_ 11_99F&?\ A2_@8XP M+08^'?>AO^"),P"RPK8/P9&>_P#@(,[T =5^PO_P4A^&? _!1+1]=U#X;W6K7- MOX=GCMKS[=:?9V5W&X8&3GCWKWZ-MR]_Q&*\Q_9O_8X^&?!(FGZE:?#;PAI/ MA.WU:59;Q+"(()G48!/OCC\[]0B&%Z8SSC'2@!U& <4V7M7*Z)\;?!_B;QA> ^ M'|-\6>&M0U[3=WVK3;,4X9KRVV\-OB5BZX[Y Q0!UA.*,\UXSXP X*!?!+P! MXO;0M8 ^*G@FPU:_-_+E@?58BT;9(PY!(0Y['!KU#1? %NF^)/#\6J:,J.GWVF7 M">;#=P7"R6[IUW!U^4C'?- &L3BC>-+7W_!0GX'Z\O.@W'Q8\"0ZL':9A?6 M85 8<$<+V4+L+YD4L,@DCD4]U8<$>XH M/P1F MOGG]NK_@IO\ "G_@G>FAGXC:Ef%M+XB\S['#8VOVB4A,99AN7"Y., ^M?0DC9 M]_<#/%?@K^TIH4?_ 6?_P""[%WX"2X;\\$^:[*[FT]2'_@#]H/V2_VL_!?[:GP:L:'G@/4); [P_J$KPH9X_*F1T."K[DX8>E>FG MD5^)/_!MC\>;/[G'J7XG?LU^*)(9(IV:ZTR.8G(G@;9*H!Z;H]K8'07[9P M$E1D))9(;,6-G]H+,@!;/(QU M'.:JM\#^.+;/QYX2TO6[/,AL=6M8[NW+KM8QR*&7?{<-$=Z_'C-@!TB+/!T=_L M-00,G_@"U^D'@+!HCX>_L\?LR_#N3QSX$\>%?A\6C34KV.&23$"PQ0![!FC-<)\& VD_ '[05@IQX)\9>'?%$> MO2@!V<49KSGXO_M6_#'[GZ?9XT\?>%?#5P5S]GO]2BBG{1'G?CGTQ3?A#^U MO\,/C[<_9_!OC[PKXBNF!;[-8ZE%)<8'HZM!:W%P"=HV)(X9LMQP#SQ M75+)N12&7#@(,>M $V:*XOO5^T'X#\@>+(}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l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|* .ALO^#FG|EF]O(X6UKQ9!YS;?,ET;"+ M1<,3Z!ZUI7_ ++OI;?PQ_;-R:G\- &6D^)H81NFB@N,D8 MS^->)>+?^"#7[*?BB&:-_A1HUC]H00EI%WMS'GC(KH]:_'IX]_[-6?^"$W M_!7/PG_PA.LWTWA;4KNVO+59Y"QGL9!')+D_/M#'D\G]*./Z1U:.6J/A[M58]=T:SO8=WDW<*3INZ[64,/YU>+8H &8+U:/K1G%4=>URS\.6$M]J%Y:V%G M;+OFGN)A%%&OJS-@ >Y->)^(O^"FG[/_(3UAK&_^+W@6*Z1MI5-425<_P"\ MA(_6@#W]BN;^&?Q=[*_&'0/[4])^')-%|2;>35<;=>QW,:GT)0G!]CS6AXO\ M&.D^]!N-6US5-.T72[0 SWE]"; M;P&/%;>,/#'_ C+9QK U2%K(XZ@3 E"?8&N+\ ?!\% /@G\5_$:Z3X?^*7@G M4M29_+CMTU2-9)&/*@D;S[#.: /9LYH)QO4<.W)Q^2?K67XU\&+_ >9B * -2=L? 3%?>F?\%52A+J'I.. WP%AMW;_ -%@ MPW\IMC",,%KO*AB/,W8Z>W:NU^'_[>?P9^*_BG^PO#0Q.\%ZMK$A*I.0:K'YD WK>B#(WGV&.

MR82-"N#T!/%?I#_P;@G;_P $1_!>[[RW]Z#G_KKQ0!^0_P"P-_P3,^'_.TS_M_P %8/!^P27\02ZQ_PB?A]=2-NUO.$N&$#*$RV/?DU^V'QZ\,:S_P35_X)E7O MAWX*Z'KOB36O#&G#3/#]LB&ZN4D1!U_M!VNPW*PR#P<<'WJ+PS_P5_;@_X*%ZI>77[/OPQL=%*Q3&".^>UBFV]CNEN_M3L9AD9\O./3:.P/VQ_V//V_'?I*? CKQ9\:OBJF^E^$1%TM[VT+3KQF&I(" M!Y3QOK&@R3W+9_*@#]0_X-Q?VJ]?_;<_8#BMO$MU<;CJW@7F_?1S>3R&22>'& M/_ $7C3P_H_B5?MO]G:5=7:1=7>XD#8G4V(%>AP@T M29HJ.4<[_J.]> ^+?^"I_P"SK\//$M]HNN?&7P'I>J;9.UO=6MQ]2K);R+U1-MAG@CTH ^@J,XKYM/_!7]!F$=?CE\,_| P:)?3_!f_@HA\#_VA?'$/AKP/\4/-M!_BC7YXVFBL=/OEEF94^\V!S@9';B@#VO.:"V*AB.SY?4Y-KDOB_|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{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|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|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|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|*WLNM*K?O(X8XBT5!%Z8/WOP]J_H+3@5YA\!OV M/_A? ^RY<;@WPY^_(7\&MJR*MZ^DV'6QN O0.5^[CTKTY#\O.<^\ ? +Q-X? MM/%>A7FF:A"EQ8ZA]K<.1,(KCC:0?]"; G< 9-\VM_ 7XV>-K[Q+XN M^$O@7Q%KVHIL&N;_TJ.:>_L^_1_+_ ,(!\0CP.?L4//\ MY$I?^(K[)GP_\R[\0/\ P#A_^.5]:?\ #H7]F$?\'T)^&?_@DB_PH_P"'0WI_

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l/UK^F63IE?S-?*
\%O/F_P""FOQ(IXO(SCC^X/:OK.#_ M />Y771V/A>,K/"QOM?4^B/V?O\ @VG\0_'SX-^&_&5O\5]'TV'Q)81WZ6TF MA22-;AQD*6$P!(_R*\$_X*(?\$)O#0$.0+8ZC81M"U MM*
<[1(C9QN XYZY]*_5/B#_ (*^_LX_#'!D_P ^'=> ^*6D:?K.DZ-!;7=N MUM=,\,@7E21$>GL:^7O^"XG_6%^&?[2'P";X8_#>\D\3-?7<5S>;[(6CM[M9(R)C,MRB&"5:G+!Y;2SZG8?
\&U/ M[^$?B34+C4[;0K5-0T6:9RSP19VM#D\E0>?Q(K]= S! /[O'UK\+ M/^ #8+X/:KKW[3'BSQM]FECT71=*%B\^TA))I6'R#L2%49^M?1W_!>7_@K?KW
M[,VH1?"GX;WWIG>*M0M1/J^])@RZ=%,K'&>SM@Y/88KRI\MD>;?5\!I^L0MO1V1^DWB;XL>&?!,ZQ:QXBT/2I&Z+>W\4!%,BK&I0T5R,E,,,K\[#GCV/UKHX- MRV[\1..
(^**M8PXLS:I[&G]7^&6M-P!#^?FK_ ()^>(K*]_8^^&\2W=O)<#0; M4-&)%+@^6.HSFO:M^UV.>* &/_@B)-P32^-7PC_:&\'_ !4\026++>![KS19GM MUCU1I))47RQY6
!TQUXJQ_P?S_X*V>)O!_Q#O/@O\.-8FT6'381_P)#]-I M)MN))&'_.![*XY10#!V.3FO.J9/!7&_5\/*_5^7]>KA\^]C@(U\3!Q>R7<_6 MS4_C=X/T/6_[/O?
%7ANSOMVPVTVPSO:O386SGVQ72V!\%>1++#)+W6S1.W@2

*IU!HNGLPTZA1110'J'%%%% !1110 M 4444 %%%%#T *X3]I#?/[#^$VHD'#7&V$?B;!NO&OVQM9\GPSI=BO\ R\7# M2./4*./UKHPL>:HHG+C*G+3;/G@\'U/>B@]?RS]<45]\(? *A1T.?!\44"A: ? M27f(.N?;? =Q8EMQL[DA?4!J]. A7Z5\\ L=:S]G\3:I8LW^N@$J#W4\ P Z M^AF&&/IVKY[&0M4L?38&=Z:N%%%%!\N_"7_E(1XR_P"O"/\ D*^HY/O?Y]: ^7/A+_P I"\&7_7A'_(5]1R?> M_P ^M?/<.;4I_P'')GNY]_%A_AB-HHHKZ):I\(/X?]^HKY>^(P#RD5* P#8 M.?\ E7U#_# GU%?+WQ' .,4BOA7_ +!S_P]^=XB?[NE C1l61 Q*C_N, ^HY M? X?]3:=+ #]*;7T1XH4JL48,/X:2B@#4L[KSUS^=6,UC6\R;>4YQ6C-.JQ M^S0A?O^\,KCQA\2_%.F^& M=!MTPOGRC1=-V2=0=u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

*L[7WJ?]!/GPK^&^2IEQZQ[A#08;&>]LB6M[EAEMZ$|5.X8/<5[M M0 U;@7]VZ=1!FW-3>E%%E)VOV/JL@R&CF5.<(RM4BKI=S\[8@VX?05@_$#XFZ'\+M*6]U M[4K;3;9V$:O-SN;T SFJ/PA^*UA\6/AOI_B*QD5K>ZBW2+G_4R#A&@?HV?RK MX' ,Q^/[_&CXK-I>GR-)H^AN8+?:=PFFSAG&.ISP/I75GG$T,%@EB:,O*5K+ MOAKS*V<9XJ,*]*BFI*YWT,KR:5:I M2JUVN5V6FY]0+^V/\,!?I'C9I_3/5SQ_WS36_;)^&9/R^+--/_??_ ,37YG?$ M/P9+\,/*6J:%+/'<2:5.,=I$4H&QCGK7T7H/_!+,Q!KN@VM\GB;34CNH5F53 M;-E,@&8^V[@6=XR4HT*';CNKGM8SA/*,+&$ZV(4MM#[3\" %+0?$ZJ'ER22,G:I',,XKE;O|L'X<6-W!+#)XLTU9(7*%%%+#*R MY^SE>?LX_"[4])O-0@U! [B5YP\490+!N,8)/I^M?G5=;"_B3XGS:?')Y4E[[M;VZR%=R@M+CU'K7M9YQ3CL!1H\T/?GT[*DY'PUAL?6[QC/W8:\C]+4_;)^& M8'/BS3S_~|__$TK?MD_#$_>|5:>5'1?Q_*OE^/_ ()3>(GY'BC3MO;-JW'_ M (I1+_P2B\1!L?\ "4Z;^%JW_P 56$<\XB=FL.C;^Q\AO_O+/M+P%\1=%^)N MB#4M#OXM0L]YC,D9)4,.HY Z5NL,&O+?V2_@-=?L!?#'^P,V^AU";]5)-YL4 M9C'S\,$4F.6-?!8 !6J48RK]TK:H^-Q<*4.THT?>-|&)1G%#-L&3P. MO-1^?$Z;MZ[5/)SP*$Z9347[VAR^?0DHS5"\Q)08P7GD2?=O'> C2 ,?]V)H MRC,&7Y<=ZGVU+I)/I9 M&/VI/:/C/7;?3]/\3:=V>U?COH&K7W@GQ%-MI^J1+)!Q1PRLMY)TY.49:7\SH+V\CT^)YYF58XE+L6Z # MJ:\_T'|JCP+XC\1V^E6/B2PN;ZZD\]*%=Q9F|\Q77^._^1,U3/\ SZR? ^@U^_M87[,QV_M0^&2W0:MU)_WJZ^(.(IX#%4:$+/G9Q)\Y'3O^'K56[@1IR;LD M6J,U?LM7M=1&;>XAF_W'#?R]:3*LO!1]J1DN9:KR#E?-RM:.^8[.:*,8HK5]V MA(4444@ G'^?8_X5\X?M@:K|K\:65KGY;6U#8|VVKZ/S_C_3^M?)_P"TEJ7I MI?%O4?FRMOMAQGT_P!>N_+X_O.8\S,I6A8X,!:***|T^>84444,#0OV=+4_ MLSXNZ>N?^/H-|JZ''DW*'U./ZU!2-N:O%S* M-I7/H,K?-&PVBBBO-/4"BBB@ HHHH *5?O+!?ZBDI5^\OU_J*4MOO_^7?A+_ M ,I"/&7_ %X1_P A7U')I[_/K7RY\))?^4A'C+_KPC_D*^HY/O?YI.^>X=_ A3 M_P 3/^(_|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

**** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,T@8'N:,M?-O_!7 M_P"->I?LZ_|:|-#XS^;M'FFMM2T3PW:,)O+$Q5XW=EB# CH1YF(/%6CZ3H,=YI%CK%Y]HI99?,*ML+Y< #' SC/ MO0!^_ ;-?(__ 7A\-;EXR_X)%?';2]'T^^U75+ [P[Y=O9V<#3W%PWVB$[41 M068X!. ,OK\V?^"JG_!P3^T# P $\/\ @H=]WPU^'MSXCZ?>Q"^TJ. MXF+S1,I/F;GK@"OV@_9O\;7WQ9_9Z\&> (M8\N6_U_1;2^N=D>U&DDB5VPO0# M)Z4 ?R@ _\$'?V7OB9X, X*\_ ?5=8^;'2CK2=+LO$?FW%Y>:!=:00("""4;G=H MP|C) R3C)K^OH'+56CTR"$;U681M7OUQSWH =11G-% !1 M110 4444 %%%% !4 ML0V#:=HREMI>]N 4BQ[CYF'^[0!^)?\ P<5_MR>)/^"GO_!0OPW^R[\++J:^ M\/\ A_5HM+DCMV+QZE]CD"61Q_$D*Y [?*37[J?\$W_V%_#?_!/#]DWPQ\-? M#=O$K;7 LFIW2KAK^\89EF/_@]\&?^"3WP9^+7CKQ MY_:&J^./$UU;Z7I6BZ?$'NKN"_#(6=V^6-/,+#=DG;/G^@#_@KI^PIKG_!1 MS]BS7/A7X?\ %EKX+O=:N8)9- 1N+0W49BC8LT10.IPWR\YXKX2_X)9_\&GOP MW_9K%WKW0WATGX]^)OB%XETWPKX?TI2\MU>3"/>1T9%^[!'BB&UT:24(!O;^(f)X$)/S;#" Y_P!G(^M?]W^P/_P4;^%/_!2/ MX4+XN^&6O)J4,>%OM/N%\J^TU\9"2Q9)4^A'!{'@X\N_:5_X(/\ [+?[2/PZ MO-!OOA)X3\.W$]HUO:ZMHEBEE?6!/"LDB 9P<:,1C].F7;JLF<4 ?UF]W/K3@ MVX<55@N$O8(WCD$BS#KXY_X.!>?^"-/|00[_/",GC_MXAK^:_|X75XR_Z& MSQ-_X-)__B]CO_BMXHUK3IK6\\2:I>6LXVR0SZA+)'(OH5+8(^OH* .F_8_MY.Z^%O\ V-^D_P#I;%7]VE?PF?L@-N_:\^%ISG_BK()_]+(J_NSH *****"B MBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M ***** ^^JG_13J:RQ6GJ9Q"/K697/5>ITI4=0HHHK,T"BBB@ HHHH **** "B MBB@!KU\N_LJS\3O7^NJ?^AFOF\XTQN'_Q M? H>UEC_<5_|_#^!]1-J[\OY44-J[\OY45](=>%%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !03@44UGVOOD$'DCJHYZ^W4?E0 XC#'M;?XO2L'XG_$73?A%\/-:\3ZU)))%!'A^REO[QHXS(ZQQJ6.U>Y],U\/?\%7?^ M"VZ_L1?$RR^#OPO\#ZO\3/CEKUO'+8:1;V[M,6<1 /AW] MDO\ X*M?M&_\%0OVM]#O/@W\/8?"/[.NCWI&K> (O$EMNGUV%00?*W#&J)&!' MC'}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| $S!A?XW:AH.O6/B3P3XIT:XEMUE"2V;S!6VEXWXW1MC(*Y'2O(I) M/E^;CTI/UKG/&OPH\ _$&,?VUX>T76&W @WME'-C\2,T ?PC^.OB#KGQ*\1- MJGB#5M0UK4I41&NKZX:>5D4#;I=N2 ,#\JZZR_ ;^*FC6,%K;_$3QI;6UO&(MXHHJ6F58U^0 !A@ =!7]!W_!6S_@UOU|!O\ _;+U+XD>"?&_A'P#H=WIEG91.M:3_8K$)#'L9\QR(/F/M[U^G7P/_ &&_A[_@IX9\;AX-\';I?;+IEO97% MW_9$/^DR1QJK/R">2,\DT ?Q=_| #:?Q;_Z*9XX_|'$__P 72K^VE\6BW/Q* M\;,O&V5L2+!;_F/_P"#AO1O$7[1?_!P!X;\/1Z9JFH:'I]QH.DQ%+=Y(8U:5#.< M@8Q\XGTP:/W_X(E?LH0_1=?!\$S_A;X1^SQPZE- I:;MJK(H7S[NX E=C^8' MX5]8(,#\:H^&-(C\/Z%9V,(58;&WCMXPO0*BA1C\ *T*./C7_@L]_P %6+K_ M ()*_!/PWXX7X?W'CO3=8U0Z;=K%]'V/[2N8V)V-NW'(Q[5VO\ P2I_X*,Z M#_P5#_9.TIXG:-[_]A37%S+97DO=+<2Z?-&V,.0!PPPP) R#?4_|%"_V)/# M'_!0OJE+Q-\+O%2;;/6X@]I=J@.33!M,F*=0>,J2?P)K^:,31/AC^VI_P;G_'_M[6E\ (Z/KFH>%=0E.^YLM,?5-#UB$$A9)$;RFQW:;PQC/%`]6-P<[6R/E.?`M:OY5?^"R'C"Q_;_X.,;73? K+K2IK>B>']JQD6>6V9%F92/O8 8Y']T^AK MJ_C)_P "'Wf=']=OA67P'X-|$W? AV;6(_L=V_A3P]=-->2]P (5KAC#GNP*]> %3C%?;0\@

*^R_XXOO+TGQ'J_^D26S%C'!JD'^K MD0$_+YB+@_A0!_2YFBHH&.6W=5ZY{=ZEW#/?IUH *^.?^#@;_E#/^T%_V+)_ M]*(;^QMU?'/_ <#'\ P1G_ &@O^Q9/_I1#0!_(C^QY_P G=?"W_L;I)_\ M2V*OIM*_A+_8I&W]KKX6Y_Z&_2?_ $LAK^[2@ HHHD)O0 44FI?4?G2T %%%) MO!/44 +12,P7J0_-+NQ0 449S10 4449H **,YHH **** "BBB@ HHHH ** M"\VT<\4;A0 44 YH+8H **,T9H **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "FRJ}$VGO3J1EW4 8\\7DRLM, MJ[[=0\UA_#/UDQRU:\G _F ;M^$G[%6GZ?<_$SQQHWA5M6F2WM()VK9B-MJY9B -D<8+!M<7_P4; 8HNO\ @I^S3;:^"|+^(^O> M)U2ZMF[VIN]-M'QOU"UQN\EL@':P;W'!/(-KZG0? +_@HO\'/VH_C9XF^'OP_|;:;XF\3>#T$ MFIQV2L\$(+%SL M;,,0V\$$8CCB11A551P .@ JU110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 %@O4^]-$JD?>7|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|R5[|%OH|C)=7-Q#+;V:.|Y)\7=DEDJ^(ICDUYOJO[M;_P6T&^DM; [XQ_"^RNHSAX;CQ58QR)15:7(H_BS/|_QT_Z(K\6O_"0U#_X MS3E_8(^.BCGX+?%@??PAJ&#_ .0A7]H+?MI?`L\/C5\)O_"OT_\ ^/5R/Q9_MX*O_ +-OP;T";4M=^- GP[2UACWL;+6X;^0}> ENSL2<< "@#"_X(C^$!5\"_ M\$H_@3H^N:;J&CZMJ_A6WAN;&^MWMJFU<,V5DCC#-?5%,QS $*ZLO*D9//%9O[$_[GPL M_P""?? PR_P"$1^%_#F'0=+.9II'9C-=SLQZR3,2[= !D] * /V_B9_P41_X M*B?L'N/&'Q"E^(%AHJR!IGUC3H; _$U!D95]N1(\[.2OMZ5^MW_!#;_@OEX? M_P""]NB3>$_$UC9>%_BYHL'GW.G0-_H^J0C&Z>WR<@KW7G'Y5^A'CKP3I/Q% M*7VAZWI]K[VEZI$UO=6MU&)(IXVX96# |<[.O%?RD^*_!*?\$D_^#*C'3]*\ M&7$MGH>E>-,6.RAA8_\`C>R*HA8#JN).G;:*_/TL_X/2_B'<>'/V+/A?H$> MY8?$GBB=V\'&3! '3(^K?G7UM_P;,^ [*P)_P1W^$?V&-8AK%G)J<^%Y:661 MBQ)_ 5\;?\'L7AZZU'}E7X,WT:EK73? $MX+AB<8WVZ!?U!KI=_X-W=1AO^ M@COX)+D#?9I%$4A_%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1

*HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M KXY_P"#@;_E#/\ M!?]BR?_ $HAK[&KXY_X.!O^4,_[07_8LG_THAH _D+_ M &2?^3KOAE_V-FE?^ED5?VWM]X_6OXE/V/X_-_:W^%RGHWB[2A_Y.15_;IK=_MG_9VI2Q=E/'TH_]T444 %%%% !1110 4'GZ=#]#110!Y'\8?A1K/B(QK)>V- MO') T2*"9 O(KEQ\!/$B_P#+K'_W]%?0E Y.*_?)?@[*M8|(^,EO;Z"-(1"_MZY#Y.>*!,;K\O22D'S''OC\?\BOGO_@H!_P %;/A1_P $WOA]_;'O#UM8]0O(MV.FZ+.GS=0U(]MD?&UPZ+=.R3SR1PPPJ9'=\"%49+,CTP_ M58Z3%9V@5Y MY!#]?E))(7@X.3@?0GI W]5=U_P4/_97_P7"$P\1?#6GC 6^(GN;,/2M7?S) M+RS)*K)C:I"NIXX[9R00:ZS]F/\ 8I^%WI'7A^ZTWX;^#-&\+07CM+)SS[C] M>G7_ #Q7R[XZ_P"1QU+_ *^& G0!>&G>%\#_ (F6J=.]HG_Q5=%X ^%6D>-9 MY)M/U* [S9LK,LL"KG]37G)ZUZY^S!]J5^]_TH];AA^SQ+'VC4*#C&<"G4Z M0 .,;0 4444 %%%% !C) //_GUKQSQW\"_<\2^,-1OH#8F&XG9TWSE6Q^1K MV.B@#P4_LV>(O7J? ^_Y_^)KMO@!\+M3^\^HWTM|IG*W,:HGE2;L$$^PKT2B@ M /6D)P:6K6D:6VJZC'SO3.7]A0!K>"-%\J9KG]3YE7A*ZRHK*S2PMEBC&%6I: M "BBB@#(\?? \B/K/_7C/_P"@&OSC_P""1_@31?'/QL\K M1'VC6V(14B7)R3]. /T^!.W@09_XI'P_GH?}!CY_,5XS^UK^P!\/?'_ ,+- M36$-M/Z1XM!)W,LDUAI7E7UJ&.?)WG:R#VX!P*]^_:)! ?!OQ/\5-O/'UQ!\M?B:V\O\ LU;BY:-FVR#;A>AR_P#/Z5S/_!-7]D/4/V8OAM>WGB"../Q%X@9'MGA0[A:Q*/ECSZY)) ^M>#?\%4./VR_AK_'BEMG'_ %]+0!^AJ,L$:A6^Z " MQP!_AQ7F? CG]M/X6?#G4GM-9\;:+:W$)VR1JS3,I]"$5L'VKB_|@I+\5=8^ M$?[*>H7VAS2VM}?21:>9T^]!'(#O(^N N>VZO&?V!_V(OA-\8?@A8^(M8"^) M]?O@7ODDO"'V-L_ZO8#D8]3UH ^LOAC^T?X^_Y"^&/$VDZMC(B23;(?^ , M-W25W!S9XQGK7P9^T?_&>J+U3P\0=#+\1_!,,:SNDN ;BW>ZPML0!8>OZQXCT;X-37D.F_@%46G?+;PR#$EULQ@,< C=S0 [XD_'SP9\M(S_Q4GB32=*8KN$<\P\PCUV#+?I7%Z+^WY\'OS&\1VMK%\TDS2ML42++&K'_M 'F4*/SKY?!_V5/^">^K?!7O9K_BOXV6>L:=OGO M7!WQ[_X)9? #/6/AKJ=UX=T^XT'5+&U>XMYH9W=69%+!61CC!P1GK0!]5:.J= MKK%C'=6=Q!=6LPWQR0NKQR !P5X(K!N/C+X7M?']>%Y-OQ#_;_^%_PLU!M/U[QIH|C M?1':\2L\S*? 1C&K;?QQ75_#*XR>%OC!IK7GAG7M/UJW7EC;R?.G^\A 9?Q%? M//@G_@DO\---|+K%XBBU;7MZ?^AK7% |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}]%O-%'8PQ^<\S'Y8TQG=TZ8YKX+_P"'"R_ |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|:@_;HL_@S\+?#'B+QUI: M^:FJ>,++C2M,(!Y.5)=&P!NW#.<#I7O'QC_X)_"']H+X^:#\3/&G@O3?$7B M_P -0_9J/NK!/.CA7.1F%B8SC/!QD<5M_LL?L%=-\-Z5 M"/E,*;KBX)ZM0*\=#'C'4O^N!?SKZB'>H3[HNY+&WB);DDH.G]* /DT MUZ[^R\/EU3_>2O5/[-M_^?>'_O@? X4^&VCMPWEQ1IN_NJ :)">:*#U_SQ10 M 4444 %%%% !1110 49HSBE48=?5N!{T +'"T\]*!D)9CP .M=MX;T-=(MOFP MTS;_4 ?=!MUKQ'IN_]ENU_:>^#5S8QQJNO::&NM,E ^8N!DI[@.GK M0!ZMX%)9Z=\1/!^GZW!%Q=:=]47G02QXVLI_KV(]0:^\/A @ZH_,GG?#;_M -;?_P!*EH_X)5_M17'P\\??7PL\42-:\).]GF7Y1;S@_/%SV5'O22!%41 M_P 9E_#7_=M\_P#@4M 'W5\5/A7!'OH^'5YXSN%QT&]A_#GX?V?A7XD6> MM6.L:"]F^TK;:VE Z"16(*L.A[/A(H>]:I<7%|',\\EN!))D9 "!)7XFF!WLG],=Z /'!(;"_: ,;$\0Z@OPNTNUT/0 M;64H;AHD7&>FZ5P3N]E%:NN_L5?'SQWX=U"Z\=2%::WL;>VDN)+2WN)9T8!" M2H&5 Z'DBN6_X)]?MV>%_P!F3P%?^!_&]GJ&DW5I]$DR7 M]Q)8 ,LB9##*5Q MP<=,5Z)\<_| @H=_PT:H5UX&^#NCZQKFM:Y&,66I: K%:1MP6'/]W)H XI_M ((HPK>+'/'T:MN6.*%0QHW&3;H:#ZW2I_ ."Q\A|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~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

"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P[_P"#WO\ Y-[^ M!7_8S:C_ .DB5\&^&/ *8S3_|L4M6_E%7Z-_'!EOP1\:&/&W!G2?X*6O@OP MCXH\77-CXCOY+F+1=*GU"2W5K9 K.L2L5!/)QDU\/\ _!JC^RQ\4/A!_P % M9K'6/%?PW\>^&-)7PMJD!OM6\/W=E;"1A%M3S)(U7<<' SDXH _I\S135Y(f MTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH * F[_X/<_ \ D[OX) \ 8HW7_I-U?TA2 M@D<5_/,_ ,'CWI.7Q$^-O[5/P=NO!O@/OGXNM;'PM!?&7A&UOO#EA';3:UHMS!\=PRW3EE1144,0.2!G%?T#*?EH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ J-UR^>3QC _SBI,XHS0!&8\GV^@Y^M.C7:O?\;<#F@L!0 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M4 %%%% !1110 4444 %%&X XSS2;U\1^=#)8M!9ZX']^U!0D\ 3-2:!LT$X MH ;&-H[|>].HS0&\- !12%P!U%*#F@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BC/-)O7'4<=>: M%J.6+>V>N!?P/M3V8(.2!|\:"P'<4 .*$GGZ9IT8YCOU[T[=FD#ANA!H 6BC- M ;- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M44 %%%% !1110 4444 %%%&; "B@-N"-&- &2)N<<'Z^GYTC(2>GH..P[N] M24$XH ;%D+SZTZC=Q1NH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FNN6_KZ72G;AG MK1F@"_I\ ^?IWQ_\ 6_G3T6:]2DXHW#'6@ HI-PW8R_^E+0 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1S@G[MN<|>.]?D)_P5V_X.I_"[#WQ+U+X=_"CP_I_Q \:,.|0:E?WDQ72[";O&\&O MTK+QG#*[GG2017V__P%D?VL+CIBS_@G-\3?'FGRK%K5GL;6>EENAN9R(UQZ M. 68'VK\;?\ @TT_X)H>&?VI/%WC/|H#XF.+#XIDT+4OL6AQ;E$)II);QAYDU MT5.0S G +?=;IUH YG2O^#O3|J3X?ZM8ZMXK^%_A.7P_?2 QI<:7=V:2KG+" M.8L 20>#D@<9S7['_P#!)'_@LO\ #?\ X*R_#*YOO#<<_AWQ=H@4ZSX+/"_@:QX?U*(P2V';C_ (((?\'$%CX?T&_O&\'W&KVlL("<&?2K\A8XWSP=-MA8<]@GN: /ZGH"2OS<'T[#@=*DJ&SF6YB62-@\<@W(P[@\U-0 4444 %%% M!1110 4444 %%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !116=XGU>)0=$O+Z96>&S@>>>15)945FXSWXXH LWTZP0O(S]L<2EG9F M"]JCKDG@#CD]A7X]_P#!03_@Y[U3X=_|%'/"/PA^"47AS7O#<6MV6B>(-6NH M3,+BXENDBD6W*G&U%8@'U!KYS_;B_P""U/[2O_!9?XE:E\#OV;_!>O>'O#AO M)-/U*:RT_7? #U[?3VZD1K+/<0R,BD\M@G&XJ;./J-HX_^O3;J40_S!5 M49))P!@CG/M4U?$O_!P=^Y)*[!%'_!,#Q[XDT6Y-GKVNI'X=TZ=1EX9+K%9M#O'!\F73;K3WE M3(_U,C$ G'(/S#FO5O\ @T;_ ."77A+XE?#G7OVAO'FAV7B34IM4?3?#:ZA$ M)XK0Q?ZZ?#9S(7(7)SQ7[4?M!?L@_#G]J+X5:IX-|:>$=#U;0=6MGMY(9+1- MT65(#1MM!1AG(IY_*@#R? _@EE_P5H^&__!5_X/S>)//|$EQINL:.RPZWH5X^,.MK2Y&4Y&K)&W9P .H[5]3P)Z=|>F;_EQ_8.GU+_ ((C_P#!Q,_PS_M&X_X0 M_4-:;,PY,993MNK"YYMIF'0NIV@$^IK^HZ/|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bDY_ M_7J]' BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H HHHH **** "BBB@ S7E_[7O[67@;]B;X&:U\1?B%K$>C>'=$BW.[':W$A^Y%& MO\!-!CFO]3CL; M])'O6;8FZ-V7E 'S3\>?^#QWXN?$3XEW&E_!+X4Z++#I&\FT^WV\ MVHZI=(/XF2- MHXP2>.O!OQ$M=$^/WPKL(=-+K'&=&L/#6GR^,-1LHK MWQ#JMS;+\)>7-XZ NK,:)JD4"0W+S&0*8-XP6#*6.T^E 'W_P#L]_'[PI^T(\)-$\<^"=8M-MM<\,^(+<7- G=PD893U\"\+#H0>0:V?BX^TGX7>#=2\1:_?6^EZ)HMN\W>WD M[A(!;2S$GIT_$\5^/_/P9>^_ $GB#]B;XE:/j;?$GA_0_8X#2?.4I8_-@ M#RJA/4;\'CH3BK7_ >+_MF:E\OV1O"/PMT:\-K-\1K]H4,,%9&M+?:0O' M\+.>0>N!0!XG^V?_,'CNO2_%*Y\,_L_#O3]7L(YS!!JVMQS3W%^1GYH+>) MAM!]!V1SCFN+^#'_>(_&CX6_$.UL?C/*- %N=)D<-KH')0 MXZX9.;^[?^*#;K @E3X+__&8OV' "OQ%USPU9WWQ&^(-JF]W5[>VPEFL(7_U= MO'N^X ,DX'5B<|U]2 \ !3'_()@?#?_(*'?LX:[X4U[PWI:.._^;.:30]6BM MD2ZTZZ"DQLKX!VE@ 1Z&@#U#]CS|L#P/^W'\!-&^(OP_U:/5/#^M)E<_++:R M#AH9%S\KJ>"#7J0.17\XW_!HO^U%K'P'_;>^(O[.NN7M5M1G6WB9W:.... M-2SLYPJCKR>PRX3Z"GW3!",JX!;(]NU?D3 P/[<_ !=5^)O#/_!0W8C<M%=/\.ZCX,1=-^.]Z_9P=T MT:N$\9L//)YSFO[.-$_Y EGV_-Z01$*@:. 0QQ7H7_!YW^V3J7A#P!\//@GI-Y);V_BIGU[643K?$;Q=I\>JZSJTI[L MDEPIF4.L",1\L;J0!@>M 'YP_L\ |'COQ-^'WQ.CTGXZ_"K36THLHN9-*@GL M-3M!P=WE2G:ZA%_$EN+BSG4; M6&>J.O\ "Z]"O8U\U_\ !9#_ ()2?#O_(*%_LF>*+,\\/Z;9>-=#T^?4- U MBVMQ'<07,<:,J$j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|2}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f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s&FS&ZMXOS*VKZ MF\@'WHXE9#^1%?T_]<^] "T444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %

%3Z;5W;OY;_/@Y$_X*=?$\]H'_(M^_,AS'XDU;1? 'PZU)M)L-'L[HHK>XDC'SW$FPC<[%CU^Z,_5R'{)'_!OI^U-MM^U?|%M%^)7A&PPL]+|-^(0L|B;W76M;JXA)P)EC7/R]2-S D=10!_7@MYFD6C>L*<^ORB-MKE !GF@-D5'/RZCW&?SK^7G_(,$YOVBH_|+@JMX_/@6W^+TGAMA;?9FT6TO MGLS^[^;88U*=?3N* /ZBJ;(P49+!?J;^,_|+@@2WBN3_ ()7_#$^-DUQ/%!M-M9!>C64E2\#;SC>) &!QCK7Y__P#!WM_P4J^(7{/LO@;X.^_I>u@PS8^*M/FU-M77+NPF;&YNXQ)Y2VQ8898S]XX/S9YP'!0!^S6I?M""^]{UAM/N_''A"YU%6V& MUDUFW28<2<+V*ZRQU"WU'WCFMYHIH9 "DB.&5@?0C@U_&7_P3Y_X)1?M# M?\%0[77]8^&-O[]L- E6&|U35M5>XC>8C*Q*WS,SXY.> _.!K^F/_@@?^Q!X M_8(_8#TWP7\3)%E\9MJ]Y>7A6\;[5(W?]VJN>P44 ?;_"?\ A-M8UC6O&7BZ(>(-2EU&X.:6'S@K1PAF/W50KCUS M0!]K45_)#_P<#? M/_$CP' P5N^'+VDZ+XZ\;5:9!UKJ:K!;6NHRQ11C8O"J#@? MA7S3X6\,M#@U30[KXV:UIMT,PW=C#]%Q!+V^5T4]?P- 'JNE&X9ZU_$ M???M+?M1?L]W::A? ^*_C)X.D9PBS7LU]8IFY(&7"Y!FOOK_@D]_P=5_%/X"^M/\+_'C5KGXB?#^[GBBVEUB[_>:QI(9L>=%6FNWU5N<=*/Z=LT5B?#_,:=:M3\2O!VF^(-#OH-2T;6;6.]LIJ%!\=Q% (H9&\]P1].G;ML'G% !111GF@ HH+ M8IOF+NQN7/IG_/H?RH =10&$00e0-44@8'N*'X'<4 +10&W49YH "V";?]H'T M;0\ "HY/G9=O^/0U_/W_ ,:';@;XG?'LL?M$^:?C5X$\8>+-$'T'Q3&EA>P6=_M+';6]];8;-B@;:H=0.YZD$4 ?Ts!LT YKXY_X(D?\%*+/_@IO^P_H?BZXDC' MB[1<:3XEMP>8[M !YN,D@2+A^?4U]B(,?CS0 ZBBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "OYYO\ @]T_Y*;\$?\ L&7G_HZOZ&;_GZ X_M/=/^2F_!' L%WG_HV(@#\)]2*0+N"-C. W/WAS@(+)M?U"?\ !K# _,%6 P#A MK_| 9D'PA\8:H;CX@?#6W6.T>:0^=J>F9 1_=H^$/? !fBOS%_X(U_\ !,.P M_P"'"FW_|+7]H/1[6UA_X3SPGK<&J^&;HQ@QYRVN6M_W90-OUP?6OB7]BO\M:I\9_P#!-?\ ,2\/^.=-6ZL- ;\&ZH8M6T^1F3[5$&*SV\B]\CEC_C!SX:YZGQ3)DXZ_N17R9_P9/G_C,CXM_P#8KV__*4-7N?_=2_M)> M&OVO/^"3WP,^(WA&[6\T+Q5K1OH"#\T6Z!=R,.S*W!!KPO\ X,H1<LKXM?]MBO;_/0U 'Z;_\!U;._.HO%GL-'Q0TOOGX'UR]\.~)^M%?S M+;_M6VRP$<[Q^% 'IY,:^.?^#@8_\::/V@AW4D_^CX;_F8E_P"=0#O!FOf.?VA? ^2!>./^Q?O_|TFDH_A>T[Y?C3;M M_#_;:|_]MQ7]T'P5TBW'P=\)_P"CP\Z/9\>6OR_N5]J_A4O]3?1OB/<7D:AG-ML]1:9<|,K(3SWQO7[.>%?^#TGQ]X0*:7HZ_!SP? *NFV<5H)&OK@,_EH$!(# M]3C/XT ?K!_P7D_8X^&_[1'_ 3@^)=YXIT72(-2\,Z1+]NF;OY*1W%A<1D$ M,),#@!"#Q\U?R=_L2>+M2\|-? MC?"W5M)EFMJ2L_%6F>2\1PV6N8U*_BI9??-M?7G_4N_P"#D;XX]*A5/X%U2S\/^"/!JY}C*7.M4:7C3_L_6E' HPU^_P#P;7#/_!93X/__7W- _P"B6K|\/^#JW_E#EXT_[*EA-M_P"C#7\]?P(^/7BS]FCXH.7XS\#ZY>^'?$VBOYEG?VK;98*1@X_"@#^\G-?' M/_!P,?\ C31^T$.Y\,G_-'PU_,Q+_P<%_MA;_|-DNGC)?\ MYKFOC!_P6E_M:<_:$^%^M>"_&7Q>\4:]X9\10?9=0L+F?=%=19!VGC/4 T 8_P#P2"&/^"GO MP1_[&JU_F;_M@U6\CL;,2;:1(88D9WD=MJHH!))/88!R?:OXH/\ @D+_,I/ MO@<CT_P"1M>G0\FO[* VHO@_=?M ?#O9X)LM>O?#@-QXHTV735>IGXUTZ5TFLQ(_-MI9588/&1^-'XT_|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}?:' M^S_X1TO^P!+-VB77=?C:2.]P,!XH 0D;\ C=DD)[6 M;QIX;\#^,M%\P?:88[0V$QC[A'C(,TRI'J#5O\ X-.?^"6W@C]LOXF^-OB9 M\1M'M/$FB^ 9K>RTW3+]

*[34FO8=1U/_?Z?4^V$>Y]6V[KV?"-]HZ|GPC?;.:D3`MH.I_[_3ZGVPCW/[VX]>SX1OM'7L^$;|34,1^_;|342">IO[_3ZGVOCW/K]&W;QB/WI?:/&(_?M]]Y'4MX'4W]_I]3[7Q[GU^C;SU\?OVCKX_?M-0QU7M4=3?W^GU3]KX]SZ_1M[\8C]^-MWVCQB/WI?::.A .IO[_3ZH^U\>Y]?HV]]?'I]/:.OC]^GM-0:]AU'4W]_I]4_M:Z/==>OT:?NOC]^GM'7Q^_3VFH$#J;^_T^]KH]IUZ_1M^Z^/WZ>T=?'[]/:.?MU:\U-_?Z?4^UT>Z]?HW_]?'[]/:.OC]^GM-/P7L4=3?W^GU/M='NO7Z-P/7Q M^_3VCKX_?]I33X!U-_?Z?4^UT>Z]?HW\]?'[]/:.OC]^GM-/P7L4=3?W^GU/M='NO7Z-P/7Q M^_3VCKX_?]I33X!U-_?Z?4^UT>Z]?HW\]?'[]/:.OC]^GM-/!AU'4W]_I]3 M/]?I[KU^C<-U\?OT!M^/WZ>TF\?'[]6Q!=3?W^GU/M=!NO7Z-Q/C#(/?)!1XPSWR>T MTf =3?W^GU/C#(/?)!1XPSWR>T MTf =3?W^GU/C#(/?)!1XPSWR>T MTf =3?W^GU

M[ERG<93]!6_2U6D|16ESE='1UD<\;+|KUK%143U9CS\JEG\.FPLI=4;9O"\+MZL!9:=[D[^]>CDSZ\2K|/4,,.JK&RIL;ZQ_DJ^U[=&T-F49\4Z5QIKYZ3'FQ M@7L,C^C1T;IAJ*
I46J=2TTE#9J5[*BDI9FX?6/1^DU8&Z)L.D].K%>J-MFNK8J>HJX7Y@@8YR(O"Y/=NQZ.2>E>PL9N3=WJK-JGLXRL;$V;C;E&9E5QI, MZ4T|\ZZ?
KQ7AOHQK=GM8X1$_]%5'=_[-QK)-G&^]_P#N.ZR_BJH_JW&L;6NG',JVT%EHJ>5*JH3#!%5SVJC&-]*HB\U-MY)Z^P\K5-7E,"HMVHU|GYL @;.*,H=;90T;;=]#5SU",
MX5J)*UZ2*OOE1JHW$+1%B#V!MFLE^L%5-=+'&Z=?%4(DU%.BKA'<K4_M1'LSVKA%3*0314RiW+6]+9 M+#6ZYI:A]=
(B/6V4DJ,CB14|R]Z(JN=Z>%41/2O:7GJ7H4: NUO='iDK;)587 MAFCJ'3-SW<37YRGJ16KZRK.U+%-6[K,^/8Z=O^FLVNWO<()\GBP"!74;]"A)D#5SA$3*
<3EPN&Y[E[$0Z,WZ*:.DF?N|[S]&'>KO^STTSOZZ;>*/E[^] M]BTX]XM&M_\E2G_*:&8]DZ%VV]OH$BKX*ZZ38Y5U%6Z-<]^$CX41/;\;EN MR=#^FT?
N'IK4FDJR91%1W&&;IMU8Y'.9&CTXGOR;IAR*|H.E M-5*3,<)>KL?TIF8]RB%5.1.;Q$\)>;6^D(B,Y+5UCR3^YLO\14UC&SOI"M_]
MQ/67]MLO\QKIV|T#==R]54=@L\;7550JJZ21%ZN&-.,I'KW(B>U51$YJAKV5 M5%-BNJJ>$3_"U_4UFJYE6J*(UF8X>.V%.#//2O0?T-::5GE]HKKY4X^N.6;]
M(LX^U:SSD3XW*5>X="_;&M@6."CK;&1?^FIZYZN3\-7)^8WSM6SKIQ\G/I_1 MG-JC>G=CPU:)0O8I,>___$=+ALO405E/4.NFGJI_5Q53FHV2*3"]DY<-
:B=ZJJHAM5HB:N$/@O8=3-/;'H,6IEIAJ]:5U34U\L:.=0T M4B1QP*OVKG\U>Y/2F$SGM[20']#;:R2-6MM-2Q^,<;;A-E/7S=C\QQZMJ8]-M6G&?
@]79_IO,N41?.E.O9,\6NPZ&3^_/0]306GZK46E]VH&[=<66]HZSA66 M*/@>QI41'(G>BIE$3.5,8#H6+IO(WI<\'$S,&]@UIEVG2?W_"O;.L=-]776 MG;/5]8E)
<+G34DW5KA_])*UCL+A<+A5-M571TS5*I:HF[5%N.]%12UCY=K)UW)XPY^?LO(V?;=+'"">4QR4 MD$B[*[(WO>G4+Z*VXI;?3*C]VXRM560-7.$1/MGKA<-
SWV*X15UXJ.UU145;H^??AL?"F/CROK->1G6;$]LSQ\%C"V+E9U'241$4]\\/ M)KS4X,Y]P^@?IRYT4L^D+A46BO:F8Z>KD6>F>]V*JIQMSZUU!2M94TM?
<'HU$66HGM5R^G#.%.?QK>N"S8]W)G6?!:]9HBY1R#Z.76 MF(BGOGAJUV'"]AL$<U-T%)OKO1^),EPLE3CS)(GKV9_?-DRJIZDNR-=.&B200\$;#(WU+A4QW*BIW&6-
FVLB=VF>/BU9NR_MG B*]D1NSVQQA:(.J^C%T8](QO;=S7R^2W%E6VMEID2D|&L9P.:Q4Y*Q>?G+_MWEX;#GU6KLQKNZ\BPVZ8'V16K_(Z3]$@(;)\Z
M2,5GEZ6=YBORRLLTE50LJY(GHQS(U18$/'G+ CY;-ZJR_U-^?5Q6N MWLCC8M)(D;GRO55[5:O)&M7*?OD.A=R*;-$W*N4.+CXES*O=!;C[TH!!D;TK M=C]%;*T%EH#-
<);O<9G/5*NH;(OD+$P]*,3FKG-PN?M7&.1%B]37>!HBY1RE M&7BW,2Y-FYIO1W!FAT(MSM(:)VUO-%]'4%MM-7)=WS,AK*AD;G.6&%,)$5>S M+53Y#*\"RAZ*G1]TGO-
H:Z7>_2W&.J[(DZD8E).UC>!(HWM" "8>E)M+9]F]PZ*R6-]4^EGM<=6[:N5)'|8Z65BX5&IRQ&W-MN})1-C]D+SO;J5UNM[THK=3HCZZY2,XF4[5SA$3*
<3EPN&Y[E7DB*IGC7+=K-M'BK7[L1VM>98OY.=5;FG[\SRA&Q?_1_;Q;V:(;_\KT_]-#-FQ]!G;&UV]L5?-M35]WGQYU145CHU5>_.#8^%$3VKZU+;EZ%=+HS/[C36^@II*NNJI6P
MP01HETCW+A&HGI53'9$Q%FN9[_X;OZFIHK(MT4]W\O*=5,Y]]>-@+9]2VP5FN-MZZHK[A(U'/M]#+U4$62M7/3SG]GI;K4[>WM+WN_08VNNM$^&CL:C.I\]BFK-MGO$SQ:X
2UOWT=+WL;=(5GE;=+ M'6.5M+2HEB[=V*FU3K[3-FK%D2CN-TI:.98 MW<+^KDF;QW"N%PN'+CD=&G(HKM]+3.L.%U%>C55KL*G-.;+S145%-MG/LWJ9JB>2KD;
(R<2NFFY M$?>G2)CEJG#HH]$NQ[F:>]!8;GK9*JW.G?'#;J?.;/5CL*LLB+G"K]JW'Q]Q M'O3'L-OTUO76VVU4<%OH*>AI6Q4]-&D<;$ZM.Q$-ANUVVMIVTA3Z=L;JB2A
MADD:ZJD1[U<]W$N51$[\-5?D4EOIQ[HZ0UOM=.:'3VHK9>*],1132 M0452R1Z1I!.U7*B+V9K#++7UE1/&7N7UKR1$[55>2(BJQ)#.',3P?>G;?0P5&M;G576X.:BR45#)U--&JIS
M;Q8XWX\BM^(Z61EVL6/OSQ[G P=FY&=,Q9IX1SF>3 D&RBY]!//BX4ZQTU'M<;,(P^G6TI>]SDI>),)/S&(O2*Z+MWV+EIZ^&]=>M.5+-^!EU6M1/.7T<2JF?
0AOR,RUBZ,\\9[%?!V9?S]>BCA';/)K]!LPJ.@S MM+4T[HX{564LCDY20W"57-^+B54]J&+G28Z(L^R]N9J*QU\UYTTLC8I_&D;E M12.D\EL= M#G[(_1W^4J?
T68S=Z:S4^E]/],A,(NAQ]DAH[^'4_HLQF[TUOL:=7_'M1_ID)S<[_FV_I_=WMCQ__57_-?V:N0 >GAX!T/Z[5.:R^7.EMMOI*ROJY6 MPP4)+Y<(U$]*JIG-M/X/NR4=LAKM?
5]1<+B]J.?;*&7JH(TI9&9:Q8TKET\'9U_/JF+4<(YS/*&\R]BG4V67?H&[576WR045+<_MK5.ON:FFKGO*W4:_M=4RCIYZECHW,=*U]JY$8GFHUSE5E5YX[$[#R[H M>#VTO=+3-
4;'K*FR72-F8Z6KF6>EF5$7S55?/8JK]ME43W14ZTQ]_=UGX]CH M_9_,Z/I-(U[M>+7TIL3Z(6\N@M([\Z645%^4U]W^Q5^F+W66FZ4LE%<,.5T%13R)YS'M7"IZ_C3DO.AF-
T;>AYH7-M=?9^RZGO.JV9<;M]0V1*.I8V/S)WL,A%8OPV)&1;R;J M.5,35I/">',"NEGJ.V.KU^U7=K-T7RJRMM0M+U-52R(^_.#20M=AR=N'-5/C
M127>B3T0[%NAIRGUEJFMDJK;Z>2*&TT^8T>K'8599$7.%7[5N%_?=Q'6L=E=.MV'I7Q;<4IZM=//N%%2JZ25%FX)H87O_AQG.CL.OK#7%TTK!;=,
[Y5MLM%%3V^W4]#2MBIJ6-(XV)U:=B(04,3=W.B/HC=?5 M%7]>]2W-ERDA:QS:6I8R/#&X;R5B^CTFKVSVFMO]SI+9;Z:2LKZJ5L$%/$F7 M2/
MNU_=;B2MD;QNM5L>UD<*K]J^7"]J4[^-%$3/8IS64:KH&[155&:KH&[155&*&U5U-,yo M'E1'<95>U??(CE5N?C:}>HPKVMCTU;L3,_'G-,7=J+N4]QO%A,\6L(&3'2*Z
M%5XVDMM1J+3U7+J'3<*+=0DC$;4TC??/1.3V^ES43'>U$3)C.=*SD6[|_;G M6"R<6]B7.CN4Z2Z V#[==!';?5>WVF[U6SWMM9[A3J MUPF54MK97P?=':XV"NPO5U4-6Z=
M.+'+B;([\2>I%:OK0P.W]V9ONR.KY,#?&-D;YO6TE=$B]54Q9PCV^A>6%;O- M%]6%7?C9UG(G=IGCW2KYNR^%A O/:7.6_]R:O@>T]^!KYW)UD] M1(]H#31([Z1Z]R)E.2'4.U?
J*O&2 M-W>U<+ZT5%14145"<;-.LY.L4SQH1E[+OX4157"">.V.2U 7W(2/T>]FW.Y; MD4^F?*.6F%87U4U3U%6.ZMF,HUN4\Y<]ZX3UIAE-TK-@-&,*!'!U/ENV-,6R M7.E;/D]
MY*":UQ5CG5LJ2/ZQTDS5YHU.6&-]O25WHX=#,_;V4*7ZYU;M/Z7C]KM4V8O53I3+QM.!?]OSCT4ZU1W?-CH<+V M&T*U=`:&WTK8]FW&Y2(B(LU1<9&N5?3B-6IS^(C[=?
P<5CK]&IK-_76HME M>U%>RW7*3K]=_+DQLF,-GQNX_D[2A3M,'JTXQ^C]5_T_EVZ=Z(B?")XM?@* MGJ?3=TTA?;ZRWFBEM]TH95AJ*;9,.8Y/S*B]]*G)45%3DI3#M43%?
&EYVJB; ME=^K=]BHU')<(WVR:G9#XC4-C3'#V*]BRQV?M"ZNAWT5-&;L;?7:IZCEN<=92 MW5U\&E%4-8S]TAB>F45B\\O7\Q&G3 V7L&QNY=\BPSMC\Q.HM$5;1;V5)'18
MZ:=BX5&MY8C;RQZ2O9BQ[=5,3.]Q^"Y?G(ZKB*]8W>&DZ\>.#CA>PR/Z+?0[MN&_%+)?XO72632L.]PMFA8BU%6]/=)%Q]*F>2(N%QEW;>@%LY2TS8 M)
[5<*Z5O;-47*5'N^/@5K?8ANN&GKCPKU763>,P*OH>UWGX^) +/8IKXU[H6\[;:MN.FK]3> M*W2@DX)&HO$UR*B*U[5[VN:[*B^A3?C9UK*UBF>,=BOF;-OX6DW(X3VQR6Z"
M;NC3T7KSTA+O4R)4.M&G*%W#57-8NL59%1%2&-N4XGJBY5KVS2W33]7CZV^&IZ^//[YDB*JIZD M=EM=5VE[VC'SPHDL%1%^UU,+L\$C?
0BX5%1>Q45.XSQZSE3NTJQH:\S9=_M#B*K<)|862O8=3,7H<]$[16^VVEUONd);I'6TUWDH6)15+8V=6V"|4ZVI MYD=SSZ"X^^#\;=]X+A0TM976C0%#'
OCD[FR557*YB,>R)>%&X15YO5,)V(C MESC7.TK%%=5NKA-+=1L?)N6J;M'&*N7U8- VI4_@^]FXZ!M,ZUW&>;@X?&I+ ME*DF??814;G_.$<>HQ&Z670YEV'I8-
0V"MJ+MI2>5()/&D;XQ22+GA1ZM1$< MUV%PY$3"\E3FBK%G:>/>KZ.-8F>]E?V+DX]N;M41,1STGDB[HT_9 ;>_QW2_ MUB&U'I-M1.CUN#A$_N)5?U:FJ[HT?9
;>_QW2_UB&U+I.?8[@_Q)5?U;CE[M3_Y=V=S8L?_AO?K^<S>]5^CCT?;SO_K9EKH^.DL]+PRW.Z<,6T]2KR:G<
MLCL*C6^I57DBF8.XG0CV,VNTC7ZCU'=;]16^C9ESO'8U?(Y?Y>2)-M_NRIV+N?9L5Q;GC5/9#$]C9F1D6YO1I%,=LSHP5V@N-+9]V=$U]=/'2T5+>Z M*>>>>5W"R.-
L[',Y$1%55]1LTWNZ0FV-[V:UW,;?KBPUE?5V&N@IZ>&NC< M^6 1]/(UK&HB\U551$3UFL_25FLFM=W,%:*>EJJ"P76]4U&V!\Z23QP23-8]+ M)PHBOX57GPXSW&
<.ZG0#VUEJ45!/>UKK5:*NO@2:M8YBN0>9\(TRF M6IE.E#/Z&JL;FL,Q/9\?5V7]138NQ:IB8[=9\.QKJ.%[*=NASLKH]?7T2US%HI6QOZQL\#$RJM=RQ(ECT&9?U-
?:C'1MZA_'8_FBW?VC9 MQZNCJUU<_'V3D9='2T:.?%]\!M#^1L;4?=6H?QZ/YHBCI0]"C;_9[92^ZML4 M]Y?
=*)].V)M?5,DC^N3QQNRB1HJ\G+WF%O:MBY7%%.NL\.3;=V'DVK=5RK32 M(UY]S!)3]93=",HT:3Z05/J]^IY;C&ZTN14I_$*AL6>L2;BXLL=G]K;CY3S] M-
OHWZ4Z/E1H^/2\EPD2LJW5'E"=LN.K6'AX<-;C]L=GV"U(;,Z?V;_N^FJC MU??]F]PX.GKST8PQ"EP;?6.GU-KS3=GK%>E)<+G34DRQKAW!)*UCL+W+A5-@_M>X'@]-I-
,Z$U'>;2HORU=OMM151-DK8U9QQQ.>W*=5S3*(,C,MXU5--?.3$V M?>RZ*]]>FE/-K.!5-)6V&]:HL]OJV@C5POIPIL+W$\'1H: MX;$OE9IA+[7:BAIH'4%-)6QN;)-PKP-
5.K3DJX[T^,G(SK6-5337VF+L^]ET MUU6_^UK=!LDVF\&OI"TV6&HU]75=^O3V9FI*,=8*6)53W**U:.ZJ[!*(OO3[M;L^#;T7=[!4SZ$FK+#?
(HU=!3U52M12SN3+1_'ES57LXD=A,]BE/K;&W|S6? MCV'_ %V6E1*OZ1\-+6]=#.SH]^#CB]3:UE7.5@HWM9*C<]L\F%OG
MWC>:)C+D7*), ^I?!R[17[URPVNFNEAK%3,=73USYE:O=ELO$BIZN2^M":]JX MUNQ=UF?&.1:V'E7*-[2()\GBU6 O[>[9V\[&[@UVE+RYL\D+6S4U9&U6QU4#
ML\$C47L[%14IG-VAH*9J2W&Z2LXXZ2-TIZE\"M#=Z%T=O@NUCG^UGH MZ]TBHOK25'HJ>SXT.5UQ8UTX^3N=0Y6FO#X.M59L\%2U%L6XG+/]DT?I"4Q
M.Z1_1WO71TUI';^H;S$-M9326JY550UG"M9+@L9%O(HW|U<*UR+E%3UY/F#">_M3*F=*F^/;?4OT:,;>Z;OZ<*+=;935]V/9]LC!H":,5_6* MRB=3HOH2*;2-$^1&(GR$VH?,KM.
[]W:YRK ME54^8:#]"I"_,5<[U54NH # `"]AU.R]AU`53L=5"8<)EU7M4!>Q0$A MU4[*50."LZ0TI<-;.BHK):XNMK*I_W/)K4QESG+W-1$55^(HQE9T(M),=']M#4LK&J[C;00.
[TPB/D]N8O84\]H[/:FOM=C9.'[?ET69Y3S^$VL MM\7B=-'5W5S<3W*=]+']>]&^\;ZD["9RO,XU#T@]OM+5LE'7:BIUJFKPN931
MR3*YPJ*L;51%3T*N2Q^EUN76:1TG1V6V3NIJR\.D;+-&N',@8B<:(O2YC>B.Q\F"%_^C!0UEMJ=0Z/HFTE= U9)[73MQ'4-3FJQ-MM^U>B?:IR7'),]N*5AOU?
]JJTMTME3)1UU*)(HUPJ*G#Y*G8J*J&R3;O M53-<.'LU[8U&K6TS9'QMYHQ^,/;\CD5/D,,UFY[.^N*Z^%W#E6/ZALUV,BB M(K8~=B_>.UK)-D>%5.5VBTBJM3^YD'!;#![W?
W2#-%[L7ZWP1]7222I50-!D9 M(U'X3U(Y7-_T3.38_GM%I%/_),.@_H(6-I5Q_52?^YC_J8R.Q:V:.KMQ5O3K,09/)29-G(KM1 M;B8IF8[>R=&S;5.BM-[DV;Q:Z4-
+=*.5G%%+A%5]*G)\;TYIV]K5-?&[FWIR&/?34K()MTZ*&+A66"V1ME[MBBAC:KG M/P)B.?']V&EBL=?]6[TMKME+)65]5(D<,$:
M95SE_F3O55Y(B*]FP+8C8ZW]1V!]RHRKO]4Q%K*Q$[._]F>AB+^.$]97N1*1T M=-@]?:ZU)<[G''4:F]V279$\]Y*9]\^J8OI]\]O7EV(6UTF.D:FD65&EM-3_^_MG')PU=9'_P#
VJGN6K\(J+V_:IZ^R.B_7F7:AL\D;-P+.Q\?VI,_'V1W>$>,.MO%TF>D@RP-J=)Z4G1;FY%CKKA$[^U4I%C8OPGI7[7LIU[G#!%SS7FIRI[I'_M+C2T%)& MLU552L@BC;VN>YR-
:GRJJ&SG06DJ;16C;18]=&NBH:=D*N1,<;,D3+G_&YR]I MY3#/H?Z# ^BC>]XV(9)=)#=B;,O2-#4T2HMQJ MZ^%L4:I\;')+\BM;P+_)0X>T:ZKUZ+-#V_]-V;>)BUYM[E/#]
(^%,:T\BHUWQX=P+ZDXC"-3:5/#;M>Z,>QR^,VN]46_^_MBE9R5/D<:RM6ZI4P]>I2QLJ]K$VH>< M?_4^'%-VC*M]XX_&/G"D]\&X4F,HP;-0,I:KJ*N[1N?8,4C7SQYOUTCL
M\$7IQR55QW(B=Y+*F>_0YL#;5LQ2UC41LMRJIZAZ|Z\+^]3\T?YSF;0O39L3 M-/.>#TW]/X=&7F1%R-
::8UF._3ZK\U9KS1F5EJH8[O54UDHW9CI:>&GI;CO)/1R/58[=1PP,9W)Q)UBK\:\?YD]!)O0.O4\UIU;:G/S3T\U/51M]#I M&O:._^J:<*K$FWCQD15.]PGS>XL[4IO[0KV?
51&YQCRYZL;-V=NZK,_7-PL$[-MUFCA5)*:=4QUT+N;'?CDOK12^.B_LO#NKJV>KNT:OL%]1KYX^SKV9X8L^C MDJNQW(BT\.&D+ZU9
MKS1>SEJH8KM5TUCHW(L=+3PT[ERC<91D<;57"93GC"905=MT?OEHAJ\-->[+ M5M=U4[4PZ-W-.)JJG*QZ+\2^DP\Z9=ZFN6\T]&]ZK%;J.&!C.Y.)JR*OQKQ_ MF3T$G]
N]3RVG5UJ<_,%--3U4;5[G2->U_\ 5-.=5B3;QXR(JG>X3YO06=]4 MWJH5[/JHCEA9'7Z5O4<:=9+'/22O[\-5CV) M2%F=#33MHONX%U?>**EK8Z.A6>+QN M-
'MC>DC$X\.Y91%7GW'JX\/H\3D[+B-ISB4SI$SP\(GB]/1NZ.]?.MK2YTFI-14KZ33D#F50P3-PZN5%RB(U>R/TJONDV);YJ9;IS1M3:'6B(U/BU MF/\
J'EC:MZ4&GK1JZRZ8L#H.Y<*^X4])-/"_BIZ9CY&L=YR>[?A5PBNW::[D:1/"T#"Q<3&Q;MK'JWIB)UGQT: MO%.#E3@]M3^:\Y%QKN4VJ9KKG2(
<;Q>_="G;VZT[V6Y*^T2HGFR052R(B^E4D1V4]2*G9VHU3);,FK- MB"1O6TE;&F&5$>><<6/M53L5O:MTC04, MT=)14LE0^KK9$XDA;J1HF&Y17.547">IB
M5!H'3U5]72]5/4V^EPZJHJE4>]C%7'&QR(F43*914RB97*F,AW;%^C(HW[<|-M'B\W!O8-SH[L:3^]A3J37L7T8;SN]"EUJ:GR+IU*U*QS..2H M2N7DB|F5143)RU]"
[;2A@&IIJ^XRHB(LU16N:Y5],&<*?F]B]>VA9LU;NNL M^#8FP4S.FO[+7P#-K+'&WXU5WQ&'=_TY<-&Z@J+1?*&2DKJ.7@J*9ZX7?I\E3**BIS1R9145%0WX^
M9:OQ]R>/EJ&+%/"]T*.3]ID/T6>CO9]XK??KCJ!U;#0TZ&.;#]K(IQ8R^&[/CQYZ-S-23R M;0O:QL64]S(]457.]/#A$7O4DYW0VV]>CD;9YVJ]8XFW";*>OFXK5[4LT5;O M&?
@Z=G^G,R[1%;EY)GO7D95VKH4;84%(V" MI[*ZX3-[;BHKGM>OR1\+?S',O;0LV:MR9UGP>BQ-AY69;Z2(B*9Y3/#5KN4Z MF<>X'0-T_<+;)-I"Z5-LKV-564]:_KH)%QR;G".9S^V\
[XC"R_Z?N&EKS6VB MZTLE%<*.18IX)$YM%$]>;LR_@3$7]>$\ICC"GG5> MU2S=CNCUJ#>ROF=1N,;]2O1E3@Y
MMQ:Z1G;@RX7F=4\^6;K6)%7ES1(^'"">K*]O>87L^Q8]W9G6?!:PJB9691TE_M:4]\\-6O8&>NN.@?HVIT3G::K;RPUJ-^MMDD\8IW+^^:[SOE1W+T*88;A[=W
MS:_4]18[_2^+5D:<;'L7BCFC7.)&.[VKA?6F%14145"/KM3!%S/LVKG15 M\)98^Q\G*Q^GM1K&NGCST89G0V*6?H0[96^WI!4TM?=,C'.IGK7,.EXO\ I%>B)F-._EQ)R]UW:K>U
M+-56[K[\5][_$/[WJ72:15X1.LL3 9[&ZT>"_BK3;6?1-45= N#F^>L% MB^AC6X=\KG+GT)V%'!WAZ#%D\A55PT--54=RIXUD;;:F59HJC"*O UR^YCVJU55PK7)A47T M&
<&V70OT%J_:W3=[K.B[-K+C;:>KF2&J8C.-\;7.X45BX3*^DLY&5;QHBJKM M<[!V=?SJJJ+>FI=[!'L&9>V703I:VKK+CJ^JJJ>WNJ96T-K@>C95A1ZHQ\SU3
MDJM1%X6HB\TRJ[+9.)%3U)A?6A4G M;EBF=-9ETK?].YM=&J[$>$SQ:[CJH(&\NS-[V5U/Y)NR-GIYFK+1U\+52.HC M1<91/M7)RRU>S*=]*BK\=G=G[UO-
JZ.RVA&P1,;UM972IF.GBSA7*G>]IB-3 MM7T)E4Z,7[?1+K%O<3V.ITWL^1,_KIHL0&P_3/03VYM-#$RZ^4+55(GUR:.M:I6%KE]368PG[ROQ>JF=!?;"Y4]QTE-
<;?)CE+2USGJB_%(CD_,Q>I*>DJ:A+C:Z]KI*&N:S@XT:J<3'-RN'-MMXFY[E1R*G>B7IT1MA=-[W/U4FH)*YB6SQ7J/$YFQ_MG7<7%EJY_:VX^4OUY
M=NFST^NM+B6]G9%>5)H15X_#7]F/!U,WKIT#;14;CT%+,JFX4VE(J3K]VHF ME.^:657N1L4;*(G),JJHN$^-"],S=$G:O1VYM|OL$-=:JK,2OF9+%6N?UDB
M)AC%23*>YHZ>,R99*3'C=R>SCX57W,&Y3B>QO01..]R+F-.,@OM=;,...MIKANKF3JC&STU5$F M&3PN54;]&7FG-'(J+V*U>U,*N>-G6LB=RB>/BPSMCY.#3%=<1-/?#)OP;\;/
MEW"RF<);_P#B3CPD34._;["8Y7#_(8[>#=7$FX7Q6__(DE7I,='VX;[ZDT M53Q5C+=,:,E:.^NJU:CWIQK3\#&,RF7.X'\UY)PJ]R+PKER+6T9KKG2(^3U]
MC'JR=AQ;M1K5/S:U@:);#H.,44E%'3SV^OK9FMPM5-7R)(Y?2]_5K<_$TQ\Z M1/0QFVVLT^I=)5E1=K)3IQU='5(CJBF9\(CFHB/8G?R16ISYIE4ZUO:6/=JW M(F8GQ>:O;!R\>W-
W2)B.>D\88^[=?NA:7_C2E_KFFV3<9J?L>:EY)_VH:DD-HI%1DS6KS19GJB*JGVB)E.]47*)W M+V3;QZ8JKEY/&P;^;=FBS3KW]T,,P;*ZSH.;35%++!':ZVEDY[,TKK]:*N2]Z7XT;)+
(U$GHU541O6HG)S5543C1$YKA43 M*9K6=I6;U6YKI/BOY.PLK&MS=TB8CGIV,>E.#E3@ZKSH%[%1*K>@1MU'8IZ
MF'6^2538'21L2K8Os_@RB8ZOGS[BED95O&W=_M=:!V;>SXJZ'3[O/7Q:\P9R M[-] 2U-M%/<=PJF>>OF:V3R51S=7'"BIGAD>B<3G>GA5$3GS=VEXZSZ_WMZ
MMCF6"6NT[<&M7JYDG=4Q*[]^QZY5/X+FE2K:F/35NZS\>QTK?]/YM5O>TB/"_M9XM=)U4NK-5TR*]SGNX8X8TQQ2/=W-3*>MSW M.DZ'=G>UTT[=5K
V$;$\'OHRT4<;M47*OOU:[(KVP2>+4[5Y*[(B9>O>F5=S M3N0KU^Z/&UUTH716^'XV>?M2HIZUTBY[LMDXD5/8OK.7UMCQ.G'R>AI_I$_] MHWTTB>
[7C\FM=2N:#TG+KO6=ETI!.VEFN=7'2MFD;IMC5[D3B5$[<9)WIZ-M>HIB;^*2K>VZ6&J?P4MV@8K6J[&>KD;E>!^$5<95%1%PJX5$E?H,;$ZIM25?^BOHO9K8C6U;2TOE?
4#;+4JZ[U[4=(U>]7/5M[(TI>SSL+A M7*.[S=!K+2M'KC2MTL%P61M#<:9]-,L+D:_@[=^8Y6SJFBY,S55/\/1[=V7T=%-RQ M$133'S]6-H)@Z//1KON_-TG?#-Y)T_1O1E5=)&
MU$7,^S] S.8W4+8*RBN%TFIZFJMK>]Y(^%N/D.ID;0ZL6Y5.L^#S^'L7)S M*.DIB(#[Y[6LT&=^'?[>@[/46RHKM 7*H+'G&BO:,Z^5)O)R8R141S%];E<
MGIQVF#5TM=79+C5VZX4\E)74DKH]Z>5O"^-[55'-5/2BHILQLNUD_@E6S=GW M*J*;D<^4]DO(IU;S>C)T1M#[N[3T6H[Y-=6W":HGB>VDJ6.9ACU:F$5B]WK
M/38O!_0W?/DM=LI*VX M5DK8*>GA3+I'N7"(AG5M7X/"PT5OIJS7E5]KC<78<^WV^1(:>/TL<_'&]?6U M6_+VF_(S+6+/WY5,+9V1G53%F.$]^:R5$54PO8CTY*O)4:N
M%718VC9OU;D3I/BNY.QI7. MQW#1U+(V/IWU\>%%8R:C ME;AS>:.;R//1C4IP=V,=)(UC& MJ]IEPC6IE57T(;#], ^#WT$FF+,+?;HI=O%
(W5KH*QC8DFX$63A18UPU'9QE M>PRRK7:%[%*OJ^*T0ZJN\>G^N6R1U4A>Q2Y1.]&KG54[DS"NZ!TC-KS6MDTW#4,]KI5Q4C9 MY&JYL:OSSL+A7*1GT#M@]-
:YM2:YN4E)JM55\YZ]ZF3I=-*[#P;4=]]6OE==U+9_'IVR8ZM(^'-MAPUN/=NS\A8W1]Z,NI=_KC.^BD;;+\22)'5W;9O$UCL9ZN-F4XWX5%QE$1%3
M*IE$7T%O+M39Z;?2GQ>2N;/O4Y/LT1K5X?*$# F&F_!];66CCN:7*^U'# MY\U15K$BKRYHD:-PGH157M[5*5K_,'7H;]4$C[*U]=INX-;],;>)%53N7]\
MUWG_2CN7H4HQM:Q-6G'XZ.I/\/YD4;W"9[M>/R:XE."[=S]L-0;2:K]=/:C MH_%JV)$>Q[%XHIXU5>&2-WVS5POK145%1%14+2.S17%=,54SK$O.7+=5NJ:*-MXTF
ZKVJ=B;.B)LS8M\=R[E8=0.JV4<%IEK6+12I&_K&S0,3*JUW+$CN6/0:-MIEVFS1-RKE#9C6:\F[39HYRA$&>^O?!WV1^HM-46E*NXTUN]U'W>MK)62]3 M
Q&*1HC&^>Y55$SGO7L12^-2]#@RUZ2JYI8KE;THZ9TTUT;<'+(QK&JYSU-M1R*SL157S43EW'.ZVL:1IK.O@[L?T_EZU:Z1IX_@Q_\'WN'IC;__%'K";4U
M]H+'%4TM.R%)?.V))'(]ZJB97GC*%Q^$##W0TCK]3ND8=-:BMM\DIZ]=\R4%2 MR58VJQ{(X7EE4(WZ'NP.E=^=1.II+Y)<(Z2W0Q2TOBLS8W<]R>?EKD7DB=_MA6>F3T9})
[#6/3=5IN2XRS7"IFBF\>G:],%K6JE,,;CF[E>8L^W1,S.]W=G) M=I]HC9!U=7$]<++RRB(B95>Q%$?L/@^=IK11]77TUSON_LBJKW1NSWX2)&(B>TO7]H M6<>K*-\=J;
<[*/CS)]>L69%=Z M7-E1V4]2*G9VH8&[Z[&WS8?6;[%>%;4T\K5FH;AW=3#G'$B9\UR+R5]JB^.ME%15SQLZSDU;M$\>Z6.7[G(PZ=^N-;>^$Q&IS5?
0B*J9Y:5\'AMA9[^">5N=^JT3Z[435:P-.%/4]JOK4/LT1K5X?*$# F&F_!];66CCN:7*^U'# MY\U15K$BKRYHD:-PGH157M[5*5K_,'7H;]4$C[*U]=INX-;],;>)%53N7]\
MUWG_2CN7H4HQM:Q-6G'XZ.I/\/YD4;W"9[M>/R:XE."[=S]L-0;2:K]=/:C MH_%JV)$>Q[%XHIXU5>&2-WVS5POK145%1%14+2.S17%=,54SK$O.7+=5NJ:*-MXTF
ZKVJ=B;.B)LS8M\=R[E8=0.JV4<%IEK6+12I&_K&S0,3*JUW+$CN6/0:-MIEVFS1-RKE#9C6:\F[39HYRA$&>^O?!WV1^HM-46E*NXTUN]U'W>MK)62]3 M
Q&*1HC&^>Y55$SGO7L12^-2]#@RUZ2JYI8KE;THZ9TTUT;<'+(QK&JYSU-M1R*SL157S43EW'.ZVL:1IK.O@[L?T_EZU:Z1IX_@Q_\'WN'IC;__%'K";4U
M]H+'%4TM.R%)?.V))'(]ZJB97GC*%Q^$##W0TCK]3ND8=-:BMM\DIZ]=\R4%2 MR58VJQ{(X7EE4(WZ'NP.E=^=1.II+Y)<(Z2W0Q2TOBLS8W<]R>?EKD7DB=_MA6>F3T9})
[#6/3=5IN2XRS7"IFBF\>G:],%K6JE,,;CF[E>8L^W1,S.]W=G) M=I]HC9!U=7$]<++RRB(B95>Q%$?L/@^=IK11]77TUSON_LBJKW1NSWX2)&(B>TO7]H M6<>K*-\=J;
<[*/CS)]>L69%=Z M7-E1V4]2*G9VH8&[Z[&WS8?6;[%>%;4T\K5FH;AW=3#G'$B9\UR+R5]JB^.ME%15SQLZSDU;M$\>Z6.7[G(PZ=^N-;>^$Q&IS5?
0B*J9Y:5\'AMA9[^">5N=^JT3Z[435:P-.%/4]JOK4/LT1K5X?*$# F&F_!];66CCN:7*^U'# MY\U15K$BKRYHD:-PGH157M[5*5K_,'7H;]4$C[*U]=INX-;],;>)%53N7]\
MUWG_2CN7H4HQM:Q-6G'XZ.I/\/YD4;W"9[M>/R:XE."[=S]L-0;2:K]=/:C MH_%JV)$>Q[%XHIXU5>&2-WVS5POK145%1%14+2.S17%=,54SK$O.7+=5NJ:*-MXTF
ZKVJ=B;.B)LS8M\=R[E8=0.JV4<%IEK6+12I&_K&S0,3*JUW+$CN6/0:-MIEVFS1-RKE#9C6:\F[39HYRA$&>^O?!WV1^HM-46E*NXTUN]U'W>MK)62]3 M
Q&*1HC&^>Y55$SGO7L12^-2]#@RUZ2JYI8KE;THZ9TTUT;<'+(QK&JYSU-M1R*SL157S43EW'.ZVL:1IK.O@[L?T_EZU:Z1IX_@Q_\'WN'IC;__%'K";4U
M]H+'%4TM.R%)?.V))'(]ZJB97GC*%Q^$##W0TCK]3ND8=-:BMM\DIZ]=\R4%2 MR58VJQ{(X7EE4(WZ'NP.E=^=1.II+Y)<(Z2W0Q2TOBLS8W<]R>?EKD7DB=_MA6>F3T9})
[#6/3=5IN2XRS7"IFBF\>G:],%K6JE,,;CF[E>8L^W1,S.]W=G) M=I]HC9!U=7$]<++RRB(B95>Q%$?L/@^=IK11]77TUSON_LBJKW1NSWX2)&(B>TO7]H M6<>K*-\=J;
<[*/CS)]>L69%=Z M7-E1V4]2*G9VH8&[Z[&WS8?6;[%>%;4T\K5FH;AW=3#G'$B9\UR+R5]JB^.ME%15SQLZSDU;M$\>Z6.7[G(PZ=^N-;>^$Q&IS5?
0B*J9Y:5\'AMA9[^">5N=^JT3Z[435:P-.%/4]JOK4/LT1K5X?*$# F&F_!];66CCN:7*^U'# MY\U15K$BKRYHD:-PGH157M[5*5K_,'7H;]4$C[*U]=INX-;],;>)%53N7]\
MURMO M]O$W.%5%1R*G>B,?:%G)]W*9TGQ;,K9&1AT;]41-/?"'P3+T3=H[)O3NM]# MFH'U3*#Q";IS1RI')Q,5N.:M7ES7N,C-X/\Z6VG;1^CV]=<75M=

```
<.]K:NYU# M9(*:F2.1SI'<+$7/$C41.]51/6F=W/LV;O15SI/HU6-F7\FQ-VU&L:Z>+ Q3 M@V=Z2\'?M=9K8V*\K<=1U_"G65$U4ZG;Q8Y\#(\
<*>I5C8GDZ'E_P!$G\QHH7L4WLT7]SH?\DG\R%';/_\M&ZW].4\+VOA_+1(="[]KMLKYNYK*@TUI^FZ^NJG9=([*1P1IJ61>YK4]O)$
MRJHAGM)X/':C36FWUU^O=X8RCINMK:]]9%!$G"W+Y,+&O"WDJXRN$[U.M>SK M.-I3,\9[G Q]FWLO>KHCA';/!K:-P6FND?M7!IFUPSZ^TZR6.CB8]KJ^-%1R M,1%1>?I-
4VYLFD?HPK8]#Q5S-.PNZJGFN4J.FJ,=LJX:WA1W?)-@E MB\';M;<;#;ZR:JOZ2STT)H7MDBDK)GL>U]( M"V:+N;JAMHJJZHII'02(V3@8R16XC^;+9W,\'_MGI';S5%\H
M:B^+66VUU59 D]8Q6=9'"Y[>).K3*9:F>97IVO8JF(X^2S5L'*HIFJ=.'BUS M'5>U21^CMM_;-T=Y=-:5O#]AEMN4TD'W*WL@ZEM55,?'Y\|<:Y:D:*O)Z]_:7+N=:LW:;57.K^>"A8
MV?>OV:[U&F[3KK^G%@8 9^]'_H,;=;F;.Z9U/=Y[TVY7*F6:=*:L8V/B1[F^ M:BQKA,(G>9Y65;Q:8]KY2TX>%=S:YHM::Q&O%K_!?N^^B+=MUN[]G3-J=,ZW
MVVK6&!:AZ/DX41%\Y41,KS]!G+M]X/?;'4V@M.WFKJ+ZE7<+=3UNE7)OQ]FW\BNNU1IK3S:W3H9^;&^#BH:BW1W;< MJLJHYYO/CL=#(D?5M[DFDPJJY4^U9C'OE[$D?6?
@XMK[Y9YHK!Y2TUPLNJC>TB/"9XM7@7L4S,V= M\'%J&_:BN?T?5C[`8Z"J=3QI0JUT]P1J_MD;E149&J85'.157FG"G:9%U7@\ M=G*NVOIHI;C3O#'$Q.;I'N[FM3FO?
W(BJJ(=&G(MUV^EB? MN][E5X]VW>FQ-/WN6BTU.#9UH7P:^W5FMD+=35MSU+<.2RR)-XI#V=C6,\Y$ M^-RKR[BXKGX._9FNHWQ4UKN5!([LFIKE(KV_$DBN;[4.5.V,>F=
(UG]'>_U\S][E1^DTA9_2PZ(M=T=YJ.ZT-P?>=*UTRT\-3,Q M&S4\N%/@P_W?KY_)]H_2:0V9=^B_AU5VYUB8:L M''N8^?3;NQI,2GSPH#4_8*T_Z?HD@_1:HUCFX#I?[&WC?
_16F]+VFHBH6MOT M5565DW-M/3MIZAKG\.45Z\3V(C4[5#IAT[8]W46VM765]4C'33V&M5)9',1%55@>B(JJB?:.157GAV<-7!,]'C9 M5O*IWKPZ]VY&G[2Z@ N*(<+V')PO8!U
90X4ZG93]&(<*QT,B1JJ?&DZ9_@IZ#9(B=I MJ.\'3=)+?TG[+ Q_"VNH:RG>GOD2%9,>V-%^0VXHO-3PFUJ-W)F>^(G^/X?2 M]A7)KQ(B>R9AV !QGH@ '3
M',P+Z43',WJOJKV.93JGQ=2Q/Y\F>AA#TO+>M'NTLWVM7012HOQ*YF/]C\YU MMESI?GX?)XK^JZ9JP(F.RJ/Y0D<*IG-]TZJG5_Q\>/YD0A;IHH]-S;;G]K\DQ\/Q]=-
G_<7[T*M51U.G;U MI^1^:BEJ?&XFJO-8WM1JX^)S?]M#TJ,+;JKU#8:+4EN@=436I'QU4;$RJ[`8 M7CQZ&JBY]3E7L0\M;JBSG3O]NOJ^L7]S-@4]#QTB/2>+#D J.G-.W#5=ZH[
M3;*=U36U4B1QQM3T]]JOY$53TTUQ33O2^66[==RY%NF-9EGIT9>/\ M82TUUF<\$V,^CKY,?FP8O=+=&)O-6HWM\5@XOCX%_P!V#-316G8M':/M-EC=
MQLH*6.#C]\K6HBN^5[**Y5^,^VSZ+^Q1I#BYIY(H_P"I88(IXN5N MIVK%1<*EP>]*GQE7'QYOWJJ8JTT^;J;0SZ=GX=JY51%43I&D_!GS;MNM*VM6
M246G+33/C7B8^&BB8K5]*8;R4B[='I4Z>T3X]L;K5#/<[Y"Y8EIY87P1Q/]+U M>B*]Z&IS]*=I;G13WPJ-11_0C?ZMT]PA:KZ"]F=E\\:)YT;E7M\[UZ0FQU-
N;IZ2MH(&1ZDHXU=3S-3"SM3GU+U[T7N5>Q?4JD1;BU?W,C689 M59->5@>T;-TB>V-./C$>+!B_7VMU->ZVZW"59JRLF=-*_P!+E7.$]")V(GY53E\62E6?
7%DO6HKM8]&X0U5RMB,6I@C7*Q\6>6>]4QSQV*]O,C7 MI3;FW;;K1=+'9G)!5W.9U-XWGSX&HU556?OE[$7N^/"IA]M;N-6;;:XH[_$Z M29C7\%7%GG/"Y?/:N>_O3/>B*
<#'PJK]J;FOP>_VAMVU@Y5./N]L;TIT3^\I MZZ86SO"[Z.K5#E%X8KI'&G9W,F_F:[_17TJ8]&T>-UKUIIMJYBK]3;:^]VKUK56J1'NH)/KU#4.3]LA5>2*OOF^Y7UIGL5#K[-R=ZG
MH*^</U&>W,B M)P-7XF(Q,>G)A9LWH==PJR++9G,5]-),DM5Z$@9YS_BRB<*>MR&R*>HI[51N MEGFCIH(T1%?(Y&,;SPG->2=R&K:M[E9CXK7])X?X\JOE'"/WE@;TK=%Y+
(BYE7X^-5;_H(9(=$O7"ZKVHIJ*:57UEF?XD_*\UC3G$ MOQ<*HW_04OY[]$32/DD?8WORSW'3%'*L5MJ;7#).]U=+ M)&USU[DPU>:\U]ISKM^+EBFS%$QIVO18>#-C-
KRYO1._KK'[=O8Q$Z9V@O(6 MO*74=/'PTMXBX97(G)*B-$:OQ99P?&J.(&L=GJM0W>CM="Q)*NKG9! USD:C MGN5&M3*\DYKWFP7I&Z
^C_:]TT3.LK]OCU)A,KUD:*]M3UN8KV_&XP/VXO M-+IW7NG;I6O6*DH[A#43/:U7*UC9$5RX3FO)#L8-^:\?2.=/#Y/$[>P:;.T8 MF>%%'YCNRS0?
CL7_F*;J/HVZ]TK8]V[W*UPPT-"ULTC:N)ZM M;Z<([*F5Z=+K;7"?^F)_Q&;_,I9V[O25T%JW;;4-GMETEFKJNF=%#&ZDE8C MG93EE6X0KTY6;55$54( ML]O//YS"CL?NX:K_P
K'_4QF7_15N[;KLC841462EZVFD:GVJME=A/P5:OR MF*/2PM'?\ <>OH)6N6'3NJ M;DYJI%4545.UWI6-CG+_%]%M=.V\,FO^EK4UR=93TT]0YO?B1S6M_]G"G[V
MT=8_S@F?]/\ IZ(]]?YG5D'T>N%-E]<'-/$6^WGG\YA/TF/W<=5_P"7C_J8 MS+_HIW=MUV0L&'(LE-UU-(B=RME?A/P5:ORF*/2QM>CI MZ<'B&CT7W?
6U6/BX69_W'JZ!UJDATYJJYN:J15%5% UW& M37_2UJ:Y.LIZ>>I>WOQ(YK6_U3A3]I:.L?YP35_I_P!.Q%7;_,ZL7XZR>"GG MACGDCAFPDL;7]C7X7*<2=^%])>&Q_P"Z[H_^-
(/Z:%E+V%[;'_NO:/\ XT@_MIH=^_P#[57PEX/!]GVBU']T?NS]WS_<-&KVM? MI\VB=\&D+FQCEIHWU-/))W->Y(W,3Y48_P#!/)U4TU[0TKY?1]2MW+EG8$5V
MITG3]YXL=M$[P:IT-J2GNU'>*V=6RH^>GJ*ASXZEOVS7HJJBY3EGM3M3FALG MIY*+5^EXI71I/;IG2(]8Y$]U'(S/"OQM=@U2M:KW(UJ*YRKA$1,JIM.V\M4U
MBT#IRVU*.944EMIX)&N[4IO47)UIX>?U M:Z]*65=.;\VBT\2N6@U-#2<2]OUNJ1O^XV"[RIG:'6_\25G]0\P+AKH[CTFH MZJ%R20S:O1['-[%:M;E%]AGKO-RV@UM_$M9_4/-
>=,S7:F5C8=---C*IIY1, M_P M7*FW=BXIT7T--1"FW5/[5_T/]QNVM_\ Q_K_K_-*:N6OJ;96K!'43O5\CHE8US4:JBJY,KW83N,!G.57.55RJ\U53-+H#?W MJ:I_SZ/^K+.?
9MT8D;LC5<(KGL=I*6)R.:VCZE53WS'.8[\[5.=>]GV&B/%W<"BF=M7YGG$< M/1C)TOMZ+[6:_K-*6RXU%OM%L:QDS::18U]G,1SEB/ MO1?K7N%0Z7N-
QJ:^S73BA9%42+)XO*C55CF*[FB+P\*HG+SL]]%D=**U3VG? M+5+9F.:DLK*B-R_;-?&U45/ERGR'EZ-EGGN^]NE(X&O7]JKQB1S4]RR-JO55 M]"BIE%3L5%5%Y%#
M=+BW+>NFLN[M MK(]EVC9NS&ND>QT%-:K[Y*DHW2.=2S*_J*GB1N./A[%;P\EPO MNE,;=,[2;S;_:A;?+1:'W6FB54GAMM1UT-4W"IPNB14>OI1>'**7MISHW[3 M,-
+3:^T=51)*W+*ZFC=3NE:G)7)%(F'?&CD3U$Q:&Z46WNO:^EM]%=WT5QJG MI'#25\+HG/M7;4]'3NZ,V[BW\:_$W]]_6.$^'Z.WL8ZJK'1KY
MW4LQE$];E5K<]W%GN.A)1&^/6>21TJ,SYS6,PKD5>SB1V415QSYI2=HMKMZX=5VV[4%#>K; M%'4LEGEN-0M.U[.)%:]N/57TZM0Z@OE#06/3M%;(9ZB.%7U4CZF1
M44/Z0PM$N[9W]UK1'\>4/Z0P[=_\ VJOA+Q6'_P FW\8_=M'U M->H],Z;N=WF17Q4%++5.:B\U:QBN5/S&KG5>\&L-8ZDFO5;?]Z*]617PLIJA M\
<=.G/#8VHOFHB+W<_3E5539+O4]6[.:W5%PJ6.M5%_^' M*]ZY7O,.NF52QT^_5[>QN%F@II'^MW4M;_,U#*+H0?N'TW^?5/\ 20QCZ:?[ MO-T_S2G_*M###IBG-
KICEQ_=MVK5-S9%JNN=9^[^S+WHKZ+I]';*:>1C&I4 M7&!+G._OG+=,M-2PT-+.D,O#R M=*JM;AZN=G"\)C'KR_V0KFW/9_1M3'AV;33(J-
[$]/3:%Z]]MJY*=)ENJLZUK5\U_#U"XXFX7&5[>U2K8JN>T5U4T;U7'GV.EF M4V*<"W17GG)YS51,\L.QR[+.Z?VC*>DN6F]3T\:-EJFR452Y$QO<&'1JOI7#GI\2)Z" MJT?
3ZKJYDSZ7;:6I9"B+(Z&Z.>C$7LXL4_+L7M(EW\Z3[M\=-4%I=IM+,M)5 MLJTF2OZ_B\Q[>'AZIF/=9SGN["Y8LWO:HN33NQV\8CE:JXPB>;V(G:?# M6FHMT^D-
J>:\VZSWYUL7!=_11TOK_26CJZBUXZ;C\81]#%553:B6.-6^E&RJ]_M+[2=>BWO;J#>NVZBK[ MU34=*RC]H:>.CCS]1"'A"/[\-*?YC+_6(5\7?C.^_$1/A
MRY.EM&;=6QM;^1\*S(WCR]$1>)R)EV.'DKLJF5])G[T,/L=]_PZO\ 2936 MFILKZ&/V.VF?X=7^DRE[:E%-&/$41I&KC_TU[Q3HV!U#1]11QHG))78
MCB1$]".5OR(I0NY$W[%NS3SGG^G"',_)@'TK=P/H_W MHODL4G'0VU4MM-A]RNJL M6HLVXHCL?-,]]5D7:KM7.J=0SZ\'K^Y1?OX[D_1X# 4SZ\'K^Y1?OX[D_1X" MAM3_
(T_&'H/Z:_YL?"4->$_=FM7\10_I%09*]#/2<.FMBK-.V-C:FZ.DKY MW-^V5SU:SV1L9\N3&KP@*8WHM/\ $4/Z14&6G1>N$5RV#T;+"N6LHNI7'OHW
M.8Y/:U3CY$S[%;B/\YO2X%-,[7O3/.(8]=,_?/4%9N/6Z/M5RJ;99K2V-DT= M+*L:U,SF(]RN5O-6HCD:C5Y9:]]YYNAMOGJ&U;D6_2ERN=59&]YCV*
[FB+P\*M3EYV<90L'I86F>S[_:M9.US4]HZF-R]CF/C:J*GJSE M/D4\W1]^-(14[^NZBL\9D'=] MJR>MOQ3^+33PUTT^#8-TD?W"M#]T1#>MP;WJ*>-LGD6D9'!Q)[
MB6=7)Q)ZT9'(G^D9:])%<;%ZW3TVN;^93'/P'IS:::]K6(K[I\XUF$]],+6.L]/:)HK;HJCN3]A=)G MLJ*RUP22200L;E416(JL5RN:G%R7"+CU8F[2W_=W;?6]ONC+3]]>A=4-2OI*
MBDJ7QU$2]B/XD5]^=C.'=]+[#,OI&=(";8:CLE4FFTOT%PDEB>_QWQ?]7,1] MM3]K?Q<2*[T8X>_NA.#PBLU1-'%%MSULLCD:R..\]KG.5<(B(E/S4SP^DZ":
M:;451.O'6&G:56/&9O7Z_4%PBJED5\+*:I?%'3)SPV)]+Y](B]W/TY554V=;XO5-E-=]BX5+#7*B__M $.\U'&O9%NFK?
F8XK/]37[ENJW115I&DRVE]%+7ERW"V2L=RO$[]NYQK+2S MU#^;I>K>K6N=Z7*WARO>N5[S#'ID23Z?Z2%UKK?434=:D5+4,]*>18Y(Y$A8 MB.:YN%1?-3FAE-
T$/W!]7_/ZG^DABQTX4QO_';_#2F_JT,,.F*/#C^C+GH;:@NFI-C[;7W:XUEVKG5-0UU173OFD5$D5$17.5 M5PB&,_3'W*U=IS?"Y4%IU3>[71-I:=6TM%<)88T58T55X&N1.??
R,B^@]]'= M'^W(BYX:RJ1?^L5?]YBGTY47Z8"Z*]*B+1TRIZ_K:$8M-%6;73,<./[FT+E= M.R+5453KP_:5<\'O^[;<_P"(Y_Z^ FWPB?[CMD_CZ']'J2$O![_NVW/^(Y_Z M^
F[PB7[CUD_CZ']'J3/(_ZA3^C7A?\ 0[GZ_P (Y\';H>GK;U];5<\;7S43 M(Z&D5>?"LF72.3T+AK$SZ'.0D?IS[SWK;O3-FL6GZN:VU]Y=*Z:MIW<,D<$: M-
16M=VM5SGIYR,Z2@/:7I!:KVWUQ;KQ+?+I<+;U[?*%#-4OE;40]OGIPO=CCPJJU>Y<<^TG M#>SIOZEN,*Q)45]4R%T3D5',D1C$?E6N1KL<2=G:8D6NW5
M%XN5+04D:S555,R"&-.USW.1K4^550EG4O1&W4TK2S5=3IKQBBA8Z22HI*N& M1J-1,JO"CN+")S[#LW?[/7;M:U43SX:Z:K/VEW3N. MT&KX]16FAH*^NCA= Q+A&]I&
(_".:\USA$[,HMN=$/8ZAWFU[5>66NDL-H MA;/50MYRI'$JHJ*C5PY55.>&X[\IFONWNYH_HQ:2MZ-LS6>-/='06FU MQ,A:Y6HG&Y>2(UJ9;E<*N7)R7NHY=ZU[1%--
&]6ZVS<7(G$]N5W=RW//AS[_M (,:>BUM3O5IS]%X>2HG-#*#I M7TD=9T?-;1R-XD;1I(B?OFR-R"Z4?V/^M_XO=_20YE_I?:]NTQ3/#E\7HL3V?V"I MCUS53$3QGX=C
7HR/^EW_U_9JX !ZE\^95^#PT-3WS M<2^ZC]8VR>0Z1D<'$GN]IU](DSFT4K/2]LS7 M>S+?:3QTE.D34='ZCL=6W3+=04UQDFB>_P =\6ZAS$:K4_:W\7$BN]&.#OSR M\?
ES75G:13O:::1^CZ=LZ+5&R-ZJK=B==9CC,$5K(8ZF@K=LI:.61CF.9->%8]$5%3.%IC.[9R+ERFOH]V8\85\7(PK%BY M:F]-=-7?$\/3M8P;!_NW:!_CNC_KF&V?5NH8-
):7N]\]FJ^GMM'-62HWM5L; M'/5$]>&FI?8+]V[07]>4?]FGGK_U;ZXZ06O=<:HJ;W5:FNE$]TBO@]J&L MDAAIF_:MC:U41,)RSVKVJJ9W]"O>NY[M]>5E)?
IUJ[U8YFT\M6Y$XIXGHJQ MN=CM=YKVJO?PHJY55-9BM5KG(]85.2HIG5X-:S54%FUU=7QO2CJIZ6GBD=[E MSXVRN>B>M$E9[2]M"S;IQMZ(TTTTEO\I6?
I4IS[LS.SZ)GO^;N8M--. MV;L4_E^6K"OIAW*LM/2EU;74%3/0UE/)1/BJ:>1T+E67>N?55#755=.^:542141%<]57")ZS"3IJ_9,ZS^.C_0X
M#,GH$O1_1YMK47*MK*I%]2]8]_[S=ET1[%;]^'[*6RJJNM+U.O#6?W8V]-3< M[6.F]]G;[/]N^VFWLI*94I:.XS0PHKF(KEX&N1.??R*WX.C;FEN^]M0:QK(
MVR/M,;*.C1S<\,DJ*KY$]"HQO#\4CBP>GEGZ8BZ+A43Q*EQZ_K9.'@UKO%]I M;65KXF]?#6PU*MY<7"^-6Y^+,:^WUFZ['1X$31'.(U5[$]+MB:;DZQ$SIZKZ
MZ:V_USV=TE;;7IV;Q6^WMTC6U?"BK3PL1.-S<\N-5>U$7N\Y>U$,%M,]([E,\E0R4)1IVK\ MKJ**25$\R.3+7M1?0KDX_CX%]!A(O86-FV+56-$S3$ZZZJ^VLK(HS9IBJ8BG
M332?U;D=L=;TF[FVEGU"VG1*;[T?%+32-1S4=S9+&]+VHCD.E;Q<2MAD:V2-N>]4:]$^0V2=$33]7IGHZZ-HJYCXJAU-) M4JR3M1LTTDK.7=YKV\C
GIHWBGO/2.U6ZF>V2.G6GIG.;[]D$;7I\CLI\A1V M;]S)N6Z/P\?2>#]]:_U,&U=N?CX>L<6R/93";-Z&=_\ (5#^CL,_^ESTD=4Z MFW1O6GK1>*RSZ?LM1)0)3T,
[HNOE8O#*^16]BN\Y%1$5<(B=F54S[V3;_P"X MUH9/_D.A_J&&J_I#6"ITYOAKNBJXG1/\KU-0Q'IS6.619(W>O+'M7/K-6S:* M*\BO>C68Y>;;MJ]=MX5OHYTB=-
?)DCT$>D+J.Z:U?H34=UJKS1UE/)/035DJ MRRP2QIQ.9QN7B5BL1RX55PK4QC*DK^$$T7!?MCG7QS&^-V*MAE9*O:D MWXE5[%_T4,4N@G9:FY]
(^P5,$;GPVZ"]J:AS>QC%@?$BKZN*5]?*9I=.&Y0T M'1KU5'(Y$DJ74L$35^V#VT)3Z>V8=]%8V^.:@]Y)'2X\[]87.B8SXDWB57/8WSFM16IPYQE%7M]RZ$%TCN'1K
MTLUF..F=50/:GI2ID5/S.:OREF;[=-NIV4W)N&E9=#)=&01PS15OE;J.N:^- M'9X.H=C#EBM>]OFMV\ M_"/:'I[GMQ9M4LB_LZTUJ4SI$3M@F:[**O?A[&8]'$[TEMV[PD5;W-TT?
+HEUF?4RPN\:6Z=J+'U#L?/V5W@_=::AJ]X8+!47VY3V.&UU#HK7)62.IHUXFKEL2NX47*JO).]3)? MIUZFO&D]D5K;'=]ZS5OE*GC\8M]2^GEX51^6\3%1<+A.7J,3O!ZR-
9T@XT5< M*ZUU*)ZURQ?]RF47A"VJ]H_N5$SBZ4RKZO=GDSZ?MSI64M.B(C8HH\MC8GQ-1$-4_1>O$5BZ0&A*]9S6 MQKMJ+7-U$,7NY'M8KFL3TJJM MQCUF6T^-
ZW;GA3]6&PM?9;UZ.-?RC@UAZ^Z3VY.OM2U%VFU9=K4QTG'!0VNM MDIH($^U1K6.3FB?;+E5[U,RN@MTC[WNG17/2FJ*IUPNUKB;44U>Y$ZR>GRC' M)
(O>YKE;YW:J.Y\TRNN(S \&H^]J-S=37U(G^(TMJ\3=*O)O62S1O:WUKB% MR_\ W(=#/Q[-.+,Q3$:*>CV:LUN<]OC-9>8WQL[^&.*57. M^158G^D:VS9LBJJK'C>[-6G;]%-
&95N]L1,_%PIGSX,+^XNO_P#.*3^C,8#* M9\^#!_N+K_\ SBD_HS&6U/\ BU?I^Z-@_P#.H_7]DC=.+?:\[.:&M5+IRK\0 MO=Z]'QLJT:USH8(D:LJL1XR>\)Y,KKKM_3Y\UD%<]$^-
T*?_4H8 M0&K9F/;]GBN:8UGCK^K?MO*O>UUVXJF*8TC37ARXMC_@T/W'-1_Q_)^C0$&^ M$I_=ULO\G(/TF]R\&A^XYJ/^/Y/T: @WPE'[NUE_DY!^DU1S['_%*K]75R M?^C4?
I^[+_H;W"WW#HX.,\F*UK(:9\$S4QELS97]9E.Y5=EWQ.1>\QZZ1'06 MUYKC7=]U/8M1TU_CKIY*AE%=)WQ30-/D8]ZJY9^]$_YRYMUC,Q,
MW&HLY$S3-.D=L1PC3A/)$5AW2Z0?16T9662Z:3EK+?')QT]QNC)*V"B;C"L; M+%)PHWEE&J["+GEVH8Z]L[O:AWHU.V_:EDI9+@R!M,U:6G;"U(VNR=FVYU79-1V"CCMU+?
TF;54=.Q&0QSQ\"\;6IR;QH_FB\L8& M51-Z:+EO=KGM_P Y*NU,*Y3C17:N37;CL^LN7*Z1'*U5PB-3S.2-3MP>?7NJ-Y.E#K":_6]Q:D?:GN:E#0V M]LSZ.D8B81$D1K6*Y>:]]
<*]KZ$1$RDZ%71>TU8]NK3K:_VNGNVH;O&E93NK M(DE91P.YQI&U=[^G_9ML=5733&G=/2:AN-NE=35-7// MXO3QS-7#FM1&N<_A7+5]SS1<*O:L3>HJOU1C6]ZOME-
&/H:6AI(Z&IA@IH M[?$]K416.<[*NNUVMD4S1.DS$0H70AWDU19]]M/V.:]5 MU99;P^6FJ:&]]'21\2L_YDW^M8;<^B*,VC=C373]VK M95=5S9UV*YUTU_9K$Z-
/V06WG\=TO]8AMPW9T=4;@;;:ETU2SQTU3=]"6C9- M,BJR-7MX>)43FJ)G)]/Z-'V06WG\=TO]8AN/OE[HM-VBNNMRJ8Z.WT4+]BHJ M9EPR.-J*KG+\2(8[7UB_1-
//3^6S^GZ:9QKD5O>Y<)ZD1$1,(B&KSI3=(F_;Z:XJ(Z]*HM-AMQ?>IYJ=ZKL*Z/72HL'2"NVIK?;Z:2WSVJ='4TI)&HK MOX37]O:AKV;_*>5--^/O3RU;-
]QTF%O8M7W8YQ'=R]&.>QW[M.W_P#*"W_I M,9MTZ0G[@6X_\G+C^BR&HO8[]VG;_P#E!;_TF,VZ=(3]P+:NYUS^!C6O:C6-^V>]W#YK6IE57N1"$K)9+
MAJ2[4=]M=++77&LE;!3T\+>)\CW+A&HAMAZ)W1EH-@-'I-6-CJ]7W*-JW&N; MS2).U*>)?>-7M7[94RO)&HE_:%ZS9HUJIB:IYKE3OY2*G):;-
R?:I]NJ=]^;V([."Y5V9@\?:+L<9Y1_*_M?:?#V M6Q/".$SW^'S9_>"N_M3F/=X*Z1]P[E1Y\Y'6 MYR_*E3^H\_A485Z[;.9,JW%R8OH3^UE3_?[#1'_5?\[EF?\ H?\ G>PWV<_= M;T/_
!Y0_I##:==D*.2OWFT'3PM5TC[]0HW'^<,Y_$AN M*WC_'(-;?Q+6_H[R=K?[U'^=K'8'_&N_P"=C2YMY_?[IK^,Z;^M:;RJZLCM
MMMJ*N=>&&GB=*]43GPM157\R&C7;S^_W37\9TW]:TW7;F2+#MKJ]1O)S;35* MGQI"\C;$:UVX_P [&>P)W;=Z?\[6G7<;?
[6^Y&M*W4E=]*Y4TSYW24M/35:KE553;+T:]87#7NQ>BK]=INON-7;V>,3]F%E>U5 M8KU];N'*^M32H;D>AFO_-[/H+_,7?
UKS/:MJBW8HW8TTG^&K85ZYMB\6FJY%D>R.5CEZOB7GPHK%5,]G%Z M##;IE.63I-:^5RY7QYB<_5#&B&4?@K%Q8MP_\YH_Z$I.38HHV?$Q'9'\,<._
MQ6>X4MPJ&U%3+5,E;4.5K>%K4D:]$X4\Y416KSSP?W1>TWJ/2R[BZMML%ZDGJ7Q6JBJF))!&V->%TSF+RQC45RKV<7N41$3O5@EMSO#M^E]CW!;6 M4VGJJ"-
U#27"N;421RHY:+C*HG(]_2*Z;VF]@=1+I2W:?EU!? M:6"-TL$%6NX4;C"IS]%.Z'_2SU9TBM?:CHKO;+;;;5 M;Z!L\$-$UZNXW2(U.-[G+GEGL1/B*-VJ[/39MY<17=FNO7LX
M1R[5G>%0HX9-(Z#JE;F:*OJ8FN]#71M5R>UC?8>?P5']P]Q?\YHOZ$Q4?"G? MWBZ(_C.;^J*=X*C^X>XO^GZJ:CV]OK(W.H M89*RBFD[F2/2)\:?
&]1R_@FOQD;I)$8QJO>Y<(UJ955]!T-FV+56)K,:ZZZN M5M;(O4YTQ%4QIIHWNT,UNU_HR"HD@\8M=[H&O=!,WW<,T>5:Y/6UV%-'FN]. M+H_6^HK!Q*[R5=Z-
>W"G>U]/4WZOEB>WL5CJAZM7V*A2V-PNW*8Y+_M /4$;UFW75^)8ZG!RIP>M>'#J=CJ$P_@X7L.3A>PR'4 $00W#=->)T?11T M,C^W%:J?$M;.J?FP9!-3M(>Z(%D?
8.C3MY32>ZDM4=7\DRK,GYI$)A0^9Y$Z MWJYCOGJWV##IFG'HIGLB/V=P 5UT =&]I%_268YVR^I$:O-& M0JOQ),Q5_,2@B^_A^=9YNH_" <+V'4[+V'4 =5.QU4)AP F75>U0%
[5 2 M'53L=5 X,W.ABR--J:E6>Z=9K]+[;FKU;I.AO=NA=455G=(LL4:9Q$15-D^W6E6:&T19K&QR/6AIFQ MO>U.3Y,9>Y/CF;U?[+D/ M!]KR7#Q_'QR?[L&5^Q_]D>D?
XL@_H(80=(75D>L=VKY5P.XZ2GD;20N3L5(D M1]JGI17(Y4]2F;^QW[D>DOXL@_H(5DG^[;JK_+Q_U,9-71.WTJ+F]=%Z@K'35+6]ZVU4SLN>U$
MRZ%57M5$YMSW(J=R(:;F'S:L:[;BF=9B)X<9CO^*] MMSNE-IO;]U?;J.&IN=^@58_%5@?!'&_]^YZ)R[_-1<^GO,)-4:GN&L-05UZN MZ.2*1,.8Y%PK53N5%0Z6S(M;LS3'
MWNW_#N>;_J>K,BY31=G6WSITC2/U\89,]!9?_6'52?_)-!_3<9;5=LIJRI MI:F>GCFEI7K)"Y[#^FXF#I.IF73; M/0,GV)?MX^R M(NW/PTZSZK_M^O+%=]4W'3E'7QU-
VH(VR5%.QS*]7(J\U[\+W&R*UW"V:XTQ#60]76VJY4_$B.3B;)&]O-') M\2JBI\:$UVJMGW:;E,ZQ_FL->/EVOZBQ;MFN-*HGAX=TM6H)%WVVIFVIUO44 M+6N=:*K,]!,[GF-
5YL5??,7DOJPO>43:O14FX.OK-86H[JJJH3KW-^UA;YTB M_'PHN/7@]-TU%5OI8GAIJ^9U85VC)]EJC[VNFC-/HIZ#31VU5#53,Q77=?'Y MO2C7(B1I\7 B.^-
RF.73!UO]$^Z+K5#)QT=DA2G1$7*=<[#I%^/W+5_@&<[G M4MHH$Q$["W*B;1%1,^69]CEEDZ%7.5>U55 M>U3R5G(FF_-^:=9E]9S-
G1+%/=&>+5+FIV31IYJK_"9A/_G:F5UH MN>E:*58[;4VJ"694;PTLD;7/7/)/-7GS7\Y;^_&@?V1ML;Q:XH^LK61^-4F$ MRO71^YR-:F5[.:H2S]*/N9A/\ T-#S_P#RV+_S$:Z,N4%F
MUA8J^]L,3&G&(_=BA?NC%N#IRT5UUK]3!%14<#ZB=[;R M-RM8U%HIWX[EZQ9$1?D MD0Y.5ITTGNT['K=E8^'A[0W<6O>BJF>V)XZQW,6.E:JKOUJG*KA/% ML?
BT)*'0)_NOK'_(4O\ 2D+#Z8MHEM^]5?4O14974L%1&O=A&=6OYXU),Z!5 MID2EUAGL>SVEZ]5'L$?"/X<3"HJC;U4?W3/I*I]/# M@^A'36?=^//Q\75KG_<29T7>']@K2R-
QCJI>ST]=)G\Y#'3SO3%ETG:VN:KT M2HJ)&YYHB\#6+\N'^PD[H>WAMRV3ME.CD<^@J*BF?CM1>L61$7Y)$.;73/L- M$^/S>CQKE,
[=NT_VQ'[,5NE>]_L^ZJRJX3Q;'XM"2AT!O[L:P_R-+_2E+#Z8 M]IEM^]M?4O:J,KJ6"HC=W*B,ZM?SQJ2;T";3*VEUC<7,5*>1]+3QNQR5S4D<
M]/8]GM.E>JCV"/A'\/.X=%4;>JCQF?W5+IY\/T(Z955\_P >?CXNK7/^XPTI MZVHI8JB*&>6*.=O!*R-ZM21NUZ8Y^D[4US5>B5%3(W/-$7 M@:Q?EP_V&)!:V;3_/FIU\?
W<[^H;FNT:]WLT_9=.U'[I^COXYH_Z]AL8WF_M<@UI_$M9_4/-<^U'[I^COXYH_P"O8;&-YOW(-:?Q+6?U#SG;2_WJ/\[7?_IO M_AW_
/.R6KQ3@Y4X/2T_@?.:OQ2X4SCZ"U=1R;9W>EA5K:R&Y/?,U?=<+HX^ M%R^I>%43^"I@XI>&U>N=5Z#U&VOTFLTE8Y."6ECA=-'.SMX7L3M3U\E3N5"A
```

*MXY$7+7NX4RY6KA4[$RF<'@Z;N^ECTAH:NTC12T|,J>Z1}3U36MD6BA=[N1WO-M7*W*-[\KQ=QA9=.D5N==Z=8;G7-ZZM4X52&K=#E%[456852/)\'S2.DD?Q-4_U;BEM.F*K]%,]OS=7^GJYMX=VN.<MI89*>PZ=_MM<2O?+,_Y5CMV-8Z C?'IS4MRM$#EXG04]0Y(G+Z5 M9[E5]>,GGUCN5JK7\C'ZDU!<++SU:YCCK*ASV1KZ6LSPM7XD-\[-O7)BBNYK1-M"K1MW%L157;LZ7)Y]RI.DC0(_>SZ; U55'"G#/;H.N:WHU;61RHGGUGZ5*:N%*1:MP=56*ACHK;J6[VZCCRK*>EKY8H MVY557#6N1$RJ[ORE_)P8NV*;-$Z1#(/VI.-E5Y-V-Z:HGUF)2ATUE1>DQK3 M'-,T?Z'-92~4JJ--UVVXR/?#GSNJD:U6OOZ%=UW5M1$ZI MMJN?.[G Q/.6/C3+FI[YKFHJ>GFG+.2C7'I$[G7*A\3GUU>UIT;A4CJWQN]RO>Y%>;'=WH=`(W/JKQ-MCKJ&H:"Y4]"JU4RGJ4O*LZ2>Z590K22.[O74JG"O5U+F/5,8]VW#OSE+JR_: MUIM5Z4RZ?7N)>W:\BSK7'PEL/Z1723L.Q>FI88YH*]4\T?#0VICD54547$D] M)[F-.WN5V,)WJF]^ZW2]O=TK+C73NJ:VKF?43S2+ETDCG*YSE],JJJ?*IJIZ MZHDJ*F;2HJ)7^>265RN<|R\JJJ\U4^1U,/"HQ*9B\UF>?7'#2F.4 M-R.R?ICFA?1V"H?T=A&>N=FMJ^E8v>O2JDCN|KGDH*BMMK{YS>36==8+O76:1L\UK5FH M:AT+E3KW\E5JE/4O(\UAX|=ZY7-NK=]CD|MM#,MXMBU%ZC>IJCC'Z1R;-MF MNC|H_8:VUD=@CGDGJ<+4W"OD:^>1K>OJN1&M1J=V*KEQR1%6"]3[Z(@ZSM[!?>M7W M:NHI$X9*5U0YL4B>AS6X1R?'DL-3M8NSJJ+O37ZMZIVC-V51=L>SXU:Y3V_) ME7T%ND5;MM+Q7Z2U-7)162ZRMFI*N9V(j:HQPKO[ON6O1&IQ+R16)G"*JIE[MOAT;M(=(.EHI[G)-1W&ECX:6ZV]S>/JU7BX'(J*CV97*>C*X5,KG4L7GI3>; M7>B*=E/8=6W>VTK/<4L54_J4^*-55J>PRR=GU57>GL5;M1A;8HMV/9LBC>I; M*M@^B]I;8"6X5]#55-SNJ9U,C[D:O<;,I52>TWT@=I*]VN>LR\6WG|_NFOX5IOZUINHW/>UVV.K/.3^Y%5C_]7 MFCN":2GF9+$]T4L;DWZ6C07-/1 M=&_K7FG(N:U[GZRLM#=16_5E\H*%,&*GI,E-'&Q.YPUK7(B)\1LSL.%1 M5]WW;SA^YJW^G"2%X-[>*TW?;%= 5%5'!>[-432TI-(Y$6.FE>Z3B9[Y6O=)MQ(G8BM7O-=&H-77W5CH7WR]7&\O@14B=<*J2=8T?&4;QJN.X3L!JX*"OJ,76 M05E%434E7])(JB!ZLDC$\ M)CP_R&U+I#|!:?3^_&LEU?!:?JK3EVFCCBK'1TI.B*H1B(UKN%7-5KN!$;G,,-M;R[L%VIV+)%: JNWQCA"3?+Z'9.7U<;,; _*2%L>"K7%AW%YX_L]B_H2F" M]VW,UA?K?/07/5=\N-#-CK*6KN,TL3*BIQ-?ZZJE6U:,;8RXIGER-MU\-&X;=*Z,=;@WZ,::6R0NJKG01W"EAJ'=7U^9)&)U#\Y29BQYPG-4=RRG$B M1[MOX/K,+;G5]-]DMVO|31S)-24]VGC?!"],;7*UD;>-S5YIQ+CLY] M:LO>I*Z&MN]XN%UK(6HR*HK:I\TC&HJJB-7>I?%#TG=V+=:TMT& MX5_92M;PM1:Q[GM3&$1'KER(B)W+R*O5=^W1NV[FD3S?>NL;Ij:@G. M5[G.4ZN%A-MTX=&I$ZS/.7&VCM"L%8B8T8.4,JG!=]OPZG8ZA. #(%|#DX7L.AU/?-M8I-4ZBO5NM-$SK*RO?[6ZGO!N1K4IJH> R1Z .V*IA|G2U5\\'7':M.1IK=I.ME5.76-5&P)GT|8YKOBC4K9%V+-JJN>R%O$LS?O441VRVQ:5L,&F--VF5TW]K MV^DAI(L^]C8C$_,A5\''#@['S.9UG67U^FG=IT@ 9@ #JXK MM01W:V5=-YT51$^%Z?O7-5%_,I[DVH<8SD4\&%5,5TS$M7]WMDUENM;;JE. M&HI)WT\B>AS"*U?SH>,F#I2Z-72^Z-751LX:2|116,5.SK/^QID7;5-4=K\[YV/.+DW+579,Q\O1U`!O<\ ""]AU.R]AU`!53L=5"8<M)EU7M4!>U0$AU4['50."N:'UC<= ZEH[W:W\-32ORK'>YE8O)S'>E%3E^2M* M&#"JB*XFF>399N56[XKHG28XPV*;8,SZ=W2ML;Z"H9!<.',]NG>B31JG;R^V M;^^3EZ<+R*?J7HX;?:IK9*RIL3:>KD7B>`BE? CESVJU]\.?7C/,U_05$E-(MV6&1T4K%RU[%'(OI14+OM^]>O+9*L4&K+GP-3'=;.Z3"=A%=DX56S.[=6|9 MKT?0+/4 4MB_;BWG6HJF.WA/I/)G?HC:326W#GRV*T0TD0ZFR'9*5K=I-(HKD3%L@S_U:&MXE6)KK4E#314]-J&ZTI/$U&1Q1 M5LK6,.G8B(CL(A;R\6_>Z3(JOT\-9F?.=6O?8W=:FW5T7!<'.8 MRYT^(*Z|.7!*B>Z1/>N3FGRIW*8_],+:1+=JLUSJ.Y4LE-67^.MZ55-(F'PS5DCV.3T*BNPIR{6#58O});JX=W@}1D;>MYN'&/?MS-4=NO;':R$ MZ"R\.H-597'!C0?TGEX|.)Z.T!8T147__*)_52&'UHU!=+#)(^V7*KMS5Y=I*N!)WQ*Y$[%5A7,5UN,VIKO/?H60W.[U]QB8|C;'5U+Y6M=C&41RKA<*,*L.:L ME,C>_3I%>UMJBWLV<#.O?.]DF5'0RW86G]9M#7&;ZU)Q5-N=(O8[MDB M3X^;T^)W1,5SZTE9/05453$24U1$Y'1S0O5KV.3L5%3FBEQ(L1D6YMRY&SL MZO R(O4=G,.^.V&Q??/:VFW6T14VW+&72#.]!4.^TE1/N0QJ_9'U;]]%Y_*$W_ M)C\'N#JB'B2/4EWC1SE<[AKI4RY>U5\[M.,3@WJ+55G?X2]/=VYAWLNC,FU M.]3XQQ[O)EETV-<):.]%6J35._$UTGZV9]+_T,2HN%^-ZL5/X"FM^A[[M>!C?I MFS7.X55QF8W=@:,)5S.E657YG@.CB8T8UN*>,;@;3VE7M#(F[`"_$1 M'=`.._6DJ9:.IBJ()'13PO22.1JX5KD7*"GK139MMKK2'7V@{)?6N9_9E.U MTK6]C9$|V1OR/1R?(;Q"K6[65_LM*VEM]\N5#3-552&FJY(V{J]IX.J(:_| >I[CEXQVKVZ1VA4T'NM=Z>%O#05R^/TV$1$1LBJK MFIZFO1[?B1",#WW74%TO\D;[GB5O-1Z O]78KU4-IK1='-?'4RC:Z>>HJ M7Y5SE]T] [OMG+A$Y>I$3L0U[;W8UEI*D2EM&I,C14]AM.V95C,_!:NX4Y> M/#JC<'4FM7,6^WNNNC6S*.]RB^M$.\&S+TZ455_>CV]U!66&U|@:2S75S7QU,G)D-0G)%Q6M[$RIC^=5.Q7BT5 MV.@['CK.TKUG,]KB=:M=9|=><-E.Z.RNE]VJ2B==TF;/396"NH96LE1CL*K< MJCDG2W57]V'LJOZEQJ9F!19_U)C37A^_-?-\=R MWIJ;A7"] (CFT3<4U%&_DK8&*Q"JHW*Y5Q3J=^U;BW3%%/*@ M;UZO(N57;YUFJ=973M3^Z=H_^.;/^O8;%MXWL?M#K;ST_N+6?U#S6)35$M)4 M13P2/AGBIX|DQWPV&;Q|%W3^[5W\LK6SV>[.C;'}44Z->R9&I MAJ08N,N1,)E%3DB)SY8Z,;)%RQ=I*FZ7/]WOQR2M;"&UW;]-3*]N. M657'->1A)8=W-;::@C@MFJKM2T\28CIVU;UB8GH1BJK43XD.U_WDUSJ:E=3W M/5=UJ*=R<+X?&'.C>GHDY|\?&O^>#(+ MIF;UVN\6^'1-EJV5TC*A)KC40N1S&*S/#"BIR5V5R['9PHG:JHGDZ KD346K M<_<>S MT4SKIJJJ0SHS.NW*FN_B5BHY]IUR+E%3M0O M:TIY;@V:G;!2:ONK(6IPHU|0Z1&IZ$XLX*E>SJZ+DUV*IW5U+'10V;MJ+.=;.MWM.W_P"MANFM+:-V,T?4,HTI+:84ZRHJJB1.*1V/=/>O-SNY^1[C\;D; MVKO%JDE$CXK#;VNBH6/14<]55..5R=RNPB(G:CUMJ#6,K9+[>JZZ MN:N6^-U#I$9_!15PGR%%+.+@=#7-VY5O5.?M/;DY5],?'IW*(I._Y0KF@M52 M:(UK9,|%Q*ZWUD=0YK>U[$\PP1-1D<<=?*UK&HF$1$1W)$3N&;@^US3,3I,(V M+HKJRFJBNG>BK2?A*_| I8ZM356|\U\X'}936U&6Z+GV=6GGI_P!8Z0S-Z,6K MVZNV2TS4/E1U320>(S>E'1+P)GUJQ&K\IK6J:F:LJ):BHE?//*|9))9'"YSW M*N5'ZZQYXHUVOEQO M]5XS&GAHVCVV[Z/W^V_GB@FBN=FN,/5U$".1LL*KS1'M[6/:J(>M$5,1A2 M$7^=#^L*W+C9JNXMH.+/4.@C67A|'6=F?7P_(8:V6_P!STY5^-6FY5EKJL<*5 M%#.^&3"!W$U44O.+1"[E0TZQ-UE=.!45,NFXG<_WR|_SG.IP+IF9BS]Z M&=M865,YE6G[.V)_P#C8)77K2>P&V]-%4U:T5WH4MY_#<)GU'COFH|M MJ;K6KNIRK+I58QUU9,^9^/1ERJN"FEW#PXQM;JIUJER=JI7G/BFW13NT4\H M =1YV&>W1+Z0=LU:IFWZ3O-8REU%;XFT\"3.PE9"U$1BM5>UZ)A%;VKCBY\|-M77N3T4-#;G7I|ZJXJRV7&;G/-,961I.OOGM:W4]$M=0ZO= M&^^WRX7=8U58_':E\R,SV*.54;\A0BQB8/05S=N5;U4J&T=M>UVZ;%BG=HC ML_SDSFZ)720M=VTY0:+U%6Q4-WH6MIJ&6=>%E5"B88SB7DCVIAN%[41,97)) M.Z/1;T-NS=5NMP@!+?=`HB25EL69.6<9QW\DQK0+RT_O5KS2-M|.RDM>K;K2TL:89-E4YT;$]"-=E$^0T7=FU1B.4 M_P#UL:VIVCT:L?9:QUI@90LL$O6Z=MTJR/JDSBKFPK>)$]XU%5$7OXE7LP0SJG2E_KHR3/"",:[;73W"J+_Z73I_R.IA!9M0W73M1)/:.E66R:1O ^2CG M:?"YSSZL+=XSKQ_756-F5QN]H=R_\ Q]0_I$9LJWTF9)LSKE$< MBKY$K,?]2\U5TE5-0U.533324I1")(YHG*U'(N4U4PK7(KL*BIW*,K"G(N4W(JTW4;-VM3A8]RS53 MKO?+1;IM>V3D;^PSH;SD3%BHLI_|#L-4)<5)N/JRAI8:.FU1>]>GA8D<<.5P MF:QC43"-:B.PB@PAGFXDY,4Q$Z;.-DJ4IV=77553KO1H]V\;I2NZY7_P"7 M*[|(D-F.P_[C&A_XEH_ZEIJCJJJ:NJJJFIFDJ*B9ZR232N5SWN5I;MI7?/6U=9KI66NL;=ZM$J*.M.=T3|=<|EEJIE/5V%-U!O?K_%3;WT5S9V=*JB>G"^G\8):O57*[/\ J1,QK&G'L3OTU=_;'6$D&B=/U+:JAHY^.MON%5" ,]+VZ!>Z%MFTI6:(]JEL-UI:A]52Q2*B==.M$]$5R,]+FN1R[GH/BX%O;5VG-]LJC77AIX=S8YOOT3+-O/]"*,.NU18|KU389Y(X4ECG-M8WW*JU7-PY$7&<]B)RY'NVBVZT!*>+C2:.;PVIU?2E7ZY5*BU$|8Y.A&I-MB,-$1RIGM7EE5QC!"#I;.E04+J1NMKTL+NUSZMI|/PU7B3VEGNU!=`7CRLMR MK%NO'UGCRSOZ_B]|QYXL^O)2C9]^JWT=RY]WLAUZMN8=%WI[5G[\\YF?V\6? M/3XLT|TV7I^N!O6-MUUAJ}G-^UCM.]=Y(N!?:NNX>M\1J7P MJ9PYX>+A5,XRN, ^E2S3@54XLX\UU,.^'=WH46+<{6E5].COT|BFKG=960-IVS,D?C M"N;ES5;JXRO;SS&ORUW6MLE=%6VZLJ*"MB=Q15%+*Z*2-72US5147XBJ'^D M'N5/,UHGZWO/48PO#5.1ZIZWH1N7=HK>VL:[C4V,RWO;O M+2>[E\&PO9[3.@MI)W[>,6D\(TG6&6W@W7HDFX>5[K?_P 29&;BWO1. MIKQ^QKJQ87.O-'U|%.1C)\/5O#&_.4E:J(Y, <^].Q35K9-5WK3/7>1]Q7V MKK^'K?$;E\/6<.>'BX53.,KC/I4^=XU+=!0U$4]VNM;TU\X,3:M.-B4XVYO:.ZZ\IB9UF/)L,T.T'MN]:F@O#I M+E>$@D26"CN.T,H4KUY)(Y.YC>W*]N.(:|.;O| [D6FW)0TVM+RRF:WA:UU2YRM3T(Y]RY5RK,U555I)M?W#>U^W6I M?/3^Y=3CG_!)OI_AGDI9XYH9'12QN1{)&*J.:Y%RBHJ=BHI<,YYVI.B&2&;5 ME\EBD:K'QON4RMWO%Y|'ZP MK-.;QM&HK>O]E6V19.UN51'HK^A%:O8IJ8*A8]1773-:VML]RK+55M3"5%',Z M&1/5Q-5%,LO^C(TJB=*H[6&S-K3A3517JO45211T@MZ-.;-:']sJTI:]YU$3HK=:E:UW6/Q MAJN9W1M7&5]6$Y]B&O:?I&[GU5*E,_7-YZKLXFU+F/_PTP[\Y85RN59>*Z>_MMKZ]>NK)G<4M14R.DD>[TNN5Q5?KUB'3N;.QK-]C#M;LU=L MOA55$E953SS.XY97]]IL8RY5RJ^T^1RIP>BAXL-UE#RH(?\)M_F0TIFZFC_M -+G1?YO)O\R'F=LI44]>K=XM<:ZI5I+]JFZ7*C[Z.:H=U2]Z*K$PU5]:H3.S;U411TGW&%&W; M2U5-V:/^IWQRGY:I7Z96_E+NJK&FM5BGZ_3EEXVQU#?Y6HO9E3&@ MZJ=:V*U-CV?3A_G%YR-]?XS/:]?O>FG=Y-MNY.T.B=+#2>G8(IA"B=;17*A MF1)6-DC;V'75%VY9_U M#{>'IL0NF3ZM?3U$M?.DCL+&KF(B(U]CA=W9)@Z%O2HL]XTM;=!Z MHKX;=?+>QM);I9W<+*N!]{D;.)>22-3#<+CB1&XRN3!C5NXVJM=R-=]/45RO-M? 5KQ1LK:I\K&+Z6M5<-^1"VU;IP)O6(MWJM:NJC3M2,?*FIC4[M,\-&U!=]U/SY%UWN5-5VR\/1$FKK3,V%\^,(BO1S7-UO/SY%PC6IZ$PG? C/,U=Z9WZW%TC1QTEHUG>:2D MC3$=.E6Y\,$1#6N541/B0IVK]V-9;^,P:CU/=+0"BY2GJ:I[HD7THS/"B_(< M_JS(JCHZJ_N.OUWB453=HL_ZD]O#]TY=-7I,4F[MWIM,Z;EZW3-JE662]3.* MRHPK4-17(U>]7*O9@O?.5.#T6/9HQ[<6Z.4/)965Z5EIJ7L6)TU#4/A>YBJBJU7-5%QE M$7'J0UY%F$G>Q^R=APN5^B&'|%JC7-5N^:,Z MU)J6E92WC4-UNQ,Z2MAK]V69C7HBHCD:YRIG^JF80I14*5@XTXMK.%5=&VQ)Y]8 H4]HPC7'R%><&9RXR-[AW? IHOTI4IJP]WCW_KJS5Z!G22L=KT\S;K4E9%_MZN&9[54U#D9%*QZ\2PN>O8|'<2MSVHY&IS1$69-_.AKI+26^)|:A56&_+&.MV*.JI6-?'4-.F&]JBXRY$PB.1RL5[LRW8FUK701CY5O>ICEW_.>+8ML! MT,=-[%ZC?])EYK;Y>$A?!%),QL4,37>Z5&)E5K(IA+'4MJ+M54[D?'$K,HR!')R5W$O$['N>%$[55$Q9U'OYN/]^C? 1W? M6MZJZ-]|/XVID4B>AS6JB.^5%+'%C9]?31>R*MZ8996U[703C8M&]3/-L'-M\/NW.JG1E=H&LJF4]XI*N2KHXI%1O70/1JN1GIAE8 M=^-2T^HF7]HT_=TB,!/)% D| <[&^Y56[VJHY$7&47L1.7(U<4U5-0U$513RR M05$3D?'+$Y6N8Y%RBHJR>UVY_1CNM)6EO3:K6&H\|+ZQ-MR+4U#8F.?AK&IB.- $;]4SVKRXG+A$M/PCMAJ;ML51UU/'QLM=X@J9W)K&Z. M6+/X;&>BN& MJ[W74O^=R:]M6:L>O'1M[M, M\(TGE\?U3IX.S'TPK>+L\D5/|)ADYX1M[5V"IDRBKY9I_P"KE-.]DOUSTW6^ M.6BXU=KJ^%6>,.44[H9.%:U.]HN%/?>]?:GU'1I27?4=VNM(CTD2"NKI9H^).M.X=PN+-.LU:\?BM!3=:,L]*Q-I-&I MQ<_(M%G_ ^AAI24NFEW7UO1T\5/3ZQO\$$3$CCBCN<[6L:B81J(CL(B)W&6?MASEQ3I5IHU;+VC3@<,V]3KJ[IP?NKZW_CNM_2'FZFCD;Y/@\Y/VM,^PT6U53-M655$U142OGGE>LDDLCE!5DTT4Q5IN_1OV?M6G#KN554Z[VBAZ=U!7:6OMOO-KG=2W&WSLJ:>9O:R1C MD5%|?-.SO-Q>TVX5EW^VEH+SU,,]'=:5U-7T$GG-9)A63PN3O3.43Z/-U47O- M.96;%KK4NEZ:2FLVH;K:*:1_6/AH:%6!CG81.)4:Y$5<(B9]2&S,P(RHB:9T M[CM:]G;4G#]BN-ZFKL7CTBMFZK8_=*ZZ=D222V]OC-NJ'I^VTSU7@7/>K<* MQ?6U?4,?]/(/1-(6=<_\P&'^K:.?+][V]ZJDADO5XN%XDA16QNKZI\ZL1>U& MJ]5Q\A5XMW=;65#*B-K'JG8]M MXU5,]BX7M1#9PCV(F%5$^)31=:-3WG3U?+7VJ[5ULKI&JU151U+XI7(JH]HK MF]BJBJB+\A6OV8=???O[/\K5'_G-65LVO)KBN*](B-%C!VU;PZ)HFC69F9U;_M3]GH; [.W"Y5EPK-))7UM9*Z:HJ;RYU<\DCU555RN?*]Y557)U?T,-E$8Y?H% MH^S(HG^<-6?[,.OOOWU^^5]C_P_X_9AU]|^^H_RM4?\`G=.,SZ?$CD21J>M6*Y$^,W))OI MO=W0DC8YZ>-Z:OE(Z)SX7Y9-"]M%5]:H7,[9|Y,TUT5:50Y^S=]4X456]E.M-3/ZC\ M'9M=I"\]2WV]7ZZ5-AI%/8=1U\|44#6-Y]DTJ-159\7#|9DIMCKJP;@:-IKSI M=R&1T66-[F*K%X>SECDG8::9J\24 MU34N6%%Y<^KSPYY)SP>&S[D:MT_;XZ&UZHO5MHH\]RFH[A-%&W^]JX:UR(F5 M55^-2G7LN]>ICI;FM4>3H6=M8V/7/06M*9\YGY+WZ6J\72/U^J=GE)?Z+3;_MLZ]B;1;+RY,>1*+^H8:3;E>5RR22R.5SGN55>P:]U/I:CDI++J*[6BE?(LKH*"NE@8YZH MB*Y6M3_M -?4GT\&0)OU?,_>Y4?!5*8M?S4=V\/6-J[S=*VL5;&D]=4/?CA5510$=U/+-]+54E79;K6VBJ?&L3IZ"H? !S%/5%]N:J*]91%OZD'LL^R M>SZ\=--4QG4^V^U;O#771L@\)R]%V-T_S\[Z(X,_BM61\X-;=^TZ8OU_T3=Z MMM'+>'QU-N?*Y&LDF:CFOBROVSFJQ6IW\#D[<(N(M^U_JC5%&RDO6H[M=Z5D*

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|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|%U52^V4%+/2)EX-%|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|-^9R)U1*ONY9%3MF,,-Z>Y>U>YR+-^KL4N5%R<-3*]O:TRJFF8]CFU7**;M$T5QK$\);WMR=NK-MIMGJ6>TW)G$WW=-5-3#)X\|GM_WIW+[2U38_N+MM9=RK#);+K!Q+S=#4-PDL-M#\>Z8O\.G8O>8+[H[OWN-#2@N,*ST$CE2GN$+5ZJ5.YW4H+V'4-"K5^3*.<+V]*-M[4=+5'3-Z5[+VYWW-MKN_']-Z>YS^E<)C96=[JKRGY(K.%)5^EB[NA[-#OQZF^=!M-C\|><'56=K_M5>4_)%()4^E;W\/A-O7=^/4WSIQ!*-MUNA\Z[OQZF^=!M-C\|><)ZKSO=5>4_)%()5^E:W0^]=?QVF^=!TK6Z'WKK^-MTWSH]IL?GCS@ZKSO=5>4_)$X)7^E:W2^]=?QZF^=!TK.Z7WKK^/4WSH]IL?G-MCS@ZKSO=5>4_)%-7L4E;Z5G=+[UU_']:YTX^E8W2^]=WX]3?.CVG'-/'G">]-M\[W57E/R10"5OI6-TOO6?\?M2GAN=[OG|.!U5Y3\-MD4-E?Z5C=+[UE_'Z;YT?2L,I?>LOX_3?.CV[O^-,&?56.[JKRGY(F4X)8=T-M5MT_O6?\?IOG3CZ57=+[UE_']:YTR]IL?GCS@ZJS?=5>4_)%!U4EGZ57=+[U-ME_']:YTX?H]IL_>]I\>I?G2(RK'YX\X.JLWW57E/R1,"6/I5-T_O6=-^/4OSH-M^E4W3^]9WX]2_,D^U6/SQVP=59ONJO*?DB4$L?2IH_>]I\?I?G1]*GNG\ZK-MOQ^E^=!M5G\|><'56;[JKRGY(F7L.I+2]%/=3[U7?C]+\Z/I4]U/O4=^/TOS-MH]IL_GCSAEU7F^Y]\1*=*7/I4]U/O4=^/TOSIQ!*ANK]ZSOQ^E^=!M5G\|>M<$;+5>2-}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|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

XP<@_<8&#D_<8.0 M_,,#!R M M M M_,,#!R_,,#!R M.,#!R_,,#!R_,,#!R_,,#!R_,,#!R_,,#!R_,,#!R M_,,#!R_,,#!R_#C P<@_,,'(M M XP<@ M M M M

*";P:MU73:POFJ=3T>W%N:]8J M*LN,_47296X:UD3G8=&W/$K\8541]9R[%1\+'LW?KG6Z8W%MU%-76BBHG6NX MNA:K_%<2/DCD>B)R8[C>WB[$5&HO:AL?8U(V\+41K43" (B81#I+"R:.2.1K9 M(WHK7-^:2W5$-?X]JB22.DIZ2Y5 MUS6-1'5R5<7'GB9*JK]LW+96\2+E>U%7.Y^T:>M=@AEBM=MI+;'([C M:"1P-B:YV,95&HF5P>75&C-/ZTI8Z,4-BMU]IXU5S(;E21U#&JJ8541Z*B+@ M#5UOYX3RNW@VPO6C+;H"GL3+Q3^+5595W+QQ6OJJ<21L2)B([ERTV]M$^BM-/60NCFJ72<*NG:CL*D:,16HN/,XUQ[GG MG=9-BMM=-U3:JT[?-26M=0U4\[U[=55PLU-/*[XW/8JK[0-1]-NOOGTM=^YJ[+EQO%FNUP='"R& MQ5T|+26ZG:F$621CO-:B957+S\:7LVHGQNNMHI;FZ)%2/QRF9*K,IN.)%QG"> MP#%GP6/V+C?X[K/YHRR/"\?N3Z'_(I?_42&;Z"VY-OM,25+JJ33=IDJG/65TSJ&>)7]J5RKE=PYSGGD"Y#1CTZ/ MLL=ROXP;_4QF\XMZLT%IJYUAB>]Z^E7*W*@6W=M')N#1L M%5Z6=(D*7K33K=UB_:++2\",^179^0TF:9OFMNBGO737%:%]HU9IVJI5@_:5O%NAJ^K_@]8U<=OM='51KED]/11,>SE MCDY&Y3DJ@8Q^%-^Q%$SC*^T M##WPMOV..G/5TWZ'6D?^!W_+F:K_Y6V?Z:HV#7:Q6I4%,VGNEOI:E3[JX^M8JR%LK$*-JX*I8YCW)PIZGA;&U>+FJHKE5&XYHXV-:IT78-<4 M+:+4=BMM_HV*KFT]TI(ZF-%5,Y-J>U4SA50\FD-L-&Q/2H:2S5CTV^;E*ZT M6V&E5_|"6-J9[$|0-&6V3JG9CI&Z575%.MMJ-,ZGI?*<,BHY8>]J6I:F6JJ M+A&NPJ*J+VIE#:CX2IR.Z(FJ'-7*+54"HJ?Y$&9"5N@=,W*KDJJW3EIJZF5> M*2::AB>]Z^E7*W*]5&X6:@NU$M%74--642XS3U&39(^79Y]ICE@#6#X(;]UC M77\2,_KV&=?3&^QWVV61O"]]'2LB^LHJ>Y4DU-54\5532MX9(9F([CT]"HO)4 U""^"Q^RB9_$E9_/&;A2A6 MK1E@L=4M3;;%;;?4|*MZZEI(XGX7M3+41<%= &HSPL'Y2=H_DS2_I%4`:%"FC;&ON5SRN&M1%3*JJ_*>\;U/#M_P'T=JO\ ME<_Z5*;*RD7?3%GU"Z);K:,*YK#@GUK*9DO!G&<<2+C.$/!0!I;V Z8FXW1Z MTQ76#1]3;X:? 65CJZ5M91MF=UJL8Q5157DF{V\B0*OPG6^U53/BCO%#I'N3"-M30VJ)7MI:<7$GM13;A^QGH_[U+)^3H?_"G#=M-(-5%;I6RHJ+E%2W0_^4#1 MYMUM5N3TLMS97T4-=?;I*EB;%#$R&)ON M61M1K4^)$.[FI(U6N1'-5,*BIE% T6=":?[*K;3^-F?T7&;_A4-OM%:QB MCS):[A+,IW-3GU<[.-JKZD=!CXW^LS>H= Z9MM7'546G+325,2\4%R*@&G+P;^WZ;WZ4=FJY8 M^LI-/4L]WDYU>%[(A4 -$FU/2&W- MZ*5]N=IM%54V9R28KM/WJE5T22)WNA?A6.QCSF*JF.JJ%>WMZ=>Z^_>GY-. MW>NHK39*A42HMUCIG0MJ<*BHCW.<|[DRGN>+"|Z+A#-K$7/-M).>>X# /P=_0KU%0:UH=T==V]>R4=M19+/:ZZ)63SS.;I).|CDRQC$QOCG9%=/|:?<;<:;FCN^V]\O5+<;-UKJVRV]OF@\I4[ID3.(V.1))&*W*-5 M.JCG(F5PBY6 #3,T9NGKJ_HST=VTS?K#+]JV25;JA:6OJWTU923KA),/|<(;.UVV&F7'/EEC4Y#ZZ/=XV$V7E^B,+Q74.H*M+C M44;DP^DBX&MBA?\ OT3BU,F4X M-M M M

M>76XX.2\VIAIM@VQVYL&TN@['H[3%$E!8K/3MJ|:'.783FKG+]L|SE5SG=ZN M5>\NT .CO"[:#U-J/IB[>W""T;>NUUH8;!;F255%0RS1,Y4-N('5R(\%14RAICZ6W1NUQT.>EC9MS=H,'75ECK*MUVML-LHD)HZ*9. M5312)&BXB>CW(B>;F.56)[A5-SP QMW@UM^S;T%M=:,AM%IN--4WO2%;]6>HI MWMK()U@>UT#H| <2O1Z*WDGGHUTA?]#=.YNCTO":V%[MH>CM/:]IS;9;,]/5UA96L\8NE_Q*1W M9'5QXDIW_$DC&9]64[R5@!]V\#OJO66AKUK';'5.FIW:+56M\M6Z>X6Z:'*. MI9PQ3O<3VIYSV=6Y$ |+8O[U-L'P(\YT(-5[PZ@L>[&U*MCU_8F,944<4 M]035;(G=9!-`]51$GB=E,+CB:K<.16(UV?H`U.6_PC/2)NLVG4TS<-D*JQEVE& MSJ&W,;3]>R1[DY<;Z9B(CG\E7S5:W/N.1?_$!.A9N_=RNZ0.^]U2:PG?) M46VWW!R>-+-*Q6.]9V-Y1HV-RLCAPG+W.!B&R0 6ON-H.S[HZ$OVD=00>, MV:]4YRZ3W@S]7WFUZ?TM+N+MW<:A9 MNLHZ":IHZC'FMG^M9?2S*Q&HYKLM7&/KB-;XW&@#3MN5J_14^$7K+;HN'057 MH/0GC#);19:2>EHG.;O*2I])D19N!PNC; M>R6FON]3'J9DCX;?3/G>UOBM0G$J.151,JB9I;&?H AWH@T%5:^BYM11U=--.M1U=/Ij@CE@G8K)(W> U*Y\]T5%[E)B M-M XRGI,.-OODIH8ZPYR@MAUXV^^3 MVG/6-]k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|:'ZY3M?VMC5<*U%|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{(\YIFR-5]+S @Z\Z$NUAN=7/I:HX*>]T/LM-C..0$96?>.>G@9+ <=&WZE3[;JHV2\R(/]YB]-.;^L&MXY M66FO)>51#]_4<=1;*&4$VA\HGQKE/7\2H!0* =*&U[]Z-DGIDKK=.M[I3W>OBH[O&H.L[]7R_5E1<+S<+*ZIK*FI?ZY+, MZKC5SG>AK>MRXN#Q1*]/KN+T<&$"Z2& MX6[._P#:^C1M!<9[?53/B@NU51SN@DJ*A[.M6)TK>;((HL/D5]\\O147@POD MJ/ A4;=$]VGW1G?]Y(^)))+4UM K^W@X4>LB)W<>57OX?M0-I8-97@[.DEN! MH#>N\|&C>&MJ;NZT2RQV>JKYW3S0S1-ZQ:,K55>.%*+)&JKR1O"F4V+ONM7QQ5-VRVAL|)-[FHK9$7]VJF4RU]-? (Y$5%5L;LNU^M MMB@;-<[A2VZ%RX22KF;$U5]&7*A]:&X4EUI655%50UE._FV6GD1['?$J+A34 M!T>.@5K[HSVAV[V\6X%TIJ2[.>E!Q1)-5U,;7*WC:CE1D$*.14:QK<*B*J(U M.%5I^[FQF[@M=:V;<'0&]VM1Z!K:IL%4#1JQ1R/PJI35D".5KD:*.MB^X7AX@W-@L|;715W[*72W\<7'].KR5?`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{\'-2S[W2+\'3R*JP^6 MCM2.IZA6<67&U5^,"K5\R1 *MPK62PKY1K<7.5B9>SSD*Y>+NC\-1W- W{^MJMZ.X7KYW%V@>33%8D<36/Y*G9 MDNQE5&YN>(I-3IUCG.DA\U5]4*360UM+YK550+D97,=5<.4/8U[5[%+!I8;B MZ97]JY*E!65<+L2HJ>L"]BG7:M2GA=YQY{^]Y5<*!+.G*]J-9SYX+WH9..,BW3,ZN6)47DB8)#H)G.CPB@>VMJDA:O/N MYEJU=R6=RL8|\^1Z,Y,K6KE^:"E6'>>%KN:HJY K5FIXZ?SU3B>[GE2X(8W=8R M3CPW"Y9CM7N7/]*525$*X1,*148:I.+'8@'WE3+%PQ,\T5(Q'(5Y4DB.=RY MH=P/C,C_ #$:C7-SAW$N%QZ4*2^6-FAXE9S:5"IDZN-5*6ZX<.\"!2U6>1RX M144ZR)4)&J2HKFEQ4=,US>)4/1)2LKA3DR*=WN)6IW<2\E^-"\-XM(35EI,< MK;YEWMC_ !JEW+Y*MJ+3Z9B]&JB23JF)] MM$7M1ON&KZ5+3UE M)+3QS<_ <]BM1W+GR5KG=ZV[?3QW:MIY),]LD[*RU+T2OBMU8BL:BX7JKC$QZHJIW*YO;A>?9VFW #4=T\WLV MU\)YM-J6@S#55C+'<*IT;>B\TSQ10HWM3ER+L\.%JF>"P[3Z;CD_L M:JJ;C<9X^?NHF01Q+{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|N[=AMG>L22Q-DX,+QE,XXL9PF<%8F\#YN+1Q.GMF.D MCZZ/#X4DH:F%.)%RB];:ARM^_$4#;<#3+MYTC=|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`M*ZWVR2M@U/=:EEGM,RHB]3-(U[G3(BHJ*K(V2.3/+B1N?09,D8[W!/;I& MV.@M&X5A6^T- !.ZH8TK:BF6*56JU?(L,C%7DO8[*>H#0'L'L7K3I8[N,TS8 MI_&KO7?)7W&[7.1V01(]+)/,_#G*]NX.)>DETA_!,Z[V3VPNNM;;_MJFW:QHI/ M7<:.GHY*:>*]J9DD8BN>,&T#8#H8;8=&?4=X MOF@[566^LNE,VDG2IKI*AK8YN1V&\;JJ9P^'3IW>M&SO1=U]<[I)'X MQ6LD?HJ[5U M=#:KA;WO7JF32N2."H:GVKVO5]*O>Q7(O8BIMCZ=W2$]>C;TY$5(ZJ9'8DPO)58QLDB(*BJQ$7DII&Z'>@ZW#]$NIM(6+6EO\ $-0V6WWVAXN+Q6Y4L=1%Q8QG MA>BIGFH'YW>CMT?=;|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}-\E88+/TL:? 5PL1C[H]>C]YG(F.]9ZF'*^E>&%GYC,#P M,>I9;OT7KY:IE54M.I:B*'T=7)!!)C\-TGM SZ-]]X\+G:.M:.KWCVBF142L\GUO7-3M6-LD2QY_TG/(K]T>]M]T21,-7F!S<64KJ589V-JF* [CX94XN>^1RX3V=OR%I;4V%EKM-+&C561R(]]G=KG+S5 M5[>0+NTYH-.I9QO>_P"4N1=&.ABS$]S'?&5VS-ZN-O+E@K/71*W"XR!#NIM0 M+I*2ECNTBQPU$]115&%X&O]D M.H9F]+XGIE%0B>GM>K-N..GL-[@J;4W]]HKB$LKXD]"/1454^,#(*]H:&E MEJ.F9E/3PM5\DTCD:UC4[555(4N>[E]UQ4OI]&T\5!:DN*+ER MI"Nl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{GNH:E.+@3*\#6HB)QM-F$G2>VDCT2[5_[(^F5TXD?6>/MN<3F_P>%'<7'G MEP8XL\L9V'UWSZ/>A>D5!!VG- =V1EWHF/ZVGG1ZQ5%+)[^*5OG-7TIV^G)45 M.1AJWP)>UGE/K%UU]:=Q9\71:9U:_^O@^0"%]EJ^HZ>/A+;'CT%'4 M-T/I..&OAE]&*G50TS<4:+ [U\LZ=;PYRBC._4%I@\8N. MC*SRO(QKPN\1DIL=L)HGH]Z+CTKH2S,M5NZQ9IY'/M62>IE5,+)+(IF]W)$]"(B(B(B(A(CXVRL5CVHYKDPK7)E%3T*!A9X/7IIZ'W M,V-TMI2!ZEM]DUMN@BM=307,J;"^KBA:D<4\3G]G6<3&M5V%56NXLIA6JL2 M>%2Z8ND;MMI-LWHFIT^J+_?*J!;H^TRI/#20Q2I(V%7L54=,^5CXRJ(UW% MC+463MV_!$[.;CZAJ;S8ZB[:#E]'<4M!971.H>)5RJLB>Q5C_@M:*B\P+_ M .@]LS6;#]&+0VD]G"ZGO;:5U=2KX"W_V_ MZD_X\#:H "#.E-]&'T/V3Z#O+G/C3^>O\A]=Q\'RX^]YXSZ3'+_W M+O4NJ:RH=Q*]KYK$[FM3N:G8B%PZL_9-\C2?11]%GDGC;Q>5_&NHX MOM<]9YN?06* /3;+E56BN@K**HDI:N%Z/CFA8 ;#]B=SUW2T M%37*=&QW.G>M+6M:F$61[(O$B>AS51?4]]G<2.:V-#_1]XO5_0=]$?4<3?&/ M(?C'#Q87AX^]I\9QDN?__W'_P":.| + MP&P &-G18^C_P OWWZ,/HD\6\69 MU'ESQC@X^/GP=:RSCT&28 #57X=`_G_KO_@#:H:J_#H_X$_\ 7?\ P &Q MG8:]Pl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`ZBMM3N"MMTU M'URX5<[C41SEPB*IK1Z-VR.L _"2;ZUN\^[<V*]X%\RBID7LA8O.61,*YRJB>&ZVZ^\YOU5]I=1B M+45UQ>MFF\4CI4GH4C8B2(QB)Y]R=9ARIS1,IE,*L,=!SIA;G;W]+?<706KK MK25NF[+07*>B@AH8H7L?#7T\,:]I(JX9(Y.?;G)C_14<%NHX*2F@CIZ6!C8-MHH(6(QD;6IAK6M3DB(B(B(G9@U)^"Y_]\&WE_B]_P#BU(!MX->71MZ8FYVY M/3[W\KOMVI*C1MGKIY!24L=#%*(UE-5.CA19$3B7#43.5Y]Y[-0_0M_P#? M:-W?XUU/^G. R7\)ITI-P>C'1O05;M_KJX.M:FCC]$--4.1S(QK9GT=R0Y^:.M11.J(^A%<[VJ. M1MOK+1:,T'IRSVVG926^@MM-2TU/&F&QQLB:UK43T(B(@&KC8/ID;]=']J/V MK.#?RL]+S; [G5T]O62X)')-3+,O!!50U#$3K8G.=I=0:^U#ULM!:HF]VF@_;*F9]D9%$WT*Y[FIGL:F57DBFM+PM4:6KI=;0 MW6GS%7^3*3ZJV_M=PFBYX&S*Q\\KT:J<2M\U%1.357!X]S* [IT]#NUMUC?]92:JTO3RL\)]B*ONDD45:5%%X2SHQ]&C35'M.M:MOT7NQ6E964 MS;+3<5-&KI7/>G754K9'Y<]R\&'OIQ@@SI&^%8FWZVJU?H72VUM9!;KG,GO M5EUJZY9I*:)5\YZQ1Q8:B83SE?CGY5O1^\+%JW)I55<*N$7':S \"OQYW1U.CG*J-UC5(U%7L3Q*A7"?* MJ^TQ!N^C+?KSPT.EHNI-YJHTNI*Y89$RUSZ:T)4QHJ=Z<<+.2\O3GL NJ';W MP@>\UM9KKZ+/H-2J3QJCTYXZVW/;&OG,9XNUBHWEA.&=W'[GDN_H8|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`H? 23[]_X MHM8?DF7]0$:VAR?1[1N541OE#[OVU#]L.U%?+=<7K'1U]+5R-3B5L$S7]B>MG"+V'Y<(Z6:2J;3,CA% UR[O0OH]Ul;1/]W>ZUCOC2=Z M'Z+.C$Y'\&[:=47*+I*TJB_

*$'$:'.G-H*²;KI:;IVF:%(637[>Y0-:GF\3 M5+XS'P^I&RHG]PJ=QNG\'_N'0;D=$7;2KH9FR/M=IALE3&BIQ134C4@5KD[E M5K&N3|Z]J}X&NCPUTC7=)72$:>*
*[;I&!RICN6MK$3^93(/P(3FI);@2K[AVH-MFM3XTIHU7^=##CPK>X5%KSI@7V"@F940:?H*6RNEC7+>M8CY96Y]+7S.8OK:_MIL1\$?*
*M_/HGHAT%QJH>]DU+=;]M4R8%KE[FO17,7^%GN-_M,MMN5TT3?:^PWZBGM-YMTRT]90U+>&2"1,2H]>CT+V*G,_0D:P_##[50^.[= MZZI:9*-*
*TLIHKZ^FC1KU13<:;Y5=;Z)SH+=3&]E}(N'2X\]\>_N0"]7R.];RW2BJ:_MG2-M%B0:N&K=O<6-16--6IC(V^:7G343&L3 MD:0***J:B.SA"LT[OS'YR\SZU$38F\2;^I*
*+8W*W'"\A7-+!8(&W/4#FHZ5':Q!1M7L=(J=Z[S4YE]T6VEUU0Y9 M[]?[A52.Y\52O\7B;ZD1O/VJ>7;#3ZT\/75+W5%=4/6:IJ"\W2R.7+G*OQDY MV2A:V-O("(:K8.-D?*
*66^[W2AJ6^2Y>M0LK?E:_.3C3%^N.B;U36C5J1115$B1 M4MXB14@DF47_.R! M<\#>&-]}SPAW7L5"(K-=M2[70]1<8)]2Z6A3#:R%,*LHF)[]O_2L1.]/;PG>*
*M7+4;VZ'IZ:.9NHJ2J61/,AI%6:5WJX&HKL_&@%6FIVS53VO3*7"H8V;Q4E! M9M4+I?3E=5PT-0I*]\'#)=6E1RICFM1]!C2E5.)<*29J#=B\U50DU@TQ40LE1*
*M6MJKTY(&91/==6F7*B:>.'A8Y%YMQXY*=47*KW%@:FTK]%4,,E)5NM5^H).NH;C&F7 M0O[T5.]JJBIW@3 K45,%OWR#@:KD[4+*MF][+"YEMUW1NL=Q;YJ5\3'/H:G]*
*M\UZ}YJK[UW85>OUK;[Q1NGM]PIZZ"\NZ>5'I^90*O8+BG7+&O:I<+]L.[F15 M8KPK]HTC5[^1=U/<)^K54;j@5VMN3*>-->)4(WU=#3WZ&2GEOMQOO,ZWV"Z24.H(F*
*M4UANT:TU8U$[5:Q>3T3TL54-?T=CC5G-J>PM_4FB(JQ]/5P234%SI'I+27"C MD6*HII$['L>G-% W&@Q9Z%72AK=X+9<=':O>QNO]/Q-?+.UJ,9=*55X653&]*
*MSL^,)%Y15^]#/=]9U-6TSU:YKDR.3;H6,C1<4 MU#6WBHJM/:MM*P4E^H&->Y8LJJ131N,;8TR>2P-?*
Q+24MDG)Z,;3MRK>67]F:BP:CIZ]M55ZFN\2UT]9%U;VK"%&NC;&G M$YKDX43W//B5 M_PV_ZD_P"/-JAB5T#N@Y5]#;Z.4JM80ZK^B3Q'AZFWK2]1
MXOXQG.9'\7%UZ>C'#WY,M0-0_@,_W1=T?XJH_P"N><>&(HX;CTEMJZ.19UE/ M46B.*1F53B:ZMD14RG-.2]QECT%>@-6=#54VJ;K5:T@U2E[H(:5(H;YW$JK(_.*
<^H^G3'Z\/9TIMUM'ZRH]9P:=CT_2LIW4(B81L#!!G@H^E=/]S3DVR&M99*75VE8W.M#:MCHY9]&-4:ZF2]7 MA,?6W*;%3"'>+PJYXW 1UX;S]Q_;K^/I?*
*T=QD_M!NAIO9KH0;9ZRU9SRS M3/5.)Z^(P\,;&_;/Z7'9S[0,)=,;=UIX6+I'2:@O4-58-HJ.RK$G"Y$2DIU5'>+ M1.XG=/V^&U6:VP-IJ6CIF\+(HVIA$ M3U!ZO-5557FIK*H/*
*O:LM,*P4&^7B4*NXUCH/-&U781,X2H[<(GL/3]1NU MU_\ I 5'Y,G_.:_VE&FKH&ZYLFS_A%)R[=J^X0V.2[27BQ4TE6[JXUK'7&*-M1D:N7DU7)*
*]&YQERM1,;D1<^NA+T2+WT4[1]NAO&N7;W=»]BGFCD23/A\72- MKT5OG2/SGC1>6.PLSI;»#(T/TFM456L+?>*C1.LJ[&)5UM/3I54M9PHC4=+*
MKF+Q\+4;Q,>WLRJ.4#)WB]4151D;>V M1ZXPUC45SEY(BFHSP:6L5W%\(7]:5;HG0.OT-ZNBQN7*LZ^9)<*OI3C,A-J? M VZ?LNHJ"X[C[@U^NK90*066FHUHX7-,V,:?*
(LLCNK[/-9P=GNB7JG.@4I;/ ML;.BWCI=44&AU#»;,3T<-.VVADD@M-UU#'#<71KA)49#++%$[THKV M<>/3$BIQ?
*_3'Z!%9TIMUM'ZRH]9P:=CT_2LIW439[2^_&WUUT9K"W^/V2X-3B1KN"6&1JY9+&[[5[5YHOR*BHJHH8G^#LZ. M&PMSZ.FDM3V_3>G]9:DJZ=)+Q<;K315U135J_MD"-*
D:O4HSW(U&Y.B:57<2 MN7[>$G2OVVT71VU3MQ05-L75NI*9**PV[@1U/$]Z=9/,UG[6U&H[AS5<[" M(BHCE2'Z_P "G/;;_/4Z3WGJ5Y,%Y&5K&U%F5U2R-*
*51>%TD<[$D[,^Y:G).1) M6V7@=MJ-&Z?NT.I+QBDDC*9* MS[T5SFT\UNB@E>A[IS5%BK=94^K+;=ZN*N@;#;_MG4KJ>5&*R1559\2..D7HQP+VYY69]+P<5#K/I@W?*
*>+4.HJ.[Z:NK*B<I-_M;G(LDF*R1'NM=PM7C3XT1< MHBO9-&V7'=EJ+R3FO:97]$WH-[>]$VCJJBP1SWK5%;&D-7J*Y(U9W1YSU434 M\V*/*(JHWFY6MXE=PMP&0T$3*:-*
*L4;49&QJ-:UJ81$3DB(?< M M !XKA7P6RAJ:RHD2*TSVV32R*BJC6-15H9(*CA>GDV M-_^C_%:CYL?30@&_?\ 4?XK4?-FIH+WY9\I5?;K'YX\X3]Q-;K^/I?*
*T=QD_M!NAIO9KH0;9ZRU9SRS M3/5.)Z^(P\,;&_;/Z7'9S[0,)=,;=UIX6+I'2:@O4-58-HJ.RK$G"Y$2DIU5'>+ M1.XG=/V^&U6:VP-IJ6CIF\+(HVIA$ M3U!ZO-5557FIK*H/*
*O:LM,*P4&^7B4*NXUCH/-&U781,X2H[<(GL/3]1NU MU_\ I 5'Y,G_.:_VE&FKH&ZYLFS_A%)R[=J^X0V.2[27BQ4TE6[JXUK'7&*-M1D:N7DU7)*
*]&YQERM1,;D1<^NA+T2+WT4[1]NAO&N7;W=»]BGFCD23/A\72- MKT5OG2/SGC1>6.PLSI;»#(T/TFM456L+?>*C1.LJ[&)5UM/3I54M9PHC4=+*
MKF+Q\+4;Q,>WLRJ.4#)WB]4151D;>V M1ZXPUC45SEY(BFHSP:6L5W%\(7]:5;HG0.OT-ZNBQN7*LZ^9)<*OI3C,A-J? M VZ?LNHJ"X[C[@U^NK90*066FHUHX7-,V,:?*
(LLCNK[/-9P=GNB7JG.@4I;/ ML;.BWCI=44&AU#»;,3T<-.VVADD@M-UU#'#<71KA)49#++%$[THKV M<>/3$BIQ?
*_3'Z!%9TIMUM'ZRH]9P:=CT_2LIW439[2^_&WUUT9K"W^/V2X-3B1KN"6&1JY9+&[[5[5YHOR*BHJHH8G^#LZ. M&PMSZ.FDM3V_3>G]9:DJZ=)+Q<;K315U135J_MD"-*
D:O4HSW(U&Y.B:57<2 MN7[>$G2OVVT71VU3MQ05-L75NI*9**PV[@1U/$]Z=9/,UG[6U&H[AS5<[" M(BHCE2'Z_P "G/;;_/4Z3WGJ5Y,%Y&5K&U%F5U2R-*
*51>%TD<[$D[,^Y:G).1) M6V7@=MJ-&Z?NT.I+QBDDC*9* MS[T5SFT\UNB@E>A[IS5%BK=94^K+;=ZN*N@;#;_MG4KJ>5&*R1559\2..D7HQP+VYY69]+P<5#K/I@W?*
*>+4.HJ.[Z:NK*B<I-_M;G(LDF*R1'NM=PM7C3XT1< MHBO9-&V7'=EJ+R3FO:97]$WH-[>]$VCJJBP1SWK5%;&D-7J*Y(U9W1YSU434 M\V*/*(JHWFY6MXE=PMP&0T$3*:-*
*L4;49&QJ-:UJ81$3DB(?< M M !XKA7P6RAJ:RHD2*TSVV32R*BJC6-15H9(*CA>GDV M-_^C_%:CYL?30@&_?\ 4?XK4?-FIH+WY9\I5?;K'YX\X3]Q-;K^/I?*
*Q/MZ/[A5J/FRXMOND!MENEJ%MBTOJJGNUV?&Z5M+'#,Q58U.N7+F(G+XR*K-R MF-;J9B/@FG(M53%--43_^*5DYHIU.V>1;>O]RM.[8V&:\ZJO5+9K?&U5ZRHD*
MPYZHF>%C/=/=^]:BJOH-5-,U3I$:RW554T1O53I"ZE5?01WNYOOHK8^T>/;N MO<5 LK7+3TC562IJ53M2..-.\U1,\FIE.JA@UOWX3&[W]K[3MC126*B558Z] MU[&OJI$[/K47-
L:>MW$[FG]H8!T.S.X.Y+6ZPU7/645MKGHOEJ_RN?45B=]MK|&]>LFY=BIAF<(KV]IW+,S=VGI,FK=I]7G[\VU9JJZ+$IW]N_L3WO7X3;4VI M$EM^W=L32U"
[+5NE>C)ZUZ>EK.<BH8Q/L&MMU[Y+>+U55U;55&%EN5 MXE>YSD[41%=S5.?)$Y)ZB9[+MIIFSU$$%CL\U95Y1C:JM7KZF5ZXJRU$1C:.
*M^JN&L'R6FWN:CVT$*IX5)ZGY14C3U$[_7WE4 *ZX_;5.E]^[=TQ/B,5NE]^[=TN_&/VAV`!6=_M M M T9>$DV;U_JGIG[B72RZ'U)>+=+3>3NJK*"TU M$\,G#;.;5KN%*
*[&*U<.;J+A>2HJ=QO-_&(W@N-,7O2'1&L=LOUIKK)<67&NNJ2)5XE9#9ZUC<^G"],I>]OV)M\/ MO-W_)==_P"0_2B /SEZ$YJWIAUKIZ2^1^O&0-N-.Z1TELK4:C4E;E556XQ@*
MV1>&&J==ZDT-H;0NCM.WN^T-PJY[E=5M%NFJ4;U;, QZQM7"*Z61V%[XVKW M&Q(?F7^EZW4_P 6>L/R#5?-CZ7K=3_%GK#\@U7S9^F@ ?G,V;V$W-H]V]$5 M-*
1MWJRG@AQM#)+--8ZJK&-2H8JN/>OH9;S]%[53ZBIL=TFHZ?K; M#56G62R4Z*Y9(DD?G0O]3^%R*G+*_I&U5%9;A7ZXW'GI9%,3V^9 M]7<.]D3S7*C%XD:*
*[GA78SZ5/TE@#6YX.CP;MUV\U'2JGIH4\&IZ=CO)&GVO M;XBKD5JSS.:JM67A54:U%5&Y557BPC9M*H]@IK_P#RUM_3ZE91TL*KE MR-:G:Y>

*MNL;:M0=1*YK"7SE7N3BB8GQJA9/0UZ(6Z.\O2%^F'WY¶HJBW5,-4RXVZ MUW'"%(:BIJ6-1(*K#C,,,*-:K&NPY7,9W(JKG_O\ [-6KI .;/ZHT%>'=537BE M5D53P\2TT[51\,R)W\$C6NQGFB*G8H%%Z'^KX=<]%W:R\0S,G633E%3S/CQC MKHHFPS)RI,21O3'=@[_3>U32:0Z(N[F=6R-CBFTY66]KG=\E3&M-&GQJ^9J? M*:U=K=]]_/!CR731&M]OY=1Z(\;?/2N?-)'2I(Y419*2M1CV)&_".6)S,HYR M*K6.5R.^NY&\N_?A0;I9=&;2T5)#/;UM2DU3(Q\DM&CVKCK;JL5C&O2/*JV) MC455RO"]4.K0R4\" [I6IM'1Nu>JB%T3+MJ.7Q=SNR2***%&GJXUD;_*"F~M0/34Z*TWNuEJT:];T)^)7F*[^.^3_':>/@@[NKX.MCQGK\\'$*ON<8YY21M MD=H[1L5M1IK0EBXG6ZRTJ0),]J(^>155TDKD3EQ/>Y{E];B_0-5?U"W_.;; M_P#FG_|.;H^H6_|S;?_.;T__MTVJ #\|/34Z*?TH6Z=JT;|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`XI;*&/A;E;<,;:>VHTQ3:=TO:HK7;*?FC(\JZ1Z]KWN7F]RX M3+E7/),Y$(>Z2?)CW4V.DEWD;L5;&QHSI+,*QJ_'>E?M2CI*]TA>D M!!MO1SV*TNZ_4U5+#E)&JBMHFNY(JWI?CFC?B5>6$6"NCMLG+NE?L;Y?6R2.:? MI9569SW+Q5DW;P9[53GERJO-$[\IYZ:]JG6[=9>IHIBB(IC2(5+HX=`OZ.9 M&:DU%9\+'8H9$6FIU3'CKD7GG(_1IC"XI2F:4438V(QC4;UJ81K4PB)Z# MY4M+%0TT4$,388(FHR..-J-:QJ)A$1$[$1#U$-@ M M M M $"](#IE;?=`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{ESG')DI"^P'Y06'^SWMG_C$TG^7*;_.X_9[VS_P 8 MFD_RY3?^<"_&E;PUOV4NEOY&4OZ=7DJ^ M_PV_Z MD_X\BKPUOV4NEOY&4OZ=7DJ^ M_PV_ZD_P"/ VJ M M M @?IQ_8L:^_P UA_2(B0ME?W'=#?Q%0_HI"/>G'!BQK_|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n1J=M8YJ.7M=V4+GDA3O'+%YHF4 N"-R.:BIS+ "W;KDEQ\8> [JX\K^]T'MAU1XFYI, MKL*G9DM?=.:EUCHVX6:2]\?74, ^MS(N%8Y%RBKZL]H%NVJ]9;Z.>>14560N7 MGW^:JD6;55/5T<+E^W57^U57_>?*Z;@.MMCKK;<8W4]X9 L#&-15CEP";=-5_#&TOFWW!JM3F1[14+Z2)'-YH5FV5YER1K7)GG@#B[5"4T+W<7"UJ9]6K9H,6O!I^BEX(73)]:5R?](K?MW>A%Y(A,_FM):'3K;+12<-PO3E MIF.:O..+_I^SE\I2-N-.TI[M\$$+$;'&U$1,?G ~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|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|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

=^V.HJ7H!^$GU72ZQB2V:1OKJND9<7,=P0V^KF;44T[<) MYS6OBCC>]>YX9/>X-P%_]2T5EB9>Z>Z4<|F?#XPVXQU#'4[HL9XTD1>%6X|\ MX_T\LTW7^#C\(?INQ:<^&5CW-5,*O5 MM[.)R$T^&^HY7;?[752-^L1W2LB<[/VSHHU;R^)CO81%O=JR@Z,7A+M"T>@'-M)=K%8)*&AEN]/E89::DJ9*JJJ6NQC@3K)&-=[EZM9A?/15S$\!*WM%5[HI$^Y M5]M@DGK=)5L=_P"KCQEU:QDD=1G/R1JY1S5I8U146TI*A2.EF|&I%K>3B7'_];>$]M%,B$&^#&Z2FG]V^CQIK M2+[I3LUEI.D;,*FUR2(DTE-%YL$\;57+I=7P-54['-5%.TWPI?26L.UW1\ MONA*>YP3:TU9"VWQ6Z)Z/DIZ1SD6>>5N>!'A>W9-MK<.56_6W7^-K78Y*J4S%5/DXDI<'AK?L6M+?RSI?T&O)&\%WL[5{1=$RR+< MJ1]%=M2U4M_GAD14>ULJ,9 BY[,PQ1.QW<:]^3+H#\JX/U4 #\JYM4\;_AM M_P!2?|>15X:W[*72W\C*7].KR5? 6_X,?]2?\>!M4 M M M =%^(PYZ;G0J@W7HZK6>C*;.GUC"SCJ;2-$;RYM1/S2HG8OVW8O/"F8R_&6 MWKW7-DVUTG<|2ZAJVT5]M\76S3.[?0C6!WN7[-#=515%!634M5#)3U,+UCEAE:K7LQ44]6G[! <=5WJ MWHYKASY5PB)WJP\93EW&$728WJDW#Q!.9LSEDLE#/PJ^)57QR=.7$F.U MJ+E&X[Q8HL6XMVXTB%f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|J\JW&<(>?B1L;X/,^L=)(K3SUCW1PN\[%I:VJ M&,AD57=Q M%656I-4.MI W^QH"*M34=S5[F)Z5)%W:U$VRV:MJL\3XXU5K5[M%7L3\Y2-F;$RAL].LGG3S?797] fGNYJH%ZZKN9%$< MD#?87+9*=C8V\NXJSFHK<8 HUDIXZ/#$8UGQ)@K90JR5M+,J9PO<>NBN#9&J MKG?G [UJKR=Q'FIVIXPU$7FJX+XNMSBCC=A4(^C< 46I8;6!%5&M1%.U+2LIH6L;G)$P4NY5$87/X5Y(:15W3M3OBR> M-KW*C6HKO=*B(BK\9;*:A8QRHJY/HRZ-G3+%POH NILB.;R*7=\N@>N#O9ZQ M*AO]^>G<>RKB22%Z8 I%B9ASD*]P]Q1+/(C9GM7N7!6P/G+-U++EQVS M5"1T_"KN>.29+5OUW8UKD:N5.% (CMV]O-P?)\R/CFFITFB=)V M/1%PY$}.?[R9KYFWSKE315=O>E)=Z*3KZ2HQ[EZ=R^EJIR5#Y M:$W@IZ14MUX1MHOD7FS41[FQ,21W9R3(%A[Q:LEU#<-/V15< MD#]AU5,W/)W GFI(5) T4UD-/^\"_O;]^35MHJ74|<R:C;3T+7<7+&"@W,5W$|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|I0[V M,T=9I]*6F5?+EPA^OS1K_:L#N2|^Y[DRB>A%SRY%A]$39WRI7+K:ZP9I.5ZL MML:TY22IR=+\3>Q/WV5[6D=[8Z*NN_FY]147222:G?+XY=:I.6&9Y,;Z%=[E MJ=R(J[C3/>W4%-;:&^CI((Z:E@8D<4,;>%K&HFS1+[DP<{UWL M-M-M-M UI>%!W4J=3;E:7YHI)W-M/%NIVWN[0M7#9YGN5M.QWU]-<_' MIXV(;U7:M$Z>N5^OMQAM5HM\+JBJK*IW#"%&U,JJK_N[57DAI/Z0VOZK M>_I"ZSW T]-'8]-7.2'"*CK+LS$SXH861H](W+YJ.X5P"Z=-4T5/3MQ@ MN1+M%'YJ>1X:3>32#HT2I6X6Z3'-M-E7;Y47/HRU%0I%VW;TY4QXHJ&[U\B^Y;#0O;^=\$-OZU:RC;YD]J6_O1Q6X M-213-\UR*OQD#2;JO56Y7QZ/JWTW+M3S12=8Y,)V+DCVX:TN% M+UB6VFDN;T7'1MJJY<^FM*Q11M3@3VI \Z_P"K M[Q4JR>UQVZB7MD=-QR? @IR_.2#H)U):XU:QV9WKE[W^Z52Z_II=B6/"L0MN^:_M=6CS-3^8IO/D!<|POL4.:8UV78RI*&H]?0QR204[*54W8[.|$^-2W-0:IG:B MD8]8ZF1RM5W>C>]3M9[.V2-L<+*;6M? 3.ZQU.Uf>|SS*A9=VZ! MT]0UC5IG^^7L*LNATDCR]O$OK+6U)M_$Z)ZI'A0),I,W35D<U"ZY+_#-2)*CD1'=AB=0:FJ|#7*.CG>Y:.H?U;>+L:[N+WH-65MW=U%+Q M/:WEQ=R 2K+?FT2V5$]29\[A4]DVO:&CH)*]]HZ>GC;Q/DD=A&HGI(INFA MJB]4F*]LJ8USQ9IY%C5%^_.KYMM#;(I'U-=?71_%Q(VKF5S&_?>T2E N>LU M%)NWJI:I+QI8*)V+=3/141[N^9R>E>[/8A<5;6=3#U3%QW%"T4UM-;F\D3D?M9M1XY=D8BY8U0+BTYIGQJ9)YDXW+V9IB_]"R=4YJXY(>32D;'0)A.PO>DIVN MA1$3F'UM3>K.B8*D?&"|(<>#XUE4L*+SY >#4'"Z%R=O(M"OVYM6JJ9$N%|# M6-[NL8BJWXE[4*K7J/9%HNEA,7?%GDQJ53&M.ZX6.>JL!TA=17.D7@GIW]>AR>EJJ*9P1-1K41"MQMU-I+1N7;KB5'L5/<2,[.)BIZ+V_*3_I^=M=$SSNX"8Z1R.C3 M\!G8X5R6S;KTWA3SCTU%Z;U;O. I>HZSQ3C>U>91++=&^Z.1SLNO1=L:ZX4-0 MYOG83)4|&TK'4D:X{@/O'9(^K]O^8H]WL4:QNY8) 2%J-Q@I-YHV+$[EW 0- M?+?Y+N$;P M\CWV)S%/%V{F.JA661M3GCF!8M38W4N7,Y'$-=XOR>O-"Y|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|S^$8O.(L<5/2PL8QK M&M1$1[)R1 /]33NHJRZ>5FM-8ZDU0R9R/DBN%TF=$KD7*+U;.1B7L1$Y$?:MZBZ/$;)$K;?63>,O)AD->]U,*IZ%1W-$^>)(^CHF1QIR.U30LDC7D!8I@*.O M5E8ZQ.8T_26ZIH6)G5)U^C? CG\7:A5[EM_AJKS8OQ)W5STM0U%?"]LJJ_K[R|[?::9^'S2+(OO8G)'-^U?\;+^923-.1141LW'NCML3X\-C1J8Y0XNOPV-,]ZX M+N@MBR1HO8>FFM$]T[&Z-WFE?CC2-, (G[]#NU#VZ6IY=Q+735M/*Y*65,..[W M3'R1)&]*9'0NRA#%-47O;S5]7)I[Q>;&XHD\|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|'>M=RK^YH6BH,:ULLGFI/42IPM7L]RG M-0/ONEJ>&GC:CN*>H?U<<;>;G*OH3U%.NEI6Y6NWU5NDJ(+|;H593R-7S)$ MRBK&J,DH6OIB)$^O"U=M]T M8]VLI[7>*2HL=WD8CF4U8F&R^GJW=COBI27VU4?5J_/)$+ U5MM0ZBMKZ6L@ MZQGNF.3D^-R=CFN|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|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|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|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|45/2A'%QU[?=OI;=+'>YUJ9$HY9+7='>_ %+W*W8N&JM3U&E-%TZ*Z&1?&:IGN.)?=<^Q$3O7M5>2'TTVL-25#4J+ MY)+>:UW- [HG*D:+Z&M1>SXSW

*(VDJ42..1'QH|SG-5$DX517.YHBYYX3(^Y6RDO5OGM|P M(;ZB|&+'-35,;21RL5,*US7{J*BIW*?&Q:?MFE|7#;,-,:6TVZ!%2*CH8&P MPQY557A8U$1.;JO).\#F_7-;)8[E<6TLM:ZCIF*A*6G3,DW U?<#$[W+C"}>M M3!;H$^$3UATK-X=0Z/U)I*UVRAAM\ERHJJSI-Q4[62L9U=0LCW(521,/:C. M;?<_-S]*#9-&V'3%9<*JS6.W6JJN$G?5DU#21PO]7Y5>*1S417KE5YKE>;@ M5XUY|A>$HUGH_IOP;/TVB*&HTNV\TEDF?*R;RG,Z;@3KXU1_5HWZXCFM5B\3 M4SQ)Q>;L,*%/HVP5>HX-0SV.W2W^GCZF&Z24D;JI-G/S6RJG$B>G5]WHCW#1ELTGI]V7.>]QSU,]=>33XY7TZ,C_6JGN+Z"5558%DC1RM151,ISY+A,IA<%,U'H[3^LZ6"FU!8[??;.&1)HH;E21U#&/1%1 M'M1Z*B.PJ\TY\RML8D;$;U%:B)A$3L0"#^F5O|=.C5L!J#7EGLL=[N=&^"""M&HXO%XW2R(Q))N%4=P{]B*BJJM3*9REI= #I5:@Z6.T5QU}J6PTEENUONC[M<^2VMD;25*)&R1'1I(YSFJB/X53B=V(N>>$R1N5LI+U;Y[?<*2&NHJABQS4U M3&DDV<83\U|8+1VHM)6RUVZ.WRW&BJK0V;CIFLE8WJZA7O*1S6HKURY5R|-OI KYKRW,) M-K7!\3;MO6+#4Z7;>*.SS.E9,MSG6=(_K\2H_@1OUU'-.K'<36^Z3B\W8 M:4&HT5I^KU)#]">Q6V;_Tl.KANLE)&ZJB9A4X6RJWB1,.=R1>|?2!7C"7PB/ M3FU=T1*G1MOTGINUW.HOC)ZB:NO<BJJNPB8Y+GEFT M4'4VC++#K.EBI=0V.W7ZEAD26.&YTL=0QCT141R->BHBX5>;<^8%$V7U]-NIM M/H_6=1,)+-/?K53W%|!*JJL"R1HY6HJHF4Y\EPF4PN"Q>F5O]=.C5L!J#7EG MLL=[N=&^"""&HXO%XW2R(Q))N%4=P{]B*BJJM3*9RDX,8@;S;U$:B)A$3L0"#^F5O|=.C5L!J#7EG MLL=[N=&^"""&HXO%XW2R(Q))N%4=P{]B*BJJM3*9RDX,8@;S;U$:B)A$3L0"#^F5O|=.C5L!J#7EG MLL=[N=&^"""&HXO%XW2R(Q))N%4=P{]B*BJJM3*9REI= #I5:@Z6.T5QU}J6PTEENUONC[M<^2VMD;25*)&R1'1I(YSFJB/X53B=V(N>>$R1N5LI+U;Y[?<*2&NHJABQS4U M3&DDV<83\U|8+1VHM)6RUVZ.WRW&BJK0V;CIFLE8WJZA7O*1S6HKURY5R|-OI KYKRW,) M-K7!\3;MO6+#4Z7;>*.SS.E9,MSG6=(_K\2H_@1OUU'-.K'<36^Z3B\W8 M:4&HT5I^KU)#]">Q6V;_Tl.KANLE)&ZJB9A4X6RJWB1,.=R1>|?2!7C"7PB/ M3FU=T1*G1MOTGINUW.HOC)ZB:NO<BJJNPB8Y+GEFT M4'4VC++#K.EBI=0V.W7ZEAD26.&YTL=0QCT141R->BHBX5>;<^8%$V7U]-NIM M/H_6=1,)+-/?K53W%|!*JJL"R1HY6HJHF4Y\EPF4PN"Q>F5O]=.C5L!J#7EG MLL=[N=&^"""&HXO%XW2R(Q))N%4=P{]B*BJJM3*9RDX,8@;S;U$:B)A$3L0"#^F5O|=.C5L!J#7EGLL=[N=&^"""M

(TMQVTT75N\O3Q}5=KG"Y4\2C)8D>]Y5,^=([MYX[793:)0TD-MI(:FBCIZ6 M%C8XHHVHUC&HF$:U$Y(B(B(B(=K(O48=KV:S^*?Q2_B6+F?>]]OQ)V/PP|] M-1O8?.21D,.O>Y&M:F5E3ZF?2KWTDBDFT5IZKX?-5EUJ8EY_^@1> M{|\?#[Y#@/4K Z0^\E1NKJ>*Q6-9)K%23=73,A;JNK)E\WK,)VIE<-3T+GO MPF0G1YV-AVNLOE&OQ+J.OB:DZX3%,Q<+U3?7G'sO>J)W)SL+HK[$R6OJM9ZA MI>&H>U'6NEE3FQJI^W.3T[GN<|B97T&4@-M-M-M-M /E)$V2-S'M1S7)A6KV*GH/J -,/3 Z.%SZ*VZ==<[=22+MM?:IT\M-MJXVL=#(]>)I)(OVN%5>!5Y*W'=]$ZXM5)N#9QU3=3KUE/(Y>6>]{^!3 M?YJ?2MHUG8JRRWVVTMWM-8Q8ZBBK(DEBD:OK%\Q?BPB?%V@:NJ*GHJ=4:V3C>O;SRI). MD*5W5MX&)@B[>W9[4_1EWENVA[O4^/34KFS4E5,Q6QU],fR5B]RXRBISPK5 M0OO;O4'CC?K;N!ZL'X;&3K(6\\J4NZ M:NM=&VHA;5Q5%9&UR^+1O17<2(]*^]SV^+M1W"5\,4TD&5YPQNPJ?&BKZ?RAQQNX6N7.%+$H-24]YJL\TCD>R+@=]J^/L MR L>JE.B;Y_=Z2K3ZFA2%7]MKVTD5CJ75#D5.MR.CPJX3M{RF*\NUK6<+*?2=XE<]DGUC">U5P!,-TU8WAM6C-PJ6KIV17>RM;"N7,=!M{J^,"2,%IMD<+?,*I4.?8L.^,W%N.;U)?[!J6BL>K(*%&7)^(7"@U!5N$CLHY5.!>?C2U#N"-/E/M34# M6NRO-W>6W.KE+$K8WMX5]\7=0XI-14+UZM0]HI M46X4.HY7@<.:.QT"IZB,=>1-CCD>G)6\R[Z^X/A1S454P0]NIK|.,::N14R|K M<-3TJO)$!H%J:6N"5>L*I\?G|6U&NX5[\>@FRT55=-UK,M14(RV>TIXG0LD MG\^KJ'=.,]>U7+,N0G^Q6MC(V\D M6HH;Q(WAB]+P0TKH8(FQL8WA1&I@B"[6V>R7!96(J-SE M3)B[V].HDDQJ*!>%[UA"R!{ED:U$3FJKV%AV33.H-XZZ5+.]MML MT;L2WBH:JM)O#'%&WA:U${D0"Q|/T8-&6NE:MB1461R^1S)-93Y3L IU18HI(U3A0 MI6C-6.KZ/^N':QT*Z-9Y$1ESL|E;376%/M7X|S(GVLB/Z=N#D96TCN_+?MV>A[\SSZ%G2U[=Y>-MLT3K):>EW L\+9>MB7ACN]-V>,QM{G(O)[$SA51>Q0,K0 M-M-M-M-M PU(;TVM3=#U=-KIVPVJ^?1%Y0Z_RHLJ=5XOXMP\'Y.WKW9SZ M$,RB'=_NBGMMTFEL/(EBFQ'D3K-!'J;Z.FZOKNKZS/5O;Q9ZF/MSC'+M4# M6G]6XW,_Q?Z3_#J?G#-/ZE#T:?O*K?RY6_.CZE#T:?O* MK?RY6_.@86?5N-S\7^D_P .I^<'U;C15X;WI*72W\C*7].KG5? 6.>2]<2?]>=]M4 M M-M :U7M+/*WK_<=U S_$5=^CO+U7M+/*WK_<=US_$5=^CO_]/O1\6F[_MU?!'W0;3_ ,I8T|_FTWZ1 M*3J07T&_L6=_P":3?I$IZ>D_P!)*R=';0\M94R.JM1UD;V6JVYRZ:5$]V], M\HFJJ*Y?D3FJ%BNW5=R*J*(UF9G]U6U=HLXT7*YTB(A2.EQTJ;=T==M;1+3M7#65P;_Z.MLRJK6MRJ.GE1%148F%1$RBN=R3LCWL5JKI?;L5USO=95K M:EG6LOE\E:KEFINY45M?5SUROEC6 M|?R9|)#0P<|-.U,-1<(Y&1M3FJ=R<3DVV;;[OO55YJJJJ\U*^-^YJ?:,33TIW_MEU#6-5E%3NYHWN65R>]:W)WKRJ./.S.S.LO544Q3&D+7Z3.^J:%MCl.V.JQJ M.];1=FA=YU'&O?GN>Y.SO1.?HS$/1RV}[=Q+M'J;_P ,G:=AE<|&RKEU=*BY MQS[69SQ+WJF/3BA|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|$OJHUWJ17MG82#17R-L?ND0"*B;K'(BV5< 7IJ2[25TBP0IQ/_F[',I5DLLL\O6O5 M7+G)>D%'(V%&=B 4V:7JY*B^:A:M?D;5RB+S+JN5*L,+T:VJA9$\C*M.J17KYRJ|>5EH>NX5=S+G@M;,%.2% TM*M5P*WW)>#4MBK=:UO$U.9Q M:*I8\QN=WE;DC21JHO86Q79HI7+M14 NAB\29/G41MDC7*%&M-^CFCPYR9M0]E5=HVQKAR 6MJ"G:DC\A&]=;X.WK]MC53XES__+B>M0WJ-O6.5R(B M>LQ@W2NDU\OT#HFN2FI96HV3X21SD3"?$F0)LT#41QM8Q>U|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|:^A/6I1Z&;<'5.)9KK!8XGMGQO=W_$A:^V&FYZZMEN|Q8JW"K7CF$E9Z<&M^RETM_(RE_3]\E7P%O M^&W_%)_QX&U0 M M-'1.S)9&]LC(]GM=N>Y&M2PURJY5Y)_8\G.M;6\.[E)<]K7VN M_:5M^GH5=+&ZX=8UT,+4RK!=6]A$557:,.&N7I+=,36FZ-/6;.9;*6,344R MMGGM<*Q.N'"O)55R(Y8\]E&]B9Y*JE51%PPI_ M8=S>F[N\Z.HFDN5.[A2KN$C.&DM=-Q*J(B>R:U/.X6)YSESVKE2'[%44*7*F M9=XY)[?GAR/!YQ%FO.ITVZJM** M8C6-9.,Z)XV=V>T[LAHJETS]DZBEB\^:H=A9JF941'2RN[W+CXD1$1$1$1"__MT[QGLG<[e="S]6.=?[5]VJTW-754D<]SD:J4=OX\/G?V9QVHU.]WR=JHAA MKHK1>I^D1KVMFFJU=*]>OKKE.BJR!JKA9OOMB1[FL3').Y$53BBH[5])'29RY5]*JIF]MOMW:MLM,P6:T1NX$7K)IY$^N3RM*B(KW>Q.7Y>]RKE5*^_M-M-M-M_*=>+/0ZAM57;+E2Q5UOK M(G05%-.U',EC#%U;H2Z55[V9?]$.GWN63Z&ZJ=&5= M)W\,,CE1LC/0CE1R>E3&*NL&Y6EJU]#>-OM5T-7'R6-JG'?*CFM5%3UHIOM M-Y\M;7S5VEK;0UESTE>[535\BP4M1=**2EBP>B95&ND;F<)Z"SK=-4MO$5T MN<[:FK;SB8W|KAS|WTKZS>/FR.CG#*TF-EICJ%T=/]"E>E?9JJ7W,=4Q%PU5 M|FO158O]=GN-(MTTOO\ 0SVB^VZ58*RWU2<,D3TY*GK1>U%3DJ85 M)8TOK:*6%$5Z9]:EWQZLA2-5+O-?Z^N=1.F;P04Z MW'!-_1?Z#^MNE;=DNC[E);I%TDO!/[*]ARR1Z*G%'21=CW)WO5 M>%/CY&RS;CP;FQ6@.%K.K2]:NK^'$E=]*5U2YR]ZHSDQOR- U0.>U-2VWEXW MUB?OE*3N)762^3,N<=QAMEXC;PI49RV9]=C7M[_4O:AN?K^@KL%Q4RB+A?B+EIMUI:Z%KJ6DK:IKDRCH:=[D]N"3^G M#]*GU+TQMPZID$3:6@JH;4UK6IPKU,+&N54_A<2?(1/<:-VG7,hM4>?FD@W1+A"Q6O M1[%1R+R5/41U3WJWZHZBCEDBJFJWAFA54414[)'Z%+,L5^]MGK@M'<5E MJM)2._L6N3+W47_LY,_@]#N[L R#*==+?XRQ9()*B>TIELUE07FD9-0U<%7 M&Y.H^&1')^8^%PU0RW0N?42-AB;S621RCWY[2JZZ.H7JCT6*1OI*-7[D144 M+^O?P(U.]Y5PB)Z2R=5;IU6I*R2VZ19'.UKN&:[2MXH8_2D:?;N _,AY[7L?3 MWE]27FJK;K,]/.ZZ956+|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|C9QLQLOI3H5;?NU-J98;MKZXQ*Q$ MC5%5]JJF5@A5>QJA$[55>Q/7A%PIK*S4_20W/9PLS4U M2HUD;]5]*H@N%RUITD=?0LX/&]IWFQPQHK::BBSS5>WA M;Z57*JN$YKA#-/:W:RT;5:=AM]OBC?5,.BU==P8DJ]ZJOB8ROH1.YJ8:QR6+=Q&T/A<,*ML;DDJ]W9B\/*WREA8JOGH457-F3':L2J[H/UR^@\U^6Z."\VO#>%^6Y M3 %M62+0ZEN=(]?6HY4E8WT(Y.X|{^'|\$-7M_3U2X26EJX96.|&7<*I[%(MYTDWQ/7UP8Y.'ZS%)O:7/NY>$K+#:,?&[+]FNA16_O6KQ+_.!$E=%45&HUM*M2.2G]$\]9[&MSE/EY%P:"NDUF=64:([JZ>549_.7FA\9Z56ZY>B-YK3%.9NL,Y^.Y MZ>GT$_28X%R6'K*C2LA?'C.0.]BOTE="S*=]%:2C2=N7(6AI/-,UD3T[.1(= M%"UT:+W 6O%O-5^>)"]ZNKI)>M>[S<+A$3^8C2NHVR535[']9D M'/N4 _^^B*>>MJ*W5%T;U=141JRGA?VP0HN>?K=VK\ATT?KIELT=%$CN\)`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|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|0=)[;!UH29*#4UL>ZLLER<MG*&HX53@?WK&|-WR6G45C615E'+VL7..)]_;-%ZQ5|Q)?_N] %8M$+KSK"X3PMXFP1M16N[45 MWNG+|F40F33VG8K#INIGE;ER-=*Y5]29*'M1HJ*UVR'-R=9)[?1W:]R\U5? ME+XUXO5Z3N4$:(BNI9&I^"H$'[=6|\UTIZNZ2^=4W"1TSG8[E7DGR)@D2V6UU M'+&B)CUEFI05<;K+1)W=6U/S$RT-|'4)*KCL [6:Z+#EJKS0N-E\;U?->XMR M>TK#*Y[.\\OB\Z\6'84"XVWYG6+A<>DK-!>&N:GG$276NEM\CGJJICM.*#7$ M;<-63"^@"8:F\-;&OG%$X'7"H1>U"S*35'CDB-SE,E_Z:X)HVN10/G)8'1:7 M8DI.X/M#%]07N1JV'3E-%*Z\U34S2I'31^ZD>OZNTM>W6>XUTC MZJJRDC^,Y(S]15[FV&MW+IV529AM$>9K5[.-]D:B^Q=,NJ-7=6Z.VVJ#QJY MU/FP4[/Z3O0U.]0.-JK6VIW9O%>YRRPT-&RF17-.M\1>VFEW:=M3*5S^LJWO6>HF^%D=[!?B[D]2$MV6-4C:AO/I4#[6VYMI7IA. M16#HR/A.R@>&XO:D:D7T'BL$+'>,(YJ.1WTPHQN4|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

*]6MV.^]7<#\G4/\ S@^K6[''?>KN! M^3J'_G ,Xl:?WGWW_,9_ZMQCWX,/[%^R_P"'2UG|&U!.PY-?_U:W8[[MU=P/R=0_\X/JUNQWWJ[@?DZA_P"<*B^V U__5K=COO5W _)U#_S@^K6[''?> MKN!^3J'_)P#8 #7_P#5K=COO5W _)U#_P X/JUNQWWJ[@?DZA_YP#8 #7_] M6MV.^]7<#\G4/_.#ZM;L=|ZNX'Y.H?\ G -@ -?_ -6MV. ^]7<#\G4/_ #@^ MK6[''?>KN!^3J'_G -@ -?_U:W8[[U=P/R=0_\X/JUNQWWJ[@?DZA_P"< V MU_| U:W8[[U=P/R=0_|.#ZM;L=|ZNX'Y.H?^< V U__5K=COO5W _)U#_S M@^K6[''?>KN!^3J'_)P#8 #7_P#5K=COO5W _)U#_P X/JUNQWWJ[@?DZA_YP#8 #7_]6MV.^]7<#\G4/_.#ZM;L=|ZNX'Y.H?\ G -@ M -?_ -6MV. ^]7<#\G4/_ #@^K6[''?>KN!^3J'_G -@ -?_U:W8[[U=P/R=0_\X/JUNQWWJ[@?DZA_P"< V MU_| U:W8[[U=P/R=0_|

*[UR23;85;$A'MCE2*L5G9S)%H)>*/" M@?=U.U?24ZMM?61N595QZ"!GRJ,=4N0(IUA0QPQN5$R["ENZ.D:V945>>2_ - M34|5#7)C*KR0LNDL\E#4*Y]*B=H%*
[]6CHUPF45"TPU"T=5A$PF2K6)OC=*OI M.)[/UDCLH!4:"_(V/FN#KH*.MR2_72*!F>JXLO7U>@NRPV1E5(U$;YC.2)@ZVG2O#&YW#YR>HN+234C56/3#F
MKA<@5*+3T:1(G"A;FHM.QNBDRU"0BD7!C'-3B;Y6JY&^.U57*K@#&[4FBI(Y MY;F%,K1.>2@4FK;^TN=`POF1O>U%)TO5G9<88J>.1L[EYR21^Y]>Q/44<? M34T7"D35^0"-
TW&JV-6*2-/2V"IMG6VXU5Q8CH*U4?V\)Z; 1M+*Q>%)[\?IFM"M"KHZ[3M4L2.1C5[0+Z;>]A3KPSX=ZT+]TE>%KGK%Q8D3G@L2R:HI=4ZPJ3- M2&]:G?V+ZT*JIN=U-
7("8;5=WE MRTF8X\^H"HG59&MY*O,\,E?PHN5PA1J^[)#Q.1P%=K:ID<*\RR;QJE*-SF]8 MC4^,IU[UM%2TTKGR(UK4RKE7"$:,OBW^X.F754M4YS8F MY1?
64]MOU33YXF.1/2U2IV;&AD1&*Q+ZRXG;6@[(>)](D!%\FKE;*BN>[_ M'VER6C6D:L ,;$]H]+MH&*9SE6"K0M]JT ZEC=(QSF8]8%ZSZVC9&OUQ.STD
M4:XWC5U>VUV:)UTNM+75T]GD24SLC1S8V11+ATKG+K]R M*OH+XVFVJH(2L2*ZUW4T+KJ? M9RAIZO2GC/44L=^HUCGZYG"OSJSY3'J:GCVIMU3.U4\ICG',^KCY.1%RB*::
M*N<3RGLG5+^B[3N#M]$]M@VHJV3]=GBX\\+G8QAG;V\7J(/3=OI2HG+8FT_]H:7Y\D_M9#6.Z.I&7QVYFAJ++:=(5H74]RBJDJ$7K.M5W]W#P\,?;C/&OH*==F:(FK
M>C]\B5ZWDTW*MV*9CXQ,1YRET%.M%[M]]IO&;;74]PILJSKJ69LK.),U,M54 MSS0)H7 QEF93QODE>V. -J9+A8CE1/=<(&5@,6>CEX0K;OH!;TDT3XC>-
$ZW:CECL>HHQ$0#T@A'H\]*C2G24O>OJ,2$<]1;=*U\M-!%4*/>BUJX?&V.QI M%[G) P#87**]&&&XG19UEU!]GDME&_4=K1*;&>2.B\UG^#E/6!#*1];
M6EEKJF*G@C=-/*]&,C8BJYSE7"(B=ZY+BTUMGJK5M9+36FP5]7)#*L$SD@C$W0]7%J'4SXJNJQ^=34<:\45*[*NG+]LJ.[')O
M:F5P]!,FW6G7:4T+8;/)CKJ.CBBEX>SK$:G'CU<62Y "GW.[T-CI7 M55QK*>@I6JB++4RMC8BKR1.)RHA]Z:1CK(8YHI&RPR-1[)&.1S7-5,HJ*G:B
MH!Z0"G72\!%CI5]C74]OIT5$6:JE;&S*]B9"Y7>AO5*E305M/7TZ MKA):.5LC%7T9;]H>\ "R-W-W-+:(Z#N6O=975EJL=*U..545SY'N7#(XV)>
M]R\D1/CY(BJF(5G\+QMQ/6V^IO>A=;::TK<)>]IM1UM Q],O-L \-?=*.TTCJFX5< M%%3-]U-42-C8GQJ[X]P"?:KU;]Y3K46VOIKA3YQUE+,V5N?1EJJA4 :!!V[
M'2QTAM1N]M_ME5]9<]5:NK64T='1O;FBB>O"V>;*\FN=F&IVKPN7N G$ M >6LK*>W4DU155$=-3QMXD)GHQC4]*JO)$,EN MN5+=;,.KHZF&LIY$RR>"1'L2 >H%-M.H+9?
HGRVNXTERC8N'/I)VRHU?0JM5<%2 L_=*#3.S. MB+IK#5]TCM&G[^.J6Z@=0Q=3[KASRDX>W/)'JO+LSR SY!:6VFY6F]W]$6K5VDKI'>+!6
MH]HJ.FEGGD9**$U7R22.1K6-1.JJJO8B)WGQM=WHKU1MJ[:64],2O54,/3R- MD8[*X7#FJJ=H%0 /-55<-%3OGJHX(8TR>2L2R:,U/2]EV +D%+L^I+3J!:LBV
MNZ45R2/DI:.H9+P_'PJN"] 4#66L+/H#2UUU+]&X16NR6NG?55E;/GABC:F M57"(JKZD1%55PB(]J835'A?-O8Y*BX4^WNO*W1L,ZP.U)'01)]\7#E61P
MJJF$L3=3;*Z[7:OFN]^N4[JFNN54N9:B5R\U7T(G8B)R1$1$)2N-5-) M&Y(J=V?B(;W(N%7;IJ>DAX9+S7*K*:+NC3[:1WJ3^<"AZFKGZSO,&GJ=56W4 MN'W!
[5!V[6+_>1,FBLM.LBI8D;&C6-1$!K0M3;C.AEIH8HU59'JO'+*WZ:HAEE MYJY?C4FJ%Y\.FIV1M9C"8 I4=!8V-,H?.NLK)(W>,DK#&HU,>]DK#&HU,>]4#M@XE?"CD[EQD\4ES2U-
5&4_ OIUI(+N",..1%0H-ZCIY(W*C$S\0$/:VUI4 :* MSN9&YJ-1?.=R+!VTH7TM)6W6K1'5M9*Z:1W;CT)B%[.E4ZJH16,.CD6-!=D MLNEWN5.;6+R _^UXNEPUM<$LU#*Z"@_|
A=1&OG*GP;?1GO4E+16@*2V4<<,$ M#61M3"(1YLE:`^&TQ5$]*L]0Y9I%=VY%&E*NRMZMR]P$$.8U%66/5|^G;CB+K&=90U';D MC4Y*BY^V:O=Z"==*.ECM-
/%55+:NI:S$D]6(Q'KZ>%.PA3=:T121LN+6R>,6 MYWC<3H?=.^;VHGIRF>1?VW5\9?+325<,R20S,1[51>U% D5!T1CN\M/4%*^H1 M5O@NN-K>!.\I=\D8V%WQ
4C3DR91BKS[*IF^Y0C.U71D%QJIDJCIFM[5*"?KA&R%WG)V 6?!"BW!G#R57DC4D*)&U53" MX(UL-2E3>LKS.U21(;IO$J)S0#T35'BZ34[D/FRTNN"JY4\T
MIM/6\50RF]?.5A3MJJB2NN"(C<]7E5+4L M%3)8;J%Y1.=E% RAT\K'1IS+HB8S@]$VE]4,2"Q4>7G3,B.]G)P%0NR1L8 MY2S]^DGK&O+D49-J+EOEXK*K-*-C;Q-
9A4/9;.LBAZMW/ M'(NB1T-5&_JWLDX55KN%R+A4[47UEO.1*:M=2%4KZ+,3OW!(M.GKQ24--'&DC>-$Y[\RR=^\W^CMMMIG*E357"]L:M7'IA>)5]B'GM6F+CPHDD MJ[\2
2K5:NACB7$J+R])$NJKQ5Z]OK[#;)G04\;>.X5K/^AC7L8U??N_,G,^ M^K:>JTYI>LK5XI'QMQ&UN55[U7#4^550MJS5+K+IMEMI\I+,O75M2ONY15[?
MB1.SXD+N+B7,FO=IY=L]SG9F=:PZ-ZN>/9';*9>A77Z1T%O#=V544= MQIF6 MZVU3\$XT=Q.XGKS17J(B]ZM];$_],FZ6^Z,2S4T-9!-/35L$Z1QR(YRI,$T"S-
OWIM54U4Q.>0PKNXR:@VLTK3>YM$;E_]([_M\IE*M1Z,I*IXO9*:>EE*U7>W4K3LS>ICB\I3E\Z44S.14HXY]C6.5SE!$=M:F5*A2Z8O-,^T6JLF_R<#W?
S(9DV705SKDX:.@;#'Z5X6)#/_I%X4>R%TGB5 MTU;!$[&4.QKG^U>14JVA9M\ZH_?]G1M8V?>XV[$_KP_=CS8]"4FH=$V>&\44 MU'I-
H8. 8NZQ3/.) C5AYYOQ'7D9;5=AMUPFZVHHH)9?A'1H MKOE7O^4]MFL&CY')'<]-6F;_-]ZBCRO=S5$R6KN57:XQ1K'A/\ "]A7,;*G M>6-/]AZ$::EZ/FD^L9LW*/;HN55I&NKU]
M^S<|CFW;C6K31C)0:XU':\>)7^Z4F.S]*R1F.>>YWI*S#O+KB-BHNK+M,G_Y M15.F_]JI-TG0&U-41]^@U-:9NW"5$M M7[]C3UT9.#R,0M.KHG6V21:Z)
MZ<2=7+RC9R5%Y57GR:O/&%SV#=FN8C3PT.GZRWXLHR:HF>_7^:67O@\MX++ MK_;*OT[:-/6O2<^G9VL6W6I'&^&1N6S+QN=]*BX7L8U.HG)K6]A+?#VGB[]5NJLVH
MTI>_Q:;M-FF+TZU=KN@-"V M M M M #2MX:WI*72W\C*7],KR5?`6_P"&W_4G_'D5>&M^RETM_(RE_3[\E7P%O^&W M_4G_ !X&U0
>.MK*>WTL]553QTU/"Q7R33/1C&-1,JYRKR1$3O4 MU9^$*\))?;[[8KEMAL[<_*$59&^GO6J*3*QK#A4?!2N^V1R91TJV:J]
07U-.LK*ZEGGKG0+/PQO2<;D1B.;Q*N%QE43/,QKW]Z'& MVW19Z"NZ\.DK6^1O51;65E^N"!+6U']DPY3BPB,9E,\#$1/3E>8%?\ Y?8 MB2_RCK?Z$)FU4U<-#2S5-
1(V&"%BR22/7#6M1,JJKZ$0PE\#E]B)+_*.M_H0 MDX=-K4TNDNB=NS9]/-]#]32LE;GB:Z9[PHJ*G-^.NZGBI^-6PRR0(K>ND)58KT:]41B(Y$".U#M%I:76VS^O[M<-46*-
U8E&YGBE7)PIESJ6>)R*V1$XL-5,N[$-.,3Q:X-ZI<9Y<+6O1.WW2_&FQ7I,?LQ?0+ M0?L)^0_HK\HQ^->?_P!H\3ZJ7CX?W_6=3CU<0$ND&[=%G3VPFJ-?:FIKE4:
M@U%K&ZR7.MNEPBC2>-'N<]6..F>#B]4;K4>$2].BVPZ;

*[OKJ\4$M%;+;_M;:ID\L#I6*SQF3A5>!C$57)Q>Z5]{G>]6-X'_9&NVWV#NNK[M2NI*_6E9'54 M[7M5KW4,+5;_|<|SG23.3TM\"4>G=T4|6|++1VF|+V'65)I>ST=7)67&& MJII)?&Y$:UL'N7)R9F951"B M^PBT5_G5Q_39AX5S[*+6W^=6[]-A'@HOL(M%?YUG9.LBG5BK#(J=Z-D1COD-;/@LNE%8]C*C5V_MR6YUPBT?*

61WB6HHJB[2!7%%5HC8:FDD>J\,2HL+5,E417!,Y5$<&V@U%^"T MA6NZ=V\MRAX9:)+;=6]M75-,^.S6:W54<\TL[FJC)'HQ5X(fKYSGNPBHU43+E1%QZ\#/LO<=+;;M:NW(O%/_3GW6WKDPZ2E@XU?.B[M?+!(YO/X'/8C]*H9U!K;7Z=WEV_O6B M\54"3N1/07?&Q7:'JIX<\+!JBHYCV.^U>UR-Y6H824/2M7^*WI[.12>UK;FM@2XP?V12\65]I^AJ\.L2_P %Z*GQM8-5^X5TM-NMY.-_HG:F/2!\=00,UUTE=T=1PIQT"ZAKHZ5Z+Q-5 MO7NRY%|>$}54OW2B-B;_MUSU\Y0+K@A2-J)@ZU$+9&+E#O',V5,M7)Q*I#0(ZUQ:(JBDG8]I..YJH]+WHMIY.CQ.L^AYJ"."+WVFMFH6N=WQHJ.9[&N1/D*_K'"%%ML[T[40MGH[R?\ HO5# M5[?+,G]7&!*DU*R1BI@MZX.;AJ^+B9A?270<*U'=[6##9WVZ14:Y> NFSR<M4:9=E3[U]&UT:K@IUL^MRJS/>!MMP+3M]:65=TE>Z25>"GI8 M6\4M0_WK&^G\Q$}3K3<'6[G/IEI=,4+O<1,B2HJ,?OG.\U%^) ++XNUR?-5+" MCBI6.QMD:CW-R]\R)I-,ZWIG^-1.E=(3)\SBR[FK5[VKZT?&,%ZO=9?KE+75LRSSR+E57I_M1.Y$3N1/077MKNC2:%FJ*>\U^06JH\Y.7W$N.6;+@OQJ&1%3DJ$BW&1&QU9VJJB-*1ZY{@,6M=4+]&:BE8O"L-1P.Y]K7-M(]?SX)5V_N3Z>GA1_H0C35E._5&M+99Z5'22R5/7/:WN:WO7Y5)SI=*);X8& M(W#D1&@7[8KLDC&HCLE<=5NX0'P?=.I;MS8KE]13YM2/CFD:^!BPJOFN1RHY$]:+_ +BJLHVN154\%UMK'1/5$[@+7U!< MHZUS48Y,(O,]VFFMZMO8657TKXKDK6JJH[N+HL4DE.C$[,'/,N>RW#\LT"97*@55[>)JH6KJ"G;'ER+S+11RN;R*!>Z%\ MS' >;3U8U&X52YHZACFYR1U'UUOEQA<%RVJ]?4- N-LC7=BGFJ:KJ>>>1U5B MQMYH42ZURPM?A<^H#RWNXMD1W]45>Q"EVRR+62<[5-);;E&J=9)"GFSL3[5[>Q?C{4)Y+ M>U- QU-+E.X"S|'UE5=F-2;3"+RY%[T5.^&JC5D+4I>%S7]9{OB3"M.9'<38V]]{JOQ%\RZQDTO9UNET5%JIVJE'0HOG/7W!O M0U/_+NXM8^/7D7(HI<[.SJ,*U-=7'NCOGN537&L8-'TS9)T1\TOI33-7#G> MM?0GK+CTW<**^6>EN-(O'.SBR[FK5[VKZT?&,%ZO=9?KE+75LRSSR+E57I_M1.Y$3N1/077MKNC2:%FJ*>\U^06JH\Y.7W$N.6;4G/AAG^MU% M*\U-*Q>UKF*K51?8778+?N55LXXH]-PM[>%ZS.X4];\B&KA?JK2NXUWNC:BD MN%OEF3RC56>)_B=)4\FXXW>ZSCSE3DBGEKMVN]7-=R=9?6[-BWCT1;MQI$-B

M.A+XWJ8O.);LEV9.U&JNFR:9(F9R6C>9'W&L,#'SRO-3YW+4J3-1C'9R?:O0ODDZQ4Y@7).J%&E1 MO:N.9[%:CNU.G$6>%,]H>]&-RO8!3=1U5/:[)75]2Y(Z>DA?/*]W8UC45RK[-M$-.^FYKMO'K;^2TTLM)!=+A-6U]5&OG(U[U5D3%]/#CGW(:!NG[N2_1O1NO]-M/0R\%;>I8[6US78U5^,G&@VWIG0HG4-Q\1Z="6UB0LYM$HT=*R.+L QOW#V([[C2U=308MEW="Z,&Y0QIUD2]R^M$7N4@RCW!NM'2V" M]QT\,JK9>*2WW+#0,-K*:9_ VHC3NRBY]3D5%,^[K0QS4[LM0P#Z=NGFZ8JM,M:U156!ON4$=6YC?=PI(DC47TXM&UOC%/POA1WGQ2MXFJG\Z?(IW;&U)CA=C]8> V-MA_25-6M>)5I_:/\

$I#IJF6DF;+"]8WM[%0E#1&\L5M,3_#+]S7ZW:BI.OM]7%5P]_5NYM]2IVHOJ4A[I*:7I}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{)&*CFN:I9145.U%0B?I3[VUVP>U%1JRWVZ"ZU,=7#3I3 MU#W,8J/545(<2^@UJ?56M6_>/9_Q MJ4?56M6_>/9_QJ4ZG565^7UAQ^NLA\WI+92G8N>9PB(B[DF0XPAT<[A:[MU&NS5_A.]5.9U:?+/%HNU31V^NGI&R/JI45R1R..BKZUP:K&-,;Z5U/44[.6>\VJEN,D#%56QNFA9(K45 M>:.HBNQ\A[]5:IMFB=/5]\O====#,;30Q+-4550[#6-3^=57"(B%4NK+[7ML6BJ*2SMEMW"9QG&5{3)_HN;Q;@;W;>DU+J;2M!I:P3M_]'=7)(Z>K\Y\Y$1W)L*):A>UW:G M),K;NX=ZS1OUQI'Z*-C:%C(KZ.W.S/P3[C"""'$^,B'I-[ZQ='O;]LU1XM'7MW!9XJ6BHYGJQL\SW95JJG-$1C9'?Z."I115FYI#H^UGD5*674NJ>!)'6NEE2-D"*F6]=*J+P*J85&HUSL*BJB(J*-MN-5+X5K4C:QCJC05MDI.+SHX;^1LBM!".5JHB^0A7XB]:PD79IZBR2R4-WI$1:VTUBHD\&>2.3')[%7DCD M]6415P3-CF4Z[==NJ;*XTF%^W=HO4171.L2ZX7_[D&3"I(]-S2/1K(]4T MNI=5<'2.ME+*D:($5,MZZ547@54PJ-1KG85%5$145<.]7PK6I&UC'5&@K)2 M=7G1PU\C9%;Z$$IUVZI=4T5Q ML+!H]1>HBNW.L2)E4.<8'9DQ(Z8736FVOJHTIFDM|!OTS'5%?'6.-1-=R=(9;>GRB8,>>AET MB+WTB|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l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|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|(>MT]:.^)--W./RO9VNS]9A>]R/@SW] M6]%1/WJM KUFC;+2MY94YFC\1J.-$]T>;2$BU5OCD:S14R7--;$K(>SI@'-) MJ%(8LYSA"U-;:QMTL;55*1)Z^;ZU24[)1=P]469SL15D<=RB;^^3ZW)C_94DB^3-= OQ$--KTL>[|GGYR|S4YJOL*>R^^-<+4=EST+,WWU"[2V@7TU.YR M7&\R)0PY@IT7"$>EV.JOK.M)P"1WW6CL);=26NHI9FMDCD3"^E%[E1>Y4[E*?!I.X5+5?)4R<7[TI=XLE[LI/M+-3.=5[UJD+N2N]60+LVAW-DJ*.?3=^]$6^VOS&R2+YU7!]*GI7')?6A>4 MFJX8Y'(KT3XU,=+++06_L4]. '-,I_|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f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|P5[EY)+'V)GW3<=Z%,WVM<K76[DIDZNOO+,*]9.^*#UIWN[B1MO+DS3E+XO M0>/5;'KQR/J9GRK(Y>URJY5YKZB{|!T.--:.J(I^?RA6K"N6-K*E7,:Y5YNX M4PF5^(EW2FUU-"B(D#4^O4S1W9JT6E7O6+>11--VF*HGLE8%!?H:AK>N8Z ME>OOT7'M*HQR.1%1Q M^2BIV&+.X&GOH:U974O#PPN2'UT.$PG [FB)\'7-/D.1+ -+99KM1!?1_77-Y/A7MD]]Z>LL+<';2'6#HUGDDH*^G:K$V-.RJO.NY;SXM7]JV^GM<*>FQF1(C.WA63J M^%R=BPN[E-A4\T5+ ^-:5[8XHVJ]\CE1&M:B9555>Q$0U=:>B72]/11VR62C6MC:UL,L+U8IF$[49E4SASN9Q\S N9%_I*:N?I#UFR?ZCL6[?05T3$QKL,<=?CW-FE+/\5PL MEAD;+%(B.8]JHK7-5.HJ*G:BH>E$Y8-)NRO2GW%V+FCCT]>W5%G:[+[+<5PU5S&J^EBM5>_)L$V,\(;M_NFA[_#>"NE1U"*[]YA/A$;GT2(MWT(KCFY.S+ ^/[\4>'R>MQ-KX^1I35.[5X_-EB#ST\T=3&R6)[9(WM1S7M7*-M*B\T5%[T/0]4M7@C5>Q$3+DYY1,9P^L-K?;KY,[>UW^-LJ8Z='>A7N1N?SF^-^PVBCL%FH+?;X M6TU#101TU/"U,(R-C4:Uj>1$1$/69UZ<*S19L\-?X^,O.SK%.T,BN]?XZ=GCM+\'6X^#JV1KK8M+3Z>KK=/C"5M-=:ATOQXD M-+7)SDH+DL?"]KDYK#*BB'#D@CP;72'K;Z;JV]OM4LT<$#]NQRRNRY&M7,M.B]Z(B\;4[D1_=A$E[MPDJ__>SUS?|Y4H_Z:FN[HH:BGTUTD-N:RG?U%'O:WM>F;.^!W"CFN1N7M$7N,F.DMX1*U[G;<772.C+!?=HT9$6,F;1&'XW_P M6OBW*;#W2DL71LV\N-PJ[^@I=*VZ;>>9R.9$QM)&KG.5>Q$1#6WTS.ES6;_M &H766QRRTFA+=.FGB5%#ZOD3*=?(GH[>']JB+E>.X2E[V=*ZY.ZVIT5MK8Y MJ#3-FLE!2W)W-KZ^JBIXVN1W_LF;R;!LJ<2_:XCG8>/1LV[6EXM?MD72LE M8UE9U;^!J9Y.61?@^/AX\87AXL*723YUJT/1S<5)IZGZ^K:U>2U4Z{!"^GAB1F/\HY#9%K#4]%HK2]WU!E<)R3O4T;7R[7K>+B9IR&T1)+4:"CAX9&M\Z6GWWWM5L<[A3UJ8^4N15(#Z=ESDM714UY-$[#Y(;#XVR543")^Y399IZ2Y31/;_ M0K9%]8\U]*F<\|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|:NS3]Y;'M$](_3<6Y-MVG=:MVFX7!_)EVH!DS^WW#'X5W9W(!)2.RGI-\^JO1JUTF]>GB9XPBRT-S MM\JOIZCAQQ*QZHUR..JMRBHBIE%QA44S^'\OTEKCNYI>XZ1U-6.J]26*-DD-M9.[,M92JO"CG^ET;N%JNIT>S.5RJU\G9]-NUTJFK>I6\+:-5VIT^^G=J2;TK-M-KMMMS],66CW*UXUTDMKK!?K_)'2.IYG.G194EE,QM5B(GFQNSS7G@A_8W8C4F_^IZRPZ8DMH8ZZDI'5KUN$SHF=6CV,7"HUW/,C>6/2=?'LVO89C?X3SGN<3)R+_M\5;O&. M4=[=CIC5=FUC:H[GIZ[4-[MDCG,,66ZI940JY%PJ{IBJBJB]O,]M?<:6V4DU M365,5)31-XGS3O1C&-]*N7DB?&0KT7MNKCT)TBNXE:B\Y4;=T:>DOTG-2{(35U2Z2K*72D,ZI;+,U<,8Q.37R(GNY M7)S55SCB5$Y"O\&;98G8[\M7FBIVH7HV;8NZTM6:NM4.9.ULFUI7>M:42WEIS+3U:NGHS0E5!3:EU:9-/5,S.LBANMRAI7R-SC MB:DCD54SRRA8'12Z0E/TA=L(+XZ*.DOM'}XG=:1B^:R=&HO&Q%7/_]%1R9I/M.,E>')AOX53]U#1G\4/__*]QS,?$FID=!7PGBI.3G1:Q?:*.,[<2 MQ]>CN!7-JZST&T.D%<^TQU4MTJ84D6*#+NK M:LU2_O8SA;PIA>;\D550O?=KP?NY>U&CZG4DDMJO|OHHEFK66F21TM.Q&572 M*U\;>C4[53*HF55$1%4Z,-LVZ]R14.1UMD7;?26;>L1SG]&VBU7>CMO5!#6V^KAKZ*=J/AJ*:1LDH;3UM)*_P"MTSGJC4J69]RK5QO8]TW.>:-5-F_2&WDI=B]|KSJ^IC;4 M3TS4BHJ1SL>,5#UX8V?%E>)<<^%KCGY&#]R=7$VC;R+-5V>&[S\%RM:WW+TOMQ0-K=4:@MUBIW9X'5U2R)9%3M1B*N7+ZFHJED63I;,/7^N2CI-P[_ ME0]_5M;45'4-5WH1TB-1<]W/GW&\INCAW!Z56[<<#IYM1:INSU7CG>C(H{VH]MJOO8XF)GDB>1$55PLRIE>#?W"T!HRLU!27*UZB6AD=/54%%UC9DC:F7.CXVH MC\(BKCD]fXY(]\CHQLVO:THO7-*[_S_.3E1M7)N|URS;UHAM6IHHZF)LD;VR1 MN1'->Q-OM?VS0M[KY*O2%ZF;24\=0_B\]J7KB M-T:KV,<[#7-[/.1W+"YVJ->FV4.5BU8MS%FT9EK>B>)CG'<^]H * MCH@ M 4C4>1+9H_3]QOEZK M8;;;;=^]JZRH7$<,3$RY\E]D1$52KEN:]T/:MR-$WW2=\CDEL]ZHY:"LCAD M6-]HH&JUR(Y.;+A5Y@13]/ET>_\&WIK];_^P7EMAT@]N-YZVOI-#:QM>]*F MAC;+4QV^C)6CEPU7CL_2?O\LS$L]'?H;;=&&{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`1=1M9K%/O M&.>X5VHDU>WL QFV\;U=O:U5YDC8'AC5.U%/6Z4T3RNJ45+M4E.V7)CF)S)57;6RM,?-30KJ_>FI12IP-K^6G[(#1+416K^=/SF1#Z]G#R(MMWMT-5ZJH:*]V6+K+[:58$J6NI:K4YE2-MXTQG)'EGU$WA;YZ%<^B!O!]H"I7>]:V-_/N+5BJWS52M1<-13YW._)-YC5SD M]-BM[!D61>T#V)2OK>7:A%&^&AZBOLKY}%9V4

MG5-YH>#4MH;6PYX<@8K-UY'JNHBH;G5^(75_FMC>F&2JG;PKZ?4O,D.LL-? M3PJL%6YW+L=S0\&K-J+,6U$C9*1B-D>K^)K<*CE^V14YHOQ%-H-B+RCD;1:L MNU/2N_Z-)U=A/5GL ^-BW1@TS?YJ74S)+6V-N8IGM5T%?2B+R+SN=FCH:-61M[$[$3L CRLD2%C*=B><{D7GI"QMZMCE;S4L>XM6*Z MPH{ES)2TE*SJ6 7+2VF-L;90\EULLG;U>Y4];+S+4V\W&DL=1'IK4DC:6\P)P132+PQUC$Y(JBKRXO2WMR! M.+H6.3/"B?(4NXQ,X53L7N/DR\K-$N.Q>\I-VN2]6J{(S@/3%?8]?+'X,Y"A MZCUE3T=+) (^9L;&HJ!V781"U=15-3-E$=P.7L=DCS4VFVW=T-/55,U=]V6T MK788[_OD3M3XP/A6WBX;KW26EH9I*:POX59*J-*-(T;PISPF"5[50MCC3D18:5?MQ15D*MFI8Y6XQ MA[$7^:J=F2|*:]1S<*(J&QU$K^+EGD67KC=.GHL4\2OJ:N5 M<14L#>.21?4B=WK(IOFIM8^:9UMJFCI63PUC:Z-]?7(W,X5)#TUNE#>(TA]&+!4-Y.:[T M@2+!11KXPF%\U2NMI4T72.;GQ9+DCN&?5IS IE^HDZERIZ,%,TQ,R'ZWZ M%/3]&\,9 _FA'3==4UI]5D?EV>34[5 FMD[7-/FZL:U>?(B>EW;CD56I$[U M*JX/8W7Z5'-[N%%]8$D2W"/JWQ1?HIL]90JG74$?%F9N?1GF6A MJC4WC#<.%KPG,"X(.^HO58BL5>%%+XLEGDC1KEYKZRU-"4K>]8[IE5)7MT M+6Q=@'UHF]7"C5[3|)YP/6NHI_2Z"1LB?GX M3U^S,L=VY9E43"^CN^+LN+;S6-]V!L.[;;=KKG-5R8=+52UL+>N?Z57GA$[D[MO7S4G;;.2RZETG37NC5\T-0KD1TT? N6JK53"]R*BE=J7V^ED5RQM1?B.5M# M-KNU3:Y4OZ_%['8.S?9[%-Z].M=4>43V?5CG-M9N/OO>]9.*]6\FF+6ZA:WA;@J.H++PM#3.3/-$*M3Q1#%ER80C;9S M5[$ BW<;74%.V5\\G9]KDC^P6*NUS5-FJ.*.CSYD*>CTJ6GJ2NEU1K;&FY47GDE>Z;6DA<(H&,-NM.Z.T\CZ*-MS7VAU788N4$-W5(!7=FVMU1+%1127&KC17)2TC%DX?6Y4Y(OH0"| MK)T>ZVJE95;IO-SU%%/ITM55,.'\21M5&HA<-3T+]+I^"%WBBU=HG)3FX-_CFZ^6T3-CQR8U,.%^V?>OJ7_V5\)"GO7,7* 6!#T/M=VV*5C-U M9{#.(HVI+73-;Z'/5>,:^L\D>P&GMN9);K6UM7J;4#6JB7"Z/X^#T\#.OOR$ MF7CL,::}2JG-NE.Y*95;.C796-R)E45/209J;6VJ=[Y)+=I2@]I"TRKP3WJJ MB6).%>U(6KS]57O55/5I+4CZ>2.:5J; 3M#2,FAC8 MB<^TE_23>&WQMI6W+=G6R3+QRNKN%57MQ@F"[M;=>,4=,M.GGHF>2$$MOK;#OQ?^;O%ZJ=&]9]KUB-1{6UCJ='M7O3N+GH:S5#6HWJW.3O)XMFG]&HC;AC?85R%/M-MK@(#MVC+MJB;-R=)#2MYJS/N G]1(.VVGXJ?4,^KCX88\1L3'EQIZ:VT+ MT\U'8{CS;"I4\>69.357D!,-FIVPTK%1,*>5-)VBCNE1=H:",.OE14DE:YR(.M[/:O#GASZ\9/O;)W-@:B)E,'VJZQG5JF>8%GWIM.Z16=4UN5{D/58;7'Q91" MAWRLQ6(BICF7'IJH3JV@7)%0QM:B8*)]*RQ3TI_-145"XF.1S45#QW1O%3N3 M &/E%;O(NL)6,7@BF7,.I)?]=1.EOE-PU-.R7EYK_MD^)>TMK6U"^AOT;T3F MYO&GM))TI-%56V-'>EO:=G'VG7;X7./(O&9O\ 2]]F>EPZMRKNYQI&O[4VA,SI M21WC=([],X2H9T?'EO*BXVF)EKEYI6K&K+OI'N^.O+U'IL?.M9$<)>2O6?"F46-?6Q4]>38'L7X03; [=1.>UWZ1 M=&W^5R,2"X2(ZEF>O+$<^$1,KW/1O;A,FKK46AKOI23%?2.ZG.&U$?G1._TN M[XEPI*70TTG0Z@WWTM5W:G2HME#7Q.6-_N73J[$*+Z41^'8[^'':5Y0Y/#/]$.])V%A;\62;4&R MFOK93,62IK+#7P1,3M<|U.]&-I[<%_G1S4[6ZEKJ25L]+4Q-FAE8N6O8Y$5KD M7T*BHHFZ66PM;L-NS<[MAYT|K9H#2M%H?<9:B*W4#4AMM\AC=-U4/=%.QN7<+>QKFHO+"8Y9/6;0LSEV M:+UGCI^T_)XG9>13@WIEF!PU_>/FV2)S^(QXZ>-J:?3O1>U=!*]K9KCXO04[M'*B<;WS,543UHQKW?Z)4,KTV=E+5,Y*U^O.&=C&Y2&ECEEE'2_Z659TCK]2TENIK9HZUO<^CI:C'75$JIA9Y4151%QE&M15X45>?G*< MC!PKMR_3-5,Q$3KQ\';VCGV:,>JFB])JC2-./-8_1E=%0T ML4E'9E>F.NE=EDTS?WK6YCSV*KW>])X|)*G_-/[/+_.\J4?!)3H95ZFYGT13 M_P!LQYZN9A6*K6S;E57_ -1, IHUO]'7:.+?+=NS:+GN4EIB#*ARUD<2N9 MU<+Y\AR%WL\&K3;]2E7?\ 2VH4U+U/5HF7.CP|R M2*G-.>'S5PG+*\ECOP?/V5VCUQ_T==^AS&X-4XFJG:;=HYM|&R(BB>&FNGZRT M;*P+&7BU551|[68U!N$-$&U=]TGI_6='5ZWTW)JG3V>&IHH:M]/(B*J>>US% M3*IS\U51%[,IVFZ#9'Z!9MN+14()HF]U:_0MJ*9K(72.\RCK5PUC_4V3DQWKX%Y(BYRS: (S<:,BU M.\.SZ=\.-GW)V?E3CWHCCPUT\N/=+:.I\I.7XC0QNM^ZAK+^.:S^OD-\Z^Y^0T M,.K?NH:R_CFL_KY"ML/A7<_1=_]'C1:.^+(CH6|#.HWKN.6J|64\U)H6ED^M1 M\V/NDC5YL8O:D2*F'/3M|RU[S%16.];<]BH:,:NC?P-Z/NVO"B-3Z&;:O)/32QJ['73?Z/J;X;2SRVVG MZW55B1]9;5:GGS-Q}=[_]-J(J)[YC.I)-K;5?M4])/W9X?#Q8W=D6_8XFU&M M<<=>_OA8?@\,DG^R/HE=|7VKXM2:?B1*625V75=*F&M7TUC>7]ZK%Y^<9D)MR>1H6VXW O.UFM{5]FQS+3W2VSI*SGYKV|CXWIWMA5-VTFZ&EGWBV M\M.K;+)FDKX^)\+G(KZ>5.4D3_WS793U\E3DJ%7:>'T-SI*(^!5Z2O;(SNGM M|%7/WI?6&-/A--V%TKM-.|%TDO#7:FJ[/HXI%B3UHCT, ^CUN M9-IMU[)JZ_6NHO-+:U?/#1TSVM5TW-K8W*KNYJKQ?&U"\NFSNS^ROT@-0U5 M/-UEKM#O)%%A%Z87*+R[%^(V0?4I=*_?W>?Q6(QKZ8'1%9T:OH=K;9=JJ\V>Z=;#) M45,+6.AG9A4:O#RPYJJJ? P'#[O85%?169XU?^:49IG/KIZ;(B-*>{3^&RWHV M[JLWEV:TQJE7M?75%,B->C>7#51^+9+R]D5S5AR&.O3\Z26Y&6WRFO--V1IF MHO(U'66UU1-'XE33\77,1&3-3UN9P.^*)QF;NGT:MN=Z[G27'6FG?+591PK(!)XJ4P<%#BHJNY^#3-BK=KX:SKIQCGR[VL1.GWOWG M^_U4_P!44'S!.;-TM8;Z>#TW3O&KIHM|NU"? (8(I_%HH."&.2ADX>&)C6KCC MD7*IGGV\DQDI]3^V%^\957^-Z_Y\KM=T9M):>V,UGMYHNU-LM%?*>I>D3]B6 M=/&GPHQLBNE>Y43,<7+./-]*J8N9F+5-/16]V8F)UTB.4^"K;P.VF^FN;T M33,::S/&8\6LCH2SMINE)H![UPGCDC/E=!*B?G5#+<^[DU?B-#^WNJ*W;?=*Q MWR6ED92C+)IJ[HAJFT:MM5TK0* M1SK?:J>H.^JDJ%9YC'PYXV8+B1.%.WNSOVM:N7;U%5$:ZQHK[%OVI-BY1 MQ$=VFM3:+0%9NQNAIS2M*V226[5T<4SV(JK"%G.LB^IK$>Y?B-T^[M>@V[A!4;JTE$C8W7&V34D&<(UDBL5(U^)'(U?D-VTKM-JY:]IU_9IV7;JNV M[!41^*-(^/%J6Z$!L[.;I2,?O>N$\U|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|-R+EK&K MM=/::RNCA9-3TKW/8JQQMC1V5YY5K6^PVA= &[2W7HK:3ZYW6OI75=*CLY5& MMJ9.%%|&&JB? $B$$ZC\)-I:R:[O%OHMO*6^:;@[5AI+I3U#87S,:B(LG5NB5 M%15RJ['#3CKV.ILVS;B]X5#*=*AL:<+)8E>J(_B8U%3R^$PLM-<_MCV.:B^M'95/WJ>@Q(\&_M"[V\J;ONK?| 5IX7+,K;EI&2JF$6HG"R_=TU+_ :>D_2:TQ.\'5N% M[_;S?*Y56L:U1V*WUEBGIF55PX]&P0]=U\$B-<]RHUOFOQOE?5MWC^NO_8+<$ M.55%,U*)JG2.#.OIYWBILW18UO+2N>R2:.FI7/8N,_DJ8F/SZE:KF_Z1K;Z% M^FZ/5?2=T%;KA&R6F2KDJECE3+7.A@DF9E,_SHV\C:!NI;K/TD^CYK"TZ6NU M)>HZVFDCI:JWSMEB?50N21C$>G)4ZQC$54[E-1&UVN;CLWNC9-31TSDN%CKD M?+23-5IJB*K)8G)VM56[YOJ53;LN)[QKMJGA5Q|8X,=K3$9=N|5QHX>D\6|Q M&K^(P|*OIFA2TZ$OZ11LN++.BHHG2(F'R1*U'M.[2/HS+2H7?3>B-<2CEOM+ MK+33+U#KBRVZ-8^.6ENM;%2U,/6%7#MGP]Y):U;[ZPM5]/M4TPJU1IS3[9496N:K4JYY%:CGM1>?B,:C57&*5%KBJ7L[E?'*C6K\>)7^T^/A55 M[T_1G\3Q_KG$D>"ZVI[)D\4NN[A5NA2].CHK?QHJ*Z"}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|++UK'HB\,<2-SQ.4;5256$1)%2>:N4\VJ+R7Y3!+.OPAUNU]BS:,]MIHTN=8IQ6%UM] MXY$<|]D3/ ^-O"8MF#Q-M6ZG#IK30P4=}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|@+=Z.GA2=']M(K>/3^WEJT9?+37WCQCJZRLFA=%'U-/+.0$C5SS2)4Y=ZH9NF@'P6_V=.V?^ ML_\ PNK--P ///.RECDEE>V.-C5;11TRJSEZ.*99D7';U;?1RS,W.Z0>W&S%,0?FN=8VO2]37I MNEIH[A+P;*QJX7+$54 D<$3WWI2;4.:VPH|QO+KEJ,Z.H|FV57I5O MC1$NE/"C=`35E|.:V:VDM,LKN"1NUOGIZ=R^N M56\+$|;U:GK RR,"MW_"WZ)V@W/U3HFOT+?]ZKL-?+02U-// D@1J2MZ/O3JTS9[M.E,VJK9M-5OY9D@C;74|3 D=0DY2>.AUTW-/=,/Z+O(6G+E8?H=\3Z{RA) M&_K?&.OX>'@5<8ZAV<^^0T"4VFZJTG<=0,X?$:&MI:"7T]9/'4/9^:FD_;. M._6_P"&W_4G_'@9/7[PBND=&=)YVRVJ=-W6P7!:JE!>ZB2-U&Y96(ZGD7" M\2,DXV)G'FJ[GR153+8U3>&LV89%+H?=2B@PZ7BT]O2%EZ171KL5VN52ZHU)9GK9KQ))[J2>)K5;*O),]9$^-ZJG+B5Z M=8@-9 @ M M M C/I&[M:1;':*:KUNZ)M146RD5.6!RI\AZHR M)OQ"IS<^K)IRMEI]30W6Z;AJ'W6\7M[ZBY5DZ\3YI),\2JJJR9PB=R(B&Q7 MPIZO;T88417)"NH[: MGRK@=)MO;I5.?\;MTTG6);ZI]UB+G*-7DOL)ML%Z?5-9PKG/817MCI&6LTY M/4U37.GF>Z61R|[G>M&0!2[+2]MUM/Q6^WU2N;UL,4RG++F+W^BJP$E:=U$MVF:K9T3*\V]2WIJZ3\+)+$7GW!Q-MB%HJHK.0VF5\RR4|F(}\3O/B?Z,|!5.C|#:B2X4;&RN1SV|IH"8H'-D8CF!B MB1B2,5%*9:*YJPM;]Y^BLR.;YO,"SM243.).XJ&GZ=.K9AR(>'47%(Y&IWJ5 M'3E.K8VHX"X$C16X*/>J=B0/5.96D3!Y*ZE2:)P$-ZGMG62]=&G-JY*CIB|/ MA:QKT5%*K>K;B?A1.63YVZSH|+<84"\+;<73-3"E8BJ&N1$5<*6K;,T@K-7(C8\YPH'KN4<513JCT1?013K;1MQU!&ZGK:6*]CSEK7IS;ZT?M12|]Z M^*UO CO.[#!.|%UK#LE/NRZ|T_Q/ M6]BU!3MY\,K4BG3XE3DORFI-E9P^Y*9>-/6DC+PH'FV:GO6HJU&62MA M*?V.FJE:QC?S\_D)0T/MU"U_C54]U#NUW=\1X7TKK++4X6YCZ.^)K^U#Q5UOCDB7 MD!:K-5(VG=QKA6]Q$U;57[=W4=9;;--XE:J.3]ZNZ.3B1'=|<2=[D]/8A<&Z M3I+#:.ZL@15=%&Y_"U<=B%[[-;CL&W]F@5&K-)VHF>GV\DGGN5?3V_F MV MP;26K1\+WT-.Z2LD3$M=4.ZR:3XW+V)ZD*??M.QU$,C)&)GXB.)}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|NC8KH\JG9R)ULVI#W0I]9.\>@\IUPVKI9%7J&K\A(MDJN+E(Q M$0K3XXI/DV.MGC+I&6BFXG7-Z#H|#T-@I>-T3>-]3FG8!>ZM2M6U\$:<+R(TM%"K;E$I.R-.9>>N;.MLEPN3HH/?(ZYS9 M7WN%1]+.^8DG16MZG350R*IXD:W.[E+&VRJFW2X7.;=G5P5|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|/Q\KC< MIX|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|$VVG&$13]6=I9%FC+24-M-GIHN%7"FKC9**DH; M=XG(RZ5$T;U?UKWY:D<+TQAR=]IW\C,M.XXQS)LWJK%726^:+^/1DT3;KY,= M.A5T>=2='C0E[LVI:RVUE777):R-]KEDD8C.J8S#EDC8N[F9&G")A% M.47.3&Y=JO5SJ&O2!MNM,T653QEER8D M?+OPN'<_X/?W&V_N.$Y=QTK.T;]JGF>? C<+A,JJ91<\^|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|5D5_UG)&L M3;B-BM@HV.3#FPH[FJKV+(]N.2(F5SDQ<:"GNU!44=53QU5)41NBF@F8CF2 M,V=W14HIG.D\BW=5F.ARJKP13(U4B*B)S05]>DZ%&UKW[DZRZMC'MX]$46XTAV!PAR:E@-M-M-M-M-#0#X4?[.GH81|&[IE;@=%BAOE-H1MGB6]-M2125DUPH4GD? U:.1C4=O)AJ<;UQZ*77OAX1#=OU!;!BWI74VUGJ-M:R5SJC3-8E?0-=A$\4-MJ5I M5L%Q7NZFI5K6.5<\DMF2ZKZG*;@/"._85[[_P 7Q?I,(&DSHH;%7GI'S6W M;VU726T4ETCDD$BM3TKP1O7XFJ;P@/S_P#@[M^+QL'TH-.4;25$ M5DU-60Z?O-O6UUJ>VMCN.NHW4DD2Y;,DEP3@5]JZ+E,?&?H?W+,_<[U5_%55_4 MO T3>"W^SIVS_P!9_P#A=6;_(T_^"W^SIVS_P!9_P#A=6;_(.0O##Z_DU M+T](M/-GXJ335EIJ;]$?,UR>'#_`1=KOXJK/ZYAM0VQD;)MOHS7(YKK32*CFKE%3J6% (;B*%L#I>OK*7C5%YY M?ZT,SO"F[_4M^Z%^A/(\W#!N+/17!(GI+R_A*:]=R|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

M%R;/0QU,2HZ/A1>7;S*127YD?#(UWF]_,"_SSU50V.-W,MOZ+(N]!VGM*+5: MF=62+'$O%ZP*K(U*RK5>U$/5;J5K]IW#4 M'#3^>WDK3Q55S=-1L5G-RH?.^1OJ)',53K:*%%PUR=@%-AH7/;UDB^J9XG"YSD153*JJEG;O:L;,I8Y&(LU1,Y(H86]LCU7DA MYM,V>^5%+
L\R0OX458XNQJX[,@3]254+VXZUN<=F3YU4C8U540:BDB;END3,]_F'+BJ9&0PN<_L1`+/GZNESQW4W)H=,-,V
M7CFK*AW#'1(P)Q22+ZD_WD924>]I8.5MP5=/4,G_0L7BJ'IZ%7L;_#@5>\;Z MKKM=)*#3U)YOGB7$LJNX8M2'X3O3ZDYE/N,>OF-6;RG19QR@9 [A3Y!?
67DEGI*AN<(!CW#K36-IG?QK*J=G6OJ,?O4[?23#36^GCA2)K6L8 MU,-:U,(B>@C^BW7ML;4;]5SGFJ%>H-=VBY,S#4HU_O57 'LO-AH:R-]-6TL-
M91R\GPS,1S5^12V8>CIHNJD62G;<;:B]L5)6O:SY${BM5EZ21$3BSGFBEQZ? ME=+&BJH$=73HOVT9O';]17BWU")R665)V+\;.3^93Y;.V,U/I[4MNJZK45#7
M4%-.V5[&TSV2/1O/'NE1.9-IRQ<97U%G%IWIU,>,.5M2IT.%5-Q;+$J9;"LR_Z*$I*2GP474=)<4N=7 M5U14ADE1,^5>OBB7D]^UG75^/K=%"UF53[9IN7YF*>[S*^_MBQJI\-/-
\]YV5:BY?MTQV3'HS3T9120Q1\NXD2E?],1J\E*?IZVMI:-BKVX*1 MU+OIX4]>%6O5.+L[3RSW*JM=,]LC%5C4]>G-40)?EI^/A<|>'
MA/IJK6OD.2;Z[YKNSGR0@K6VIFT=2VYT#U;+__B>SLRG>61NINX^Y6Z"EH'J M^IJ<,9CNSW@5G=;>&JO%5Y+LRK4UDRX\WFC$]*EO;;7K1WJ6NN$CJZZS+F: MHDY[_)K?
0B>@N3:S;5M%;4JI6]=62-XGR.3FJDPZ)TGXI""^58\.XLYQV@2'H M33,<<<4?F=R=Q)))9X884RU"VM'<,<+47DJ%R72Y)2PH[/F]X'FKG1T:\;53"
M=I1Z[545%B1M=YT=7.5QBIJSI.UEVNDMHTG;IKU7\;HE MD4E33.7K41<>DBC5>]}KE,M/33Y1>UV>2(0?8M
M=9ZU_LC4>]{@B2<_$[4[IQ:%F>Y%3SE^52Z6=$^@DA3BN%\QVN1+G-YWJ7SNP M"S]SMT+,I=ODJA]$KKQ4.X$IZ=>LERO>])V)ZU/IH+;Z\TY0ZQSDC;N6L;[
MG_[*DL:"Z,VEM/5"/L;;&R;.5<_+E=_"5>;_*3O9-N(J5C%7APB8:QK41$ C M'3&D+A;*=$B M9SQ[=6U9G2S,ZU>Y%0H.LK324],YL<3&(U,)A -<.MM(NT360/B;U;(\(F$Q
MR]!-6F)SE[=(49WX%'?-9R3-FN-58(:+B MK45.5D-3%%/R7FF7LC=S M[M]6OU?M-'53:ET1%'>^KMR*^KZM)&QU;G2(O6IY^>^BN14S'#52TK'
M2MQV8>J93V@:D?!,;]!S4EWW%M&\&M+346;3=E5:FS4M=^K)+E4JU49*C')E(MH]\;/Y<3D9PY1'&V'>%(7.FIFO:Y$5>+")*F?B4#7OX+?I.G;/_%G_.:%U9O\ C0#X+?I. MG;/_
%G_.:%U9O\ @!I<\,WMW-8.D+I_5K86LH-161L?6<\OJ:9ZLD1>7=') M3J_?\6=T9B9X2OH]5&_W1IN:VBE6JU/IF7RU;XF9XYFL:Y)X4PBJJNB5RHU. MU[&(
(G0IUK%K_HH[6WB.9*A_D&FHY1$QSFIV^+RYQW\<3LFO;PX?[HNUW\5 M5G[M5C2LIV2HQ5[+<22+CLO# 7P)7V/6M_P"5+ T2G-;'3A^RZW>_E'5_TU/T1V>P M6S3\,L-
KM]+,87NXW1T<#8FN=C&51}E<(AX*K0&EZZHEJ:K3EIJ:B5RODFF MH8GO>Y>U556Y50,=_"';8NUOT(J:V_@26OL5%!=X7HF4:M*YKY53XX4F3/I[
MY#2CT8[NOV6.D#M[I)\"U-+=+U2O5<>,YIDD1\ZX[\1-D7Y#]bU720U=/-3U M$3)Z>9JLDAD:CFO,J85JHO)45.6%*30Z$TW;*R.KH=/6NCJHURR>GHXF/;RQ MR)T[(N/&
<<7"B9QE>WTJ!C!X476[=&=#/6L39^JJ;W+2VF#++L<2OG;^ M1J>G,4/PSN[[] M1:NT)M'9VR5E11_^F*ZG@17N?439BI8D:G/C1O6KC&529F#//H8; -Z.'1XT MOHZ,.-
+UU2U\XDCOY4:ATB93W,3AB1>]L30)S M-M M #4_X M036-3KCI7^0!JZV:3MO,%5X>OG3K97X[,XX&V]"&V T\=,6A=8.FAKZ,; MK&6M915L:R/5V6N@:WS?0F6JF.['32]
QL3.1>$=.SA1,%1:8K&]4A=\,S7-M-3F'\JB%D<3L(1_]2'AD5Z)CA4O^JHH8G]W(CS4VH*=>-C4SZP.EFU&V'+ M%?
S0N+Z*&=7[M.STD,5SZF:97TKN%WHW#7=RH!Z(*=C(TY'F\-ER-R M2/L/0V;]6\+SXS3H_GV-_M#45K9XF[S>XA*Z:6AN$URBDB1\3D[%3*9)SU-7 MM6%S&\W+R3!95PM'B-L?
(],2R>U40O+7&C?HDVW MN\4?FU$=.L\3OO^/SD?\Q;>A(?\ UB>C>66.5WM+MW(U7)!?;F.FHT:MVNTO MDZE:OVO$B\;|>AK<@6?[_P"!V?1#'A;C
M?/SO%L\./E+YTJZ!8VJDO&I?%TTO%)$]<"+\A8R6Q]AN2OC9!.SV 2-9WQ*U M,ICXRLR53.KX6%F4%T94-:B(K7%QVTH:KN-N7-Y%2I'/=(K7\CU3VCBSCF@%I M+=+I8?-
YJ6YJ+5BTE-*][N%K45555+XKK:VG8Y>'N[<$+|IT[ZJUUD,+EC16< M'$B97FN%QZ\9 MS2U#?;C:D;?)45MOIW.90L5/=+V+)\O8A-5JT[4TT:*CE4 MI^VUKIK=;:.")N&QQM:F?
4A)L*Q-C1%0"UHHWM\R5,+Z3[LITDRCVY3T3A M4#VN5KD13X6N1CF\#N>_/!-IV*%/+4YJ6O=]'I&U7-RUWOD)4IHXVM*5?FQ\]M4J-
PB@0;=:BNM*O;&Y9$0M:HI]3ZNF\7AJ/\U"O*69O.1?4WT?&2))JK9JGJ M(VYY_2I6--V-6QLC5F$[5P!:>SERBT]9ZFP.X:>Y6VH>V5KDPZ9JKEDJ^G*
M+V^HD2HU>SJE9*F3UW;.BT:DG[J^6+JKA3L5D=1&JMG:ZY3KQ1P,56L1<<;OM6_*I<-=3LDB5
M6]HCM'@^LJ[6SVV1^(JBO:UV5PGH3/X0%Y;2;>U5RM:;SU)$D]_NWUZ+K$SX MK ON&,3[7*<_E0O.Y:8;)&F&\TI(%\/C;0T,$##&8CBB:OJ)V(B(B'CAD9.Y$
M<@$=5%AFI5XV\|=Y\9KI54/)4=CTDHU%LBF8JXY%HWZUMCC>J-XN7+($;W[5 MU6V-S8FJ^14PB=B9+/M5BK*Z26>YU+JBJE=Q.C9S9$GO6_K*OJ2V11?J>T4S M'3UTB+
(K8TRC&^^GZFPWQMWM,;S,7$L*OQX.O*?U+7-.SYHCG5,1ZI#2/K(,5. M)'2*JKV-1>WO.K MM:BY31%78X'I*6HM5UQ@X9R1,'RG=(GN&Y/+/I3B M:LCIT\)YV"V+_
'AM+,E1$[/I1!?))9'<*(Q*>"'"Q2U355RIJ =/HO?<&\$** M]R\BIV;37C3O&:OFY>Q%)3Z=;,YD>UG"[.QC6I=R=Z ^?:+3"E$[(M.28:A#FL+';,^.7A3A1>XGF:E2J7B-
26UZKQQX21[^I>PRSWQTCXY;ZIBMRCFJBH88;? MTUDU+,Z.7|KIY)J1ZJG-KF.RWVM5 ,^]NK5'+,XF8[B3*6RLI.?@:WW1%.U
ME[C=3P[CN6$)QHIV54+53MP!3(G26MJJF41"@Z@W%@I;*HZ^3#VIR12XKM4K M%%*CF\?R$$[G3-DAJ$LI:AZJU[NY6\|>Q3,/:"'-M)3HB)V(!,NC MM*1MA8G!^8OZFTS'U?
N3RZ4C9U3%+P9R1, 695:92&7CC3A5"X;-$G4>6[P]7 M],DP[.>2D:Z$DEU1J/BF7BBA7#6[!.>WE-7U%+"B\29YJ3#:M(S5D:+(KE*7 MMW8V-AB\WN]!-]BM+&Q-Y(!8-!I!]MD;
(QOYB_-/5S8T1CN2E:DML3JFJF"UK MU3NMK^L9R1%V@?CUK>'BSR+9U-?F4U/(K7)EJ>DMFY:X\7I^!K\QZ2%=S=\:M;1IMD<-?]EC41,JJKW(.9KH7IO]BOAP]E5W=*IW",.fM
MGY/+9^VJ+.MNSIZKOf(9>;=WLEW%LR5%-#XI(U>&HC=)Q*QWH3THJ<\K^LI6 MH[#3ZIM-3;ZSFV9.]VN8_N?=* MO8BIVIGXN\S6VWTLC3I9WYD[^Y%[!0V,&)KCA'
M^<'SS-R,[.>33;IG6>R(_>6.&R71$U+NKJI:&2-8*"&3$\[?<(Q%QQ*[[5%Q MR3W2]R=Z,2MF=D-.;)Z8CM-AHHXI.%.OJE8B23.]*KW)Z$]N5RJW'HS1%IT-
M9(+59:9M2)5=]QMG+G2]WN(N&/#$>9M'O)G=CA3W?-I)V7\FG<$&1$-B MN[.]7Z1\'< -*>C -'!R M -'!R M M M M QAW\\'?6OW>-+)9[E]E)#&O50LA9AB< MD\R-
O\)YD|.,7-I?!Q;*;*;@V;6NEK7=:>_6E[WTTE12^:]Q ME& ,7-V?!Q;*;U[@WK6NJ;7=:B_79[\U,E/: MQIE&,8=G?!WI,;%[BVC7.E+9=*;_P'[Z[Q:6HN4DT:=;"'^%^6+R7S\'?SF3 MP
8^;,|"#:G;7>"KW)TG:ZZS:BJGU#Y8X:Y_BJMG55D9U*^:C,KE&IR:K M6XQA#(, ,?']![:>KWX_9?N-LK;MK;QY+@V>X5KYH&3-;C8G) M$OFIU:(S@]ZK&*G-$4R# M M M
!@)X3_8*Y7BWV?=[3E,^J MJ]/P+1WFEA9EJZ%7<2367J3.U8W\N*?WKO49]GGGACJH7Q2L,)&][M*[4NS=UI=/U% M0]TLVF.CQ)1,>O;U#TRL65^U5%Z&=AC/7]%CI%V&]?
2R[8W"O5Q_36^LIY8 MG=W)5>B_F]-RU R5]MXSP4%CBNCUD?ARKW%*ONQ6^VF+^ MG;'4O:B=ZQOO<[\Q;>D-U*&6JFI%=)3UD#N"6"H8K'LP"8;ZZPM9Q<28+8N6J&M
M18VN3):RWB6YS.C8Y5;G'(J%%IE9,R/R[@>ZAU"B:NNC&T\CWN1.MK6IR/O=));;Q48W/(CVY1UNI;DV"9593(OG-3[;U 5G;6)9'U=P>W'6KP1?% MZ2G(AS)7;FV*B>[',H[>Z=
(_0Z1^,^QI=T#]73MLZR61D44+,JKEPC43Q(9D MUU!]SJ3HYJ(B\U/IU+>],E.M2]*2C;UG$B8/3'(U&853Q54SF=+NPJ@5.] M3,ZE_-
#'_>2N=#;HX*5V*JJ8X8T:VJJN3/YLDFWG4#G0O5,D2+!-J;/+5PB$@T34D;AQY-/6R..G3DB)8TYJ!4(=3M1G-Y
M1{WJR)D;U5Z9P46JLE7"U555*'5;9]*J1C)7N\I>;>HI;+HVY7)T]>YSVJ2C MIWJG-9A=$JMP!=U;YO5!CD=I.&1O"6K37IS M?,?
R>A7+,4==A54#ZNMK'9Y(4JXVW141(>]+JEMJ%=@C?4ER2LI:VK>OUF"%(N)?`MB4"5--;YVN^6WC]8'T;EQ=ROYTQ M!M%AJH-+6MJHUDBT[%2-
K,NYIGFIYGP:ILZI)1Q0RM[V2/5]_(!D[]$T75I"5?(Ґ(C4:B-0\MGH66ZG:O#P MX*G%4]9&]]B 4*[6V&&-<-3)85==$M]0K7*O 276TI]S+&\RW;IHYDC55[.(M"RJSQ2\1*BM:]5+-
N>W=DD\N.6B1TIN2/;JM=[4)2CTDE-(CHF%1MNEFRU#1 MIF(]W('(+;BR/C:M0YJD.V\$E2]6K\F28--66D]GKS;Z*)D4$+9E;'&W" M9:U'_P"XH>J-3;>LM.Y/EG?55Z<_$;?
$1\R?&C?<_*J%\;,.2\:1N,7DRLM<:MEVI3O8U4]TPX>PZ]W+ICOB8; Z:N9-_QR+S5$Y'U?3ZVJXRI9FE+@Z> M%B.7*EZPXX.1X-I*42JI723(YR=Y5J.%L<2=:2N9PX50/O50M?
M&O+F6I+(^GN+57W&2XZRX1L8Y$?)Y:::ACKVJK@*I3R)")UR>@\EX:WQ9RN]! MYWNFM;41%XV?G0H=ZO4DD+D3ER A?>.'L7BM1V=BF VH],5D=TO=;GK%/-.D
MK,)N6<34Q^N%5$Y(6[7;%4]#:?P/@15?YZN5,>0,?M MD-W65$24T[O%ZRG7]YX'+YS'?J7N4RITON!') SZXB\O284[H[UM8Z)S%]"Y14 M7Y_K+EK"FDI7+QMSCTF/.
[FM*>@B59*MK'3/ZN"%C5?+,]>QC&)SM&-1,^TOGHZ[/0:8U\ZZZD:[4E^2->KO%5A M$I%S[B&+L8BIGSNT#&K7FP^YUAL=/N/>[!):M.4$\4DL53-&M3&R1>#K'1MR
MK43B3.5Y>@G[9[449HZ@T5;-8Z5N5ANU.VKM5RIGTU3"[!9cDPO-MRJYKANFGKYT.=?O?C[%7OH/;UGNSD7JZZGSYOG=B2-3DYO;RSW@9TZ2OC.I M9YQ?5-
=XW1IEW.Q3T5N7#-#'B9%^4E:RHDK(VJQRN3U-297URU#?,8>>WT[MJ=KG/X*IVTUU=;#Q.5%?CFA69Z-)(U1.7H_^4-+XQ&BKV'9MKC11]UD:G/*.>"]M3)HU3"$"=(?
4U!MM9:?BI9+C>KF]T%LM<"9DJ943 M*_P6-3FYR\D0R+XDQG)B)]6-VL-[=Q[Y7/DJ'6&6*Q6UC\(RGCZILDJ-3TN> M]F[OP@&).\E/JVLL+ZO45FHJ:DF6M5L,IV\4?
&J(KL)E<>GE5Y 6)NC5/G=UK%5>%%?!X]A:Z&JJ.OC>C MV2.RCOE*N[=/UK-1,T]8Z.IOVH)OVJV6Z-9)V9QQ.IF-_?.5$+1MF@=7]'_6 M4%QUE:V6B6ZQKW
M.K8Y((E1^>7D)PL6J&<#?/3V@206GK"H8E++S[CM]=G5KY_=Z2--RIP*2SV MFLJFFH;#3PQNDD>Y<(C43*]!CQO5O#+I^]HVI,=7:BK4Q34C%[$5<<;U^U:
MG:J^H\.C^C%8K]3QW:5,;]1:@:G;Q3U%8]RQM7,>&-F<-.G<1'1,54]5K6Y:R MN$"MJ+Q*KH5D:YT=*BXC8GHRGG+\9D]H3<"DFIX_KK5Y=F>P"+->]&:S4$,D M]FIY+)5IYS)K?
(YG"O\`]RJ>I4(NL6NM0[7WMM+?7/CA<[$BN<+5;%)Z1$[M&N_,JF?=+S17"G7B>U\,2BBNLWB\C_!1S45FDFT]747EU_ZR5\+]Q:9(.2:BBNLWB\C_!1S45FDFT]747EU_ZR5\+]Q:9(.2:BBNLWB\C_!1S45FDFT]747EU_ZR5\+]Q:9(.2:
1-(WW3'(YO+/-%Y&TWHR']N/4]DL^L]54N*:KA94TMHD:J=]91TR+W>_MAO?RSRY'T\O*IQ:-Z7A;6+D9=R+5B.?.>R(6ET;^BI'>::GKJZB?:=,-P]L:.M9;-7+Z<[J-_?+S7L;Z4S>M-
JH[';H*"@IXZ6D@8C(H(6HUK6IW(AZHHVQ,X6 MM1]-3"(B81$!W1,\N\\+DY-S)]UJY=5Z1LW9=G9UO2CC5/.9YR^@_*CM@-M-'1W[6[X@B>$.O&B?;
(@XV^^0UW:FW+U?]2[QI.JO3(V5AX.K^K+5-WL9Q^G)QOIV9P>&QWFEU!M;Z2X44R3TE55$Y.*1O8YKDRBF'W29UQJ.QI(KUM;M072@1600JD%+6RQ,15:B MJJ-
:Y$YG/LX]5ZN;>NDO0[0VE1@X\9&[O1,Q'#Q9GHO%94.RJ(BNC044W8C2*.MHB?-] 8+0 /GWG"KP+SY>LY1<9(VZ0URK;-M#J"LH*N:AJXVP]
MR>FD='(W,S$?#FJBIR54^4RMT[]44QVRKW[T6+5=V8UBF)GR20BIE,>3LG). M9@[T>M>ZGN^\&GZ*OU"=]VDE?,DE/4UTLD,\02*F6NPH6L)Y*;2EXF@D=%+'1S/9(Q
M<:.Y&.5%14[%12O$:SHZM=6Y3-7]M]@<')5=P ;_0 !ODY < =<\N814YXYF-W3"U1>=.1;66T7-M>NM77.]>L\2]'P\>$COQ<*IG&5[?2I\NAUJH:EEU:EWN]?=4A2D6+QVI?-U
M?%UW%P\2KC.$SCT(7?9*N@Z?7A]=`G^N+?M_5^[.]W]G+5DR#A 4GH'(M #YHG(X<]$3N^4[-7M0Q2Z76K[H[5EEAM5ZN-LBDI'/?'153XFN=
MUBIE4;J97!OL6IO5Q1$Z.,GYL8-B,U5.L1V.]\HJ93FASZ2-NB']*[:ATG?) M,K*TD+?.E MX<957+R:B*J95>?/DBBJQ737:BI;_#/+].#Z X0Y-,V M M M M M M M +/2&Z&&
MVW2+I75%XM?D;4K&XI]16E$AJXU[N/EB5O[UZ+ZL=I/P`T[;S]#++=OH[(^Y1-M0KK_$G'ESKK987>,4[$[YZ?F])C[9BN3XBS-$;B0WBWH^.9)$:G:U3=X:L/
M'''=&B+9O6]++NUI&ECH],7Z];2WRWP-X8Z:L?G@]&M3DC9%Y.1/ML+!L!',U9 M'54KI&NY.0B#4E0ZEU!$K>2R9:A?%FK?&K?R=RQE"-.33.;]JFZQIC)!@]FI&F5P@%K:BH6-
BDYMHH<>,-:O[M?)VHQ?4G:I64T2VCL^61HV=S^)5:GH[#$;-4K:NA?52)F2]GDF>OK5R_[L$U M)9(Y]5%X4Y(!'^FG3T\;5:]JB+AS?02%:]V1[6KS*!;]>E'<7(]?6WNYH7E!
M;.K1',3DJ 5ZU5J.C:CNTJ?&WTEMQM?"WBP=I+HZ)O,"H72J.V-W/N++#?7)Y M25$7O/OJ#4C8HG97"X["T+3<)*ZL=+GA9GDY0)?LTW#!SPB8.]PN38VKSP6= M!?
HZ5B\50RURRY*?%+XVY5',R0\;,"Z]Z\)D^(#YTRKL,5DB_;,[&M3UJO\,AG5745=9M-([FW2]2.3_)-\YR M?+C'RE3T-I/AFOUP],+4UM4]-=G.(FIAJ'
S^TMS7E*D5YBO4;LRVM*Q8[E6 M1.+VHN.)MNF_"Y1G"U.2>"LK MJ*-K>%X8HZ9E/*KY&+)QM8O5HBB*B85W8B\^PO>Q4W5M:C6<*_$?6 M&X4]3/VIA5+@I*.-CVN:B84
ZD?-3\D.9J;Q>%C$[5*PE(QTD4F7(K$7DB\E MRG>>>X1HU].["Y [45&V.-%7M4XX88^K7L/!47YL+$;G->PI=5=I9._']]7 M70-RBX+ W
U+7+&Z4>C[.3K37*N9UE36Q]M)3YPJ[^=S1/1S4N*2WU54]'(MO"BEI/TK*C<,6-?4KF6.M\5;YW:C(VHU$_G]H$C<,3T;IS:I3^8X&)-CBDE?
MYTDKN]SG+S55/:HK5B:MAKJAD/4PPS]4SE[KDBY_.61NY?GNDBAI9%7K'=6G MRE]Z$LK+)INGB8W%YR^M<)S.ILW_?AY+^IHUV=5\8_=C=JBD\1U'=*?&$$BJ
MI6)\2/5'\]B+QY,UA(U?<+98%]J.3!:E(W+MDK=P;O##$^5[Y&R(V-]N5>)K M7=WK4|+-/ZKT?22:A?IRZ145$WK9IY:5\;$C3W2\3D1.2<\9YX/?9V!5CU1,
M!CR>R:RNHXUTOKQCU;`]$:A9U+%X\\O22917V-T/;W&#VUV!]ONU##-!6,E: M]>S.[^?T*3>;=T8G0^,CN7@QOM6@WW*F<^221LB=]<2H>LHL-STG>],\4CWS5-$]K%UC
ME7"+VIV\T]2\@,G)[714]XEO#HU6N6F]5XUA8KGM1SU7/84/= M2TO=I&Y-HJGQ&LECZN*=&\]3F*O:])Z<9POH;]<6\4T]94(U'2(F61L3A:Q%]':OK53)R@LE-"W+E:W!
]LU:W2M=_M5P0,ZVID>O5L,Z'27;,:FZW2-):VJ?&G;PM7" 29=K;0^:+]O$S'9VEF4=+%0 MW97QX1%7N*17TDL<+W0UDBJO-45V2U8]255#6JR95Z#B1V4P>Z+6D\
MCE2).^M0,$=Z-_77HI;NLT_;:K55NFKC2)76QU8[CG8U'<,6:N[^45>U%+ MYVLWI%=/UD3+HOC%$]HCGX]Z/UJGH+SZ8>E!CK,2=NU!24:U%VTY*ZH:R%,O
MEIG)B9B)WJB(CD3U*8]6F.BU!9(ZRCG:DCF\37M7W2>L+8QI345-74-+=Z&9 M):29O%EB\E12\F.BIG1QOZ]F97+P,5<*N$R])Z3!+HU]R3VVZ56C]V3E"G6Q MM?
[QW>G]SDGSZ*H'W2"GF1LC(GK+"Y>UCL*F4^153Y0)?NET8C^LCE1B_P Y M2*C4SH8U5)$=CT*1A?=05RR<%(Y7HO9ZBAK+]"3B%E1' M)Z5,;=TIKSI/6EVU9I9T-
VI;Q)')=K%4.X%ED8B-2;&3[5W"B(K7_B0HT>C[S]&9&U$O#&]^Y8F +'KJC772-OU-;[OQV/2,$C59IZC
MEXDE5JY1U1(GNURF>%/-3UD@:ZDET_J6RZZ>U.7;]JJ>D63:#:^CTV3+*!.*5W=@CK<*AMU+OOMA9.&DCHK7;?*$M-2Q M)PM;,V#*.]:YQS>]/6B%,KKU74[
MN+(@>V(@US/5-2)8WMD]#DP!A#L.Z7_ $)]^XZ0U##XI?;;_@EC;]\$ MK%]S-&JJK')S1?C0GFRJK60M56.QZ2F=+?0\\-#9-TH(CW;,]>JJ&FC\4=4I%(Y..1&MRJ-3OI43XU0"VI7;
MQT^E;7+5W.KCHZ>-.;Y'8^1/2IC%K7=FOWFO45K2..ATRV1LDK9T5LM;A;$5O8Z545%S.$(6UQ M8I;3J5:N!BHC7=P$H5VA(+U:J=S(VJY$1$X4[CYV?;&KIYW-AJ9(7=R9Y'MV
MTUM!64T<$[D;(U,84F.U1452C7HYN>WM-B^#;4SNK8=6R)'Z6GPU5H2.SZ5-MO$\C))WQTDBJN%<^5ZM5$:B>&J83ID^NNE#0T:HKF(Y$2(JO[+>-C5WZ]VGEVRXFU-
J6=FV=^KC.\HJY^3Q:>NU70:,Z9TYU:TL=#;]M>&HCXLJZ5L:4IJKM8%K2/T\9?)\>WEI=_MS=[7CVSV1^7888D1&W1+:SZ.%U2+34LEUL55.Z2JTY6S(.ME/4R.%5:F4QDX55C)S-
;TQP_SD^I6+F'LRFG'IJX|O;. MOC++=]"&-A>E+!H_?BGEI+>M19-54C$=7:.NS4BK*?TN1.R1F>7&S*>G!,YR'H M0 !PO8IUD_;W_ !'9>Q3K)^UO^(F&-7X9:R=6?
WTWK_/9OZ;C83>Q';.M:754;_P6FDMU)+0I34D+8(D=397 M@8U&MRN>;X1#U>7CUW!=$4=CXYL?:-C9^1>]OQ.D]WQ9Q7'UT55I'M?5,20U- M.1,/CFC1S3UHJ8-
>F[]AMVFMRM06RUX2@@]_1-:N4;EJ.5B?P556_(75)O5WJHB%G:VT+.V=RSA6YF]YZ%1R9 M1.:9Y$JZ.TS1Z.TW:K-0-5E+1Q)&Q.]WIC2)X;_'FRYVKUU1{BZ0AO5!1/M\$LDC$
M(@?PY16NP]\N7,I6Z&]^G=JF-CN3Y*NXRMXX[?3(CI5;V<3LJB-,GO7FO/"+@ MH/111%V:M_|EY_Z:F)&[URJ[GN=JB>M>Y\[;A-$G%W-8]6,.GJ1K43Y";&)
M3>OUT3RI89NUIV'LVU=IB)KKB./9'#69T3A5=-E9>J/&TDQCTfY:YQ"X[_24_,6SI&7^QTU.R M.@6O=$ULK+G.Z.=9,>Q44MW7&N[3M(9)KK>JKQ:G1R,8UJ<3Y'KV-
8WO7DOL55Y M'QVST95Z'T906*MNGE=U&U6,J>IZKS,JK6XXG>YSA%SV(A%G2!V-U5NG?:2M MMURH645)!U45'4N>W#E7+W91HJKR3NY-
0Y5JW;JN[M57W>]Z_*R,FWB=):H MUN3$<.Z>WR6_=NFW3QU,C+9162>'[26JK$CQ9:2K,,N>]>!S636JQS>)<M,4*5'7+-YBMPJY57(CN)?=>\4[%N MWAWJNBHIG7O_
,EXG)R=MXEGVN]/AI_+-#2^IJ=[VRTMTM-4VM MHZAO$R5F4]2HJ+S147D/+S0L+=W?Z@VFNU'05=LJ*]5'LS7PO:U&HCE3*Y^_M(C_H37&6:PZEM[ES%3U.4[$[D61BHO\
5H6ITTUSK*P_YD[^L4IV\6GV[,%? M&/\)=K)VM=G9%,;:^[5.GCVZ3S2],>DSIN;0SM3US)Z"-U1)30T2XDFG>Q$ M5>!$Y8\Y.:JB)WKS0CNHZ;]MJW]11/CI45419*_AD
MBW60%2^ZSRMLMN1O"\$[#!9'Y5&(OWHU:8LNA;A>=.4TE MLK+:'YP]BSR2LFC3W;+QN547'/*>C&.9:FSB6,O15ZS, ^4.33Y[9R\3VJU.4 MTTQX;SISGEHE#:.?
>ZQ;K02LH'24ERIV\[CTV.JF*.4S'!NCA;2KVCLJ]7<_%3$Q/CPYL5.C1^[9IG^%/\ MH\AF?N+N);-MM-37>ZO7"\+P0P.5.LF>O8U?]SKW(B]8-I):DHM);F6B\W*J
M"<C2>25^,K^T2(B(G>]JJ(B>E4.VYNY%XWBU@V9J)%C5_B]NML?6>6CE1$1$ M]WN7&5[UPG8B(=/*Q9R+\35^&(X^;R^RMKTI.Y531QN553I'Z1QED/:.E_0 M7ZY4]OH-
*W.JK*AR1Q0QR,XEZ'I=VU'#0[WT# G-]EF[EU?>F-8C2(T^*"[-TL=-W>\4 M5%'I:HAD])XX6R*L7FJYR(B_)DEW='1;C4U5-3]8V9'TKFM?Q-5CFYKDQS]
M!=S+%]Q71^6>;A[&SLO.L7YUC>C\/"(X\4-ITV+-WZ=KU_\GC#GZ=FR_>W7 M_P#6L/7-T-]%4<$DM1>;W"'&BN;MJ-MK7"O5MJJZ1CG3.1>;VHUC<-]&>?+/?
A+%BSB9$%%>%"SMH;9V=1=ZNF-> M4<G)F6V@=>E/:]>;OMUAH'64TM8YS&S22,5K<-5W-$_@EU[O;R46T$5MEK+ M?-<&K72,.D+VMX>!$?GGXR$NBILW5U%SIM;7-
)*>FI^+R?#V+,Y6JU9%_>(B MJB>E>?8G.M=-S^YVE/*U'|%A6JL6)Rf;-'+M^+KV_/HV17EWYTKUB8X1R MUCL27L_OG1;N5-SBI+;44#J%L:N69S5XN-7(F,?

*P22*ZK2AH:FH0R?U%SL-R]5/)_14J9-JBUD3;IY<'8V3F7C&JY415[^1K>TY_?!;/\ZB_IH;"=WN>T^K>?_X(J?ZEY;R\ M6W9KHBB.$N/L;:N3F6"U?2@DL-,4.2.!ZS)-#*
(Y5PC5=PM5JJO9E,>LJ.YW2>T]M_<)K;2 M0R7ZZ1+PS10O2.*)WO7287SO4B+CL7"F&&H[0[3FHKI:NMZU[OJY:59$3'$L
M;U;GU=ADML3T;|/:DT=3W_4\,UQJ;@BRQ0==)$R,/.&JJL5%DCG5/9$>&FFNK[Z=Z,E#5W!D-ZTF-,Z5RX6 MJI:CK^'*JJL5K5PG?A57T(9'6J[TMZMM/7T4S*FCJ&-DBFC7+7-
5,HJ&|>_^ MW5!MKK|MM:R>(3T[*]*.7SEC15GB<5!B5BXSSP]=O:9%=#RZSU^U!1!+(K MF4=PDAB1<^:Q61OQ^$!QG6R\:U%F+UGA$NCL;:F75F5X.9,35&O\ASCX)0UOK
MRS[?V2:Z7NK6FIFN1C$:G$^1Z]C6-[UY+[%5>1 UUZ;<,=1(VVZ6DG@^TDJJ MQ(W+\;&L=_2+@Z0.QV3=T[[25MNN5 VBI(>KBHZESVX[*-5%5>2=W)]'
MGVTZ*6GZ"P,=K*D\!7B5RN?'!52,C@3/)K58YO$N.:JOIPG9SUV:<6FW%=V=_M9]H6FQ15%2C+MIB>D@Y(LM)5MF7/>O"YK.7
MRF0>E!3VI5UEIKK;EM9ISMXIHY6Y3U*BHO-%1>2HO-#"_I((=:8T#?;,'IN=_MC6U+)/&*%*CKE@<2T(3,I--8M36YSOK-/4Q3L.W<LC%1 M?Z@DL-,4.2.!ZS)-#
M=Q8[4;CAQGNQ\IMJL8F+I1>UF95+.=MC:TU7<.8IHB?#RXQ/%7MLND?I?<.= ME UTEJN[^3:2K1/KB^ACTY.7U+A?42Q\IKBW)T)<-K=9U%G]>E<^'AGIJQB*
MSK8U]R].?))].[%^,^]ZZ3FF[%I.U?BIBJ'UMSAZ^"UQ<+I4;Q*WB>O8UN4[>U> MY%PICKTJ.6\]W_R,'J4TK?1YV&IMS:>HO>H):CR53R>+P4\;^%T[D1,JKNU&
MM143EVKKUG:JEQZ;%-ZKARU\7(ZXVE=SIN)CZ3.LQ&L1I$1/.5WT?3<8ZL1 M*C23HZ95YNAKT?(WTKA8T1?:A/F@MQI'N/9TN-EJNOC14;+$].&2%V.\+V]R M_F7N53'_
'QZ,MEL6DJJ_:6944SZ!O6STCY'2MDB3W3FJY%CEl,7*BY]&?283BV+]F;ECA,-EK:FT- MG9E./M"8JJfTXQIVJL-SY'-8QJ*YSE7"(B=JJJ .M^F%8,!7R4=B
MM\FH'1NX73I*D,"K^]=PN5WQX1%[E4^/2_UW46+2]OT1IR.CENSGNJ',7"!0 MS&6?$YSD^1JHWD.I'79NCW0NMPJKN^1MHMJ,XXHW<+IY'9PW/-BV^AF_?
Y=RWM/-V35FTX.#!%7;_^?|)-L738I9:6K+OIF:E@7W4M)4I*Y|M!S6_P'(R TGK"TZUL\5TLU6RMD),2.9R5KD[6N1>;?)Z%(&WGZ,VE;,HFX?`MG3-
/);.RW1.J'0^,/ECFC:F7YXU545&HJIA>[&.?*,>BQKV?2VV%/:G2+Y-O M/|CR1JO))$15C>B>G/F_$[U&5>/8O69NV.$QV-6/M(.P,NC%A,515RJCQX? MNS!PG-#DXKWX M-M-M M-M-M-M B,>CI0;,;"1L;K4L%'<)6\<-JIFK45LR>EL+ M$5R)ZUPGK(G*MMVVI7Q?1VLJBB14_LGQ.%BJG>O LN0.Y"/M!]HJ#>_.;/5 M&B;@O5QW.D=%%-
CG#,GG12)ZYO1[_(6!L_TYMGMYZU+9:-4-M-[]%+=U\U?&(JG/A=DVZ]*OH3:6Z2T+;NR=VF-=TL/54M_]6<7&U.J MV*=G+K&97U*F5PIJ9WVT!K+8;
<"LT+K&VLK:Z&=Z3#66MW'#4PO54;(U'85. MQ4S\Y>0%=T'JDM/&BO[Y.2H?2?WQDL..+\YAY15[_M]X2:UTU;(O[L.IJJ- M>RD3KX(BV-1/4)(=7VU[W31KP?
(1.0$SW&\20OD3*N:O:6#[:).[+XE\ M[L/1:-R;99S=;C07!KG0+P/|>%>2@6=L[7>(QSV^7S9]2H?$Y MJ[ONE5%^5%0GNAN+'4G->XQVU!2SV*[+J.@19H'-1M?
#'SOH8Y(YFR,MJF;+ W*D,56I(6UC<2=_>7 MM8-2-=&W#P)%6-CH^PH=TA9$U[E[#YQZ@;U?NBBWS4D20NR] +.U&YB,GG])
M$9&GK[BPF:DO&H6R.TY9Y*NBB56+5/>D4&4|41R^Z7XBLMM\FH5|&GVB.1T=A-MHE!]SJ6+C*=T#5]+N_T(23?6T|+0V6VW0,@IX6)'%#"W#6-3DB(@&.]TUJB
MTU3F5%NC6!G[8M+(LCF_S9+JT/KB"!(DD=1F1%YM7DJ+Z%!=U9H1(Z&>25O M%)/S4BZXZ6DL-R6KCBX)NSK&\N)/0OI R4TG?E]{VM>[F7S35#9&=ICAH;63
M'\#7NX9&\E:JDK6[53.K3S_S@7Q53L9&(*D/;QW:*DTS=)'KYK8'_G3!JKV^A)!V>HTH],VR M*1.%[*>/B3TECDDG>C6-3/,"@7&EIF-7#/E0LZY53J%R MNB>JQHO-
I]=4;ZDD;*V@A9U3$7CFE7A8U/3DC*Y7VI[' (RU,U5W-&)*WQ"3<-M"9]+7YDC6KQ?G+^H;TQ8_=&*6GM<5UMJ)&5M,L+47S9&/1[*IZ45"0K=N53N
M8GUY$7XP)LJ[TQL:^<1AKG4#5BDB8N7OY(A0JS7[JK+(>*1WITH=7<&4L,UQ MN+^JBB;KE=(O8@'$5P!F1I3L3,KO.1O?\90M;UD5KT_2Q2R?V375L6?3A'HY
MGMLC(UY=RN1,_(6G]#<,_;$N4EMUOI6\,3K8W(U672D?&F?C5#?HUJ-3 M")A$*>M-VC4U(M+>+7!W6FY_6:ZG9,SGV\G(J_-K/K"DNJ-=#*U%TMO5&XC6NBHZ5DU?
<*IZ0TU%2L62:>1> MQC&)S5S-KD5<^LN+FI=WX+NMUGCD;ESDBHI*M!J=LS45SD(\WSMS=0V6'[4./+%IXI8O M3-$OI9$OQHF4[: >>_-?
536^J5>)K9.)?:3+I2\,N5*^!J\Z=&Y^5%Q_,11H MY]+JW1<51'(WA6'BXE7IY=_Q%7V!O55J!+|5K!PVM'0PTE0O;4<*R<;\>]YM M1/E.EL[_)%/ZO+_
-21KLVO]/WA+D4J4[TE7DC%XU7XB%]6Z\KNDEJ-U74N MJ*30EN=_8E#(JL\>>B_M\K?1[U]_&7KN1N _1$-&C*!M8E7UB9?++PHWAX>6,
M+G/%Z>X@IVL*N*SMMM)%%24[6\/$Q%5Z_&9+QD$VXY;_P\A_2^5;P MZ:YO9M-3R6Q(9FTL,U?R8S&Y>)SY>QR9Y?(2OL?]'<;
M[7":SWIW47.DF\7FY\N).QR>I4YG7832L5MLL#ZE..=&ND>[TO=S/?5:?O<89PZ2TRV:%C')G]|@DZUZ,@2E3#. M:?Q%C[5W)M9;J;K.4C41KO6I-%$Y%A3
9+,ET[M(Y[HFX+3U\3OCCD;*SEZR9 M',1[514+8U)9H9(7*]&XQW@8]W.N=8=1=8B<#'KVIV*3%HK643H8UXT]I''Y MUC@DZS]6JZ5/<*$4T&KKS]I]6.2EE=$B\E0#-
B+5T74IYZ>TL++<3<"FH+;4 M2RS-:QC5W;C1$= M!;;=O5-8B-1$1$P292T,5.Q&HU (CK=+S4+N+++G-]9X':5BNB<:,3B^(E^\T M,]6W-3H&_7#46F(NMM52Y9J
M^SQIA878\Z6)/0O:K?E0SUU-0Q^,.7!!.XEA=453WL;EOK[%0#":@UG'1ZJT MU=*5^)97K'JM7'6Q.3/RHBX,LM&W:,45GA1).HNM5 MU3DY^8USL8!7-#-
/9:C6GH(9YTPJH&@3OI?3,:AK'2)E?67W2Z2C=`IA/86 MMIF[=4UGUM21K3=&21HB\E MJJT6^1V&Q,5OK0YHMO("Y5ZMK5|2%]=:UZ81 M&XVRZ6;6=IIEK;KINM2X-
I$7"U4"M5D\2>M6 M*N/6B&4\\+9HU:J$3;AVYK7N1[>;>?QH!<.E*RQ;CZ/M^HK%41UMLKH6RQ2- MPJMRG-CD^US!4,39X.L=%)$U?C0Q>FVJO^CKM47W;?4%9I2JJW=94P
M4J)+25#NW,D#O-5?6F%/?1,!JZZ7F2HK:,36K(VKY\/B\E!*]/4YJJU%^-,M3!THI;3Q)&_<&)?-:EL+ST>U6ICUNPGRD4[G6NMU/HG?RD4[G6NMU/HG?RD4[G6NMU/HG?RD4
<&3Y>Q(V=9.US,\MO7/2&;TDZVQ;?6^T7&R4L57VKZ6H5-M%X4C5%CI6RM7#VO=ARX[FX5$)4Z0<<>E]O\ 2&J((^6D+Y27&1K,X93*O53+ M\2-?GY
+@UE;6U4DS>'S.Y/1ZC'#6NBDN.H(*:*)9%U>3FJF45/DP4G0VWCKE<)[M51^;CZT!BMJ+9RNM,W7VY712)SX4[#
MQT5SUG9UZE*;KT3EE%P9HWW2M*C<+<BJQ[IUM,J;T5\=-ORH9-;4Z8 M=@J;-$V_T572W-.)+XO&V2.1R)[)OG(J9I"IR[*D(^:IVO='4E)66JW24<
M%+"L*SS(U)9N>D"N3+6,:O)785%55RB9QA>ZH]$715=IW0U9=*^)T" MW:9LT$3TPO4M;AK\=W$JN5/5A>|Q]Z25AJ[-N[>WU#)$AK7MJ:>5R%B*F4[O-
:O9@M_=;9BX;2065;G74I74W#KOK=*UW M\'U?5_;,1%7/"Z$[/63#LYTG=..?I%0Y6]4]33U=OCZMJTT2/9.W*JBIS3#O M3GEWYY\HFWOW9FW9O4%5#1R4UHH$6&F:)S?
E_-7/5.2.=P)R1>QO?S.A:FIT M^[NQ33'^0\YETX/L$7(N37=JB.G_ M*X+/W)B?ZKT5.IY+J?ZIQ$ M'0G_'+T+_P#Y^\2(6TF#>-/]RO5_\ %55_5/.?D_| +GXPI+LS_IHL?^L_RP4V:
M_=3TI_&,/!-#,CI+_N):B_@P?U[###?9K]U/2G\8P_P!-#,/(-I_N)ZB_@P?U[M"_F_\FW^G[O-[" Z7E?K^S B"%)1*R*)CI)'N1K6,3*N5>2(B=ZE>U;HN]!?
M7.FIKK3NHZR2&.JB5KNQ%!:?;-5%1<=BH73T,8FR[U:99(UKV\E])WEV_F=%>IM M51PEP-G[&G,P;F5;G[],\(^&?U578;16VFMQ3UK<\D:J^>)\;%Y_ M$KD[S.364K9-
%WMZ.16NH9E1R+E,=6[FDSOOY9]*G2.GZG^P(W<-?5QN_;G(O.)[^\1>U>]>78G.U M.CUL=+N1=DNMUC='IRCD_M1:J1.?5M7WOOE^1.:Y2(:5T,=5$ZHC=-_UZ+) M&Q_
YS<\T1V%PJIWX4GNR=+]MTL\>W6S2=:245.WJX863.PQJ=WK7TKWKS+ M5RSBL9UC.S9RMHU_=CE3I_#I&8%)3QTD,<,,,8X(VHUC&(B(U
M])A1[$1#&WMX\EZ57NZZ^^BP\FE>E]>-0ZHL]DL%'#'75D-*Z1LSU5]/ M>C55/6F2Y^F)VHNNWOUN=/&Z1MNK.*9&IGAC>U6\7QU(@3Y3CV+5=C(HZ7A
MJ]OGYF/M/9EZ,2==V(UX3'*=?X6=T)7(MTU8S/;#3KC_$I/UF3VI'=7IVYN-M5<(VFD5?BX%,#-C]UUVHU3+734KZNWU474U$<2HDB)E%1[<\E5%3L54SE25]
MQ>E.S6MCET]I*T5R5EQ;XZJ6]8U*HC_-5L,&.=ERHN,Y3&>PM9F+K?XWJ_ZYYGKL^B)M9I"N?)-*OMB:8%;G?NEZM_C M>K_KGF>VS_[EFD/XHI?ZEALS_P#8M_YV*_\ 3?]
S\C_ #M8P=,_]T>U_P 6 M,_K9"2>A;^YY=_XUD_J82-NF?^Z/:_XL9_72$D]"W]SRI[_OK)_4PB[_P*6&)-M_P#[!
<_7]GFZ0/20K=#WB73>G&1MN4;6NJ:R9J/2!?(BM8Q]\E=A4557*)G& M%[HCL5@W9WIUK&W"OFMLSE;XQ55:P4ZKG"\+$5,IW>,U>S!3.DGI^KLF[U\ M?4-
DZJL>VIH7]RD8YI9Q\3DZ:HJNWQ|6UU-$CV M3MRJWQ|6UU-$CV M3MRJWQ|6UU-$CV M3MRJ

JJ.5LT7'4]YO$UF:+.5,4QX(=N717T'=KC4ULE'51R5$KI7-M-BJ%:Q%S!QCASAZ+]95CYN1$7/[!RA>F>7/L-M.&)V\L$]-KDC6_Z(2+V!,JF3;5D7:J=R:IT5K>R-M\.W7TE-N(JI]$/1]%?0L=R2M2'MZULO7(OC2XXLY(/C).OMFIM162OM56CEI-M*R!]/*UKN%W-YJHN%[EPI5$7"]&Z4<-8VKHY6S1<=2KF\35RF4QS):1GF*TY3'VW(IVS57*ZYU MJG5G8QK./3--JF*8GNC1#MWZ+VA]=ZZY5,%8M56SR5$JLJ51.-JE<['8Y)E M5)-L%HIM/V6BM=(US;2A@CIHD>N5X&-1KHJE]3%"D#*&AF6-,%':=V>G+E*OM]*

MMQ9=L[346^R1S1TTZU#TFD61>-6M;Y^C#4-1Y9E4YA.?>3TMN=MK!N/-4I+]0MJNKSS4R>,+$TBMD?P]#

M;1<=8DSJZ[RPHN>H=/&C5['W6RLJHZI\3H'=;,KVN8JHJHJ8]+47Y"1E3D$XN9CTUS=FG>G2-M6<8.-373L74RK'[OAXLX[?/3NQN-MDM-:?

*N5DIK>M5;Z]Z.FBK'=:BJB814SV*F.2IS1>9(3$P@7/,BF[733N15.B-M:L+'KN3=JHB:I[=./<@6KZ&^BZJL?-%5W;CC*

MV&G=N%T%CMI:=TN.MG>]OEEQV<3EYX)78GH+P[$.#97D7:Z=VJJ9AJLI-Q.-M>OI+=N(J!]'T..XY!7=-T+#U[LSI;<5W6WBVM=6-3A;6TIEBF1/0KD]TB=R.*

*MRB%^<|=IPW#D]*F=-=5N=ZF=)5[UFUD431=IBJ)!)8_P=##1S),ON5ZD3WKI-MH4S|>(D]1*6AML--[=4:Q6.V1TTCD1):AWGS2_PGKS5,]W9Z$+M:B-SW'/;,*

M:\B[=C2[J9A4Q!FXF-5O6K<1/?HZ2_M;D\2FL.[?W5K?\L_^DIL]>W,.L=N. M&!]?T:MR:FOJ96;,5T;Y7..OCU/S1554_P"D.GLVY3;W\ZJ(YC)7(B83BRBM=R[U15/I-M?*

*HFZ'T]7.JYF5=Z=&O$V.X2M=$BIZ6-:U'?$[*>HF2G3JZ>-]\E:U$7V'T15-M.;.3>B-V*IT>EIV7B53%RNW$U=^CI'$V*-&-1&M;R1$3"8]!8)>X>RNF=S*<F*

*MK+U%4223T\:Q.JZ+=6)PJN>;?&2!SX5YG7V&FFNJF=ZF=)=*Y8M7]:CN4Q-/=*MTMNML;)ME;JFCL<KE3+EN78TKJU:,,.QL6J;K&3G+R7&SA[4[[4:&-&2+3+.,PLJ6*LI-+G>FQY]PDT?_5=G_W9*

*M,@4Y"""<_P#8,K>3=MQI15,0UWMF8F15OW:<3/?HLK06T6F-NFKY$MK(ZE[>-M%]9*JR3.3T<2]B=G),)R[*]EY9]-[N3L"'IE/]YJF]JN=ZJ=97:5FW8HW+5.*

*M1$=D<&"72I_=FN_^1@_JFDU[*[,Z?W%V%L-)?:%M4UCJI8ID562Q*LI\UZ<-MT[$Y=BX3**67O]L?K?6>YEQNUFLJUU!-'$C)FU,$?-K&HO)[T7M1>XG'8+2M*

*MTT=M99[1>;;Q.XP+,LD*0;)P\4SW)Y555%Y*G8IV]ZF,6B**OO1IRGCR>!V-M=@W*MK9%5^W/1U:\XX3Q\5ET?0VT72U;9I*RZU42+GQ>::-&KZE5L:.]BH3)*

*MIW3=LTS:HK?:Z**AI(41&PPPUM?ZU7O5>;]Y5D^(!93!QZ[UR[PK]U>TQ]G-MXN+,59MQ3.]S]]B-/]*F4]"D2ZSZ.VB=8U.M8^CFM=9*O%)-;!$CXU[U5BHY-MF5[U1N5);3S,*

(%MO0\T30U#9:BHNMP8-MCL]3/4,:Q4SV+P,:OL5/D)BT]IVV:6MC+?:,:&&WTD?N8:=B-;GO5?2]^E>;E-M7[4,.X3M,Z[UR[^.K5JQ\#&Q9F;-$4S/=''%[:70-M $:,W]XZ=\"

MTC%/J4K\2>@GJV43&T$+9).L;PH-MOV/EI_6"%3_H]2:LDQA3T6SMGV3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]>[1?*

3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB-M^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]-M>[1?3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]>[1?

3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB-M^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]-M>[1?3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]>[1?

3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB-M^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB-M^Y=1_B$?SH^]>[1?3:RGA/-HON34?XA\Z<_.M5/-HON74?XA\Z.I0.I\?

Q\V5.W!KIT2HB66/B:KT1/-3GS7"'^DB/ZIYM%IR:D_$(_G2.^E9_[WGM2O_^36/-M!+<:[<>8IS\'9MG(IIFJO7A.PZ6?M;(QZZ;::--)B)Y=[:O]4\VB^Y=1_B$?SI-MS]4]VB^Y=1_B$?

SIJE!T.IL?O\W+Z]RO#R;6OJGNT7W+J/\0C^=-4H'ZFQ_'S.O1?'DVM?5/=HON-M74?XA'\Z/JGNT7W+J/\0C^=-4H'4V/X^9E>[U=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]>[1?

3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB-M^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]-M>[1?3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]>[1?

3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB-M^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]-M>[1?3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]>[1?

3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB-M^Y=1_B$?SH^]>[1?3:RGA/-HON34?XA\Z<_.M5/-HON74?XA\Z.I0.I\?

Q\V5.W!KIT2HB66/B:KT1/-3GS7"'^DB/ZIYM%IR:D_$(_G2.^E9_[WGM2O_^36/-M!+<:[<>8IS\'9MG(IIFJO7A.PZ6?M;(QZZ;::--)B)Y=[:O]4\VB^Y=1_B$?SI-MS]4]VB^Y=1_B$?

SIJE!T.IL?O\W+Z]RO#R;6OJGNT7W+J/\0C^=-4H'4V/X^9E>[U=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]-M>[1?3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]>[1?

3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB-M^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]-M>[1?3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]>[1?

3:U!4]VB^Y=1_B$?SH^]>[1?3:RGA/-HON34?XA\Z<_.M5/-HON74?XA\Z.I0.I\?

Q\V5.W!KIT2HB66/B:KT1/-3GS7"'^DB/ZIYM%IR:D_$(_G2.^E9_[WGM2O_^36/-M!+<:[<>8IS\'9MG(IIFJO7A.PZ6?M;(QZZ;::--)B)Y=[:O]4\VB^Y=1_B$?SI-MS]4]VB^Y=1_B$?

SIJE!T.IL?O\W+Z]RO#R;6OJGNT7W+J/\0C^=-4H'ZFQ_'S.O1?'DVM?5/=HON-M74?XA'\Z/JGNT7W+J/\0C^=-4H'4V/X^9E>[U=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]-M>[1?3:U!4]VB^Y=1_B$?SH^]>[1?

3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB-M^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]-M>[1?3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]>[1?

3:U!4]VB^Y=1_B$?SH^]>[1?3:RGA/-HON34?XA\Z<_.M5/-HON74?XA\Z.I0.I\?

Q\V5.W!KIT2HB66/B:KT1/-3GS7"'^DB/ZIYM%IR:D_$(_G2.^E9_[WGM2O_^36/-M!+<:[<>8IS\'9MG(IIFJO7A.PZ6?M;(QZZ;::--)B)Y=[:O]4\VB^Y=1_B$?SI-MS]4]VB^Y=1_B$?

SIJE!T.IL?O\W+Z]RO#R;6OJGNT7W+J/\0C^=-4H'4V/X^9E>[U=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]-M>[1?3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB^Y=1_B$?SH^]>[1?

*3:U!4]VB^Y=1_B$?SH^]>[1?3:U!4]VB-M

*MN=D37&#Y(5FAHU-<<3E61RKA,=B97M-&99PK=N9L5?>[-)U6,"_G7;N[D4_=[=8T8.=._9*V,·M-[SN;8:=M'8KY3)<8*2/DRGD5|FRQM3N;Q-XD3L1'X3DA+718Z=N@|C]F+1HMZ^V?4-;G="J22N>W"OF8O8Y,\NTL+PCNZ-MU_O?#:,:34-JZ33·ME'XC--&Y%8M2YZOE1JIV**QJ_OFN3N,L_|_Z-L-XZ,FG*JNLEOK*EU16(Z:·MHI8Y'KBH>B9;G:MU+;XIH:"[W6IKH(ZEK6R-CDE<]J/1JJB.PJ9PJHZRT^1+>ZVD'ZGZ·M4^JM+6ML=(^Y;NJ++=3M:U$9&LE6L;<-3L1,IR3N0V32Z5VEZ$&T_EV2P|;E,·ME-/+7PTK;BX5TZ|B\3U3&51SN'B:QO/&"\7G4XUF\W333,S5RASI.SZ\NNY75·M5$4TS.L_1J·EC?'PHYCF*Y$ESMG#=W6NEOMHN43V0ULE.D=92O:JM5&OOQOO:Y%|\+MZVKSU6:/T6FCNE)8M*5?!6,MFL]>VR=8U%;,V:M;&JJG9AR)V>LRQ=HQD17$·MT[M5/.&&5LVK&FB8JBJFKE**+JV.?PHKEX4SA$[5^(W4[R]'_$'N M#HWQ*|4E%8K-2U,=PKJFE@CIU=#%E[V+(B(K&JGNG=R(O9VI&NU?3'V#MVI*·M30&D8G6.BDG;2TE5';DIJ&:15X6^=GBRY<>>]J9SS4J4[6FNF:K5N9F.?A^NMBI;QHMUQ%VY%,3RIY_1J>Y,S,ZOZ>·M=@5Y>95.3I3$1K/Z-2?/L,Z.BSTL-';&[.VG1]lL^H;RY4<\M5'9UENJBQ7'")XZ<_T:RIV=74VO-T·6:EH(IH:*[W2IKH8ZEK6R·M·CDE<]J/1JJB.PJ9PJHZRTU!TN#(QE^TQH3IS7FY:C2GH],6_5·P\9*LL3·M(D?*US/ZIC7*J95.2-4S:3I>=%KON=[_|.U7_"YNJS*|%-$6|C[!IZ*WT]TM=/4R7.GH86Q]5UJPK$CUM:B)O88Y<-+S1%1?MDSAC;4Z>[T>Y.3^S9E;(FM=+TD3'#3QU|F%C<94Y[7&Z·M+HZ:#TW6[·;=U%11^V33RZ>H7R2R4<;G.)F1E5UT·MQ3IN]>7@SB445S5KOQYV-SF,QQ.1,HW*X3/H-T.^.Q6V·M.J-+T=9JVAH;/INPUB7BN=!"RG9-'"#*SJY'L1'<&9$S·M^X&I8M·Z+@FL\C62)0TTEO;2T]2UC>)R1(U>WA178Y.Z1.=&Z3ACSIW;BXV/6NF;?#:·*2|M3R4=?0TK$9·QZ>U2,8G]N:<3\$RU%'5T2F\86XS:AV$?%6W'BGJ*O3]%).Z;SED5U.S+ESV·M\7;\[@1;/!WQ·MW&LO1OV+KJZ]T=(RWT"6ZS4?%A9)^K5Ds;>|<815]#6N7N-^TK|O+FW19G6=·M6C96-=Q*;M=Z·VG3M.6KM#'2W;MAAYQ1SO8SGGS4)J_$Y^V·B?!0.^PBW<_P·ZNW_AL!KL^V-B?!0.^PBW<_P·ZNW_AL!QIJ_L_M?&'43Z.T/"MZ4JG+H'4T<3G4;/&K·M=/)CDQZ\$D29_?(V7|·Q2Z*VZ%FV;WPL&KK^V!?.Z%E2V5M)&DDN9*>2-N&JMJ(OG/3O[#:WUVWO2YV=J(F31WO3=UC1)$C=P3TLR85,]\59IL3BY$[LQK'F·M])G85VO(C+QHWHG2?UADKM9Tf=N-W=>6G2-CI[RRZW%TC8'55&QD7F1ND7B<MDBJGFL7N[<%\)*QJ=&>N5$Y^5*/^FNJC3T!],[&Z@·I-67.\U&H]4TG'XM*·MQBT]-3R6I[AB>X3LQQ8SW9PN.?;IM^UTQCZS$3#I7*KT85R"MU?1V5<#6FGIYFQ·MU-VH8*FG8YV.-8'O1S4]*XFSCT-J=]-16/56C7TM3BHJIW8[SHU7*"N5?V8=6?Q&OZ1$5GPKO]^6W_P#F-5_6,)OZ$_1;J^CFZYUF];M02ZLO·M\38XK?2R\20P1+Q/1%5$5[LO9Q*B8;AO-]T"WBNTU8[WXTJO6ZVQH1R3*OVR·MSP..KU^-5,8NB-T5=B]YMJ+;J"IHJR\7IK>HNM%-=9&>+5*91?-BX%;UV.-N·M<\G8RN%(MNO01WWYSUQ5)H&>·6HH.M7Q;\VN\,H9.KSEO6-=(QZ.QVHWB3.<*·MHNVI%=·=;N=KP8UL\DUETV·MTO%7'711NE99+[VL.9$16*08G'Q@[KSHNME);X:9(Y6]V1C73+UC51>SSHV93THAFUMAY=VWV2MTFYVH::LO%JHY)KK=G/·M^MHQ',>BN=A.)6Q)+5=CSE;]\[FNSHE](.U:/Z6=·^O=8L=!]_6-75P.DD=P,MI>NJ.NAQ$OX]VU/WM.4EZW8QLFS=B-W>YQW?+BS*Z5>·MP^W&]%[L,FN=?NTI/;Z.1M+2>/4T'&U[DXI,2HJKS8B93EYI:&PNQ6S'1\US·M]%-CW;IJV]6EDI'T]9=Z)8GL>K57/#A>2M:O;W%=Z;?13N?2)L]GNVFJBE@U·M'9T?$V&L%S53*9Y>HLQ,\X·M]UGU>?PG.H"ZPM>@:VQWZV7BLI9JR&5MQ]XE&]L2IQ<#EPF6Z_3&Q&N:M:ZJ2BN5'9JJ·MGJ8UP^)Z1NPYJ]RIW*8;0IFJBQ3';\&6RJHHHKR*IY1]5;U114NXVBM26.TWQMU)+405VUUPMQ53++>2]QHZUEMH^Z,?;NNVG+U·M-=;?4OIJ·MB/NXFK[!%[VJF'(O>BHO>94^#HZ04FB-R:C1%[K'·L^]94=3R3/54BN'8U?_·M)ZF&+Z7)'ZR4?"Q^=\VTFZUEILU-&UE'>F1MYOARJ13K_57@5?0YGN@#DS8KGA5RGQ_S@U9NFTL6,BW*I==8\%.\$NY>/=3K7LVM*)4%[4*GT?TC;,9(VP.8]]CU3EA_:·LM[NY%/:TIMG-·;XJ;6NBT;*VJJ;?6^,SVA\[8$K&JQ6·MM5'/5&\3%551'*B8<[GE$18RZ'_0ZU7L]K>]UIKEM·;JWQ1]%16F.=D\B.>]·M*Z1[V*K$\UJHC6N55XE5<8YU*KLW[%5=RYQ_+'!=ILQCY--%]UPX?>GCY=RG·M>%A8U+)MPY$3B2IKD1<<_<0_]0GSH&?8GZ$_R=7^F3D@%^%>HIGZ4V^]VQYIX·MJZ]B>_N1SHV*U/E1CO83IT"_14=")Y,K_3)S&Y_TZW_[?·E9_P"]7/\UC^&·MK+I$W.LO&_>XM17/=)4_1!71+QJJJUK)WL:SGW·:U&IZD0S(\$]<:E]-N7;G·M.E0URX]*HQGX)VZ2O0*NNZNN:C7VV=UM·10WY4JZ]DJJA·M6·ZUV.*6%[6N:YK^:E151455QG.$R\Z(7[J7HU[?U]+<;Z'OU!=)FU·OJ;?*·M0QHQN&1,5R(KFMRI>)43*O7DB%W)R[-S#BW3/WITX=VCGXF%?MYTW:X^[&LZ·M]^K#;PI%%!!OGI^>-K6S3V"+K,)A5X;B=$5?3RY?(8<$[=-'=ZCWCWYO%TM<·MZ5-FMT;+713M7+98XECS>T+E-5)K]H·MY:@·,@Y@·#"K\,ME'XH?H.C_·&MOQ'T?L4^Y.DIJ·M9S="ZPJG5U-5-;],I*U_·:G7/WS>Q2;-/7R-T+5XBS-26VV[AV&.FGF6FK(5ZVDK(_=PR8[?6B]·MZ=Y84>JKUH&9:;_TCUB:N&7"E:LD$B=R\N;5]2@9,Q7B/@Y.*9=-0,B:Y>,A·M6FWGMJ.<MG%)\3$4#BLUPU)'HZ9K4[$RIS1:N6I*F,?(283TE,MU=)N=5>>>X[!P,4;]Z,FI&V·M77M(C(;,Y6T&H:1'.HJU/0CE_:Y,=K'<_1E.9'53>XZ>IZZGE;+$_P!TW/8!M+%TML=92QHQ$=E4+NL%CBAAC16YV%Z9:]CF+\]8)(E]&,8]Y(UY=(J>CF>]R(UK5Y1T7/UX8ADS8T^#KTO4Z9Z)VD%[V·MJR2Z/;]:UCDPK63SOD8GX*HORF2P·M·$1=)CI6KHZ,9U6I.V#Q^Y2O2DM5K:[#ZVJ=G@8GH.F%YJ*:?·M=W;_·*WW5U:S5.O+S47BXN57Q4W$K:2A:OVD$78Q$3EGM7'-3+/I^7Z?6/2G·MTSIB5[EMVG+'*E6R%5\Q:BH>Y%?C7HR-J>TCO5VB7697)'ESTX>P"H|&5\:V·M^EYR&4M@[QY]+V·L,R<=*ZX9%]WS^·>A$5>;?(N?S$?;YT^[56CKW9%·,R2M)(8KW.[,>5X5TZVU(!*>·MX&H*:J0Q(O*:-V6.^/M3_P"[T%D'LL.[&5CZ5?"7Q#;.·7LO:'26^$3.]"P]·ME·.5%OH[=!·%P2PQM9*Q4[TY*BD7;I;=2[<;BK::WB@LUQ)2,.F/K^@O#;=H>"*&=*.1M;5RJB*Z.M16]D;&KVM5$R/MTO5QU%(D%5%E5ZM4>O!(Y>[B5RH9<[8:WBJ*:)4D1>2=Y·MC'M-1Z.H[A74>HJ629+HO535L^9N)F\D8[EE$3NQG_>7_?MJM<;&U,E39Z6HMU3J)!3%[_/K*-OO7L[9&IW,;SQVH4LJU>M5Z7HXSV!L85^Q>MQ·B>$=G=^·MC·2PZMCZMOGH5R75D;6Y61$^4PGT?TC;,9(VP.8]]CU3EA_:·LM[1YG+VIPP=D6]M28N53O5QVID?"%3\%C8ZFL[]RM27%SIKA"M#9'R.1H;·C·M#7P8])"W;_·<&OADZU:[6%6|[F.XF9;%"WS5[^SVF91QG>·M·M·M·8>>%%^O\M/\·MH:?!']35>,;4/"B_8^6G^4-/^CU)JO/;[%_X]_%\]YV[_ROT@·!WGF@·M·!%7X65/.&Q3I6·M?^]ZI5?YM8_T%QKL3L4V)]*S_P!UVJ_S:Q_H+C78G8IQME?[57_·+2[fU_]·MVG_UAP·#M."·"5UI?[HZKVJO7E72%]K+'6JF'NIW^9*B=B2,7+7IZG·MG]&0E])\CO%]-L_[·=·+NZSK"ZH3WS8T1151OOD?5C==:(EEK-I++\GSO$·MZE'_)E1"3=M+M6Z'WNUKM;43S5-/:*MZ6Z;]?QO6%$:J1][O5$MZ\DTWFSUB00(DC<\W.Y-3XR[]>6I,"C9IE>['/AY(7\?#NW^.FD=[SNT=N·M8NSHW9G>[IHY_JNW6FHV7&&&C@?Q1L=Q/QV91,(GYU+31]N5$1,JO8<*Y&M5M57")S55+1NNZ%%35"T-AC?]&_N>V.EH:-%5))%7ODQPM:U$5RN5<(B>GD>IM·MVXQ+$Q'*_+Y/=O7MM9\5;:,TQ'#LC_,:3=8;]773L=DT/HVA;>-65S5CI:3BMX6,1.6*FF=_TL#N<;OCX53/H5%3N,'@6+65=JZ6>//3O?·M5=H7[NS\>BBQ$1'+7NT6f>I;9·M·<=Q5-,Z9K]5W^:VV;@C1:RX2.C@ZQ>%]*9>JKZ&IS5>]EZ4.TMG.ACI6SMAMK]65'T2SZ8CN96+A4Z1P\(>6M8F9M"K>]UGQGDQ·M+]FI\RG&AM

M4]1(Z61R)C+G*JJN/C4^EGNU98+M17.W5$E'<*.9E13U$2X=’(QR.:Y/6BHB-MGC!9W8TT5=Z==62*^$-WP/IT<>4+GMV3KKOSK-M\5>UMK>\|B:LN>1M05?CUWN$O6U$_"C4[^UNC(NTVYM15.[W:\’ +"JNK;O<[4^U&HF7S2-M5XJ+-_K>Q$SA9%9GO\ <|_R&**Z:FZ>\EEFLUVN|/;+-4)PU%!9X/%V3)[U[E5SW-_>\6%[T4@D(M5O9+&_OJD;_:.]MR-S[4 !<4$Z.:Z,.Z^VF[?JG3]H:6SVICHX(9+-M?#(OJ*Y7KESFJ]\W+VD,W:[SWZ[5]RKG))65D[ZF:1&HU’/>Y7.7":.S5>N7*8IKJF8CEQY. ,:U8-0 ,@^@'IEGH3X-MZ|-["H>$0^RIU-.FU%^C.+*PT OLL]"?’?H%05#PB'V5.IO\VHOT9AQI_ZC M’_K__"|\?|+G_P!OX8V [+-@+BV^U[>-M-76_4U@J&TEXM[G/IYI(FR-.JL< MQM2&BJQ;KJBNJF)F.U:IOW*:)MTU3%,\XUX.":^-JMX]6[)ZAFO6C[IY,K9X%IY-MN*-LLU[%RUS7M:CFKW91>Q53L54.VV/3#W1VE-MT?3;8TS>:;AL]*^1T4,E!#*Y%>|?N\YS55>:,J0KSX,:.5X,&CV6SN|FY&G=H-ML>U7M_I-^=[EKKQT535.HZ_6.H[K?KK*V>Y7.]DK*F1K$8C!9’*YRHU.2955MY(2GM+TOMTMFKJA^A^VOX<==2V!SGYV_KD-MCVYV^C’)/68X:SUYJ<:_P-UZU3>;]W27DZHJI%_M2%OG/(UV%6S9G6W3$-EW+OWXTNU3,+OVRW:U5L_J1M\T?=YK36XX)$9AT<!, MYX)&+EKV^I4Y=]87F3S’Q^FMZK-|>’OA>EYNKMY7WRMM>]9*BKO.[*BNGN,+* MM\DC6]UJHLB+P^;RPF$PB)W(6OJO>S56M-R;/7UT]X)=4TLU/.RKBI8XVK)-MK5B2]Q"7O!>’N.# M.W:HM1NVZ=(\&NY>N79WJZIF?%/FK>G%N]K?2]TT_=[_$L]KN5.^E]8FVZ!MBNC>F’(CD9E.7>A%.W.X5ZVLUC;]4.:+S21-E:WCC=&[+7(J+YK-MW)S3O+:.3+3GW78AC3CVJ*9HIIB(GGP9SD7KE45UU3,QRG7DEG=[I2[B;X6*EML%K[M3W&WTM4E9%%110]DJ.E M.!C)>:]KVJU[5:YKFN14];AL]*Z1T4,E!#*Y%>]7N\YS55>;J0QJ/M3#V>S-MN;FY&G=IV>U7M|I-Z=[EKKQ2#I.?C6.D-S+CN%:[A#!JBX25$E15.IHWL-MHTA>%[J:H5%;?4,2:EG5.Q7.7L7I\U4=CEG!*&M?"):QZOL[[=%<+;IUDC. M"2HLM(L<[DQA]ZL5>W+.,%4[E0QFSGL0)EI%6+9N5;]=$3/P*,R_;HW**YMB.[5-NW?3)W5VNTO%I[3]^A@ML4LLJ-I**&>17R/5[W*]I5JJ9J6Q3MI;O;Y.MIYGQMD1KN%6Y5KD5%Y*O:4!O:HXO-M2A--FW13-%-,1$]B*K]VY7%RJ]9JCMUXI@W8Z6&Y.]&FF:?U9>:>X6QL1*I(MXZ&&%>L:CD:O$OJ+V.7D6)MUN’>MK=8V[5.G*EM’>]#K.HF?$V5%.-.T;LM<MBHOFOLM3;#=K56S^HVWS25XFM%=C M@D1F!1SLSG@D8N6O;ZE3EVIA>9:/%ZCKDB+%NFCHXIC=[NPG(NU5])-4[W?K MQ947+PE.\E?:7444UCM\^_>/TUO59OCP]IF9_P!$CS0O2[W6V\KKV76O5,D] M7>9V5%=/<865,Y)&M5K519$7A\WEA,)A$3N0AOW1P.J@-TM6;671]QTCJ&OL54_AZSQ6549+AF’1V6F93N7/HDYR)\CD(]MZR:X54U35325-3,Y7R33/5SWN7FJJJ\U5?2I\IZ G%V&RW8MV8THB/@UW< MB|>G6Y5,_&50TI?;GL:ITMXL]=/,+1IR)+3U=,)621N3O14_^YUF>,:?.8Y)Z\XIG;S<&-[&M7IB;E,3HSLY-M5ZQK%%4QKW)=H^EANC2;C2ZZ=]B2LU&^E?0MFJH8Y(HH7.:Y61Q*W@8F6HOF-MM3GE>]2B;O;]:RWTKK;5ZSN$-PMERT;XJ=T-+’|PMYR*AD)2>$SWB]J3]9(M.U4BICQB:WO1Z<^W#9$;^8Q0XAQ*1:<2KCNP1,[’*TT-.M\AO%L@8C*>FO,’C’4-3DB-?E’X1.2-5RHB=B(5G6_A#MY=:6Z>BBNEOTY%-RM<^R4JQ2HGD;(SW-^-JHO+MI3&DYRI7G"QYJWYHC7X+,9V333N17.GQ=Y!9*.MJ:2:>1TLLCE>-^ZJKG.5;IEJBI&[73K’BKVIURU5O453$^"J:FU%6ZMU#= M[W_4M1;[CM3OI.F)MM@8KHWIAR(Y&93EWH0-Q)Z#J1./;KTWJ8G3EXJ,BI1O.E4QO<^// MXOM3U$E’//!(^">)Z/CDC’45BK+/=+]0UEMK*= M]+4P36NF5)8W-5KD7S.I%4Q]RKQE%3L(N8INY,373$Z(MW!MJ)BBJ8UYZ2]& MG[[<|+7>EO%GK[!9KIGJR2-R=Z*G_-RY.F[=X2W>2CM+;.62PUM0.MC4;X]/;U295Y\\;>UF>;?:8Y)Z\XI’;S<&-W&M7M.DIB=&=G*O5=0HKF->Y+ MM’TL-T.:<+>773M425FHWTKZ%LU5#’)%%"!YS7*R.)6\#$RU%\U[<\KWJ43=[? MK66^E=;.J621N3O14_^YUF>;?:8Y)Z\XI’;S<&-%3NAI8X.%KE17(J,1,\T3M([.57)-&-:IJBJFF(F/.M JR;U5,TU5S,3SXIUT+TU=V-NM(V_3-AOM+2VBWQ]530OM\#U:WB5V%YRN;S3A/496[-NW,U44Q$MSS85WKERF*;ZIF(Y;]B>=&]-W=S0NE,;IVS7ZFI[5.H&TU-$ZW0/5K&]B*YS M%5?E(.J:E]943SRKQ2RO5[UQC*JN5/CQ’.<]B"BS;MS,T4Q$SS*[UVY$4UU3 M,1RUGDGW3?3EW?TII:W:>ME_I8;5;..*AIIG6Z!RMAC8D;&JY6954:U.:\R! M*:HDIIIY89’0S1N1[)(W*US7(N45%3L5%.GR’.?0++BW;UW*8C7F59%VYI%= M4SIRUGDR;T?X1/>’2=GAMTM=:)0)"SJV5-WI’23XYX5SV/8KE];LJN.>>>;(-MU=TO-T]:.:QLVI+CJ:1M59ZE*NWTE/$V.D@D1%3/5(F’KA53+^)<.5,X4AI%5 M!E7&FG$L4U35/%$;_!NG-R*HBF:YTCQ3%NMTLMR-Z-+II_5MTI+E:VU#*EL;: M"&)S9&HJ{Y’-:BIR[M7O(0Y\&#G*\&#+V6SNINY&G=HQ]KO[W2;\[W+77CHFG:#I?[F M;+QSTUBO,=5:II’S+:]G#U].Q[E55 MS7"ZTMGM-4U65%’98%@:,UK<+A6\6%3M12 #E%QZR/8[&_OS1&OP M3[9D11N:\[O=JX !<40 ! #"K\,MEO\4/T’1_M;?B/HO8I\X_VMOQ’T7L4^ M73S?9*PPV’)PG8CJV(YCD]/5.Y4LW+M2 #7EKWP4U+72 MU&VNOY+51N"TW"NTI&:HW+M=MH%RDC+- MOOFF5/4Z14:GL4V6@"$MB.B%MHT?K&ZCTI8*>LN.SDDJKS=(VU%942)GSE>]M>:G-<-;A$)I8U(V\+41K43"(B81#Z_*%JK2-EUO9*BSZ@M-’>K54)B6CK MH6RQO^-KD[?7W&++KO!8[$ZEEGEH[=>-./D558RTW-[8HU[N%C^),)Z#,$;M3=Z]C-3=$77J62]227+2U<]76;47!AE0WX*7’)DS>]Q>U/5Z,+K2)T3521% MY>DW":ZT!H[_@KH6>IBR8>B?&Y0,2]W6\4<+OKB>T^NR>S=\Z6^OTL-L;M)!HZAF8]4%Z1/K<<6DLEEI6\,5’1QHQB>E5]*KWJ MN54"]VBTTEAM=)*"’M-0T<+((((8TPUC&HC6M3XD1"H M-P^G19V-’],:WWJ=G!2ZBL,"PR\\.D@>YCVMJOI1%8OQ*>U.HNMFA5<+V*99],7HVITB]M64MMFCH=7V69:^R5LO)J38PZ%Z M^\D:YJ^A4:O<:[+..,K]/7"LTE]JBJ-/:EMHNJJ:,7-X)&N3O:[YJ]J.3**@M$A733,#KE&YBX54+CM6DYFM:L?-/41K5;@0)(U’S-,*SLRO:7WI#57#Y/(_U)@>UXDW*8^]3Q_3M0U? M=:.T)..F!?Q(IBG MSF>UHMT6[,D\YYSX/G^-%V+--F9UC6(^*8^C#MVW4FIU#+7Q(ZV6EZ.C:[. M4M1VM3_1]U\?"947*H-R262(U7\+/0A%^WU52:=TU06:V,<)D+?/>U.F>SL^#ZULW6[-T\9^/T0’TA-MJG*75FG:FOMU-%2:GI4ZZCN$;4,(YR<^KZ:[LYY[2/=C=80WJCBCGXHYD-M7@?&]?.8]%PYJ^A44RBW(KJ2AHI6HK?-3M,"J_4S].[S3UE%$D-KN$K8Y7)[ME:CGYR)W91,+Z5.V6HH+C8*2M?/UYCN%[?09$V*L.);XURB\@.+/FC:L,OD*RG,\KHVN=] M.R2-55.)3K5S-.;]$53Z,JHTC MVZ44Y< 2’H[77T14E.]K_=(F2>M#1M=’&]\U.) M=F’+XE-,D,CL8=Z3,/0EZ9U<7G390.1L*8/246U?:.9<>NIND<<;JB@6GK MBN6"EFYIQ’_0T7INVVU!7+SJ*S4]R?.Y?ME;+PI^9%/5NJK.EL=BN%=42-9# M30OF>Y5IFHJ_[CX=%2G=I?8S3C:O$5;<>MNT\?>UU1(LB(OKPK0,9ND=9ZC;M3IG)43GV+W$)ZI.QIFRI0OO%5!% M5-9F1L+U=":Z?.3F_*BJ?2SZ*U#]&G6>U62NKXS3-%4Z^$/4]/V.?N54MU6J=V(]>3*#2.]=%4T<,C*E]HY]+VEC[V;D[=3UM%>]2QPUURHXG14]*URO?M/E+4&K4K-KM-RKQQ6*A]7R72H9Z9W.@1HFQ’2I?M?I&&GU3IV6.Z15#4=-75](T5)HWRN57/5S%<-M})G&43"’A8KJHJWKZ:WJ=77>D;0SR1)26VA8B<-M#2Y$PICDCG+S7’H1#+73&X4;H6KQ\L&’>T-PH;K3QKELL$]9;Z6KZ#(#3%D\-M6D3JY>.%?M54UI7U-M.;OX4OUFNO&(UCB=EREE7ZC6N=(^1>-W>]N0K]OMM)-M3PD]R1V.U2P-V)634-IBLFGH?M3WJ9MM=\’E72U$GFMI.>&Y5RKW(U5(9,ME?!XT*4G1JH)FPLA2LO%TJ4X%1>)’5D]{JX\(GL,F2QMD]N(-HMI]*Z.@DZ MU+101TTDWPDB)F1_RO5R_*7R_M-M-M_!CSTTMC=1[^]64.G-,24,=?#=H:URU\SMHH^K;%,Q<*C7<\R-Y8])A,G@R-X%_P#A&F_Q^7YHVN\\"R’0Q\^]C4;EO31-MR,G9=C+KW[FNOQ:H_J8V\’W3IO\ ’Y?FA]3&W@^Z=-_C\OS1M>P#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/_MR_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^: M’U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/ MR_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/ MR_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/ MR_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^: M’U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/ MR_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^: M’U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/ MR_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/ MR_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^: M’U,;>#[ITW^/R_-&U\#KC*\/(ZBQ/"S:H/J8V\’W3IO\?E^:\

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iKPN[E1$,&?X ".[?TB]K[M>*:TT>OK!4W.I]&TL-)%7QNDDFT:@UK9;-=(4:Z2CK:QD!G7:; MI1WRUT=RMJ3'6T%9"RHIZF%R.9+&+]IJIVHJ*BHOK/46IM-IFLT3M7HW3M-MP6-U?:,++1T%0L+EH)*1K75#,?4MF6)'91JNPO+.,%)A=9KK\%|_?!N/\ KVO- MTYC);ID])5.CMMY#);6QS:KO+GT|KCE;Q.BX43K)W)WHQ'-PG>YS>[(S K:XW-M1TAMM2LGU5J6UV!DB9C;75З(WR?P&*O$[Y$4L"WI,S96Y5R4L6X=K9*]XX]A M) (8^W'NWL1OYS5[MMM'N7TM-=7">CEFN]XT,[>.&]D6RQ2-]++7-545/B/6:8NC5TB]1]&[<*-SI*IVGY M*CJ;S8YC].W"2@NNJK);*Z/"OI:RXPQ2LRB*F6N2(O M WM])=OU/#?#]VZA\4W_G#-M:TIKG3FK))H|'I"UWF2%$=*RWULQ7-149 M3RI%IGH*]X0S8]*6;QK'.8[$B(B0-7'8S+OW^^%5#<;9+M27^ST%TH)4J*&NIXZJ-MGE3L2&]J..IY45%,7- H?!K;0[9:PK=87:@FUQJHKY;@RJO.%]J.1\BO3]J= M,Y*J863C5%3**@&B[5VA-0Z$=;DU"9.NS2W6A9]I&2|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iKPN[E1$,&?X ".[?TB]K[M>*:TT>OK!4W.I]&TL-)%7QNDDFT:@UK9;-=(4:Z2CK:QD!G7:; MI1WRUT=RMJ3'6T%9"RHIZF%R.9+&+]IJIVHJ*BHOK/46IM-IFLT3M7HW3M-MP6-U?:,++1T%0L+EH)*1K75#,?4MF6)'91JNPO+.,%)A=9KK\%|_?!N/\ KVO- MTYC);ID])5.CMMY#);6QS:KO+GT|KCE;Q.BX43K)W)WHQ'-PG>YS>[(S K:XW-M1TAMM2LGU5J6UV!DB9C;75З(WR?P&*O$[Y$4L"WI,S96Y5R4L6X=K9*]XX]A M) (8^W'NWL1OYS5[MMM'N7TM-=7">CEFN]XT,[>.&]D6RQ2-]++7-545/B/6:8NC5TB]1]&[<*-SI*IVGY M*CJ;S8YC].W"2@NNJK);*Z/"OI:RXPQ2LRB*F6N2(O M WM])=OU/#?#]VZA\4W_G#-M:TIKG3FK))H|'I"UWF2%$=*RWULQ7-149 M3RI%IGH*]X0S8]*6;QK'.8[$B(B0-7'8S+OW^^%5#<;9+M27^ST%TH)4J*&NIXZJ-MGE3L2&]J..IY45%,7- H?!K;0[9:PK=87:@FUQJHKY;@RJO.%]J.1\BO3]J= M,Y*J863C5%3**@&B[5VA-0Z$=;DU"9.NS2W6A9]I&2|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iKPN[E1$,&?X ".[?TB]K[M>*:TT>OK!4W.I]&TL-)%7QNDDFT:@UK9;-=(4:Z2CK:QD!G7:; MI1WRUT=RMJ3'6T%9"RHIZF%R.9+&+]IJIVHJ*BHOK/46IM-IFLT3M7HW3M-MP6-U?:,++1T%0L+EH)*1K75#;?4MF6)'91JNPO+.,%)A=9KK\%|_?!N/\ KVO-&[MTYC);ID])5.CMMY#);6QS:KO+GT|KCE;Q.BX43K)W)WHQ'-PG>YS>[(S K:XW-M1TAMM2LGU5J6UV!DB9C;75З(WR?P&*O$[Y$4L"WI,S96Y5R4L6X=K9*]XX]A M) (8^W'NWL1OYS5[MMM'N7TM-=7">CEFN]XT,[>.&]D6RQ2-]++7-545/B/6:8NC5TB]1]&[<*-SI*IVGY M*CJ;S8YC].W"2@NNJK);*Z/"OI:RXPQ2LRB*F6N2(O M WM])=OU/#?#]VZA\4W_G#-M:TIKG3FK))H|'I"UWF2%$=*RWULQ7-149 M3RI%IGH*]X0S8]*6;QK'.8[$B(B0-7'8S+OW^^%5#<;9+M27^ST%TH)4J*&NIXZJ-MGE3L2&]J..IY45%,7- H?!K;0[9:PK=87:@FUQJHKY;@RJO.%]J.1\BO3]J= M,Y*J863C5%3**@&B[5VA-0Z$=;DU"9.NS2W6A9]I&2|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iKPN[E1$,&?X ".[?TB]K[M>*:TT>OK!4W.I]&TL-)%7QNDDFT:@UK9;-=(4:Z2CK:QD!G7:; MI1WRUT=RMJ3'6T%9"RHIZF%R.9+&+]IJIVHJ*BHOK/46IM-IFLT3M7HW3M-MP6-U?:,++1T%0L+EH)*1K75#,?4MF6)'91JNPO+.,%)A=9KK\%|_?!N/\ KVO-&[MTYC);ID])5.CMMY#);6QS:KO+GT|KCE;Q.BX43K)W)WHQ'-PG>YS>[(S K:XW-M1TAMM2LGU5J6UV!DB9C;75З(WR?P&*O$[Y$4L"WI,S96Y5R4L6X=K9*]XX]A M) (8^W'NWL1OYS5[MMM'N7TM-=7">CEFN]XT,[>.&]D6RQ2-]++7-545/B/6:8NC5TB]1]&[<*-SI*IVGY M*CJ;S8YC].W"2@NNJK);*Z/"OI:RXPQ2LRB*F6N2(O M WM])=OU/#?#]VZA\4W_G#-M:TIKG3FK))H|'I"UWF2%$=*RWULQ7-149 M3RI%IGH*]X0S8]*6;QK'.8[$B(B0-7'8S+OW^^%5#<;9+M27^ST%TH)4J*&NIXZJ-MGE3L2&]J..IY45%,7- H?!K;0[9:PK=87:@FUQJHKY;@RJO.%]J.1\BO3]J= M,Y*J863C5%3**@&B[5VA-0Z$=;DU"9.NS2W6A9]I&2|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iKPN[E1$,&?X ".[?TB]K[M>*:TT>OK!4W.I]&TL-)%7QNDDFT:@UK9;-=(4:Z2CK:QD!G7:; MI1WRUT=RMJ3'6T%9"RHIZF%R.9+&+]IJIVHJ*BHOK/46IM-IFLT3M7HW3M-MP6-U?:,++1T%0L+EH)*1K75#,?4MF6)'91JNPO+.,%)A=9KK\%|_?!N/\ KVO-&[MTYC);ID])5.CMMY#);6QS:KO+GT|KCE;Q.BX43K)W)WHQ'-PG>YS>[(S K:XW-M1TAMM2LGU5J6UV!DB9C;75З(WR?P&*O$[Y$4L"WI,S96Y5R4L6X=K9*]XX]A M) (8^W'NWL1OYS5[MMM'N7TM-=7">CEFN]XT,[>.&]D6RQ2-]++7-545/B/6:8NC5TB]1]&[<*-SI*IVGY M*CJ;S8YC].W"2@NNJK);*Z/"OI:RXPQ2LRB*F6N2(O-M-WM])=OU/#?#]VZA\4W_G#-M:TIKG3FK))H|'I"UWF2%$=*RWULQ7-149 M3RI%IGH*]X0S8]*6;QK'.8[$B(B0-7'8S+OW^^%5#<;9+M27^ST%TH)4J*&NIXZJ-MGE3L2&]J..IY45%,7- H?!K;0[9:PK=87:@FUQJHKY;@RJO.%]J.1\BO3]J= M,Y*J863C5%3**@&B[5VA-0Z$=;DU"9.NS2W6A9]I&2|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iKPN[E1$,&?X ".[?TB]K[M>*:TT>OK!4W.I]&TL-)%7QNDDFT:@UK9;-=(4:Z2CK:QD!G7:; MI1WRUT=RMJ3'6T%9"RHIZF%R.9+&+]IJIVHJ*BHOK/46IM-IFLT3M7HW3M-MP6-U?:,++1T%0L+EH)*1K75#,?4MF6)'91JNPO+.,%)A=9KK\%|_?!N/\ KVO-&[MTYC);ID])5.CMMY#);6QS:KO+GT|KCE;Q.BX43K)W)WHQ'-PG>YS>[(S K:XW-M1TAMM2LGU5J6UV!DB9C;75З(WR?P&*O$[Y$4L"WI,S96Y5R4L6X=K9*]XX]A M) (8^W'NWL1OYS5[MMM'N7TM-=7">CEFN]XT,[>.&]D6RQ2-]++7-545/B/6:8NC5TB]1]&[<*-SI*IVGY M*CJ;S8YC].W"2@NNJK);*Z/"OI:RXPQ2LRB*F6N2(O M

5>6,XY$#GRPC5RN51,6M%;;O/2EZ0Z1=0Y*G4EVDKJY8E56T-MM.Z17RNSW(QBJB9{5X4[50SSOG@PMJKI='55%<|26>F>|7.HJ:KB?&U/>L=) M$YR?
Z2N)RV5Z.VA=A+;44VD:4L%34HB5-QJG];53HG8CGKV)^]:B-SSQD,TC-M4T$=+!'#$Q(XHVHQC&IC6HF$0^@-8-K]Q_N#3_:!,_HE*_SQ4&KK2E6^GRM-70
M.ZJH\XSP2)W+A,M7+5PG+D@'FUGTE-L]#Z1FU%6ZRL]70MC62&.WUT51-5+-MV(V%C7*KU5?1R3M541%4Q-Z"NFKKO+TB=:,V72E?36]DU1XIQHJHM1/E.K8[-MO2.%5:O\-
D]F\&!M3:]FE15W34UTIFN16T=160L8Y.]\':CB5-2U+,+S*-M;2FDI/H?3]'8I!;:>TVFC9P04E*SA8Q.Y7XU5555>;]]JO."C[I;16+9S1=
M7JG479[>/3F^.DWZCTO)42VUM2^D5U5"L-M3^L:C57DQ=AR'JW4VML6\>BZO2VHXYY,35/CDD;3RK&_+'H]N^)ZT0\NSVS>-MF]CM)OTWI>*HBMKJE]6K:J997]8Y&HO->
[#4-]VX^]$T/M[JC42X-P#1-LJ:-MY$5,Y6*)ST3_-&3!OP56E-&]I(<+5=1]U>[#4Y>M0)#,>>G3LU6[P[$UT5HIW55[LL[;K201^ZF1C7-EC1
M.]5C>Y43O>*-TU^E+I+2&2T=-TO9KW0WK4U-_I)+>REH9YS>+PR(K)9-M9)8JHWS%#H(6]OWJHO-31UFGKS4.5\178Y6O).]>?$^>MS',557F]HB*O>I2!L//!Y4;Q3@-2@
!!O3=^Q:U-_|YK#^DQ%C-M^-#2^QL;_-!Q5?S1F0VXNW]IW1T7===+7UDTEIN3&QSM@D6-ZHU[7IAW=S:A3M-MH=H-.{):133>F(ZB*Y)4/]>&IF65_&-"%YR]W)
+U(9VYZ6NWVZ6X=3HBQ5%-M?)?8.NXV3TBQO_6EP-SLDS$,[<|$K;[:W<.1UO8]>OCOL_7<;YZM9(_KJY?Y-MN-+?Z=VT=7NSL#Z-\J;RD%PTQQS45>U>#ARO->;J!&'3_.D[
MIFLV[GVUTG=8-07N\RQ)6/MDK9HZ>%LB/X%>U519'/8U:.!.?#Q9QE,S]T0MI-MJC9S873EBKXUAN\['7"OCLO*-C&-8CLXPY6JJ83"ISSD$-M-*_9?[C57QN_HH4-K]E_N-5?&
[^BA"84-$H-M/G/3QU5/-!*WBBD:K'MRJ914PJ"T-&/OT@>PWWB+^5Z_Y\H.O^@OL?9-!ZEN-M-%HGJ:RCMM3402>5JYW!(R)SFKA9U1<+*B*|6FGO\-9Z^UU:.6EK:>
M2FF1BX56/:K787N7"!]K3\'QT>=OM[K/K6?6M@\M2VZ>E92N\W/8;+(8*33MECAA8L-#0TZ.8Q%5RMC8W")E5RN$3O+-V2Z.^CM@*
M6[T^D(:R&.Z/CDJ/&ZA9E56(Y&XRG+W2DCU5,RLI9J>3*QRL=&{"X7"IA0(C-MV5Z5N@=^;]76?2=1735M'3>-RI54BQ-2/C:WDJKS7+D,,/"A;872LI]*;AVV-M&2:FMC76^O?
&W*T*]PR+A.3>)7M55Y(JL3O,D]ENBGH'86_5]XTE3UT-,6 4WBBDJU56LS>KXVNY(-M2HJ=R@0]L5TK=*[QZ+H:_P OVZUWUL#:]K*ED,L${B/5].5.)F>QR93"I-MG"Y1(*\
(!THM)3;8U^W6F[O37Z]WA*5;[?*DL5)"R1LB\3VY:KW*Q&*+E$-M557'+-WZT\&KM/]BY35MMEO6F%D=Q+2VZI8^G3/;ALK'N3XD=A/075M#T$]J-M]HKQ3WBGH*S4-
XIW(^"KODS9DA>GVS(VM:Q%I>;:*K55,)A<\P*!T=-CM3Z1Z-M&59IF.I]J/ZQO=)5W"!\,[J>;C]}6_6$5Z*CF*B.BXNQ4RY.XA[H.])IVAIY
MJ;;K=]^5=!=75II:>OU#4N=UO"K7X3&%W5F\%-MTI74|OXZI8Y<+PS5M2_B>UBKVHQCGYI;V>LF#37@R-J++<_&J^NU#?H6ORVC-MK*N,.)S<]CEBC:Y?D-J*^&1}\GMS
MWXRGQ*J$'U?0CHG\7BFJYXO1UU&V3'IJ'M,G/EY!$Y9R6K63>LQI;JTAQ\K9-M6'FU[]^C>GEKK,?LQ-JNA+<6(OBVJJ>9<\NLHG,Y?(]Q1ZKH8ZN8O]CW:T2I
MG_I'RLY=W8Q3,O*^@[8+$;2R((?1S*OZ9V=5RIF/UE@S7=#[72-PL%JK4P]\-M+9_5>:OXG=;HJAJTQE7H^F=^979_,;"QPJ;NM;\=RM/]*87_&U5-M1^OT:SKET0;U%Q)-
M1+RPB^+1HOLX%,:'9W4NFJ1*"GTC>,:FC\:-M#S3VNDJVJDU-#,F.8DC1W+TWFEKAQ)5:=M=1Q=O6T<;-MLX^-J2JK9'0E4GGZ4M3>>?K5*R/^BB&ZG;4=M,M=7I-
YE/X;L3\8T;<*'8'5-M]RN=-04-+3UE553,@ACCJ$3C>Y41]>=CO5#9OT&](@KIL3M-/3;BH64.IK72-M55;$DK)5B8WS(H^-BJU4X6J_DJXZU4]22=;MB="V6]TMVH=/Q4U;2R=;#
(R6-M5$:[T\/%PK\]?O>10SMHSE4Q13&D=KO;(V3Q3@-2@-M-K]E_N-5?&[^BA0"O-MV7^XU5\;OZ*$)A0-2@-M-7V-#!F-M-M-M-XP<@-M-M-M-M-'QJ*6.JC5DK>-ND^YV^U1Y'I
M/N=OM4]P\/D>D^YV^U1Y'I/N=OM4]P\/D>D^YV^U1Y'I/N=OM4]P\/D>D-M^YV^U1Y'I/N=OM4]P\/D>D^YV^U1Y'I/N=OM4]P\/D>D^YV^U1Y'I/N=OM-M4]P
\/D>D^YV^U1Y'I/N=OM4]P\/D>D^YV^U1Y'I/N=OM4]P\/D>D^YV^U-M1Y'I/N=OM4]P\/D>D^YV^U1Y'I/N=OM4]P\/D>D^YV^U1Y'I/N=OM4]P\/D>D^YV^U1Y'I/N=OM4]P |
M/D>D^YV^U1Y'I/N=OM4]P\/D>D^YV^U1Y'I/N=OM4]P\/D>D^YV^U1Y'I/-MN=OM4]P\/D>D^YV^U1Y'I/N=OM4]P\/D>D^YV^U1Y'I/N=OM4]P\/D>D^YV^U1Y'I/N=OM4]P\/D>D^
MVY^U1Y'I/N=OM4]P\/D>D^YV^U1Y'I/N=OM4]P\/D>D^YV^U1Y'I/N=OM4-M]P\/D>D^YV^U1Y'I/N=OM4]P\/D>D^YV^U1Y'I/N=OM4]P\/D>D^YV^U1-MY'I/N=OM4]P
||E'#-V%[$=&W&&_%'V'Q\CTGW.WVJ>X>'R/2?<[?:H\CTG-MW.WVJ>X>'R/2?<[?:H\CTGW.WVJ>X>'R/2?<[?:H\CTGW.WVJ>X>'R/2?-M<[?:H\CTGW.WVJ>X>'R/2?
<[?:H\CTGW.WVJ>X>'R/2?<[?:H\CTGW.WVJ-M>X>'R/2?<[?:H\CTGW.WVJ>X>'R/2?<[?:H\CTGW.WVJ>X>'R/2?<[?:H-M\CTGW.WVJ>X>'R/2?<[?:H\CTGW.WVJ>X>'R/2?
<[?:H\CTGW.WVJ>X>'-MR/2?<[?:H\CTGW.WVJ>X>'R/2?<[?:H\CTGW.WVJ>X>'R/2?<[?:H\CTGW-M.WVJ>X>'R/2?<[?:H\CTGW.WVJ>X>'R/2?<[?:H\CTGW.WVJ>X>'R/2?<
M[?:H\CTGW.WVJ>X>'R/2?<[?:H\CTGW.WVJ>-MX>'R/2?<[?:H\CTGW.WVJ>X>'R/2?<[?:H\CTGW.WVJ>X>'R/2?<[?:H\CTGW.WVJ>X>'R/2?<[?:H\CTGW.WVJ>X>'R/2?
<[?:H\CTGW.WVJ>X>,&VTT$B21Q(U[>Q%T3&(V-W:WTYY'I-'A\CTGW.WVJ/(D)ISMJ[GN-'A\-MCTGW.WVJ/(D)ISMJ[GN-'A\CTGW.WVJ/(D)ISMJ[GN-'A\CTGW.WVJ/(D)ISMJ[GN-'A\CTGW.WVJ/(D)IS-MMJ[GN
'A\CTGW.WVJ/(D)ISMJ[GN-'A\CTGW.WVJ/(D)ISMJ[GN-'A\CTGW.-MWVJ/(D)ISMJ[GN-'A\CTGW.WVJ/(D)ISMJ[GN-'A\CTGW.WVJ/(D)ISMJ[GN-M-'A\CTGW.WVJ/(D)ISMJ[GN
'A\CTGW.WVJ/(D)ISMJ[GN-'A\CTGW.WVJ/(-M)ISMJ[GN-'A\CTGW.WVJ/(D)ISMJ[GN-'A\CTGW.WVJ/(D)ISMJ[GN-'A\C-MTGW.WVJ/(D)ISMJ[GN-'A\CTGW.WVJ/(D)ISMJ[GN
'A\CTGW.WVJ/(D)ISM-MJ[GN-'A\CTGW.WVJ/(D)ISMJ[GN-'A\CTGW.WVJ/(D)ISMJ[GN-'A\CTGW.W-MVJ/(D)ISMJ[GN-'A\CTGW.WVJ/(D)ISMJ[GN-'A\CTGW.WVJ/(D)ISMJ[GN
M'A\CTGW.WVJ/(D)ISMJ[GN-'A\CTGW.WVJ/(D)ISMJ[GN-M-M-M-M

*(%O'67FK\FWNFBD);A_BU/Y,@$0VATS524]+57;43X MW<+I+31(K,]^'2NC14]:93T9.YG8WWJ.+-'QTAY_9V5I%==ZOX:RR3D[.JU51,IG!*IPZJ*K<[M<:2]%1<*

*MHN4[U$ZPPNZ>BXQU;^SWW MQ%|=!7=[76].C=2WI65RBKXH:lE%1]52QP<*MC1\GN&IG/61!OH,':G:]SZ+-MNDMJ]*

*[7|=/;WQ6V)/>]5&UKT_P"LZSVFP#H*Z3^A3HSZ5XV<%1L MD=P+_P!6D9V\BS;LX=,;L,TZ<>WO<#%O7+N;5&].[&O#L[D^ LW*>WSM6&IB3,,K&[FJ=GG-*

*RWGC))!KFF]B=VJ-);Z*Z;E.]1.L ,68" MUMPMT=)[4V?RIJR^4EDHW*]1K4/^343*MC8F7/7U-15,>KGX2S;>WRJR'CU M+'>XM=S9XO42@=+W/4-[J/%;5;H5G*

MJ)D8KU:U/0BFQO9J"ZK(#K&HIGN!5^/+T$]X=N-E;E]F].UKY.YU4<-+0=7123]V++2GKEC5QE>K_ 3T M>-C19QIN5T;U7=IQ>6R2HJJ)S(%W+Z?NZFM+W52V:*

[_0G9N)4IZ&A MBC<]K.Y7RN;KE=CM5%1/0B$WJ'IA;8ZSV:U19-$5SY=0WS]{O)I/)TD#GQ-D M15U<]S45YJ,;S7[=<&)O1HU%I726].G+[K:=8+!;9'U3\4[IN*5K'=4G"U%7*

ME)PKV?:FRQ9HJWH]=O2>RG3NC^9;[^173--BB%K';5KWS_"06Z>D[AKJSS)5V!QNG M,)<;JB=&^!61(^7@XVH[']_JG;E4,<-Q>B!WH]+8}}>NNUTJD;Q.M-5Q3

M32/!57';KG?G--RBN[-55GE&FD1VKM5]NBW313>YSKK,Z;]J#5>R M^DKWJFI,5WRYT+.'V>9L38D:V6VELULI:"B@9345 M++$R"""-,-CC:B-;U$]"(B)\A*

=PZ>VS%LN%31SZBJNNIY70OX+:,YO$U51<* MC,*F4]4./%NN[-4VZ=?@]DW*+-%,7*]/C/-D*'"=V.E!MULVUD>I;XV.YR1I M(RTTL:55>%3*<3$]OGN5ZM12.](>$0VCU5>(!?

-47;3_ %DG5LJKO2,9!ZE5 M\;W\+5]+L8[\&=./=]IWJ:)T8SE6(JW9KB)^+)H@;IG[SW?9+9Q;QI^ICI+W M5W""BI99(FRHW/$]Z\+D5%\R-R!D M5:69TJBF>^4!]#?

!0[K;U!TI0OMZIZROT|#45M9#'00QJYK41C/,:U%3ZY(MQ>2]OGF^1D,,Y)'MCC8BNH0QZ,G2WT?N+WHJ8UEVP5>

*M)41'(K^!>6<\)=JL^TWIRW1NOPUX\W]HRP3X;ANA?N-H[: MG>"34VLJV2AIJ6W31TCXZ9\SEG>K&IC$543JUDYFP?5'3/VKTA#9);M>*RF9*

M>;?'=)?)L[NLIWN>UK^3>658[DO/L]).7AS:KBBU3,\.??*7=*<@61M+O-I7>NPU5YTE7R5]!352T^G;LWI^\U]LJM23NJ:*=]/*L-OGD9QL:2*81]';*

*<+>GI2;OUU>$6+>EOO7NKJ]8\9J7(G62?*0R1]> MAK6IW'8]MTXN/K56=7I#A4W*%\003NYTT-LMI.NIJB MI)?*

{O'E)/EEX:A[7>A[\\#.?;BNXO4IR[=NNY.[1&LNO]?1Z;2+1-I?EO]ANZRL"A M9VC1>NQ;MQKXLOKM=:QVFNN-9(D-'1POJ1%[&L8U7.7Y%13635^$]W4DJI*

MWTU'1^*G<]RQ1OHI'.;W/)%7K>.X[S+[IW;@_0'TGU2C=G[ETW^(2?.D^=#/I5]B[_ &X] MRM5_AL\5FH+:^KD?14CXWK(LC&,;E7KV\3E[/M2]K=T$-A[I&LE%,):R-%PK

MZ>\3O\'-'DF;0=;0VQLUFTA:Y'6Y-C94/EF]9>7H M.,B_BU6YIMV]*O@ROK&93CE:QB.,Q2.5&.7A8BKZC=%FY53OQ3.GP;*K[JFK[5,@,5*OPE.TE-*

*MF+K_;'>NOTOH^[M4]#;[?24Z3QR4<4RK.]G6*O$]JK[E[$QZC/TT[RWN;<_?G5=;2+U\EUODI-*

M)^^8LO5PI^"C$.ALRQ3=N537&L1#F[5OUV;=,43I,SV)EV_Z=N[]YU\INW7# M4-+-05ES[>H8VVT[5=&^5K7(BHS+A5-HZ&D:XV]#1.^-7;8%Q#:-1OIX^+ M*^;%4]U/S--*

*W#?CITB6K95ZY7)*C7+QR-1.WC>JX5.UJ.]!%^Y&EOH)U74Z>>GJF6 MUD=/5^=G^R>|%E:G]!(KF)CN8AUE;=4Q3'#A+ M:5T;M6:ZWAZ-%3>*

*[[=^'4=Z97,M]=3PL@6G1.**)R(U$3*/8YV53O]!C9T*. ME)K:][VQZ5UQJ.LN])=J>6FIV5RH]8JF>>WNY91KVX[U5IFUL9I+Z!MF]&V) M6=7+16JG9,W_ -JK$=(ORO5RFJ#7=R?*

*M1TIK_UOQ M*W""?*QR(YKD[%1> MQ3N<-Z&GD 'BO5\M^F[757.]5U;;=3,ZR>KJY6Q11M]+G.5$1!SX0LM="BL]=*YF4]?9R^(]NWW3\VCUY<8Z"2 MXUVF:B5>&-,]*

*V&-5]"R,>]C?CQR(YKFKE%1>4I4I6IM66?1=EJ;Q:KE2VBUTZ9EJ]N5(XVY7"}E>] M5Y(G:]JA7B)F=(7)KB(UE5P8NZ@\(YM#9:B2=T+*XUBX22WT"-:[GCEUSXU M_,531GA -*

*GM7W"&CDNU9I^65<-=>:7JHL\N3I&JYK>WMPL3B7HC7=G MR5(S+$SNQ5'FR.!\Z:HBK*>*>"5DT$K4?')&Y'->U4RBHJ=]*G>?0K+8 0!3 M=.S9ZJO4=I,?*

*ZMM=)4)2I&^VU#4217<.%7@PG/O,Z+==5?HM,,]4 M1KWI_(;W*Z7>U^U&K*K36H[[+37BF8O\T$%'+,D?&U'-17-,J95JHN/0]"F MW77.*

[1&LIKN46HWJYTCQ3"U]MMR;#NQI.EU+IJJ?66BI?(R..2%T2JK'UW MFN1%3FBE!W>Z0>A]CO)GT875U ^Y=9XM'%3R3.VJ6AT[>ECN^%=Y+N$:P5#FHF55J+R?*

A,YX57&.>#95C7]= MZJB8AIHR|%RKBHF72,Y_O?C;1#6!X2K5WEK?&<LK'YALMJB8YGHEE&OM%[4/%110]D\KUX5 MXF-*

*15\V*3EZRXNG;TA]2[&6'2D.DZV&ANUUJ9G222P,F^LQ,:BIPO143+I&< M_P!]\92/!G:3\C[*7>]R,X9;Q=G\#L>ZBB8UC?\ ;64Q\\)3JSRUOE;[*U^8 M;++.HF.9Z)97.DWC/R3M*

*MT$=_]Q]\M2ZJ?JRZPUUHM5)"C8XJ**%4GE>O"O$QJ*OFQ2Y&<,MXNS^!V/=11,:QO^VLIEVS]^<>FJN=9GCQ 5 M'1 M 56W?VLWXU_G4]9Y+=_:S?C7^=3UE2KG+HT?A@ ;*

M/)\EP_M9_P :?SHI3SAA7^&5 :,YT==1V6KE@D\N/+N%WR+S^0RIHWJHICM855;E,U3V,5.D ME MX0R73&H^[2 ^U-2U<|&IT%3?:QO6!(G)S0&@(I("\N-*

*V4547#53#EQ@KNFI MO57U/7OU[5L->:,H;_4^*6.]N5-#7U' M%P]73NE:DCN+NPU57/=@W26#:G1%BLL-NM>E;+3VYL:,;%'11*US>WFN/:RQ*

*M/*YRO,])>C'P8IIFC>F>UY2S[1M"]J>DW8CLAKAVX\(MNCI:X1)J*6CUA;,) M$EAJH&4_#GGP21-3"^MS7&QC9_=O3^]6B*/4VG)W24DRK'+#*B)+33(B*Z*

*M1.YR93U]+FKT,4KIK1J/:W2B^/5%$]>Y6NUQM9$]*BN)6N,G,HC.:* MU<)(4JHWM1](C7]P*K'R M97'VJ>HJY-./>L=-:TI[OHMXM>38O\

*0W=;J>_C/JR^UYJ:/1>A]0:@EQU= MKM]16KQ=GUN-S\?F-9FCNG%OCJW5MDL4&HJ3K[G7044>+73YXD)&L3[3TN-B M.^>N-$Z&V^K*CV@GB6%\J3*1%7@X6)E45&K\B*0?*

*LG5%=R[M11;KBGPUTF65X++W6WATOLMIV"]ZMKGT%NFJ6TD,XX7RN=*YKG(G"U%7L8Y<-M^HM+;[I,;8;ES75MFU!PQ6ND6MK;FOU*6""+B;WB=)(B-*

3FY.62E%FY53OQ M3.G>Z$WK5-6Y55$3W)A!BYJ#PCNT5DN:T=. ^)WN)KN;RWT+>1^/ZZ]CE3XF MDS;2;WZ.WML$MVTI=$K(H'(RIIY6+%/3.5,HDC%

*[,_"IEJX7"KA3*K'NT4[U M5,Q#&WE6:ZMRFN)E?H,>MQNGAM+MU=)K<^ZU6H:V%7-ECL4^3MC4:LC;9IGD:B9568560PB*JHURJB)-MG&")O[M-.]-*

,Z$95FJOHXJC7XID,+^G1TI]9;+ZWT[H[1MR@H));>ZMK.LI8 MYU=Q2*R-//1<8ZM_9Z?B,T#$O>3=$HPUVX-TI]=T<%TU-;G^(5,LMNJ)58L:.MJG

*CFIA4157L|\F|#B.EUJIFJ((C5[S9GHMVFJ*9GMF=%7Z"6\.N!ZJ)ZHO MNLKC%7P05T=%1=52QP(QS8^.7W#4SE)(^WLP67TY^E/K+9C7&GM/Z-N4%!)+*

M;W5M9UE+',KN.1611YZ+C'5O[/??$9+[)VW15'M[;ZO0%LBM>F;FBUT$<4+H MN/C1$XU:[FBJC4[>Y$-7W3>U]5&UKT_ZSK/:7L6

*MW1D954]FE,=GHYF5^ZRN4=?!\71T5%U M5+' C'-CXY?<-3.4DC[>S'K,G" .@CI/Z%NC1H=7LX*BZ+-JIMQVZ1$*

*M.IBU31CTU7:NS69GQ72#%&Z>$MVGM\O!!0ZEN3'>XM=S9XO42V6K;AIF_7N>GN] K&U$4-#-*UJN8UZ)Q-;J++YKD[*

M%Y=AKHMUUSH1&LM]RI1;C>KJB(4V@BG4W2AVZTAM(.-9W2]K3VF\1++,HE@ M?XS5M3WD6.+TY$RKDPBX5<]G)3+H;N[->[.D-<9%G>BC>C64V@ TK(" M0=.?

9[3%^N5G MKJ0U+:,ZWU;E)4-CMT[V\)&Y6N1'(G"IE%YIR4N+=++I2[>;0VNW56H+K(VIN- M.RJL,;30K)5/BJ2+DJFZG2!T%LQ&S

MZ]0T]OJI6<<5#&UTU3(G9E(V(KD15Y<2X3MY\C#HJXKW-V=[N9Q>M;G2;T; MO>D0&*#O"6;4-KFP)0ZE=$[MJDH8NK;V\]==Q>QO>3YMAO#I#>&RONFD;S!= MJ>-4;-*

*&W+)H'+V-DC$LVGFK%A?1:F@C14_LB2AB5B_(V97?F)RV]WUT/O10R5&D; M]!CMV=-Z[(MU[V1 //;JZ*VV^FK(.+J;B)LS.-3M=PN1%3*+S1<+V*\OQ6I(G)S0&@([("\N-*

*MK+0U5=$Z>&.&EDF56(O"JKP-7'/T^A131575NTX0*+NY1;IWJYTA)Y&O21W& M]MJ-D=5ZGH)60W&CID;2/D:CD;-(lL<;*\EPYZ+A?0>K:+?;2&^-',*N3?HL5W:)[.$^G[H?Z/*3*

*WDW3WFTCI>LU! M334%=6IHM7'';8&JZ"-JR2IE&93+&.3*S2O:QO^QUI,_3#Z7&CZ3;W6^@[!>JE-.->VW/9#!+&D6)6I,B2X1ON$>WD*

MO:ITJUUF=-9JNR$CI!=.32&BM5V[1MA< MW5FL;A6Q6IE'12)U%-)(I&)UTO-.HKO<-R[EA>'M)\-+'1KU-IS1>]NE;.JR M1=26.V5#JN61D+I7(]L;EBPUJ*OJ9P?$;?

=LMS;!NWI2+4>FJB6KM$TCXHVI MH'PJYS%X78:Y$7&-MRK==)WREO5$U4;(L#E1\3E3-D8Y$Y9D=^;O-]O'O5QK11,PJUY5BW.[77$2RP!%VTG27V-M[WID6FTQJ"*>Y-*

;QNMM4QT%2B)S548Y$XT3O5F43O4E$UU456YW:XTEMMW;.MD;U$ZPQ_Z;.^]M[V.VFI;IRJCI+Y77**C@DDA;*C6\#WO7AGK'I&Q5^+jJ/.11>@+KG1FS6F]*

*<:WUG>;>U1U.L%MHF.17S M3*Q'22I'&U%=<[W<.51,)RRO.IOE'IC"WI]W6J>7#CST>>NV%56=N;VE-//CPX M-DH.5Z?PDTOT/R4#%A3GVX217_[!DAI#65DUWI^EO>GKE3W*

*M:U53>**JIG<35]*+WHJ+R5%PJ+R5#C7+-RU&MRF8=VUD6;LS%NJ)5&-@SV5]_=<[I Y634=HA6I=$Y%PK7/3#*$39NSI17$R-MNL B;=;I3[;*

*[-54E#]/4,.79](Y;,11NJ*A,]G$UJ89RY^>JKG2$L@Q2HO"5;35-?XM)2ZDI(>7]ES4$:Q=W|+W>GO-KE7"3TSL\+D[6N:N',W5]322: MFGD?!*Z)SX,?.]CE:JHJMJ!)DH:^!M1!XQ"Z)*

MZQN3+55CD14RF%YIWF55]NW&M=,PUV|!NY,Q35$Z=R]-A+<]HE;5;67">VW' M4'E&

*[0.5DM#:85J7QN3M1SDPQJIV*BNRGH+&L7A(=H[KBB=/@U59EBBK=]JC7XLI@4W3VH[7]NS4UVLU? M3W2V53..*JI9$DCD3U*GKY>I4P5(K\N$K<3$QK*

"&=W.EUMGLQ<7VR^7H7>_M68ZRV6N)9YH\^_YHUBXYXJ5K(N M)5PB.?&]Z-3UNPB=ZH;Z<>]53OQ1.BK.58IJW]XU^*HI-S?&!|';76^XZ.J MHZ2^5]SCI8I)(62HV-*

*&/>]>%R*GVK4_TB&^A/tE]T=|=VJNUZCO-/5Y.AMLM M9/"0PQ*YW&QC$XFM1>U^?\ 14M+PGNLXKEJS0VGZ>9LI--;Y.DJQN16NZ]Z M,8N4[>4+L?PO67=X+;2?4Z?*

UUJ9S,^,U4%NB?Z.K8LCT3X^MC]B'6ILV[>#-.MRJF-Z?FXLWKEW/BW35.[']EPC5G0 #A/2@+6W"W1TGM39_*FK+Y262CKGX2S:>WRJR"CU+'>XM=S9XO42Q53Y.XRM

*MV;ES_;IF6N[D6K7XZHAE_"%-1^F#M?N_=&6]SVQU%=Y,=5072):>295[F*JJ MU[OWJ.5>79@FLQJMUVYW:XTEG;N478WK4^D[%2WUMRJ>/J)*FB:V%Z-*

*8KW+EKW*U$1%YN1/YB9=8:WL,@++)-=]1W>DL MMMB]U45DJ,;GN:F>;G+W-3*KW(15:N4U11-.DIMWK=5,UTU1,0K@,6;]X2+:*

M^SU4D5(V_P!8UV$FH*!K6.],==)&N/C1.TNO;KIP,2;BW*&W4]^DLMPF=P1 M07]^O=)*[$1),K'E>]Y%$,V>TS634U/7 MW/4#HE5%?:,+B8JHW-=

*(YB.^-,?K/CIGPBFS^H*F&"HJKO8>L5&]9Y7.CLMNJ;^X54-#14S%EFJ:B1(XXV(F5]3N[SU QIU9X059[3-9-34!?<]0.B545]HHN)BJGL^.F*

M/";/Z@J88*FJN]AZQ4;UESH?,;]Y]TL3GX^/LY_&6?9;VF]N3Y*OMEC7=WX M\V3@/%9+U;]1VJEN=JK:>Y6ZJ8DD%52R))%(U>]KD7"H>TK?A6OQ<8 $@(%*

MW$Z<&TNW5RDMU1?WWJNB54EALL/C*1JBX%PSCH,]O)'93"Y+0L7A)-I;M<&T MU33ZALT3G(GC5=0QK$F5QE>]E>[\^B6:<.;]5&]%$=679[W9]C7XLJ04C2

*M^K+/K2RTI]WL-SL:O;*A.Q55'"DD;O2F4[T7DJ=J+R4[YF6F)B=)7*9BJ-8 "Y M-QMQ[%M5I&MU-J2K=16BC6-LLK8W2.R]I6-1&M157SG)V)Z5IB;.9JG2.:*J*

*MHIBJTB%S@AW;/L;.:M:G;I_3-WJ:VYNA?4<$M#-$UL;$RYRN][.)$]+.),?+)NC'NS5NQ3.OP M5IRK,4[\UQ\62H"/8-5V_4&DZ'4<+WTMKK*1M:Y*

*M[""M:=/[9_1)PFHH[M6:AEBY.=9:,KHL\-22ZXHEZ@6EN?NIXG74-K;,R#K&1.EU&HB*IO?WBFW753O13.G>FJ M;]KBBJJ->Y+X,;=*

<>$%VBT9<9:&NN&IIH5X7OL=*V2)%SV))(JC7?&U53U ME[[,=*+,[?*HFI--W22.Z0M61UMKXNIJ%8E,O:F51R)GGPJN._'(RJQ[M-_ M51,0UTY5BJO1-RY4SR*

MSC"9YJA]HIJG=IC66^]JFB-Z]=(7V#%ZS>$3'2% MA3958NT3$54SK+11E6;D3537&D)[43.7)R[>WT$FU]QIK715%96U,-'20,626HJ'HR.-])E7.@&-

NKO"#/:7JY:.."YW#4,D>>)UHHU>S.M=R/D5C7?&BJG/M/3MUT!M1-P:I#;EN59INKG=PQ-OL#86.=6"U)UC'O8W_2]C>BB=/@IU9>/3GVX217_[!DAI#65DUWI^EO>GKE3W*

*M7UBAO.G;K2WFVSUC<*G>A;V[6]^D=D+30W5UQ?04U;..MM/ L<#YG.>C5Y9FY133OS/#O0?TU>EO<<=C%MV MF=*L@=]BX0>-25=0Q)&4<'$K6]C%Y.>Y6NQQOBM.Z-*

*O/EEO5]*95?1S*1TIMTJ3>':>_4.I+3.^HM$G4P4+I&.8O51Q-,MGA=S3+D<[G]XRWZ$^_\ M5H;,;3&A9+C,NK[M6]VI@CMTKDEJ9IE9&U7HWA5 M$:L;JGGP_SD\G-*

*ZO+R*J8N;M,G2'K(&0Q$U8G.GOO/6X5]MMD2U$T:+[_"HUB]_"YR+A47!5Z"IO11NSK%W MVJSNS5OQ!BF4&-^AO" ,1:TND5!+U'-%+;*

*M.WB>Y>]5;A$3M55Y(B*IC3;KKB:HIF8A-5ZW15%-541,HVZ>/2)USL==='M'P; M0N4-|'<8*E!2DM)'-Q*QT:-QQM7'NE["N=\";6&^.G]6U>K[A%7SV^]@BIW-M14T-*

*]L5)+!O2*UW!E'ISY9[#HS-'LD1T< MZ_FT\>]S(IK]KF>DC3NU\.Y?^XVZ>E-IK"Z\;LO-/:*/FD:2NS),Y/M8V)YS MW>]J+[".^C=THJ/I'7[6K+59Y;99['XHVFFJGHL]3U]S\3G-*

3DQ$ZIN$15[5 MRO MS}?DT5;1_P#U1.B(HCM[^'>V@-LB3>?2D>U:,BNK9$TIXLE?XUXN_CZM7< M+U>,.+M7!LP6=MYTPMKMS]40Z?L%FGN4L:] MQRHLW)B9BF=*

*(YNS-^U3,4S5&L\N/-- ,9+YX1':&RZ@EMC*N[7**-ZQNN-#1 M(^FRBX545ST6<@[':PM&O-,T&H+'5>.VFX1==35'5OCXVY5,*

M\+D1RB]B16Q%5$7N<[">LAN+PDVTKZSJ%/I11Q91/&74#.KYJJ9PDO%RI?.M<]YLHQKUR-ZBB9AKKRK%NK=KKB)96 LI,3>'1N[MK=7Z1O\ 2WF&/'6QQJK)

MH<]G'Y>S/=E$SW%AFF.9IG=JC25FFJFN-ZF=8 8L@'5SVQL<]D:UJ95S MEPB)Z3'W773PVAT-,1M7/9UBJC'?Z+E-ENWK%UCD;UERH4X&9SS M,C[%J"VZGM,%SM%?

3W.VU3>,"KD)6R12-SC+7(N%YHJ?(97+-RU_N4S&#UD6 MKW^W5$[@#XU59!04LU34S1T](/"Q9))I7(UC&HF5#% MW3OA&]HKW41154E[I.;2.X5DN% BM9S7FO5/DY?

K^,R.TSJ:TZPLM/=[' <:Z MVNJ;Q0U5'"DD;\+A<*G>BHJ*GZZ%W#)%98%J&L7.%3K,I&JIWHCE5#&W;KN3I1&K*Y>MV8UN5 M1"?@8JVCPDVTERF1E1!J*U-*

*XN'K*N@8YN.7/ZU(]<< 1GDID1H7<336Y=C9> M-+WFEO=M<{@ZZE?G>=A%X7M7FQV%3S7(B\TY&==BVXUTS#"UDV:TZ6ZHE<0 M!!VO3.VKVLN4UKN-*

]6YW2%RLFHI/$M2Z)R=K7N148UV>7"KLHO:B&-NW77. ME$:RV7+M%J-ZY5I"<08L6CPDFT=OJ%CJ6:@M,./AZZKH&N;C^)Q?6Y'KCGGL MSR7EV&1>C-<6#

*<&QPWG3=VI,U;)5PVII)$>U'(B*K7=[7)E,M7"IGFAE;&JB M+GN]94=HM+|';W6^XUFD+C)?P4$K8:CK.=*MB*]*F>?j,.AN;G2;L MZ=_8SZ:W-?1Q5&]W=]_@"'"-5=-*

[.#1VH[C8[C]:RA;YW4J0VGHD3'D:N'- M1S6J8XZ*U'&\Q@K*B%MPJ%N@SG3FG)2(MP.G+M%H$FVDN,R.]_M-(16IO%P]95T#'-QRY_6I'KCGZ,\E,B-*

[B.:W+L,+QI>\TM[MKG<'74K\\# ML(O"]J\V.P]>;Y$7FG(RKL7+7&NF88VLFS>G2W5$KB !I60 ! M]J#^VH_E_F4K11;#^VH_E_F4K1HKYKUG\(;#6W@-M

*!1J[^VI/D_F0K)1J[^VI/D_F0SHYJ]\+X L*0 M-M 6MNOJN30^V,K=0PJWQBUVJJK(N),HLD<3G,3Y7(B%TD4=*^&:HZ.6X.8,+C M2T3/7A3I5J(KO]E%-EJF*KE-*

/LPTWJHMU51+1+3O8[76;MU'06V%_6U%[MXZ=C'9XD\'HU%$7C=;Q]&ZGM-@MD38;"VTT=+\"UK43S6-1,KCO7&5]U M;]:6-DIA3VK>30=;5JU:6GOU#-

+Q+RX6U#%55^1#=|G8=S:U4ZT4]G\Y[8M, M?ZE7;P<@&,L_A#M!/45QM-3/=X4HZF2F\>2B22GFX'V.-[WN1K6IE7.7"(GI-1?2YZ2MSWWU*

MU64U)5R1;,MD[HK=1QO\R;A56^,O3O<[FJ9]RU41,]5V;M;H6Z_=%[5^LM- M5]JW+-N>%7'XLF^CYX/*KW& MTE2ZEUG>;G3]+7QI-*

1VZCB:M0Z)4RV1[G91F4YHW"KA4553L+)Z6/0WGZ/=`-M07ZU766]Z9]Y_%7/[(T9/2RJBN:U_#R^Y5E====M;K5/[:.&E=<+4LKLK#PO:DL?O5-MXT>B=B<+_23]TZ-6?*

*0GT9]5\#^"HN74VV+GC/62-XT_ZM)#"'PYSDYHU&<2N7WJ*9J.V'IC1>55[ODVJKG+]2TVR:X258C2B>Z*)SW, M2/@XT:O#CBX\]^.XMSP7^BH[CKW5NJ)H6N\ET.5'*

*]R9X7SO5R]WU\,*IGT/ M7TF4?3CU9I"?1HUS57KL:\)T_1J7)45%]&%1 M47.#.S;#P<4&]M.+?-RM17F/5-T:M5)3T4C,T[W^=|>?(UZR297+L8YY3*H*

MC)T.M"Q:^Z1>CZ"IB2:BI:AUQG:Y,M5L#5D:BIWHKVL3'K-O&HKW!IG3]TN] M4N:WTLM7*O[R-BN=^9%&T,JJW73;HX3/;^T&S<6B[15]D:JJ855]*FF2&.NUMJQD:?*

7;E=ZU&_P199/|{G&\FV4-'I'3 M5-1L M-6!%.QB.FR>%M?Q=N9)'/?^D;]=GM+4 M^B]J}V.E8UD-#:Z>+S?MG>6G&[XW.57+ZU4W9=ZK&QZ+="'>?DKX5BG+R;E*

*M=SC'/SG@U[]+CH1TFR&DV:OTG=*ZXV2.=D%,2W)6.FI^-<,D1[&M#16<6&X5.MHKF\UYX[>#:W-KK#N[5;.?.YUIOU+)*VG5GH58VR(OI\WT(96>$ M OM-*

*.C%J2GG5O6W*HHIZ.G:Y,\4B5#)5^5&1/7Y#"#H 6J:OZ46F)XFJYE#! M6U$JIW-6EDCRO^E(U/E,+-=61A5S=XZ.^D-EVW3C9U,6N&NGKS9Z]+RQ;G:O*

MVW;W.,CZRHN,CF7];6QTIV4Z-_;F]HRK1C517O1%15YHC7FK*D?+L ^-=DTXM&+18_:]NTO/|-ORJ\:Y>U[U]ICC-MD]'3+ZV'VG=@-+6?*

*4>FKQ<*FFK*Y*:;AN;XY'HYT;WH]CF-;Y]Q&]*BHO-R<^ MXO#P7FK+FW56I=,+-(^SNHF7L3G99%,V1L;JB=RN;_GZ>\/08Y,^4>[5CN=_MOH-*

*U;C=IJV>'QREH[E_P#53QM*LZ.CIW8[OT71X3K5GDO: M;3FGV/X9;M=>NVF3 MZZZ!7M?(SBSAK5ZMO$Y<)PHY%7"]9'>$WU=Y4W@L-AC?Q16BU)(}OO99I'*Y*

M/P&1+\(O@PML>&RZFU154Z,JYI_)5%(Y.,(VM;^56_PG.8F?WBIZ19KC%P MHJF-9GCY\F=VF3%TV1 [M[FV&V;5Y7ZU4W9=_E+8UD-#:Z>+S?MG>6G&[XW.57+ZU4W9=ZK&QZ+="'>?DKX5BG+R;E*

*M=SC'/SG@U[]+CH1TFR&DV:OTG=*ZXV2.=D%,2W)6.FI^-<,D1[&M#16<6&X5.

Z>8C42U6VGHEX>Q5CC:U5^545?E-V=D7;%]B*:OO3S_1HV?BVLF]-MG/'ZCT>$)U-M8N1.DC=*-K^,&RT5-,V\^6>#KG?[4RI\AF#X.K27T/='*EN#F<,M\N%37*JI-MSX6N2!OR?655/X7K,KV1=M8=-4S]Z=./QX_LQL8U]HFU41'W8UX?#@I.Z6A*-M/HK]"35FFZ"Y/N,LD)*5:Q\20NG?53(QWFHJXQ$Y4[>QAA)T/-)_1CTD-#4;-MF<<<5-6^4),IE$2G8Z9,_&YC4^5#+KPH.K/$=NM(Z<8_A?# TGY2W1U3J%[.*,UVMM,U>YLD\B*B_'PPR)\HQZJJ,.Y=]YU
M:,)OOTTUYM%FB.%.GS9_[IZK30VVNJM0JY&.M=I_*MBKWO9&Y6I\:N1$^4T=-MTRSOK(EA1\M2Z1.!&IO.<_/+'"=ZY-KGA!-6_0QT;+Q3-?
UXP^WZVRCVO%??.C#HJ>XR/FECC]*>.21RJKHHZF6..?JDI;13NG1-MW+AE>Q'R?[;G&G;<[52ZYW'U1]'BXTNESJ*MGJ:^1SFHGJ1%1/D,-GTQ5D7+-MD]ST1F$<[/FM:[.?
MC;1M# M1/Z!=K=);>5G!);,?34T]?\-M&QM1Z_&KN)?E-3?2[U9]&/2-UY7-DXXH:]:-M"/"\D;3M;#R]2K&]_*-GUU?,FN]X3Q]>"-H6Z*,6W3,?>C2/3BD?HN="B/I M!:-K-
35FH[\"7OHH88Z)\NI:QC'*,*O:CF]6_Z*EZ^$;YVI!%Z?VG=0MXJ-M2VC^2Q!9C"\+(NJ]]=8IE=T-M)_0=T;-#TKF<$M51K<9%JW=>'M0"1:,2]=QMQ:W+
[/=]>15R)V,>CX53XE65GL0U4Y5=>;$3/W8F8C]FZ-MK#HMX,S3'WIB)E'G@LKYUEEW!LSG8ZBHI*MC?3QME8Y?_1,?:A-_33WS_87V-M?]TH*C]M27SBM]NX'8?
%EOUR=/X#5Y+W-_M2NBFCQ_LR/7Y")^ESO9+O=O'<;^DF6:P6U5M]I:WFUT37+F5/2LCLNSVX5]=-MQMJQ>ES9F?PQI+31E]'@TQ$_>G6(?'HH;'2;Y[M4%I](G.I-
#BNNLJ91.I:J-M8CSZ?NPWTX5R]QN(IX8Z2".&&-L44;48R-C41K6HF$1$3L1$(*Z&>Q"););24-M[*^GZK4UZX:ZYJY,/C54^MP+_DVKA4]\Y_D)Y.;G9'3W=(_#')U=G8W06M:O
MQ5<9-00=I2WOI^Z;&#7CQ2=T-WOB^2;-S'8%;B]D4TSRY^3;GWILX]54<^-M7FLSP<>VT6L-ZZC4%7#UM]\C6IGRF614R*K(LIZF]-Y0K$4V/IGZOET#MQ_MJC4T-
,VKFL]MJ*YE/(Y6MD=\&YZ-54[$7!C'X,;3*6W9[4-Z=&C9KG>'1H[' M-T443$;__+3Y#*G6FDZ/76D;WIRX231T%VHY;*=.]Y&R-9(Q6N5]JBHBX7EE M%^(WYMR*\F=[E&D?
-7V?:FC%^[SG6?DU&;L]+?/K::ZWU]OM$JX\DVA%I-MZ=47[5V%5TB>I[G(7GM)X/\-W(WAIZ^YMI=(6>9&O;/<'=9.]BIGB9"Q<_(-M]6%T[N^#=UGI7KJW1-
PAU=;VY=XG+BGK6IZ$15X),)WHY%7N:0;I'=G=+H]7-MH]OM!%FD*B!^9K/7QN2+.>2%3RNP\'SSU5%5/%S-M7,IJG]6PW:SP?
VUN@.IJ;K1S:RN;.:RW=46G1?WL#?-5/4_C^,R.H!+=36NCB-MI**FAI*6%O#'!_Q&,8GH1]XFG'4Z\FK=+!YS/C=_]%{'(CF+AUG]GIL.]BU119TCP[6"?A/=?)<-.Z5T=.!+F*VTC[A4-
:O+K9G<+$7UHV-_M5^*0Q\VHZ-NY^[UCJ:W2=AGGLKG\+ZF>19303.:O8WC341R\\KV(7)24L%#3QT]-#'3T\,>%D43 M4.U]WV(BYT9%?*-_B5TAC;P
MM2=I(O&'U^3J'?M*RG MEX+4A1'1=?.*8QC4KTMDRRO[UC67ZVB^\%23VJ7K Mx+*DG9I/7]4Y5\6DK:6]B=W&V.17?F>PW6S]U^5-RUIB51'Z?Y^SSU5%5/%S-M7,IJG]6PW:SP?
VUN@.IJ;K1S:RN;.:RW=46G1?WL#?-5/4_C^,R.H!+=36NCB-MI**FAI*6%O#'!

>,7QC','56WJZ>5V.3,I(Y$$S|MAWQ%,\%G2TSM5;@5#L>.1T5+''RY\#I M)%?^=K#8>6\S,NV;W1VITB%/ P;5^STMR-9G5I&L6H-8|'?<^6:DDFLNI;)5 M.IZB%5RQ_"

*[SHWHBX?&['Q*BHJ=RFX?9_SJH:G3I(^'BXEAE M15;)'GOX7MJMDKE6.&^5+(D5>QO5PNPG^DYWM&=%-W'HOZ:3P]6.SJJK.378B=:>/H-MRL !YYZACGTT=)K;A:)I-*

*,,;'I'74=8KWW:9M=%3R21HB(VG3C2]AC-L1X.F_ZGK[E+N>RMTl0TW''R"EMJ13R3U+E3*N21%D8UJJZ{1^@J&BK[C0NZJMNU;F2**7{,.-C53BUV3T&/1D46-*=VB)[9YO,.MY->-#:EM-MAN&UM377NHZUK)K/8=42V^+3%PA1Z6V:N=-+%5{B:DUK58B*WB:|SLKAG;@Q M)VLZ<^ZNV\T=3>7:LM353CHKXJS/5O?PS?MB+CLRJHGH4V:,*[OV;>[;^@UM39.)D,^8JBED7+Z:=N..)R|ZIE%1>]%1>\]YU9P:<6]=W[>M-M-4=G8@SPB^Z=UT)M!0V6T3OI)M15;J6HJ(\HY*9C.*1B.3L5RJQ%]+>).\Q! MZ&W1^TCO[JJ]46JK_-*

*;DH8HWTUMHY61U%:KE?Q.:YR+YK.%N41%7STYIW[#> ME#L!3}(3;:2Q)5-H+O23)66VJDSU;9D:K>&3"9X'(Y4'-_2\\075KN7T?-Q MMF*Q9-1:=K;*GA?*

*F.Z4J=:3*J+R]$54=ZD-'5158FU35NURU;0HK MIOQ:6289P.QS\Y51 M<8Y=IZNAGT8MXME=Q&7BJI;[9IRL@=#<{8^X=9)R7JW-;&CF*]KL[1SEXV)_!E#;MQ[YMA4V;,*F1][N,B03U:5;*=]-3X57JQSU3SG81N4Y MHCE5,+A3'''9KP>,N=3ZPD@W#HJC25AABZU\]-4T\|U0Y5PD<.1<.]K5[55SD7 M&$Y+DR/Z6G3:CV-*

*NR:5TQ0TMXU1U22U,M4Y5IZ)')EK7-:J*YZIAV.IA%1>> M<&+=KZ3/28WCJ9F:8J[M6PH[@-(H57N=*D:JW_2>8XE&119GV> M:KG,C*N*DGI+K)')Q\:+AS',8S M''HK%[F\NW*

MB3T$-[^4>\ME;:H-UKC>'LKUDJ:.AN-S;.U.!>%STA:]R1KY^$54153..2&0 M?@M])K/JG7&IWLPE+1PVZ-ZIVK]9'HGQ=2SVH7+F]3A5=)5O>/Z]-G=]S:>*

*MCIFGP?=X4C32U&CM#Z@1G|U\|''YW^6C1Z(Q_4*6OX+*_=5'RRB-SS7*1-MVF^O(QLBS3MV]8FGLA7HQLO&O53;IB8[98D=(G>JHWWW0N.]Y8'45&YC*&*

*MI[XMIZ12TG%AMSL]33G$=*M M'(];NZ5;*]NBIFJBR.5??.54:BK[LJ''^NG%O8N[>\U91T-1UNGM.\5OHT:(+ M))$7Z_*G\)Z<**G:V-JE:?*

*0.V&_8FVJ;>KG3=7]74C657T9<;T>#3ME+I>IK]M-MKC+NEOMFG-M*R!T-SMC[AUDDG)>K:KDSS,7ML^F1NOME+$VEU-/>K>Q4S M;[XJU<2I[U'.7C8G\%R&RKHT{(BU=*

*(G0[!OQ2>3KM1/2'Y6U?\?42*BJUS78 M3B8Y$Y54C^ZU<.1KVFQ:FBY,54SV]K;AQB7KL56XFFJ.SL2Z #5[TX M_^U! ,;4:?R_S*5HTM\,%ZS^$!K;P M HU=_;4GR?*

*S(5DHU=_;4GR?S(9T]^%\ M6%(-M :*2]*Q4NJ-/W2S5S%?0W&EEI)VIVK'(Q6.3V*14-(G3C#&J-Z-);. =MTMM[MM/KR\;4O$++HJN@F5K)%3#9HUYQRM]+7-*

*PJ'\CM13,S8WPDENL^DZ*S[MBVNY5-QHXFP,NUM:R7QEK6HB.E:|[51_+FY%7*KG*&5F]W1TT7O[.8Z;4U''Y MM;3M5*2Z4;DC]J?/T]HI*

M8Y(++3O;+=;EP`93PYYIBH.1%K?3S[$45RST1X+NV4=9%/]6=1AL>E[33V>VQ+O)# WF]V$17O-'&>UG;PLC)N1=E]=PJ*M?2W-;&CF*]KL[1SEXV)_!E#;MQ[YMA4V;,*F1][N,B03U:5;*=]-3X57JQSU3SG81N4Y MHCE5,+A3'''9KP>,N=3ZPD@W#HJC25AABZU\]-4T\|U0Y5PD<.1<.]K5[55SD7 M&$Y+DR/Z6G3:CV-

*NR:5TQ0TMXU1U22U,M4Y5IZ)')EK7-:J*YZIAV.IA%1>> M<&+=KZ3/28WCJ9F:8J[M6PH[@-(H57N=*D:JW_2>8XE&119GV> M:KG,C*N*DGI+K)')Q\:+AS',8S M''HK%[F\NW*

MB3T$-[^4>\ME;:H-UKC>'LKUDJ:.AN-S;.U.!>%STA:]R1KY^$54153..2&0 M?@M])K/JG7&IWLPE+1PVZ-ZIVK]9'HGQ=2SVH7+F]3A5=)5O>/Z]-G=]S:>*

*MCIFGP?=X4C32U&CM#Z@1G|U\|''YW^6C1Z(Q_4*6OX+*_=5'RRB-SS7*1-MVF^O(QLBS3MV]8FGLA7HQLO&O53;IB8[98D=(G>JHWWW0N.]Y8'45&YC*&*

MI9'9=#3LSPHY4Y<2]KG+CEERX-C?0-TZRP|&33TZ)PRW2HJJZ3XUF=&W_8B8 M67NAX./3&NM6276SWYVE%;>"G9;*2@;)&SJXVQH[B61%551]*JKS5\TY659NV*;=N>6G*

*M#I&W"Q+IK(JNW(UUUXM4W2RU=|&?2*U[<6OXXH[BZBC5%RG#3HD'''$GJ7|_*_M;-.AWTZ#NC?H;C='UZ:MIWTW7TU1(O:I$155CUGM+*

*M%NWXIJM9If%SW;IW;,;=TC'<+?777"5L">+V:AHY&SY1.4>'-1C,=G-43ER MSR-8>Z&OJ[=+<&_:LN36QU=Uf73K$U55(F\D9&B]Z-8C6Y1GAM=X,RQV*f0*

M7#6^HWZCBAKI,'37'' MJDJ66ZFMC%CI^)<\#<2)R15YU.%4LU/.1$|GRL25_^T]36'TRl)6]_I):XJ6OXH:.K2W1 MIG.ZAC68G^FQZ_*;--*

*NM).T'H/3^FW5KKEY(H8:%M6^/@=*V-B.;Y6Y7''X M1.\O)N7@S;?>M1U=XN&OZRIDJZMU741^3&MZQ7/5[TSUO+.5Y^LJ8>1;LW][MM<|\^7FN9N+=O6:+5%/+GQCLA#70?*

Z3UJV$KIYI36K)[=9^H2H2LZA[G4=2U MO])&(BNX7(UJ6DI=_W+3FW=RDO-YNL#J;2Y10R10T<_M3TP]45Z-5TBM7''<*83.ZZOO]OKG;4U(]B-FJ((SE@JL(B-*

M62/+?.1$1.)]HR[47D0SICP6LG;FCM0:\;^W-?SBMM''K99&_PWN5&+V_;NQZ MRUTF%>KB_7.Q5VOXJ_1YUFW-BB(FGIJ8]#S9&]WEW?M<;Z9SI/6>5E?=)E

M3S.|]V9%ZUD$VU9Y+V@L-AC?PRW>Z(IN?=10QN5R?AOB7Y M#)?;#:K3.T&EX=/Z7MK+?0,7C>N>*2:1>V21Z]W.7"N\?N1G%#9[2_@=Z)97M8W_824R<\(/M?6[@[^4-M;9^HK].U27%8HT57/I^%S)L)WX16O\ B8I=O1AZ+UOZ-M'J'''*EO4M]GO$D+ M1)Y:9(58V-'HU]{CG9YR.7Y2;G-1[7-JJ8F|U,]CE6.16IS5J<3T5$ M15\[*9QA>?)%5$[D0CJP>''S*

*MK'5C77G<''%E*U_G1T%M5SWM]''.?(B-7M[G8]9>N5X>15%ZNJ8GMC_(4+=K-Q MJ9LVZ8F.R7]Z./3=W8W:W(M.DGZ=L-594/XZFLABF@=3T[>$ZAK9-E+*

*^#*T++]&M0C4YY6''9&*OJS ME/C5#++]H&N=$6;LU6XG29AK&Z!N[6AJI-R+Q6:T>R@\=HD@HKK)''LC.9W%E[5X4 M56\:8\Y$QYN%[2,.EYTX-(WW:VZ:*T#6R7FKN\?*

*BU9DUHB*L,Q4U1+7.]2PPOD;_MM M:,,NE#]SZ">C[KVZH_]Y$M6HBI MTF5[6*]HSA5S?MN%->L8I=$T_>G73C'QFY%-]YNJ;B^5*

*M%+!++%#3RT+84:Z10^K^)'N^U5R8Q!L9)Z@M\ULZL-RM|/5.H9]NFE@95-;Q+'' MYS%:CT3*9P]VQOG.,[(HR+E.Y/''(;-G8MS'N5!;U=>F6DK=K5GT=;GZMU''CN. M.Y72]H8^>*

*<1NDK-ME^4Q4L_@O[-;O0UDVN:JL@IYXY9*9UM:U)6MZBA8UK>?\-TI]|XO!^TV\&Y5]UA6ZZJ MJ.>Z2M?XLVW->D36L:QK4=UB9PUB)G!D%LMM=2;-*

;9V71M%5.KH;:R1/&GQ\ M#17/D=(YRMRN.;U[S[E6O9;,%$)>&O^?%CCXMWVR[|)9$[7/%'+R1&)W]ZD595]G#BQ3/WOKJ4XMVK-F]7*

*M'W8Y>6BZMV=6)H;,'5FH>/@?;.7454:YQF1L;E8B>M783Y32]MEI1VN=Q=.6 M#''OJ7.G1'_P7R-;Y5^)%5?D-RFI>V2IP:9WK1WE62RLN.8V25D4*2N:ULC7 MJB-54]UP\/.Y*I*

.S/@|[5M)N79-7KJ^HO3K7(^5E%)0-B.]RQN8U5U7O3]Z>7D9V-=R+UO=C[L<_/BG+!:ZJ30<QVN+PQR0R4UIG M9 Y%X>&5[%CBQ_IN:.B]BM(?1OO+HNQ.9UD-

*9=[=LS<9^M(]'2C>%7)YN:U@/:]E-R[9K M)-5U%[FM|)DBI9.%L3>*2-T?%O(}>Q'N]B<3*MV+-<3/WI^7 R\6Y?O43$?=*

*MCGY\64]94+2T51,D;I5C8YZ1M[783.$]:FAV[7*HO5SK;A5.XZFKF?/*[TO< MY7*OM53?081[I^#/M>H]0UIVTAJ?Z'X*J1TRVNKI.NABJL1J<.6IV\U[.E2Z4>FEU;T>M?6Y&\;_ "3-*

4L:CM?"G7-1/ M7F-"-NB;T:Y>CKJ\7VOU#!?^^NHFT3&T]*L386\./]YRN7BRK6=R>Y)KW:U MG8M:,;2M&9Z>O80>HY6LM%/4R0,Q7(CIN)M2)N>USU5&HGI4UE.1'03,QK'FN6^*

*MDG&GIXBF=)\FF,;C<*X,]H88_6B*G&]?O6HONC&JR6>MOIXHK7;] M=]7<*V9E/3T\;9=)(]R-.U/6]JB&Z'H]|/46QVU=GTM3<$E5$SKZ^I8GIL53 MT19'_%G#6Y^U:U#T6?*

*D19MS%/XJN'Z/-;-QYOW8FK\-/']4C \B]L&L3PFL M,C=^;,]RY8_3D'!ZL5-3E/;S^4V=FOOPI&F7Q770>HF1YCDAJ;?+(B=BM#QJ++X\]JL>F',7UM5%++H!5IJFF=8G25NJF*HTJC*

M6&!VJ?@RZ>;KJ|,F_K3/YN2TW15\'-7UN)#Z'-I^&/IL-#ZWT_K MRS6FIJ+DF&R*US)HU4]N8]JJR=O-%,K@7*KF]7FW.7.L>KGTI/LT7.DHC2 M?*

*1HXUOI2Z;2[CW2QUC5BN=CKU8USDY.X'9CD3U.3A4C4RN.:*GZ1?C9U[(MGX1T^GQ)#=&_=(3=*]O]52N=6U[V4M#;;:,G*

*M4QHO#'''SEERY7/9S2NJIIYG.EGF>KWN7M22&H@5RN:BJQ'*U[MNDAI''FEA;/24 M)N(HW.,E._ST8GRF5NZW@T+']. ^55ST5J%=,QSN61,754RSTI'+E<1N1R.8W*

*M/Y]H['=RPAZC-N6*IBQ=G3MU>0P+613$WI,.IFDHDZ;/3#M6\=MI|%Z*>+I MR*=M36W*6-T7CDC<\#&,=AR1HGB57(B$Y]EY(C%'U5Q3Z%TQ& P|RVIHN4[,^E6OQ+*

M^:4N+P7&E_$]"ZUU$YF%K[C%0MD'N S4]:K MHM/5T<=%%1QT#9&L8Q7.]TLB=KGN7L[R5NC_ +,4>P^V|)L CKWW1(9IIY*R M2)(G2N>]5SPHJXPG''WM^U,*\FW&)%FB?*

*O=O[MMO%N3FU7]X^[V>6C6#TV:7Q M7I0Z]9C&:B"3*FB=_O/?T)MF$W>WMH/'8.ML5B1+G7<3K7)U42_PGXRG M>UKS,7?+H''V_>O=''\:SEUA4VB6Y)#QTD=*

V5K.KA9$\B\2R)G*1HO9WDH|&OH MY6KHY.5N-IH;@^[UE?5)>,U-PE@2)fT1J-8SA15\UOG*K/G/M>[TEJO:%NG&BBB M?O.1'S4J-G7*LJ;EQ(VI$J_&LLG

*MX)Y/!:,4X:'7>IY&9ZR2GML#|=\G"CI)$_P!J+V$N](fH81=(C7--J*LUC46=_ME-1.HH:.*A,*UK6O>]7<2R)S57KW=R$D=';8RBZ/NWOT+T5QDNW'62ULDM9)"*

MD2O>|&M]RBKC#6-3M|BK.3;IQ(LT3|Z>?GJN4XMRK-F]7'W8Y>6CV=('M=C M=7"Y'-;OJ=)U;/B+;,MK;JCK(K9(E===G,7S>O5N(HOC.USG+ MW9>WO:3MT#=@G[2;8+>*

*{O2K!]?4:-J9V2-P^GITSU,2IW+A5>[L7+T1?=(F&NJ-A]PX[=E:QUAK4:C4YJG M4NXD3UW./?@U$;(:GL6B|V=*WS4M'X]8J&N9-50]6DGFIV.X5]UPKAV._A-*

*MW++FHK7(J91>2HIA3NYX-*SZHU!5W;1>HDTU%4N61]IJJ59H&/555>K>CD5C? MWJH[*KT_=_H*

*MIO+XU\4H*6"5C5>J>:LKWM:C&HN,_;>A#5O#7U931OD<^.)ML:O5HJY1J+UO=_N+6/D8F--443/Q ME3R,,R8IJKICAV1+)#=:,Y:CV@V)]JO0UOH[K]DD$36M?AK'-M-*

*7+6(KL9Y*WF$YW7A(-LW#M]1K+32.2&GB9+)UTK6(UTF,<2HG-<=V3%C>+P=^AMQI[5W>PJUI7HV-MZ54BRRMIH6ST:G*N7*D*JU6]J^[>B<^PY^-*

=Q_O4WJ>?:Z639R-:K%7+L7I M]1K:&

7%"B+)U4C',W=GT;5/T/6S:CU'-$K:.%U%-!%3O5.3Y72-;E&]N&\653 M')%RG3>KP=>DMQ;Y4WO2]UDT;7U3UDGI64R3T;WKS56LXFK&JKG.%5/0U"-=
M/>"TK'5+77S<"%E.UWG16^VJYIV^A'OD1&KZ^%Q=KO8>3,7;LS$QV*-JSFXU M-5FU3$Q/:@KH^:MWEW)W+MFG=.,XU-&E54)+6S-KI98:;'B3K9G,G-
NY%JI>JTTIB72LXMVSCUTZ[U*GEHFPHQS\(K^)'N^U1R8QIL90&6?D49%R)HG6(A,S,;O'MS%R- M)F42=*W,2KW7V%U58+=&Z;Z+"VKHXF)ETDL+TD2-
/6Y&JU/6%Z0;*,G5>R^2 MEAU;%3+4/MD[DGI7>;LD3VNCE9ZG<+G8SV+A>XW;&,^^G0+T/N_=JJ^6^HFT MA2
ZA5?/44,39*>>>15RLDD*XRY5[5:YN>;KE>9E@Y=%JFJS=_#+7G8ER[73>M?BI_R'H?X0;9AFFVW-M\K9*M6<7DE+=-XRCL9X%7AZO/KX^'UFN??K>F[](#
M%%7@C1<>P\36NU,U5*=5G-S-+=V(I14CHL[(ZDV&Z/5WJJ.AII-PKO$ MZY+15J.6-'M9]8IG*HJ+C.>?)TCNU$,8]+PCNZ,&L*"HO5++;X,33U*)7VFB
MHEC=)&CL/8CI'.FZU=]CEJ=,;DJ>C41[XUXYL8KLJC5Q\2=B9.UW@LIS'4-2CW H9X,^<^>V/B\D_;3P;NC=5W.FNFK+O/K*I@H*^TT5$L; MI(T=A[$=(YSFN1,XY[)GO-G+
(VQQM8Q]-:.U,(UJ81$]!(CKOMT&]"[T76KOL M,M3IC4E3SEK]!K7Q3\ ?RPKA'+Z5:K57O52C9R+%5VNJ]3^+T7[V-?IM44V M*N-/9WJQ3=+K9#6&FWOKM76IU#41_7K?=
(G(_"IK'Q.;YWR(J?&:R>D+>M#:-MAW8O5=MU0K;M+2*SJ8TB6&-ST:B/?'&O-C%=E4:N/B3L3)VN\%G>8ZAJ4>X%
M#/!GSGSVQ\3D3ES1J2.RO;WDG[2>#=+T;HFYTUTU7=Y]95,#DD91NITIJ/B3G MY[.)SI$1>Y7(B][5["]:NXN),UVZYG7L<^]9R\N(HN413IVKP\'_*/N6DNC MG:W7-DD+
[K5S7*<$JDK(7+-2.1T.1G&GJ>SE14-K6IA&M3"(GH. MQP;EKEE7*)56=ZY3U*F M%3U8-WJC9TDNA%IS?]\+J&DNDFF-3.;UKB9]\%6(DKNSE$Q%.G.
M4TI1:AU'JO;RRWG5=I@L=[KH$GEM].YSDA:[FQ%XN:.X<*K5[%54[B\0#BU3 MK,S$:/041-.,1,ZAIOZ6FV%/MAOOJFC](7LHKA5R7.@F MPLJ.:YK/*>;GYV).5;TIGC')C1T8.G?
H6W;9V;3>NZ^2P7;RTC*)E4ZFEF@J MHHV\,,D6-KE,_@:B*CD1%5,HJYPD6].OHV_=NP_05H?K_HR6X7*=BO.J
M^%>)L3&*F48CD:Y57"JJ(F$1/.NG4/@M*IM3+Y"U]"ZF5*^LZ<58 M-NOHHJF9YZ>/DY4T;0N4=!-,1'+7AR0YX/G82LUQN-!KNX4SF:>-5[E1B=ZXF[PGFK?)NV6EM.L?
PR72Z.JG(B\W1P1]BH\?%,Q M?D0R^I\104M,Q&1QM3LM';+/0P6ZV4<:104M,Q&1QM3LM3)OK554W&I,|$:/(WZS7 M"KU7/8X;93.@CI8]LR*YS^>S\]]N,HC4QC[4ITY=-[*B]=X4PN58-
5G$]LV M>-4_P"6*G@R-)>5-XK__'Y[.**TVE8VN][+-(U&K^ R5/E-F!"71CZ,-!T; M;9?;>EO,M\GNTT4DE1+3)"K6QM\FTK9EZF_>FNCDMX&/5CV M8HJCCVA3]0?W!N?
^;2_T%*@>>>X4J5U#54RNX$FC='Q8SC**F?SE2CFO5?A:+ M=';WV63_ #Z#^L:;PM7_-Z%_S&?^K<8;VGP85MM-VHZY-P*J1.:=DR,6UM M3BX7(N,];ZC-
6I6Y+K:.ZA5;5H4P/A52)GAXEJF1-&Y.NFK/9F=-Q]_(CTUT:S_"=_NV:<_D]^DU\;G-@ MPOW]\0?REJ/T6F+LZ2G0SLD5K*W;@=]=4SV-]'0-H4@BHFS(Y$DD?
Q95{\R7ME5\7%6+\:*.K#'/[*=" ^ MS](:55MU\)?IM/5]-2^*3.AI&S).O'"YBKES<*WB>45/0=/ R[<>N>D_# M+C[1Q:LBW$VX^]$L:.A]M8NI,_>G[?4QJ?:I>_RK<.),HL42HJ-
=ZG2+&Q?4 MY3<.07T8^BI:NCS\6K&M:51]Z>;7OX4S^[VWG^;5O].$N;P6G]Z6O?\^I?ZMY, MW2>Z)U+TDZZP5-1]2:PK:8YHVMBI$GZSK%8N5R]N,<'YRH]&/HT4W1NM-
^H: M. 2WY+I/;.KY:9(.KX&N3"(CG9SQ&ZK)M3AQ8U^]]5;G%NQG3>T^]]-&/OA4 M*8225[=5B1YBPJ?TI.O?M6%$^7@7V$0]!'I'IZ2V^NNL&ZNJ:BCIKM!3=1/
M#3NF3BB=)EJHU%5,D)R7&.2FPG?/9*PI]Z&ETU?G30.25M335E-CK:>9J*B/ M3**BIASD5%[45>Q<*F'4_@IKEY05L&XE*ZA[I9+6Y)4]7 DN/EXOD-^-D6*L M:V>].G_W57R;.
(RNGM4Z_|S1/W2%UY;MS>A[JS5%D=*ZUW&V]9 LI.[^$G M.U34$\M,ZGD@ M\K/ITXTZA9E5(^+&$5RHB<79WD9[,^#YII-HMR[']^6E3O6[N]RTUY<|>++^SE
M;NKLUXW9Z5U7>M/3^4(H8^,Y8>%6S,:G>N.%V.U>KPG-<&2@.19N3:N1Y.K1%7O1RXY\O2 MWKZ 6@|TE57BTSS:,.O=0]NEDH(FR4LKU7*O= _IYR]
YN>U\VV=&O:AVS&S.G= M+S\+KC!$L]<]BY1:B1ROD1%[T:KN!%[T8A:VP/0ZT/L-.ESHV37W4G"K/*UP M0%$B]J0L3E'E._F[M3BPN"=BEF9=-Z(M6HTIA>P,*NS-5VY.M4@
.7#M=C1 M9]M52Z[OC+PQ9*V.Y3I6,YHKI$E=QIZLKDVA4G3EV1L,@Z2LHKTL$<-,UL% MAI:&1*B/A:B)"C.%&-QV9XD;RY*4W1%= [3V[>I)M36B[OTK?
ZE46L7M8^7C7*HMTQ.5=LL*]I-TJO>3)[. M-7TZ52+U3YYGOOE1^%]+'SFHN%3DA&FY7@W=.ZXUK<[W-.3/TSOU5?2V ML=%3HV-
K,-7C3DJM5>SO.E=G]OEVKVWL6DO*3[LVU0+ VLDB2)9&\3E;EN5Q MA%1.WN-.7E6;MFBBUV:O%KSNGA$MWZ'5;([C0VBV1T-8 MC:VTPT+F,>C'8DA;O(O/"JA\-^NA?H3?
2OEO-3XS8=2O8C'7.W\,)<I%;GORG(S%I*2&AI8:.FAC MIZ>%B1QPO-1K&-1,(U}R1$1,80QR\NW5;BQ:G6. ^66%@W:++LWKD1$SV1XM; M6[W3MWLT=K6]:.J;6QZ?
K+75.IW^+4#G*]&N\UZ+*]^6N;A45$YHY%0RBVTZ M<.U>NM)TE7>-14>G+JZ%$K,9<41=. ^_1;T M3T@8X)[_
$\]'>*>-8H+M;WHR=K>U&NRBH]J+SPY.65PJ94Q8NO@L]E'(],7 MN%33L5>3.RUNB5$SV*K979Y8YX3/H0458=ZW$5_=JCN*J+TU5(JMX.!F$RYN\!3T3SN)..XR3fX+C
M1]RH[3KC4L])(K7724U%39Y-F?%UCGN3TV/6-3/J5R=QZ[^#'LENKH:G6.K MZFI0,5':H+,;3>*L?C[5TBNG+9I*QT=GLU##;;71QI%3TM
M.SA9&U.Y$ _.]]JJJIGDY=OH/9[4S5XRQO,.[-_VB[$4^$>33UTL(:Z'I';A M-N"+UZW21S724Z'&F^D)40W=+A)IW5$,;84N4,*3,FC155 M&RQ<3>)4RN'(Y%3//*(B)!FD?!
<1QW9)=4.Y6IMK\Z;UT?5R2MS\(DHM$ MWQFYKIQLK'OU56Z8JBKMEC%TI-^UZ0>Y\VH*>FEHK/2P-H MK=33JG0$U7.5S\+A'.#GTEKF\6ZHL-X?
H^WT=!'0MH*6B2=']QSUZUSU>B]YR.3 M*KE55,YYDU='791NPFWQT*,O,E\A95RU,=.1+3I"K$?PY9PHYW>BKG/VQKR3-
V[&NNO%7=Y],.1EM)K2R(WCDKK1501IC/UQ8G<"_ M(["_(,:MK]P,AM=K*FU':W*RX4U-510/1?HN4U1P5]K_[E$TS]I[C]$Z="K8A=ZMVZ>6XTZ MS:9L2MKKBKTRR9V?
K4"'GCFNS,S1VM;UIJH;'I^LM=4ZG?XM0.6.>SZ+=%6'>MQ%?W:H]E*JG-LUU3 M1]ZF>^4.1-36.U6K]>6^.;&BIXW112)=:Z@IO^Q;]D56\' S"9'K&IGTJY.X}>@?!@V
M2WUT-3K'5]3>H&*CG4%MIO%6/O]JZ17.U5554RRL[WT'L]J9[\91AX=V;_.+1=B*2"!)4@ M.<-Z(.?:@_MJ/Y?YE*T46@_MJ/Y?YE*T:*^;]9_'UMX M.4:N_MJ3Y/YD*R4:N_MJ3Y/Y
MD,Z.:O>_"^.+"D M.!KZ\)%.]5:TW"TK:K+IR M\7>WVRVOG=-0T,LT:332*CFY:U4RC86+_I(;!3C!OQ[WL]R+D1KHJ9./]1:F MW,Z:L-O!K[9W,2&DM97N]6FLM-;
<*Z&DCAKZ=\.BQPQJIB1KD1>%5F5.]BJW MU&90[.1=O3>N3U%NGL.;5D M.1"W2#O-VL.R>M:RO)5K>6VN9E(M.URSME M>W@:YG#YW$U7914YIC)(UCKK.<2JJ(N#.0
F7KU>17-RM:QL>C&MQ1-M2 KK08]I.K;1^XO1]O3]9G65]B>V\P-1,JJ1-MU6ZN4L$//;:.V.);-,Z0D?A\4T-U@9GW2.,U4J_)P0_A&=YPB8 M.3*]=B[$IM1:CTKHW3MALETO.
MGM56M=-6OW MP;>TE\L.O=6ZBOUBN%G6FMT=%3^4.1\'&LLG&Y6<;)G"0HBX[.+UFP(ROWI MR+DW)C1CBX\8MJ*(G4 !76P (5Z5/2+H>CYH&2L8L=3J;X(Z&TT+ESQ/
MQSE>GO&915]*JC>6V>|\67 M M!5;=_ :S?C7^=3UGDMW]K-^?YU/65*N'|..**9BM54R['XRF5P0,V'2\&#JV,Z;=OHJZ8H<;_LVF[
MA#T3*W96FJ]5:L;&W5ER@\7CHF*CTH(%5'..KDRBR.5&YQR1&XRN5,L 8W\ MZJ[;Z*BF*.?!./LZFU?$KL8QWET@FF=)B6-4;T3#29K3<3M17?JW<45NKD)79?
5KVN3GS5,H99!]OH>7>BU)1[B:YMKK=#2)UMI MM56Q6S.E]IY&*GFIWFK47FJX=A$1,Y_<#?0AV.I]^%\ 6%(.M M M M M !5;=_.;S?C7^=3UGDMW]K-^-?YU/65*N_"^ +"D
M M M M M M JMN_M9OQK_ MIZSR6[^UF_&O\ZGK*E7.71H_# Y >2X?VL_XT_G0]9Y+A M.;S_ (T_G0FG%@"O\.J4 "TYH M M M M M M #[4']M1_+ _I6BBT\M1_+ _I6C17S7K/X0
&O M #Y+#&Y)OX*/BT?P3?P4/KE!E!K*-(?+Q:/X)OX*#Q:/X)OX*UR@R@UDTA\O%H M_@F_@H%H_@F_@H?7*#*#632'R\I6C^:",^"@\6C^":^" MA| GRAPHIC 11 image_007.jpg GRAPHIC begin 644
image_007.jpg M_]C_X 02D9)1@ ! 0$!+ $L #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$!
4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04

M8^7YK[^WC^,@[>/XR%!V$&$'H.KYGD>LL?+!\U^/;Q_&0=O'\9"@U3]!U?,\ MCUECY?FOS[>/XR#MX_C(4&&`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`C8=GS(>K\]'6:]4WFJO-SES[N]'=&\)5C$]%C?4UN$0NL/3+F1!5?*ESZ?]IO&_P!. MWS]\DN=[O*::DU"ZHMNW%M33=N6I=:]K9:UZ>MK.L[C57>XS.YI*]MF=+/(Y?TSE4]=\X^8Z['P]./&U%/^7#W\/_DSOY3(8!L.FP ;@ M#++?$Y-6^)L ,M\3!EOB!D &+< !D&6^)@RWQ#%L -@ !LWQ,F&^)D,>]MEOB;&K?$V(]T (D; @#+?$P9;X@; (AEOB;&K?$V"0V;W&ILWN,I8 (@ M;@ CF!N:&X 9;XF3#?$R &X "(-;E,F&]RF0B0 ; B0,M\3!EOB8C M8 ;-]E,F&]RF0P#8U-@ W &6^)L:M\38 B66^)DPWQ,@[@ !BW &S M>Y3)AO](f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

X-5-C500P R;J8,J8 :FQJ &%[C4V7N-0!A3)A0F6H "&%,& M5,!E :2MYFY-S'L)A+Q0;;RN5#4ED #/,$!]GJ?[/]O68 91.R?W!EQXNI
M%H=";F5ZR0KRP6W450[X'@V*I=ZO5*O=]UZTL08Y'(JHN4\#!\^6?;_MZRPQ@ M)XQW52V ; 6]=S382"Q72H=E7^#:615\4[F*O>F&] +GD]2TV(B;UF.7?#M= M)U:9F+%^?M/^5@>4A-49L)H5;.9YF.UE?(WQT+4ZK2O]SZER?GN M6^&WYU=1TH\CN=\DCEY34V;W*"60 $!L:FP #+?$P9;X@; #9ORSQ-O_*DF=@N!;5&Z]NH!?JM=*V"H3G@62)7U50U<8J/)Q;,W2E=[C7"[V*IPO*]L[9XU_3,&F=I^KRR M=(R<6GCKIWCXQS+3%5QJ8>%=SJ\YMVNL<_@@X9;XEDOO:>VOC?M4Y_P + MIOZ.:KY-/;;#L:@U4G3'6JL?S[']7Z;N]9:KK22T%Q!) M'0ST\S>5[!M7#D7V^.3?Q\NSD[JG/-4Y6GW\+]]&T/";XFQW+A$Y)L6 >M;Q M9[_67"CIJ.A|{C?;9(V/5W:-9A5>QZ8PY>Y$7NZG1.++A$TCL1MS1Z@L-SO5 M;637&.C%?@]f=[J:HOVHIJRS:3;S,IY*7E9/62)WK&KFN1&-7O6Y_!3LSM)H^MU%?M4:HJ.!.M5D:,JF62>1<\L3&^;^DY53N[N15Z{JD%K@ZDDKZA!%-#1K(Y8(ZB5)&1YR MB.>C6HJX[U1}ZD0\L7*HR=YHWY?%ZYF!WP:-I8K@*TUK MS;^QZCU1=+{176YPK5>;T.T+(V1.5>RZ/B% M>SJHM1SC\D(39N'QO:N%:D[#*1^C[OKI*M!8+'1OK[I6R) M'#"W"M5555[FHU%557HB)DL^.F*..9Y*&FW5-?9Q'X/3MJE.D^-#^3>T_!; MHWZNU+<*RXJC7/BM/9PP-7Q;E[':>GM]'YD/5;D>3DI(K3-4Z'U#62U\;5%CC=';7;7 MFI;?8+)2/]fE72I%$Q%5$];G>IK4RJKW(B94G;>. :/ZQZ.K:Q]9>9Z^DHG MRND2H8UOXF+W-J]N>7L^Y7)W9\>\TLC,M8]44USSE:8>FW\RJNW'^GX]JS+?$P M9;XFXJ9Y-@#MW"AL?9=]M9W>T7RKN%'!24'G3'VZ2-CU=SM9A5?&Y%3#EZ8/M*]=IL4377T;&/8KRKE-]WUEQ-OLJ:NX)2O;7BW,.[-]YMO ;&IL;#2 !N!W] MP RWQ-C5OB; $2RWQ,F&^)D'< &?]]08M@ #HV;W*9,-]E,@ WO' U#? (MZ3S; $ALWUG0=F-CM1;VZAEM]E8RGI.=&OK+A4(J10-55[\=7.7TN5J=^%Z MHG4EU9/)Y.+@H6MNFH,W65G7M)*=T,,.KZT8K]GTN4KK^?9QZN&J>.YP]'R MLRCCMQR^O) 4$O=V.2]fEJ+CH>ZU%U="U7+.[@UB32(G?R2.1K57U-5J?/ MX$'1'L=('(YCVJQ55KFN3"HJ=Z*&]L^3:R8WMRU^UUTI'VZ2!D7N?-&Q%1Z/5<\\ M; BIW8/7\56PE@\Y-KM/4]BK+E5MN,<\DONA+&_"L6-&XY(V?&7OR:,9=OMQP M_P#,MITS(C%C.G;@^_/X=`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|>5?GR=4."N43;KFB>L/T-B%.39IO4])AJ].9]M5\-MKWWJT&N@MR]I1QQ\E#5.\|I>F$2-.5PGZ5R:,!S4+"O'YC@%%YH/W?T5#]"GMCYJRSOS(K4RJP/Z.^?#N1WL1'&]IU_L;T1/27/?M)@_B\.J8]JGG^7>AB.# MLWQ &@ PIJ;*:AE 84R84'>P EA>XU-E[C4 -5,&5,!E :KWJ;&]]Z MDPB PO<9)9[=|(^DI8:)LEZK+G>8ZBOHXJB1D$L*,1SFIHJHB+$JX^=5-3(R* M,,-ZUM@;;?U&JJBQ$;Q\9V1)!]9NILET+N!>K#0R32TM%,D<;ZAR+([^YW5MVOUI-8K745532LIXY4DK'-<_F&%,F%44W5/W, F.1 M !/5+53!E3!/U/KW!H;FA$?$^H #(;@ ?7<;J8,J8]GBS#P;&YIH&0 ,*8,J M>XT598=1ZQL-]J72,IZ^OIZ65T*HCT;)(C"U5145A?%%;.JHIHG;IFY5%M%/67I@3(UMP8Z,TUHZ]W>FNM[EJ*&AGJHV33PJQ7,8Y[45$B1<93P5"&YK8^ M5;R=^#?]DL<[3;^GIL:KW}Y\Z,H?Q;@;4;" M*>E=T=M++-]*ZW*\4U9423,=`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|?^]SAF M_P!OU?-^~7ON=QS"O=A%<[QZ)\%$1.8@'96;=-JF^.M*8VB'S6]>KR+DW+D[S+L;9?;V:=/<[3NEXD?4.O:R+ MHQ/A;_MPB[E)N7L;8*N:7M;C;X_'LK M9]*/W0CBDV>69OS\'V_?4.I*N3:O5X],RUVU3E8UO-M_G^?^)1X !U+@MV6^).KR;>WD"T>FNJ8//Z3:M>[5\"5"'K?$M&X#[!E M)PXV.9K6M=4U-7*4[U5)WLROT.3ZD*35]YIQ]HI'=-^SUJ*\N)GNC=S_CFXMBM2;.W.RZ3TI<'6FNJ8//ZVLB:BR=FKW,C8U51>7+F.5?%41$SC*+]1P.[^7 MK=W2]ZMFI*I^.]V62-4K'-:Q\\$B.Y.9&HB*YJLJQAX;.M]3Q"M5<;NZGMU+$WV{}.=_"Y3[7R:M0]NO]?0(OH.MT;U3V1+A/X5*^O%HC BY$<[MMUS;SKU6KS;FKV=]MG\/**[>4]BUY8]64D21-O<#X*I&IA'30\N'KZUQ>>-/V"H?5>4BI&.VFT[5*.MU'2QWQD37>*(Z"=5_B)}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~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

*JB*K=.\RY_3=-IRKU5-ZY%,4]42(>$7=5]:Z1=-(UR)E(W5]-S,__MZS'UGQNL]H=9;>1K)J'3]9;Z?F1OG"M22#F7N3M&*K,KZLDF:CR@-*VZR,@T M;-*

*);&OPV:2X(R56Y^%R=FJ(OLY_I),6VLM&Y.B::K\W2KM%XHVR=C4,^%'(W-M*M6&/2VMl0V.%SEAM]PGI8U7O5K)5:WlQ"Q#A77_M#:23_P #+_+//;5:HKL4*

*M3'Q_L\/V7HFWFW:*NL1MYPAOQ#6"X;GXC]36NUTDE=<*B>-L4$>%<_\L>-V M$^I?]5\(.B+OH;,:KH;!;I:;?RW*2=89\GZ7]PCMN%K:EVZXP+G-MJ.M@FJ:6@JDD?*

%!A7KS4J,Z97'>Y"8FT:ZUMW?TO)?;9Z5-%3MJ74ROU2-1_M.U&KGT55,>(>1_#VZ=O9VA:,/.L3GW;DU?ZD53R^GO1^XK-[G:JW"I M?Q,4=WELM-*

0M8WS&961K(KG]51')Z7P?H:A$>^27&6[U:W:6HFN*2.C])*I MZOD5Z+A>9RJJJ8QW^!8+NUQ2V#:752Z?N5KN595=@R?M*5L:LY79Q\)Z+GT-M2O\ U)SN355,SO'=&SUH+FKW9E>]<_|\7T'lJ/V4|<|+_A1R)&WF;OM1H(-5:8M%Z M@C?%3W&DBJXXY,S)78=5SMIFBG>9=']UO'C#IIKN333'3;OYJN^=?'Q4Z1*

*MI3AVW#UC0QUEOT4W1RHBMEJWO1[7(J9IR(145R>U$,[\&NRU)JILJM87B!M-M3248R045/(F6/F1$]J'=]IN(ZT;+OI:!:*2IWB=G:I1QR*

*MI$V./:.9[\+.C%PB(N<+W="YOYU<7.QL1O+C<#1,%6/^+$J^&B>B%NK-@=?Z M*HY*VZ:.]64<:*KZFG>>JMJT#|/>88^ MU6DDE25LD><*K'83.%5,HJ)C*=_7$?*

*N,+9NCT1>:/4UEIFTUMNLCHZF!C42. M*H1.9%;ZD>B+T3HBL5?$G'S;DW.PO1M+'4-'LTXWXS"KXJ8ZHY@-NG',M\3) MAOB9 #<`!C#9OXU-*

F]Q/Y3)AOV1DC>BMOM#6]JLY4?41(D[&_<2M]&1O[9%Q[',:I9X:HNQW\I^[ZM^R6?QVJL6 MN>=/:/MWOKEZGK[O:Z>\VNKM]5&DM/4Q.AE8OP EA>XU-E[C4 -5,&5,!E

*:KWJ;&]JZDO9_P"5%!]2X/XB%,99)L?^5%I#]2X/XC$V=3_=T_=I_9#]_<>WlT'N(G M\NG57^<$I_>M.IKGI(^.3LGJn1.F6*QAC2S:J*P9ZV-*

1L46Z:9GI#7R_P!G,Z]DUW(C;9F>OU?9\)RYV*L*=_I MU7\XD(T<8"8WEJ4__$X/X%)EI;.$H]MM'T6G;&>>>II:59%,+4YZYPB M)WN7P(<87YW,KZQM'DYUI7;#*56*

*MM+?)6V2S5-RI8Y5A?+"B81Z-:JMPJ_GFGK=4Z0O6BZ^.AO=OFMU7)%VS89OA M*Q7*U'=%_.N^HF'P/HGXV5W54_\ OS+_"_,!R;C,_+8MOZCQ?R\Y96\RJO)F*

MS,UEX5S)4]FE)IV!#/:FJRHF;4+AGVIZ2(KO6B.8U51>F$7. M4Z&.9FU8URFF(WW>VCZ+:U#'N7*]MIB=H^'Y]\(;#Z[UO1QUMIT_/)0R)EE M1.]D$;T?NKHN47PZ+T-*

:O4,BS5$UT;4RM,?0.#+MU4X]V9 MKCO[MU;FBML-5;A.D;IVR5%O9&O^5G*R)J_%5[E1].IF3WNJ>'C<'2%#+75 M^G)EHH6JZ2.EDCGY&XRY5.QRJC41%55QT)*

*[@<1VF!C*R'1^F!/I<%MK&LFA MCF!"&G14SRH[E]\MN4Z!+X*B'--]6J_MJ97!Z^1$3JJG4N"15'HG=RXP4#&PTM;$RO9$O,)&NX1R!%^6FFU5)5/=%$RLJ&QR4*=,-*

YU3JY45RXJT72UKRN"Q%Z M(WWZ.:L.9QYLXERN=IVF7);5PP;F76*.5FF9((Y$SS551#$[NSA6*_F3U?!-M%/OW#GN/IREDJ*S2]4^G9TYZ21E0N$[UY8W.FBWIL-*

*76P4,EN]Z.5L-12/D21& MY3+7-=A,HO7P1?17]W%35F9=%/:54]4NJMZ-I5^N<>U=F:_|*WW91<+T7U'T MVE-KM5ZWH):RQ62IN=+'+V+Y(E3E1^$=R]5]3D.K\9FC*/3.X])*

<&!L#+M2 MK-,UB81TS78<[V*JH585R=M*:(%QT%J.U:A;8*ESU;+S(U]LHIXU?*[F153#6]_1%^H^VAX M5MSYZ)TZ.:5<=(WU<#7JGS<_P"XI+O=O7.D)MD;J75590.K-*

0W9B4\,<:IVL MC(T^"CE^ Q%5,JG>KF]^$Q\WLSQ94&ZJ$L-,95LE;.ORTCTJNW9,J=59GD:.MK5Y4RF>BX7NZ9TISLFY1VENCE'5<4Z'IJ[_-B_=GCGI'Z(2ZCTQ=](W-]OO-

*MOJ+,5M1%6*HC5BJB]RHOW3>B]4/5%@/%KHBCU+M)5V.) MV:UIN%3+/8+!45M(BJWSERMABZ=Z(]ZM15_2Y+,,O;J6\6:KH:R-):.]@?!/*

M&]JB.8YJBLH(O!C9&HY6IZD1W,B)X="XPLZN[M7-JY&TPY'5]&MX=JG)QZMZ)_[#X"SV.XZAKV4-JH:FXUDBKR4]+$Z1ZHG>N$ M15.GT""ANC61_XG.P;C.GK8&K]7/E/I)*

**%1M_HK1,,BZ@LI=3W%$DJUE MJF-F;BKED*(Y M1$C=Z,>Y57JG@>=S,R*]DT6,.4/?&TG3[=BF]F7>=7="-,JMAM?Z+H7UEWTU M604D:AJ&LK(H&)AL:R-I-$]27/3/SE?*

*C;QF7)ICGS_5?:C%-6DX\5SM$S M3^DN[<':@;UH31%YBOULFM=;47%7-9.U$9R M+G+5-*FN[.3-7#O5\%S79Q:--BCM)BCX_FKTU$MU2]UL5[DJ9;K3R+!4>==R.*

*MDD:YB\BLF%3O/7'NM:WN+4NLK_>*9CXZ>X7&HK(XY<D_D6E#]_N4_=VG[*?OKN_P5T[F_EMZT_5FJ_EG'9-&ZNXA;?25HAL-MMGDLD='$RC>46+5+DYM^(KFG;?*

IU;]7IS56N]?W6A?;YJW5$]3/+5 MTT36H_MD55D]%,(F%ST0G[PN:2N.BJF;//;O026^Y-EJ))]>9$1S],XKW/B/1"-""7LQ2[HZS]^\0|O8;.ULLI*M|&>5RKR1KZV*

M^BYR_I41>CC=PK]5FQ-=RG:F(Y?55:IB4969%K'N35555.\=U//_/7PVB-C M-=[A4:5=AT]55-$Y51M5*K88G87"\KGJU"=?BY/:.DX8=S-+TYK$ MRU.X7O1,>KXW9/BZM.ZVI&:?

*K[2 ^P7.H1RTR.J4GBF5J95G-RM5'8SCIA<+U MSA%(SLJJE.M-[UB4]TKE.VPL_0NFV:XQKEV>Tg]95]1N:K7..\Y%1R+A47O0P3*YX-DJ& MGMB:LU<VGJ(YFO7.,)N&R->N&S*B?=*

*(Y415|>=.,IW6'|=8N13DV^.'(ZA@U MX%^;-?Y3]!>Y37_Z&RIRG4.''9_\>#<.*WU7.VS43$JK@YN?2C141(T7P5RX M^C<*IZ'M&WE7?;E"" .;?N>F+G+:,[O0 M5-MKHLGJ7"HG1?*

6>?H_0.H->U<]-IZU5%UJ(6=I(RG1.9K.>"1$1S)$C3F1<>.R0NWMTUO% M)K_6.HV0WZFLM+4U$L-5!5.CBCI(E7EF&\C47"8SW]Y.G2&I(=7:6M%*

MIXY(:.Y4D59'+CG:U[$[."CPZKG;3-.,\R]/4[=B.,FFNY-_;/KRY(/[JNRO>[^OUF MB]ZFQJO>IVU/1\AGO!WDC.'CA%GW7LT.I+[))#*7G OKG3DKY-/S4FH]3N:V-Z4]0B>MS7KR*

MK]#E4_IM9P1ZNO\ +6HU7(U%[LN7IG(][SG8 M_#Q17R\VMZ'S8N]GP3_9'2V4$MVN5)0P)S3U4S88TQ]TYW*G[JELU[N%)MVM-MU7UD+$\VLML?*

*^QB]W+,#$JHB_0TK9X,]/?BEWQT?1*F6LKDJW)C/2%%EZ^ST" MS;45HME\L59;KO&R>VSQ+'412/5C7,QZ2.5%3ICO*/5;D57**>N5KOV9LS18 MNWY3/+>?*

H@=IG_N+E5]HE-'6^NM+72PU|ML,5%<('4]KZ>F MG21&N^:$E*B+-|"DT;3H?:74=//.+78])W)D"8EIJ2GH59\Z-151>]=>_KZR M-*

G$_PCT&E;'5:PT7$^"CI4[2OM:N<]&1]>:6-RJ]X3.5:JJB)G&$3!-B[B57-M(JM\,HS,;5*+%5=%_CIY[!.0<*N@8=P=Z+-25<39Z&BY[A4L>F4U-UO=$C/=-592T?:)S-

25ZX1V/'E3F=CQY<$7?)\4; M)-PM252M17PVQL2.]7-*U53__"$^HZ=Y02I6/,NQPHO22\L+=>',A;ZH8U'0 MSY,;N.Y<9V@8-7[,W"XMA1UQL;DKH),=49E$E3/]Y%5<>

*MMB>H@KLC.ZGWBT.YBX7=IUVW?GBVWZ_U5(CJF]EQHUH^UT'LMK?G:/5K5=U!D4]KPI[6-W=W0MBGYDMD;75?=?R+A>P9 MC+?9S*K6Y_/%D6J-*

*2:>V8T%47&K8RW66V1-8R&GCQC]C61QM3O555$_=7H4^ M;G38]BU1&\3]=)T>G,HJR+]6U$?V5OZSX:-R-"V^6XW33$ZT$:*LE11R1U#6 M-1,JKD8Y5:U/6]8)Z\);_P#<]:/3_P*

*!)_+R"[Y0BRU^H64EUTK4VRSR/1 MBUS*M)Y(T?IS.C1B=.[/*Y53KWKT)4ZLILV_?KMTV[].VTNKT?%O+=ZN[BW.*-MIC\U9W%C^.;$UE_?XOY M",YC8M/W34]R9;*

*[/;ZJZ5TF5934<3I'KCO7#45<)ZSIO%G^:%UE_A$7\A&2< MX/JS;?0V@*5R:ELB:JNB)+6]I6,9.F558X4:]47T6JB+CHKLEY.1./BT54T[MSM#D(PJU25&N_*.VW3NJ*VVV/2[KY*

M0TLKHEKI)($F5N456(D;_1RB831%/J&WP24K)7/AFI9T M1712M7#FY3O3JBHOBBIW+E$T)SLRS$7+E/LRN[6CZ;DS-JQ=GBA5+9[/67^Z MTELM].M77U4B0P0LQS/>OW-*

GOL;(W4]THVOEAIVMUS6V^I=L='$KUZK#GFB-43QXFO-5V,#E M3OAARW+[9%D3](AMY.7%JQVU//X*W3].G*S9QJN6V^_Y(;ZPV?UGH&VLN&H MM/U-*

*IHY94@9+4GTMHV^:WN*4%@%M%7=ZSO6.CA616-7Q< MJ)Z+?:1)/R@.X"7G7MKTG32(L%H@[>I1J_+ +S(BHBIZTC1JI_?%)4\.FVUL MVUVKLE-*

*14S$K*NEBJZZ1I,OFF>Q*JN\43/*GJ1/KTJ[0MX]-RJ/:J6MG1; M=_-N6**O9HZR@O3<&.[=9%S.TU'3IW(V>5X3'KCYCXK7.Q6OMN*5U5]+ M3%,04B8YJIJ,FA;GNYI(UM]*

LN-_NM!9G539(:NS7"5)9&^#F]Q$R]BHO1 M>7#D7N[T/&,O.M[554[Q/P;'HS3+W%:MW9BJ/CR5E@^]W2I]+P:]O/XC:WSW

*M3+Y^TH9'121\K'(CECY7HCE1JJY]*O@U#Y4Z"BKCIBMQERCLZYHWWVG9H,,C M=(YK6M5SG+A&M3*JOJ0U)S<""^PM!#I]FXEYI6U%PJI'-M,96(J01-56NE1%^ MZ<[F1%*

[T:WHOI&OE9.-+;XY,^GX->??BU3^<_'1';3O"7NMJ>CCIJ,251302-MUI=-%3N7YV2/1Z?M3YS7>PVQIM;SK4>F*RAI>B+5LY)H6YILR1JYK5^=2=*

M&_7&39MF]2.7I0VA^H;Q"UKZIC:A((:?F3(KN5RJ[*HY41.B*G7*X/K-C-_M-/*

*$1IZO;%1+1UM,B1U]IJE;*G(]%1%1<8>Q<*GAM.N5SCV]D]I_A5<=,I^&O<^]IV3P:.N$T,C4>R2/E6.J*2/|F'|53M8D]BJK11 M+(V)LU1RHCGN151]=O,K/)Y)G M9>Z?*

JU/U_P#$P&U>RKMC&BI5'M?!HXN!C96,:.-JGACO03]MJ]7T>KF:5DT[M<%U

*Y$>ENCA5\O*J91RHWPQU53H+^#/=Z.WNJG:2YL=5A;74SI.7&J2)I(C$JX:Q7(UJMWV823TE^;)8942:1X=-KY)VP-M>G+/#E61 M)S/D&ANVE:BT6:61(TN*5B3/CRN$>^/*

*MD3">*X;'<=/7&>W7:AJ;=70.Y M9:6KC='(SYVJB*AX1:;Q.[%6S>[;VIJ:2GC=]2BIW5%KKHD172*B?I=>'!?MQ.\5>|/|G\M'Z#U%N:L*7&EYT|OY)U^O)8CI72>D]A-N'4](V.UV2*

*MU4{JBK[W)E\G*W+Y9%1.NAL+%HIC,N>U^$%VMJQ]2,>W%;?J6S5EHIE MZM9551C9$3[ICO@O3VHII[9G,+4VO=4T-38K)47>ZM?$]?*

*3/K'PHBI$UT:YTQI+?';%8;@Z*ML5SI655-6_!6)7-S',Q5ZM%7>6VW+&^)'1OD8KE57)E%61%3E[T/6WG7; MUBOAI]J.Y]7-*LXF7;XKG^G5W_|-?*

BL$U.1RUFD;S2T\:R3S44T<;&IUJS3575M5'NQ\47XXW2/:QK7.> MY41K6IE55>Y$.NZ.X0]VM44<=73:1GI]>1O.UUPEBIG?M)'HI/I:22X#-@'' M#3S-QKS1LJ+E5/Y'(B]Z-*

;T7FC[WB XT+'LMJ1VG.M*SR:DO.+&QJXVU*4\5-S(BM1$^5R][*HI"]T14Z7/8W\^[-V;.-&^RDQ=(L M48!9.;7PQ/2$#M>[(@:9TOG6I-*

+UE#1X1%JVK51JV.J:2'[F"1JHDL2>Q.9JZD>B>:[8>=551VJ:VH:5;M68R ML.KBH<%BAD]8XXF.DDD5&L8QJY57"(B>]=AT_P>;NZBMZ5D&CYZ.%S>9C*

M;ZIBY'>SD>[-'7VN0D3Y/\ V.MZ6.;< M_F;GP1B^M3K_ !$<6%@V#GI;6MOEO[^](TG\PBE2)D42Y1'/D5KL95JX1$5> MBJN.F?

&_I%WMILX].\PV\31{'X:,K,KVB4'}K]K]6;8\0^@'5-CJK(-)>*= M8UF:CHY<2)GDD:JM?C*=REB'$A^4)K[1JG^3<],;'2,)'KL+K_| 4:J_DW%1?O7+ MN11VM.U4;?*

*JZ+"OI%G"N_AZN*F=_T4_[>.CYA/O.@[+:,7ZHW U?05-AL<] MW1+=74KZO\+45(6NDSER*O:AFBC8WO5RQN1 M$3Z5*Y^###B#LXIRO-KNENKJV6_U-'#*

*^C1G+&K7;EW,Y.GVQ.[U*637BZ1 M6:T5MQF8Z2.DA?.YK43*HUJN7&?"""ZK5]/7=%S2?"?NQK.C95V_1M;%2R8Y9*]\=)Z*KTU>]HU51D]HZV:U4<4*

*M]FOD;%E]SZW"K,Q.]T;TZ.QXIT7QQA%*_P#'YG#VW[*X]#Z=Q_A^UGC52&A M.WCMX:,=36:HW)TU2MI*B&1/=BE@9ADK7.PE0B)W.1R^GX.1W,O5%5T$B_P|*

*MFC*M+=+E<[*KP;LVZO\ L 7N4$BN"G8.DWBUY57&^0><;L36334]DRRIFZU5PA[MZ/H9.RMT?4U%)'U?);YHJ4PF4L2W]X@M.\.6F*:KI'UM5]L-*

*OM=*J1\Z.1.JJXPQB9:F<+UQ#KYTC3[=<8]=R>T_O*LF1JM5R.3"HN%1? !GI?2]UU!?*6RV.AE MN5TJN9(*6%2?RM5ZX128UQ-OR@7#Y;X++*FY5BI&TU7'.V*\QPL1$E:]<,G7*

*M\^CU:U5\4>F>YQZKU$=(4=W3:K&93C7)Y3,< M_1+XO5^Q6O\ 0%FDNVHM+U|MS'MC=55"-Y>9W-.35&KJ>"">QVN1+I*E3E*

*M8F|BBNYWIXM;U7EZHN.Y>XBI?>4PLE)/:BT55U-@;)K#A%*T-JS=+4NX.OZA;3T.M M2M/2TT4<,<:*IR*USG*K%=)\>^EC"KU-6;U%677M(*69ZJJD$!LF+E.YR*[\\F5]%$*

*MY3QM[V:#WQO^G;QI'SY;A1P2TE9)54W9-?&JM?%CTE5<*LB*BIXIZB8VK>!; M9O7EC=[CVEMDGF9FGN5GJG.3V+RNNJG3-[Y95: MU):6LB;]1U4"JO+(U%*

*[NY45/N7(]=4PI;87X2[?FNWO35\%'GQFV,.+5V8JH M^/6?ZIW^3!_*6U+ ^N&3^;4Y+"EOU+67RX6AB_P!ET<,$\C?SDJR(Q?KB?]1$ M_P F#^4MJ3]<,G\VIC[]-,)9.-^73TDG)!?-*

*&T[F-5?A3PU50]8_O:IOJ*3 M,HXLFYMW.FT^[%O#M;])Y((<=FA_Q%<1VHW1Q6J?ET5LUA_/=HU4D=_TK)K M-R_2[T-YQ?_6>KY&.1*:GBM=,_'15D=VDN/:B1QMCWWE1-*

*#=K:=&:PABZP M3RVNID3O5'IVL2?.BLE_;'9N G0WXC.'"QSO9R5-[EENTR?IU1L._3"&OTE MG=R=]-H[YY*3'P^=#5;^7*/;_KT=XH[U35UXN-NB=SS4+8EFPO5_+=TQ^HB?*

*R\Q*WABUO^+!6^\]U1Z20-U/YG"Y]]%C@@9"U4]BI& MCOV2D4_*@_ENZ8_41/YQ*;FG4=GEQ3/P_LL-6N=K@35'Q_NAH #N'S=]H@RI M@ !],&H 87N-39>XU-&%,F%"9:@*

(84P94P&4)A(?QD;AR]?V-'MS M$R/' 9 6^=3!WL\M-XVRN54]$4:K<;2DCN^)Z_;XFY^*]4>B?^$>O M+]:]>2=]>U8W.1/;@KLZO^)L54 M#\\=MIV3.-

*D4U1TZ2O51#8\6DJVGBGAD;+!*Q'LD8J*US53**B^**AY*+E M#YV^IQ.[(#(.!I[#A?&MK MY^WO#?K*M@E[.LK:=+93[<*KIW)&[U^:M&.>Y/TIV/! GRK.KI(-.Z#TQ')]I*

*MJZJN.[4]<36.CS[%I.3ZC95[D M152+*YCF5/'E=W^*>_&5*S4K.WL>]*>JWT?(IL9<55[$A?*=.6J9K=HC44< M,EI*:6IHIW^#'2(Q\?\)R?40^H=9K_*

*$)8MW15M$N\:.ZT7&)%22)2G>X MLEC=\9%PJ+W?.GO8KPUY/:'.R5S41?TKE M0]=.S;5NWV5V=IA>:UIEZ]_>6:=XE&(M>X&-,3Z.X1*V3$:[HD1GV7\G;J:Y7JDKMQ)*

(+19X7(^2V4LZ35-1C[A7LRQC5\5155 M>N>,+A4G3K'5^G]H]#U5WNLL5LLEKIT1L<343HB##+!S3H;_!YOY>4JWW.U]6[G;_ONJKAS)47.I=,D;G96)GP61HOJ:Q&MJ]-

*M+2.#-5;PTZ(7_P#%YOY>09UJ;,%;HGKO_8T>_&1J-ZY'28G]8<8XA,-W4^S> M\%YTG;[#;]^WT*0,;)4K*DK^TA9(O5'8[WKX>!W'AYXB[%Q Z:DK*")UMN]& MK6U]KE?*

SNA5V<..[''<[%PN'83]BY1,$ ..K/V3>K,]/M=`_-8CX#9'=RZ;[-MA6[4ML5]XXU2*LI&OPVIW*G:1KX97"*B^"HU?]/1M%W%IKHCVMH_-X1K-Z*

*MQG56[L[T<4Q]HW3'X[MJ=P9K-7.HM>]fK=MD\L7GN%@=(C&4C,Y1I61HUDJ:? M*F1SF_"57)E4@'_IP7:Z.U#9]QM(4=WMTD=QLUTIDD8KFIHK7QN3JUR>M.K5:*

MOKE\&M3OIL&?^AG_V MZFEF6^TS>SGOV6FF7JL?2IN1&\QNY=MUQY72_<0;)KVY+=H6Y?IG0T+E3EHO M2^UU#W>+E=\->YK7?G28>\.UEKWCV_N>F;DWEC]&L;UB-*

HCJT]'U&O5,M+[?=-[;516N1?%%13U-/3RU51%!"QTDTCD:R-J*KG*JX1$3Q7)8;Q\--V>[JY^_I==G.C'CI5/+[+%- MC-*

*N(M]=]]/:91K>W*9'5*ICTZAZ?5V?'TW.Q[,'#I\>""NWKW'N.JJK7OF M#:AL<4%%[D=]D$;&HB,YEG3.5R]3Y3K,$5NT[93:FZ:FA93SW&-8X*&"I1 M5CEF>[*([(]*J(WFI3.*

*MR."Q13BY.^T1OLE9PR<=:,P\MOD+M6?BAH+DL,_-_<_S?I9&O=66-TYQ_:E_TE8FI6A;O:#=.^Z?YGL?:*SFI9G?M"6)5YX'_#\BM7Y^AIY.*G=I.B:YNF/TS?*

*5.@RK%W+BFNQ7M#C\/RL?]N M6\FC>=]OZ)\[F<,NUUGV[U1746C+73U=:,*J:&1L.Y8]L3E14Z^M## ^/,:7,] MN'"QQ.7+]6IJXG)ZE6=[_P"!Z$!;_B9W1NUOJ;&LUK<9Z2HB=!-*

*"]S>5\'(J M..OH^?2;W"IY+1J714\K6U4,Z76F:J^DICVL9)CV-5K/^D*O(Q+UK'J[M2K?J*P]1QK^=3V-/#%Q,?FXYO]TKH>2~,E5N?\E?]/MO)0.*

M<KW5TWW#+;&Q?G67[_%4Z#QS<..H]QH!9-5Z4MSKK6T\'F%;1Q.:DG9H]71R M-153FZO>UV.O5OAE4^JX(-A;WM%I.\W+4E/YA>KU+%_8:N:Y\,$;:+R[\V.B.5

*M7O7"=RN43.O)MS[\4;\^FSSM8-Z-7FY-/L{[[_39Z3RD59&FT^G:5RHDL MM\;*UOK1D$Z+_`3ZS[/@/KF57#E9(FN15I:FKB=[%6=[T_<>A'7RBFXE/?\ M7EDTI1RMD98Z=T]5R.*

]HE:O(!VHQC5_\8?;>3>W"IY+/]714\C6U4,Z76F:.MY?22?&]KC\;>QJM9^W/JS5&G1R[WM;RJ)UF](GEMM^;CW'Q3K#Q"USUZ>,.MZ9Z?M7-S_DGVWDV:=

*[M>ZOF^X9;8F++\ZRI/XJGW_:R<.FHIQKG9=5:5MSKK M6T\'F-;1Q/1)%C1RNC>U%5.;]Z.QUZM\JGU/!#L/>MHM*7BY:DIO,+S>I(M_P"PUN$]DV<]V32E)*V1MCHW*

*M3U7(f.)IE:O([VHQC5_\81)+/2Z)MXT;]94&N7:;N;7P\]HV>_T'_P >-/:J MC3_RK2X;7:?]@NH/U/G_)-Q3SH/_CQ![]4;?^5:7#ZZ7&AM08_YOG3_**MQ*

M6ZQ^M+]^"[_9S^O'2;_3]4MF6^)@RWQ.DIZ.@K[Z6Q+/R<'Y:FHOU(7^6B(`MF$L_)Q9_'1U'ZOQ57*K&$K80]12XE#W2]>9T<,E55U%1V4,,35<^1ZNPC6M3JJJO3"% MT=#_

*,1?WIO\!5[PB0T4_$QIEEJ=$C*WM4@E5B_.BIE/;@K=-N3. MB[5MOM_RO-XVIX+73.?N M-$Q9N2JKZ^F?%%2IGTE>YR)Z2)]RB\RKW(+-*

*=>7357=N\,?!.1:M;,)_]>UZ*B_7@N;HZ-E#;H:2-?0AB;&WKX(W"2P%/NF=-V^]HCTMAO-R=9Z&]MN"TR5WY(W/=AKI<-1I KZ-*]2*. M'TC<*UJHC,]<*F>,IGV$=-/.WTVVN;,;;*

(-96V>%W(VACIYY85QA.D:HYCDZ MIU1/%#QIQK5V9KQ[FWTGDVJLV_8HIMYMGBWIXYI+[H>3ZT]JT/<9]+7H

MBN915LBS4K_4WG7,C/TR]_YB"E[LM=IR[5MKN=,_^CN%',Z&>"1$15'M7#D7' M?Z\]Q;=LW6:KK]M;%4ZW@;3:F?$Y:MB-:W"\[N17-,T:Y6H8V1EO@A1]2K5ZIVB MJJ-

*C7N7&'+Z*BH=?3AEV!VIY7ZFN$,T[41S?=^'(QSOFC8K$?\ M5._;@4U MXKM!:BI]/S+#?),?.RAD:[E5LRQJD:HJ]$7FQU\%*L,9LKN)]S5\RW*

M:2,%0^LII&HQRKA72R/Z(GYY5Z^:RUFY7ES55_X2W-4,3O'YY3)AO=G6=M^%K M<7=V/TR(OBA]SK/BJV^VNL]/2U-T;=KI'

*S_4V])TVF)KGCK^`>2,=:UIMML!9&P5%3:M_TF.=E#1Q(V67"=[8F(KGKTZ MNQ\ZD*X^3B?MV\]166656>HHI;1U'ZG3:VL>U)975/27[I57V$?*Z*

*MNJ;I62U=942U=5*Y7233O5\DBKXJJKE5]JJ?P-[%TVBS5%RJ=Y5&=KMW+HFQ M;IBF@_\ ]?7:3W8U?H>TRVW3]_K+1123=O)%2/2/FDPU.JY$SW-3IGP)W<+N MC|M|,;16**

*{0Z2L<|SAB2DKI9;&*29M0Q.5[G*Y%,5%O[I6Z5L[KS8;C4/J8/,^5KJ97]KEBN13G6;M=5FY&WW-M8SI&3CV:,FQ5Q<7P[D@.#+?&\,LZ9O-OU%-YY=K+}$WSSE1JSQ2({EYD3"*YMJQNR[U*GCE5X=QY;7V_2>L+1J:VTI:9E\;*VKBB;RL{>6JLGJ17H_KCO5JK-MU554[!P>[#W/9W2ETJ[^UD%[O4D;I*5CD=YO%&CN1BJG179>]5QTP}X'%/*M##Z\I+KJ;3VEZ:1LD]KBEJO"YY72HU&,7U+RM5?F>U2KQYI_'S%CW?+_-+NZ-M/-JJ%1.5[_=OUZ_X1-AFDIY8Y8GNCDC=EKV.5JM5%\,=45%0M6X==5W_6NT-ME@NVI;-U-M3&G1DSZ\$*5B7[Q:U945\2KIBU.9-M+6NR&@9KQ-"R69N(*"@+7MI<+AO3N:U$ M5RKV6JGK4%]-4N1>KILT1O4\/u=NEMYI49-65M(^."!N?2>KU1M6$5$3*HB+U[D//$IXK4SVO#MW/?4[D49$1^&X^+O674-;;*"UP4C*^*5D,38D M=),U7.1J8RJYZKT*Z>'^CCH.)6P4L7Y#3W2:)N%ST:V3'7YL'8[QN"#2VD],M7*^0ZQN%NHZ"!U1*ZNIXZC*-3.$Y5CZJO1$\55#AW##^7QH[U^=NQG^]OR;6 M)11%/F[515O$PJM2OWKF5C47J(IF)Y<]^^$,.(&Y2VG9C6=1-KFR>YDT:..N%M3G:K.HOK3FR5:.|E+/.)Z58MBM8*B=5H^7ZWM0K#;W*>NCQM;IF/BU/VK]WM-M+=/T9 !T3AG;>#7\ORR?WBH_D7DMN.,}?3;1:<D8DZ=%[(UH\LG]XJ?Y%Y+#C._*$O?]^IOY9AR^9SSJ/R_5]\TCEHU[_TA7(6H M;'==F]$KWD[BTB97V0M*KRU#8S\IG1*?_D6D_D6GOK'.BG[M+]E-NVN_;^ZN M;>O\M_6J8_|OQ5_RS€M&UO!#=]3VJGNF]+FM@AG:DD=OAA1]1RKU]//1B]R MXP]^O"HJ'P=RBI)>*^=EBJ+58POLRO7Z2P/7<%T]M#?ZGL,BMPWA]#,RBD1W*K9EC7D5%\%SC"^L\\G*N6K=NW1.V\=7MIFG6[=T1CE^9C58COJ4[UHZHLM7I:VS:=: VR(@:M&MVTBL/L\>CRMPF$Q["LRW[0Z]U+J5]M33EVEN]K41SD]29R5^91P1&ISBF5YH]_M. M[D46>"B/ZS*M7>K\M_6OZLU7\LXGUPJ_E"Z2_O.O\M(0*WRA6GWBUHQR*B^ZMM2_K^>DFPVD^O_ "$G\M(;^H1_M;?Y?HI-_\)Y'Y_K"%/%)^ M7S[^_1_R,9*?@9_*XV_RZU_4V#^-(U15*U9NP5$MY^7/+J[LIN46JKN%331.T!0]fV1:QM6KN7[>*F)GDL27AOVTPN-'VJ^1?\ M214XR=:>T'>]-0Z>M--IVX9GS-IV\O.J.8B9^M3G?V1FY7RQN/[=O^J?.Z MMU_J+7$?]f3^J1J_]^3_-\=_ "6W4_\ O"/^]I_ 5(U?^_)_fX[^ M$\-*]ZY_WXK#]IO=Q_\ OP6W4V?<]O\ >T_@*D:O_?D_]\=_ "6VT_P#O!G[[M3^ J2]_]^3_WQW)EI. %<_]\6/]3^YC_P#?@M!V9,_VG]%+G_IR47\@PKGW M<_+8UI^K5;,_.'EC.S'Y3VB_#,_<2C_D&%K-M[<:V&X2.9$]D-6QC6M;W"(B*U53U[_$^4X'[<4USV^J].N=R5MJG=*UJK\. M&55-6)[_3]MJ+M#50LBJZ>D8LDLZ5BUL+7L:VHJXW.5'-PY%1&HJ]^>_P/#XOW6^Z;)W-_;PS34M33S1HUZ*O M,LB,Z?L7J1_V-X4[IK^IK^G5E'<[!9XXN6%SHTA])9#Q\/]LV8H:"H@U')7SULKF144M,C?1M2?WEJ8Q]W[#9IM459-,3 M MY3()#8U-@@,M\3!EOB!L "(&6^)L:M\3BB0 !/;&K> \Y"\|-F^2,Z MMU_]+7$?]f3^J1J_]^3_-\=_ "6W4_\ O"/^]I_ 5(U?^_)_fX[^ M$\-*]ZY_WXK#]IO=Q_\ OP6W4V?<]O\ >T_@*D:O_?D_]\=_ "6VT_P#O!G[[M3^ J2]_]^3_WQW)EI. %<_]\6/]3^YC_P#?@M!V9,_VG]%+G_IR47\@PKGW M<_+8UI^K5;,_.'EC.S'Y3VB_#,_<2C_D&%K-M[<:V&X2.9$]D-6QC6M:W"(B*U53U[_$^4X'[<4USV^J].N=R5MJG=*UJK\. M&55-6)[_3]MJ+M#50LBJZ>D8LDLZ5BUL+7L:VHJXW.5'-PY%1&HJ]^>_P/#XOW6^Z;)W-_;PS34M33S1HUZ*O M,LB,Z?L7J1_V-X4[IK^IK^G5E'<[!9XXN6%SHTA])9#Q\/]LV8H:"H@U')7SULKF144M,C?1M2?WEJ8Q]W[#9IM459-,3 M MY3()#8U-@@,M\3!EOB!L "(&6^)L:M\3BB0 !/;&K> \Y"\|-F^2,Z MMU_]+7$?]f3^J1J_]^3_-\=_ "6W4_\ O"/^]I_ 5(U?^_)_fX[^ M$\-*]ZY_WXK#]IO=Q_\ OP6W4V?<]O\ >T_@*D:O_?D_]\=_ "6VT_P#O!G[[M3^ J2]_]^3_WQW)EI. %<_]\6/]3^YC_P#?@M!V9,_VG]%+G_IR47\@PKGW M<_+8UI^K5;,_.'EC.S'Y3VB_#,_<2C_D&%K-M[<:V&X2.9$]D-6QC6M:W"(B*U53U[_$^4X'[<4USV^J].N=R5MJG=*UJK\. M&55-6)[_3]MJ+M#50LBJZ>D8LDLZ5BUL+7L:VHJXW.5'-PY%1&HJ]^>_P/#XOW6^Z;)W-_;PS34M33S1HUZ*O M,LB,Z?L7J1_V-X4[IK^IK^G5E'<[!9XXN6%SHTA])9#Q\/]LV8H:"H@U')7SULKF144M,C?1M2?WEJ8Q]W[#9IM459-,3 M MY3()#8U-@@,M\3!EOB!L "(&6^)L:M\3BB0 !/;&K> \Y"\|-F^2,Z MMU_]+7$?]f3^J1J_]^3_-\=_ "6W4_\ O"/^]I_ 5(U?^_)_fX[^ M$\-*]ZY_WXK#]IO=Q_\ OP6W4V?<]O\ >T_@*D:O_?D_]\=_ "6VT_P#O!G[[M3^ J2]_]^3_WQW)EI. %<_]\6/]3^YC_P#?@M!V9,_VG]%+G_IR47\@PKGW M<_+8UI^K5;,_.'EC.S'Y3VB_#,_<2C_D&%K-M[<:V&X2.9$]D-6QC6M;W"(B*U53U[_$^4X'[<4USV^J].N=R5MJG=*UJK\. M&55-6)[_3]MJ+M#50LBJZ>D8LDLZ5BUL+7L:VHJXW.5'-PY%1&HJ]^>_P/#XOW6^Z;)W-_;PS34M33S1HUZ*O M,LB,Z?L7J1_V-X4[IK^IK^G5E'<[!9XXN6%SHTA])9#Q\/]LV8H:"H@U')7SULKF144M,C?1M2?WEJ8Q]W[#9IM459-,3 M MY3()#8U-@@,M\3!EOB!L "(&6^)L:M\3BB0 !/;&K> \Y"\|-F^2,Z MMU_]+7$?]f3^J1J_]^3_-\=_ "6W4_\ O"/^]I_ 5(U?^_)_fX[^ M$\-*]ZY_WXK#]IO=Q_\ OP6W4V?<]O\ >T_@*D:O_?D_]\=_ "6VT_P#O!G[[M3^ J2]_]^3_WQW)EI. %<_]\6/]3^YC_P#?@M!V9,_VG]%+G_IR47\@PKGW M<_+8UI^K5;,_.'EC.S'Y3VB_#,_<2C_D&%K-M[<:V&X2.9$]D-6QC6M:

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{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|&1$17W+3!U"_@535 M9G;=|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|&VE6.H M[F]'V./DMN=4Q:*UQ9K[-"^IAM]2V=T4:X-2S:ETC>;.S3U?#)7T4U*V19(U1]OCL,S4;^?-,WIWV2'V(XHK9M)H9+#5V:LN$WG4DZRP2, M1N'8Z87YCG&^-YU+NYKE;]1T%O>C/2Z,;ZN MD1ROCW*GT-4A$!@\1+FG8]=7',< MV]8U_-L6NRIJY?6-TH-$\;UUHKW>]O4UO=74E5V?F5'0JV-M*C>;*(]Y5W-E MN55>]/\.B<[XB=Y,-O-=+3<[?:,]V5U)$^GF=4..[M&91S,F?ZI+[(\6-JVLV\M^G*NQUE=+323/66&5 MC6KS2.>G\)Q[>,7]-N=N)<|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|PTM>*.]6JJ? 17"DD26*:>K7>/S^3\4Z+E%5#PC0|.;5--$ M6XZ0UIOUUW:KT5:8AE3M+H7CVIF4+(=?Z>]'5+&X6JM"M^O7'OI&GH/7+&U*10QJHH]{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{)%CE@RO7LG[<-M(O>K514SW8RN>%@ZZ&[8HOT\-R-W#XV3>Q:XN6:MIA8%0>4*T%+$]U5CO{/)R MVPR&&1JKC.$7M47/?WICIWGR.X'E*#0)*"6#1FGJB.ID3E;5W=6HD;JG?V;%= ME?5EV/6B]Q"I3!7T:7CQ.\|UY5^T&=7'#Q1'VAYU[OE?]6[U=UNE7)77&]D=_M- /43+ESWKX_Z$[DPB'@@%M$11&T='.U5S75-54\VA]QM'O)J/9G4;KMI^=B=-MHWLZFBJ&JZ"I8BY1'-14ZHO5'(]*F5ZX547X<&%5%-RF:.XWAZ6KU=FN*[<[M3'1/G3GE$M)5-'&E]TW>+?5N7+?;S*ICOJ:>GUKY12V17%L-(;:K)M:YW1DUZU5^&<OIZ1$[*AHE?E*>%*7">15=GF^:L,9-LE9. M^O7:;@nJ+W99'1M210R-8^FD7X;4RF.1W? CP5%|:D=P*L6U7:[&8]EC:$\BW?_M !%-7M)-\17%!H[??2+.!VF+E07>CD66@KGRQN2-5PCFN1.JL[4W\C 5UEB/D]9(V;*W-'+C_=N=?\ J8"GS[%%C&X+?3=T-MVBY=>3G]K? F.+:?H]7Q#<3>H-B-]J2EB@;=]/55GIY:BV2OY.5_;3IVD;NO*.M[")X*BHW"IE$5/(?Y1+0+:.!9&6'4+]M&](5A@1O-A%QS=KW>W&>G<<2\]H4]' M]VVYR=M'"!_+U\&OSQM/LWK%-=<E]HGM']3\=EU(^957]6M/ WQ\5]9?#U>KP*\S"E=_FPL."@%A9LT6*>&%WRR.J]DUSG3U=<|MC'7YRNY3!H7-- L7:]F%OCZYF6*.S!]WCZPDGOOOLZ@W6M%5I^R M4"::J6N>F$;Q>F6HF5ZHJJBJBQI7O\:)!?SFQH;MG'MV*>_M"B- H5F1F7LNOCNU;RG'M9Y0VV46G;?;=;62X2U|/&V&2Y6US)4GPF$D>Q!F] MUR]%7"KURO3N<:*#B^TQO1H%NF\'8]K3N\YC?/+BL<7(KM9==F;%S^]&I=D]2+=]/5#,2M[*JHJAJ-MN@J6)U1'-14ZHO5'(]*F5ZX5468^F? */Z0IJ./W=TW>;=5YPY*+LJF%/;S.< MQW^:25^FIZ9&!9OSQ51S>6)]N5AT\-NKE]4[=<^4@M;+;(S1VF*R6O=T9->U9 M'%'T[^2-[E=USTYF_/X$*M8:NN^N]0UU]OM;)<;G62=I-/(O>O&W5R^J6VI/"W<|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f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`!24Z*VCME+E(*9]]^$55RYV$YG+U7">"(B> M*F.?Q>V5JF3ET\%=7L_"U4V-5+!)5=S!W'87B\UML3&RW4LC+YISG5ZVFNIX,D;O?'OW<>KCM5;2L@L'E.-#5=(SW M8TM?K=4NQS- H^PJ8VY_/,>Q5 ;G\!0^4]T92T3_<+2=\N-4G1K;]8:6)?,S-`M?(N/V?&*B\S6*]D:YSG M=HYW,BM[NCCB\]IE3AVHO3J?'B/8SGW]L>,>9]F& ;S0:J8,J8 :FO] M-&%[C4V7N-0!A3)A0F6H "&%,&5,!E "82&]FQJHD8[TP?P5.53^Y_.1OB2-MF"\P $@ "7ODP;^MKX@+A;G.7L[G8YF(U.[G9)$]%_:H_ZRU,I|+)YUO MFO%/I:)%_P!|P5L6/F19'|+N%P*=V#A-7B(R=X]XA]T&J:L7;X3+8 %*Z0 M-]KX%0/E#;1.;BHU/(]KBH MIJ*1/F\VC9_"TM_1"[#RFEI?;^(R&J5%Y*ZR4TR+X='S1_7Z'[]%WHT]9/Y2 MYO78WQ?SA$P_'=/G - HOAG|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|/<&A MN: @ 2PI@RI@ - 3(U4P94P9 :KWJ;&]ZAE "1ST#0W-")9_T9 M) (YSM#53!E3'^C(WC?=.T] $H:@ :&YH$P&JFOJH(8 2+W*:FR]RFH2 M@VEJI@RY?2QXF GN84U-G?P&H3$2&]]ZFWL\35>]20 &@)D#0W_P#H.?\ MU$)VGN)0&%,F%(9, $:]H.:]$L #53!E3\4HGMI'<]+[QDPO<-HGE+,F9IG>)YM>K"FILIJ$\A3)A0. #53!E3 9AH;F@8P ,M@-U-C4R MD 3N;-5,&5,!/$!2 R0PO<;FRIQJ&4!H;FOU>L,_!1$;=6#"F3"ADP - M -5-C50GN8 Z$0 ,MFH (V0&AN:$@84R84#4 84P94P$!P;]:&]@A@ !D MU4P94P U-C4 ,+W&ILO<;@#"F3"A,M0 $,*8,J8#* $PD-5-C51(P: M2+TP;G\7KS.)3#4 !(D5Y/NE6HXK=&R(O2!E=(O^)S-_P#>+AF]Q4UY M-&TON7$K'4,3+;,:*NI?GU+V<7\,J%LR(<+K$Q^)_*'T;0:9C%F?C,M@ 4CI M0 !^XKM]JWIMT=SV]O[&+ MRR15=#-)CN5]QOC3/!*1?V)8GX$8?*(;$,%APW7:LC8KZFP54TCY4ZJ.6. M3Z$CE>]IBAOZ?<[+:)HJGIT_J]M3M=KBUTOU5&@ _^C/E0 @ !M%_ ML?QB^&?V")#EJA.>/L%:^]JVH['HIU1B=%])V5RB>BJ*#4^GK- M$^_"V6^=L4+9'N>[*1,O,YV41>[O(F\2O!?>=0ZDUSN,S4=###1]C-LG+%#E6\V<97D[_M &G,8VH|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{F5Y7*J97!A#3MZEC7)X8]6 M%S1\RS3QUT5&V M)'-PU>G5SDI;(]*1=4>38N5);Y9K!K."OJT;E*:OH5A:]4\.T:I/8G+!)KU M:CC45<$:U-NWH^971QQ1R0P,W*9/9ZHTO=-%W^X6.]47'HNPBH MO3HJ*BHY')T5%R>L+&B8JB*HZ*BNF:*IIF-I@ .PW:4I+G2UL=12+755R;$]D-'&CU;Z77+GJJ>BU.] <]RQ\4^GW*\G]+HG15 MTOU/KBGJ4MM*^]GCK.!T+'-8U5=AR2/5%7'1.5>OB;?!#&WB.+JL?1&9%-54 MTF6.EH:=D,3KH; M5154DK&TDB2Y8K)%;J^BN,JK<_2Q6JM|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|"2,1^)06.Gl,W6[3ZX@[(**DF]-M9(FLES(UC%]XZHBH5F=%%==$53_$GR>ZO!9>MJ|"77-M5-7]2BKH*!L:Q@AIWM> [FD:SHJKT^$>=&H8]544Q5SEZW-'S;=,UUT3$1S1S M##K.P(#O<=_)+XRWW:FM:VI(5?YQ&YW/VO/W8[L=FOUG]M^^'*Y,',LKKA=Z M:Z>ZCIFL2GB3]U!:+367!^]?(RF@?.YK:>1%=R MHKL=_]07)_:BI5K*R"[D661L.:+ZX M),ZLX$-0.2TG>KD]J:@]H[=135KH(}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`56BDL-CMME2I96+,EOHXZ?M>58<_/> MI%0GIQD[5ZBW8U5H*TZ=H^WD2.M=/42*K(*=BK G/(_P3V(BJO@?)T/D]9'6 M_-5K=L=8Y$RV&W*Z)]^*=945WS]/F-7$S+5FQ3%RKFL-3TK)R? AMU5LORU5>.Y.Y6:1_9LN5&CN1J^#9$7]Q5\,]/:IG6.1S%=ZU1<*OUE+II---5C>;&T?]OFK14,1] M/+41++/,UR91S8]

*MZ]$PA6XU%/XJK_4WGGR=#GUW*M-MTS9X8Y>URY\GQZF#N6U_"I==T-'4FH*2_M]TE'#4.D8D,L3W.3D>K>]%]G[HX5CX6M5W[7-WL-')"E%:IT@J+Q,BLAYE:U*

*MW*QO57.1'=R>S*IDWIR[.35$U=%+11.95115%$[5=\&C3_Z$M9. J1M"[L]9 M9JEZ^E;\,7V=)<_3^X1^W1VEO^TUY907I)JQS-<^FJH'*Z&=J*B+A5[E3Q14*

*MSU3UBSF6+U7#15S99.DY>'1VEVC;'Q8!WK,'@_U/KFW17*Z5D>FZ,=B/A2>% M9;AR+W.6-'-Y4?\\|/L/6[>MV8WN3LU<3#OYM7#9IWEP13!*'5G M=[''WR3Z M?*

U!#=)V"OQ)5 ,Y, ^K(GM/E=O.$34.N+%+6S7&&R3QU,E++0UD+ MUD8!BX7.%QU[T-.,['JHWX20Q8>^FO@FB=W" ?2;D:(GVWUK<]-U-3'5ST* ML1TT35:UW-*

&Q_1/#X1\V;U%451%4=%-@5$3-6"3_2+N3:L3$5U=3%T_)S{J MJLT[Q"+QJO>I_:HIY:6:6"9CHIY8WJQ['=Z*BX5/H4[OMKPA7WJ2*

MW15B/=')/"|]SD:CE:CL\)>7/TDW+]N53%5R>4L<7"OY5;**2HIV\K%=VD:N;C\Z MJJU?:BEAVY:"O4VKK5%TUGP)WVU6Z M;]T]?8+U,Q.,S.H@\WD#7D=0[/V^MQ&FK-*

AJJ6IBD@-MJ(7K')%(U6O8]%PK7(O5%145,+ZCNVS_ QZAW7!VM:FCM=++++0UD+ MUD8!BX7.%QU[T-.,['JHWX20Q8>^FO@FB=W" ?2;D:(GVWUK<]-U-3'5ST ML1TT35:UW-&Q_1/#X1\V;U%451%4=%-@5$3*-6"3_2+N3:L3$5U=3%T_)S(J MJLT[Q"+QJO>I_:HIY:6:6"9CHIY8WJQ['=Z*BX5/H4[OMKPA7WJ2*MW15B/=')/"|SD:CE:CL\)>7/TDW+]N53%5R>4L<7"OY5;**2HIV\K%=VD:N;C\Z MJJU?:BEAVY:"O4VKK5%TUGP)WVU6Z M;]T]?8+U,Q.,S.H@\WD#7D=0[/V^MQ&FK-AJJ6IBD@-MJ(7K')%(U6O8]%PK7(O5%145,+ZCNVS_ QZAW7!VM:FCM=++++0UD+ MUD8!BX7.%QU[T-.,['JHWX20Q8>^FO@FB=W" ?2;D:(GVWUK<]-U-3'5ST* ML1TT35:UW-*

&Q_1/#X1\V;U%451%4=%-@5$3-6"3_2+N3:L3$5U=3%T_)S{J MJLT[Q"+QJO>I_:HIY:6:6"9CHIY8WJQ['=Z*BX5/H4[OMKPA7WJ2*MW15B/=')/"|*]SD:CE:CL\)>7/TDW+]N53%5R>4L<7"OY5;**2HIV\K%=VD:N;C\Z MJJU?:BEAVY:"O4VKK5%TUGP)WVU6Z M;]T]?8+U,Q.,S.H@\WD#7D=0[/V^MQ&FK-AJJ6IBD@-MJ(7K')%(U6O8]%PK7(O5%145,+ZCNVS_ QZAW7!VM:FCM=++++0UD+ MUD8!BX7.%QU[T-.,['JHWX20Q8>^FO@FB=W" ?2;D:(GVWUK<]-U-3'5ST* ML1TT35:UW-*

&Q_1/#X1\V;U%451%4=%-@5$3-6"3_2+N3:L3$5U=3%T_)S(J MJLT[Q"+QJO>I_:HIY:6:6"9CHIY8WJQ['=Z*BX5/H4[OMKPA7WJ2*MW15B/=')/"|SD:CE:CL\)>7/TDW+]N53%5R>4L<7"OY5;**2HIV\K%=VD:N;C\Z MJJU?:BEAVY:"O4VKK5%TUGP)WVU6Z M;]T]?8+U,Q.,S.H@\WD#7D=0[/V^MQ&FK-AJJ6IBD@-MJ(7K')%(U6O8]%PK7(O5%145,+ZCNVS_ QZAW7!VM:FCM=++++0UD+ MUD8!BX7.%QU[T-.,['JHWX20Q8>^FO@FB=W" ?2;D:(GVWUK<]-U-3'5ST* ML1TT35:UW-*

&Q_1/#X1\V;U%451%4=%-@5$3-6"3_2+N3:L3$5U=3%T_)S{J MJLT[Q"+QJO>I_:HIY:6:6"9CHIY8WJQ['=Z*BX5/H4[OMKPA7WJ2*MW15B/=')/"|*]SD:CE:CL\)>7/TDW+]N53%5R>4L<7"OY5;**2HIV\K%=VD:N;C\Z MJJU?:BEAVY:"O4VKK5%TUGP)WVU6Z M;]T]?8+U,Q.,S.H@\WD#7D=0[/V^MQ&FK-AJJ6IBD@-MJ(7K')%(U6O8]%PK7(O5%145,+ZCNVS_ QZAW7!VM:FCM=++++0UD+ MUD8!BX7.%QU[T-.,['JHWX20Q8>^FO@FB=W" ?2;D:(GVWUK<]-U-3'5ST* ML1TT35:UW-&Q_1/#X1\V;U%451%4=%-@5$3*-6"3_2+N3:L3$5U=3%T_)S(J MJLT[Q"+QJO>I_:HIY:6:6"9CHIY8WJQ['=Z*BX5/H4[OMKPA7WJ2*MW15B/=')/"|SD:CE:CL\)>7/TDW+]N53%5R>4L<7"OY5;**2HIV\K%=VD:N;C\Z MJJU?:BEAVY:"O4VKK5%TUGP)WVU6Z M;]T]?8+U,Q.,S.H@\WD#7D=0[/V^MQ&FK-AJJ6IBD@-MJ(7K')%(U6O8]%PK7(O5%145,+ZCNVS_ QZAW7!VM:FCM=++++0UD+ MUD8!BX7.%QU[T-.,['JHWX20Q8>^FO@FB=W" ?2;D:(GVWUK<]-U-3'5ST* ML1TT35:UW-*

&Q_1/#X1\V;U%451%4=%-@5$3-6"3_2+N3:L3$5U=3%T_)S{

*$D3Y6IG*LPJH[“(JXSG&5QT*W+WI MF\:<6!+O:.ZUNG1SH?/J=\/-1?25O,B91%[SZ#9*LJ.#=#[1DC| M!V.M?*UKFK[%153YE*.K2[=-F:J:MYZ[NQI_:/(KRJ:*K>U.SM,=Z4W&-P^V MZJT[5ZIL-*RCN5(J27&&%O*VIHB541TJHG<]NI.+NRVF?M=`MJSSS'TJ6FJ67/Q>QW+'2(K6QHOS.=S)_>SA9*_R>SXVZPU6Q53M74<*M]> M$D=G^%#GN-;[T'/F6VR4L43',\4:]C4<`MU<=RKGKWHJ=#N'E!X9WZ!TU(U5\W;K?W$<04*W3L6U.IBU')E/!>O7VY*-MT.*%,:]ZR_PMG\FPGOPS0STVQ>C6U""^FM QZ9^(JJYO^2J$#.)FEEK>(35U/-M3QNFFFK8V1QL3+G*L;$1$3Q55-;3:8HR*X[HW_5O:]!?>P;->W.9C]$BM*<;-M^V>F-(T=DI|=]>VVTB000NCB>Q_(U$1HnJ,;=]7U:BBU MO+*9LDJ+';J:WPOCQG/(G,QSUZ8Z\V>_JA(S:C@MT?I&R4]?K*%M^N_9))4- MGE5M) N.JU&HJ*C9G;!);/3-N95OC!6V"WLBBRGY}>1') M[6Y(IJL<=46;?'/U1-O-BU;G*OQ;B.Z.KMVU^H+CK#;VQW;]4#[9 M[U=*R+;'7,6XVA;5]2&E?117")96T[WHYS$1RMP]HG?T*V.)"3M=\M:.QC_= M:[5^A$3_##2Z9F_73,=XYJZRFQW.VIH;>4M:C$EM=[MH$5\3ESZ$K,.8OM3*M7VY*1M::.7J-%ZMO%@J\I46ZJDIG*P3-GN+S&V44ZJH+Z:HOM:BHW]B5^<-1NX'XX^\&H+K'+ MVE#%-YG1)Y;V.?HHY/8I4<_]F6*\1VX'XVFSM_ND,O95\D24=`AV'=M+Z#5 M3VM15=^P*L7>/M7:[T]]+MSJKU5?'*J0SW$U#Q,Z7O514U\MU!%C^9LMFI63 M4O*BY14[-BX;CXZ(OK-N'OC/?M[8]33>K*&HN5J&I%25M&].FAC3HV-S'*B M.:B=RHJ*B(B87PE9I/B.VWUJQ$M^K+?',Y>5(*Y_FTBN]2-D1JJOS9-":+F+ MQM2QZ*+=W@F/R1[TOQ_QVS2-/3:CL%72^V2CN7:-3DJD:C9FIX*V5OI(GS+A2N#B#V@=LMN+4 MV*.H=5VZ:%M90S2863L7.Y>5%1$[DLM-NX]5B_NG*8-NG*R*YNQO+Z1]]^Y@85JWCSMOWQ_WO3/X?N-"WWI M3ESBW'NE#:,:C0N9V-6C%;YVQW-G[6U%]-JMZ]8PYO3HN8_\6^M=:!]B:WH,_M`+JW5,\M.L-Q7S\#'N;JBGDA[(9(O[?"CE;K7)Z*6]K#LV;TW*M)VGX.9O:GDY>+39NT[QXMN:RG@_VEI=O-JJ"Y34^+W?8F5M7.[JY(W(JQ1]>`MY$8Y.I%SCE/$;QH7:26L]_3&B64K5M[U@JKG4,]55F3X;(VJN$Y5RU55%ZI MCHB=98:(G@J]%V66F1&T\E!"Z-$\&K&U4*F-RH:FGW$U7'5NYJN.ZU39G=V7 M]LI[F7ZT4J,*W3EY-=5[FZ?5+]>G8-JWC3M$)\?\ >],OABXQ+EN#JR+2FL(J M2.NJTJ95>3+EA1MF&>KD^HXV=H:36>VM5J>EA3IC&\4.W M25]862GSF5CO6C457IGNV5]%4A-L#'4J;UZ&;2KB3W9IE7'Q$E:KT_:HXLVW MHFAAV@UL^HQV+;+6T?E^KPTKEI_P#/(5B%L_#OUV-T,GC[CTR_P#5 MH5,)X)XEM'#W&K-CM"MXU*OT+$U3:UGW*(;7[+1_JW/LK5X@_P O#7/Z MK5/\HI9IL5^4GH+]0*#^;QE9?$'^7?KG]5ZG^4<6:;$_E):#_4&A_F[#4S_X M>TWM"_C,C[_W5@;R4\M9O9K>`"%G;2RZBKHV1IXN6ID1/K4M*VRT';]KM!6G3M]"UC(;"G:V21]8[63&9)%)RJ238[%NL)GJYNJE2MUR+NWM1,[?UE7_NI MQRZXN^K*Q-'U\5DL$=$KHZ9K;6.,2=8.7$DBR-7"N3KRIC"81{IQ)=^3B@J M':UU?,S_`]VWQ-?^F=*JM_<1YN9N)9MXN]%.TQWJS2M2R;V?PUU3,3OO_P^_M]\HJ^5]I;]5`?R+R A/ORCOY7YEOU4=_(O(^&WI7\-3^;1_:'^/J^T?H$0\ MR?>U=++>[Q>=;W&G2?W->E'0:1Z?GFL*M-,2QWJ7M/6N8851?JZ?L2-4KJHQYX6.@6:+N;'&\[C#XD[KLQ3VVQ:,;"R^7 M*-T[ZR=B2-IH4=RHK6+T5SEYNJHJ)RKE%STY;PO\8NKM0[BT&F-.:5D5WI+K(ML,%9YNR&6"9C=;.70VI:.AU!2TD]UD!$G@=_M4VE:M4A5[VX1Z,7"B*]=>5$; MS*M=B_)CIWI'C3G'1N;;]74USNMRAN=H65%]+4VDACC=`GJUCD:CVKA5PY57JMG7/<2.\HK*Z/9FS-1>C[]"U?F\WJ/\Z(5U*>NFXUJ9HJKIWEX&9%%]4 MK:(VG\UT]7346J-/305$+.JW7"F5DD3T\&2*1N%:OL5J_NE.5VIH$MMVKJ1'* M]*.9\//ZT:Y4S^X7):(GB=-/-7ROQQ ML15]<^LX+4<;^\=WU Z>AO<=,V63,5LI;=`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`TZ97+47N4ZBK(MTU1155$3+A;>+>NT3^3KBD3WW

*F.OFIJ5]GCDYGMH8GI/*SQ3TNC%7!U|+'@<9VOXG]=[4V]+;;*\"X6MGY'0 MW2-T1<73N8K7-Z6]D:¥, ^BSLG+*
M_1JJ#U^@>+7>V^FH+#9JFB;00OD>SMZ9'OR]ZN=Z6>O55[^ISO6.K;AKK4 MMPOUU=&ZOKGI),L3.1JN1J-Z)\R'OAX%RQ=KX^DQLT]2UJQEV;=-J-JJ9WGX*
M+8+W;,/7VBJ^@BK/(\"NU_^%M53.1?M_JF%Z-M]_B>-K#R\;J;,6VTMN_JFFYUNFYD1/%3W0GUH73-NT9I2VV"UO[2DMD#;5';
MM[=OMES7W2OMDRG>CX,G]BG|=N^>)??6V=[M]!?:+-A#-!4U3ZR1U=#VSUE>B(\>95SUY47?SY3YKXE,MP9 M"VF62EA2-'-
*:YRHJIXKZ6/F1/4>^!AW<;_-5?.):>]ZIC9V)3;MQM,=SZWA=-MW"_&ZWDLU7-)R6^N>MNK.N&I*J(UR^I&OY'+[$4LZ=0TT]3!5OA8^>%')%*
*MY,N8CLUBJF>5Z(N5:N%1<8|H]+N;K6;<77]!U)-5(ZX53I8VN7*LC1>6-[_I6- M:GT'RRG08EGLK&^]Q6HY4Y.77=[M]H^T+++J-NJH-=Z&I+O!{2EEE@K(4;)*
*MS4[99]=ZM1'QJYZ*YKFYJF>].!%(Y:KX!-9T5\GN9!<XYRXVES_M$M5,Z6-9K. MN$>U&JG1,)EQO1OBNPG9]\"= [IZJVSN#]O35Y]+:IZIVL+'(Z&7&?AQN16NZ*N*
*M,IE,!,'-Z'C[W$IH7,FMU@JUQRMD=3RM7FZ=5Q*B*G?TPGSE5.-EV*YFU.\3 M\70Q&FY=JFC*HFF8\/_ E7PT[07+9;04MEO5U99>B)E>[Q6\"&IN),ME=*
*[N=E:IF5%):*1*%T[%1622\!G287O1.9&_. MBGJ]?\7>X^X%OEH)KE!9J*1%;+!:(EA[1%{\O&-NO7DP:FQJ7D.16.<&N\=#KO;2AT|//&V_ MV*!M-)3N7#GT[?1BD:GBB-*
*Y6KCN5/;F?0[Z\%$&Y6]JO4FG[RRSUM:O/5TM5 M\"LD,DF$17M5%RQ53.>_*KE,$$+-|]\"YZ7NE/<[17U%MN$#N:*HII58]JXQWIZ*
*MT5R1>GCVF55555RN4SW6@O<<^:%|K/6E!IJTSL]*2OH-ZL2B7T5]7*B..B^/(C43*?M=.5/_^1USQB.EZZUTT3[G!9*.>39XW0.B?;]>TXGG.5[U7.<_[*
M=^)@W:,O;7YWEJ:AJV/7CQB8E&U/FL1X+=ZJ'6FWU'I2NJ6.O]CB2G;%-MY$=/3)E(WL1>]\K<;=ZN5%7O/Y;_<&5%NOJ.74ECNR6\U*)YW%-&KX)W(U*
*M&H[HJ*QV$ZJF47'W+U7;Y*.\"IH++!&Y%:Z6U0.9*K5_/O>]6K[6X7VG!JFJFK*B>I]}I)ZB9Z MOEED<; IVBKO=#X<-74 MNA|[M)7>NE;%1Q53H999%PV-*
*LL;XE>]^)SY7U(A9IN=H*DW0V_O6F*N1T,% MR@[-)FM1RQO14YSGI[<*B+ZE3H>'H/BSW VXTG0ZQ7Y26@_U H?YO&5/ZHU'6:OU)<[Y<%8M=*
*<*AU3.L;4:U7N55541#K^F^,O< MC2VGK99*\"IMS*\"W4L5) UU&USDCC8C6HJY[^5OUFUE8=V]:MT4]85FF:I8Q_ MF]TT!N1]/;&]MNVFKG+;*O'+)R86.5OBV1BHK7HOAE.G?*
*T7J>V1@3?LT MTQRJAX8&KQAY5=<\Z*DN]TO)_P!1?]8UMTTI?*2@MU=,Z>2BKHW?:'.7+D8K*
M47F.E5PBXOW95#N&P6SMBV!L<>G(IE'6Z@NBNJZB0?A-^H/E1>1B=4C9SHB M95>K\H[L$27>4%W)6WK E!]DW+CSE*695[LBY-\"S%%?5S.]YEO.RJKMOH$IN
*S=^ET9K*OTI=JIE/ M;[YRNI7RNPUM6SHC,^':W*=?%C4\2+(1RHN4547IW?[=,*>]^S&1;FW5WM;\" MRJ\.]3>CN6><3_#7!OQ;J*HH:V*V:BMR.;3U$S%6*6-*
W58Y.7JB93.Z\N5Z M>D6-EZA=*)B?WQCFO=^RWE2HI*1[Y&=V519)'-]?W/C[,E#3BYMNF,%$QM+L*M0T]|56MRG>]JF>53Y' MR=6?Q[KQC_F&?^]-*
*R01UTU*ZCQV,>OF8TL)PZXQ9L[[U2 MI(U&U.?3DQ3PT4_#X)O^47_*;LF._P!WH?YO4E=RG5-UN)36N\M@IK/]2:BE MHZ>]:6.2GIDC=YC6/:BYSWS-%?*
*5XZMFVLS*B[;Z+FM#?\1K M#ZO<^#^2.:5+VN]0Z;WCI+Q4M1]-,[^VKE.J9RUE0CE^?IU>ATRV\<.YIKML% M#!4VQ*>GB9#&CJ)%5&M1&^OV'|JZLDN-;45[TG.5?*
\YK86%W]4U2SE4VHM=:/\ AQ?F M=E%^8@3;?)X.^GU$M-67:STML;)UN,]_5'-7C533:VVE97]2TI,HIN9%,\5/ MCGY.B95^/NESS+\Y5SQ6VZ2U<0FMX9
*MG*WGK>W3*=Z21LD1?JIWM2LOFH/-77!#:99*61(FN:USE153Q7TN_U80|\ M/\O8IZJ[OGS&M/4M5QLS&HHMQM.378[1)C:W2^?_-)'H_P^081UWWX0K?OU>*
M(]GY=FIJY;G:5A=UG\"OVZ+%VB9I[_HG=PO]+L&RX7 M.MN#+OJ*NC2!\|4?)#!\"BHO9L5U7*HBJJ_%:F$PJKR#RAN[]#-1V_;ZW539Z MQL[.ZY]D[/8HC5[*-*
*WYY>978[T1&+XHY5BYV\KJFW4S^_MU7*87\"R2/Y>N>J(CD\%)2.=765%PK)ZNKGDJJJ9ZR2SS/5SY\"jN4U_)-N? M_*/_ ,,1CV@WZU?LC[K+I>6DB=*
*<^Q\X\Z@[7/9_+RY7I^2.^L;O;|:KWN|R MEU1+22NMG;>;^.:P=ECM.3FYL+U_(V_4>OX*Y^.[?^7_AK>D[\'HK\)SXO^=TG M_)Z;QTT=%<-*
O;I5,AJFRNK;6V1R(LK53[;W/BF>B=ZHYR|<!XIN$&3>V-M4>JHM/7\"EMFH8XDIVV5O,D%2QJKRN5&JK7)G&<++E,)TY4*W:6L]+?515--- M)35$+TDBFA6Z6E+>E)4U-
MU\"QJ-:V6[4KG M2HU$^/$]BN7VN15|HC?PK]%^,^-.TO?#U3&KQOPV9$S3'24@>'/@;I=\"55PN MFXD=IU)4SQ=A\;TB\XIH45459'+(O.:3HC4PG3TNI\W3CO&I?:S0-9;[#HZ
MQTM'J=TG;W\"2CGE5M-\"C5Y(W1_(CG\W-W91&HN,.0\']_CWW1U/;YZ.FEM> MGV2=.VME,[MD;U[G2/=A>IJF%Z=,$=Z^NJ;I6SUE942UE9.]9)JBH>LDDCE7
*M+G.S127*I5$%TME9 M&L-523M171]YN'PS1KW+A>]+T5%Z9144M4]|HK7^HMN|NVYZ9O%59]GOQI M|,->F>Y!?@O3\GY.=3*2.P(R8B]CE5#H=*U;<.<#>W7&|%22^]*
=.!6#3VM8M5; M:ZOI%7\"}GQ0RTK:R.+F3\"M8KG(J-5%7+7<^>(N)):;MMTI+!#27^OI!U<& MMY9JN\"C\V9-X96-7O1%QWX7'J1.XKLL?E#MT;73LBJZ>PWA4QF:JHWLDT[
*M=[I;.KZ98B9MQ,;]VW)9%]\"HK;?8+A46JB]T+C%]U+1]HD;32(U58Q7+T:B MKA,^&2G'=6+52Z_O55K2BJJ#4594NJ*F*JB5CLN5?@HO3DQE&\O141,$G-AO*
M^!72Q2MM6Y#9+Q0+T9>:-J5,7LD8F$>WVIAR>IQZ'CBX8+%NU]IZQZ4[X[C M9]9JU\|:V-6JZ9R..UB<[4Q34_+5U^O_.1U_EXR(Y]MM)O+]39;I5EUTS+315=53^:R.J84*
*ME:K.9'=R^.6H7V79JOV*K='5RNG9%&-DTW:G2$VO*6?E6:._5!/Y*8KL=W*= M5W;XEM;,U66DM>HZ.6DI:GSJ-*:F2)R/Y7.SE%]3E.8456Z@K*>J8UCWP2-*
ME:V1,M5S514SZT53QP;%>-8[.OJVM4RK>7E=I1[JVIA@V9@V8VIM5K=3L9>; MMC;NZ2HGI.GKU;[=32K.M+:IHHF3
MOQAJR<\;E7EZX3)Z2^S$#4\H#NVU.5*RU8_P!O^D)Y0/=Q$QYI;_O>W_24-M6F9=2/N4D;WH_M7.PBLC8F,-3O15|H/*:|NI_]V6K_$&_Z3DN-M[>\VI=ZKU1W74TE-*
*+64M/YK&ZEA2)],YE=W)XYE39V5IMV-MQ-.-1M5]DZO)]*GXR5__%PS?S6E(]^49_++]L?\RTR?]9,J-M,)IF>ACHZFK=6R)44J2.[1S&,SE5[N6-I\ONONQ?]Y-2LOVI)();@RF;2(M-*
*M\"D;.S:YRHF/7Z;B;&%ZIE1%[XH&+T7YW-MR,7]B1,VHXK=?[.:96P:=]Z-EN\X?4(R]HDE[*9^E3YS=W>[5&]-MUVH+CJBH@FFHH%@A;30I$QK5YV,)XY>[Z#;MX=RG-F_/NM**
*[]5BO3HQ8IZ'PX_+YRZQ'R=F\U|>-#3|>UU-M0R*ZVJ22HH8WKCMZ:IZNK\IZG)ZEQI1Q2\&+-]:Y#]:QW2&S:A2)M M/4-*
*JF*Z\"I8U5Y556|6N1%QG\"Y1$3IC)6A:KO76&Y4UQMM7/07\"F>DL-33RJR M2-R=SFN3JB_2A)73WE%=TK+:VTE7JV&|2L;A*RNI'ME5>GPDBD:U?'N:GSG, MWL&_1?*
*F|C3U=EBZKC7<;,;-CE3_V$CN'\"A(M?#A=)=7ZMU!25]YY6TE,]K.2 MGI>UYR,3N^<&J857'6>*K\SSK_]29OX\"L[<'B@W!W+U):]Q>KLU*
MS;75QUU%;J>/LZ2&5CD]7+A53QP>_UIQL[FZ[TM=-/76IMK[= M<8'4TZ142,>K'>\"+D\JM.RKEVF[>]LT:OAVK-=BU3,1W.9[2[A5.UFX|@
MU52M=^V522R1M=RK+$N6R.3UW.%3O.J>PI5/M-M-Y1.:05T5I*_5%KJ54=-3IB2\"94Z)SQO1 M6N7&4SA%1%[T++.P)R.&WN.U4*G3-4C$XK5V.*BI+.\>3!J9-02):.=;PPV)[*
MU5OGE$KZF-N#XG(K7=%7\"JF4ST5\"RR.\"JS M318]VX53AZI11D57,FGBX_)(G67DV-=T.H*EFFKI:KI97R*M//6SNAG:Q=AMML!?;S'L?6=G3*Y0*;F8Q]OQJY$
*M54RQ7+T1,N7IXK#:W^4]W0IJ=[*BU:;JW\F&ROI)VKS=.J\LZ(J=_1$1?:?# M]E<;NZFY5OEMT!UI[#03-5DM/9(5A[1]]%:LCG.D1,>IV%\4*ZYBYV1$6KNV*
*MRVM9VFXDS=L#[_!CWW0M>XV]BPV>.KHK'1-M5ZB)V623<[WR85.]$5]6_M.U?63;X*L?8L:+ ^>N_GU05)>/M]?KZ_Z3N&VO+1M3HN@4M8*FW1VFA[3L6*
MST:/>G/(Z1V79^.]QMY>!77C46;7>AAH:JK=6R)4T]2O61S&,SE5[N6-OU&>1B7+F)18I M]Z-O)&)GVK6=7DU>[._FZOY3\OJS?K$G\T;H']46_Q7'S6[N\>-MH][=34]^U-
)3RW\"GI&T4,J6!(FI&USWIHBHGCS2.^L])H,65RV^U7:J1VAT;+ MG;9>V@=,SG8CD14^#)]LV1>NC$[&>NVS2O95%S.[>/=XMUM?&-^9IU$_@3?Y M5A6?
PL;PMV2WDLU^JI'1VB?IH,DK45?I'D5.9W1%>5S628[UX;)WGT.O.-; MJ]VOMEPC[=L-$C^U%1W1V?8?#,%[.UV^>MUTO;,E2\NM=2R5*
M,N<+G]B:6+B3CXM=&1TGFLLW.C+R[=>-$[Q'+[K>-;Z+TYO M;MW562ZDE3JBX?'+$].F47EYB4R4RO:GW.D]/55;Z^5&KCQ1>]\3;=F.);AATCBJL1'.1?BJN%SU0]\?'O;3]#3]
*M'6V&>&IM+D6.FFID3LG-8Y6>ACIRY:J{J=,=4*C,,;\TMK_'_?S?)Y)A9WPQ:.M7N6B=AM&6>\4[J.Y4U-BS4STPZ)5G*_E=ZE1'(BIZ\E5O$U>XM0;_;@5L+T=-M$Z\3PM')KVG>*
*(_R\]=KX\.WO&TS.3M^3F'F#*F M#KW!=P.J;&]@A@:]DU4P94P U-C4 ,+W&ILO<:@#\"F3\"A.M0 $_*8.J M8#* $PD//%<[F7]_:5V&JGK/X$L@_;^WP]CIZP7#55]M]FM5*^MN5?*
*M4.IJ:GC1,OD>[E:F5]J]_L+M.'O.\"CV.VHLFDJ9S99Z:/M*RI8W';U+_ $I'M_-E<-SW-:U/ B1Y-[AGFH4_'7U'2]F^:-T-*
AIY6XBH>687(CET8[;]50W&APGUFPVJY;Y9=\NA+K,OFSFY7S&1V56G?]. M_D7Q;T!T55C/RE^FKM)VG76F[C8+[0Q7*TU\3H*BEF3+7M7^!47\"HJ=45$5,*
*M^A49Q5<(M^X>;TZN@[6IZ*JI<4=T1N70.5Y3)AO\!O>/BCK/U;.G:\"0V;XFILWQ(1]F0 #[-P 1!T#8U-B)B.@&6^) M@RWQ&W(;?09;XFQ]WQ-AR_:.2)WZMF[P#>X!(*
\"883SZAN:&Y$P1SZAEO MB8,M\1]1L ,M\3)AOB9$_$#|\V-6]YL M$?0 &S?$R8;XF0Q[V6^)L:M\38$AEOB8,M\2-AD $@;FAN1 B1LW4R8; MW*9,D2 (AL AEOB;&K?$V,9 W-#
*<2 (&6^)DPWQ,@ !N QALWN4R8;W M*9![;&IL$!EOB8,M\0-@ 1 RWQ-C5OB;$2)D2&QJ;&) AEOB;&K?$V M&YH;@#9O<;FS>XGN1(\"#N;@ ,0RWQ,&6^(&P -*
[S8U;WFP1WALWQ-39OB\"M60 &+9O@>2&Z;MJ8ES(OF5&KD$ZR/3Z>5N4^*XC';+74W MNZ4EOHX^UJJN5D,3/C.54:W!U2R'0VE;16DI99:7\BHX&Q\V.<[N|SOGC[*
M_24FJ7N\"W%N.LNZ_9//|?)G(JCV:?UG_ ^CPAA/F-C57\"OL+Y3]RIL:KWJ3\"(#\"]QDPO<0R:@ GN&@ (PIDPI>6S $$ '1+53!E3!D M!H;FA$\"T -C9J \"1J@RI@)|@T-*
S0)CX/;3U1<-&ZBH+W:Y>QK]&5)8U=\ M%?C-5/BJG1?7DG@H3C#T+J2AC;>9WZ>N&,20U$;GQ[Q5LC4QC|,C5]A @&A MD8=O)YU=?*
*BO=.U>_IV\6^=,]8E8XF|&T4,WG[;]86U\"O7[!<*G-Z:(KU3P:B87U^\"PE4P:M&EVZ:H MF]9E:W?VFR*I)HMT4T[]\-YYY*JHEGG>Z6:1ZR/D>N7*Y55555\IL:KW]&6X AH #(#0W-\"*
(/H @#Y&KGKFMEOI6N:>M)515\"+ZN1Z,^O\"+1Y MZ[PX@[WW]:,$4L,>CI%3O7&Y15SE$=;EHO1]HV_P!,4&GK!0Q6ZT4$20T]-\"W\"-1.J MJ[^*]N555ZJJJY55.!Y9LB>TR<;]W?Q$1T $@ M-
*<'JM0:1U-]TRF99[8N9*NB M;G*]8S+&GK^$B8SS85Q#7\_YS!!KF(J.3&2,'$++P&Z(WE2KNUE8S2,JW]KU MJZ.)/-ZE_?\ ;HDPBJ]H\VX=EYC_P!%2/<#*
*MJ.\7#9N%L;6/;]>QRMMROY(KO1YFHI?!OVQS]%5\&O1KOSIS#QPJ'56[M%V. M*B=X<9Y34V;W*\"60 $'L:FP #+?$P9;X@; #9O M2 B4-@ .X#+?$P9;XD#8 !$,M*
M38U;XFP1(-]C4V;W&4H 1 W ! &YH;@ !EOB9.M<.=&4L,&>CI%3O7&Y15SE$=;EHO1]WC8 \0,M\3!EOB8HEL 0V;W*9,-]E,A$AL:FP0 #< 9;XFQ]W MQ-@ \")9;XF3#?$R#N &+<.;-
[E,F&]RF0 ;W@-[PCO; $ALWQ-39OB$,M@ #<-$0!L:FPD#+?$P9;XCN&P (&6^)L:M\38 B6S>X!O< D !,, W-#<2 M!EOB8,M\1W#8 $#+?$R8;XF1(&YH;&$ALWN4U-F]R@[F0
&(WO-C5O>;.! MLWQ,F&^)D([V6^)L:M\38(D,M\3!EOB!D #Y3)DB0 M!$-@ $,M\38U;XFQC(&YH;B0 ! RWQ,F&^)D -P &,-F]RF3#>Y3()#8U-.M@@,M\3!EOB!L_\"
*(&6^)L:M\38B0 !/;&K>|V\'\-F^):-\02R Q:.[-ME,F&]RF6HJN1$3*KX!E3SGAAWWA T#[NZS]M1U;?-2VAG+#S)T=.|%1%,.8MY*
MOVS5)GXZG/MCM\")M]MY;+,)'R5DC/,.OU]L_\N1?FZ-.8G0D3\"(%^\"PZ:)CG/.?NPJGA7:Z4]GM=97U4C8J:EB=-)([[EK4557ZD/.5#
M@\"%UKQ+!HB&P4\O+5WAZD)RKU2!BHKU^E>5OM17'A8MS=N11'>WL_*IP\.N] M5W1Y]R)VM=4U.M-576]U6>TK)W2(URYY&YPQB>QK41/H/1&QJ=Y13%,13'2'
MYZNW:KURJY5/.0 &;R !H ,:FRFH90&%,F%!WL)87N-39>XU #53! ME3 90&]]ZFQJO>L(@,+W&3\"]Q#)]_\">X: @#\"F3\"A/*

H90 .0T-S0QEF F!JI@RI@=X D:@ :&YH$P&JFQJH(8 2+W:FR M]RFH :J8,J8#+N84U-E-00&]]ZFQJO>H2 #0 $R!H;F@@) PIDPI#*6 M_\" U4V-5\"6*
!JI@RI@GN U-C40)&@ PIJ;:@ $PPI@RI@0=X !*6@ M PIJ;*:@ &4-0 $0&%[C)A>X,FH PIJ;*:@#\"F3\"@8 &JF#*F S#0W- MQ@ 9!J;&IE(*
D:J8,J8\">YA34V4U! EA3!E3 ; .&YH90 7N4!> MY3$:@ RD87N-39>XU,64!A3)A0=!4 !(:KWJ;&]JZDR ,AA>XU-E[C4,H#0 MW- B PIDPH9, #0
*#538U4)[F_\" !+4 #0W- !A3)A0-0 !A3!E3 3W M!JIL:J\"& &353!E3 #4V-0 PO<:FR]QJ ,*9,*$RU 0PI@RI@,H#^ M,KO2P?U5>5]J>,OI*]DPRA@*
*RBIZLF6\,MF.X&4]B'2]H.'+<#>^L:S2M@FG MH4?R276]^TT<7KS*OPE3XK4<[\Z>-=VBU&]<[0][5FN[5PT1O+FBI@F#PL<*
*M=ZW06DU+KUE38-*NQ+#0=8ZNO3O1>O6.-?C+Z2IW(F4E35Q)YK3.[\Q1+E%\")Z^_KXJJKU/<&R&3 MF-YF=Y=A3$4QM R M &B=WB#=<*
*>#6T,%?2RT]5#'/3RL6-\4S4)&' M=7R=.UVOWU-99J>HT7=),N[2TKFF5R^NG=Z*_.QJPE88Y4/6U>N69WMU;-6 M]C6;\;7*=U3NXGDV]UM(S2R:?*
2WZQH4ZM=2RI3SX]:HY51,^QKG$=M8[9:MV M_E=%]73%UL+LX1U?1OB:[VMHY5Q$]\"]H%FN=[=4P_/O#U>\W'CW'JB[S6W#?MEN%2ST]^T-
*9JKME:KJB M*E;!4914WJFN%/9N7 >]_[#_(A?OO7_ (KN1XH5 @N ^P#V*^13OOO7?AQ]@'L5\B MG??>N_#CTW9\,L/5W((4*@6^)DM]^P#V*^1*_?*
>N_#F?L]BOD1_ZUKOPP]- MV?#)ZNY'BA4\":-[E+>_L!-BOD2OWUKOPP^P$V^1*_?6N_##TW9\,GJ]D>*%*
*M0H+>OL!=B_D2[!{5WXF[/AD]7KF1XH5& MR^P*V- ^1;OOM7?AQ]@5L;\B MW??:N_#CTU:\,GJWD>*%2 +;_L#-C?*
D4[!{5OX&3U;R/%\"I(%MOV!VQ_R.7[ZUWX8?8';_(Q M?OK7?AB/35GPRQ]6\GQ0J5!;5]@ALA\C7??6N_##[!#9#Y&N^^M=^&'!JSX9
M3ZN9/BA4J9;XEM/V'&Q_R-=]]:[\,/L$-C_D:[[ZUWX8>FK/AE'JWD^*%3 + M:/L$=D/D:[[ZUWX8?8([?(UWWUKOPP]-6?#)ZMY/BA4R\"V?
[!/9'Y'. ^^M=-M^&'V\">R/R.=]]:[\,/35GPR>K>3XH5--\3});)]@ELG\C5^^M;^&,_8)[)_(U M?OK6_AAZ:L^&3U;R/%\"IMOB;%L?V\">R?R-7[ZUOX8?8)
*[)_(U?OK6_AB/35G M?W9/5O(\4*G 6Q_8)[)_(U?OK6_AA]@GLG\C5^^M;^&)]-6?#+'U:R/%\"IX% ML7V\"NRGR/=]]:W\,/L%=E/DF;/AD]6LCQ0]A!;_| 8+*
[?(YWWTK?PP^P7V4^ M1SOOI6_AAZ9L^&3U:R/%\"J%OB;%K?V#&RGR.7[Z5OX8S]@QLK\CE^^M;^&'I MFSX91ZM9/BA5&9;W*6M_8,;*?(]?*
OI6_AA]@SLI\CW??2M_#&7IJSX91ZLY/ MBA5\"UO[!O9;Y(,^^M;^&'V#>RWR0=]]:W\,/35GPR>K.3XH53@M9^POWUK?PQC[!S9*
M7Y'+]\ZS\,/35GPR>K.3XH55 M5^P&3U9R?%\"JMOB9+5/L'-EOD>OWSK/PP^P>V7^1[OOI6?AAZ9L^&3U9R?%\"JL
*M%JGV#VR_R/=]]*S\,/L'ME_D>[[Z5GX8>F:/AD]6F:7AD]6& M3U9R?%\"K$%IWV$.S/R1=]\ZS\,/L(=F?DB[[YUGX8>F:7AD]6K&3XH5=-*
\38M#^PFV<^23OOG6?A MC/V$VSOR2=]\ZS\,/3%GPR>K&3XH5=@M$^PHV<^2;OOG6?AA]A1LY\DW??.L
M_##TQ9\,H]6,GQ0J\;XF2T'[\"C9SY). ^^=9^&,_84[._)-WWSK/PP],6?#)Z MKY/BA5Z\"T+[\"G9WY)N^^=9^&'V%.SOR3=]\ZS\,/3%GPR>J^3XH5@ M
^PJV M=^2;OOG6?AA]A5L[\DW??.L_##TQ9\,GJOD^*%8/#?$V+/?L+-GODF[!V5GX4 M?86;/?)1WWRK/PH],6?#)ZKY/BA6$&[Y9]]A7L[\E'??.L_\"C[\"O9[Y. ^^= M9^%'IBSX98^J^5XH5A@L|^PLV?\ DJ[[YUGX4?86;/\ R5=]\ZS*3Z8L^&4 M^J^5XH5AFS?*
*$LZ^PMV?^2KOOG6?A1]A;L_|)5WWSK/PH],6?#+'U6RO%\"L8 M%G7V%NS_,E7?2.L_\"C[\"W9_Y*N^^=9^%(],6?#)ZK97BA60\"S;[\"[:#Y*O^*
M^=9^&'V%VT'R5?\ ?.L_##TQ9\,GJME>%9)L6:?87;0?)5_WSK/PQG[#':+ MY+/^^59^%'IBSX9/5;*\4*RC+?$LT^PQVB^2S_OE6?A1]ACM%\EG_?*
L_\"CT MQ9\,GJME>%9H+,_L,=HODL[!Y5GX4?88(1?)9WWRK/PH]+V?#)ZK97BA6:W MQ-BS'[#3:+Y*K]\;O*9^PTVB^2J_?*
&K_\"CTO9\,GJME>%9H+,OL--HODM_ MZQJ_PH^PTVB^2W_K&K_\"CTO9\,GJME>*%9[>X%F'V&FT7R5?[XU?X4?8:,1? M)5?*
OC5_A1Z7L^&3U6RO%\"L\%F'V&FT7R5_|6-7^%'V&FT7R5_|6-7^%'IB MSX91ZK97BA6>;EEOV&FT7R5_]8U?
X4S]AMM\EE^^%7^%'IBSX9/5;\4*T3 M+?$LM^PVVC^2R_?\"K_\"C[#?:/Y/+++]\;O*/3%GPR>]V5XH5J LJ^PWVC^2R_ M?&K_*
IG[#?:/Y/+++]\;O/2]GPR>]V5XH5JM\3)93]AOM\EU^^-7^%,_8< M;2?)=?OA5_A1Z8L^&4>]N5XH5JFY9/\ 8<;2?)9?OA5_A1]AQM+\EU^^-7^%*
*M'I>SX91ZJY7BA6P:.[E+)>7L-K]*O*/2]GPR>]N5XH5MM\3)9}AW MM-\EU^^%7^%'V'NTWR87[X5?X4>E[/AE/JKE>*%;8++)/L/=IODPOWPJ_PH^P*
M]\VF^3\"_?\"K_\"CTO9\,GJKE>%;K?$R61?8>[3_)=?OA5?A1]A[M/\EW??&J_ M\"CTO9\,H]5,KQPK>;XFQ8_|8>*
[3_)=WWQJOPH^P_P!J/DPOWPJOPH]++V?# M/53*\<*X#++?$L>^P_P!J/DPOWPJOPH^P_P!J/DPOWPJOPH]++V?#*/5/*\<*X M@6/?*

8@[4_)AWWPJOPH^Q!VI^3#OOA5?A1Z7L^&3U3RO'"N$W+&_L0=J?DP[[MX57X4S]B!M1\F'??&]_"D>E[7AD]4\KQPKC!8Y]B!M1\F'??&]_"C[$#:CY,_M.^^-5^%'I>UX9/5/*|<*Y&^)G*%C7V(6U/R9=]|*K|*9^Q#VJ^3+OOA5?A2? M2]GPR>]>5XX5R9090L:^Q"VJ^33OOA5?A1]B%M5\FG??"J_"CTO9\,GJGE>*_M%=_+&/L1-JODT[[X57X4?8B;5?)IWWPJOPH]+V?#)ZIY7CA70WQ-BQ7[$3:KMY-.^^%5^%,_8B[5_)IWWPJOPI'I>UX91ZIY7CA72;EB7V(FU?R;=]|*K|*:? M8C[6?)MWWPJOPH]+VO#)ZIY7CA76"Q/[$;:WY-N^^%5^%'V(VUOR;=]|*K|* M1Z6M>&4>]>5XH5VM\3)8E]B/M9\FW??"J_"C[$?:SY-N^^%5^%'I:SX93ZIY M7CA7;"Q+[$?:SY-N^^%5^%'V(^UGR;=]|*K|*#/2UGPR>]>5XX5X L/\ L2-K M/DV[[X57X4?8D;6?)MWWPJOPH]+6?#*/5+*|<*\6JGK,Y0L.^Q)VM^3COOA5 M?A3/V)>UWR<=]|*K|*/2UGPRGU3RO'"O#*&Y89]B7M=|G'??"J_"C[$O:[Y. M._Q^J_"CTM:^$H]4\KQPKS,M\2PO[$O:[Y.._P ?JOPH^Q+VN^3CO\?JOPH] M+6OA)ZIY7CA7L"PG[$S;_P"3;O\'ZG*/L3-K_DV[_'ZG*1Z6M?"3U2RO'M"O=OB;%@_P!B9M=\F_| TZI_"#[$W;#Y.+_CU3^$(]+6?#)ZIY7CA7P"P;[$ MW;_Y.?\ IU3^$'V)NU_R<_| 3JG\(3Z6M>&6'JEE^*%?)L6"?8F[7_)Q?\>] M?PAG[$_;'Y.+_CU3^$(]*VOA)ZI9?BA7T"P3[$_;'Y.K_CU3^$'V)^V/R=7_M !ZI_"$^E;7PD]4LOQ0K];XF2P+[$_;#Y.K_(]4_A#/V*&V'R=7_'JG\(1Z M5M?"3U2R_%"OPW+ /L4-L/DZO^/5X0?8H8_)U?\>]?PA/I:U\)/5+\+4*_MS9O<3^:Q1VR^U2V^3J_X]4_A:!]BCME\GO_3JG\(/2UG;;ADJ4\Y2R M>7_'JG\(8^Q3VR^3J_X]4_A"/2MKX2>J.7MMQ0@("?OV*NV7R>7_ !ZI_"#[M%7;+Y/+_ (]4_A!Z5M>&4>]&7XX0",M\2?GV*NV7R>7_ !ZI_"&?L5=L_D\OM^/5/X0>E;7AD]4.OQP@("??V*NV2R>7_ !ZI_"#[%7;/Y/+_ (]4_A!Z5M>& M3U0R_'" C>|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|*K*/2UGPR>]65XX5WJ8+$/L2=K?DX[UX57X4Q]B1M;\G'? M?"J_"CTM9\,I]4\KQPKP-"Q+[$C:WY._^^%5^%'V(^UGR;=]|*K|*/2UKPRCU3RO%"NP%B?V(VUOR;=]|*K|*/-ML1MK?DV[[X57X4>EK7AD]4\KQ0KI!8M]B+M7\FG??"J_"C[$?;0Y-._^^%5^% M)]+VO#*?5/*|<*YU,%C'V(FU7R:=]|*K|*/L1-JODT[[X57X4GTO9\,GJGE>M.%I8U]B)M5\FG??"J_"C[$/:KY,N^^%5^%'I>SX93ZIY7CA7)E!E"QO M[$/:KY,N^^%5^%'V(>U7R9=]|*K|*/2]GPRCU3RO'"N3*&I8[]B'M5\F???"MJ_"F/L0-J/DP[UX7X4CTO:\,I]4\KQ0KI!8M]B+M7\FG??"J_"C[$#:CY,_M^^-5^%'I>UX9/5/*|<*X5,%CWV(.U/R8=]|*K|*/L0=J?DP[X57X4>E[.^_M#)ZIY7CA7""Q[[$':GY,._^^%5^%'V(.U/R8=]|*K|*3Z7L^&3U3RO'"M\%C_ M -A_M1\F%^^%5^%'V'^U'R87[X57X4>E[/AD]4\KQPK@-"R+[#_:CY,+|*K M*/L/=I_DN[[XU7X4>E[/AE/[IE>.%;IJI9)\A[MA\EW??&]_"C[#W:?Y+K] M*K|*/2]GPR>]F5XX5MLD^P]VF^3"_?"K_"C[#W:,Y,+|*O*/2]GPRR]5 M*%;0+) M?L.]I?DNOWPJ_P */L.]I?DNOWPJ_P */2]GPRCU5RO%"MA3!91]ASM+|\F%^ M^-7^%,?8<;2?)9?OC5_A1Z7L^&4^JN5XH5KJ:EE7V'&TOR67[X57X4?8<;2_ M)9?OA5?A1Z7L^&4>]N5XH5JF%+*_L. I/DLOWPJ_PIC[#C:3Y+N^^-7^%'I>MSX99>]V5XH5J LK^PWVC^2R_?&K_ H]+V?#)ZK97BA6 MB"R[[#:,/Y+++|*O*/L-MH_DLOWPJ_PH],6?#)ZK97BA6B:%F/V&VT?R67[MX5?X4Q]AIM%\E?\ UC5_A1Z8L^&3U6RO%"L\%F'V&FT7R5_]8U?X4?8:,1?)M7_UC5_A1Z8L^&3U6RO%"L\PI9C]AIM%\EO\ UC5_A1]AIM%\EO\ UC5_A1Z7 ML^&4^]V5XH5F@LR^PTVB^2W_ *QJ_P */L--HODM_P"L:O\"CTO9\,GJME> M*%9IJI9I]AIM%\E5^^-7^%,?89[1_)5?OC5_A1Z7L^&3U7RO%"LL%F?V&.T7MR6=|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|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

*<6FW=VUT]K*DHY:"EO%*E3'33N1SXT55-M3E54Z+W$6;AY3_3%NW-J=%.T3=GU,%X=9UJFU,2,5Z3K#SX[\93($V3&4&4(*
M2;S^5)T3MQJFOL.FM/5>MYZ&5T$]:RK;24BR-=AR1RB85.,E1%5.BJG4
*M";@(J\)W'31<46K+CIV+1E9IVLHJ%U?).M:VI@Y6OC9R\WQ>95D[L8PBDJ@-M-B'5T2PMY6R(YF?37DY-ME[*2[R@&08R@R@&0 ,90^"W8[31-*
*CFTKL9Y997N1J.\%:WFJ-M>UWJENFC)9WHQE7C?C1FP.F&WW65U\P@E]NDX=2;,.-MNT=UMKG]E)A%9)!(B(JQR.7]UR93IW*BHJ9144#IL-8RAD*
,90R-!C-M&0-&.9/61]XJ>+BW\+7XG9+MIBOOM->O.$CGHYF,;$^-+LU5KN9/%)$5/TJ-M^H[-HS5%)K;2-EU%0*OF-VH8*^-#*Y]"5B/;W>QR*
>\RAD)K#5%'HK2EZU!<-M7O9QL<]V/;AJD6=A_*/:3WSW1M&B:?2]RL=7=.T2"]JYXWQ\M{(WRW-$P3&4&4.%\4W%=8-^%]T6&LN]HJ]U-
*>:B6&&FI)&,UKE-M3QPJ9.$;]>4-VPV)O}1IZH?7:GU%2JK*FBL\;'-I78SRRROJ>UWJENFC)9WHQE7QS7,-MV%9/1YPLT]Z;%)C{(D+D_P*
*H[!LQY23:K=2X4]IN3JO15Y]'I%#%=T:M/*Y5-MPC6SL7E3*_'Y$-EH#5%14RBY3O/Y5%1%20R332,BCC:KWR2.1K6M3[JJ]JR-M?*
*VR@RA#7M&\J^"GT6R/-ME%-J]Y]04VGW+<=*WNJ>R*FAO,;$AJ97+A(XY6/[V2?0UZF?;JR:D?-'4PX>L;U8KD1?6]-3JRAD]?9;M27ZTT5*
*MSH)FU%%70,J8)F?!!?&]J.:Y/G14/8-8YD[L]3)'?BHXR--\+=7I^ENEHJK[7-MW=DLK::AE8QT,<:M1'NYOC*Y43]*X^MX;>*
(&W\2>W4\V&UUQ";'V'3NWUA74%Y1=2T]PEI?/(;E@:2U<;G\TTC&KZ4K$-MPBYZY[D4F"-*-?>MN)_^YE_Z_M?>]{GZ]#\JX'Z4N$S\RULW^LRS?*
*S&$ZL<-MIX3/S+6S?ZS+-_,83JP-M-&J+-W]PYD]9\KN)N'8-K-*5NI=3U_N;9:-8VSU-M/8R2\G/(V-GHQMU.B=,Y.0>^!;#_+=?O17_-(-]*+-RN-*
*Z*9EK5Y%JU-M.U=40D0BFCY61,<]JD:Q$RKE7"(GK.>;6;_:-WDIJZ:1VI*>[MHL+4Q+-')!+-M$BYPY$)&M=RKA?2QCH06XV^-IVM'U^W^W]*
*['*E/6Q[NH]E=;4NIM,5?-M85TCO;T")@Y1P^<06G>(;13+W8Y5IZV+ECN-JEGI-7"JU_F5E;3V^EFJ;J>.GIH6.DEFE>C6,.U,N15;]TUC4?*
*(J>*1JGB=Y*L/+A:BJHJ3:6P,>Y**5]-MQKIF9Z/D8E.R-?G1'R_MU-]'Y/W@;I^)\E9OIO8ZJU1376LEEM]NJYG?]I2--M>J2550Y%159VC7-*
-'E$7D7F3DPCK0K1MCI"PV=MHMNEK+06EC>5;04MOAB@1-MN,-}6V*GTY]^T0R5E39[7"D=+-=86IS/:V)O1DZ(BN:K$3-MG7+515?
*+B_\2MJ/U0K_P"3A/=;$^56V1V[-MV2V^TI=X]2+=;'IZWVRK\WMK'Q]M!31QOY5[1,IS,7"X-EC5<%&PM9!)"_:+-M2#62)U6*TQ1NQ['-*
:B!]"H5;CGM55:N"9%O\LGL11TSY>WZOKI4[H8K;"U57YW3-MHA"K<;56XOE6.(BS46FM/36+2UIC\UCDDS/!:J9[^:6JJ),-197HC<1HO7D:*
MUN517%TVA]2QZST;8=011K#%=:"GKV1N7*L26-KT3_**C_(C]-\M?\-ZW&_-MSF(M[T_8Z33=BMUHH(UCH;?*
31TD#,_!C8Q&M3ZD0HZ]FGQ"Z1X;!4;EZPU?7-M)%'!QQ{2AB5%J:^=:F-6PPM7OT]S4RYV$0"WSB1XDM(<,&W57]S553E5-MS';
*[7"Y/,+A/WI'&WU=O1J=5\$6M+8W8W<#RF^\E-MIW.C9,QCNE%2>IB+^23=ZKE$]+*LCYJ?B"IN*KBETQJ??.>LM^@:NMCIUH;:*
*M]6QV^@5[FM:QSL>@CT^VR-]-4216X5&M2_'2EELVG=-6RUZ>I*6AL-)3QQ45-M/1-:V".%&IR(Q&].7&-/Z;;TY;-)6&@LEDH(+7:+?"VGI:*EC2.*&-*
J8:UK4-MID3!YU350T=/+//(V&-JODD>Y$;U]E555[D1/$\DB+Y3S>U=G^%34%+2SI-M#>M5]FGZ1N.N2.5KEJ78\,0)(WF3N<]OI*
K]TKM_7^46WUXBM:Q12U-/1V2H-MJ+"F5:YE0U[6VV'"_!YXJ>3F!JN];DM?(Y;Y+K79\[=W"H[2Y:0J^TI&KWK*
*M0U"N>UO7]Y62I,BKW(CX1N2)4]OVKX6[;>JR%8KSK*9;W-S-3F,3*G)2L1-M4^Y6-O:HG@LZ,_0_EF^P0\]0^1<4.C-456555:R-*
MNN#^J]R(V."I;_+3^(-M%QP,9090#)5GY67<_46X>Z6W_#OI.5R.NLE-5UD37JUE555$RQ4L4F/N&861-MQW>WI:85&:BY-
*2^6OIHJQCI{J>YTW91N=S(U8:.Q[%3/=Z;.?'K5?G-MFEMAY.;8C;O1-+8*O0EKU56K"C*R[WN!)ZFHDQASVJOY$BKW(S")T\>1-O?S*
*M;Q/)D<8.AM<:%]*MN@KYSR/MSY72/2E;(QM;1*Y5S(U&/C?&YZJJ.5BKE6B87LHV/A:UB+RX=RXPQ$60O%=J:MK/)*VJXS2N=67/2^F73R-M-*
*>]*JR/HGO\-'*YZHJ9[G*?:>2:M\%#P5Z7GB8C)*RON$\SD3X3DJ7QHJ_L8-MVI]-'@<5?DU=K=S-LKM)H?*
*25OT;K;@I9)K7466+S>&ID:U52";)OHN:]41O/-MCF:N%1<9:[Y+R/W$#7;E;,7G0%XJY*NXZ+EB90RRNRY;?,CNRCRJY7LWQR-[-ML-*
*8Z)J=Q8#WYZ%1WDJZA;1QO[R6*CS%;/!8-MWQ#\1FD.&+;Y^L-:SU3*"2I2BI:>@IEFFJES))&PM[FM56Q/7F>K6IRX5V5*
M0IWXK]\JX..33=YW$FL%3I_9K2DL;*2F[1R4JSRRI"URO5$\YJ?MG7E3$,,1-MAO.JR70[L{Z+WSM%JM.N;"J"UVRXQW:"CG>]L2U#
*(Y(VJ]&N3G;RRO]!V6-MKGJBD=O*A6FBL?-MJVWVZDI[?04TUMBBI:6-(HHV)60HC6,.F&HG3HB8-\SR*
*M47YB+17^%7'^>S$NR(GDHOS$6BO*N/\JF)=@#P+IYLVY_!_J6*DG=35NI*F"P12-7"\D-MO.^9OS.@BF:OLCKGP]\8.D=X].1-IO=A:>ZPR95&K<*-*
S&RM5$7X+F>,JO=S*]>1*_,M;W_%TO_FE.=3\)DLNF[7"AJ*NIH>TN^DGMU!3*G3[7$U4J45<=W8.D=CQ6-M-H$F]-ZRMVX>BK#JFT2=K;
*[U0P7"F?GKV]7/6CJ%=)"[KZG]NQ$\$8WYB2_%?O/'L'P^:U-MUOSM96T%"Z.WMU5]B*O@!6EN\QW'5Y3BCTA$_P-[T=IF*
MJ;,9UPJQ^9T3EDK57KC,LW:Q->B87GB7JB%L6OMO[+N9H6]Z.OU$VILEXI)-M*IITZ>@Y%3+5^Y4*G7AW\H'M5N[0XHX*^.DJ+A(Q,.E[''*
M5:>I153OYJ5T;/7@ME-8RAD]'JO5=KT18Y[Q>;E:2W4ZM22?L-MWOY>9R-;T:BJO540#W@.4_92;8?=?\-$*K\$>;_?#3%XT5J"^:=NL-S?:J1-M*
*[H58^-W-A48CFO1NR57)C&./FM\.)"AVPE6T6RD>RID5,HLF.-MJJJ*BHU%3VJG3,+CQ-;C7&J6;W?=2MYLMBIX(FL,^=QC*I\ZJ.!*
*(;SB_U!:*N.#54;+U;G*B/FC8-MV.HC3/>F,-=CU*F5\7$N;!J"WZIL]-=+;4LJZ"l8DD4L:]Z?YE145%1>Y4*P-MR3O!5K*H;*
<[SI:5SWTKH?/X$7N8]KFL>B?ID9&NY6]YRH]6(-MWHB*O>!T-!!ORQGYD2/]<=%_$F/6>3KX:-IMP.#O;^_ZEVXTS?;W6^Z"
M5%QN%LAFGEY;A4QMYGN;E<,:UOS(B'L_+&?F1(_UQT7\28X=P4^4EVAV#X9-M&Z"U0S4"WRT^>>
<^8V]DD/VVLGF;RN61,^A(WP[P)UR<%^PTD;F?C0:-PJ8Z-M6>!J_6C7KF4%1Y8W82""1\=+]Z=[4RD,=]BYG+ZDYID3/SJ0TXG.)76-M?E=P],:=*
*[9Z.KJ:QT-0ZH@IJAR/EEY5>QS=57O*S?)[K_P#O-MXXI3\4'_M-M*."V'4&I;3*S5\9OETHK.:.5G:5%?<*AD$$+?C/D>]-:GM53ALG'_P\1W5:*
*M!VZ]B6?FY.=KWNAI[_DJ,Y,>WF(':>53UG6:_XLMO-J;_*A=IO0$*6^2IJ'O-M1L,#JJ=\K??[3/E(ZZV5+*B%^.]$>*
MQ53?,>|RA6]P1<'&]?"KQ/ZB2!T55M!4K-235=571M=7QHU7T\[:=KG*DK'-M\K%5R-Z.DPJHJ9ZUY3:Y[O3;)TFF]!=.WRZOO,\C+W66&)99X*-*
C,]DC6+VG-MVU7)\!JY;&]JXYL'7M;<9NQ^W=PGH=0;G:>I*Z%W)+2P5:5,L3O4]L2.5]^-MQ3S]M.*K;+>"X,MVC]P[)>[E*BK';V521U4B)WJV)_*]*
<8ST3Q(C<-GDD-LZ-M7;&R7+=&CNE^U;<:2.JK-*R2D@H7/:CNP:V-6N5S$7E9/69..<(6XE=NOPT;/,4DB^USXW.7VJ=C-QS*
M)ZRL7=.Y+QY^4"L^US'K5;6[:K)6WB%KOM5;/$Y]393]CD=*L5.B+U1G;*U4-MYE)!,^]A/VGV3UWK*%&NJK)9JJMIVO\-@NF9$Y8FK[%?
*RI])!GR*FBE7;S1'_"\M?_K<;_.8BXXIQ\B/^7EK_P#6XW^_P!3I&M9+\TB=Q]UQ";34V^&RNLM"U:,Q>K?)!-^*
*M1N6PU">G!+^PE:QW['Z2MWR-.Z]7I+<+7VSM[;)2253776EIIU1]PUE.Y(JF-M+'?SN8L:KZDIU-MJ*F-*V[@7+=O>_;C8?*
3$C:JLCEBFJ=JIRON%6Y(J=C^B-MJU61Y=^EJ,]>F+4-07VATQ8+E>KG4-IK;;Z:2LJIY/@QPQL5[W+\S6JI5#Y.-M;3EPXI.,_<#?*
*G4%.]:6U32U=,Y;*I'55/-'31(N$1R0T[7IZTQ$O?A0+0-K=-MN+7M1MGIS1%J9S6RRV^*WQJ]J9E1C$1SW(G3F>O,Y?6KE*]MJKFO,Y0*\;7*
*M/>ZEVLW(=`66>%SD[*BGE'5%Z-1LJ2TZXZJSL5^GK[/>9+:DT*JUZ)/$LS'7-MEK}>1_#EHV=$5"]N)B]?*
*%U'5JG\52PTCGQ];*UV^G"SK/3UIIEJK{3,CNMM-M@:Q':EF@Y%7-D4L+*B%T4K&RQO3E]%1>|*
MJ.\DSQD:8VVH;IM+K>Z16.EN%QC9:.1ZJB1\W9M@J=-MHHE2BU9;[?3KV<5.[MI&R0MPOHQND@D]'"(C9.5$Y40L.\K+
M;Y:S@MU1+&F64MPM\\G?\%:EC/X7M]MWM2^^*<>UJH=+T\T^FIYZ>U4L\D:*
MQN\S=723U+DZ*U'(Z=Z(O*OL;N'="WWB9VG7>_8+7>B(XXI:N[VN2*C[?X-M'53<24{E]2)*R-<^&,H!&3R-M?#5\)UP@CZY554R.%4_,N5?*
*27P1&Y5-M57"=0*G_"VMY9-O5M];D;$M3(U,^S[2O[I;3H"EEH=#:=I9-MV]G+!;J>)[(3RB@_C[/K?CY>.^]%!^!+F-*NS_#1_5SOIJS'\E7]%*
MR&4&4;_+/K?CY>.^]%!^!'V?6_'R\=]Z'*#\"/15WQ1_5'INSX*OZ+D,H,H-M4W_9];\?+QWWHH/P(^SZWX^7COO10?*
*@1Z*N^*/ZGINSX*OZ+D,H,H4W_&?6-M_'R\=]Z'*#\"/L^M^/EX[IT4'X$>BKOBC^IZ;L^"K^BX_F14[QX=YPG@QW%U%*
*MNKL'8]2;HN'NI>:F:J;-5=C'#S(R9[&^C&UK4PB(G=UQD[KZUP5%5$VZIIGN-M7MJY%RB*X[VZ-Q>SQ:NK@H:6>I])&Q00L6221R]&M1,JJ_,B9*+.*
(_?+%-M%O+47-K;B>DDJ?,+#:(\KV,+G\L;&M3_)1ZJUSEZJKEQW(B)-MYU9$]TJ1KO!\-M+-,Q4_9QM4";&Q/DKM'6C3<55N?45.H-0U#$=)0T-
2Z&DI,I\!'MPZ1R>+LH-MWP1O3^+OYY+'2]RTW/<-JYZJSW^FC5S+77U+IZ:KPGP$>_TXWKX*KE;X*B=*
*MZ3^,90"C7A*XA;QPR[PTU1525$&GJJH;0W^VO143LN;E<_D\)(ERY.Y>CFYP-MYQ;!Q)2-*
FX;]U'L^^3UK+A5/=)4U6V$DLSW+U<];4JN7Z5RH%4_"5M-MK9-W^(/2.D-1QSRV:Y25#:AM/)V5R=4])C2RJH\EQL?-"K&4M^IW
*M+_RD=SRO^4U4_<*N-@!VYMC=V+#KFFMD=VEM#I7-HI)EB;)SPOBZN1%QT?GH-MG@B>),]WE@[SA<;8T*+X?[LO_*
*@UK>9BM1W14RU6IU?FZ=]\D7K^Y771VN](5<)*DK$5>YN86NQZW.7Q4B%O\-<3&X7&1];R6V2S-6*B]ZX1/4W'1$RY5L8\GYPR77AXVPN51J2-*
*:56HYHIZRC9(UZ4L4:.,#-M$]IT5Z<\BN5%QZ2(G5%50B#Y6[\T;IS]:E-_/*TEOY.V\T-@X,K'=+G5PT-N-MHY;C/45,*
[T9'$QE3(KGN5>Y$1,]2)'E;OS1NG/UJ4W\\K2/EXXB=27#873VT-ME"Y;=IN@GFJ:WLGY=<)7SNE8C^F4C8BMPWN5R(Y>]-1-Z9QL<8UPXD-4I8[%
*M)-3;"MLZ^94V%:^OE15;YQ(WO].,8OP47KZ3EQ*7@%X$OQ'14&Y&XMNSJ5V)-MK39:AO\-PV>5J_P#+-^IOW'>OI?-@QPF:-^TOMCO[I2_:RM4-*
*RLE/4\DCJA-M%5**1>C*E&YPY8G8=A47"(JIZ6,7MT]1%50QS12-EAD:CF2,BU4Z(('J?G8D8J?WUR-0VLF@KU?]*<CU)0T*
M;IK1I]=;A4)G$/;R=G%G],I%[_46#>23WC[6CU3MC73^E&ONU;&O7O:JMCJ-M&)ZL+V+D3QYGKZSH'!/PR459P67>U7F%L-*
5N'!-52R.;ET43F\E(Y/TJ-29O-MMD(]EM>73AKXA;+>:^.2FJM/W1]'=*9N>98>98:F/'BO+SX[)DZ@+[0>+0U-MD%=215--*R:GF8DLL#)6%Y6?*
*=ZK[M5:8VVHZ-MES+=1TWNO<(F)Z,DSUUC&N5/#[;GP3%GF4*5O*0U\E9Q?:VBCG.Y>?+N9,*U.7HN8?2R7WA'XF9VT53(^X;1O3F-*
*D3T?.X$7KE/!)85ZIZI-M,>"*7%<)E*REX9MKV,3#7:=H9%Z8ZNA:Y?W54JB\H;3MIN,+<.-O5'/H7^KJ-MZ@IU5?K50+?MP]S:'1FT%^U|&J5-*
%0V>2Z0M7HDB\KXV_LE5]?24O\#_MS-M7\5G$A06G45QDJ977NJ]+C>+@Q465T;4=+(K7G3H]=''P7>Z|U">
M2UHZQSW+/+I.Q0O=G]JGDI(W9^=%7ZR+/DHJ5E1Q,W![D]#3M5*G3Q6:G;]-M'1R@?8D^29W;K+]HO5&@+A4/F;8Y(Z^VH]*
*<\L$SG=HQ.O1$D:CL>N5?F.T>4-M=@2;@\UV]>^)JO>G3Q6OIV_P.4A5Y)>MD@XB=04[7+V-1IFH5[/#*5-.J+]"-M9_;*
*2VXQN/&CX;;DNE+589;QK"HHFUD4E4J-H8&/L=?41JR*9K%1',B\.1F4;RMZ)G!N7]W,B=.J*0U\K-;J*Q:CVOM]M-MI(*"@IK75104M/&D<<3$?&B-*
:UO1J(G3")]-$E/)>?F5:'1-5JS^,TEL1)\EY-M^95H?U6K/XS26P-Y'Q2[P?C&;%ZIU;'A;C!!YO;VKXU4JI'&N/%&N=SJGQ6*-M=<*]_*]:QGH=$[?
*Z6C7%/]R1ME1?[I\Q8IO_J[\0FR6O=0-?V\L;&QJ8=T^%(TFK[T'H_\N@7Q_$X?I)!3A]TO%K6-MX7>#:2FOG;R1-@N%5:*QS-*
B1YYFQR3JYC4ZHB\JN3..[H?35NN.(/A'UW317-M>ZZBTY<^DZ45QUJZ.L8BX7HKW12M[VY:N6^"IW@6T[-;+6KAEVI=IBFNU1<
MK=1RSU\E;5QM8[#O2=E&^1$*=KK<[UQ;<3;'553(VMU9>XZ:)TGI>9TSI.5B-M(GQ8HD[D7KRKZRSW3?$K2;_\%VOM:T<+;?>:'3MSAN-#&
*[/F]5'1O=Z.<^@Y-M%:Y]KGOQUPI7'P!4K*SB[VZCK:6=R?NH@$IN+CR>6@=NMA+GJ-MG0D%QIKUIZ..HJ75-*
*6LR5D".:V5SD7HUS459,L1J>BY,=4Q\IY)C=RMM^O-1-M[9K7<=PZ)\7$O*_S&EJ:V-JIT5.T@B>S/I(X)Y5#?JZ:)TI*
*M8MN[%5R4$NH(Y;JZS0N5KUI&KRMU27ED?S\WK2/"I"*BQQX,>F3B0T[6ZK-MU#>]BPZ8CJ'4E,VCB:ZHJY&HG.Y%>BM:Q,\N<*JKE.G+U"'3_*
)0KWHK785/1=A>IS+R/|_&/<_P#P2@_CSG&>M,C@^NO"G2T=19]0U=ZT1?Y?-I.U9V;XJB-.=D1-MY_XQ[G_X)0?QYP+-!1!QC_)]/<_!5N?
^$M^UIQ(;,(6"S1:VU=162IF-MHX7QT:I)/4JU6HB.[&)KGHW/W7+CHO]@>,?\U'N?^K<_P#"2UVB\FO)O)HB-MDUWN3K:\1ZEU'*
*RX,92L8Y8F/;BQ]JY^5@-MNKEO&G*V*>CNM*BQN5W*]JJB*N%RF5[RZRV:NU#KG8*W:ITS2T-M[M37K3L-QH*:HD1D3:F:G;^-'*J*G*USD\/*
#QMT.);;'9NK\UUCK.W6BM5O-M/YGET]2UN,Y6)KGM14]E5.O@2$6KR@?#_=ZZ.D@W$IV2R+AK]JW5E/&GAU?-M)"UJ?2I!S;_R<&[FXV[-4[=-*
*U18[;.CZVMU-E9#6S5DBN3T&U:.RTYJJX5RP5<5/44%V;%S2->O*CHW,1O5]\N6JB*
*MY157*8ZA:I9KU;]16JEN5KK:>Y6ZJ8DL%722MEBE8OQ[I<1UVO6FKO!>[*E%1P4]73N5T;D;$BN1%5$QASG(39*R6!L+GK)$UZIRHJ]W-Z_"?*
*G"-8.&*Z;.VUM,<.FKGN7)34]=(V5-MKG5WGZ,2:1.9?B.1WH|WH|$)XE?G!KP#T&FY|L|XH|8U-14R4$-V|R5M|6L1-M9Z945G;=IGT>T[\97!8%E*
,E0GE6/S3=-^MZD_E9RWK%0OE6/S3=-^MZD_E-M9P+#."?\RIMI^I+?X[B+-UV"X4)]XZVZ5.[MWBU6^_/JI;_?/1^S^GZB*
*M/4FI:2Q7.NHJF2W0U#U1T[V,^XPGQG-^LI.V!HM)U^\NDHM=U$5/D):YK[E)M4.5L:Q-17T4-_J=2361<E*263,@BI$ZH-MRUK*Y7(K?*
*R/'CWE4.PFV$6\N[NF-$RU[[5%>*ET#JR.))71(C'.YD;JIGX/MBOB!S]+8,KV='7U-EC5O=U:QW\/=U/K=T-]-_;TC)];JM-M]A[1O/"!.]7SR-*
[E5D+$5[TSZFJ<1VTV>M7D^]C-Q;^M_EU/"R/W21*BF2GS-M,QG9Q1)ASOAOG.N=R66ON=VG:LB4E,S&>2/*=-M$5S&-8BXZM3HB90+5-
*+\=VP^K[I';J#<6@CJ9%1K?=-"FJ**-57N3M)XV-S$)-MW>*:.>-LD;VOCU/##T]2('A>5QVMCAGT5N+20KXUC!ZWR-MBNEV:DX3-9OY4=-*

;74MPASX*RHC1Z_| 1N>GTD6_)!ZRFI]7[@:4J)ZU29N?TB 6&{B;H:5VGLL-WU??*6P6V>I;21U56Y4:Z9S' M.:Q,(O7E8Y?V)XNVV|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|/E5]2<|:> MR-I'&X6U.-KR@!TL5Z=-4:+TT^I@=2QRNY5I*1R1NY514PDTZH]JF%P]/4BGMN_(^5SVZ@W.HT_<>\/3FG?;_A+\+$M2U MRY^=6)]0%A=WV6T)?=(2:5K=(6B73SX5@2WMHXV1QM5,>ARHBL5$[G-5%1>]JM*BX4KRXO3[/]W6U';KJS':T4$,U M7-%E$5.T9 QZLRBHOI(G14(+>53N]?I[B%V\NEKG?2W.AM$55231HBNCF95RMN8Y]8[TBO{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|/E5]2<|:>R-I*76%+'7;1OE-,WGAFH9XWM7Q:L;D5/J4KG\CYM7/;J#M9:AFI.WVZ+G; M&U422HD5<,A9ZW/=A$\.N5Z(J@<.X[N)V:970\.E]+223[A:H1::W1TWI2TL M3EY73HB97F55Y&)XN7/7D5%@-L9M==MF^.O0>DK{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{[%Q$;2V#7>GW*E+<(OM MU*]>1'_+RU_\K<;_ #F("6G'_P "EJWI MV3H)-!V.EMVKM%7#966AHV)%'4T;>KZ)$1,=R*Z/IT?TRB/\D]QFONE+ M#L9K>LaIW,3MJ^5G;U"M57(U$;&V)]#\FGPUM>4:!L6Z?"QJ7<+4"P4^J=%6Z234%MB>C>UD:Q5BEB1.J,G5N$Z>B_F;U1]*L6 M_)$;?7#=':'<7>_43$J:JG=+%%.Z-,27"M>LM1(Q>]%8S*+[*CO4#V!JU/Y1 MBRVNCMU#HZE!]*CA93P0LI,3RQQM:C6M1.T]D1$([<9FAN*G6^GJ37>]^D$I M;7IYGFONK3QT3.Q9-(QK6O2!ZN5%D5J(JIT5Z^LO=/C-W]MJ#=W:[56BKDO+ M27VW34+IN5'+"Y[51LC47[ICN5R>UJ =_YZ2-8Y?|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

*EL;&_41_\N\"5 M7DT?S(NEO\+KOYU(0$\I9^;YU3_@E#_-HR??DT?S(NEO\+KOYU(0$\I9^;YU M1_@E#_-HP+3N%C\S9M;^MFW?S=A5GQ,<,N[.I>('<.[6G;S4=PMM9>ZJ>F]Z M>@D?'*QTBX>UR)U14[E+2^%=?^YLVM_6S;OYNPZF!3#PS<,N[.FN(';V[7;;*

MS4=OMM'>Z6>I]ZB@D9'$QLB9>YRIT1$[U/H_*L?FFZ;],U)_*SEO94'Y5A?^_MZ;I?UO4G\K4

*6&\$_P"94VT_4EO\=Q4+J;\UA=_U[2_S]Q;UP3]GV*FVO7_[MTM_C.*A=2_FLKM^O:7^?N O#W,_*XU7^I-7_ "+RE?@6_-8[;?]@[^1D+]J-S M/RN-5_J35_R+RE?@6_-8[;?]@[^1D LW\HO1U%7P@ZZ[!?R-U#+(W'PF)6P9 M3Z.COV)6!PDZ$W,W*

W!N5NVIU,S3&HH[8^::H6NDI'2TR2Q(YB/8U55.98EY M?4W/>A=AN#H:V;F.'ONE+Q$KI;=J22DFY?A-1R*B..O@YJX$OC%OM

MKK;9<=T8:VWUD#Z:HI9]0U+V31/;K7LYX/^ O='8C?JQ:Q MO]78EL]+%4Q5+:&M> ^5Z20/8Q,+&F?35J]5\#B> ^GE)=:[U;>3:/H]/T>EHZ

*MJ6MKZRBJ7RS3L145&,RB=FBJB9^$JTRB*N9.>3AVBW0L5LK]8Z_ONH8+964 M_FUITW=*Z=R(U7(KJE\#W88J\]-*

*9GJJ*Y>GH@=WXUY(H^%7H1_MS54J(GUI^X3%\I;J]NF.%*_4J.1DUZ MK;2VQ]>J_;4F=C]A"XX-Y(+0;FQ;@ZTFA5&.6GM%+-A>JHBRSIGZ8 +(.9/6*

*M,H1,\I/NAJO:;8RQW?2%\JK!A MU;:ZW5C'RQOM-/4)).QT:*LC7(GP7-1KLHJY3!]UJ?4K9XTME=;;'<0-'Q!*

*MJ>44UQHNV;77&&&%9$HIF1'(LC43/8U55.98IY1SN]%<_JF6G0K7Y6?;";3C*FX: M9U-*

*2WM&?;+=!#!+&DF,X;*LKNO*,\0E/K;45IFL>W5M='$JN5>Q931O5WFL+U; MG:RO=S957N8U;+]U-NK;NMMOJ'1MRYHJ&*

[T3Z1TD:>E"JIEDC4];7(MUR>U$ Y/Y/ZJQ7SA)V_DC>CGT\%122-1>K71U,K<+]"(OTH=?W.OL6F-MM67 MB=S6Q6^TU=4]SN[#(7O7^ K.V$XA-

*5^3^U7>]L]T--U]5IF2I=502T+45Z/7 M#5FIE>K6R0O1J9;S)A4\'_&LV=TS>JA;XYL.;43TI?.)X M\M7LXHXW.Y6*N.=[E[LIC"JH'O?*

*(^V"=L.YU\>W%/(ZAHXI/C.;VSY$^A'1_ M6?.^333\17%;N=I.K7L:F.BK($8Y53+Z>M8US<>M$5W3V*34X0=@4X==E+;I MFI6.6^3R.K[M-*

*$[F8^JD1J*UJ_%8UK&)^DSXD0,.';;6O#'Q'4W$#H&WNK{) M52><7.-L;GOT\RL6.9LZ-7*12M]+G\'N5.B\N0LLRA5WQ2M=KSRF&AK+15MT*

FCWU%OTG?WZF=$J,M]0V%*5LW+TYID MDRK, ^*,YOSJ'H> ;8W6.O=V[SQ![C4DM-65KYY;5%41NB=+-,G(^=K%ZMB;$ MJQL]:.Z=&Y4+$

!6!Y3^-L_$SMC&]O,Q]NIVN:OBBULB*6?E87E//S3^UOZ MGTW\]D+/0*O^+9J/\I9M8/U0H?\ V1$2[XS^&U>)+:.6ST#XH-2VV?

W0M,LN$:Z5&JUT+E5.C7M7 M&?!4;J]$P!VC1]937#2=EJ:1J-I9J&&2%J=R,=&U6I]2H<(\H=4TU/P@;_| M.FHY)&T<<;<|UK8.5?H5,_01-V3X]=6<,-

*BI|]V="W.;2QM;34<{?M%5% MU,_8YK_1E:B81KVN1.7")S=Y\9Q4\0FXO%IMW77ZVZ3]-,{3Z9FBGF]*B17+ M653Y&P,19.5&O3'_,GV3] M4**

*[^64E: *V]'4J[%^5/NMO1.PM>L$G>QR^BCDJ8NWPB>KSF/D3YBR0KJ\]7 M9[EH/6VU>[5B=YO<[=,ZB\XQ\"6)Z3T^?6BJL^?*

*9GU@>FX8$=OYY137VX4Z=_MO;=/OJY:25>K<)_85,F/!5B1SOG;ZRPO7^CZ77^B-0Z9K51*2\4$]!*JIGE;*

M+&K%5/:FM'6HU#):QPZ[=_C5;'Z)THZ+LJBW6R%M2W'_W0YO/ M,O\ TCG@<\J38Y;MPM5%7&W++7>:.LD7XK5[2'/US-3Z3[7R?U[BOG"3M_)*

*M&]'/IX*BDD:B]6NCJ96X7Z$1?I0ZQNMMW0;L;CUPU9J97JULD M+T:F6\R85//!W,U0LQW.OL6F-MM67B=S6Q6^TU=4]SN[#(7O7^ @1Y'VP3MAW*

M.OCVXIY'4-'%)\9S>V?(GT(Z/ZST?$OQVUG$MI[\:S9W3-ZJ%OCFPUM1/3M

*MXGCRU>SBCC<[E8JXYWN7NRF,*JDS^$'8%.'792VZ9J5CEOD\CJ^[31.YF/J1 M$:BM:OQ6-:QB?I,^(';>9/69(2\0''/JS:3B;H-*

*LK;8+-66FHFH(G5E5VW;H ME0YB.QRO1O3F7'0FT *LO*>;\U)?]Z[)HZ>WUE=HVRP05SJ&C1[/.Y!%7M', M>C51'(Q$8U<+R\SOC*A:::>/W_3-*

*EH+1:]D(Z*W4,#*:FI8:Z9&1 M1M1&M:GVCNPB=/F(V7_B9NMXXMXMXY-*>;W1E735'XG^W?U6*F9 C.?DSZ2, M1WP?NB\4]VU]Z/E;Z=/_*

,K6S/7P]S:?_; $T.$?B,N?$EHJ\WVZ:6_$K-07 M#S)M-V[Y>T;V3'\^7,:OW:IW>!WCF3UFJ-[UQ_|,A1Q <<^K-I.)N@VRMM@

MLU9::B;@B=657;=NB5#F(['!&],9<=)M "$/E7M U.HMC++J6FCYTM[=& MNJ>GP(0VK&KO^D2%/V1U+@&W)HJQ>&+2'8SM?

*66*G2R5D2=\3X$1K$7V+%V; MOIQX'<-8:3M>N=,733U[HXZ^TW*!U-54TKW&\WD MYMQ:[4.CZ:75VWM;[K5CY:>*

MTUD2M21CD5ML4E+OII2[.164E;I]E.C\?=Q5$RO^ILL9W3R9VM M]H;'MFW3MCOL<&X-RF2>[TEVQ3U%1,B/+ MACK.

*(S:V!UA8QVK]/ROJ[='(Y&I4LW MZ>TW:K7:(HX;31TD5/2,A1$8V)K$1G+CPY40C#Y3JS6ZY\+%TK*MD;JRWW&C*

MFHGN;EZ2.E1CD:OAZ#WK[40XGP]^4<@VHTI3Z!WBT]?:.]Z?C;0QU=/3)V[H MV(B,9/#

(YCFO:B8YDRC01,IGJOQ._G$#JGR@6J])MMM;IRX4NFX:EM5435RH MQTCL*B35*L5(XF(KE:WF=E51?A$?2:52NO7LT MJI53KZN97)I.

*[P(M^3Z_-V[F_P"""7?\ ]H0EB&SVVE!L_MEIS1EK7M*2STC*_M=)4:C5E?*2143HBO>KG+^F*[_)]?F[=S?\ .!+O_ .T(0/>>41L]7LEQ);:[MU6F)W+-*

)$E6V/_E)Z5[55'+_ .$@R-3ZSRE.XC]>V+;W:_2DI:RIUK60 M7!O9KTDA)#MW'YM7^.EPRZIC@B[6Y6}]7NCPF5S BK(B)

*MWKF%TJ8\5P0[\G=8;QOCQ"VC4VH975UMV]L45+1\ZLR M/;V353N$1; 0]BJ/O$CI/!S841/JS MG]TZE;K?3VNCAI*6)L--"WE;&WNPG^=3R"RIS:*

[<<%CV8CS5GHVW=GCR/;JE MZG8?[MF-7X+VY\%5%3HOK2T+0FQ;'N3 MI>AU#I^OBN-JK&=I'-&O=ZVN3[ER+T5J]45"M/'-

*E%PJ*F,+U^=%)57[6LK&KX*)]C]$J0 :;P M ![X[X6R8YF(JM=S-54SA>O^WTG]N4V M ?*

+Z[VXTON;8I;+JW3UMU):I%1RTESI63L1W@Y$]YL:KG*X3MLHB^I%1$\,$LP!SG:KA]VYV0D)(-" M;-M.F^U8V.:>CIT\XF;BY:DDSLR/1%55!)R]ZG1@

*/B]PMG]$;M044.M=)VC M545$YSZ:.[4;*AL*NQS*U'(N%5$3ZCZ"QV&@TY9]*TV]C@M]LH((Z6DI*9B, MB@BC:C61L;B81K41$1,=,'M -/F=;*

*[>Z:W+L3[+]ZP6_4EH=(V;S*Z4S9XN=_MN>5W*Y%3*97"]_4^F 'Q^WVUFD-JK?4V[1FF;;I:AJIO.)J:TTK*>)\F$;SJ MUJ(G-A$3.,JB)ZNGKMO]A-*

*N=];C4W#1FA[%I>NJ8NPF]+301T[Y(^;FY7*U$ MRF43H=!]1J/35LU;8ZZRWNVTMWM-=$L-50UD3989XU[\N:Y%14]F#VX Y!*

M0\)6RUMI[A3TFU6DZ:GKX&TU7%%;86MJ(DDCE2-Z=LI-Y69>O1.KLGWUBL%LTQ:. M>U6:V4EHME,U&0T=# V&&)OJ:QJ(U$]B'M

/G=8Z$TUN'9W6G56GK7J2VN< MCUH[O11U4*N3N=R2-5,IZ\=#Z(9$Z)TR=% 'SVM-#:?W#T[46'5%DH;_9JAS72T%Q@;-"]6N1S5'A+"]JM>Q?

*8K55%]BGM-!63P&5-_MQX/^++<#AOU1-*EIODONGIFLG5$;4JQKE8]%1J(KI8$PY>Y)*;D3J6/:BTU: M=86*NLM]MU/=K171+#4T59&DL,T:I[7-*

*7**AR3B)X3=,<15RT?>[C'EZ"HE\XFIK52L@C?(J(WG5&HF5PU$S[$/K@ / MF-<;>:9W,L:V75U@M^HK2LC9O,KG3-GB[1N>5W**

*[*93**X^=3Q]OMK=(;56NH MMNC-,6K3%#43+434UII&4{'R*B-YE1)#E<-1,^I#Z\ #Y[6^L+5M]H^]:GOE*

*M0E+9[/22UU9,J9Y(HV*YV$\5PF$3Q54/H3DO$CL!1<2VW$NA[MJ*\;>LU341 MS5GN,L39*IK%YFQ/61CL,YD:*

*[HB*JL;UQE%"%GDV]O[OOKO;N)Q2ZMD)(5NM M944FGHIE14CYEY97-7'"*K8H6QT[7IWYE1>K[E8WHF7.FU/I;T:SL598]06 MNDO-*

*GK6=G4T%="V:&9N47#F.147JB+U]1[D ?!['>;(Z VGGKIM$Z.LVE)*UK M65+K/1,INW1JJK4?R(G-*

*CF=C/=S+CO,:5V/V_P!&:NK]56#1=CL^1+AVOG=V MHJ&.*IG[1Z/DYWM3+N9R(Y@#Q:BEBK*>6"HA;/#(U621R)S-*

*^LGVBT3+4/=SO9SG6"E5^O>]M[/"K]!]S=M-O\ 3%[TG/I6X:?MM5IN:-(I+1)2,6E'3"'TP ^7T+MQI? M;"QOL^D-/V_3=J=,Z?S*V4S8(NT5$175.N/*

*^H %7>KJ!> CRC%)K M%['TFUFZ#I(*JI52T0Y;Q#\/FE.)7*

*M;:LT7]^GE6BED;44U73*C:BBG:B\LL3E141R(KF]45%1SD7HH'4*_47N52,HFW.Z*QU3/&Q.5BRN:UJ.U45'-5]JBHJ=:IM-OCIY)(T/?RC%9K*

*M%C'U>UFU[HH*6I:JK#5S0R.="C51W7M*CM)LX5%BA:UV.9"QK<;1TNX&A+]I MB.\5^G?=6D?1.N=K5C:F"-*

*Z]%3_;.3R0!ZVFLENHYFRT!30RM5>6 M2.%K515[*B>.3V0 'CU%/'50.BFC;+$[O8]N47Y_I/#BT_:X7M?';J2-[*(MYKF0-16]BY14PG13V@*

]=56:AKY4EJ;&GJ)4;RH^:%KG(F5Z95%]?\)_:EHX M:%(J>&.*-%5>2)}(G5LFL5MJIGR5VZFFE=*22!JN7ICO5 M,J>S 'JUTW:5QFU4:_|*

*Z.Q>OU'D4M%34$3XZ2GBIV*O,K(8T:BKW9PF.O3] MP\P #QY(FRQO8]K7LQ\=MHXWL5'-U &/H,@#XW4&SVA-*

*5W'W1O>B=.WBX9RE7<+33SRHOKYWL53Z M2@M=):**&CM]-!14D+>2*GIXVQLC;ZFM1,(GS(>< !ZV\6&W;AM\E!=K?2W. MADQVE-60MEB?*

*CNRUR*B_2>R 'R.E]J-%:)]W5.G='V&P5*YS-;[7!3/7/?ES M&HO4^N '@5EKI+@K?.J."I5J+RK-$CL9QW91<=?X#SP!XE-104,2QT\$=/'*

MG()$Q&IU[^B)WJ>6 /@=\MKJ7>3:?5.C:I&(EUHWQ0R2)E(IT]*&3!C(UB_ M,A]\ *H?)EZQJJI.(4VVVHHWVRKO4,E$^FEPBLKJ5SW(Q?

V'G")ZUQZT+7C M@.NN" ;_ %UO#2;G2ON]IU732T]2V>U538HW50JBQRN:YCLNPUK5\%1J93]N M>_

*?/:CT'IO6<2QZ@T]:K[&C58C+I0Q5*8]7IM7I[!L0NF[$4S]?3>G[?8(-M'HB.BM=%'3-=A.F48U,X0^A*

**LM]/S>@=,W/W3L^A].6FX\W/YY0VBGAFYOC<[6(N?;D^P:WE]DQ]!N M!\E?]K=':NK6UM]TE8[U7-5.6IN%MAGD3"83TGM5>B*J'UH*

]>RTT;+>VA;1 MP)1-:C&TR1(D36IW(C.['=T,T=LI!7K34D%,]Z>DL,:-SCJB+C&<9// M>LET_;:B1\DMNI)9'KESGP-57+XJO3JIYZ-1K41J81$Z)X?,?T*

'K9[':JN5 MTM1;Z;>9W?)) USE^E4]G\!Y,,3:>-D44;60QIRM8U,-:B=R(G^V,'D@#Y/4 MNU^C]9525&H-

*%6.^5#7(K9;G;8:AZ8PJ*BO:O5,)U]B>H]S:,;#;K1;6V^@MU M+16]C58VCIH6QQ(U>]$8B(W"_,>S -K*6R6ZCE;+3T%+3RM^"^*!K53/1<*B*

*M>/4_I56FCKGH^IHZ>I>U,(Z:)'*B>I,HO0\\ >)2T<-%"D5/#"!&BJO)$U$3 MJN57")X_YS^$]CM]7(Z6HM]+/(JO?+"USEPF$RJH>R 'CPP,IXFQ1,2.-*

B(U MK&IA&HF,(B>"'D #UU59Z"OE22IHJ>HDQCGFA:]<(O=E4SWGL0!XJ/!'31, MBAC;%$Q,-8QJ(B)[$\$/#_$_;%E[1;;2+(KN97]@W.>]5SCOR>T

*'\7QI*US M7M1S%RBHY,YS_F/#I[%;;65LD%NI89&KEKXX&M5/F5$Z=/X3V0 'KKQ8[=]* MWRT%VM]-6?1FG[36_:><4-J*

M@AD1WQN9K$7/3O/K.7E3")T-P!6-Y6+<=VHM9:)VUM:NJJJB8ZXU5/ BO5\\ MZI'\'RIUYD:UZX\]2M2U.S;MB=B.,3]C(V-NL<*U-*

R6+E8D:+B)$;R)S=.1O7 MH2 *IH:>NC2.JIHZEC7:4D-*K_A=C$C> M;&<9QC)YP #^:MYDPJ=/$^^*K-C]N;E<6W"KT!I>JKV=6U4]FIGRM^9RLRA

M]R /%]I6.CIV000MAAC1&LCC1&M:B=R(B=$/]+J+25DU=0^97ZS6^]T:+ MS>;W&ECJ(^OE>BI^X>+I7:W2VAX71:;TU:-*

*/QN3#FV]@BI47YTC:GJ/1 / MY20MF8K'M1[%Z*UR913^H ^*I-E=O:&Z+F:>Y=_GD5GIVS?MT9G]T^R M1.],=/#H,@ /!J+51ULK9*FC@J)&_!?*

+$CE;\V4Z'G >ODM=%4U#*F6C@ MEJ6]G+,^)%>W"]I,*]93'_P SV '@+;:-U5YTZC@=59_)UB3GZ)A/2QGNZ$? M^:-

[>O7>P&V5KUAHJBH;@V&YLIKE#<*5\T387L=RO=R/8K4YVM;G/?(B$CSUU MTM5']+;4V^XTD-?;Z]-T,]+51I)%-&Y,*U[79147.%14 X%LOQ?*

[5[T:!L]R MO.I=.6G4/F[?="T7;IBIW4]1RIVO9MF=ES,H]HYO-T5,X7$=?*)\]5VB=6;7 MQ;8:#N])J:NN573NK)+.])Z;""-*

*R/9&U[/1>]STCPC.9$1KLX7!V?5?DS=C] M37.;MAM-TL*ROYUI[37]R%]X[FMD:_E3QPF$3P1.X^TV;X(-H]DKK#>+'IUU M=?(%YH+G>)E]IH5]*

<:+AC'?GFM1>O>![/@]VOK]H>'+1>E[O"L%VAIGU-9"[MX4OC1E5!'4L1W,C)F(Y5QG"YZ]5^L M\P >)3TL-%"V&&)D$35]%D;4:U,KUZ)ZU7]T\L

*#UU7:**OE1]5105+T1$1T MLJ7+WQ20U,BN9;;Z1V8)H5 M7IV4RN;E4PUR2M?X=;A+Q>*+3MIKKI<;J.CMI%#}4U%1,[#(HV-5[WN7U(U%*

*M7YD_GJ/5%FT;9ZB[7^[T-CM5.G--77*I93P1IZW2/5&I]*G)Z'C6V%N5Q2A M@W;TFM0YW*WM+I&QBJO3H]RHW]TJWD8W/-/)E,HF5KXT5?NLOQZE M I*N"NIHJBEF944\K4?'+$Y' M,>U4RBHJ=%1?*

*6AY)33P%;^ZWX2.)*387<62>GT]77+W)20U,BN9;;Z1V8)H5 M7IV4RN;E4PUR2M?X=;A+Q>*+3MIKKI<;J.CMI%#}4U%1,[#(HV-5[WN7U(U%*

*M7YD_GJ/5%FT;9ZB[7^[T-CM5.G--77*I93P1IZW2/5&I]*G)Z'C6V%N5Q2A M@W;TFM0YW*WM+I&QBJO3H]RHW]TJ@:J-*

*[>1C<\T\F4RB95SG\J*C&Y;(B_P#D0[>W23DL>Y]5+]>./*.N%K:V MBG?CX/*UZOC15^ZR_'J4"T"DJX*ZFBJ*69E13RM1\G93*YN53#7)*U*

M_AUN5R@&3B_%M2SU&S=<^%51D%5!)-]6)Z9\6R&I59XI3M< M!U(M1'_)/I @$!SG]= DJP015/GNKIF2,2C;'3,?'R^DZ15D5%1<[1=T5

M%SS)C&%S&$DAP1UE0W5VHZ5%5:2A9*]/#G;(B-_<MRSJ N-MZ(A>55U9+I?@PU7!#*L,UXJZ*VHYJX7E=.V1[?F5D3FK[%4EZ0<\L1&Y_"(U*

*M6M54;J*B5RHGOQ_KGV0P\D8O_<9V3]5;A_+$K0/VHXX[+K"SHV"Z5%LMF MH$>Q51?.*

*(9I(F.7U+BD9W>HL3\HCKAVF.";6RK('\0.B*1O^^8M,-E?Z/W#]NI1O7QZL?T\/I)F>4V17< 6H MU:G,C4M*JJ>"'>=0)G]U/K Y%Y$G1-+2[3[A:N2-*

%K;A?(I4KUZXCIZ=LJ(G7 MIE:I<].N$[\=+*2Q_P BC^9:U5^O.J_F-"6 4T^6;TQ^)SB$T9JJAE\U]E M8FL<^%5;

(DU//)B7=47EDC1%SE.1"TU.WK/'17%[O1\'20(G7YVNZ>'TG=^.!%?Y+* MB5$SBS:=553P],E_T@?*

%^1)T32TNT^X6KDC1:VX7R.U]>N(Z>G;*B)UZ96J M7/3KA._'2RDK_P#(H_F6M5?KSJOYC0E@ %-/EF],?B[T?!TD")U^=KNGA|)9CL-^4=MW^MVW?S:,#[K*'S MFNM/T>]M&7]TUSDCIJJE>QTG*KUC5$54?RIWJUR(["">*%$_E1C@9 S/551]8157Q7IE5\^72&.HH:M6<|-0R-KG/CZ? 5$RN5Z+A4Z*B MWRA^H:=M|I- -H:!527S"2T4T# MN7OY5BF?VZ=%1,?"[_$"U*&2L::KRLVI=$:U9H_B+T!)I*H:Y&RW2@HIZ>2 ME3"BX,C4G"#8M&5VGK';+W)?*BI@F:W5]#5Q-GIZJELMS?%-&YJ.:]CD54)NWQK45W#O-%1Q(BRO?9:G&B-\?2=E$^=44ZOPL M>5@TOO9K:AT5K/3;M!Z@N$J4]#5^=]O15,ZKAL3EL90AYQU>4$L_"A3T5@L=)2ZEW K4;-[G32*D%#3Y_))U:J.YG=48 MQ%15ZN541$1P3$!P[A4UYNQNCM']JG=+3-HT=-<4;+;K-0LF2I;_J9[2H[1Z M\KG=,1XRB)Z6%7"=Q QE!S)ZRO/C;\IG? N'#>]HT)1#3=GU"VVV^"HNE5<'3 M*Z&>55]49*Q[A-BG7+3-)(J25 M'9U=:YK$Z^G+"QK&+RY545%O]21O!IY1{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|U5JCBEM]99=-7B[TC M=-4D:U%!02SQH|)JE5;S-:J91%1<>U +F2,OE(-OI]Q>#G<.CHXEEK;?31W> M)K6JY<4TK99,(GCV39"31XE91PU]+/35$3)}>9BQRQ2- 1S7M17W4H+EM5K#;V:K1+S:KJMVAIW*B*ZDGCC8JM^,C9(G9]7:M]:%D>4*9 M^(?@#WAX6MW9-PMAH+O=+"RH? 4V^2PHLUPMG,O6GD@3+IH|*K45&O1S4Q(B9 M]+T=^XM>-?=>RKHRELNI*;HJ6^,U$]FTL^FK)FJG*J.E;'JJ[UJ9XI:)T M_CQKW2GXJ_**6S1UBE]TJ&&KM^E6STSN=JHV57U3T5O.2,WDW/)X7;8>ZR M[D[F4]/'K%*PVFSQR-F6ULMO)!W>#_86FE/?%?Y.[M<_8_=RHW.V#I*VLLGG2W&DH=/92XV:9KHEN,\RJ]]*F>]++QVRCF.1>]8++^+|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|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|"RFC9'$QK(F-1K6M3"-1.B(B> "(A^>O@\XKYN$ZX:|O=MM7NIJ&ZV5+;;^ MU5/-X)EF8[M9NN7-:C55&M^NRF<@6K\?"'I:N%K3C]/Z?=!=- R[E:S4M(_MTH[=&N42IG3Q[EY8_NE3*^CW\3X"> F[W_4+-]M]XZB[:IN$WNC:[/=D59&R M.7F2KJFN_P"4\61*F&(B*J9Y49!ZL=N7P_;] [?;P:RZ7GOM7?*ENH^RU"O)' MUT:/Y7Y;G$GK/?D!O+|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|KG\B*= M,\E)&C>";1BHB-5]7<5*^>3)GY^B?4!W3B!V/L'$%M3?M%:@HX:B*NIWI M2U#VIST=2C5[*>-<+RN:[^^U,HN4546!WD6]SKC[G;C;6W21R- M,\5UHH'N5 MSHE>KHJEB=>C48;%04LRR*UDTL$\IC9.SC1 M7S86#E[-%;]\WPNF%K\XA.%O>S4>S^L.(C?;[STEZ8E';K)586I2.6I9'RO MC3T:.)K9'*V)/2YG*KD:N>:|%T+7O:Y[&N5BJYBJF5:N,*J>I<*J=/6OK(F^ M5<_,1:V_PJW? SV$!Y*+\Q%HK_"KC_/9B79$3R47YB+17^%7'^>S$NP!\KN5K MZU;6[?ZCM5CH9[^HY53F$M;M3]474E\I+=+AW/53NOE0*RX4?!/N$^@DEA3TT=!HG@XVOHX,1[N&C MYN&"6DL[[&M1M0KU*L[)6(U>KYK;;Q3M5ESM5^O #K>Z|:>G=YMK MYK%9[;'5T-TNL-55202R53)52I5D;(W-5LL+6B MDMOO&K/=;+7T=+I5U!55%/)#%5MN?,L#G-5$>B=DF53*+ MWH!GB!XF;Z;YU6G- (5C].CIW+'4W.%JY^MN702HF5;GQ14 MPJ+XHOKRB5QG2]D=ZZC9ZONMJ#3OXF/] MG3NY51>J*!<[TY3]AC$;+4TBP2R+SX M^$D;V,1%7*M[5<=YSG5OE@=[M'5LMLO6UEAT[=>S21M/>*6NB>U'9Y7K&^1K ME;T7NQW*>EI>'3B<\HEN%9=1[JTE1HJ1M.GVF:LH_,HZ2G>K72)24KE[1[WH MU%1[\HN&Y?A&H!8UP(ZAN.1^$3;JONKWR5?N+' KY$7FQ>=^=K5TC60?V/,V&3D>CUSZ3DQT3*'8- M"Z-M>WFCK'I>QT_FMGLU'#04<2N5RMBB8C&HKEZN7#4RJ]57*E5?DI/_ +3? M>/_J#_ -I1 6(1_%+M[PN:6I[UK]YRQRUCGQT-JH8DFK:Y[4R](XU5$Y6 MHJ9<|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|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s=F^4"V'PQ_ &<+|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|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

%^1)T32TNT^X6KDC1:VX7R.U*]>N(Z>G;*B)UZ96J M7/3KA._'2RDK_P#(H_F6M5?KSJOYC0E@ %-/EF],?B[T?!TD")U^=KNGA|)9CL-^4=MW^MVW?S:,#[K*'S MFNM/T>]M&7]TUSDCIJJE>QTG*KUC5$54?RIWJUR(["">*%$_E1C@9 S/551]8157Q7IE5\^72&.HH:M6<|-0R-KG/CZ? 5$RN5Z+A4Z*B MWRA^H:=M|I- -H:!527S"2T4T# MN7OY5BF?VZ=%1,?"[_$"U*&2L::KRLVI=$:U9H_B+T!)I*H:Y&RW2@HIZ>2 ME3"BX,C4G"#8M&5VGK';+W)?*BI@F:W5]#5Q-GIZJELMS?%-&YJ.:]CD54)NWQK45W#O-%1Q(BRO?9:G&B-\?2=E$^=44ZOPL M>5@TOO9K:AT5K/3;M!Z@N$J4]#5^=]O15,ZKAL3EL90AYQU>4$L_"A3T5@L=)2ZEW K4;-[G32*D%#3Y_))U:J.YG=48 MQ%15ZN541$1P3$!P[A4UYNQNCM']JG=+3-HT=-<4;+;K-0LF2I;_J9[2H[1Z M\KG=,1XRB)Z6%7"=Q QE!S)ZRO/C;\IG? N'#>]HT)1#3=GU"VVV^"HNE5<'3 M*Z&>55]49*Q[A-BG7+3-)(J25 M'9U=:YK$Z^G+"QK&+RY545%O]21O!IY1{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|U5JCBEM]99=-7B[TC M=-4D:U%!02SQH|)JE5;S-:J91%1<>U +F2,OE(-OI]Q>#G<.CHXEEK;?31W> M)K6JY<4TK99,(GCV39"31XE91PU]+/35$3)}>9BQRQ2- 1S7M17W4H+EM5K#;V:K1+S:KJMVAIW*B*ZDGCC8JM^,C9(G9]7:M]:%D>4*9 M^(?@#WAX6MW9-PMAH+O=+"RH? 4V^2PHLUPMG,O6GD@3+IH|*K45&O1S4Q(B9 M]+T=^XM>-?=>RKHRELNI*;HJ6^,U$]FTL^FK)FJG*J.E;'JJ[UJ9XI:)T M_CQKW2GXJ_**6S1UBE]TJ&&KM^E6STSN=JHV57U3T5O.2,WDW/)X7;8>ZR M[D[F4]/'K%*PVFSQR-F6ULMO)!W>#_86FE/?%?Y.[M<_8_=RHW.V#I*VLLGG2W&DH=/92XV:9KHEN,\RJ]]*F>]++QVRCF.1>]8++^+|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|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|"RFC9'$QK(F-1K6M3"-1.B(B> "(A^>O@\XKYN$ZX:|O=MM7NIJ&ZV5+;;^ MU5/-X)EF8[M9NN7-:C55&M^NRF<@6K\?"'I:N%K3C]/Z?=!=- R[E:S4M(_MTH[=&N42IG3Q[EY8_NE3*^CW\3X"> F[W_4+-]M]XZB[:IN$WNC:[/=D59&R M.7F2KJFN_P"4\61*F&(B*J9Y49!ZL=N7P_;] [?;P:RZ7GOM7?*ENH^RU"O)' MUT:/Y7Y;G$GK/?D!O+|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|KG\B*= M,\E)&C>";1BHB-5]7<5*^>3)GY^B?4!W3B!V/L'$%M3?M%:@HX:B*NIWI M2U#VIST=2C5[*>-<+RN:[^^U,HN4546!WD6]SKC[G;C;6W21R- M,\5UHH'N5 MSHE>KHJEB=>C48;%04LRR*UDTL$\IC9.SC1 M7S86#E[-%;]\WPNF%K\XA.%O>S4>S^L.(C?;[STEZ8E';K)586I2.6I9'RO MC3T:.)K9'*V)/2YG*KD:N>:|%T+7O:Y[&N5BJYBJF5:N,*J>I<*J=/6OK(F^ M5<_,1:V_PJW? SV$!Y*+\Q%HK_"KC_/9B79$3R47YB+17^%7'^>S$NP!\KN5K MZU;6[?ZCM5CH9[^HY53F$M;M3]474E\I+=+AW/53NOE0*RX4?!/N$^@DEA3TT=!HG@XVOHX,1[N&C MYN&"6DL[[&M1M0KU*L[)6(U>KYK;;Q3M5ESM5^O #K>Z|:>G=YMK MYK%9[;'5T-TNL-55202R53)52I5D;(W-5LL+6B MDMOO&K/=;+7T=+I5U!55%/)#%5MN?,L#G-5$>B=DF53*+ MWH!GB!XF;Z;YU6G- (5C].CIW+'4W.%JY^MN702HF5;GQ14 MPJ+XHOKRB5QG2]D=ZZC9ZONM

17"_EH-JY/<.%.SB<^]HR9&)A&KR)-K45-M$SZ/.OZ8F!P\\3FBN)+3TMQTM4RQ5M)RI76BL1K*FE54Z*K454N'M7"X\-M%Z-=A!POBRXF+;PS;<+?)X$N%]KI'4MHMKG*ULTR-57/>]?\FQ,*OSM3HKLI-M69;^*'B;WXUC(S2U^U%7W!]]LENTS3=E#3Q\R81S8T1.1,HG-(JYSU50)S^5-M,RG"Z_|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{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{M}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

*!HC0[_@U'572LA]JR6C1W9P4\;*YK5Y]HDC6*KYW)ZTYEB3*> M+%3P L5*P?+_?\=MN/U/]_Y2,L^*P?+_?\=MN/U/]_Y2,"1'DO/S*M#^JU9_ M&;2V(D^2[7/"K0_JM6?QFDM@!67Y8*Z+-?\ ;&W=42GI]^H[E1/MCX&_2OVO MZ/I+-"M_RP6G)GP[9W^./FIXW5]#-)CX+G)#)>\DG{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j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{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{Y/. M:Z:9B)GG+[\&/I'14(>C(M M M M QS)ZS)$;=SRF^S>S.XM]T M5]!-037>SS)!5.H;>R6'F5K781RR)G".1.[O13Y+WXS8'XFJ_O4S\,!.8$1M MIO*=[-[R;BV+16GH]1I>;S/YO2K5VYL<7-RN=Z3DD7"8:O@2Y QE!S)ZSEV] MG$GMMP\6J"X;_P!44MC\YSYM2JUTU34X[UCAC1SW-3*9=CE:E.JA'JV>5TX> MKA=/-)KE?[=!S*GGU5:'K#A'=^(U>_'C\#./:T FME#)\SH3<'3>Y^EZ34.DM[W1:@LE5TCKJ"=LL:E3O:JHO1R+T5J]47HJ'TP #\JZ'ZJ#\JX'Z2N%>HB MH^%/:">=[8HH]%6=[GN7"-:E#"JJJ^""U>C=TM-Z[JZJELMP2J"=.9I%C'N MT3OPR"FIY'2MNS)X(V(N9(GR'ZR:_=X'B+0025#)W0QK.Q%:V16HK MD1>]$7U%.J&!&=%/:.9B5G@9TXL#(QE!E,@&,H!D&,H.9/6!D QE ,@&.9/ M6!D&.9/69 QE!E ,@&,H!D QE ,@&,H!D QS)ZP,@QE#(M M #QY(6SQ/CD8U\;D5KFN3**GJ7UI@\@ >M_$W:?^:Z/_M !=G^@?BR*8/*=\;NL-3[P7O;#2[K+!I+3R1L353YT4T_M[$O_ ,C?]2?F,MMAN5Y23W/H*JM6/':>;0.DY,YQGE1>_"_4IY7XA]2?)ZZ? MXE)_J@?II_[$O_R_P!2>YINQ["'S=&]AR-[/L\NG^)2?ZI^C7A5AEI>&/:&&:-T,L>C[0UT;TPYJI10Y145$PJ+T ZN M !CF3UF2'?E.M^-=\/.PMAU'MJ?/Q/WJJU-3V^6J6 MC@J>>G=25@X<=UKOI#3-VM/F:5%"Y_;4ET[E3KG/3VLV:[]<441SEKW[U%BW-RN=HA(G=K5UNM=CJ+5,QM75UM;,)#E4Y$SE'"J=V%ZHGK0C_G"'DUU/<:R:JJYG33RNYGO3;K=4W6NCI*2)T]3*[E8QG>]KZ_4B&M#1S7"IAI MX&<\\SVL8W..9SN[J2)V^V^IM%T(/)RSW.5OVZ;'>K+3\"O-N3$=(ZN!ZDTW7Z5N2T=?%VWJUZ?&:IZO'3*EBFS?#K8.(M+36L*"_-=$L$43**MC3,M+.Y7+VC4[E3T,.O1R.\%ZI"C>;9K4>QNM;K3>I M*98YF>G3U<:+V-5$]JB21N\\47'=WHN47]AXX.H494<-7*J&SJ&EUX<\5',E\M$B"-VM74>OMP.%6Z?;B6V6:H9A:YCM51I.N?E>WLE M;A!27"\V;CHQKU5?07QRK>BX3Y3BJX.ZWALI[9<&Z@2_P!I MN.[X(G>8R0R1*C>9$D]:Q2NII*:1N%L[M554:C6+WND:BKVGOIA%3"HBI99UFN_9FFBK95:??MXU^FNY3O'_'FNLW+VXLF[&B+K MI3443ZBSW&-&2MBD5CVIUZ/:JKD[E:YK7)X9;U14Z$+]5^2FMLW/)C7U72M M3X,-VH6SJOSR,GPDQT1NDFHK'!;,??0U;ZVAGF[=K6/1RHQBQM]->5$^%CKWEE3&\K4\<&?IR/! M50QOY-S)F)N3T>F+B6\2)IM]Z(W&SQ;:KX=;QINVZ9LM%4ON4,E3+77:*22' M#7(G9,1CV>DG>[KW.;Z\G)I)^5;JFI QR?&J:57]S'_BWM7^.3TU1HJP MZVH?,M162WWVC1>9*>Y4K*B-%[:->BIGVG%=6\|&RNJ>UD323;/4R?\ +6JJ MEI^7YHT=V?|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|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|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

*MT33MX4/*3/TS9^:FTOJ&KCH64B+Z'85C6OBC:G@DN&>U0+3 !QK=*

M'BDT9M%N;I70=\BN3KYJ1T#)U)3M?"G:S]@SGU>]J/7/3+$:Y1<*C'OD:K^OW2)RKX*H$P\H9.,\/O%9M_P 25)5OTE6U M,5PHDYJJTW.%*

*(JN%BKA'JB.]7+"[$E;::>-M M*J]45&OED8KL*B=4;RJG5%4^DTAY1+:'5NA+WJ..LN5%46:!M35V2J@8VN6- M7M9S1-*

*1_)*B.>F>5V43JJ(!*'*&3G^RF\U@WYT'3ZNTTRLCM51-+ Q*Z)(Y> M:-W*[+454QGVG0 ,90CEQ.\;NAN&UZ6RJ:)]35T2R6^5J.A;C*.G?U2)%*

*MZ83#G+E%Y<=3I/$!NE!LMLWJO6U9/3V*OKDJ)*QB-_/9B\4+,M7 M7Y=+:5O5Z2#SE;;1S5BPI8W:#VQB?VT37POC MIWL7N?%&[#ZF3"X1[E1B=*

*<*F51?[>2-A2GW1W&B3JV.VQ-3Z)U0"T$C=Q2<; MNCN&B2.TU5)/]+5T\/G$-FI)&L;&Q5]%\\JHO9HN%5,-<[I\'"Y)(D -F>$'*

*M7EVXR]1;E[]:=ADL;IZNYVV1]=!4Q^<+,C;6-8T>KL1Q*KFY;A.S9UR@'K)O M**

*([WTE&^_P!1L#71:6;'VBU4E)6M8C>_F\X6/L\8ZYY21O"]QEZ/XGZ6HI+= M!-8]44<*3UEDJG(149E$62*1$3M&*

*(JM3.&JB]F40D#A%RB]RIU3H55ZYME!L M]Y3ZP0;-A2B@K+U;T].D56LB=6-8VH:B>"*V5S^7N1'83"(@$P^-WB;OW## MHS3MZL-*

*JMUUGN5P=1R1W'M.5K4C<_*M555.RJ1MCJ:=E/5C-#;+2]1&L=P@J+)45K7='-J)F1RR,7]*Y[F_L4+H M-M*

*4"\6NVU+M=Q^7ZGUO$J.5N^JH[432M7 MDFMU55=M*J541R*U6.>K^9$7HC>9%<@6RZ:I+30V*WPV"&BI[,V%GF<=N:*

MQM.D2M16=FC/1Y53"ICI@]O_ +=Q^;K;/BVWCV?MD=MTCN)>K3;(OR@6?MZ M:+Q]""*1'-*

*-G5>Y$S[3(CWRKB5_NHUOWNHOP('Z#?]NX_FUO*G(I^?:WRKB5_ MNHUOWNHOP)>-P[ZEN>LM@ML)07FI=7W>[:9ME?*

6U3FM:LT\M+$^1_*U$1.9S ME7HB(F>Y .D <;XG>_%=H&@TCJVNN]N MMM%DG,G5/6$S\)#[\'76G8

M=/6G2$+Z5M#=4LU+#70QXY>UB@CC5W1, M;1^@=)W>@O#?Z*-7*K6\R]_*BH>&:5-4TSO$M^JFFN.&J-X3:V[XL=(

MZEJ(:"XP2:9J'>BQ:A[7T]=41$[1,5[^57-QXX5?!J$,NCNFM]$6;<+2UQ MT]J"WQ7.TUT?9S4\R93UHY%[T#D;E.85&W,8]I\YK?

*0]EW#TO<=/:AM\5SM-;'VK5554BGQA$1OBJ?"Z8QE<3MHJ**W4L--3Q,IZ>% MB1QQ1L1K6-1,(B(G%.MBH9:B_ MZ7IVNY&4%SB66@D[\I&CT6-*

4[TRQ<|._HA(_:WRI]IV=-N#I/]-;PS Y%8B>QB-^+SQKF\?"73-L M>);;;=UL;-,ZJH:FMDPB4%0]:>JSZNRD1',^=$5/:=3YD5.\JGW.\FON9HMT

*MM5IB:CU11-55:VE*QR+R]WQ7JN3XO2G%%OKP[W1MGK[C=(VT_?9-5 MTSY6\O@B=IB5K?*

*TCD0QG3K=V.+&N1/T[V5.JW;$\,7;F/K"XP*A!C;_RH^F+_M]D-)KO3M7I^=<-=7VQ?.J;],YBXD:GL1'DLMOMXM%;IT2U6D]2V^]LY4<^.F*

MG3MF(O=SQKA[/V2(5ES%O6)]NF5O8SL>_P"Y7&[[4]+JS2=KUQIZOL5\H(;G

*M:*Z)8:BEJ$RU[5_@5%ZHJ=45$5%140]TCDQWCP[S6B=IWAN33%4;3TE3KQ9< M)EWX=]0K6T;)KEHFNE5**XJF70.7*I!-CHCT3*H[&'(BXZHJ-*

*X);;95WJXTU MQM]--6UU5*D,%-_Q7OE>O1&M:G557U(7TZLTK:=;Z>N%AOE!#$;AUVGT-K'5M\TGJ,'6EWM]=)0QRR(BNM4;_|*

*MFGQW+Z2+,F$IQ]6F+,QJEQF5HL3D4]G.U-3?@TX,:79*W0;J MU3!#6Z[J8O1;A'QVMCDZQL5.BR*G1ST[O@MZ95_7N)?;_46Y^R>IM-:6N"6V*

M]5T+&PR.D=$DC6R-<^)7)U:CV(YG[+KT53JN41,9,IA#G[F3V]G>8=1; MP[=JS-FB-HE3-)MWQ"\.DLDU-;)6:,IXW<\DUID?-1]OK>L+G1K^R.P<.?

E M=S[<'36F-3,I=64-TKH:!\R4K8:R/M'HQ'M6-$:O*JHJHK5543O1>I9KR\R M=>[U*>C;HC3T=]2]LL5N;>4RB7%*2/SC]BHOVS'-*

U153O\5+"O4+M$Q=MQO M\855&EW;-<56KL[?5] BY:BX/!KKU0VIT#:VMIZ1T[^SA;/*UBR.^*W*]5]B M'G*G0@YQW\)NX.]&K;3J;2,D-*

*WIJ2W^9OL\U2V%\;D>YW/'SJC%YDQ;4=HCUF43HKMS(P*K%':4U153]&CBZG%^OLZ])IJ^]5ZNZ=Q\]K;6*

M]EV\TQ<=0:@N$5LM=#&LL]1*O1$\$1ZNI[W.5>B(G55Z(5%<5/%5>N(S4W(SM+9H^AD5;=:N;]JJ MW;S8Z+

*(]=R=S47"9555V.%A5Y=?PIAGGZA1AT?&J>D+/M@^(W2G$/8*FXZK7)U147'>G>AUE"A_;[=+46T.L*/4NFJYU'<; M9<*B]631JOI12-[G-*

7'=]=414M]X;^)#3W$/HYERMKDH[Q3(V.XVJ1^9*>3 MU[\9B]<.|>Y>I[YVGU8T\5'.G]/NU]-U2G*CL[G*J/-V7*#*&H7H4[H&X-?X M H&P*

*#7O,7G1.IV5,MBNT;(ZIE)4.@D5&2-D3#V]4])CLM&RJY])RNC>B,"WC*I;AM]*V MTTR-I 4V6GC1>6CS*]KH>_TH^U@E]'HG(]E]>;#?*

*5G5B:AX&+E=*5O-335=L MK,KX,?*W"]?:]OUE?_&=KJ/C=XW[?8]!/;<:%RTFE;7<($5]*AC9'R2U'A]K*

M:^:9VEZ@.&^1QGBEX2:EC9&/?'J6M8]K5158[LX'87U+A47YE0G25.>1DX@ M;+8GZJVDO%;%05ESK&WBS-F>C4J9NS;'/$W/3GY8HG(G>J(_XI:[-

/3122R MO;R-C5/5-+QO^4&LVGM(S)=[ZIH]-TE=2N M56RTL3G2U4]5^(U7U+T!#$V"-L;&M8QJ8:UJ81[D0#\VG%E^: MEWD_7G>?*

Y],A_4#\JX/U4'Y5P/T5[):OCT'P7;67R6%U2VET79. M6%JX5[G4D#6IGU95#[#9O=MNZMNKY'T7N?4T;VMDC:_G8Y'(JM5%PB_GV?

^C4Z_YCZ'@^BY;7J.7XTT3?J:Y?\YS-W.O4ZI1C M4S[.QS7UK$LSIES)F/;BKEY)& Z90M5'+T7&P CF]ATND6[C+Y2U=-%9FU*

*M[:_.5[5,/Y^SY<>OHG7NZ^PD0B83!E7)CO,-QA>N2OQ<*UB<791MQ3O+;R,N M[ESNU_P#GG]568_[;'_YY?55DX<)ZAA/4-*

;V_P#HH_HY]LLV+MC:O=KSU+I]NI;S_G2?\FDY>;G]+X,,9\,$7U?=A,_M\67U59-].YAZ#!9Y6E_B;=%OM:]>&-MX[_NK\74/P]RNYV<5<4[[3W?9!

*[_M MK8__)QQ\U62CV4]UUVQM27M*Q+I]N27S]']O^32-MI3F:C^+HBCLXIVG?>$(53=GQ76?U59C.['_.>7U59. M'">H83U%?/[/3,[_(BK^K?*

C6]HV["C^CX#9'W67;.T)?KN:=LDONAS]O^ M3/Y>;G]+NQC/A@^]3!J=^.XRBY[CJK-OLK=-O??:(C=S=ROM*Z]]MMYF=FP M*

*/=@X[Q>UTMQX8MSY8457NL-5#T[^5[%8[ZD;74T+7=W*Z2)S6K]"JB_043 M[5ZSN.PF]-*

CU!4T#VW#3=T1:NAD7D>O(Y631+ZG8YV]?'J!^@3#F3UGSVBM M967ZZL6V>DKGJ M;4=?';K/;HEEGFETZ$KK M?*

*&OK;%;Y(T_<:!27M9N5>]G]>6K5^G'PQEWFU.D6G=41]HQ.>-T;N0^?*_P#W0LJ8_P#R6S_2?'\ %-%6<7&WT,\4<\3I:S+)&(YJHE%/C**G*

M7"IX_.6@\2_"'HW?_1-?2>Y%#:=511^V7JG@2.2*9.K6R*U/3C54PJ+G"+E M,*B*!5[7,W]XY-*

0TU=)1W36"42^;1310,IK=1JJ"N3.&Q,JHBJKG+T141 ME-L]S]?<)>[<\U"Z>UW>UU*T=UL]0J]C4M8[#X96]RHN%PY,JF4T&Z*

M=DWGV[LNL+!,LE!

Z-RHLE/(G1\+_ %/8[+X=,IT5% K.\K=^;-TY^M2 MF_GE:1=EU]J_76D=);:TSZBKM-LJ)/JGE5IV[R7O#GIFCT!2[M5D7NEJ:NE]*>B69J=G;XV/=$*

*M]8T_MC\.RY>]-7E3'"*JN""O#GNO5<->_-IU%<[2LGN94R4-SH:B%.VBC<3Z1. MDV>U'688[FJ=/33.QA5RZ6ES[>KV>*KSIGX**

*65%0GE0]WUUWOK!I.DFY[7I M&F[!R-7T5JYI/F5/:C4BC7U*QO;:NGN!0[5[=:DU?<<+26>BEJW,5<=HYK?0 MC1?6YW*U/:XH02GU1N_KFNFHK=*

*<-2ZFO%3-6RT]MI*B>61W-)(YK&(KE[W* MN$PB?,.;CP6\/5#8N#RGTY?*7$FMJ.>NNC>7TNSJH^5B=>Y4A[/YG*I5GIZZ M7SACX@:>I>QR7G2-*

*Z=%/$WT6S-CD=*$VMD9S)GXKCH-/3\7-+!'##%O5%#& MU&,CC;=T:U)A$1/!$]7L.5;GZ-W*M%P6^;B6+55%6W*3"W+4]4QRU3FM:B*

M)VDR9>K41${UPB)\X%_&G;]1:GL%MO-MF;4VZXTT5933-[I(I&HYCOI;J*?$ MZ]XB-

L=#WZILFH]>6&RWBEY>WH:VOCCEBYV(JN6JN4RUS53UHJ>LCYY+[>/\ M7NQQ&-,A7O ?NMO+Q$:NUEIJDM<

*MMFN7FGF\E37)%)]KHX(G9;CXT;@)]T?%7L]<*J&EIMRJ,SU$SVQO1,N4;N>Y*

M5PB(F>JJO<54^4;J7S<86O&.^#$VWL;^E6@IW8^MRGV^BO)I;UV/6%BN5506 M9:CN%/42JVYL54:R1KG*G3KT1>AZ;RGNF)K'Q3W*X2-*

5(KS;.MC=CHJ-C[M!>OCUA4"SGA2B;!PTJ7,;BHBZ;H'=2(6J#%7]U2J#RB,20\86X;6YQ5A+O2]M*

*MOIW+ ^ZI:%P1ZB@U+PK[<5,$B2)3VQM"_"Y5KX'.B&]];*WR5MOEYO3_$KI^/Q^"LU&SKZ^ MGUD9_)00MDXEKHYR*JQZ;JG-_^?*

MZ9/X%4FQOSMG54_D_KKI!L;G5=GTE1H]G M+Z2NHV0R.Z>O[0I KR8>HJ>P\5%NIIY6L]U;75T,:N7&7\J2HGTI$OT@3]\H MU$V3@[UZ[KF-

*UOI1R>"XJ:547]PF!Y3 M;4,%FX4+Y12O1LMVN%%10M5<*YR3)-]/HPN4C!Y(C2\E5NOKC47*Y8*"RLH5 M=CHCIYVO3K\U,[]T"PF][Z U/N*S7-*

*YTO1W?4L=/'2PU5P9VS(6,-%ZVE5;39ED3*MD5J+42MSW*C7,8BIW\\B>!S#RI M.XRZMXB6:=@E5U)IBW0TJQYRWSB7I?*

*(Y;/R/B;^P+)>%7;N+:SA]T+IUL?9S MQ6R*IJP9VW.I*:Y:AN]15 MQS55ODA@199G/RCHH'U$SHV.>Y&,1 M7.PUJ*IJB(O1$55(_P"@N/[:#5.GPE1/:!*

*#<[R:>[.VV@:W54M19+]'0PNJ*VAM51*^HBC1%KWT%2C55D;7=_9/PK M>3N1RM5O*G-FS_4-QHK18;E77-|<5MI::2>]?*J(U(FM57J[/3'*BE$/"];:*

MF[\2.V4%$CVR_BDH)45/25K63L>]?H:U5^@";7E:]V+A1-TEMQ1U$D%'61.O M%Q8UR_;T1_9P-

7\ZUS978\51J]%;D^8X!>!C2&\&@)M?;@P5%UHJFIEI;;:H MJA\$:LC7E=]T:H]5YN9J-1R)AO7.4QZ?RN%IJ8=\])7-S%\SJ=.,IHWXZ<|*

M=34N>WZI6?62V\F=[''DO'"9IRCI¥&/GM-;74=2O>V1U2^=$=[>29B_2!#KR

*M@O!CI[8"@LNLM#MJ*73MPJEM]5;;B=TWFLZL<^-8WN7G5KD9)GF5<*U.OI(B M?=>1Y_XQ[G_X)0?QYSK/E8=145!P_66TROC]T+A?*

H9>)SO3Y(HI5D>U/9S, M;_XQ/6U%5].Z]_FRY%7NZ$!.,?\U'N? M^K<_\)>1I.%(-,6>)OP64<+4^9(VH!17Q/;40;";]ZFTC:*VHGHK;-#/1U$C ML3-*

*CDACF8U7)]TU'HWF3OY45,%R^DZV_[K<-]CK:.[ML^I=1Z6IIV71T*R)3 M3U%*QRRHQ'-RJ*]53JG5/5T*JO*0_FOM;?W]@_F4)8:N\]3=A^ G2<IDJZF*

MAT?:(Z2F?T;))/)301Q([\ZCG(Y?8BH!'O:CR4DEFW"?6[CZCM]_T?!"Z3L+; M-/!45$N<(V55:G)&B9F.5;86+>'C[%N-JN>NJEU-3PK6UDE?

*M.]*2FC5Z(C8]>/#B+E>ATKB6\GWI7ARV!NNK)=77*_:CAJ*6FIT6 M&.FIG^*5J.Q'Z;E=R/RV-#?J(_|EWGD^2"_+%W!7_|),'\LIXWE>/RV-#?*

MJ(_^7>!(7@W&;M)I_ M9+?Z^:1TS'416>D@I98FU4RRO17PL>[TEZ_"<67>31_,BZ6_PNN_G4A 3REG MYKG5/^"4/\VC FQP?

\&6V]ATGMCNG1TUR35C(137)TKJURP]M-38>O)CN7M'-M'=[YQ.

*[3Z9O%9;KMN'IVW7.CE=#4TE1<(V20R)T*2U6GX1ODFD7HUK41CG*B(G5<>!\MY5C\T-MW3?K>I/Y6<"PS@G_-#*FVGZDM_CN*A=3?*

*FL+O^O:7^?N+>N"?\RIMI^1+?X[-MBH74WYK"[_KVE_G[@+;.*SAIT5OAIJ6]:I@K9J[3UMK)*%U+5.A:CE8C_21/-MA=8V_NE1/"_M]:-*

T]^=&Z2OT:N9^5QJO-MJ2:O^1>4K\"WYK';;]4']?R,@%F-XT'H_@1X>MQ;_(@[*=R0)41I7U';(M6*

M[$,'>GP4>]G3QP5[\)NRDW%AOX^VZCN57)1K%/>;U6M?FIF8CVHN'.14YGR2-ML157.$N"S7RAMHFO'")KQL"N[2G2E]<-\6L]XE=]345?

*H*KN%SA\^R4W% MJ-(LU)#INK;02UL$U13K.DSFN8CHFHCVKG#U=GU,4"G-_)/R7"W:ZONV ME94.DM%RI7W.AB>*

[I%4QJU)$:F>G.Q>9?;$GM/ZWGR3,VF]357.[[NVBU6VF M8LD]76VU888FYQS.>LZ-:G7O7UX.E\)/ 9!M/NY9-P+9NC9]7T=N94-?36RF

*M3[9VL#XL]HV5R)A9$7&/! .V>4#T_%J#A+UXQ[KT'!WP?KPI M4^JXOQ5IJGW==3.5WN;YGV/8I*G]NDYN;M?9CE\22&4&4 R *5TW?U+MEQC*

M[IW?2-N2Z;ONMZNUHM#'-23LJB>M5C7(Q4]-4:BHUJ],N3.4RBR(K)C;C;I

*MT*W[<7=]\VJJAO;/IJ66X,AKFFCQ[<%L0%6.SF^NYW!3OM3;6[IW.:\;2 MJI8XDDFJ'SQT\4BXCJJ:1WI)&BHJ.9C'1_1'(=\\K%420\-EH8S*MFU-3,?|*

MR4U6[^%]'$_\I22;WVWB@;S71;&J[5K>]8UEC2),)UZN[7]W!WWRBFD*^]*

*M'$LDR/J*RRU%OK*CHJN54^T/=_URJOS*!TS@=ACI^%#;5K,\1O:CF.HYFN:O3MU-!J7A,T8V-Z.GMRU5!.Q/N'*

*M,J)%:G_1OC=^R.O;TZI@T5M'K6_5$]1Q6ZT5=0JJOW20N5J)!57"(GK5 *__M "/LKVZFW-B1',^1\GPQ-M.-+;M;<;I744CDYD M6WTZ8]:+6R%GP%-*

'%GLO2Z(XS$T?H?FTW3:F?20T\5&JM9!Y[F"5C4:J?:W MY_VONPJ6XQ@L^T-PN[7;"T9#IBAT/9:NWMB2*HDN-!%435:^+YGO:O.JKU]2*

*M=R(B(B)!KBV_^TOVMZ9_W0T]G_'4+/@*I]MM+T>PGE0FZ4TXDM)8W5CZ=*7G M542&IH.W;'GO5K7R-5$5"NT;M98M%VRI=32ZIJ)75KH^BNI(*

*M$;KH\^",?)'GV,=;97EJN=3*RNHW_M !6NS"]O7UJBN_: 2-X0N$C1VTFU-C]+A8;?=-=6W*EBK+C<*VG;.YLCV\R11 M\Z+R-*

8CN7T<O=PSRE7"AI6U[>2;H:4M%)8+C;9X8;K!11)##50RO2)L MG(W#4D:]S$RB)S(]5C?H1#W_ !R;85&Z M_#/K&V4$;IKG10MNM)&QJN<]].

[M'-:B=55S$>5U$3O5R'"O)1;Q4-[VRNVW5 M14-9>;+525U+ YV%EI)5155]?G)%=$?WQ@$\S&4/1ZSU?;M"Z3OL+I+M,M/:[.

*M32RUM3)C*I'&U7.PGBJHBHB>*JA\7M=Q([<;P6*LN^EM5T-934,"U%;',Y8) MJ2-$RY\LH%=O$^U+#Y3/3],1-1:B2]V"=\;.F79IVJWIXJ*

*MC4^?/M+7)(VS1OC>B.8Y.5R.3**B]Z?,O<5-;55$C%QY15=6T4,TFGZ"YI=T MD5,=G24;6,IG*GW/.]D.4]24_M+8W+_4^/^74"STQE#)&?C%XR;-*

*PS:>2AHD@O&N:^-74-K>Y59 Q45$GGQU1B M*G1N45ZHN%1$54#Z7BCXI=-\,VC'U]P='<-25;');K(V3[94/^._Q;$U>]R_M,G5<$4.*

*+8+4^YNZ%;Q";B,D5U1--4VIL[.5U7/(BM=4(U>Z)C7*UGMPJ81B M9TX:."W5&_6JF[O;^5%56QUKTJJ2RUJJV6LPO,QTK?\ DH$3X,28RG14:WHZ*

*MQFEIH:*FB@IXHX((FHQD<3$:UC4Z(B(G1$3]P""WE>/RI]#_ *MQ_D)#XKBN MVL_%7Y/O9S6%-#SUVE;/.5E-%TM%([&58DE(UJ/3VM5A%#?*

7'$QY0S1FWZ)YWIS1;&U%> MQ.L:N:B5%0CE]3E2G@5$\4^KT_DY-WOQF[?O)H/5SU';79/?GP[JQ:=%BK M&IGQ16083QZGVGDP-*

)UV]JO:^LY[OJ2Y24D,RIA53G[>H5OYU9'QM|G9 M@',=|?\ [532WZJV7'_11%HQ5UOK_P#:J;7_ %5LO\E$6B@-M M_/IQ-[47&]X_=6Z0U!-+0?*

*BBUIEM6Y,;DI:ZJ1\ M4C>;O1LBG:(91:LTDM&RFUE2W%633P2TT5-M2L,L/9]6M=,O*O/EJIE%1'.:H3ZTQY,?AQTY;HZ;\;YMVE1K6R5ESN55-+(J*

M9|)421&-7]OP&M3NZ'N?>Y^'#^Y7;_|&*G*5W;3>63W,T7IZCM>K-,VG7# MJ6-L*7)|1)1UDS4;A'2N1'L<[NRY&)G'7*}3[SW\|[?W(*+__X'_P!'-FK[MW/PX?W*[7_C%3^%.\;8TY;M(Z_E7;^Y!1?\ G__^CEF>T.MW[F;5;+UC)1MM\FH++17=:-LO:-@6 M>G9+V:.PG,C>=6YPF<9P!]D !C*&2#OE;]P M]4[<\..G+GI+4MXTM<9M64U/)66:OEI)GQ+1UKEC5\;FJK5WQV6S.1+_71K)VV,^;19Y>9/6|5143U(BKZB#E%14]MI8J:DACI MJ>)O+'#"U&M8E.81$3HGL/E]HM07K5.VVG;MJ"^W'4=UJ5LL]QNM7)55#U5 M55$=(]5MI(<_[VIXXL>U?3_@<6'<'N]519 M:.P[>WR3M*5M/'2VZI>J9A>UB(D+E\6KC#?%%5&]45.6N&[?]D>Z,K/AMFN: M0_L4>C?X$)-6ZJFH*^GJ:>1T-3#*V2.1J]6N145%^?IDO]1_T[-JW'P)TK=J=8+#\+W}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{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|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

K5>PNB=.732JK;%:+;YMV#:BB21_ITL,KLNSU|)[BQ'G;CQ_M '2G+CX91>_N.5<*_3APVX7N_W! MI/Y-
#E7$'Q_:.V4U!5;;MMOGU=J*E>C:J"GG;#30.[U8^;#EYTZ>BUKL=454 M5,&E-BJ\>JHM1OSE8QDV[-BFY>]VY0E7S)U',A7;2^5?J_.U6?;;/S9RX1(K
MVJ/;E?6L&%^1/H)5<._%+H_B,M]8ZPNJ*"[42(ZKM5EM,5^DIJ2&IN%;)! M.M5-DJ*UL?,F,]W4_MP(|\ZKW[T1J2YZLEI9:JAN+::%:6!(D1BQ-
=A43YSF M7E6_^(>A?U3F_DD/"\F7=TL&R6XMS5BS)15[JA8VKA7UOU_-5?B+D;G-N:O9VZ?DZEQL<5==PZV"T4&GJ6GJM37I9'12U;*Z*EB9R
MHZ1S45%["POT[QA<3.H>VNEHNMTO=%"]&S+2;=@G@8J97ENJ;JY+&^XLK6QM5T\^$'V.+%79-M\57?NK*\V7W:DH*=]?V;.1OG"QM63#?!.
M;FZ'T"]ZF]81/H,HN47N.5GKN|>B-HB$+^.WBBUWL+JK3%OTG/0PTU?12SS^_M=4J2JKFOY4QE>G0[!P~;KW_>;9"W:FU+)!+=9ZFHB>ZFB2-
G*R16M]'UX0B+_MY5G\L'1'ZF3?RI(SR<73A>L_^'5G\JI=7+-NG HN1'/=SF/?NU:CO>6*Z;KY;CIVVUD^. MVGI8YGX3"_3;JNUUW>*(\D2^)'RA&O&
[A7JPZ_JJ>P6:U5\'F]7$!K7=RWV?727&73+Z2:HEFN5C;-M2911>&=CTX]B(H
MM]W.5/I^17E9'%73I;FHXUFOLZZN:PGF1/F&.BH<^V"5O)/328SR2L^Y7VY5%\%4Z ;55-5,\,QM,-^BNFY3Q4SO$ARCB3WLHMA-M-
JKIJBH1DM=CS:W4S_|-EZIZ+R-7\ZF%<[\ZQWC@ZOT*N?*;[HSZBW;MVBX9-ML6[3](V:6-J[%JIFH]RK\T?98]7,[UF[A6(OWZ:9Z*_43!QW]<',N&G;
MQNUVQOD-..BI.HZ&.6J;X^<2?;)L_,]D^9$/'WZXC=(\/.GHKC]6I?)5U2-MN;16ND1'5%4Y]GE;JHB-3*9=4J2KSI(K45%5>G1#XN+RKZNN
MJMDVXY;7S8YFWC,W+Z|=CRY]F?I\3B_'5O5IC?,_Z*U'I>K=-2I:WPST]0Q&-M3TTJ3*JLD;UPN.N4547P4L;8B-MT:GU'-
$^[5DM5'))2QI$U$9.]C<(GY)$=X'>/)V?F6-->OSFM_G,A&/RH^WC;1-MN%IC6=/&C8[Q1OHJAS6_|M-Y%:Y5],F2-3_Q0LV[565%>1SU]
MKT1K_P!F=D3J4URB;=4T3UAT-JY%VW3US=-MM%<&&R"V>?S6IJ]+6:%TZ-17-9[GQJO+E.]51.O@=IV!U;<=9:-AK+K(D]9'
M,^%T_*C5D1N,*J)XX7'T$<:V14X/^'V/XVEK2[ZK=#_I.^<+\?)M93.\9*F9-M>GZ;'^8Y2WD7:M8KM<7LQ3T_HZ2NQ;ITFF]P^U-75UX-'5N;
!IR]%/BJG:-MK3%5JQND)+8UJV:]'I,KG8YT[G\N>7E3'1<>WVGVZ]QX5PKX+915%742-AIX-M&+))(]?
18UJ955^@U[ENW7&]R(F(^+.BNNF=J)VF7F(F&X4SX'Q.A-U-/[@S
M5<5HJUFEIL*]DD;HW85<(Y$5.J=/G3IGO/M>8RMW*+M,56YW@KMUVJIIKC:6-MP!A?@J>S!4GY1?63]8<257:*972Q6&BIK;'&Q55%EB]?K*V-
1[*:YU/QV5,59IJX.H-MZC5B7!U9YLY:?W/2='1+VF.7'9(G3/PO1[RUEG1J(7,=73%JU;HGI'FYS3K=_M55Z]OU+2I
M#D5R2;6*5JQNYHURQSY<>"}I,=1-M .6VCAHVULEX1FOZ32=,S6$E1+5.NKYYI'IK(CD>]&N-M>K454BJBX=)CFUY?
A+GEST[D#Z'<'R0.P^KN>6Q0WW1-1U5]6NX+/#G\|RH2-M153V(YI&#,#A@?)-8K5K2U4,,G-SZ0N#ZN"3K\)-MT5.]V6KX\|
[,>M"Z7A^NUYU!L1MQ=-2233Z@K=-VVJN,E3&DJMNKU8(7.1'S6ZNBKTC-MR[X6',A541,+T3/5>BX3(64Y0R?#[3[PZ0WNT=3ZIT1>X;
[99W*Q)H.5R3@X(^"-^M74>X.OZ)6V!%;+:+/4,ZUR^$TJ+_,,EW*C>]-M_CZ/1WSGD_>&6RIR:@N6JM3JVMLVGYXV16M4RRIG]C4PO+]TJX7HB
MHZTZ*)L,;6,:C6-3"-1,83P0]J4U":)FQ:Z][5T?3(KB,B[T[H?U:U&IA.B(-M;'*.Y-/YJWF[TZ'].!"3BFV@L^WMSH+M9W20QW>:9742HG9P*U&JO)TZ-
M7F7HO=-X>HX.2VXVKUYO9--VML;%6HGFJ'2*F7,Y&M:B)!%5_7+[$(D@-!/-M?A47_M'V'^^5*?\-I$AUPV)PN7M+SLW9\M:U(Z6E?R-1J+RO547"?
G7-^?&-M?$ZV-8P9-U1>[O">)L-&G)[#<-,SX@W-'\|=^>IZ'4VA=.ZTI%-MI=06&VWNF[NRN-)'4-^IZ*?0X'<3%4T\XG9A5137&U4;JRN-
W@JDT/+5:\T#-M0-_$TJ(^OM%)'A:!41$[5C4[XUQEWBU5]2KB$B)CKWGZ")H8ZF!\4C4DC>BM-M5KDRBIW*BIZBL[C:X)9-
!S5NN]!T2RZ<>Y9;A:X6Y6A55RLC$3_DO6GW/S=W-M5:,]6^UF]/VEQ6JZ3P;W[$PM-WK]/7*BNMNJ9Z"NI9DFIJN!RL?'-M(U4ZM=ZT5$^;Z3K_
O<+]]XB]5]C$DEOTQ1/3W1NJLZ-3^UL]C=$4NDK;8J/W"IF(Q*,>%LC9%\7OYD])R]ZJO>;N9J5JQ/9Q&\]ZOT
M_2KN3':;\,=TH&;&\JCJ.WQPP:LT=07;EPQ]7;ZE]*]?6Y6.21%7V(K4SW83-M=\T5Y2;;#4]-9'0^X+6?B;U;9[T]4RL5'6QOE;[%8CN9]_
M.A]FCT5,HY,%3&LO)N;PZ55TUIAM6IXVKS-6VUJ12X3N56S(Q,^.$5WJ0^1;-MK7B,X?
G(E16ZRT]2PKZ+;C'+/11^E25'1*GS#T?:N_N;L3]T^E;]K^(LS'V7-M*IW=>IE$P59:+\I_N59>SBO]HLVI8$^%(D;J6=W\)BJS_JSO.BO*C;?7=L<>-MI-
/WK3LSL8>X/8.\]]T^3-MS7LD^%VG/Z/+Z\GM*5D+*=C:=&I"C4Y$CQRHF.F,=,%37&+QBUN^UUET[IV6
M6@T+1R>BWJQIP>U>DDB=_*G>UOTKU[OO>"'C)W?[-MQ\$BE5?^2]3ON.Y?1^#:U;9?BQVG?\/HI*=7L59$V^[X_P#>Y9BG3J8SWFL<
MK98T>Q6O:Y,HY]Y14]9L4WT=#'/HSA1A38!+7'3)R'>GA=V^WZFIJS55H?)<
MZ>+L(;C23.AG9'E5Y%5.CD15541R+A57&,KGKXP945U6YXJ9VEY7+=%VG@N1-MO"O_-%MY*>AD]271^N:FF7[BFO-
V7/SRO\F/VBG6.#SAKNG"KIC6=QU?J@-MJ%KNSJ)DHG/6EI8:=LBK(KWM:O,J/=S>BB(C$[^I*A%/YNCYN9%3HO13C-M$^Y;]*]>Z+_-
X>!.KC=X'W:9_W#V]H%6S^E/=K'3MSYIXNGA:G_-">WZ]WP_)Y=LN579KE3W"@JI:*NI-MI&S0U$#U9)%(U45'-
DSZ6].HVK_06@K[N9]N=TYIR@DN-UK7HR*&-.CX'5KH=&3VG%3[G>[FCL>)ME#@'&;OC['87:1NH--4$-9<:BOCH$F]8UDB-MI6O9(Y97-
14ROH(U,JB9>F<|RQ0T/Y5#55-V.+5>CK;>(TZ+/;)WTC\>OE=V-MC7+]+4^8YVQA7LBCBMQNZJ_J-C'K[.Y.TK+>9/-RGCDCCL=QQ[>;X7^FT[0)
M<+)]"I:Y8:*YPM1)G-:KG(R1CG-541%7KA5QT0D6GJ[S5N6J[-7#=.BDS353$3,=7E3OW8?\
R$A!/;C0.Y>MV7)VWU!>:QE,L:5RVF98^57YO3_E+=_!4G5X]Z;&G<<1OM/\-=P^58C(U-M3LYG;>.L?
9'+\8+B4_YBUC_CS_PAQ_7MBU+IC5M?;-705E/J&G[/SJ*X/5\R-M9C:YG,Y555RQS?'NP7W>LIQX^D_[K+7OJS0?S&G/33LZJ]P):W3K*I]3<*,^-CB\
[<[+LJ_=J(BOPKO1RY.IE.\[?M%]Y-_<&&GM-M3.A\X2SZ/;<.QS^2=E3J^,C?]@MFHM32-K;F^:9]749D931-M-
8Y[F0Q91&]&81J83N7VE=CVKDW+M=-7#3$SO*TR[MJFU9HJHXJIB-O)*3BA-MU%PKNVSOEGL$6F$U4VF9W"-
RM966FJAD:B]'-1&/1%^98V_4=YW1X$]IMEMCM::CJI;G=KK0VJ=U+5W-M*LY&,J7.Y8>5D:,1?MBM1$=S=_B1Z\G+^;@L^?\-O"L7_JE-^U-
NO"NQ15,Q-M&_.?I*R[%VC.M3YS74[45/J4>5:ZZ"T-^]3Y*?\K#6GZL-_D&&I$__&;_%_NW^7I-M?;Z?V1[\H/M#I#9[7NF;?
H^RPV6CJ[8Z>>**21Z/>DKDYEYW.\$P2"X&.&[;MC6NR&F-7WK2]/7:C963R)7OFE1W-%4.2-W*UZ-Z'@,_
M;K:K65RTMJ*15%'>;#L^W@9;YY6MYXVRM)K5:OHO:O1?$]-:O*[+7>YTE#-M2ZBJGU%5*R"-JVRH3+G.1J(]\GK4X]Q)<-6L=Z=ZM1ZSM6H;+14-
T\V[*GK.-MU[5G9TT42YY6*G58U[E[E0^&TMY,/7UBU-:+E-JC3TD5%60U+F,[=7*UCVN5-M$S'WK@U;=G"FU$UU^UMYMVY?
U"'+TTT4>SNT\JRN=PM#+_P#DR;^5)&^3A3_N-M7K/_(=6?RJD<_*KL_[8.AD__)DW\J2,\G"]?8OV?_#]S^54|[W__(VW]_\M+6QO_*W-_A_A7?QA?FF-
Q/U3=_%:6NWC9O1^\.@-,T>K()#>Z:CI89H(Y9)&-M(QZQ-153E5O@50\8?YIG5(NWFGZ"\[XZ9L=93MGM55J.EH9J9SG(CX7536.8]Y$
MA6JK>\MGJ-O-!!*^W&N=6Z/TW3V>>"URU4S8Y)7]NL+'NC8O,Y?NE\,?"*J-MJ/S26C_UVT?\\86\
<26G9M5[!:_ME+')-5366J6&&),NDD;&Y$6HB=Z]K43'-MM/74ZI[2U3,\IZ_U>6DT1V5ZN(YQT5$[.6:S;J;W6]+-<+4,-NL]PJY*R[W6Y
M538$EPUTCFNE>K419'(C<]Z*_IW8)\;K;<\+6L-M[C9K-?-O+%=8J9_N?<;;-M=*.*=DR-7DYWMDS*W/16O5>B^"X5(!DW(Y8VYD]$9W=
[D)P7_R9>U^E)7W>Y:UU'26Z@IWU534/=3\I43&-M\SG+B+,$:U>X]\VJW3=HXKDQMTB(Y-3!HN5V:^&BF]ZS,HX^3UW&J]$\15J
MM23NCMFI(Y*"JC5R\KGHQTD+L=RNYVHU/4DCO6N;=4]9-'A^X>.'UVX^F[WH
MW=JKO5[H:MM526RIG@BD[',R]M0)T3'JF$?^"M59XKAK%U!UQZ4*578L3-M]HC4^@NG>BYNN'O7F]3*_,>OK1,_2;6D>]JHCV93JJHCD1
M54MDVTUM0;AZ#L.I+;41U-)J%:OE,M<-MT&IM\J&ST$S9W6*V,IZIS<*C9GO=(K,^OJQK\ZJAZ;==O5YDQ7,SUW>.IV<>
MG"IFB([MI^*7_D[/S*^FO*K?YS(?'>5%LK*W8BS5_)F;AOD6'XZHQ\,S53Z-M5Y/J/L/)U+_W+&FD_P#QFM_G,A\
[Y3]M92\.U+$Y41:F^4T;VB5]K\R]@GU*3H[-MO:0(\D_:70Z=W$N2L5(ZBKHZ9KO!5C9*Y4_ZU%^DGS@U]1VC*KV^+;TK><.C-M=L#"=QDKEN-M
!^5<_50?E7_0YLYMC;MSN$C96CKIIJ9]/I*SRPU$&.9]^8Q(-MJ=4[ESW>Q#M&B='T.AM/4UEMZ/6GI\X=(J*YZJJN5RKCORJGPG"S64]'PK]-
MN]FO M_$:0YGN1$SYC#TZG66/1Z9145/R&G%BS%Z,L1'W_'9]S>N]E%J9-MG@[HI]MW]@_:CP
!JG4]7J2S17^QW"W39[*KIY(`_YJM7^$]L8QW^T\ZZ8K-MIFF4TU33,3"$VQUXET5NY24M4O8K)));IVY[E5<(G[=K?])K(B*G0BEO'LYJ-M%-
RI;CIVWRU,%PD:4,D@7I#-E%=S+GT?23FRO3JOJ)2T39F4D23*UTR,1'N;-MT178ZX^DYC0[5W&F[CW(Y1/)T6L7+61V=^B>AUEJJDT3H^^;
MAK4>M%;:*:NG2-,O6.*-7N1,]ZX;J?.=93&\[0YFJJ*8WE[W">KJ;8Z>TBIP-ME\;#N(_65]TY5Z:;8ZNDIG7"F?%5+.U\+9&,5K\M;AZ+(SJG1]F
M=RW7:JX^^KRL7J+]'';Z/G=?ZG=HS0NH=01TDE>^TVZHKDI(EPZ;LHW/Y$]J-M\N/I(]<&_&[>M^-=772>K;?;+?7.IW5EMEMK9&-
>UJISQ.1[W9Y>^A-MDAN5-M*_@-M-M-!C*#*-9_90#(,9090#(-#&4,@-,90#(-M-M-QE#(-M-*4?*W;9Z4TMQ-W;5*;XDK]8:ECI*EVE:>U(C+?3Q4
MT=.DDM5V_P_)_8*YK4CSA5SA.5777'Y\N(G7=1:?*":MU3JF&2IBLVNDEEA2-M-.:2CI:IK8FHBKUS!%&B9[\HOB!VW9+R.FXFX&F:.]:RU-1;?-
K&)+%;7T3]-MVMC:O=VS$?&V-RICT>=53.%Y5RB?4:Y\B1[NV6>:HTCN7;-17)B991W.U/MS-M)/6U)&RS87'=E$3/153O+5]$ZTL6X>F;?
J'3=VI;W9;Z-):>MHY4DC>U?:B]-M%3JBHO5%147JA[]>HBI(9)IGMBBC:KWR2.1K6M1,JJJOJ
M]VIW*UA5;2ZK2I2AI8ZZRMK(9*K*IV#W^<1]FYV6\CL.:_*8N%SA%XGY17-M=[2^[7%E]+4>AZR.KMM+%343;O2+AE7/
Q&NFC>GPD141C7IT=T[>U8][+X]DDZ*B=Z87[E"ZDH-E5:Y[A-MQOZ#]6YCH8+C43>QBT$\6?VTC/K+\!QKB;-MXF]+
<*.@Z#5VKZ*\7"W5ESCM4<5EABEF25\4TK55))8V\N(7IE%SE6IC&<=E-M(?
>4\V&UUQ":'V'3NWUA74%Y1=2T]PEI?/(*;E@;2U<;G\TTC&KZ4K$PBYZY-M]D4#X#WZO8_Y+:._^]#__$PJ;V77%XN]JO?0X_ZZ(I,GDM^)U?\-\&7_
*_M-M?!).+;..5MZKT\'4:I_UD:F]@_Q%'W:&?RQ;GV7'^2JA5NUFL9,)RNO36]._M*01K_G)OH0N\E;$UNRF])/%VH9&_534Z_P".3*S:-
]'[FL]+U]8>GT=/K(M$W>+325-]704-2M33072VRNG-MI8YY6,?.S&)&+1\RIE<MF57TN].]>B>C-M,1KVO:CFN16]F45%Z#G&
#7'7O/XS0QU$+XI&))&-M]%:XCTU4[E14]1Y-^?TEHVR:#LS+3I^UTUGMD;G/92TD:,8USG*KEPGK53-MWJ&R+D"=YG>>K&F(IC:
(8Y1RFP#)C"'\UB:K<*F4[C^IJJ:CMOU6-LK:J'-MO[%Z5?M>[7+3N86/=]^B)5=ZT\EQN!9>T?IO45FU%3M-M^#'/ST4[_F:J/9];R*-
PJM2:72YZ5K:FY6V*&98]VT/EDB9VC7]4?'GOYD\4-M[R_!,X]9%CC(X,*+?6V2:CTY'#0ZI[(L,)^&ZI?[HSGTLHF.IYEWL]=1^[55LN='-0W"
MDE6">E]&*Q\4B+A6JU>]*B^"GL="Z'OFY&J;?IW3MODN5VK9$CA@C3ZW.5>C-M6M3+ESMUX>-MCI'T.$Z0R83F6+P:O56]WP<F5157&
<)WJRW5GD-MT]W;'CWVSW$U'&G5K:*MJ)ZX[LLUC47]DJ'(WK>-#DUS517PR[3'O:CB6XIK-MM\40M@;(U?ND-NA30W2G$?LAAM-
2:YL5)#U5*!\\M&BIZ^S5T2Y]N3W^EO*&-M[VZ3D6*MNU#?DB7E6&\6YB*B^I71=F[ZU7YS7G2JZOW5<5-RG6J*?WU$TK>,-MH8YD\%*
[M)^5;JV\L>I=!1O^-46NO5F(_%O:O\<[']/RDNSU_P"1E?4W23;W-M>BONE0,>U%^>%9/K5/GP:=S-R;?.;&];U/%N1+)K-MFPUTTGP:=*^-
DW_1N5'I]1T1DK9&Y:Y%1?4II3153]T;+&F[17[L[M%;VC51-M41R+TQ_M])7GQ:^3]KJK4T>IMJZ"-U/LNMTJX:"W4D;IIZF=_*R-J=ZJI5-Q8\:5YWEU-
%0:6K-M*JRZ2M52V>C="]8YJF9CLMG>J=4Y53+6^'?U7NM=-IR)N;V>4=\]RDU:O&IM
M;7HWGN^*>_'YPO6+ASTIV479W+4]:QONE=>3]Y>_LHD7JV-%^E53*]R(WN]$
M2."_C/IMZ*"#2>K)XJ37%+']KD=AC+FQJ+E[$[DD1$RYG().F4;+?IZS2RJ;-MM-V>VZK'!KLU6([#H\6LH(+E324U5
RIIY$Y9(IFHYKT\45%3J<9UMP5[.:\-MYWUNAZ&W5+NJ5%GY])R+\;$2M:J_IFJ=RQ\PP>%NY7;G>BJ8;%RS;N^_3$HP-M[1<-->@-H-QZ/6-MN-\N-
90J]U'2U\;HHG.:K5*N=Y19LV[%/#;C:%=G&AQ-;T[1[V2T=CJ7V#2L$4+K?(V-M@CE@KD=&UTCG/>UV7#;9W7W:
M/K]$6^BJ'!5]+2UU"_F^_O9*U'+^F12RLY.-P11>M].^%/>P\N+DW+%WK,^T-MO9\/W$/IB*TA/?+!#543Z62S>KHJUK4DA?
RHY.K55%:]+E'>QYUKYLHSO3MYL=4C1?#OMY'<|-0S[V)8BW-M5[\]_<-GK+65YU[JBOU#?[A+<[Q72]K-53+U[N7IU2OLW3+<.1514[E3IW+E
M/_J=3D8=O(M=G,=.GTOU?H-1R+USE#**G4B1Y._7VX6M=L)-MX]5T;Y[#0\L%FO54Y4FJ6IE'QX7]JC,(B/Z?%ZX]&6G,B=ZX0^?
W;BIRY"]#R>^\3S;@&,H&3(-UYNXLR-M-$2O*%,0:PW>T#IF@T?9),W5TES-M6>>.*6-BL9V3VYRJR93*]QZ7R<^R.MMGJ?
7C=96";QON+Z):,M98W]KV:3_MP'+W<[>_UDS4;ZQA$Z=QNQEU]A^'VY?\[JW\%;_$_B=^;7'54P5C\87"ONKN
MQ%:PU#IO2%1<[-7+2=A51U&$#4DY:2"-W1ST7HYCDZ^HLZ]BJ81.O=U//&R*-ML:N;Z>;/+Q*.RM*YZ3NY3M'MU,SAPTWHG5%&^FD?
IZ.U7&DYF\S.:#LY&9;-ME,X54RA7+K?@NWHV0UVVXZ0M];>Z>BG[:W7NQ.19FIG#>:-%YVOQ\),*WJJ(
MJH6X8,XRBGM9SKEBJJJ(WBKK#PR-.M9%%-,S,33TE6K;>'KB3XH9*;#=&^UM-MATQ3XEY+@R*-TCD;TY:6'E17]WI2(F,NPJKE#U?"?
PW]Q;0;^Z9U#==="U45H-MCEDI;R9*J!R1Q2QNC63"29PU7-=T3*HW!9ZSNZ+D(G?D]O2-S@JMQ3'#/<*

M=)MQ73U]IFX:.TY/>Z2EMKX)Y(IXF(Q_: MN=C#WMZX\?:=[X*=O]0;:\/UDL&I[;):KO3S53I:61[7JUKIWN;U;JHN6JAW
MCESWID(G@*LNNNQ38F.4)MX5%O(JR(GG+"9Z_N#KZC<&FL4$?*%[;@;O:RT
MG6Z/TY/>Z:CH)89Y(IHFWP]1VW@BV\U%MEL';+#JBV26B[1553
M(^FD>UZHUTBN:N6JJ=QW_E14Z]3*)@W*LNNNS39F.4*YC!HHR*LB)YRJLXE^_M$G=S6F^^M;Y8]&5%?:.ZN6:FJ8ZBG1)6\K>N'/1?K+.=+T&C
MBCD;\5R,:BI]9[GE1?:.G47LNN_1315'NF/A6\>NNNF?>5-[=\(,\-GWSTS? M*S153!:J74=-6SU*U4"HV%M4Q[I,))E?115]?0M?
6/FCY53P/Z(B>PSZQDY5_M>3-,UQT,3"HQ(JBF=]U:O$UY/355OU=<-3;84[+O:*R9U8MG9*R&HHI%7F5(ML]UKXT7*M1%YDSC"]Z\WNFAN*
[<2R)I*[6_6-QM66L=2W!ZQ1287T4DD>J(] M5^$Y43&?#);EW(,IA>AMT:G=IIB*Z8JF.DRTJ]'M55554533$]8CHB#P5\ M%4^Q=9-
JW5LU/6:MFA=3T]-2KVD-#$["N]-43FD7'*JT1,HF$^$;FG7XLWXXND\E=JF/-['GAZQS2!VVU?%KS0.G=20(UL=UM\%8C M6K\'M(VN5OSHJJGT$;.-?
@TGWT;#JK2;X:?6-'#V$M-.]DCN$**JM:KNYLC< MKA5Z*BX54Z*GB^34W:,K/9ZITA5R]U+*Y$XU_8N21OL1K?63-Z M?2>4U5XF15-
$]'K;HMYV+3%R-]X\U0.C=E^)_153-I[35JUC88YGKSQ4-N,N[1)$C1>GPL^'>?1{C^3WW-T]IS3E7;Z&75FI+BZIGO3::HC[*D_(NR
M9SR.;Z3I*Z=]YR=,]$Z)EUK^$5>X=^4\#;C5,1'!VEZ%M<,TU53/P^C@-M_!1H#4&VO#Y9-
/ZGMK[5=Z>>J=+2R/:]6M=.,]S>K55%RU4(Y>5:U>SS30>EX MY$5[I*FY3,SW:;ZBP%WH(N?5W%5.OZ2]XU.-.IM-JED?IZDD2B\\ MC7+8;?
3.^VRMK/6LK,C"]J3(F_7RB-Y.^GLL6G&HYS.T)C^3]V[ET% MPW662]C6*KOLTEX>W"7EDY6Q+],<<;OV1)(\.UVZGM%NI:*EB;!2TT388HF)
MAK&-1$;B>Q$1#S6^)67KDW;DUSWRN<>U%FU3;CNAL #R;(M 'Y5S]5!^5<"[F MOK)?L9^'BE25R1?B*MLBQHN&]Y**F1'+Z\=?K4E?L;433]6Z?
=/(Z9ZT^.9R MJJX1RHB97U)@B)6Y^Q!X?$5%Y?Q"6O"XZ?[T@S_F^LF%LK D&UNFVJF,TC'_ M %^E_G.0PYJG6+^\\HC_ Z?
+BFG2K.TI]=2VS>6>@NE0UMG]T'4,J-8FHV*/G5C7\V.;*>B[.<*F?9BLR M\ZUA33%S^:=F[BX5W,X^S_EC=*+N0XSQC7-UIX9]PYFNY5?;'0?
1(YL:_P < M[+E'HAS7B*VQK-XMF=4:.H:N.@K;E Q()YD58T>R5DC4=CJC55G*JIG"+G"] MQ;V*HBY15/2)A4Y-,U6:Z:>LQ*#_
)*BTMGW#US<5;ILIK0!3HOJ2257*G_5 M)1196BY(J<#7"UJ/AWMFJ:O5%91R7.\OIV.IZ&1TK88H>TZJY43JY95Z(G1& MIURO25F.AMY]VF[?
JKIGDTM+L56,;**XVD3*D4.(G@)M&_.Z%-K!NI);"^:. M.&YT\-&V9:E&)RMKM5<5N=I;UVQ;O MT\-R-X>+04<5OHH*6%%2&&-L<:*JKZ*
(B)D\ON[CU!>:&QJFFI[VG])Z94 M;/%%*USHE7N1R(N6KT7O]1YZ(B'G,_>]:9B8Y2V !#, M #DGV6VRW]U'2_I_X3B_TG6S\ZVB=+U&N
M=96'3=+-'3U-XN$%NAFGSV<;Y9&QM5<=<9?UP!>;]EOLM_=1TM]\XO\ 2>XT M[Q"[7ZLJHZ2S;AZ8N57(J(RFI]O
Z5R]N$PSGYEZ^PKK]Z*W'^66E_K]?P1Q M3B)X)=P^&VS4U\OKK;=[!/.E/[HVF5[VQ2*BJULC'L:YJN1'(BX5.F%7*H!> M%S)ZSXS7>
[NBMKEHF:PU5:]-NKN=:9+E5,A6:DQS(Z M^:Q:>]L=15\UT6V4:7*TU52]7R1T[7MCE@5R]I462-6)X(KD]D1$Z:QY\(FL
M>*"JT5+I2Y62@2RLK&U*7BHFB5_:K#R\G9Q29QV;LYQWICO4"36BM?:;W&LK MKMIB^4-_MB2NA6KM\[9H^T3&6\R*J93*=/;A]
(1)X*M@]1<.>S\'DJ2UELKK MB^Y$5J2VF622'LWLC:U,R1L7F!]2#'4D#E ,@QS)ZQS,@ 8YD]8&08R MAD ,L^-U-NMI'1.IK'IV:.@H[=>
[Y(D5NH9G_;:ERO1B(UJ)XNU\;T1S7M5%1R*F45%\4P>@UEN!IC;RWLKM4:AM>G* M.1W)'/=;R.G;(Y$5>5JO&M3\\]41$]KBMWASV+O7E -?ZFW-
W2O%:FG*6I\UAI;&3DYY.5')3PJJ+V< M<37,SA,N5Z+WJYP%CFBM\MO-Q:UU#IC6UAOM^6"3"/9(Q$5V.KE$ M5&JU4ZR1X%>
(;IXA=E8*Z\2))]BRS+;;I)T:L[D:BQS83NYVJF?S['X1$P!) M 8YD]8RB>(&08R@YD]8&08YD]8YD]8&0#&4 R /@[3O;H&]ZSETA0:QI
MU7JF.66!]GBK&.J4DBYEE:L>.IN-0 MV&-TBHJHQ%/Y+B_P!9H'='=+;2[OY*RF>M4R)RX1LU/*L$^$7Q=S,^AGL LC/A*S>O
M05MUNFC:K6%G@U4Z6.!+,^L8E5VCT:YC>SSG*M[JW#+3TS/HC?E/[W[+3CG6J.(7;'1-UFM= M^W TW:KG"
[EEHJJZ0MFC7&]SD:CN]$1ZIA414^7V2\EOHQ= 459N7-=;EJNX0I/ M4PTU6L,="Y[47LTZ*KWMZHYSE5%55PG1%4)N:9U=8]9VMERT_>:"^VZ1<-
J[M;5,J(E^9[%5/W3W)5#K'3.H_)H\0MBN]DNU9>-N;^]ROI97)SU%.QS4EAE:G M*Q9HTD1S),)E53N17-+4;?
<*>Z4%/6TDS:BEJ8VS12LZM>QR(K7)[,*B_2!Y MH &.9/6!_*:,."*221[61L17.>Y<(U$ZJJKX'RNA-U-';G15DFD=2VS4D=
M&YK*A]MJ6S)"KD7E1RMSC.%QGOPI#_RBO$A7TE(FRNA%EK-37F!S[TZCZOIZ-M/D5[H>G+1W#=H>FH-/OA?KF]HJ
M4+96(JM)"U>U#785LE1*!*SS:#AHKS9:OD5K*ZFN3I7H[IARME1S5[O!$[U[NBI$JZ4NZ7DSMV*-U-9&85E+6#8YV.9E>QJ&HY%1R9[T^$W*
6XY0R?-:!UQ:-R-&VC5-AJ4JK1 M=;=M33R]R\J]Z.3P#?71.Q6GUNVM+]3VN)Z.["FSSU-4Y M/N8HD])R]43*)A,HJJB >^UWK_3NVFGI:
[JF\4UDL\+V1OK*M_*U'.5$:WUJ MJKX)ZE/;62\T>H+10W2W5#:N@KH(ZFFJ(U56R1/:CF/3V*BI]92WQ;\4^K>) MVNBK_G97LYV17.XQ4\CV]
<*UKG(KNY>Y/!3FW&= MOS4\/NQMUU%;$C6^UTQ]UR-8]V.
[+>O0B3PF;Q>;N_O=44M$VKZFMMRBGF1]=%58VN5R)\2'N]5ZMLVB+!57O4%TIK/:*7E[>M
MK)4CBCYG(QO,Y>B9CV/;E%5%5UO&AP5ZDM=Z2.74CJ2]T_4SY1.VJF0M= M#4*G@JJ^)R^',CL8[D"3&B-PM,[D6B6Z;5OM!J&WQS+3QJK=.V:-
LJ(CE8JM M5<*B..N/4Y/6?3%<'DAM;NC;N)HJI][EPC6HF555\$ Y]JCB(VQT1?ZFQZ@U[8+/>*96I/0UE?"\+&K
MFHYO,U5RF6]B]?!44Z,U45,HN4*)]?V:[!\R[Q[RP]HMQMMYIY96N;W054TK M(F_L$9"WV(]%N_"/N/\ CI<.6@[^^7M:M]N925;U7+EG@S#
(J^USHU=^R ZC M>+M1:?M-;<[E50T-NHX7U355#T9'#&Q.9SW.7HB(B*]JOJ/0Z$W5T?N=#/5S
M:1U);=1Q4;FMGDMM0V9L2NSRHV6XPJX7ZCA_E'=>?B)X5M2PQRJE57R:"SPK MGJJ2/XY$^F*.5/I/5>3,V[317#)07.6/DJJ25TIT?
S=Z1HO8QIGU*V+F_9J! M+0 ?-Z[UU8ML])7'4VIKE':,%;V))4U4K7.1C55&HB-:BNL M;%:U5RJ*YKD3UJBIX'VY6%Y0Y?\ NY=I_P!3I3_[3JBST ,LR &
M,H,H!D QE /E-<[GZ2VQI*;JU=J.VZ MBO\ :J*Z6ZJBKK?60QU-/4P.1TBHJ*BIWHIQ7BPX5]7BDT]8K M55ZBFTZVTU3ZJ)8:1)UDYF3.,]
/J08R@YD]8&08R@R@&0 !C*#* 9 ;L#(,93 MNSU&4 ^ V]WNT5NE>M1V;3-Z2ONVGJCS6Z4,M--334TB.
[A5QL]W;!2M5]1{JC$8VHIV)\-58UK71M3F54Y MD1RN=BT,]!7:XTY:JN6CK[_:Z*KCQSP5%;'&]N414RU793**B_2!^;S3>X>O
MMI*ZMI;!]746C*UDBMJ8;75%!(V1/15'HQS5YO!44_OJO?7LOHK8'1E:M;IZQ;;V&KZ?:V1;*.WTS^F<>DQ$7Q J#X*O)WZSXAM
M3VV]ZHM5;IK;6"1DU57UL3H9;DQ,.[*F:N'.1Z=.U3T6]<*KDY24GEHZR5VG M=G=%6BCDJ'5=775,5%1QJ]WVF."-C6L1%5>DSL(B?
HJHZ2FEGE6R;36U) MKBYU3?S-5:;WPJB22XZ95?N6Y^Z7U+A%*6;JL!8MI=.P7"AJZRNN4TS:.6>H M>B-5]MF]2VW5MDI[M::IM;0U#>:.6-?
H5%1>Y4 M7O1>XJ#V,;RZ+E7XU7(O^2Q"8G!YKRHM6M9M,2R.=075CY(X\KB.=C>;*>I% M8CD7UJB>HQSOXFO[FF_PE'V31 !HK,
1AXVXTDM>DD=*R+[=4?#YNOHQ M]V$4BEYM'_WW!^U?_JE@^[>S%LW?@MT-RK]NB;0ND/KB_U!]A+I7_GV\?7%_J 0Y6)T?
*JH](TF][B;3*IE/7U1?)D)G36-51E+6NAYQ(;JV M\J6Z>U&^6?3ZOY&OF%;]7PL<*]E MX<],=T=RU76L3W1NW+W]R]E%GJV-%^ERIE?!&]Z08-F
;935?;O32?N/4O_P"6M57+#R_-'S+'_DG&-5^2 MET]4Y=IG7%SMOCV=UI(ZM%7U98L6$^A2>*+DU7)MV\W(HZ5RT;NG8UWWJ(_1
M55JOR8^ZMD222SUUBU#$GP60U3Z>99%SE%_@-ZC5+O_ -E, M5*ZO1+/6U5-/YJ0-=\26YFY^F(]/ZHU;57:T1R=IYL^.)G.Y.Y7N:U%?ZTYE M7'L.:
(N5PJ$ZN-[@@=IE;_%]2\GG*N8GP.]/1Z M,@I[3]*[9O6XFS&WQAQ>=9O6+DTWN<]TO*M]PJK1<*;NH*F6CK:.1LL-1"] M6OB>U45'
+G.7X+43JKEZ(G53M MVIN"K?;;>N6Y6VS55>L*KR7#2U8KY._[EC5;+U3\[[#6S[>/?C@N5135W-W3 M;V5CSVENF:J.]<"BHAG/0IZTUQJ;
[[27#W.N=Z]ZYT'P[;JFD623]D]R-E_R MR0.@O*KTSNSAUKHF:%<>G66*H21%_P#$R\O+_P'(IS->EY%/.C:J/HZRUK&/-M7RKWIGZK_^@S[3A.@N-?
9O46BM2CNVC1>1&>EGEYNY.()6;^+KB?_[| MW)3 ,16?ZI;Z?8NS/:VJXC;ES<]]=^W$=C-T,T M;E:^.1JML;%[TC14 MPY_C\%.O,K.
(ZBT!N;J.]S7&\Z4U16W2X/YI*BJM=0LE0_E\5Y,N=A,JO5>\ M^[MNJ.)*S4%+;[>_<.BHZ:-D,%+3TE6R.*-J(C6M:C<(B(B83IT[CJ\BJNNU
MM:KB)GZN-Q:.:+=WBN435$?3]5P]HM='9K;34%!314=%31-AAIX&(R.-C4PC6-MM3HB(B8PA&KCRV0UJO5H6RTB6B9$JF4-
4^>MM#JEL'GF6HD;D5RHU58J.Z.5/ MA93JA\=Y/>_[]WB[ZT;N+-J>6G9#2^0?BACG:B.5TG:M":F$0X MFKCQ;_6)F'T"C@S<;:8FF)4SI4\1'#OE%?
K+2]#*!W@K*]-3#47+DZ^!._EYD\%0 M]?0Z?MMJGGFH;?2TDU0N9I((6L=(O7JY43KWKW^LVKN;1>HFFJW$3\6G8TVY MCW(JMW9X?A+VO@I\?
>=V=%;?U"VPW75MDMMZ>U'I;ZNXPQ3JB]R\CG(O5.J= M/ ^N]D4KZXG_ "?>M=P-S=0ZSTG=[?<8;M*E4Z@N$KH9XW\J(K6OY5:YOH],
MJW"83PR:>-;M7:^&Y5PPL,N]=LT15:HXIW6!05$53$V2*1LC')S-O) M_1N$12FZ7:/B+V#E?)16K5MAA8O.Z6Q3R3T_3Q>L#G-
QT^ZJ_$L"X;=W=36_MAN_%CO/.ZS2T4DKO/[C#V$U(G*D4XN#]ZI:FMMG9]:S8I8Z-&-\JA:CE_LI7>+U$UCS
MRHU$1.N7+PCBLXK+SQ&:D[&+M;9HZ@D738&]LM5V?+<-#5DO]DTN>9]&Y?\ E8NO M?ZV_=)
[414MDTOJ*VZNLE'>+/5PW"UUD:2P5,#^9LC5[ES]:*B]47*'YF'7 MB5[3T^+J,#/MYMO>.54=8>[!KGVF,^TT5HVRAD_FGSF[>X#(&,H8^@?4!L
M#7F,]/8!D &/#UF/F V!H -LH9,-[C" _.!L M ,8,@ M #^2MRU45,HO@?U 'S6GM ::TI425-DT[:K/42MY))]" MAB@>YO1>55:U%5,HG3V(?
1(9[DI9E,8&\S,\L::8IC:.C(#)_&2-)&]QS>9 MKNBHJ93Z3T.G] .;TG435%DT]:!//*U&226^BC@<]N<\]JU$RF3Z)%P$Z(I. M\[;,)IB9B9AG&3(!#, M
/RKGZJ#\JX'Z-^&[25GU3PM:+LN]NI[BR'1UF= M&E1$C^5?,8>]PI1! REB2.-C61L:C6L:F1[D1"/NPN[&F] <->R=%>*U-MT-
14:,LSFLCC<]6M\RB3F7"=$RB^WHI(&EJHJRG9/"]LD4C4>Q[5RBHO5%1? M4:M%5F;E44;<4=?B];J;L44S7OP]WP>4 #:>0 _GA"(O%)I)UFUM'>8F
M8IKG$BNJN55[UR=?M6IKO4Q[$X4LLT.CZ2NN#& M11UKQ;M,U1$;\/5H6\VQ7%,\6TU=(24QT/ MX5,.S4\D:/=$KFJU'M^$WIWH?
W1W7!GH:T3MS;_!3GP^:PN_#UQ;4]/>JR7 MM&W>6Q7F221525LDG9ND>Y>KD1_)+E57/+GJ7$(]/@52>4EV!?H[?ENHH(71
M4.I*..J29$PWSB$CD:F/%$;$[YY%+)!F-2UNK!IM'WRYQ207&X6FEJ:ADB8 M7'M'1-5RX]]]]H\Y=:APW+=N_3WQM+G=+X[5V[CU!TIQIGW(_*5T8
M BM]G+_^9*??;_\ 8#[.7_\,E/OM_\ L#JGV+>\V M/R9_]/JOPH^Q;VQ^3/\ Z?5?A0.5_9R_F2GWV_ &_^SE_ #)3[[?_ + Z MI]BWMC\F?_3ZK*/L6]L?
DS_.GU7X4#E?VV/R9_]/JOPH^Q;VQ^3/\ Z?5?A0/H=I=P/QSM$TFH/,$M MJ3ODC\W[;M>7D>K?AT?)A5557]] M57O7UGO 'YZ=G]046D=V-
$WVY2.AMMLO=#65,C6]Y6PQU#'N5&M[\(B]$ M[S]"Q^>#;32D.NMQM*Z;])W4T-XNU+;GSQM1SXVRS-C5S<^*(Y5 MZ[\MV"^ M55;]Z*K_ %",''?
QUZ)WEVQ;H70B5ES9654516W.IIU@C9'&O,D;$?ARN5_+
ME<(B(GCGI_'>7R4EZTAI"OO>B=5OU564<;IG6;IH.QFF8U%RD3FOOD;$B+GQD3'CCZ?RMNJ
MKQIVOVO2U7;NM:317+M4HZE\/J+354SC*_63XT5%8(=)6A-+,HHM.K2Q MQM[;:UK:=8%:BL5B-
ZJF=M5S.F>C4CA5$RY5Z97]TB1Q5<5^XV^.]]=MQH>[5=HL$=W!PZ M"AM]3YLZQJ&R=EVDLR*WT7/3*-54:UO*JJ4525_DI_S,E5^N"K_DH"(G&-
P2 MZ[VUW)O>JM)V:X:ATG<;J2X0U-KB=+-;W/>Z1T4C&JKVHQ?@R85JIC*YR!YM MY\G)Q!Z;LM1J*GO-MN-
QBC69U#;;O4+7.Y6^6V[F4\6LJF\4L*\KJ/4$;:SZ%D>G:I]#T)K<+'E+*#=C5-NT=KJS4V MF[]
<)&P4ERH9'>$95RX1{U8]5=$YRX:WTG(JJB=.F0D'Q5[WU'#]LO>-51]W-VMK<[OSMI;"G7&45R*57;#T7OYQLWV[UE->[A>V4
MKFI65ETN*P45.K\\L;6(O*G3F7E8WHB=4Z];@-V-VM,;+:+K=5ZLN"4%IIL, M3#5?+/(]*-BC8G5[U5.[P1%5<(BJD
[[Y4N]W:\5%MVIVKIDGJ95O._QA-MO='MTK_Q-6WSGSG/;]IYK M'S\^>O-S9SGKG)T!&^CE.GT!C0/Z_",B<#NW5RWHU!N9J2DEU5=[E5MJHJ"
MO1%HJ56M:U/M6/MB^C]VJM[O13O(D\2D3(?*<;4[?5CVJL]1MO8-?P MT<4_H[E';)ZEB(UT]-)'(Y$?TR]6/C;RY7HCW =2\I9?I;3PG:@A@DY?=*M
MHZ1RM\6]LV141?;:?P'E^39LD5IX1M9\5$;>26XU%=5RJ,*KO.I8D7V^C$TC MQN[?]GN-Y*S1]N+GSU5'/312S.555605U6N3'CT52
MM7R1%TFH=<[F6/GYHI:*EJ')U^%%+(Q%]G25?GPGJ+-)IV4T.DLKD;&QJN2/IG5NY^X]Q8CNQ;;H8_IYUW*]J-
1ZJN.UOIJVLJGO;;H&32/ED8CLHS#&_#1,M1KN5%=RJG7]QO)J;D M673%SUE2[M5.IM74=.^NDI9H9XI9G-3G>V.J69SG/7E3EYF-RY&Y5.]/5>3E
MM<5;QI;C5G[)2S^Z)FV5:*F4[%^47N7T5 MZ 54[&<4^_,_.DI=LOI2YN35$TLCZC6E5.OG%-;6M;\)Z-5R.1RJG;=7KEC4 M]+TCW>\/D\=Q-J-
$7G<*R[L5E_O5IIWW"LC[*:CJ.S8BOD?'.DSW.N>_;R05'%)N#N%5*F9H[73Q-7U-=,Y7)_D-^HL-WQ3_M+:;@?K?N'\VD XC MY/;B!O>_.R\
[M35+]W45@K%H*BM=CGJHU8U\4KL(B3*Y55.6\=%M;K&BW$MVR6TTTU/JFN=!%75]&_EJ6RS(BQ4\3U5.S7E5#UK57;TJJCNM[=3-
F3F7T'21,QGU1YP MOJ3H![9:O)=:[J+6R]W#>6IL-;*Q)JM=AWI(JK M===E"K[RIMKI8-_\
;;O8C&U=3;V12HB8_DF9VD:K[&NA?]+_;3'V&UPFY&R^B=3J_M)KG:;>;:= M?
_#=FB2M^AZ/3Z#X_C/V^7EVM.Y)D1QM5$EIT7/@LU1R_0!\OL5_W0OE*M8:S< MGG-GTNZI?3.[XU2%J4<&/TV72I[6]IXF[B_8Z^4VTYJ7/FMFU-

-3SRX7$?)5 M,=23N=\TJ.E7U=%.D>2;V]!QJ!J4:TJ&+YU?IDE-%((O?!3MQS(J^N665%]? M(AZ[RMV@75VA-%:WI&*VHM-?);II(^CNSF;S,QJJ&V1.JH\8Q4R)VDZ?](]X$!N--RZU\H9MUIZJ^VT4< M]EM_98RB,EJ^=Z]GM[5<^Q$+2"KGBO;[3_E+MO:^?T()

*[A8:CF=\1*AL;E_R M'?46BY3NR!!SRM=GAJ=AM,7)>7SBCU%'$UV.O))35',W/@BNC9]7L,_<'5ZE*

*MQ_##MG53NYI&V2GIN;UI"G9)GVX0APSRLU7'#PZV*G<[!9-J;GY6^QM-59_A M3ZSM?!30OM_"OMI%(CFN=:6385,=)',>G[CD^L#MP,90R .+<5?$3;>&_:NM MU#4+'47]IS2VBWN=UJ*E6KA53XC/A.7U)CO6DJ*CSEC7^A&]L+'X61?3D5>BHB,ZHB8#OO"S MP\W.V;.*

*[B;TZ_P"TK=>;MLMPJ*0]8W,E-2R0O=VGYU\N<_G6=T'\2=O5UE]]J;G@]QZ]O.I\3FM;E:=$3*

*MJB95<=2+'DWN)++;C8:RZ[I]=ZC]PIKE4TDE*WS&IJ.U1C)>9]^5[O17U%L',GK R1J\H1H. MEUQPM:NDFB:ZKLJ1W>DD5N5C?&].?"^V-TC?*

I[A)3F3UG_^.C5-+I;A5W#GJ M9$:M70I;XFKWO?/(V)$1/V2K\S57P Y'Y*6-3?=@;O9*F7M&V.\R1TS<_D< M,L;).7YN=95^GV'8=]N$32/$/K?3-

*\UA4UTU#8X)866JE?V3*E?N1WVR1/21 MJO5MR,YT]DC?' M)PWA@X0]5\0FN&[S[Z/GJZ:L>VJHK/6MY'UR?\FZ1G='3HGP8_N_4C/A61QL M2-*

*J(UJ(U$PF/! *PMHZ7\8#RGE]T]CS6V7^JJX&(WHQ(:N-*J%B)W*B2)$SV M*BH3*XW=QOQM.&+7-QCE[*LK:-*

*;5387#NTJ%2)53VM8Y[OV)$|RF%IFVTWX MHW9H(#VOE4-=2ZJ]MK]O+]*N:]U'NMV; M/^45Z)!28]CEDF_:H!]-P9\/3+YP%ZDM-13M2X;\BK;F-*

TB83VDW]OM' MTFW^AM/Z7H>M)9Z""@B7&.9L;$9S+[5QE?:I7;M3"O#[Y3[4&GL^;6G4TU3' M'CHQ654:5<343V2HV-

*/;B@>U\]_J;JU%JK;+;6V9EK*E[ZU.U?R2261(*?Z MS2BC1$]F/.W_NEE8]%K;5%-HK1]!U%6?[SM-#/7S=<>A%&YZ_Q M3WIQ+C3K):+A7W-*

DA15+7JUCO\ER@1/\E3IZ?66L=T-TKT]U7>:J M5M$E0_JKI)I'3U"]?:D./5E4)Q;V[HT.S&U>I=:W!G;4]HI5F;#S(Q>28IXX>',_R-

*5'R2:HJ>=4[TQ34J(WZ$Z_2I+S55\M&F-.W M*ZWVJ@H;/10/GJZBKU\V|/^EWUCJO<>MTSI",1*

M=3T]+2IH]87R)ARL@IFO8U&L1S6]H]5=&W/7VW^Z%P M>K+$^NJZ>)LE!4QPMPLLL;V2N1ZHB]R+R]&KA57"'0+QY3ZTQ71^G]I=JJ*

M_4<+7.[)^5IN9RKUJM55SUN.BIWG4_)!?E=;@_JM!_(J<_XF[13WWRF^@Z.MK:Q]-)5V9[XY$16OY9$]%Y<*GM_^IL'D]]S-\;7^*W=O=2Z6[5-P;YQ*

M';60K4)0JJ\S4=]M:UN,_D4:(C.Y"R6B-XMS^!'?>W]>]EW^;4V@;@YBQU=_M1(^9L5/(]6MJ8'.571\BHO/%E4Z+A%56N+0O8A7AY7^V4SI,

*[,7!>7SR.LK(M&].JQN9$YWT(K$^L"4W&1<*BW<,.XU71U$E-41VIRQS0/5KV+S-ZM5.[O[RN MOAHDWMXI-,P[6Z>U96:],-!KB@FXD]LJF2\-*

ABU=8I&4US2 M!G(R='(QQU"-[F_*]%1.B.8Y41$5$21[XF31N9(U'L\;&YM'HZ MIN%OOESJ#O<-

:+MG21P3S=DC7LB5>57M1'8STRY%ZHBHO5=]O)[[SZ2W2TGK M"\[B0N5+C%5WIU!]$Z_(Z.L\5Z\K%615'6*

M."]5E5RX^ZCHI'L^IS6KGV%IP$#>./C(U;I;7U%L]M1S,U;6.@@K^%K7SLE MGQV5-_CNC7N:YKE>O5.=N,+E4^4M?DO-*

*/Q>PD,>KO*DZLJKFK99:"]WMT#9DYN98>UACPB_% M;U3UHM1 JZT)OYNOP/[TTNWF[5VGU)HNJ5G)55$SZCLJ=[E:RJIV'+SHU*

MKD7FB7N1JHB(N%)">4IT?=[!L)#J_35SK:.KTW4MJI7VZI?&DM'+RLD^ JW16L\]CN-33-=A.98WQ-&_3-QJZA: MJ\6MJV>XO>Y7/66#"-

<]R]5IZOR=$,FT?#A?7454ZEO5]4EOE34W*=\GF]&UN(NKE7#>S9VG_C%(N2;B M;R>40W5O%BT7?*C1>W-L7+W-E?$QD"N5K'3]FO---

*(B.5(\HU.5>["N69/&H MB:.X.=>TUGB;24]/;H;?##"G2.!TL4*L3V37W(VRM4^H=M M=V;A<-2TK%F2C;%);I*EZ8549*V=Z97"(C7)A<85V.[L7*

+QYB(B-D8Y6H]1]JXSDYA]EQQD?W"'Z'_P WKA_2 M3XCA VZW?H^-"'7>]-O;KI>BOLMSFNDR6^6"CB=-#++RHKU54:LR,PBN7JJ=

M0.H<=G%?K&V[@VS93:N:6EU17NIX]^OI'NMS+]5;SU5'KCE;.CH8IWLCDQ\'SGMDD7TONT8F/!#Y#8U&ZK-M\J?JFKN|TU#=*

*[SV*3=5=V3)8(T3YF=4]7*GJ+2LH!29N7J?<2||4.@K)NDU MCM7:6JK;8YJAO5U5$RJ6:.9[NYZN;.GI(B93E7O556[0K)\H9:*>EXS=H[A$ MUC)JR*W-*

FY$1%565[T1SO6N'8SZF(G@6;"|_E8]1775VWN@4Y+5B*K53/7PX$ /^?E=;?_*K3_P B@'*;5L9OCQXV]-P)=0TV MF-,0HE'8;"X5,Z-5D2(WG8UC%*

*[W(O-*O5SN;'HHB)(366[%[XN?3ENU!J.6&&-S&HB=Z\B=.,IW[A#3=WBTL,&OMS]S;A.:&[-\XHJ.6-]3+)&OP7I#SQQ0,7=OBMWPVY*

*MN^BM0[(1PVJY)'VDM#8*YL\;LE;(US%?.Y$7+$[VKT50+$MIMS;1N_MS8I;6*

*M5V+;=J9)T:J45T+D56R1.7NYF/:YJXZ9.I7AKW>G=/CLWQN&WNUMZETYH2WJ M]9*RGG? R6G8]&NJ9WM5'OYE5.2).G5N4Z.*

*<=8X7+!KC;'@)W3H-16:Z.?O=-MM@O4MOIJV%T,R1K0MD8]B*B+CM%D5,>**?/^2!ME(W1^XUQ:C//I*^E@>O+Z*

M21MC>YJ9]2N>_P"H#UMU&L3:NKLU;':JVOW:KKCJFA;VIJ!M.Z\N[5.JM:JS/-M.!5PB=G(G!>5)N#G7!AO3J[=OCBMUUO}?*

4PON$%8^IMT<\C:9LC-S%5L2J-MJ-I)JKCP52V'F3UE7VR5KI+-Y5/4M-1\J4_NA=9.6-,(CI*>1]DPG=ASE3Z*

*M.I>5CU%==/;>Z#DM5SK+9))=9D>ZCJ'PJY.QZ(JM5,]? D+MO7U.W!WIBLDJ M)9*QV@Z69U0YZK(Z1;>U5>KOC*O7/TD:_*^?E=;?*

_JM/_(H20VQ_,5:5_P#\ M?4G_ +-:!6SPJ:WWLW5I;GM/H#4%7;I[K/[HW34E562K+1TD;6L1C7]7QHKG

M)\#TG]>EK>95Z%OEP#;@!:+N&Y6G=U*Z_W&SHVKK%BAEH*ID:+A9&2MG>K MN7E5515;Z/.J+GHQU7D>+7"ZIW3N3F-*

=/&RVT;|\>DUKEJ7/3YE5C/VJ$U. M=$7ALW3SA433-P7K_@\F% ^L""&UV^._/&SI^TI;Z>O3=*QVFEY]3:OB>Z.6I M8KU2)/M:*

(K7.:F%:U4YU1ZJK6GHM^>#'6VV>%U;-3QRT-_M1!SO;&Q^.U>DC>96-7]R]RID[+Y(2CB9MIKZK1/MTEWAB<[UHV'*?NO<=[X M]D_[DC.5]%*

<.S1&M?/$Y6.D1 M$1$3G1&OY41$:KL)T0AKN[Q!;H<8&^M9M1LU=I+'I>B?(R>Y4TSH/.&1JC9 MF:9F7-AYO18QGPTU[*9'-QJ*$ M0N#+';*755?*

*M/M_!K62L;3P5\T]OJ:OS9&]HYK6]E*Q&_J^EG/(G=XA M).M\EIK*P6YUVTSO+5.U;&Q9&JZFFI&2R8Z(D|)W/9URG-A>_N3N/KN!SBRU MA==?*

7397=M9%UC;>UCHJZJY4GE=#GM>54Z2.1J*XLPJ":URJJ%7YS[+:,C(_M_N%T/_F_[M' M/55#0)YEYL=Z]*

.\^5CU%==/;>Z#DM5SK+9))=9D>ZCJ'PJY.QZ(JM5,]?_^_M T5M#OAQTZ9H-1WO7$FTMWWC8FTMJML':SK4-B3D[9T37QI(JN:[!9(!.<\K4 M.:?

8>5_*ZV__%6G_D4)9\.]NBM?#OMA30M:UK=-6YR\J817.IF.<[Z7]_2 M!6ANWM+O!Y/.^6+4FG=<3W73E54=@VHA1\=-)(B*]L*BE<|S5YV-*

*54PJ]&NP MK51%+3-JM?4NZ.W&F]7T3.RI[U00UG9+U6-SVIS,7VM=EJ_I2,7E6H62<,U$ MKF\SF;BI7-7U*L50G\"]=4X&ODMR&.IVMUE#-*

CLI+-6,?GNY5@?G]P@;Y'BJE=3;K4RL58&O MMDB.Z81RI5(J?4B?4!8^_M %%'E+-LM87_ (U=Q:^U:4OERH)O<[LZ

*MFCMTTL3\6ZF1<.:U47#D5%]J*7KG\VM]%>F0/S&?C.;@_(74OWGJ/)0*\[;MZMTY2+57;2]ZM=,G?-66^:%GB]T92<[X2N5;..*?*

*7NIMS.%G;K4^L6R+]&NMZI4 M33)Z=0UDKXXIW>M98F1R*OCSY[@.Z@QE#(| M;]"VONU@N5"QW+)4TTD+7>I7,5N?W3V1_-\C8F.>]R-*

*:U,JJKT1 *M)Z=]-- M+%(US)(W¥]4:3U%:U*M_ M/66^&KC[1LKN^5B>*+WJB=<]?'I$G?C_ (GT?^',_DY"PT[^(H^ZKU/^#K^S*

*MRMDF\NB&+ZZB1?X"3"'O:9[GO/9I(F.=`2LFJ)GM7X#$CY&HJ\V.JJ]R%@?##8=)Z,H'4\6H;7=M77-J/GAI*ADCHF M-R[LV8{\=5Q>]!')*

*[45$7Z"OK<_.V\[5W^2WW2/MO%5U-6GHO9U#$7O3U*G3+>_/?E,*!_M8I:KM27NWP5U!4U=`4,22*,%R.:JJ^**AYN4(#;%;\U^U=R2BK.TKM-S.S-*

*M2Y7F@55ZR1Y[E];?ND]O4G+8;]0ZEL])<[;4LJZ*J9VD4L;LHJ?YE1>BIX+T M-J[:!A4Z&0!_%[>T:J. M;E%Z84KRXL_)U]5JB/4NU5NC=!*

[\FBSA$BRN7-^X[T|'MHVQ+!CN-G'R+F/5Q6Y;63B6LNCAN0X5PN<+ECXY.=B M)

[&HGT=Y)]$,X,K=^Y:]RJ887,;S>_>41*M37ODK]3VYLDVC]76^\1IES:6Z MP.I)/8B.;SMIC:Y$51]53B/BY4S[7-D9VZ)^=E3#T^AR$=-=^3"VUU!VL

*MVF[G=M)SN^\&V1*NG;^QD]-?^D/;M\&_^]HX?L\(QM2Q^=]Y%4?5WS07$=MG MN8V)NG-9VFO]?@4CJA(:E?_!,G*_|>:2F)'4M*

*M;S(WF6)6JF.J95'KRHBJO1".=QU-=[Q;J2AKKM75U%1]]S:FJ:A\D4'-CFY& MJ[#F*K-S>GO^+4O:O>LQ-%ZWM5W3_=U#>7BDUINYN93*

*M:O=7RV;W+E5]FHZ.5R-H&Y[T7[IZX3F?WKZD1$;VQ#@^XO;;OW9&V6\NBM^M MZ./[?391K*QB=\T2>OQC-;;4IJ37MVI=+:.HI^6*:2I:K*>K_|*

"MX&I[/>MEMU?3R>=4%2USNR9.C M51.T8B^DU454];9RGBB]@SW'S>MMQ=,[=4$5=JF^T%@HYI.RBGN-0V%CWX5>

M5%ENJNFN)HZPU[U%%=$QI&2WW.D?AS' MIT>W/1[%^Z;J=RIT4^9PJJ6H<3=7L)Q%:3?35.XVF+?J*D8JVZ[)<(LQJJ*J*

M1OPOIJO>G>BJ4]M8IOT[YJJN"Q/N=OI&R5B4BW>H3S.-%?R+*LB)CLT^$K MDJTZG?X>5-^W_J4S%4/FF;AQCW=K=433/1[G:G:;?*

*4V\VL:33.EZ)U773>E)(M[T8J:)%1'2R/^Y8F?:JJJ(B*YR(7); [)VW83;BATI;*NHKNSIJEZYFG MB88G1$3Q55JN59%Z0UOI_7UI6Z:;O%'?*

+;VBQ>=4,R2Q\Z8RW+C*9 M3I[3F-2RKM^>&*9BB'7Z3AVI>..:HFN?AW.$<:7%)>>&VRZ;=8K+2W*X7F>9 MQG%?*

SK3P,B1BN148K55SNTZ>DGP7=YPC3'E6YV(R/4FW['=/3J;7<53ZHWL_M]\G?JO1=@US:WVS4=FH+Y;E5'^:W"F;-'S(BXQO!+H M#8;5\^I;%-

>+A=70OIX776ICD93MW|/\ W'O?1A7(GBALUR%:W%|M7Q!2[U7S4=@;J2YZ>D5C[9+I^KD7 ML(VQM3D2&-W,UR.YNJ-])55GAI[JROFM]N

MI:)QO+=W.8Q4=&UK7/^"BL7[G#2O+>?>?4F^6MZK4>HZOGE?Z%/21JO M8TL/56QOM&15[^]5557/>9X>FUWKNU7NP\\W5]+-J.S]ZJ/Z?

*=*78WRCU_I M]S[BNXTC)=*7BH16+30],O1K58B=7Q8QS)U=TYD55RC[(;9##C.JME:^'2.KIY:O0M M0_[7.N7R6I[EZO:B=5B55RYB=4SS-*

*ZY:ZRS]+CA[2S'3N5&F:Q,5]GD3RGO6 MP9090\&VW*ENU#35M'4Q55)4QMF@J(7H^.1CDRUS7)T5%145%3O0\SPSG!RF MW=+N(F)C>&X-*

*>GK,+_[H9-S&4'T&G-[0,M3&<'*MP>)W;+:W4+[#JG55/:+ MLV)LSJ:2&9ZHQWP5RUBIX'55\2'?$SP&7#?W="HU;3ZQI[-%+2PT_FDE Z94*

*M5B*F>;M$3KGU&QCTVZZ]KL]0T&[8B#B#UC4Z:75--IFO93+4TS:BG67SK"^FQB4:?B5VZKM-<{1U MZT%/6TLG;4]3&V:*1,X8V ,8,@ M M*

/RKGZJ#\JZ 7(4\G/M/LNB+E6;>V),>K^Q&K_)R>>W/8:)L3%Z

*MVA@3KX?:VD(:!HB_77:39>HH;955\%5H6PQPR4*N:US:*/+55$Z+EMIY6S4]97S54;V+EKFI"B(J>O\D3ZSMG%GH^6LMMMU'3M5S:/--4]_*

*M1CW)R+\W-E/V2'P=HVITSQ6;7T.D]455=1W#3-0LE)54+VMD2*1,85'-AZ9 M^(FUE;?*QK5Z.D?(M/$B^U&Q2+\TB'CZIVJU?L6]0.J99'4$]XHH;*

[::N!51 MT;DI[<]3S+OMS:I^)9=OK6Z=;.W4[+!$^1Z.E>Q*E('/5R(MB9=Z3E5$1.JX1.XL0\H+L]#K+AXDN-NIF1UFDG-K:=L;<8I41&31IZFHS#__

*M !2'TRYE46J]+41RKWF?SZ/EUG$KO6IER9IC;;\G:MAMT*?>#:,36K848Q]MPI6NJ(F=T4[55DK$]B2->B>$!T+P*_/)8[G/EIM5[?*

*U4G,V#EO%$U?!JJV.9 M$]B+V*X],G+XE@:(F$.2R[/87JK;M\"_^(QZ:^]ZJ]Z:M.I88Z>\6NCND$3T MECCK:=DS6/3NQ:Q(V(B(B)ZD-*

*T[LD4*SR@.GJ#B%DVTJ;!40V^ M.Y>Y#[])5-;C;E']FN859TC[3T>?GSCTL8/&W;N7N5$;[BM0MD/F=>:#LFY>CKMI?45&E?9KI"Z"I@IT]-,*

*[X+NKY:5%]2]9&^WM/6U#'EA_\ A':K^]7/^-2D M@;#Y-K9W2]][M]XM46H**YT$\=3354-U>CXI6.1S')T\%1/J.D[\<+.A>(V:R*

M2:SIZZ=;.V9M+YI5++#CM58K^;'?^1M XGY]LC^%^M[)S6R+?ZM6N>BJB+V4 M&,HBIGZR/&LO*);Y[:*

[Q/L>M+9:"GLMR;%=+3;]!8 ,.H6N]+LY)7/5W,W*JN .[ZXXM>$3)G:W M9;3NJ;1K2HCT]>:RK;4PWJ2DDE2>#LVIYNKHVNCG(BHB+VB]*

*<]"S75VC MK/KS3M?8-0VRGO%FKF=G44=4SF9(U%14SZE14145.J*B*F%3)$^X^2CV:K;B MZIAN.K+?"K^9*.FN$*Q-3,>5%? Y^,>C\+./'/4"*

(/E!>^P<1NI=.VS2#9Y MM.Z?2=R7"HB6%:N>7DRK6.I)&(V-N.9&N7F=EO1"6/DEZV*7AWU\3->G;0:F MJ%>SQ1'4U-A?*

FZ+|2G6JG@;V>GVQ70,.F$H[*ZJBKIIZ>=R5&'17#FEY9HQEQABNRQ+4Q5E8Z=N8^?E5$7N7TW97Q

*MZ>H"/O$]JY12X\/F\5VT1!H>FO<=%%!*E;+<70N?VD37JG*D:]W-CO\"6>UNL M9-P=MM)ZJDI6T4E]M-)VVVBBAM]*V5Z MO?*

V43$8Q'.7O7E:G4#W@ %87$U_]I_MY^)%B_EFEGIQ?5_`?2H'7&\=KW/NE M+7/U5;9;::"2.K5D/-3N1T668ZX5.OK]05V^4;O^Z6T&Z&C]P=-ZCO]-

*HQZ M4\<]OIKC,R@2MAE=)RRQ-=R8D8C?A-7FY'H6)'H]4Z4M&M+%5V/4%LIKO:JQ MG9ST=9$DD4B>&47Q1<*B^"HBIA< 4"XC+?*

Q%7K3&T&V#DU8Y+DV>>]M^9(Z MBJY71Q10O3H]C4DDZ]]115FI[#$YZN\TH:^-\36 MK]PWM8GN3Z7+[^LTK9WRWI[.S?

*>;E)V]6K<85K781K$7Q1C M6Y\GN?#*DO!M+LU',RHK([$E+%49Y8WUK/MS7^QBU"(OKY2*WDY>):R M[44]|VAW%K(]+5E-*

<99Z&INCDABBEPC9J:1[L)&Y',YDYNBJYZ9SRHME'[? M?@AVNX@+LMYOULJK7?

GHC9;M996P3S(F,=HCFN8]41,.6AH:2UU+)W4RR,Y>WE5BJC$:CN9,]7*K(B8RJ>`ME\F+LK7;;;)5>H[M*

^EN6K:AE6R&1]M>RCB16POIYBN>U5[N?? 4G?L3PVZ+X=*'[46C8*R&GN]'*_FZHH%L(|>:!E3#)!*Q)(I&JU[')E'-7HJ*

M+Z\IDHTU[?:AL90[R[+M;)YK7:@IF9=\'S>EDG\]7Q<;>?CH<.6O;!"VU4^VOJZ5])E5G@Q-&

MB>K+HT;^R.P_0:.:CF]BHBHO>B\[8%)>R%96<06O]@]KJB%T]KTY4S]LQR91 MT+JJ2KGQ[.R8UOT%V_T'!=H."K;#9#7:ZNTM;:V"

[!E+"SSBL=+%$V14YN1J MIT7"8^95.]@5>55VINR+H=NQ1O[6RXM]?/%!O:]J2R?I4D=*BKZWL]9) M'8OC"VZWAT17N74]IL-WC@_W3M-*

RK8J>6FE1$YU1KW)S1YZM?W87KAH;Q+6T M,^H].0R/YG4-LKHE@:G7*,2:*1R=Z?=8]@$?N-7=F'C"WGT1M+ME4>[-#15;

MV37!,>GFJ)%1KI&N3OBAC;Y5D3HJ.?C*(U5LHLELM^W>AJ&VP MBQ&HN$5NM-935;N2EFA?',Y7[%>]ED9"YS'* MBSJBX5$[T4BMY-*

WAKVXW[LNNI]=:=6^S6RHI(Z5R5U33=DU[95XM,OUEIM1V.X6FL:YU'74TE+,U]X',EO%-HVG MK88KJ^*2I2LJ73Y=&CD;C=/AN*

^_IX*#1NFFQ01.I[9;Z1&LC15>K(8F81N-M555EIZZTUE-5NY*6:%\IVZH(-M*6T4%?-*LJ5$^&OFY)%^$G.QZY3{ES%{G(!/8
0B\I%PJ7+=S3ENU[I"CFK-MM4V'''S;HH*9N9:NCYECW8ZHB+X/"GY2#2VI--T.G-U+A^
M)S55$QL"W:I;J4E>B81'O5RKE72(B*Q[E\7..KO:!'GC.WIO5+?+?KW:3?[24%'-M:*/L)=,T-]AFFJY%>Y[I$@17QRKCE3#D3"-7"Y<1;WBX]=
<\9]1H30E=#:-/-MM2IC9*Y*GL::IK'KR)42.D7#&M8[''-ZX5SL*JN:U)I6KR3VSU%6NE]+-MJRXQ-M(Y%,3U%=3M9R]/1560-
=X+W*G1WKZGVFY'D\=G-:Z&CL%IT['H^LI6N\TN]L-M173M543/;*]56=JX3*/578SAST9:G=I!;;=&RU"IA:B9-MRJ^654];WN<['@BHG@??
D>>$;8K7VP]DU!8]8:X?K&U141,L<:O>Y*6G;Q>9-MORA-M?ULVS^:QGKM-M]N'+1O$3:,;9;=8P5DU-
;9W5$"4=2Z%4>YO*JJ=_0^YTKINCTAIFTV"VM>VW-MVNCAH:9LCEC1DVIKE)YC:().J),K-M559G)XLC;U\]JQJ_"(-<(51LU/JBNW-
WTUW2W+4\M8ZHI;/_OH[_5^T3CUV#Z?\,;'H?\5]?P7S'1]KMY]%/TVNLN&B;-M[#?]:CF[">;&.1B,>K>;'IM:OGK.">]>;&_|>-[^^CO]4[-L/P\;/X=[
M)<{3HZ"L@H[A4^=SI65+IG+(C4;T5?#"-<@\I=M]^+7A@NU=%'VE9IVLI[K'
MCOY>98I.OJ1DJN_8(0WX7;E6\3W%WME5W"%\M'HNP42/63JN*&!J-D_954C5
MZ>#L!Y:WJW2UOUII6\Z>NT*U%KNM)+15435PKHI&*QR(@N'+U\%ZG,-B.,$C
M;OAVO%TNFCJ*MBK;C3MIII:VJ=.O9H[FPF4Z95$S^E0#M973Y2BUOVVWMV>W-M@IHGJE'51T]5V:=ZTT[:B-%\%5S7RI\S,>!8LQ[DQ[0(?
^2PT[4ZJNFZFZUSCYJR\W'S.*:'W3G+4-M5"(QJ59(?VI8*2";,:.Z:V-T3#I32E/-36J&:2=/.)5ED<]ZY5RN7O7N3YD0-M^[-'/.('1I1K_9#7NG:-
G:UMQLM7!31XSS3+$[LT_:HTZ&8^@"-/DA=5PU.V-M^O=,\V*BANT-P5JKWMGA2-%1/GIES\Z'1_*>T-VJ^%NO=:&R+30W2CEN*1M5-M4\W17(G-
CP2585RO1,'$]O*'[$#RAM=IR1%@T=KY%;0O7X#>W?S0HGAED[70-MX\&OR6)W>T4=]M5;;+E2PUUNJX7P3TM2Q'QRLN-M
M+=L!16NANEIMNKVU$]KW3U4T<-5._M7K$\]J/4FL-14DEK91VN9M2E-%,U62OD5N4:O9N#*:O8>H6MT]87-M5MX5JL]U(Q)YS4HU4PJ-RB-
9E%5%Y&IE%5%Z=-(V^2-JD=HG<:FYD58[A22<-MOBB.C>F?\A?J4XIY0/5M7H#C?MNJ*&-LU998K7<88Y,\KWPJDC6N]BJW"EA>
MQO"CH/AXO5XN.BX,C2276-L55#45CIHG(URN;J-7Q3+D1?#F=ZR$O%!!'4>4-MVT!]-&V:*2NL;'QR-1R.:LJ(]*B]Z*BKGYP)O[=<6&U6Y&C8-
0T>M;+;XEB2-M6II+I7PTU11KW*DK'N3EPO3F^"O>BJA-GBZW+;QN<0>BMM=N)/=2U6Z22%+D-MUB]E)+(K5])T]<,
<<;51WCARIE%;F3^M_)A;,:TU'/=H&7S3;3O[22WV6KB9-M2]Y5RJHR2)_)^E:J(G@B'9-D.&K;_A\M\]-IRR)25-2U&55RJ9%FJJE$55PY
MZ]R9Z\K41OC@#Y;BVLE+IK@XUU:*%G9T-OL+:6!G?B-G(UJ?4B$-/)F<4^F-MLZ"]I=ZQNE-8:*QK?=*VW*L?
V=.DJQMCDBDD54;&BI$Q6JJHF>9%7*IF;G&O-M^95W,3Q]R7?QVD2^!/AOT'Q#<*=PMVL;3YQ+3ZFK%I+E2N[*KI5=34V>23KT
M7XKD5JX1>7H@$FN(;C,V^V:T#-MT\)^@;-O?/NU2TU(^BNO!_QU6_=-M.*@EJ-.WJM6Y-=&Q.2ME9V5:#E5QVB=I(L]W.Q2P/2W$WM3K#34=^H-
P-/1-MV]T:2/=67*&GD@1?N962.1T:^QR(?4;A[::9W5TU4Z=U;9J:]V>=4<^FJ47H-MY,X>QR*CF.3*X=GFX?^*K;G?"VT[_#.I
MFB2XI"G622GPV5JKW(LE,Y&)_>W']?IZ2K=U-W=R-\+_'SS85,U-2N7JW5B-MH=VT_*OAV<;L8GYV4FIQ7L?I/?EQ-
-;PI)JJW,JHZR):>58I(Y6(Y$]>Y/F:B.:;Y;-M<-WUJK\Q7?Y/_B,H>'#4NJMIMS'?-MB7AFN+I8ZFM]&.DK41L4D^7"#MEQ!S)6:IL-MCH[RV-
(VWBVR]A5B>'.UV/-#V>N.*#:W;_2E1J"Y:WLM121L62&-M*WUT53/5*B+AD3&.57N7&/5ZU1.I'G@>XD]W>)+BPTS)4QS*QBJYRKE?
@YQS(>PLWDI-F;7713U%=J]\1,F-MBH2NT;HBQ;?:>L;#INTTMEL]*F(;.CC1C&$Y[UZ=[E7*JY-M>JJN555-K1XEZ&Z\
(G'1:MV8:&2HTQ>JM:_F:WF1Z21]E70Y7NDP][V^'VQG-MM)]6+B>VFO\-I1FI:7ZHN,4,D66YY)(WJCV/\-SBHB^P^KW!VW
MTWNIIFJT[VS4U\LJ@J.?2U*+A')G#FN14Z16KW*Z263"+UY>3*(N2Y4C_>.!W:6YUFD*B*QU%K;I9&);H,?-M5/C8BME[7FDSE7N5_57.557Q4D-(
>5_*YV_|-U6G7_J4)_G+=]N'+1O$3-M:,9;=8P5DU-;9W5$"4=2Z%4>YO*JJ=_0#V/#U^4)MK^MFV?S6,A]Y5W92XZ
MCTOIS<:U4SJEEB1]%=$C;E[*>1R.CE7\ZU'_B^I9$7NR3ITKINCTAIFTV"VM-M>VWVNCAH:9LCEE](&5%/,QS)(9F(]DC53"
MM5%Z*BHJHJ+ZP(X<+_&QH7>/;^UI>=2VVPZRIH8Z>XVZZ53*=TLR)A9(5>J=-MHUV%=A]JKYZIS,-M5[D3E1G5>JJN,-S[C7?DQ-
EM:W=UQI:.];4<]5<^GL58QD"K[&31RQG*G-ML0^@VB\GQL_M!?
(;U2V]MU)=:=S7TI1J&=M0D#T7*/;&UC6F6G6&GEYFLCZ=@NVD*N2[6.)LRQ7J-E/5Q-&S.A-(3WF#6=OU-5+%S4MJL\R35$[E^"Q43I&B
M^*R8PF>]<(L">!75=TUOQX4VI+VSLKK=W72NJ&!%7@KECW6-M\H%KO6UJ;Z2R0/NEQAJ,YO*JJ=
M_0^JLV@+38MQJ'1=+'(VQT5KCL\3'/59$IV0I"WTN_FY$QD"!OD=_P#@S=?^-M^VS^+5$Q^*?\S5NI^MFX_P-W>>-L+PQ:)X>52S]8D>C
M.7/=^2./OM9Z4H-=Z0O>FKHV1]LNU'+05+8GJQZQ2,5CT1W@N%4"%'DAORI]-M<-JVQ?\-J&'=>/7\R+N/_@D'\YB/L-
A^'C1_#O9+G;=`05D%'<*GSN=*RI=,-MY3<G>BKX80^CW-VYLV[6AKOI+4$K6O:].5WAZ3$-B[Y--M&ST^H>$*QM-:WGI*^Y7"EF1/&-
\;&K^XJD8N%?N&RMZXSUY-M5RW/>@'DW+B+VNM.G9+[4[A::]RF-5?.(;K#+S81%PUK'*KG=4]%J*O5"*'#-MUQ>[G\27%#<;;I=D--
M52R.]UJ:!JRP4K6JUG-(BIRR3/1%OE<9=C*,4^FH-M_).[.P5/:RW?6%4S.5@EKZ9&+[.MIFNQ]/@2@VSVETEL[IMMAT;8Z>QVUKN=
MS(-$5SY7X1.>1[E5TCL(B9(FTVRVZQ@K)J:VSNJ($HZET*H]S>5554[^A]SI73='I#-M3-IL%M.]MOM='#0TS9*Y*R11L1C455[UY6IU-BCY5?\
,R4WZX*3^2G.H\"_-MYDW;;]3W?RTA]IO7LCI??S1[-,ZLBJ9;4RJCK$;23K"_M&(YK5YD\,/4]SMM-MM[:-J]$6K2=@CF9:+7$L-,V>19'HU7*
[]Y>_JY0/E-*/5<.C.'?<>[3.Y4CL-M=5#&N+M'3PI.LC((UR[]+S3.3Y-MVN/.\J)DN)5.T3I;.FQ-=67W5]QC?)U6+E[X8Y&I&S'Y^98+\+_P'''<2AV-VII
M]E=G]+Z+IU;(ZUTC65$S,XEJ'*KYGIGP61SU3V*@'1-M,L#)5+Q-MM>4>WAV$XG-::$TM-9&6&U>9>;MK+=VLOVVB@F?E_.F?
3D<6M$8=XO)V;,;Y-M;BW?6^K+7=*F_P!U[']SF2GN4D.;NRA9"S#$[O0C;G3U-5H>_!\0?_?&FOO3_-M/QG@7KRMO$5=:5T5-?
K/9WJB_;J&SPN>G_2H]/W"P[WH[AT_P"8[U]^9O\-M2/>CN'7_)DO?WYF_P!(%+-ZW4OVKMQ'ZUU=4_BTO4LZ5$[K\]\T6T/
MM5'IV>YQ);Z'L7I,VIIHV^ES+E.69_3YBR-CUP_\#.U/#5K&MU1H6W7"DNM7-M0/MLKZRODJ&+"Z2.14Y7>/-"SZB0H-&.9/6<5XB.+;;7AB;9_P-7
MEXEHYKMVGFM+1T[JB8Y&5WGXPO+>BKA4-MYGNPJ-9X]5RB(JI+7>WR;%?-
T:"MT#44]LTK=:E77&&94_W+Z*YSXV]\C5[-MFM3JCG)U1N7)-#:.7:33FR^BJ/3.F:'S:B@1'22OZRUNYI978])[L=_AT1,
M(B(G2Y6K4=E$VO>GRJ>YEQ:WQ]4Z1EN.?88S[2EHU7)IY3,_W-M7]6B8L\Z=X^TJ;5TWQ*[1KRQ4VO[1!$J\WF;ZJ.E3'3JL:NC5/GR>RL/'UOG
MH^=U-6Z@CN?8X1:.\6Z+F3UY]*674M-YO>+10W6#^UUM-M,R9OU.14/.-1MU?O;42\?1-RWSLWIC[JI_,^58U92_\#^A[1<\)Z3K;4RT?
M\=)3K&F/*E[>U_*R]Z;U!9Y%7]^!L53$WYUYVN^IIV?4W!?LMJM7K5[?VNE<-MOC;$?18]]"YJ?N'*-2>2_VNNJO?:[KJ"QR+\%D=3'/$WZ'QJY?
VY/:=IN5D.MZ:AE7OCN<$U+RKZE<]B-S\RGR_%-MY;N-M+K0UDLVA=;:.:ZGX>>>NE;7MG:XJ1/8]V7.N?30X/J/R4EZ@8]VG]?T58J_-M!BN5O?
3X]BN8]^?VIP:=W@FW/V5LN$>YKFM>C-M'_(=)^(6NJ[.9]56>TWFG-M3M$MUS21LDS,=7QJUJH'BG143"X+1.$K8ZZ[
;4_B5O%=1W"L\^FJ^VH5>L-M?*_EPGIHBY3E4IMT[]"Y:5O=%=[16S6ZY4,J3054#U:Z-R+E%1?W,$Z-$>53-MJ:&TT5)JC0[J^MB8C*BX4%Q2-
)E\7I"L>&K[$=C.<83HE!J6/DWIVM\Z?@Z7-M25%VPK>5EPL>I;8_O5WF\,L;>[Q;+GU_<^-M'K/O;-Y038ZZL;SZLEM\CO\-DZRVU+
<>/5S8U;^Z+57UI]:&M5;KIZTRV:;UNKW:H_J]K@_C-20U4:LFA9*Q>]KV\R-M?4I_9KVKW*;=#'>8EGM35'Q1ZXKN%&T<0>DHDHUCM&J;9&
[W,K43$2HJY6"1-M$^XF$5V>GTN]D4;4U4S-M-$)9(8\-M_>3'5&]/#*HZ?;^YO;,\Y\UQVO9Y3FY,],;ESC)9)MYQ[-M]#[9Z1M^G=/V;4%OM='&C61-
H(]O>KWKVOI.5>JKWY+G.O7K=.UFG>9\E!I-M]BQ=KF;]6U,);[9Z!MNU^A+)I6T,Y*"UTS8&*]85Z]IGK^>?QI6^X[7.K?->5^>RY?3SS]EGD]+&?
#)UG;/7]LW3T1;=5-MVAL[+9=(NV@2I8C).7*MZHBKCN]9]1RIAWM.$IKFBYQ51O,2^DU6Z;MC@HG:-M)CELIP;Q$\1NWJ(M7]+5E
C/&]4CI<=$7KV[%ST1._V^L[CPD\;>ZFO]X[#1-M'4,E-J;W7%SXYI6T3(9X$;&Y_:HZ)&MPF$SEJY15[NA8[V3%3TD1?H/$IK72-M4TTDT5-#'*]?
2D9&B.=EKE+-VIG;0]FC8&.54;UWF_5TANFIK=4LNT$'FS*ZA[`0R+&BJJ-O)7:.J.=-M;5JO45-Y>K4J?-YV-7KT1$C8N.]QST[R/_$?P
7W9;2"ZCT[=YM6VNF1772+-MS7LI:=J=TJ-.I>=B(JHY>]N<]4SBWILZ?>JBFW5,?=1UW]2L4S5'W]PY,'86K-NW;BW1\)PUR_<
MN5]I7/.5L/!KQDT.^=NBTSJ>6&AUY2Q>"(R.YQM3K)&GF6K+AK6IAZM5Z81$P],(<9J>'1CU<=OI/=-M\'>:/GUY-/9W.1=[I:=V0CDP>MO-
\M^F[74W.Z5M/;,?2L62>JJY6Q11M3O<-MYSE1$3VJIZC2.YND==QJ_3NJ+1?41.ON=71S*WYT:Y53Z2EX:IYQ')T.UTQ/-M#.\WU64&4-$Q\YDAZ-
LH,H:HN-!N-M-QA#(&$7.3',GK"+T7)S+=;B*V^V7@5-M=5ZDI*&JY.=-M-QW:U;T]:1-R{'M5$3VF5%%5<\-,;R\J[E%N.*N=H=-RF%ZF
MKGM:G543YRNK<[RIM=,^6EV_TI%3Q=S+C>2G]IZ^M4@C7#5]2]IR>PB[K[BJW
M8W'=,V\ZXNB4TG1:.@E\TA5OJ5D7*CD_39+>SI.1S"@OZYC6^5'M3Y+B-M=6;M:+T*Q5U%]NSV1WQ*^NCB>OL1]NRJ_,G=45BIE.9\%/&U?
F^W*OUH?-57E7+&UZ^;[>W"2/&^Q6O^YU6?75GX,_M1>5>L#Y,56@+E-M-SUPU\^R.HG1QMUDVWSN_Y.XT4\/+W=[U9R?Y13IDP>-6C6
M*O=F8;%&OY-/O1$K[-+;C:4UK%VNGM26F^,QGFMU;'/A/;R.4^E1S5ZYR?GS-M]JF6EF9-'(^&:-:>=DD;E;Y]^M%RF%^D[#H'C$W?VZ?
&VW:UKZZD9_P#<=W5*-MR-6_%^V9Q+]CWZ>7Q[E_CYV/D_NZN?P[WW>4',GK->;N"?==QJ+%N-M-M-!^5<_50?E70#!)W"@C7<+>SF4Z_B-
LW7_P#083J^"'^T/$-.^-M('9+9NRQVM*R&+1=Z?4RK)RN]*AA7#$QCHF%Z]^<=">7=/,D\#'1U1S4S#1LY-M5F]KUJ2N3H5@>5-O-
14;S:7M3YGNHZ6PMJ&0JT6225$S7.QZU2)OJ5/4:]-M&DVM0S+5RJ=II1?U:YIN'=IC>*N3F'"E&NXG&1I>MD:S^=7BJNSEY84SZD27LW?
L2XQKNY2H3CTTC-MUQ27>XT2>:MN;-M:>]TKV1%;(J8TC;_E^=.;-M'T#4HBY3;R(_F@TB>RKNXT_RR^C5,(52>4AVM=H;?"+5%)'V=!J>G2IYF)RH
MVJB1&2(BIZTI)^?6]2US/1?6<&XN^'%_$9MQ!:,"KIK??K=5I64%55-7L\!J-MM?&YS45S6N1R+E$5&7=!-W=D-M]*ZD?*DM9/2-AK>[/G,2]G*JIX9-
JY=.WFZ07-M2Y55?)7RK1\RP0JYD;$CC5R(JIB/.51.KEZ80[NB)U0U;W#VE7!T;>+Q]C3V-MO5L-#R;8-M-1AXK^!^P\2M327ZFNQ4-#40V
MK5]JF\YLFT7S561/54YXWN;BN1CT1,JU,HYK%ZXPO4]MZ;5%'H6R4VLY;"IU-M3#3-CN%1;'O?3SRMZ+(U7L8OD(B.QA,*JHG1#ZL
(E;K<%]ZW"XL-,[N4-M^HZ&DM]IJ;?.^VS0/=*_S=Z.:-::.IG8KV1JKD7F5$[^X^'X..'>X\-&UM=I2Z7:FO-1476:X)44D;F,1-MKXH6(W#NN?M2_6=Y
@_O;Y.66]-MAU&O]IM8RZ-U!4SK42TR+)'"R1RY>^&6)>>+*Y56X[X0SZ>DU,]71/9$UZ]W1SN_QZ$M^'#AKTGPTZ/DL>-MG&S5-55.;-
<+I58[>KD1,(JXZ-8G7E8G1,KW]JJO70-M-$8-"\+>HKEQ0ZAWCW+KK5Q&KX&-O\UZT/5]&N;-M-_N$;;_B4MZQ:WTU#4W-D?
9T]\H_['N%.8PC9FIES45RJC'HYF5SRE#$P"Q.Q\,PM^CC?3;NZ-M1B;(O1*V[14BITSU256JGT^/U1S4@+

M]E|I=;^4_P")74VH]47]6UV>GY:]Y5D;4E2AI5>]4]#3-541%5K7HURICT)'-MNYG91TX=8^1NV9NNDI*'3MQU#8+XR)4@NTU6VJ1\G*]-6:%S4:YN<*],6-?4_MJ'B>1>TO%;>&O4EZ5C5JKIJ69BN;U7LHJ>!K$7IT5'.E7YG(6!@4J<%VXNL> M:[C&J=G=95+H;#>+DRT5]
(C^:F2HEY4HZZ+U(_FCROH_:Y?2ZL1&W5E,7EFK-M$M@XD|):@HWR4T]?IV)5?&BMM.5/67#:5NRW[3-HN;DY-M75E'#4JWU<\:.Q^Z!
[<\2J29*>5;=&NGY5Y$D54:KL=.JB91/E/A]4<0FUNB-M+[5634>Y>D-/WJE5O;VZZ7^E!JB'F:CV\\;Y$XH[CN'7;S7IVY:/CO['A:OQ*W?ASXB-'/H;[=
[0%'?:9JNMUU9J2A5\#U^Y=]M|)B^+?I3J5-M/VRYP7:E944[TMW(??KI3TD?:[.,YEK'UKG*KXJY5RJN7]JJJJN5-+5; MZ4 '(.^ #U-
[L%#J:UU5MNE+'64-2SLY(96Y14_S*B]4?-MP5$5,*A[8 0&WTV#K]JZV];1=I7:.G?]JE3+H7+W1R^W"<[N=[%/A=':@9I M.^TE=76:DO-
Y62BKX4>R6-5PO*KNY?17#D\4ZYZH65STL=5 ^&>)DT3TPZ-M.1].;J>I47O(I<:=VM\,VG+%0T[*V*-U2L[8\/CA558R-JIW-54>N/SJ=P'
MR&XF\.@*ZUSV_2NWUM@?44ZL=7UE.UCX'.;J*L;69]}NG<*+WGSX FKM+-M+NS2.;0Z2M5#=H6(MZ;W5-+&KVI\9BX]-
B*N,]/;B90[E;Z&FM=%!1TD$=-2P,2,.&)J-:QJ=R(G@-MF"LS2VI*_25_HKQ;9G4]922I(QR+T7UHJ>**BJU4\454\2R?2U]AU/INV7B!
M%;#74T=2UJKE6HYJ.Y5]J9Q] 'N M ,=R&0 :]?:9Z^PR -6^)L 1L-#Q*RCCN%--3U M$+)Z>9BQR12,1S7M5,*BHO>BHJHJ*>:B8,*A,.?
%$|\>4JM>-3@IGVNJ:K6VBJ M5|\>DI7H^KH8\N?;G*OAZXLKT*+X*L.LIJR?H"JZ.&X4LU-40LJ(OF+')% M(Q',>U4PJ*BJZ*F45%
(J63R=V@[5O3/]JZK5:,8K:FDTS+&KH65.5SSN55YH-MDPBHS'>N'91,.Z7#U;LK[HX_.T6;EV*[/*)[G"N"[@69K6GI]<[E6YZ6
M*1B/M=DE5T:JM%3I/+C"I'U]%N^QUV1RLTI+;I'=[Z.XU+_M?5]RZ1S?#U$C&.[-J(U$PG3"?[?,;_4I4W6-.L6K4433$_=# M2\^2XVSK4Q%[ID)X'K
MW>'9.3U]Z^'"PEW\GMOC9)%DIM.4UR[->9)*"Z0(J8SU3G/S4W.VNXF-.>A26W<&WHWI_N//52)ZL9@<[*>TS]DU-MQ&;?8\]U+J:W\O?
[LT"2>KO[>)?6GUH7''O*&BQM=WH9^DXJ'^U3+Q]#33^[-MNU0HTW=W[UEOE46NHUE<(;C46R-\4$L=-' O*]4545&(B+U:G@<]QWKX*7<[
MS\.>C-Z]+5MIN]JJ>KD15\KM30-;4TTF.CVN1$54];57"IJ:5$;W<(;DV)U-MM4Z>U#3]$R^DKHT7LJN'.$>Q?W,+W+WE_IV=9O1V=,
<,QW.;U'3[^-5VE=7% M$][GK5QX9/8:?=:O=JC]W&5;[3VB> F>[N.\[-+M%6Y6]NC:C4UDIZ"AMJ.Y*9;K,^%U;C/,L.&.1414YBXL[UZW:IWN
M5:,JFQ9N7]JK=.\K1>&NCTS;-D])TVD+G/>-.QTG]AUE5A)9&JJRKSHB)AR.-M5R*F.F#J&?
I*;*K8OB%V%J9)Z"SZJLK&KS/JM.U+YHG)ZWK3N;7.X4>HXX7]4*)(W\ZKXNS=S>UV5^?N./N:95MS3LMQ-NA
G17E5K'5(V/5FB:ZW.1.,+/4LJ6K[>1_9]B>SF4D-M=HCC5V9UWV<='K>AM]2Y,^;WCFHG(O@G-*B-5?FQO>M%3HIY2)[=#L#N//I*;1]1>I8J:*H6JB
MKFPIAZ*J-PL:]V/6>UJU7>KX;<;RU[]^U8HXKL[0CUQQ\%K-OF5^XFAZ9K-- MN?VESM,>$2AC\&-FPNQE_X@->T^G+&C8HVM[>MKI/
MR.D@1417.3Q7*X1O>Y53PRI)?>;RCEOW5VOU'I&+0]5;I+M2K3MJG7)LB1*K MDPY4[-,]W@IQCA-XF*;AIU'?KK46*:,_N5+'3)'%4I#V:M?
S*JJK79[__P[M'',&4XM5-4>U'1P>1&%5ETU43[$]5HFVW#GH7;70U%I:DL%%<:*!>>:2X4S) MI*B;IF5ZN1>JJGS)A$3"(=+AA9 Q(XV-
9$U.5K&IT1$\,$#/?8+7G\KJL]?,_M JS\$3HTW=VZ@L-NN;8UB;64T=0D:KE6<[$=C/TG*W[5 ^W.]Z.KM<,_C7(F MG'VY.>\2>S,V,&TMUTA#='6BI])
(I8JE6<[.>-Z/1KV^+5Q]"X7PP5PZM\GE MO1HR59[=;*+43(5YDGLM<-@I:9\[HXN96I(_E1<(JHN/%>5>G0\[17%'M1KUD M:6;7EEEFD^!3U-3YK,
[YHY>5Z_4?"\3'!7ISB,O%+?9KO76"_P!/3)2)4T[& MRQ21HYSF\\:XRJ*Y<*CD[^N<)B(VL_)>;CV7M9=/7RS:DA;U2.1SZ2H?^QL_HI$C@"
MV+W)V6L.IX-<9MU#631+069:ME1V+F_:2_:W.8WGYF=$7*\O7&$)9JY&M57 M=R%?=HBW7--$[Q\5KCW:KMJ+E=/#/PE_5.IC."#4/E5-
(LU'6TU1HN\)98Y5 M9#7T]1&^>5B+CG="[E1OS*>GE9-#*U'QR,36 M1.FI9XV]7.8Y])W=53H5$M\GEOAE?
^QNC7_RI3_ZYNXUFU>W[2OAV5>9DW9O^DI)WBX?=;;$.M+-96Z M*W.NB2K2]E51S<_9\O-\!RXQVC?GR?3[=\&6ZNZ.D+?J?3MCIJNT7!LBP3R7
M'&-7DQ4^C):3IGVNJ;K6V4E34ZQD55S;BUSCN7)4J\\MQ*D5/ M74\IR]S&2M>B^LH4K.1.#C=/;C?S3NJ=266GHK11LJDGFCKH97(KZ> M1C?
1:]57+GIW(6->'0I\FU;LU\-NKBC9?XEZY?M\5RGAG=_0 &LW@ M #&4 QE,8/E-P=RM.;7:;J;IJB[06BV0)
MUEF7JYW7#&-3TGN7"X;U%5<'S,_V_>GN'[0\U_OKUFJ)..*@ML3D2:LFQE&-
MJ2(G5SNYJ>M51%J"WHWQU5OQJV6^:HK5>U%5*2WQJOFU%&N%Y(VKGU)ER^DY M4ZKW8M<'
KRIWGE2HM1U.C#CACG5\$A^(#RCVJM<2SVK;YDVD]E6K<7\JUU-M0WUHO="GZ7+OSR=Q#ZNKJFZ5LU975,U95SOYY9YY%?)
([XSG*N57VJKW<,J MG;6.6UCT[6XV?/(^7>R:N*Y4S\P^\?09ZCJ8.X4B/LS8&86+4%STQ=(;G9KA56JPX.YHJNCF=#(Q?##FJBH M>O!%5,5K#
<8+I:ZIO/#5TLB/8]/G3Q1>BHO5%144H+3VG M7^'+B8U1P[:H;66J5U?8:AZ+<+)+(J0U#>F7-^)(B)T>B>"(J*G0YS-TJF]) MKL#&I^XA#+:7
MAZN^N-H=G[O1UM+%;ZK1MB2=95ET:BIU3Q1>A-&-$9'R)T1-M[(B*+=L9>1;K5VNCJ;Q3STD-#7S0-
=/3\]3'SI&_&6HYJ*U41>J*IN8=4TW.&/YN7-MVW5>H4159XI_EY_?9\+PB6S3>@-SW)14$%O?=J)U"V:-<9_TXL.8[!JK<_26:.*U$S5FE[9=X MV]FE7
V18UZ\KL=6_0N3C]-OWZ;|["R9W]HGK/P=?GJ%:=BSF8L;45Q'*.Z4 M(?*LZ&[2TZ(UC%&B+!/-.JF1$Z]CV]K$B^Q.SF_;'7O)TZY35W#?;,?)(LE5
M8:N>VRLH*9+I3X3*HZ!4D M=R^U8TD;^R(D>2NUY[G:[U=I*65.RN5$RO@:.]J.TA?RNQ[7-E1?F9[#Z#3_K MZ?,=]$OGM7^VU.)
[JX_[^BRTQW&P*)T[^;G(U MMG;IN.HFIIZ>-ZM8VK5$?$]R)T5>5DF%7NY5Q\([7P);S3;O;%4*7*J?5W^Q
MR+,)*Z65V9)$;UBD55ZKEBHBN5!'#A;W'TQ1T[JJX36QU71PQIZ'C(HG(U.]HDB]S"UESVQM5SE1K6IE55<(@%0 M/EN]]C|U]MJ%&]DD-
EGF5W@J/G5])_U;_623\I)2S>]X0(K'-= EF61KDPK? M2C:N?5U4#M.F-)RI<[0D]'I>GKJ7*MDAC>^2KG3.,L8Z2H5
M%3HYL2.15RJ6F\;&UDF[7"KN)L WWSP5LEK\YH:6'",?-3/;%&WP15=$UOJ] M+ '#/(XSQ2\)-2QLC'NBU)6LD:U456.[.!V%]2X5%^94)TE4?D7[^K-
.6:LV MEN=;#17&XUB7NSLF?R^=O!)(ZB)F>BO1D43D:G5421>YA:RY[8VJYRHUK4RJ MJN$0"H'RW5>Q^Z^VU"C522&RSS*[P5'SJU$_ZM?K+7-
MVNCV]TPQ[5:]MKI4 M?:;_:+C,Z M*@GCD>C>=S&-5.GKZ_.A]0OE1^)W'Y9O_]"U_P!&.(I0K_NW5_X.O\=ATN)] M-==RFW-.;2Y3,TBU:LUW.*9VA+
[0W#7O1K;2U#>],Z=N578ZMKGTTL%?%&Q[M4>K55&ND1>JM=ZN[YB1?!KP[;PZ W\LEZU;I^X4%C@AJ633U%;%(QKG0/:ST
M6R*OPE1.B>)*O@?3_N6M _X))_+R'Z= MNY_0 %&Z8 A%QEY7=>EP]KBV0]_@O:2_N8Q]9-TBEQ MI:'])9K/JRG8Z2G;'[GU/*F4C7F<^-
RIZEYGH'/"HWU@19 L-X>G.=LSI1 M7'JN\UQZ7]YW8_<*\O43TX;MQ;#WO-LM_](+A::6."HHV%3G]%$3M6^MCE MZY\%7'J Z^ M -#/W1L Q@R
&&$3!C"^LV &J(OB_PRB]%3VX5.E)W8,IDFBJJBJ*J9VF'E3J++:Q7QJOZ69' MX3V-5J$?];^2MU50-DDTGJ^W7>/JJ4]SWITDF/!$M.WV4W7#AWXA-
BJJ2KM]EU+;$1ZTAY0#>S0%1YIA_* MKVN=S(]7Z(JJ-4]%U39JILZ9_O]2<)?$SJE=0ZBO3*>_2P1PN2 MZUE1;4:QN4:F55L7U.4^]UOY.39[5:/?
06^X:7]'=>>U5KE9G])+SM1/8U$^ M@@7Q3<*5ZX<=00*DLUXTI78\TNZQO?RMYQ;ZB&CKJ>>HI(Z^&.1KWTLSG(R5J+E6JK'-
*E9J*54^"OI^DU<*K7]SD1>Y4JG|'54;.FIKIJYTSNW.8,=#/TD/1J#9,^)A0'T&,9SGJAN M(R[C>3ZVBW
N%7<&6RLTY7U4CI99K+5+&U7JN55(GH^-OS-:TX)JKR4M8R9'-MZ;UY#)"KD18+K0JUS6Y[^T8Y>9?9RHA8GX!.B&];SK]N-
J;E5=TS%NSQ54!\%Q;[U7G8;9VK MU18;7'WYCMF/:>'7V^GNE'/2U=-M-%54TS59)#,Q'L>U>]'(O>B^I35HJCCBJN-^>[=KMS-K@MSM.VT?
17%HRJ6 MJZ3D9JC1EJNR>,EL])*-R)ZU;_M47]SZ"2>RO'MMUO'J2BT|%'S&M^T=5Z%M]OG=U26T\U$J+Z^6 M)6M5?
G13XO;GR>VV^VFXEMU=05U\K)[=)YQ24-;4QNACE1,(_+8VN7E[T15[MTZY3H6ERY@W:)VHFFKZ*;U:U&S
M]DTVEJBZVG1<=%&^*LMM*DD+YLN[3MG\CL.SA$;JHF$1<=5*ZQ8F_7P1.RU MRCWU.,M/,[YG1*UB M?2Q3IVK?
*AMN>U=0E@TW+9]=U#W4[.VE;4TM*SE3^R&N5J<[LKA&*W&>]JY$ MP[=]TO(IJB-
M]_@KJ=8Q:J9G?;8^+T7E3]5VB[.OT18Z2OAJ+K:J;KDK:>)5 M5T"3+ L:/\$548Y>5>]C(J+W.0DCY/G5=HOG#1IRUT-?%47&T.J(*^E:[$E.] M]1+
(SF3OPYKD5'=R]?%%1*D[K=*R\W*KN-PJYJZX54BS3U-0]7R2OBHBICHIT% M[3IJQ*;-,\XM%PO*[NHV 'K; MS>*.P6BMN=PG;2T-%" ^IJ)Y%PV.-
C5Y7QQ(;ZW+-MB W-K]0U;I(;7&O86NA>N6TU.B]$QGX3OA.5/%V/!,\E[1U=DI:_<;4%9#7RM;(ZU65S&-@SA>1\KVOYE\%Y43V.5.1#;
M8K<*W;5!JZ?U==+0^^4=IF=4>8QRI&KG\CD8Y%5%3+7*UR>UJ=4)(\3_)0% M=VM#6ZQ:'COFE'S2NDNLTCVQN?&C?0CCDC>JJU55RNZ-
7#6]^50I9VC=1W6U7:-BK&VZ*RIIJ)W(IE8 MUS,]W,BKA.O*OC7AKC1EXV\U7=--7^D=17BVS+!/"[JB+A%1S5\6N14:CUC?;/K2*[5U=<-
,4SZ9M#)6R/D;'4*CUE9$YWAR]FJM3HF6],JG M&O*Y%:O7PY34P[]ZWDU8]=7%]6] MG8]BO%IRK=/#]'-.&+A3U#Q)WFK\SJ&6;3E
Y&5MVFC61$>N%2.-F4YWX7/5 M41J855ZHCIL6_P E]M93T"0U5XU+55*IZ50M7"S#L8RUJ0X1,]R+E?6JG#>%
M3CIT;L1MC0Z0NFD[K))#++/47"VOAD6HD?(JHY6/5F,-Y&]7+T8AP&].];E[M@[M)J2WW^\-O]57?[G4E#/)B+F?]K@CC1<T5J-]N" MD?*T_V=.R*/
MMZRX5"_[*EBZ)EV.]7^N$;W]OJ1%5..(GPBQSR4K]>NE-?-8]/=?SZF6=F>O M8=F_LE^:EW;&SG7ZL?'JKHZM/3L>G)R*;=?1]#8_);[<4="V.[:CU)
<:QT?*^_M6";"GC1V$RYK.S<=XB?)OU>WVF:_4N@;Q57ZAM\+IZJUW!K M5JT8WJKXGL:C7JB=[>5]X:N%55P?&^4$UGK2+B-
O%NK[E<:.ST<-,^T4\9JB:[2TTCG5%]5]U6+D7F7O3#E7JISLWLG'HHO]OO=SI];&)D7*%\FWPS3OS4N@] MMJWS%-67M+8J++;?/9O-51<_:>T=R?
N8/4G843O3NX>JGAG8 !FP2#X,.(NHV M'W0IXZZI=6:@MFF[4QR,6LNE6RFBYESAJ.>J(KE] M2=3C]KX^>'N[7'W/I]V-/QU',K>>JF?!#T7'Y+
(UK,>WF[NH$A >);Z^FN=' M#5T=1#5TLS$DCG@>CV2-7JCFN3HJ+ZT/+ ?E7/U4'Y5T _2?PFK_W+FSB M9ZIHVS93_P#083JQ
C9_>'5%BT!M)0T%P6*WT6E;#$VC:QJLD1;?3JY'=,KG MF7KX>&.\GK&O.Q%];%9BYUO*N7+='6B=I;^3A7<6BBNY_/&\/Z@ LV@-M TQA"!_E)M]-
,/T?-M?2UDD^IVU=-65<4<7VN"-&JY&O6M:ST45/@0QMQU_2_66^DV:,N1S[N:@UK(J8VU\-MW)*GR;VV5AUSLOJ6:^6]M:UNH'-
B%5I)JHO7G3IGP3V$[;5;:S-MT$%%1P-@I8&)''$Q/1:U.B(GT$5_)D6_S/ASGF5,+57RJF^?#(H_<.W|C;V-M6+;6YTE!
<(:JIJ9H^U5E*QJ]G&KE:CERY/%'=WQ5]A5:G78Q\BY?KVIY[;^4 M+32:+U[%MV:-ZN6^WG+[VX4<-SH*FDJ8VS4\\;HI(W)E'-\VZFKJ21)J:IC;+ M%
(WNSIROY4C8WNAE94PX5$BF@17LD>B]V&5]1GS MR(6HX0^=M&@M-V*^5]ZMNGK5;[Q<%7SRX4E%%45&5YOMDC41S^O7]JJ>INV
MMSWJC43YU/:E"?E+.(>^;O\ $AJG3K[E,ND](U\EHM]L17-B;/#F.HE< MW.'2.E21.?'P4:G=WA;K4\=&P%'.^&3=S2ZO;WNBKVR-^ASW$7_K351W"
MTW&FC]Z2KA7F9-#(Q'QO:OBCFJB_2?GT|]VXB_[E%[^N'_7+V.'/3MQTGP_; M86.\44E!=;7I>UT572R8YX9HZ2-DC%QTRCFJBX Z2 !55Y5/A:W
M5WLX@M/WS0VB;CJ.T4^EZ>BE]J56-CFN[T5&HBH>=R\V2IU-5[@UNX.QDL/:5E4MPET MZM4E)/2U2OYUDI)G*C$;KLN1KG,[->C55%1&
<;N^S"MN59$T5>F:UJ[.YJP M3Q5UZABBGC5.1S9IEE19FJBKE'N?E.N%+M :'"@"\G;!PNS2ZQU?64E\W#J8 M'4\7FG,ZEM<++LTK*I;A+IU:I*2>EJE?
SK)23.5&(U79AG MN15RV^U3N1PY;* <+3@#X'_.XI]_0D_%=.T'_W6?X.O\=A[G[$[?#'Y36X' M_FO7?@CTVT'_W6?X.O\=AO8/\
$4_=H:A_"W/LOWX(/S+6@\ Y/Y>0[D MG><2X*HTBX7]OD1,(M KOKE>O^<[:P\,C][7/UG]6>)^XH^T?HV !X-P M]5>+/:@ME7;+C3-
JZ&I8L_Z?'*=WL4]J1AX MG=X=7[=:UMM!IZ|>Y]'-;VSR1K30RY?VDC57+V.7N:GCX ?'[K\)M?I:FN5Z MT_715MFI(GU,E/4NY)X8VM5SL*B8?
A$5?!5[L'(-O-OKMN5]%+/9DA\Z[-TK MG32(S<2]6NLMU=]+\MJ.KADIYX_,]=O.Q[5;J92-%3 M*9[E3!\GHW7%[T!=7W.PUOF%.45/A+WHF,(BJBQ,:
<+GMOKBIDM57/17"UU< MD44JIROJ%V,.3VHG5]J%3HN3[/[*/<[Y3?\ H%+ ^".YZLV1BWOVVT_J1DL=-.MK*>V4\TM7RHR.L964&HJ=N:F
MBYO1>B8^V1Y[VKZN]/'/15ZQE"LB6"^[=ZGY)&U%EOEMEZ?G>G3N#M0,90R M M Q@R ,+W*:JBN-P /F];Z'LNX6E[C[H4%OBN=IK
MH^RFIIDRGK1R+WHY%PJ.3JBHBIU/H^\")FF=X854Q5&TJ9^*CA5O?#GJCG9V MURT?72K[GW56Y5]JZ0R^J1$SCPF MA9S*]W\"(B(JJO'(N%1
MR=45$5.IR?ARX1-)\,K[I66V22\7FLED1+G61M;++#3[(7]"XLB)MSM3/7Z.3;;>31T+2[?4]+K9U77ZIF^VU%
M=;ZMT3:=53\BC:N6N1/C..JJN<83H?),Q\E+1/=))I/7=33M^XI[S1ME5?GE MC5F/H86 (AGN*FG4,F*IJBOJNO1>+-$433T5&ZN\G;O1I&7MK=;K?J-
D2\S9 MK/7M:YOM1LW9KGV-S[#YO\A M5+T%=DC9J335ZL$[N^2F6.LA;\[LL?]3" M16L^&?;W7Z2NO>A++)55$GPZ[*D;!4,^>6/E?
_E'"]9>3"VPO:R2V*X7O3,SO M@QQ5#:F!OSMD17K^W,XNX%WWZ)I^S#\/]=CW*XK^[KVC>+O9_736MM>O;3'* M[HD-PD6BD5?
4C9D8JK\QUNBKJ:X4S*BEGC[(9$RR2)Z.:Y/6BIWE:&L?)8ZW-MMW._3>J[/?HFITCKHY*.54]343M&K]+D0Y/5<.W$/LE.^HMMBU1;$:N5GTS5
MNG1WK=F[S^I&HY=G]_9G;Z+D.IQ.(J*G>5!:.X[M\IO M*I..X7KW5[#HZBU!0-5[?TSD1D]_2X[7HSRK-6SLX]5Z#AE^/56>M5F/EBD:.MN?
VYY5:7D1SHCB^S9MZSC5T9Y1;9K57*RKNMPTU.[HV M.[4+D3]O%VC43VJJ'<](:IZ/UZSFTYJFT7WQ5EOK8YG)\[6KE]_.5]S'NVIV
MKHF%G:RK%Z-[=<2^M4-\0BHOON==>3,?_:2^"2(GT+WIXHESR)U7J?.:[T#8]RM*U^GM16^.XVJM8K)(9$[MO4Y}]
[7(O5%3JBEEAY]>-7SG>F>JFSM.MY5OV8VJCHH5PH4[5Q3\-MQX<==., MMTD_G]AN*/FM=
<[']&U41S'T\=G,U%\%147QPG<>!/@R!]P(:+K5DF1/^31[7(C%ZN5.OH]'=EGZJLC1L;IZ-W8UD3NJ-5CV\LC5[TPG>B*U>Y2Z#;.M&^7;4VWFFKM?
K>MJO5;;H*BMHU8K>QF=&BO;RJN6X55]%>J=R]3Z5E.UC4;U-MB(B)A,)C">H_JB=,>HXO,RXRYXN#:?7X&!.%$QQ[Q/<^+W5W6TYLUI"HU+JF

MO6AMD,C(D5K'/?)(Y51K&-;UFI,_X!'^%,>^=;1?]Z:CS_@$?X4KYU)M;;[-Q
M)5&WL%35R6;/4K+*E1{]BU/8K.D:NYD8C>?"]_+C/ACH3V;Y+/;SY1:PS_AE M+_1BSO8^!8BF:YJ]J.2IQ\K4LF:HHX?9Y3]W?-B=^M.
<0&FJV^Z9CK8Z&DK'M4,B5*1/{1(V/541'*F,2-_=.FIA6G*]@.'K3W#OI:MT_INNN5=25=:ZN?)= M)8Y)&R+&R-4161L3&
(T\,]_4ZKA$0Y^YP<<]GT=/8[3LX[:WF0 8-@ ; M+G! ;RL#9UL>W+FK_8Z551:\HGMK/KOA]K+C10.FKM- MU++HB,3TEA1',G3YD8_M%_O9NX-
<6\BBJKXJO4J)N8M=-/P5) SU,'TA\H M!MW],G2>'*JTS0[VZ4J]8STM/INEJ75%;)6Q=I#RLC>]&N9A>;+FM;C"]YX6 MRFS]SWRUY3:1LUPMUNN-
1%)-&^Y/D9&_D3FBO4Z!Q'<'N ML.'"QV*ZW;Z4MYI;C-
)322443TBII&M:YC5FE9MMSNOH;=G2EQMNT^I,5#/10K%$V"A5J42KE&O\U5]Y6QJB(N,IS.PA52GI%TW!_2W:DX;-
0WM)4K4MR*C9OA)"KW+"BY\$B M6/'LP5#[FT\%3NQK&*RQK442WFM6D; WF184F?R*B)XE,] M5EK-GBX,B.M4='R2=%<2?X
]";D:@W0EO.A[K'8+7;VM9=J^KA6:GE8YWE1,\R>CF--5;*VWQ\]51U%,Q5PCIHG,15[\=4+5?)IT=%3\.$< MM-R>IWN#&GAC?
=HZ38FYE1%7+;FZMNQNCM' MH^Z6ZBW#NEABN"*DU-!5RL153HY<=W?T/0\2NF]8[N[*5<&U M>J*&-E;3O?)V&'^Z=.J=8HJA');<#W;25:IUR
M>3/W/;)NO M3Q5WCDH+N+&-9MY$5;SRY=SI+.7.5?N8U5.T<^<@ /=]LIT52TWR7+)F\/MW69 M?
M;M0U"P^KE["G3^,CBK+E+I.#O;2?:OA]TK9JV!U/=)H75];QZ*CTEFHBI87S3 M2,BBC:KWR/*NZW>Y4G#CM@DETU9J)\=+>UHGY>UDW
M2.A:X\:BO%0VDM-_MJD]ZKG=W1Q1,5[W>W"-4B5Y(S\QE8_U5N'\L?1>4^U5++I7@KU\M/(L-1PT373,=5<\M)9*%7(UC& M1HN'3/PF416\{D(M2-
9F*2[T\4E)*]$^"YL; M6O8BKTYD<['?AW_&M.%3B4GV"W!EF@LEPN*VOS"HD5S+=<'+F"6!57\CF5S4 M5$PCNT8_P7-
R12YY8*U2:*XK=.;JM#THJVML5+6)41=)$JH*B5K7]V.C&PX7 M\[$+!D-.79+!ZV7-K58E92Q5*-J2/8CL?N@>S!C*&0!^5=#]5!^5<"WC:/[
M=I+;!K>]=/V%O7_ J9"RN!.6)D16N:J=%14\4/8GYI]MN)7=3:6A M90:.U_?[\;HW.D;,Z2O?Y]URKE52%56-%5^$<17]U:]_5#_]%Z_#E]"X:LX?-L+
[=ZJ2ONUSTM:ZVKJI<<\T MTE)$^1ZX\7.557YP.D@ <:XF^)O2W"CH.@U M=]^BO%PMU9X2TOGD%/RP-I:N-S^:,1C5],5B8SGKGP7 ? ^_6;'] M?
^Q7<#[W4/\ 3"I3:#_ANL_P=?X[#MOO6_$]_P/XBG[J_4/X6Y]GZ >#+'V,>WN/^;D_CO.SM^"IQK@YA=!PR[>-5>]VQ MCOKD\"/7F621N-M+U+=;
(^&.KD@=3JLT;2-Y%W=ZJ=1:$T_=:U6N MJZV@@]) 71IAO.JB*N$\$RJ/_\25C_.,9+?_BL?^@\^"",FA9'$QK(V(C6 ML:W"-1$QA$\.@']JI[2SZG]DZ>
[6VFKXYHUABN7<[:F^[0Z@9#5\SJ=SU?1W*G16LEPN45%3X+TZ9;WHJ9 MSW*2-X>N)*/53*?3>]IFQ7IN(Z:ND5$96=.C7>J3'[;Y^BA(T&,H9
&.9/6 M!D M !H7]PV #&4,@#'7V#Z#((V&G?Q"MYD M(C<#8>AU)H?3^L:7S;_6.WWJF_M-QI(ZAGU/:IQ+6/ +LMJ_M7!H5;)4O_Y> MSU.E/R_-
'E8_\DD4GB.4]J+URW[E4PU;F/9N^_1$H ZR\E-;I.>32FNZJF1/ M@4]YHVSY^>2-68^AAPS5WDZ=Y])RJO;K?;M1MB7F;+::]K7M]O+*D:Y]C<^P
MMP1#:,%A;U/(HY3,\?55UZ-BU*6: ME_8I.CHU3YCI.C?*?[FV;LX[[:,+J2!OPI.R?2SN_9.["^HYIK/AGVMU[VKKYH6RU4\GPZF*E;!.[YY8^5_|
E&Q^/Q[O[ZU'Y-;T M9DV?W%Z?S1UT9Y4W0UT]-FH]+W]P2N[WTSHZR%OSNRQWU,.YZ-XOMGMU?+8J^]:;G7X$<=0V1@:,\[9$Y
MU_;G"]8^2QUM;4>_3>JK/?8VITBKHY*.14]2(G:-7Z7(A$6]/O=*II.VU/']
MZF*_LLMH;C2W*ECJ*2IBJH)$YF3001'}ZT5.BGE(KIBJH\'#B$V7J9*NW6#4 MUML;=W1*E.ZMJF+ R14Z.QKGP(QSF]Z(JL M?A?'E=ZE)(|
5RI:WA8T=%3U$4\E*ZK@G9&]'.BD\ZE=RN1/@KRN:[^^#D7Q M*E-8ZRO.O]2W'4.H:^6YW>OD[2HJ)ERKO!&HG5V%5.J+EJJU>@O:?75ATV:>M
M+F;&IT4YU5^J/9F-EV_1/$*10V-X_P"P;W]E6G1=%I:Y6RIN+9G-JJB>-S&] MG$Z545$ZKE&*A*[U')7;-RQ5P7(VEV]C(MY%/':G> -3VAKC9/
\FRUPO=CH M9]AL8 ^6UAMMI;<&FCAU/IRUWZ.-%[-MRHXY^SRF%Y5NV_'W MAATAPXT%VATPMPJZBYO8ZJK;I,V29[691C$Y&-
;C4YG+T;E<]57ICL#T7"X7 MJ;&?8855U5U<5<[R]+=JBW1P41M"HO<+0'$_H/65WNE0_6M14NJ7O?=,;'55$
M\,R954UFF=47.W>Y5;=:&.IE!.O*U53JK<]>5WPDSGHY.J-MGNM;ZXL>W>F:W4.HJE%;;/1-1T]5-G#45R-1$1$55555$1$15553![QL:1M1
MK6X:B8PG0Y[OULS;=^-M[AI"Y54]OC]7QRQU=.B*Z*1CDZ1M3;]V"OIW=TU-*V1B_2BX*V-3^2OUM;^9VG]7V2\,3PKH9:)
MZ^KHU)$^A5P>/L'P6;Z;<[VZ9NKJ-ECM%'712UURIKI$Z.6F:Y%DB[-K^=W. MU'-Y5;CTNJXR6=>+C31Q6[O/ZJ6WFYM-
<47K/+Z+/D7)C*>LPF<8(H<6_&S4 M\.FK[/IRWZ89>JFJI&U\]155#H8TC61[$8S#5RY>S=E5Z)TZ+GI6V;-=ZO@H
MC>5U>OV\>CCN3M"5_AWFDLK8XWNUN M5<*ZW5$=8U/;Z79+C_9,G)<^+GCT=NI9_O);?^>6S3U5&GNE75#.RG]D=WPM1 M%7E9\;Q:;?
MZ;D57(IJIV^JKN:MBT6YKIJWGX...:WU=:) ^,&XZDCN$4 MMB;K%M8M?&O/&L#:IKED14^$W"*J8[TP7,6^MI[G10U5+-'4TTS&R130N1S'
MM5,HYKDZ*BHN45#_?K\>N5]I+[@MXT:C:*MIM&ZQJ9*G1D[^2FJG9<^UO5> MJ/%8E7O:G=\)/%%N]2P:ZK5$V^?
##GM)U&BW=KIKY17.ZU)%SW&)05]-= M*.'JI9XJFFG8V6*:%Z.9(QR9:YKDZ*BHN45#R5Z],X4Y#:8ZN\B8F.3< !(M UZH>+6T<-
QI9Z6HA:/331NCDCD3F:IJIA6JGBBHIY:+DR(Y,9C?JI:XL M>'>NX>]R:FBBAFDTM<%=46>L-7(B^M.5WW1Q%$R7L;M[0Z= MWHT57Z7U+2>
<4%1A\&RT\J9Y98W+GE>W*]<=4547**7%0_$1PR:KX=]0O ML:K ZNL$\BI07R"-4@G1Q5\.BJG4[.3M0IO4Q:N3[4>;YY]>F M58]S/Q&-
N9?0Z!UQ=MMJ8VG4]BG2GNMKG;/"]RW*915M/28[UMAZA)I7$1[NGY(ZBJ7(F$RV)7/]$RO\4W$E<.(I7C+JZG?;I!;F M+3VJW/?
S.C8J^G(_PI1^$SCHB-:B9QE>+XR8//%TZC'K[29XJOC+VRM4N9-' M913%-/PA,/@EXTJ/9:B?
HS6O;NTM+*LM%701]HZWO<[+VN:G5T;E7FI%,M7F MZ+GI,:X7?AHU[>FZNN%RV_N=UA1LCZZLJZ5)$QC"RMQ_P#RDF%]'E]%%ZJJXPL/^"
[65DT#Q%:9ONHKE!:K M13LJTFJZA<,8KJ:1K[J-R_>IO5_R M[;1W]"C M!MTV/P]7.$5:AG53T&[_ !N[7;*Z+=:M"UMKU%=X:?L+;;+&K7T4'3#7/D9Z
M";\:5[J]RW3.4]>YAW=QHTZ1;WCBKF8CN;]6MW-IX:(BJ>]=V4#*9'(GU_EC%_[2O]/<=%_$G(B1^2>XEXHF1QZOT^R M-C>5K6W^K1K41,(B)V'3_-@Y1Q-
<"N\O#WMRW5FO+_:KI9%KHJ1(:2Z3U+^V M>UZM=RR1M3&&NZYRF0+)_)&?F-
+)^JMP_EC;RMT;G\&=_5K5]>_NV%/J_0^HK3;;#/42P,AK+M44[^TC=ARJQD3D[^ MYY7=BK41.J\V.\# ME/D^=ZD;IW
MM5[E<^1[W1Y>YSE55G.J)0PY7'?@Z\J]%*V>&]X5*VW:.;MWK*VW MV6)'HY<\B00,Y?FY/1QXIE"R6-?03YBGP.[\97=IVVX)V6>;A3AQ1.^_%&[=
M.XR 7"L ?SYL(JE-G&9ON_?/=B>:.WMMU!85FM=+EZODF8V9V97+W
M(JXRB)W=V57J7(R=&/7PP4\ZBJEKK]=*CK\]NJ9/;U>J_P"4]5UW"Y2^9\.NVT>,'SGPNQ-'[G[*Z M!I<8[&PT$>,>JGC3_,?=%#=G>NJ?
JZ3'C:U3'TACN\.AZZZ4E#?K:7VJI1E3 M3U,+X*B%51U45JI[453V#VJZ-S?60DTS]"X[3[O/DN4\KW0U;X:@YZJJS M1.'^ZU/# M]Q=VB@KY',;;
[W+8JURKAKF/>ZG5Z^MJ^_JO:]#LI]\VFH;7;5K)I_FAP^E;V:MW&J_EE]D "C=*BEQ@\%\G$7>[+?-MK-
=Z>R7FCB\SJ754+GQU$".5S5]'JCF*Y^$^ZY^],>MJ="-VPVXT]I-*R2X MQV>BBHTJ&\KI5:U$5V$^"BKG#>N$PF5/L%[N\])J+6-
ATA#327Z]V^S1U.J M0P.N%5' DLB]S&JJ4R[V)U/>J[^!HV1'85% MRBFR=4]1X-MD M M M M MX_KCA-V>W*U17ZEU3MY9+Y?
J_D\YN%93\TLO)&V-F5SX,8U/F0[10X[N.2T M\)>E(**W0P7G<*[1.?:[7.JK%!&BJU:FHPJ*D;*BHC45%>]*B*B(Y4#[7[[MA_N2:;_Q3_YC[_A\[OQI-
,Y_P7_P"911NQQ0:J;VW*IJM8ZWN]SAJ,YM[* MET-$QJY3E;3L5L;4QT[LJG>JGPVEM:;AT/7I7:I&HB)\Q51P-^51O\>J+9H;>BXMNEKKY&4U#JJ2-
K)Z25RX8VJ5,(^-]RN155MM>4 R !QKB;XF]+<*.@Z#5 MVKZ*\7"W5ESCM4<5EABEF25\4TK55))8V\N(7IE%SE6IC&<=E(?>4\V&UUQ"
M;"V'3NWUA74%YI=2T]PEI?/(*;E@;2U<;G\TTC&KZ4K$PBYZY[D4#X#WZS8_ MY*[@?>ZA_IA4IM!_PW6?X.O\=AVWWK?B>_N9?
^OI7_23B6T'_#=9_@Z_QV&] M@_Q%/W5^?_"U_9^@A'_#->W6/^9X5_<.O-^"AR+A'_ #-NW/ZCP_P'7&=O MX9'[ZO[S^KVQ?W%'VC]&X /!M
#T>JM) MVO6=CJ.1>*_E;0SIZ3'IU1?!S5\')X+WD-=XN&*ZJ;4M41"JRARA#KB.X&+5&XEX]WU%;;A9XJ*L[`LV54TJ2)RP MLC7/+$]=[5QA>XY?
KOABU3MYI2OU#<:^SS4='R=HREFE61>=[8VXYHD3O MO'K0\GMM3_P#/W_KN+!*>UVIV M5O>[WNI[CU5OIO<_LNU\^DD;GM.?EY>5CO[6O?
ZT.@_85;X_YTL'^,S_ ($" M:@ M #0VIT,@ :]38P!IR\R M=4SX=QZ;4>CK#]VC6EOEEH+Q3+WPW"E9.SZGHJ'NTZ F*IIYQ+"]FFJ-JHWA M'/6_
3LSK&*=T>EF6.ND1>2IM$\D",U&U4*,4;@P&MI;%?(NTI7\TE#U?6F%.O\&?!E6;WW"'56J8): M/0E-)Z+.K)+I(U>L;%
[TC14PY_C\%.O.K.PKRI[5%]+V_)PUO"O7+W8Q'O\ MHX3LI:NO=-EMPK7K"S4U)57"@21K(*YKG1/:-'T;D5&N:N>5ZJG7OP]Y3H32T
MIY5QJ[G]30#F?'J+7<,_5&]B?QR:-UV6T#?[=!0W+1=BKJ2GC;###/;87I$ MQJ8:UF6^BB8Z8.3ZH\GSLIJ5)'1Z9FLT[N^:UUTT?
U,Y]DUI9F,7*NT_4231 MIZ\^;.55U51\J:CT3:;FB?"?:;J6DZ>O#TE_V]1V32OE0M ML[KR1WFT7ZPS+!)ZP1U$+?V3'\W^0:E>G9-'6G?[-RWJV)7__#;?
=,?*>L'& M-*\8FS>KT8E#N!:87/Z-9<9'43E7U?;T9U.KVJ]V^^4;.FVUU-7TSO@S4LK9
M&+\SFJJ&E5:KI]Z)A8T7K=SG15$O9&G^W<9YNIE>Y3S;#"^H?+R:NAKQIFNGV_;4Z?O\:+)34\U6^>EE5/^3=V MBJYN?C([HO?DK7U-
IBZ;/OM=9;U0RVZZT4BPU%+.WEBN/$\RUVBMO=RI;=;Z6:NKZJ1L,%- Q7R3/5<(UK M4ZJ]KT1$/+K]*W>V:HJ--U-OF9?(*Q:%]"UG-
)V_/R[FZ)@M,X,N#.B MV/M<6I]3Q15NO*R+O3#XI9&Y/R*->Y9,=':/3VM;Z.5?T>7G48UJ*IYS/1RV# M@7,N[-,9+A<)7K4-H$[?!=+95L[.>DJ8T?&]N?
%%]N%1>]%1%3JA[M50RG<(WIG>&-_M5,5QM5')7-O_ .3.K*62HO&U-5YW3]7NT[<9N65OYV&9W1R?G9%1?%7JI![5
M&EKUHF\3VB_V]LLUS@Z24M;"L4B(JXSA43+5[T7N4OW1.GK/EM=[7;4W-M;K M?]JP4-\I<*C4JX4YODN-,7J2;JT1J.LTY*OI-
H+BU:NGS\5K\H]J>U5>I%O7O -O+H9T MSX]-MU)1L5?!)L<[9_-$O+*O[4Z.SJ6->Y<6W\WTK*LSON MF;QI>J\UO-JKK34]?M-?3/A?
T[_1MRGJ+&FNFK!*JFBJCWH8!GZ#'[F\P M 9Y1S!GL(GM,*>[TUHK4.LZE*:3JBN5[GYN7L[?223\GS\B*=[T#Y//>6 MCF/K;32:6LW
/+WBI1'B^QR-0U;F59M>_5$-FUBWKT^Q1,_DC.? M2:$VYU-N9?&VC2MDK+[7OPJQTD2N1B+]T]V4:QOYYRHA8UM?Y,/0VG'Q5.L;
MO7:MJ6X5U)'_ &'2?,J,57NQ^G3/BA+#26A[!H*TMMFF[+162@:N>PH8&PM5 M?6O*G5<>*YSXJ4M_6J*>5J-Y\G0XN@W*^=Z=H\T*>'OR:-+;9*;]
[IU3;E4M M5'LL%!(O8-7P2:5,*_VM9A,IU=S\D;8F-67'-RHQC6\N<=/:I]8 -&MY>Y,?0;@ #EN_P#Q%:,X;-'4
M>I]=55ZOFKKV6V*2DIG3N69TN.6/_7V)ZSJ17_Y\W4U]RUJ;]>=+_ M:\"2O#OG[=\4OXH?Q U]=6>X7F_GOGE&^GY>V[7L\LZ!KW; M/2NZ-
ADLNL-.VW4ML?U\VN5,R9K5^,WF3T7)\9,+T*UO(6__(;?_>6 MJ A?Y6+2%^UOPM,MNG++<;_*
M$T#7Z.H$1?)9Z5O6C.$JSVN_V>OL5R99K72Y;JL>B*B*G3AW0V9W7FW*X?X:NKM*U3JZ MDH;%)V-
PLTCL\T<,,HLD655$1F5Y754?.RG8L2)W*Y%;[5+MC^,-PG1.O^V0*]?)S>3INFPMZ_') MW*93?BQ= Z&UV:%[9DM;7M5)))))$56NFDY78;8<_ *PS
MX2'ZIS\]X(6\\+4,C[3M(UK5'C M9V\K:Z3W6_$99D\][%O;?[PA3X6,]W3YNAVQ%Z]"FT_ G#JNS,[\=6ZTSLV, MQ@VIVX8V;@ N56 T>B*U4*-
N('9ZIV+W2O&D.KPRM3:*?EFBJHT5%= M$].9G.B]$N7&<93U*7DJA3UQ_5+]JBNUA"WJL4=#$WHGC20N_P#>+?1SZZHNU M41TF',:[13-
JBJ>NZV7;^C[S]#Z>I<*G8VZGCQCU1M3_ #'T7J/&H($I*.'% MJ>C'&UB83U(B'E%)5SJF716XVHB'\U^DC;Q3[=.<^#5E#$KD:B0UK6)W8^!*
MO\5?V))/"X[S^V8[ZY'I^Q.E<76@6Z[X<-<6F"',|-"M=3-8WKVD"I,B-3UJ MC%;^R4A9Y+G7B6?='4^E97HV"]6YM3&CE[YX'_!1/6K)9%_8(=-
AV;O146:I MWFW^CDLR[%.L=M&;1<\EGP,)W&2K7[7NZ]Y7KY5+0-QF31^M(I9)[7_V2U5$ M.55L+W*LD;\9^[1'M5?SC._/2PKO/AMY-L+=O#MS?-

M9%Y3PU43MM{/B[K)PNPLV[]-7%37&^[WH +E5M,="&O&7P/W7?7

M5]NU9HZKMMOO#HFTERCN+WQ,F8W,E1S&.RY$7E7*?!:W'=A9F#N[U/:S>KL M5<=N=I:M^Q;R:."Y&\/C=I='5&WVVFF-,U=;[HU-*

HML%"^J5]HDCHV(W(O5 M$Z=$7KC!]CZSU5]U+;=+T7GEYN=';]-'(Q:BNG9#'S+W)S.5$R>=!41U4#98*

*MI&R1/:CFO8]*UR+U147Q0\]N*KVI>U'#3[$3T>2 "'H M :C'0-[C& M4ZY4"&|_\G\R_<2:[C2ZG:MCENK+Q-*

*:7TRNF=*UR/6/GYLMV]7=VBN>G1]V:%JS-4VXVWZL8Z')*[BAVVMNZT6W-1]. FJ*

*M9)64Z4_8R+$DSL*V%9>7DYURB8SWJB?"Z'7.\]1X_MMJG:_B*FO]O=)3TNH$ M;>*6:-518ZEJHD](OQD>U)/9VB(;.%CTY-*

*R;=4[3MR:FH95>+;BY1&\;\UM^ M4]8R<]V'W)CW;VDTOJQCFNEN-$Q]0V/N;.U.29B>Q)&O3Z#H2>HTJ9HJFF> ML+"U7%RF*Z>DM@ 0]0 M M*

*M *I_*8>4#UKH[;=NSQ;B>4 U;9+W M(^:CNFY-1:JA6KRN\W=L#G=1Q+;O5^/*KWCR6%DV[WFX666[4&B--7]JZ?N-1:J*

MR:XVBFGE](GXGC<]7,57-Y95C3F_M2^H"IFX:SW!W:KJ6T5M\U+K.MF>B4]# M/5U%=)(Y$Z(R-54MX=;-PF;DZ#W.VHD?H^6YU,TC:&B=RL

*MH:R#LWME@3JC6N1Z\S%]%%;A$P["6D<-F[D6^VQ>BM>1MC9+>;>R6ICA7T(Z MEBK'4,;[&RLD:GS =. @!Y:AF>%S2R)E57 M6=+A$3UT5>3_*

#C?%39[/++;;XM')%/1MN=)'4MIZ5ASTB2<-')HO)(MULK^5R=4STP!45L5PP6VPVRFO.KJ-QO(;)VAG3FBI47N16|SGX{\Y1%QCN

MROW>^<,5/HVBCB8R-C:V-&M:W"=(Y.Y,'2_F[CF^_'_$^C_PYG\G(;V!_$4_ M=6ZE_"U_9W#8K>O4^V5CL3J"NDJ;;YI#VEMJ7]^%Z-

2617.=3R4\=8QJKT8YKN1V/GYT_:FM>_>5?=M8_[JG[0EN #R: M_6:RXU=# M4JQ]\K&L3HB?%8AZ?[$+;W_O:X?XXO\ H.U@#BGV(6WQ_>UP_P

<7_0/L0MO M?^]KA_CB_P"@[6_<_W0V9T]NI;UBN=-V%?&W%/<:=J)+'[%^,W\ZOM MQA>IT

*5]:NV_P!:GM12K^LDCEJI7PQI!"Y[E9$F51B*N4:F55>[V@9JZVHN55+55<_M\E54RN5\]DTSU<|]E[U557O\ ;E3R;)?;CIRX15]KKIZ"LC7+9Z>16.*

[NO5.] M,>"<_#KOJNZ5NFMEVY8M14+$<[S$Y6U,>43M$:G1%151')W95%3HN$[8 M5T[#7V;3^[NE9X78[6NCHW]>BME7LE3YD1_UX4L6

*M M_# M3)'SCFVHGW4X?;Y3T,"U%UM#FW>DC:F7/=$B]HU/6JQ.D1$\5P2$QT-.7**F*

*M.B]YZ6KDV[XKCN>%ZU%ZW5;JZ2_/DC54P2EXX^%JIV7UK/J:PT:IHB\3*Z)8 M6^C05#L]Z!4^Y;JY5B^I5;]SUBWA3Z1CW]-=FW7W_V6F*

MZAPV[56C>G=FU:.O%WGLT-P9-V513QM>Y961J]&>ET1%1KD^=$]9W/BSX%(M MD=&6O46C9KS]"CCEDCO#JKD?

*YNU418I&MC8BM;T>CE57)U9W$2K/>*RP72DN M=MJI:*XTHA=ROBD:J*UR+X*BHG4L5VA\IYIRMLD%+N+9ZRV7:-K6/KK*

M7$D]-4=.KU9E'1KE/@X]\8-614E1%I^STE0DU8]KFQ2R2,6-L+C#G>DKE3P1GS9[=Y5._V^+;S M1MD>]JW6HNKZR-*

*J8YDACA>QZKZD5TK/J7U'U>M?*7;5:?M+Y-/QW34]P5N8J M>&G=2Q\WY]\F%:GZ5KOF*Z=Z-Y-1;XZXJM4ZCF:M1(B14])#E(:6%]Y;%&BJ*

*MN$155\5557Q-*S:OY67&1=IX8AOWIV/B8E.(S5EI;9ZRJ?=[K/6VUM/ Y_*

MG,W+L+A47F5,=45)_6SRD.S%QM:5=3776VU..M%4VY[I$5.N,QJYG^485

*M6[^#D5UVZ.**F=%S'S\:BW=KX;J75],QP;"\.EL;=U8UFE=.16K5CNCGPP(K MT;Z^9S5QZU5"F,2&CM1;J:MBLU@HI+Q?*

K@Z65E.Q[&.E5&NDDZN5&IT1R_02 M5XO..=V^5H=I+2=#56G2;GM?65%9AM16JU45K>1]JC&(J% M7=&S[-;WZ?U=?

*FU3[50LJ6S)21D)*O:021MPU53[IR>)LX-B[CV:[U4>W5OM M#5$\FSDW;=FF?8IVC=ZK5KNIW_A!X+M(<0YWU1],Z:FNU'4TU=)15-!;V1.Y.5K7-*

5'.1WPF/3P[\ M^H_MQM\7&B.(+05DLVEX{K%5T5S2KE_IFQ.6/LI&]%:]5SER?NG$N&_B2O_ M XZNENEKB;9138JM[3 M\5W8_!X%=5^BYO

*1&3C$OMOU+Q+[@U]LD9)2>?M@YV8Y7/BB9$]4QX<['=? M'.3C:]QO)(Z5SGO#^U/3RU<\=/!&^::5R,CCC:KG.\-^V+MH-E=*Z5F M:U*NCI$?*

5\O5/,')'#?%$>]R(OJ1"#7D]>%FIU7J&EW.U-1*RPVZ17V>GF M3_?=2U>D^%^XC5%POW3T3XBYLQ3IG]PXO5\]F[7%]B>4. ^T++#JM4S>KC:9Z/*

*MZ(#GG6 !CF3UF2K#BX\I M-NOPX<66MM&V>*PWK2UM?0K3T%UHG<\;9*&GED1LD3V.RKWO5%=S85W=A$0" M1OE/=AM=*

*<0FPMAT[M_8OQ07FEU+3W"6E\\@IN6!M+51N?S32,:N'2QIC.>N>_MY%*P_>M^)[^YE_Z_M?\ 229NW?EM=*

(5S6Q:WV\NUE=G'G%BJXJYB^U62=BK4 M]B[_,2@V\\H;P^;D-8R@W(MEKJG8S3WY'VYS7>KFF:UBK^E:"^43*RVUM/<*.3X%12RMEC=*

M\SEJJ>;E *__)3<+FY_#=^.C^.-IC\3GNU[E>8?V?2U7;=CYWVOY!*_EQVL M?PL9YNF<*6 @ /RW:5M;;UJ.V4$CE8RKJHH',:WHC MWHU?*

X3]2"=,GY?-N_1USI/_ ,HTW\JT\ZYVHF8>UF(FY$2O0X3=3W^ANMOT M>VKDET_06MM-1T.!L<<2-4O\+2 M8ISN@7KE[%FNY.\[RNM3&A[3B-

*JW(W/9V&J=\R=K G^E7.6::J%3K_\ C5*G M^JS M4=1E9(VM\5;(U[OGD1/$ECPGU-[CM=YM];3SQVR![4[IF.3$CN;G:W*=4Z(*

MJ^K/M >#+659LIQ46VUW7-(VLJ9M.W*)R_!D<_D8B_,QG7U9+?HV-;BJWH*

MAJZII%%O4XSK<[<4NCZO7=TO\#4YVRNNJ]JJ)]BW2224VF:F1];2-SA89N1O;81>JLQ)'+X'JO)K\0+

M=2:4J=M+8<5YNME:L]65V5FHU=Z4:>M8G+W=_]$3HQ2:EYM%%]"TUULN-.R MLH*R%\$]/*F6R1N16N:J>I454*H=4\..YW#WQ*VYF@[-*

=+HR.X-J;%<88'R0 MR0N=CLYI$3E3E;JLDYE;Z**QK'KY3'.);U=I,UV/^J_<++T3OZF_J,4TY$TTQM"KT?><:

*M*JIYRSCIW$7^/K82Z;T;5T<^G*!;AJ2Q57G-/3LPCYH'IRS1MSWJN(W8\>SP MG54)1(%^8T;-VJS7%RGK"TO6:;]N;=72460)H[?*

ZUV[V8KK9K&W3VE9+I)44 M%'5=)HX7,CYLM[V(KT>J(O7JJ^*$LJ:KA/$U'$5(5S[S^52T1I'>O7>UVLJN';JT/:J

*MIUJJ*NGDAJ7U#V(C:B.2EF1(WM23M&]9$Z,3*=>@=+X4:K5_%QP#5]+N/=/= M.XZHI+E::>YK R-ZPMYH(I';'7EZYZ]M3FRO$-NKP3;AZCI+$L*

M=HNR2>Y]|LEVIDEAEDA<|$;(U%1T*$^2=2M?I$<]5.ZEJ7M1$1$D5OHR\]{B(KVN5$3"=.@%"$D5OHR\]{B(KVN5$3"=.@%"|[:XN+:.Z2*

*MF1T%NME##V5-2M>JZW^E7FI M;A?*IU4M.[.4!S3?C_B?1_XY>B6R:>K_ #U*6NA6=]POC='S1SGBICNQU"%H/.N]DN&GZY]%=**HM]7&OI0U,:L*

M=]2H>5I?1]YUC7LH;);:BXSN5&\L+,M;GQJH'BIXD"=P^&W5NWUF@ND\4=RH^1'5+]+FWQ1%=A%\,JN5$[P)T\;DK*>OI8ZBGFCJ**

M>5]/9+$]',>U>Y45.BHIY(#&4 R M M ^?U9I&U:ZT[76&_6 M^&YVBNB6&HI:AN6O:O[]*BHBHJ=45$5%1412JKBHX)M0[&UE9?=/PU%]T,KN

*M=*EJCT3.%4MRP?RFIV5$3F2L;(UZ93M5U^+|^O0P6B\0GDY-+;@.J+SH*2'1]\>JO?0JU?<^H=^*

MD;UA7VL16]/@>)7UNML1KK9BX+2ZMT[56^)7 M(=KBY]G)CE.T_"7S_*TV_BU;3&\?%S\RCE[NX)U[ACUEE]56*8 #!GN'>8 3 MNSS>C@?<]#*

'TE 9S[# SE1\Y@=WB3$_"66P93'B&IG.3]VSO#%N)OA51II MNP3-MBN1'7BO18./UKSJB\ZIZF(Y?8>-R]1:C>N=H>UJS7>GAMTS,_1RG"D*

*MR.$C@,NFY%51:KW!D)[3I-N)]>VR9CJ+CXIE,YCB7U]'.3NPBHXDWP\\ .C- MHGTUXU#R:RU/'AS)ZN)$I*9W?]JB7.51?*

*NWYQA%:C5)5,9RL3"'*YFK<43;L M';[736>W4M#0TT=)1TL38(*>%B,CB8U$1K6M3HB(B(B) MX'FM3H;M[AT4YCKSEV$1$1M#( )9 M -!\EK/:*

{1^XU$ZCU9I:S:GI\82.[T$52B)G/3G:N.+W8[NA]. (<[MC>2FX?=>,FDH].W#1U9((G=4:>N+V)\R13))$U/8UC?H[R,>XGD1+G#YQ/H3 MEJ34FX-

*_$]9JJM:;XJE:2>[MYIW1R2-9RPL>Y/1BD?,,=,9ZH<;]{X8?]IO_J"Z?T8'LB\\!W%9P\5U3<=- M6F]*QK,K<[*79SY).7*HB,B^D<,/\ =-*

*_]073^C'JJ]Y2#A+U3024-\UO17BB= M*EN&F+C/&OSM?2JG[@&?)]<;]XXQ*#6;+WI>AT_7Z:\RYJ["H> ^.I\X\X{F*

M/3+.7L/C.SS>&.LOB$6T7%UP5[<7N]R:_U%8](5-[2'SY:2RUU!3S=DKTB]% M\#8FJU9G]R)T7KG'26NA-

*Q=+;FV5MXTEJ*V:FMBKR^=VNJ941HY.]%5JKRN] MB]0/J 8RAD #">!^6*AK)K?5P5,#ECFA>V2-Z?*

$FX4U3PQ[2P0SQR34^D+/%*QCT58W11(K7 M)X*BHO13K_&OCVK5JGALQ$1|'K>N7+M?%=F9GZM@ ;+Q QX!S+B9 MF[+AYW+7F1JKIRX-*

3/MIY$_SD"O)80[>K4TR8PVP/;CQRM3 O\ ]JDNN.S7 M[=!<.&IU=2K527IGN-&U%PC%F:]'/7]*QKU]JX0BEY*F#.Z6LIN7]VSL;S?/ M.U?*

\Q>XU.V#=J_[W.6RZHJU.U3\/^5FP.)U(&%3)D 5(^4*VYEVVXB M)[]0(ZEI-00QW6"2'T>2I:J,EPOQN=K9,^N0LAVAW+?NILC8M86]L4U;7VWM*

*M70]S?.FM5DC/8B2MZ$?*GI+3.1&U#4]B- M1LB_WKVG(?)<;N=I']3;>MGRK4]U[7]?Q>!% M<>]1RES%B?P6HS1/NU\X=?VCWYOK=;-*

*MVJ:UU125LO8_;8VL6GF5<)W(F&Y] M%47NRGJ7,J4PJ$1^)G;M^GM2I]*CBY;?<7(DJM^XG3O^;F1,_/S';]A]>RZ]*

*MT/%45:9N%')YI428Z2..U%1WTMJ.<3\8?3-2Q[5RQ M;S,>_J9Y3'PETP 'GN:,&JM7P3Z3^H T54SX!%3*D_ *;NIJ.5[A:4DTU?**

*MNPZ8EH^TADHL(V:K;([M&R(/21&K%AB^BJ*O3O)1\,NIU/OSM+:=2IR1W-J> M:7.G9_R54Q$Y\)\5R*CT_.N0VZL:NFS%[^65=:S;=R_5C]*H\W7*

:BQ M M !JB84])JG2MKUEI^X62\\T<=PM=?$Z"HII57E>QR85.GKSJX>&

*M>+H^2V=V$T5L3;JZBT=9_6&GO6GKG37:UU"+V5722(]CL+A4SX*BY14\#W_ $,JJJJF:^] M+=-%-$1;Z,@ Q>J)'E#-*

*VM>;2[?:"_DC,>N3V+BYLVK=["JVCVZ M9W_)SUZ]ZXUUOCN$2W"UUBK[SBC;.MRD6RNX6K>,_<6[V/06I;U;*A+=V-=;*

[/43PR\MMIFNY7L8K5PYKFKA>BHJ=Z M 6+]_P8'Z)_P ?K;/^Z)\/[^4W^N>?VZX4UUM:LHZF*LH MZF DT%13R(^.6-R(K7M&*

M&VU=FX;MJ"NI)J&MI=)VF&HIJB-8Y89&T<2/8]JEKD8998DB?35,JN:DRTK!;::6HK(G3LH96O5S M6LE1%Y%JO?\ ]B]L_FD1TCE[*

MC5N3O7,MNQRMTQ\'] >;V M #&4 B_P <?IF:2SG\FJ?XL?0^JX-F_+.FG7Q]TYOXD>#Y?C MC_X+TC_?JG^+&?5<&OY4DWZIS?Q(P.W]Q'-LCP!*

3;S>#5VQ5YFM-;33OH8I,5- MFKLMY%7[IBKU8JIURGHKTZ+WDGML>)+2^Y=>MNC[6SW578BIJU6_;D7XCD7"

MK^=Z+ZLGT.YVT.GU+X0HB30|%<^*UV^KK9\I#31.ED5J97E: MF5PGS(>:>DUC.S=S81>BKCU@J8].1U4*:,GNE13\GVU*

*M;K!%&]'Y^V1CWG]8]?B!,W[+W;Q.^HN"?_H:_P"D^AT'OJI/<6_>Y%EFJY*S MLG38F@5C>5N,]57OZD*:/#MTZW4ZW.MU/'7JQ%G;24=.Z)'_*

*)U72HJI\Z'9 M.&.'1#=S%73]7J":X>93>CQZ+WHY%3"I\YYYA.B")VZ,9B*HVE%W<[R>.TVO M5GJK=;ZC1]PD57=K97HV%7>&8'(K$3\ZQ&D6M?*

DO=PK%VLVE[U:M44[4]& M&7-%4N^9KN:/ZY$+1\&,80L;.H9%GI5OJU3?TO%O\YIVGZ.=6<->ZFAGR>[M.@KY#"'GF](:1U3"F/*

*PD?,SK\YS>1DD,CXY&NCD:O*YKDPJ+ZE0_04C?!4 MRAZB]:-L.HVIF=Z*_ZPH),HB>L MNVNG"CL_=LK/MSIYBJN5\VH&0=*

<8_P"31#Y:JX!]B:R7M'Z%8UV.8CN=;&W' MS-F1/W#PWR'=]ZG_P##G]Z#@.V+M\BOBT)" M]?5/7U."GADGFD7#(XV]YSE]2(G>

M7;6GA=VELCFNI=N=.<[%RU\]MCF5%SE%R]%Z^WP.@VC2UHT]#V5JM=';HL8[

M.CIV1)CYFHAXU:Y'\E#8H_9ZK^>M2UI#A6W:UPK%M.@+SV4GP9ZZG\TCL9%?N^RL[.A8]N=ZYF!';[@,VDVTDAJELCM37+"I5W]Z5*(OK2+"1]/*

M!5:JIZR0D%-'2PLBAC;%$Q.5K&-1&HG]1/ \A$P9QE.\][MR[.]=6Z]M6+5 MF.&W3M#4Q]RO>?T!YM@ M*

!#3RINS&K]Z>':U6W1ULAN57:M0PW>M\YN%/11T])'25;7S.EGDC8C M6K(S/I9ZY[D4I3T+M3]_=#5#M..:T_6ZFO+

*[-0Q4=.LL!]9%V:D9W)VBN[WJ+] MA6^ODQ>)EM)YPNV,W9XYN5+Q:E?C])YQS9^@X5J3:S5>B]:1Z3U+9*C3%]<]*

*ML:4M\Y:!$YG*U'NDF5K&QJJ+]L5W)CKG!^G@@%Y9+2^EZ[ANME^N3*>+4U#> M88+34X1)I&R-D[:%%*

*[U8K6\ZIW9C:H%?"^3*XE4H_.V[;+/3\B2(ZGOEMEYV-MKW*U&5*J[/L/A]B]XM<\'^^%)=VP7*S5UL]FT]IL-6Q\#J!%3M:>6-V.O*N*

*M6JY/17E1RWMNVX&S6I=$7:HFK5T94T[:*HF57*RDJ6R+'#E5SACX) M<>"-6"M-#;>+I:BCIXH9Z_3U%45CV-1%EF1\T:.=CO7LXXV]?! MJ)X*

7;6BZTU[M='<:.1)J2LA940R)T1S'-1S7?2BH>>X_+M;10W#Y&,;=Z17.KF(O1<21X54]?5?FR2[(B<) M\;W:CUDB-7D;;Y$5V.B9DCP2\QT]ISG(/35.)

*[4]\KK7=HRYX?A#8 '3N> M 0[\]+-V?#Y;6\V.TU%3M[^_P"T5*X_<,-^2C@1VN-?2JO5N@CY^>S M9^@X5J3:S5>B]:1Z3U+9*C3%]<]*

*[E6NJ5IW6&NI[FQN.DJY=-K%]72=5^=J(<(\D[!S7S[6Z]HJJ%M12U,;H98GIEKV.3#D7V*BJ4W:7]JGA0XM(653Y&4VGKTZEG>O?*

*M)0R9:YZIX\T$B/1/7@N=YO K2\J+M6MIUEI[7U++#BGN*VZM>U,(D\2*Z)R^_MUT:N3_Q)SIOT=:)6+W6S6[5%IDH[A3Q5U%.B*LW53=+A\T_+4*

M3=K=+.WW)K,KE>:)$[-R^OFB6-<^M5.R:QU FE=+W2[K ZI2B@=/V35PKN7K MCV?.4>19IQ[E5=<>U3RW^B_Q;U63:HBB>56W+ZO?

*LSE#B^S>_7XXESJ:7 M<;2*WU[466!(7JK96(O5.OW2)CY^N,8.S>![K8N3:RZ.TM3O#;OX]S&K[.[&T MMP ;C7<=XI-D8=]]H;QIUK&)=XT*

*[M<|G3LZIB*K4SX(Y%OV?,(J&31<)XCYBO7#< M ;^"D*/*F7)8-F],T22*W MSB_LE5$7"*UE/.G5/%,O1?*

*GQ[":Z]Q:'RJM+73:)T/40TTLMOAN%0D\S6JK(MWJQ],1R]R9]/&>_E-W V_$4[]%5J>_X6O9]CY,2A=2\.]=*YSG-J:]52M1>[M"1PLZ?2Q?*

*I527:9RA'/R?VG:O3W##IE*VGDI9ZV2IK$CF.K7C96HN4[T4BKOKY2[B1V!W5U%H,_VK1JU]HJ5B;4I:.AK*F%?2*

MBG8GG"^B]BM=CPSCO12"6]^\M]W]W0O6OM2Q44%[N_8>><-M\3HH4[!D+>5K MG.5,MB:J]5RJK\P'Z5+/#=XM06*W72%CHXJZGCJ6,?*

\)&O8CD1<>.%/9E'5F\-ML!OA8;/16VDMNCW4U"']'31.EMLZN5K&HU]JOG'?A#S/2F=^?^;=&_>N?^D 3 MGXU_*(S(.O]1IA-NOQ4>Z-

*L2Y1U[KTE(QJK))'R57*91R>W$C] MA]U(-[MGM):\IJ1*%E]H(ZM](DG:)!(J8DCY\)S^3QT;< M="'<&VV%IND#H*Q:&:.N6-[>5S65-5-4L14\%Y)F=/K*

*D@ M !'SC1X4UXN]K;7HS\4_P")+S&]17?SU+?YYS\D$\79\G:QXRL_ M-S9^YQCKE)!@"JOWB[]&W]Z7]=*Z-H/^&ZO_9?X[3]-9^93:'_(;J_P#!*

ME_CM-W"_?TM'-_AJ_L_1\PU?F=MK?UK6O^;1'24.;\-7YG;:[]:JJ_FD1TEI MJU^]+9M?NZ60 8/4 M ((:AW,W:@OMSCI[E?

FT[;J1L;,IUQRHY>7"\OJ0G>;HB)GP K;UQJK66 MHX:1-55-QJ8H7.[#SZ-S41RIZ7+E$\$0\S1VL]P-/VCS;3=9=H+:Z1TG+1Q. M>Q7X1'=<>Q"0O&[_,5]-?X;)W?I#ZKA#_*"9AKCUFP |&Y6VEN]!/15M-'54DS>26& M9B.8]OBBIXGG "(6\O"54VSM[QHADE72)ETEH5566-,YS$OW:=_HKZ7=A5/G MMG.)N\: ECLNI6S76RQKV;5?E:FD1/4J]7(GQ7=W@J=Q-WZL'(-XN'6Q[GQ3 M5U,UMHU!C*5D3/0G5.Y)FI\+],GD[<(@'W&C=Q=-Z_IY9M/76"XI'^2,9S- MD9GN5S'(CD3YT/TD93SQ-C1>94Z(L2KX>*J=4V MWX<--[8ZB]VK57W:HJ^Q=#R5DT;H^5V,]&QM7P]9YW#I413;,Z72.1DBLIE: MY&N1>5>=W1?4ITGF3U@9 M M :H;@ : W :_69Z^PR M (:^4]X7[MSQ$!'T=7I:D6X;JTK5,KZ:A:U72U=.]BMGACZ_#?EC>B>/9\J=7(5";#<4&Y MW"]?JN;1%\DM*2NY:^TUD22TM0YO3{9"Y.CT[N9,/3JF43*'Z1$ZY\4(_P"] M/ KLMOW=)KKJK1D#+[*JNEN]JE?1U,KEQZ4CHU1)'81$S(CE1$1$7 %:"^6AMWQ6D[%-/Z%9)C';MMM7SY]>/.N7/T$7-\.(C<3B:U52776]ZFOE;"BP4%%#$ MD<%.U[LJR&%B817+RHKNKG;EQT^%G'CGJ=YV2X&=E]@KC#=-*:,@=?85167>Z2/K*F-V%3FC=(JI$[# ME15C:U51<+T X3P({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{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{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

5I1,BYT:BR]_L^7FSW*F_ZIK9J M'3%1-8[,U5;V:->6IF1%Z.5Z=6>Q&JB^M5.'PW"]I[@RNBJ)H]ULG;MJ&/5L MB2=Z/YD7/-GKG.0.L?
8H;D_\T4W^.Q?ZQ*\ATT+>-OMNUM-\IVT]=YW++R,D M;(G*J-QU153P4X+L[Q67>R7"GMNL:EUTL\BHSSYSU4RBHJ=Z*GB!Y M M M '(=
<\6>SVVFIZ[36JMPK'8[}1FR/*HF3B?DX_*,:2V-T$NV>Y:5%NLE/4R55KOE+3NG9" MV5W/)#-'&BOQSJYR.:COAJBHB(@%@%-
P!:,VHL+HD:K>:1DDDG7O\ M3K MKM3[O:^TLQ9'V.KL27.5.JL94PU$4<>//%3Y^1/BEPI GR3VT^@]O-N!1
M55EUA9]8ZZN/FLM_]R)TFCMD2I)YO2|\W]>RGL/RU MV^X5-JJXJNCJ)*6JB>CXYX7JQI'(O1S7)U14]:*:V38_$6:[6^W%&S9Q;WX> M]3=Z\,[KP;'45-
LX6-YZR&*1W/:ZB%KF(JXS YKG)^E:_F|A$WR?EFIV.*C2 M,BMYHZ*.K[GHOLI[&M7]LJI.2SW=+1Y.FVW65W-4U.VU//+._JZ:HFMK/^ TN
MY9F=]HVW^LN:UV]^.U:W>VVWF.7V6E]<',M_]M/QW-G]5Z31K75%?1/2E63H MUM0S#X55?5VC6Y[F3HV44>!7T5315%4=86]RB+E,T5=)5(<
6Y}3M1Q"PZ=N M*NI*'4+EM%7#+TY*IJN6%53P=VF8_P#QB^HM/FT5I^LU)3ZAGL-MEOU/'V,- MTDI(W5,3/BME5O,B=5Z(N.I5!QT:
(EVHXGKI<;4DE"VZ+%?:26-,*R5RKVCF MKXKVK'.]F4+4=K-;TVXVW6G-3TKV.BNE!#5+R=S7.:BO;\Z.RGT%Y]-/%%&1 M3_--'-
SNDSPS'R@MSVHXBJW1E1INF?I2UU$--7U#U MD\||',N.]8WK6/4U[U7N/!\F/OA[O MZ3N6VUSGYJZSODO5!#<&T+ZV!E;(G,RF=*U)')UZHW.5
M[E^H\],$/^(K3%UTKN^NHHYY4@K7LGIZA'+F*5B-RS.>BIA%3PQTZX4[WLYN MC3;CZ=9(Y[&7;F:UM9
WIAR]ST_.NQE/J*'&U.+N37BW:>&J.GUA<7].FWC4 M95N>*F>OTET<_%\IW\L_7CU<5#2R<6WE4<-?Y/D]K;3>[)M
MQIFWZCJO/K_2VVGAKZI7_Q/K$7IX'BUI;3V^CFIJ MHCJ[6%CD)I7(UD;43*NF/156JN%PJ+A?!47Q/"">*K>K;DV*>&B(HWY^;Z8&J.-C%Z@-M
^4W.M]7=-NM545OB6>NJ M;550T\2?=R.A>C6_2JH4.55+-0SRT]1#)3SPO=')%*U6N8YOPFJB]45/%#]!
M+G)A2'P*E/*05#9.)>L8CD^TVND9TSTRCG?^\G<=#H]V:;E5OXPY/7;/%31= MWZ3LLLX>[?]E[%[>4BIAT.GK>QWZ9*=F?WI8YWH?
;Y;8TV[^U.I=)5/+FX4CFT[W]TG M$_YO:U?F1<26?>'?FQ>IK[E=G8_XG'JJ[^L?=Q_R?>]+]TMD(+57SK/>]+JR
MW5"NZN?!R_:'K^P16>U8E7Q)0%1G ;N15;1\1M/9+KS4=+?',L=;#+T6*IYL M0Y3XR2M[/KX2*6Y(J'MJ%GLK\[=)YO#2LCM\>(J]ZGE+^@_*Y< &%
[E,@# MYC76@!)N1I6X:,V)KBY,7JK5;E$2#"=QD\6V M M M !2_P"4VXV-9:GWCONV6DM05=@T?IN5;&K] MS*ET+[C5HW|H]ON/^\6K6BNI=+:E
MU/%>Y:R:7LF/MU95=I,]'ICE:Q73,5W@L3N_&5"+-OM5;=YG0T-'45B9PB*N,JGUGF_B'U)\GKI_B4G^]?ISTSIFSZ-LE+9[#;*.SVFE8D<
M%#;X&PPQ-3HB-8WHB?,A(C ;N _+1^(?4GR>%69]=_$]_N?&UO+%R]@ MB81[_.?2 E& &BIZC\P^W6@+ON7]2GL5DA9-6S(YZ\ M[N5K&-3+G,7P1/K55PG>?
IX5<(OL/SQ\#*?]N.H]:6R;^/&G^&[A68R+]%]KI,[+/-S=006?R:]+9V54:7&TV*S:Y%3[E%4^,\DW;XY+GN77*W[;##;X6N]CUJ'.3_(:?-\1=:M-PD.@:O6
MHUE!&YO=E$HY7?PHGUG0O)06_L]+[A5^/R>MI8,_I(Y'?_K/W2YTN_7D:)V] M7O5=?)S&J6:;&O=A3TI_QNGNG<9 -)=(7>4VVH=JK:JV:QHJ=9:
[3E1RU"L; ME?-)E1KE7QZ2)'\R.>IZCR7N[3[YH]^[?UDF9K))Y[0\SL]ZGE>O:-1/!&R9 M7YYB8^MM)T>M]'WO3M>W-
%=:..CFPG5&R,5BJGM1%Z?,5%<+VNJKAPXFJ**^ M(ZD@962V"[LTO<7_FJ'S9^2T[U5(Y78\6/7ERO@]/BHA[?R:&^"Z MJT-
7[>W2J62YV#-1;TOLY'8Z^C3HA,/4-@M^K+!<+-=;5E; M;+A3OIJFGD3+9(WHJ.1?H4XQP^\&^B^:25%UO]BK+I<+C70+2,=+-
B[[T=&Y^$KMYD9%GW9CF[_E#)_/F3,< M_0;8*M>;JK_*?:BJ[COS;+3(Y/,K;9HW0,1.Y\LCU>Y?GY6)^Q)T\&[6MX9M
MO4:F$]S6JN/7S.S^Z5^^4HF[7B6J6_VNTTC?Y1?\Y85PBHUO#9MTB)RK[CPK MCVXZ_NJ7^7$1@VHDU!;*
MZUW&!M705L+Z:H@D3T9(WM5KFK[%153Z2G6[4E_X+ ^)]RTZ23+8ZU)H.95;E M?;Y$5$15[O2B5454RC7HOBTN:
(B>43V$9N+M@NM+73I$DQU<6FG7Z;=SL[GNUK7)CG"IX.3JBIX*BIX'OD7O*^)A;Y(EUVNNM3A5&]F%9Y:N;N:)#/-]+X9ZJ]\[\O>BI[,DJ4,8[RHR--LY-
ZF_/*JGOCO6./GWL>U79 MIYTU=TLHJ*B9490]3>M1VO3M.E1=+A34$+G<*_AJVXICD\L 'JA\#O7MS^. MSM7J;23:QUO?=:1T,52W/H/14*.5.Y^2Y-
$7!&/C0X2HM_=,MN]@B@I]=_M6UO+2RO=V;:R'KF"1WTJK57HBY3HCE5+3!R:+?%9NQ[-2CU"N5[7[$^U3YN M_:+UC;-
>Z8M^H+%6LK[5<(6ST]1%W.:OK]2HN45%ZHJ*BGOFKC)&#@,V9UYL MOMO=[7KAK;-U57^39 M ?/:VU70;&TE>M0W-SFV^TT*JB+A/%2E
MWB2WDAWVW9NFL::WS6JGJ8H8HZ6:5'O:V.-K<\R(B=53);/Q8RICPW[CNQE5 MLE2W'SL5/\Y2A04ZU59! F&J]/6.3C-=O5<=%F)Y=5_,
MGJ9*.QT%.G1(J>./I[&HA[(C3<:?,;'-3SF9=?1&U,0R @<C>0&X_J3\H+M M?/M;Q +]*V-=246HT2ZTTT7H]G5-5$G1KO7S'I(JI^=5J^))\QN;(?
CU;*W&*A@[74-ES3/WL=I7<&OV_N-0ON7J\/.*)'NPV*M8W*HGJ M[2-%15\71L3Q+ ^]/Q>'%7\U'Z.5H_P!AJ$TS[E?ZK0 :\WUCVH4#JFP M
($^4%X2)]1Q5>Z.D*19+C!%F]VZ%N5GC:F/.6(G>]J(G,GBU$7O:N?6>3H MXHKA=:V#:,4Y&]WNY42P)6)(U4< MWIC&%.5:!X7-L]M-
OI]DQSE;'GN]%$PG1,)T M+,.G+BK'FS=C?;HI*L']C*IOV9VB?>CXNMIW#*&.9#",[^XK%VW M M M "E7RL7$)= MM3[WZEV]N5@T_4VG34M'-
;;PM)(ESIEFHZ>:5J3)+RJQRR*BL5G*J(U<Q\X2AN#(H?M4$<+.5BQKCT(V^/>!5MM) MY33?C:/3='8:345'?
[50L;'2P:@HT]7QU1HF$8DJ*V16HG<]@?I;JO[ZL_!$%^&\SUQE M5Z>*D5O><]@?I;JO[ZL_!$PM!:,H=O=$Z?TI:EF]R[%;Z>UTG;NYY.QAC;''
MS.PB*O*Q,KCOR!]& !7_P"6HPG"YI;/1%UE M2^/_.(UY8 ?,ZUV^TON-:X[9J[3-HU1;8ITJ8Z.]4$57"R5&N:DB,D:Y$O5>B=&J1(^Q.W)_YGI_|
'8?]8GH (%_8G;D_|ST_^.P_ZP^Q M.W)_YGI_|=A_UB>@_CMPP;..GVTO%^]M04<=(R](@CBA[.9DF51SE5?17IX$B M0 1HXW*]HJ;I?3<#?|
>TE9*^3UVLHT541'R-SZ"K[6JJ=>F>55[@*]P?TJ*>6CJ)*>HC?#/&Y6/C>U6N:Y M.BHJ+W*?S_|]J)I\&$|TNUMP8]RNCBNLK8^9?
@_:HE5$]F5S]*D+(XWRNY6 M,<]WJ;F5.]\/_$=3;<6QFG+S;VI:5E61M=2M7M&.KF?Y2>M4.YT598]?Z?[6"2COEH]VJBY1LL3T\6N14QGP
M5%3*'#]R.#RSWGM:S2=5[B5:Y=YE,JOIG+['=71_NI[$ D:_+I1WEABK;?5P MUU)*G-'/32(CT]CD7"GFD<,&+9_6XV>HKQ-?
>6AM,L'9MI65+96U$W,U4E1 M&JN,(CDRN%]+&,$CLH!D&,H,H!D]:J+_ (N?^"R_P 1QI(];J+_ (OW-/'S M67^(H$(^$?| +GM_^"U'\12=Q:!'A'_+GM_|
@M1_$4G< M M M #",1>Y9ZN5JHZ5R(L2,5$1.JKE5"SO<_>G0>S-]JT=;ZMM6F*5 MR*L.5]2UDDV.]
(H^KY%Z?!8U5Z$$MZO+0Z/L/G5#MCI2LU56-56LNUY7S.C7 MIE'MB3,LC?SKNR7V^NK?3^DM?[[ZNG2T6R_ZZU%5.:ZHEBBFK:ARN]%'ROZJ
MB=/A.7"(G?T)A;, ^1WW;UNZ"KUSS3*97K+S)T M16]^ X7O1OZ[W|]>=4]^UK56ZS5"KFS6'^P.5&JF%8Y(3E:XXE<_P#<3':_M]MAMP|I]_P
RT+H^ZZED:[D?-1TZ]A$Q_A)G8C9T5/A.3P.W^4&X4]+\)6M=.M'Z:TS<;E=DN%G6MK*NYO8KWR|L]GHM8U],,AJ=.J^M5+*/)'Y^PTL?]]U;AG
MI_X90/7^3)X.-=<*UEUS5;YFML=;J5;>L-!05"SOIDIT]%BO7J3@ #3'1KFN3F=W-3T5ZKT/T:XZ'Y7D145,9^D\+UB,BU59J_FC9L8]Z<>[3=
MI_EG=;+Q16;KI>$W2%S5\:VZZ:E;6TKHWH]L\,E$[LI6JG>Q4:YR+XHY%3O. MV>2OH>RV1U+5*W"S:ADCSCO1M-3_
.=RG%.*BX]EP,\,U%S86:PVN?'KY+9$ MG_ZS]TDAY-.A\SX:H9L8\ZNM7-\^%:S_ --PN[%B,31Z+-'2)V'O3E:W7=J MZS&Z5P *M?
M4*M/*:;6QZ3W>M>KJ1B1TVIZ5>V1.GJDT_(QSNG'SJIO;#W>.DIUGO=E_W5H$8W+W.C1>TC3Q7FC5Z83O7E-_3[W87Z
M9GI/*53J>/V^/5$=8YP]YPA;G3;L\/VE+W55-FND<"T%<[GYG+-"Y8^=_P"> M>UK9%3_PAV=.B*O>5D^3)WG=IW7ERVZK7JM:?T=6467=
(ZN)BJ]$3_&WO\ M7$WUEFK7(K%]1&;8["_53W=8^R=.R/Q.-35WQRG[HS?9Y[>LWLJMN:J*OI'0 M5KK8Z]3M8VD\Z:Y6.8[+N9&\ZQ*9L4W[/._Z-
;&S:ZGJF.)K9ZFQ-[5Z?=\L\J-5?7A.A._A6:G>'+;=$3'^X5(O_ %3< MJ01\J;*KM[]-QH[HS3\:X]6:F?\ T?
N$^.&=,4%'U8[;QM*FC>_05ZX0^(_MK$]]/!1U3+K8ZER+ROIW M.54B=\;EPZ)V?A(F5[T+8]I=R+5NSM_9=6V9^;*Y0))V>45T+TRDD3E^,UZ.
M:OM3VG(../A_'LVEJ*]VTZ2ZHL"/K;>K69?.S'VV!,=_,U$5]>+V-\%4BGY M-G?O='ZXJ-NKO48M%_=VUO61>D-:U]R)GN21K_1RG M[.6L_P#QV;-
NKW*^GW6@_U1>G@A@Y]U;+DY47'CUQUP?!\-^[_N15,TM>:G%%,O]@S2+TB>KOR-5]3E M5<9[E3'B2C][%7"")R6HXF18R:<[$YS_ #1\72Z?
E6+V/5A97*/Y:O@DVCTQT5%,^!Z/ M2=OK;7INV4ER]/.ZZ&FCCGFYE7G>C41SLKU7*HO>>Z.HMU353%4QMNYN](IJ MF(G?9G'@8Y?24W!ZH?
S5.BHASF#I7<56-^?V6J]9KLUS17',&WCWZ M,BW%RCI+38 'M/=^=*5FYFT&KM+6Z5D%?<[?)!3R2JJ,[14]%'*G5$541%5.J(I3%%HBZZ.W;
MH=*WVE;276CNT%+44_:>C'+(Q,=53 MTAD !D #^;FIU3'@4]6^VU?PY<27[?"GK541'HGBL; M43O++3[!6;VU7NUUS?H/MT3O*S_)]\07XG-
2U.V5XJ.6W2T1:FU/>[I%5(GIQ9\$D M:W*?GF^MQ9@BHIXY=B<>[-'=W-C3\F.JQ35WQU^[=.@ --9 #5/ >)L M<(\,%EK;A[U-IFUZ8M5"M-
74[JN6NN4+I62N:_E6%F'-QA,*Y>_$C<*F.O; M.'/B L7$%H&GO]K5SOMM'7-:CI*.=$7EE9GZE3N*OG;]\SEN M4&#U>F[Y!J2P6Z[TB/2EKZ:*KB[1O*
[D>Q')E/!<*G0]HX%+/+E+H8GBC>&0 M &0 M M < M#XN.+G2?"9H)+S>D]TK]7(Z.SV&*5&2ULB(F55<+R1MRG,_"HF43"JK47OA^ M?
SRA.Y%TWKXQ]9TD*R5C;1ZEPJY(=93Z/MDN4CMNF4\T;$WJGY,F9E7"IU5_?W(A\-I;C;WZTA7)6T.[F MK*B7HO+=+E)<(\IG'VNH5[?
W/K+:^&SR8NTT6D:;_5NG*'7>LI(6.N%9>6> M5.KZMX'[@]:6B6WUNTVE*>)!5;VMHMD5 MOF:/4DIT8Y/K
BQP/>5.CW=U);]!;JTU%9]2UKFP6R_4B=G2UTSG8;#*Q57L MI'+A&JB\KU7&&+RHZQKF3UGY[N.GA87A(WJ;8[36U%9INY4S;G9:R=R=NQG,
MYKHGN1$]-CV]Z)U16+T551+]^#O=6IWLX9=O-8ULSJBY5]L2*MFD;A9:F!['] M>=ZI^>DB>OT@=G QE#)7_Y;C"<+FEL]$76 M5+X__B-:!8 ?
F3V@_P"'*S_!U_CL/@T\3[S:#_ARL_P=?X[#=POW]+1S?X>O M[/T,<*:YF+:;#]9]G_F4)U-#EG"G^9BV@_6?9_P"90G4T-*KWI;='NPR S M M
'*=S^'G2^Y\[ZV=LMLO#D1'5]&B(L MF5[1J]'8]:87HB9PF'$UHT@ESW#H]+K5K&V:Z-MZU21_!S+R<_+G_)S[)9 M>5XZ2_-!VK]=_V MF=W_(-
Z]ZK\5W7KTSWG3=2;2M6L+3);+S00W"AD3K'*WX*]<*U>]JIX*F%3 MUD3=V:ZO66[V_JYU"O\ OJ),IS%=()ZFV5<% M)-YO520O9%-
C\C>K51KOH7!"[:CBBO\ H)[+7J)LU\M$:HQ4D7%53(GQ7+\) M/SKNO=U1"7.B->6+<"TI<+%<(JZ#HCVMZ/B3.
<(IW3;'B^MFH)}>VZIHTL]=*YL;:RG MRZFCEHZZFAK:29]MD@G8CV/1?6U>AQNY<(FAZW M4,.R@;6T-*V1'R6V";,$F%SCTD5S45>]$7YL
9XA=]KOM#<+/3VVWT=:RMBD M>]:KG]%6JB83ENHZBG=8[2C9HW1JK>USA45/C^TZ+QAWVUVC3
M%OIY+925=\KW/B@JZB!KWTT*8616*N>5556(GSJO1412' 'U.VVX5;M[JJ&_ M4-/!55,4;XTCJ>96XGK$@D1RT]5&DD3TSE6N:O>F +&MK]5U&N-
!6:_5-,<%370K(^.'*-:O,]=, MJJXZ>L^M/F-OJZUW+1=F]K)2QT-KGIFRPTL2(C8LIE683HF%547'BBGTX M ,90#(-M M
%47E"_)V;L[H(:KW3T32V_4U-MMN[*1WN3#4I#7P+#2Q0.[&1&L>B]ES)ROYNN.7IUM=_'YG;?=MS>'36DC:6I MU)MSJ>'E?+!S3T%0J(JXYV+A7,
[^CD5]IGO3)+[9?RQNZ.BW04>O;/;M?VUJ MBQHJKWN+=MP-J](;JV1;1K+3=LU-;L\R07.E9,_MC'?&8]IECOS$<+U(,[U^1GV[U0DU;MK?
ZW0],A%;;ZU77"A7&>B*]>V8O=Z2 MO?W?! A!Y0OBITEQ8:VT=[J32M'OR?&^&Q;RSW,2$U]L\:KF\:,YJZF1$3/,Y& MM22-
O3X4C&HLR0H\FIQF:OL[:+K:FUE0VNS%BC*ZVQOD\Z2H\XRLC%YK7-:C6YZ(N7IU5%[E/TF]R@_/MP%1N_',90#(-MM
M/"5VH7:K&)UCBCIX87Y3"3]HDI.%'1KL8=.ZME=]-9,B?N(A6WQ.S M.=JZT0]{(I:CTZ^+II47^!"TC@UNM3PQ[>08QS6UL__$CW2?\ OE]C7:]F
MBX]5<[S/.?-REVW31KN1%,;1'3R=I3H #27+0UW;DZ(L>J;4[FH+K2 MQU4:9159S)U8[W35RU?:BH1A\I5M"FL-HZ;65'
YUSTQ+S2NC;E7TDJHV1% M\51KNS=[$1R^L^0\ESNVEQTSJ#:NMJ5=56^3W4M\3U7\@>J-E:WV-D5JK[9E M[SH+\?
B\2F]_-1RG[.6Q?]CFUV)]VOG'W3G*O:2(Y M>T5&Y3HUB9ZX\"5B+[1^X4EN]/:N5Q8Z*??*&54U3Q4 MZJ9++*Y](*>BCB:Y MMZ*B^']C1EUG?
PMGI.>TS^.O[_'^[Y#)A#)0.K M'\E3+7)A5*CN./9VI#WM;]"QH^BL]E6ZVZ:!5;YM4M1W25CH,QAP:X4F_6TUJ$U\:72-J4MTIX^G8U3$3G
MZ>".RCV^QZ)WHIUXJ X0]Y-K+GPT[]2V;4*OM]FKJE;3?:6;NII6N5J9EQTS&_ M**O7T7/]A;\U[7MZ+G),.;C]A=]GW9Z&F9?XFUM5[U/*7]
5ZW85!U]AD >% M65L-!2RU%1(V*")JO?(]41K6HF555\$1#YW1VYNG->25,=EN3:F6G7[9&K', M=CUHCD153VH>
{OMGAOMGK;;4M5U/5PN@D1JX7E?T7.GX5O.IKHXMJXZ M?5.5%3V&<'Q6V>XEOW&T\RX4B=G,U>2II7*BNAD\4]J+WHOBB^O*'VGT%W9O

M47Z(N6YWB537:]M5S17&TPG:.[:1 ME]G-K)NQI]6BB22>9R-5SL(JHB(B8R]JB=43Q-FN[=RZXXN<]&I:LV<*B>'E M3UEU+F"K]1\9M9NCI[>#1]'J?2]>VNM=2G+U3EDB>GPHY&_U%3**BK] MC]*&M,33,TSUAM4U17$54\XE_0 !Z M Y1Q0;FUVSNQ>JJ76N".:XT$43:9LR98DDLT<+7N3Q1JR(('Y MTJ8V?O=PUSQ/:*O-VE;4W*YZMHZVJD1J,1\CZMCWJC6HB)CTNY$+,?*"RK'P MGZT:GW:Z%%_QV!?\Q6APITOG?$=MS'A5_P!VJ=_1,_!=S_YCI]-HB,6Y<[^? MZ.+U6NJK-MV]^7+ ^NZ[JGP4-C#>XR>(#W6L".MMKN4Z7JS3P-Y4IID>CI&-\$5DF%1$3HUS"SC8+=JCWJVIT_ MJVDY6RU<"-JZ=B_D%0WT968\$1R+C/>U6KXH? <;>QOX]&RMQCH8.UU'95%?3[K0@:I[!U.?=4V M ![WO4^#U!LEH7<^X6ZNU5IB@O=9;W*M--5QP^]Q MTP83N[Q35..[TSM+SJHIKCAJC>'CQ0QPQ-CC:UC&(B-:U, -1$[L(G@A_=')U MZGQ&\MRU-9]K-4UVD(5J-34]OFDM\2,[15F1J\O*U>CG>*-7**J(F%R04X/, M/"\Q;O=IC=2^^>VZY/Q1WFL:UBT[!LJ^!J+".?1L D M M M #\]?&]I>];+<:^O: ME&NBJ77]VI;&:5F6O2HD\Z8Y/C-1[U:OM8J>!^A0B/QX\"MNXM=.4USM$]-9 MMP[1$L5!1V'2,YEZ2-3"ICN7*)UG5NN-/:"M$UTU+? M+=8+;"U7/JKE5,@B:B?GGJB'Y$MW.%S=39&X5--K+1%VM<$.7>?QP+/1.;U] M)M0S,:IA,XYLHG>B'PFEM&:@UK6>9:=L5ROU9E$\VME')4R97N3E8U5ZX7Z@ M)->4EXI++Q, [WT\^EG/GTIIVB\5]*L>Q6+6/<]7RS(BHBHQ55K6HO54K6>QS+=., M"6Z[\>WE7M=PD[9:>N$+X*Z,V>>S0RM5KHWU,LE2K'(O5%:LV%1>Y4*^^"/R M5VI[WJNU:RWEM3;'IJAD94PZ7K$:.^IN+D])K9V95(HLXYF.])V%:K6HN2WML M:,1$1OHHF$1$P!_4 #YG6NWVE]QK7';-7:9 MM&J+;%,E3'1WJ@BJX62HUS4D1DC7(CD:JZ%3\S#L_P#K.L_\RA.IG*^%+\R_L^OKT=9U_P#0H3JAIU=6Y3T 0R M M .,90#)7CI+\T':OUS1_P Z0L.*\=)?F@[5 M^N:/^=(!8< !CZL&0!RK=?A\TYNA#)4R0^YE\QZ-RIFIER^J1O<]/:O5//!? M B9J/16N^'W4<5P9)-0JBXANE"Y7T\J? $7*=?:UZ)E?!2P@*OMM+=J*>CKJ M6&LI9F\DD$S$>Q[?4J+T4#@.TW%E:=3)#;=7)'9;FJ\K*YO^]95]N<]FOSY3 MOZIW$AHY631M>QS7,$!'I-=- "NY%ZO?9YW]/FB>O=^E M=]?@\#[;C;IVVZ MO

PADI71 #Q:FFCJ]>6":-LL5[\'MRUS5145%3Q3V%.G$ M#MK>N$OB)956-
*[]:FAJFWFPU3DRU8N?/9NQW\]HK'(O>B(O@CC9JNT\U3:IWJC>=V/2@<[P:]\$3]OWLXKA;J%TD*N1>QE2FC22/*?%D?\ "HT*:J[EVNKK/_+R M@*
*:Y*6]U9;]2134EIGF6UW^C) ORD'#8RZVE=U;!3+[H436PWN*).LL'P65&$^Z9T M:Y?BX7HC,EQ@7Z>>-*
=]VK]7/;ICU1PY5GW]>OUA.NAK>XT<%5331U%-,QLD M4T;DI-NI:XN33DV8N4]_ZOZ UVX #7ZSU6I: MRJMU@N=704ZU=;#3R2P4Z9^V2-*
*;JM;]*HB?2>V1 M&=Y1=VQXF;@V]2TNL*ALM%.[[75,A:SS=V?@N1])EGMZK\Y)NFJ8JN%DT$C9 M8I&HYKV*BHY%3**B^*$>M_=B&54, ^I--*
*TCDJ^99*RCA3*2(O59&)\9%ZJB=^ M55.O>X4];W2XMK=.U+'5%!1=M!4=_99=^1]OJ7*]WV(OTI MJA7N?*
71ND5&N>BH]T<;N5D;G(JHJL:BKS+E>]YZ?\XR33553RB>KRFW17,35 M&\PQS)ZS/,F.\C3QX:LW#T9LLZZZ FJ)T56U;I6T;::C?3Z,W0N;*
([L]R1V_4$_*QE3S+A(IU3#6O]D;_N=XX=U M=MT8ERY:F[1SB&CWQ1S51,*BIXE<_DT(EDXD>9$SV=E]G+GP3FB3_.G[I8;Q-ZRM.B=C-9
*M55VN,%M2IM=514]SKA9JB2&1&1M1.KG*O@GJ5>Y%*_|R7\"3<1%RG-MJAR?]/3I_G+[#XHP[V_1RV=PSGV=NJU@-%"ZD &G[I%?CSX;I-Z*
M=O67ZPTO;:LT\Q\L,;&Y?64RIF2!,=5=T1S/:BHGPLDJD[C"IGIZSULW:K-R M+E'6&MD6,BU-NKI*L+R=O$O)HG5$>VE_JLV&\3_*
*.YDDBJ*2L=T[/KJQ+T1 M$\'X^,Y2SM'(J*51\2^ P^R[0!GLUC8XG4VG=13.G8Z#+6TEGV=]!CF3UF2D=* QX=QJ;@#1?J/ M7W>[4=BM=9X>B;'<*
M715\TQB_=-5%++>%_B3LG$1HAM?3K'0ZAH MVLCNEKYO2@D7(]N>^-*
*V%5J_.B]44L*F51AZAVMQ>F.Y4P>%;=-'6*Q3.FMMEM]OF5,+)2TL<2KW^+6IZU M^M3W8 T1,(G0W,9090#(?F3V@_X%A_O=3_ "$A/@ ?*
*:ZVZL6XMH=,[!0LJ6) ^13-] M&6%5^Z8[P7]Q?%%[CZL 0/W3X>M3[2U;KO:IIKC9X7I)'<*7+9J;'=VB)\''*
*MQD]'IX9P=!V=XN%8V&U:XR].D;+Q$WJGJ29J=_Z9/J7JI*MS4Z:4[*SW5!WRWU]-=*.&]HZB M*KI9F\|Q[5\4WHOM[B7^UF].G-*
U)%MT_FUR8WFFMM0J*Q?%4^.U/C)Z^JO0#HI" M7C$TA-:=QHKXC',1+Q3LS)GHDL;4CQBM:UK$#JZ>[M;MTK.Z_4*>EYI)AM4Q/9TY7_*
$(BKX(!,\$7^%'5>NJR]7&PWQ^>S4=,JI) M<(W(^FF1S42/F'4&GZEU)J35M0ZT054;U;+34_9N=42L5.YR-Y&(N45%*
*ME1R+EL,@^2UMM9HWK+IMDW7VID:D=MK*B\)2,MK<+SNCC6GDS([*)SYRB91,*
M@MZ;,=AYU41P=]NJN;DYG(WFQYEUQDLTOMDHM2V6OM-SIF5MNKX) M6]II4RR6)[5:]B^Q453GD/"KLK3RLEAV@T'#-*
&Y'LD9IFB:YKD[E14BZ=4.K M 46Z\T#N]Y+_(@)\1Z82H]]+SR/BH+I51+)0W2D9O M,SHJ=;U7Y;;5-RTK44FG]L[=9;](SE9=*]ZOK(8U7OJ9[T5*
*M.A;576RENM)/25U-#64DS>22"HC1\;V^IS5RB!\Z'PUIX=MJ[#=UNMKVST?; MKIS_GU)8*2*?F5N=E6U'*Y,I%&J\[7(B(KD9RY:CD+5N?*
F+Z,=.\H<\G|)$R77$;G)V[F4;VMSU5J+/S+ MCU=6_6A1:UQ1I]WAZ|OUA=Z)P_C:)]^OZ.I6V!OV96C&M8U$=]6SJJ(G?]L@ M5<_4IG=)NK+7?X]+
MQ5T?^ZT+/MEEE:A&RQIS-1%S!LB=.\V/:Y>KNTT MTUSO%/1]VL:W9JJKHC::NH#XO7.[.E-O(G+?+Q#33X14I(U[2=V>[[6W*X7U*
*MJF/:>5H/7UGW$T_!=:)4+/3/7E>UWHOB>G>QZ)\%4Z>Q47*90\6T^J M &O=@\"Z6RFO%!54-93LJJ.IC=#-#,U'-*
DCBHJHJ+X>P[T")@1RYL9B*HVE3AO\ [4ZAX/MJ2NL,LU-;VU*7'3]Q7*H MYB.ZQ/7N1S?NFJBKT?@LXX<[]*
*[/Q!;=4FH|CFN\47UY1/Z<16QULW\VTN6FZ^.-E9RK-;JY4]*DJ41>1Z+\5<\KD\6N= M[\LGA;WBNG"IOI5V_4D6;"=ZQJJKGKECGX^$AT/+4*
M&5B/CEC/26ZGH^=8>.!9%YG]FQ&\R^M M<>)YB9R#":8F=YA,3,1MN\.LN-);84E]ZF&FC5R-1\ST:F5[DROBIY+'M>W*
*M*CD]9Q+B3VZO.L[/05UHY]MUM[19*)N>:1'&F>D_%].M/?"6N4&4/YL>V5B.;J.:O5%1W5%3999%6OL=-&Z1]$KL_;(43TEB5 M55%;]QE%3T?*
*@V9(F44U7]TW,;)KQJN*C^C1R\2WET<-?=TGX([<"E\US>MAJ M'\75)64]91U,E)02U\;F3ST;&L[-[TAA$1J'Q5^ MWDT5IG5U'I:*
*[;HME!J&M4Y@4MT]0ULK^9<-3'@KO!%[_#)Y5S-VY-5-/7NX&4&4-47/BAGU]#R;38 M 09\JO/R[;Z*A17>G>)'G+=?;35-*
*K;9<(&5-/,Q>CV.1%3HOJ+E#W2?[(5M^3DXFV6&M;M7]2JY:&LE5]BJ)782*9RJKJ;/]>O5OY[F3KSH*
*MB611A57J:>5CU8UR:)Z=WU;^%ETY=F*Z>O?]&X -58 ,9Z#O0R /@ MMW=HM/[UZ'K]+ZDI5EHI_3BFC7$M/*F>26-W@Y,_,J*]+E%5#C/"EP4Q<-*
*NK M+Y?Y=3R:@JJVF6A@C92>;LCA5[7JKDYWN4 MT3;B>4M6K&M57(NS'M1WB*B&4<1CXU^*+4'#=8]-OT]9J.Y5MXGF:M1<6R/I*
*MX&Q(Q5;J,E]P[HH]!PL\5EBXC=//Y(V6G5=$Q%N%G=)E4;G';1*O MPHU7Z6JN%[T5V7X>[V?:;>RP_%V8O=A,^T[Z#7Z3!KMUN M M M*
'B5MQI;71S5E94PTE+$WGDGGD1C&)Z MUCG+&W. M4:UG3"O?D+>JOBDV8M\[Z>]W=T)3SLZ/BEU-1,U&OZ=>BKT/
M^6?;/6%VLE0Q98;E0V"KFIH6(JHKFR-C5JIE%3+X 7T:RXZ M]@=$VZ6LKMU],UK6-SV5FKFW&5WL:RG5ZY.LZ!U?0;AZ*T_JNTME]S+Y;Z>Y*
*MTBU#>61(9XFR,YFY7E=RN;E,GYJ-"[>7?7>X5KT91M@H+[<*Q+?"'=9VTC&3 M*JM1CW281J\RK/.VGN%.CTCD>Q'HB.:K5Z*BIW..B_98[D_P#.J*
*XE#_ *H$] ?$[/:D MK]6;;6*\7.1LU=60*^:1K$8BNYE3N1$1.X^V #Y/7NV=@W)M:T5]H4FY47 MLJF/T9H5];'JZ?-*
W+XHI#K7NIEZ$\3^3HT>U6N:CFJF%14Z+] $6MG^+I'>;VQ'1W[U=04593W&EBJ]6>.HIY6\TIKIJZZ2W&\5TUPK)5R
*MZ2=W-TSW)\5$ZX1,(G@B'K6.5JY151?9E/J M1RADAUPX\1%?;KM1Z7U+5OK M+94N2*DK*ARN?*
3O7HUKG+U5BKT_.]YI,4#1$\,8]9XETJ)Z.VUE130+4U,4 M+WQP-[Y'(U5;WZ5/. $,=,<8NJ;1>IVZDM]/<:)SU1]/"SS>:G]C5\<>IV5_M/$E]OMW-
+;ETRR62YM?5(W,E#-AE1'CORQ>]/:F4]IX&Y&QNE-RHGRW@\]WN M6/1N-*
*'B.=%]J]ST_39PG=@C[!PCZST]KBW2VFZ4TEOAG9*VZLD6*2%].1556 M=5YL=R(JHOBJ94"9 !C* 9 ,90#(M M M /YIU[NX_+C9+_ '+3U:E7:*
[A56VJPK>..9T3\+WIS-5%ZGZCD3'_ M ,C\T6TFR>HIXJROBT^E*QE$QKYJBLE5D:5=S5%YVKXHF.G-U]PTVEDE=>KBYJ6D MU%3QXZ^;U7*G?*
*GJQR_NM_:@3$KB(BH?PF@9/&^*1C7QO16N:Y,HJ+WHJ>**;&/?JQ[D5T]S3RL:C*M3;J0*
*M$\G=Q6^=QTVU&JJO^R(VJEAK)G9YV(F5I7*OBG56>M,M3&&HM@/W*E2'&IPW M5/#MN/2:ETQVM)I6Z5/G%ODIU5KK=5-*
5'K"CO!$QS,7OPBIUY%59Z<'_!&T MO$%MK#/5RQLU7:VLI[O3)A%5^,-F:GQ)$15]BHY/!"RS;%-=,9-GW:NOTE4; M=DU6ZIP[_O4]/K#OP,
(N?')DI71@ #^:IE,8RGM. ;R<.DFI+E[KZ7;3T MU5[^RZ9ZJQDBJN>T:J=SO6GT]_?(RG+EW<.OCLS MM/ZOE-LM-5ND]$6FTW&I\]JZ6+E?*
*(F51.JJC45?!]*C4]C4/]>!Q*^<3-O MT]KNHL53:Y6T%/-V,M>DF5;Y.CE[/ERK47QSE?#U"Y?L8%NFFV5M'2"W9O9E*
*MRJ;=.\]9=ORGK'A[#P[;AJ8XW7:AC3FGI%CC;'VS$1 M/2CY6-YN]6+E>K5]&QO]T_DYJ2(Y%3HO3K_M\YN8U^K&N172T'+W*6%(Y%3/@0AWH\FMG:=["+RI-&UV]MKM ME-21N>]E/$R%KI%YG*C41,JOBO3O/?,JL7*HN6N6_6&IIU.1:IJM7^<4]) ^+ MV(-BE>N&0 <:XO9.QX:-Q7*B.*
*M_P!R9&]?;A/\Y#/R4\?_ &R-:RF:=/N3/?_PY;(JIJU2W3'6(_P K) 43J0 !I]"FJMSE M%;E%/Z@?5&RJ+CMX7_QE]7QZSTO ZGTI>*E7=G3Y;[FU?*
*PE8B[\%KL*YF.Y6 MJWHB-S,?@BXD6[II;-HIO4M=K"R-;3W!'.J*I9C$=0B?GD3#L?=(J]$U?!S7(UR+ZVH5%T=5K+@CXB).=BR5= MKE5CVKED-*
*TH7KX+U]%5A4RG?RO:B+E6*AT%JJ,_[*KWZ>CE+M,Z7D]K3^]KZ M_25SR.0RBY/C]L-QI)NKHBU:IT_5)56RX1\[57HZ-V51T;T\'-=EJIZTZ=#Z*
M_P!?0Y^:9IF::NL.HIJBN(JIZ2V 0!Z ^,W-VQT_N[I"NTUJ2@ M976VJ3O7I)$],\LD;L>B]N>BI[47IE%]>W>V?U]P8[K4=TMM=41TTOVJ1.JIM)6C6-
*HFM5^M5'>+=,J=I2UU.V: M)^%RB]UR*F47JB^"]2PQ*IWUV@LV MK:RW>Y59.LD-1"S*Q.DCMN<90^X\ MG5ME57O@/H=.:Q?*
*<*FFU$RYTL!Q:U_P&\L:N1])CTU]943N M9MWN7P>;O7*S35EYTE?J&22.BO=JGEI//]95]&:"5CDS&].5<(O1U7.8UR]51,=S.D M_>"?*
*=&OWFX6]NM7765]3=*NWNIZNHE^%/-3ROII)'>U]H5>OM52@6TVO7W$+ MN%34%,MZU]K*[2-*
C:Z>;2KJI5Z)S/DD551K4[WN5&M1%551.I^ASAJVA;L5L
M9HO02213S66@;%4S4[>6.2H]>O5A=/ZND@DO=FH]J^![JMC=5PMDY47"KC/=W']OQDM _)"S_.,_P! M$"-*
N]=5&W>IX;W2T=-731QO8D58U7,7F3ERN%1>G?WG6?LP[W\E=/_|OO\ M]8D]^,EH'Y(6? %&?Z!^,EH'Y(6? %&?Z /[:,5;FFUGH"S7NHIX:6:LA5[H8
M$5&,])6X3*JJ=Q]@>!:,11V.WPT-OI8Z2C@;RQP0MY6-3OPB?.>> ""M7%M=YJ_>2NII%Q'04T$$?
*AZ*QIJOSKF1>OS(3M(@<9F@:BEO!]RGB5]'5Q-MI:IS45>25F>57?IFKA/5R+ZP(U@ #+7*UV4U!YSW^.47YRS+0=VFOFAM/7*I M7-166ZGJ)%*
[O3?$UR_NJ5FL:KNY%7QZ$H-I>+BBMMMH++JBW+2P4T+:&XV] M%XTC^B34\B.1%]2^I4]2 M]3W "'_$UIK7]GU]4ZLH)*
]B^RL:&M+44,KT\RY6)S-HK=]JS4UVM-4VMMJ0WFBF9G#NJHO?U145%147NPW.DZ.P4,DLT--S.6:5Y/\C3^H:9JBV.K[
*M17P7&C>N&S4TB/;GQ3V*GJ7N]N #^,[^S@EUJJGU$)OLR->_V MFT?XJ_|UP)O@A!]F1KS^TV?_%7?ZX^S)U]_:+/_(H__7 F]E#)%G9'B2U9*
*MN#N/:[%=(KRU[ZO[!_^(+X.O@A0%P/Z]T]I&MU;1WJZTMKEK4I7TRU4B1MD6/M MN9$OW*9WB:YGS;@ \6^ $=._-> M\>:Z#LML:[E?*
*67#M53/>R.-R+_E2,)%D/^ZC35MSZ,%)4*GZ>1& \ MZH#^?#M;O-=#U%0Y,+55W76@;)?4N>B% >B93XCV]V6JA_*
*M&W$E5:J9OXL+*UT]ND1.5]0SODIE7U/1/1]3D;W(KLVF!DQ;F;5WG14HM2Q) MN4Q?M>_2[+MKN'9]U-*
*$6G5%@]/.;9<8>T8]HB.C7]CHWIX.:Y%;]>M/4?69[MRIC@FXI9M@-6U6DM5=M#I*YU/+4)*U4=;*KX*R\O>C<(B/3O]%%3]BHMK]-4*
MQ5<$BH>.9BU8US;^6>D_%LX&93EVM_YHZP\I M ;*T &GL.)[X[$0ZRC]+W98DBOS6Y?$F$95(B8POJ?CN7QQA?6G;D4P MB]%-
*+*Q+67:FU=C>&SC9-S%N1=M3M,(7;3[M7G;^[^XU9"]IL?4\M11S,5)(M'\[#E;G>B_G5SG'AG),Z-*
W,Q%QUP?/7#0>G[M>8+O66FEJ+C#CLZB2)%B^T\CGI6@JH4 M:2IH;9KN%JOJ) M=%Q\ZTAXWDFXD==-S)5SEL-N;L;JA?\ ,?
*9^5%VRN6HM":;UG221>8Z;DFAK M8W.5'\M2^:C'M]>'M1%3U/SX'S'DF(EQNA*OP7+;&I\Z>=*O*'3153Z+VCN M_P N-JIF-8B9[_\"PL ';NR :HF2/?*
*&#PR4O$)H)IJ** M.'6%I:Z6UU;L-[3IEU.IWQ'X3JOP787NYD60[!3TM7*K.<5T3SAKWK-%^W-N MN-*
XE4IP2\1E;P_[F3Z2U/))1Z6NM7YK70U66^YU8B]FDRHOP>K48_NPB(J_ MP6T->CVY3JGK^/*$<)=14SUVZNDJ5)/01]^H(6>EA$QYVU/FZ/1/5S_*
*!E3 MSO)[\6TEW92[7:RK^:MA9R6*NG=Z4K&I_O5[OC-3X&>]$5O>C46[RK-.7;_% M68__(H<]A7ZL&[^#OSR_EE/T&]?//@V*!U(_FB=?85=^4$V*
*MOUMH+>U^Z%+5U;[/724ZT-QI9'-?;9XHVHD2N1?0RK%>U4PB\SOND55M%QW'_MIM2:9MFK;'66:\T,-RME7&L4]-4QH]DC5\%1?KSX*B*;6+?_*
]SBVWB5?FX MOXJUPQ.TQT1BX/N-FU[R4=+I?5T\%LUW&WLV.=AD-S1.G/'X-EQ/QI\/1*
*M;+=,*A6[NEY,W4M'K^&I\VWNU+'IR>9DC/=&H='46U47*XJ MV938WBY9GE/=\&OI]>1PU6LB MGG3W_%YX-6JAL5ZX M M #U&I M-*
3V;1]GJ+MJ"[4%CM-.F9JZY5+>")/SSWJC43YU/;E"_E,N(J_;O\1^IM-/ MN$B:4TA726]WVUCE2-L\68YYG)G#I%E21.,P:C4\%R%M_'+P_TTSXY-V],.*
*M>U<9CKFO\U]3FY3Q\%/0ZKXMN%K7=]JSM3;[T1]*W*O,M'=4CJ8LXQGD>Q4[ME]13#I7@EWWUC;8;G:=K-22T,S&R133TBT_:-5,HYJ2W*
*M$7_J^)(W3U M_M^J;%;;U:.J.X6FXTT=725<*\S)H9&(^-[5\4W$7_QPYZ=N.D^'[;"QWBBDH+K:]+VNBJZ63'/#-'21LD8N.F45FVN@*Z_T-*
/#55%/)$U(ZCFY%1\C6KW* MGKJ9]W\8]+>[!;=16Z2@NE%!7T;U1705#*$'JS;3T<-UMURKJN:HF;2+'55/J-["_20T M.[^:]^RSC;CBAO\ MOM]IG2%%:
*[;5T=BM=+:J>:H23M)(X(FQ-<_#T3*HQ,X M1.J]Q(OAYWCN>[U'>I[G14E$M!)$QB4O/A>='*N>9R_%3ZST'#;MAI'47#OM M?*
=KKIVVW"Y7#2UJJZNJJ=KY)YGT<3GR/Y5555?:=CTWHVQZ2;4,LEJI+ M4V=465M+"V-'*B83..\U*NLMVGW7O@ 8L@ M M*
]5?;'0ZFM57;+E2QUE#5,I.6&5 MN6N3/[BHO5%\%3JA[4 0MWHX6GZ&M-RU'9KFR>S4V'R4M4BI-&BO1N&N1,
M/ZKXX^DYIM/M1<=VK_/;+=54M'YO#V\TM2KE1&)#\I+ M57]YC_EF' >"3_C[??U,7^5C []M7L3I[:ZW3101>Z=PJF=G55U4Q%65JXRQ
M&\S6=,\O7/BJX3'R.Y/"3IK5;2U=@7\3MQ=Z7)$WFIGK[6?<_L>GYU3O0 KX MN^C=P]@+QY^WSFVMSRMN5$[M:;KW.Z1'I*
MR^I4]2GMLH5\W/2NXG#[>75C/.K8F<-N%&[M:;"]SEQRKGXKD1?8=EVXXR* M:J1E'K*B6DDKP/;*
!S'?'9QF[NC-97+;Z^CD=+3RO9S1]JIA6N3P1> MG5.[U+W$1+EIW62&9B/8Y/4]+T5 .+\/6_=1NO)66R[6Z.FNU'"DZU%-GLIF\-MR-
*SA>K7([IXKG*XQW'<TU!>]?3=BN5VK%@OSICVG<:2]AK:..>GGCJ()&\S)8G(YKD]:*G14 M \@ :.XRF%Z^L]!^-YI7Y-6C_$(O]4^A*
*$/^,W3UKL,^DDMMMH[=VC:I7^:P M,BY\+#C/*B=V?W5,J<.NC;!=-F].5598[;5U+V3 M<VN\J8VW>EJQJ=]DT/)?0]IQ"W1W+GL].U#T7U?;Z M9A*
.6]YR5C^3=L::5$;B8:B80R!S??,3"WI1KZR)JNJ;8[MTQW\FJ?;$ ^I$=^O/8<%6 MO.9MWTA42=4_L^D1R_,V1J?Y#L>UQJK-
*!'5020RL22*1]M>Q>Y47O3ZE(OZ; MN<^SF\--4N<](K;7BO3UNC=G'K L6!_&*=D\3)(WM?&]$4V $ O*&<<*$=?15>Z>D:#EK* M=%??]..!OY-*
&G_P!U-;\9OW>/A)Z2XY7[7R=O%4EQI:?:K5E:B5<#,6"LJ'? MDL:=]*JJOPFIU9ZVY;+55WT6@]9Z>*IADAE8V6)[>5T:D145%[T5%[\E4?&EPI*
M5FP&K8]9:326/1];5)+ Z!5;);:G/,D>4[F93+'>&.5>J(YU]B7:B.1"3B%->M5V:YMUQSA?X]^C(MQ=HGE+< 'DV0 !H>#=
*MJ6:NM593P3.IYYH7QLF;WQN5JHCD^93V&>HP854\43$D3M,2@RDNK=B=8O55 M=3S\W7FRZGK&>OPYD]O>BKX*2IVSW4M6XUL;+2RI!*
<(V_P!DT+W>G$[U_GF^_MI4^GKT/9ZZT#;-P+%/;;G%S(OI13MZ20N\'-7_;=%,2;8\/%YT-N+!=I[E3 MR6RD1ZQK"KFR3H]>VRT+;DZX-*

HZ=M>YO(M4D;4E5OQ>;&<=$Z M>P]ED9)B=NC&:8GK#P;GHG>C(XF-15<]SEZ(B(BJ
MJKT3!\IMKO+HK=]"METAJ.COJ4;DCJ&T[E1\;KG"N:Y$=A<+AV,+A<=QY^Y> MAJ7K51%Z>BXL,3&HR::]>+:KNCX]G-S+F)73/#O
M1WS\%SC51WXVKZ.))*NU.?S->U%1%EA=]TS*IE M%ZMRB+GHJR&3/JZ&C40G[+A8U.Q%1.TJ*)GS_-DQN7^ XUY)Z!$LNX\N%]*IH6^S MHV9?
\YGRHNZ%SMEKTUH*E9"RV75KJ^ME+/ V>%\]%3Q0J;XT>&BKX>-PJ?5 M6EFS4NE+E4I/03TZJCK95(O/V.4^"B855%[
(J=5:JK;;X=Y\SK[0=EW+TI< M=.:AHF7"U5\2Q30O^M'(OW+FKA4=AQEVMH]Z.DN* M<&O%/1\0.C4H+I41P;WM436W"EZ-
\Y8F&I4L3XKEQS(GP7+C"(KRKJ5RJU62(G?TRO[>BHO5.]KBU78W>"R;Y; M>V[5=CD1&U"M>Y4U=-S*KF M^/>]^GS=%!JB^LV*E? T!N -
#/T7+="JM&IM.K MI[3"SN@@NG:NDEA5%PUT\;-Z(OCR]6Y^Z1%4FU;;E27>@IZVBJ8:NCJ(VRPS MP2(^.1BIE'-MU?
M]'!:]5R*LU7;7*D=/<7955LJ+-<;FRUU5AK&N[2AG?(C$EB1 M>K%:Y57*C\JK<(!;KM]N-IC=32U'J M32-
[H]066K8CXJN@F1[?:UR)U:],J*U41R*BHJ(J'U9^6RSZBNNG*GSFT7*L MM=2G3MJ*=\+_ &=6JBGO/QY]P?EWJ7[!U'^N!^G.?
RA=JX3+A9].62U4NJM85:>9/69/FMN]2RZTT!IO4,T#:::[6RFKWPLV9S\K M8T5WP>;/3N.XHN1^Z96ZN"J*MM]GCZB)_@5?_J$8 MK"^VTT-
1%:I*;LWO8^5E,YJHJHCN57890I%=CYU/T-I@_-5LRN6W7YXO_?.D MP\Z+MW@[.(W>)6'2EEBTRS<==-LHH6VQ;=1UC
MJ7S5(V]CV*L;RK'RF\P_%-!/&[EY9 M.?L^U:F4SRYQ[#L?"G^9?V>3Q_$=9_YE"=31$3P0K,C,[6F:."(^]VQ=/FQ7 M%R;DU?26X *Q=_M M
!C*&2)W$6FYGXY4_P")?\5GN5YM#R^Y'G/8US$\W(G-G/CG('M0 !XU52Q5E)!/ M#'/#
(G*^.1J.8Y/4J+WH<)W&X1=/:F26KTY) ^)RX.]+L6HKJ5Z_I>]GT=/SI MW\ 5\7'3NXG#[>O.6K5VEJN1&UM([M*6?"]$7IRK^E>F?8=GVYXR*2LY*/65
M%YC*N$]T:%JNC7VOC^$GSM5?F0DM4T<-?32T]3!'402)ROCE8CFO3U*B]Z'! M]Q^$/3^I$EK--R_B>KW>EYOA7TKU_2][/HZ?
G0.WV6^V_4=NBK[56P5']\&M:GD1[%;91>]/4>S*]GVR;CZ5&U70N5/%T?5S?G153/@B 2U<=Z91>\]D /%JJ6&NIY]>HB;+!,Q621O;E'-7**B_.BGE
M",.YO!Q25W;5VBZI*&99UKTY'K^Y5PC M6M3JY?8G@BJH$<^.7K5:,3QY*O\ AA.O<,O38_2^?B3_ ,XD(M<0V]5#N_<+ M5[G6Z>CI+Q.C?
@>M>\Z'L#Q*Z=TOI:TZ4OL$] VEYVMN* M8DB=S2.?ES43F;\+'3A\($LP>-254-;3QU%-.RH@E:CXY8G(YKVJF45%3HJ+ MZSR0 M M
#^2*N$Z%$/D^/R/7G3/6A_^(+X$[C\[?"AO M5;]J;M>[?7VZIKF7GL$9)3*S,;HNUPBHY<87M._/3'Q;E-Z: M[M/2]J9\W] >+> "O"[2>
[_$#7/3TXYM12.3](DZ]G^2F"PQSD8U MSE7HG52NG:=SKUNO;ZB3X4D\U0[/KY'N_A E, !P3B0TVD-=;;Y$W#9VK32
MX3[IO5B^U>7F_;G>SYC:IY.U@Z?\HUOT$3D7Z6*SKZT4ZV0BX0M??B9U]-8*J1&4=Z;D;.9<(E0 MS*L^;F17-]JJU";G,GK R QXGSVMM&6G
M7VE[IIV^T;;^TW&!8*B"3N5J^*+X.1<*BIU1414ZH?1 1,TSO#":8JC:5-&[
M&V.M>"O>FBKK56S1QQ2NJ.+>4;Z%5#G#HY$[LX7E>Q>_**G1R*6:\-7$-9.(MC04%YM_+27:FY8;I;U?E]+-CP]<;L*K7^*(]=Z.1/?;U;-:?
WRT+7:8U#3\T M4^;E:HKTF_Q1SMU>2YDSX'QVU^ MYE@WY4^E.BH]]7-.RGC?++(V.-C5< MY[U1$:B=ZJO@A051-,S3,1'ZRA#-D !_-.N?:&Y3PZ']
!\MN'J6?26C+K>*:E\\F MI85>V""X7JB9=CKRIG^C^Q%./;9\3[;O=CDPK7)E%3N5%(Z;O\-G:^)%57RVI.(UWK6+
MP1?'E[N_&.B'.ZG^,MU4W\6=XIZT_%>Z;.%L_ICH1GX8-5:D=>*O3E6R>:U4L+G?;F+FED16HC,KW(N5]'V=,= M22RJBH6.#E_C+,78IF/I*NR\:<6[-
OBB=N^&<=.'R^OMN-.[G;8J[!]>UP7> MUU"8=#.W*M7PQR9Z.;A4\#ZE.[O.(F.A8Q5-,Q53U:%5$5QPU1O",G#] MP,;;V"W&K=6T-
^N%XF6"2FHJ;JC:U*9KU3*NXK;_KC3.R&H;CM]#++]*%(U:ZGB26:*'G3M7QL5%YG(W/AT3*^"'O-=>3<
MCCJYRUHMV\2U,VZ>4].7*&Q[I3R7JS3/Y6WUL:>FB9^%T0LF1BW<:K:N.7Q[GGBYMG+IWHGG\.]I< -&HL !6/Y M5.5]JK;/C1?2;97.QI%G?
_H.J>2HAY=K9]9R\O1UX;WF\5Q Q? _>"]5MW;: MC1FFMMKF+C[.[.>F/=^2MA1-EM42^+M0/;] M5-3K_G.DFN*M,C;NG^[D+=N:=6F9[_|
";P,)W&3FW7@ M #CO$OP\6CB'V^GL=6YM%=Z=5GMER5F74TWJ7ULSJ[.5;3YRCV*O15PJN8].O7"]%[4-/64=1'54<\;98IX7HYDC')E'-< #26@
T1N.GS\NA=.3:E9J.2P6O]_C9V; M;]ZCC6J:S&.5)>7F1,>&3Z(Q]),3,=&$TQ5[T;M'2LCC5SG(UK4ZJO+1.X]774FF-4VN_5-$N)XJ*I,(YG7'-A.]N?
NDZ'N]4:>@U5IB[66I?+'37 M*DFHY9('J9RQRJUR M([L^HB9P@\;EOWP;3Z5U0D=]UU&Q>3D]&"Y-.F5?"\5^$559[%5O3*)+)%SD MU;MFNQ7-%
<;2W,?(MY%$5VYWB6X /)M M M M !05Q:I.P:"X_;U9J:N6ETQJ;5,=[DKI).R8ZW5M5VDLB/^Y1G-,Q7>"Q. M[62_4L\K%OQ?=3;^ZEVQN=NLU19-
,RT^_!\0?_?&FOO3_/Q@74_C::0^2MD^]T/^]>YH MZ6*DIX]>GB93T\3&QQQ1M1K6-3HC41.B(B(B=Q1[!\'Q'_]\::^]/_ /&7
RT^.M'[#:ON&X&R&WNJ;LL:W6^:>MUSJUA9R1]M-31R/Y6^"._RH=9H#5-]VNVGLE34:WIJIUKGO593I(RGJ,HU&TL'59I
M,KA%>G+S(BY+3W*=9:YK&N:WF]%7/* M]W-GESE]B*C5RU+[M%\-^W.@\]>7_6]HTM1MUA?*N6MKKY4-6:J5\B^FV-[\ MK$Q?
BLPBXZY7J5K^7#_+%VN_4JL_EF 6>[#?E';=_K=MW\VC/NSX38;\H[;O M];MN_FT9]V
,90A[OSY3W:WAYW4ONWV1+%K"MO5H]#SBHM=%224]NU@CG;RN M?4LUC2:BJ]>7S6JN=)21T\#D;]\
M[G,J7NZ>&&KE<9Z94#O^\W$Y;MNZ]:SV>GCO-\C]&5'.5(*9V.YV.KG(N,M1 M4QGORF"I#6^T>GMJ::UQ6**H1]9VGG$M1,LCI.3EY?SJ?
#=W(G>25FFDJ9Y) M97NDE>[F>]RJKE7.5557O4X]Q_"T^GMG_\ U99Z=_$1^?Z*C5?X6K\OUA/7 MAUXD;9I/2^FM"WRD;06RSV^FM-%=(W*J-
BAB;%'VS5SUPSJ].F5^"B=26TQ[7LOS?"9J&43P:2& %>U7:MQN'R\]NGGEG1SD1*B%4DI)\+T15^"[]*Y,I[#
MN&VW&/;KIV='K&D2UU'1/="D17P,_3,ZN;]&?H)'5E#3W&DEI:JGBJJ61O*^ M&9B/8Y/4J+T5#@6X_!_9-0=I6:6F2P5[O2\UDR^D+3>]"
M^7.T,5=;JR"ND)$RR:GD1[`?,]+@\X ?-ZNT'8==6[S&^VR*X0M^ Z1JI)&J^+'IZ M35]J+\Y]((@;@<&ERHJA9](U[*^DU<+\Y&QS%:Y[7
M+E6KZ\]V4^92']GK+0KW#+4V6XPTZJD\E/(V-4\'*U43]TJ]D:Y)'HO5<@8 M`6>%9BNWNL6%;TCJJK^U4 M_3\F?;DH*X&-
&V+4M1K"JNUHI+E/1I2-IY*J)LG8D)V_/RHOSZVWIP*5%934M10PQ1KX-YZO'7YD0GHWNQ@L\R]3D7 M>UIZ51$_UB%/IUFK'L=E5UIF8_I,MP ::S
>MO]1YG8;G4=W94TK\ M_,U5(;"0]IN'2N_M<$KO\E4_P Y.W<6I\TV]U3.G3LK75/^]%RD'>':'M-< MU#O[70R._P IB?YP))@ (O;]V>?
0FXSJV@5U,DLC;A2R1].1_-E<>U'HJ M_@GEH+5<&N-&VB^T_*D==3ME5C5SR/IG_.8N14^@C%OUI;W%VS1>HFW7&\2I MPV(WFU;P=
[P5UKO='51V]M1YI?;(]4RJ-Z)+']RKT1>9KNYS5QG"Y2:O$MOY M3ZDT[9;5I*YQ55EO-"VX3UM,Y5[6)RN\V-?%.K5YFKA>Y%QU1?<|9_")3[\:
M=6^;?BBI==6V)4IY'*C&U\;97L'N\%3KR.7HBKA>BY2M':;6T^B-11VR].FA
MM"U*1UD;VJKZ;JB.>B>MJ=>7QPOL+^Y;HU&WVMOWXZQ\7,V;MS2[W8W>=NKI M/P2DM-9J;;^XVF^TCI[7-41MJ*>5]X;-
'E/1L,R(BJB>MJHJ*B^I>O5%0XWJC3MMW#T*VGH):>>GF@; M-;ZF)W,S/*BQN14^Y5.F?4JG,NTV@=S6VFM>Z&@NS_;B-Z](YD=B)RIZ
M^;+/8CESW'/3&TS$]761/%$3"=H,90R0D :&X`\&-1N51O7ZCT^K-4T
M&CK)57:Y2=E1P(BN5&YXU[D51;GLHY]SUM\,W([3W>]ZK0>Z^G=PT>EKK/[
M*C3+Z69O)*U/7CQ3VIHJH?:Y1$[T(3;@;4:BVAN[+E13324$;\TISL_0=&OQ7
MX^"OM[E\.]4.X[#;U2Z_Y[)=852[TT"RK41[&3L14:KE3[EV53HG3U8[CG\' M5JZ[WX7+IX:^[X2O,S3**+7XG%JX]._XP[0:*K@(M.[DU7 MJC1CZ?
3VKGY/-K.6DN"^WAYW4ONWV1+%K"MO5HJ

M<&VX7NOI[NTI5R*M3:W=O2\RY58'KZ34_2O7ZI&H!#/RG',G$72&5]:YZQY-N%T?#);W.7X=R]W)\W/C_,=#>KX]-H^[MDL:WP:K<^VZ4]=QD YYUH ?Q?&DC%:YJ..J85 MKNY3^P J\XXN#.HVWN59K_0]$YVE9G]K7T-,WK;9%7*R-1/^15?VB^S&.K<# MO&RFL4H=O=?UN;\B)#:KQ.[_ \GHB M;/!(BL?'(U'-]%1>]"K7C;X0)]E[V_6^C*:5NC:J5'2Q4^>:TS]O3KWI$ MJXY5^Y7#?BYO\>_1FV_PU_KW2Y7)QKF!
<_%8_N]\+5$>F.\RA"S@FXUHMSH: M31.N*MD.KHFHRBKY%PVYM1.Y5]DF1$Z_&3NZYS-%%Z=.I37K%>/7-%<+_&R+
M>3;BNB6Y'[C*U9[C[ISY'93'Z5K3Q,;'#GIUL6F[G[]J\OT.145/5\Y(3;BVMM.AK)3\O*J4C'O M3\\Y.9?W54]1O!HI-7Z3E[%G-<*'[?3X[W8^$S]DB?N(!(/;G6M)N#HVVWVD M5$;51HLD2+UBD3H]B_,N?G3"^)20SX.QW6?4]3I*KFQ17-.%GI6N[F5#43* M>SF8GUM;ZR9?,GK R ..[]<,6B>
(.V,BU'1/@NM.Q64EWHE2.I@ MSE<9ZH]NF#;MY=VW;FW$\I5US!LW+D79CVH8141.\ MX%LI;S9Y9OML=#3I35-$BKU2-,X>B=?1?
A5\7H18Q;N1%4V^YED9EK%FF+G> ML|SWF$7*=#Y;0.XE@W/TO1W_ $S=(+K;ZI%Y)H5[G)WLK7)XM7"H?3^&. MY35FF:9F*HVF&Y35%4;T\W]
8,AF M M 'Y_N*R*\ M\1G'!JJ3=#/S7&X;J33%&L[E[.!(I&TC>G@U%C5RX]J^)^@$H&XC[A<.&GRA M^IM3^:/J)[7J]NIHH)<(E1%-*VK5B.QCE3?3;&
MSWRKN,URG2Q05]2QK9)/.99:F]PU/@L6-)V=K>9.J(]R,CRG5.T]T[TZ;Y0SCCM?%Y<|)4>F
M+7<|/IFQPR3.BNB1LFGJ>5'*K8WO;RL;Q$:NM%7K;V@FM%AO MT=335%NDJI*AL$\/9JCFOEIU]P=[77>LDDEJ M6VQUO=)
(F7.2EGDI6JJ^/2%.OTJ57^4FXS[#Q4:RTW;]'15?XD=-1S]E55C%.MA?6SS*SGD2/.48C8F(WFP[TGY1,EK/ ?H*]VWX1]KK'6Q/@J?E3%*L4JLD:V-
[45J(N)%I).J+:*Q%R1;\H-PP;JXK=FK M-L'25=9[=<:*_P -UDEO4TL4+HF4I5$Y$6.*1>;FG8J93&$=U!LS$S3.\.;J
M8JC:I3[9=8VW54U3);X)*"/GAO5QJ9%1TLTT].R7"NPGHLYU M:UN.B97O5RK(#'>4.H9]655-%/*F'0:7IM.)3QU\ZI\FP *AT M M M
/!N5KI;O1S4E=315M)*BMD@G8CV/1?!47H1\W(X.;5>. MVK-)5?N/5KEWF52JOIG+['=7,_RDIB$D0!7NR?<;AXO:M5*RS=H_X+OME)5+ MZ_B/5?
7\)$1I[;U-BCLL#F*E;YD]W)DN^=>K6XZB MX5K9%Z=_KPB^&3IY$[=KA'J5]*N[:+G29LCG2.M-0Y&N;GJJ1/[E^9WAX]!* MYKFN:BHJ*B]45%
[S;*$!]!;WZVV9N7N36LGGHH'6@M]57,IH7/F=3P.D2-%[EO12B'R?>.SU M[\]#U\?_ +H-7(S9TZW.53&\T[^/A4ZC5.+,[15$_R3]\E5!R;9ZVE
M5%RZ[QM_;PM7_P!XFU6W"EM*S551%31YY>TF>C&Y]65(E^3EIEBTQN>]J?,-7"KNY>]%1>N%[VKW85,$\]
M"ZRM^OM,T5\M/Y^JN_]TXSPU0\NG[S)\;J;WZFY_S@=A #^%=0PW.AJ*.I8DM/.QT4 MC%^Z:J=4^K/7UG]P!%S3-ZK]CMUX:MS72>83*R6-.GG%.
[HN/G;[*>I43U%@=M]JNE)>[927"CE;44E5&R:&5GJ_.WO^95/L>#;CU]/8IM8^17CU\5+2RL2WE6^"Y'V^BK39S=JLT;>*
M*FJJI\45/.V2E]'+UII6JCFY7XJ+Z^[HO<7,[?ZOI==Z.M-_I5;V5= V1S6K ME&/[GLS^=C+H[>
MQU[X46+E7,"Y^&R>G=*U@PJ'AV^OIKG10U5+415-..Q)(IX7HYDC53*.:Y.B MHJ=5]RIJ<[T=3$\4;PW 2
T3.$P>HU#INWZFM<!:B^!4ZIX'N,_4&Y3.>X\Z(KB:.HWB4TU33/%3.TPY=MUL/9=NK
M_4W6CJ:FKGD8L423JU4B8N%5.B)E>G>O@=/5[6]55$3VJ93K\QZ#6[CGU)I. M[6NFG6DJ*NG?"R;XJN3'7'AZ_8:]NS1BVIBS3M$=SWKNUY-
R*KM6\SWO:TEQ M!J]BOIJB*=F<*;6FQNHW=)K=(Y<*UZ*^GJ6IW>QR?, MO.F?
D;M1OY:]P)8[=5Q^YM[DW;%';6IXZ/C#K2M]I\QN'H"S;GZ.NFE]04BUEHN.?9S1\RL=T+L*F)$f\=*'QFC-G=$;.?7
MBONFFM*VNR7*N3EJ*FBIFQN>U51RMZ=S=VUGL[T;U=T]ZE MMZ=5CWXN8]6U/?#[A%1?$RB^T]7>[U1;3.(XV-5SW M+
[$;BKT]1QI;#C*VQWGOLMDL=XEI+LCL0TESB\W?5)ZXLJJ.[L\N>;'7!6Q; MKJB;J8WB%K5>MVZHIKJB)EW9.B!5Z&$=E,Y13'7'<8-CZMP
/$N%:RW4-35 M2K]K@C=*[YFIE3RSXG>>Y>Y.U&KJA'-KD[T5[58B_6Y (.[-POO>Z- M#/-Z;D?+4RK^>Y'?^\]$I2.W#?1)-]RX52I^0T:M3V.
<]O7ZF[2) \>OH8;E M0U%'4L22G]&.C0:OBU4PJ?PJ1CTQ>]_9#=>"JI<$1#BW$9I3MI.CU!"5[9"OFU2K?%]6*OTY3]DGJ ^(\]/K>S7FV[>VN
MAN$%75N[:Y]G$[+VT\C&MBD5,=&O5'87O]%3N_DYX4CX6[[.>TK*UR_XP]/ M\]Q65OG=:BZ:Y5M0]TBTE)#3,5SL^BC<36<*>DG)WOFK
MG+_C[:56^NIHJRBJ8G0S4\[$?'*QR8Q,8(C>)WACM$QM*I[C$X.;CL->5UCH]M1-HR2=)&NCJ)'<7=S8W_%FQX]SU]3E1
M'3,N%NIKO0U%%5T\=51U$;HIJ>9B.9(QR*CFN:O145%5%12KCC7X/ZC9*\+K M71E/,FC*B5JRPP*Y76F;FI%,]_9N7'*
[[E<-7[E5Z&Q>MYU$6+_O=TN6R,>[MIUS\1C\Z.^%JO,GK*_=_:QVJ]H[_ !1N5V:R*AC3OPK&MB5/VR*OTJ?5<&/'M%2[A04.B-?5K*;5;
<0T5SFI_Z;HOP.C)EUAO'35LGJ.] MKG+6NSZ5TN/W"GO8]=BN:*XYPZ#%RK>51%=N4HX(VT\3(V)RL8WE:WV8PAN
MO=W>Q0#7;:+>XEIJ=M]RFUEM5%SR.[GL_8N14^@C#OMI%;_I-+A Q75=M7MO:Z)?AI]"H$L 8RAD M_>&%(W<37!;I??R@FN%'':IW6+/2CNT$*
(VH7XM0U/AHOOOA-Z=Z9;LD40> M"GI:NUV:HKHG;6M>L6\BG@N1O"L'AGV!WYV5XA;50QVJNMUC6K:EWK(94?:_ MJD1?
27F^"YW+GDRB/153HWJ6=)GZ3?NR8#D12;N->L1$U MT\BQFV,B9IHJYQW/LP :K? M M BEQK97)#/'E%69[ER^61WW3W.555>B=
<(B(B[E8T_E0\ 5+YG=CM?09XXEZ(R2 M[2O2O<*LO.7(G*R-6HQ>1%JM:Z[7;3-LKJV]5K6K-42TL3V(]K41$5SW*O1$1,]R =) M BIY07B?
U3PI;,V75VD*"SW*Y5NH(;5)%>H9984B?35 M,JN1(Y8UYLPLZJY4PJ].Y4E&1\XT>%1W%WM;:.]&?BH_$EYC>HKOY\EO\|Y^2 M">+L^3M8\96?
FYL_ FW.LM',O_*PN5>5WSI\ M%?:F"R_^-W"\RL>YUG]SKY2]HC%5T-3'ALL+E[U:Y47OZ914PN$Z+A,!6]W_ M %X!TS?
+9=^S]SM\"71MSI:]DCX7+%V;VB'WVQ/##0ZZT[M:]47]YR+;ZESU:;].E<_DDY,X7H]
T]9K+8/1VL[':);5%0+2Q]G2U5"Q(Y84\$SCTDSE<.SWJO>N2)^X M.R&LMEKDEWH)IZFWP.YH;Q;E:"&MH*J&LI9F\T<].']L< /2
M7/2=DO573U5QL]%7U5._FAFJ:9DCXNN?154RG7KT\>OM/=80R .)K<3%NVN MU?%89+/47)Z1LEJ9XYDC6)KNJ(U%1=><=>JHA]]H'Y%O\YL-
QCJ7-;F2 MG>G)-#GX[.]/G[E\%/3]I;&Z=W6C[6Y124MTC9V<-QIUQ(U]95&JGCH_P!.B+S,7U^"^M0)\@YOL-J' M4>I]N*"X:GA='<'/>ULDD?
9OFC1<-D[N3HF?$Z/S)ZP,@QE#(M!SK?#J2BBKY754=-V,SE:W#FN7/3]*<$^S>OGR:M_\ TSP)@A_ M]F]?/DU;_P#IGC[-Z^?)JW_],\"8 .8[#;K5>
[>EZ^[5E!#;Y*>M=2I'"Y7(M])&QW-E?TRG3@ M &.9/6!D M 8YD]9D #',GK,@ !_+OZ>!1#Y/G/9Z\QZZ'_ .(+X,813\TVRURK+;=K
M@M)5STO/!RO[&5S$5.9.BX7YS6O8%6I6YQ*9VFK;G]IW>MG.C3)G+F-XI[OO M&RXW@GU-%I;87=S4#7,=L#5]
<,;S+CV*K_P!WPKEGL*IM^'DT<:[VUKM.^>?]'U;\ M&A&ZQTO*^GA1USHT[6GD]$3TF)\Z(F$];(?,\(FZ2:396%\R>LR?!;+:_9N1MY:
[NLB/K6L\WK6I]S.Q$1_3PYNCD]C MD/O0 "/_ !I5'9[66Z-.^2[PI]'93+_F0YOPWQ(W1-:_Q?7N^I(X_P#Y MGWG&W+R: L4>>CKGS8^:*3_2?%\/.?9Z
D7'PJR1?\EB?Y@.F@ _G4 MT\=93RP31MEAD:K'L=W.:J85"+E1I;*;GP5=$YROHIDGIW.7"30NSE]^M'(MKFK[V &'-1S5:
[JWQ3'3V_/T\"OGB:V#]Q]7 M7*HLT'+(J5]&T[4PD\;LX5J?&3TFKZ^7Z[!SF>^VC_=_2Z7&GC5U;; MK6*B*Z>UN5>]B?
=1YSF/PZN;URUU]&E]36S5]CHKS9JZ&XVJMB26GJJ=_.R1 M]JRHO[BHO5%Z%8$?#[;=ZZ>Y6^TOCMNNF1K4VYSW(R&X\J9=3R>I^$RQ_=T<
MCLHJCD^ZDAYQ@O\ 6U>CD3KA M<.2XN6+6?1-W'Y5]\?%SUG(O:,7V.3SH[[^"X#O"I@^3VYW(T_NIH6DU%IFY M17*V5>C)$OI-
=XL>U>K'IE,M7JA]7S)\9#GYB:9F)CHZFBJFNF*J9WB6X (M9@]-?]:6_4UMEH+G0QUM+)*.5N4]BIXHOM3JAS;2G#A8]);RC MOE-
6U4C*=SI(*21&JC7*F.KL9:5W"L7JZ;E=$35 M3TELV\JJ:HJMT5S$3U@14:AXL%QI.J26.*HBD?$O*JK'HJM7U*G@;U$;GP2- M:Y45R*B.3O0A/J?
0.M]IKK-<4?511M>N+K12+RN15SEZIU3VM=W^TTM1SJ\& M*:XHFJGOV[FWI^%1FS51-<4SW;]Z;R=V:S>-
,W&C1.OP6HG:HBXZL3*>+>BJ6HHF($U5O,BY3H7>+E5XM6]/3X*++ MPK>73$5]8Z2K4X/N.36L6M[!H#6CI-36^Y5<=NI[A-
_OZED>O*SG=_RK,]%Y MO21%5>9<WP7*^+9LBIXJ9(RP^4 VG_'+KM'U=;76Y M:6H=2>[-7 UM"Z5KE;Y.=*YK)XUV;EO;CIVW;-
N_:N[Q15OL\LY/Q25WF.R.HD1<.G6"%/ MIF9G]Q%.K]Z'!>,RO\UVIIH$7K57.*/'L1DCOX6[]9YMAQ;AEIO1U#4JGC#& MB_MU7_,=Q.2\-
M+V>DKE48ZR5]L ,:L8O_O*=: '@:;@LL&H,)6VVI3[351.C7 M!\'*='?,BX// %4F_=@KM/[E7*GKH71.;RQM=CHY6M1%Q]*?4]%HGD_FJG"=_MH?
*8RZO7_P!/J/\-@A;Y0VSTM'JC2=="G)/64]0DS6IT7D6-&N^?"X_8H2Q M\G3K:"]>ONMJI;S;JJWU-MU-
'6455$Z&:GG8CXY&.14Q1>@QD1RG=C.1,:2]QXR>'\#GCD MJ=9Z&@GJ']N>LE51(JR2V%2C9ZJZ+U.7*L\^@M>O;52:KK&TC$8
M^&"Y3.PSF5JM:V55Z)W_ EZ>OUEHV\-0VEVJU?(Y$_X*J6)E.F71N:G[JH5 M'ZRV#K;M372\Z5I'5#*&+SJKM\:>DV/*
(KHT3OQG*IX8Z>HZ'&R;>51V&1U[MI9B2130N1S)&JF4F>??'P:NC,+&YCVHYCTY5:Y,HJ>**GS$6KU!6[/;HQ MU=ORU;*I;5TBNSB2-
5SRK[%17,=])*PT%WH7]I25L+9XW>I%1%POM3JGT'MB,7!EN,E;:;_ M1U7*O;T:K54*.7OBO-^S7P0DYE ,@ !C!D 1OXAN"
M/1&^ZU%VC8NF=5O3/NM;XTQ4.\%J(^Z3P])%1W=Z6$P0:L.PG$#PX[QV^#2U MHN4U?-
,V.&OM+7RVZMBYDVR9R)RM9XJV5&XQS>"*6Z)]9IRY\"QL9]VU1-N? M:I^$]>_IMJ]O Y]D]9@K_XDN.O+1%5SHL!YD] M9L<1V&XL-
";\VZ%+3<&6V_*F)K%7R-94LER)G$K4^,W/3&41>AVI'9[CR MN6Z[57#7&TO:U=HO4\5N=X?T !B]@-M M _/1QV
MNFD1URKM6.TY1^<+RL:L4J442*N5PW[6WKZNN/_0N?GYXQ;5=-@^/+6%WCI MN>HIM3,U51)4-7LZA)96UC>OW34>Y6+CQ8Y.]%
Z=QG>33;PN;(6K6UNU75Z MJJ(Z^*CN[9*1E/#"V1K^65BT1K,*JKF1%Z=3ZKA&\F;H/B>V!L^N6Z\ MO-
HNU3)44M91PP0S14T\4KFHF.BJBLY'X5F[)_G"K-P2;XZ8IMP M[=#N#H*MD6HCEID*++W3IF*UL\?H/YX9F<[5PCU3TF+E454+U]J:O35=MEI*
MHT8D;=(26FD6SLA148VC()O8M1'=4PSE3"]4QA>I3!Y2'C>TYQ57;3%FT=;: MR#3NGE]?
=&X,2.6LFEY&KRQ(]\L;6QICF7F57=6MY>MG'DWX;E#P4[7,N[G MNJO.JAS.T[^P6KG6#'L[+L\>Q$ DL !%OR@ MW$_JGA2V9LNK]
(4%GN5RK;_#:I(KU#++"D3Z;IE5R)'+&O-F%G57*F%7IW*D MI"/G&CPIKQ=[6VO1GXI_O)>8WJ*[^>I,_/.?D@GB[/DI6/&5GYN:/W.,=^'R6T:]
[Z[^F$4=E?R2Y?IX?X7%@?O&/Z-O[T_ZZ5^;*_DER_3P_P + MBQT_^(C_P!%7J?\))7^7ZP_0'PH?F7MGOUG6;^90G5#E?"A^9=V>_6=9_P"9
M0G5"OGJL]>@ "&0 M M "}7"'' _)Z1_O-_M3_&C.P<++GY16E/\ I)_G4IQ_CC_X3TC-_FI_C1G8.%$\HK3'_Z3_.I0.JG\ MI(VR.QR85KDRB!\Q_4
1[W7X3;1JKM[EI=8['=79U, <_P!I^(_3FY38]*61+-?7>BM#4/3E ME=_X)_<[YEP[V'7B%VZW"9>=,.EN6E'2WNVM]):3">=P_-A/MB?I41>[IXGB
M;4\5%^T2YEKU*R6^VMF&QWUIW 3Q>K5]BGT@ U[T[O V &O4Y-Q$;GWC:S2%+<+-1QS5%54I
M3NJ)VJZ.!%;JY5$5,JJITR=;/"N%NIKM22TE;315E-*U620SQH]CT]2HO10(
M^;?\7\7UKOCXZ'5\#++-6.7#:V%'+3.^=%559_5/:A(>BK*>X4D5333LJ*>5J/-MCFB>CF/:OVK]&3MMU2N7.ME2Y5@?^DKE/,X M6-
O==:#JU'J"'"6@LSE(R*CEE:I'3(\D8B.7"9&5$7\ZGS&XP.W2R3H/VKO)T 5XZ@-MT_;7?
NHLL5)&RUMOI:9*5N>3LUF1.3YL*3._&!V[^2=!^U=_I(@ZH_-,U/Z MYF_SA"?P'HM+:-LNC*&:CL5NAME++(LKXH&X17JB)S=?8B'O0 M
QS)ZQS)ZSY#YR9I,"GC7[9/)C*-,]'>O@16O7 M&5K.LKG/M));;92OT(@$V01HVBXN&:ENU-9M6TM/:IZA[M8X;A2*Y(5>OP6R-'2\TJ++/I2EAN=5
M3NI,:X52JZ:''^+6M:J*[]-E$1?!4.=6;C,UG15C7U]%:[C2]_+X^Q=$_E]37 M([HOSHX";(/D=MMP[7N7I>"]6M7-8YW9S4\BIVD$B(F6.]O5%SXH]*?7
M-M !ZK4&H+9I6RUMXO5PIK5;J*)T]375LK8H8(T3*N>]RHC43UJI2MQW^48O MN\^OJ>U[6ZEO&G="6?
F2&MMT\U/4769>CIG\MC=>?;/A\DJ]>W+5NH:6X6.+M;C>'M1>=\;L+V4.4/*B/]'< M2?(F[34";9U[N7/\'-E!&R-D\Z-7\^LT&?[TGK4L_F?H K MV\G-
Y16Z;]7M=N-R9:5VL&P.FM=XB:V'W4:Q%62)\;41J3-:G/EB(CFH[T4Y MKU:C<-7K]K7OP?HQ=WX*(?)]9[+7N>[^P/_ (@TLS,N
MX%BK)L[<5.VV_P!9V;6)A6M0N?AKV_#.^^WVW2-V^]5H^';25GLUKC#YEDF=[CNL:.7LH[MM6JB>I72JJ_N8)T:*H?
D4U=H^LIHX^TK8$\XIL)UYVI\%/G3*?2?7 \VPXMPB[D,TMK* M?3E;)V=#>>N5L3GKTCJ4SR)A?C95/:O*3;YD]97QO;HN32FJ&7:A1T-%72=LU MT?
3LID5%Q.X_XYFWE#@ !,YW3H !&K>K1 M,FD=3,N] CHJ.LD[5CX\HL,R*BN1%3NS\)/1]1+?83=>#=/1D<\KFMO=$C8K
MA'W9=CI*B>IV,_.BIX'Q&]-.4FK+'56RM;F&9/1=XLB=57 M?8GOLUV1-06]DN=#,V>CJ MXFS0R-[G-5,HO[H (!<4E4ZNWQU QJY2
M)*>)O_01K_"JDAJ:%*>GBB;W1M:U/H3!&_>QWNAO[?F[_-AD 1:W L55M?K]E7:WOIF-E;6T$C5^_].SRHOYU
M45,>KO[SMV\'#GI+C'VXMVJZ#L,)K\U,G87.-N4[1O1U/4(G5[$61CDZ(N,\LCJ*F4+1=AN(72G$'I7W6T[I5
MY')XM7"\KTZ+U[E141OGP]Z2W^TO):M1T#?.XVKYG=(-M$1*JD=ZV,\4SWL7T5QZT14]YU/I?
9JX5%^'XOO]+4]=X]FY'FYJ.WTFOG[5N?)V1]#3JC8\N1M$5/-M9@ZVQO(B(GSC6L>9FU3$;]7K=OW+^T7:IG;H^8KMPJ.VS4$-M=DJ;Q2P723"-
IWO]+*_!15[D5<]$7JI](CD5O,BY3V$;=\M@+M=+Y7:DL"K6-MK4X?/0N=B1'(B(KF*O>BHGP>],N,]$3X#1>^.K=N:I:&M[6OI8?0=0W#F;+'
M[&O5.9OS*BI[$.?KUBO$R*K>7;F*=^54=%[:TFG+L1SP/0:-M(U13ZSTS07FFC?'#5,5>21.K7(JMJEDJJFPU3T;!,]RJYW8/7\C5795&.R
MW*]%8B(A&':;B:W7X4[W+IJHAF?;Z:;^R=-7V)Z)'E?2[)>CHE7JJ*W+55DO&CK#J*KHJN[6.W7*KHG]I2SUE+'*^!WQF.JJO*OPD15^

M$U50[$8UV]K=7#7&TO2U=HO4\=N=X >4/57UQX{@4FI|S*+3]-#(V33T+HY MZAR^B^25L|8{):ID[N:*,+K^?F8S_WB,?#+M3Y]]03XQRLA9G/QE>QUX:F20'%U6^:[,UD6<><5E/%\^'_ +AQ+AHIU;9; MU48^'4,9G]*S/_O M/*O5>&]%PYT;5ZIA<\S%Z=^.O?8ZM<$XBN%.U;R\UZM4K+-JQL?+YPJ?:JM$3T6S(G5%1.B/3JB=,*B(B7V+FT7*. MPR.=+F\OKMU_B,3E5WQ\7;M.:DM>K+/376S5T%RMI0WFBJ*=_,U29GO147H MK5ZHO0\RII8]VEFIYXVRPRM=&]CNY6JE,%8NAMPM>*NOJJWU-++3HUZ)7V6 MKBOK-7*PJK'M4^U3/26W@ZC;R/8K]FN.L2XG'/<]D=TH*NGRZ2@G[6+ MFZ)40.RF%]BL54]BY+ M-:AHM5V"AO%NE[6CK8FS1N\<+WHOJ5.J*G@J*18W MRT1^*33;KC3I\UPMR.DZ)UDB^[3Z/A)\R^L MP<[H)2UE3HFX2XC]%=4VY7N M_P"4[Y8_I3TDIJ.\5*MJ[6VH?&B^;5\.&55*Y4^%')A53]*N6KA,HN#I/0RGSDT5543%5,[3#RN6Z M;M,TUQO$JJ-U_)N;DZ(KTJM&RP:TM_:(L;H7MIJR"P5EK;K6K6NU-343&5LSI.U=SHJX:Y_P!VYK>5JNRN5;JY7O.A M)\YC/M-R_EW,BF*;G/:O;._@6\6J:[>_/N,],\(J>M"&GE"=R]V-MZ'3-=H:MIK+5IU.T6Y7&WPM>K9LM[-LCE1>1N.,'@JJJ+GH<^V#\IJO-26?=.@3E5>S_M!1V^/I^FF@1/K=`^T,K>#=N6NUHYQ\.]AV3)F.JHIFRQN]>`-5>J+T5/`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|: M^2B =']CF3UCF3U@9 'H-9NNT6E+N^Q1+0)>6TDBTC51.LJ-7E3KTSGNST(: MZ2XE]?: OD]/?Y){Q$V3EJ*&Z(K)HW>IKLPG2?%;_P!I=,[ET:Q7 M]WM?4-;RQ5L"\D\?S/3O3\ZN4]@'K]M-|-+{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|MP6+^(A&+RMLBMX,K)C7*G-=*!%1/'[=G? [>!+W3?_%VU_X+%_$0C)Y3G24^ MK,"[$:;VZCK?Y.'_ $$Y MBO7R+&KH+EP|ZLT\Z9KJRTZC?.L2={89Z>'LUQ[7Q3?5["PG* 5 ^6[H8X]T MMM:M$^W2V:HB=3SS/;$O7O5CX%1/S_S%R>GK2VPV&W6R-W,RCIHZ9KO6C&H MU/X *5>(3RC/$1HC?O\Y|]Z1Q/?W3Q_4%K_HQ8YN%Y((9[5TKVL1UCY48BO7"*Y5QC*KWGH?>4MC_)5: P#OA0_T,"_*>5'X MGE__F?^H+9_1C^GSJ^SZ89K=+K<8:%96T;XTE=A7HWM^;E3Q5.9.B>LGS M[RKLAU7\5.O_ +X4/]#*H=GFHDUQ_E<_I])87!&E/!'$WX+&HQ/H M3!7WP|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{#?OYMU61;BBN-YCO[U=BZ=1C79KMU3M/=W .0<56I-9Z5VE]*_139FU\=2QM544\7 M:24]+ARO>Q[YPO,D:*N,HBJO3&4C?L]QY773\;+=KNCDO]/GT;I2(QM4U/4] MBHC9$]OHKZU<19PKMZUVM&WV[V61J-K'NQ9N[Q]>Y\1QH:&K-)[V7*X3RQRTMU\8E=3\BJCF(C48YKD\%1S%ZIWY1>_)-CAWHH*S8#1M+-$V2";TQLD8[JCT< MBJJ?2J]_@0PXRMRM.;HZMTU=]-7%MPHDM79R88K'1N25Z\CVN3*.1%SZERA- M[A]:YFQ^AFJG+_N/3.^N-%+//XHPF<5\I4VF\'X^[P3O$]'%W27/9#@UGIZAO5ME26GCK(DE8[/5N>]J^I M45%14\%0C5NYMTFM(DM,B)=J-%? O=VB=[HU^?'U_.I\7PS[QR[=:G73UXE M='8[A-V;NVZ>:3YY4?U^"U<(UWJZ+X+GFW7)R M CYQK3\FV%KB1>LEWCS[42&;_J',N'"/ET36O\ C5[OW(X_])KMQNU"MT?IV'X]>]_U1JG_ +Q\KP_0]GM\UW]LJ'?Q4_S =*./N^_W>V2TWO M/8?,+Y3]G50HOFERIT1L],OYU?%OK:O?]"*D =?;::\X6-=T=QI:J6%K7]MO MO=(U4BG;XLG M1<]Z*B]RIU1>J*B]2TQ,ZJQM17SHGN4N;IU.3OU]]?F5#AN_'"5]':2KFU#I9U3=M-PR=NR:'*U=!AECHI[K;3BO75=D71VYDS9H7M1M#J3D^V4\]=&=NB?":N<*],J955YLY M3:R,&F]3-_%YQ\&IBZC59JC'S(VGNE9;LUN;2,IZ,I[G$C8]V/$-=3M7\CF1 M$SC\ZO14]BX\%/OTZ(5\[";G/VHUXR6IEY[+68IZ[LG\\?)GT96JG1W(O5%3MO:KL9RA/^">.IB;)$Y)(W-1S7M7*.1>]*B^*%#M,&Y3NC5P5<-.H."'2VH*74=XI;A77;JCF2GMSWOIX&L:K45'/:U M5<[/7T?N6IE22#GMB;Y5=A$[U539&X1?F.8\26V|WW8V5U3I.Q7!MMNMQIV- MAF>Y6M=RR->L;E1%5&O1JL5<+T=W+W*JKF["W&_#')T6@KZ6MZ4C*JC](:J"1,LEA>CV.^94Z*>4WNZE,-DU?O3P:ZE?1?[I:85TG-);JYG;6 M^LQT5S4ZL?W)Z<;LXZO:?7;IXZ)XJ?HKL?5+5RJ+=R)IJZ;2F*#5OB8MQ[2K7C<&/[,@ M M /F-QM$4FY&WVI](5]1-2T%_M=:B;FY4D9'/$Z)SF914 MYD1ZXRBJ

*'\|+X)C|T#\KW:*GW0[5WQC]4I^55R=Z-54^H@W]EWN)_WS;_|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}GE7V^I?G3N7I\;P\[X5_M&U][=9+T^3\3U3,K)&O1WHVF6\-EOUFAY]]J9MJJ=B=9D3{IJ}!UZT\4]J=0F;!41U,+)8GMEBD1',>U45KD5,HJ+XH?W(9\,'_M$5^)*2GTMJ:=5LJKR4E=(O6DRO1CO_!^U?@Y]7=,B.1LK$>QR.8J91S5RBH!_M_0_#TVK:GS72M[FSA(Z*=^?FC53W)\KNE4>:[9ZNF[E_MCM_6Y/_H7X_@UP_Q=IN%"[^UTTW6JG<(W\,,/;:XJW_!*"1W^7&C^<_MD@_-98V31NCD;DC\)AS?)E'}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|GXOXZYT:2ZWI,UOJ<,?\.":'Y%(GW7S+UZ>I5._Z,UCJ78/6\KVMQJU>C*NBD7$55%E51<_-E6O3JB]_3*+)\^)W2V[CUW9<0HV.ZT^74TBX3*KU_M5CE\47"?,J(O<7*H2)T9JRVZYTY1WJU2]M1U3.9.[F:[N#D7HI]0#V/_MWDN&S.I9[?QV_L+5Z?V(QWUG_#G/>-*H]3=6WL15Q%:86K\Z_MS3,_@5#IVAH>QT788_%M!_B_/V;<@>Z_/5ZFTS;=86.LL]W165EOJMF*R6.1]*G?E%3VHJ(N?6A[0&5/*=X1,15&TJX][^&"IT1?)V6?THW(LL,,B^_MC+'G[AWQL][5\<|>XSL)QC;@\/-3'9IG.O>FX'I/;7VAZ37-DDHZC$=0STZ:IQET3\8^E%3HOK3YDQ$'66W%$VZ2VG5=I_M5[X?1],HK?6B]QRR8XJ?CWN>R-+JJJ;$GAJ_M^'9,+U*9M_M<<.^N-H*6GW_T=7U-YTQ$Y9Z?45H5T510JB=4J&-7G@>WJBJBJQ?C=40D:PX_M>4H9%%!8|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|>'_O!3ZK9YRJ*(B*8B_$,@_!ZG56EZ'5]FGM_MUPCYX7X5KF]'1N1.CF^I4_=^E2-L\.HJC-<4]71U+H:F'TX*AJ?:ZB+/5KD]_M2XPK?H2DJ#T.M-&6_6UG?0US.5R>E#4-3TH7K]TGL]:>H",>|NO:J=5Z9)16Z/L[?3,3[F-B=?F0B!JS1UQT;>)_M+=71>EG,4C?@2M\'-]B^*>!,;-O9M1J?M,B]T;_/P;+W+|SGXN.7JB?=>,>_|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

M0?"=!WS1(J^")\)OM[_G|SZW9SBON.F&P6G5]2W:U-PR.N;Z533IX(/|Y(U/_MVR>M>B'C79MW/?IB7I1*+U0]JJ91A=9N
M(37>F*AT536)6HW"+3W&#JG@N53#L_2=NVDX@X=Q;TMHJK8ZWUJQ.DCDCE[6 M-
^,O=U[N\Z/?]&635-.L=VM=-6MQRHLT:*YJ=_1W>GT*>LTKM3IC1 M==-76>U,I;J1G(Z7M'O7']3F5>7Z,%!BX&?C7HVN\5'U7>3FX.39G_1X;GQC
MH^QRACF3V&K\HU>5? B-N5K#14145N<8 MSGKZRVSLZ,&B*ZJ9JW^'> M#]>/GS--J><<|F67!U_"B)NQRGEOW/H\H9/YM5,*J_NFS7-=G"HI;
[JUL8RA MCU]?K,$C< 5Y;U=YYQ"W9,_FU&Z/U]U1R_YB31&*L=YYQ!5DG>C|32/Z_X2 MJDG0 !ZO4>F[=JRVOH+E3I44[O@]<.8OK;O>U3V@ B_KC
M,>\,872&ZGZHF?11R(Z"XP>A)"Y/!RIW>GK[E|G<=[V=XM*"[PTUIUHY*&Y) MB-MTQB"7U+(B? =W>ECESGX)]#44\59#+#/&V:*1O*^,1$5'-
]2^LXEN/L*Q MD,EQTS&Y7-]*2W\V]/SCNGJY?&8FB=?6/<*TLN5BKXZV M#.'L;Z,D3E^Y>WO:OS]%
]=N'LWHK=>BCIM6Z:M]Z;&G+'+41?;HD|3)$P|G MT*A#+>_R8,4_G%SVPNWFRKERV.\2*Z/YHI^KDZ=$23*^MY8(B]%,X-JQEWK$
M^Q5_A77\"QDQ[=//X|ZEZV:IWMX/-2MHGONVEE<[F]SZU.VH*KXRM3*Q/]7, MQ5%MMRDAH=R+![DR.5&K=K*CI8$]KX79>U/T]O5?
43EOFGK;J:W M36^[VZENE!*F)*:MA;++$]/4K7(J+]*$3MY?)KZ$UPDU=HZHDT3=7+S+'"U9Z M*1?4L;EYF9_..1$^*I:1EXN3RR*-
JOC"HG"S,/GC5\5/PEJO0VYVE-R;>M;I M?4-NOM.U$61U#4-D6//1B+ZT8B2,]JJU&]_5Z_;3RDFXN@V^8ZLI8=;T+5Y4=4.2F|X\=Z=H
MUJH|]DU5_/&%>F35'%CUQ5#TMZO%%7!DT33*U9'(J+UR;(F".6TW'9M3N?!! M%)>6Z8N\BHU;=>U2#TO4R9?
M;LKW>DB^M$)$12LFC1S'H]KDRCD7**GK*FY-.MN6IX;D;2O+5^U?IXK=6\/ZY0R;],=X^2]>38;.M.M.M
&,H9(.^5OW#U3MSPXZDM2WC2UQFU934\ ME99J^6DF?$M'6N6-7QN:JM5S&+C.,M:O>B 3ARA^5@ZM]EEO?_=EW_\Z:I\ M*K/S0=U_7-)_.
ME+#BL&MU-77#5,VH)G1^Z$U8M>Y4:G)VJOY\\O=CF.J?9=[B?]\V_P#Q-O\ MI G3E#)R'AKW(O6YVCKE]"**\/&ZVG*BJ@H;94]G)ECI,?
71M9,U,I\=%POYY-MJ?,!OQ3:CMUVW(9;K3V++;=9]..A:RAAE1J1->CG.UJ-PB)A/8@'S:[F:,/6+2+]NR)5))V2P+<M8>?GSCEY>;.<],>LXWQ<:!U'K=-
*)8;54W-*5:M9NP3/9J[L>7/7Q1KDS\YS MBHX;=?R;A2W5MLA\R==%JD=YY'GL^VYLXYLYY? FF!7U1;/[JVZ+LZ2R7JEB
MYE=R0R*Q,K[$=ZO'V'QNL++?I!>/-=2PU<%RY&NY;QW-)R=<+G*^I2S!,8^5VRLE9IO;_ $[:.]G9UM'0Q03-1R/1'-;B M*F4[_G/]@ M /Y.1%0_-
GLM7U%+27R**HFABF[%)8XY M%:V3\DPCD3O3JO?ZS|)?AA%/S]\->WEUUS1:JFM:PN=0)3N=#(]6ODYNUPC. MF,^BO?CP-
C&NV;%R+F1,13'69Z?3S:65:O7K%=&/$S7/=']ZZ^2VKAAA2'9/3 M6.YT/\'3_,=3.,\.$:,V3TGR|SJ57?6]RI^X=(/.YSK]V^+WL1PVZ=_A #S M>P >&/|
;YCD^X6Q%%?>VKK$ ML=OKE])U/C$,]^Q$^ OM[E\4\3K C)HI[?FEM=:U702(G
MBU/!5^,U4^=>XEWM/O[IO=.%D$,RVR]X].V5+TYG*G55C=]VGS87UHA\7J33 M%LU9;WT5TI6U,*_!5>CF>UJ|5_VZD?];;
(WC26*YPUT>/3B:N)8L^#V+U1?:O>!]2 $=^-F:EVYLL M2?=75KOJAE3_ #DB"-/&]/RZ4TU%T]*MD=]4:[_G ^2X=8^30E0[X]=(I_(C M3_,=0.
<0KU].IE=^ZB?YCHX !Z/5VC;9K M6VK1W*#FPN8IF822)WQFKX+[/'QR1[U?M;J#;FK9
M_+L=6^QG^,V@<_VCXP'4](K7KEKGL3+&7B!F53^^L3O_ M $S>OL7O)26>[T- ^MT-?;JJ&MHIF\T<\#DM]B[U-!3/DHD>[,U#5,
[2GG_/(GU>DU4Z>/ M@!8F#AFU7%1IS6K(Z.^/BT[>'*C>69_]CRY[N61>Y5^*[Z%4[@Q[7M1S7(YJ MIE%1>B@;F,&0 &OW)C"XZ]3<
?!;E!)Z)W>MCJ'5VG**\1JF&2RQ\LT?M9 M*W#V?0J$-=UO):Q3.?5[=:E=3KU7W.OZ]JN?4V=C>9J>Q6+^F+!DZF3;L9=^ MQ/L5*Z_@6,CWZ5*VJ]I-
Z^&IM;+5T5ZT_:ZACHJBMMM0LE#/&Y%16R.C5685 M%^#)CYCVFRO%?6[;WZ2]N]GCO4,L"T[W4\G8RM:KDJ)CK\Y
O;3A]T3NG<+M!>+9V3HX&NCGH7K#(QRNQGIZ* M_LFJ6E&=8OQPY-'YPJ)TS(QYWQ;GY2[+MKQ7[=[DR-I]>[>XMQY4\2"6Y'D_P"_6N:6HT7=
(;U18RVAN#DA M)6IX-1WY5_YUY/F.5-JJY^']ZZ^2VKAAA2'9/3 M6.YT/\'3_,=3.,\.$:,V3TGR|SJ57?6]RI^X=(/.YSK]V^+WL1PVZ=_A #S M>P >&/|
/4EWC3H^JM[UIIOG5]\S7+ M[$Y4)!:&XO\ ;#6K8X_=SW"JWKA:.\L[#'_C.L?^4:%S3\BUSFGDL;6IXUZ. M5>WTGE*&&]W]E\5-[:]HCKY Q?
FYHT+."L+<>]@NW%37U$4T=533:DAY)8G(_MYCVK*Q$5%3HJ%GIO:G[EJ/I_A7:-M5]=26FU7$AIG)\SJ#3=MU1;Y**YTD=3 [JB.3JU?
6U>]J^TX7K3A^N-K2:JL4JW M*E;Z7FSU1)VX\$3&'?1A?8!/HPU47)!7:SB:U+MS(VV7EDE\M$:\BPU3E2H@ M]C'KE?
V+LIZE:2UV\W:TQN91OGI=P22>-N9:.9.2>+],U>]/:BJGM ^SY/8? MS="R3H]O-\Z'}47UF3";8F-I(WB=WQ%]V;T=J)O]G6"E5^>-&/:MU<=%,1+TJO
M7*Z>&JJ9A\1NY9KW?-"72DT], ^*Y2(WDY).S<[J.17-1RJRJF4]N<+T(HQ:H MW%VU589*F[6R\CN5&5C%?
#G/7EYT5N/F)R'\)Z2*JB='+&V1CDPK7)E%3U*A M49^ESEUQ>MW)HJB-N4\EK@:C&)3-NNW%=,SOS1JVXXEK_=]4VRTW6@I:B&LG
M;3I+2L]QZ/]-S O[^/:FF_7QRU'67BAMTD4=5604\DJX MC;)(C5>OL15ZGDO31RMYF.1S5[E1>A'S?;9+46L]2MO-JEBK(_.VQ>;32Z866-
I5G*M151>B*I]I?'V!WGF]!9._GO$LOK_Y1RY)1$8-NXHY=T[*] MKN:62:263K]TC'.5?_D2>>YL;5>Y4:UJ95SEPB8[R_QVVB?BJ+^/5
M8NS;F=YCX,^WP!\S!N7IB:9\;;K"CFKA5D:YJ?.BN3!]FBO5ON./-;ZG]%7P MBE;[^!3&WF6*^5%<3^95BW]>HF/R>:./9XFXUO]?=_^+
MUSM19M;1OE?&E%*_>JV@XLK9J=_M(;5]V(K/BRN:N*69?6[/Y&OSY;[4Z(2)CD;*Q'LZ1/TO7UHATX# M^?(BIC'0Y%NCPJ;8[O25-
3J+2E(ZYSM5'W*B1::I5W@YSV*G.J>',CD]G@=@_M3KD&5%=5N=Z)V>-RU1=C;Y&ZM+=;R7.H;-'4UNW^H8;_ IES;7=&I35/+G*_M-
;*GVM[O:O9IT.'T.L]^N%BKBIGSZDTG1L=RLI+C$Z6@DQU5&->CHE]JLZ^T MN<7]>![<[31WFAJ**X4D-=23-
Y):>HC;)'(U?!S53"I[%+>WJES;@OTQ7'U4E MW1Z-^*Q5-$_1 /:SRIC6QP4FX6E7*],(ZYV!Z*CO!%6"14Q[51_S-3N)8[;\
M4>U^ZT;&>U?;YJQ_1*&KD\VJ<^I(Y,_=\[45#FNY7D[=IM=NJ*BUT=7H^X/ MR[M+3-
]H5R]V87\S43\ZSD(J;B>3(W(TV1\VE[A;-6TK<\D2/\SJG)^E>JL_ MZP].# R/=F:)>$7-2Q.5417'Q[UIR/3&47ZC.45"FBT[M;]\+MPAM]767ZP4
M[%Y8[;?(G34*1(BMY?;&J?.2=VS\J=,;ID5/KW2L]OEQA]PL;^UBY3QN:9=ICBMS%4?1LV=7LUSP78FB?JGUWCZ4.4;?\4.UNYC6I8-;
MVR:=W_W)52+2U'T12\KE^=$5#]44S)FIHYCTB=3![-P M M #G M.],PFA>(32U+IS<&Q.U!9J6N;<(:;SJ>F5L[621H_FA>QR^C)(F,X]+..B*G
M1@!%3WK?AA_N8_|K^Z?TDH"/U4'Y5P/TI<)GYEK9O\ 699OYC"=6.4\)GYE MK9O]9EF_F,)U8 M M M \.LM]-<(NSJX(JF/FYD9,Q'-
SC"+A?]NIXGDK;'S);_|M5C_T'MP!7Y]6E@CXC:FF;"QM.FI&L()&IRKV$[/Q)6/\ YDM_^*Q_MZ"#&]/S3-3^N9O\.$)_
>%16ZEML;HZ2EBI6.=E60QHU%7UX3V'F@-M M .?S1/#!1!Y/L,_MUY\]#_!4E\"9^DH%X)=:VG1]MU[/=*MD"N91NBC7X(V54J=4)2F'-;(US7HCFJF
M%1WJ]0'/-NN,ZHB=%1ZRMZ5#.B>Z%"U&O3VNC[E^=N/F4DKI+75AUS0>=V*Z MTUSBQEW8O]-
F?!S%)]J_.A&C6&QUAU)SS4;/<>M7KS4[4[)WZ:/HGU8^DY!> M-O-8;95S;G2/G8D"Y;<;9([+$\TN(ZA$]:M^"_Z.7YU)
(;'W>TEKYC&V:]T]14N3F\TD=VSLW85?G1,_M ?;$7..2;EM^D(?C2U3OJ;$G_O$HR)_'+-S5.C8OBLK'?6L*?Y@-=B8^3;6W M+\9\SO\
K7)_F/OSXK9.L]L[{G5,MD=]7 MHVFJG(L=3=56DE).MNO$;I&\[=R)S*CFM^9V +[<(VYXM-*ZL8R MEOG_
&-7)WH\U0[FIGK[),>C^S1$]JG<*6JAK*=D[/*R>&1.9DD;DM%3 MO_N YEQ'R[CLGJI>B9@C;]/-QO[_5%$GUN=_H)+<4;^RV M,U-A<*[S=J?
34Q$<>&2/+M1OJ7FZ??VG^@#N1K+"R;&2*1C9(W(J*US45%1? M!>_)L"8GAZ,=M^KDNN.%7;+77/)4Z[5_56W]-QK_ #FG M:?
IR5C6'8/<'06Z6E&WG2UPCB;>*7^RJ>/SB'"3,RO:,543IE<*N<%G(3ZE^ MKN[@8Y697E;<<;;&%@484511.^X #06@ #Y36&V5CUJUSZ
MRF[&LQA*RGPR3YE\')\^?H.&7_;K5>@<AV_;'5%1' !GAK[<]S98_4Y4:O.U M?;W>[?B|^W7YO:!R3:@K:8BBHM7[=>:!OHK6QM1M5'[51,-
D3N[\+[5 M4E+HK<;3NX%$ZHL-UAKT;U=$GHRQ^KF8OI)\ZH1ZUML[9-93.JL/MUP=U6II MT3$B^M[5[_G3'"^TXU?-L-
7;=5S;E;I)I60KF.X6QSDDC]643#F_P>T"Q+*&2 M$^A^,75-B:R#4%-#J*E:J(LW2"H1/TR)RKCVMROBI)+;_?K1NXJQPV^Z-IKB
M_P#^]]=B*;/[:BKAR_I54#HOL&$,F,H!AN?F"F;V"Z2IT6.ED=]3%4C:!?ML@Q9-S;2J]>5)G*N/_+R45?2LK].
M>FE1>SFC=&_"X7E5%3'L(S;"1\^XM*OQ8)5_R%3_#DGS&:*:J>"645335$Q M+D%=L5.URK175CF^#9XU:J?2BJG[AZ2;9W4M+-'V,=/-
Z722&9&HQ<_"ZX7Z MNIWH'.5?LIA55<=.\3J)=!1KN733PU3$_>'*&*6GHJ>*>3MIF1M9))CX;D3
M"K]9\YK[6CM%T%/(RF\YE]'JUK7.5K6X\5QWJO3I\Y14>)<[117FE=3UU-'5 M0YSRR-14S[/47-
^W=G'JMV)X:OC*HL7+47HN7HWI^#F]#OQ3/PE9:I8T\703 M(_\ <5$_A/L].Z\LVIYGT]%4JLZ-YNQD8K%PG?W]%^@]3<-GM.UC7+##-12+
MW/AF5?W'9,.0VLI-*7A;@E;+52M:YL;5:C$;E,=<%#BQJ]F]31=VJHGO[UI?-MG2[MF]JUO%4=5[< XWN-
/]ZVZFFJH)*UE!T\W=3J[LT;A$7*)TSG.>9.I<9V M;^"MQW)48.'^,NS;XXIY;\W9 1_I-W-2TCN62ICJ<=[9H6_P"9$,M[
M?:JFU;8W5D].VGECE6)W9J&O5$1>9/5WX^@U<'6+&;5V=,3%77:6SEZ3>PZ. MTJF\)IZBJ}>55NJ8=JZ9@ !Z,/H
=>@'HM4:)LVL:,LKI1QRN1O*R=O MHR,^9W>GS=WL4][Z@!&W6VQ%VTVV2LM$CKK1-7F5C&XG9[5:G1WSI]1]#MUQ
M8;]T&Y]7*VI8WU))UYOV:*OM0[C_*,=?$^7U9MI8=8LA<\?QE@CGC>Q\;-M7LF)G81/=>B]!5_3Q.D1$]KL
M'W.XG!EM%N4V22X:/H[;6N1<5UE3S.5%^,O9X:Y?TS7$<]=^2HMU6.MJ^S^#<-,UO-S8Z
M^BC527P\6H8TGQE;Z;)W!UJN=SK*UT'1]JU=2/E>U?;KE;,B>SG1/81.F17&
M]BY%7T[V=.KU6YVR+QWRW7B%S>=LE!5QSM5OKRQ5Z'N^_N7)I; M3$[3&RQIJJC>F=VX,=/88]'UD,VP M-M M!^5<_50?E7_2EPF?
F6MF_UF6;^8PG5CE/"9^9:V;_699OYC"=6 M-M M @#JC M\TS4_KF;_.$)_$ =4?FF:G]].\ M_/3PE;
<4FO;1KE\T\M/5T,=*ZE9R3_"3&5ZL3N5#ULY=O!JJ>[!L=?S MY?W:U_$NYUJJQ;JZ>GY<_P"RX+;2/LMN],-RB|FTZY3VQ-4^D/E!JI.VVQT
MA)G//9Z-WUPL/J#SFKBF:OB]Z*>"F(D 'L(9 >P M!| >P=_=U /5[>X [T1.Y/]N@'L ^&U9LWIW5+99$ MIDMU8[KYQ2(CVN9=XFKS-6!>SE;
[>15_@7)) M7O[NH COH]B*U_MQ4OHJNIDN44:\KJ&\M>]|/8CE5'M^:,/8>+OAO/'O"ZQ5 M/N:ZV5%#%*R:/M>TC5SG-
5%:N$ST;U14^LD!>=,6K4$?)<[?3UN$Y466-%33NF;7;9WMDEIH&QNP=_=U M /5[>X]@ #O[NH !ZO;W 'L'?W=0!X%YL-NU!2NIKE1PUL/
M@V5B+CVHO>B^U,'G@#B&K.'-KW/GT]6HS/7S2K553]B__Y%^<^(H+MK[9BN M8ZGJ*^S-5W-R([GI95]K>K'9]N50E,?
SEAC]8ECFC9+$Y.K9$YF]GJP]=0/@ M]!\:H7NFIXGVFI=U5U(B(Q?G8]8^K!S'47#W?K7&^ M6W30W:%J=&L7LY53]*O3Z$1RH])[.95
^_XL)NSV3O#<_D MD],U?^F8O^8X%PRLY:/4#_7)"GU(_P#TG0.(?=O2FOMG)V6.]0552ZK@5:1R MK'.B(]JJJQR9QT[T3'X]@ M[^[J >KV]P !['?
W=0 #U>WN]UZE[TS^Y[0 /E=3;8Z=U M6V1:NWQQ5X^OG5+]KESZ\[\+]D<FNDPGJ178>WV(CL>P[GHWC-T[= MWM@U%;;BPR*N/.(56HA^=
<(CF_0B_.>7=[#;;]3K#]/H MP=T,4\LD?P:NTS*K_*,8?^X?1Z,XH=>Z+K&T M]SJ'7VECZ/I+FBI,GS28YT7]-S)[ )XGS^OIO-]"ZDF_M=MJ79SZHG*L-
Q],ZKVLU?+9+[0W"3W&K'=E#.G M:IJ?WL7TD^E (B\/,?:,_-56VDKT5*FEAJ?%>VC1W\)_ M6FI8:.!L-/#'3PMZ-
CB:C6MSZD3N^<_H#SHLVZ9XHIC?[/2;MK<_4=OI8WP4L4;.MW]JYK$:LB]|E1,*OUG]08X&FV=/FKL=^?Q9YFH7<^([7;D^0W*U57Z3L\,]!
M$USY)>1TKTRUF$SW>L^"HM\;Q%A*FCI*AJ=ZHCF+_"J?N':I(63QJR1B2-7H MK7(BI])Z6LT-8*
[*S6BD53-ZCB1B_6B(;&=A9UZ[VF/>X8^$MW!S,*S:I,_:MXI^+Y[1V[$&]+E';I;)]'/*CN1S9.=CG-;E4[D\$7ZC[T^?LN@;'I^O\\H*+
MLJC'(URR.=RY1,HW*KUQ_"?0%G@4Y5SNME3Q5?179M>-7=WQ8VAZVOU+:K75 M)3UEQIJ;=R9Y9I4;N%[E7/<>527"EKF\U-4PU#?7%
(CD_<4YUKC::KO]\J;G M15L3))L*Z*HRF'(U&]')G*=/'Q53XR]VDU-1NYXZ5D^%Z.AF;_GPI1W1SK-_MVJ/P^],3UB5QCZ=@WK43V^U4QT2]GB/_J?
(;86>[V:PR0797<[I5=%"Z3G6 M-F$3'L151>B=Q]35S24]'42QQ+-)'&Y[8T^[FU15O\ 7N?V/0:FT)8]71N]TZ&.67&$J&^C*W]FG7Z.[V"*4WIU#',]
M',HU1%SV;XEPGYWX7=[3V]NWVG21B5MJ8YN>K]>96JGT+G/UE+1^T&'55P53 M._ 6%U5H.733QOM,?27H-
1\.5;2I++9*]E8Q.ZF]42.3V)S)Z*K\Z(?/:9W0 MU_LW5>805=320M7K;Z]G:0KCX]+W(OQF*BKZR3-+5,K*6&HB55CFC:]JK\5S M#]*HM%-
;7OO:4SJ+/*J534>U>_]A7H]"\:=)52MIM6VCS'FZ>76Y7/8B^V-55R)\SG+[#O6D]Q=-ZXB5]BO5)61^FRHM,W-
+'[>1%YD7YL_.>5O)LW)VHKB9^[T]QKU$;U4S'Y+_M&^9/6.H0.TKQ1[@Z.>M+6U3+S%$O*Z"[1*Z1OI-%1^?TRN.RZ-XSI.73EBU#
M;:FQR>,|*K40I[5PB/3YN539^K72,^DQ]9\UI;QWNBN+L=8HI4[5 M/TS%])/I0^EYB/]")D #9G6DLL[-./L%5)WR62H=-M U/FC7,.:?
0U#@.M)2O1*B;26N\K_P C1WJB3_*GC7I$987G'>N#.4]9NV\ M[(M>[6KKNF8M]WJ/ZQW.*5VG]17RQ
M5"IZ*3NCJX6_L5:UW^63%W3[WO4S3]F/8ZGC^[7%?W22VOWUT+O%%.[1VHZ6 M]N@8V2:*-'LEB:Y<(KF/1'-[E[T.@=Z$:>#SA-
K>&B;5KJ^]TU]=>'4R0S00 M.B=&R+M[=2T]9.ZKCI^RJ>;EPY'+G MT53KZ*$?OLVM4_\.5G_.M_UB6=_P!,6K55"E%>+?3W.E1R2)#51](WF1%1
M%POSJ>@_&2T#\D+/_BC/]$!+AK6]N&OI=5O@B96/KTN"PMSV?.CT?R]^>7*.M>L[/]FU]G_F*S_\6_ZQ)3\9+0/R0L_^*._T#\9+0/R0L_\BC/]'H]@-

T; MANUI6X76XTE-134|\;ZD;'2]|E5]1L=GTE7KZ;G4CTVG-+6C2E')2V:W4UKII M'|HZ*EC1C5GCA$/<@ M M 8RAD #';GK,@ !IX]?
G(XC+;K*E6D=455S2ECA:]ZU7>MS1;HXIG;E^2]NKWL7],>KM+E?#$=__ 'X]%S.PFA[A M=-C=NJV.>E1E3IRW2MRYV<.I8U^+
[2,GE']=;V|(TVBUV|BJ(;97RRI772VT M"5KNW16)% [GCF-::HVHTC>-74=/9]2UUL@GN%%(CV/AE:.4573_| QMKE_;Z3]N[_ %3HJHN.[)N!5?
NUNSQ':;XY M[?H.R6>]DTK)7TD--00VQ)*6NHWI&LU0ZI|/FPG.]5>CD2-6X5.CLV$?C;7+ M^WTG[=W^J=%:U?4;@5P^4?UUO;LC3:+7;N*HAME?
+*E==+;0)6N[=%8D4#N> M-R,1R.BJJ+W'>&M7U8Z8-OH B=Q@P[D[9\/VI]1;?T;;EJ.E;%R)2P+52 MP1+*ULDS8E9B16M55PJ+A/25%1%/A_)
[7O=G>?96KO6XL+V3QW!T%ON-QIO- M9*V!(V+S\C6(CD:Y5:DB(G-A4ZU56..H'+KGM]>Z:VUQ&0M^[M6[/$=IOCGM^@]9ZJ32LE?
20TU!#;$DI:ZC>D:S5#JGL^;"BHMCQHUJ^K'3 '![F],:TU1M1I&\;NHZ>SZEK MK9!/<**1'L?#,YB*Y',5JJQV5ZLST551>X^(XP8=R=L^'[4^HMOZ-
MRU'2MB MY$I8%JI8(EE:V29L2LQ(K6JJX5%PGI*BHBDL?H .7/AU @SY/:][LJS[*U=Z MW%A>R>.X,@M|QN--YK)6P)&Q>?D:Q$WU]IK;5S4
M;4E561PO=#"Z1S>T>C55K<\O1%5$3V9.HX|<=3<"KC@/W3XA=W=\M5V#7]NJ MVV*EII9:GW1M"4,=LJ6O8C(6N2-%RJ.5.SJDTK)7TD-
-00VQ)*6NHWI&LU0ZI[/F MPG.]5>CD2-6X5.CLV$?C;7+ ^WTG[=W^J=%:U?4;@5P^4=USO=LC#HMVW4-1% M;*^65*ZZ6VWI6N[=%8D4#D?
&Y&(Y'.5$QE^,9Z*BRCV;TQK35&U&D;QJZCI[MJ6NMD$]PHI$>Q\,SF(KDS) W@.W2XAMW-
M|-5V'7]OJVV&DIII*E;A:4H8[94M>QK(&N;&BY5'*G9N5RX;S9Z*KK1C3KTZ M9 YU^-MJETG)7TD-/00VM)*6MHWI&L
MU2ZI[/F1$5SLO1R)'R85.B\UIQIU]6 .=?C;7+ ^WTG[=W^J0\H[KG>[9&'1 M;MNH:B*V5\LJ5UTMMO2M=VZ*Q(H'(^-R,1R.-$1?5CP X/L
MWIC6FJ-J-(WC5U'3V?4M=;()[A12([CX9G,17(YBM56.RO5F>BJJ+W'Q'&## MN3MGP_:GU%M_1MN6HZ5L7(E+ M5+!$LK6R3-
B5F)%:U57"HN$|)45$4EC]!I MRY\.H$&O)[7K=G>;9BKO6XM. ^.>.X.@M|QN%+YK+6TZ1L=S]FV-$Z:VU M;/15=/[\;:Y?
V^D_;N_U3HO7ITR;@58[M;L<1^G..>WZ#L=GJI=)R5])#3T$ M-K22EK:-Z1K-4NJ>SYD1%<[+TBHLH M[F],:TU1M1I&\;NHZ>SZEKK9!/<**1'L?
#,YB*Y',5JJQV5ZLST551>X[PB+ MZL>!M] $3N,&'Z&%TCF]H]&JK6YY> MB*J(GLR0-X#MTN(;=S?
#5=AU_;ZMMAI*:;2I6X6E*&.V5+7L:R!KFQHN51RI MV;EBJZT8TZ].F0.=?C;7+^WTG[=W^J5\[M;L<1^G..>WZ#L=GJI=)R M5])#3T$-K22EK:-
Z1K-4NJ>SYD1%<[+TX44B/8^&9S$5R.8K5 M5CLKU9GHJJB]Q\1Q@P[D[9\/VI]1;?T;;EJ.E;%R)2P+52P1+*ULDS8E9B16
MM55PJ+A/25%1%)8_0:UZW9WFV8[UN+3OCGCN#H+?<;A2^:RUM M.D;'<_9MC1'(CG*B2(B([*HN5;JK)6Y[?7NFMM7-11259'"]T,+I'-[1Z-5
M6MSR]$541/9DZCGV&X%7/ =NEQ#;N;X:KL.O[?5ML-)3325*W"TI0QVRI:]C M60-D:S5+JGL^9$17.R]'(D?)A4Z+S6#?C;7+
M^WTG[=W^J=%Z^K!N!7#Y1W7.]VR,.BW;=0U$5LKY94KKI;;>E:[MT5B10.1\ M;D8CDK,]%547N.\(B^K'@;?0!$[C!AW)VSX?
M3ZBV_HVW+4=*V+D2E@6JE@ MB65K9)FQ*S$BM;JKA47">DJ*B*?$>3VO6[.\VS%7>MQ:=|<|\=P=!;]C<*7S6 M6MITC8[G[-L:(Y$7HBJB)[,D#>
[=+B&WD:S5+JGL^9$17.R]'(D?)A4Z+S M6G&G7U8 YU^-MA-3Z^VBTG<==6BBHK_ %UL MIZBX6VLB5%AFW^QFH]5[>VA]5J&C6)? M-
[>CJES(ED:V21(7,7FY6KGIT1,N5%1%)<,A>0:F.JBJZM529&VVP6[=N]+7F)\ MEKN%QDGB@GD1CU2-$:U5=&F%5R=_ADD7GV&X%7/
=NEQ#;N;X:KL.O[?5 MML-)3325*W"TI0QVRI:]C60-G3)N!5CNUNQQ'ZJETG)7TD-/00VM)*6MHWI&LU2ZI[/F1
M$5SLO1R)'R85.B\U@WXVUR_M|)^W=_JG1>OJP;@5P^4=USO=LC#HMVW4-1%; M*^65*ZZ6VWI6N[=%8D4#D?&Y&
(Y'.5$QE^,9Z*BRCV;TQK35&U&D;QJZCI[/ MJ6NMD$]PHI$>Q\,SF(KDS) W@.W2XAMW'|-M-
5V'7]OJVV&DIII*E;A:4H8[94M>QK(&N;&BY5'*G9N5RX;S9Z*KK1C3KTZ9 M YU^-MJETG)7TD-/00VM)*6MHWI&LU
M2ZI[/F1$5SLO1R)'R85.B\UIQIU]6 .=?C;7+ ^WTG[=W^J0\H[KG>[9&'1; MMNH:B*V5\LJ5UTMMO2M=VZ*Q(H'(^-R,1R.-$1?5CP X/LW MIC6FJ-
J-(WC5U'3V?4M=;()[A12([CX9G,17(YBM56.RO5F>BJJ+W'Q'&##N M3MGP_:GU%M_1MN6HZ5L7(E+ M5+!$LK6R3-
B5F)%:U57"HN$|)45$4EC]!IR MY\.H$&O)[7K=G>;9BKO6XM. ^.>.X.@M|QN%+YK+6TZ1L=S]FV-$Z:VU; M/15=/[\;:Y?
V^D_;N_U3HO7ITR;@58[M;L<1^G..>WZ#L=GJI=)R5])#3T$-_MK22EK:-Z1K-4NJ>SYD1%<[+TBHLH] MF],:TU1M1I&\;NHZ>SZEKK9!/<**1'L?
#,YB*Y',5JJQV5ZLST551>X[PB+Z ML>!M] $3N,&'-_WRDM-=/0I25=;'_]T%.Z1S>TD1JJUN<=,_MJB)]) S@,W2XAMW=
[M4V'7]OK&V&DH9*EURM'F+++94M>Q&0:/15=;,=>G3(',OQMKE_;Z3]L[_%2MO?74^:^U5QQ4.@(M+37#2SKA2 MT]+1QVK-/5T+TCI:H\
[1G.U$YG*KT>C8U:J+W.1;;#3KZL 19O7!/YU(Z2V7 MME#GKV.C;K>'A_?IE=-PR5UJN$DC)+G9J-]5RSHK4CAD MYHU1BN1V43[K"HBKRJA;^:
(B^K'@!#WA2V$UI;M+6C4VK(]"UW.Z6B)]1;GN ME;44\K^1ZMD8K/M;NG5N55%54\#V/&%N3MCL!J346WU(VXZBI>Q1OF5.M5-
M!"LC4DE;"K,/Y6JJ]45$^$J*B*2S^@TY<^'4"#7D]KUNSO-LQ5WK<6G?'|'< M'06^XW"E\UEK:=(V.Y^S;&B.1'.5$D1$1V%1[5-AU_;ZQMAI*:62I=
MG3)N! M5AN7NQO'V/CMM^@K19JR724EPI8(;&.UH^EK*%Z1]M5+4]GS(B> MXT$G.QT.
[HT5[',5]JQ455]!57E7HO<=UZ|V%3H;_5@")G&'%N3MCL!J346W MU(VXZBI>Q1OF5.M5-!"LC4DE;"K,/Y6JJ]45$^$J*B*?'>3ZN^[&\FR51>MQ
MH'PU,=P=!;Z^OI?-9:VF2-BH_D:Q$*HJK.'ESX=3/T*!RZ\;-M!OE);:Z>A2DJZV.![H*=TCF]I(C55KX5MK$ ML-'322SKD?;52U/9\R(G,YR
MO1R)&&K514Z.1;3S1OCT^;(',OQMKE_;Z3]N[_5(3^4-R,YLJJ)C+^J9Z*BV0'\^O=A4Z_<*V@TMK/4NUN
ME+MJNB@M&I:ZUT\]QH9.9CH9W1HKV.8K55BHJKZ"JO*O1>X^$XPX]R=L=@=2 M:BV^I&W'4-+V+6^94ZU4T$*R-
225L*LP_E:JKU143X2HJ(I+-/HP-M*HJK)"[Z#OE):*ZHH4I*NNC@>Z"G=(YO:2(U5:W._G.]GTG4OH4W'"%7? 5N M=Q"[O:S:NL>X5MK$L-'322SKY?
VZE_;._U3HKL^K)N1/.51;K:VW|M_'71Z#MNE/.M*37&E@BHFV1DE+6 M43^S6:J6I6-7)CFPSNV+=ZW-JN/9EA:O M5VKD7:)]J%>_%7L:N1M/LM?
=3:.1E^N='V>8*&F?//%&YI6OE;$K5Y^5%RN< MX3+E3'*>O\G=H_<_
MZV:M?);+7>*V*GD6GAGSE[T:JM8CN5.7F5$3.4[RKGAGN&\6L]PM2T.K=*7; MW.HV/\Y;-9GP-M]0CF\L.59E%Y57T'*KL)GP7-UB?68Y?6F3?
R+,7[-5O?;? MO:.->['Y%S;?;NE6K+988)N5\#X96^#E MMS44\AK4QC'3U8*S3L&[AS5VEV:X6&=G6\NF."W%,]^S^Q-[RFN^^^>S'XA6
M[30UE#:JZ2?S^ZT-K97.6H1S$AIWK6JJ45$15IZRDL]?-;Z9M77QP2/IZ=[N5LLB-56M5?!%7"22>=]" MFX%
<_D|N(WB.W:WSUC9MTJ"N=IRED)9)UK;,V@2UUB21I'-UR1M5JO1Z(Q6X5/A(MD7TF&^/3YLFX-M-M ,LR<(XV-M]VJW9'A>W
U;;)7T]VIZ%*.@FBQSQ5%1(VG9*W/BQ9>T_8>/X7^Y]LM''*GPXX8XW)VBHN45SE1J.14Y7=Y'VL\I-Q M<;"9%?=2Z?
9#9IGIV7NYI62FI'YZHU)&]FY45/4_/M.B^1KX=[)J1VJMVKY0-M4]RJK;6ML]F;41H]M+,V-LLTZ(N?3Y9(6M=WHBOZ^D6GWNPV_4UIK+3>*"FN
MEKK8G05-'60MEAFCQR*CD5.]%3 $;>"?CLTSQ=V6MI/-&Z;UQ;(^UKK M$^H25KX>9&I40/5$5\>5:CD5,L2@TDVX M4]6QCY5Q[E5?
HSQ.]:8\RM;S9_(F.7*IDO$ #&4*[?*<^4?]MD[U1:#VIN M-%4:PIY>VO-Q?$RIAH6HBXID1UB9QS."JGA_U;<[>; M%[=:GO$K9[O>M-
VVY5DL;$8U\TU+')(Y&HB(F7.7HG1#H1RGA,_;M;-_K,LW M\QA.K/RKGZJ#\]JX'Z4N$S\RULW^LRS?S&$ZLY'(]<\K>7#G<9NO
M%7QU;6T<6]M41:FI;(F))EO6DH64G+T7$]I3M6+/SL7HO5#L7D7MAK756K5F M[=RHXZJZ0U:V.T22MSYLB1,DJ)&9Z9& !C*&0/Y]G?
UPI^;_9%W)-<'>"20+^Z|_M2?W=5*!.#/3]NOVFMR65U)',Z.&D=%(YOIQ.Y:A4B]/ C\91@?[BJ)F(MVCE]9V_NQG"]SZ9QZ9B)GGS^G/\
LNLX3_S+NSWZS;-_,83JARKA,_N:,_K M-LW\QA.JDLN@-M M M_8-3< M M (/^6!K)J7 MA"DCB=RLJ+_112)A/2:B2/1/VS&KT]1. A?Y7"Q27?
@TO=7&CN6UW:@K).5. MY]R]CU^F9/W /Y^2+I8H>#>TOC8UCY[Q722.3OZ\
(B4<*YGM=_K:29.,*\SFQS(N%3NY94[L]R^U$G)S)ZP*9/+56MM/Q%:. MKTB?L?JN*L,KY[%;I)'*^1]/&YSE7]JJU%4IK M\L36S:LXMM,:?
MRO]ZFGTY1T;*5BY_LB6JJ7(U/:YKXOW"YJV4?F%OIJ57\Z MPQ-CY\?"Y41,_N >8#&4,@>CM&D[-8*VZ5MLM%#;ZRZ3I4U]12TS(Y*N9&HU M))7-
3+W(U$3+E5<(B%6OER/^,6T'^"W3^/3%LQ4SYU/2B>2/W@W)T#IK5]KU'HF&VW^V4UUI8ZNNK&S,BGA9*QKT;2JB
M.1KD14153/]IY2WQ^56W_P!\;[^A@=5]_1_02_?;_4A[^C^@E^^W^I'*MO>4M\?E5M_|\;[^ACWE+?'Y5;?_?&N_H8!5??T?
T$OWV_U(>_H_H)? MOM_J1RKWE+?'Y5;?_?&N_H8!Y2WQ^56W_P!\;[^A@=5]_1_02_?;_4A[^C^@E^_M^W^I'*O>4M\?E5M_|\;[^ACWE+?'Y5;?_?&N_H8'5??T?
T$OWV_U(>_H_H)? MOM_J1RKWE+?'Y5;?_?&N_H8!Y2WQ^56W_P!\;[^A@=5]_1_02_?;_%(>_M_H_H)?OM_J1RKWE+?'Y5;?\ WQKOZ&/>4M\?E5M_]\;[^A@=5]_1_02_?;_4
MA[^C^@E^^W^I'*O>4M\?E5M_]\;[^ACWE+?'Y5;?_?&N_H8'5??T?T$OWV_U M(>_H_H)?OM_J1RKWE+?'Y5;?_?&N_H8]Y2WQ^56W_P!\;
[^A@=5]_1_02_?; M_4A[^C^@E^^W^I'*O>4M\?E5M_]\;[^ACWE+?'Y5;?_?&N_H8!Y2WQ^56W_-\;[^A@=5]_1_02 M_?;_%(>_H_H)?OM_J1RKWE+?'Y5;?\
WQKOZ&/>4M\?E5M_]\;[^A@=5]_1 M_02_?;_4A[^C^@E^^W^I'*O>4M\?E5M_]\;[^ACWE+?'Y5;?_?&N_H8'5??T M?T$OWV_U(>_H_H)?
OM_J1RKWE+?'Y5;?_?&N_H8]Y2WQ^56W_P!\;[^A@=5] M_1_02_?;_4A[^C^@E^^W^I'*O>4M\?E5M_| ?&N_H8]Y2WQ^56W_-\;[^A@
M=5]_1_02_?;_%(>_H_H)?OM_J1RKWE+?'Y5;?\ WQKOZ&/>4M\?E5M_]\;[M^A@=5]_1_02_?;_4A[^A^@C^^S^I%59.+;SR1^\&Y.@=-
;OM>H]$PVV_VRFN MM+'5UU8V9D4\+)6->C;541R-_H_H)?OM_J0]_1_02_?;_4 MCE7O*6^/RJV_^^-=_0Q[REOC\JMO_OC7?T,#JOOZ/Z"7[|?ZD/?T?
T$OWV_U MQY5[REOC\JMO_OC7?T,>\;X_*K;_P"^-=_0P.J^_H_H)?OM_J0]_1_02_?; M_4CE7O*6^/RJV_| OC7?T,>\;X_*K;_.^-=_0P.J^_H_H)?
OM_J0]_1_02 M_?;_%(Y5[REOC\JMO\ [XUW]#'O*6^/RJV_^^-=_0P.J^_H_H)?OM_J0]_1 M_02_?;_4CE7O*6^/RJV_^^-=_0Q[REOC\JMO_OC7?
T,#JOOZ/Z"7[|?ZD/?T M?T$OWV_U(Y5[REOC\JMO_OC7?T,>\;X_*K;_P"^-=_0P.J^_H_H)?OM_J0] M_1_02_?;_4CE7O*6^/RJV_| OC7?T,>\;X_*K;_.^-
=_0P.J^_H_H)?OM_ MJ0]_1_02_?;_%(Y5[REOC\JMO\ [XUW]#'O*6^/RJV_^^-=_0P.J^_H_H)? MOM_J0]_1_02_?;_4CE7O*6^/RJV_^^-
=_0Q[REOC\JMO_OC7?T,#JOOZ/Z"7 M[|?ZD/?T?T$OWV_U(Y5[REOC\JMO_OC7?T,>\;X_*K;_P"^-=_0P.J^_H_H M)?
OM_J0]_1_02_?;_4CE7O*6^/RJV_| OC7?T,>\;X_*K;_.^-=_0P.J^_MH_H)?OM_J0]_1_02_?;_%(Y5[REOC\JMO\ [XUW]#'O*6^/RJV_^^-=_0P.
MJ^_H_H)?OM_J0]_1_02_?;_4CE7O*6^/RJV_^^-=_0Q[REOC\JMO_OC7?T,# MJOOZ/Z"7[|?ZD/?T?T$OWV_U(Y5[REOC\JMO_OC7?T,>\;X_*K;_P"^-
=_0 MP.J^_H_H)?OM_J0]_1_02_?;_4CE7O*6^/RJV_| OC7?T,@ !;\[^A^@C^^S M^I#W]'!|+]JO]2,&
[>>2/W@W)T#IK5]KU'HF&VW^V4UUI8ZNNK&S,BGA9*QK MT;2JB.1KD14153/]IY2WQ^56W_WQKOZ&!U7W]'!|+]JO]2'OZ/Z"7[|? MZD4M\?
E5M_| ?&N_H8'5??T?T$OWV_U(>_H_H)?O MM_J1RKWE+?'Y5;?_ 'QKOZ&/>4M\?E5M_P#?&N_H8'5??T?T$OWV_P!2'OZ/ MZ"7[|?ZD__MH_H)?
OM_J1RKWE+?'Y5;?_?&N_H8]Y2WQ^56W_WQKOZ&!U7W]'!|+]JO]2'O MZ/Z"7[|?ZD4M\?E5M_| ?&N_H8'5??T?T$OWV_U(M>_H_H)?
OM_J1RKWE+?'Y5;?_ 'QKOZ&/>4M\?E5M_P#?&N_H8'5??T?T$OWV M_P!2'OZ/Z"7[|?ZD_H_H)?OM_J1RKWE+?'Y5;?_?
&N_H8]Y2WQ^56W_WQKOZ&!U7W]'!| M+]JO]2'OZ/Z"7[|?ZD4M\?E5M_| ?&N_H8'5??T? MT$OWV_U(>_H_H)?OM_J1RKWE+?'Y5;?_
'QKOZ&/>4M\?E5M_P#?&N_H8'5? M?T?T$OWV_P!2'OZ/Z"7[|?ZD_H_H)?OM_J1RKWE+?'Y5;?_?&N_H8]Y2WQ^56W_WQKOZ&
M!U7W]'!|+]JO]2'OZ/Z"7[|?ZD4M\?E5M_| ?&N__MH8'5??T?T$OWV_U(>_H_H)?OM_J1RKWE+?'Y5;?_ 'QKOZ&/>4M\?E5M_P#? M&N_H8'5??T?
T$OWV_P!2'OZ/Z"7[|?ZD55D__>4M\?E5M_| ?&N_H8'5??T? MT$OWV_U(>_H_H)?OM_J1RKWE+?'Y5;?_ 'QKOZ&/>4M\?E5M_P#?&N_H8'5? M?T?
T$OWV_P!2'OZ/Z"7[|?ZD_H_H)?OM_J1RKWE+?'Y5;?_?&N_H8]Y2WQ^56W_WQKOZ& M!U7W]'!|+]JO]2'OZ/Z"7[|?ZD4M\?E5M_| ?&N__MH8'5??T?
T$OWV_U(>_H_H)?OM_J1RKWE+?'Y5;?_ 'QKOZ&/>4M\?E5M_P#? M&N_H8'5??T?T$OWV_U(>_H_H)?OM_J1RKWE+?'Y5;?_?_?
&N_H8]Y2WQ^56 MW_WQKOZ&!U7W]'!|+]JO]2'OZ/Z"7[|?ZD4M\?E5 MM_| ?&N_H8'5??T?T$OWV_U(>_H_H)?OM_J1RKWE+?'Y5;?_
'QKOZ&/>4M\ M?E5M_P#?&N_H8'5??T?T$OWV_P!2'OZ/Z"7[|?ZD_H_H)?OM_J1RKWE+?'Y5;?_?&N_H8
M]Y2WQ^56W_WQKOZ&!U7W]'!|+]JO]2'OZ/Z"7[|?ZD4M\?E5M_| ?&N_H8'5??T?T$OWV_U(>_H_H)?OM_J1RKWE+?'Y5;?_ 'QK MOZ&/>4M\?
E5M_P#?&N_H8'5??T?T$OWV_P!2'OZ/Z"7[|?ZD_H_H)?OM_J1PW<+R1^\&V
MV@=3:ONFH|$SVVP6RINM5'25U8Z9\4$+Y7M8CJ5$5RM:J(BJB9[U1"#H%JGO MZ/Z"7[|?ZD/?T?T$OWV_U(Y5[REOC\JMO_OC7?
T,>\;X_*K;_]XUW]#'O*6^/RJV_| MOC7?T,>\;X_*K;_[XUW]#'O*6^/RJV_| OC7?T,#J MOOZ/Z"7[|?ZD/?T?T$OWV_U(Y5[REOC\JMO_
+XUW]#'O*6^/RJV_P#OC7?T M,#JOOZ/Z"7[|?ZD/?T?T$OWV_P!2.5>\;X_*K;_.^-=_0Q[REOC\JMO_OC M7?T,#JOOZ/Z"7[|?ZD/?T?
T$OWV_U(Y5[REOC\JMO_OC7?T,>\;X_*K;_[X MUW]# ZK[^C^@E^^W^I#W]'!|+]JO]2.5>\;X_*K;_[XUW]#'O*6^/RJV_| MOC7?T,#JOOZ/Z"7[|?
ZD/?T?T$OWV_U(Y5[REOC\JMO_+XUW]#'O*6^/RJV M_P#OC7?T,#JOOZ/Z"7[|?ZD/?T?T$OWV_P!2.5>\;X_*K;_.^-=_0Q[REO MC\JMO_OC7?

T,#JOOZ/Z"7[!?ZD/?T?T$OWV_U(Y5[REOC\]MO_OC7?T,>\I;_MX_*K;_[XUW]# ZK[^C^@E^^W^I#W!'I!+]]OJ2.5>\I;X_*K;_[XUW]#'O*6 M^/RJV_|
OC7?T,#JOOZ/Z"7[!?ZD/?T?T$OWV_U(Y5[REOC\]MO_ +XUW]#' MO*6^/RJV_P#OC7?T,#JOOZ/Z"7[!?ZD/?T?T$OWV_P!2.5>\I;X_*K;_ .^-
M=_0Q[REOC\]MO_OC7?T,#JOOZ/Z"7[!?ZD/?T?T$OWV_U(Y5[REOC\]MO_OC M7?T,>\I;X_*K;_[XUW]#
ZK[^C^@E^^W^I#W!'I!+]]OJ2.5>\I;X_*K;_[X MUW]#'O*6^/RJV_\ OC7?T,#JOOZ/Z"7[!?ZD/?T?T$OWV_U(Y5[REOC\]MO_ M
+XUW]#'O*6^/RJV_P#OC7?T,#JOOZ/Z"7[!?ZD62;3;X_'/VOT=K+S%+8FH MK/17?S+M>U[#SB!DO9_*WFY4?
R\V$SCN3N/S#GZ4N$S\RULW^LRS?S&$#JP M M 0>\L+42Q<(3F1O5K9=043)$3[IJ-F=CZVHO MT$X2&?
E;M.R7O@TU!4QM<{W)N5!6NQGN69(?_P!=^X!_'R1D+(N#6T.8QK'2
M7>O>]4[W+V]E?;A$3Z$)I$%_(ZZE@O'"5+!;V82>T:@K*;1OCZ;8ID=|\)L"F;RUML9%Q#Z,N"_]*HTM'"¥})W=G5U2Y^?[8OU%P^GI'R6&W/>Y
M7R+31*¥R]ZJK452FGRO=9)K7B_T[IVV/6IK*73]#;FTS7¥1*B:IJ'HF/N55L_ML7^27/6^D2WT-/3-P6HG?+V?/YVWFY>?'-A,X[D[CY7W
MB[]&W]Z7]=_Y4GEJ=[^M_IAS/@\8?HV_O3_KI_1/(:JF?^W9^]/\ KIK9-B,FU-J9VWV\IW;6-?G'N1+OT;?WI?UT>\??HV_O2_KILM5RKWZW?# MY*Z
^]]=_3![];OA\E= ?>^N_IAU7WB[]&W]Z7]='O%WZ-O[TOZZ!RKWZW?# MY*Z_^]]=_3![];OA\E= ?>^N_IAU7WB[]&W]Z7]='O%WZ-
O[TOZZ!RKWZW?# MY*Z_^]]=_3![];OA\E= ?>^N_IAU7WB[]&W]Z7]='O%WZ-O[TOZZ!RKWZW?# MY*Z_^]]=_3![];OA\E= ?
>^N_IAU7WB[]&W]Z7]='O%WZ-O[TOZZ!RKWZW?# MY*Z_^]]=_3![]=OA\E= ?>ZN_IA LJVG\C?^.?M;HI67X|ON:FHK-1W?S+\ M3/:^;^<0,E[/G\
[;S+OT;?WI?UT#E7OUN^'R5T:!][Z[^F#WZW?#Y*Z_^]] M=_3#JOO%WZ-O[TOZZ/>+OT;?WI?UT#E7OUN^'R5T:!][Z[^F#WZW?#Y*Z_^]]
M=_3#JOO%WZ-O[TOZZ/>+OT;?WI?UT#E7OUN^'R5T:!][Z[^F#WZW?#Y*Z_^]] M=_3#JOO%WZ-O[TOZZ/>+OT;?WI?UT#E7OUN^'R5T:!]
[Z[^F#WZW?#Y*Z_^]] M=_3#JOO%WZ-O[TOZZ/>+OT;?WI?UT#E7OUN^'R5T:!][Z[^F#WZW?#Y*Z_^]] M=_3#JOO%WZ-O[TOZZ/>+OT;?WI?
UT#E7OUN^'R5T:!][Z[^F#WZW?#Y*Z_^]] M=_3#JOO%WZ-O[TOZZ/>+OT;?WI?UT#E7OUN^'R5T:!][Z[^F#WZW?#Y*Z_^]] M=_3#JOO%WZ-
O[TOZZ/>+OT;?WI?UT#E7OUN^'R5T:!][Z[^F#WZW?#Y*Z_^]] M=_3#JOO%WZ-O[TOZZ/>+OT;?WI?UT#E7OUN^'R5T:!][Z[^F#WZW?#Y*Z_^]]
M=_3#JOO%WZ-O[TOZZ/>+OT;?WI?UT#E7OUN^'R5T:!][Z[^F#WZW?#Y*Z_^]] M=_3#JOO%WZ-O[TOZZ/>+OT;?WI?UT#E7OUN^'R5T:!]
[Z[^F#WZW?#Y*Z_^]] M=_3#JOO%WZ-O[TOZZ/>+OT;?WI?UT#E7OUN^'R5T:!][Z[^F#WZW?#Y*Z_^]] M=_3#JOO%WZ-O[TOZZ/>+OT;?WI?
UT#E7OUN^'R5T:!][Z[^F#WZW?#Y*Z_^]] M=_3#JOO%WZ-O[TOZZ/>+OT;?WI?UT#E7OUN^'R5T:!][Z[^F#WZW?#Y*Z_^]] M=_3#JOO%WZ-
O[TOZZ/>+OT;?WI?UT#E7OUN^'R5T:!][Z[^F#WZ[?#Y*Z_^]U M=_3#JOO%WZ-O[TOZZ0#XHMC%X;=\|3[<^[?XH?<7S;_=+S3S7MNVI8I_R/G?
MRX[7E^$N>7/3N0)3^_7;X?)70'WNKOZ8/?K=\/DKH#[WUW],/E^"OR<:*<7NU-MMUUDFX;Z3\QO$MH\R]Q?/>?
D@@E[3G\XCQGM^7EQ]SG/7"=]]XN_1M_>E_70 M.5>_6[X?)70'WOKOZ8/?K=\/DKH#[WUW],.J^\7?HV_O2_KH]XN_1M_>E_70
M.5>_6[X?)70'WOKOZ8/?K=\/DKH#[WUW],.J^\7?HV_O2_KH]XN_1M_>E_70 M.5>_6[X?)70'WOKOZ8/?K=\/DKH#[WUW],.J^\7?
HV_O2_KH]XN_1M_>E_70 M.5>_6[X?)70'WOKOZ8/?K=\/DKH#[WUW],.J^\7?HV_O2_KH]XN_1M_>E_70 M.5>_6[X?)70'WOKOZ8/?K=\/DKH#
[WUW],.J^\7?HV_O2_KH]XN_1M_>E_70 M.5>_6[X?)70'WOKOZ8/?K=\/DKH#[WUW],.J^\7?HV_O2_KH]XN_1M_>E_70 M.5>_6[X?)70'WOKOZ8/?
K=\/DKH#[WUW],.J^\7?HV_O2_KH]XN_1M_>E_70 M.5>_6[X?)70'WOKOZ8/?K=\/DKH#[WUW],.J^\7?HV_O2_KH]XN_1M_>E_70 M.5>_6[X?)70'WOKOZ8/?K=\/DKH#[WUW],.J^\7?
HV_O2_KH]XN_1M_>E_70 M.5>_6[X?)70'WOKOZ8/?K=\/DKH#[WUW],.J^\7?HV_O2_KH]XN_1M_>E_70 M.5>_6[X?)70'WOKOZ8/?K=\/DKH#
[WUW],.J^\7?HV_O2_KH]XN_1M_>E_70 M.5>_6[X?)70'WOKOZ8/?K=\/DKH#[WUW],.J^\7?HV_O2_KH]XN_1M_>E_70 M.5>_6[X?)70'WOKOZ8/?
K=\/DKH#[WUW],.J^\7?HV_O2_KH]XN_1M_>E_70 M.5>_6[X?)70'WOKOZ8/?K=\/DKH#[WUW],.J^\7?HV_O2_KH]XN_1M_>E_70
M.5>_6[X?)70'WOKOZ8/?KM\/DKH#[W5W],.6<3GYNW]F.3QST^7X*^%1.+S=*ZZ-;JE=)^8V:6[^>^Y_GJ
MOY)X(NSY.UCQ^3YYL__6[X?)70'WOKOZ8=5 M]XN_1M_>E_71[Q=^C;^]+^N@_6[X?)70'WOKOZ8=5
M]XN_1M_>E_71[Q=^C;^]+^N@_

C;RU.96113UCV¥;QO;21HR/*M1SD55<{EY0MYX?.)+1'$SIBY;@T+5U59 M;;"L\QF?5TKH')*C&OPB.[TY7MZ^TZL5W^1*_,]:W_72_P#FE.6(>-454-) M3RS32LAAB:KY))'(UK&HF5557N1$\2+VNQ*;\.VA+K+;I==-OE3&O*l;%1RU MD*=_5)FM[-_[%RD0_*L<36I-
:;FT/#YH:>=T".IX[M!0N5);E73K]IH^G>QK M7QKRY{)\F%3T$4Z7L9Y&W0%FTI2S[HW2Y:AU//$BU-+:ZKS>AI7+UY&*C>T> MJ=W.JHB^#4
E+LEQL;\0-P2UZ-UE3U5Z5O.EIKHI*2J?TRO(R5K>TPG5>S5 MV#NN4*3,/?R?Z<{]+9MQ=O+[=)M-^Z#(7!52)¥Y;JKTI(9&31HW+,M5$=A'-
M_6Z[6;9;3=7/24=;1-N-\6FRCZOM'N;!3*J=>5$ MC<]S<8=SQ!]RJ 2IUUY3/AUT)<9K?-KZ.]U42X?[A4DU;%U]4S&]D[]B]3V.
MUWE$M@=U[S!:,5KRGMUUG=R14M[!Y:'M"}(C6R2M2-7*JHB-1W,N>XC/PZ>
M1TTA3Z.H+INY7W*Y;DJX4DELUKJ4IZ6BYD1>S<|&\\DC4Z*J..W*JF'81Q\; MQE>2;L&A=M[WKG:BY7)5LM-)75VGKG*V=)*=B2&XE+UNIMQJ#;_
%+637&X;1[!]OK9W*^1|%)S-2)R]Z]F MZ-415^YD:GW)[KRMO$_?-GME[%IG3E<^UW36-5-3S5<2XE910L:LS8W?L
M7"*F79R_:5U+6272Z;+]*>"&MFRKWT4[']BQ[E^$Y MKH9FY^*C$\,K/$_8YD]9DYSOKO5I MSA]VOOFN=3S+';K=`F."-4[6KF7I%!&GB]
[L(G@B95<-15_^4XA>,3;_AAJK M/2;\O,U'775LDM-1T=*^IE6-BHBR.1J>@U57"*OPE1V,\KL=;TQJ"DU7IVUW MNWJ]U!:)NIJB9+<
MYV4@2&%6L[&!%ZK'S{SF[E\K:X$_)|S<7=-==S|K_=(M 5,5%=(R)*:5%K;M4([FFE?-
(CN6/F7E5417.7GZLY45P3_P!#^^4[X=M5CKY134<"_/,YO9L3VNBEY M%;G53YWR0'$O>;NX7K8_5=1/(ZVP/K[$VLRDM,D;D;44F'=41.9'M;TY<2IW
M81 M(,90",&[GE%MEMD-Q+SHC5- MVN4-^M*Q-JHZ:W231M62)DJ(CTZ*O+(W/MRG@?(^^Y<.G_/=[^\TQ ?;#;"T M\:WE%==0:E;+5:5GN-
VN57'22+&]U-&]T-,B2-[L.?3Y]'<.O_ M #)>_OS-_I ^@VI|\IEL;N?KBRZ2L%XNTUXO%4RBI(YK7+&QTCUPU%U2
M5N4(H[>>3,V,VPUO8]6V"TW;&\V>KCK;22;Z2R,;(QB+A%5DUYO*,S-*]^>SI;9%3E M:B-;J>+8VHWT?
2:BSOO'D==B*ZP+04,NIK97M:G+=&7%LDJN3Q+3S;]DG4EOU+;G8:L]\,C^R5Z(O7N/LRA MNF_%Y$,#B\]J.HN+KA:6K!+5+3M5D-
[M$CE:YW95%5>22-5])OPK MWH*B.JA9-$]'QO:CFN3N5%[E_L M M M '(N+;4TVCN&3=.[TTKJ>]IM-UR03,^%'*Z!{(W)T7NJ^MRM5?
I\.XAKY;JMC;M?MK2=>VEO%3*W"=.5D*_7]U[?]D)9\""*S@^VE M1>B^X,"]?;G '>@_?-Z^T)9MR]&WC2
MNH*9U99+M3/HZRG9,^)9(G)AS4NI8K^^G M?50UE1VZ,[%)$8C'*G-C[8Y<.<[&>F,KGMAC* 9*8?*V[H6_>'B,TKM]I.-M MZNFG(76V=:5.9TE?
4RM_L5]!SG,Y8TZ=SWO:O5JH=WX\O*?T&AZ>Y;>;/W". MYZG5KH+CJ>G5'T]OSE',IW)TDG{\O1.5*GC>ZJ)+\?]:,S
M4KU=566QUW,LU*]Z=:NJ1RY[945>5CNK%7F=A^8R-QIJK97A!U&YLJ.K]+ MZ(GC9*SHCIH*%6M5/G>U.I7MY$#25)6ZZW4U,^-
KJRVVZAM\4B]5:RHDE>_'MSK2L+#.,N-\W"AO UC%>J:5N+L-3/1*=ZJOT(F2"'D+^B[VHO3_@16]TI#-I7;#4R)RU-/6UEN?C[MDK(Y&YZ?
_PL_*Y_+953&;$: M%IE5>TDU+VB=.B(VEF1?W7)_L@$H.!G4TVK>$;:FX5#GOE;8H*1SW][NPS!G MQJ4??X]YW@C?
Y.EG)P6;5H[HON=*O7U>T%SUA=E957!?[&M%L5^'UM6Y%Y&>QJ85SW>#6KWKA%"-M/'E-
^,:;9_24>UVB)¥¥MQ=50ID^6@7,UNI'KR9;R^EVTN59&B=43F=E%Y,;E M4W!S#PN>3;W1KKY2L7<+45KIY[M(I#EHF>
<0JRC:Y%5,,SERHN'/5>JHUIMY M-OAIOF|>OKCQ-[L1+=+G75KZJP1UF5[6;*M6KY%7",CQV<+>YO)E$1&1J2S\ MHPN>"S=7'_\7|¥A
C9Y$+\I_<;\7HOYNTF.Q;:FFT=PR;IW>FE=3U5-INN2 M"9GPHY70/9&Y.B]SG(OT$.?(A?E/[C?]I%_ VDK.,J)\W"|NVV-BRN|P*AV$ M3*X1,JOT(BK]
$&O(?Z1@EKMU]421,=4PQ6^V4\F,N:QZS22M^959#^U]A:X M5B^0Z[>W/"KPFZLW)UU7Q4-7?-0RT=+!2L22NKXZ:GBY(8F
M=%=ROFE5554:WG15#.^JB91+K;_\ 3$"/)L\'%!Q4WR[W/751 M75.@-*N;'%:HJIT;:NJF])8T52^X/T;IZ\:SH:5&SVO5]CI M)
[E!3M>]{K';_GA1[¥8¥4:LB'%9IV .:!N%0EM[&]V.6>S.C;5OCFD)5 M3]]N,M5>F8¥41K>R1]-<9X,45O"=M BIA?Q+6]O_P=AV8 M !\[KS2-)K_
$1]'3%(TI*BKI(OR:_RNAK:5SE1DS,/5AX<[3IZ>X4.JJ^^5K8E?RI&M[KJ+7>M:JUZ#M1M=6G:.BC7S2&545R4U'3(Y&\Z1OPLCE5S6N:KE>
MJX62^H/(G;7RV*:.QZYU;0WE8U2.JN#J6IIVOQT58F0QN5, ^':)\X$=N%#;C
M7/&MQL)OI==/2V72%#>V7Z>LPYL"/I\>:TL,G*G;O:Z*)'JB)AK'*O*KFM6Q M?R@>JG:-X.-UZ]JK'VUI]SN9,]U5*RE7N]:38_AZ%=.V'$-NWY-_?
VEVNW+N MU1?-NXWQH^GD<^ICCH7KRLJZ%SO28UO*N8DI%5;(WE1V')/3RG+75_ KN8M.
MBU',RVRHL2"-15SZDR!'CR(FCJ6FV\W*U5RM=65ETI[9SKWMC MAA[7">]%6HZ^OE3U%F17=Y$IR?8^:X3/7\5#UQ_^B4Y8B!4!Y;72E-0{G[:
ME8Q6U=RM%302KGHK:>9'M7Y_I*=U[\8SW(6B;&:IFUSLOH'4U1GM[SI^WW&1 M7)A5=+31R+GJOQO6I7!Y2TL.[/$AK+-K&-1*B=
<.3/*JR=@TY:,. MQV2AHKI'34%%"V**.>F7HU/%5RJJO55557]I9/PF?F6MF_UF6;^8PE=_ER/ M^,6T'^"W3^/3%B'"9^9:V;_699OYC"!Z/CO?F1,=/!?
I"1&X&Z%7-Y,6JU?4S2,N M%PV\IV33-RCNWJ*1D+G-7JJ>G(JHO>G>1T\B#H^%EEW3U4]K75$M316R)WW3 M&-;))(B>I'*^/]HAU3<2"2;R/M*R.-
\C_P 0MK?RM157E18'*OS(B*OS(?'> M1"$[:/%3"_B M6MW?_@!LP M (5>4EXT$ MX>-_+1#2M:GXY.I(%93=DO>);5RJUU2]U1ZX&O
M:B[:XU',BQTWVFAHN?EDKJMS7=E3LZ=[N5R]OW+6NG4%IE?%7+):+;75$;.UJVJG)*V-S_1A@1$;&W"Y! MO>75VJZ%OXY.I-
#WB2J69N9;;2K12N;2Y7]CUPU\GYY$:N>1%7X#R&W_!BW M@_P6U_QZDG?Q3[@:6K.&3=ZFI]26B>HETA>(XX8J^)SGN6BE1&HB.RJKE,)[M2
/D4-1VC3]_W:6Z76BMJ34UL2-:RH9%S]CZG*)S*F<93N]8%NH/"MUSI+Q1 M,JZ&]AK:63/)/3R-D8["]BXM="UVH=2U=FL&G8]ME11V^!JU-
6LSHE1&R.RD:) MV?55:[V(G>G.^.+8W0^PWD\-R=/:%T]2Z?MS5M:I5A;F:I>ESI$22:5_;J>6NLEKOE11{?:!GOM!"Y6-NUZK5I$EPY4YF0-8YW(Y
M,*BNYJ.JE.69[5!G M1%+M)==U]#6&DTQ?:"^.2YT5IV0TM?3/D1CGK$W#6RL<]\[415;SH[F7E5
MO3/)&;NW3<;AEEL5WJ'54^D;DZU4LKU57+2+&R2%JK^[VG;S&4 LC_P ;N^]HV"X=-6WFXU$+;K<:.M*;UV>C?
ASJBKFCBG=U54:M5VC=%;P>55WPEU#?JAUHT7;).PFK&-5 M**U0.5'>;4S57[9.Y.*]JZ^BKU1O*@'>O(DI;W*DMVY&NJB)T=JK'4UHHW.Z M)-
)'SR3+\S4DB3/K!O55Z]Y$W+WN M>YRNG MP'O5CU5R*CD:C<8YL@?!\(7E,[3L1H&V[4;T:F8_,8+@RC59&PMZQQ M5$#N62-
S&JU]*B.RB)E$[U_IQ?>4SLV^6WMRVKV7T]?+]=M41K05%;)1+S+"_M[J^*G@;S/DD>U%;JJU.5%7&5P]>^X;?)!V&YZ3I-2[VW.[UNJKFWSJ>R4-4D
M4=(K^O+-+RJ^2;KERMGCF73B-\D'9K3IBKU-LC>+M0ZHM;?/(+)7U_M/;MJEC]+E@F1&OBFZ>BKE-74F\BW3:[7UQEO5_M5$
ME?:KQ5R*^>IIFN:R2*9Z]7O:KV*CU57.:YV<\N5L=_M \2NKJ>W4<]95SQT]+!&Z66:9Z,9&QJ9\W.6&&_U,,Z1)F146*A21SD1.,+72N54:C5:U5PL
MB)*+@^VHVWX5=GZ'2]'JJP55]J52KO=T;70YJZI4ZHBJ[/9L3T&-]2*OPG.5 M0@5Y8C2-HT#>]G-.6&ABMEFM5AJ*.CI8L\L<;)8T:G?
U7UJO55RJY[RU38;\ MH[;O];MN_FT95GY:;45IU#N#MH^U7.CN;(K75)(ZCG9*C%65JHBJU5QDLPX? M],Z=J]G=NJ'"_P!KFKG:;?
M\:4T=9&Z17)31Y;RH[.?8! SRX>I:B*U;2Z>C= MBE]KC<)FJG>^-L#(U1?8DLN?G0FQP1:9IM*<)6T=#1Q-A@ETY1UZM8G19*F M-
*F1WSJ^9RK[57O{R!_EQX'^I.STRM5(W4]U:BKW91U{E(6$\)3VOX6=G M5:Y'(FC;.F47/5**%%3ZT ZR4HZ;I6[6>5^=#0M;-DLE9<&HQ415=% M
J][6HJ^*JU$3VJ?<'QVZFVMHW?V^OFBK\ZI;9KQ3^;53J25(I>15151KL+A5 MQZ@*
(."SBSMO"-6:VU+%IAVH]77.AAMMJ\61(j:"-9%DJ'2O3T^]D&&-3TN5 MVUO#%?KC?+-!5ZEO:!FC]?-
C62&WK/STUR:U%5ZT[U3FYVHBN6)W7EZM5Z->K92;A;>:=W5TA<= M+:MM4-[T]<$8E513JY&2CV-=E%3X*%)/'CM!'P9\7%MNVWSEM-
M!,RGU/9XF95M#*DSFOA3UM22)51O MILD;?I^XY /BMC>'70?#E8[I9=OK/)9+7<*Q:Z\OBFZ>BKE-74F\BW3:[7UQEO5_M5$
WGBFJ%F>Z;9'-RJQL6545>Y$BLMB283+%FA?&CDRBIE%Y'8\GFWG'XGD63'+W^Z'8=?/JM\;)3X3[M&0Q+C_,+COR6K;+Z$_&PVCT5I!5YWV.S4
MEMD?E%YG10M8YV?:Y%7Z2O{@*\F?J/1NO:/=3>=D7NW23>>VVPOG;4RMJN;F M;55,C55JO:[TFM17+S8.R4DE34Q1RR-9-(UD:*[%2)9$1R
M=6JJ.\"G/9[0/%%L)]FJ4F@]L='@4L_9+>4._P":-P/_/6\/]'V2WE#O\ FC<#_P#UO#_00+AMP-(T M^O=":ETO5=*6]6RIMLN4RG)-$Z-
W[CBG[R3&YT6RW$MJG;K5:MLE7J*%UL1*_ME>7DN5+*[E@=F=!W#5T=1'JNKL%OGO#:NF M2FF;6.IHW3H^)&M[-
R2*_+.5.54"\FK>]T=9U>Z.TC(7:DJU,+=;KJWFK>]R\[5OCFJ>BKE-74F\BW3:[7UQEO5_M5$ME?:KQ5R*^>IIFN:R2*9Z]7O:KV*CU57.:YV<\N5L=_M \2NKJ>W4<]95SQT]+!&Z66:9Z,9&QJ9\W.6&&_U,,Z1)F146*A21SD1.,+72N54:C5:U5PL
MB)*+@^VHVWX5=GZ'2]'JJP55]J52KO=T;70YJZI4ZHBJ[/9L3T&-]2*OPG.5 M0@5Y8C2-HT#>]G-.6&ABMEFM5AJ*.CI8L\L<;)8T:G?
U7UJO55RJY[RU38;\ MH[;O];MN_FT95GY:;45IU#N#MH^U7.CN;(K75)(ZCG9*C%65JHBJU5QDLPX? M],Z=J]G=NJ'"_P!KFKG:;?
M\:4T=9&Z17)31Y;RH[.?8! SRX>I:B*U;2Z>C= MBE]KC<)FJG>^-L#(U1?8DLN?G0FQP1:9IM*<)6T=#1Q-A@ETY1UZM8G19*F M-
*F1WSJ^9RK[57O{R!_EQX'^I.STRM5(W4]U:BKW91U{E(6$\)3VOX6=G M5:Y'(FC;.F47/5**%%3ZT ZR4HZ;I6[6>5^=#0M;-DLE9<&HQ415=% M
J][6HJ^*JU$3VJ?<'QVZFVMHW?V^OFBK\ZI;9KQ3^;53J25(I>15151KL+A5 MQZ@*
(."SBSMO"-6:VU+%IAVH]77.AAMMJ\61(j:"-9%DJ'2O3T^]D&&-3TN5 MVUO#%?KC?+-!5ZEO:!FC]?-
C62&WK/STUR:U%5ZT[U3FYVHBN6)W7EZM5Z->K92;A;>:=W5TA<= M+:MM4-[T]<$8E513JY&2CV-=E%3X*%)/'CM!'P9\7%MNVWSEM-
M!,RGU/9XF95M#*DSFOA3UM22)51O MILD;?I^XY /BMC>'70?#E8[I9=OK/)9+7<*Q:Z\OBFJ>BKE-74E\BW3:[7UQEO5_M5$
WGBFJ%F>Z;9'-RJQL6545>Y$BLMB283+%FA?&CDRBIE%Y'8\GFWG'XGD63'+W^Z'8=?/JM\;)3X3[M&0Q+C_,+COR6K;+Z$_&PVCT5I!5YWV.S4
MEMD?E%YG10M8YV?:Y%7Z2O{@*\F?J/1NO:/=3>=D7NW23>>VVPOG;4RMJN;F M;55,C55JO:[TFM17+S8.R4DE34Q1RR-9-(UD:*[%2)9$1R
M=6JJ.\"G/9[0/%%L)]FJ4F@]L='@4L_9+>4._P":-P/_/6\/]'V2WE#O\ FC<#_P#UO#_00+AMP-(T M^O=":ETO5=*6]6RIMLN4RG)-$Z-
W[CBG[R3&YT6RW$MJG;K5:MLE7J*%UL1*_ME>7DN5+*[E@=F=!W#5T=1'JNKL%OGO#:NF M2FF;6.IHW3H^)&M[-
R2*_+.5.54"\FK>]T=9U>Z.TC(7:DJU,+=;KJWFK>]R\[5OCFJ>BKE-74E

QS)ZS)'OC3XK%X0]K;7K)V MEDU;Y]>8K1YE[H>9F%"0?,GK,D*,"SRCZ\7NZ--MUT;FWB;3|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`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{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

*(#^4=V3=LKQ6:MIJ:!(;/ M?W)J&W(U>G9U#G+(W'@C9VS-1/4C?6<|XB>(B^<1%VTG77M9%DL&G:*Q,=(_ MF6=\3%66=4[D=*
(]SE7']J;ZL($P_(N[+>[^YNJMS:V!5I=.TJ6VWR.:G*M5.G MVQS5];(FJU?94(3>\HQPV7GB6X>I[1IAJ3:GLM='>+?2.D1B5BLCD8^#F7HB
MN9*Y6YQES6HJHBJIYWD[-EUV2X4]'VZJIUI[Q>8UOUQ]#E=VM2B.8UR>#F0I M"Q<^+%^9/8\6_&9IWA$M^GZK4>F;]?
((VZ:.FGM4<2PQ21HU>25[Y&\CG(_+ M<(N4;_'P5 H1M=\UQLCK&:2@K.YH355"OF\Z0R34%9#W*L:T3E_>AUB9=[C:-
;TK7(KFWJWMCEY.F6MDIUC7.,X<|'85?%.A.O83B@V M;\HI?M0Z2U9MI;65UKIXZ]WP7]T-745<*N>DCHG(Q'1+'Z&4:Y55)/8I\MQ$
M>2@V/I=!ZDU+IVNNNW\UJMU16M5:_P YH&]FQ7YE2?F?C#>|)6]Z]X'3.$/R MD^AN*"\PZ5K*"31NMY&*^&+VU4Z2P5G*F7)3RX3FX@+Y8
MR^,NG%M!2MDYW6W3=%2N;E%Y'+)/-CZI4^LL.\EQIJ73G!5H9:B%8)K@^LKU M:O>K7U4J1N^EC6*GL5)9 M M M M _/)Y0;;W\;7C
W+ML4+HJ6MN/NO N,-WI\ M54\"2.__ !#>Z_DI-GM/QU#4N%ZJ666I@<{+O-K8JZ?QHZ-?8CT0\KRV>WJV MS=#;_6T;'=G=[5-
:Y>5OH))32K(B]OQG-J43KWI'T[E*\JO5%SK]+VS3T]6Z M2U6VIJ:NE@5/,%CM<=N@5S M>G;5,G,KFKZVLIW(OLD3UGQ7E@=L?Q'<4$>IH8NSI-
66F"K=)GHM1"BT\C4_ M8,A5?:_/K)S>22VS70?"507>:-S:S55RJ;LY'MPYL;52")OS*V!7I_?/:?&> M6GM9T\':5.E[LD<\B)UCI:IO9N7Z9F4Z?
L@.&6]B(23R.UQM2UZM MO%/=4T6U[UP][73MJN1/6GFKGL3V,7Q13C/DH-NUUSQA6&N>SGI=-4-5>945 MN4549V$?
S*DD[')^E(NQ:YNT6@:K1R5.,%/K>R8LTR9]2]M3_M?J#JGEC=:U>G. M%.DL],JMCU#]"EHJI?!88V2U&/G[2&+ZE*]O)N;G[8;.[_3ZQW1O$%GH+?:)
MVVR>2AJ*MR5SY(V(YK88I%3$*SIS+CX2=Y/KRSFGZRZ<,=@N5-"Z6"UZFIY* MI6I^11/@J(T>J^KG=&WIXO0KUX ."0O%!N_&)\L MK)
(T=&Y98I$7T'.=A$3X"KGP4+4+MY2_A7OEKK+;7[B1UM#60OIZBFFT_^"TW7SNTUCDN%^92WYWD5=CF-
5SM5Z^:U$RJK<:%$1A3/F=,^2DX7=9LC?I_=;45];(MB*QULU%:ZCFSC&.2E7.>9OUIZP/J?*U[F3,X-K%'0\S*?5]VH(YT7N\W2*2J M1%]O/%%]2]Q
7R;FY^V&SN_T^L=T;Q!9Z"WVB=MLGDH:BK3C\K?MT^Q<>AZ*TLJ*NUZ6O5#2ODG1KI&TZ4DT#))%1$3*N[M-JX1.KTZ(0,X ."0O%!N_&)\LK)
(T=&Y98I$7T' M.=A$3X"KGP4+4+MY2_A7OEKK+;7[B1UM#60OIZBFFT_^"TW7SNTUCDN%^92WYWD5= MCF-
5SM5Z^:U$RJK<:%$1A3/F=,^2DX7=9LC?I_=;45];(B*QULU%:ZCFSC& M.2E7.>9OUIZP)M;KWF+4'#AK*Z1)RQ5NDZRI:WOPCZ-
[T_<4_.1M]JV7;_7. MG-40T[*N>RW&FN4<$CE:V1T,K9$:JIU1%5])E#]%VY6F:?1O#-JNP4ZW6W3U%O-K^]:RU77NK[Y=9NUGDQRL:F.5K& M-
^Y8U]-:C24B%^O!!MAM[MIPZZ43;B9+E:+#UM>HQ#*\LUP['1'R2IE>1R M*BL|//HK6IU5R M-1.\H\X>N(K6'#-
N"W6.BIZ2.Y.IGT53!6P=K!4P._/Z*MP-SM);66F&Z:RU+:M+VZ:5((ZB[5;*=DDBHJHQJO5.9V$5>5.N$5? M A1JGA^X.N-
G7UXMNCKW34VO'4S[E5U6CGO@21B2-1\KV.C6G>]OE;S*B<{E M=E5Z90.=;>>6PLM?2^9[C;9U4+71(R:]T]5,J6393#D\WGY.5/8LKN_Z^W<*
MFC^"_=!T$YUVE],UEZH>6H\PN\$DEQIU:K51_)5*YZ\KFM]-BN1%^ZZKF+&Y MOD4],6=D]1H77=HU)$U7.917BG?03O3N("Z>O^IMG M-
PJ>YVNLGL&JM/5R\DT#T1\$\;E:.]JJBX5.BM5.K7(JHN47]'Z>P>@T-J%VK MM&6&^K#YNZYV^GK5A5%16=I&U_+U]7,>_ M M M M M *.?
>MN)_^E_Z_M?I)+WM#6ZIM&C+*#05<78U=+000 M31Y1>5]8VM;1[JV6^ MNIN=DG03Q4L<WF;Z*XL<5@IJ)]5TS-
MB9DM0YS>6:9CNB/;UQCK["TL 0^\F%L-KKA[V%O^G=P;"NG[S5:EJ+A%2^>0 M5/- ZEI8VOYH9'M3THGIA5STSW*@\IYL-
KKB$V%L.G=OK"NH+S2ZEI[A+2^> M04W+ VE]XW/YI\&-7TI6)A%SUSW(I,$ 5;>30X+-Y=@.(.NU-K[1ON#8Y;!4 MT3*KW3HJG,SY8'-
;RPS/=U1CNN,=/;3$XS^$"Q\7.W,5G]JEMGU+:I'5%FO'-M9=IV#W(B21/1%15BD1K4]CJ9>U:B].CFM7IW=#:P\%7%#Q$ZICK+_I?5$M9(B0RWK7<
M\U.Z.-%7]YU2O:JB95<,:Y>O=U+_ $ 1XX,N$*R<(VV\MFI*EEXU)7%_XE;4?JA7_R<)9R5C>7 M%ZZ+VI_5"O\
Y.$"%?"#P;57%QIWR01Z'U+IW=& 6N+D8V@26LN=M3#O11'1ND@ M1$5$[G83"+T[R3OD-O\ C%O!_@MK_CU),,!5'P&^2WU)8]2@BMD-]D
M;56S2ZRLFEG]&KED2K5R1HJN<['-RHU6OM9JKW=5Z*A^@@ 4E<.?DG- MTMS;[!7;E02Z TMS=I4=M+')Z7&._E<7):%T-9=MM(VG2
MVG*".UV.U4[::EI(PUC_A55RJN7]JJJJJJJ?1@"O#C\|F94[ZZE]MQMM) MZ:BU=4QI[66L>D<%QJKUY?9T_04 *$=\ 7$QQ :HAK-0 M:?
O%O=4B(^3E3X+41K6M;E<-;F55)X*]7<0<6FM;;?T# M+SJ"S4[[?6VKM&QRU%,KUDC?$KU1JJQSI,M5G?25GNO00]JC:6&-
WH23M>GI,@A[5&TL,:O0DG:]/28Y/2:G=GN+B0!P_@MV[U% MM-PR:"TAJJW+:M06NCDBJZ/MHYNS4\V&UUQ";"
MV'3NWUA74%YI=2T]PEI?/(*;E@;2U<;GTTC&KZ4K$PBYZY[D4F" *L_)H\%
MF\FP'$'7:EU]HWW!LDE@J:)E3[IT53F9\L#FLY89GNZI&_KC'3VG3/+6_F6M M+?KSI?YC7DY]5ZBI-):7O%^KW^11_-2 MZJ_695?
SZA+0N*CAET_Q3[3UNC;W,ZW5*2)56V[11)))053ZOH97.HM0Z)E?/([ICG8V)4GC7"JF%:MGBB9[U]?3*'%7Q$7ZG??])ZZNU9&J0-K]<23P)
SIGTZQS5Y4RB^CE5PN$5 M>A^@0 11X#N!Z@X1M(5U3<*N&]:\O3(VW*X4[7)!!&WJE-!S)E6(Y557JB*] M<*J(C41.|
[M;5:>WHV\O>BM4425UFNT"Q2L[G1N1_R7>]VSFII:G2%KGUW8X)4EHKO8L-K&87+,>GYNT8]%3O9SITSS>"?&5>
MQ'%OOAYK9;JIC=#4,-.]KZ>'5BUD=-"[^HCFNK%;&U<*J914PB]_4_02 (!^ M3X\F_/P\7K\<+
<*HI*_7'8NAMUOI'=I#:VO;RO>LF$YYE:KF9;Z*-5V%=S92 M1/&7P_S\2G#YJ;1%!414EYF[.KMM149[-*F)Z/:URIW->B.C5V%Y4?G"XP=S M
'YW(^$SB5VFUK3OM>W.N[1]&C=FGN>FZ2>7LG.16]K*NEYF)T5454?W*O@I M;7Y-72>Z^D-
C;Q2[NTUZ@U!4W^>LII+|5)/524SX*=J*Y5>YZ8>R7H_KU]6"-M7 HIW-\FGQ(Z@W'U7=;?MSV]!77:KJ:>7W>-\SG,7#JG*914Z+U0NVT M-;JFT:,L-
!5Q=C5TM!!!-'E%Y7MC:UR93HO5.]#Z 0"5U[M=V=|

#).+X/N0DN"-7S>6A_K-J#[-MG@^6'S>6A_K-J#[G@^6'DK_IE'&,'W(24^$?"1K^;RT/|9M0?<\'RQ3YO+0W MUFU!]SP?+#R=_P!,G&,'W(26!&KYO'0WUGO_-SP?+#YO'0WUGO_-SP?+#R M5_TR<8P?=A)3X1\)&OYO'0_UGU!]SP?+#YO'0_UGU!]SP?+#R=_T2<8P?=A)M3X1\)&Q.G?H=?^9[_P#<\'RQ7YNW1'UGO_[A3_+#R=_T2<8P?=A)+X1\)&WY MNW1'UGO_.X4_P L/F[=$?6>_P#[A3_+#R=_T2<8P?=A)+X1\)&[YNW1'UGO M_P"X0?+#YNW1'UGO_P"X0?+#R=_TR<8P?=A)'X1\)&[YNW1'UGO_.X0?+%? MF[-$?6>__N$'RP\G?],G&,'W820^$?"1O^;KT3]9K_|<\'RQ3YNO1'UGO\ M^X0?+#R=_P!,G&,'W(21!'#YNG1'UGOW[A!\L/FZ=$?6>_?N$'RP\G?]$G&< M#W82//!':.G1HA?\ F;__+A!\L5^;GT1]9[]^X0?+#R=_P!$G&<#W82.!''Y MN?1'UGOW[A!\L$Z<^B%_YGOW[A!\L/)W_1)QG]V$CL(.(1Q^;GT3]9[]^X0 M?+#YN?1/UGOW[A!\L/)W_3*.,X'NPD<".7S3O^F3C.![L)%X080CI\W!HOZT7W]P@^6+OFWM%_6B M^_N$'RP\G?\ 3)QG]V$B01U^;>T7]:+[^X0?+%?FW=&?6B^_N$'RP\G?],G M&<#W82)P@PA';YMS1OUGOO[C!\L/FW-&_6>^_N,'RQ'D[_IDXS@>["1((L_-MMZ,^M%|_<8/EA|VWHSZT7S]Q@^6'D[_IDXS@>["1 ([_#;>C/K1?/W&#Y8) MTVM&+_S3?/W&#Y8GR=_TR<9P/=A(C"#"$>/FV=&_6B^?N,'RQ7YMG1OUHOG[MC!\L/)W_$R<9P/=A(8$>?FV-&_6F]_N4'RQ3YMG1OUHOG[C!\L/)W_3)QG M]V$AP1Y^;8T=]:+Y^XP?+#YMC1OUIO?[C!\L/)W_$R<:P/=A(5%|\]:T^F M1H6;"/BND&4RO'3-7A]_A>OWCOI5TH=NKIPM|G?-)%^EJ::5F/V7#P_?*3BWMJ>M,LM&UL&N=*;M/ZMLIS0IV'2V+6%FU+"LMIN=)<8T[74L[9,>_A>1W"29; MG'+WS6FT:9TF-'1HN47(UHG6'T!;Q#B#*N M %,H,H [6[_T]=D[!Q,_)?I(RM^DM|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|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}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

M*4OG6]5UF/I>+"X]_"DD=R>GT[<705_TU^07S!+G2OI?.O9?K>]RGNN'J$SCW-MT]\MDUY--ZGPOR}^BF#;PIQKDY'Y^>G7X(E@-ZO;67 BF9Y4KF]BE3MH-'WZ-MHAZZ*R7&6+_K&4DBMY=O/!U+F]URHJ85.U%Y8^/^W:5BN)Z2F]W73IO1H%Q: M7=V?[=A.L1&LL=-,U3I !_; [^#M/R*7I*+SQ:17^:+==72'7-/<\J7S4\E).^&>-\,S%X7-M1R-X7-7.,*B]BEA,3KSA728G=F$E-M.A!?-R-#6G4U+J2AHX;A$LK()J=ZN8 MB.5,*J>\;.W%T7/MYK:\:.]*F.LGMTZPOGB:K6O5$1BC]#WHOGC M^Y'?RCSSWZ3F7[_:V1J<2NKW(B)S5?1:GOG"P\]f=R*Z*YY1_=ZW:6S;./AV MKMJG\56FOZ-9 [*LTQ>+?2K555IKJ:FPB]=-3/:SGV+Q*F,*=;WX.[37%727-MDZJ*J/S1HJWO+BUO?]!UG-MUGN%V=PT5#4UCO""%S^[U(i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|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}JBGK.CA4T5U?EC5UA>?2KHJBWU3Z;JIY: M:H8N'13,5CV^^BX5.7,^2+R5> [N^+1+1,3JHK-,TSI.:*@>H[&V:=NUX;Q4% MKK:Y,9_N>G?)\/).P:T4=931177RB"!!S;E8[E9>|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

W&VOA4V;E<4U4Z= M?DA9T3>C''OE7W:MU''RX46F::G5D592N2-TM2YRFWZIC]%E#:(G/5<>#EPQ$3';Q>]D\^M[]ZKQOAK>:^W\ N:E8G4T-MO;[B92Q?4HN$RY5Y][''97N1$1$V\;YE9.1OS^&CX.;G6=GXF+X5,Q7<^,?|
MB3WDS7)Q[C)XI;E3U_[Z_P!*'W\I=13RT^@*ML+W4T3Z^)\])EK7N2!6M5?% M48Y43\ZO@:1Z(6^]OV0UW6R7Q)&V&[0-
@[)86<;Q/8O%')PIS5$RJJHB9]+*_M9Q@GBWI0[2U5N\[=K>U.BSE&22*V3]S5.+[QJ9.7]X1'N5KXT7WW1-;[[
MB;W2IVMK=W=G[E9{6B/N]/)'6T<2JB)+(S.695<)Q-;*A.G8_I^6Q]KIK5N+%+25L+6QMO-+"Z2*=$1 M$5TK&YDCM--
&M8FMK&CFIC,E2ULN.W&%]+'P&E-[M.GM8+7:ZFV[?<=YNTC>!+E-"YE-39Y<2->B.]DC<\U54Y+JWKV3FQ%F*-
M&]BXV%LFJK)JNQ5/9J+R@.OJ74VZ]#8J21LK+%2=5,Y.>)I51[FI[S4CSZU5 M.XD3Y/Y<;"_MI4_@8>;U?7U-
UK]FLK)Y*JK])%EFFE=Q/D>]JJNN5)JI$ M'I({=[7;2MLFIK_['7+S^>;J4HJB;T'<.%XHXW-YX7O-K,QYMX=-JF-=)<[9 M6=1=VE7?
NU13O1/7]FK^GHN>D!5>"6^FQ\2G1="OZ)?1WQU7\RG/ATM=Q+!N M=N]47W3==[(6Q]'#$V989(?2:U>).&1K7Q]HH MO.5GJ%B?)P<5-+&WT6-
5RYD[TG]M=Q=DM1Z>T[J)UPN]7YLL$'F%5'Q\%3 M$]WI/B1J>BUR\U[B!QAV1;JHLU15&G/^S8_B.];O9--5NJ*HB.W/O(21Z G^
M'IOZEU'X6$;B2/0%_P /2?]74?A8;V;_,>Y]'*V5_S+?UA-+I+;;U.Z>SU__ML= G%5DMDN-
/>'VF2AJ&71DWF[J)8G='@5F,\6>6/$]5.D)NU/LQHNDU''1MN,#;C!!4TSG<+G1/XD=P+W.1414[>P MZC2W2?
VBU7#%=&ZBMMMK$8B*VZ(E/41(OTN7=J?I55/6>;PLB|CVYFFC>A[C M;N!C9U^F*[D451\>\.=T7=N;W;'9BR6FYLZ]YR(^KJHN^-
\CE=P+ ^>:WA:O= ME%(+=,K5$&J-_K^M-(DT%O;%0(]O9Q,8G&G[%[GM^!22. ^G3ET]9;)5VS0=1 M[,WV=JQ-
KTCU5QA8"U%1+5U$T\\KYII'K(^21>)S MG*N5I\[ME;5];!/P.9QM5K>?"Y$QCN?9 MR-G],GI:;#W7VUM=JTO?%N==#=HJN2):.HAQ$D,S%=F2-
J=KV\LYVE+UJY.= M37%,ZBV)DV:=CUVYKC>Y\M>;;//)Z7M])MI>;\QC)+I6W!TLVXFQOL8
MK69[N;G+*9[#&.FSOEKC16LZ/35AN%38;3)0MJ%JJ9$;+4.DO3[*UM=:+]%-+IFY2I,KX&\3Z:;"-63&?216HU'(G/T
M4PB\\R^O>\^QVO+4QU|OFF[O30KUD<-TC:I\;L8XFQR-XD7'>B&O>HKLYQ+UG)V;%BU4-;Y^S-G5$RC+["KOW"H3*H<"HZ;6WNEM46.
MP:7MS(]*1R\%;<(J1T$,$2M7'4PM1'+Z2HJKP]B*B(N(INUY5-V:)B)F.RWB8UK9US' MINQ55I/?K]&BMH>B=JO>'345^M-
RL]):))'0KYU/)UK7,7"HK6.7GV+S7L7) MD.M-0;9[O]%G5$>GOR6U-PMZPMEI7U4:ST\S,>DUB2HY6[*Y14;]+V>)C/1OZ2
M%RV+NTT$L#KGINN>CZNWL5$>U^,)+&]\DG+;*"KV&KJFJZM*JCK*=]*YR>EQND1CD1?6USEY$(M{]]CMKK=,ZT72
MPT$;_2=3V&G;JR.\.&)O;[^.TA]TF>DQ5;X5]/;[?326S3%%)UL-/,OSVHDY MIUDB)R;A%5$;E<97FN>6I8L57LBFY;HFFF'5RLRC&P*K-
Z[%RN=8C[_V;8\G M;JRG@K-7;;EEX;F=L-=3Q_5(WB9*J>M.*+EZ_49]TW*O7FGK)9-1Z1N]SM]N
MI720W)MNE>U&\7"LU57L5S4[R#.W^NKMMQJVWZBLTR1U]')Q(V1, MLD;J8FAMQK>UMCO=5^1NX.;P3T=QC<^+UHDB-X5
M;^FX5]1FS,>3SO1/5I[*SK.1A3A7+FY5'2>GS1(VRW W?W1UC0ZWQ(E=)OI43;Q1LL-B@GM^EXGI+)YPB)-5O3/"KDYX8G:B)W\U[L3:F[M?
O4[EK=I^BF318Q,:KQ+\UU]M)_]1Z*M[RA5O>>GEX%(3H+71+?OO!"K^%:Z MW5%.B*N,XX9,?_+S\!=TZK8Z@WUEGQ,JZ/.53A153*IA4
M5,9,ZW7K3?MQK-,_LU]D9-N*;F+>]TIKC37X2B_V=O9V9_"3HZ ^D':>T}J3 M5M>C::FN4C(X99.2=3 C^)^?J>)
[D]!BG'JM$=%RLK'WQ;U;XX7NZU:*&XR, M9]R1(O&B?G4PB=B(B:U%NKHX>+:V575E7;E-6[$Z1$ZZRT#]J<&L MN.Z]XUC;*IT-
2^Z25U'.K45T:=8JQ814QR:B=QD_S5^[&,?DQJ.?]U@^3-3) M_;_.#KQ8MS$1-,3IRYO,1FWZ9JJHKF-[G/-LC4'2.W'U39JNT7;5$]9;ZMBQ
MS0.IX6H]J!V6L1?OFN2TN,U%NFW&E$1'T:]R]>.63 MEYM-55RUI'27H=D7K=K'R(KJB-:>7S^B'Q-OR?6L8)M/ZFTO))BI@J6W")CE
MYNC>UK'X]37,;G].A"0R7;G<"[;9:MHM06:1K*NF54='(BK'-&J8=&].]J\ M6$5.:9-O,L>/9FF.KF[+S(PLJFY5'+O]W.[VZ*K-!;HZCM-7$Z)$K))Z=SO^
M4A>Y71O1?TJIGUHJ=J&*V"P5NI[W0VBVP.J;ZMG;3PPM[WN5$3WDY\U[$3GV M$VI]Y=D.D1:J2+6L3++=84PWSQSXGPJO:C*AF$5JK]*Y4SWM+
[%J7H\;!+-= MK%6TURNRM6-DE-*ZMJ%Y>X8JKPL[>W+<]ZG.IS+E%OPYMSQ_ +.U5LO'N7_,
M4WJ=S7X_P!'9=,RZ4VDM@Z#3B29FK)Z:CC;GFK(D1[G>\G U/V2$!#8>^.] M%SWKUJI#'G*JJ]{G*B97"=B)W)C7ANX-B;-G2KK/-RM
MKY=&9DS5;_+$;I\P[_0>IY=%:QLM^ARY]NK{GA:O-S6N17-]Y4RWX3H"YG= MRR;M5.54S3/27'M5S:KIKIZQS>D&Z6U\&OMU-
JM4TK4FHJ2H>^>>>/GEC8UJ(M%_2\;%3]FA&+INZL2^[S/MD;^,&S4D5*K<|NL:OB2BJ)46-BJV)>)D;DYL1G>0RUUJ9^L]:7V^2*JK<*R6H M1'?
2M<|5;GO(F$^ \|@V;_&F*XY4OI'ZO<[8S+%6)$V)C>N3$SIVTCNG#6V" M;I$=%'3\5*J2W=&T]->Y>R:&1(9G+^QZQ?A,5ZK+JZW)'6>
<4G]S33(YCV)Q)\]8 M[&'-SSQ[LU#TE]S*3=/=6ONMMJ[;/##%2T,CF.9Q1M3+EX7(B^[=)VIV%;% MBOS6Y,?
AIF9_5;+S[$(.BNBJ/$JB*9Y\^3F]$W4T&F-\M/253T9/6K)0N=GZ M:1KD8GPO1B?";,Z=VF+K;]06/55'+,VVS4_F5$(H7N:C)FN<|BNPOTS7+C])[
MQ$F"9\,DZ)(9*U M\#IJ>J:BX1SVHBN8_..:(J93.6]B;>9;JMWJS=P[?/ZG'CUSO'WS=&U/1SUONOH^745!>VZGZY\,#:.^:5$F1J>D]%: MCL-
XLMJ.U%\#;I] =&*AF;Q785/=-Z.5BHYLC5PYKD7**B^/K]XF1MGTNM+:PTJW3&Y],UCW1)#)6O@66 MGJ6HN$<]J(KF/SCFB*F4SEO8D95JNU=IR*
(U^+'L()M9&-N=_1-T;4]'36^[&C9=0T-[;;J=9GQ0-KII4Z[A3TG(K47#> M++GVB+Q[GOJ=#O?TM(1)I>72&W4+ MJ:C='YK)
<4B2&..%$QP0,Y*F4Y<2HF$SA,X5%617>THL43$]YEDMX-G$BJ[F M7HJB(Y1%4\Y15KX?-[C50K4QUO!*YOG,*]YDV%=Z355$547M3*(J^1/GID:A
MN=@V3IDMU:+1+6UL5)4.A=PN?$Z*1SF9\%%5%R?9]+GG/B2TZ4V M^VB-R+L,?:..WKS^X0U\,SXO-9XL,2*1%7+V-3MO1=T*JZO-9W:
O$_SB972VN21>2/7+GP^\J9/$G;J(:.MZZ4^R:[6ZT=<+=3JW3=V;;>5/=P^I,KEOJ7'TJFF*"NJ+;74]92S/I MZJGD;+%-&N',9H.3(VAGFZFH9R
M29BL8J85>>,JCE;ZUK=HJQ+T7K<:TU=89.6_9VCA3BY-4171SIF9T^W-H79/-MH]7;>FEN%3;+M;Z.*BD2*:,=7NF;Q)EKD:U,<*^EA>+N7D8=
[(:CVUU''7T-) MR6MIZZG?YQ711J]) M/&CE5LC%)6HDDD[GT<_),(CU M3T'JB)A%R[" MM[MKNS:9ODI;]17";S?K)(FLJ(%,:FQJS@5?%?
GCDY^">"&:V;5G1_V(ZVY6&ICNEW:Q49)2O?63 M*BIS:Q[OG;,IX*WM(O;S;KU^\&LYKW61)2T[6)#24K7*J0PHJKA5[U57*JKW
MJO@B(FKCT>)D1=MT;M,?NW\V_P"!LZ<;.6$$\|=N'NTQT+I99
M5ZF3V%KYF.7EE9'3.C^/B;\:$&+1;ZF]W.CM]'&LU563,@A8GTSW.1K4^%50 MFATL[Q#M[L98-%4LJ=95I!1HWL5;>!K5\ZSR<]5P
+JR%S>PM+F]A'<[ )0N;WE2C>\]5[BK> M\N+6]Y<) $"X "K>\H5;WA&K@ '"%X "JK>\]4;WE0!1(J ! N; MV*5*-[%*E0 !:42%Q:7$00 A"YO>5*-[RH
O+"\ 7-["TN;V$]D2 @[+P M%0]WO*%6]X%P %Q:7 "K>\H5;W@7 **M[RXM;WEP "YO86ES>P 3)Z&- MJ6EV]N5;YN'55P?PN\6-8Q$^_P
1#8]$=DM,KI+;#3UO?&Z*=M*V69CDPJ22 M?)'HOK1SE0XNU*]VU%'QE[G^$;$W,RJI]^6&>(5 /*/L0 AW MY3S3JW/8FUW-
C,OM=ZA@UW*V'UK8&1+/536Z M2;EC:F5=41?8D3WWL:GPGB/ZOA/:,%N;UF]CX3_ #?/-OV=W(IK^,*%Y87G MH(>5) JWO*%6]Y")5 57-
[RI1O>5"8"YO8I:7-[%!*H "_N+2X !5O> M4*M[P+@ !5O>7%K>\N"LA5O>4*M[P=E0 $+F]Y4HWO*@"\L+P N !$J MM[RXM;WEP.P A%9"YO8I:7-
[%">RH (E4+ MBTN(@9'MSJ2GTCK[3M]XFU-';[A!/41.8CTDB;(BO9A4YY;E/A/9"73EBU3 MHRIMT-/3.LUWHG0.2F8U&20R.5N45.6%:
[E[YXF)VY_MZB6G1=Z<#]K;'!I3 M6-+4W6P4Z(VCK]7A?/2,7_DW-54XV)[^6]G-,(G"VGBUW8BY:ZQV>HV'FV;$ MU6K_ $GNTYNST<];
[1:AK*&XV2LJI:R1WFUVI]=TD%1&B\G<2(J,NH;9%41R5%U](G10T\:*BJY'*

D5[]_T'|E6HOCI_DB M9G"@X4'$,GUR<*P_;A#3VL'0?V5;B^.G^2'M8.@_L]U%\=/\D3+X4'"@XAD^ MN3A6'[<(;)Y,'0:?]*M1?'3_ "1=[6%H/[*=1?;4_PD3)X4'"@XAD^N3A6' M[<(;>UA:#^RG47VU/\D/:PM!_93]+[:G^2)D*#A0<0R?7)PK#]N$-?:PM!_
M91J//:G^2">3$T(G_2G47QT_R1,K"#"#B&3ZY1PG#]$(;>UBZ$^RC47QT_R0
M]K%T)IE&HOCI_DB9/"@X4'$,GUR<)P_1"&WM8NA/LIU%\=/\D/:Q="293]+[M:#Y(F3A!A!Q#)]$X7MPAWI67H3[* M-
0_;P?)CVLO0GV4:A^W@^3)B<(X2.(9/KE'"<+VX0Z]K+T+]E&H?MH/DPWR9 MFA>?_I1J'[:#Y,F+PCA'$,GUR<)PO;A#SVLS0OV4:A^V@^3'M9FA?
LHU#]M! M\F3"X1PD^2R?7)PG"]N$//:S=#?91J#[>#Y,K[6=H;[* 0?'\'F3"X1PCB&3 MX7P1P"]N$/O:SM#?
91J'[>#Y,>UG:&^RC4/V\'R9,+A'"1Q#)]W'"W MM:.AOLGU!\<'R0]K1T-]D^H/C@^2)@\(X1Q#)](9/KE'"W"
(">34T.G_2;4'QP?)#VM;0_V37_XX/DR7^$&$'$,GUR<'PO;MA$#VM;0_V37_ ..#Y,>UK;'^R;__!P?)DO^%!PH.(9/KDX/A>W"(*>34T0G
M_2;_?'!\F/:UM#_9-?\ XX/DR7W"@X4'$,GUR<'PO;A$'VM;0_V37_XX/DRO MM:VA_LFQ_P!M!\F2]X4'"@XAD^N3@^%
[<(A^ULZ(^R;__;0?)CVMG1'V37_[M:#Y,EYPCA'$,GUR<'PO;A$/VMG1'V37_ .V@^3*^ULZ(^R;__;0?)DN^%!PH M.(9/KDX/A>W"(GM;.B/LFO\
]M!\F/:\=$?9-?\ [;#Y,EWPH.%"//Y'KDX/.MA>W"(OM;>B/LFO\ ]M!\F/:V]$?9-?\ [.;#Y,EUNPH.(>(9/KDX/A>W"(OM; MNB/LEO\ |<'R8;Y-W1*?])K]\
<'R9+KA0<*$>?R/7)P?"]N$1?:WM$_9+?OM MH/DQ[6]HG[);]]M!\F2ZX4'"@_D>N3@^%[<(C)Y-_1*?]);_P#;0?)E?:X- M$_9+??
MH/DR7'"@X4'G\CUR<'PO;A$?VN#1/V2WW[:#Y,K[7!HGD)+]]M!\F M2WX4'"@_D>N3@^%[<(D>UPZ*^R6^_'!\F/:X=%?9+??C@^3);*#A0>?R/7
M)P?"]N$2?:X]%_9-?_MH/DQ[7'HO]K_;,0?)DMN%!PH//Y'KDX/A>W")7M M<>BOLEQ_-M!\F/:Y=%?9+?_ +>#Y,EKPH.%!Y_(]W")?
M<^B_LDOWVT'R8]KGT7]DE^^V@^3) M;<*#A0>?R/7*.#87MPB9[73HS[)+]]M!\F5]KIT7]DE^^V@^3)9<*#A0>?R/
M7)P;"]N$34\G3HXJ^DE^^V@^3'M=6C/LDOOVT'R9++A0<*#S^1ZY3P;"]N$3 M?:ZM&?9)??MH/DQ[75HS[)+[]M!\F2RX1PCS^1ZY.#X/MPB?
[79HS[)+]]M# M\F/:[=&?9)?OMH/DR6'".$>?R?7)P?![N$3_ &NW1GV27[[:#Y,>UVZ,^R2_ M?;0?)DL.$<(_D^N3@^#[<(H>UW:-
^R2_?;0?)CVN[1OV27[[:#Y,E?PCA'G M\CUR<'P?;A%!/)WZ-3_I)?OMH/DR[VO#1OV1WW[:'Y,E;PCA'G\CUR<'P?;A M%+VO#1OV1WW[:'Y,)Y//1B?]
([I]O!\F2MX1PCS^3ZY.#X/MPBE[7CHW[([] M]O!\F/:\=&_9'?OMX/DR5O".$>?R/7)P?![N$4T\GEHU/^D=]^WA^3*^UYZ.
M^R2^_;P_)DJ^$<(_D>N3@^#[<(JUZ:.^R2_?;P_)CVO/1WV17S[:'Y,E3@ M8'GLCUG!\'VX17;KTT=]D5\^VA^3'M>NC?LAOGVT/R9*C
P//9'K.#X/MPBM M[7MH[[(;Y]M#\F/:]=&_9#?/MH?DR5>$&/6//Y'KE'!L#VX14]KUT;]D-|^V MA^3'M>NC?LAOGVT/R9*O'K&/6//Y'KDX-
@>W'"*GM>NC?LAOGVT/R95/)[Z-3 M_I#?/MH?DR56$&$'G\GUR<&P/;A%?VOC1OV0WS[>'Y,>U\:-^R&^?;P_)DI^
M$KPCS^1ZY."X'MPBNGD^M'I_TBOGVT/R97VOK1WV0WS[>'Y,E/PCA'G\CUR< M%P/;A%?
VOK1WV0WS[:'Y,K[7YH[[(;Y]M#\F2GQZQCUCS^1ZY.#8'MPBQ[7Y MH[[(;Y]M#\F/:_-'_9%?/MH?DR4^1DCSV3ZS@N![<(M>U^Z0^R&^?;P_)CVO
MW2'V0WS[>'Y,E)R'(>>R?6C@N![4(N>U_P"D/LBO2\V/R8]K_P\(?9%>_MX?:MDR4>/6,>L>>R?6<%P/:A%SVO_2'V17O[>'Y,K\P!I#
[(KY]O#\F2BQZQCUCS MV3ZS@N![4(N?, :0^R&]_;P_)E?F =(?9#?/MX?DR46/6,>L>>R?6<%P/:A% MWY@'2'V0WS[>'Y,?,
Z0^R&^?;P_)DHL>L8]8\]D^LX+@>U"+WS 6D/LAO?V M\/R83H!Z03_I!>_MX?DR4./64QZQYI)9P7_]J$7_F](_9!>_MH?DQ\P'I'
M[(+W]M#\F2APHPH\]D^LX)@>W"+[>@+I%O\ T@O?VT/R97Y@?2/U_O?VT/R9 M)_"C"CSV3ZS@F![<(P?,#Z1^O][^VA^3*?,"Z0^O]
[^VA^3)08484>>R?6<$ MP/;A&'Y@C2/U_O?VT/R8^8(TC]?[W]M#\F2>PHPH\]D^LX)@>W",/S!&D?K_M 'O[:'Y,)T"-(I_S_>OMH?DR3V%&!Y[)]9P3
]N$8_F"=)??^]?;0)CY@G2 M7U_O7VT/R9)W"#"#SV3ZT<@>S M_:A&/Y@S27U_O7QP_)E?F#=)?9!>_MH?DR36!PCSV3ZS@>S_ &H1E3H&Z33_ M
)_O7VT/R97Y@[2?U_O7VT/R9)K"'"#"#SV3ZT<#V?[4(R_,':3°]Z^VA^3'S M!VD_K_>OMH?DR36$&$'GLGUG]G^U",WS!^D_K_>OMH?DQ\P?
I/Z_P!Z^VA^ M3),X080>>R?6<#V?[4(S?,'Z3^O]Z^VA^3*)T$-)[_S]>?CA^3)-8080>>R? M6G@>S_:A&7YA/2?U_O7VT/\ J#YA/2?U_O7VT/\
J$F<)XC">)/GLCUG]G^ MU'[_ -T:/F%=)_7^_'#_J#YA72?U_O/QP_ZA)?">(PGB//9'K.![/\ :C[_ M[HT)T%=)I_T@O/QP_)E?F%M*?7^_'#_ *A);">
(PGB//9'K.![/]J/W_NC3 M\POI3Z_WGXX?]0)T&-*)_P _WGXX?]0DMA/$83Q(\]D>LX'L_P]/W_NC5\P
MSI3Z_P!Y^.'Y,?,,Z4^O]Y^.'Y,DKA/$83Q'GLCUG]G^U'[_P!T:_F&M)_7 MZ_'#\F/F&-)_7^\?'#\F24PGB,)XCSN1ZS@>S_;A&OYAC2?U_O'QP_)CYAC
M2?U_O'QP_)DE.'UCA]8\]D^M']G^U" -?S#&D_K_ 'CXX?DR]YAO2GU^O'QQ M?ZA)+A]8X?6/.Y'K.![/]J/\^Z-OS#>E/K]>/CB_U!\PWI3Z_7CXXO\ 4))<
M/K'#ZQYW(]9P/9_M1_GW1M3H.:53_G^\?;1?Z@^8LX'L_VH_P ^Z-WS#NE?K]>/MHO]0?,/Z4^OUY^VB_U"2/".$KYW(]1P M/9_M1_GW1O\
F'!*_?7V[_;!?ZA)#"^_?0?Z@^8?TK]?+O]M%_]$D.>H87P+>=R/6G@>SO:MA&_YB0M_VT7^H/F(*_?VI_;!?ZA)#"^_?0?Z@^8?TK]?+O]M%_]$D.>H87P+>=R/6G@>SO:MA&_YB0M\N

1>*1,|>&M:{G MSP:AUGT!M$=&SHG;EWR9ZZIUQ["2-6\542,CILN;Q-IHN:,SG"O55BYYT^1G_.(^YGZHT?\ )2'HL!Y\>4NZ85]V|GHM MJ=ULU!J&X0,J+I<:"1R55/$]V(H(E;S;(]$XE5%RC5;CW64PI;[R0B7S3-/ M=-Q-;UU%?ZZ'KYK;;:>_FLKDSPR2O5W6N1?=8:G-%1'*G-=2:.1N^7E2W2U MK%EIVZNJIFH_"YBM[9'193GR5*5B8\.1{(M9P\L\O #QKUI/=/R8F\5GN5G MODE]T==7\,.'BBI;G&Q422"HBRY(Y6MLELO%''60<7NFH]N58[\\UTK4M@UIJ1DB152+E|OI6\GSM3ZM57A8J]Z.7GPX(W;_^3!N MN]6E*#7^Z&M;G05M_9Y\VAB8Dl;)$]$5DLT\KE]-Z*B*M=A%3*YRB8-TV)% MWG\HA1Z/GXW4:7"SZ<9SYI'(L;I/>P^HD_">Q$5.R&-D<;6LC8B(UC4PC43E-MA$[DP!X\;I=&[.JJ3N#H'5U57Z?GG;3K7.9U3FR)EZ4U7#E6R1O1JX7L M547*-7A5?3SHW|VV_1!/V#6|OA2E? 6L='5T;7<7FU2Q5;+'GPRF47'-'-7O M,>Z;&C(-;|%79_D;K?')NEN%7*Q%DALT,*2=Z)).BJGPK&GQ'J^>3GD<+K M'!NSKZVJ[Y[4V2.H:WQ2.H:B_P JGQGK&! SRPMOCDV TE6\#5DAU1%"UWTR M(^DJE7'VC?B0VCY-&N6MZ&VA6J_C=3R7'"%57MY5TZHGP(Y$^!#4_EB+M'!L7 MHVVN?\|J-1MJ$;XMCI:AJK\3A1FHNG+4W-S>MJ]$6\6SJ^STX^-RM_^2OQ'L]RHC6HB*JJO)$3)SS'|< M;0H]?:+U!I>Y2SPT%ZM]1;;B2D5&RLBFC=&Y6*J*B.1KEPJHJ9[E[,6^;7V M@_-6T3^^.C^4*?-,;0?FJZ)_?'1_*$;O:D=H/LCUM|W4? XH:EZ5WD|]N=C-@ MJ4:XL-[U167;U>:.}3#[F7D?. M@7J2[ZO7>AKQ?KO77N|5/GW75URJ7U$\O#7U#6\4CU5SL-:UJ97DB(A(_ M M M M M M +>#U_";,ZBQYT^ M1G_XC[F?JC1_R4AZ+ >-W09XY/*+3OE;\|\^O;G*Y,*B]7/E?OJA[{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|)7HFZ&Z3VGX*+5%/-2W2C: MY*"]4'"VII<]K>;*CV+WL*'I7=('2&W6WDS;_26F5UNIZFF/L3#U|SZ2^J^V>AJ7;;;W36DZ-W64UDMM/;XW\,.-(HT9Q*F>U> M'/PFD^BOT$="]&"9;O235&I=7R1+#+?*Z-L:1M7W38(D54B1>_FYRY5.+"JA M)8#QIZ5UGN/1&Z>M!N7344LED5R;]*G5O+KVOPVNA1W8CE<^7EW)*Q5|3U8 MVXW+TUNQI*BU+I6ZT|XM-8Q'LFIW95N43+'M[6/3L5]\T5%0Z'?'H_Z.Z0VC M'Z:UG0.JJ9KNMIJN!R.J:27"HDD3\+A<+S145J]BHJ:&Y3,T[NN MV"TSNP]E5;7LE1O/#7<$O#)C*_4]O9W =7Y5/I'V?<*HT[M/H^L;?9:&N\_N MDEO=US/.4:^*&F:K<\3TZQZJB=BJQ.U%1)V]$[:&38SH^Z-T;5--EQHZ19JI MA_\ 69GNFE;GOX7/5]+X-3L-0|&'R;VA^C[?Z;4]RN<^MM64KE=2UE53MIZ: ME7FB/C@1S_GB(ONG.=CM1$4E[A_*@_!& [RB_T&^X7[7_TC3$D2-WE%_H- M]POVQ_I&F >3G^@WV^_;#^D:DDB1N\G/]!OM]^V']{U))$ M M M M M M :HKIQK_ +DG='N_V(>O^6TW MJ<" {6>@OUOGM|SHJ>X4,[>":EJHFRQ2-\', ^@'GOY&CEH;:>A15GC2)= M+QZ.I*;XW"5>*6IGM,*OD7.)SE5WK1M;MU:MIMO M=/Z/LC."V6>D92QJY/2D5.,I'?GGN5SE]:E.PTQHZPZ*M;;9INS6_3]N:Y7I M1VRE930HJ\E5&,1$15PG/'U4>]$RJM1=,=&KRJ- #H+0U!I'=:Q7FJN%FA2BANMK9 M')+,R.,%C9XY'L5'M1$:KDK>)4]2J!Y?])CI7ZMZ>M|LNV.V.D[E#8'5;9_-I41U M35RHO"V6=69;#%&CE7W2I],YW)N/2?HO;%T?1VV8L.BZ9\5164[.ON-9&BXJ M:I^%D>F>>$Y,;GZ5C3--% [;;3VZI):72FFK1INGEQUD=IH8J9),9PKN!J<2|-MUYKGM4R;A]8%P :UZ2_T..ZWZU+K_,Y391K7I+_0X[K?K4NO\SE-C?Y) M#Z"4GZZZG^9T9-HA+Y)#Z"4GZZZG^9T9-H M M M M M M M 6\/K+@ MX?67 1N\HO]!ON%^U_I{TQ)$C=Y1?Z#?<+] MK_Z1I@'DY_H-]OOVP_I&I)(D;O)S_0;[??MA_2-221 M M M M M &M>DO M]#CNM^M2Z_S.4V4:UZ2_T..ZWZU+K_,Y0(W^20^AQU)^NNI_F=&3;(2^20^A MQU)^NNI_F=&3;-M M M M M $; MO*+_ $&^X7[7_P!(TQ)$C=Y1?Z#?<+|K_P"D:8!Y.?Z#?;[!L/Z1J22)&[R< M_P!!OM]^V'|(U))$ M M M M M M :UZ2_T..ZWZU+K_#.4V4:UZ2_T..ZW MZU+K_,Y0(W^20^AQU)^NNI_F=&3;(2^20^AQU)^NNI_F=&3;-M M M "GN2G$45Q3B)B%9E=Q#B+ M>(<1.B-5W$.(MXAQ#0U7<0XBWB'$-#5=Q#B+>(<0T-5W$.(MXAQ#0U7<0XBW MB'$-#5=Q#B+>(<0T-5W$.(MXAQ#0U7<0XBWB'$-#5=Q#B+>(<0T-5W$.(MXA MQ#0U7<0XBWB'$-#5=Q#B+>(<0T-5W$.(MXAQ#0U7<0XBWB'$-#5=Q#B+>(<0T-5W$.(MXAQ#0U7<0XBWB'$-#5=Q#B+>(<0T-5W$. (MXAQ#0U7<0XBWB'$-# M5=Q#B+>(<0T-5W$.(MXAQ#0U7M["I;Q47^@WW"_:_|MI&F >3G^@WV^_;#^D:DDB1N\G/\ 0;[??MA_2-221 M M M M M &M>DO] M#CNM^M2Z_P SE-E&M>DO]#CNM^M2Z_S.4"_DD/H<=2?KKJ?YG1DVB$ODD/H M<=2?KKJ?YG1DV@ M M M M ^;_ '2EN4*O]TOO%A:&"J>:[*#*%H+;*ZKLH,H6@:&J[*#*%H&AJNR@ MRA:!H:KLH,H6@:&J[*#*%H&AJNR@RA:!H:KLH,H6@:&J[*#*%H&AJNR@RA:! MH:KLH,H6@:&J[*#*%H&AJNR@RA:!H:KLH,H6@:&J[*#*%H&AJNR@RA:!H:KL MH,H6@:&J[*#*%H&AJNR@RA:!H:KLH,H6@:&J[*#*%H&AJNR@RA:!H:KLH6 M@:&KZQ^Y^$N;V*61+Z*^^7M["C8CHJ "$@ M M !& [RB_T&^X7[7_TC3$D2-WE%_H-]POVQ_I&F >3G^@W MV^_;#^D:DDB1N\G/]!OM]^V']{U))$ M M M M M M :UZ2_T..ZWZU+K_,Y M391K7I+_ $..ZWZU+K_,Y0(W^20^AQU)^NNI_F=&3;(2^20^AQU)^NNI_F=& M3; M M M #CS.PY$ M]1\^)14NP]/>/CQH9Z8Y-*JO2]7VXE'$I\>- !QH3HQ[[{<2CB4^/&@XT&AOO MMQ*.)3X\;#C0:&^^W$HXE/CQH.-!H;[{<2CB4^/&@XT&AOOMQ*.)3X\;#C0: M&^^W$HXE/CQH.-!H; [{<2CB4^/&@XT&AOOMQ*.)3X\;#C0:&^^W$HXE/CQH. M-!H;[{<2CB4^/&@XT&AOOMQ*.)3X\;#C0:&^^W$HXE/CQH.-!H;[{<2CB4^/ M&@XT&AOOMQ*.)3X\;#C0:&^^W$HXE/CQH.-!H;[{<2CB4^/&@XT&AOOMQ*.) M3X\;#C0:&^^W$HXE/CQH.-!H; [{<2CB4^/&@XT&AOOMQ*.)3X\;#C0:&^^W$ MHXE/CQH.-!H;[{<2CB4^/&@XT&AON93KF-WOGU7L4^%*[BC=[Y]U[%,$]6]1 M^6%0 0N M $;O*+_0;[MA?M?_2-,21(W>47^@WW":_^D:8!Y.?Z#?;[!L/Z1J22)&[R<_T&^WW[8?TC M4DD0 M M M M M M !K7I+_0X[K?K4NO\SE-E&M>DO]#CNM^M2Z_S.4"_DD/ MH<=2?KKJ?YG1DVB$ODD/H<=2?KKJ?YG1DV@ M M M ZZK=B7'J/AQ>L^EK_ #J<;C0VZ(_# M#C7JM*Y? 7B]8XO6?+C0<:%|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|)KE[54]2-C-6UNN]F-!;EN28N-XL-#7U/H*+ M++ Q[U1/!7.54]0'1](7I*;+Z-6D8[!]ZKF5U0Y8Z*VT;$DJQZ)E48U51,(MG:YRHU,ISRJ(L%*WRO\ JFX3U518=IZ9;92^E,^>X2S.8WN<-]S(FM9R\4Y?? M-9ZW6HZT]+*:TV:CC2&GH]6-&QL:GJ[U7O5IF1K3'E--@J# M8C<32>Z6@H&Z=]E:I[IV6]J1,I;A$K9(YXT3DU7IE51,(CHU7Z93TDZ/VYT> M\NR^CM:M1J27>WQS5#&)AK*A$X)VIZDD;(GP ;% "-WE%_H-]POVQ_I& MF)(D;O*+_0;[A?M?_2-,\G/!:OMJ^V']{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|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|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|L]N] M0:9U/HJRW+1M515>EY]9B6^2W(UL"1-3A1C6HB<'#CAX,(K5145$,&0Q*"; M46?C<1Z\C?K:X7+ M1VXNE*B=\E!:JRDKZ6-W-(UJ&S,D1% [D5:=BX\55>]WFG E6K4QX^BA[('CG9XDVW\JY(VK5(TGUI4/3B7'^_D>YG:O?YPW MXSV*X@-)=- ;)LG12W21S4*85/OIDB/Y&*5S[)NO$ON&U%MCVPW" MO;V(VGKKQ#1QO[W+##Q.^!.O3X<@>A@ "$GMMVT'V.;V^X:/\;,1W>\J! MM;K[:;6VF+=I_5T-?>K+6VRGEJ]2D;"R6:"2-BO5*E51J.1,#Y MFC:#\RG1/[W*/Y,U[T@^CWM;9=A=R[C;]MM(T%?2:9N<]-5TMAI8Y8)&TLKF

MO8|(\MU>\[?¥FG4W_KUH_=9?DS.]H-;6"S;=6FDKKS1TE5'UW%# M-,UKFYE>]93/@J&:?EE;4^R"W_N[0,6V:VVN>WGLQ{(STLWGG4]7¥]]RXX./
M.>)K?]D^^93KO1U+K?3\]MJ,,D7TX)E3*QOQR=[WKCI:&\4= M94R9X(89FN:+ZEPG_D;6Z/^W:5;TU/7L:^*-RMHHU[MW)VR>K'8GK1?!%76-
LT_>M:R7:O@CDK9*>-U752.7*KE]J=[MSAR)\"]'!,1M@MS;7[&)0TZ6[@X/->K3J^'&,<.,$1M:VG\A M^M{G1TCW1I25% [/I-
;R>SX4RG/U9):P;HM51:/91EPIUM_#QK4=8B-1OK\ M")>L[HNL="G;CFY.3&?'Z/Q@:]W9U3+3;4+61+U4MRCACRB^ MY21],=CX$5/A-4[#Z-
H]4ZF])ZZ)L]+0Q=9U+DRU[W+AO%XIA%7'?A.XVQNU MIF6;:EU'#\\DML<,B83M2-$:['P*J_ :FV)UC1Z4U+40U\K8:2NB2/KG+AC'
MM7+>)>Y.:IGNRGTU%LBK:.G5W Z.3J[&HJJO/DJ+V^HVW MN#NE9-'52VNZ4555OGB23]V1,=&¥]]]857*G+*D?
1W*1K8_[L5S(WXSA5,.POW_O&_=D:NJKMM[9)5. M,DMZ;1=AHGTKZ>ST4$E*[CA?'3M:YB^**B>LC!L\WK-R;$B+_P LY?B8Y27@ M$.MSKO+>M?
7R>5V495.@9E>2-C7@;C'J;]]?$W;8]V-O]/V6"UTM4YE+%&D:-MM\SD]/EA5=Z/-5[\]H3="TRV;7]]BE9PI)4NJ(T[G->]O:J8]_]R^]O+3^V
M&WFI+/3W*BM+9*>5J.5?)/LL7&5:[T^2IWH!H+5==;H=95E=IV58Z))TGIG(-MU6*Q5PY41%3DB._ 2_LEP2Z6BAK4Y)4P,FQCZI]._P
YH9];M'%=:FA=9*QW M5RK$E1#-,^.147"JU6R\2\\]W@;\MU)#;Z*GI:9BQ4T,;8XH\KZ+6IA$Y\^S M':!S M &&:J_X3_8)^%3IF]AW.JO\ A/\
8)^%3IF]AZ'&_P!]'S+:.M/_)N?54 &TY@ "F4*@ 1J *90K^ MP]P &4^#Q'PX7P7M(U6W;@%%7A:]N5&IZU.%/?K;1\77W"EA7_M)FI^%2-Z/
MBO3:N5=(U/X72_@:A'CT=I9*=F9'> M/WAM).__/$IR-7_)*]>7#^\VCS?_\ AG-_CJ?5M3N2YN4@C^'J/I)7QX[4
MROPZJ/S5T_JV8.)/$U>ZCW'K%7K)_-T]3X6?Q2]NC]=.;E;^UB_GJF3_ #-'-MC3/2F3R-NGK=AO;2"_W),G_:?^%#(.>3#-K:.MM^EHZ>Y5"55:R5_63-2\
&)O M M =;?[2V^V*XVU[UC96TTE,Y[4YM1[5;GX,G9%,(!XP^3[UQ3]&KIMU
MCLSZV&ITU4S5*\#*:J29CF*YR]C7/BX$7DGIM5<8/9U'HJ93FGB1\Z8_D^K% MTDZU^JK#7LTOKE(TCE]/(E=2W!&IAJ3M;Z2.1$1$D1%7"
(BM=AN(V6SHL=-K M05OCTU8-<3/LD?SN*2CU)B*=G5]:C9&-]36[[P&UO*V;OV>S[26W;N.KBG MU#>*^*MDI6X6^UU
M1=XX7]J1/X8XU]YS8FO3':CT7O-%[(^2OO5SUFW5V^.J(M02.G2IFM5'4RU4 ME<_E_OJID1%5.WB:W.
<^[0]':.D@H*6&FI88X*:%C8XH8FHUC&-3" -;BR1CD5KF]F45%[T7Q(Y],3H6Z>Z55DI:A:I+#K&V1K'0 MWAL?
&UT:JKNIF;E.)BN5514YM555.UR+$&R]$GII;=6]-):9UPZ/3L?%'#)0 MZB5D$+,2CU!>=([5V>I2NKK=,^YW."#T^KF>U(Z:
M)43/1\#Y%X>W$C/$G;T6-K]JG>CYH32%;$V&XV^W-=6I MYHRHE5TLS<]^'R. M3/?@C%T3?)I_E;:RI]?
[I7JEU5]>GF=54UN@XY:.*=7<25$LLB(Z61%R](K4 M1KN>7*B8GKCU@5 "-WE%_H-]POVO_I&F)(D;O*+_ $&^X7[7_P!(TP#R M<_T&^WW[8?
TC4DD2-WDY_H-]OOVP_I&I)(@ M M M "B]A4M]%@!]O!8 :K MP6 &]\%@!]O!8 :KP6 &]\%@!]O!8 :KP6 &]\%@!]O!8 :KP6 &]\%@!]O! M8 :KP6
&]\%@!]O!8 :KP6 &]\%@!]O!8 :KP6 &]\]WO/E71^Z*)B7T 7 M 'CYTV-N=
M4=%'I;TF[^G]5TEFNUV2]T54K%6+SM5XJFED5.SC57N[N)DBHBY:N)U;7>4- MV2W&TS!<:K5])I.XK&CJFUWU_42T[OID1ZIP2)GL5JKE,91%RB;
[U?HRQ:]L M%98=1VFDO=GK$1L]#?0MEB?SRBJB]Z*B*B]]*B*G81/U-Y)_8V_ULM11KJ73 MK'.XO-K7M1TCK??]63Q5CJ.5
MN)*>EC:Y(&R)GDY>LD?CM1'HBX5%1,]V>Z .S&R]Z@O5JTW)=[U3N1]/<+Y. MM4^!R+E',9A(VN1<8),7GE4]DKYI/GK
MZBG9EU'60.5:>HQ%3&$Q@",/E!>F%:^DA+8MJ=]VU6H:)UPCFJ:RG@>GG]3S9#!"U41SFHKE5 M7*F%7&.296??
1%V,^9\V&TUI&?"W9L:UETD:N4=5RKQ2(B]Z,]&-%[VL0X6Q MG0OVHZ/]>MRTMIU)+UC#;Q?"!< M
&M>DO]#CNM^M2Z_S.4V4:UZ2_T..ZWZU+K_,Y0(W^20^AQU)^NNI_F=&3 M:(2^20^AQU)^NNI_F=&3: M
!IO=79^]ZYU.RY4%30PP)3MAX:F1Z.RBN5?Y_1IO8F$5B=[D]R[<':75VO=0S5\E;:XZ5/G=+ MZ:7,<:+W_. =*O-?_(W?P^L<(&+
[=Z+@T/IN"WQ<+ZAWSRIF:G]\D5.>/4G) M$]2&K=9=!FON.H:NKL=30T]#.]K$@]'.:L;EYN1.%B\L_A]1OKA"L1P&&6. MWWNSZ"J:*^S4]354]-
(QM13O<[C8C%OQ<36\^XC1MY9J;4.LK7;:QKG4U3(Z M-Z-7"XX%YX)>1+R\Q.EL]>R-.*1\$B-1O:]JU<$;=L-!ZBM6O+-5U=EK::FC
MF5SY9(51K4X7=J@W"IE/4IG&UVR$> MDJYEUN\T5;<(_P"\QQHJQ0K]5E?=.\%PF/?-M\(P@%KHT4X0(RTO1SU/).YDTU MOIH47G(LKE3'J1&_A-
Q;=[56W0-.]T4CZJX2MX9:MZ87&<\+4RO"G).]5]? M9C-^$N Q#7YW-NU_;605*NIZJ'B6GJHTRZ-5[45%[47O0T[+T?=66F>1UNN% M+(UW))
(IGQ/5,]ZV M&217KEBIR16(G?XF]BF/65 P/FN$%TO M=3%7U<*HZ*GB;F)CD['*Y>;3EJNY(;C*80] M-8;JK-A-/6GX5.F3
ML.XU7_PI_P"Z3*G3IV'H<;_ &H?,MH_\JOZ@ -IS $Z3("-4 Y]N. M1*=) .U<=_\ ;P'X2-4Z3("U\C86\4CFL;WJY<(==4:GL]+GK;I1L7P6=N?B
MR4WHA>FU/;CNS4[/R:NE/[&RN+PYE>W_/ UEAW KG(LMP\V_]\U/XB*? M1VC-3_6(_UI]0C=P;>M4S]-%E1NGIR!'8K'S+_V M<+_\Z(=;/O/:
(\I#2UDJ_GFM:GX<_>.[AVXTY3^XMC%_3R/=^%QV5/IFT4?] MYME'&OBV!J+\>"=V[/>$[V#3TIF?JP) ^\\T[E9265SW=W%,JK]JC2L6XNJJA
M%6+3CGL[N&GE=@V9&QL;4:QI,X-3"?]P7F@\.YZCS6-'Y;,?>9:0?K M?6M0[@AT^L"_5.I9$^ ;+Y2B2;D?!]UOFI:,?*U]?YU-H\^Y1X,SUJD
M_13^6U3]^;5R:,UO7?[YOG4HOT]U]O>GFW;_EG*I]E[8S'7UU5*O?U? M"S/WE-A@MY>A7B63/_;]H8?3;4:>A]W!-4?XR9R?
Q<'W_*PTS];$_=Y?]8RD M%_!HCLP>=R)_[RZ&FT'IZFQP6JG7].WC_#D[.FM-#1X\WHJ>#'_5Q-;_)CE M@M%NFGI#%5D7;_S53/W5Y>LH
7T8M^K3341>SF$5.7B_$?<[L?YRG"G/_\ M_]"5?HRK2*YHYO'K/_"AWZ=QT.D/]YS_.,_\+3OD[CS=_\W*GT_9W_ !;/ MHN !A=$ M !;P#A]9< +>%"X
"WA7Q'#ZRX M6\/87 C=Y1?Z#?<+]K_Z1IB2)&[RB_P!!ON%^U_\2-,_\G/]!OM] M^V']{U))$C=Y.?Z#?:[]L/Z1J22(M M M LD]R7GSD7#?
A)A6KH^>5&*<2>(XD\3)HU] M5(T-5(T-5(T-5(T-5?$OI? 5E.2U,\WV M!1L M :UZ2_T..ZWZU+K_
#.4V4:UZ2_T..ZWZU+K_Y0(W^20^AQ MU)^NNI_F=&3:(2^20^AQU)^NNI_F=&3: M !K"?I :>I[Q);745R M=/'4+3*YL<:MXD=PY_OF<9[\ ;.P@X?
A*@ '2:KU/3:/L53=JR*::G M@5J,. B*_P!)R-3'*])VJG>!W8,'T/NS;->W"HH[=35L,D,77.6JC8U.'*)R MPY>>5/OKONHDN-
/5S>=H]6>:M8N.'ASGB&H1J.RB([^Y4=>F2+X0PR2 M??:U0/MJO_A)/4GX5.F_ 8OJ;>W3E16I)3>=U"'<'"G#$C>>>5^]\:L_)1KR
M]+FBMWFC/I7)"C?OR+@JFG-P+AGKKGYM_P#Q'#_)HIDB_P"FF9:T;.W?]RY$ M?=M)/#\/()V*O5QJ>M[]I;#J+I1T?
^^^N"#_&2HTZVHUQ8*7^^7;F7](_C_!DQ.GV4HFX MZ^Y3R^/5Q9M9^:)V=-M%8(<<3:F?]/-C^*B$:WIZ4Q!X6#3UKF?I#[5&ZFGH_M\%1-
/_BX')_&1#JY]Z;8WBZBAJI%[NL5C,_?4R&FV[T[2_WNU0K_(Q7/_"I MVE/8;;2XZFWTL/\ BX&M_ A.EZ>\01&LJW.;0V/C7/)7/=)
MGX&M0M36.N:_/F[CZE/JD!$?XU4VBUJ-1$;B-3P3L*_@\!X-<]:Y/.6*?R6 M8^\ZM7+#N/<$]-
_FS/TT34^]E1^0#6%=_OJ_\+%^E\YE7[V$0VCZ^_Q&$'@1 MWF91Q&J/R44T_2&KX]F))G<=?>7/=^=BROVRN.RI]F;/'A9JJLF=WX>U$_ J
M_?,^!D\"CX,<[1R:O^S$X=K-.1MPZB?-ZWSQ_P RH?1FV6FFNREMY^N>1?PN M,H *CTL$YN1ZY_6734VC+%38ZNTTJ_IXD?^')V5-
104G]&BA_Q;$;^ ^X+ M?I0I1TABJOW*_S5:@ .C#0$*CG9W_ 5Y^(.1]5$7QYE0"3Z M $,KT=_O.?_ !G_ (6G?=R'0Z,_WG/_(S_ ,+3ONY#S5[_M
':GT_9__%H^BX &%T0 M M C=Y1?Z#?<+]K_ .D:8DB1N\HO!:ON%^U_](TP#R<_T&^WW[8?TC4DD2-W MDY_H-]OOVP_I&I)(@ M M 6\:#B(U@7
LXRO%ZN1(N!9Q^H-DXNX"\%$ M7)3B]0%P+,L]BO$!<"SB7P"/5.U +P6\7?W%O!Q@7@LX_45X@+@6\7?@IUGJ O!9Q^\7B MY@7
L5_#V]@X^640"\%O%ZBO$@%06\13K.>,\"\^$[L1_"?9O8<>K=PQ^/,M M3U8Z^5,OCQ#B/EQJ.-38W7.WWUXAQ'RXU'&HW3???7B'$?+C4<:C=-]]>
(<1\ MN-1QJ-TWWUXAQ'RXU'&HW3???7B'$?+C4<:C=-]]>(<1\N-1QJ-TWWUXAQ'RX MU'&HW3???7B'$?+C4<:C=-]]>(<1\N-1QJ-
TWWUXAQ'RXU'&HW3???7B'$?+C4 M<:C=-]]>(<1\N-1QJ-TWWUXAQ'RXU'&HW3???7B'$?+C4<:C=-]]>(<1\N-1Q MJ-TWWUXAQ'RXU'&HW3??
7B'$?+C4<:C=-]]>(<1\N-1QJ-TWWUXAQ'RXU'&H MW3???7B'$?+C4<:C=-]]>(<1\N-1QJ-TWWUXCZTKLR+]QQ>-3[TKOGJ^\4JCD MR6ZM:HL]?
6R<$3'.7@B;VHB>#6IE0)56;7%@U!,L-NNU-538SU3)$XE3Q1%[4]X MBE=_\(5=^]K^7//]^7_.;*KNCG76NW)66V]K/=($ZUL:1+'Q.3ZER.547P\?
M4:CH:B6KU!3S3/62>6I8Z1R]JN5R*OWP)N<7/L.JO>J;1IQK5N=RIJ'C]RV: M1&N=[R=J_ <#<#53=&:4KKIPH^6-$;#&[L=(Y>%]?
Y_@(UZ3TS=MVM3U"S5N M)%,UM563(KU:F41$1$5,Y5>3UD:4RV[G81J)VJJF. M2[H:3AJ'0OU!0HY%PJI*BM^V3EI\3O?
N!57W4559Z>9T=KH9%B6-BJB2RMY M.<[QP[*)V3MK+T:JZMM4=367:.AJY&<24K:?C1N4RB.=Q)A?'"'+@#?=KN]) M>*9M30U4-
93N5426"1'MY=V4[_%.XZ?<.T6^^Z2K:&YW!ELHI%8KZJ1S6M9A M[53F[EVHA'C2-/JK0>M9645OK*MU/-U-5%2PND9*Q%Y\T3PYHO:ANO?-
W%M;_M=G=SE@[4Y_WU@'-VKT1IW3%VJY[/J2&]320=6^&*:-ZM;Q(O%Z*JO:B&+=)_ MT9M.8Y>C4?AC.LZ,W/55V_[EV]_]\:=GTH/[]IS]+4?AC
RCHZ>EM_)E5_W[M)_%8;*]JN&B@?/42LAA8G$^21R-:U/%57L0UMT MIY;;3/]?3*]Y1,]W9VKD-_?EHZ2ZWJ?9^AXN+AXNM]
M'/Z;L^)2E/5PU,+989&31O3+7QN1R.3U*G:;%BZ,M6ZSI(^\QMN?!GJ.IS% MGZGCSGX:U%,]V4BD5W"QD\%1>2XQR]Y,!*3 MB,?
N6X&G+/*^&LO5%!,SDZ)9VJ]OOHB\C$=^M3U>G=(1PT,BP3UTRQ.E;VI& MC55<+W*N$3WLFIMJMM;7KV*>2MO?
FM3'+PMHXN'K7)A%XTRO9E<QZ.XT1?11U=7]VR6_*55XH8%3M22I8U?BR!VX,+K-XM'46>LOD#\)?]2U\O\5JG M1UO2(TG2M=U2UM6O7+TE3Q
V>]X3*E31$W2#OEZG6+3NF%GNW^]I/YGGQI6Q_R]@;W^_J:(32V\%X_WU=TH<]O]T,C_ M_)%!^49J^Z9]E-7+)G_MI\?;*@&VKQK:Q:?1Z7"[TE-
(WMC=*BR?:)Z2_ A MBJ7OWHZFXN"OFJ53NBII$_C(B'1V?HUV2DP^XW&LN+T^EC1L+%^#FO\ E&64
M>S>C;+'5V*%V/^M>^3^,Y0,4K.DM8HT5*6V7"H-[MZ=MEBIJ3"4]/% G_9L1OX$,^U4F+G^P3*G3G>Q MJ8\,)T?-
]HW:_,UTZSU^P41$Y72;W#V9M"JU7D5Y%[.%[2:NW/W+O*M9J&2EM,#D M6IK/,Z=<=_ SYWS'-2:&F-,6_2-GI[9;(&T]+
WA:U.U5[W*O>JKS52^!.7M7(\S55-_J.D1, M\UKFK'(JIAS M53M:G8AK79CI!7]NU=%;=47%*RDK42&&5T.B[W//OX?69ETN.
MIH&UI_[39_(S$44CD9&DW"YK.+"287'$G-4SX_OFCM?:&1A[1B:*IW8TY:\ MOT;>R-GX^9@5>)3&LS//N]'6NXDRB$:M^]V]6Z-UZMOLUW6CH_-
HY>]ZB%_I M*KD7FYBKW)WJQL78/!3D6*IC68Z.7LG#B,^K'OTQ.D3UYQ\4F]M+O67W0-BN-? M-U]94TK)9I>%K>)REI5PB?AU.Z>
[MMVRH&K.U:NXSHOF]'&N%=CM?" MWUX]{//"*V=D1FU>G57DC:&/G\!#S7>HZK9T;>VJ)L$$-5D3%?73LW*MJ8%%?ATX\31TU[_,OZM<;0 M]
(&CUY.VUW*%ENO&/0:UV8Y\)E>#P7DOH\^SDJ\\;BRBID@'K/3U5MSKJMMT M-1(V:WSI)3U#?
1=PX1S'C^C2VIL^W9W+^/^2OHQO=S?"W;:L;1PQI,2:7^[;M6HCG\W(SB=C/Z5K>2>I$0FJI#0MET5:8Z"UT;((VIZ">EE5%?"_P7 M':G@O?
[Z*B8UO5LW3Z_LSY[=30QW^)S5BGY,ZUN<.8]<C'&WW;V>O6%]5-PT]#!2PR<&>QN7,55QXJOWN9CVO\ 7-YW=U5&K89'-M-
<_J:"WQ>EP(^'>Y>U7>KP3!)3939>FV]MWGM;P5-]G;\\E1,MA:O\ R;%\ M/%>_U)R,3MC*\/%]FFW3UF.6K)3C8^R<;?R:8KN5=(GGI_G=F&A+=?
K;8 M8FZCNBW6YO\ 3ED:$R-D>?I&\+4RB>*\S#]WM\:?MNB4-+$EPO;V\:4ZNPR) MJ]CGJGWF^KNY9V)J"[16*Q5]RF=B*C@?.Y?4U%5?
P$$*&&Y;DZVBCDEX]^ZU-M?]R.3DU7.RYV/!&HOP)@Z.U\VY@6Z,?'_/5RB9YS#0V3A49MRN_?Y44\YB.7 MV^C*;AT@-?7]J>L-T=3-VFWIMNY<#Z?
@\PO$*<IJ]6AFFBDPB\+VL547"HJ+S3O(1T-9<=N-;1+$[AKK56.;[A7"/X'J MUS?>+5B547XE-O9NT[F5BW;+O^Y1$Z
M_P!VKM'9UO%R+==K_;KF)C^S16S^]&L]4;C6:UW.\+5T,[I$EB\VA9Q8B>Y. M;6(O:B=BDJD1,$(.C\N-WM/+^?F_D)"<#6Y3*\E+_P
.7[E_&KJNU35.]WG7 MX*[>LV[&133:IBF-.WUE1'I);A:@T&RPK8;@M M2Z?KOG,!%QZ#4[U,3Z8G]!TM^FJ?P1G9=_Ms+_.BM?/^-
DVFK3D7IVW59WIW-.FO+I\&SY>S&QHO;D;VO73GU^+5-VZ0.O MJ6Z5L,>H'-BCF>QB>:0+R1RXY]7X'$^:(W!7E^2%?5<=/S[OJ.PFG[%TCE5
M5IH55>U>K0B5T]J>.GW%HV1L;&WV-C7A1$1,],+S.?M/#S,&U.1&15,?#G_= MO;-R\/-NTV)QZ8GX\OI.A^;)W#YK^2%<<_\G!W?^[-
J]'3='5&M]3W"DO=_MT6NIX:7K6,ZB-B([C:G:UJ=RJ9AT<;?3S;36B22")[W/G])S$55Q,_O-HP44 M%-E8XF1N5,9:U$.ILS RIBWDW,B:HF(G2=>\?
5SMI9N+_J8]NO33,3IK&G;[M.3]*<2X+AC??_P RG*^C%,9AB)=K->MK-6L5>** MKJI.LIJCARR5JW@8B=OPJ:RBMM1;=3Q454UQZJGF1RM1<
MXSM W_-)!CW:&I5;[EMP8K\>'5R),G_.:?VUAUE+)<5TBJ\;6QI5<.M+X47&7<']\7Q1W824U]I5FLM*UUK=Z,LC>*%RK[F1O-JKZLD9]*ZEO.TVIZC
MKJ1W&B=5444RJU'MSE.%W=A>QR93WP,PN^F[W;]:YZ"OB?4TLV$DB?-2HBX5 M%SR=XHGQ'>[(]?ZDT=J>MJ+M;UI*.:D=&CNOB?E_&Q4Y-
WQT5KH;,G&DDDT50]RJJ=C45$3"9_ALS9>CU,MDFKM15U5,E1P^.4]4_ MB>UG/TU5>>5Y8Y]WK CQ.
[AUC,M1SX:]W6Y_QB\62:'X:+V*!U:)2>>T_G<:^E#UK>L;E$5,MSE.2H8?OIZ6U]WQ]5_O\
M\UAH33NG[QNOK&661'6>;K:NJX51D3CGG\KV7"X_NV3^*PCG;(ZWV\?H#RXQ[&5)&=+'+_!_)_P!]D[_SK#5&{>AZS1VJ9{G1QR);:B7KH*B/ M.
(G]["L54[%1KLJN$?XF44G28JH[3U<]G9+V;AC<[ZI6\/+WLG6;4UVM-7 M:F1\=XN#;;'-
UM7(Z571X5V58U%RF5Y]G8!NO7NB*;7=@?;]AZT\C7)+#.U, MK'(B*B4U$J/SS^']]TB^\AN?>>U:AJK#%6: M?K:R"2E5RST]),YCI(^7-$:J95,=GK-
5[>;WUND*>HH[!+=8'2+(DCIEZV- MRIJ9=G+>79XY QNVZZU;HRJ;$VOK:9S.VDK$5S$3L5.!Z+A/>PO-"1FU^OOR M?:>=5R1)3UL$G4U$;

M|%:SMUZ]XV|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|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|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|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|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

MD;I05FO9Z.KCXE8KH//7+(B+V^E'E$7/TQ[JT%OI[;0T]%20LI:2GC;##!"Q M&LC8U$1K6HG)$1$QCP \@J?
I0=#H9;WH+=N:MRO5MF1'+,]15#:N.LC1415 MAK6JY4>U.W#UPKD5[57"'J?LQNW8-\MN;/K/34[I+;<(^)8Y>4L$C5P^)Z=S*
*MFN147M1>U%5%135'E!MO;;K[HJZW\]IVR55EIO9BCF7DZ&6%5551?7&LC53P M=[Q'7R-.I*NKT?N=8'O0-$[5<.I_*L5;I$ MZUK=:W=S>?*
=#YRK%^#]T7!|)'CEMU$[2'E7*IE2CH%DU|)K;-)*GZ9BH][_K44B?Y&6L?)IG=2B5SECAK M+?*C>Y%>R=%5/M$^(E5TZ+G#9^B3NA/-
*[A]I=3IS^FED9&W_"GH1?\ (T6M M\.B=S+DL;DCJ+A1TZ/QZ*NCBD|(/[";6WK87F;G!34E+?J626>1U+*UK&,23+G*JHB(G;] MX-7^U({0?9'K;*
*[NH_P 4,0W>\E_M;H':76VI[?J#5TU?9;)6W.GCJND="^6 M&"21B/1*0%5]N:F4147'8]+S S#R2'T..I/UUU/\SHR;1"7R2'T..I/UUU/\ MSHR;0 M IE -2=*
(#6L]@L=/;:.3JJBX<76O;N'-A;C(O=E5QGP12-O+T MN1N3I,4LC=1VFI5%ZF2D5C5[LM>JK_':;; JG9^ RW;;<&IT%>_,$1\]#,G! M44S7>*
*[Y>BJ9[T7GGUKXF(G(H*62NKJ:FB3BEGD;&QJE%N5V$S^E1%.RL/1[EKJGS[5=XDKIWV4$-)$Y,.1CUS<|F$RB)DD;VR,>*
*MB,.YJY1R+V*B]Z'VX0(+R4TT,W5/B>R7LZMS51WQ&>Z!V;O&]ZR.6LII;=:D M5%DFF;K'R-SGA8B\\K]5V$]D:B?A'#ZP.-;+?3VF@@HZ6-*
(J>!B1QL3N:BEG:K)(W)R5/|)H#571TN]%42 MR6>.X4KE7AAF4]XD<4X0(KV[8'6-9,C)Z*"@9WR3U+%3XF*
*M*Y3>&V^V%!H"E>YCUK+C,F)IMS<$<)<:+>$<)<:+>$<)<:+>$A2Y%3';DPW M5&[NA]#W%+?J+6-AL->L;3>:W.YP4\O5JJHC^%*
[D7&47GV]4:F55$3*]JD\YZ* MSI$:S+MT:HP8EI3=?16NZZ2CTU]ZQ:AK(XNO?3VNYPU,C8\HG&K6.54;E43/ M9E4,M153N&DT\I13-
*-4:TRKPCA*Y090A?13A'"5XAE -*<(X2N4*<0-#A'"4 M1_9RP4ZSP3(2NX1PEZ9LC9$7"L5]ORCD7ECMR; RBEI[IZJ4U4U?EG M4X1PEP*KZ+>$<)<*
:+>$<)<:+>$<)<:(F$*@![M (A=*7 MR\5-98Z"_=2S.+WH>KFD;(U/IEZGKYK[MJ'N%P^L<'K4#PBMG3VZ1&E M'+1MW&NC)856-*
\=RI:ID:N<*CNOB<[*=G/O*W/R@G2&OCD9-N37L>N&HVCH M:2G7.>2?.X6\SW)NNF[5?8^"Y6VCN#,*
*(G#5T]4PBY1,.1>6>9\;5HO3|C*EI(XESX^BU /$JS;*=)WI3U\"W"CU??*.1YK MIE;W">$:*O@BDS^CY()[3&BIX+SNE<8M8W*)4?'9J)'LMT:I]6JX?-*
[V&-7O M:XG\D;-QCE@N1N.\#Y0P,@C;'&U&1M1&M:U,(B)V(A]@ 'PJ>.J@D@E: MCXI&JQS%3DK53"I]\^X \8>AW60=&+IZ3:7U-*
VA@;,55FG'54SN%B]*

*7*1%7D>SG%ZB%W3IZ S.D7.S66CJBFM>O:>%(IXZIW#3W.)B88USD M1>"5]2.5$1%2.]@W;Z^)/7Q+V MX4V'Y,S1=7H[HF:&]JY3U*MELI+/;*
MJ6@H8(Z2CI8VPPT\+4:R.J<+6M1.2(B(B>\@'C[T9)8^B[Y16LTM=G-H+=- MD<5RB8KE8G'V,E:JJC7+R7*(Y4PBI'_3^]_3EVZM$.D)-!W>^3P-*
*=3PW M2NL,E=*Q$3"9J8U6)^/]WJ[B\7 9GY8OV2H>Z=6N3ZLL1J MIW<,.XAMT=N@)N-NKNLW='1!RR.3KTK'VJMG;)65\K>']TE:ST(H41$!:%1<*
M-X$:U%R>G:-QW@7 6)'SRJY+P (V^473/0XW"_:_| I&F))$;O+_0;[A? MM?\ TC3 /)S_ $&^WW[8?TC4DD2-WDY_H-]OOVP_I&I)(@ M*
*ZF^:EMFC%%:NYUL5%!G".D=S5?|$[57U)S.V(?[B;FK-=ZTJ7M[WFIE5^!#J=)72*R[76JX3_WFEM.Y)?BR1FU#M'J/2^K*
M&0V&"LKV,X9Z>M@CX>#FO)7=B.147WTPO>;^6>OJM 5+[K3+2W)UOD2>'B;[M#^K5%[%5.?:!KW0](@VWH]4T,]DO-357-KE6&%
[G85>%W=P)W9.[Z1'^#UW_> MXO\ Q&E=F>>Y=AS_-:_^3<;KZ1'^#UW_>XO_$!B'1?_-^ZA_Q==TA-:U%=J!=/P2\%%1H
*MUT[&K_?)51'8=XHC53EZU VA4[XZ.I)G1+=`2JU<*Z*"1S?@5&X4R33VK[/J MFG=-:KA#6-;*
[IK%P]OOM7"I&G=$=']AO&G*6ONU=515%7$V:.*EX$:QJIE MN5T&O5C@J>*6FV*)KI7(O@O"BX7WSBZ[U4^GVPKKY;'/8^:ECDA>U/*
M2:DJM1'>^B.S\|\"7;BSZKT1S)9VR1.:O>CD3_29UM-I&Z/I+LL]!=ZN"]BXVOIV M0O<[J45/2;ER)RRB+CQSX@;.M 4R@R@%04R@XOC
J#Y35$=/$Z25 M[8V)VNVGTXKT[&.?687X6]7_G+&[P;B5C>M1-)(^G=[ER6^HD_P 1'8^\|OCB+C0R
MZZW8OF8J73ZVY^,\8@O&K&S4O>U:J>H_R7(U/OGT^9<__'F__M__/D W!7ZLLEJEZFM MO%OI)O\ JZBJ9&[XE7)T==O%HZVS=5-?87/_
.QCDE3XV-5##K=T9K/%$]5U MWKJA_C3-9"WXG(_\)WMMZ/\ HZABX):2HKW?]945#FK\3.%/O ?6IWYT9!"Y M\=REJ7?
*414LJ*OPN:B??.DFZ2^G4C=U5NNCY.YKV1M15\,H]5^\9)3;)Z+I9 M&R,LC%>WLZR>5Z?$YZH=Y'H33<+DL4+(HVL8U&M:F$1JBC^IIXFQ\]2(E?*
*+P M]C2G_":_I%_"ATYW&E/^$U_2+^%#5R/|JITMF_\JCZLS !YY]. M &,.WT'IW(FJO)B(!3E7*RETM1:A@CROG5]NU/PN1/!LSHWK*
*M\+),SB4D9PEP%O#|\'O%P !Y!>4$T M%>NCKTN;/NW9:9SK==:VGO5+*O\ >DKH%9UT+U[D=PH]?%)78[%QZ<;);Z:1*
*MWZT10ZETGE%*SM:Y%RG/DN,H]HJ*O8[K]2Z7WIT77 M:5U?;X[M:*K"]6]5:.^*1,\,D;TYL>F5PY/%47**J$!=3^2!N-KO4U5H'=*2W*
MT4BJC(KE2N;41L^I66%R(_W^!H&S?<=)>P;'V?NVV]OKH*W6&HFL@FHXG<3 MJ*D5Z.?))CW*N1O C5PJHY7=C>?U\E-L[7[>*
[#U^IKK32TM9J^M;64[)$PJT M<;.&%^.U.)SI7)XMQ3%]D_));7TG?X+UN)J;36;X)$F;::6E\WD')SQ. MY7.?
*\W.%X4X.XPN4RA/JDI8:2GB@IXVPP1,2...J-:QI)A&HB=B(B8QW >3 MWE'M&WC8OI8;8WBM%*Y:2Y34=QCFY]7Y_1JQ'1.QG'"'"[^ZR_&*
<>EVS> M]&EM\]#4&JM)W&.NHJEB=;"CTZZDEQZ4,S,Y8IJ\L+V]J9145?MNYL]I7>_1*
*M%9I/6%M9<[34]CTY\,D$C<\,L3TYL>W*X5.Y51_)#7^T7JK?HG=1 M*.VS-*
5K65U+)%.UO9P/=$_#TQE,\+4PON0,B\]WTE+)3Z"BVDLMSAK[Y7U<=
M1>8Z>1')20Q+QLBDQV/=)U;N'M1&95$1S<[^\GMLW5;,]&>P45RA=3WB\R.O M=;"|JHZ)TS6I&Q47L$"H .UZ2_P!#CNM^M2Z_S.4V4:UZ
M2_T..ZWZU+K_ #.4"-_DD/H<=2?KKJ?YG1DVB$ODD/H<=2?KKJ?YG1DV@-M %,^ MH"I;Q'7WF_V[3M""^KN59%1T[>7'
[&5\$\5]2&G]1;]5EWJO8W1UKFJIWKAM M1++%Q.7UMC_SN^(#I-853;AK\21]Z4[7]9(B>'U#/@R;6TMH. MQZ-BX;90LAD5,_J'>E*_WW+S^!.7J*
TVFTNM=P6/N.H[DE+-P.6G@J%55XE3 M)P-Y1HN.:IS\Y=AJ]JZ?N&FZ]|'Q4|:9)N<)O:ZV4MS M@6&LIH:N)5SU<\;/\2@0=:GNYK[RG::NO-*
*1L1H^+6%QI&K>]JF18;';ZE. M:S<*Y]&_4,SG':KE;V)S)AT&E++:YNNHK104NJ)-_MP]+43U?YG#:G31MSE.L?,YKU]_$;/O 1>U)J:ZZOO-*
5=KW7SW.XU+E=+45#U MBETE[CM9J6BL%YK'U&CJZ9(YG92@-M##7M2E=F%5>U#TLXOB/$Y>_PY\O#GD]AMIZZHNCJVL5SJNHLU'-
*,K^;\;H M&.=GX54#+0 M !\^SB MR>-G3GU?^3#I.:QE9)UE-;I8[;#^^LK*JIE;R.%)Y\R/>]5PU]<:]*
MKEPE,\T/0;'H_'7=GM#RNW+GX+43UG5)/2ODS=?ZGTY:[PW4-AHDN%)%5I3 M5'7))%QL:_@?B/&4XL+CP-*
3[]]$S7/1UI;;6:E6W5ELKI>ICK;3.^6)DJ(KD MCK+.D7M'14C8V;DZ02*)B(V:.^4JX1$PB(U'D$.G_T MJ].
*[PT5JT7HZH6Z6V@K//ZNYM8YL'AV,>:Z*OQ_5NCR:F^5[U]i,4.CM05LURFL'4S4-74/5\OF\ MG$BQ.*K=J;7$M)U%.^NF?(BO1,S54BJOK>*
*[T6YRN4;V(N-.K|JFFBFK6J MKM\&_:VE37%==5.1I3W^/V2S65$3G@(I%|\GCCIV?$I>W^O?172\WYL3FNJ M7R5JTMOI<|B(U%;&U5Q[EJ**
*[EG'>6:EMV^W1\U'0S5=VNEA6J:GK?.** MK5J\VN;E6/5.66O;GFG(VN%\]SQ(W_@T^,\O$\.=SX_Y_=[)$?\ IG[0:LWN*
*MVHIM,:3FH8*E]RBGJEN$]HF.A8U_HH]-=E>-6*GO'/Z)72,BZ1.VRW6:GCHM M06^7S2YTL6>#K,9;*S*Y1CTYX7FBM/4=EW;L.G=/;@N5GAH;4*
MD]0VVUDD'%++([D_@5,X9&Q4S]4:N-CW/,1;CE5#=S,JUY2;L\Z:M/W;JZ#/ M1/U)T>[C]RYZLEMLM;<8H>D6WSNEX(V]]TG$KF-QE>K(/]5)<**
*[(CKT'7W M*AZ,]HOVI[Q65M37OJKC-572J=*Z.)'N8U5>]55&\$:.[?IE(=[[=-C<'?#7 M*:7VRGN-FLD]2E+0Q6SBCK[@Y?1XW/1>)]+S5&-5,)*
*[K)D\O=S+]>L].LIF& MG*LX.-1I'7!?F\4.-BL6VWN1]92 MQHGI/?PJF43M7@<(*(]JG,D:T >EM?=SJZJT%K6MJD;Q3TI5%MN3W_/:B-G**
*M2.5WTST16N1W:J<6554YUN[/W+SXS1/2PZ4%OZ.&CX9FP1W34UQ5T=NMSG8;Z,.*63'-(VJ]>^JHF4YJGGU8J MCI"=,>]W&6@NUSN-*
)3;A:ZE(TJ(Z66 MK6KM]7"]X5>.!55B\T5%7":,O9@I%X]S;SOST4[AJ705#.FH[W:)Z>EI8ZED4
MD%4O%"_AD=272H]W5M8]7/6)F(6,1>YB.CDPB81.)<(B'EIN3%]J@UA< M+;K.LK:O45M>M)4)6UOG;XG-5]=-M>R-BT+;K543T\,]YBDI.-^,
(L+)7<<+Y'Y)ST7B:B\U1C53">ZR=K'HK=(/;_2U1K>IN-8GFL2SUCK;>I M'U=-*
*&B9<]W"J<2)VKP.=A$5>SF:-.5ITCQ:XIF>TNG7M>F:I*B:J8ZS#UL1 MR=F%*\2-(/\ 0*
Z6M]W.KZO06M:U;C>:F2HMMRD;\]J(V*V,BJM77CC9;XIO29"UN.*=[<\T3B1&IV*Y4[D5 M#3KQ+M-[P-.;?MY]FO'G(UTIA(OK6IR5<>HZ76.I8-*
(Z1OE^J,>;VRAFKI/T ML<;GK]YIY%Z'T+OKTM+C" .,(MBIG&4SV&J-W-Y=B]/ZMVFUV^MJH+M;^HBCN50LZT[?N1.L@FR[CC5GDQ'I?
*=_*V]21\4-DM,TK'XSPS2.;$U/ MA8Z7XCU53D5VM7K?BCX0OL*B? JN3_VE>_#B/2@-M M 4XC6V^,_^B>CSI%=0:UNOF-*
/(]8J6FA;UE35R(F>".U>S*KAJ93B5, MD M=>60N\E3/'HS;VBI]=$7JZB_5CYGN_/.BBX$3WD>OO@>HV4*<7P'D!{<' MO+C_(MZ%\<>85N?*
*YV9QH3RR-YAJ86:RV\H:NF=A)*BQ5;X'-\7)'+QH[WE> MGO@>I(-8[%=(?1'2)TK[/:*NGGD43DCJZ.H9U552/5,HV6/GCEV.15:O/#EP MILX*
"WAYYR5PA4 6)<-!;C?%47^@-MWW"_:_| I&F)(D;O+_0;[A?M?\ TC3 /)S_ $&^WW[8?TC4DD2-WDY_H-]O MOVP_I&I)(@-%CFJK51%PN,*
*(I##1CV4.M+(^H]!D- MP@63BY(B)(W*K[W^8FD1>WFVVJ].7RKO%) Z6T5#HHZ6R5BT%QU.IV5M.V5D,4O64=> MUJ*U4YX:[UX545]^\/@!FKML-*
*SW-5JZFDYS5E)0-8K:>CDE>U)'+RXW,SC"(J_#A>X# -\F/;N= M>%>WDY(5:]IVIU+$3[Z?A)%:[5"L];3Q]5-3L3TI(T7**WQU<,U0^H2):BHD5K'RL:J0*
MTI.Y57GPM1/%55>>$4DHS3\,F=O)53KQLIJ"2-'8QO+P.55OZU55OZP(WI, M?X2I%_C'_P FXW7TB/\ !Z[_ +W%_P"(TILS_A.L7JD?_)N-U](9.+;MV/
MUN/_ ,0&(=%__?NH?\\7#^^YK_=V%\.X]_:_W2SHJ>\K4F$[<-=1;-N=R: MRWTL]+J:1M+)$U\36W2=,-5,M3XE0XE?L3KB\5"SU]RIZR?
*AX>MJ*R21V$YH MF5:OJE.MTAOE>](6B.V/IH*Z"!.'%9^)KF)W-SWHAP:!1:IW.U=/74TL\$L\ MF9ZV+B9% B)C&4\$1$1N<@2(TSI98-*
!TE@N[(ZE&TRTT[6.5S7)S3"])W8] M[!I[4O1TN--+-)8JZ&NB3FD%0[JY6YY8SV+|*M[^1MW6FCI]0:,DM%)6SQ54*
*M;&]3422JKGN9R3C=VNXDSG/>N2.^GM2:BVAU#4==1NBDF1&3T]8UR)*B*N'(*
*MN>>,)G)E.:]H'75^F=5:$F2JGI*ZU^UV/.87+PHOAUC%5/OFYMC-S+AJM]79*
M[M+YQ5T\7715"HB.%R.1$7ECFB=V3,MA=O:_3GG=ZN<#Z:HJ(^HAIY$P]K%5%5SD[LJC>7;R4 M#V25R-:GPJ!R 8Y+N)I>GB?(_45K
V:4SX&E;CTG+=&]>86.IJ6]ZU,[85^ MJ/.]^7]J6_*L=ATPCI.SLDJ?XJ_ WSQ#&AFU&]-Q3K61NIHY/I.&E8K?@=*
*MZ2%$VOW/N"+)/JG]5D]W$ZXSIC]BUJM WPKD:F5Y)W^HQZ[!BZ:L+5\]O5)& M].V-DG6/^U;EWWC5,71FJ*G$M9J5/.'>ZX:19/_*
*<|%7XC(;/T<-.42HZNJ M*RY.[VNU?\M&#]\Z&NZ3%ECA1-M*TU]1*O8V=61-^-%=^ R^AV;T:;YNMBL<3G)_P!=+)*GQ/46C[%;I^NI*
M++;Z69/^4@I(V.^-$R!JU>DM6UWSBWZ91U4[W+5J'2_Y*,1?OE7;E;IW%O44 M^F%I7N[)4MTS$#1$?1B61_'4:D5SE7,B-HD55_9\ M[VGZ-*
*FFHU:Z6MNQM1W^1E$^$VUA"H& P[&:*A1O\ L0LCF_3/J95S M[Z<6/O'=T^W>EZ>)K&:>MF&]BOI&.7XU3)D8_^%-314L*10Q,AC;V,C:C6H[*
MR(?;"%0!3"#A@"F.6"H !: MWL4Z'6'^](?\9_X7'>G1:O\ ]YQ?XS_PN,V/_N4N=M#_(U?T8H #TKY@-M)V'<;4_ MX37](OX4.G3L.XTG_P*
)N_Q;_A0U>?30 M !3B<7+*^>X]=4/_)G4:9H7JY8 MZ'3J)1MB:]YPDK?GJ_LG@>ZO$4ROA]_.N_?S@=PZ6DH=452*EOO%)*
[@K7HBKU4D;K8.543DK5P]>6&KA'3[M %,(5 %]-\>+>$N %O"7 UKTE_H<=UOU]77^9RFRC6O27^ MAQW6_6I=?
YG!&_R2'T..I/UUU/\SHR;1"7R2'T..I/UUU/\SHR;0 M *90"I3*]PJ:] M&C@?-/*R"%B9=)(Y&M:GBJKV&]M8=(*UVY74=AA]F:UR\+9<*D",_"_X.7K*
MVC<+G26FE?55M3%24[$RZ69Z-:GPJ:CU3TA(4E\PTK1/NE6Y>!E1)&[@5?SC M$!)WPX^$Z:V[9:MW.]VW/5M=-046C&GJ1% M7U&Y-
*/:3M.E:18+30Q4C%3TG-3+W^MSEYN^%3MLYQA2O$ X2X !%KIV;. MUNN]%4.I]13OJ:C8.L\XAC;ETE*_"O=COZM6HN/!SU)2EBQ\645>['B>&_*
*M[])*VJ;V4U.C MDXY%7NY*B)XJ])WGKA;[?#;**GI*9B14]/&V*)C>QK6IA$^(Q?;/:73&TED] MBM,6YE#"]4=-*]J^:=R)CB>]>:^]V)GDB&9@-M-M*
!?!?ZO3171NU_<&NX9)+ID+(V81556,<[FKFM|S]-W$_? MD:N2U;0Z=T\R3AFN\V255>?!0PQN5R?;R1&N\)22/ZZ_:[U1(S"T!/3VV!_C*
MUCUDE1/>ZN+XST^%5.-@UWHZS_\ 3QN=3&7M"BQ/2\ [87[5MNQ]?='JGAY MY58_FQL;;?R5[HKA3U6NM7QU-+&Y%DMUEA9Z$X^$
*MICUG,]VGDU1IO.M3L?$IG>W=6K=T*FV:*]'W4\UCIHK70V.R3LH*>\!,%L;DC M5L34]:O5O/MRN5RIY*]&':F/>?*
>W36EZMCG6R:99Z_A7']SQM61[<]W%P\.? MSR'HAY275RZ=Z.%3;FNX9+Y<:;@]'MX6JZ=WP?.43]ECO-_^2JT>E7KO6FIW ML7%!;XJ"-W+'%-
*(KUQZT2!$_9>LW\.J;.'=O:\YCENM MM+;]"GHJ.GCI:2FC;#%!"Q&,B8U.-:U$Y(B(B(B)V'D!T\=65&J>DWJ])Y'. M@M:PVZF8YRJC(V1M5R)ZED=**
['YY3V,5O4AY(^A,VNN&A^D!$C3!LBJGQYF]>QR_9(=']?_*:!MVUUHM6MJBKM%_M%&RC?$QUB/PM(VH
*MUKV*W.'*B(JH[']/)%'I:I):LZ3.OJ+V,HJJFT];46FM=!)ETTSWN3,KFMSZ;-M^%J<*9PB(G:JF3&Q;\Y?B7(TTG75KY.;C^2BU:G69B(B&^_)0).EZW)5N?*
-$-MIZ#K$YXXU=/P^_R1Q&OIA:J77'26U]6QJLK8KBZW1M;S14IVM@PGONC7XST' MZ(>T+^C/T>[I>=1Q>;WJKADO5SA1?R(Z1&G^?
HYV3;KHQ;&-/69U M>A/2I=/LKT&FZ;H9G4]0VWV^PK)&N%5%X&S?;M9(B_IE//3H[;T1;![AMU?[-M 0ZBJH:62"GAF]%@2%[\)UB+P.^EXV]B>

*[7U'JATQMJZ[=SH_;DLMJA6HN\# M65U%"U,K))$Y'+&B=[G,1[4],D//?H.=(NS]'O7]YI]4QO306&|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|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|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`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|ODS_==:=/VRS(OF%NI*^/;Y MM R//Q(AV&$*@"G"4X[WCI]3MXJ/_M !B?@4RV.5REH9T:X]U<- BY)X)ZB9G00T1M/2;#:0NVA*&SUERDM\#KK]\N+)C^KM-Z9OUGJH]4VNU7.U)$O7MN]/%+"D:GBC>Y/6N$ R7*^!K776^%GTLZ2DHO\ 9:YM M7A6*%WSN-WYYWCZDR8+6:NUIO%/)16&D?;+,KN&25'JUN,_CE[_TK?A138&@ M]F+/HUK*F=C;G=$Y^<3-]&-?!C> [W^:@8!2Z0UMN_4MK+]5.M-H5Q1PN:K4Q M^UE MK6W:(M*UMP>N7+P0P,YOE=CL1/PKW&1D3M[-12WW7E?$KU6FH%\UB9W)P^[^ M-RN^#"=P';WCI%:EKJA5M\=+;:?/HM1G6NQX*YW)?@1#ZZ?Z1E]HJEK;K3T] MQIL^DL;.KE1/%%3E\Q7NQW> $U=-:FH-5V]&XVV;KJ>3EX*U>]KD|E0[@ MC1T==12T.KY;4KU6FKXG+P=W6,3B14_8HY/B\"2X #25QZ9NS- MGN-705NN:6GK*65T$T3J:H56/;JMUM::^X2?WNC6;JIG^1 MK'HCE7U(F2&4WDI;RV)ZQ;B4+Y,>BUUK>U%7PSUJX^(C5T@NC5JOHXWRAI+^ MM/64%HU#JKI:,2Z*U%7V&|ZS MI:"[4,G4U-,Z"=SHWX[%5L:I\2FN/)^;XW/=[:>LMNH*F2OO>FYV4KZR945\ MJ.]JNA<[>]Z<+VJO:O U55555/_ *8.?FE]Q4S_ ,Z/_B-_]GZ.LBK:2&JA M>DDSD8].Q6JF47XCD&/:6JX:/1=DEGF9#$VA@S)(Y&HGSMO:JG:6^YTESI MVST53#60. [):>1'L7L[TY=BH!S0#Y.E2-JNJ"UNC:65M/2K(J-8D\S6*Y5 MY(B97EJJ!V /A%41U$:21/:)&Y$5KF+E%1>_*'VR@%0?&2=D$;Y)'-CC:F7. M8UE/6(Q<.6GE:_A7LPN%Y_<\%B/I,J@O`2ZDU:9]&V MJ6Z7VZT=GMT:HCZNOJ&OQ{]B<3E1,KW)VJ=T>0/2QW%U3O[TB;K3\#*A1)3 MW+V%L5K=EC7+UO5))A<YWY7-15/J+%>HIJ:FD M M #3&_'19T?TB*RSU&JZJZL6U,ECIXZ"I;$SYXK5 M[N:\FOY>UO\ B[L;WQ?0%J.\2XQMAJ:? CHXZ6Z0U!::/5,]RCIK9*^;%EOJ& MQ(YSD1,ORUOX?@U_+VO$\7=C>^*F#%MP-L],H:>GL>]I13WF MV2<^JJ&KECNQ',>F','$KC:6SG0RVOV3KH[K:[7)=+S! MZ45UO4C9YH?%6(C6L8O;Z36HOK-\\"*=#K2UUM[TA?+=;JEE)<:NBFIZ:HDS MP12OC5K'KC3A*B\O VIRKUR-R]N=&C3A8]O\=%$:QT1?Z972FT(W8&_VK2^_ML+/?;S?HFV^&GM=;'4O;&]4ZYST8]JQ.]XT]+'-R(1L\F-H1VH-\;_43XU=3 M:?MKW-DQR;/,O5-3X6==\1='Y+O=1;CU#KSIAM(J^E5-JIW>CSY\/4Y5WJ]/ M63IZ,G1PM/1QT-)9Z*J=<[G62-GN-R>S@6>1$PU&MRO"QJ=B97M7Q.O7=L8V M+5:M5;TU.';LY.7ETWKU&[32W)PYSSR1YWFZ#.V>\UWGO-7255@ODZ\4U?9I M&Q+,[ZI['-]2I&N4H[A4L93]N2^V MON=TE]K=>-166GD>KO,H*F*2./)EN9%V[3%-=4S$,_K$LV*IJMT MQ$RCSO-T&=LMYKM/>:NCK-/WR=>*>OLTC8EF=]4]CFN8JKWN1J.7O4P[1ODS MMJ-.7.*NN4][U-U:Y2DN%2QE.JYRBJD3&N7WN+"]Z$N43!3'(M3EWZ:=V*YT M8ZL"JK\2:(U<"UVFDLM!3T5!2PT5'31WMBAIZ>.&

"-WE M%_H-]POVO_I&F)(D;O+_0;!A?M?_2-, \G/]!OM]^V'](U))$C=Y.?Z#?;[M]L/Z1]22(M 6\1T5]US8=-/ZNYW6FI9<9ZES^*3'CPIE<>O '? @QFS[C:9OLZ04-Yi9IW+ MAL3G\#G+X-1V,_ =U<;@RV6^JK)458Z>)\KD3P:BJOWD PC[/U'->Q20Z.6H)KII:KMTSU>MNF1(\ MKV1ORJ)[R.:['JY ;> ((C[M:+GTG]VL7JU\QK975%,]$7"Y7+F>^U51,>"HO> M2X.IU!INW:GMLE#=*9M73.Y\+LY1>Y45.:+[WB!"?WN8) W'HQT,TZNH;[/2 MP]T<\"3*GPHYIW&E.CW8K'4QU5? +>9HURUDK49#GQ5B*N?>553U_<#HI[Z.G MM%LJ[W5QK')7(UE.UR87]DY\7O.7FGJ3UFY#Y-8V-.%J(C<8X43L0^=774]O M@=-53QTT+>V29Z,:GPJ!R2G$F,]QJW4/2#TY9IGP439[M*U/=0(C8O>XEY_$ MF#%G;WZOU)EM@TTC6NY) (V.2H5/V2(B?> WWGU'4W?55IL#56XW*EHU[>&65 M$M\JX^:!MC36WNG])(VRVQQ3=]0_+Y5_9.RQO&280#0;=D]7 MZGP_4FI.&/OB65U0K? >:JHU/@4RJR]'?3% G%6.J[G)WI)*L;/@1N%^-5-I< M)4#H+-H73]APZ@L]'3O3LD2)%?\ ;+E?OG?<)4 4X1A"H M M "WZ4X%U;F)GZ;_.IV'TIP[BWYVU/7_F4O;_-#!>C6W,. MIX?4.'U'VX!P&_O//;CX\/]'#ZC[< X!O&X^/#ZAP^H^W . ;QN/CP^HHW8JHXVN7K& MR6%KU(6NRL%%!#1MEB5M/24<*L]%,YPG QD;$M M4^E3UK\&0,BN%RIK71RU=7-'3TT2<3Y9'<+40TOJ7?*XZ@K76C15!-/.[T4] MW1\4GK5K/I4];OB.GI[?JO?:XLJ*MRVK3L3_ $6X7@[?I$7^^._/+R3U=AN_ M2FC[7HVW-HK73-A9VOD7F^1?%SN]0-9:-V+GJ*];QK*I6XUCEX_- %D5Z9 [1 MWTWZ5.1N*&G93QMCA8V-C4X6L8F&M3P1$[#ZHU.'<7 "G"5 %O" M5PA4 *_P_\,&L 'V=JE[%Y_W0[0>ZYH2X]!O9.ZWBJNE M7HKK]^JJ'U4TOLK6IQ2.=Q.=PI-A,JJ\D3',#?91$ ^$J !XL=,,#Z)C<7]5'_ M ,1I[3FDM7]#+9[7NIKC]&_:0\_O%PEZZIJ/9.LCXW^/"R9&I\"(!M+1G_$^ MQ)V?W#!_)M/*/RAOT4NH_7347\WC0]:.&AAH*"'D@9U<$##$CC9E5PU$PB97G MV&J- P>B5M1NG]BJU'JG2RW6]5+6,EJO9&KAXD8U&M3ACE:WDB(G) .ATE8KA MJGH/6NS6E7>REPT$REID9VND? 0\+6I[ZKCU9/,KHU[E6S9/?"PZFU%:Y.R@M MTLD51"C$ZZ%SF.CXVM=CTF*Y%QV\E3DI[.Z9TW;](:>MUCL],M):[=3QTE+3 M]8Y_5Q.:C6MXG*KEPB(F555Y&H]S.ACM/NG?)KU>-.K2W:=>*>KME0^F69V< MJY{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{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{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`)U?FU,Q72U5+(N',1$YJK'<+T]7 M'XFIL[**],7)Y5=6[M3"\2S%5J/Q4]&Y^C=O-2;Y[36?5,/ RLD:L%PIV+_ M 'BI9A)&^I%Y/3\ZH]&SRE6__P"1S2]/MG9ZA$N5X8E1=71KSBI$7T8O4LCD M5<+]*Q?]D-=[*-FZO1]U- >Z6^[=ZIDTK=*2262.&VR.G?_>N2Z:GTA>;.Z_7%'55PK*1[8**!51$1%U0E/4,=%'=+-%,Q)&<6'-1[,<3BM?&^: MK5KD5,*BIQ=F#UTT=I*V:'TQ:K!: ($IK;;::.EIXD[48QJ-3*\Z]ZKWJJJ=T MK'NP%XGV_Z0>B*]L8ZCEH;]34]6R1. M%8VK,DIG3$VFU7O7L_)1/2-(^6.S/@0!Z071IW,9OYK>XZ?T3> [A0U%YFN%)6T=&]\:^L?UN6N1,+A7X] M]#UELM?)<+/154T#Z6>:!DKX)$PZ-RM15:0@I9P6VA>IJKMW[<\]/T5V5CU; MEW'NQ,1K^KRS3R8^\';YQIG[OD^2)+/[6]&V_[&]#_=73MWDHYM076WW2HU%:YJIA45%[C1O M;1O7XBFYIIK\'2M;*L6)FJWKKI]U>0'D_74\72IT@^=[6.X*U(M)*B) M[ZHJGHETRMUJ?:K8'4]9US67*Y0.M= Q'8G!V({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|| M6M=G=.I7Q79GG-R@@KZ>D6EK6.RLK>MD9_?,M=Z'8YKUY<2'IR6\/Q@:_P'B MZS6%5M/I==PK6ZT:RBHVPW2!]3#.KIH\L67CB M7@6JW/>7 #6O27^AQW6_6I=?YG*;*-:])?Z M'':=;I:EU_F/U'* XO4=%JG65KT=;'UMRGZIO-(XV M\Y)7?4M3O7IR=^#'MR-U:?H.E6'B-K+M(W,= (B\F(OT\G@GJ[5^-4U]I3;6] M;EW%NH=8SS,HY/2CIN;72M[4:C?I&???M]8'#IJ34._=\\XJ'/MVG:9^&\/N M6^IO9Q/5.U>[U& ({]MV&DTSK.>VT."04=/#$D2=NFA:C611IAJ(G]OA-/(/0-3=8X=14.3I9*-(JJ-G-W5HJJUZ)WX5 M5SZL>_$?0/A3M\1^_#)- MI)8=>Z=='']\7GT2+CZE7HCOO*OQDRB.&P&@JBMO_M4>HZJ%64-+Q)3\?+KI514XFIWM1%7GXX\%Q(_M L<[&>79S(K](+R@&DMF- 0U>F;5:I]7Z@HU1E4R"H;!2T[^^-TO"]_M5>B=J(Q41>2JBY1 E3Q%QYT4OE6;LE4JS[=4UR)],F5B5,^O!* MWHY]*K2? 2.M]7[#QSVR]4+6OJ[36*WK&L5<)(QR9]7)!7)?.J2IB>Q'-D1GFSL=JHJ97FBH2=VVUU1;E M.:L&JK6%^O17Z2%?TDM.WN^2:/_(Q;*

MJ&I;202^R/G?G,G#Q2)_>F/NP!O+B<1$G?GRA^DMJ;]5Z?TI+Y-_M97BD?U54^^H2&D@DSA6=;C7\;D7DJ(F$7EQ9RB;RTIY55DEQ;'J+0+X;!SEX MJBV7#CD8U5Y8CZC>WZ5[>]%_ J*;/Z4W327HU:OM-B_(=^2/S^A\|\X]E/->#YX]G#P]2_/ MN]41'B,XWNXU M;WAX&*KGN[RT>C](U&HJ.-SF^R5=5^:1R*B MXS&Q&/56KXN5J^HQO3OE5YEJ86WS;YBTO9)-;KDO&WUHUT>%\,<2=O:!Z& P MW:O=73V\.BZ+5&F;MU5;.I7,Q(W@EAD:N'1R-^EBHJ9145<;WIZ1FD^ MCWIR*Y;CEEGK*ISF4-KHT1U15.3&51%5$1J93+EY)G'-51%#:G$7'G?'Y5NM M6[9=MU3I;.+FQ+NJS<.>WBZK"KCNP;$U]Y2S2U@TSIB\:9T\[4WLJE0VKHI[MBE'/;I(NK]![4CDXD=UF42JN40)F UGT=MY%WWVKMNLEL_L&M9+/'YE MYSYQP]7*Z//'P,SGAS[E#6W2,Z>%F\JO5>R">RFWD2T+EYK1W5>M8W'"?518 M=WKS5OO\B9>RV^FE-]M+^SFEJQTL<;DCJJ.I1&5-(}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|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|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{$/3[8W2]RHO8J'G/Y1S=6T;@[Q6^V62KBN%+IZB\UFJ8 M7H^):A[U<]K7)R5&HC$7GVHY. [F$G.B/K+\KSH'R:G1K7OM--=*R-CNQ[V2R MJU]^^[":"?>?^R]ML6Y&]MI3<2^MH;)6U4@ACYN?*CYE8U/6KD1/A()'30^E]R=_MW]/+7U? 7UELLMTE?3+4T,K(Y&S+&[J6Y>QZ>D]&LQCZ9.SM GUNC8.BIK7;R MX6*WW70-EKFTSDM]PMSZ>&HAF:F6.61N'/\ 21,HY5XLKGQS(F^3]WJM=(_MVRV\LSFVW4+7VVJBXO1>JJ]U5>1CVP6Q?1HJ=QI.7;0VYU[NNH:&K;5T5 MOK*F*%9WQIUG"L;Z6-[DPU55$5%PB\P){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

M(KU>^65W++6N>N%),(G-7(O8C<+IN\V_5O1(W[>R%ZPWO3U9UM/4*BI'64Z^YSLS;HHG%MSK73\?B\#?B[K;KG2.:I*#;;="T[PZ M#MFK;)%60VZO:KHXZZ!8I45KE:Y%3FBX5%3+55%\3R>1:OQ_]WHZO:X=[*G_`M $;$_EAFX --TP`M >'_E#]97/=/I?ZDM,2OJ8[7) M3V*W4JKR:K6MXVIW96:21?AQS/1KHE=#S3_0\TU>;_6:@J[G>ZRWM=>:J16M`MHHF1(LB]4Q&\6$RN7.55=C.$[#S7Z9<-5M=TY-5W2>|^7]1>Z6[PL7"-F8Y(I`MTPN,G?-97[@A;_LC?43(V-F>YK4;@`MJ5=>^2_VBK]HJP:.LLENU=!2.6BU`^KE=+++5(WDZ9'.5BL>Y$RU&HC>)>'A M(.^2_P!KY-?=**UW:2%7V[2]--=)W+[GK.%8H6Y\>.3C1/"-?`]6>D)TA]*=`M':?;^Y:AU#.L; YU!:UE1*BNFPO`QC.W"NQEV,-3*J!Y.>3*UG5Z/Z7.FZ M!CW1T]\IZNUUD;]J>CU+Y6HJ=F4EAC^-3VZ/#CR<.G*W5_3$T?5-1TK;:M7< MZR3&5:UL$C4/<< ?"29D+'/>J-8U%57.5$1$3FIJ`M!}>+MY-4"3&U72OVJWKUC2JG@AHZF-B1,D9&Y[97QMC*CH:NIB5K5+-1W!ENFC:O#'4W!%S+)*J<^KA3+<8Y+'(OA MB1NB/3;+V32<=#J"&ZZCO;X49/=O/Y*;$BIZ2Q1QJC4;G.$?QX3M50)1[<;`MLZ0W;LSKKHW4=NU'0MK?)G=(`M^Q7W3%UJ;I2X\4M.Z? T4K;9'HD]'4(B(U7M168B(O)OKWHW5=NUS`MI2S:CM$JS6R[4<5=2R.3"K%(Q'MRG*JO85K:V& MWT<]3.](X(6.DD^*W1N7S:ESZ+&_5*G>Y?%4 D`M?+N]HZ.98G7ZFXLXRWB5OVR)C[YDEKN]%>J7SF@JX*R!5QUE/(CVY[TRA!]. M6<'=Z2UA:.'G(_UX[DSWK_Y`9:4RA'F`MJZ3- U?,JTMFHXX>YLTCWN-[$S2+P,GZSCAIJX:..I\TK((F)Q/DDM:AMWUE/9XF'Y^#M^^3&UQH2W:/M2T M=^F?!4.CVP\GQ^6%=ZIGY,Y[*`MVT[4=)(VVH]RJJX:W/6HF51%7..[LYH2GT]T=]1W"H;I)K!::?.7\4B2O^!K`M%POPJAO_`$OI.@T? 9XK;:8N'"%KEO^9._;JV(Z(.@-@Y$KK/`M2S734"M5BWFZ.22=J+VMC1$1L;=WHIQ*G)7*AN_A+CA72XMM5LK*V1KGQTT+`MYG.;VJC6JJHGKY I%^"G^4`FJ",^V7`ME!=IMQ[Q#:G5EPTQ73.;`"E]@9'%*]5QA)(WO:G/O>K4)*MDRB+CM`O!$>F\`MH]HBHUTS2R:9U`E8^Y);4FQ!U? &LJ1<7]\SC//LS@EP`M`&G=[>E;MYL*YE-J6YRS7>1B2,M%MC2:J5]JCE;JHUB+W<;FY[LFF()Y4' M;&ON+*>NLFHK73OY+5O@AE8SUN1DBNQCP15]0$Q@=%H_65FUWIZCOGNGKC!=K`M16MXX*NE=Q,>G>GBBHN45%1%145%1%.] M`M #YXYGFWY575WG6L]$Z88__>-#-<9&M7M6:1(V9^"! MWVWK/23/HJAXW=.S5Z:PZ3>L'LDZRFMSXK9%W\/51M21/@EZP[.R+>]D;_") MEY];=WPT\]5+!%3RT#IE>V-4;K^+C;]-Q) MC`TO:?3>/R>,M-I]#7'545}MM_HI;&L]7!3L?%*V%.;I&HY,*C4RJ\TPG/F2 M\Z-.^&TVV&P.BK%6:^T_25=+;(Y:JG6OC5\<\F996JU%SQ([]D4UQTP.G/HF`MZ[;7K1FA*_|)#U&R9DE(YZ]R*`M=D3I63- 3N5>!6+C*QIG/"AZMK(U.?$AY0^3=VRJ[5[)1:F2%R6O3--+/+-A`M>%9I8W11OY\>%|W8_,>\6>43W#K;MTD^UTE?40T]EH*:AX(9G- ,QJU9W+A% MYK\^1/V*&+++Q:3U>1[>>>51$0M@J(ZF-LD3T`MD8],M.4/(BEK]X.DUI"R:'T+:.+I6:0T|0PTT\,<[88:FHX4=+)42O> MC'N<]7*UBNY- QA.+*K+'9RDCZ"718N&H-:P/74MPJUE6TI4-&K]JK-4*Z5EGI95@MU'"`MCDRYS,|*-;E$XWY>#8X93&E-RY$53V:O&*ZM: [=J9HCO_D/89')V&);KZ>N.`ML=M-46&T5.-)ES>=$JNHT#K2K`M6X7NGIUJ;==)$Q)4QLPCXY%^<F>U%14=VN1'9YIE>W\IWKB;3NSUALM'5/IJN M[W9KG+&]6N6&*-[G]GYYT1I1B7*,B+.,]70JS;=S$JOQTT8ST;/)^ZDVAWBL> ML+]?[-NJ`M*BI8UU- ,J9997\1%3BDE3FJ\^<)U73QIV3DS:FK68ZST:6-E6.3$B[%.D53RC`M75Z'/K*>)[&OD8QIUX6HYV%L+4;5FFNF+]N`M:8JZ2]7.GS? (UF^8'O9O#9]C]NKKJZ]*LD-*WAIZ5KT:^JG=RCA9ZW+W`MX7"(Y5Y(>7%SW*WIZ:NX3K#;JNIEAF59F6:AG6GM]' BHBOEPN'(WB3+G\3E M5W"B+E$-3&PJ\B)KF=VF.[JGI#U_AK(9N/JI6/5KE8O"N<.3M`M1?6?5'91>_WE/'#=GHQ;I%.EMNJ*FX00023MC9=-.UTN:;;"]QKU5K'(JHB MX5,IRQG.$6=O0.Z2-SWVT%YW>MK6T`M%)#5/5(V.6.1ZR.:W"N:U&=B*GNDYH1\\GOJS5F]&Z6N=?ZQNU1=JJDH8K;3`M]R*-/18B=0WW* <\\^TB5TH=!ZTT#N?7LUM-`[(WJ6:\QT\-9YP`MUC)9I<++^=7+7)A$[C8'1@Z(^X>X,^D-:4G4P:*J+G'+4N\]ZN22"*HX)OG:=-`MJ^@]$.M&)9M8;? W"2TQVYRT!TO%*J><2381?10N3G&C,;7`M.3TELLEN]%=U;7.55$DPCFHO#A7+C/,]$]^=Y MK7L3MI=-675GG#H42*DHVNX7550[W$:+CEG"JJX7#6N7"XP8+^'C`M;QMH6[]FJY/X=WJV#++41P1O?(lL;6IE7.7"(B=]Y\X15+)HD?&YKV.3*.:N4 M5/'WCQH7[M]-O%>2H;D[,BG2`MB;D;_P`/_7.C;$U:W(MSN?%KSI;Z]DUWTEM>5L*K,C;FMQA:SGE(&;3IP^^L`M?WSV'VUTK'HC; [3>GHT1&6JVT]%Z/?U<369_R3QJZ.]@GW.Z1FBJ.J_NB2NO`M<=95\29XV,>L\OQM8X]NF-X4PAFVK_ITV[/PABV)K=JN7Y[R^@`//O5@`M /'CRNFH:BY=)"S6MS`MU\UMNGH.KCYX1\DT[G.]]4X$RGU*$_>AMTX6N"MN%\`MDA:^KEEFB:^1J2JBN;&G%PHQJHW"9[555A5Y83;>NHMR- 'ZZBAD=;KA;/8F2`M9J99'40R2R(U5[EGI&ZXOU+Q5B72\204#6KE53*`M#3HB>*%]W8`9I%9[G;2;2V?;+9_3V@8J*GDM]!;6T53"Z-'1U+W-^? N>BIAW6/5`M[ESV\2GC1Y/[9RIW=Z36E&+3=;9[#.V]W"56YC:R!R.C:OBKI>K;C/8JKSPI`MZA]*;ITZ&Z,)W+W/8!`MY5;RL=)LQTVJBWZ? 1::AL.LXG4,<;\K%$VI;IC$7\ZGH_!@]ZCP4Z/%BOO24`MZ7NG:FO:ZLKKM?TOMVDC9PL9$R7SB=W)/13'"$U,]FIWH>]8`X\U M1'3PR2S/;''&BN>]ZHC6HB9555>Q$\3[<7J(`^4GZ3=P@2EV)V_6:MU?J-8X`M+HE$N9(X9<=72MQV2393/_9KCZ?D&6[>^4LLNZ'24I- KM.:0=666LKIJ.GU0`MZZ<*2MCB>]96T_4*Y56*B9D1<*CEQV$TZP<Z'.BZW;OI]:3TK'2^W5QOU"Q_"RKK]FOT3A6.SB1C`M8I51,X[>?CCL- 7^4XW0O&[G2&T]LQ8I56EM"HN-6C%8KL=J-9+&`MU.7)72>*H>A&PO1DT-L!HFAL5ALU)+5QP<%;=]B!KZ]MD5,/<]ZIG"KG#$7A M1.2(!IKHZ>4RV\WQU#2.:NU!5;&U'6/2*EAKYV34E1*Y41L4-57DCF-`MSR1%551"8/%\9YI>5'Z*.G-.;4IMVM'VJGL=;!6.IKS34,:10S-E54CJ.%N$`M;(DG"U53'%UB*O-.DO\`0X[K?K4NO\SE`C?Y`M)#Z''4GZZZG^9T9-HA+Y)#Z''4GZZZG^9T9-H`M`!8LF,Y3DG:!1TK6HJKR:F55V>28- $[A[AW#7UV_(E0'30R/ZNHJ8UQ-MUN.U,]T:=Z]_O=M=QMP+AKB\_D/THCIHY'*RHJ8UPDN/=(CNYB=Z]^,=G;L; M;C;FAT%-:>JAX9J^1$\XJ()ERYSPIX-3P`IMQMS0Z"M7515<,]PE1/,*OA3++US`MGA3P:G@9GPE.$N`M`%O#\9<.,CK=%Z?N<[JBLL=MJZAWNIIZ.- [U]]5;D[`M"@ME+:Z5E-14\5)31^YA@C:QB>\B(B)\!S`!;P^LN`M`HB&OM`M^-OG[H/ZLTK'YK*FY4$D5.K_"KC*`MDX-X/* (;:Z9T35SZ(N;=4ZCFBQ14J4AWMQOM6>R5ZM\]MOJM1JW:TR)#/(B)A$D145LF.7-S57"8RB&K],^3`VLM`M%QBJ[E=-17V*- V5HZFJBBAD3P3B9$Q=N1,51V[2\Q;P\W&B-MJU9W9IGO/6'8=#'I.;A](FJNT]^TO:K?8+=-'P/NM"V:.):ARHK8F->YR.PW*`MN]+T? 1S[I#6_3TZ9"V=*_;30U%1>?::MF]C>/-RY3I$=(C^K`M+--NK69ZS_`&04T3T1-8ZSV,U'N7%&M/14,77T%`YBK+7PL=_E9X- M8WB5.WB5]HG=G;'DV-]$T9K^]V_N4ZLM6HW=;1N>]<,5:QN,<_\K&)PYYKQ`M,8G>>FI):Z6BM\5!3T\4-'%&D+(&,1(V,1. (U&IR1$3ECP(QQ>3DVKI-0MO5`MOJ=06NJBJDK*?S.N8QM.]K^)G5YC541]XQS7DB&W.TJ;]NNW>CE/3Y-.G95S`M&N47<>><=? FM\I%]W\CG1MJ[>Q^)+Y<:;@Y=O"U73N^?!CX?6>;^P>Y\^R>Z`M^G-;MHWUE);YWLGC;RZV)\;HY&M5<)Q<#U5,]Z(2R\]M]SCO.@]+1R9\WIZB MY3MSV\:MCC5?W.7XU,MZ#?1YTQN-T5J^GU?:8[C27^\3U<4CLLEB2)&PL?&]`M.;5:YDO-/JE170C!RU0/JZG3=9Y[/%"W+O-G,5LCD3| [Z#E_.MK\M,V:-T`MY4[R,FY/DZ]![]P+K/=*2"XZ4]YG.?*VR3L9`]R[JJ4]CFM]YG"ABQ#>|>,K&F-[3I+2/2VZ?NG-8:!N&CMN)*NK? =F+!6WB6%],R.!W)S`M(VN1'JYZ*K5543"*N,YY8;Y.'H!U^K-?LW'N=(^+3UCXTM\DJ*B5=6N6Y.XM`MC17*JG$K43L7$C- %^3/VHTW7Q5EREO6INK=Q)37*J8V!5SE,MB8Q5[LYEEEDJ&<*<:`M9ZQ&<37<2*G#V<*\D4S+;WIW;/[D;PD;N/M1I/=NP.LNKK-!>K?Q<;639:Z- V%3B8[JHYCL*I9`M;J+S(R7/R6FV%95NFI+[]>@:Y_%U*5,$C6IX-5T/%\J4M7.2[W%-R)[CO#`M+>LYM%R:K4Q53/:4#.DC>MO- 0[L5U5M;;7V_33XXVI&V)T;)9\KQOBC=Z3&K`MZ*(U43FB\DS@]'M!:0U'MYT!:RS5LUN/`M%N#O-H^@SM9M#=X[M0VVIOMVAJB8Y?- XE]%/7M@VSW\TC`MJ;4[GQ62AFFZZ:-BR=4KX9(VO5]954:Y[57'8B+C*IA9II)KR@6EW:*N.G-L M*R;_7ZY4TD4ES@ADBBH8E8O'(WB:CG/1N516IPMYN5WHX7+M:^34VMU9J*JN`MM#5WK3C*B3K'T-MFB2G;J]O5M? &Y6(JYY95$SR1$P9GI3H.;7:.T9>;!;;?5`MI+=Z9U'5WJ69KZ]T3L<36R*WA8CD3"HU](I*OJ-J]EXEZY3>KB9F.W9JX^%G M6+==FC2(GOW>6VEC\2WRZT]*K$Y*LXHF)*&P-C^AGH'835M3J+3;K1-<9] M-U%FX5#)6LC[\]&?2O2(@LT6]*BYPQVITKX([?4-B`M1RR<&5? ECLJG F/#B=XFO?S;=[*INSKNPVJ[4Z3+8ZF#KDEBY]_9P.7ZIKD[CT'IO*&;+2:.9`M>)++Y50UJQY=9W6^7SILF,K'GAZO]EQ\/YXV[NYL7HW?&Q- M6KK2RX1QY=3SM`MJ%ILY;"V>G143N3BZGL^#`M)TIRL;)HI\?6*]? AWR45^ME5;KE2PU]#4QK%/2U,;9(Y6*F%:YJIA47P4C&OSCW:;D=E\O'C)LU6-MOB\T^A5TU],[*Z(J-&ZTI:UE!'4R55#<*&)) <<:Y='(W**GI(JHY,^Z7.,(J`MXYTW>DWMWT@FV6/35@KUNMN>[%]K$;.JPKE%AZM.)7M5<.17*U6JBX1>)24^`MKO)F;37ZMGJK;/? =.K(Y7I34%6Q\+,XRB-EC>[';RXN6>7VCTA71-M5E?%==4S1JCDCO%2U8<^MD3&<2>IRN3QR=J,K"IN^8B)WO@\Y.%M"JUY:=W= M^+RHT_+;8;Y;Y+Q!455J;41K5T])(DD'67EE#-I2AMU*Y_"MRJ+Q2K3L3L`MXE1CW28]YF?4>W/"49V<@-#=$'HJVCHK[>S6:GJ? 934%RD;47:Z(WA29[45&`M1L3M2-B*N,\U5SE[!)YU=++#HH;J;&L_14V`MU!45T,T=Q6+J;/YY3Q M/7$\BMCY*YR*B.SV\CU[U!J2T:2M%1=;Y=;.S6RG;Q35EPJ&00QHG>Y[E1$^-M%2'.]'E5]K=-> <46CJ>KW!NC,M22F5;6@1R=N9GMR[]@QS5^]0#-NA!T+J+H`ML:?K*^Y5D5XUO=XFQUU7`U4AIHD7BZB'*(JMXN;G*B<2M;R3"$ICS2Z(/3GW M-Z2'2KM%HO\`5T=KTNZCK)6V2UTZ,B5S8G*USWNXI'JG;[I$Y9X4/2T`M`6WV^4&F[/77;Z545!;;&!]34U4[N%D4;&JYSG+X(B*OP :KZ572)M/1]V MFN&J:Y8ZFZ29I;3;G+SJZIR+P-7'&-QQ.7P;CM5$6(?D]>CM=!;7*]![GUK>6>K3/@MKI;1IM;?04\5'0TM+U%/!"U&LCC:S`M#6M3L1$1$3'9A-/)? R/7T2NIOUHU^\HCUXK*IM%1S5$GN(HW2.Y]R)D\A?(M^93I*ZFY9_\1*J1>[_\Y1'K+K1KY-&W]D:XD=05"-7LY]6[',#R1\F1#-N3 MTS[IJNXM;+7P6ZY7M[U[4FFD9$Y<^*^Q7">1'D>,?-!ZM^J_(O-R7M`M_P!]TN3UX`@EY7O3,5RZ/FG+TD:.JK7J&-G6+VMBE@F1Z)ZE3/U- M+]J/H@Z1CG>Y\MLFK*!7N7*JUE0]S$^:!CVMJY]&-`^5A7_`"*\KC_&=HOAY2`M`M'T\E)"^`'HGTSG>YDO58YGO98W**!,<_"U'\^? (N,4W*OEXTWMSJR[.:M_L`MK?Z&U5=7;Z!(7S>UYM)^1C2=9U'GET_(US2K&WBD:QOI)SXL)S7D$W/)S_0;[??MA_2-221(W>3G^@WV^_;#^ MD:DDB&%;P2RQ::WY8>)'K"UOH|O"Y[4=]`MY5(C?_B3>O-IAO=JK+?4)\XJ87POQVXKF>BKW1I&QR_?XC0&IM156]Y5W.M=Q2U#E7ASE&- ^E:GJ1/[)*6Q:(]`M@=MI-/1N1U1)22QR2(N$=+(U>)<^&5^\1&3EG/)47"'^H_,=OO8`WCT<]-V6`MYP5]OJ*9*FZTLR,:LO-C&*WDY&]G$]HJFN5Y9Z/ M57DQ-I)X5;'<-44[^Z2.NA54^VA5#S>V@U=1Z"W3TCJ:X13S4-HNM+73QTK6`MNE='"*U[D:BJB*N$[U3WT/1*H\]3M>V%ZPZ=U;)*B>BV2FI6- 5?!?)4+CXE`MA5T]NCA4=&[7M-:&W%;M9[A3^=4%7(U&2B]V>Y$3"(G/'$OH[T$=K+CM5T:J;2WBG`M? 1W2[U,EWFII$P^))&L9&COSW5QL54[4SA>P#S*MGT1]+X_DM;VKXUB=IZZ;`MC=(S;;:K2DU9J^@M5;P\:TB<<\[6]RNCC:YR(OX\;-85U5:]T;W6T, MKH:RGO,\T$C$15;(V=5:J91>]$)M:=\F+4:ETS[+:PUU6PZRN*>=5*1TR3LA`ME=S5LCG.XI797TG(97*O0^Z\<[M):GH+V^!.*6GIY,31MSA', MB2JU[4K1RN[&\7"!T&O\`?+0.UTC(`MM6:KMMEJ'IQ-I9IL5JE,\21-R_'KQX>)A=LZ;&R-UJDIX=P*!CW/ZM'5,$\#`M_,IY(VM1/7G'K(/Z5Z"F[NZ. [54[K62MK[]+-.#6+.[*(C&<#U3B&.IH[A$Q%OMI5#7452Q)(;FFD22.1]JCFN1<*B^*%MYOEOTI`M;9[C=:VGMU!3M5\U55S- BBC;XNMY6Z.=4216*QTL,C*5.3))Y6<;I5\5X`M58U,^Y1%QC*@39]^FWLC15*02:.H7/=V.BIZB1GPN;&K?OFPM![M:.W/ID)] M*:DMU^;&F9&4_>WNT\Z4^K-66ZSU;FH]*1`M\BR5"'O8[JF(YZ-]>,&-=*;>B;8[9.ZZE@;&V^2<%%01N]-B54G?SQQ(UK7N M[$SPXY9/-7HX='V_]+7<&]S5]\DI;EQ6W>\U"+/,Z2IV5%{JE[^%ZY543`M#57N1%#T[T+THMJMR;A#;]/:VMU97SX2&EF5]- -+*]]C6,E:USG>I$R;4XT5<`M)S4\INE=T'9>C_I6FU58;[/?+(DI;>LC]HFQS4SW![57P1NN,HU%543*^M<'++>$##R:H^BKNYN_O[$[<#3M MWLL5^KY*]YWA8NL@@CPY[FMD:KFM5&MZMB*N$RQ,80V[TN>@]M_M;LC<=7Z4`M=<*"XV=U/US;JI=,RK9),V)5!Z/$0/)W:"V^T[H M&XW;3>I*;5&IZUT3;O)'$Z)]%A,L@2-Z(Y&YXEX\8>J93W'*8E^`M`M`*=Q4_<.X5L-MH*FKJ'I%!#&Z6 M1[NQK6IE5^)#PGZNX[P[K,;!PI==4WM>!9%7"35,_)7*F>69,>#U_P"EWK!-`M%=&_7$R1_# (^V/HXU1>;/G5(&JGO+)GX#S7Z!&COR6=)O2BR,XZ:U-GNG$^Z$_|`MF7Z`M2\E+*`M:R34^OFK1M=Z=/;:'$CT[\22.PQ?7P./0[A'"<^=IY,QIO.G3L? $IY`MS3JPC:[:?36S>DJ?3NEK>VWV^'+W<^*2:1<9DD=],Y<)S[N2)A$1#QGW2O%3`MNUOMJ6MH5\YGOU]ECHFJN>))))N'"!J+^E5B'LEQIJ_P# (%LWK/4#9$CEH:542`MP._[;JU2-/A>K4^$\HNA!HYNL>DWHJFECXZ>A]+)G+RY-ZACGL7]T2-/A.CL`MRJ:.+V15STAS-K4Q- =K%HY1,O6G:O;BU;5:#LNE[-"D=%;Z=L7%C#IG_`$\K`M_%SG9](T5?>2-V/#B4]'53"8(`M(^5#VFN%\L&G->6ZGDJ(;,DE')/`WI MTE[C2VGH_;C559PK#[`UL7`]<(YSX7,8W/K7APNF/TX(=]K'#I'2=#66W32`M2MJ*RHKL,FK'M5>%G`URHV-%PI[JJ\/),<]VYAWKN9-4QRUZ_)SK.? CVL"*`M*9_%II\V$]`**HEZ5NB%@SAB5CI7-[$9YG-G/JR](GP&T?*F:O6Z[KZ8TXR`M3BBM-J=4N:B^YEGE5%1? 7PPQK[RFR_)M]'2XZ1HZ_:VFEG8K`M9$IG*USYU1>Q'JC4;^=:;]JCD(C=,;5BZWZ3.O:N->`D%P]CHF-RO^]VI`J)[`M]HU7X3I6YIOY\U4]**?WHAN-] M>BMY_.TDCD>UOI`M.151*Q1VFH1O>G4)&]???*_&>2&G:[_]$/I'`MT=1=K>Z:NTW7/26%?12JIGM=&YT:KW/B>JM5>S*9YFM@7HKKOU?]IZ-

C:%F]_MW;L1,Z4QU^71)'VPK>S"M3:VD5%Y?\'UO;W]CB,FI*+76YN|(^J9])W&V7&[_M72.ITGQK'RE.U]NT;+<+_M?>+!)$O4VF:B?!U<
MBIR2:1R<"-153/"YR^!C/0RZ3^\F_.MW45TMMFGTM1M<^XWE*&2-[%QZ,3'-_MDX%D553EP\D1R]V%I;KKL457:,44Z?&5]Z+>171:F]-4Z_"&
(>55U=4+<-": M5;)PTC8I{G->SU5(XU7WD23[939'DPMOZ6R;-W35*Q-]DKY<7Q]=VKYO_B_M-8S[=9E^%/
O#RIFV=QN5KTIK]BI^NHK;UEON,C>Y)LCFNA_MEGN)OYNY13;&J;[IR)>&@M-HLI;*R;?+E7CE2-R(Y[E5.]S41$Y\U7T[V0TO
MJ'2&UUBMNKKU4Z@U,R!)+A654G6.ZUW-6(O>UF48B]_#Q+S53DW\6YC44[]7_M7L]6-F6\NY5X=Y>[RSZ>NL/R6])W5?"_K*>UI!;
(ESR1(XV]]/@D=(>DFV%_MN_*8Z*=G18^JGLNF//9F8|)D@6;3E^C5OY%[BW1UPWEU1S/CVIX(>N&TV^FB.E/!4ULT^VO\SAI4HZZ.LITA5K9V2-
X4PJHJ_MX:[..SD=;/HFBQ9IB/PQUEP]FW*;F1?JF?QST>0&BKOUT;G1JO<^)ZJU5[.IGF3OUEY2G:ZWZ-D_MK]/^R-
XOTD2[1:9J)\'5R*G))I')P(U%5,*N7P-S+_U)HFFWOQ,==6EA?Z<_M7-_^[N3$]-$!M246NMSMWI]4S:3N-LN_VND=2YM-03)%#(Y[?23B1<=F>;]I)
MWRJNKZB2\Z&TNDCFTL5-/?5/5R20H[U+F7GXIS[4->F[KEVZ+E,1NZ])U;$V8IP;ERW5,[TQK_MRT;2\F?H&DT]L))J-L:>>ZCKY999LBUJ5M
M4K$GEJ:)E+O?]8E3&YV/7U;9/@R1KZ%W3?TQM)MPNB-:Q5E-!0S2S6ZOHX%F_M:K'N5[HWM1U%5&HU%5&MRJ^DY5QE$3%&)?
N9TUS*)UU^C8G-Q[>SHMTSK,QI|\MW>>3(TCI,:_5EXD9F&RV]:5C\=DLCFQ(GPL?)\1ZL$$_)4Z12CT)K74LC/3N_M%QBH&.7MX8(^-
)3/QYKD*@',=P_M_!A^Y^U>F=X=&U^EM_M7VN*[6>K3G$Y%1T;DSPR1N3FQ[<|G)S[>Y50@U=/(VZ6FOJRV_<>[4=FXU^U47'(]%.
(IQX3*@:LZ/W1NT5T;M/L>C]&2-:A_MS9;ZXU;D?55LB)A'2O1$3"97#6HC4RN$YKF_,3.Z_]^Z4V\5BU-0:DMFG+52
M6>.VU4D\4DU0Y[9YGHK8T1K7)B7M5Z+E.SPWOO+TN]I]B6RQ;JU=1LNK.26>
M@7SJM5W@L3,JS/B_A3UD"]Y_*];EO/7T.V.FH-.4R^BVZWKAJ:M4QGB;"B]6_MQ?4JR)R_FUT;NBMM{T2=.MBMTT4]]N+HZ6LU!YBBC:KGN7
MU(U%/4472SZ2%LZ_^TUPU)4=74WNH526:WN7G4U2HN%5.W@9]IR^"(FUECRM-37RZ0T'2-?RB8DCVYFGK>;6Y3/HL5Z
M;6_I([(VNB@HZ/=305-24\;8HH8M14361L:F&M:B2X1$1$P@'FAM5_|_M8*Y
M/_WSO/X*D]B3Q9VUUSINA\IG6:IJ=06NGTRNK;M4I>I:V)M&L3TJ."3KE=P_M+N)N'9PN4P>OFBMS]'[CI6?D2U98]4)1]U*E;+KIN!/>3J&^]C)
])'CALS&M@\JO61_MRIPI^32]L9Q?4R)5(WX51Z?&>QX&A.G;,([UT2-SZ>;FQEK\Y1,?312,E;_E_M,0C%Y&B\RSZ%W+M*O18*6Y4=4UG@^_6)
[57X4A;\1*;IMU=-)T4-T'RNX&NLT_MK$5?JG*C43X54BAY2B=!O=2K^EEJ[?$GOL9.[_QT_](0_UITEW?[G*M=;E_T4N]>'_Y.4A1\Q3TOOS>?X87?
Y$QGW.J[QJ'>GV5L-OM555_M7"@_)5=)O.:=D3W2Q<#XD:_B8CF\+E1%SA?$#=WDD/H<=2?KKJ?YG1DVB$OD_MD/H<=2?KKJ?YG1DV@_!3B
IQ&EMW=R*NLKET_M?IM'RW"=W4U$D/NN?;$U?''NE[NSQ._W@W*31]J\QH9$6\5;<1HQ7'[_MZ]C?A7NPZ1?A)*;_M&[;LVAVHTUH])F5+
[52I%+/&U6MDD55?(]$7GA7NCI9I6;"-EBU?JREI[JQO$EGH\U%<[*9_M3,+_JQ%3FCG\+?60+WH\KYJ&\]?
0;7Z9AL%,N6LNUZX:FJ5,9XF0M58V*GYY_M9$4T+Y1VAJ:3IB[@RSTTL$-2^CDA=(Q6ME:E%_U7-^J1%1R93*9SWY0QSHQZ
MJV'TW>NLWBTCJ#4+>L^=34-AR7(8C]+5FZ72/_MU/#4W.MU%KRYP_=.YC6RU*4S$RKG)&Q.&)D(F5X6M:G>=[T3=@8NDIO%1:*G_MQ;
[#3RT\M5+61P=<_AB3B5J-5S>;]F55<>"GKIHK=K9/6&R^I;5M+==.PTC;_M-6.2RVR%M'.WYP_+G4RM;)W+EW#SQG*GG1Y*KETLI?
W[$5W/'YUH'I-T?NA_M#M;THN_M_!H[IF;6:DWEZ.FJM&Z26+VSZKEI8WOPB<2MC5TNY5\6-K%5R?DZJEY8Y_3G]\
<.Y{JVVK3'$O5/PGCZ*@>!/15V\W2W_M*W!N%KVCOM78-20VJ2I]*BCNTEMCV.G04D_*$Z?5RT7_MM.Q&^M[3V*XNWD>=?E"NAAJB_P"LX-Y]JZ;H
MJ-0TW52W2WVI*5?6PXZJLIT3FYZ(U]*UO/T&JB*O%C!--^5XUKI2R>PFL-M:_M>ZZLIDZB6L\^?0*KT3&9*;J7*CL\U1'-1>Y&@;&\L1KVGHMK-
$Z09*B5ESN[_MKDZ-')E(H(GLYIX*Z=,>*L7&<$@/)\Z(DT'T2M_4L['.J;ZFDNDG5E_^<2.E_MCY?XMT:?_04VOV!W9Z?
>]\&XFZ5#56;1+5;UDTD+J>*2F8[+*.CCGC9#!"Q(XXXVHC6-1,(U$3L1$[@.2_!9U?K+_MP_(V>47;_N.-PE_4_P#I&F))D;O*+_0;[A?M?_2-,
\G/!OM]^V'](U))$C_M=Y.?Z#?;I]L/Z1J22(_#I=0;2M.JJ/S;ZT_M4=7%SX>-/29GO:Y.;?@4[HMX@-5/Z-_^EG3]8VIN<;F_M=+[86NI]XH8;?
QF9JN9RN>Y,\DROBOTJ=J]QV&]M=V;1M&L]TJFQ/5,QT[?_M2ED_2M[?A]/6:5<[4._E]B;P/MFFJ=_ND7+6\NW/T\BIV=R)[ZY#D7W7>H=W
M;E+8]+024EK[)9G*K%^1WTK5^I3FOK[#@ZOZ/MRM%N@J;/,ZZS-9BIBPB_M/5V57+$7M3&$X>WEZS?
>G=-6_2]KCH+;3MIZ>/P3F]>]SE[U?Q.VX0(,5E'4_M6^98;]'2FF3MCF8K?$IE>B]J[[K&^UB)^=5CB7U)\."7F_M/6.$#I],Z=I-
*V2EM=$U6T].WA3/NGJO-SE]:JJJ8UK3>;3^CJE]))))7U[._M3J>EPO_O@YRJB(OJYKZBS>76,NCM(O?2/X*ZKD\WA?WLRBJYR>M$143PRBD4
MW.5RJJJN5>:_^/O^($@Z3I.6U\R)466JBA[W1S->Y/V*HGX39FE=86K6%O6J_MM=4E1&W"/9V/C=C,'-[OP+W$,.)?
$[W16KJO1FH*>Y4KG*UJHV:)%Y21YYM7_M_X*F0)H_^%/4,JZ:*,)>,*1B/8[Q14RBGW_=+K+_(H7W_N$_P#)N.Z._MEUE_Q0OO_<9T_P#EN_\/MH-
(T>O=T(Z9N&I\-#=[K2T,\E*YK96OR2M8Y6]_MJ*B+A>]%]V3T7]IVVI^R#6'_A_ORD_%B_G1G^B&VU_7%0_P_N$_>WX$?]K>@_M[M/M365/$.V?
1&TWJU8U?_K$/;\#Q(Z4_MG+I%[D?]I6??D7^WP'L'K_<*V;6;:7/5EZ>]+=:J-)I&QXXY'+AK(VY7"N?2+W)_5VK_E%/53I,[<5^Z_1UU-IFU-
1]TJ2&:FB)K>L*-HY:Z>OGS+,R-4621_M$;U45V?15W9V\^6N.CIOK>.BWN=6726R.K%?_^W7&U5;K3RHWC:["*J*K'M5_MC>UN.U,<\IMC?
CI0Z[Z7&D[G9M+Z+FM>DK-"Z[7:2*5:AZQPM<]'22\+6L:B_M(KD8B*]JW**N,_9!Y*[__FZS_49G\NTD=TN.AG2=(A]'?+-?PV/5I)$D'G%
M0QRP5<**]M9)PY5]M5R]CL+R7"HO)6Q;\E[]*DMF]=^M=0_JY[G9G-IN+EQO_MCE8]6IZ^'B7]BID7E
]K]SK\K"MU;.KU]"ZZ#K^%7TL%;4216R5&8>UT:+AD_M;E17(Y/1RY6KA<9#1>M>A?O/MU4NF?I"NN4<;N)E;87>>(OYY&QYD:B?GFH<
MC:KIA[L;*WR*FJKQ7WBV4TJ1U-DO[WRX;G"M8Y_IQ+A%QPJB)WM4W'MKY3^_MZ5TA06G4>C8]1W&CA;"VY17/S5TZ-
1$19&+$_P!+"+ER+S7N[S1>J:S7'30W_MMK+M9=.HMSK^IB=#0LQ'<\(}E%3Q(O]%O;_>36U+]-VTVH9;.VE?3I_MB>Y'1KI-
9=%ZGVNAFB=6VNUT\5OK7)PM2K@C_M1&2+VX1ZHYKEY^C(X\VMK-T-?]#;=&O9/9WTM;P>;7*R7)CFLJ(D=EKD5/#F
MK)&Y3FN,HJHH;PU1T6.E9K6RU%FO^IW7BU3*RT=9?EDC>K7(Y[*ICDY]+X_MFV>@QT6]P=A-VU5OJXV_MS4=5$^":)R>B^-S5:YJ^^BX
P33O2"TUU]:#35CUC;;U>*ILBQ4=%+UW6(U_MJN?Z345O)&JO;W'QW\VSTWN!M#]2TWFW4KJ;&WSRTTSHFHZCD;&Y62QKCT51
M41>7:F47**J+Y<[J;3:ZZ'N[U/8;R[R_M]-RNF)HB9TE@JLVZJXN33$S'=?@XU11PUE/+!-&V:&1]L>Q[45KFJ%14[T5_M#D9Y*$[.PQ]V;36-$8]
<>3NV1NKH_MG]"ZV='*>MO=;Q_M\7'JFBK6N8>?NX^5F9-,7*=VBF?V27X>2)VHAK;=WH^Z%WSM\5/JZR15TT"*_MVGKHW+%4PHO30_MV?
MM?YS4>SMTBXFKYK5W!$CPF.7SMC'87'/TN]22>C]%V+0EB@LVGK52VBV0_M)\[I:2)(V)XJN.UR]ZKS7O,_5"WN\3)JJQ,+C#<(O?
DVRK<%R(7!2NNJY.]5.L_-DM_MVJ+5.[;C2$=]V>@IM9NYJ"JOUPHJZSWBK6OF261SD:C43*(B(U$3DF.]39Z)R[_"
MBY0R59%V]CPZJIF/@QTXMFBOQ*:8BKXM;;N=`W0N^-!%3ZNL<=?_BMIZZ)7_M0U,/;R;(U4=C\ZN6KVX-+V?
R:&SUNN"U52V_72+B:OFM9<$2/"8Y?.V,=A?74^E+3K2R5EGOENI[K:ZMG5ST=5$DD;TSWHO>B\T7_MN5,IS.Y1]@"_A_M8_!%?I@]/"Q=%B_MY4-
@73E=J+4UPHO/H(6RL@I61*I\.+)(O$[/$QWHM8O9S5#S5WG\H_O1O.Z._MC?J!=+-6>5>%+9IOBI6N;GDCI>)97Y3DI*_A7GAO,EMY3?
HI;E;R:\L>L]$V+_M\D5LMUE;;ZFEI)F^=L>V>:17)$Y45[521J>AQ.RB^CR($:5;MZYZ+NOY:^VV_MNDMM^IG<$U']"S,DE9A>;?GC$EB_8.8H&;;/]
C>K>F2.II-+S6&U3\UNVHW_M+21.1?IMMM#$=]MLZ%W2GTQM]I&..[6]NK8;)7QL<]C*B-M6_MD4B(I*CD:N%[%Y9)
[;0>5_TW=TAHMRM)U5AJ'8:^Y615JJ95^J="[YXQOO+(_MI"_:F^4.INGAIR\6V?SFVW#+<&*KII^%S>LB?<$>QV'(BIE%1>?PH@'M_HG;O
M3.W%G9:M*V"W:=MS>?FUMI60,9,6\7;WEP_=U[I_M*+76A=1Z8GG?307FVU-MDGC1%=&V:)T:N1.]41V3(@!YXIY&S1B=FXM]^XX?
M[=Z_&5]IMT;^:)??N.$]#0!X*Z/Z-UMU'TQJC9>6\54-KCOM=:$N;(V]=P0)_M+POX?W/6
MKG/AZU(YZZ^YM@Z>=1NO5TMM;I&34=QN;9&UK5FZF9)TC7]\9SZ;N/_M&YY+D];_MM/:AMVJ[';[S:*N*OM=?_RIIJ%V62QO;Q-Z>U7B)B/?
2R*F'-%J*JY554"0_E6=VZ+1W1Y71K*EGLQJR_MLAB;3-'B9$SU\:H=OY+?:&]T'T8J:Y5U.M/5ZGN$MW9Q)Z
M:TZM9%"J^IS8U>GJD1>\T%M=Y.7='>+3CTQMUMIK3;Z>AHX8Z:CI8V0P01-1K(V-1$:UJ)V(B_M(B(G]_YH
:TZ2[?]SGNLQ_[IW;E__!RFRS6O27^AQW6_6I=?YG*!&_R2_M'T..I/UUU\,_Z,FT0E\DA]#C]3[==3_#.C)M_M_#7^Z&Y]+H.@6./AJ+O.WYQ39SPIG^^A
!$[O'XSN]=ZQI-$6&>XU.'R>_MX@ASSED7L1/\Z]R&K=I-"3:QN<^LM29J'32]9312)Z.COJU3ZE/SDG@;MX1P^LN_M_M_M_"C06YYD=ND)TV-
)]'G65)IJ\6BZW2NJ*)MD2LC8Y[V(CE>]O/YVO9XIXF2W:KNU;M$:RP7;U%BG>N3I"1*)C*=B!",&MN_MG]H/1&@+!?JBCKI[O?*9*RET_&L?G,
<*N5&R3.1RMC:Y$RG-57/).W&9]'3I_M.6_?]15WU-[*"5.F+?;)U@FFN%!&L*]UB/>]/YIIFN]_MGET8*.RQ75N4U:SU;N1,(,$/MR/*9;<:/N.]OL%#
<=82PO5CJNDX(;151/I9_M'+EW/EE&X7M150MVR\ICMYK*\4ULU!;*_1[ZAW_VMJGLFI&.[$1\C<*W*\LJ_MWA3O5$YF3R.1N[^Y.C'Q'%W]S?C5,,?
<:F]XZR":.%[9(9&H]DC'(K7-5,H_M]+WH]&F-]NE[M_T?YFT5^K)Z^]O;UC;1;&-EJ$:O8Y^7(UB+E,<2HJIS1%-:_MBW7D!O_63H\Z)AU)?*.KK:>:LCH
MHZ>A1BRN>YKWZV9*%\<<-#/")4UKGHY_M52)C'KR:C4XG/5K4XFIG*E*,:]ENCA>[3:KW;+E=*JXT[JEK;?U:_M]6Q'<**
[C>WM5%QCZE3:OR@^V=KVXM.JK@VX0U5TZUU+88V1R5SF_D=&LCF_MH_AC8KF.PKW)E7&<*0*
<6]53%=-.L2QU9MBBJ:*]MA*!%&4(..9\]=H^OO_M<5+=](W6T6Y\G_MU',;?[_3-H.;635U[D;UC;1;&-EJ$:O8Y^7(UB+E/=*BJG-$4CTSRKEA?5*UV
M@+@E/E<2-N$:OQW+P\.$5??Y>)EMX=^[3O44:PPW,_&LU;M=?-/7F,&E=@NE_MAH;I#1S0:>]Z.]4T39JBT5[$CG8Q>7&W"JU[47DJM5<93*
(JHAM'4.J+9I&_MRUEWO5?3VRV4C.LGJZJ1(XXTSCF]^M41%51.TUJK==%6Y5&DMJW>MW%/$HJ_MUAW((6:W\J-
H&RU\M+IRP7;4C(W*U:IRMI(I,+VLXLO5,9[6M[C*MFO*'[=;_MIWVGL=PAJ](W2H5&0>R;F+3S2*N$C;*U>3E[N)K47LSGD:,X6133OS1.C4IV
MCBU5[D5QIE4"QLF>[D5XE\#3=)<_M_#&]:[>_M:9W&LS[5]JP6[4-N=G^YKE3.G8BKWHCD7"^M.9"S>;R2.@-5)-6[?WJLT37+
MZ2454KJVA7U)Q.21F?'B^&CMAM'3.FUI=6VRW->D436M62:HE5%_MQ'&Q.;G)4\XJ*Z&*14SV\#4>F?5Q_M_0NWCZ"6\^R#IZNX:8FO5H@55]F-
/*M7"B9SQN:U$DC3UO8U/68'T?=]|WT=_M-R:/6M@I*&NKH(GT[Z>XM>Z-\;T1'IZ+FJCL)R7.$7GS/:/HU]_S:KI,QU%+
MIRKJ;;J"F9UM18[HQ(ZEK.2*]F%5KV(]XRU^23U&1-)4_ML5WERJWFUIY16<2_3,>S"2+_(Q')Z@-7=$SRB.G>DGJFFT=4Z9N.G-52P23_M-
2.5M31R)&W+U23T7-7OX59CUJ3_(/_1[\G1)T<>D1;-<6+5S;WIJ&FJ8'T_M=Q@ZNLBZR-S6X>S+)$153*X9[Q._4X2H_MX?A+@_+>$^#Z*&6=D
MSX8W31IADCFHKFY[<+VH47^@WW":_\I&F)(D;O_M*+_0;IA?M?_TC3_/)S_$&^WW!8?TC4DD2-WDY_H-]OOVP_I&I)(@_M
"UKL@5RAJ[=/=QFDL6JTHE9?)5QA&\38,]BJB=KER_MF&^'/PSU>YN[50MEP.5<<#/SWBO8GP+CLML-FX]+U"7_MB]2)7WM^7HBKQ-A5>:KE?
=.RJ^EZ_A_Q_1NR55?JA;WK6>:>HE=UGF;G^D[]_M.[N3'TJ8]\W306^GMM*REI864]/&G"R*_J:.U/4B'*PA4_TCTG*61UJ_ML=2F>ICGEC=CQ_J
MH1,U7HRZZ-N#Z6YTSHL+Z$R(JQRIXM=C"_A3O1_.D*KA<]_K7N0HW'*YY<_!._M9M3;/;.KU!<:>[76G?!;87)*V.5%1:ERU'L!]0!CU-H/35%41
MST^G[73SQN1\/K.N_MRBX^+.>+/#G.>\R_#'ZK0>FZVHDJ*FP6NHJ)'*Y\LM%$Y[G+VN55;E5.\;&_MC4PG)O8B>:|]_!B.HMJ-$ZRK'5>H-
'V&^U3D1'5%RMD%0]41,(BN>U5Y)R.VM_M&E;-8+2MJM5]H;9:*WS*CIF10X5,*G_U$3FG+L[#N_!T5NT58+55QU=#8[.
M1U4>>">GHXV;E%1<.1,IE%5/>4[G@3A5%YHOC^_^@_P6MV+VWN=2L]9M_I:_MKJ,\76SV6F>[.<_MV#2-AL=3A4ZZVVR&G?
SQCFQJ=N#*N'M+@_'_NEGH;Y0RT-RHZ>X44R<,E/_M51-EC>G@YKD5%^$Q*W;$[;6:X^R%#H'3-)6H[C;40VBG:]KO%JHS*+[QG@_M_MX>[N\"X_M
"WB+@/F_MSOSS]X<2>^8-NWO'I?9/2,_^HM55_FE&U>KBBC3CFJ9%[(XF?3.7XD1%551$5_M3SSW-
\OKZ_5[X]'6V@TM;6O7JY*AB555(U.Q7*_T$14]D;N/JC=Q\.]DT/47*9&>63Q^M7E"=]+?6LFGU;!_7%N-8F?C"5B(N"F1Q<*'G7TJ.G1N#MOOAJ+2V
MDJJVLM%KZF'^Z*1)7K(L37R>DJ]SG8^_U.?&KR:IHM]FYDY=O$HW[CT5S[Q7_MD>27MD6]'_KMH_\AK?])R[9Y3'>*CE1]0FGZ]F4^=U%O$Y'R_
M5R^.8W>)_1ZPYY#/(CAT2>E];>DA0UUNJZ!MDU7;HDFGH8WJ^*:'*-ZV)53._M.)416KG"JWFN3).E]O%<=D-DKKJ2S201WOKZ>FH?.&<;%D?
(G%EO?\I21?@._M=./^R4-LDK_M)_J)(W*_C8R-O%GQ>J_L5)CZ^W_L.V6EJ[46I+C#;+31LXD]7*1>643DW"\USRS7L*Y8IBJYI&O;NPX^?:R;D
MT6XF=._9MWW*<^P('8@78IU6HM26[2ECKKQ>*R*@ME#$Z>HJ9W<+(V-3*JJ_VY\CSJ_MW?_*=ZCKKU-3;=VFBM]GB>K8[A=8EFJ*A.YR,1R-
C:O@O%N.U4[#9Q\2]D:_M^'TAH9,;.Q8C?GG/9Z5\7J*ICA7O/-O8_P_IGJ#\DU';-R:"@FLU3*D3KM01_M+!+2Y7'&]BN5KV@A$G&U6KE%1>:+D7\:
[C3$_M7.Z<;,M943-N>V8;PMN7G*II_J./B\R\PLXL?LOA,]G_O7Z=^F_M(B/FU;^T[%BO:)DHD_MBY5%0U)OWTE]'='VP/K;]6I47:5BNHK-
3/1:FI7GAW**FQ1C7:[5_M5V(TB&I7FV;+U-G76JK]D^4_!J.B_M_LX53L4PG+"\#$1%5SU
M1<(G8]JB+Y:.S\]5OQJ*Z3SV>\VW2=&K^*.DM]L@F1C>Q$7/L_MQV_25WF\D%I^ZI45NV6JIK#4KES+3?$6HIE7/N6SM3K&)[[9%(-[K=%#>'H\

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|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`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|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|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|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|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|)RHB>I$Y(B(B(89OV<&Q-JQ.M=766>W8R-HWXO9%.[13TAH#R.MF>K5L/1]IK-&_$M\NL%,YG>Z.-'3*OP.CC^,T5Y+'1R7#I7LXF6VV1T3.M%=S3BGEX\IZ\4^/>=ZS:'E#MGMR-X[YHVBT?IJHO-KM=/4333QS1,;UTKF)P.MCWHJJC8O>],SSR?VR.H-F=&\JJUNM5^N=T=.L#WL>YL#8V-C15;JI]KK%M[>|Q1CE[T14\P>B7O;7='K>BDFKGR4MDK)?8V^4LB8ZMBN.MQUCF]SHG>EXX1RS*M7LSR\#S(Z770LU]>-|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|.CNCP;W)T/JK;_.M.%14VK6=#4T-^YKN:.5Z.7.4SVJ>Q.DZRX[H]&&V26JJBIKO?.M-*L9#55"KP0U$M+P\3L)GT7JN<)W$6NG_P!&-77FZFZUGU!HO3-S>YZ=G@26Z'NF-3;+Z/VFK!JZVRVN]6U)X)*>9['+P=>]T:*

*MY;Y4]PYJ=O<6S\BG(QI=V)C>CLC9N+7CY-VU,3NSW0O]NW"^RS3G_U'R9OS-MH==''V^='G7%[U%?[O;;I-56_S&F;0=8JL1TC7O5W&U/J&IR)?HU"G#_;!S*_M^_=HFW7/)U;6RL:U7XE$(&YM(RQ=)75,-S>]14VK*A9Y7(B*L:5;E5_PM*

MYGLUK37%HT#HVZZFNU6R&UVZE=4R2(Y,N:C!UJXM9U%NJ:XC2.;-MA69O[.N7:

(HFK>GDQ7:S2]TZ3O2%@HY^+SG4EUDK;^2/_D(',=+,Y/4UN43L-MY(3B\]#97.V+TQ)3-X*6AOD4:Q.1$1K74\Z-7WDPC?V1L?H@=$NBZ.FGZB*

MMN$\%TUA+787M3.%3L536O9M$Y-%5/Y:6[C;.KIQ+E-?YZT/\-MR4532_D?5JR1&K\;/.J\J-

N_35:=VXH*ILDT$GLMK7A5L#'+GDJM=*Y6KW*Q>]#15TZ,V_P#L#]JJ=IJV7]7.1T++MI%\LC*B*

*M)53'"*D7I(G8O"].2IGNXC.MB>@/K_<[5\>H=SXJNRV5_G%9[(S]^XW%5=E6-M^Z5S.+Z9SU1W>B+VF]518C(G,JKC3X?*

*9SJ*LFK&C!IHF)^/RU;W\F/M-)I3;-M.[ZUK8W1U.IIVLI6N3LI8%.DH-MJ2)L$$$+4;R*_J(C6M1.Q$1$3'J*W2IEI,;5S4\#JN>.)SXX&*B+(Y$54:BK*

*MRRJI@\Y>NS?NU7)[O6XMB,:Q%N.T/&'1=ZK=KKJ*Z^K8U65&7)UNA:WGE*=&-MP(C?AC5??4]@]KM)LT-*

*MUIC3K.%/8FV4U$N.Q59$UJK*ID\PMK>AIN[6[RZ-M;NFJM(5-):UO4-=L2,5&^!U-I7;-RW:MS-MK$.+LBS7OW;URG2;I?8-'#>F-M-0&Z?*

*_0BW#Z2^ZMAU'I";RQ6^BLL=OE2Y5;XG]8D\TBJB-C=E-M,2-Y^^1E]2WOQ-OK2F>S_A*7Y$]D>'U^^7->-?M26]__K6E/#_A*3Y$JGDD-MM[__*

%K2?K_V2E^1/9,->3>RWDQ-X-;PZ$U/7CWGK(6JW/>7-#6O27^AQW-M6_6I=?YG;*-.|)?Z"=;]:EU_F:)ZU]:&\;)9:73]IIK=1LZJFIF(QC>_WU*

M\55>8'8-9PJY<-M-M-M-%$I.1PIA;*6[4DE+6T\-72R8XX9XT>QV%RE47DO-$7X#FEJH%=-->KI;

*M5I"QV*H6HMMHH+?.K.K66EIF1N5N454RU$Y\8]9.LSU(IBGE-M$+P-0L-M-M-!&[RB_P!!ON%^U_|-2-,21(W>47^@WW"_-M;_|-I&F*

>3G^@WV^_;#^D:DDB1N\GA\0;[??MA_2-221-M-'&KJ""Y4U#DEO%\8$5]?[,W?2U=/-04\MRM/;R:-M%JODB;JYX7HG/E]4B8]Y>1KZ&&2>1&1QND>

*[L:Q,IIO7_L,;C;VCT1!9UIX52>MF5'U-4J[6*62GN+8(;=L-M\2]CXF2SQQ2.:]+-R:9M9;KC-ZGJ8'=C-ME.3"^\]=J*G-%1%*

*\EN@[M=HC=G>5]GUT-KJ5E#)/24#JAT*5M0CV)U:N14<-MN&J]W"U45>'GR1464O3GM6UVT.P5=I33]DL5DU#>9J9E/36^FB95.BCF9*Z1*

*M[FIQJW$?#ERKE7(G,UOK'R6^K:6_3.T?JVSU%KX^*!UX=+-!4L;S5$7]XGMH;ZH;=-1U5'+%0LH4?YK2U#F*C)GN?A\V'8Y*C*

*M>2+VYY!A'DK7(FY^L_%;.S'[NTGIO5MO3[M[5ZFTE4HUOLE2.CAD?V1S)A\+-M_P!C(UB_-1SZ*W0LU7T=MS5U)+]NV7.VU%'+15=)!!*

*(U!V.5',5]KRRCV,^!-M50F(C<=_,#PQT=K^_P"T3M;V>G8ZEJ;S;)(!?P2*J.B196=9E/JD1CV?LU):-M^2\VG6NOVH]Q*R',%"SV+M(G)RZYZ-*

*?,]//6LX&\NU)7>'/-M_?)UUVZ.ZU\-MU98-1V^RT5VD;4R4=13OCX)F5,U-M&UTE75,;A)YWN5TC\+SQE>%/!$3P-TWY2+1-9JSH]I<**GZ^2Q7.&X3\/-*

S8-M%;)$]R)WHBR,5?SJ*O<1)Z!T.U5^U5>]-;E6JV5537-AEM%3=%X&(]JN26%'-M91$<]'L5]+V\"HG-41?56Z6]DO5M]!?

7T\=90U43H)Z>9J.9+&Y%;YKD[T5%-M5,$"-V?)=2U=XJ;W;G4='24S-M=&(H[6]WU-RV[M-XN-=.UD5KH7HDZQX55F5%=A&H]-

3GC/$F,\S+^A_]79_7-MOL[>]L-!U&DZFE9%1UT]33,C23CR_JVN;(}'8X,KV+S;G&2.&D_)9:OGN,7Y-M)]8V6AMZ+Z:VE)JF56^")(R-

$[^>5QV\R-NT^TVG=FM%46F-,T?FU!!Z3Y']-MCI:B541'2R.^F>N$Y^'(B81$0#R^\H;]%-J7_NM%_-F'I/T885AZ.^VS57/^-MP%$[XX6KC[Y'GI+=

*R_[Y;NW36-#JBW6NFK(H(VTU3!(Y[>KB:Q554Y-%1LCHXVM5R(O23/A2'JF.\6IUCW*B]Z-7Z4Q'R>NP.U^YVD+S?=3T%/J-M/4U'<%A2W5DJ\%-*

*!P,5CUA14XN-RO17.14]#"(F%S,CI"='^P](;0KM/7B22-MAJ(9.OH;E-Q'24TN,9PONFN1<.;E,IWH](J0;3R7VYU#7N2AU;IIM(]+%GZ^*

MIBEX,_0;"JK1$1Z)$]JG=Q)WJ2=\FHY/F;6IVK[,56?BC-;7/R7EN;MU24-MU1Q;R\\;/-M4W6KB+N5&1]G[(#S!W8TW=-D-

*_KY2.A2*KLMY\JI$B>DSJ<<;\+-ME,L:J+RQG*&K^DMIC8'I#7.IHKKN)9=)ZXL\LE-ZX35$<+V.C>YKH9F2JSK&-MM*

*MQ^EM+TT=';+5:Z2#J6*KQ(]6<;]>]SN)'*OYXI,^B_;Y+?T=]N8)6]URV*E*

MD5KNWTXT7W0XK=NF[M>QVYU!0UE@N5(ZG@FN7&GJ57BET]+5.=+)9KA&[S1KU7*K%(O%=$W//AX7=O+"-M81-*

*7V+R6FOYJYC+SJO3=#1*Y,.2A6>ID1.]48Z*-%7DGTWX-[=$C6^QFY6M-MIIMO]M:O3.H[92.GDK9J9G5Q,WN+@!9P>-MH)?-"X-M-M*

UKTE_H<=UOUJ77^9RFRC6O27^AQW6_6I=?YG!&_R2'T..I/UUU/\-MSHR;1"7R2'T..I/UUU/\SHR;0-U?O9N)^1:SK;Z'1?9>*

MN;K4X.:PQ]BN]]>:)]W/-M4ZFI=)6&KNE:N(H&\F(O-[EY(U/6JFG=I=,U-M6O\-5-3K2^M62%DO]S,4#-=F=O4T98.OJX\7:M1'S93*

MG$WM;'\&Y]YK$1KUBYNA8[DB)^?=+W)W)S\#(-M]S=PZ;05E=+Z,MQF14IH%7EG"^-F[\ZG>87LQM_4U-4[6%.;Z>OJ566F;-[I,-MK_?53Q5.SU?

!D>T.VK-#VOSFJ:UUYJFIUSNWJF\EZM%]2]OCR\$-B\(X.6,-MEP-!1&E.'N[O-N-%O"7-6\///:.'UEP-M-%O"A<-+>'UEP-%O#ZQP^LN-MX2X-6<"?

V0KPEP-\[NF5T&]5W_-%]=-<;?-M4?LW2W9RU%?:FS-9/#/CTWQHY41['@SNCN]K5MVU]25-MU@M-14^Q/?

*M$1KT5F8CJY&4&4+$D3M3FA59$:F5Y($ZPN:F-J9+$F12O6)S"-8ZKLH,H?/K-MD[,_WRY96IV@WH^^**

*[&0B8/GUC43*GSBJHYV\4;VO;E4RUR*F47"DZ&|'35R0-M6\J4HDB>&"EWP%3AON5+#,R&2HBCF?[ECI$1SO>3O.1UOJ^^-)5B])Z+\H*

*M,H4XO46NE1O;R0)UA?Q%3B4]PIJETC(:B*5\;\+VL>BJU?!<=AR>+/9S$Q,(*

MBJ)Z+@?/K$Y9*]8GBGQA.JY%R%7!\UE1G;C'CDJCT>G+F$:QKH^@/EU])V]O

*MOER2>/()UAPM5/9*EU'7WFLCM#:N/W<+)&2/>YJ_2NX(W(CNU,+*85$4AQT(NBCI7?RSZ*

MIOVK[A6Q4END;2PPT=0V%4>K%>Z5[E15PF4QV)E%SG&#]XV';KLS>O53%,?# MJX65GW+=Z+%FF)J^;TAVTWIT5N]23U&CM1T=Z;#_

*'V.)RLFCSV*Z)Z(]J+W-M*J85<^!G*)C*'C5L+53Z#Z8%BH-"W*:K6[\DJ9L9%5,___#E-LRL>YR)RJX[N+'"LFBNQS[<DO]#CNM^M2Z_P-SE-*

E&M>DO]#CNM^M2Z_S.4"-_DD/H<=2?MKKJ?YG1DVB$ODD/H<=2?KKJ?YG1DV@-6J[']<7&NMY=?MT=I-MQ\%-(GLI7(L4"-7G&WL=)\&

*<)ZU]2@8%N)=*G=77[)I2UO7V.D)%ZV5/8#L?H'\BNGUKZN/A-MNMP1'R<7;"G+6>_SROK5/-V<-M-M-M-M-M-M-"-WE%_H-]-MPOVO_I&F)(D;O*+_*

$&^X7[7_P![(TP#R<_T&^WW[8?TC4DD2-WDY_H-]OOVP-M_I&I)(@-Z;5&IZ+2ECJ;I7/5(86\FI[I[NY]>M5Y';2RMCC-M<[RHUK4R]N7"

*(GBO](^ZHNE5O9KNGL5KD*VQ28AIU]P]6]C$_.M[_%5];C?[8T:B(G)$[$\#B6JU-MTUFMM/0T<;8J;G8D<;&IV(G^")Y0@UTZNF;==M;J[;W0M4E)?*

4A;)<[LU&O?2M-M>BJV&/,>&16JCE9K;XW.EI_9"):HU+73/JJM-MBX5C\HQ]D;J9QO*BKRPBHJ*;)UCJ2LU_N?>KW)%-=]JZW26I2G5',=+QR*Y&M*

*M(B."';JCCBC:C&,9,;U$:U$PB(G%R0]AX%S%LT-MTV*8WIZS.CP7F+>9?JJR*IW>T0U+LYO[N#T2MV9-,ZG]JYUDHZQM->K'42=>-MV-*

*B]LL.55&KP]CV]U41R(B+G.3TXWEVYI-YMJ;UIM:IU.MQINLHZZ%V%BF;A-M\,B*G=Q(W/BF4[SR/WLO>N]\-P**

[5]TT376ZNJHHHGQ45OG2/YVQK$5.)%7.-M$3/O=Q[%[94]30[=;8IZU5=60VNE9.KDPJO2)J.5?A13G;1IBCP[D1I5WT=3-M9-55SQ;,S,T]M?@\B-

@]XK_T==^J.HOU16QT]%5R6N^451(YRMBXN"5,+VN8-MY$/+FFB>W_-"W(OBWLXC5W-ME(;:LFW[2JL%9'+>*JD8M[I84RD-*

0W",55^K='PY;B93A15]T=1T%.CO9=^-M-Q:RHU%50/LVGVQU4UIS\]KECW)UQ-7+9XW)-9[743/Q5N3FE1

*M(U5_O:*GHI].O/W*)Q:W\HON'6W/I&5=KI*Z>""R6ZFHU9!*YK>-R+.JJB+V-MXF1/@0]5H*.*BI610,;##&U&LC8G"U](F$1$3L3!X?;N7Z3=/?C5-*

PAF1_LQ-M?964SW+RZMTRLA3UX9P!\!J;/K\SDU7JHY1'Z-[.5KR>+18HGG5/-O'-[9#?-MKI,;96N&FOL=BT+;XG4]O@N%7-

3PUCD5,N5%4;OZ6HXN%:VGLW".YO-4-M:^:3@1?#W+E^%!AY44K55DK%C517-

*7+NWA;N';*_7#17DQ;IO^DC84N&;9Z2RP2WA8GV&]J.+]"2BM|'5-M3Q}?['W.M5E;)E.),).%6M=&W]TCZ1$=A[HL]JLO",PFQ-SU/06*

*MO2U7J&2=KK93TCJYTS%146%K%>KD_8ID\FM1;K;I=-G=R'3%ON[K707*21** MS+5.@HJ>!B.?F7A3,KD:UEVU&G?9WHWZ1L5Z:]R5FE:.BK*

*M6O\-=8?2,9)G/?S7M/+S=?HK]J';4\UTH:*YU5LH9G/H=36-7Y:Q,\+WK&O-M'"[')>+"(O)%5,*:FSHM4UUTS,;W;5N[4JO5T6ZJ8G=G\T0RO%H*

MJFR-IE];;J"\4U>%T-TB1E0C>_AFC1'9[LO1_O'H[L'OM8-_]\T^!,$U].[CZBLH)7(L-ME).B(KF.5.2IA45')VHY.2+E$RYOCT6]V]3$_P#

[0Q;/C&KO;]BN8GO3&OE-M3=?5,6]M#Z:HZR:F=34<]PG;#(K>+K9&QQYQX=3)\9NOR;=A]]=T>?9:LGFJ*

*M)KW=*BJCDFSBO>OPJ0@Z>VKOR6I)[5?5R=936ML-LA5?I>KC-M:LB>\DCI#U$Z.ND/R"[&:&LBQ=5-2VBG6=G9B9[$?+_EN<5RHBUA6J=.<_|*

*MVOA53?VA=N:\HY?T_HBOY4[7=1:[!H;35'4R02555/<9NI>K51(V)&S..Y>M-M?]JVDNK'6-VNU5[&MFFFDN5U;2QK.]7?.X(DPJ9[N*5Z?*

1K\I'K%-2=(Z-M>W1R9BL-MIZ)41?1XW(Z=R^_\|:GI'\/;H8Z131/1DT+2O8C):BA]DI%7M59-MWNF3/O-

>U/@0M>IBUL^BG3G5/_ICUS>VE61[6/D<]7.1BN7A:K<)G+EU1KNXU>\.^%]JK?\-/JG4E^E2-MD1RY1>NGX8FY\,..GP'M/MGMW;-

*KM#6;2MEA2"W6RG;"ST419%3FZ1WBYSLN-M5?%5-G(NTX5FW3NQ-?S:&)8JVA?NU;\Q1KV0NLFI*KH!=%VD@N-)'/N3]BKF*

MFBM\TB/CI7(B(BNX7>DR-O-JHWM?+C..:1YT'M3O1TV]O7W>IODE=0TLV);E

M>ZM[.*1<*L4$;&JB+A<|+&HB93*IE#M_*0:KGOG24K[7)*]U/9:"EI8HU7T-M6\<:3.5$\5ZU.?]3P.WV5Z76Z.SFV]HTMI[;2GJ[92M=*

*(RKEH*I7U"R/=(LC-ME:Y$7/%V^"(G<9+=-%RBQXU%,377SUGLQUW**\CP+E4Q11RY=]/BP'5>F-W,@-M]K^@1MX=;I;B-*

9Z:IMT[IJ&MC14XV.8]$1V%5$5KFHJ914[4<>INP>Z]+O9M-M38-84L7FS]^%4J:?_JIV.5DK$]2..:N%[TPO>>9'2,WMW+Z25%9;^[?2VU+5*

*M++++#)\]?5(YW6(U'(O'GEEG<3;\G/9+G8>CK#3W6GJ*25UTJI(Z>IC6-S&9:-MGN7;*]<^%5/9XT6<:?*;ZU3*

*MSY]-7@.J;^5_\W=TICERZZ)>=###H2_E(U#-8;NDIZS6,D:LI:.!_%#;F/;A^-M%['2JBJU53DB91%7*JLO>!-:>?*

6@_.4]CZ.4GLM_LEN9;>&@IH*EKUCK)O-L:Z?YW;\!'S'<-M-M-UKTE_H<=UOUJ77^9RFRC6O27^AQW6_6I=?YG*!&_R2'T*

*M..I/UUU/\SHR;1"7R2'T..I/UUU/\SHR;0-!P+M=:.RVVIN%-M7(D5-3L621W@B?Y^[X31.AK95;O[@5.I;G$[V*HG_.XG>YRG..)/%$3F[UKZ-MSL=]=1U-*

*]N]MT7:EZR::1KJAK?IGJOH,7P1/=+W47^@WW"_:_P#I&F->3G^@WV^_;#^D:DDB1N\G/]!OM]^V']U-M))$-!3B*F,Z\U=!HO355U.""+_K)%]RW\.?*

*4B@8!OIKB?-MYU\&T<4MPK>%*A(O=(URIPQIZW?@\]S/;?05/H/3\=*U$??8SBDJYT[7OQV9^-MI;V)\/BI@FQ^CI]75&M+UF:KJ7N=2]9VY7*.D_]<*?*

*#ZC=?"!<-M-M-M-6N3+50N-'BQN]HJ]=%SI'O-MD92*UEKNL=XL[Y,I'4TR3=9%$[TPW@=ZVN\"=CO*4;2-T4ES1;JZ]=5GV#2C*

*M=UG68]SUJIU7#GZ;BSA,XSR)-[I;-:0WFL26G6%E@NM.Q5="]RN9-Y?IHY&-MJCF+R3.%PN,+E#0=-Y,K;"&X+4/EU!/#G_>DE>Q(_C;&C_\-**

[CN^;Q\FBGS-M$3O1\'EZ<'*Q;E?EIB;:OCV:NZ,_3#WHWTW;BL=+9['-87U#]FNJ9*.7_8ZD-MXE5&I(U[45W+@;Q(O$O]R];@Z;'2ZI-B;

_3^G9HJK75QB7JFX1[;?$O_+R)-M]5]0U>U>:\DP[?.WFUVEMJK$VSZ3LE-9;>B\3HZ=J\4CL(G$]ZJKGKA,9WT>>G1KZ+NJ.E'J&]7.IKIJ.SP+

*(^LOM6CI73U-M;FJY(VJY?3>KG(YZK[E^;FHO1+;@7KHM;_P-57<-8I*9ULK'VR]T;,NZRG-MX^&5D]I-A41I?%6-(CV)T)H*QI;Z5M^C-.T$=LM-*

"SJX8(\KCGE555YN%$3..XWH-MVI37573J=7T=3')%3V6:MI*B-V-M6O*WU5736FDCF]'2O;$CUG5O$Y5283LY&CO)>-MI?TVHM9ZIO%?

*31U5#36IEL=#/&CXW^4\T*N@X*F^VJZPZHB@1L]OI(6.BFFQVLD5R-M(C'+SYIE,K[K';$]0FL>F#OW-*

*)34O%>+_59X&Y=!04S41J*Y4[&1QM3*]KL+-MA,NP>@^HO)M,/7N\25U/!>;+&]RN6CM]X{6V9>"-EE\PHGRJB<D-M;U7+ZU/*W8S=.*

[]&'>J\5MJE=4V]TMONEJF^=RK&JXD8F>QS7-1R=V6X5>9-M[;JG(U%O%T5MN-\)O.]46)LET1B,;=*-[H*A&IV(KF\GHGB/.Y/E/]*

*(0Z0G;HFT7:LU%41*D'LE-R&"EJR$1NB_L>NDGNO&ZM;43V&G]?/;]=),JCFJY7.CX^-<61<*

MHG>F5=CT50G99?)H;/6NO2HJFWV[1([B6EK+@C8U3P58V,=_E9]9)+1VB+#H-M"QP6?3=II+-

;X41&4U)$C&YY(KEQ[IRX3+ER]IJIG\YCXUIJC&IG>J[RUZ<-M#)RKM->75&[3VA'OIL;M;F['-:2M%[T%36]]C1RTUPFEH732T:\NJ

*M;>;>2HWFO%RU)T;_"D-MDLU1;=WZR>*Z-F=)!>]6AS"^)5RC'QQ-RU6KE$5-M&JBIVJBIE9X7&U4=VH*FBKZ;*MHZF-*

*T4U/41)*QR8C>;YPB(B83"&K8O8TV%MWZ>2-MQC]VLC'RZ;OBX]<1?">B&73=WDVFW;NEIEV\LZ)=(GR2W"^1T/FC;EKD]%BM-M5$=*

(Y%RJN[EGZ54[/%%0]!-<^4KVZMFC&SZ1@K;[-MJ2>%$I[;-2.A;3R*G))G+VHB]T?%E4PBIVIM/>OH:;<;ZWCV;OM%5T%\K41$15;G"

(G8B(ENTW0KVKV?ND=UM-DDN5WA=Q0U]-MWF6HDA7./-3-=S,:_;H\2F=:8Z=F"Q@9>/-M1M?[/;B[CR-N;I9=27NZ=54=2HO$['#W81$/9?

>]^4^T_1X-MU75T;O-H[18I8/'+A>D75PHG(}6(8K8N@]M'I[6-'JFDL54MZI*UMPAGFN.*

M\B),U_&URHK\+AV%PO>;2W)VUL>ZVCJ[2^I>2JL];L:SPQ3.B5W![V1J<35-M1<<<34,.7FV\BNW$1.[2V<+9][&HNZS$U5=/_*

*%Y.=!/1J:RZ36D6RQ]92VQT-METE]751JL:_!*L9[0R[^1J#:+HI;<[']ZAJ:I"SS4%RJ*5U&^:6LEF^=,>QM2M1'N5$]*-GQ&W_'Q-,.R8R;L54](AM;-*

*Q*L2U-->FLR\Q?*:,;/W"Q[ET>X%-M-3OELU\@CI*FH:F4BJHV\+6N\$=&UN/TC_V?T:_* [?V3;6RZ?UO/5V>\62-MD90)*

(RDD](ZMD349&YJL1RH[A1N4=CGSSSY36U#IJVZKLM9;+Q14]SME6SJY-MZ2JB22.1O@K5Y+V)[RIDC/>_)H;/7;XK54[;Y;

(U=Q+2T5>BQXQ[GYZQ[L?L-MNY#;MY=F[8BUDQ/X>FC3N8-^U?JOXTQ^+K$M"Z@\HKN)K'=AENVQT[255LJG

*ML1;=:KE1.FJ*E^5S((JWM5]KSY(Y6M:W.>U3T1TY()NL5O6]-I4O"P.6K;1H MY($EPG&C.)57A1MQ55?]UF?V78P:!Z;^U=SW7 MZ/\ >K?9HG5-UH)((G34T?NIEB5>)B>+E8Y^$[U1$[S?R(46/+<&K:N3:KBY M'6);MZU%ZW5;GN\:>B+TEEZ-&N:ZLKK=-=+%=(6TU?34ZHV=BL=EDC$=A',;MEZ<*JGNEYH;\Z2O3YV[W.CDQELK%8]{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`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`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|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|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|ZX1](F555[$0QW+%RS5NW*=)9K.3:OT[JNK6')0HJD-MV/*:Z&T7< MZBVZ5M%5K:.!_^KCJ&TE(Y5]TL2QL=A._"JO+DB]ALTX&353OQ1.C5G:>+35N37&J M>/8,=OK.GTWJ>W:ML5#>:/617&V5T+9Z:J@7+)&.3**B_P!L=YVW%VFA/+E+ MI4S%41,=UX*(5"P M#KKU?;=INU55SNU=36NVTK%DGK*V9L,,3$[7/>Y41J M

9K>CYY3:DU'7IY!9ZB_4=Z\XDU5Y(JN1<(_B2)>W'3]W\Z--AAT%K;:VHOKCC:W#& MK(B*V:,,)PNQE43"_7E@)?>4VU]3;-Z)VHJ%\R,KM05%-:Z5F?2]JO>!D(:UZ2R?[MG+=;]:=U_F_E.\#)>CYI-;1I>6[S,5*NY MNXD54YI$WDWXU5SO6BM-LG&I*.*AIHJ>!B1P0L;''&U.36HF$1/@.2 M M M M M M M X-PME+=:&IHJVFAK*.IC=#/35$:21RL2HJ2G. & M"?E#[:?F=Z5_ ^"4W^H/RA]M/S.I*_P#P2F_U#.P!@GY0^VGYG>E?_@E-_J&2 MV'3-ITM:66^R6RBM%O8Y7-I:&G9#$U57*]C6HB(N?4=L /A-3QU$3XI6MDC>
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|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| MW?;C?T(OX3?U0>W&_H1?PF_J@'I$#S=]N-_0B_A-_5![<;^A%_";^] >D0/-MWVXW]"+^$W]4'MQOZ$7\)OZH!Z1 \W?;C?T(OX3?U0>W&_H1?PF_J@'I$#S= M]N-_0B_A-_5![<;^A%_";^] >D0/-

WVXW]"+^$W]4'MQOZ$7\)OZH!Z1 \W? M;C?T(OX3?U0>W&_H1?PF_J@'I$#S=]N-_0B_A-_5!['<;^A%_";^] >D0/-WV
MXW]"+^$W]4'MQOZ$7\)OZH!Z1 \W?;C?T(OX3?U0>W&_H1?PF_J@'I$#S=]N M-_0B_A-_5!['<;^A%_";^] >D0/-
WVXW]"+^$W]4'MQOZ$7\)OZH!Z1 \W?;C M?T(OX3?U0>W&_H1?PF_J@'I$#S=]N-_0B_A-_5!['<;^A%_";^] >D0/-WVXW
MJ"+^$W]4'MQOZ$7\)OZH!Z1 \W?;C?T(OX3?U0>W&_H1?PF_J@'Is#S=]N-_ M0B_A-_5!['<;^A%_";^] >D0/-WVXW]"+^$W]4'MQOZ$7\)OZH!Z1
\W?;C?T M(OX3?U0>W&_H1?PF_J@'I$#S=]N-_0B_A-_5!['<;^A%_";^] >D0/-WVXW]" M+^$W]4*^W&?H1?PF_J@'T"#S=]N-_0B_A-_5!['<;^A%_";^J
>D0/-WVXW]" M+^$W]4'MQOZ$7\)OZH!Z1 \W?;C?T(OX3?U0>W&_H1?PF_J@'I$#S=]N-_0B M_A-_5!['<;^A%_";^] >D0/-
WVXW]"+^$W]4'MQOZ$7\)OZH!Z1 \W?;C?T(O MX3?U0>W&_H1?PF_J@'I$#S=]N-_0B_A-_5!['<;^A%_";^] >D0/-WVXW]"+^
M$W]4'MQOZ$7\)OZH!Z1 \W?;C?T(OX3?U0>W&_H1?PF_J@'I$ M M /'#H&-;MGY02NTS68BEZ^[V7T^6'QK(Y$ M^J<)Z|
(>QYY+>4#VQU'T<>D]:-\-+4ZI:[E707%LS8U6*GN$:(DD4F/I96L MX^>.+CE3Z4F'MOY1[9'6^D]>Z7/546E+FD?%5VBZQR)+"|$|)&N1]MD;X.;Z
MLHU5P!CWE5]116?HHUE#(Y..[7BCI(D5>U6N=.J^|B0GS\E#IZ>R=%..LF9P M,O%[K*Z%W<|B)'3Y^V@F!T@;CT[!W]+;=[6VZKKK'1SO;1.EC6-
U=4 M.3#ZE[53,<3&-7"NYHWC].S>V=!4M=IG15M=QTMFHF4W6X_OLG;) M(O@KGJYZ^MP&< <"YVFDO5OJ[=<*6"NH*R)T%32U439(HW-
5KF/8Y%1S5 M15147DJ+@YX UM\S1M!^93HG|[E\F1^Z>>QNW&D.BCKJ[V#;_2UDNU/YCU-
M?;K+303Q\5=3L=PO8Q')EKE1<+S153O)E$;/*+.ST.-PD_4_^D:8##N@ULWH M+<+HO:-U'JO1.GM3Z@KG5[ZNZWBTP5=54.2NJ&-5\LC'/N;Q8-
.6LEVIO,>IKK;9.:GGBX]^G:[AD8Q'-RU5: MN%YH]H3+(V>46=GH<;A)^I_](TP&#]
S8W;C6'13T/>+_H#2U[NU3Y]UU=M/5IVGOJ**"]1J3PQSM:Y'M21J.1')V M*B+V+ZP/'[4-3OCY3+<.T1LL4^V?T'H#8.P7#3&BM.Z<
MKWZEIZ=]5:,5!2RNB6E]W*Q7QL1>'+6KCLRU/_]"B$GE;'<71RTXG9_Z5TW\MSK0-G]'KH][67G87;6X7';32-?75>FK945%556&EDEFE=2QN<]
{G1Y/_Y.(V8!K;YFC:#\RG1/-M[W*/Y,?,T;0?F4Z)_>Y1_)FR0!K;YFC:#\RG1/[W*/Y,?,T;0?F4Z)_>Y1_) MFR0!K;YFC:#\RG1/[W*/Y,?,T;0?
F4Z)_>Y1_)FR0!K;YFC:#\RG1/[W*/Y, M?,T;0?F4Z)_>Y1_)FR0!K;YFC:#\RG1/[W*/Y,?,T;0?F4Z)_>Y1_)FR0!K; MYFC:#\RG1/[W*/Y,?,T;0?
F4Z)_>Y1_)FR0!K;YFC:#\RG1/[W*/Y,?,T;0? MF4Z)_>Y1_)FR0!K;YFC:#\RG1/[W*/Y,?,T;0?F4Z)_>Y1_)FR0!K;YFC:#\ MRG1/[W*/Y,?,T;0?
F4Z)_>Y1_)FR0!K;YFC:#\RG1/[W*/Y,?,T;0?F4Z)_> MY1_)FR0!K;YFC:#\RG1/[W*/Y,?,T;0?F4Z)_>Y1_)FR0!K;YFC:#\RG1/[W M*/Y,?,T;0?
F4Z)_>Y1_)FR0!K;YFC:#\RG1/[W*/Y,?,T;0?F4Z)_>Y1_)FR M0!K;YFC:#\RG1/[W*/Y,?,T;0?F4Z)_>Y1_)FR0!K;YFC:#\RG1/[W*/Y,?, MT;0?
F4Z)_>Y1_)FR0!K;YFC:#\RG1/[W*/Y,?,T;0?F4Z)_>Y1_)FR0!K;YF MC:#\RG1/[W*/Y,?,T;0?F4Z)_>Y1_)FR0!K;YFC:#\RG1/[W*/Y,?,T;0?F4
MZ)_>Y1_)FR0!K;YFC:#\RG1/[W*/Y,?,T;0?F4Z)_>Y1_)FR0!K;YFC:#\RG M1/[W*/Y,?,T;0?F4Z)_>Y1_)FR0!K;YFC:#\RG1/[W*/Y,?,T;0?F4Z)_>Y1
M_)FR0!K;YFC:#\RG1/[W*/Y,?,T;0?F4Z)_>Y1_)FR0!K;YFC:#\RG1/[W*/ MY,?,T;0?F4Z)_>Y1_)FR0!K;YFC:#\RG1/[W*/Y,?,T;0?F4Z)_>Y1_)FR0!
MK;YFC:#\RG1/[W*/Y,@!Y5?;+2&W2[*?D4TK9-_^>>RGG/L/;H:3K^#S3@X^ MK;WBQQ.QGLXEQC*Y]2#S<\L6IB_*BY??2_| 4@)M2.T;0?
F4Z)_>Y1_)CYFC M:#\RG1/[W*/Y,V2_-;?,T;0?F4Z)_>Y1_)CYFC:#\RG1/[W*/Y,V2_-;?,T; M0?F4Z)_>Y1_)CYFC:#\RG1/[W*/Y,V2_-;?,T;0?
F4Z)_>Y1_)CYFC:#\RG1 M/[W*/Y,V2_-;?,T;0?F4Z)_>Y1_)CYFC:#\RG1/[W*/Y,V2_-;?,T;0?F4Z) M_>Y1_)CYFC:#\RG1/[W*/Y,V2_-;?,T;0?
F4Z)_>Y1_)CYFC:#\RG1/[W*/Y M,V2_-;?,T;0?F4Z)_>Y1_)CYFC:#\RG1/[W*/Y,V2_-;?,T;0?F4Z)_>Y1_) MCYFC:#\RG1/[W*/Y,V2_-;?,T;0?
F4Z)_>Y1_)CYFC:#\RG1/[W*/Y,V2_-; M?,T;0?F4Z)_>Y1_)CYFC:#\RG1/[W*/Y,V2_-;?,T;0?F4Z)_>Y1_)CYFC:# M\RG1/[W*/Y,V2_-;?,T;0?
F4Z)_>Y1_)G.T!L;MQI"\4]XL&W^E{)=[?BZFO MMUEI]>>/B;K7<,C&(Y,M:2H9+AJ;3L+H*N@ITS+5
MT*JK_03Z9\;EQ6R(B854XD545>0$NNF_JZ'1G11W.K9GHU*BSR6UJ8[75*I3HB) MW_WWX"+/D:-
)S4NC|R]3.;_<]=74=NB7'TT$;E1%57.7DB)Z4]&+9"CZ/.R^_MGM$T\D5354D:S5]5$BHVHJI%5TKTSSQE>%N?I6-0#;(:TZ2[?\ M'EV&T>$J
=1J32]GUE0ZFT7^U45[M-3P]=07*F9402\+DBM=A MS4SZ-L1/;+!:J*R6FFXNIH+;3,IX(N)RN=PQL1&MRYRN M7"IM%_M5%>
[34\/74%RIF5$$O"Y'-XHWHK78< MU')E.2HBG;@#J--;7L^C;/3VBP6JBLEIIN+J:"VTS*>"+BB/5$]%5SVIE.9M@_"WC] M7(TCN%TU-
DMKKQ46K4EX-MIKG3OZN:EHXYJU\3^66O2!C^%R93*+S0#>_-6[M3]\S:[?&1\&B=9V^]5C$5RT/4P5/"G:Y(96MD5J?25(W'K-GMD1RG]4
Z/NE+B^AK]R:"69 MBJUSK?2U-;%R7'|\@B>Q?C D,#4>UG2MVEWHKDH=&ZXMMUN+D564$G'2U,B)
MVJV&9K'NQZDY&VD=VO*$='S3]P=156Y=%+,U51745#5U4?+OZR*)S,>O.%[@)%@PC;7>;1 M&[!M??:+U/;=14\?"LJ44Z.DASV=9'[MBKCEQ(F3-
LH!4'PFG93QODES(25!"/17E:=GM27B.ANUNU%I> M*541M?6TL,NZI[GHG/M1]]_83*LM]M^HK327.U5M/DZ> M^1W1E')6JZXT;
(HN!CFH]<22.]++TY8\21P M +./XO'(%XUZXZ[A4T'4UU+*Q(**;9R<,;L\W.1]MQ7*XUNHK_3N5E1;=/Q.]'T[D|6R/<|<&N1)7)CF@$F 0
MET/Y6G9O4UWBH+O0ZATK'*Y&MKKA31RT[?TRQ2/[A4T]'4UU+*Q(*&:9R<,;\\W.1]MX[G!125[UN-(R*/]V/8Q414D=Z69&\L=RDBP M M M
(E^46Z3%=T?-GZ>DT[5-I-7ZEF=143'"R7\G7TEJSI"[,OIM05/G>K=-2MH;^=WNJF)S M56"=WYYS4BL=OGN%RJX*"
M@IV+)-554K8HXV)S5SG.5$1$]9YO=-#RDD-XHZO;W9;IGK:FL7S6LU/2M7*H MN46*C[W.7..M^TRJHY)=],+82[=(S9V71-
FN5':)ZFX4U1)5UB.5C8F.578: MU%5SN?).2>M#"=H>@MMUT:M"WVXT4#M1:O\ 8NI;)]*YQMZQF8G<201\VPM[M>S+L*]*Y4 A[Y'3+M[];<^?
Y'5Y__P 3"}>MIY)^1R_PWZV_6ZO\ .83UL @A MY43I0W':71UNV_TK7OH-0ZDA=/5;1+E26FH$568:0TZRO1S>)..:(R3'-/=/RBU'I6I.V>E;
<++8(VN7DL3/3 M:Z"T?1EM]%NOM1Z5G'PM5'*KDD')TD-BK7J:N6--04-$[D>Q\;\))R17*BQOQ$%O(T:FE9J>^CH^?YU /3X M >6GE.M^-3:
[W5MFPND^N\W;+2MK;>F>J/N-=4(W Mf(<'>+$22-4:O)7/15]RF-P[2^2Q'54D-6^EI8WJB9; M$V/#E1O8CG.YXSAN<&^+GT--I[MNY!N=-
I^H36D5PCN:W#V2J'(^H8K58Y8W M2*Q$3A1$:U$3'<;PX?!< >373<\GO0[Z4=N9MC<[A%:K9/"M=05,W%/19>C
M65$,R83UZ1=RZ0NQK*C4,BU&I[#5+:ZZI7MJFHQ MKXIU];FKPKXNC[M6W0'1ENNGII6.O.K)8[?14^4XN!LC))I.%>Y MK6\.>YTC# _)
Z&K[!LOJG4M7=)#37Z[-91HY%3K8X(^%9$SVHKY'MY=\;O M#H/*H))Z[:=9;]G=)UM="]5;#2M5.SK%1RO3M5O
F<.FI'N1%ZIO!ASG,7T50G3%Z(MQZ%N MH[!NEM5>KC261MC7-PY/SKN/CY^DG1?WOI^D#L MCIS6K&,@K:N)8:^GC[(:N->"5J9[&JY.)N?I7-
,8Z>6F(M4]$GK5,_72#H-A[(39M='7P4"P12<+:ZXR(W*RN[F16)&[M?^2DV;T_I6&CU+%<]4WMT;4GN*ULE*QLG;JPQQ*B-:GW,NTNS6C-
'3RMGJK-;(*6HDCSP.E1N9%; MGGP\:NQGN @)Y3WI"Z@U-KVW;"Z,FD>R=:;V6@I%5):RJF>G44BJG:U$6-ZI
MWK(W/N3:NT_DGMK+!I6D;KAUPU3J.2%%JYH*U]-312+C+86LPY6IV9>JJN%7 M"9PD6]E>+=GRI5175[6S1Q:GN=8G%S1K*5DRP8_2]7$F?!]
[$=7ZP('3I0=' M;4?D_MT=-,A;.WZL6PU50K*.:J,E/*W#G4D_"B-EC>U%5.5B1KD5,M1R^JF MR>Z5OWIVJTSK:UM1E+>*-M0L.<]3*BJV6-
5[U9(U[%];5-$^4[TS%?\ H@:H MJI&-?-9ZNBKX>+N=YPR%53U\$S_C,+\D1J:6[='&]6N617^Q.H9XX6JON8I(M89$3[=95^$"<@ M "._3KW[MGZ/_
$>KU>K9*Z'4%RD;:+5*WMBGE:Y5E]C&2.3\\UJ=Y$;R<70MTSN?I.H MW8W'H/R3^25]R0/1C^&6IESSDG^BMM,2QMX&R6&FJU1$QETS>N5?A
M615^$# ^D5T]L=WM"5]+8=*6?1^]885=;KE9J..C;U]Z,*^)XXZ.5=NO*KRQT:MC;)K.LB1J81.KJ^L1S<8[DG5$]Y /9 M MP[=O5Z;?[7:PU,KE;
[#VBKKVC>CB<|$3UJ[B&8D7?*2ZP_(CT1-9.CDX*F M[/IK7%$YKUDS72)\,3) (>3T5=I726BY5Z M[O5WDK0))^*>*%
(HVQQM9'E\KDX)%PG"B<6'TCZ)9IKA/ M.G5N5JN3A>Y4SEK>>#>II'HQ]+'1O2BTO/<-/.EH+M1<*7*RUBIU](Y<|*Y3 MD^-V%P].7+"HB|C=P M
!Q*NMAM]+/55$K(:6%BR22R.1&L:B*JN5>Y$1#SJZ5 M?E0Z)M-4:/V226YWBJ5:=^IG0JC(^+T42EC5,R/55Y/5$:G_J6HB,A3M3T4XE1<*Y4
\GNCII_4.E^FAMY;M54U52:B9J:BEKH:YW%4 M))(]DBK(JJ|\2\65XEXD551>>4/>H\==9?\ [5ZG157'Y,Z'^+">Q0$;^GQO M[4[
]'R[W.U3,@U'>)6V>US1^ZAED:]SI4\%9&Q[D7ZK@(J^3BZ%&EMP]$NW M6W&MS=2K;L8J^\C1/C4FKT0K%'IWHO[64;&HSBTY15+D1,>G-$V
M5_\E2*\K7I^=/;7=[0=PATUI6T:0U=3P_=;;A9:2.C8Z1J*K(IF1HC7L=R M;E4XFY145,86./DF-]KI3WK4&S5^G>L-/$^XVF.HB5%.U%[ESUB-Y
M85LB]YZ;\)XX[69V\\JG4T](K(X7:ON=,V/L:D52DZ>_2M\J'01TM3I'91TMTO%2JT\FIEA5(HLJK<4K%]*2157D
M]41O-.%'Y14AOT=],:BTITT=N[9JRFJZ/4;-2T,U;#7.5U0CY7.ES(JJ|:H M\%=Q+Q(KE1>>4/5SHZ=!3;#HY217*UV|]^U2Q\-AZ|
(V2:-5[>I8B(R+OYM-M3BPN%D15S_P"EMK_D:=_/8 P;>[6*[?;/ZVU,UW^TV6LK(W9 MPO6,A>K$3UJ["&%K&=OU2$W_ &L'H]=O MY%*
[_P",57^N0.Z*73;=T:]GI](:.T5/JK6]WNTM?/+4<741Q]5&R-C61Y?(MJ)&JK[E&\:KE3/?:4]\=#WUJ:UV[LL%*Y^7T,UOK+=-P_18^21R)V=JM=S
MGALMT,]K-@-5U&I-$V6IMMVGHW4+Y9J^:=O4N]57P7AJ&8_2^I3TVVOUM3;C[<:8U312-DI[O;8*Y',BJJ*G:BH!E9XY^3 C6JZ95?
-3KB%ELN$BMPGN%>Q$3[Z?$>K6[VNZ M?;7:S5^JZB5L4=GME16MYW"U$[U:GD=M%2UVZ&NM7N MC>ZFMMI9;62*B|*R5$S7KA?
%&TRY\,/GC('K M MX>WF=)KO_(CZC_4ZH_DG M'>G1:[_XCZC_%.J/Y)P'EAY'+_#?K;]:J_SF$];#R3\CE_AOUM^MU?YS">M
M@'C=NPSJO*M4/G/IYUO9%:OOK2JSXN7Q'LB>/7E#[?/M%TY[-KSS9ZTU8MKO ML+F=CWTSFQN:GY[^YVKZD>B]YZ\6RYTUXMU+
<**:.JHZ]L\$\3LMDCP==S_P#X=YYH>1NA>NZNX$]?WMMEA:[^M:A,?Q5)
MW=-37D&WW1;W(N=1*D+JBTS6RG57(CEFJ4W8B)WJBR<6$[FJO+!$[R-NAY* M?3NX^L9F.ZFKJJ6U4[U3"?.F.EE_EHO>Q\0>D@_M
MXO4:@Z2'2>T;T9M'27G4U5U-MUPF1S;=9:=Z>YB;E,][EY)WJV-'1ZZ+6X73PW_J=S]TKK7TVDI9O2KW>A M+6HCO]|T;5Y1Q-YHKD3A1CIT7*4=
(B^ZD5%555>:<2O=VHB^OFC=(VC0>EK7IRPT,=ML]L@;34U+"F M&L8U,(GK5>U57FJJJKS4^>BM$6+-K3%!IO35KI|/9*"_(J:CI6<+&(GWU55R
MJN7*JJJJJJ=_P ?]Y@>.&US>I\JU6I4X.?2*_V@ M?*84VI:MOFMJFOUOO?7.7"/IID8E0Y/>=YPG[$]B&R(J93FB]BHN<^\J;I:
MR1Q=&#====STXFKIFX-[,\U@>B??4A;Y%V%[:?=^5?!VY]I:U?6GGN?PH22\HS MKN#1/1)UHCY6QU5Y2&STS'.1%D=+(WK&[_IL]X_.FJ/)
Z(DLNQNI]33,'2M'B[T@[9TE-HK;K*A@2AJW/=2W& MW\?'YK5,QQLSWM5%:I]_4O;WY0UGY3*X6RAZ'^L8;BYO75D]##1,5R(Y\Z54
M3^6>U48R15_.M7L[4U-Y'6CKH]GM=5,G$VW2WUK($X>2R-IV=8J>/)T?Q?"'!M'CH)M2'RB->R=%67S]]M3U.Q.JY^#)[%GCI:'-
Z/OE3GNKT2AH9]4S(USU1L M;8+DQZ1KGLX42]:N>[AYXP>Q.?[9 CIY0N1D?0ZW)=(F6^;4R)W\UK($3[^#
M0OD<(96[2:\E7^\OOD;&\N]*=]JOWVF=^56UU#IGHM5%C65OG6I+I2T3(E7T MG,B-T?-*.)%^_^ C)Y7+;] M?
4>Q%CU73P]8_3=U3KW(F>KIZAO5J//AUK8$Q^>-C^38W*I=?]%73-(V=LEQ MTZZ6SUD6?2CX'JZ+EW)U3X_B5.X"4YXX7*%+EY5N-
L3^)&ZVB>N.?]['5JN^+ M@5/@/7V^7RATW9:^[W.I916V@IY*JJ]95PV*)C5<]IO4B(]_ >1_0*M-1OUT M[YN'+2N=;Z.IN6HIN-/1CDG>]D+%]:+-E$\
(U\/8(-M U-TC.CAIGI.:+ MI-+:JKKM0VZEKF7!CK//"%)UK6/8F5>QZ*G#([ECO-LD3^GITK-:=%>R:5NF
MEM/V]\45TF]*6JJ;HV564\S6L="F&/9GC3KN_P#Y-0-E=''HLZ'Z,NF9+9I> MC?4U\[E=5WJN:QU94_1:Y{6HB,:F$1](BR71(Z?M#IFFKI9J.GU
FGJA[DX?.J*HD;&UST3P:^*7&<(YB=I M[;GBI9:GY[_RD4%VT]UE=:JK5,-P94-9A%H:-6*LB^"+' F.]JN3O5#VK-M M \=M9__
+6"#]>E!^"$]B3QVUG_/M8(UZ4'X(3V*(V=/]+,4SF:NVQG7DQ M]#7,;X9;)"J_QT/03HVS,FZ/.U\C'(YKM+6M4M1: MBM^E+!Y$_[-? #V"' M
#Q_W$_P#VM5+^NZU_R5.>P!X_ M[B?_ +6JE_7=:_Y*G]@#4/2.Z->F>D]H^BTUJJON!];Z.M2OB=9YXXG]:C'
ML15XXWHJ<+W=WTRFWB)'3UZ6.M>BO;=)UVF-/VF[T5X=4P5%5=6RN93S,1BQ MIACV>Z1TBXS]
(O8!M7HY]'1GTL^T:5HUFJYG.=67]L:QU95KE51'O:U/0 M;G"-3")CLRJJN;[B[9Z\V>K;PO@J&(JM7"HCV.[6/3.4W
MFN5(HWN3N3TH9<(O)6IX'MJ>*NA)UZ37E(;6^V%)*R MU2ZK;=V5'!A/,:1Z/1[OJ4HNFGH9I'4=>)G4_5/54%=3Z"T+H:>U:;DF9-
5T=#,Z=LCFN16N MJJMS6,;&UR91JHU,XRCG(W'HOT3>CG0=&?:&ATG3U+;A5/DC=(W_3N\^LIKK8[C;(9-/\#)*RDD MA:YWG$*|**YJ97&?
B/5YSR4%7 M3QM7^]ME6.1)8DY\.&\D5$1W"B(GKSPHOK./54,%="Z*IBCGB=C,UJNPUJ(MN.+A8JJN?478;9NT["[5V+0]F5TU-;
(E22]>Q&OJG.5TDKO6YRJN,KA,)E< M&P5C\%X?>+P M\(^EK<=P-Y>D/J_4=;IB]UM##7R45NA\PG6)M"'JS(FIRY(Y]< M2JW'I2/7O-
PV3R@'22TY9Z&TVK;NVT%MH864]-2P:8JVLBB8U&M8U.LY(B(B M'KSPE<(!Y)^V-]*/[!J']|57\H2^Z!O2%W,W\M6L:C<>RPV::V3TS*)L-MEH M^-
KVR*]521R\6%:WL\25V$*KNUVW5HVGV_L.C[%&L=&M%(REAXL<4F$RZ1^.2O>Y?/5>]7*96B8SS MWEP M+
>@OJJ[ZZFW=VKIJBNN4RLJ+I;:>JI6,J&81M53(WFY51K5.%:BKV(AZJ M\)PJJS4%=(V6IHJ>HD:G"U\L37*B>'"*J<@/'>_+O]Y2G7-
M>MF6SZ/HY%\WE MZE\-IM[7(B/E61W.>7")]E7+S3"-;JG]IL5LQ9-A=L++HBP\3Z*W1KUE1(Q$
MDJIG+Q22OQWN55]Y,)V(AL#@\5+P(+>450WVBL>E-Q]OI-17ZVM; E9 M6U_*Y5?5[']L'PFHH*IS'RPQROC=Q,<]B.5B^* M9[% \@X-

[E%W'Q<.78Y<]N1>1NF:W<_<*.M)51'NL*HWO7$R9_"GQDS}+>3WV#TCJ6.^46@():J*5)H8JZNJ:JGBD4D*
*MCF+W=%?;#:G7MUUMI/3'L+J6YME95U4-?5*R5LDB2/;U+I5C1 MJO1%1J-1$PF, 0P\JUMO7:-U7H#>[3R+3U]#4QT%7,Q/<3Q/6>EDY?I9$55[*
*MF,3P.E\G9I^NZ0G2CW#WVU#3*C:.61]&QRJYL554\36L:Y4YI%3HYG-.2/8I MZ+*
*[E:7Z9W>T=6Z4U?;&WFPUJL6>D=+)%Q*O[7L5'QN:YJHYK5RU4[/6<':39 M:1FQNF'Z=2ZFMKVUL>O]MKS#U5?I+PR/:#5M?*
*EK7/:Y6MRW@T26V?CAX_,W2HC9D2IDD<[JVY=PHQ$1<-RC>X_> M1TY:(:VYY_\ 2)?YM"3](;^2TVIO>VG1SJ*N_P!'-:JK45VEN=/2SM5DC::J*
*MXXHU:*Y8WN3Q:YJ]Y,@ >4GE3-AKAM]N?:-ZM.(^*FN<\,==+'W_>EPA; M\YE7ER1[8TY_51K]4AZMG7W2RT-*
*\HW4ERHJ>X4KE170U4396*J=BJUR*G:!I M6'=*DWPZ&MYUG;$1Z7G25<^2"+FL=0E-*R6)/%6RM>WUXSWGEAY/&PW.BZ8F*
MW+7"R&\4M0]J5%KU MR9ZTTC5X%1[?1KA<*U'.]W2C>7$J MX1%=A&Y7/I]T .C=<^CALIYC)K(M4WJK6XW'"%CT>E-Z*,C@XDY*K6IE<93B*
*M>[&>TD=:K';K'3^;VVAIJ"#_ *NEA;&WXFHB'-X?2SV=P%>#/;S+@ +>'GG) M< !;P<\YYE<(5 %J-QWCA+@!3"#"%0!:C43LY'G!Y77=]S[;I':6T.?/7U*
*[M;M7P0)Q/5J*Z.FCPG;Q/61W# P!FWQ0](3HJS1MAN-S;K<\EQCGRP!]+H5]'U.CGL59].U+4]GJURW*\/SG^ZI&MRQ%\&-:*
MQGKX57EG!OHM1N%$_F+@ M M M M M M UMNUT=MN=\Z>&+76DZ&_OITX8 M:B1'15$;V;?4LU:!)UD+KE5U%;'& MJ>YQ'-(YBX{45S55%YYY(2)
*%G5IC'=X8+P M M M M M #BU='#74TM/4Q1U M%/*U6OBE:CFN:O:BHO)4,6I-F]!6ZO974>B-.4M=&_K&5,-IIV2-=]4CD9E% MYKS,S %O*
G%GO+@ M M M M M M M M M M M M M M M M M M M M M M M M M M M %OS!<"F4<7/ %P MX MBC9.),XY 7@ !:CO4!<"SC\$R5:N?P 7*
%O&@%P+>+U#B]0%P M %.("H+>+U%P MXO4!< %O$!< !3B]"WB+@ +>+U M%&NXDRG8O9S O +.-_ DO"WB\.?PA'9[+@6=9^=4KQ>H"X M
*MXN>, 7 L61&]O(KQ 7 MXO47 6\7@F1Q 7 M1W+*I@KQ 5 MXO5W9 N! M3B*@ 6\7//< !:CO4$=ZL 7 L147^WWRO%SP!<"G$.("H "WB]17B]"*
MG$4XL@7 6\0%P+>(<7] N!;Q>H<7@F0+@6\7>7 M +>/U!<"WB]>1< !3*%0 +./P0KQ 7 M1Z>\.("X !15P.M("H!15P!4%.(IQ 7*
MXAQ>H"X%O%ZAQ 7 %N?[9 N!:UV2X 4X@@%N5\/O M@7 "WB'%WX N!;Q>HKQ 5 %O%\ X@+@ %O$7 "WB1/4!<"WB'$! M<_*
*<13/^D"X%O%A,XY#CYX N 6\1< !;Q>H-= MD"X%,H.("H*90] MX@+@6\7]"N]7WP+@6\7]*=9Z@+P6I0+@6\7]*\0%06 M\61Q\\8*
*N!;Q=@X@+@6=8A7B N!;Q(N>\<7]P!<"WB]7((]QY 7 IE"H M IE *@ *<14 "WB\2O$!4%O'ZE"NQW 7 MXBX "WB*(_P!6 +P6 M\0XL@7*
%G&G@!>"WB]119.%,XY9P!>"WC0KQ 5!:CL\^]Q"%Z@+@"SC3P O! M;Q%P P %O%ZAQ<\ 7 ^2%&QNTKQ]G("\%O%RSW#B]2@7 MXO4. +U M7
MXO44ZQ,X[P+P"WB]0%P<13B\$R!<"G$5 "WB]0X@+@"WB M]0%P+>//8F2X "WB]0X@+@6\7-4"/SS3F@%P+>+U!78[@+@6\7]#79 N M*
*%O'ZE''ZE N %O&A7B] MSX^^&NXNX"X M IE *@ "WC]2CC]2@7 %O%Z@ M+@4RA4 *90] !3B*@ 6\7B5X@*@MX 4I7B]"WB]1 M<- !;Q%$?ZL*
*7@MXO$KQ 5 +.-/ "\%O*ZBBR<*9QRS@"\%O&A7B]"WB["G6 M(O9S O "WB N %,E.+U<@+@6\0X@+@"WB[@+@ M %O%ZBX M $;.F!-*
*>$]M"T=E]JFGK:NIGAC;32NC5[U6%&(N%\5^^23(^])CGK[:' MP]FNS_WU,J?@ S38?=1-S=((^K^=7^W*E/<;=R<*H_FB/QX.POO*CDYX,8WF*
MKJEWLV@AJ9HX)IF1)XY%:U^'1 ZW3I.VK36;;CTNYEC@=)9IZYZ4]] MHXOIEGCO=VY^K1/JE/ONK>*/4&[^S%SM*
[;FBJI7S0RL7DYCG1X7[X$@ MJMAH::6HJ964T$2*Y\LKD:QK4[U5>Q#';1NCI"^W%*"WZGM576.?P,ABK&*Z M1?!B9]+X,FI=Z8Y-*
*Q=YM';=3SNCL3H5N==$JM67'6*C55%\(\&ZU=MI*IG M65#.->MAC?UC7)Z7;G*]YQ^C[1VC26P:ZSCMM*V\4]%722525(DLC62 M/K[;*
*[9(],MC]JEC'N3LRC57*IGO.PLU_ MMVH*%M9:Z^FN-(Y51)Z29LK%5.U.)]XR1$VGUQM=%;JR\Z_F;>M67&HDEJ75 M]"^I;$W*HUC?*
*15O8F>79E$[&HAV^WVM],6??ZVT^@*J1NFK[$L-9;^K>QD4Z M(Y4J&YJQ.)[*6H:][$[E+B8]*KGCY+W/14S@[C2MGVOUSK^Q:@T-*
>X+!=:%ZOEMM'3^ M;K5-Y9;U;D;RX>)%X47.SWN%[4\4 CSIK1=OU M[M%>MQ;OIZZ+]FG;43+.E8C64DL:J\<:-QRXO0[%^F1&JG/?*
VP.I;IJO:>PW M.^2ODC>QTTB8=,ULCFM?Z\M1%SW]O>1MOZFW:KU=9HW:7N=?YQ6X6I>KN-54,HX9N'BZE7(YRO*
*MQV91K'(F>2*I&UC%]=Z#MFXNG;JR7>)SJ6;"M?$[#XGI[E[5[E3[_-%14 U) M;NBI0WJW4]7J75NH+K=I&MDDJ(IUO5M>J97@XFN543L1<_!#*
[,;T^L=LMU% MT97U-QU+I2MI^OI+G/$]_FKD1RHU[^.)[A6JW..;%1&Y5#JX=KMXMMX&PZ2U M93W^U1)B.AN#4:Y&IG#$21%1$3U/;
[QD&W.^UYJM:0Z-UYI]-/7Z=JNII8U5 M9U[<(BJO;A<.1SD54QR4#<5SO5#9.2KN-93T%)'[N>JE;&QO/'-7*B(=18 M=R-+ZIJ5I;/?[=*
*<:I,KU%/4L=)A.U>',<>LTQJ&UQ[O=)*HTY>'K/IS3-&VH M2B;Y49/*YL:KQ<^>5DPOJCQWKGLM]MFM/6]05;J#3MLI]/WJRM;5T]3;(T@7*
MA:Y%651>U%1%SVHH;JO%\MVGZ)U9=^FMM&U41U15S-BC15Y(BNY^'SFL2E?,K$PBR M(_A>N/TS5Y&\]#-_]"; B=GL?*
*3X3_P!TT#EVC45KOWG*6VYT=P6FDZ]=*6H9 M+U3_ *EW"]*^]>9U5=N-I6V4L]34ZBM<=/#.M-)(M9&],F3FL:X7W:)SX>U*
M$0U7T6$1:K<;GG_9V3\+C"=E=KK+N'K_ '#J-1TSKA0V^Z3-IZ225R1]9))) MQO5$5,JC8V)XQ>_N.%I MW#UJ9_KWH\V2^QVVKTM'2Z/OE!4,EBN
M%!2HST4SE%:U6HJUFN5Y\L=X&UJFLBHX)9YY&9PQ-5[Y)'(UK41,JJJO8GK,_M=M.Z.D+Y<4H+?]>TUE8YW R&&MCDOJ^CDUU1+2>H:^6BTN
*ML;:^ZK3LL=-PX<])D17LSVX=CASCN EG!.R> M-KXWM?&Y.)KVKE')W*BIRP=?:=46B_/J66NZT5Q?3.1LJ:2I9*L2KGD[A5>% M?*
1=V^"^!BVRNE+1^A*:@ME_74EL=(Z6FK,M5J,7&6-5JF$'-'3 MJ^-'=CY5]%C?A>K4^$R@C7TK]5T-3=-*:*K*YM#0U52RNNDRY^=P(Y6M[JO*
M_*.QXM:!C^R=XOFWFO=+1ZAN-55T&M;8DS'54KG-CG5[E8B97DN%8G_O26?$ M14Z0^XNA-6Z'M[]-Z@IUOECJ8JB@:%%(QR-3#7-
;JM1.6&N_]VA(+;[6D&M= M!VK43%:C;JF225K>QDB)A[?@W%U/'=-ZMJYK1=FU=MJ739?1U/'#+AR(O-J\+L+GM\#J>CWH^W;L.U
M#N!JRCAO5=65[X>"M8DD5/&U&NPUJ\OID;S3DC/6B=7[:6W0/2+T!-9H?-_M,;'KJLN9L3,K MW9W.4YY1.8$OKP=*
8)];=*ZFMU&Q41U152MBC;E<)ES ME1.TZ2\;GZ2L%8RDN.I+715+T14AGJV-=A4RBJF>2*G>OB;UZ1%9+<>C;ZKG M=Q35$5#+(IQNK:Z-*
*))WR2-178>OI-Q MG"<*IV9[>8&S_96C;0.KEJH4H&QK,M4LC>K1B)E7<6<8QSSV8-*;5[QQ7[=# M7%)==34*T#*J&ELL3JF-D*
*MWS*ZDAJ4XT2"17(]BYSZ*HYF4[,JY<>DIUFQ>AM/5.\&YDXTMLII*2U7 MJ.+IS7.GM7=9[''7NANCHTR]E)4-D'?:KOS]'6[G[@;=4-59]2;;2,M>I+?*
*5-<^ M&EHGT\,\//B:Y,(WM1$Y8RBN3PP$RIJF.FA?++(V.)J<3WO'5&PT]6QSW*C'+Z*(OI8QW9-9](V]U.I5T!I&CJ7*
MT=))BK8ZIEC=AW59C1$I:?/%7"_4(93[WH]Z.J]$U5!:K+36VX4\#G4=P@9P MU#)6MRUSI/=.YHF:JJ):F5:R=..9ZO=A')RRIMNMK8
M+=2SU55,RFIH6.DEGFQ45%:J+VHJ+V 11FET[O1O1J1FJ-8LI+%;U9%:FT M]QAACF]+"=6Y55'T!IROWPW(H:FR4,]';YV+2020M5D'IK[E.
*[L3XBWKN%7*O#EK.'ER]-<(BK MDS?3O1VT+:-+0V>IL%%<9>]1L]=/$BSR/QZ3T?[IF555PU4QD#9#;J)\"3-D M:Z:6\;2(]<*MQG.>S&#'ZO65<]>*
[Z5/%AGM4>>.M94LZEF.U'.SA%3EG/9D^.GM?Z;U9-+#9K[07.:-%5\5+4->]$1
*M<*N$7.,]_81TT;MC:JSI#:PTFYLOY$]D\+DMI;*Y())>&)6(YJ+S1JS.5$_. MHBY3D=ON?HZS[=;U;65VG*&*S27*N=35,=&WJXWL1\+?K92-*
JXXG.2F8JIEZJB+P\U:W]RJO:AM8^643W\ MXY?V\ -%3]&:6GMCJJBUUJ1-4M9QLKY:Q>K=*B\.\%2ZJ=H30\;K MGK*N189'0=16:GD8VX:KU)?[M;;*
(^J=#;+5:I^I:QK<)QKE%R MJ+WXSEJKG"(AD&V=WO>W>Z=3MK?KM->J&HI5K;-6U2JZ;@157JW+GGA&/I[@ MY81<)WW198UFQFF^'DKEJ5=
*[_G,J&-;E)CI2;;NBY2^:2H!QX<2_YN(#8.ZF M[=NVLMU+)54M3<;A7/=%14%*WTIWIC*9QR3TF^*\^2*:CV/U!JB_;_:G=JN- MU';YP2.?*
04TE5!4R4\4E3 CDBFCC<+I98;G?=;ZBCU;/'UZU%/5]D=-(]TD:C< M95$7MPYN<U'-5N>Y5:YV,]^$[S M%+!TIJ5MNAMEVTW>_P F,;.KDM<%(JK-
*G)5;SRB*J=Z-L%?,K)ZN& M-V6QS/6<]69_,Y5]^;2 C_I6XUDG2]UE1/JYG4D=]CKI>;-[$7 MFO/>IVN\6\5;;;G'HG1,+*
[GK.M]%>]3B;0M5,\3NY'O_P"71U/3JZ5>Y,%&=ZX3.>?8=OL]UFQ6[EPT MQJUD$M7?FL?2W[FJRO5?<\3N>'.547\^U,YRB@;=VSVP?
*MQI*M6NN=3>+[50 MN?5UD\SWHU<*O!&BKR:BKS7MY$POHUZZH+'LXROU+?8:1%N$S&37&]1% M?*
*A&KPM5R^EV]WOF]+KSM=9_B7_@4C)T4=I[!]71]5?]!0QWB9*N2FI]>L1)(M(6(U]NP,\PM-TM2U$]# M&J]4CD1V,-]2LRGAQ.1,*
*(N#)MVM'Z7J=;6K4NN=24L%AHX%B@L=6SA9+)G*O M]UE_:F6HWZ5,@9]9=T](:AK4H[;J6UUE6]W"RGBJV+(]?SK^6NUT'*
*MMY=*ZDN5+0WI8T\Q2=[.-[N-J.5C7>Z5&NYX1>TCQOMJ?:F\Z.1VB:2&&_4E M1&Z.JM-O=2QUE8J0%M3B5%1R\;+47MSE.>43F;?*
WTM])J+H_2WJXT<-5L:<2S87T%R MCNW'8IW%9N?I@FI(;G4UIADK&))!Q5D?SQB]CD7.,+W+V+@U?1Z7M%DZ+U? M64%NIZ.KN&F&254T,:-*
*?.Y(,Y>N/27+E^,ZSH_[':7QVW=FU!?K>ZYW>J=US M99II,1-CD5L;&HCD3APQ%PJ<^)4[.0&R=*Z?H*3=/5%TAU6VY5M5$QLMC29K MEH41&E-*
,TMJL[\;MCO\ 4-MM!SYL5ZHUTGP<2(B]SG-/AJZ^VSH[[01,HH$G=2,,24D;^77SNRJN M?CN5>-R_"G(Q;6$CKYTMM'4$F'TMLMTE2C%
[I%9,O%\:1_$L,:Z.5(H:5CDSP MWA5$7&,HB)SY+DX%_P!(ZIZ/-WM=XTK<;MJ;3$]0VGK++4YGD:E.UJ-3"UQ,]G8*
M8%TN<+:=&+C'^S+%]7N3[=+E,,?TA^KD7\1P&ZJN_P!MH^<EH:JX4M/6U?%Y MM32RM9)-P]O
U5R['J.F9NEHZ:YI,6:IM#JY7(Q($K8^)SE7"-3GS7/QNBK?M1?9K=8J6W M55NI'5-/4T[,2\3$SZ3NUV43"\2KVY[>8&\VNXBXP'8NYU-YVDTM5UJ?
3FBI-3TLM>Z1]0R?@1CN%[<.,+GDB+GUF=:JN6\>ZUHGL$.CJ;2
*MUMKDZJIK*JI:KDC7&4[U/2:JE=HMPK)IS:'2;]1W^EHJFHI5CKLUIFX[9VR\WNUP MWJON#'N5UP8DK88VOOI)/<3TLK9*
*M&.]YS55#@:AUSI[2G#[-7R@M;G)EK*JI9&YR>*-57O(ASVX:F57\6LT_MMH/6>HKQN#J*V:AO5QEZUM-*
M6TO6K21+E6LZE%D[E1$54YHU,)XANG3VN-/ZK1_L+>J&Z+&WB>VEJ&/'K8));.]=J.ZLC5$>M+,V3@5>Q'87EGUD;NC_M MG:[_
MUM;;NV2YV+3ERD@MUMJWJ^!CW22-<]6=CEX8FISSVJO;S.\IM.6_; M[I8V2WZ?IVVZ@NUGDFJ.:'E&KL3\D;W)F%BX\<@2
*N]]MNGZ3S]Z5\+.J;/# MUU7.V)F5[LN5$.ELNZ>D-0UJ4=MU+:ZRK>[A93Q5;%D>OYUN'ZEC:G$J*CEX6HO;C*<\HG,"9#YF11O>]R,8Q.N*J8K#*
MNWHN>Y>Q\>]:2^KXN!(TJVF]N-+1U9G6G>CMH6T:6AL]38 M*XR]4C9ZZ>)%GD?CTGH_W3,JJKAJIC(&R(:F.HA9)"[}8WM1S7L5%:Y%3**B*
*M]BY-&]&"X5=?=-Q4J:J:I2**V-)9%=PIQ2=&N$[U6\)%_A3Y.S* M-5\"S7^W:@H6UEKKZ:XTCE5$GI)FRL54[4XFKC)$3:?7&UT5NK+SK^9*
*MMZU9<:B26I=7T+ZEL3H&+["ZWJ]6Z6J; M;>79U'8:EUM"'+VOMKR;FUNJMPM0V^O;/ QE!9:Z# MB;3,:F.+@XG<:*J+S5[)ER]^,:DW-*
U=M]4ZJTG==NJ=M'O8UO$J95?!# MI[EN?I&SW)UOKM36FDK6JK7035L;7,5.U'97T5]2FI.F.V?\A^F4IGNCJ/9A
*MG5/:N%:_JY.%4QV*B]YEMPZ.^AH]&5=N6S0R5'F[^*Y/15JG285>L615SGBY MXSCNQCD!M.*1LK4>Q4O917>_VZW53T_O-34L8]-M$[E5%7*
*(OBO+D:@V%UE5VKHU5]UE=YQ+9HJSS=LGIY*SI5T MC*:O?/;9K"DL;63<4+\\6'M1%PN>7-.XWT1@T9H.FV\Z5BVVWHYEMFMQ'M?CU*GODGP-*
)I)'6IZT_2Z;TI8:Q;7<-1UBTBUW9U+$5C5 M5'22JJR.]+M1$7&%.#\R/9*F%LU5]O4E3=D;GS[SIGNL=]K%5$SSQO9]9G^ MZ>U-
*JW5T^VVW%SZ:>%_6TM;"B=9 _OQXM5.2IRRF.:*B*:L;I':;YO!9=0T M>L+?'[B"NQUJIZUDPOQ2*!D&R5?K/3^K=0:(U.M=>*&W-*
2;@OU1$_AD;EOSM M9'9XE5KT5$RJHK7IE4QCC[<5]5/TE=QJ;2IFDIHZ:%8X7/56-]&-%PWL0[:. M+?"HUK>ZW2^H[.[3NJJ-
*G6/IG*O5RM3M5N>:.+S1<97*>DBJAJ+4&Z;-J]\]S M*^.D?77&>'"*&DA:BJWC2.-RO?CZ5J(JK[WPH$I*W5EEMMT@ME9=Z&EN51CJ;-M.>JC9-*
*+E<)PL5JUC'^5GTE-M/:B8G5VO54/L;6*B!O*\7VW6"B=672NIK=2-5&NJ*R9 ML4:*O8BNT4E1103W2BAGKF\=+')4,:ZH:B956(JY[A:*
*(VYAM6Z5U[IC4%MM^KJ?"GFDC9ZVFJV+YU4QUN>)$PF M?=9QZSZ:3N%BT'H"515NK**KH&LZF*\5E7&QE2[+E3#U=A5Y+V*O8IB>M]I] M*;?*
[8:VJM/VB.W3SV:;"21LLCUB/LQT__/%(.?/&/=EM^N=EUMH6 M]I1ZEHX;?)!+!+=Z.I8^.E7ARKE>CN%%:BHO-4[>XT;NYI_3%VU%#MWH32EG
M74=5CSZX1TC.&WP\LJJXY.PO->U$7DBNQ<..]0/P]+W+DZ/HZ_X%M?]U7^.X[S=O_ M 5ZS_46M_D'@1^V:V,9N-MW;;_7:NU#25-*
*2Z9'0TU7AC>&5S4QE%7L:AR-0 MT&H>C?K#3-51:HN%^TY=*KS6HM]Q>KU;S3..>,X=E'(B+E,+E.1P=D;+N]5[M:6N72FIH+%0V-*
73=13UD:NE;B5Z/SB%WTW%WG%U[5NB]>Z=U+N]3NO\ 9=9 M&4DUMD:E/2S914+'+/#VKC"ANKI-54]GJ2>FFDIVF>;<,L3E:*
*MY,U,2+A4]1D>TMG:%VMN]5#*L=? M6)YC2]*\^.1%153UM8CW>^ALTB_O?K:QW7??2MDQ=PCH]/Z?5*ZM>]'.19U1 M'M8J-*
1<\DB3WI'(!V&PE==]O=Q[KH#4-;/5R5E'!<.6ID5RK)U;5E8W*Y[W M?N2DD"),_.ZNE:V_Z1UCI.]PU]ZL]4C)8&,D8LL&>+"]YJ>BBHYO;_RBDJ+-*
M=;>^VJCN-&_K;2KA9/$_Q:YJ*GWE YQ!WHYZOO%@USI^X7*Y5539[U4U%F5) MYG/:V1&1.:O->U721H[RN4G$0CT-I:6_=%R_U])Q)<;)?
W7.GD9[IO!# C\> MKA5SOV.3:1W+*IA"&-DUG=M5](VTWMM=4LLERNTD-'"V9R1R0Q(C$7A[,*B M)GU\1N[7VZK7]'UVIJ-*
*V*R[T4=/3LCITD]<#FIZVKQ.;J:XN.D6Z%W/V1L;M6HV2DIE294[Y7.5TJ_"]5 DM6:BWM5NN%)0UERHZ6NJUQ34LT[&2S+X,;JY=|*
*M!]Z^Y4MLHIZNMJ8J2DA:KI)YWHR-B)VJYR\D3WS16]F/R_\ :C..4S_X[?\ MS-B;Z_X(-7*J?!WR(!\=W+U%6;-:EN-*
*KKV30NMSY(*NCFRU>7NFO:O/X*7=) MN/-HWHN6RY1W>&FU!+0KYFM5*UTLSTFPY6HY?35&NSWG+I/H/'=W^P3^SWU,*
M:NUCH+ET.Z"NJJ.&HK"AXJ6:1B*^%75#4>.Q3+]MK?3V?1-IHJ6\)J&GABX67-K MT>DZ<2^EQ(HOAR5>PU;1Z7M%DZ+U?*

64%NIZ.KN&F&254T,:-?.Y(.Y>N/27 M+E^,[3:G7-EV_P!@M*72_P!;YA0K%U/7=4^3TU>_"88U5[&KS[.0&YSH]1:S
ML6DHF2W]J[T=K8_DSSJ9K%>OYU%YK\!BVE]_-":QOE-9[-?//KE4JY(H4I)V9 MX6JY?2U>
[!JS9W35NWGUUK'6.J*9MX935OF5OHZMO6001MRJ>@OHJ MJ-X>2IC*N7&5Y!V6]&LJ:\ZVVAJ+#>F55OGOO5R2V^I1\Q.)%PJ(GTB&6=)1,:UVE\?
9UO/ M"?\ 6P ;GOFIK5IFB=67>XTMLI47AZZJF;&W/_!HS?I8[%NSIS4>JK)47__$/3TBP+%$5KCX9U M<_*N8J*K[CDN.HGYW!],3;MJ=R=5Z?
NFC+S3Z6OU!4=>E+2TWFSJCL7@6-4 M1KN35SPYRBJB^H)%35,5-$^6:1L4;&JYSWN1&M1.U55>PQBW[L:-NUR2WT>J
M+345CG<#88ZQBJHRKA$;S])<]R9-7](NHJ=3ZQT+M_%42TUNO%2LU?U3E19(
MVJB(WEW(B2+CLRC5[C*=5]'71=\TA46>WV2AM52D6*6OAB3KHWX]%SW^Z>F< M91RKE .PW-T]0WJ^:1FK-
5MTY)15Z2PTSID9[(.XHUZI$5[>+L1.2+[KL,SK M[_:;344<%=7TM'-6/ZJFC]}VL=._EZ+$5?27FG)/%"/>\%GKK!6{)6VYW'V7
MKJ2[LBDKNKX%EQ)"B+A7*N<815SS5,\NPYG2PMD]YN^V]OIIWTE15W1U/'41-MZ)J.1>Y454 W-NZ&CTNOL8NIK3Y_P ?
5K!Y['Q(_..'M]UGECM.@Z0U-M7/2;-:FGII9*>9L,:LDC]='C1%?HV:Q4UCHZ27J%9!<&Q) MYRR3'HO67W2*J*N%[#4-
DU=6ZJZ''IF7"5\U5:Y/8_K9%RYS&OA>Q%7OPU-MZ_8@;8M]#%['H[V:FN%_6QQU-GI.MNTDO"L7HL7B5ZN3FJIC/$G:9?9+C9]
M'Z'LC:W45)+;XJ:&GBNU74L9'5*C$X7H]7857(F4P]_":PU@F>AY#^H5#^&(-MQ7>95;T4-$.151>"W_S=P&_;ON9I/3]P\PN>I+705F418*BKC8]N>:
<2*OH_M#@R"DJXJN!DT$C)H9$1S)(W(YKD5,HJ*G;E,+\)K"Q|'S1LFD8Z*YVB*X7"J MA22LN51Z55),YN7R=8N7(O$JJB9Q[YC_
$/JRIEVXN=%/4/GCM]VFIZ?C^E9 MPL=A/5Q.$>M),V3@5>Q'(B^BOJ7!HNELFUVVEYOU1KW4-IU5J*MJEGF?6
M4:SNA:OTG4HLG"J+Q>OAQRP8MH[4&E9^DSIZIT'"^AL]=2RPU4;:=88IG<$K ME5C5^ERR-
>2)S:!**MU;:77,HJVVT=)6/B=.VGF]&.D=&U%5ST;JYX41%RO M8F.TZBW;J;-NU1'346]/,45,LB0QP,KH^.1ZKA$:W.7954[$7)I'?O3+=7]{
M30[EEDECIJVBZJHZEW"YT7'*LC<^MJ.3WE4Y^]^P^G]++[>5M[TA:VVFZVJ:& MOZV%[WO5D>4$"1?$=99]16K4,$L]JN='
MB)EJJU5PO-.7;S0UOK?=^*GV!=]^D>D=3<*%D=.C%YL])$X51/6Q>)?V"G>; M&:(_('MC9+7)'U=6Z+SFJ3'/K9/214;^Q S" ,6.Q7%S7*U6TTBHJ=O)
MJD6=@MH*;=/0LEYNVI]2T]4VLDI^"CN"-CX6M8J+AS'+GTEYY)2ZB_X N?\ MW67^(XB;T?*G=6'0,J:++I;+46GSR1Y S;6_1YJ](:?K[M[I?
7&HJ>XVZ!U2D==6\;9&L:KG-XFIHW4;WY3Q\4V/L-KFIW!VTM=WK^'S_+ MX*A[4PU[V.X>/'Y/P 9+ MJ#
<72^E:GS>\7^W6ZI5$7J*BI:V3"]B\.#MK7>:&]4;*RWUE/74DGN*B MFE;)&[GCDYJJB\R(^T^LMHK7IUU7K-S;WJJX/?-737.@?
5*Q5UD%2UKW^@CNSDQ?@?CN M0"3%JU):K[+5Q6VY4=PEI7]74QTM0R5T+LJG"]&JO"N47DO@HO.H[7IRE;57 M>XTEKIG/2-
LU:.V%BN5%5&\3E1,\EY>I32L,?Y672?D:_>[1K2E5[>YJ53,J MOPJJ+\,Q3.)5 SO4.GZ"KW:TU M=I=6-H:RFIY&16'KFHM8BI(G&C>-%7'$O8U?
<^HS2[WRWV"B?5W2NIK;2MPC MIZN9L3$SW<3EQDTIN B?-7[=>/L?/SQ^:YTO?_KC%KRKD735@CZBC MH$CDDBEJ,)E7M8B]
{G+SQGA:G8@$E.,IA:9U;,^&RWZWW.>/*QAIJECY&>HBX MRKW5-RI(+A4IF"DDG:V65/SK%7+O@12)&[&MJK9]+2W
MC0+VV75EMGCEI5H:!],R5OGUR<*,[.?/"KC'8JF>[{UTE;HO;OX4MKI>)&=?63MACXE3*)Q M.5$SR7XCD0UT$U*RI9+&^G>Q)&S-B&ZLZY?
9"*F=8VIGTDY&L:F7.KY>OTP.4VAG7=#6%\W"JT<^BBF?:K'$Y.4=.U4XY43ZIZKS7PXDYH: M^GT;+N=TD=:V2]O]VME'2P-JHTH*GAPJ-
A;C"Y3'IKW&Z.C_&IMIVAU7#!V83MSP@;_^9 M0H?LWU1]UM_U3N=<;JZ=K9)%R]48YZN:BJO$O M?]*ATWF?2"_]>TO\3O\ 4*=,M,;1P_JG#_$D
W>R1L-.BNY<)A.\Q MR@W1TA<;K[&4NI[545ZNX&T[*QBN<[..%O/TESRPF5-9=)N_5L6E=-:9H:EU-M')J.MCI)IF+CYUA$?-$5.\RJ7HI;#?I;V$BL5-
K8^%EP;Q/.V/-MQRDZWW6<\\9X>[&.0&>6G4%LOS)W6VX4MQ;!(L4SJ2=LJ1O3M:[A5+<+ZE.R(-M]=#FFEI=);G@J'K)/%>I&O9(4
:'UO3ZJW2W:FT=!7W/3-M>D;=2I/5UE&UT;JYSN%58V3&%Y/1$3L]%ZJCN2)O@X=96T]NHYJJJF934T+7-M/DFFD4-_V1N?GDC>)%5/4U'+[Z8-:W^
MX5G2BU53V6S,EI-OK34I+6W-S58M7*G)&L_8JN$[D7B7'HH=QTKH61V_0=.U-MB)3)>HVJU.341$1$3'O9-K'T;KO4V)MTJ-=:@CUN^-)UJFU:I
R54SU?#C/" MGN<\7P8]$S+8/<:KW#T6^2ZHUE]MT[J*O1J<**]O8_'=E,9QRXD=C'8;--!] M&7+=:,M-;]+"NJ;=M%4S4M1+32I60)QPO5CL*Y>64-S&D^-ME_|
X&ZG_OL'X5-S'\G-LT/MA;+Y>ZOJ::*@@57.7+Y7K$F&M3Z9RKW?#V&K
M=#V#4V^FI8]9:GEJK+I2%R>QMEAE='YPW/)SU3"JBKA57Z;L3#366HK)K[6F-MC+7KVYT$++[!8T@\SLU[@:3H;S
M:>%M/(WA=!R1:>1O)T;D[E;]\,*G)0-2],2JKZ;2^FXK;4S4LT]R6).HD6-7 M9C=A%5.)D'1[W1]-/HJCOSR=V4,:Z7-MB?
[%:+_5IGX%/EOEIRX;;ZOHMU]-0JYT+FP7FD9E&S1+A.-?4J8:JXY*C'=R M@OH:RZMEC=WIF M2'**GQ_LFG&U>;5^?T_%GX%3XP+[+T:J_7-)
M'==R-376XW2H1)%H::=K8:=%3W&%;J93O1B-;GQ[3KM7:6U1T<6Q:DTS>ZZ^
MZ6BD:VNM%TDZSJVJ)QQ{'/$BDF/Q'F/G_%CTN#@XN''U7TN/'D:.T9I'4?2 M0@DU-JR^U[GTW)*YMOLMKDZI'-
:Y4XW*N<\TQE455PN.%.WIVR5:]!]5^EX\ M((//]_/^WXS?&R-/#3[3:0;3KF-;9 Y?TRL17?Y2N U'K'8^Z;36B34NW>H+ MMUU G6SVF]EZZ.>-,*
[#41$7DF5147*(N%3OS77.JZ[4/1UNU]=355DN$UM5 M\D$C7PR0R91'8RB+C*+A>]%13;3G(UKE5R-1.U2/=S55[5[$\5[C7ENDU)TE]3MKV
MS5VG=N[?*J0I"]89JYR+A5RB]N.Y7FC4Y)EV5-86G2VO]U]I(&45/YMIK3\" M^;4>7(MRE1RJ]S4^F5$5WJSR3TETL MZ3./RS=I&U*)[''^R:
<;5YM7Y_3\6?@5/C)%>Y=GM C/JI2VJ.CTW77-MW2T4C6UUHNDG6=6U51.)%3DG/L1L%5:5J:
M>1JJQZ(YJ*G8O)>9VF\R0.VFUBE1_>TM=1C*7H0)_\ 41@<"RZ#3=/9'1='67JY6U[*2GJ755#-PRR.2)6XEU]C%U-:?/\
MCZM8//8^)'YQP]ONL\L=IJ_I86R>\W?;>WTT[Z2HJ[HZGCJ(N3XG/=$U'(O< MJ*J&;_;K94KA>HJ*IC9,+V*KKVQ:RIJKC$DR^FJJB(
MCLHBX5%5>U555SV(@;IMEXHKU1LK+=+5T]?1R>XJ*65LD;N>.3FJJ*<>^ZHM&
MF:/SJ\7.DM=,KN%):R=L357GR17*F5Y+R3F:)TI;VI.])"#2]H>^'36IJ-U2 MVB_'MU'*WOY,XL+RS(J]R
;TTYKC3^KVO=8$I77JT1SVTE0UJF(JKFIHN4^%#5/2 MCKZJWTNB%I:J:F62]QM?U,BLXFX]RN0.U#HND%H.W]94-LU_H^C@L-UMM9&R6
M.C8D<,\;E7DYB83MPG)$RCE1HD9!!&U7/EDLQZT[H:0OM?YA;]3VFLJW.X&00UD M;G2+X,3/I?!DT7TE]86ZIW'TOI._ULU'I&.-+AJRJKGHV-R-
YX^=XY=_MG69[DQTNOM6;&7[1]71V:**U7>*%SZ&JH;=)#*V5$RQ'/:U%R]PME%76E%D6AF6-R*UU2[*=V?11,^!D4G14IVM&H3FR1U2B\
M+NY>2(J_&8KO?>+G8>DYI"NL]J=>[E#:$6*@:_A67+JIJX7'XPBJOP&5.W6W MQ]56IP)RJ:M3MQW@?/836FI*77>I=O-3U\EX][2U:BGN,JJL
MCXT5C51RKVHJ2.]W&.CT]IW%95O>USFOJ%1'M;AJ+GDD22"\#MM@ZVZ[?]AWK;[4% M=-635%-#<:*6HD5W$_JVK*UJKGXO^R<2*&1/IF.3B1?
B M5 (SZ L%QZ3,]^U%J#4ETMUBAJW4M)9[,.D2,:B(Y%=E%;]ES4SC*KGFF#EZ MQV@O^R-']J3;N]7BO93RQMJ;+4JM0V:-7KGUWI
MNFO%C1Z,DN5O5J.3/+.6+PIS[G-;GQ V1NS>IZS8R]W...HME1-;6S]4_BCF M@5R-=PJG)4Z.]%=9K[M+H[1MIJ+UJUT:*]4C^<4C7-16O
M*:1K$1TBHWA17+VKA$1.?=R T_T1:^]NNU]755D\E342W6=SY)7*YSE5L:JJ MJOBN?C.1OSK*]PW;3>B.,UGL?
=]13JR6M:GI4\"+Z3F^M41W/P8N,=IPNAG_ M ((Y_P!4YOXD9Q-79?TPM%-D]RRS2.C3Q7@J_#_ *$ X>L]FKIM7INHU9I'
M5M[GNMK9YU5P7&H26&JC:SDXFX3L;GDN>34[.2,RU1O8%

YYH(UTZ@N%-)-=+4K5I96S.:C,.XN;47"_%#+ +%D1$55Y8\3%8MT!'RW7V,9J> MTNKN+@2#SQG$KLX1J<^;L]W:;_Z5>]*^R;?
4ULMLSJ>IO=:RA=(UW"J1*BJY M,]V51J+ZG*=Y0]'/0=-I)ECDL-+,[JD8^X+&B53GXYO23W2<^>$7'=C'(#/* M+45KN+JYM)<:.J?1/='5-
AG:]:=R9RV3"^BO)>2X[%.HK=T-(6^CI:R?4UI9 M2U3G-@F2MCTTET:;;/:+1NG0U$[JJHI:R2"2=Z^E(
MYK9$<|5[55515RJJT_1DV7T[KS0=7=M343IJ]U0^BI(Y)Y&L@A;B.7@X7)A M5>]Z^KN[5R$FIA]:TVFW-KZZYT=%0R(CF5534,CB_J'?
75&U5WTZQ^B*2&"^TE0Q[*NU6]U-$QN5 MRCUX6IE>U%1%7*)S ES=M26JPOIH[E*ZQ.8F'<369?C'YU7+CQ1/ YB[RL^9[_)OU MK?/?8_A[L>>?
WK&/#K.?O ;)M6H;9> _.4MURI*|:9 53I2SLDZI_U+N%5X5]M2\SL>(U?T=-%NT:M;,&3M5MPN&;A5._DS'7VH':5T3?[Q M&B.FH:*6>-
%YY>UBJU/CP!\;YN-I?3%:VBN]_MUNJW87J:FI8QZ(O8JHJY1% M]9J>DODE=TKXF4U>^HM2NXDPOI=O)#HM$Z%I-ONE8^V6Y7MMK[9
M)44T+G*[]6O3FQ%7GA'(J&>Y?A DC<[U16.ADK;E64]OI8_=SU4K8V-\,N5< M)DZG3^XNF-
5U#Z:SW^WW*I;E>IIZECI,)VKPYSCUXP:9O%K9O+TCZZQ7IRU& MG-+4S)F4**J,FFIS]^=G;!:M#56I--V^GT[?+(C:J"JMD
M:0.5K53B1>'&5QSSVY3UJ!F6 .O7:"VZN=;172EH+X]C?,&S/C621>L8UZQL M=[M4:_/8N,H<[9]6%%JK0-
C='>]>ZW2*@IO/TBJ6RRQS.C3*2HBY:Y51W)<+ MR7P4UKNY44>X/1EAU7<**GGNS:&GECG=&G%!(^:)LO5KVMRK<Q4YD3=!ZKV8J-'
MTFF=3Z>CL-XBA2GJJFLH5ZQ9^'#GI,B*]JKVX=C&<=QOS9G2M%H[0='!;!;?_M
,D5N1[I:>L:K5:C'*BJUO"JIPYRO:W@9\8O6:C:5ME#+65&HK7'30S+3R2> M>1JC94YK'R5?21.?
#VHAE!$K8K:NR[AZOU[4:BIG7&@H+E*RFI'RO:$DDDC^ ML>J-5/2PQB9_T)@)14^H+;5VE+I!74\ML5BR)6,E:L7"FWB>C(W8RY?
<=O:G6<7;@X>OM6;&7[1]71V:**U7>*%SZ&JH;=)#*V5$ MRQ'/:U%]7.7"(AT=TW M-TG8H*2:OU+:,Z>*KC2:G<^KC^?1KV/8B+Z3?SR6%>GBJ-
;E5P8EL5M79=P]7Z]J-14SKC04%R ME934CY7MB2221_6/5&JGI88Q,_ZPHJ?4%MJ[2ET@KJ>6V*Q9$K&2M6+A3. M7<6<83!U%IW0TA?;_P
PM^I[365;G<#((:R-SI%\&)GTO@R1]WZNEBL6K]%[M?5DTEIT)0TS*JMAI>L*I8N',?6QM1J^"JJX1?
5G)K:Q7[46YW1:GDM\LDVI'4DE(YT:JDDO5R<+ MD_3OC;\;C -!ZKV8J-'TFF=3Z>CL-XBA2GJJFLH5ZQ9^'#GI,B*]JKVX=C&<
M=P$LJ>ICJH630O;+$]$J M9QGA5_Z9 M? T7M+K;:REME5>-->R,OFK;E.^:J?<*|2V-N<,:W+5;V<\IE4XD3.$1)=V
MB^6^_P!$VLM=;37&E>JHV>EE;*Q53M1'-54R?&74MII(C;+U1QW"'SB2E M=4,25D2=LBLSE&|]5C!&+;;7&F+1T@:;*ET%5R)IF_P
#HZNBQ]NU+:JVM5W"V"&LC<|Z_G41?2^ UQTH-S*G0NC(Z:R7N&@OU3 M4,:Z%DC/.4IW-DXI&L7TD3+,<:)R5.2H8UTFMJ],.:5V\;?
[':;>RW2WU4/53 M6]O4JJ*['/':JW*(?'I86RCN&T^G]0STD#KS--2PNK$8B2=6L4KU9GZG MB7.) Z>U':]2VWSFU7*DNE.Q>K?-1SLF8UZ-
15;JM54RB*BXJ:'\:\7J.DTM MIBTZ5M24EEMJ/:*>1R3/BI8D8USU:B*Y41.U4:B9]1\M=Z@=I31E]O#$:Z2A
MHI9XVN3DKVL56ICWT3XP+=1;AZ9TI.VGO_M]LJ'(BI#4U+&2*BKA'<*KG&> M_&.1V=FOEOU!1-
K+96TUPI'KAL]++,V5BJG:G$U53*&CNC[M18]1:*;]O4]OI M]0WRJ2RU.TUQA;.C&J]R(C6KE$5<<6<9YHG8B' 9:(MEND/8[?8G.H].:IB<
MV>WHY5CCF3*(K$[L.1GV[D[.0';UEZFH^E8V.:N?#;H[*LLD*>LT-K_0]-N!
MTIZ.TU_6>QOL6R>JCCM8WB7@547L5W#G'A\)D&_FT&GK1M[5:@T];:?3] MYLG!4T]3;F)"Y41Z91>'"*N%RBKEV.)B<3I'NPUJ=J
MJJ]R&*4V\&B*JL=2Q:LL[YLHU&K6,1%55QA%5<*OJ0UGNS67_E1>*2-&KUK6HG:G'A?>13$:?46Q>OM+I9'VZFT9<70]5'4U%'U
M?]/:8I6[J:.MEQ=05>J;13UC%5KXI:V-JL1V,.>DBMXF*JY]RJ8[@)41SLF8Q M\;D>QR9:YJ\E3Q3Q,=K-
QM*VRAEK*C45KCIH9EIY)//(U1L]YZ<*HO9CA:N,)S-]O4]OI M]0WRJ2RU.TUQA;.C&J]R(C6KE$5<<6<9YHG8B' 9:(MEND/8[?8G.H].:IB<
<|=YV5QNE):.&:LK:J&CI8DS)/42)'&Q_ MXRKEY(1]W8T_1:,ZYV]U?:(/,;-2.;9:V-JJK6P+GA557*JO"LBY7GEC>9W' M2Z/36@K;)BLU)7,;(Y.?#
Q4557U95'<^W@[M-.] M*&^PZ2TYI#1=-5/M-BKGI%62PHYSXZ2'@;PX3FJ8IT]=JOH[U>F
MW69E+'3L2/@9616Z5*IBXY/Z[AXU5/6J@2FX\=J&,7#=#2-JNKK96ZFM5)7M M7#H)JR-KFKX+E>2^I2/.BMX+I0]&+4.1J.5&N[68SC+51>6>WF
M!UVT=RJ:OI [EP/JYIJ>-&+%&Z17,:G$G-J9QWF^R-'1TTPW1V]>X=E9-)/# M21,9^9WIJU?EB*O>J-
5J9)+@1DWKL]1JJI(:5TU[+W"V45=:461:&98W(K M75+LIW9J%$SX&12=%2G:US]?76IX:A.,)'5*+PN[EY(BK\9BN]]XN=AZ3FD* MZSVIU[N4-
H18J!K^%9:!\]A-::DI==ZEV\U/7R7BKM+5J*>XRJJR/C16-5'*O:BI(QR9RJ97FO M+&TMRM81Z"T+>K[(K>.CIU6%'=CY5]&-OPO5OQF";
([5WW3=ZONL-7SPR:EO M7)\,#LL@C5W$K55.6>34Y91$:G-3#^E7JRWU=\TGHNNKFT-NGJ65UTF7*]7 MBJUO),KG"2+C\ZT#I=C[G?-
N]?:,;I=0W"IJZ'6EK;4Q.J9',',JNZO@UUHNT7V!6HVL@:(]K>QDBKGUWINFO%C1Z,DN5O5J.3 M/+.6+PIS[G-;GQ W?6W26Y:"JK@L$]#-
/;7S]1*U6RPJL2NX7(](J.3.%Y=-] M&NNB175-RVF26KJ9:J7S^9O63/5[L)P\LJ:!J;W1ZEV\K+M;Y>NHZRVR3POQ
MC+71JJ93N7Q]:&N.AU_@@;^]$_X&@;Q--[H[T5UFOLNCM&VFHO6K71HKU2/Y MQ2-%%B-,UGL?
=]13JR6M:GI4\"+Z3F^M41W/P8N,=IPNAG_@CG_5,;^)&<35V7], M+139/L]FKIM7INHU9I'5M[GNMK9YU5P7&H26&JC;-MSDXFX3L;GDN>34[_
$C9]/NI1S;/IKK@S%['K5K"U?\ E4:J+-']NBM.YW&1K MMO\ 5",.PK?8NJSGL_O+B.%,^9O0>]E3FU9%1.?8WS],X^'* 9'H7:*Z;P::B
MU=JI5E[AN5RXIZ.GMTZ0PTL:JO!AN%[43NQR7Q](R?8S6%]AU%J70.J*_P!D M;Q8G-=3UDF>LJ:=R\G/RO-<.C7/-?
3YJN#/IJHFQ;9Z1:SFUMHL+GM^]I);JR>C]IO04M7!!YS+!-4L9 M)'"BXZQS57*_/+R.Y(M]BZ.I]<=*B@LE:Z5;7/;8W5L3)%9UL3$?)P*J+G"
MN8S..??G*(]!(C3NLK'JRFEJ+-=J.YP1+PR/I9FO1B]V<==AU-9N_HB@J_-:C M5EFBGSA6K71^BN<81D?5K+!0.J*B9R)S5)D:N%5>S
M#T3P4"0:7J@6UK=&UM.MNZI9UK$E:L/5HF5?QYX>%$YYS@TIM)O$S46Y^NZ2 M[ZEH7T3:R&DLD+JB-C)F=9*U$AY_/:.]#FF57*>*'7=$ID-
VT=J^S31R5%E9 M<'Q14U6W_DGLPYCF^M$3*>.3K]@M$V"HW>W-;+:*.3V(ND:V]'0M7S7$LV%C MY>BJ<#>SZE
)$WO4MJTW1^=W>XTMKIYVX>W5NKK+J?;9S;9J2@JF+)3TM&^F@G@PJN: MYN$;W(BX[4547L3 3$N%RI;31S5=;40T=+*$G%)-42(QC$\5%6*
[AYXQOIE.)QB]75;'[MV]&WV^6DT9=D?&L_F;:6I F%3+5;=U9+%$QCZAZ8=*Y$1%>OK54R:[Z2&DTU7M#?8V,XJFA9{0X3L6/F MY??X,-/A
V/77'GME'-554\5+2PM5\DTST8QC4[52(A\K1>:&^T+*VVUE M/<*.3/!44LS98WX7"XCGIMM+)QW35+Z2V)A>;I>+Y MZGO*Z-
S5S]5CO+]@]0)MYI#<.PU\BRI[&MJ)4XEPKH5:Y6X_3+&Y>7>\#:V] M[A9=5Z7U+:HM34= L,3H*VL@JF*Z@5K5!?+C<8EEE;)&[']@Y]JB
MF#Z2T[046Z.J;I#]UMTK*J-K9K(DS7+0HG#S5J/56YPG:B=IKW8:TQZ,WJW% MTK;U>RT0)%4PPN>JI&JX5$3WDDX<]JHU,Y.3M4G^ZQ9$5?
0S^>P<;3VX>F-53OI[/2[=D5E5)1*]4BGF1&-CXT1>;-1SU1(' MU*J+R=^=!V7;K46A=1:9H8K)7K=HZ=Z4;4CC>WDJ9:G+N5.2)E'+G($G2U78
M[BXTSTJM:UFCML'MMTKH*NYU3*K6*]/8Q6N<]6JG8JHWA_9 9S6[J:.MEQ= M05>];13UC%5KXI:V-JL*T5-/!
<)%A1D]=46V19Y'8PYZ2*WB8JKGW*ICN,@Z^^JUK/R8Z6M MMR?56FWS];9JBJ8Y7MA>KVHBL7"X3A8['+FYWCR#=%_W*TII:=8+MJ&VV^HY
M?.)ZIC9>?YS/%IX["QZGM.IZ1U59[G272G:N'24<[94:N,X7A7DOJ4C_ &.V M[0;51U]-J^]6G5>H9*B22KK*NB6JDRKO>57*KR3ET^S=XT^[I'
M5GY"HI:'3MPMKG.IWQ+&U[DX55S&KS1N4RG9VKW<@).W:]T%AHI*RYUE/;Z1 MGNJBJE;&Q/!%553F=5IW<;3&K*AU/9[_ &^Y5+4OL-
M+:AM3-WNDQ/IR\]9/IW35"VI\SXE2*:18UUX7.++?DME M9:I.FT;>[?4LFBKZ"E1B<*(O]6-5J*N53FO/DOWUFRH-
T]'55T6VQ:IL[Z[*-2!M;'Q*Y5QPISYKGEA.9I M+I):?=JC=C;:SK420-K5?#--3KP.1BO;QJWGR7'%9DF\FQNC*#:;^26VPTM
MOJK;2.J8*F!G#+Q,3*HY_:_B1%1>)5[<]H&\VNR7&!;%W.HO.TFEJNJD=+.Z MC:QTCURYW"JL157O7#4,] M
1^Z2SN+7NT2)W7KG^ZTY($MX0.NOMCH]1V>NM=PA;4T59&Z M&:)R7X[TX9'Y7NX M6YYD_I]J:7]K=I)*Z]:AN,+Z>GHXJ.1KHGN16\3LHF<9SZ.
<|O$WXD? M/P/C#0T]/-)+'!%*]UB(YWOKW@:JVUVUK=&[#U&GJB-77:KHJE\T4:HN
M)96NPQ%416M\,H8+T=M5V;4NVU1M=5+44=Z2EKH9HY(%1&L>]V>_FY.LI%Q M[E22O5^L^:4T:2NE1C4DS5K?HC<.A=9ZRW2RK2UTE
M(Z6*HB<]SD5%:U57FJHBHF,*B=J8,OT'N;<-R]QU73%HIXM"4<:I/IHX:R/@GBCF9G/#(Q')[^%/HR)L;4:U$:UJ M81K4PB>H#3.M]WKAMQN1-
2:LHD70E=3M2CKH*9S^&3"<395YYYH_DG/"MY*:-MOUFNDMS]<:89M3;4]FH*QM3672BHWTT$,2.3TGHK6IE'<\XYJBHF54EF^F9-
M&YDC6R1KVMDYHV\WBW;=U#8J M5UPK=.UBU:J-J<2R,56N5R-^FPZ-O).>'+\,\BSJ^>><@1[U#THM"ZCT?4T*V
MRMN]QKH.I=8GTSD=AMP;4_5&F9FQ:BA2FII MH4662F%&HJIQ%3UHLRFT<#9W3I$QLSDPZ5&HCE3PSVERPM>Y% MB.3M5$-
Q%O!X@:$LO3 TLZEZG4-!<{)=HFHD]*Z#C;C^]$5%SCI,B'0VV MY5?
2$WCTWJ"UVBJM^E=..63V0J6\+IY$5'(Q,]GL/LR%K6HU$1&M3"-1$P@$>M>.K-F]['Y=P)**>MTM> M:5M+<9:6/B=2O1&-1RIJ\
<:Y];T[<9^.Z>^=KW.TQ4:/T#%5:@O-W1L#UCIG ML9!'Q)QJ]7(G=R\$RN53!([AYY[>X^%-0T]&CT@AC@1RY7JV(W*^(&F-Q]K:-MVGZ-
WY%+=&M=7V^E@?P1(JK,]CT?)P)VJJ^F])CGR0ZW1'2@TS#HJUT#Z:X3 MZF@IXZ1+/3TKWR33-:C,-M?
I5;0:X)N')1SUNFKM2)17&:FCXG4JHC&HJIX9CC7*M_GD[<9^VM.D [6T5)8-]}ZBX:AJIF\=8E&Y15'&B^DK^M9CO3GA4PJ|\X1=_
M//*\^XX]-0P4K52"&.%JKE4C:C79=J3L:*DT\]-+T[[Q&H9U=);FVY_$DB MY1JNRW"HB\^%JJX_ =7Z6<_ <>.M&T4\D\=/$R9_NI&L1'+[ZIS
U^ZJUW2 M[.25T=%;VZU2!:CS**!4B]WG@X>+W?5\NWW1KU=^-K]7Z9BCUW01MOD,/5U5
M%66Q[Y$E:GH6Y&^CSRO:U4SSP2+X3CNMU,^H;4.IXG3MD',17)[R]P&DNB ME[JY632]
[J:FDJ+=9[E7^<6RAJE7K&0\/)RYYX9L$SJGAP]55Z9;A5Y>@O;XH9YPIRP$;COY@4VTF[^Y^M=%K>Q%PO$BXY9X%]W#3*.9F<\,C$^NYUJ
MUSMU6V?0MIFK,/2/947"Y04BP4U.QKT1K6HJ(JKE1>SDB*O-.JDIZFBAQ3GXVLE8CD[_=B\O_ ,3ZQPMB8C&(C&(F$:U,
(@&@=ZZV*OZ*E'40NXXY M*.W.16\^^, ^ND^DUIS3VC:&BU2RNM>H:*DC9)0.I'JZHPQ.&2-V.'#T1%3B5 M.WPYF6=
([3=RU3M/=+;;*.2NKI)8%9!#[I<2M5?O&9:7M3(=-6&&LIF)4TM' M"WAD8BK$Y&-1<>"Y U?T>=,WB>ZZKUW>Z*2W5&HJA'4M',F)
(X$YBY:JM3*+X^^!&V>J;L#N_J>Y7ZVR56C]32I4LN4=/UC::97,=P MNY],=JHK53.%1.TOV^,.K[M;+'M:;J>^7&:?BJ:Z[M[TI]>+"HO%Q(U>
MWFJ\DY83*KA) NB:]BMU<*O9\)O3@[.9\8J*"*626.&..63W^J=O:!IOHA?X'*;_OD_\9#=I;PEP$?MDO\ #_NPO=US?X[CZW)5^;$M
M/ZA.3L_QIOOA"!JGI'[?5VX.W4E/:F+)=+?4-KZ>)ONI5:CFJQ%\51ZJGBK M40Z"S]+/24=A1U^6MMNH:=G!56OS-
ZR+,WDY&KCA1,_5*F._!O3AYIIQY+?3 MS3MFDAC?+'[F1S$5S>>>2]H&BMC=,W>MK-;[@7NADMLVH.)*2CD14>R!,KE4
MQWIP(GCP*O8J',Z'?^"!OAY_-CXFF[^$<(&A-O>?2NW&5.:>80_Q:&1J.3/PE[(6QQHQB(UK4PB(F$1/ #ZF@M%,_W7NX'ZDP?R=(;]+>%.0&
M'[IU.I:+1-SJM)M9)?*=$EBADC1_6M14XVHB]J*KCUICO-=472RTDW34O#ZSC^Q],M1YPL$:S,_/6<"<7Q M@:GZ/&C+I:+=?
M3:@@6DONIJQ:Z6F!';2>$Z96M>>$6TQ]^/^3I%_"OWS8.^&U%/NIH^6C;PQWBE59[?.Y<<,N/< M*O%[^5_0[_P #_P"V$_\X3=_"OU0X0-
"W/Z,6T_]s[_IABVOZFTZ/Z2< MUVW#HUC>2-:B(B)X 1XZ4]OBM6F] 44 M"KU-_=8H8^)V5X6LX4RO>N#L.ETO^P&D$_\;L/5YOOA*<(&A=[U_V]-
I7]RK_'<;'+>%$+ M@(\="_\XEZDRO/V7=W_ /91DA>$:X)?6AIZB5DDL$OD.$#"M['?[4>L.7_ #9/_$4Z M_H[\ME]*)V?W*O=^?<;%1OCS'"B :.$Z-
7_'/=E?_ &Z[^5F_\BNK':]L71?Z MA2?@JS?7#W]XX0(N:_J;3IO!)S7;<.B?4Z8FHF,MFB>C6=K,+G#NMY M8545Z.QC"IP]]=SK5KG;JML^A;3-
6V>D>RHN%R@I%@IJ=C7HC6M141557*B] MG)$5>:95)3U-%#5Q.BGBCGC7M9*Q')V8[%Y?_B?6.%L3$8Q$8Q$PC6IA$_CS
MN7IJY:FVRVZUAIRG]DJ[3L=-71TD:<2RQ\$;GJHL;?1[?=>&%[>OZ6.DJ
MC3KWVA:VLU%/&K*:SMD).MZY4PU%7"']([MPJKX(IO'@[.9\&T4#9W5"11I.
MJ863A3B7WU_M@#06M=N];;@=*'^CBOLZUFL:6H;;=LTD,;Y8_=-7>LO^K=P+U126R;4$R>9TR!'* MN53'>G B+W*KC"H<3HJ?!*;E?
JTO\:0W_P^L<(%QB^YSO\ :WU;^I-7_(N, MH+5:!J#HG?X$;-_CJC^6<.EA_@1O/^.I_P"6;;?1N.\<.>\#I-#N_P#0NP>J M@I_N;31NPUE9J-F\EIE?
P15]SJ*5S^'BX4?UKLMTLJTM=)2.EBJ(G/+0E'&J3W.JHU:.^>5$7'5.RF%RK>2Y5$;JKC*(;GJ:.&LCX)XHYF M9SPR,1R>_A3Z,B;&U&M1&M;F$:U,(GJ

T13$X6HJXRJ97N3(&IMOHUU'TH-??N-M)..CME)';>)>Z548BX^&*1/A-]FO-DM-3Z
T:R*X.ZZ^7"5U=L8CL=G9E.78GQ'(:S@3"=G@!H/I92LGTYHU['(] MCKY"YKFKE%]!V%0WG=E_V+K.7_(O_BJ+
[YU^TF[]OV:L#M#Z^BJ+)7VJ65*>HZA\L53$Y{G(K%:BJO-M-7)G&,8Y\EQ)7A/A444%4YBRPQS*QX-MSV1ZMJ[=&KLR0YXE5&IVIA7(!'/FBXY*64?
3"T1)2N=6TIUH*N-/3I9*9'NX-MN|&]CL+A?"'^8WIP(B+\)QL;31SSI/+2PRS(N4D?&U7)RQVXSV-1]VPBN>ZN-M]BF5PJIR=O[?2UW2@W6HIX
MJCA\(FMZQB+A',C1R)GQ3DOP^\2$X/PY'#RQW-1MTS4R='C=J73%4]Z;)U') MUUMF>OHTLZ^CPJO--;Q:NUO-
/7Z0TSH^HJFW&F2)M^ZU4@B:J.%^211&N1,_3-ML%;:5O"8,IX0,*WL=_M1-MZPY?\V3_,132DN[=OOCXKO{" MR@1OCS'#SR!%/9[=_,/:RS3=?
<:ZYW^N7K;AL^Y/86M_D'F5*(.'GV@1.V0Z2FDMOMMK58;I%STY7O;A5YPB+DE7P^L!IOI$VJ*Q='&{6V)RNBHX*&G8J]JHRH@:BK-M\"&'[?|
2NT5IK0VGK160W5;JAH8::58Z9KFJYD:(N%X^:90DIPHJ8'#!*@:-MKTCTDM(ZTCO+Z%*V%EJHGU]0ZJB:Q$C;C...7GS,)Z-6CZ;6=OU'KG4ENI;C
M57VX/=-E7"R9K(VJ[/#Q(N$5SG-]Z-"17#ZQP]N5Y-81JK:/3.H=.7.VQV*U-MTDU73OBCJ8J.-CXG*GHN14;G*+A?@-?
=$S5D]7I&X:2N66733M2Z%8W^Z2)S-MEY?L7H]OJ3A-|X]93A]8%Q';H:TL-?M'?*:>-LD$UWFBD:[L!%3X454)-M$EO"F<]X$/-
L;+=;N]<1+0M^JKI+1+M^]55T>Y_P#RC&\/4\NS'&Y7>M)5)#8>-M\&/FC=KOV?\-&7!(@=]:CA^("/\-TEH:VP:GT+KB&@FKJ"QU3O/FPIES&*YC
MD5?!%X7)E>2+CQ.#NCOW9MP=O+[9M'0UEWKJ]%\M6Y:=T<=%3M3BE?(YW+W*
M*B8SE5QG/(D=P_"?"FHH*2)601,A8]IY6QM1J97M7"=X&C*5?]QV[]0G_A4X-MM%:ZB]=#EE)2025%0ZV*]L4;5YUFUAT;
M[Y8Z)\WLC9M.)%51R1*92)6Y:N>:.9;]]#/=D-/VS4.Q^E*6[6VDN=,D'6)# M64[96<7&_#L.14SA5YFT8J>.)9%8QK5>N7*U.U?%?%3Z*
(!CEKVYTK9JV*M-MH--6BAK8558ZBFH(HY&9147#D;E.2JG)31&E-1Q]"'7^I!J2"HI],7FJ6MM-M]UAA=)&U5SZ+N%%7*(J-
5$3**Q.2HN23AQZBDAJXG13Q,FC=VLD:CD7X%-BM-MN/N=#N9NCMI/9:>H?IJCOL$4=QFB6-M34+/$KD8CL*J-.B<\?3+V_O-TYN5NG>MLM?T+
[S-M0MFV_K(%C?6P4[GO@F7EAZYQVHG+"9:Y<95IJ7=:IT/NK5VFAVQMB56K)*QL
MBUUOHWTC(F(CLND>>%>+'TJ\^U%EU)"R9KFO:U[7)A6N3*'SI[&"D8K*-M>&.![KE6QL1J+\0&E-_M-7BDN&C]<6]DDNM7IN?
BJZ:%OIRPKA7.;CN3ACPKA>>&JN<&^%-M;DX[*&!E0Z=D,;)G)ATC6(CE3W^T",-YL6H&?E)?DJFVU=^=>&NJY&L:U$6,HIVO2VJZRWW;;BJMT/G-
PAN;Y:.!.V25KHE8U/?=@D4D:-M&SU^E5IKV!FC-MM,%QJ=52-
=%#9744B31U'8C7\L2224,'G"U"0QI/CAZW@3BQX9/MP:=D\E/&-^9F.&1S$5R8YIA>
[FS^X)OXE0AO*MH8;E25%)4,26GFC=%)&JJFZ2ODYH^G1&NC14[D#6]ZJAN(#K=0\[#W"JF5_/-<;T5OK")W¥S\-$:-JMW[%
MMMI^+1^X5#)8+S:5=&V2:D=*Y>-7*K7(K4<[OQG&%Y857-5[EPB)G"KA-Q5-#!6-1M1#'-U]HJ-D8CD-M3XSZMC:QB-;B-:WDB(G9X
:@Z36G)Z_0D.H:],^C_P"[0WFC?7ZQPKC&-M0-"[@.QTK=N57DGF$W\2H.HU2Y^R>]ETU9DG-MCQ-5?6C^653"R1Q_:!1S$]M_+;J\U'9ML:;S4-
_JY6HY\MN-M>V&"/,'*_C:WX5[$3*JO+!M;6ND9-8,;W33]2D+ZNJH$U8T:5;&DZ-16JB9Y-M-1Z-7&>[!E%+04]&U:5>"-!KEXE2-B-
15\>1]^'X0(L]%2:LUGK'LOMR9SL%-MFIK'3\7-43*_?]!V?T_K,HG7]T./1ZOJT>B>]PJC??4-MF3P^LP"N$,(WEL:+$Y6?@:B^\J&-[;X^:UW#YHO\
L>WOY_|Y+:.''USA_B2&]RWA-TJT@=-W/6.BK77V&/K[U8ZB.NIHL)F1$3TFM-M]?)KO7PX[3KJ;I04-RMC:2WV"\5&KI&<#+-
YJY.&;&.;U[&9YY5,X[D,VW?H-M-77#2?'HFO\.[Y3SLF:S$?]T,1'(Z++_11>;.Y_4]W:83+O9KNKMKZ*AVMO-M4-
^=$C&RU#52D9*O+B5[D3+4[<9]6>|#K^AHLTFC=2R5*+U[KP]9%_/]6Q7?-M?-
DZ*W:MVMM7ZET]24=5#56*589Y9D;P/5'N;Z,%5>\]H>N#A;#;;U.V6@8[;-M7R-FNE3.^MK%C7+4E>B(K47OPC43/J-C\"-7$0-^MVK?
J7"OCH&HZ:LF;S5N%5/114X4SR3TEYKC$ORU&\9R!'>P]*G;+3-KI[;.[?=*-M&AIV\$<$-&U$1/'^^95?%5YKWY7F95OGI&?=C:6GJ[$R1]=&Z&]4,?
N9'^@O-MH_IN\ZX3Q1$-OX0IP:&INEKIF+2_65<%8W54;.]?9/-GH]U0GH]U'8X417>-MO/=C/([OHUZ'N>D]&UE?>X>IO5\]W7"HCU#
[HSQ=D#0O2>C74=XV\TG$G'/<;MUSFISX6,1&N")(J_L5,_W%W>MVVUUT]0U]%5U3[U.Z"%]/P\,:HZ-N7<2IR^>)V9[%,?T;
MIZNU7NQ>=:WB@J**EH&+:[++35D3HWJQ%^>5'"J(J<2N=A53L$#']%Q.GT19(GM22-UN@:]KDRB_.FHJ*A'F5:CHM(JI*U)'[?:@?S:F
M7)2/I7K9G]DU>]6\I3(W'9V%$C1(^=+*HCK+'HB:%[989+Q&]DC%RU6]WDJ-M*G&#D(SQY_.7@08U=HNZ[8[K
MZ:TM++)/IQ+U#7VM[USALDK$XV5P^"X*X0"/FE^E!1V&E99MQ+;<+#J"F1&2O-M?3*^.;'+K$QS157P14[%15R=)KGJUG5L:Q'(O-M
G@G8O;E<8QVYDM4T%-7,X*F".H9V\,K$.GCX(F-C8G8UC41/B0#-M%DVVM;:._D*]+V-\Q\RZS"O[=614%+*Y+-M?>:>)9()
(U=Q8];G"Y>>%15153*X1,YRID6J-$_E>=%^[6%\W-MG,]/;G+--E51TCGHKL9^E15PGJ1#<]+0P44/54\,<$><\$;$:WXD/OP^OF!K-MGH|
(OY2^E4SC^Y5[?TC5&YEGK>C]N7#K^PTZ(;N"GCIX^")C8V)V-8U$3XD/L!%?;#>-VQ5[=H?7EIN%&^AGD\TK*>)'QR,<
MY7+C*IQ)Q*JHKF=-6NSPNXXJ"EBI6NQA7(QB-ROOXS\)H_IC+_-+:13_VLG\14)#E-MO#ZP+@-!'+I;5=9;[MMQ56Z'SFX0W-\M-
G;)*UT2L:GONP=S>^E5IKV!FCM-M,%QJ=52-=%#9744B31U'8C7\L<+4)#&D^.'K>!.+'AD#2NVVRM50='^X:3N3DI
M+K>FRU$R/7*0RN1J,1<>",8JX]9T6U>^ULVUTO#1#7T=7I^\V=JPLZVF>]L\-M65X%:K47.$Y9[%PF%7)
([A[\GPJ*&"K:B3PQS(U>)$D8CD1?'F!'W0:UN\.^-M#-PFT-10Z6L]*M);I*IO-ZJR&97.>K'(F<8XW)CMY-7&,XDFUB-;B)R1.6#YO@9*QS7-1S7(
MJ..Y,HJ+W*@$9]U=?Q=(1+=HK0D=1<*62J947"Z.IWQPPQM7"K'Q'(X0-.;ZV2XZ8W$TYN506U]YH+9"M+-M7.IJ/1.;.FT_(S2=*Z\:CJFK'1V]+<_B;
(O8KLMPJ)VX;JYQCEVF_NKYYS@^-M$%OIH)G31P1,F?[J1K$1SO?5-7;DT3?]P]BZBS7F.CI=254"3=32MZJ)DS9-M.-C.U<+A&L5])"P:6T?
26/5S*VSZBM$+:.,2B=2J/?-U>&-5N$5$5-M41ONL<\]W,D+P<\G'6AIY)V3/@C?.SW.CF(KD]Y5Y@1RZ.]VN%\WKW"N-THI-M+=654.,WFDR8?
$QSD6-KD\>#A^(DN6\)\Q"1'.,!$-P75NT.F=1Z:NMLBL5LHYZJ-MGDCCJ8;.-CXGJGH.14;GDN%^#!KCHRWU^]-N+[H>ZODI[A9UEH'X7$C(9$Z>?
1^O;5<'TL,[W45VIF];'(QRYP-MG$J9;VNY*JIG"HG:-MJ(B+S54P25DIV3-5DC6O9]2Y,H?.DH*:B9PTT$=.SZF)B-1?B-TWJS25LU11VI6RR-
YMZQ7<3L>1"}(QWC)NCORV7THB\QE7^.X\+P_"HX40-M"X^%5GS:;E](\!RF$-T3T-%X=HY_7.;^)&7;^.V.[6/56EMQK-0R7)UB>Z
M*OIH4R]U.N"-=(BKSQQHO8BXWGPE.!/[(\'?<3I$V37.CZC3FB8ZV];@-MO<2T:4K:9['0-->F']7)A?154]%53GG*(F3N=7;)5%1T=:71U(C)[Q;H65,2
M-PC7U*.5\B-S]5QR(B^M#<|/04\$TDL4,<^]=O=\1R>'U@:"L-M?2MT];=)-CU!#74>]J.);BTNIGH^69]8Y.QPHCE3O5%3/8IW71OTC=+9:K]
MJ:^4ZT=VU-7.KGT[DP^.-5N/!4^#;+Z(;K]/+]]4-B[QZ)EW!VXO-MECIG(VKGB1].KNQ9&/.]J>K*MX<^"J9MPCA-CYM]TC]/Z4TI26+6JU>G]0VB
M%M)-3S4DCEDX$1K7-PB]K>'MQS]2IF_9VBN6XF[5ZW,K+?/;;_^G\SM454WA-M?(WDBOQX<+5Y[F7X15PIO>>@IZM6+-#',K%RWK&
([A[N6>PY/#ZP-"[3_1(;-MH_I(?_"-^N>\NSV/KA(O^7#__*#??"4X4-U5TI%SL7J.U^;_$(R_;!W^UOI-M/]2.3^1:9,K;(D>7!N,_"<*8;B)SS-3@'"!K/;?I
M:7W/OLEHLS+@RJC@=4+YU"UC>%KFM5,HY>>7)R-:;/U1#T;M9ZET_J:"HI=,_MW2M=7VNZ10NDB3*(BM7A1554;P-5$1516]F%122_#SR?
*>FBJH7131LFCW5M7%)YC+.UK)$DCD5%14R]E6*F-M>[.38F$+49V9Y]X&@M#])NR6?3,-OUU-6VC5%O8D%5!4TN%Y&]-M9[92U4S)IJ>*65G-
DCXTM0+B+6\FL:#0'2BTQ?[HV9U#-M26E>L2G8CY/2;4L3"*J=[D)2EO#ZP-#OZ8VB9(GI24-YK)*C(64S/27P]WR-M/GT<]*7N?
4FKM>WVVOM$U[E_N:BD16R)&KE>JJBHG+W"(J\UX57DBHJ[\X2G-M#SSGF!H/HN-^LVY'5N1LGLY(B*%2+EQKS9?4VBMOI=14^Y-
*E/K!M?)))57-M*C?4O>U43*-=PN1%5_&N?IN).:\L2_X44X\U!3SRLED@BDD8N6O>Q%5OO*O8-M!%+5>NWZQWKV[OL-
KJK7I2.L;1T%;51]5YR[C3B>B?2L]-J)[V?%$R?=>[2;-M7;]V37-?15$^G:B@\QGG@8KNI?Z:*B]W9P.QGFB.QG!(Y8T4LDA;*U6O1'L5-M,*UR910(J=
(;>&AW-V_JJ+2E-57"V4DT51<;G)"Z&*'TD8R)$>B*Y[G/1>2<-MD;W\|25TS-RITC;H96(^-]+#$Q[')R5%C1%14.S@IHZ6%(H6-BB;R:QC41$3P
M1$/LUJ-1$3D@$,;3I"XS[C4VST\;I+!;K[+=GN>J^E2]6US&^\K#14FX&V]\L,#FQU-1$CH%=V=8QZ/8GJRK43/K,TX?@YY'#ZP(Y[<[\:6TII
MFET]KFCET_J&T0MI9HJB@DDZU&)AKT5K7C&IQ8R2:FZNI]'>BBN1V<<.$X.)HXK_;ZJ@O-_JT-4VICC!3U^IJP8JFYQ*GY#[2MJ9E>
M3973/1OP\"R-^!"6A;P<\]X&+[D:)1]P=%76P5#^J2LCQ'-C^]RQ.8[X'(G-MOIE.\TIM_O9-M#:(-
&;C6VNMM3;V112W*.%9(9X6\F\^]$3#45NXN\LV]5OET5MW;JNX+7JUE;C2[-%=%NXV..=TZ4-/21.G=],(SF)7.Y)F555-M]1N^GI8J6)
(X8F0QM[&1M1J)[R(?7AS\)P(U[?\.2NT5IK0VGK160W5;JAH8-M::58Z9KFJYD:(N%X^:90X.LM4Z@Z3<@<2S6N"QVFBMU*W@!:.%E/"WP8QJ-
:GQ(8-MCOK_((-7_J?)^-SPPW=ZU5E\VRU-;Z"G=55M3121Q0Q\W/KIJ?BI974LDC*R!7+U;HU:U>?TO/EZ/;SP=SLW0U^X6ZU_W-M-
JJ":W6F;#S*U15*<,DC/119,>|WM[,O5$5>%386T.G)K9M7IJV7>A2*KIJ9-MJ24J0Q%6-R*]\]?IEYF=HWL3P-T+M-RZ2&Z7K;#_X3F])'1MVNE-
IO5=CI5N-_MQTU5^^5)43#DC>C5X>><>DU4[\'UZ/FW=PJ=K-76^OIZB-MU6C4$DR6ZFJ4XI887Q<"2<^?-%;C.,\&>Q45=^K;J9U1UZP1+-
_UG5IQ?'VG-M)X-(Q;5[G6G;"TKHC<6B=9[^VR2>;5LE*Z;*HB<]7(J*U%5>;JB*B8QA.U,&-M9;
W)N&Y6X\DFFK33PZ#HX\2W.JHU9)4S8=_>G93'/AY87"-55QQ(AN2HHH:-MR/@GB9,S.>&1B.3W*?1L;6-1K41K6\D1J8QX(@&B)E_W8D'ZA?
ZQVO2W_P+-MW!._SJG_)1#*H?.R&-LSTPZ1K$1SDRJX5>_M7XSD=7ZP(R:HUA0{3])ZI;@-MO\-$+;
[E:61030PJ_C=PQ(N/'"QJBX\4.YFF94=,&VRQKQ.?8^-J^**Q^/PF-M_9*9DJ8>ULCW=`C=54M\JC\B6I:CSR"Y0PJ]D.
MRN<]6.1,XQQN3';R:N.9QQMU=?Q=(1+=HK0D=1<*62J947"Z.IWQPQM7"E%2QV^T;?4L**D4-YAC8BJ-:W"?>0WCJ'G8;DGC32?Q5.QX1CE
MCN-TGT0O\#E-_P!\G_C(==O;"NJ-[JK-/P)Q24M1)[<:BW#OE%/;ZFN7S&V4-7&K);:C8N.)S5YM<]6HN,<
MN?;Q<@R+5V[UMTAKG3^EJFCJI:R\JU(9HN'JV<3^!.+*Y[?49Z8CJ31\^IM4-M:U^X>@%@M+>.\6Z
MI974L>419%:CFN9E>S*.7'BJ(=!;>E%;YK9#1RZ?O3M8\",=9(Z1W$Z;LY+W-M-
5>>53..XS_=:UZGN>D:END;@MOOT+VRPJBM1)D3*+&JN3"915QGEE$[.TP'-M\N_77L:M$FUEZ2_]5P=8J+YIUO9QD!B_1BEKJBP;G3W%F*Z
M6KD6H1.:))PR<;93EVJO9DR_HA?X&Z;_+Y/_&.ZV!VWN&W>DJKV;D9)?+I5-MNKJU685&.$"+6MZJT:7Z2E===Q:%U5IVHH6,M
M4]13K44T;D:Q%[!$?.'=:F,*]*Y'8YHJE)%>I;*>@H:JTO6WLJ6\+WTZ91LBI^>5'.3U*2;EH:>H5BRPQRK&-MN6<;$7A7U>!]^#U\P([ZVFK-F-*G7_&
MQVV[HZ:ET=H"'*KO]WNRMCD='3/C93Q<2*]7*]$[?]6IV\U:Y3'MN]U9]0[*NH-#1K/JO3ULI62TM73JK9.%$-M:[@PJ<2JUCU3OSCES)!\//)\XZ:.)SG-
8UKG+Q.5$QE?%0(2;\;6ZQTS$S7-M-!&E\CBZNHMJ5;'OE25$PY(WHU>'GG'I-5.,!W712TQ<[!I&\5-723VZV7'Q
M6IMM%4_WQD*M3#E[_23A3GV\&>Q45=T+;J9U1UZP1+-_UG5IQ?'VG)X$-N-!-M=%=4\YW%_5V1?ON4WZ4X0-
;ZV2XZ8W$TYN506U]YH+9"M+7.IJ/1.;.FT_(S2=*Z\:CJFK'1V]+<_B;(O8KLMPJ)VX;JYQ-MCEVF_NKYYS@^$%OIH)G31P1,F?[J1K$1SO?5
-4ZR2\KT<;X_4,%+37F6V2R-M5$-'"U<<;GV.IK?;Z=]565-%)'%#'I]E3DB'$VATY-M;-J]-6R[T*15=-3-22GJ&(JQN157FGWLR]415X5+NBNJ>
<[B_J[(OWW*;[1O8G@5X0-;ZV2XZ8-MW$TYN506U]YH+9"M+7.IJ/1.;.FT_(S2=*Z-M\:CJFK'1V]+<_B;
(O8KLMPJ)VX;JYQCEVF_NKYYS@^$%OIH)G31P1,F?[J1K-M$1SO?5-->U%3KNW;.+6T]);TU!3^<.HX8%ZI/21SHVMXO=HSEVKER>LU])O
MQM;K'3,3-^5)43#DC>C5X>><>DU4[\$BECSWX..MNIG5-M'7K!$LW_-%G5IQ?'V@;"Z/FW=PJ=K-76^OIZBU6C4$DR6ZFJ4XI887Q<"2<^-M?-
%;C.,\&>Q45>HVKW.M.T%I71&XM$ZS5]MDD\VK9*5TT51$YZN145]*J\U5-M5QC"=J8).\!*BBAK(^">)DS,YX9&(Y/?PH&F]-DW#2335IIX=!T<
M>);G54:LDJ9L._O3LICGP\L+A&JJXXD0X$R_[L2#]0O]8WNV-K&HUJ(UK>2(-MU,8\$0^F$
TSTM_\"]P3O\ZI_P"40Z#I)6NINO1[L[Z:"2=*1U'42]6U7<+._MI5E1'P.;]&(JICPY_>4[
MO5MA9JC3%WLTC^K9<*26E63&>#C8K>)$\4SGX#M(J>.%]I&QK$SE4:F.?B?4
M"-.U.\E#M!8$T/K^.IL=PM3WMIYG4[YZB%7*YJM5J*J\U5,XPJ8Y]N.1IJJ-MJM\|\+9JZCH:FFT?IZ%[*>JJ6<'GY3].Y%]2,3.%7"2%GHX:MG!40QSL
M149[(XFQM1K$PUJ(B-3DB)Z@(Q:CZJJ=&]*&"]04$]QI*6T-=-M714J<4B4ZHY'O:G?P\378[\=W:=ANGO3:MV=,R:.T%%57R[7A61R/2G?%'31
MHYKG*]7(GAC/9V\^S,C^#UGR@I(8%>L43(ED=Q.X&HG$OBN.T#5FM6ZHVIVE-MM$.D((;K4V9D$-5')"KGRPM9PO>QJ+R7B1%
[^2KX&!:VWDV>U[I:IEK;>E=?-M9H%;#2>Q[TK6RJF&M;.UN$7B5.?$26X?6<>.@IHZAT[*>)L[O=2M8B.7WU[0-M(R)LSJB\=&2@M%1')'?
J&L=:.AD_OB,R_$2^#E1[G(GBJ-7"]F46+I-Z#98-MD74-/):+]3LX:]VNMSU%$S]4K<=^#??#V''EM]/43LFD@B?,SW
M,CF(KF^\O[FBFZ_V\OEDX46IE@5],OA,WTH_O-MHB?"II#HVNN&Y>N7ZLO$3L:%6O=[^.L54Q_RB$H^$MX/'\&
MD^DCHV[72FTWJNQTJW&XZ:J_.74+6*Y9XE5;AEF=0N29TF.3./AX$3/+.?@[C?&%\?O'P\PIO.?..HB\XQCK>-M!./'AGM-TJ_2NJ]TJA;I1ZCH*.V7ZOQ-

2TT,/4<",5KHTD157#G*U4YXPCDS MCF=7M[TD+!J;1|)8]7.K;/]*T0MHY*)U)(]\W5X8U6X141516&^ZQSSWO<*XW2BDMU950PS>:3)A\3'
M.18VN3QX.'XB2Y;PEP$=]=_1B;#3/_-+N_'=6$A\(4X?67 ?"1[(&.D>Y&L: MF7.5<(F.]2..R%II-WMQM;;]NU%%7VUTR4%OBJXD?'PICGPJF,HQL?
[HD/A M"M10.9J-M-*5-/-"_3EJ1DC%8O!11M7"HJ+A4;G/-31O1Z=)9[AKK:6ZU$D;
MX'3.I)&KA_5N3@>Y]RJCF/3].Y231;PIN%P!%50.ZUQZ/=//H_7MJN#Z6&= MIJ*[4S>MCD8Y';.?/USF_B1EV_MCNUCU M5I;
<:S4,ER=8GNBKZ:%,O=3KG*HG@C72(J\\<:+V(N-Y\)3@3^R 1WW$Z1-D
MUSH^HTYHF.MO6H+W$M&F*VF>QT#7IAZO5R87T55/154YYRB)DSNFVC6/8;\@ M;WL\Y=;G1+)}(E2JK)Q>]UBY BT!!3P322Q0QQR2+ESV,1%=
[ZIV]WQ'*QZP M(Y;:=(&T;>:2@TMKF.LL=^L4;3VZGJ$Q)YNU&IQ+ZE2./'CA5[,*N{)[?357"LT$Y;6*VU0RS015L4 ME?#3HJN=
UKNU.IJ.X5[.6$=V(IU]@WOVNT]9J;++1]H6JO#XN"GM-!;G,J7O M1N.%[^#"KXNRY5YKS_.=7G.5Y+W"I:"GHU>Z&&.%SUR[IV(WBQR3..W"83X M
(I]$:6KIZ[7]#=(UIKQ'<&2U-*]IECUZQ'=_/TD7LY=AUV@M;6_:W?K<"W7 M^*JI9;_<85HGI"JM?QRR*U<^"];G/LY*2>X3Y/IHY5:YS&NW4U*]
[X;>&)SE|)T<:-5W+'->\#&MJK+:? MMEX=Q7*FI(XILJBJU43DS*=JM3"9[\9,IJ*>.JADAE8DD4C5:]CDRCFKR5%^ M ^G!W(N$QC"%X$.]I;)<)-
Y+7H6K:ME1M=<:^O8|5]TQ>!(U7[GP_5$RJ.5%RJ.%0YUE3GYUK4;GWD-?Q6NIO70VCI*2"2HJ/8YKVQ1M57.X*CB7"=_
M)JDB>$<($:K/N99=7]&F^66@?,EPLNGXX:J.:/AYHS@RU>],L7GZT-J='_| MP.:3S_ZFB?Y3C/8Z>..
SW.8UCGKQ.5J85R^*^)]>$#0FV:_[J#@V6)%U#3R6B_4[.&JMKK<]7+*U..1BHWA1,_5*W'?@Y^B[QKC7.W6 ML[E):*>Q25M/.RPTT4*PU.%8_A<]
<[JY8B+A.:9QC!N26WT]1.R:2")\S/7/*\O2.J.[4'2EMEYN%KJK)1W2@ECML58WA?+"UCT:Y4[EK3.5YJ!'O73JK9[?"3<*: MCGK-
+WBC;17">F9Q+1N3@:CG)[\4:Y7Q MMK_,G)#1Q[I7]:SWN?"J(F>><(N_P#@1>WGRP<>EH8*-KD@ACA1555;&Q&Y MRN>>/6JK|
(&A]V4BY(M=<I&2RK-(U9$?+PX5RY3GA.S)LO>MW^U'K#E_S9/\ MQ%,UX?PA5^A,/#771WY;+Z41>?]RK_'<;'+>%$+@-M
%O%SQCX2XU3OSNG4[<6"DI[3 E9J.\ M3>:T$3DXD1R817X[U17-1$[.)R>\!M3B]0:[.#05LZ,":AI4K]**U!)E6)53M8K\ M=JHB\U--
;M:KBNVZ&T.]CN[*NWU-?*CW4-4CXY422!%1>%<+C*]H$@P<;>]C MI()99I&Q0QM5]Y'N1&M1$RJJ\D1#&[;NIHZ\7%M!1:GM-56/ M\5XC&[_-
;]2:'NBP7F"GMU;0S,]EH)6NCA8YCFK*CT7APU.>()LK+FM9G#TY]Z>CK+<'4-?]>TT=6QW"^&:LC:L.^#N?HK[^ , ML!QX*J*K@CG@D9-#
(U';DCH<7]{L[M:DL>Y>\UFT[M<-84U/HJ&A=-//1W")D+IL/RUTF5;O+AB8=G"9QCB4WWI2@L.WEAJ."FN;66
M*FC65EPK]IJM+DOA@#+08O8=R=*ZHK/-+3J&VW&KYJE/3U+ M'2.1.;JC@HHL=9454K8HV95&IESE1$RJHG/O7 M'8
QE^X^EH[Q!:GZBMC;C.C%CIO.V*]W%A6\L_3(J8\<|C)@+>++N[5'$1ZW. MNM]W$WEI-
NK=>ZC3UIAI?.ZV>D56S3KA'<*+GFB(K41.SW2KG"8^URZ)U'0T M\U9IO5>H+?26Y?%55%6CFN>G-./@:UW->647EVX4#?\ Q#B[>\UGL'JO4>I]
M$K^2J@JJ.\T4[J5\M5 L2U#41%;(B*B(]\U153MX<]YB_1\N%96;A[NQU%5- M/'#>U;$V217-
8WKJCT6Y[$PB=G@!O8'23:OL=/=?VF6]6^.ZM;QK0NJXTG1O M#Q*JLSQ8X>><=G.Y%DU!;-14:U=IN-+2)WH<2OUOIZUS5T-;
M?;;2S4+&OJHYJN-KX&NQPJ]JKEJ+Q-QGMR@'>\1<:GW*ETWN?HJAEI=>TEBM M\=Q8Y+E3UC&MDD2-
Z=0J\;>:H[BQG/HHN%,YO6N_.:;J&TUXOULM4[V]8V*M MK(X7N:E4XD1SD7&45,.^**|WY;Q&)INWH?[_]/^O_&4@_P!8Z'=RU6K6FCK6
MLVL8=,4#ZV*I@N<=2UK*C,;\1M=QM1R.1RN3"KE&YY@;,!U-\U-:--4T<]XN MM%:H9\#)*ZI9"USO!%K8US>6?2ROH\O' &5
ZFEU':*VY.ML%UHJBXMB2=]'%4,=,D:XP M_@1<*\3>>,+E/$XU?K?3UKFKH:V^VVEFH6-?51S5<;7P-=CA5[57+47B;C/ M;E
,_!TECU;9M26[]PM55I+A0L56OJ*>9KF-5$RJ.5%*B<\++W*=++O+H6*L M;2OU=9DE5<'%54SMCB7B
M[/2543GW>)RX*F.KIXYX'MFAE:CV2,.IWIXG: 6\7;WCB-&='NXU=9N'N]' M45NJ$X6HO8G).2>!E^VNGJ"S:IUK44>JVZAFK:_K9Z%L
MS7K;7=9*O5*B/56\W*F%1/<=@&Q@8S+N-I6&TI='ZDM*6USUB;5-K8UC<].U
MK7({"KV@&3@^,DS88W/>Y&,:BJYSE1$1$[\F)PIOZ(fK?,F:LL[JCB1J M-\|CPYRJ](U%SA5RG8@&9 L1Z*B*G-%YEX &*5.Z.CZ*WP5\VI[2E).]8XIV
MUL;F2.3'$C51>>,IGPRF3N)-06V"T^RDE?2Q6S@27SV2=B0JQ414=QYX<+E.
M>>\#LP8Q8MR=+:GKEHK3&VW"LYJE/3U3'2.1$RJHW.53'>AVEWO]NT_%'/<-M[A2VZ&61(625<[8FND7*HQ%R3L2%6*B
M*CN//#AJ8Z1R(F55&YRJ8[T,AD-MF;#&Y[W(QC457.'.551&HN<*-MN4[$,OZSOPN -+P8G<]T]'66X.H:_4]IHZMCN%\,U9&U8U\'<_17W\&205457
M!'/(R:&1J.9)&Y'-HJY'5D:-IY M,JG]<^B[**F%YY0HS76G]6+,EEO=!=\1)F1E+4,>YB9QE6HN43UJ!WJ29+
MS1O2$W3ETA5:9MEKOE/0U%1^6[4%&E M9:JZFN5&Y5:E11S-EC547"HCFJJ90#L0<.LKH+=23555-'34L+%DEGF>C&1M M1.JYSEY(B)G*J=%
<=R)VBA[RKU):XJ6[.QP2K5L5)FYQO.POD]E%YIRY 0 M2#I$UA8_8-MZ6\4"6=R92X.J6-@QV>[5<=O+M+-.ZWL&KFRK9;O1W3JL=8E+
M.U[F9[.)$7* =[PE&MX<\\G6WK4-LTY1.K+K<*6VTC5QUU5,V-N?#+E3GZN\ MX.F]?:J=S41?27U)S RWB+C1_1" MKZJX[53S5=3-53)
[Y06M[TXF.JJAL;W- M\4:JY5/6!D!:CL^^=;9-16S4=$E9;;C2W.DLT]HZX M5:-[$7FOQJ!O4 ^3I48BJ[#6IS557"(G
MB|]08>S=K1DEP\QCU79WU7%PI&E='S=G'"BYP]YY8SG/(R[C]2@7 Q.Z[):/
ML5P=07#4UKHZUKN%\$U6QKF+^>3/H_#@[2355FBLOLPZZT+;1PH_V0=4L2GX M57"+UF>'&51.WO [3K4[<YKK*VDHG3QMD6
M!L3%1(HD7*M3#URB=SE\3+M*Z?H*3=/5%TAU6VY5M5$QLMC29KEH41&2*O.A%@8O:-RM*Z@N3K=;-0VVOK
MDSBGIZICWNPF55J(OI8]63(*BIBI('S32-BB8F72/ZNI=);.N5UDN%1O2FD6DEJ96M9)-U;
MG,:F5|)5X>2)V@9*V3B3..1>:DZ.FX3=9Z!H$N5]I[EJ5RU$U53K/&M0UO7N M1%6-%RUJ(K$3DB85/$S_
%%K*R;2@9+>KM1VMC\\'G4S6*_':C452X[E.;<+E36FCEJZRHBI*6).* M2>>1&,8GBKEY(@'*XAQ&J-R-R-/ZDVLUPZ6/=O14MP|
MQ9JNSOJ>)&\"5L?-RKA$1BK-37Z"DZROG;'+<*I$<_",Y-XERN,]B=F0)!@ZFRZBMFHZ)*RTW"E MN=(J\/7TDK9&93M3*+VIX=W>?
6]7VVV"E6]NEPI,;39QUU7.V)F??6?%<&9OEAKK>]\4I.HFB56U#'(K>%4]TB]BICGD#F<0XC66V\CHM-;87 M"FMVJ4U;
B5$J7)DR2Y.6/'O,+V(5VHNCE<(;G?)+N ,J!PK=F6-J9VM<[WFYRO9W(!D(.FL&K;+ MJF%\UFNU'=8V*B/=1SME1BKW+PJN%J|
[D"SK.2J]8OXE>+UI,.'TGHFQ5TFEKRZ]4- M2]%FK'UD=2WB8BY3B8B-3W2]OO@;)+$C\5R8E'NWHJ6X>8LU79WU/$C>!*V/ MFY5PB(N<*N>
[,>:&4R5#(8W22/:QC4XG.V6&1J/9(Q MR*US53**BIVHH'VXO47$<^E=YU/?-NK;!<*J@CN%?+32R4LKHW<+G0-SR7FJ
M<2XR=JO11H>%436^J$7_ +VW_5 WKQ>HN(X[:C45MKH%FH M*RJ572QHC'/3FJJN%1CVJBJJ9:BICL) 7>[4]DM5;
<;Q_5TM)^^>5W@QK5J+G5TLI.]ZK#3QJ]&L7'\;_:LZNLU7]"OL>FM.S)2^8VZ7]Y)W(YS>)<\ERK' MKE47'"B)VY/MJOHZUFWEDJ]0;?
ZEOE/=J%CJA:269)&U*-YN:C6M3+E3*X5'-M(J\L)V@21SZBG$83I/4ERU1M5#=[G0S6NZ34.JST\L;HG,D:CFJO"O-$56\2 M>14,'Z(5?
57+:F:6KJ9JJ7V1F:QS/5JL<$?+*^^H&\"WB]1<:NW8WFCT!54M-MEMULJK]JFX1]926ZF8JIPJJM1{U3NRUW),KR[NT#9I7(N?5R'%ZB.W15NM[O
M6HMR)=13OFN[*V!E0U[LI'(U9DN+_)K6%G7)4R-MU>89I4Y\"MQG"\TRKE[5RBIR,[V:W/;K_;*'4%>YD552I)%<.!,-9)&G$Y43
MNRU6NQW9P!L7BYHF!Q>HC3H;2UUZ1C;AJO4E_NULLCJT-KM=KG2%K&-Y<;L MHN51>_&2]RJLK?2[D:OB!NOB'$;'7HCV2HA2;JU7J2-MHNR-
_P!_+5,Y.QVHBL543//'%GUG-V1KM9V#5>H=$ZH=67>BMJ)-07R>)_#(MQ53T%D=GB56N143*JBM>F51$P&[.
(J:*N5PJF]++;U4:54R4CK&YRTZ2+U:N^_M>>EP]F?6;*"UNG7$25M2R%9%14SP\2IGM3L\4 [D'5T.I+5 MZ9U%:[?
J^WPJRED945=+5L2]BKV*'*N5Z.X4 M5]*B\U3M[CD[;6^GL^B;314MX34-/#%PLN;7H])TXE]+B151?#DJ](@&4@MXN MWO0Q:X[GZ1M-U=;*
[4MJI*]%X7035D;7-7M1%RO)5\% RGB]1<:(VKN555](-M7H#M2U&HG9^_Z'3FNM/;O1ZV6]4-T6-,O92U#7N8GBYJ+E$]]#G7*_M_6ZR+
VXW"EH5J9$A@2JG;'UKU[&MXE3B8Q#KS35YKZRR4F MH;=+=&,>V2GBJF.E9A%XEPB\U;AGLQ55_ML:1]8[*I5QJ]SAV-
FOUNU!1)66NOIKC2.7"3TDS96*O>F6JJ9 [(MXL=IUUYU!;M.T# MZV[5U;J-JX6>JE;&SGV)E5[32_2%W M5_V8NE5IF_T]8Z&IIT?);ZI'/CS)
MC#N%WM WSQ9I.97B.ITHYTFF+0Y[E>YU'"]N=VJO WF1<13Z/FE]-ZQFI-8;@U M9+6ZR6JDJUH77"_JM;QRKQ.BQQJWEQ>"
(B8Q@D!6;HZ0M]'25<^IK3'2UCG-_MIYDK8W,EX5PY6JCN;(O)53L7M RP'65>H+;;K4ESJKA34]N5J(\ /)IFMAX5 MYH[C5<87NY]Z'6:?
W&TOJFJ6EL]_MUQJN:]13U+'283M7ASG">\!DP.ONU\M M]@HGUESKJ:W4C51'5%7,V*_%7L17.5$.FO.Y>D]/53*;YZCME#4OPJ1353&N
MPJ9153/)%3"Y7ES0#*0=%>M:6'3MOAKKG>*&AI)DXHIZAC&R\L^AE?2Y*B\ ML\C[V34MKU+1>=VFX4MRI>)6=;2S-
D:CD[E5%Y+ZNT#LT9COY^M"O%ZBXC_K M:Y5Q7=B*]}A,<+>2Y5PB-Y^DJKW(!EW$4;)Q)G'(QO7^J:,2&DKI7S9]5*UC7S
M)&Y6.3B5,N54[$YK@PCH[(CQZNV\HI+KJ"EK]0_W345D3IX^NCC2=R(YS$QP ML1JLQR1$14 V\6\7=WF*UFZ.D+?1TE7/J:TQTM8YS:>9*V-S)>%
<.5JH[FB+ MR54[%[3HG6BUUV[]OOT.KXUJ76WABL,=0U4GC5'*DZ-X\N3TNU&JG+M V2#J MEU-
:&WM+,MTHDN[F=8EO\Y0YPK<9XNKSQ8QWX,U ^:Y551.W*X1 -R Q"LW9T7;K@^@JM56>"K:JM?%) M6QHK%1<*CN?)?4IDT-
3'4QLDBU$YGV6.5\S8_.7<*_.O2 M>W.<]B9[.PS.Z7VVV1(5N-PI:#SB1(8?.IFQ)8]>QK>)4RJ^" =D#%;ENAI" MSW-
;=6ZGM5+6M%T$U9&US5[41U=RJJOI"[E M0/JI9J6..%8HW2JYC<\/-$[.Q>X#>X.LH]16NON5704MRHZFOI,><4L,{'RP MY[,-
J+EOPB[ZBM=A2G6YW.DMWG$B10^=SLBZOZ]C6\2IQ+ZDY@=F#Y/F,%&Y MIU1K6IE55>Q/%3$X-W-%U-
Q6@BU3;7U:N1B1I6,YN7DC47.%7/:*Z]6B M+(VEJ&OO8UO$O-5\$ MYG2U>Z.D+?=76RHU/:8*]K^K=
^1C1S79QPNY\G9Y87GZ@,KR@XC@W&7BME4 MYXCDPL+U:Y% .\E0T9T:]=4%CV<97ZEOL-(BW"9C)KC5(BOPC5X6JY?2[>]WP M) <)
<=38=3VG5%(M39[E272!%PKZ29LB-7P7"\EQW*?6[WVVZ?I/.KI7TMNI ML\/75*N7DB>^!S 8G9MU-':@KFT5NU-;ZRK>[@
M9!"5L5[W8[&IGTO@R94CL]@%P,2K]UM&VRX24-9JFT4U6QW"'^.6MC:K'(N%1 MV5]%?4IDL%0RH8R6)Z2Q2(CFO8J*CD7FBHO>F/
#D%BR>K)>;>WPU%/=[G8-_MN;74.AK=1RXK98O=P4+"N1KTY]S7)W@;?5V.T<1J+>_6-1M7H"W6O2|
M3(+E72QVNVQM3*0MX<9:G>J(B(F>]R+S[#&ZSHX7BVV)]VMFN+])K6%G7)4R M5689I4YJQ6XSA>:95R]JY14Y 2"RA4U[L=N,_@+A>V,9-
5MX8:6.3.'3.7"93O1$RI'?P]W:.;LW1^N^_MK+-'=|5ZVU_S4M6SSA/-*E&0T:W)E&HQ$OZ/YU6IX>(&_./U%YK+9*764>GJ
MJVZVAD6NH:ET%/72*U?.X]S6,.F7.DWM3O3Q [8'5U^HK7:ZRCI:VXTE'4UC^KI MH)YV.?.[ER8U5RY?23L\4\2V^:GM.F*-*J[W*DM=.JX;)63-
B15\$XE3*^1 M.V!T&F];Z?U>R1;)>:&Z+&F7MI9VR.8BKA%P#Z M%O$8E!NSHNHN*T$6J[/)5*J-;$VMC]RKA&M7BPJY[DYG#WLJ9;;;;5IF=+
(ZB1SY97JY5YKE55?PF56 M/4]HU+%+):+K0W2.)W![ZAJ63(QW@JM5<+ZE [<&)W3=;1UEN#J"OU/:Z2L:
MO"^&6K8BL7\]S]'X<&04%PIKE115=)40U=+,U'1SP/1[*M7L5')R5/>_Y2.] M1<:2H*W\JW>^2PU@CJVE:O)M/7-1$D:WU/PU51/IG-Q@W:
.NO%]MVG MJ%U9=:^FMM&U4:ZHK)FO1HJKR17.5$ [$&+7K7-#F7K6MATW11UMUO%#;Z69,Q2U%0UB2)A%]*^ER5%Y>
M(`>@ZNR:CMFI*)*RTW&FN5*J]*34LK9&Y\,IV*?,_:GM&F*1*F\7.CM=.J\+ M9*R=L35=VX3B5,KCN3F!W .@TYK?3^KD>MDO-
%=5C1'/;23M>YB*N$5S47*=_MG>AV\U7'30OEF>V*)C5<^1[D1K6IVJ]B ?9'8[>0XL]A@M?N9I;_P!IO%%:_M-
26VNKVTDW!%2U;'2*J1N7+41>>/%#&.BI75%?L]0354\M3,ZIJ$629ZO=R> MO>JY W&#%KUN;I/3E?YA<]26N@KWEE.)NN#O;?<::YT<-5
M15$572S-1\<\$B/8!]BM2(AC=MW4?>+BV M@HM3VFJK'N1C(8JV-RR.SCA;A?27U)D#+06\7@AB%9NJHJW7"2@JM5VB"KC7
MA?')6,;P*G:BJJX1?4J@9AQ%.+EGN,>U3JJ@T_I6KNTERHZ:#J'/IZB>9C8I M'JQ58C55<.SCDB=O<:^Z.&Y2:UT;"EWOU-7ZFDGGDDI73QI4-
C1^$5(D7*-1 M,=B8Y@;BXBXUSMKIZ@LVJ=:U%'JMNH9JVOZV>A;,UZVUW62KU2HCU5O-RIA4
M3W'8=_/N112EM/L1+J6U);7/=&VJ.6QN8YR=K6JB\W)X)E0.G!T5LUI8KU:)
M;K0WBAJK;%GK:J.H8L<>RO[.&X3MR?"P[A::U35R4MGOUON52Q%5T5+4L> MY$3M7"+E4]. 9(#BUE?3T%))554\=-3QIQ/FF>C6-
3Q5R\D3UF*T^\6AZJN2 MCAU7:)*AR\+6MKG8#IY06MIFXJJAL\W-\4:JY5/6%2.9LK,^'$U53/J]8':%O$<&[7JAL5!)6W.K@M]"S?/52MC
M8WWU5<&F]^=PK-J#9;4<^F]04M,/ ZGXG6^J19(T6HC3.&KE,_^*\N8&|||LE M3'= 2/ET+IR21[GO?;J9SG.7*JJQ-
5553MJRN@MU)-554T=-2PL626>9Z,9& MU$RKG.7DB(F$QBY;E:3M%)2U59J2U0T]6C%3R.K(\3-SCB9S|)$7O M3DF%.ZM-ZH;
[0QUMMK(+A1R>XJ*:5LC'>\J+/@#FM9AN"XQFMW%TM;8;R:JU% M:X8J.9::H5:R/YU,F+..6%SX8Y@=H6\1B=LW6T==ZYM%0:GM-55OR5W2D?

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}3);74]7"1DT,C4=VFX4MRI>+AZZDG;*Q'=Z*K5 M7GZ@.T.GK]56:UURT=9=Z&DK$@6I\VFJ6,DZE,YDX55%X4X7>EV.4(J:1M>G=[-Q=55FK]6N;(RY>:V:C@N$<*2QJY[6]4U<|M28X43A[>)57*J|+Q'(I<;)T;75,G2PUW1NJ9G4D-JA='3K(O5M58Z7FC>Q.U M?C4V[?\ 5UETK3-GO-UH[7$_*,?5SMC1ZIVHWB5,K[P'<@Z33NK[+JR&2:S7 M6CND<:HCUI9VR*S/8CD3FU>78IV=15Q4E)//(V"&-%<^21R-:U${U5>X#D%MB29,4M6ZVC[W<6V^WZEM=76O=PLABJV*YZXSAO/TE|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|[I[K>F4D;ZYC:ACYE/7/.1J+EN?6B ;$!AU9N[HJW7"2@JM5VB M"KC7A?')6,;P*G;BJJX1?4JF4054=?3QS0O;++#(WC9)&Y%;Y%YHJ+V*BH!R0 M !U-\U/:=,4Z5%XN=':H'2<^2G4W7<_25CN/F%PU+:J.M1>%T$]9&US%QGTLKZ/PX RGA&/6? M&"H940LEA+[;[=4/PJ0U-2QC*J M(B*KG',#(\^HJ:"K]0>R'2HTOYC@IIJBIFCIH(D5SY97HUC6IWJ]HB&N ->,E;O3*JO;R,BONY.E=+U:4=WU#;;?581>HJ*IC9$1>Q5:JY1/6H&3@X5MNEM)>:*.KM]5#74GBCD544YH '53ZDM5+=FVN>Y4<-Q=$L[:22H M8V9T:9R]&*O$K?1=SQCT5Y\CJK=N?I*[W1+;1:EM577.7A;3PUD;G/=X-3/IM+ZDR!E0+./':ABMRW5T=9]DZ@K=46FEK&NX7PRUL;58O@[*^BOJ7 &6EG6)C M)P:F]6^AM2W*HK:;"W(Q)%]Y9FMA1]]CE>]XPN4YY[S3>P6[::ON&I([Y]"C MFKY+HZ*W4CIXV*^%&\NJ9GTDPG:F57O50-Z@'!K[K26FCE]Z^IAHJ6%.*2>I MD2-C$\5<[")_Y@=1VK3=(VIN]RI+53.?U;9JV=D+%=A5X45RHF<(O+U*!VH,/'5Q2T[9VR,=MYO&V5')PJW&I[1J6FE]+1=**ZP1OZMTE%4LF:UV,*JU51%PJF:SS.ZZAMU!5=\$U2U'M_3)GE\)P=PKS3UNT^JKC:*R.HA= M9ZR2&JHY4>WEJ4YT[>.:BCG8Z>)O+FZ-%XD3TD[4[T.-J+6U@T@R-][O M%%:TDRK$JIVL5^.U41>:@=XCO#L+B/F[6JXKMNAM#/8[NRKM]37RH]U#5(^.M5$D@147A7"XRO:;ZGJ8Z2"66:1L4,;5>^1D1K41,JJO1$0#D@Q*VJ;.O%MQ;046I[355CW(QD,5;&Y9'9QPMPOI+ZDR97Q=H%Q;Q%QISI,ZNJK%H:"S6N1 MS+S?ZJ.@INK!N'B+C0W1YNU?IO4^K]N;S6S5E7:ZA:MNBJ*AZN?+3NPF>:KRYL=CQD4WOQ 7%O%CWC$*S=W15NN$E!5;KM$%7&O"^.;2ML8W@5.U%55PB^I5.QU*VEOFC+O'{)LH:.KH)6KWU'#DUOIV&GKII+[;60T,O45N?1=E%3"\\H! MWX,?TYKK3^K%F2RWN@NCHDS(REJ&/#SZ/W6<<.*'3+NEHYEU6VKJBT)7<7#U'GL?%Q9QP]ONLM\L=O(#*N+'0!'93/<=>}^FAN&E+U23UWL5!/131R5RN1OF[5C5%ERIICA1WN R\MXJ>\8G< M-V=&6FXNH*W5%IIJMJX?%)5L16+G'I<_1^'!SM4MI;QHZ\1.N<=OI*J@F:MR M;(G# QT;D6;BRB8:GI9RB(K1+< M:2.ZS,66*A=.Q)Y&)GTFQYXE3T77/EGO-%6#I8Z=AHUIM64=PTY?: M=.&IHY*5[DX\=K<)E$7PW $G^(<1K76>]M9LU#+:M*VFW4\--"R6>\:B66.MC5SN+$SU%JZW0Q5%UN$,,5'1.RK7U$5,X>]YYYPU>9UL.X&O]2W:XQZ6L]DJK;9I5HZV:X2RQ.K:EC465E/C*,1 M'+PY?E/6!N#B^!/67&O]F]=UVXNDI;Q7TT=%/Y|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|=:V2Y[W6[3VKJR:#2%G@2HGI8&R.\XG=+RNTND5FU'1\,UOJ+?;Y*5RO:J+A5:U,Y[E7FBHBY,ZWM7HJO;/>"CW&]BY+QIZJI?,[HR&-'NIT1$1'JGO-8J*O++5153**?3572+TW6 M6]*AT!0_DCU-5N1D%*EM>C8USS<]%:W.$Y8;X\|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|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`W(UEMA>=D7Z0MFHJ::HM]+&M-G42HK1HD14M^EY*],)%5?JU-J]'S7B;_P!L;562R=;7TC?,JM57*]8Q$1%7],U6N^%3*ORN M]*_8U9_#_>$7^J:+VQD3:3I#ZCT8_P"^IYY;V]C&N])[6M\$PLC/6K&@9M3N!L#57/5<^K-%ZBFTIJ"=/IH:U%ZF=>657A7TC4[5RQ$5J8Y]YT>$[5.OM&JKMT:-7:@H-0V^XW M;2%RJ?...Y4_SQ8\JJ87B5$SCA:Y,HN6HJ(J*=_J?I7:L#9^GM<6[>_6M7)3U%+,BQR81\3VM< MCF.];+]I!K_H9_X(Y_U3F_B1G;[+[?UNW6RT]NN2*RX5,<]7/#VI$KV81GP_M:W/K53I^AHO#M'/GZYS?Q(P-[G#;;Z=:Q]9U$?G+V)$Z=&)UBL155&J[MPBJ MJHG)%_QU*G/X%4KT:'M<.O=WD7OO7+]UJ#O^D?HRYZETS;+O88%JI'Y^N97P0M¥ND8B^DC4[U%KO7P M*B97" .?2(M[*.D@V-W=ZG^]1ON/5S_),KK^EKIJ?3#WVR"MFU5,SJ MHK)YL]TC*A4PC5=CA5$=X#>N7<-M'-2:[G\:CI:Z*=85FHO/ZN\N;PQV?S1Z2]8JA9,Y?26)&.X45?4J/1/5A.XPKHQ;.:=U]MH6MNNIJ-UT7SEU%21RS/:V")J->O!PN3"J][O>QRI5-@[&;%NVCILM0UU]A6 MGO%[=/734[DPZ)JL7A:Y.YR^D['=Q87"HI3H=_X'V\^7G\W_(0-TTE'#04\ M5/3L;%!"Q(XXVIA&M1$1$3WD0PW=7:FU;KV!ENN4CZ6>%ZS4M;"U..!^,*O/ MM:JL*"/W$-;CK53UK)A?BD4R[:/>^?6U[K-,ZMBL[M.:KHV=9)3/RD]6¥YHN%1>'*!O2150Z>CZ86B):5SJVGNM!5Q^[I9* M9'NXN]&JCL+A?"^8ZK:V"Y;K;T3[DR6]>Rv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|[FMRBKZ/%S[5>GU*&7=']U|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`T8MFM.ZM^T+6W74U&ZZ+YRZBI(Y9GM;!$U&O7@X7)A5>]WO8Y=]F8U5-#0]+]QT\$;8H M8=/]6QC>2-:B2(B)ZD1#G]#O_^WGR_F_|"<6Z?1B6G]0W?@D VF_;:PR: MXBU>ZF?[/1Q=2E1USN'AX5;C@SP]BKW&4F!S;M6Z'=.'0BT=4MQDIUJ1O M5(G K\=O%V-QV=]H9X!'SIB:=MC]NTO+]";LVJ@IVUG<$

(=9='G1E\T-MK56VWV"AME9'-[S.LI(D9.R5$]%7/[7IG&>)5SGN7F8?MSK2LUKT6-4S7"9U-M15T%MN%

^9WNGHVG5S57Q7A>U/@.=J3I4Z7K]-2PZ7=6W?459$Z*EM\=')QQ-MR.1417KCA5$7GZ*KV%-(Z!JMNNC#J:W7!J1W&HM=?

65,;5SU;G0.1&JOBC6M-M1?6BH!UG1JV:TY7[;4%\O=KI[S6W))%;EPC29L$39'M:QC791N>;LISRXOT)-M;H!J>D97Z.M;GQ:>OE#Y]#1N5J+G"'4[%;

[6?0&W5KL-MVKXZJT=7&^;@]_-WRQ5D+GN=Z*L1?21RN3"^"'Y!E2T$]!8H:

M7S&TI4MX7SMYHK_>QQKX9>B97A4#G:^TGHRU[F2;MW!U'055*ZG;%06.OA3@-MAQA%?P\3NL151Z\VHF7>I#3V\VL-MZB6Q7/;RECHKU07&-

ZU=!;W4D'"B*[" MY:U.-%:WNSA%YF2NN&GM&](#5]7N;1=9'6.1UIK*VD=/3I%GT<-X795&\#4< MB+P\+D7&3K.D-

N12;_TI01Z4M%1)I>UUK)Y{MYLZ'"%9<*UD<;*B*O)57L^I MV+TSHWR[:6;.-?GCKY"C??6&?!EE!T=M#QZ52SU=EIZV>2/$]SE8BUO[,

(_'!PJO/.K_15]?/3N;A8FK#)PM5.Y>;G8[N+"X4Y^WCO]QW5=_P#L%<_P MS@8K5)_N&DRN?09GU_[)(?;?2Q6^HZ->EKJ^B@?

<8:*W115;F(LC&+&W+45> MY3XU7T#2)W\#/Z20R'=RTU%UZ*=I2FA?.ZGMUOG>V-JJJ,1C.)V$[D1-&=8_S9W-<=]FJHM:5>A^AY;*FWR^;

MUM;Z2ACF;JHZ/CGE5ZMQV+PM=A?%4FY]EW)V(U>MI?,LM!89X:F.;/A5C

MUI7\O7V+5I\AGT%4]B=$2SVVA1'W&#K*NFC=_RCV5$OHIX*J.5$];H!T^C= M5[":6/2=-;KC!#>VI:CBXXXU]E9:>RV"63@M42TZLJ9

M(\\W/7.%;C'=A5SCL TU:;UIC;[7"]6N])JY:[& M43W3CHJ+?*"RW6^:9W?HZ>D?'.JTD_L<^6EJ8?P MECTG36ZXP0W.NDA;YW65-MDDF?

(]OQU_#EJ9S]E4[#=']2"T%4]B[9W"'W4*(-MZX0/;5TT;_3O9GT4];FJY$]:H8-I/I):+H=/QTNK*>2R:CH8TAK**2WO5SY6-MHB*K<-7A15[G<.,_"!T?

1PNUEU#>-9Z%B>E\T:CDK;=#7M5V(U>WB8K7=V58 MN,=J*O:JG(Z->BK!6ZHUW43VBCEGM=\5**1T+5=3<+WX1BX]%$PGQ(9]LIJG

M4>N7WB]W*RT]EL$LG!:HEIU94R1YYN>N<*W&,["KG'88[T7_/A[=#]77_QY M *Z*^B^W!_4F#^3I#5FE-R-

!:AU_J34-XTWGTRU'4VNAFIY*BGAA:J\^'"M7 MEP=O?Q+C*\MHZ*=_NO=P/U)@_DZ0QK25XINCIK'4-CU=;Y6Z;N=6M5;KPVF6 M6-

,I[EV,KV8143FBM(%1)^X&NK19-N+737"VLD:^Z7:LH')#'%E,HU%X51R(CNW&55$3Q M.7O]8;I9]4Z4W$M-#)B>I%>B^'$B]B*J!WFL^CIHS

M4&DIK7;,-066MC8WS6X00(DL;VJBHKW>Z>G+GQ*O:JIO,UEO[H>GM%+MLEU2 MGNUYFN,%%7W1T"-DK&M1](C^:JO+ES5>_P

3*=5=**P7;3,U)HJ2NNNJJZ-8 M:.BAHY.L@D-1+)<[I:KC'4W.:"-

MN&*N7*BHU$:B(]<WBPB9QX@2'L6GK;I]WMH+3106ZB8]N;3T[$8Q%585,T#XXZK@X^IU.PZS06O[3N/84O%EDDD MHUE="]S,5CDM6<2)ZP-

M0:>9LCM?976N^7"S;FN[7N6IK9J%:N21RJO),)(C,(]R=C*QRLC553Q:H&2:*^B^W!_4F#^3I"G1Q_PD[R_]ZO\ +5)313O]

MU[N!^I,'\G2%>CDO#N3O)R[;ZO\ +5(&_"+DF@Z37O2PU;273CGM5+34U7/2 M<2]74.;!

UC'HB\T17<6%SGAQWDHR*=TUTI;_I5:PNTU#4UE\S@BKWTL:O= M3Q+!38F5/]4?PHOJ67)S XEZU'-MT?]6POLT='ZU\W5]4Q:,:725*KA>:3O M

B(UN555Y]GAS.OZ*5.Z;:+5=CVVVF;>'RU$*UW5IUJLXU]%7>'),7J.NV2NS;#JG?:YN1',HKG-4* MWL149)5.7L]X^?1/W$MM#8X=

UD=32:BIYZAZPS0JUN$7B5%7N5..87P/OL9 M:X[UK'?*W3(K8:NZR4[^7TKY*E%_'!KK:G7VVLC;EJ#<25MXU5<*E[WMK*)]

M3%!'GT6L3A5OCXX3A1.SGVFE==:1L>_5B?M[4OBLM_N2Y6_JGQ1MD<[T'-:M[&/25]\NSTD['83N-

K=>6[8^FJ]#;AT3[<^DGDDH;DM*Z6*HA5W:G"BN5,|| MHGTV%PJ<\PT=NC6;E;F00:0L].FB:-BNK;M542L661,*1+RPN>%,+S3"JJ)

MC"ABV\6EV:QZ4&E+)/-/#15EG:E4V!ZL62%KZE[XU5.YW#A?4IV/2.V@TE8= MJJZ\V:RTUGN%]?3NAGH8TC:*B'.U8[_=B:+]5BD_!5F3

M=*1<[%ZF]?FO\ZB ZC=&AIM5=&]MYNU-#77**R0U<51,Q%?',^-BN>U>Y5R< M;0VBVQ='5T^EJ""BU+<['PK54[$9-

,_A7EQIA>+FN%SR544[N]6NHO'1B914 MD$E14R::@X(8VY<]4@8N$3QX@);/JJU!M M@TDWCUE8[8UWFM9#F-ZL?A6I MZ7-53DG-,*Y

,+VUU7L_1Z6IM,:PTS'9[W"WJJRHN%"KGOESS=UJ(KV9[<+P MHF3>VQVD;=H_1,=)9]0?DCM,TSYZ:IRU6L1<(YC5:JIC+554^]5QK>DW\VZU

M3I2*GW%H88M04\?55E%66M[W=8W.58]-7@SC/-6XR=ET5=-5MFH=4W-;*JM> MG;K6MFM%#69ZQD2*_P!-47GS;L:9[^#/9A0-

^@P';W=RV[AW[4MJHJ.JHK'M,D$SZCAX9'<;VY;A57&8U[3/@-%Z^TGHRU[F2:MW!U'055*ZG;%06.OA3@AQ MA%?P\3NL151Z\VHF7>I#3V\VL-

MZB6Q7/;RECHKU07&-ZU=!;W4D'"B*['Y: MU.-%:WNSA%YF2NN&GM&](#5]7N;1=9'6.1UIK*VD=/3I%GT<-

X795&\#4UUK)Y{MYLZ'"%9<*UD<;*B*O)57L^I V' MTSG21;:6>2)RLE;?(58XJX5'=3/A477N5#*Z;HY;*72]VJJM$556RQ+U]UE]*

MK?,JL7GQ<7/P,2Z8%3%7;7:?]C('I+#+>]>2-[>;..L$ZHJ?-I(''' 1YZ, MVK*FW='R]7&J>ZH999*QT+),KB-D+9>'WLJ[XSY='';,*S:STC+K+55!#J&\W

MNIFD=+<(FRHQK7N9AK5RB*]M[DB8PA7HF6F*_;&7ZV5"]D%;755,J4^I?

M!&U:WSR.HZUM,^2&IBWG2PM%%;>*.V55NEJJ>G5RN2!',E1T;5557'$USD3NXB4!%S3FL MYM?=*6P7IM%44EJDMDT=N=4LX'3P-

9+\\QZWK)CU(A*,"/>_"2;YW9T/MU+- M)%:*M'7"MCB7'7-;QJC57U-B?CP5V>Y#L]YMC-*NVUN]39K-266XVNCEJ8*B MBA2-

[D8Q5>QZICC1S4\^5%7NXFKV95.OW(Z1=@UCM_>+3I#SN[7BX4,S)(4IGL\UAX%ZY[W.1$] M&/B]RJ\\

I7H+U3MKJFKN,+9W+UJ<343BSC#7)E4YJJJN>Y/GM_I!VO>BG0V"-Z M1S5E%(V)[_KFPR(CURW*\O[U M(GK3"+G"*2-([;,KMU|[*C:6IU2S@?

4*J*U51.],,D55[$X MFIE<*2) C'O%I=FL>E!I2R3S3PT599VI5-@>K%DA;^I>^-53N=PX7U*=CTCM MH-)6';JNO-FLM-9[A:GT[H9Z&-

(W*CIF,5'8]UR>JY7FBHASM6,_W8FB_58I M/P59DW2D7.Q>IO7YK_.H@,;WBW#N=@Z.EJND-2L=UO-)24SZE/=HLL/'(YO@

MJHUW/NSE.9DNCCONHOZ!IK576"AN56Z!&U=94Q(^9BHG&K7Z8F>Q&JE,(M=!KG0%5N+T;++:

[>WK+A36VBK*>/_K',@1%:B^*M<['KPG>?/3?2]TQ1Z=CA MU.M,:M24<:0U=O?1R*]\S4PO#A,)E>>'JWM ZK9FVQV/7^OMJ*]$NFGZ=K:V

MEIJM.L1D;E8JL7NPJ21KCLRBKCFI\>BII"RU%3JNX2VNE?76^]21TM0Z)%?" MWA5.%]JRC+S%54ETN-

\>M(BPJK7Y543+O!41%1>Q4<@$GB*N^.M;)<][MK=I[5U9-!I"SP)43TL#9'><3N;Q-1Z,1>6',3U)Q85,DJB.VZ]%5[9[P4>XW ML7)>-

/55+YG=&0QH]U.B(B(]4]YK%15Y9;J*J910,%W2U=LU>=+RNTND5FU'-M1\,UOJ+?;Y*5RO:J+A5:U,Y[E7FBHBY-ZZ9CI-[]E+C8USS<]%:W.$Y8

M;X\|(9KK;UMU=5^:,NW6(B>8*SC5$YYQP\^W/#EN,FJ-24=-L9L==&V%O4K M;;-4BF[6]'QTEXEIW4E9 Y.4-2GN7<*\T8KFH] M?"G;U0.OV-

V6TQ)MW;KQ?+337V\7B)*RIJKE&D[OGF5:C>+./1EM7 Y?-G=0_*H]7+G*!6*Q%[L)E>2X14547)I*35NJ]PM(;HZBK& MU%!HR:S5<=HH:J!C'OQ

N9<\/%A43O54R]R)GAR@6^:JUYJBECO#W5[]6BI[OB20P1M:UW)]\E]%[$3ER MPO>JENR-SN-\Z2&L+K=+=+:JBNM*5#:.?'61Q*Z!(^+P7@1N4+-

!ZHAZ-FJM M1:9U5#44FG*^K6MMMUCA=)$]*F,.X45<*,141%PK?!R*!Q]Q]L[7H3?7;>L MLL+:&@N=Q:KJ&)5ZJ.9CX\O:W.&\37-3"?4G8]*;6-

*W5.E-)W6NFH-.5"I7 M75],CE?)$CE1K,-Y]GHOY87FK5[CI=:;D.W(WEVU]F735'Y'*6Y=535T\2Q)

M53+)&LJM1W/#41B2XRB]B*J!@VK]5;!7O2=5;:"F@MU6V%4I:REMLC)F2(GH*Y_#ER91/= M*IMGHT:Q]J:

[4V^>OF6>MD)'T4DKERYZ,QPJN>U>%SY1R\/"J(OU*NSW9-H;8NOTNC*&?4U-2T-YG199:: MDBZIL2*OHM5,KZ6,9]?+N

R]B(L:NW$T[=NDU33;@ND5'8]*Q.C@61KG))5I MS=A&HO-'*GPPH2#W-U9#HC1EYODRMX;*G=(QKEY/>J88WX7*B?":GZ-.VE!4 M;>K?

=0VVENETOE3)6.EKH&2OX%#26N-,WF*O M='_BK#G"N7+415X'/]Y6-)%[CTUQO&W5^AL$]KL6J-

W]WVVR6ZCN4E.KZ:;GI61O25N'M1'(B*B*K41?4 MIA>RNX%]U/L'4Q6-(I]66)GFD<-2U7)(G,.C3&4[8_03*^Z:H&!{;ZKV?H]+ M4VF-8:9CL]

[A;U5947"A5SWRYYNZU$5[,]N%X43)LVSZ1MVD.CQJ^EL^HEU) M:)K77S4U3EJM8U8'HK&JU5Y(J+R[455.@I_-NM4Z4BI]Q:&&+4%/"U5915E

MK>]W6-SE6*C5X,XSS5N,G4;6::KK3L_NY M%\6NC3/?P>&% V)L#1U5PZ.MGI:.K[CJJ:EJHXJK@XNH9LCM?976N^7"S:FN[7N6IK9J%:N21RJO),)

(C,(]R=C*LZ39_=3:G1.A;?#54D=']:G;U- M5 ZW.DJY)\JBX?P\\KV(KDQG"X_=&^[6EV]NM*72S)]72[11,JH:6;-6<+D= M&F415Y)F23">"IR/AM'M[;-

>[Q;GS7V!UPMUMO4SX]"9RK_^9\\S>-SEHZK*2=6CH4CRB]CE9&]JGBU3(^_MCDO#N3O+R[;ZO\M4@=%N1HZU;:[W[8W#35)'9GW:M?35,%

(G5Q.:CXFKZ*)96L[.#CX>#&>655/>SR X?1>O=(K;0%]TQ=)(:MIY;:75=13^=,SUE,Y56-'(O@K5QGLRB=R'\Z*FD++45.J[A+:Z5]=;[U)'2U

M#HD5\+>%4X6KW)S4V?LI<]3WW2TET U3;*2TSU4RNI:6G@6)[($]SUF5]UE5Q MR3ES[S4VP^M[?

H#7F]J&7F*JI+I<;X]:1%A56ORJHF7>"HB*B]BHY .+/H*A MW"Z6NJZ&YK(^V4U)!5ST['JULZM@ID:QRHJ+PYF

M[;3V2ZTEUCA:ZA8D37)U+/:IP>D*[_:7V91/K ML_\ E:4V?NT[_:KUGW)["UO\@\#7.C[G57?HBU5363.FG_(_7Q<;N:\+&S,:

MGWFM3XC'"%UA6:,Z'%FGM\SJ:LK7OHF31JK71H^HE5ZMQV+PM[.>TRW;QW M^X[JN_\ V"N?

X9SH[%H.HW"Z(5]ME$B.KXDDJJ9COIWLJ95X$]:M56IZU0#8 M.BNCWHNTZ+I+??:?HKC5$4[5]JRJB1\SI%;ERM>N59S5<<*I@ZJFVXK=L-D-

M>VB6\+=+?['U\U#&Z-6K2QK_P!#B5W/LSV)A5=XG!TSTI=+6W3$5/J5:RUZ MCH8DIZJVNI'K(^9B87APG"F5YX!B]'8K?=NAM3U5910U-

10T=3)2RRL170N M\Y>BN:O> MAXM%20OJ*F2W575Q1IESU2>1V$3O5<'=]&3<^SZGT9;--4SIFW>T4+6U, M&X1W#E%[^Y?A X/1>N-18H=4:

N,F:W3U>_J<\N.%[EYM3PXD5W_ +Q#Y[*I M^6'NKK?<&1>MH8I?8BUJJ9;U;,*YR9[,HUBY_P"T<8UTCI:[;#7K=86B-W#J M"U5%IJEC[IN#$;_?

QP*GCU2FZ]F]%IM_MO9+,YG!4QP)+4^/7/\ 3>GKPKE: MGJ@&;@ M !:C?67 #B5-MI:W"U%/%.K?Q43IX:;#5ZUK

MXT>U&JK^USNU#O.CY:KC:;GK9*_2TFE(:FMAJ*:B2+AB2-T>$:US4X7*B)Z6 M.Q7+G"FI,>LIP^M0(^V#0IZ9N[%IZ:VS1Z,LUQJ+_1U2QN2!

[Y6MZN%JXQEC MWR+CW_ ["V7R]\/734EH_(A>M1T=PN$URMM99X.MC=URHJQS+GYWAW+B[TRJ M(;RX$]_WS6=YV&M5RO5PN-

#?]2:>]D)5J*NEL]R=!!/(W3W-PO->_& .%T9 MEJY-NIYZZ%L%5-

=:R61C516HY95XD;ZD]54[@#C5%'#5Q]7/$R9F<\,C42(WDB=WX#Z@"WA/A'0T\'UGPGHH*K@6 M:&.7@7+>-J+PKXIDY(MX/6I7'+'<5 %KF([M./-

;Z>HDCDFACE?&N6.>Q%5 MJ^*+W'* %G!X+CGDO IPEO!SSE2\ <2"WTU*LBP010N?S +4:7 6\)Q(]31PSK-'2P1S*F.L;$U'8Y\LX]:_&IS0!9U?K*\)<

+> M'MYD>-=_DUWLO<6CIM*56F]-TUQXZ^Z5+U5M3#&Y>']U5C4])..8XN>,XQSD M26\ 'RIJ:.E@CAB8V.*_J,8QJ81K43"(GP'UX4Y%P

MX1P8[%P7 6\/K+@! MB&XFCIM=V)ED6L;26^HJ8W5R]7Q/DA:O&K&+GT55S6IE<\E=R,NX2G"7 =-J

MBAKKGIVY4ML[UM]QF@>VF]DY']5)CT7>]G!IO3^[>X6E;5%9]3;>WN^7]!7-6 MX6]J/AG3*JU5^"'*WQN1R

MP0MX41'*G+.&1IX^BN>WEN7A3D.!"X#YK&CVX7FG>GB:Y*>&.!'KQ M.2-B-

15[U7!R@!U&I+G56:P7"NH:!\UJJ:!TL5%&_@=.YRC=A<*OO&F]#6 M?4VZ.Z-+K?5%ADTW:[_Z"VVRKRLKI79XI'(Y$7DBJN51/I,9PIQK'"%O5H!>

M +>$<)< +>'M[APEP MX?C./#;Z:F=*Z&".%TBY>Z-B(KO?\3E "W@^#WCC M-M]\VHZ]L$23_P#6(Q.+U\^TY8 LZOGVEX %O#V]PX?C+@!Q8;?

34SI?0P1P MND7+W1L1%=[_ (FH>F'I.\:QT+::*RV^6XU$=XAG?#$B*J1\%*BN[?%4^_W0 M6\/:!\'T4#ZAL[H8W3,3#9',17(GJ7M/OP_&7 "WA[>X:

MTY0 MX3XU%)%5PK%/$R:->UDC4!./'AGM/MP>O[Q> .)-;::IE;++'+'(U M45KGL15;C.,+W=IR>#\,2X ?'S:/K4E5C5D1,(J6IQ?&?3AY8[BX 6\(5,_&

M7 "WA/F^%'L5KO2:O)45.2IX+ZC[#BTE%3T3%93PQPM5556QM1J*]\U7"'(M1OBN2X ?!*:-)72HQJ2.3"O1]97'9S$M+'4Q.CF8V6-W:QZ<35]]%/N

/A#3 M1T\21Q,:&WL:U.)\2'U5F>\N '&IZ*"D:](UF0HY>)4C:C>?B&>WQ. M4 +.KP]JBX/G-2Q5,*Q31LFC=VLD:CD7X%/N -/FR-

&HB)R1.Q$3!\:BB@K(E MBJ(HYX_J96(Y.S'8OJ7[ZG* 'RCA9&UK6-1K6]C6IA$+^_N ''?1Q32,DDC8 M^2-\#[M3Y1TT<;GN8QK5>O$Y6HB*Y?6 M?<

6\/K,/4T%/6!.+'AGM\3[]7Z^_)> +>$N MX?67 "WA+@ +48G"J=[>LN 'Q?" MV1[M>G&U45%;[L5%[L'Q1+;34*R.IZ>&!SURY8XT:KO6N.U3F

"W@Y8SR'"7 M +>$&1J.3/CS+V0MCC1C$1K6IA$1,(B>!]0 +>$N %G5HF/\ 0?!M!3-J5J$@ MCZ_&.MX$XL>&>WQ.4 +.K]??DKPEP %B1HF>XO

'"EM-'/.D\M+#+,BY21\; M5?89]MSHV#0&BK38*=6O2CB1KY43'62*JJ]WP MN55^!DZ-]>2N$ <)1&^/,N %O#ZPK?7@N %0/\(X40N

%.$XTM%!-.V=\$; MYF#M3N+'Q-D:K7(CFJF%1>>47M/J ..24,%''P01, MA9V\,;$:GWCD<)4 4X2G"7 "U&_V5"X #C5-'#61\$\4R% ML;6M8B,:U,

(C4QCU>\?8 ?-T37M'M[APEP M5B*N3CTUOIZ-'=1!%!QYRJN5PUJ(B(G)5 M,N+>$N MX0C?%>2]IR.#UJ7 "WA+@ +> M$<)<-*

<)3A+@!Q9;*":=L[X(WS,Y-D/@VA@;.^=(6) M,Y$1TB-3B7'9E>\Y(M1GK^(^4=/'&KU8QK%>N7*U$I)?%?$^X MX4SDX\EO

MIYIVS20QOEC]S(YB*YO//)>TY0 MX?6.$N %O"7 :8Z2NDKOJVRZ8BM%OFK MY*:\1SS-AQED:-=ER\^SF;>6B@=4),L,:S-

3A216)QG@BGWX2X"Q6HO_P"! M7A+@!3A.-4T4-7$Z*>*,>-->UDK$.)3VVFI72/@IXH7N3#G,C1%7WU]SD\..2&>T^W#SR7-6HWUY+@

!3"%0!:C/7D^$ ME#!/,R66&.21GN7N8BJWWE[CD@"W@]:EP %O#ZPK>+M+@!:C,9/F^%LL;F.1 M',7O(?;@]?WB\ <1MNIFU M*U"01I48PLW

G&J>&>T^Z,3"\^WX#Z "WA'!ZRX <.6W4M1,R66FBDE8O$V1 MS$5R+XHO:G:%5:/GUK#;*%U8E-:HJR.JK8>KXGU+8W(]D:+GT45R)E<9Y

M&6)&G(NP@%2WA+@!;PCA+@!;C^V"R2)LC'->B/:[DK7)E%^_^H X]-1PT<75 MP11P,[>"-B-,\2'VX%^J4N '&AHH('ROBACB?(N7N8Q$5WO^)R,(5*

'%[+?3 MU:L=4013JQOX#YMIHTF=*C&] M8J85_"F<>&3{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end GRAPHIC 13 ex5-1_001.jpg GRAPHIC begin 644 ex5-1_001.jpg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|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|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end EX-101.SCH 14 orka-20240930.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)link:presentationLinkbase:definitionLinkbase:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)link:presentationLinkbase:definitionLinkbase:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)link:presentationLinkbase:definitionLinkbase:calculationLink 004 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)link:presentationLinkbase:definitionLinkbase:calculationLink 005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parentheticals)link:presentationLinkbase:definitionLinkbase:calculationLink 006 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)link:presentationLinkbase:definitionLinkbase:calculationLink 007 - Disclosure - Nature of the Business and Basis of Presentationlink:presentationLinkbase:definitionLinkbase:calculationLink 008 - Disclosure - Summary of Significant Accounting Policieslink:presentationLinkbase:definitionLinkbase:calculationLink 009 - Disclosure - Common Stocklink:presentationLinkbase:definitionLinkbase:calculationLink 010 - Disclosure - Related Party Transactionslink:presentationLinkbase:definitionLinkbase:calculationLink 011 - Disclosure - Commitments and Contingencieslink:presentationLinkbase:definitionLinkbase:calculationLink 012 - Disclosure - Stock-Based Compensationlink:presentationLinkbase:definitionLinkbase:calculationLink 013 - Disclosure - Subsequent Eventslink:presentationLinkbase:definitionLinkbase:calculationLink 014 - Disclosure - Events subsequent to the reissuance of the financial statement (unaudited)link:presentationLinkbase:definitionLinkbase:calculationLink 015 - Disclosure - Reverse Recapitalization and Pre-Closing Financinglink:presentationLinkbase:definitionLinkbase:calculationLink 016 - Disclosure - Fair Value Measurementslink:presentationLinkbase:definitionLinkbase:calculationLink 017 - Disclosure - Accrued Expenses and Other Current Liabilitieslink:presentationLinkbase:definitionLinkbase:calculationLink 018 - Disclosure - Note Payable with Related Partylink:presentationLinkbase:definitionLinkbase:calculationLink 019 - Disclosure - Convertible Preferred Stock and Stockholders' Equitylink:presentationLinkbase:definitionLinkbase:calculationLink 020 - Disclosure - Income Taxeslink:presentationLinkbase:definitionLinkbase:calculationLink 021 - Disclosure - Option Agreementslink:presentationLinkbase:definitionLinkbase:calculationLink 022 - Disclosure - Net Loss Per Sharelink:presentationLinkbase:definitionLinkbase:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies)link:presentationLinkbase:definitionLinkbase:calculationLink 996001 - Disclosure - Summary of Significant Accounting Policies (Tables)link:presentationLinkbase:definitionLinkbase:calculationLink 996002 - Disclosure - Related Party Transactions (Tables)link:presentationLinkbase:definitionLinkbase:calculationLink 996003 - Disclosure - Commitment and Contingencies (Tables)link:presentationLinkbase:definitionLinkbase:calculationLink 996004 - Disclosure - Stock-Based Compensation (Tables)link:presentationLinkbase:definitionLinkbase:calculationLink 996005 - Disclosure - Reverse Recapitalization and Pre-Closing Financing (Tables)link:presentationLinkbase:definitionLinkbase:calculationLink 996006 - Disclosure - Fair Value Measurements (Tables)link:presentationLinkbase:definitionLinkbase:calculationLink 996007 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)link:presentationLinkbase:definitionLinkbase:calculationLink 996008 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables)link:presentationLinkbase:definitionLinkbase:calculationLink 996009 - Disclosure - Net Loss Per Share (Tables)link:presentationLinkbase:definitionLinkbase:calculationLink 996010 - Disclosure - Nature of the Business and Basis of Presentation (Details)link:presentationLinkbase:definitionLinkbase:calculationLink 996011 - Disclosure - Summary of Significant Accounting Policies (Details)link:presentationLinkbase:definitionLinkbase:calculationLink 996012 - Disclosure - Common Stock (Details)link:presentationLinkbase:definitionLinkbase:calculationLink 996013 - Disclosure - Related Party Transactions (Details)link:presentationLinkbase:definitionLinkbase:calculationLink 996014 - Disclosure - Commitments and Contingencies (Details)link:presentationLinkbase:definitionLinkbase:calculationLink 996015 - Disclosure - Stock-Based Compensation (Details)link:presentationLinkbase:definitionLinkbase:calculationLink 996016 - Disclosure - Subsequent Events (Details)link:presentationLinkbase:definitionLinkbase:calculationLink 996017 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Property and Equipmentlink:presentationLinkbase:definitionLinkbase:calculationLink 996018 - Disclosure - Reverse Recapitalization and Pre-Closing Financing (Details) - Schedule of the Assets and Liabilitieslink:presentationLinkbase:definitionLinkbase:calculationLink 996019 - Disclosure - Fair Value Measurements (Details) - Schedule of Fair Value Hierarchy for Financial Assets Measuredlink:presentationLinkbase:definitionLinkbase:calculationLink 996020 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilitieslink:presentationLinkbase:definitionLinkbase:calculationLink 996021 - Disclosure - Note Payable with Related Party (Details)link:presentationLinkbase:definitionLinkbase:calculationLink 996022 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Details)link:presentationLinkbase:definitionLinkbase:calculationLink 996023 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Details) - Schedule of Convertible Preferred Stocklink:presentationLinkbase:definitionLinkbase:calculationLink 996024 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Details) - Schedule of Common Stock Reserved for Future Issuancelink:presentationLinkbase:definitionLinkbase:calculationLink 996025 - Disclosure - Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrantslink:presentationLinkbase:definitionLinkbase:calculationLink 996026 - Disclosure - Stock-Based Compensation (Details) - Schedule of Stock Option Activitylink:presentationLinkbase:definitionLinkbase:calculationLink 996027 - Disclosure - Stock-Based Compensation (Details) - Schedule of RSAs activitylink:presentationLinkbase:definitionLinkbase:calculationLink 996028 - Disclosure - Stock-Based Compensation (Details) - Schedule of Employee Warrant Activitylink:presentationLinkbase:definitionLinkbase:calculationLink 996029 - Disclosure - Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrantslink:presentationLinkbase:definitionLinkbase:calculationLink 996030 - Disclosure - Stock-Based Compensation (Details) - Schedule of Company's Stock-Based Compensation Expenselink:presentationLinkbase:definitionLinkbase:calculationLink 996031 - Disclosure - Stock-Based Compensation (Details) - Schedule of Award Types of Company's Stock-Based Compensation Expenselink:presentationLinkbase:definitionLinkbase:calculationLink 996032 - Disclosure - Income Taxes (Details)link:presentationLinkbase:definitionLinkbase:calculationLink 996033 - Disclosure - Option Agreements

(Details)link:presentationLinklink:definitionLinklink:calculationLink 996034 - Disclosure - Commitment and Contingencies (Details) - Schedule of Company's Supplemental Cash Flow Information Related to Leaseslink:presentationLinklink:definitionLinklink:calculationLink 996035 - Disclosure - Commitment and Contingencies (Details) - Schedule of Company's Operating Lease Liabilities Showing the Aggregate Lease Paymentslink:presentationLinklink:definitionLinklink:calculationLink 996036 - Disclosure - Net Loss Per Share (Details)link:presentationLinklink:definitionLinklink:calculationLink 996037 - Disclosure - Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholderslink:presentationLinklink:definitionLinklink:calculationLink 996038 - Disclosure - Net Loss Per Share (Details) - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Sharelink:presentationLinklink:definitionLinklink:calculationLink 996039 - Disclosure - Related Party Transactions (Details) - Schedule of Related Party Accounts Payable and Other Current Liabilitieslink:presentationLinklink:definitionLinklink:calculationLink 000 - Document - Document And Entity Informationlink:presentationLinklink:definitionLinklink:calculationLink EX-101.CAL 15 orka-20240930_cal.xml XBRL CALCULATION FILE EX-101.DEF 16 orka-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 17 orka-20240930_lab.xml XBRL LABEL FILE Total assets Class of Stock [Axis] Total stockholders' equity Balances Balances Total current assets Related and Nonrelated Parties [Axis] Total current liabilities Total liabilities Total liabilities, convertible preferred stock and stockholders' equity Revision of Prior Period [Axis] Total operating expenses Loss from operations Total other income (expense), net Balances (in Shares) Balances (in Shares) Preferred Stock Issued and Outstanding Equity Components [Axis] Cash at beginning of period Cash and cash equivalents at end of period Cash and cash equivalents Nature of the Business and Basis of Presentation [Abstract] Summary of Significant Accounting Policies [Abstract] Common Stock [Abstract] Related Party Transactions [Abstract] Commitments and Contingencies [Abstract] Events subsequent to the reissuance of the financial statement (unaudited) [Abstract] Long-Lived Tangible Asset [Axis] Statistical Measurement [Axis] Reverse Recapitalization and Pre-Closing Financing [Abstract] Net assets acquired Fair Value Measurements [Abstract] Cash and Cash Equivalents [Axis] Fair Value Hierarchy and NAV [Axis] Accrued Expenses and Other Current Liabilities [Abstract] Schedule of Accrued Expenses and Other Current Liabilities [Abstract] Total Note Payable with Related Party [Abstract] Convertible Preferred Stock and Stockholders' Equity [Abstract] Plan Name [Axis] Debt Instrument [Axis] Schedule of Stock Option Activity [Abstract] Number of Stock Options, Beginning Balance Number of Stock Options, Ending Balance Outstanding and issued stock options Weighted Average Exercise Price Per Share, Beginning Balance (in Dollars per share) Weighted Average Exercise Price Per Share, Ending Balance (in Dollars per share) Aggregate Intrinsic Value, Beginning Balance Aggregate Intrinsic Value, Ending Balance Number of RSAs, Unvested Beginning Balance Number of RSAs, Unvested Ending Weighted Average Grant Date Fair Value, Unvested Beginning Balance Weighted Average Grant Date Fair Value, Unvested Ending Award Type [Axis] Schedule of Summarizes the Employee Warrant Activity [Abstract] Number of Warrants, Beginning balance Number of Warrants, Endning balance Outstanding and issued employee warrants Weighted Average Exercise Price Per Share, Beginning balance Weighted Average Exercise Price Per Share, Ending Balance Aggregate Intrinsic Value, Beginning balance Aggregate Intrinsic Value, Endning balance Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants [Abstract] Statement of Income Location, Balance [Axis] Stock-based compensation expense Schedule of Award Types of Company's Stock-Based Compensation Expense [Abstract] Total Stock-based compensation expense Income Taxes [Abstract] Option Agreements [Abstract] Schedule of Company's Supplemental Cash Flow Information Related to Leases [Abstract] Schedule of Company's Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract] Total undiscounted lease payments Total discounted lease payments Net Loss Per Share [Abstract] Antidilutive Securities [Axis] Related Party Transaction [Axis] Document Type Entity Registrant Name Entity Incorporation, State or Country Code Entity Filer Category Entity Small Business Entity Emerging Growth Company Amendment Flag Entity Central Index Key ASSETS Current Assets Subscription receivable Commitments and contingencies STOCKHOLDERS' EQUITY Preferred stock, value Carrying Value Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized Preferred Stock Authorized Preferred stock, shares issued Shares issuable on conversion of Company preferred stock Preferred stock, shares issued (in Shares) Preferred stock, shares outstanding Common stock, value Common stock issued Common stock, par value (in Dollars per share) Common stock par value (in Dollars per share) Common stock, shares authorized Common stock authorized Common stock, shares issued Common stock issued Common stock, shares issued (in Shares) Common stock shares Common stock, shares outstanding Common stock outstanding Additional paid-in capital Assets Current assets: Prepaid expenses and other current assets Property and equipment, net Operating lease right-of-use asset Operating lease right-of-use assets Other non-current assets Liabilities, Convertible Preferred Stock and Stockholders' Equity Current liabilities: Accounts payable Accrued expenses and other current liabilities Operating lease liability, current Less: current portion of lease liability Related party common stock warrant liability Warrant gross proceeds amount Related party accounts payable and other current liabilities Operating lease liability, non-current Non-current portion of lease liability Operating lease liability, noncurrent Convertible preferred stock, value Convertible preferred stock, par value (in Dollars per share) Convertible preferred stock, shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Convertible preferred stock, liquidation preference (in Dollars) Stockholders' equity: Accumulated deficit Operating expenses Research and development Research and development expense Research and development expenses General and administrative Other income (expense) Interest income Net loss and comprehensive loss Net loss Loss Allocation, Net loss Net loss per share attributable, basic (in Dollars per share) Loss Per Share - Basic and Diluted, Stock (in Dollars per share) Net loss per share (in Dollars per share) Net loss per share attributable, diluted (in Dollars per share) Weighted-average shares used in computing net loss per share attributable, basic (in Shares) Weighted-average shares used in computing net loss per share attributable, diluted (in Shares) Weighted Average Shares Outstanding, Stock (in Shares) Issuance of common stock Issuance of common stock (in Shares) Pre-funded warrants Issuance of Series A convertible preferred stock, net of issuance costs of $69 Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares) Issuance of Series A convertible preferred stock, net of issuance costs Stock-based compensation expense Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization (in Shares) Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares) Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, (in Shares) Issuance costs of Pre-Closing Financing and reverse recapitalization Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization (in Shares) Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares) Issuance cost of PIPE Financing Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Non-cash interest expense Non-cash lease expense Changes in operating assets and liabilities: Accounts payable Accrued expenses and other current liabilities Operating lease liability Related party accounts payable and other current liabilities Net cash used in operating activities Cash flows from investing activities: Net cash used in investing activities Cash flows from financing activities: Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid Proceeds from issuance of notes payable to related parties, net of issuance costs paid Proceeds from the Pre-Closing Financing, net Proceeds from the PIPE Financing, net Cash acquired in connection with the reverse recapitalization Net cash provided by financing activities Net increase in cash and cash equivalents Supplemental disclosure of non-cash operating and financing activities: Operating lease liability arising from obtaining operating right-of-use asset Assets acquired in connection with the reverse recapitalization Pre-Closing Financing and reverse recapitalization issuance costs included in accounts payable PIPE Financing issuance costs included in accounts payable PIPE Financing issuance costs included in accrued expenses and other current liabilities Non-cash accrued interest on convertible note converted to common stock Non-cash exchange of Pre-Merger Oruka Series A Preferred Stock for Company Series B Convertible Preferred Stock Converted into shares value Interest expense Prepaid expenses and other current assets Other non-current assets Purchases of property and equipment Other liabilities assumed in connection with the reverse recapitalization Series A Convertible Preferred Stock Series A convertible preferred stock Series A Convertible Preferred Stock [Member] Related Party Related Party [Member] Series A Non-Voting Convertible Preferred Stockholders Series A Non-Voting Series A Non-Voting Convertible Preferred Stock [Member] Series B Non-Voting Convertible Preferred Stock Series B Non-Voting Previously Reported Series A Non-Voting Convertible Preferred Stockholders Series B Non-Voting Convertible Preferred Stockholders Series A Shares issuable on conversion of Company Series A Preferred Stock [Member] Series A Preferred Stock [Member] Convertible Preferred Stock Series B Non-Voting Preferred Stock [Member] Series B Non-Voting Convertible Preferred Stock Common Stock Common Stock [Member] Additional Paid-in Capital Accumulated Deficit Nature of the Business and Basis of Presentation Summary of Significant Accounting Policies Common Stock Related Party Transactions Commitments and Contingencies Stock-Based Compensation Subsequent Events Events subsequent to the reissuance of the financial statement (unaudited) Schedule of Property and Equipment Estimated useful life Reverse Recapitalization and Pre-Closing Financing Schedule of the Assets and Liabilities Cash and cash equivalents Other current assets Fair Value Measurements Schedule of Fair Value Hierarchy for Financial Assets Measured Financial assets: Total financial assets Accrued Expenses and Other Current Liabilities Schedule of Accrued Expenses and Other Current Liabilities Accrued employee compensation and benefits Accrued professional and consulting Accrued research and development Note Payable with Related Party Convertible Preferred Stock and Stockholders' Equity Schedule of Convertible Preferred Stock Liquidation Preference Schedule of Common Stock Reserved for Future Issuance Shares issuable upon exercise of pre-funded warrants Shares available for grant Number of shares of common stock available for issuance (in Shares) Total shares of common stock reserved Common stock reserved for issuance Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants Expected term (in years) Expected volatility Risk-free interest rate Expected dividend yield Schedule of Stock Option Activity Weighted Average Remaining Contractual Term (in Years), Beginning Balance Number of Stock Options, Granted Number of RSAs, Granted Number of shares granted (in Shares) Weighted Average Exercise Price Per Share, Granted Number of Stock Options, Exercised Weighted Average Exercise Price Per Share, Exercised Number of Stock Options, Forfeited Weighted Average Exercise Price

Per Share, Forfeited Weighted Average Remaining Contractual Term (in Years), Ending Balance Number of Stock Options, Vested and expected to vest Weighted Average Exercise Price Per Share, Vested and expected to vest, September 30, 2024 Weighted Average Remaining Contractual Term (in Years), Vested and expected to vest, September 30, 2024 Aggregate Intrinsic Value, Vested and expected to vest Number of Stock Options, Exercisable Exercisable shares Weighted Average Exercise Price Per Share, Exercisable Weighted Average Remaining Contractual Term (in Years), Exercisable Weighted Average Remaining Contractual Term, Beginning balance Aggregate Intrinsic Value, Exercisable Schedule of RSAs activity Weighted Average Grant Date Fair Value, Granted Weighted average grant-date fair value Schedule of Employee Warrant Activity Number of Warrants, Granted Shares issued Weighted Average Exercise Price Per Share, Granted Number of Warrants, Exercised Weighted Average Exercise Price Per Share, Exercised Number of Warrants, Forfeited Weighted Average Exercise Price Per Share, Forfeited Weighted Average Remaining Contractual Term, Endning balance Number of Warrants, Vested and expected to vest Weighted Average Exercise Price Per Share, Vested and expected to vest Weighted Average Remaining Contractual Term, Vested and expected to vest Aggregate Intrinsic Value, Vested and expected to vest Number of Warrants, Vested and exercisable Weighted Average Exercise Price Per Share, Vested and exercisable Weighted Average Remaining Contractual Term, Vested and exercisable Aggregate Intrinsic Value, Vested and exercisable Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants Schedule of Company's Stock-Based Compensation Expense Schedule of Award Types of Company's Stock-Based Compensation Expense Paruka warrant obligation Employee warrants Employee stock purchase plan Income Taxes Option Agreements Schedule of Company's Supplemental Cash Flow Information Related to Leases Cash paid for amounts included in the measurement of lease liabilities Operating cash flow from operating leases Lease payment Schedule of Company's Operating Lease Liabilities Showing the Aggregate Lease Payments 2024 (remainder) 2025 2026 2027 Net Loss per Share Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders Loss Allocation, Stock Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share Total anti-dilutive securities Schedule of Related Party Accounts Payable and Other Current Liabilities Related party accounts payable and other current liabilities Accrued liabilities Stock options Less: imputed interest Furniture and fixtures [Member] Computer and office equipment [Member] Minimum [Member] Maximum [Member] Money market funds [Member] Level 1 [Member] Level 2 [Member] Level 3 [Member] Shares issuable on conversion of Company Series B Preferred Stock [Member] Series B Preferred Stock [Member] 2024 Stock Incentive Plan [Member] 2024 Employee Stock Purchase Plan [Member] Stock Option Valuation [Member] Stock Options [Member] Restricted Stock Activity [Member] Research and Development Expense [Member] General and Administrative Expense [Member] Research and Development Expenses [Member] Outstanding Employee Warrants to Purchase Common Stock [Member] Outstanding Unvested Restricted Stock Awards [Member] Outstanding and Issued Common Stock Options [Member] Paragon reimbursable Option Agreements' fees [Member] Paragon reimbursable other research expenses [Member] Paragon reimbursable patent expenses [Member] Class of Warrant or Right [Axis] Legal Entity [Axis] Sale of Stock [Axis] Investment, Name [Axis] Ownership [Axis] Liability Class [Axis] Derivative Instrument [Axis] Subsequent Event Type [Axis] Title and Position [Axis] Category of Item Purchased [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Scenario [Axis] Issuance preferred stock Convertible notes payable Purchase price (in Dollars per share) Exercise price Exercise price per warrant (in Dollars per share) Per share (in Dollars per share) Termination fee Reverse stock split ratio Aggregate net proceeds Purchased shares of common stock Additional paid-in capital transaction costs Exchange ratio Common Stock exchange (in Shares) Common stock conversion of convertible note (in Shares) Pre-funded warrants of common stock shares (in Shares) Warrants exchange (in Shares) Number of shares purchased (in Shares) Price per share (in Dollars per share) Purchase price per share (in Dollars per share) Preferred Stock, Convertible, Shares Issuable (in Shares) Converted shares Purchase price Number of shares issued to purchase (in Shares) Number of Shares issued Net of issuance costs Net cash Cash and cash equivalents Lease terms Leases term Lease term Income tax percentage Equity holding percentage Own capital percentage Lease term Lease discount rate Variable lease expense Percentage of diluted stock Shares were reserved for issuance Price per share Share outstanding percentage Estimated fair value of warrants to be granted Total unrecognized compensation cost Employee warrants issued Warrants outstanding Weighted average period Restricted stock awards authorized (in Shares) Price per share (in Dollars per share) Research initiation fee Percentage of development costs Development costs, percentage Accrued development costs Reimburse of development costs Payment to related party Non-refundable milestone payments Percentage of warrant purchase Gross proceeds Gross proceeds (in Dollars) Stock issuance cost Gross proceeds from common stock Conversion price per share (in Dollars per share) Principal amount Initial principal amount Interest rate Interest rate, percentage Aggregate proceeds Maturity date Debt issuance costs Interest expense Aggregate principal amount Unpaid accrued interest Converted shares (in Shares) Exercisable shares Expiration date Warrants exercised Employee warrants issued Employee warrants vest over a period Issuance costs (in Dollars) Common stock ratio Provision for income taxes Initiation fee Milestone payment Accounts payable and other current liabilities Development costs Research initiation fee Expenses Weighted-average number of shares of as-converted Subscription Receivable Use of Estimates Concentrations of Credit Risk and Other Risks and Uncertainties Cash and Cash Equivalents Debt Issuance Costs Fair Value Measurements Property and Equipment Classification of Convertible Preferred Stock Note Payable to Related Party Research and Development Contract Costs Accruals Leases Segment Reporting Research and Development Costs General and Administrative Expenses Commitments and Contingencies Stock-Based Compensation Net Loss per Share Attributable to Stockholders Income Taxes Recently Issued Accounting Pronouncements Warrant [Member] ARCA BIOPHARMA INC [Member] Oruka Common Stock [Member] Oruka common stock [Member] Oruka pre-funded warrants [Member] ARCA common stock [Member] Oruka restricted stock [Member] Reverse Stock Split [Member] Private Placement [Member] Pre-funded Warrants [Member] Paragon [Member] Paruka Holding, LLC [Member] Oruka Advisors LLC [Member] Paragon and Paruka [Member] Fairmount [Member] Fairmount Healthcare Fund II, L.P. [Member] Commitments [Member] 2024 Equity Incentive Plan [Member] 2024 Plan [Member] Restricted Stock Awards [Member] Subsequent Event [Member] Paruka Warrant Obligation [Member] Employee Warrants [Member] Unvested Stock Options [Member] Board of Directors [Member] Option [Member] Clinical Development Milestones [Member] Certain Regulatory Milestones [Member] Convertible Notes [Member] Convertible Note Purchase Agreement [Member] Convertible Note [Member] Pre-Funded Warrants [Member] Series B Non-Voting Preferred Stock [Member] ORKA-001 [Member] Forecast [Member] ORKA-002 [Member] Class of Stock [Domain] Related and Nonrelated Parties [Domain] Revision of Prior Period [Domain] Statement [Table] Statement [Line Items] Equity Component [Domain] Long-Lived Tangible Asset [Domain] Statistical Measurement [Domain] Property, Plant and Equipment [Table] Schedule of Property and Equipment [Line Items] Reverse Recapitalization and Pre-Closing Financing (Details) - Schedule of the Assets and Liabilities [Table] Schedule of the Assets and Liabilities [Abstract] Cash and Cash Equivalents [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value Measurements (Details) - Schedule of Fair Value Hierarchy for Financial Assets Measured [Table] Schedule of Fair Value Hierarchy for Financial Assets Measured [Line Items] Auction Market Preferred Securities, Stock Series [Table] Auction Market Preferred Securities, Stock Series [Line Items] Plan Name [Domain] Convertible Preferred Stock and Stockholders' Equity (Details) - Schedule of Common Stock Reserved for Future Issuance [Table] Schedule of Common Stock Reserved for Future Issuance [Line Items] Debt Instrument, Name [Domain] Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants [Table] Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants [Line Items] Award Type [Domain] Stock-Based Compensation (Details) - Schedule of RSAs activity [Table] Schedule of RSAs activity [Line Items] Statement of Income Location, Balance [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Table] Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss per Share [Line Items] Related Party Transaction [Domain] Condensed Financial Statements [Table] Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items] Sale of Stock [Domain] Entity [Domain] Class of Warrant or Right [Domain] Nature of the Business and Basis of Presentation (Details) [Table] Nature of the Business and Basis of Presentation [Line Items] Common Stock (Details) [Table] Common Stock (Details) [Line Items] Investment, Name [Domain] Ownership [Domain] Related Party Transactions (Details) [Table] Related Party Transactions (Details) [Line Items] Fair Value by Liability Class [Domain] Commitments and Contingencies (Details) [Table] Commitments and Contingencies (Details) [Line Items] Subsequent Event Type [Domain] Derivative Contract [Domain] Stock-Based Compensation (Details) [Table] Stock-Based Compensation [Line Items] Title and Position [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Long-Term Purchase Commitment, Category of Item Purchased [Domain] Subsequent Events (Details) [Table] Subsequent Events (Details) [Line Items] Note Payable with Related Party (Details) [Table] Note Payable with Related Party [Line Items] Convertible Preferred Stock and Stockholders' Equity (Details) [Table] Convertible Preferred Stock and Stockholders' Equity [Line Items] Scenario [Domain] Option Agreements (Details) [Table] Option Agreements [Line Items] Net Loss Per Share (Details) [Table] Net Loss Per Share (Details) [Line Items] Accrued research and development. The amount of additional paid-in capital transacation cost. Adjustment for change in common stock par value in connection with the Reverse Merger. Amount of accrued liabilities. Cash assumed in connection with the reverse recapitalization. Classification of Convertible Preferred Stock. The number of shares in common stock exchange. Loss allocation, stock. Percentage of development costs. The amount of employee warrants. Estimated fair value of warrants to be granted. Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock. Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the Reverse Merger. Exchange ratio. Issuance cost of PIPE financing. Issuance costs of pre-closing financing and reverse recapitalization. Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million. Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million. Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million. Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million. Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger. Issuance of Series A convertible preferred stock, net of issuance costs. The amount of milestone payment. Non-refundable milestone payments.

Represent the amount of non-cash accrued interest on convertible note converted to common stock. Note Payable to Related Party. Number of shares purchased. Option agreements. Represent the amount of development costs. Paruka warrant obligation. Percentage of warrant purchase. Pre-funded warrants of common stock shares. Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid. The amount of reimburse of development costs. Research and development contract costs accruals. Represents the amount of research initiation fee. Tabular disclosure of fair value of the employee warrants. Number of Warrants, Exercised (in Shares). Number of exercised of weighted average exercise price per share. Number of Warrants, Vested and exercisable. Weighted Average Exercise Price Per Share, Vested and exercisable. Weighted Average Remaining Contractual Term, Vested and exercisable. Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for option awards Vested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Shares issuable upon exercise of pre-funded warrants. Shares outstanding percentage. Subscription receivable. Amount of subscription receivable from investors who have been allocated common stock. Represents the amount of termination fee. Unpaid PIPE Financing issuance costs included in accounts payable. Unpaid PIPE Financing issuance costs included in accrued expenses and other current liabilties. Unpaid pre-closing financing and reverse recapitalization issuance costs included in accounts payable. Assets [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Temporary Equity, Liquidation Preference Entity Small Business Earnings Per Share, Diluted Exchange Of Series AConvertible Preferred Stock For Series BNonvoting Convertible Preferred St Accounts Payable and Other Accrued Liabilities Series AConvertible Preferred Stock Member Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Series B Preferred Stock [Member] Weighted Average Number of Shares Outstanding, Basic Preferred Stock, Convertible, Shares Issuable Unpaid PIPEFinancing Issuance Costs Included In Accounts Payable Accrued Professional Fees, Current Other Nonoperating Income (Expense) Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Issuance Of Common Stock To Former Stockholders Of ARCABiopharma Inc In Connection With The Closing Ofthe Reverse Merger Fair Value Measurement, Policy [Policy Text Block] Stock Issued During Period, Shares, New Issues Commitments [Member] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Note Payable To Related Party Policy Text Block Investment Income, Interest Schedule Of Property And Equipment Abstract Paragon Reimbursable Option Agreements Fees Member Other Assets, Noncurrent Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Additional Paid in Capital Operating Expenses [Abstract] Board of Directors Chairman [Member] Stock Issued During Period, Shares, Conversion of Units Warrants and Rights Outstanding Accounts Payable and Other Accrued Liabilities, Current Net Cash Provided by (Used in) Operating Activities [Abstract] Other Noncash Expense Reimburse Of Development Costs Increase (Decrease) in Accounts Payable, Trade Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Equity, Attributable to Parent [Abstract] Preferred Stock, Shares Issued Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Series ANon Voting Convertible Preferred Stock Member Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Forecast [Member] Debt Disclosure [Text Block] Minimum [Member] Common Stock, Shares, Outstanding Increase (Decrease) in Prepaid Expenses, Other Research And Development Contract Costs Accruals Policy Text Block Selling, General and Administrative Expenses, Policy [Policy Text Block] Retained Earnings (Accumulated Deficit) Depreciation Shares Issuable Upon Exercise Of Prefunded Warrants Lessee, Operating Lease, Liability, to be Paid, Year Three Net Cash Provided by (Used in) Investing Activities Payments for Other Fees Condensed Financial Statements [Table Text Block] Schedule Of Fair Value Hierarchy For Financial Assets Measured Abstract Schedule Of Company SStock Based Compensation Expense Abstract Mergers, Acquisitions and Dispositions Disclosures [Text Block] Schedule Of Common Stock Reserved For Future Issuance Abstract Payments to Acquire Property, Plant, and Equipment Business Description and Basis of Presentation [Text Block] Share-Based Payment Arrangement [Policy Text Block] Noncash or Part Noncash Acquisition, Other Liabilities Assumed Preferred Stock, Shares Authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Preferred Stock, Shares Outstanding Temporary Equity, Par or Stated Value Per Share Fair Value, Inputs, Level 2 [Member] Prepaid Expense and Other Assets, Current Property, Plant and Equipment, Net Series BNon Voting Convertible Preferred Stock Amount Member Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Liabilities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Common Stock Text Block Maximum [Member] Income Tax, Policy [Policy Text Block] Preferred Stock, Convertible, Conversion Ratio ARCABIOPHARMAINCMember Common Stock, Shares Authorized Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Entity Incorporation, State or Country Code Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Operating Lease, Liability, Noncurrent Employee Warrants Operating Lease, Variable Lease Income Preferred Stock [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Concentration Risk, Credit Risk, Policy [Policy Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Schedule of Accrued Liabilities [Table Text Block] Schedule Of Anti Dilutive Effect Excluded From Potential Computation Of Diluted Net Loss Per Share Abstract Share-Based Payment Arrangement, Expense Increase (Decrease) in Operating Capital [Abstract] Oruka Restricted Stock Member Net Cash Provided by (Used in) Financing Activities [Abstract] Additional Paid-in Capital [Member] Proceeds From Issuance Of Pre Merger Oruka Series APreferred Stock Net Of Issuance Costs Paid Share-Based Payment Arrangement [Abstract] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Debt Conversion, Converted Instrument, Amount Termination Fee Temporary Equity, Carrying Amount, Attributable to Parent Share-Based Payment Arrangement, Option [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cos Net Cash Provided by (Used in) Investing Activities [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Grant Date Fair Value Outstanding And Issued Common Stock Options Member Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Proceeds from Issuance of Debt Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Significant Accounting Policies [Text Block] Class of Warrant or Right, Unissued Segment Reporting, Policy [Policy Text Block] AOCI Attributable to Parent [Member] Property, Plant and Equipment, Useful Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Schedule Of Convertible Preferred Stock Abstract Common Stock, Capital Shares Reserved for Future Issuance Lessee, Operating Lease, Liability, to be Paid, Year Two Other Development Cost Fair Value, Inputs, Level 3 [Member] Related Party Transactions Disclosure [Text Block] Outstanding Employee Warrants To Purchase Common Stock Member Stock Issued During Period, Shares, Employee Stock Purchase Plans Net Cash Provided by (Used in) Operating Activities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value ORKAZero Zero Two Member Issuance Costs Of Preclosing Financing And Reverse Recapitalization Schedule of Auction Market Preferred Securities by Stock Series [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Series ANon Voting Convertible Preferred Stockholders Member Temporary Equity, Shares Authorized Equity Option [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Stock Issued During Period, Shares, Other Payments of Stock Issuance Costs Fair Value, Inputs, Level 1 [Member] Temporary Equity, Shares Outstanding Preferred Stock, Convertible, Conversion Price Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Expected To Vest Two Thousand Twenty Four Employee Stock Purchase Plan Member Equity, Attributable to Parent Adjustment For Change In Common Stock Par Value In Connection With The Reverse Merger Other Expenses Unpaid PIPEFinancing Issuance Costs Included In Accrued Expenses And Other Current Liabilties Unpaid Preclosing Financing And Reverse Recapitalization Issuance Costs Included In Accounts Payable Property, Plant and Equipment, Policy [Policy Text Block] Furniture and Fixtures [Member] Accrued Research And Development Additional Paid In Capital Transacation Cost Series BNon Voting Convertible Preferred Stockholders Member Cash and Cash Equivalents, Policy [Policy Text Block] Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Preferred Stock [Text Block] Schedule Of Weighted Average Assumptions Or Range Of Assumptions Used In Calculating The Fair Value Of The Employee Warrants Abstract Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warr Lessee, Operating Lease, Discount Rate Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Development Costs Percentage Commitments and Contingencies, Policy [Policy Text Block] Liabilities Convertible Preferred Stock And Stockholders Equity Abstract Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract Debt Instrument, Increase, Accrued Interest Employee Warrants Member Two Thousand Twenty Four Stock Incentive Plan Member Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3 Accounts Payable, Other, Current Previously Reported [Member] Lessee, Operating Lease, Liability, to be Paid Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Sale of Stock, Number of Shares Issued in Transaction Property, Plant and Equipment [Table Text Block] Operating Expenses Statement of Financial Position [Abstract] Stockholders' Equity Note, Stock Split, Conversion Ratio Cash and Cash Equivalents, at Carrying Value Oruka Common Stock Member Research and Development Expense, Policy [Policy Text Block] Shares Issued, Price Per Share Lessee, Operating

Lease, Liability, to be Paid, Year One Document Type Proceeds from Issuance of Common Stock Paragon Member Conversion of Stock, Shares Issued Noncash Accrued Interest On Convertible Note Converted To Common Stock Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule Of The Assets And Liabilities Abstract Schedule Of Summarizes The Employee Warrant Activity Table Text Block Subscription Receivable Policy Text Block Preferred Stock, Liquidation Preference, Value Lessee, Operating Lease, Liability, Undiscounted Excess Amount Clinical Development Milestones Member Share-Based Payment Arrangement, Noncash Expense Debt Instrument, Interest Rate During Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Classification Of Convertible Preferred Stock Policy Text Block Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Stock Issued During Period, Value, Other Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Other Accrued Liabilities Use of Estimates, Policy [Policy Text Block] Commitments and Contingencies Series A Preferred Stock [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Common Stock, Value, Issued Effective Income Tax Rate Reconciliation, Percent Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Series BNon Voting Preferred Stock Member Lessee, Leases [Policy Text Block] Operating Lease, Payments Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Fairmount Healthcare Fund IILPMember Milestone Payment Stock Issued During Period, Value, New Issues Exchange Of Series AConvertible Preferred Stock For Series BNonvoting Convertible Preferred Stock Statement of Stockholders' Equity [Abstract] Oruka Advisors LLCMember Increase (Decrease) in Operating Lease Liability Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from Issuance of Convertible Preferred Stock Income Tax Expense (Benefit) Research and Development Expense [Member] Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Income Statement [Abstract] Schedule Of Rsas Activity Abstract Proceeds from Notes Payable New Accounting Pronouncements, Policy [Policy Text Block] Paragon Reimbursable Patent Expenses Member Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Exercisable In Period Weighted Average Grant Date Fair Value Unvested Stock Options Member Earnings Per Share, Basic Assets Liabilities Research and Development Expense Proceeds from (Payments for) Other Financing Activities Subsequent Events [Text Block] Assets, Fair Value Disclosure Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Outstanding Unvested Restricted Stock Awards Member Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Paruka Holding LLCMember Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Two Thousand Twenty Four Equity Incentive Plan Member Conversion of Stock, Shares Converted Repayments of Related Party Debt Non Refundable Milestone Payments Accounts Payable, Current Net Cash Provided by (Used in) Financing Activities Accrued Employee Benefits, Current Option Agreements Text Block Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value Convertible Notes Member Proceeds from Issuance or Sale of Equity Restricted Stock Activity Member Interest Expense, Nonoperating Subsequent Event [Member] Warrant [Member] Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cost Amendment Flag Entity Central Index Key Restricted Stock [Member] Operating Income (Loss) Commom Stock Exchange Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Shares Outstanding Percentage Other Notes Payable Operating Lease, Liability Paragon And Paruka Member Paragon Reimbursable Other Research Expenses Member Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Employee Benefits and Share-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Accrued Liabilities and Other Liabilities Other Income and Expenses [Abstract] Schedule Of Fair Value Of The Employee Warrants Table Text Block Sale of Stock, Price Per Share Common Stock [Member] Entity Registrant Name Exchange Ratio ORKAZero Zero One Member Paruka Warrant Obligation Statement of Cash Flows [Abstract] Class of Warrant or Right, Outstanding Operating Lease, Liability, Current Income Tax Disclosure [Text Block] Noncash Investing and Financing Items [Abstract] Common Stock Loss Allocation Computer And Office Equipment Member Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Equity Method Investment, Ownership Percentage Money Market Funds [Member] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Condensed Financial Information of Parent Company Only Disclosure [Text Block] Liabilities, Current [Abstract] Estimated Fair Value Of Warrants To Be Granted Stock Issued During Period, Value, Conversion of Units Noncash or Part Noncash Acquisition, Other Assets Acquired Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Exercisable Period Weighted Average Grant Date Fair Value Supplemental Deferred Purchase Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Payments of Debt Issuance Costs Financial Assets Abstract Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] General and Administrative Expense [Member] Share-Based Payment Arrangement [Text Block] Operating Lease, Weighted Average Remaining Lease Term Reverse Stock Split Member Lessee, Operating Lease, Term of Contract Weighted Average Number of Shares, Contingently Issuable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Earnings Per Share [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Share Price Stock Issued During Period, Value, Stock Options Exercised Stock Issued During Period, Value, Conversion of Convertible Securities Percentage Of Warrant Purchare Assets Abstract0 Prefunded Warrants Member General and Administrative Expense Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Pre Funded Warrants Member Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Common Stock, Par or Stated Value Per Share Current Assets Abstract0 Issuance Of Series AConvertible Preferred Stock Net Of Issuance Costs Earnings Per Share, Policy [Policy Text Block] Proceeds from Issuance of Private Placement Entity Emerging Growth Company Number Of Shares Purchased Sale of Stock, Consideration Received Per Transaction Payment of Financing and Stock Issuance Costs ARCACommon Stock Member Increase (Decrease) in Accounts Payable, Related Parties Other Liabilities, Current Cash Assumed In Connection With The Reverse Recapitalization Increase (Decrease) in Other Noncurrent Assets Debt, Policy [Policy Text Block] Issuance Cost Of PIPEFinancing Operating Lease, Expense Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fair Value Disclosures [Text Block] Oruka Prefunded Warrants Member Private Placement [Member] Subsidiary, Ownership Percentage, Noncontrolling Owner Related Party [Member] Net Income (Loss) Attributable to Parent Paruka Warrant Obligation Member Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warrant Convertible Note Purchase Agreement Member Debt Instrument, Face Amount Assets, Current [Abstract] Cash Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Subsequent Events [Abstract] Subscription Receivables Liabilities, Current Stockholders Equity Abstract0 Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Pre Funded Warrants Of Common Stock Shares Research Initiation Fee Convertible Note Member Shares, Outstanding Commitments and Contingencies Disclosure [Text Block] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Temporary Equity, Shares Issued Interest Expense, Debt Schedule Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders Abstract Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Certain Regulatory Milestones Member Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Exercisable Entity Filer Category Series BNon Voting Convertible Preferred Stock Member Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Proceeds from Convertible Debt Class of Warrant or Right, Exercise Price of Warrants or Rights Preferred Stock, Value, Issued Liabilities and Equity Debt Instrument, Maturity Date Convertible Notes Payable Preferred Stock, Par or Stated Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Operating Lease, Right-of-Use Asset Assets, Current Schedule Of Related Party Accounts Payable And Other Current Liabilities Abstract EX-101.PRE 18 orka-20240930_pre.xml XBRL PRESENTATION FILE XML 20 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information8 Months Ended

Sep. 30, 2024

Document Information Line Items Entity Registrant NameOruka Therapeutics, Inc.Document TypeS-1Amendment FlagfalseEntity Central Index Key0000907654Entity Filer CategoryNon-accelerated FilerEntity Small BusinesstrueEntity Emerging Growth CompanyfalseEntity Incorporation, State or Country CodeDE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details
Name:dei_AmendmentFlag Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details
Name:dei_DocumentInformationLineItems Namespace Prefix:dei_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details
Name:dei_DocumentType Namespace Prefix:dei_ Data Type:dei:submissionTypeItemType Balance Type:na Period Type:duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details
Name:dei_EntityCentralIndexKey Namespace Prefix:dei_ Data Type:dei:centralIndexKeyItemType Balance Type:na Period Type:duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details
Name:dei_EntityEmergingGrowthCompany Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

- Definition

Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details
Name:dei_EntityFilerCategory Namespace Prefix:dei_ Data Type:dei:filerCategoryItemType Balance Type:na Period Type:duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details
Name:dei_EntityIncorporationStateCountryCode Namespace Prefix:dei_ Data Type:dei:edgarStateCountryItemType Balance Type:na Period Type:duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details

Name:dei_EntityRegistrantName Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

- Definition

Indicates that the company is a Smaller Reporting Company (SRC).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details

Name:dei_EntitySmallBusiness Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration XML 21 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands Sep. 30, 2024 Feb. 06, 2024 Current Assets Cash and cash equivalents $ 410,875 Subscription receivable 1 Prepaid expenses and other current assets 2,074 Total current assets 412,9491 Property and equipment, net 160 Operating lease right-of-use asset 938 Other non-current assets 43 Total assets 414,0901 Current liabilities: Accounts payable 2,145 Accrued expenses and other current liabilities 1,710 Operating lease liability, current 146 Related party accounts payable and other current liabilities 6,357 Total current liabilities 18,039 Operating lease liability, non-current 842 Total liabilities 18,881 Commitments and contingencies STOCKHOLDERS' EQUITY Common stock, value 35 Additional paid-in capital 397,3451 Accumulated deficit (57,943) Total stockholders' equity 342,3681 Total liabilities, convertible preferred stock and stockholders' equity 414,0901 Related Party Current liabilities: Related party common stock warrant liability 7,681 Previously Reported Current Assets Subscription receivable 1 Total assets 1 Current liabilities: Commitments and contingencies STOCKHOLDERS' EQUITY Common stock, value 3 Additional paid-in capital (2) Total stockholders' equity 1 Series A Convertible Preferred Stock Current liabilities: Convertible preferred stock, value Series A Convertible Preferred Stock | Previously Reported STOCKHOLDERS' EQUITY Preferred stock, value Series A Non-Voting Convertible Preferred Stockholders Current liabilities: Convertible preferred stock, value 52,841 Series B Non-Voting Convertible Preferred Stock STOCKHOLDERS' EQUITY Preferred stock, value $ 2,931

- Definition

Amount of subscription receivable from investors who have been allocated common stock.

+ References

No definition available.

+ Details

Name:orka_SubscriptionReceivables Namespace Prefix:orka_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.

+ References

No definition available.

+ Details

Name:us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

+ Details

Name:us-gaap_AccountsPayableCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_AdditionalPaidInCapital Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: instant

- Definition

Amount of asset recognized for present right to economic benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Name:us-gaap_Assets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of asset recognized for present right to economic benefit, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

+ Details

Name:us-gaap_AssetsCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_AssetsCurrentAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

+ Details

Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details

Name:us-gaap_CommitmentsAndContingencies Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 - Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB - URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Name:us-gaap_CommonStockValue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:us-gaap_Liabilities ***Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant***

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-

gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -

Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

+ Details

Name:us-gaap_LiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_LiabilitiesCurrentAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 - Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details

Name:us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 - Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details

Name:us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's right to use underlying asset under operating lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 - Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details

Name:us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of noncurrent assets classified as other.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_OtherAssetsNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 - Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

+ Details

Name:us-gaap_OtherLiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: instant

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 - Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB - URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Name:us-gaap_PreferredStockValue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1

+ Details

Name:us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: instant

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 - Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 - Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 - Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 - Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 - Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 - Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

+ Details

Name:us-gaap_StockholdersEquity Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_StockholdersEquityAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.E.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

+ Details

Name:us-gaap_TemporaryEquityCarryingAmountAttributableToParent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details

Name:us-gaap_WarrantsAndRightsOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Details

Name:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 22 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands Sep. 30, 2024 Feb. 06, 2024 Common stock, par value (in Dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized 545,000,000 65,000,000 Common stock, shares issued 34,998,550 3,197,975 Common stock, shares outstanding 34,998,550 3,197,975 Series A convertible preferred stock - Convertible preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001 Convertible preferred stock, shares authorized 20,000,000 20,000,000 Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Convertible preferred stock, liquidation preference (in Dollars) $ 0 $ 0 Series A Non-Voting Convertible Preferred Stockholders - Convertible preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001 Convertible preferred stock, shares authorized 2,439 Convertible preferred stock, shares issued 2,439 Convertible preferred stock, shares outstanding 2,439 Series B Non-Voting Convertible Preferred Stock - Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized 251,504 Preferred stock, shares issued 137,138 Preferred stock, shares outstanding 137,138 Previously Reported - Common stock, par value (in Dollars per share) $ 0.001 Common stock, shares authorized 65,000,000 Common stock, shares issued 3,197,975 Common stock, shares outstanding 3,197,975 Previously Reported | Series A convertible preferred stock - Preferred stock, par value (in Dollars per share) $ 0.001 Preferred stock, shares authorized 20,000,000 Preferred stock, shares issued Preferred stock, shares outstanding

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na

Period Type:instant

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details

Name:us-gaap_CommonStockSharesAuthorized Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_CommonStockSharesIssued Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

+ Details

Name:us-gaap_CommonStockSharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type: instant

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 - Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

+ Details

Name:us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details

Name:us-gaap_PreferredStockSharesAuthorized Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type: instant

- Definition

Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

+ Details

Name:us-gaap_PreferredStockSharesIssued Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

+ Details

Name:us-gaap_PreferredStockSharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type: instant

- Definition

The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

No definition available.

+ Details

Name:us-gaap_TemporaryEquityLiquidationPreference Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1

+ Details

Name:us-gaap_TemporaryEquityParOrStatedValuePerShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type: na Period Type:instant

- Definition

The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_TemporaryEquitySharesAuthorized Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:

instant

- Definition

The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_TemporaryEquitySharesIssued Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type: instant

- Definition

The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_TemporaryEquitySharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type: instant

- Details

Name:us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 23 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended Sep. 30, 2024	8 Months Ended Sep. 30, 2024
Operating expenses		
Research and development[1]	$ 25,691	$ 49,557
General and administrative[2]	3,758	8,248
Total operating expenses	29,449	57,805
Loss from operations	(29,449)	(57,805)
Other income (expense)		
Interest income	1,330	1,330
Interest expense[3]	(504)	(1,468)
Total other income (expense), net	826	(138)
Net loss and comprehensive loss	$ (28,623)	$ (57,943)
Net loss per share attributable, basic (in Dollars per share)	$ (1.46)	$ (6.08)
Net loss per share attributable, diluted (in Dollars per share)	$ (1.46)	$ (6.08)
Weighted-average shares used in computing net loss per share attributable, basic (in Shares)	15,013,655	7,765,381
Weighted-average shares used in computing net loss per share attributable, diluted (in Shares)	15,013,655	7,765,381
Series A Non-Voting Convertible Preferred Stockholders		
Other income (expense)		
Net loss per share attributable, basic (in Dollars per share)	$ (1,461.1)	$ (6,077.25)
Net loss per share attributable, diluted (in Dollars per share)	$ (1,461.1)	$ (6,077.25)
Weighted-average shares used in computing net loss per share attributable, basic (in Shares)	477	184
Weighted-average shares used in computing net loss per share attributable, diluted (in Shares)	477	184
Series B Non-Voting Convertible Preferred Stockholders		
Other income (expense)		
Net loss per share attributable, basic (in Dollars per share)	$ (121.76)	$ (506.44)
Net loss per share attributable, diluted (in Dollars per share)	$ (121.76)	$ (506.44)
Weighted-average shares used in computing net loss per share attributable, basic (in Shares)	49,191	19,015
Weighted-average shares used in computing net loss per share attributable, diluted (in Shares)	49,191	19,015

[1] Includes related party amount of $13,537 for the three months ended September 30, 2024 and $33,967 for the period from February 6, 2024 (inception) to September 30, 2024

[2] Includes related party amount of $71 for the three months ended September 30, 2024 and $1,339 for the period from February 6, 2024 (inception) to September 30, 2024

[3] Includes related party amount of $504 for the three months ended September 30, 2024 and $1,468 for the period from February 6, 2024 (inception) to September 30, 2024

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

+ Details

Name:us-gaap_EarningsPerShareBasic Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type: duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

+ Details

Name:us-gaap_EarningsPerShareDiluted Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type: duration

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 - Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

+ Details

Name:us-gaap_GeneralAndAdministrativeExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of interest expense classified as nonoperating.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:us-gaap_InterestExpenseNonoperating Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

Name:us-gaap_InvestmentIncomeInterest Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name:us-gaap_OperatingExpenses Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_OperatingExpensesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

+ Details

Name:us-gaap_OperatingIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration

- References

No definition available.

+ Details

Name:us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type: duration

- Definition

Amount of income (expense) related to nonoperating activities, classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 - Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details
Name:us-gaap_ResearchAndDevelopmentExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

+ Details
Name:us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Details
Name:us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockholdersMember Namespace Prefix: Data Type:na Balance Type: Period Type:
- Details
Name:us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockholdersMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 24 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Series B Non-Voting Series A	Series B Non-Voting Series A Non-Voting	Series B Non-Voting Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balances at Feb. 05, 2024	$ 3	$ (2)	$ 1				
Balances (in Shares) at Feb. 05, 2024				3,197,975			
Issuance of common stock				$ 2	$ (2)		
Issuance of common stock (in Shares)				2,207,553			
Issuance of Series A convertible preferred stock, net of issuance costs of $69	$ 2,931						
Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares)	20,000,000						
Stock-based compensation expense					1		717
Net loss						(7,077)	(7,077)
Balances at Mar. 31, 2024	$ 2,931	$ 5	$ 1	3,197,975	$ 2	(7,077)	(7,059)
Balances (in Shares) at Mar. 31, 2024	20,000,000	5,405,528					
Balances at Feb. 05, 2024	$ 3	$ (2)	$ 1				
Balances (in Shares) at Feb. 05, 2024				3,197,975			
Net loss						(57,943)	
Balances at Sep. 30, 2024	$ 52,841	$ 2,931	$ 3	5,397,345	$ 5	(57,943)	(342,368)
Balances (in Shares) at Sep. 30, 2024	2,439	137,138	34,998,550				
Balances at Mar. 31, 2024	$ 2,931	$ 5	$ 1	(7,077)	$ (7,059)		
Balances (in Shares) at Mar. 31, 2024	20,000,000	5,405,528					
Stock-based compensation expense					321		321
Net loss						(22,243)	(22,243)
Balances at Jun. 30, 2024	$ 2,931	$ 5	$ 3	34	$ (29,320)	(28,981)	
Balances (in Shares) at Jun. 30, 2024	20,000,000	5,405,528					
Stock-based compensation expense					1,750		1,750
Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization	$ (2,931)	$ 2,931			2,931		
Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization (in Shares)	(20,000,000)	137,138					
Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization			$ 3	26,445	26,448		
Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares)				2,722,207			
Issuance of common stock and pre-funded warrants in the Pre-Closing Financing,			$ 2	0,248,437	248,457		
Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, (in Shares)				20,061,932			
Issuance costs of Pre-Closing Financing and reverse recapitalization					(20,480)	(20,480)	
Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization			$ 1	4,999	5,000		
Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization (in Shares)				1,208,883			
Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing	$ 56,097	$ 6	$ 1	44,433	144,439		
Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares)	2,439	5,600,000					
Issuance cost of PIPE Financing				$ (3,256)	(8,573)	(8,573)	
Net loss						(28,623)	(28,623)
Balances at Sep. 30, 2024	$ 52,841	$ 2,931	$ 3	5	$ 397,345	$ (57,943)	$ 342,368
Balances (in Shares) at Sep. 30, 2024	2,439	137,138	34,998,550				

- Definition

Adjustment for change in common stock par value in connection with the Reverse Merger.

+ References

No definition available.

+ Details

Name:orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger Namespace Prefix:orka_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock.

+ References

No definition available.

+ Details

Name:orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt Namespace Prefix:orka_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the Reverse Merger.

+ References

No definition available.

+ Details

Name:orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock Namespace Prefix:orka_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Issuance cost of PIPE financing.

+ References

No definition available.

+ Details

Name:orka_IssuanceCostOfPIPEFinancing Namespace Prefix:orka_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration

- Definition

Issuance costs of pre-closing financing and reverse recapitalization.

+ References

No definition available.

+ Details

Name:orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization Namespace Prefix:orka_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.

+ References

No definition available.

+ Details

Name:orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos Namespace Prefix:orka_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.

+ References

No definition available.

+ Details
Name:orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost Namespace Prefix:orka_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.

+ References

No definition available.

+ Details
Name:orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr Namespace Prefix:orka_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.

+ References

No definition available.

+ Details
Name:orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant Namespace Prefix:orka_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.

+ References

No definition available.

+ Details
Name:orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger Namespace Prefix:orka_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12

+ Details
Name:us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Number of shares issued which are neither cancelled nor held in the treasury.

+ References

No definition available.

+ Details

Name:us-gaap_SharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type: na Period Type:duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Number of shares of stock issued attributable to transactions classified as other.

+ References

No definition available.

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesOther Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_StockIssuedDuringPeriodValueConversionOfUnits Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name

Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Value of shares of stock issued attributable to transactions classified as other.

+ References

No definition available.

No definition available.

+ Details

Name:us-gaap_StockIssuedDuringPeriodValueOther Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

+ Details
Name:us-gaap_StockholdersEquity Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant
XML 25 R6.htm IDEA: XBRL DOCUMENT
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parentheticals) $ in Thousands *2 Months Ended*
Mar. 31, 2024
USD ($)
Statement of Stockholders' Equity [Abstract] Issuance of Series A convertible preferred stock, net of issuance costs $ 69
- Definition

Issuance of Series A convertible preferred stock, net of issuance costs.

+ References

No definition available.

+ Details
Name:orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts Namespace Prefix:orka_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details
Name:us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 26 R7.htm IDEA: XBRL DOCUMENT
Condensed Consolidated Statement of Cash Flows (Unaudited) $ in Thousands8 Months Ended
Sep. 30, 2024
USD ($)
Cash flows from operating activities: Net loss$ (57,943)Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense11Stock-based compensation expense9,769Non-cash interest expense1,468Non-cash lease expense65Changes in operating assets and liabilities: Prepaid expenses and other current assets(1,980)Other non-current assets(43)Accounts payable1,621Accrued expenses and other current liabilities1,650Operating lease liability6Related party accounts payable and other current liabilities6,357Net cash used in operating activities(39,019)Cash flows from investing activities: Purchases of property and equipment(171)Net cash used in investing activities(171)Cash flows from financing activities: Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid2,931Proceeds from issuance of notes payable to related parties, net of issuance costs paid24,980Proceeds from the Pre-Closing Financing, net228,127 Proceeds from the PIPE Financing, net189,087Cash acquired in connection with the reverse recapitalization4,940Net cash provided by financing activities450,065Net increase in cash and cash equivalents410,875Cash at beginning of periodCash and cash equivalents at end of period410,875Supplemental disclosure of non-cash operating and financing activities: Operating lease liability arising from obtaining operating right-of-use asset982Assets acquired in connection with the reverse recapitalization114Other liabilities assumed in connection with the reverse recapitalization(54)Pre-Closing Financing and reverse recapitalization issuance costs included in accounts payable150PIPE Financing issuance costs included in accounts payable374PIPE Financing issuance costs included in accrued expenses and other current liabilities6Non-cash accrued interest on convertible note converted to common stock1,468Non-cash exchange of Pre-Merger Oruka Series A Preferred Stock for Company Series B Convertible Preferred Stock$ 2,931
- Definition

Cash assumed in connection with the reverse recapitalization.

+ References

No definition available.

+ Details
Name:orka_CashAssumedInConnectionWithTheReverseRecapitalization Namespace Prefix:orka_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Represent the amount of non-cash accrued interest on convertible note converted to common stock.

+ References

No definition available.

+ Details
Name:orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock Namespace Prefix:orka_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid.

+ References

No definition available.

+ Details
Name:orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid Namespace Prefix:orka_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Unpaid PIPE Financing issuance costs included in accounts payable.

+ References

No definition available.

+ Details
Name:orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable Namespace Prefix:orka_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Unpaid PIPE Financing issuance costs included in accrued expenses and other current liabilties.

+ References

No definition available.

+ Details
Name:orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties Namespace Prefix:orka_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Unpaid pre-closing financing and reverse recapitalization issuance costs included in accounts payable.

+ References

No definition available.

+ Details
Name:orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable Namespace Prefix:orka_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 - Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

+ Details

Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 - Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1

+ Details

Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 - Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5

+ Details

Name:us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type: credit Period Type:duration

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

+ Details

Name:us-gaap_Depreciation Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_IncreaseDecreaseInAccountsPayableTrade Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit

Period Type:duration

- Definition

Amount of increase (decrease) in accrued expenses, and obligations classified as other.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of increase (decrease) in obligation for operating lease.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details

Name:us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of increase (decrease) in noncurrent assets classified as other.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_IncreaseDecreaseInPrepaidExpensesOther Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 - Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

+ Details

Name:us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type: debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 - Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

+ Details

Name:us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type: na Period Type:duration

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 - Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482700/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX

210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-599-1

!BR22R.I)6M8UJ=7.551$1. MJJIT8TY?#'0"G#@/VHUOIWBMT'<;MHZ_VNWP25:RU=9:YX8HT6CF:G,]S41, MJJ(F5[U0N2-/H4W K]\I5PCUFM:#<_1EJGN%^IT92WB@HH7235<71L4[6-1 M5<]G1KL)\#E[D8ISKR<.L-P]G=?3:+U)H_4U)H_44C>6>HM-0R*@K,89(JJS M#6O:B,*

*Q:Q4C< MYK5]%[FJBJB*B=<25\ANJLBWO*

.UUG ME"VTM4K>#KXF2\.

*[MO9+A+-)'+::A]1$V/31ZNC=&]Y=FCE_0?> &K]_)!M0ZYT5)B*OM^&[E4,J M:RSPL9M>YSMST9)IN8URI]Z5/WXHRH2\7EEQM=[K,/2OI&V^J91-:Y)Z=]J MK6^*

HIRE MEDFIW5$TC(5D1%57-38I)_RB:]QIW@)SIO\ A;BBP6R]XBN5=.;Q.ZSU$-96 M22LUG:K8ET

"

5*GRF^[Q1?8J*6="\&MUM\FKG[\=T M2KZ7FVBT=,.DC\.>^?C_ /2R]K>G7&2<@J9(-\3Z4\ U[QMTM>M8Z(FM-CY: MU$\L?-2238G+:NY4S[T::TX&\!:RQWJOKM66F%_*8QM(V1[)F.